www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 1 articl internet base intervent smoke cessat stopadvisor peopl low high socioeconom statu randomis control trial jami brown susan michi adam wa geraghti luci yardlei benjamin gardner lion shahab john stapleton robert west summari background internet base intervent smoke cessat million peopl stop smoke low unit cost long term biochem verifi ed evid scarc intervent eff ectiv smoker low socioeconom statu high statu lower onlin literaci engag websit aim assess interact internet base intervent stopadvisor smoke cessat design attent direct peopl low socioeconom statu method onlin randomis control trial dec 6 2011 oct 11 2013 uk particip ag 18 year older smoke dai randomli assign 1 1 receiv treatment stopadvisor inform websit randomis autom unseen random number function embed websit establish treatment reveal onlin baselin assess recruit continu requir sampl size achiev high low socioeconom statu subpopul particip research obtain data laboratori analys mask treatment alloc primari outcom 6 month sustain biochem verifi ed abstin main secondari outcom 6 month 7 dai biochem verifi ed point preval analysi intent treat homogen intervent eff ect socioeconom subsampl fi rst assess establish separ subsampl analys studi regist intern standard randomis control trial number isrctn99820519 find randomli assign 4613 particip stopadvisor group 2321 control group 2292 2142 particip low socioeconom statu 2471 particip high statu rate smoke cessat similar particip stopadvisor control group primari 237 10 220 10 particip rel risk rr 1 06 95 ci 0 89 1 27 0 49 secondari 358 15 332 15 particip 1 06 0 93 1 22 0 37 outcom intervent eff ect diff er socioeconom statu subsampl 1 44 0 99 2 09 0 0562 1 37 1 02 1 84 0 0360 stopadvisor help particip low socioeconom statu stop smoke compar inform websit primari outcom 90 8 1088 64 6 1054 particip rr 1 36 95 ci 1 00 1 86 0 0499 secondari outcom 136 13 100 10 particip 1 32 1 03 1 68 0 0267 improv cessat rate high socioeconom statu 147 12 1233 156 13 1238 particip 0 95 0 77 1 17 0 61 222 18 232 19 particip 0 96 0 81 1 13 0 64 interpret stopadvisor eff ectiv inform websit smoker low high socioeconom statu stopadvisor implement easili made freeli improv success rate smoker low socioeconom statu seek onlin support fund nation prevent research initi copyright brown al open access articl distribut term cc introduct tobacco smoke estim 6 million death worldwid year 1 major contributor health inequ 2 mortal morbid smoke avoid smoker quit ag 30 year 3 develop countri quarter smoker quit ag want stop 4 face face support combin drug eff ectiv intervent cessat unaid quit eff ectiv method 5,6 fi nding uk treatment wide access cost smoker face face support half attempt stop unaid 7 improv wai engag smoker stop urgent need low socioeconom statu group stop smoker fi diffi cult 8 widen social inequ lancet respir med 2014 publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 onlin comment http dx.doi.org 10.1016 s2213 2600 14 70214 0 cancer research uk health behaviour research centr depart epidemiolog public health brown phd gardner dphil shahab phd prof west phd depart clinic educ health psycholog prof michi dphil univers colleg london london uk nation centr smoke cessat train london uk prof michi prof west primari care popul scienc geraghti phd school psycholog prof yardlei phd univers southampton southampton uk addict depart institut psychiatri king colleg london london uk stapleton msc correspond dr jami brown health behaviour research centr depart epidemiolog public health univers colleg london london wc1e 6bt uk jamie.brown ucl.ac.uk http crossmark.crossref.org dialog doi 10.1016 s2213 2600 14 70195 domain pdf articl 2 www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 internet support low cost option treatment smoke cessat reach million smoker attempt quit unaid roughli 70 smoker uk regular internet access half interest onlin support futur quit attempt 9 internet appeal smoker reluct engag face face support er increas conveni confi dential reduc stigma present altern struggl access face face support mobil geograph barrier benefi ts compar low cost conveni altern written materi includ opportun interact tailor potenti internet base intervent previou research eff ectiv produc mix result limit scarciti biochem verifi ed long term outcom 10 compon account diff erenc eff ectiv diff erent assess unclear internet intervent present call black box restrict descript content 10 establish crucial compon eff ectiv intervent research report transpar content smoke cessat websit 11 stopadvisor interact smoke cessat websit promot transpar detail content develop websit publish 12 websit built open sourc platform lifeguid develop stopadvisor inform addict theori previou research user test smoker low socioeconom statu pilot studi stopadvisor show promis short term eff ectiv usabl 13 aim assess long term biolog verifi ed eff ectiv intervent trial health inequ prioriti assess eff ect intervent diff erent social group import 14 assess behaviour intervent adequ power detect eff ect low incom group 15 knowledg previou trial internet support smoke cessat design assess eff ect diff erent socioeconom statu group absenc research exist concern onlin support eff ectiv smoker high socioeconom statu basi appar greater literaci engag support websit compar smoker low statu 16 address issu pilot studi stopadvisor report analys show intervent similarli eff ectiv accept user rang socioeconom statu group 13 implic typic inequ onlin literaci successfulli mitig user test panel smoker low socioeconom statu develop stopadvisor 12 robust fi nding need assess adequ power trial studi examin eff ectiv stopadvisor smoker low high socioeconom statu method studi design particip onlin randomis control trial dec 6 2011 oct 11 2013 uk enrol particip ag 18 year older smoke dai make quit attempt stop smoke websit send email remind 7 month contact email telephon particip recruit notic english depart health websit call smokefre notic invit smoker part studi compar method onlin support includ link studi websit individu interest particip read studi inform elig criteria ask inform consent complet baselin questionnair studi design suffi cient power assess eff ectiv socioeconom statu subsampl separ event heterogen recruit continu requir sampl size achiev subsampl high low socioeconom statu studi approv ethic committe univers colleg london refer 2808 001 protocol17 approv trial steer committe randomis mask particip complet baselin questionnair randomli assign 1 1 stopadvisor inform control websit page static websit give standard advic 12 base wide manual smoke cessat practition 18 randomis individu level restrict block complet autom experiment involv unseen random number function embed websit code identifi treatment websit reveal particip click submit button end questionnair treatment alloc email address particip secur websit prevent contamin particip research obtain data laboratori analys mask treatment alloc formal assess extent mask success procedur variabl list tabl 1 assess baselin enrol individu automat classifi ed socioeconom statu subsampl establish respons baselin questionnair 1 low socioeconom statu compris individu work long term stopadvisor http www.lifeguideonline.org player plai stopadvisordemonstr articl www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 3 unemploi routin manual occup nation statist socio econom classifi cation ns sec code method 19 2 high socioeconom statu compris individu classifi ed occup group ns sec code method develop content stopadvisor websit detail 12 briefl develop inform 19 theoret proposit identifi ed prime theori motiv addict 20 33 evid base theori base behaviour chang techniqu 26 web design principl principl user test smoker low socioeconom statu theme websit base success uk nation health servic nh stop smoke servic aim simul expert stop smoke advisor sourc inform guid smoker process stop structur quit plan tailor support er 1 month quit websit present standard templat hybrid navig architectur combin choic content menu tunnel exposur kei messag quit date particip access interact menu includ screencast explain websit fi ve tunnel dialogu session tailor quit date intend smoke cessat medicin success obtain medicin reason quit session present behaviour chang techniqu focus help goal set action plan quit date emphasis import abrupt cessat acquir medicin make routin minimis urg smoke target quit date develop specifi cope strategi anticip diffi culti quit clear expect natur diffi culti case deliveri techniqu design make interact natur intervent interact calendar set quit date email remind quit date particip access interact menu 13 tunnel session tailor report abstin urg smoke low se 2142 high se 2471 total 4613 stopadvisor 1088 control 1054 stopadvisor 1233 control 1238 stopadvisor 2321 control 2292 femal 658 61 632 60 804 65 796 64 1462 63 1428 62 ag year 39 8 14 8 39 4 14 3 39 2 11 3 38 3 10 9 39 5 13 0 38 8 12 5 marri 504 46 490 47 643 52 641 52 1147 49 1131 49 children 704 65 690 66 678 55 656 53 1382 60 1346 59 white ethnic origin 1029 95 970 92 1152 93 1134 92 2181 94 2104 92 present full time educ 121 11 116 11 71 6 71 6 192 8 187 8 post 16 year educ qualifi cation 548 50 525 50 321 26 293 24 869 37 818 36 cigarett smoke dai 20 5 9 4 20 3 9 4 17 1 8 1 16 9 8 3 18 7 8 9 18 5 9 0 ag smoke initi year 16 2 5 3 16 2 4 3 17 2 4 9 17 1 4 2 16 7 5 1 16 7 4 2 previous support quit attempt 431 40 434 41 450 37 509 41 881 38 943 41 previous behaviour support quit attempt 616 57 637 60 721 59 798 65 1337 58 1435 63 made quit attempt previou year 394 36 353 34 457 37 441 36 851 37 794 35 confi denc stop score 1 7 4 8 1 7 4 7 1 7 4 6 1 6 4 7 1 6 4 7 1 7 4 7 1 6 stop 1 week 459 42 433 41 348 28 388 31 807 35 821 36 smoke 5 min wake 465 43 400 38 324 26 298 24 789 34 698 31 hsi score 0 6 3 5 1 4 3 4 1 4 2 8 1 5 2 7 1 5 3 1 1 5 3 0 1 5 ftnd score 0 10 5 6 2 3 5 5 2 3 4 6 2 5 4 5 2 4 5 1 2 4 5 0 2 4 time smoke urg score 0 5 3 1 1 1 3 0 1 1 2 7 1 0 2 7 1 0 2 9 1 1 2 9 1 0 strength smoke urg score 0 5 3 3 1 0 3 2 1 0 3 0 1 0 3 0 1 0 3 1 1 0 3 1 1 0 mpss mood subscal 0 4 2 6 0 9 2 5 0 9 2 3 0 8 2 3 0 8 2 4 0 9 2 4 0 9 time complet onlin recruit min 11 3 6 8 11 3 6 0 10 3 5 9 10 1 6 1 10 8 6 4 10 7 6 1 page view complet onlin recruit 19 2 2 5 19 1 1 9 19 7 2 5 19 5 1 5 19 5 2 5 19 3 1 7 data mean sd low se individu work long term unemploi routin manual occup nation statist socio econom classifi cation code method 19 data ag smoke initi miss particip high se 1 stopadvisor 1 control low se 3 stopadvisor 2 control mpss mood subscal mean respons fi ve separ state depress irrit restless hungri poor concentr se socioeconom statu hsi heavi smoke index 28 ftnd fagerström test nicotin depend 28 mpss mood physic symptom scale tabl 1 baselin characterist articl 4 www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 effi caci medicin anticip frequenc stress social event respons various aim boost motiv effi caci strengthen ident smoker provid specifi advic behaviour chang techniqu address potenti diffi culti plan futur minimis occurr post quit menu includ frequent ask question progress section audio video link stopadvisor facebook page 12 follow 7 month enrol outcom 6 month abstin websit advis quit date 1 month enrol follow data obtain onlin questionnair email particip respond remind email telephon contact detail telephon number daytim even mobil invit contact structur evid base method maximis respons rate 21 invit personalis cite monetari incent respond answer import inform decis make websit wide refer univers fund trial attempt direct contact preced pre contact inform particip contact particip report meet 6 month sustain abstin point preval criteria 7 month follow ask cotton dental roll provid saliva sampl post back laboratori analysi improv respons rate particip kit receiv 20 gift voucher irrespect return sampl 21 outcom primari outcom russel standard 6 month sustain abstin rs6 defi ned report smoke fi ve cigarett previou 6 month smoke previou week verifi ed saliva cotinin concentr 15 ng ml22 particip report nicotin replac treatment includ electron cigarett saliva cotinin concentr 14 ng ml saliva anabasin concentr 1 ng ml 23 defi nition classifi ed particip report figur trial profi le particip violat protocol altern email address view websit alloc high se stopadvisor 1 control 4 low se stopadvisor 2 control 1 protocol particip exclud analysi classifi ed origin treatment alloc particip met primari secondari outcom abstin criteria particip high se subsampl alloc control websit view stopadvisor se socioeconom statu 7785 particip read studi inform 2321 assign stopadvisor 1088 low se 314 lost follow 68 previous report smoke 246 assum return smoke 364 lost follow 51 previous report smoke 313 assum return smoke 724 contact 7 month follow 1088 includ primari analysi 1233 includ primari analysi 1054 includ primari analysi 1238 includ primari analysi 919 contact 7 month follow 710 contact 7 month follow 960 contact 7 month follow 344 lost follow 69 previous report smoke 275 assum return smoke 278 lost follow 70 previous report smoke 208 assum return smoke 1233 high se 1238 high se 2292 assign inform control websit 3172 exclud 1298 declin give consent 1419 complet baselin questionnair 455 inelig 361 uk 75 daili smoker 19 duplic sign up 1054 low se articl www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 5 smoke meet biochem verifi cation criterion continu smoker secondari outcom point preval abstin defi ned report smoke previou 7 dai follow 21 verifi ed saliva cotinin anabasin quantit indic websit interact login page view time spent websit assess report abstin month 2 4 enrol report quit attempt 7 month follow satisfact rate websit month 2 7 enrol due low respons rate outcom omit main analys unblind data appendix statist analysi sampl size establish α β 1 power set 5 project 3 intervent diff erenc 8 5 sampl whilst ensur 80 power detect diff erenc socioeconom statu subsampl event heterogen anticip eff ect size smaller observ face face behaviour support clinic meaning potenti cost eff ectiv 24 minimum total sampl size 4260 2130 subsampl requir log binomi regress analys dichotom primari secondari outcom calcul rel risk 95 ci model allow initi assess homogen eff ect subsampl inclus intervent socioeconom statu interact term adjust sensit analys chanc imbal baselin characterist intervent group interact term provid assess homogen eff ect repres ratio risk ratio rr intervent eff ect subsampl particip low socioeconom statu intervent eff ect high statu true intervent eff ect subsampl rr ident sampl error ratio 1 interact altern interact initi analysi show heterogen intervent eff ect socioeconom statu subsampl assess separ subsampl anticip possibl heterogen specifi ed threshold absenc homogen eff ect 0 10.25,26 protocol specifi ed logist regress odd ratio or measur eff ect rel risk improv understand provid protocol analys calcul or percentag point diff erenc 95 ci basi intent treat principl individu respond endpoint follow attempt retain analys classifi ed continu smoker rs6 criteria 22 post hoc sensit analys examin model exclus particip full time educ classifi cation subsampl low socioeconom statu assess eff ect result individu inappropri classifi ed reclassifi cation individu low socioeconom statu post 16 educ assess result extend altern operationalis socio econom statu report smoke cessat 7 month endpoint show eff ect biochem verifi cation compar websit usag test assumpt equal varianc analys spss version 22.0.0.0 studi regist intern standard randomis control trial number isrctn99820519 role fund sourc sponsor studi role studi design data collect data analysi data interpret write report jb ja rw full access data studi jb final respons decis submit public result fi gure show trial profi le 27 randomli assign 4613 particip stopadvisor group 2321 control group 2292 2142 particip low socioeconom statu 2471 particip high statu fi gure 1 1300 28 particip lost follow fi gure 1 258 20 individu report usual smoke time 6 month fi nal follow classifi ed smoker sustain abstin rs6 primari outcom mean eff ectiv follow rate primari outcom 77 1300 258 1042 4613 1042 3571 3571 4613 rate dissimilar intervent group intervent group diff erent socioeconom subsampl fi gure 1 remain 1042 23 particip assum continu smoke rs6 criteria baselin characterist particip assum smoke diff er intervent group intervent group diff erent socioeconom statu subsampl data shown recruit sampl daili cigarett smoke measur tobacco depend high28 particip stop 1 week regular smoker tabl 1 60 particip previous behaviour support quit attempt 40 previous type smoke cessat treatment tabl 1 baselin characterist similar onlin appendix articl 6 www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 intervent group diff erent socioeconom subsampl tabl 1 intervent group irrespect socioeconom statu show similar level engag trial recruit websit spend roughli 11 min view interact mean 19 page tabl 1 rate smoke cessat similar particip stopadvisor control group primari 237 10 220 10 particip rel risk rr 1 06 95 ci 0 89 1 27 0 49 secondari 358 15 332 15 particip 1 06 0 93 1 22 0 37 outcom analysi interact intervent socioeconom statu show clear evid ignor heterogen intervent eff ect primari rr 1 44 95 ci 0 99 2 09 0 0562 secondari 1 37 1 02 1 84 0 0360 cessat measur fi nding evid adjust baselin characterist adjust data shown analysi outcom separ socioeconom statu subsampl subsampl particip low socioeconom statu benefi stopadvisor evid primari secondari measur compar inform websit high socioeconom statu evid diff erenc shown tabl 2 adjust baselin characterist neglig eff ect comparison tabl 2 post hoc sensit analysi examin eff ect stopadvisor biochem verifi ed smoke cessat particip low socioeconom statu exclus full time educ classifi cation 237 benefi stopadvisor compar inform websit remain unadjust primari outcom 87 9 967 60 6 938 particip rr 1 41 95 ci 1 03 1 93 0 0346 secondari outcom 130 13 88 9 particip 1 43 1 11 1 85 0 0057 adjust primari outcom 1 48 1 07 2 04 0 0170 secondari outcom 1 52 1 18 1 97 0 0013 model sensit analysi examin model low socioeconom statu particip reclassifi ed post 16 educ smaller subsampl 1687 result consist primari analys stopadvisor versu inform signifi unadjust primari outcom 80 9 869 60 7 818 particip rr 1 26 95 ci 0 91 1 73 0 17 secondari outcom 111 13 86 11 particip 1 21 0 93 1 58 0 15 adjust primari outcom 1 27 0 92 1 75 0 15 secondari outcom 1 21 0 92 1 58 0 17 model fi nal post hoc sensit analysi examin eff ect stopadvisor report biochem verifi ed measur smoke cessat 7 month endpoint basi similar rate fail biochem verifi cation criteria intervent group analys show similar pattern result report tabl 2 appendix subsampl low socioeconom statu stopadvisor show benefi compar inform result signifi report 6 month abstin 141 13 1088 114 11 1054 particip unadjust rr 1 20 95 ci 0 95 1 51 0 13 adjust rr 1 23 0 97 1 56 0 08 report point preval 227 21 195 19 particip unadjust rr 1 13 0 95 1 34 0 17 adjust rr 1 18 0 99 1 40 0 07 statist test report measur particip low socioeconom statu subsampl fail reach signifi canc relat decreas power detect percentag diff erenc group increas absolut rate stopadvisor control rel risk 95 ci odd ratio 95 ci percentag point diff erenc 95 ci primari outcom abstin 6 month high se 147 1233 12 156 1238 13 0 95 0 77 1 17 0 94 0 74 1 19 0 68 3 27 1 91 0 61 adjust 0 97 0 78 1 19 0 95 0 75 1 22 0 75 low se 90 1088 8 64 1054 6 1 36 1 00 1 86 1 39 1 00 1 94 2 20 0 02 4 38 0 0499 adjust 1 43 1 05 1 96 1 46 1 04 2 05 0 0238 secondari outcom point preval 6 month high se 222 1233 18 232 1238 19 0 96 0 81 1 13 0 95 0 78 1 17 0 74 3 79 2 32 0 64 adjust 0 96 0 82 1 14 0 95 0 77 1 17 0 66 low se 136 1088 13 100 1054 10 1 32 1 03 1 68 1 36 1 04 1 79 3 01 0 37 5 66 0 0267 adjust 1 39 1 09 1 78 1 41 1 07 1 88 0 0081 data se socioeconom statu rate report smoke fail provid biochem verifi cation 5 207 4613 primari outcom 9 392 4613 secondari outcom rate similar intervent group se subsampl particip lost follow count treatment failur odd ratio rel risk specifi ed measur eff ect protocol rel risk calcul improv understand case adjust analys valu relat log binomi model calcul rel risk primari analys unadjust adjust result present sensit analysi adjust model includ characterist present tabl 1 tabl 2 eff ect stopadvisor biochem verifi ed smoke cessat articl www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 7 stopadvisor regularli control websit term log in page view time spent websit tabl 3 eff ect evid socioeconom statu subsampl slightli larger particip high socioeconom statu stopadvisor group 1216 particip 52 low socioeconom statu 535 49 1088 particip high socioeconom statu 681 55 1233 particip chose interact calendar set quit date 741 32 low socioeconom statu 327 30 high socioeconom statu 414 34 opt report stop smoke drug receiv ongo advic tailor drug type socioeconom statu subsampl particip access pre quit interact menu item select fi rst visit section entitl secret success aim boost motiv effi caci strengthen smoker ident er advic stop smoke drug low socioeconom statu 302 28 1069 particip high socioeconom statu 436 36 1223 particip item remain popular particip revisit menu quit date low socioeconom statu 105 33 319 particip high socioeconom statu 133 37 359 particip fi rst post quit date dialogu session particip report crave receiv regulatori control tip request addit tip low socioeconom statu 108 53 204 particip high socioeconom statu 181 65 280 particip particip visit post quit interact menu item select fi rst visit smoker low socioeconom statu 260 progress section track dai quit monei save health benefi ts accru 68 26 audio relax techniqu 54 21 section featur galleri motiv pictur music improv mood distract 52 20 smoker high socioeconom statu 378 select section monitor progress 140 37 cigarett addict 94 25 frequent ask question 91 24 visit menu progress section remain select subsampl low socioeconom statu 142 67 215 high socioeconom statu 219 68 320 assess outcom omit main analys basi low respons rate rang 972 21 4613 2211 48 4613 particip consist analys primari secondari outcom appendix report abstin 2 month 4 month enrol numer signifi cantli greater particip alloc stopadvisor alloc control websit subsampl low socioeconom statu rate ident high socioeconom statu appendix report quit attempt similar group socioeconom statu subsampl satisfact rate consist higher stopadvisor control websit appendix discuss fi nding show rate cessat similar particip alloc interact stopadvisor websit advic control group intervent eff ect depend socioeconom statu stopadvisor eff ectiv aid smoke cessat smoker low high socioeconom statu stopadvisor result greater usag static advic websit health inequ global research prioriti strength studi knowledg fi rst focu eff ect internet support smoke diff erent socioeconom statu group panel fi nding stopadvisor help smoker low high socioeconom statu group suggest concern onlin support eff ectiv smoker high socioeconom group unwarr 16 find previou studi shown smoker low socioeconom statu engag internet base support 16 arisen inequ onlin literaci user test stopadvisor exclus smoker low socioeconom statu success produc eff ectiv websit group 12 outcom expens fail meet smoker high socioeconom statu futur research explor possibl view tailor content stopadvisor socioeconom statu meantim stopadvisor stopadvisor 2321 control 2292 test mean diff erenc 95 ci log in high se 5 0 6 2 1 4 0 7 1267 20 1 3 6 3 2 3 9 0 0001 low se 4 1 5 7 1 3 0 6 1113 16 4 2 9 2 5 3 2 0 0001 total time min high se 26 9 38 9 1 3 3 2 1248 23 1 25 6 23 5 27 8 0 0001 low se 22 1 34 4 1 1 2 5 1099 20 1 21 1 19 0 23 1 0 0001 total page view high se 93 1 119 8 6 1 5 2 1237 25 5 87 0 80 3 93 7 0 0001 low se 75 5 105 0 5 3 4 1 1090 22 0 70 2 64 0 76 5 0 0001 data mean sd analys tabl unadjust se socioeconom statu data parenthes degre freedom modal number log in 1 treatment se subsampl appendix log data present categor time websit underestim time page unknown lifeguid intervent interact browser lifeguid server page load commun page load server time page calcul take exact time page load lifeguid server compar exact time previou page session load user close tab type diff erent websit address bar interact browser server identifi time fi nal action occur tabl 3 usag stopadvisor versu control websit articl 8 www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 implement easili made freeli smoker high socioeconom statu benefi evid show websit lead group success quit eff ect cessat smoker low socioeconom statu modest rr 1 4 fi nding clinic signifi huge health gain stop smoke eff ect 1 rate 6 month sustain abstin result 3 addit year life 100 40 year smoker treat 24 addition eff ect size dissimilar mode deliveri behaviour support meta analys cessat 6 month compar minim control telephon counsel rr 1 3 44 studi base 1557 success 12 388 1201 12 423 particip individu counsel rr 1 4 22 studi base 564 4665 433 4922 particip mobil phone base intervent rr 1 7 fi ve studi base 444 4730 240 4370 particip 5 internet base intervent cost eff ectiv intervent potenti reach small ongo cost absolut rate cessat high studi 8 intervent group 6 control group smoker low socioeconom statu 12 averag group high socioeconom statu comparison rate 6 treatment group trial internet support report biochem verifi ed measur sustain abstin 30 frequent cite assess text messag support cessat report rate 11 intervent group 5 control group 19 high rate particip alloc control websit present studi draw attent pragmat natur trial test eff ect stopadvisor real world treatment includ support er site particip recruit trial increas rate smoker high socioeconom statu compar low statu show establish gradient success rate group 8 quit rate reduc particip alloc stopadvisor smoker low socioeconom statu compar high statu salient point gradient reduc rel alloc control websit smoker low socioeconom statu intervent engag larg proport roughli 60 smoker previous behaviour support fi nding mitig concern internet support engag smoker treatment establish evid base face face behaviour support law attrit electron health care specifi es substanti proport user drop complet treatment 31 mean usag stopadvisor fi ve log in compar favour relev trial 32 mask variabl user substanti proport particip stopadvisor futur research examin prompt remind engag increas proport user maintain interact treatment websit studi limit recruit parti cipant directli internet studi shown intervent eff ectiv kind smoker low socioeconom statu access internet futur intervent reduc health inequ result panel research context systemat review consult recent cochran review meta analysi eff ectiv interact internet base smoke cessat intervent 10,29 meta analysi start project includ studi obtain search computeris databas decemb 2008 pubm 1990 2008 12 psycinfo 1990 2008 12 cinhal 1990 2008 econlit 1990 2008 11 isi web scienc sci ssci ahci 1990 2008 central cochran registri control trial 1990 2008 29 search medlin relev mesh term onlin system internet smoke cessat random control trial databas search free text term internet onlin web smoke cessat rct randomi ed control trial random trial includ 11 relev randomis control trial found signifi treatment eff ect rr 1 5 signifi heterogen eff ect size cochran review april 2013 search cochran tobacco addict group regist record includ term internet www web net onlin specialis regist includ result central medlin embas psycinfo review identifi ed 28 relev studi clinic statist heterogen limit abil pool studi 10 huge potenti intervent high impact low cost conclus exist research produc mix result limit scarciti biochem verifi ed long term outcom 10 present trial address limit assess 6 month sustain biochem verifi ed abstin internet base smoke cessat intervent eff ectiv smoker low socioeconom statu high statu appar lower onlin literaci engag support websit 16 present trial knowledg fi rst evalu websit design attent smoker low socioeconom statu focu eff ect internet support smoke diff erent socioeconom statu group interpret fi nding show interact internet base smoke cessat intervent stopadvisor eff ectiv inform websit smoker low high socioeconom statu user test websit exclus smoker low socioeconom statu success produc eff ectiv websit group 12 futur research explor outcom expens meet smoker high socioeconom statu meantim stopadvisor implement easili made freeli smoker high socioeconom statu benefi evid websit lead success articl www.thelancet.com respiratori publish onlin septemb 25 2014 http dx.doi.org 10.1016 s2213 2600 14 70195 9 smoke depend uptak issu straightforward hand smoker low socioeconom statu tend access internet high statu 33 hand express interest onlin support 9 diff usion internet access rapid increas 34 research high incom countri fi nding necessarili generalis countri low socioeconom statu group onlin experi skill uk cost eff ectiv popul approach cessat includ internet base support appeal individu low incom middl incom countri assess need context approach recommend confi dentli unabl comprehens assess particip treatment trial eff ectiv treatment stop smoke drug kei moder eff ectiv stopadvisor complex intervent develop basi evid theori user web design input primari intent websit maxim eff ectiv fi nding diff erenc log in time webpag page view control intervent websit similar socioeconom statu subsampl suggest type usag mediat eff ectiv stopadvisor smoker low socioeconom statu futur research identifi causal compon possibl seri fraction factori design stopadvisor refi ned optimis 35,36 trial detail transpar report develop content websit aid process 12 meantim trial pragmat shown stopadvisor eff ectiv type websit typic smoker low socioeconom statu search onlin support uk static inform websit fourth socio econom statu complex concept diffi cult assess interview present ns sec measur benefi tted valid occupation base assess socioeconom statu limit classifi cation worker low socio econom statu group dichotomis version limit account greater proport particip low socioeconom statu full time educ high socioeconom statu ns sec measur accur report eff ect socioeconom statu respect compar smoker high socioeconom statu low socioeconom statu post 16 qualifi cation marri heavier depend smoker start smoke younger ag consist limit benefi stopadvisor inform control websit slightli greater post hoc sensit analysi exclud smoker full time educ subsampl low socio econom statu stopadvisor implement easili made freeli health organis improv success rate smoker low socioeconom statu seek onlin support clinician continu recommend smoker face face support combin stop smoke medicin recommend onlin support contributor rw sm ly conceiv origin idea develop websit trial obtain fund jb awag coordin develop websit jb sm ja rw wrote studi protocol jb manag dai dai run trial includ particip follow ja jb rw wrote undertook data analys articl written jb input coauthor jb guarantor articl author read approv fi nal version declar interest author report receiv grant nation prevent research initi studi jb report grant pfi zer submit work ls report person fee pharmaceut compani make smoke cessat product submit work rw report receiv grant person fee compani develop manufactur smoke cessat drug submit work patent issu nicotin cannon nicotin deliveri devic acknowledg studi fund grant nation prevent research initi refer g0802035 fund partner relev award alphabet order alzheim research trust alzheim societi biotechnolog biolog scienc research council british heart foundat cancer research uk chief scientist offi ce scottish govern health director depart health diabet uk econom social research council engin physic scienc research council health social care research develop offi ce northern ireland medic research council stroke associ welsh assembl govern entir stopadvisor team author includ expert advisor elizabeth murrai programm judith joseph graphic design write consult clair dowi follow research assist becki richard aleksandra herbec harveen kaur steer committe includ peter hajek chair queen mari univers london paul aveyard univers oxford emma croghan depart health lindsai stead univers oxford cochran collabor matthew walmslei public health england repres nice mrc commun team depart health share materi provid crucial support recruit ab lab collabor agre analys saliva sampl cotinin anabasin cost anonym peer review draft suggest propos post hoc analys
ac ce pt ed cr ipt author 2015 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com 1 exploratori analysi smoke physic activ outcom pilot randomis control trial exercis assist reduct stop ear smoke intervent disadvantag group thompson phd1 greav c.j phd2 ayr md1 aveyard phd3 warren f.c phd2 byng phd1 taylor r. phd2 campbel j.l md 2 ussher phd4 green phd2 michi phd5 west phd6 taylor a.h phd1 author tom.thompson plymouth.ac.uk 1 plymouth univers peninsula school medicin dentistri plymouth uk 2 univers exet medic school exet uk 3 nuffield depart primari care health scienc univers oxford uk 4 popul health research institut st georg univers london cranmer terrac london uk 5 research depart clinic educ health psycholog univers colleg london 1 19 torrington place london uk 6 health behaviour research centr depart epidemiolog public health ucl gower street london uk hta 07 78 02 isrctn 13837944 ukcrn studi id 8937 lrec 10 h0106 59 nicotin tobacco research advanc access publish 11 2015 guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 2 abstract introduct econom disadvantag smoker intend stop benefit intervent aim reduc smoke studi assess effect behaviour intervent promot increas physic activ versu usual care pilot randomis control trial method disadvantag smoker want reduc quit randomis counsel intervent 12 week support smoke reduct increas physic activ 49 usual care 50 data 16 week collect smoke physic activ outcom primari analys consist intent treat analysi base complet case data secondari analys explor impact handl miss data result compar control intervent smoker initi quit attempt 36 10 odd ratio 5.05 95 ci 1.10 23.15 greater proport achiev 50 reduct cigarett smoke 63 32 4.21 1.32 13.39 post quit abstin measur exhal carbon monoxid 4 week follow show promis differ group 23 6 4.91 0.80 30.24 benefit intervent physic activ found secondari analys suggest standard miss data assumpt miss equival smoke conserv result reduc intervent effect conclus smoke reduct intervent econom disadvantag smoker involv person support increas physic activ appear effect guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 3 usual care achiev reduct promot cessat effect influenc increas physic activ guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 4 introduct smoke biggest contribut factor health inequ 1 smoker disadvantag background i. low socioeconom statu attempt quit rate success quit lower 2 lead increas dispar smoke preval upper lower social grade unit kingdom 3 similar trend observ unit state 4 suggest intervent specif design group 5 good qualiti evid effect smoke cessat intervent disadvantag group limit 6,7 research need increas intervent reach smoke cessat success 8 rang intervent option need increas reach reduc smoke preval locat servic commun set develop role outreach worker e.g health trainer 9 develop multidimension complex behaviour chang intervent specif design disadvantag group 10 smoke reduct viabl altern tradit abrupt approach smoke cessat 11 english smoke toolkit studi 57 percent current smoker report process cut 3 varieti approach 12 smoker intend quit month cut nicotin replac therapi nrt make quit attempt abstin follow 13 cut smoke reduct increas motiv quit highli predict quit attempt reduc smoke depend relat success quit 14 nrt popular aid smoke reduct 31 smoker believ sustain nrt guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 5 harm health 15 disadvantag group sceptic effect nrt meet quit 16 stop smoke advisor manag express concern combin nrt smoke neg health consequ 17 research support smoke reduct nrt quit don’t quit smoke reduct pharmacotherapi behaviour support appear effect abruptli quit 11 review exercis intervent versu usual care aid long term smoke cessat 18 identifi 16 randomis control trial smoker wish quit methodolog limit adequ power found signific increas abstin end treatment report increas abstin rate 12 month follow variat studi length type e.g structur group base exercis physic activ counsel content control condit complic comparison studi review time introduct physic activ vari studi studi promot involv physic activ week quit attempt studi focus prescript exercis session supervis exercis profession promot daili lifestyl activ manag cigarett crave withdraw symptom epidemiolog data suggest physic activ smoker attempt quit 19,20 rais possibl physic activ facilit smoke reduct cessat induct quit immedi wai increas physic activ put facilit smoke reduct guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 6 cessat induct 21 includ acut reduc crave withdraw symptom 22 shift smoke ident 21 reduc weight gain 23 mechan put support behaviour counsel approach promot innov approach usual smoke cessat intervent trial intent treat itt analys assumpt particip lost follow smoke 24 essenti reflect assumpt baselin valu carri forward assumpt problemat correct potenti bia result statist test favour effect treatment attrit rate higher control group evid suggest lost follow necessarili smoke 25 29 approach handl miss data smoke statu follow suggest e.g multipl imput miss data provid reliabl estim treatment effect 30 32 data articl pragmat pilot randomis control trial rct assess feasibl accept counsel base intervent design support smoke reduct increas lifestyl structur physic activ disadvantag group uniqu current studi focu reduct outcom set abrupt quit date examin role reduct induc quit attempt wish quit immedi smoke reduct intervent work set quit date 11,13 reflect guidelin tobacco harm reduct 33 aim explor effect intervent smoke physic activ outcom 16 week compar control base complet case data guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 7 disadvantag smoker defin social class c2 skill manual worker semi skill unskil manual worker casual lowest grade worker pension depend welfar state incom suffer mental health problem singl parent ii conduct secondari analys explor implic approach handl miss data effect outcom method detail inform trial method intervent develop found elsewhere34 particip ethic approv studi grant nh nation research ethic servic committe south west uk recruit place neighbourhood devonport stonehous plymouth 3 depriv area uk 35 sampl size calcul scenario analysi recruit method baselin characterist sampl report taylor al 2014 summari 99 adult moder heavi smoker want reduc smoke nrt report plan quit month recruit mail invit gener practition nh stop smoke servic sss follow telephon call commun approach inclus exclus criteria guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 8 particip elig enter studi 18 year smoke 10 cigarett dai year report quit month reduc smoke engag moder intens physic activ walk stop 15 minut regist gp nicotin replac therapi nrt reduc smoke studi focu initi reduc smoke quit express desir quit refer directli sss enter studi wish nrt exclud avoid confound effect physic activ smoke behaviour exclud sever mental health problem substanc misus due potenti difficulti engag intervent larg uncertainti complex deliveri potenti put safeti research risk exploratori natur studi particip requir convers english criteria assess screen research approv interest particip gp confirm individu elig enter studi base provid inclus exclus criteria pose threat violenc research opinion gp potenti particip enter studi approv obtain procedur provid inform consent baselin inform particip randomis web base randomis programm provid accredit peninsula clinic trial unit receiv usual care usual care exercis assist reduct stop smoke ear intervent usual care involv advic inform local guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 9 sss specialist support quit support smoke reduct part standard care exercis assist reduct stop smoke ear intervent consist 8 weekli client centr individu motiv support session 4 session quit attempt telephon person assist make direct smoke physic activ behaviour deliv team health trainer 9 usual care intervent dose driven particip basi support reduc arm studi wish make quit attempt studi period encourag seek support specialist stop smoke servic full detail intervent uptak sss found trial main report 34 primari end point 16 week post baselin major outcom data 4 week post quit expir air carbon monoxid confirm abstin collect time particip free make quit attempt time point studi measur studi pilot rct formal assign outcom primari secondari baselin 4 8 16 week data collect person week 4 collect telephon number cigarett smoke dai calcul percent reduct 16 week smoke depend fagerström test cigarett depend ftcd 36,37 expir air bedfont smokerlys uk calcul expir air reduct collect week 4 report physic activ 7 dai recal 38 object assess physic activ acceleromet actigraph gt3x pensacola usa particip ask wear devic 7 dai baselin week 9 week 16 collect week4 physic activ data collect report guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 10 calcul total minut moder vigor physic activ mvpa week averag minut mvpa dai number complet 30 minut mvpa dai number complet 150 minut mvpa week accelerometri data calcul averag minut mvpa dai number complet 30 minut mvpa dai quit attempt made 4 week post quit expir air record trial expir air read 10 part million assum repres abstin report smoke past 4 week 39 data analys primari analys outcom compar group base principl intent treat complet case data multivari logist linear regress binari continu outcom secondari intent treat analys complet case data imput data binari smoke outcom analys multivari logist regress base assumpt particip lost follow smoke baselin valu multipl imput chain equat continu smoke outcom analys linear regress base baselin valu carri forward bcf observ carri forward locf multipl imput chain equat mice mice analys imput model built group outcom binari smoke outcom continuo smoke outcom binari pa outcom continu smoke outcom com.ibm.drl.hbcp.predictor select relat missing research team thought priori reason link missing includ arm baselin number cigarett smoke baselin confid quit high low baselin ftcd score baselin expir air guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 11 gender ag 150 minut mvpa week recruit method letter phonecal ht alloc mental health problem addit baselin measur outcom variabl applic e.g baselin mvpa includ imput week 16 mvpa logit command predict mean match normal continu variabl imput forti imput run model reflect 40 missing longest follow 40 binari continu physic activ outcom analys linear regress base baselin valu carri forward observ carri forward mice analys adjust baselin ag gender ftcd score variabl reliabl smoke abstin 14 health trainer alloc minimis factor randomis imput model built group outcom binari smoke outcom continu smoke outcom binari pa outcom continu pa outcom analys undertaken stata 12 result 16 week 62 61 particip provid outcom data loss follow similar treatment group figur 1 intervent particip attend averag 4.2 sd 2.7 8 support session detail inform factor relat attrit report thompson al review smoke outcom particip intervent arm 35.5 control arm 9.7 made quit attempt point studi odd ratio 5.05 95 confid interv ci guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 12 1.10 23.15 greater number particip intervent arm 63.3 compar control arm 32.3 achiev 50 reduct smoke 16 week 4.21 ci 1.32 13.39 secondari sensit analys show increas odd make quit attempt studi remain assumpt assum smoke 4.84 ci 1.1 20.31 mice 5.51 ci 1.17 25.98 increas odd achiev reduct 50 smoke intervent arm remain mice 3.48 ci 1.01 12.03 base assumpt smoke odd achiev 25 reduct expir air show differ mice 4.11 95 ci 1.43 11.87 intervent arm tabl 1 primari analys show decreas adjust mean differ 95 ci number report cigarett smoke dai 5.14 9.09 1.22 ftcd score 1.56 2.68 0.43 greater percentag reduct number cigarett smoke 39.03 61.92 16.15 intervent arm 16 week secondari sensit analys support differ assumpt bcf locf mice tabl 2 physic activ outcom differ odd achiev physic activ outcom shown primari analys arm secondari analys show increas odd achiev 30 minut mvpa dai 2.54 ci 1.05 6.14 locf bcf mice increas odd achiev 150 minut mvpa week intervent arm shown locf 3.61 ci 1.48 8.81 bcf 3.21 ci 1.33 7.77 tabl 3 guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 13 differ continu physic activ outcom assess acceleromet report primari secondari analys tabl 4 discuss articl present data trial smoke reduct intervent focu physic activ disadvantag smoker initi quit studi kind give insight cessat induct rate enter trial quit make quit attempt illustr potenti variat find result differ intent treat assumpt whilst find encourag studi exploratori priori sampl size estim caution need interpret result due small sampl size potenti lack statist power precis individu intervent arm initi quit attemot compar usual care suggest intervent design support reduct potenti lead increas cessat attempt initi desir quit trend greater success intervent compar usual care achiev 4 week post quit confirm quit promis posit effect intervent report smoke depend amount cigarett smoke dai intervent impact varieti smoke outcom disadvantag smoker secondari analys show assumpt lost follow smoke potenti conserv compar primari complet case guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 14 analysi mice conserv natur assumpt assumpt loss follow meant particip smoke contradict find primari analys i. achiev reduct greater 50 week 16 appear assumpt potenti estim benefici effect intervent 30 32 approach wide advoc research deal miss data smoke trial justifi intervent fail demonstr posit effect physic activ behaviour 16 week secondari analys show increas odd intervent complet 30 minut mvpa dai 150 minut mvpa week compar usual care 16 week studi underpow detect pa complet case data support increas pa imput complet case analys conserv compar approach imput miss physic activ data mice show 11 peopl intervent complet 30 minut mvpa dai bcf 17 locf 19 compar 5 complet case similar differ shown number complet 150 minut mvpa week suggest complet case analysi physic activ data lead underestim intervent effect present case intervent primari focu smoke reduct meant increas physic activ address regard longer term mainten support need sustain increas pa level disadvantag group undertak leisur time physic activ undertak activ work activ transport part due low car ownership 41,42 relationship cloud understand guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 15 effect intervent gener increas physic activ 43 minimis focu structur exercis lifestyl physic activ particip recruit materi recruit activ smoker result potenti ceil effect increas physic activ intervent investig physic activ level disadvantag smoker need understand influenc exist physic activ level chang behaviour group pilot aspect trial current work mean feasibl method emploi analys data show promis applic larger trial confid result demonstr due low sampl size prematur draw conclus work view influenc polici practic trial pragmat intervent close happen routin intervent deliveri uncertainti trial method design pilot trial resolv uncertainti opportun conduct exploratori analysi main outcom studi present encourag find pilot pragmat randomis control trial add limit literatur role physic activ smoke reduct abrupt quit fulli power trial test effect counsel base intervent focu physic activ smoke reduct disadvantag group need trial examin mediat role physic activ smoke reduct qualit explor physic activ regul smoke guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 16 fund work support nation institut health research nihr health technolog assess research programm grant number 07 78 02 view express author necessarili nation health servic nation institut health research depart health compet interest pa consult research manufactur smoke cessat product rw undertaken research consult compani develop manufactur smoke cessat medic director nation centr smoke cessat train truste stop smoke chariti quit share patent nicotin deliveri devic author declar compet interest acknowledg team acknowledg research work health trainer project juli lloyd maggi kelli mel fairbairn insight tireless effort trial naomi southern dilig administr support russ moodi team stop smoke servic plymouth support staff gp practic involv broader commun contact support trial richard byng contribut research fund nation institut health research nihr collabor leadership appli health research care south west peninsula royal devon exet nh foundat trust view express author necessarili nh nihr depart health guest ay 21 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org ac ce pt ed cr ipt 17
research 1the bmj bmj 2015;350 h2415 doi 10.1136 bmj.h2145 open access 1popul health research institut st georg univers london london sw17 or uk 2divis epidemiolog public health uk centr tobacco alcohol studi univers nottingham nottingham uk 3nuffield depart primari care health scienc univers oxford oxford uk 4depart obstetr gynaecolog st georg univers london st georg nh trust london uk 5health behaviour research centr depart epidemiolog public health univers colleg london london uk 6school kinesiolog univers minnesota minneapoli mn usa 7depart famili prevent medicin univers california san diego ca usa 8plymouth univers peninsula school medicin dentistri plymouth devon uk 9primari care clinic scienc univers birmingham birmingham uk 10divis primari care uk centr tobacco alcohol studi univers nottingham nottingham uk correspond ussher mussher sgul.ac.uk addit materi publish onlin view visit journal onlin http dx doi org 10.1136 bmj.h2145 cite bmj 2015;350 h2145 doi 10.1136 bmj.h2145 accept 23 march 2015 physic activ smoke cessat pregnanc randomis control trial michael ussher 1 sarah lewi 2 paul aveyard 3 isaac manyonda 4 robert west 5 beth lewi 6 bess marcu 7 muhammad riaz 1 adrian taylor 8 amanda dalei 9 tim coleman10 abstract object determin effect physic activ intervent smoke cessat pregnanc design parallel group randomis control multicentr trial set 13 hospit england april 2009 januari 2014 particip 789 pregnant smoker ag 16 50 year 10 24 week gestat smoke cigarett daili prepar quit smoke week enrol randomis 1 1 785 includ intent treat analys 392 assign physic activ group intervent intervent began week target quit date particip randomis weekli session behaviour support smoke cessat control support 14 session combin supervis treadmil exercis physic activ consult main outcom measur primari outcom continu smoke abstin target quit date end pregnanc valid exhal carbon monoxid salivari cotinin level assess adher level moder vigor intens physic activ report 11.5 90 random subsampl particip physic activ object measur acceleromet result signific differ found rate smoke abstin end pregnanc physic activ control group 8 6 odd ratio 1.21 95 confid interv 0.70 2.10 physic activ group compar control group 40 95 confid interv 13 73 34 6 69 46 12 91 greater increas report minut carri physic activ week baselin week week week post quit dai acceleromet data signific differ physic activ level group particip attend median treatment session intervent group control group advers event birth outcom similar group significantli caesarean birth control group physic activ group 29 21 0.023 conclus ad physic activ intervent behaviour smoke cessat support pregnant women increas cessat rate end pregnanc pregnanc physic activ recommend smoke cessat remain gener health benefit trial registr current control trial isrctn48600346 introduct matern smoke pregnanc main prevent morbid death women infant smoke advers pregnanc birth outcom includ miscarriag birth prematur low birth weight congenit abnormali ti neonat sudden infant death 1 3 high incom countri 10 women smoke pregnanc 4 6 preval low middl incom countri rise 7 smoke cessat pregnanc improv birth outcom 8 behaviour support help pregnant women stop smoke 8 nicotin replac therapi pregnanc effect pharmaceut aid contraind 9 major pregnant women receiv behaviour support smoke cessat stop8 interven tion add effect behaviour port need physic activ programm add effec tive behaviour support pregnant smok er convinc evid physic activ reduc intens urg smoke main relaps smoke 10 pregnant smoker trial evid physic activ aid cessat mix trial vigor intens physic activ show long term benefit 11 trial small design topic evid physic activ programm aid smoke cessat mix pregnanc compel rational drug contraind ineffect exercis shown reduc cigarett crave pregnant smoker randomis control trial physic activ smoke cessat pregnanc lack studi add studi suggest physic activ intervent benefit help women quit smoke pregnanc physic activ remain gener health benefit pregnanc http http crossmark.crossref.org dialog doi 10.1136 bmj.h2145 domain pdf date_stamp 2015 05 14 dganguli highlight dganguli highlight research 2 doi 10.1136 bmj.h2145 bmj 2015;350 h2145 bmj featur made evid difficult interpret 12 adequ power trial need moder intens exercis brisk walk accept vigor exercis peopl 13 moder intens physic activ iti recommend pregnanc pregnant smoker recept interven tion 14 conduct parallel group randomis control trial assess effect physi cal activ intervent smoke cessat pregnanc method studi popul april 2009 novemb 2012 recruit pregnant women telephon antenat book visit conduct hospit commu niti clinic 13 hospit antenat clinic london surrei kent cheshir unit kingdom pregnant women book deliveri ari care set small fraction women deliv home primari care midwif led unit pregnant smoker definit high risk expect care hospit inclus criteria want stop smoke want stop smoke agre set date quit ting smoke week baselin visit ag 16 50 year 10 24 week gestat cigarett consumpt daili pregnanc smoke cigarett daili walk continu 15 minut exclu sion criteria medic condit potenti exac erbat exercis advis exercis doctor inabl provid inform consent plete questionnair english drug alcohol depen denc want nicotin replac therapi recruit women irrespect current level physic activ motiv increas activ studi protocol intervent wandsworth research ethic committe approv publish protocol15 www.trialsjourn content 13 1 186 particip provid writ ten inform consent offer particip weekli session 20 minut individu behaviour cessat support start week quit date end week interven tion aim support smoke cessat reinforc commit abstin solv women prob lem maintain abstin incorpor 43 behaviour chang techniqu defin publish taxonomy16 protocol 15 provis reward conting successfulli stop smoke emphasi impor tanc avoid laps manag withdraw symp tom urg smoke enhanc confid prevent relaps enrol randomis particip behaviour cessat support behaviour cessat support physic activ intervent combin supervis exercis physic activ consult fourteen session supervis exercis offer week week week weekli week session particip walk moder intens tread mill 30 minut immedi treadmil session women receiv behaviour port treadmil session occas total consult support aim identifi opportun incorpor physic activ women live motiv physic activ reduc urg smoke behaviour strategi improv adher enc plan 20 minut consult incorpor 19 behaviour chang techniqu studi protocol 15 women advis activ 10 minut time progress 30 minut activ dai week emphasi brisk walk pedomet digi walker sw 200 yamax not ham uk suppli research set indi vidualis step count target provid dvd antenat exercis occas women receiv behaviour support smoke session session control group se sion attend particip paid 7 travel randomis independ statistician gener randomis list stata random permut block ran dom size stratifi recruit centr 1 1 ratio enrol sequenc conceal research confirm consent elig onlin databas alloc reveal feasibl mask particip research group alloc data collect collect person smoke characterist women baselin includ score fager ström test cigarett depend 17 report moder vigor intens physic activ pre viou week bout 10 minut dai physic activ recal interview 18 edinburgh postnat depress scale score 19 confid take physic activity20 stop smoke 21 alcohol consumpt 22 weekli cigarett withdraw symp tom 23 weekli smoke urg combin rate strength frequenc 24 antenat book ing visit midwif measur women cloth weight shoe digit scale contact women ask advers event research midwiv examin women medic record monthli advers event record check research midwiv matern infant outcom data deliveri outcom primari outcom report continu abstin smoke quit date end pregnanc permit temporari smoke http www.trialsjournal.com content 13 1 186 http www.trialsjournal.com content 13 1 186 dganguli highlight dganguli highlight dganguli highlight research 3the bmj bmj 2015;350 h2145 doi 10.1136 bmj.h2145 laps cigarett total occa sion 25 abstin valid concentra tion exhal carbon monoxid 8 ppm salivari cotinin 10 ng ml measur requir valid assess level carbon monoxid weekli week quit dai end preg nanci cotinin measur week post quit date end pregnanc secondari outcom includ valid abstin week quit date report absti nenc telephon final follow month birth complet januari 2014 week quit date assess weekli urg smoke weekli withdraw symptom confid take physic activ stop smok ing assess edinburgh postnat depress scale score end pregnanc month birth research weigh women end pregnanc method midwif antenat book visit assess adher assess report physi cal activ week 1 4 6 quit date end pregnanc 11.5 random subsampl particip target 10 physic activ object measur acceleromet model gt1m gt3x actigraph pensacola fl 90 women ask wear acceleromet pilot work show women toler devic worn waist start studi valid wrist worn acceleromet commerci practica ble altern report physic activ primari analysi physic activ accel eromet worn hip fourth week quit date consecut dai record dry land activ wake hour minut epoch nation health servic behaviour support smoke cessat offer studi nicotin replac ther com.ibm.drl.hbcp.api report particip receiv 10 shop voucher complet end pregnanc month postnat follow up 20 maximum statist analysi anticip cessat rate 15 control group basi 9 pregnant women smoker stop smoke usual care antenat visit behaviour support 6 7 quit 26 base pilot work 14 pro ject cessat rate 23 treatment group calcul 866 particip provid 83 power 5 signific level detect absolut differ 8 percentag point occurr primari outcom group 15 control group versu 23 physic activ group odd ratio 1.69 rel risk 1.53 prime aim assist smok ing cessat pregnanc improv outcom pregnanc latest version cochran review psychosoci intervent support women stop smoke pregnanc show evid intervent effect help women stop smoke improv perinat outcom 27 main subgroup review compris counsel versu usual care show rel risk 1.44 achiev abstin late pregnanc outcom individu trial smoke cessat pregnanc detect differ perinat outcom intervent statu evid shown meta analysi trial review pool intervent pro duce rel risk intervent ver su control low birth weight 0.82 95 confid interv 0.71 0.94 preterm birth 0.82 0.70 0.96 increas mean birth weight 41 18 63 rel increas rate cessat similar size aim detect led meaning improv perinat outcom expect trial analysi intent treat basi assum particip miss outcom data smoke 25 logist regress compar proport women report continu smoke abstin end pregnanc studi group adjust recruit centr assess statist signific likelihood ratio test estim effect odd ratio 95 confid interv secondari analysi adjust recruit centr potenti import prognost baselin factor cigarett depend ag depress matern educ level partner smoke statu addit test interact baselin physic activ 150 min week moder vigor physic activ versu 150 min week moder vigor physic activ rate smoke abstin end pregnanc assess physic activ level affect smoke ce sation rate exclus physic activ group assess report 150 min week moder vigor physic activ baselin report 150 min week moder vigor physic activ week week quit dai smoke abstin time primari outcom assess influenc assumpt miss data equal smoke effect size test scenario associ ation smoke miss data hedek method 28 rate withdraw symp tom urg smoke confid quit smoke confid take physic activ calcu late chang score baselin week post quit test compar score group compar nicotin replac ment therapi behaviour support group χ2 test log transform log base 10 report weekli minut moder vigor physic activ bout 10 minut normal anal ysed differ report physic activ dganguli highlight dganguli highlight research 4 doi 10.1136 bmj.h2145 bmj 2015;350 h2145 bmj group time mix effect linear regress model account person correl time model estim differ treatment group time point adjust visit time baselin minut moder vigor physic activ interact visit time baselin minut moder vigor ou physic activ recruit centr ana lyse acceleromet data kinesoft softwar version 3.3.76 loughborough uk file 10 hour valid wear time dai retain analys standard cut point determin moder vigor physic activ 29 studi group compar mann whitnei test acceleromet report moder vigor physic activ restrict analysi bout 10 minut comparison report data includ moder vigor physic activ iti irrespect durat week acceleromet worn wilcoxon test compar report moder vigor physic activ acceleromet data compar depress score group mix effect linear regress adjust visit time baselin edinburgh postnat depress scale score interact visit time baselin edinburgh postnat depress scale score recruit centr model correla tion repeat measur end pregnanc month matern weight end pregnanc compar group lin ear regress adjust earli pregnanc weight recruit centr end pregnanc weight record birth conduct separ regress gestat weight chang postnat weight retent birth logist regress linear regress adjust recruit centr compar fetal matern birth outcom group fetal primari analysi singleton birth conduct sensit analysi includ multi ple birth cluster outcom account approach woman cluster number offspr cluster size 30 χ2 test compar advers event group result figur 1 show number particip enrol exclud women exclud post randomis women physic activ group enrol sequenti pregnanc enrol remov women control group inelig baselin visit randomis erron inelig patient mistakenli randomis trial accept exclud particip data intent treat approach risk bia 31 785 pregnanc 774 singleton 10 twin unknown particip withdrew consent baselin characterist particip group similar tabl 1 half 54 smoke 10 cigarett dai report 70 achiev recommend 150 minut week moder vigor physic activ bout 10 minut 13 follow rate primari outcom 88.8 697 particip similar studi group 88 particip 11.2 complet assess analysi primari outcom 43 48.9 smoke follow assess complet evid lack signific differ enc rate studi group remain 45 particip 5.7 particip assum continu smoke relaps particip attend median treatment se sion intervent group control group tabl 2 physic activ increas base line increas significantli greater physic activ group 33 95 confid inter val 14 56 28 7 52 36 12 65 week week week post quit dai fig 2 tabl 2 28 women report receiv nh face face support smoke cessa tion offer trial 60 women report nicotin replac therapi num ber report support similar group 90 particip 11.5 total sampl ask wear acceleromet fourth week quit date 78 87 provid valid data 37 physic activ group 10 provid insuffici data wore devic technic problem particip provid acceleromet data similar baselin characterist assign behaviour support 395 receiv behaviour support 395 assign behaviour support physic activ intervent 394 receiv behaviour support physic activ intervent 393 women record smoker rst antenat visit 8096 randomis 789 lost follow 53 fetal infant death 15 unabl contact refus attend 38 lost follow 35 fetal infant death 9 withdrew consent provid baselin data 1 unabl contact refus attend 25 includ primari analysi 393 exclud analysi meet inclus criteria baselin visit 2 includ primari analysi 392 exclud analysi ow enrol 2 exclud 7307 unabl contact 2169 declin particip 2324 meet inclus criteria 2583 reason 231 fig 1 flow particip trial particip lost follow includ women experienc fetal infant loss assess smoke statu research 5the bmj bmj 2015;350 h2145 doi 10.1136 bmj.h2145 total sampl seventi cent valid acceleromet data dai median durat moder vigor physic activ dai acceleromet includ bout 10 minut similar physic activ 7.5 minut interquartil rang 0 15.5 control group 8.0 minut 0 16.2 0.816 includ moder vigor physic activ irrespect durat activ level dai tend higher physic activ group median 38.0 minut inter quartil rang 20.0 52.6 versu control group 31.2 19.0 44.1 differ reach signific 0.538 week acceleromet worn moder vigor physic activ dai bout 10 minut significantli higher report acceleromet case control group median differ 23.2 interquartil rang 6.1 37.1 minut 0.001 physic activ group 29.7 17.1 49.4 minut 0.001 signific differ smoke abstin rate group follow tabl 3 rate valid continu abstin end pregnanc 8 physic activ group 6 control group odd ratio phy ical activ group adjust recruit centr 1.21 95 confid interv 0.70 2.10 week valid abstin rate 13 physic activ group 16 control group odd ratio adjust recruit centr 0.79 0.53 1.18 month birth rate report abstin 6 physic activ group 4 control group odd ratio adjust recruit centr 1.55 95 confid inter val 0.81 2.97 fulli adjust analys yield similar find tabl 3 sensit analys show observ effect size statist signific independ influenc miss data primari outcom signific interac tion baselin report moder vigor ou physic activ 150 150 min week physic activ effect intervent smoke abstin end pregnanc adjust recruit centr odd ratio 3.03 95 confi denc interv 0.68 13.40 0.129 evid report physic activ physic activ group significantli smoke abstin adjust recruit centr odd ratio week 2.21 95 confid interv 0.48 10.12 0.321 week 2.36 0.41 13.51 0.362 end pregnanc edinburgh postnat depress scale score significantli higher 0.017 physic activ group compar control group tabl 4 signific dif ferenc score group month signific differ gestat postnat weight group tabl 5 baselin characterist provid data depress weight similar total trial sampl compar studi group baselin week post quit rate confid particip physic activ physic activ compar control group increas significantli 0.004 signific chang rate individu withdraw symptom urg smoke confid quit smoke total number women infant advers event advers event 217 55 physic activ group 219 56 control group odd ratio 0.99 95 confid interv 0.75 1.32 supplementari tabl bmj.com signific differ group advers event advers event tabl 1 baselin characterist studi group valu number percentag state characterist physic activ group 391 control group 393 mean sd ag year 27.2 6.1 27.8 6.5 mean sd ag leav full time educ year 17.8 3.0 18.0 3.3 mean sd weight kg 69.2 14.1 70.9 15.9 mean sd bodi mass index kg m2 25.6 5.0 26.6 5.6 mean sd gestat ag week 15.6 3.3 15.6 3.3 mean sd edinburgh postnat depress scale score 7.6 5.3 7.7 5.0 median interquartil rang cigarett smoke daili pregnanc 20 12 20 20 12 20 median interquartil rang cigarett smoke daili randomis 10 5 12 10 5 15 median interquartil rang fagerström test cigarett depend score 4 2 5 4 2 5 median interquartil rang expir carbon monoxid level ppm 10 7 14 10 6 14 median interquartil rang report weekli moder vigor physic activ min 210 125 350 225 130 360 marri live partner 230 59 221 56 partner smoke 261 67 250 64 white 308 79 298 76 profession manageri occup 46 12 53 13 smoke previou pregnanc 186 78 193 78 edinburgh postnat depress scale score 13 68 17 75 19 report 150 min week moder vigor physic activ 275 70 273 69 report walk main type physic activ 301 77 313 80 pariti 0 1 317 81 309 79 2 3 67 17 75 19 4 7 2 9 2 previou preterm birth 68 17 61 16 extrem high confid quit smoke 89 23 98 25 extrem confid 30 min physic activ 5 dai week pregnanc 274 70 277 71 take alcohol week 6 2 5 1 consum 3 alcohol drink drink dai 14 16 3 4 baselin data record particip physic activ group withdrew consent shortli randomis data exclud 41 women full time educ record particip control group record particip physic activ group record particip physic activ group control group exclud 92 women partner race ethnic group report categoris standard uk censu categori exclud 297 previou pregnanc previou pregnanc durat 24 37 week number previou pregnanc progress 24 week exclud 617 women respond applic consum alcohol signific differ group 0.011 fisher exact test variabl relat primari outcom adjust analysi signific differ group research 6 doi 10.1136 bmj.h2145 bmj 2015;350 h2145 bmj includ matern fetal advers event probabl complic pregnanc neonat advers event birth outcom similar group includ miscarriag stillbirth neonat death birth weight preterm birth sig nificantli fewer deliveri caesarean section physic activ group control group 29 21 0.023 tabl 6 includ twin birth find birth outcom similar discuss supplement behaviour support physic activ intervent effect aid smoke cessat pregnanc behaviour support find observ women physic activ group report 33 36 greater increas physic activ women control group intervent period strength limit studi studi limit previou trial physi cal activ intervent smoke cessation12 overcom implement multicentr trial offer intens physic activ intervent support increas physic activ aid smoke ce sation addit supervis exercis session assess valid physic activ group robust outcom continu absti nenc offer pragmat intervent readili integr routin healthcar nh baselin particip averag gestat ag ag cigarett consumpt similar particip recent larg pregnanc smoke cessat trial conduct unit king dom 32 frequenc occurr advers event birth outcom similar women gener repres women smoke 8 find generalis pri mari secondari care set preval probabl depress baselin slightli higher report pregnant women gener 33 studi approxim size previ ou randomis control trial investig physic activ intervent smoke cessat deliv face face support 12 anticip recruit 10 pregnant women record smoker antenat book visit preval smoke lower anticip extend recruit period sampl 91 target 866 quit rate lower anticip power calcul reduc power studi confid interv odd ratio effect intervent show level precis estim achiev sampl size impli rule twofold increas abstin end pregnanc compar control upper end confid interv point estim suggest effect inter vention clinic meaning addition week outcom quit rate tabl 2 complianc intervent assess time physic activ group control group rel chang 95 ci median interquartil rang report weekli mvpa min baselin 391 210 125 350 393 225 130 360 week post quit dai 1 162 280 190 425 206 240 140 420 1.33 1.14 1.56 0.001 4 135 270 180 420 157 210 120 340 1.28 1.07 1.52 0.006 6 90 277 180 400 121 220 130 350 1.36 1.12 1.65 0.002 end pregnanc 188 155 100 240 187 140 60 240 1.25 0.96 1.61 0.093 6 month follow 147 180 80 330 136 135 60 285 1.16 0.85 1.59 0.339 mean sd time walk treadmil supervis exercis min baselin 390 12.2 7.5 week post quit dai 1 163 19.0 8.5 4 134 15.2 10.8 6 90 17.7 10.9 treatment session attend 391 4 2 8 393 3 2 6 mvpa moder vigor physic activ rel chang physic activ mix effect model log physic activ adjust visit time baselin minut mvpa interact visit time baselin minut mvpa recruit centr median interquartil rang number session attend physic activ counsel smoke cessat behaviour support 2 1 4 particip receiv supervis exercis session visit time pr ed ic te se lf po rt ed ee kl ut es vp lo sc al 1 week post quit 4 week post quit 6 week post quit end pregnanc 6 month follow 1.8 2.2 2.4 2.6 2.0 control group physic activ group fig 2 comparison report level moder vigor physic activ mvpa trial group time point predict log scale mix effect model research 7the bmj bmj 2015;350 h2145 doi 10.1136 bmj.h2145 higher confid interv narrow dif ferenc abstin treatment control minim upper end confid interv reach target sampl size result suggest clini calli relev differ quit rate lower previou pregnanc trial rigor outcom measur similar studi compar outcom measur 8 pre viou uk base larg trial smoke cessat inter vention pregnanc observ quit rate end pregnanc 7.6 7.8 group receiv behaviour support smoking32 34 simi larli observ quit rate 6.4 group interpret find bia outcom ascertain explain find follow rate 89 equal high group 6 particip assum continu smoke relaps effect size independ influenc miss outcom data 10 report studi behaviour support nicotin replac therapi similar usag group doubt influenc result low attend affect outcom women physic activ group attend median 14 se sion low attend rate coun sell physic activ substanti increas physic activ level low attend explain potenti treatment relat advers event physic activ group indic physic activ intervent increas incid advers event mon smoke cessat trial major women fail quit stop attend suggest failur quit partli led low attend qualit data report base interview particip suggest low atten danc influenc pregnanc relat ail ment poor psycholog health lack social support evid intervent influenc process aid cessat confid quit ting urg smoke withdraw symptom lack evid intervent reduc depress score score sig nificantli higher physic activ group control group end pregnanc margin differ small clinic import 35 36 explan depress find consist qual it data report relat popul interest requir inter vention intervent group ask chang health behaviour simultan smoke physic activ cope pregnant attend multipl treatment se sion particip demoralis find difficult achiev result margin higher depress score end pregnanc nei ther evid intervent reduc weight gain effect outcom smoke cessa tion depress weight limit intervent group activ lifestyl fail suffici rais physi cal activ level compar control group reassur number advers event similar group suggest physic activ intervent safe increas event pregnant smoker 7 fewer caesarean section physic activ compar control group find consist recent meta analysi observ significantli lower risk caesarean deliveri women undergo physic activ intervent tabl 3 primari secondari abstin outcom valu number percentag state outcom physic activ group 392 control group 393 odd ratio 95 ci basic adjust fulli adjust odd ratio 95 ci primari report continu abstin end pregnanc biochem valid 30 8 25 6 1.21 0.70 2.10 1.37 0.78 2.41 secondari report continu abstin 4 week post quit dai valid 50 13 61 16 0.79 0.53 1.18 0.87 0.57 1.31 report continu abstin 6 month birth 24 6 16 4 1.55 0.81 2.97 1.66 0.82 3.37 adjust recruit centr stratif factor adjust recruit centr fagerstrom test cigarett depend score baselin particip ag randomis edinburgh postnat depress scale score baselin ag leav full time educ partner smoke statu baselin smoke fewer cigarett quit dai 36 week gestat 10 week birth valid exhal carbon monoxid salivari cotinin level measur requir valid biochem test valid report smoke probabl fals report cessat 12 42 women 29 physic activ group 19 44 43 control group biochem test valid report smoke probabl fals report cessat 4 51 women 8 physic activ group 7 61 11 control group tabl 4 matern depress valu number mean standard deviat state visit time epd score β differ physic activ control group 95 ci control group physic activ group baselin 393 7.7 5.0 391 7.6 5.3 0 end pregnanc 194 7.2 5.0 189 8.0 4.9 1.06 0.19 1.94 6 month follow 133 6.6 4.7 146 6.8 4.8 0.52 0.45 1.50 epd edinburgh postnat depress scale result mix effect linear regress model adjust visit time baselin epd score interact visit time baselin epd score recruit centr research 8 doi 10.1136 bmj.h2145 bmj 2015;350 h2145 bmj compar control condit 37 studi report pregnant smoker po itiv result caesarean section expens nh mode deliveri complic abdomin surgeri report recruit physic activ women baselin compar pregnant smoker similarli recruit antenat ho pital 38 report achiev recom mend level physic activ activ women attract trial promot physi cal activ similarli activ women recruit physic activ intervent deliv routin healthcar explan high proport particip live depriv commun qualit data report suggest women lim it access motoris public transport reli walk main form transport mean particip experienc benefit exercis make difficult detect appreci differ smoke abstin rate trial group ceil effect evid suggest treatment effect influenc baselin level physic activ insuffici power detect interact intervent shown stronger effect sedentari popul target altern explan particip report activ level support acceleromet data show previous observ 39 physic activ level higher report acceleromet limit 90 particip monitor acceleromet baselin characterist women simi lar remaind wear acceleromet prefer assess physic activ acceleromet particip pilot studi show women toler wear report activ primari analysi particip blind treatment allo cation higher report activ physic activ group compar control group bias knowledg alloc consist find overestim report physic activ versu acceleromet data tend higher physic activ ver su control group addition acceleromet deriv physic activ level similar trial group includ moder vigor ou physic activ restrict bout 10 minut physic activ group tend report physic activ week control group suggest increas activ sporad bout last 10 minut remain women physic activ group fail increas physic tabl 5 matern bodi weight valu mean standard deviat state subsampl matern bodi weight physic activ group control group mean differ physic activ control 95 ci gestat weight chang 74 66 earli pregnanc weight 68.3 14.4 70.3 15.6 end pregnanc weight 80.7 14.9 81.4 14.8 1.08 1.08 3.23 postnat weight retent 63 65 earli pregnanc weight 66.1 14.6 66.2 12.8 end pregnanc weight 70.7 14.1 71.3 13.4 0.11 2.27 2.49 linear regress model matern weight chang end pregnanc depend variabl randomis group earli pregnanc weight recruit centr independ variabl weight measur birth weight measur birth tabl 6 birth outcom treatment group valu number outcom total number group percentag state fetal outcom singleton birth physic activ group 384 control group 391 odd ratio 95 ci miscarriag 6 383 2 10 389 3 0.60 0.22 1.67 stillbirth 2 377 1 2 379 1 1.01 0.14 7.24 neonat death 0 1 391 0.3 calcul mean sd birth weight 354 3132.4 581.7 359 3146.8 640.0 14.50 104.52 75.52 mean sd gestat ag deliveri week 356 39.24 2.1 348 39.26 2.1 0.02 0.36 0.31 preterm birth 37 week gestat 35 356 10 26 348 7 1.36 0.80 2.31 low birth weight 2500 38 353 11 44 359 12 0.87 0.55 1.38 admiss neonat intens care unit 27 352 8 36 356 10 0.74 0.44 1.25 apgar score 5 minut 7 8 344 2 11 351 3 0.74 0.29 1.85 cord blood arteri ph 7 2 130 2 0 125 calcul congenit abnorm 9 346 3 6 348 2 1.43 0.50 4.13 assist vagin deliveri 46 357 13 32 359 9 1.51 0.94 2.43 caesarean deliveri 76 357 21 103 359 29 0.67 0.48 0.95 outcom 10 women twin 8 physic activ group remov denomin includ twin birth find birth outcom similar odd ratio mean differ adjust recruit centr stratif factor outcom defin priori advers event outcom publish protocol consid post hoc outcom matern death advers event judg relat physic activ intervent denomin miscarriag calcul number randomis minu number elect termin 3 elect termin exclud potenti miscarri denomin stillbirth calcul number randomis minu number miscarriag elect termin elect termin miscarriag exclud potenti result stillbirth outcom denomin number singleton live birth exclud birth outcom data miss variabl outcom protocol consid post hoc outcom supplementari tabl bmj.com list congenit abnorm 0.023 research 9the bmj bmj 2015;350 h2145 doi 10.1136 bmj.h2145 activ level compar control group plan case intervent offer routin healthcar rais physic activ level suffici aid smoke ce sation pragmat efficaci orient trial greater incent financi complet exercis accel omet measur sampl need establish physic activ aid smoke cessat pregnanc evid chang report physic activ iti higher quit rate analysi underpow confid inter val wide conclus studi evid pragmat physic activ iti intervent effect aid smoke cessa tion lack efficaci trial involv thrice weekli session vigor intens supervis exer cise observ benefit physic activ interven tion long term smoke abstin pregnant women smokers11 remain intens intervent aid smoke cessat pregnanc intens exercis clinic inappropri pregnanc experi trial suggest uptak intens intervent low difficult integr routin healthcar addit provis comprehens pro gramm supervis exercis repres larg invest justifi programm effect intervent substanti conclud report physic activ programm assist pregnant smoker stop smoke recommend physic activ pregnant women remain gener health pregnanc investig contribut ori bolooki midwif janet brown midwif sarah cleari midwif carolin dixon midwif juli fuller midwif gail hard midwif maggi hart nurs tracei kilban research assist rachel lex midwif zoe magrath midwif ilia papachrist research assist beth steff midwif bettina wanninkhof midwif independ member trial steer committe jim thornton chair ann mcneill sue cooper kim watt serena cox dale eslig assist analys interpret acceleromet data contributor mu tc sl pa im rw bl bm conceiv studi wrote protocol obtain fund mu manag dai dai run trial includ particip follow mr sl mu design data analysi ad advis studi design assist design analysi matern depress weight mr conduct analys author full access data respons integr data accuraci data analysi contribut interpret result review approv final manuscript mu draft articl guarantor view opinion express articl author necessarili reflect nation institut health research nihr health technolog assess programm nihr nation health servic english depart health fund studi fund nihr health technolog assess programm grant 07.01.14 funder role design conduct studi collect manag analysi interpret data prepar review approv manuscript decis submit manuscript public compet interest author complet icmj uniform disclosur form www.icmje.org coi_disclosure.pdf request author declar support organis submit work past year pa dai consult pfizer gener smoke cessat advic product rw undertaken research consult compani pfizer glaxosmithklin develop manufactur smoke cessat drug past year past year tc paid speak educ event part wholli sponsor compani pierr fabr laboratori franc manufactur nicotin replac therapi rw unpaid truste stop smoke chariti quit unpaid director nation centr smoke cessat train relationship activ influenc submit work ethic approv research protocol approv wandsworth research ethic committe data share guarantor mu examin request full dataset period year date public particip give consent data share data anonymis risk identif low transpar lead author mu affirm manuscript honest accur transpar account studi report import aspect studi omit discrep studi plan relev regist explain open access articl distribut accord term creativ common attribut cc 4.0 licens permit distribut remix adapt build work commerci provid origin work properli cite http creativecommons.org licens nc 4.0 1 kallen impact matern smoke pregnanc deliveri outcom eur public health 2001;11 329 33 2 roger jm tobacco pregnanc reprod toxicol 2009;28 152 60 3 salihu hm wilson epidemiolog prenat smoke perinat outcom earli hum dev 2007;83 713 20 4 nh inform centr infant feed survei 2010 earli result nh inform centr health social care 2011 5 tong vt dietz pm morrow al trend smoke pregnanc pregnanc risk assess monitor system unit state 40 site 2000 2010 mmwr surveil summ 2013;62 1 19 6 al sahab saqib hauser al preval smoke pregnanc risk factor canadian women nation survei bmc pregnanc childbirth 2010;10 24 7 richmond you’v long babi women tobacco epidem addict 2003;98 553 7 8 chamberlain o’mara ev oliv al psychosoci intervent support women stop smoke pregnanc cochran databas syst rev 2013;10 cd001055 9 coleman chamberlain davei ma al pharmacolog intervent promot smoke cessat pregnanc cochran databas syst rev 2012;9 cd010078 10 haasova warren fc ussher al acut effect physic activ cigarett crave systemat review meta analysi individu particip data ipd addict 2012;108 26 37 11 marcu bh albrecht ae king tk al efficaci exercis aid smoke cessat women randomis control trial arch intern med 1999;159 1229 34 12 ussher mh taylor faulkner exercis intervent smoke cessat cochran databas syst rev 2012;1 cd002295 13 garber ce blissmer deschen mr al american colleg sport medicin american colleg sport medicin posit stand quantiti qualiti exercis develop maintain cardiorespiratori musculoskelet neuromotor fit appar healthi adult guidanc prescrib exercis med sci sport exerc 2011;43 1334 59 14 ussher aveyard coleman al physic activ aid smoke cessat pregnanc feasibl studi bmc public health 2008;8 328 15 ussher aveyard manyonda al physic activ aid smoke cessat pregnanc leap trial studi protocol random control trial trial 2012;13 186 16 michi hyder walia al develop taxonomi behaviour chang techniqu individu behaviour support smoke cessat addict behav 2011;36 315 9 17 heatherton kozlowski frecker al fagerström test nicotin depend revis fagerström toler questionnair br addict 1991;86 1119 27 http www.icmje.org coi_disclosure.pdf research right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib 18 blair sn haskel wl ho al assess habitu physic activ dai recal commun survei control experi epidemiol 1985;122 794 804 19 murrai cox jl screen depress pregnanc edinburgh depress scale epd reprod infant psychol 1990;8 99 107 20 marcu bh selbi vc niaura rs al efficaci stage exercis behavior chang re exerc sport 1992;63 60 6 21 west willi doubl blind placebo control trial dextros tablet nicotin patch smoke cessat psychopharmacolog 1998;136 201 4 22 babor tf de la fuent jr saunder al audit alcohol disord identif test guidelin primari health care world health organ 1992 23 west russel pre abstin smoke intak smoke motiv com.ibm.drl.hbcp.predictor sever cigarett withdraw symptom psychopharmacolog 1985;87 334 6 24 ussher beard abikoy al urg smoke 52 week abstin psychopharmacolog 2013;226 83 9 25 west hajek stead stapleton outcom criteria smoke cessat trial propos common standard addict 2005;100 299 303 26 lumlei chamberlain dowswel al intervent promot smoke cessat pregnanc cochran databas syst rev 2009;3 cd001055 27 chamberlain o’mara ev oliv al psychosoci intervent support women stop smoke pregnanc cochran databas syst rev 2013;10 cd001055 28 hedek mermelstein rj demirta analysi binari outcom miss data miss smoke observ carri forward multipl imput addict 2007;102 1564 73 29 troiano rp berrigan dodd kw al physic activ unit state measur acceleromet med sci sport exerc 2008;40 181 8 30 gate brocklehurst randomis trial includ multipl pregnanc analys bjog 2004;111 213 9 31 fergusson aaron sd guyatt hébert post randomis exclus intent treat principl exclud patient analysi bmj 2002;325 652 4 32 coleman cooper thornton jg al smoke nicotin pregnanc snap trial team random trial nicotin replac therapi patch pregnanc engl med 2012;366 808 18 33 gavin ni gayn bn lohr kn al perinat depress systemat review preval incid obstet gynecol 2005;106 1071 83 34 hajek west lee al random control trial midwif deliv smoke cessat intervent pregnanc addict 2001;96 485 94 35 affonso dd de ak horowitz ja al intern studi explor level postpartum depress symptomatolog psychosom re 2000;49 207 16 36 matthei calcul clinic signific chang postnat depress studi edinburgh postnat depress scale affect disord 2004;78 269 72 37 domenjoz kayser boulvain effect physic activ pregnanc mode deliveri obstet gynecol 2014;211 401 e1 11 38 ussher yoon west al factor exercis particip attitud exercis pregnant smoker smok cessat 2007;2 12 6 39 harrison cl thompson rg teed hj al measur physic activ pregnanc int behav nutr phy act 2011;8 19 bmj publish group 2015 addit materi tabl advers event list common advers event
origin articl effect commun outreach tobacco cessat intervent india cluster randomis control trial babex trial bidyut sarkar 1,2 robert west 2 monika arora 1 jasjit ahluwalia 3 srinath reddi 1 lion shahab2 1public health foundat india delhi india 2depart epidemiolog public health cancer research uk health behaviour research centr univers colleg london london uk 3school public health rutger univers brunswick usa correspond dr bidyut sarkar public health foundat india delhi 110070 india bidyutk.sarkar gmail.com receiv 5 april 2016 revis 2 august 2016 accept 7 septemb 2016 cite sarkar bk west arora al thorax publish onlin includ dai month year doi 10.1136 thoraxjnl 2016 208732 abstract background tobacco kill half million peopl month low middl incom countri lmic urgent identifi potenti low cost scalabl tobacco cessat intervent countri object evalu commun outreach intervent deliv health worker promot tobacco cessat india design cluster randomis control trial set 32 low incom administr block delhi half govern authoris resettl coloni half unauthoris j.j cluster commun particip 1213 adult tobacco user intervent administr block comput randomis 1 1 ratio intervent 16 cluster 611 control treatment 16 cluster 602 deliv assess individu level 07 2012 11 2013 intervent singl session quit advic 15 min singl train session yogic breath exercis control condit compris quit advic 1 min deliv outreach contact made household visit measur primari outcom 6 month sustain abstin tobacco assess 7 month post intervent deliveri biochem verifi salivari cotinin result smoke cessat rate higher intervent group 2.6 16 611 control group 0.5 3 602 rel risk 5.32 95 ci 1.43 19.74 0.013 interact type tobacco smoke smokeless result chang materi adjust analys control particip characterist conclus singl session commun outreach intervent increas tobacco cessat lmic effect size small impact public health scale high coverag trial registr number isrctcn23362894 introduct tobacco million prematur death year low incom middl incom countri lmic 1 million india 2 small increas long term tobacco cessat rate import public health impact 3 combat tobacco epidem requir comprehens global strategi includ taxat smoke free polici dedic healthcar ser vice encourag support cessat 4 implement lmic limit hamper weak regulatori enforc ment infrastructur 5 cheap scalabl tobacco cessa tion intervent build exist infrastructur strengthen tobacco control indian context 6 opportunist advic health worker found highli cost effect inter vention promot smoke cessat high incom countri hic 7 increas 12 month quit rate percentag points8 offer assist import part process 9 limit evid effect quit advic lmic physician smokeless tobacco repres import gap evid base kei messag kei question potenti low cost scalabl commun outreach intervent singl session advic 15 min stop tobacco combin train yogic breath exercis increas abstin rate tobacco context low middl incom countri lmic compar quit advic 1 min bottom line simpl cheap potenti scalabl commun outreach intervent increas smoke smokeless tobacco cessat india produc effect size similar physician advic high incom countri read number tobacco user limit resourc lmic develop cheap scalabl intervent combat tobacco knowledg trial establish effect singl session commun outreach intervent stop tobacco low incom commun lmic worldwid sarkar bk al thorax 2016;0 1 7 doi 10.1136 thoraxjnl 2016 208732 1 smoke thorax onlin publish octob 5 2016 10.1136 thoraxjnl 2016 208732 copyright articl author employ 2016 produc bmj publish group bt licenc group.bmj.com octob 5 2016 publish http thorax.bmj.com download http thorax.bmj.com http www.brit thoracic.org.uk http thorax.bmj.com http group.bmj.com paper attempt fill gap evalu intervent singl session smoke smokeless tobacco cessat advic singl session yogic breath exercis deliv healthcar profession commun outreach india tobacco major health inequ preval quit success rate lower depriv group 10 poorer countri gradient tobacco 11 improv support soci etal strata lmic arguabl import focu low incom commun countri outreach involv tobacco user contact health servic 6 limit resourc lack afford pharmaco therapi proven effect smokeless tobacco user provid assist present challeng lmic india smokeless tobacco user smoker 12 promis cultur option context yogic breath exercis pranayama easi learn practic preliminari evid reduc cigarett cravings13 14 promot quit 15 fore develop commun outreach intervent includ train simpl breath exercis control crav ing aid cessat ideal evalu multi compon intervent involv multipl experiment condit allow deter minat activ compon limit resourc main prioriti find intervent work understand optimis base camp establish opt pragmat effect trial intervent compar closest usual care ethic accept condit mimick feasibl routin prac tice cluster individu randomis chosen minimis risk contamin close knit natur commun treatment deliveri assess individu level guidelin complex intervent develop evalu 16 studi built extens work advic hic proof concept studi breath exercis field studi set 17 specif present studi sought answer research question effect singl session quit advic 15 min instruct simpl breath ing exercis compar advic vba 1 min promot tobacco cessat deliv reach worker low incom commun india method studi design pragmat cluster randomis control trial set low incom commun urban slum compar treatment intervent arm includ singl face face session quit advic singl train session yogic breath exercis ba ybe control arm compris vba assess perform baselin immedi treatment deliveri 4 week 7 month deliveri treatment studi approv ucl 3051 002 public health foundat india trc iec 122 11 ethic committe particip elig particip current daili adult tobacco user ag 23 year live select low incom communi ti provid consent particip recruit studi start juli 2012 trial conclud novemb 2013 propos studi area contain approxim 36 000 adult live 32 randomli select administr block larg commun spread wide geograph area delhi india low incom commun select previou tobacco studi conduct youth ag 10 19 year 2009,18 adult ag 23 elig avoid contamin previou studi intervent particip intervent condit receiv singl session tobacco quit advic last averag 15 min short train yogic breath exercis quit advic contain behaviour chang techniqu shown improv quit rate 19 includ cope train medic advic social support relaps prevent breath exercis easi learn practis kapalbhati normal deep inhal forc exhal anulom vilom altern nostril breath chosen cul tural shown control crave 14 written standard oper procedur research team includ script quit advic standard video train yogic breath exercis increas fidel iti detail publish protocol 20 control whilst control condit advic tobacco usual care prefer assess full intervent effect consid uneth singl control session involv quit advice21 pro vide verbal inform harm effect tobacco advic stop tobacco last averag 1 min procedur randomis mask censu survei adult urban low incom commun delhi conduct establish sampl frame studi 17 low incom block studi area stratifi commun type govern authoris resettl coloni unauthoris settlement call jhuggi jhopri jj cluster equal number identifi inclus cluster identifi list elig tobacco user finalis cluster prior randomis cluster intervent control arm random sequenc comput gener block ensur equal number commun type interven tion control condit base random sequenc 16 cluster 8 commun type alloc treatment ba ybe control vba arm particip blind alloc cluster randomis trial conceal alloc research team feasibl baselin interview conduct doorstep potenti particip identifi tobacco user invit particip cluster divid geograph part street lane outer compris equal number household equal number particip approach provid consent check elig formal written consent obtain case multipl elig particip household consent tobacco user identifi sampl frame recruit treatment deliveri team consist member medic graduat research physician field investig commun health worker train initi supervis medic graduat research intervent deliv 2 sarkar bk al thorax 2016;0 1 7 doi 10.1136 thoraxjnl 2016 208732 smoke group.bmj.com octob 5 2016 publish http thorax.bmj.com download http thorax.bmj.com http group.bmj.com field investig 1 dai classroom train intervent deliveri standard tool script quit advic standard video train yogic breath exercis content deliv face face technic local languag hindi group follow visit compris face face interview resid particip 4 week 7 month base line visit due cluster random blind fea ibl follow carri team field investig measur measur includ outcom measur pre defin isrctn registri publish protocol 20 primari outcom measur 6 month sustain abstin defin russel standard rs criteria 22 allow maximum instanc tobacco whichev form 6 month preced follow conduct 7 month treatment deliveri biochem valid sampl includ smokeless smoke tobacco user salivari cotinin detect tobacco exposur assess elisa cut 20 ng ml equival 13 ng ml ga chromatographi mass spectrometri method 23 report abstain cut consid continu tobacco user particip lost follow accord intent treat principl rs cri teria 22 nicotin replac therapi nrt medica tion assess follow exclud fals posit cotinin result secondari outcom measur 7 dai biochem valid point preval abstin assess 7 month treatment deliveri 4 week follow particip ask tobacco past 7 dai 7 dai point preval intervent group particip ask yogic breath exercis found point scale rang help baselin standard socio demograph smoke characterist assess addit ag sex marit statu particip ask employ statu emploi highest educ attain primari educ cast lower cast household incom 5000 5000 rupe month particip ask start tobacco depend enc assess heavi smoke index 24 modifi smokeless tobacco user quit attempt past year length attempt support confid felt stop smoke point scale rang confid confi dent lastli advers advers event monitor record medic graduat research studi sampl size initi power calcul base 32 cluster 31 particip cluster need 90 power detect 5 differ quit rate treatment control group tail analysi 7 2 20 effect estim base earli similar work25 assum intra cluster correl effici icc 0.01 typic kind studi design effect 1.24 account cluster randomis low intens intervent substanti attrit rate trial evid base method increas respons rate dropout rate 20 25 6 month follow common 26 reduc power detect effect intent treat design27 due uncertainti icc estim recruit 20 cluster 37.2 particip round 38 particip result final target sampl size 1216 38 32 cluster sampl size provid 90 power detect larger differ 8 subgroup analys analysi primari secondari smoke cessat outcom base line group differ analys mix effect log binomi linear regress link function categor log logit binomi continu ident gaussian outcom variabl lme4 packag 3.2.0 bate dm lme4 mix effect model springer 2010 account cluster observ prefer protocol complex sampl analysi 28 analys conduct stata 13.1 result condit cluster specif model confirm margin popul averag model generalis estim equat xtgee command exchang correl matrix account cluster 29 icc determin analysi varianc method 30 plan subgroup analys intervent particip smoke smokeless tobacco dual product user inter vention provid train health profession train field health worker interact term includ model assess homogen effect subgroup sen sitiv analysi analys receiv treatment effect estim adjust covari account chanc imbal baselin characterist intervent control condit signific level multipl comparison adjust benjamini hochberg procedur 31 studi regist intern standard randomis control trial number registri number isrctcn23362894 result shown figur 1 85.9 1213 1412 elig tobacco user approach januari 2012 novemb 2013 agre part studi common reason take part lack interest follow rate final endpoint high 95.3 1158 1213 differ arm differ baselin charact istic sampl tobacco user recruit larg male middl ag marri employ primari educ depriv measur hous hold incom half lower cast tabl 1 slightli tobacco smoker smokeless tobacco user substanti proport dual user tobacco product 20 year moder at depend made quit attempt year past quit attempt last 2 month previous quit support particip gen eral confid abil quit chanc imbal group except cast signifi cantli particip intervent control group lower cast tabl 1 primari outcom 2.6 16 611 partici pant continu abstin 6 month rs cri teria valid saliva cotinin intent treat analysi show particip intervent group time abstin 6 month sarkar bk al thorax 2016;0 1 7 doi 10.1136 thoraxjnl 2016 208732 3 smoke group.bmj.com octob 5 2016 publish http thorax.bmj.com download http thorax.bmj.com http group.bmj.com control group absolut abstin rate increas 2 tabl 2 yield number need treat 48 produc addit quitter differ materi alter remain signific control covari valid 7 dai point preval 6 month total sampl margin higher 2.0 24 1213 particip intervent group time achiev 7 dai abstin 6 month interven tion group result materi chang control covari tabl 2 report 7 dai point preval 4 week 9.3 113 1213 primari secondari outcom abstin rate significantli higher intervent group control group doubl rr 2.03 95 ci 1.30 3.19 0.002 12.4 76 611 6.1 37 602 4 week follow 61.1 373 611 inter vention group continu breath exercis 19.0 116 611 dai rate breath exercis help mean 5.3 sd 1.8 advers advers event report pre protocol analys primari outcom analys data particip receiv treatment significantli particip intervent group control group 3.4 21 611 1.2 7 602 0.03 miss treatment alter effect intervent rr 5.48 95 ci 1.46 20.51 0.01 includ potenti effect modifi type tobacco smoke smokeless exclud dual user poli dual singl intervent provid train health profession train field health worker interact term main model assess effect differ group evid type product pinteract 0.32 poli pinteract 0.85 intervent provid pinteract 0.90 affect outcom discuss trial tobacco user low incom commun india 6 month sustain biochem verifi abstin rate increas fivefold low cost intervent combin singl session quit advic yogic breath exercis compar quit advic increas 2 absolut quit rate close obtain low intens intervent observ hic 8 33 34 result compar favour previou evalu intens intervent lmic roughli doubl short term abstin rate tobacco 5 absolut quit rate lower expect reflect simplic intervent provid pharmacolog support broader challeng make behaviour chang intervent relev context extrem depriv observ 35 physician base potenti scal set india inadequ healthcar deliveri system popul limit access physi cian medic noteworthi averag famili incom particip 50 month 2 dai make nrt unafford fund govern follow nrt medic figur 1 number particip cluster enrol studi includ primari analysi 4 sarkar bk al thorax 2016;0 1 7 doi 10.1136 thoraxjnl 2016 208732 smoke group.bmj.com octob 5 2016 publish http thorax.bmj.com download http thorax.bmj.com http group.bmj.com tabl 1 baselin characterist particip characterist total 1213 intervent ba yba 611 control vba 602 sociodemograph male 79.7 966 77.4 472 82.1 494 mean sd ag year 46.3 13.6 45.2 12.8 47.4 14.2 marri cohabit 86.4 1044 85.2 517 87.5 527 employ 70.7 856 71.7 438 69.7 418 primari educ 35.3 426 33.3 202 37.3 224 household incom 5000 inr month 34.1 403 35.7 212 32.5 191 lower cast 43.8 512 50.7 290 37.2 222 tobacco smoker 63.8 774 65.0 397 62.6 377 smokeless user 58.5 710 58.8 359 58.3 351 dual user 22.3 271 23.7 145 20.9 126 mean sd ag start 22.4 9.6 22.2 10.0 22.6 9.3 made quit attempt previou year 20.0 229 22.3 126 17.8 103 mean sd length longest quit attempt week 7.6 30.0 7.5 33.2 7.8 26.5 previous support quit attempt 3.8 46 3.8 23 3.8 23 mean sd heavi smoke index score 0 6 3.0 1.7 3.2 1.6 2.8 1.7 tobacco 5 min wake 38.0 458 40.0 243 36.0 215 mean sd confid stop score 1 7 4.4 1.9 4.5 1.9 4.2 2.0 pair superscript letter signific group differ 0.05 adjust fals discoveri rate account cluster natur data quit advic yogic breath exercis quit advic case miss refus answer case miss refus answer case miss refus answer thirti case miss refus answer forti case miss refus answer twenti case miss refus answer sixti case miss refus answer twenti case miss refus answer seventeen case miss refus answer sixteen case miss refus answer case miss refus answer case miss refus answer scale 1 confid 7 confid tabl 2 effect intervent biochem verifi smoke cessat intervent ba ybe control vba number percentag point differ 95 ci intraclust correl coeffici 95 ci model 1 rel risk model 2 adj rel risk model 3 adj rel risk 95 ci primari outcom abstin 6 month 2.6 16 611 0.5 3 602 2.12 0.74 3.51 0.014 0.000 0.033 model 1 5.32 1.43 19.74 model 2 5.10 1.46 17.84 model 3 4.54 1.21 17.01 secondari outcom point preval 6 month 3.1 19 611 0.8 5 602 2.28 0.72 3.83 0.014 0.000 0.034 model 1 3.77 1.31 10.81 model 2 3.71 1.25 11.02 model 3 2.87 0.92 8.93 outcom measur biochem verifi saliva cotinin particip report tobacco final follow ask provid saliva sampl failur provid biochem verif low 1.2 14 1213 differ treatment group provid saliva sampl lost follow count treatment failur result condit cluster specif approach mix effect log binomi regress present intent treat analysi base particip 1213 result confirm margin popul approach yield compar estim primari outcom 5.33 95 ci 1.30 21.90 0.020 secondari outcom 3.76 95 ci 1.31 10.82 0.014 result model 1 adjust chanc imbal includ variabl tabl 1 data miss random imput standard multivari imput chain equat mice stata mi chain command burn 100 iter 20 imput suitabl mix dichotom continu variabl 32 analysi base particip 1213 result model 1 adjust chanc imbal includ variabl tabl 1 particip complet data includ analysi 1009 primari outcom conform russel standard guidelin report abstin 6 month occas tobacco tobacco week final follow 0.01 0.03 secondari outcom point preval 6 month defin complet abstin week prior follow 0.02 0.07 ba ybe advic yogic breath exercis vba advic sarkar bk al thorax 2016;0 1 7 doi 10.1136 thoraxjnl 2016 208732 5 smoke group.bmj.com octob 5 2016 publish http thorax.bmj.com download http thorax.bmj.com http group.bmj.com quit assess report particip due prohibit cost 36 knowledg trial rigor design includ longer term biochem valid outcom establish effect pro activ quit advic low incom commun lmic commun health worker earn 100 150 month 1 dai train deliv intervent intervent equal effect provid commun health worker physician research total studi materi cost 200 intervent highli cost effect cost 10 treat tobacco user 37 studi benefit assess evid base theori base intervent standardis methodolog includ valid longer term outcom extens prior field work low attrit rate number factor con tribut effect reach intervent yogic breath exercis addit reduc crave 14 po sibli action insula cerebr cortex 38 appeal due cultur accept cessat aid element support referr expens medic proactiv con venient deliveri intervent particip home engag tobacco user treatment free charg drawn tobacco user irrespect iv readi quit lastli advic centr evid base content 19 tailor specif cultur context target user smoke smokeless tobacco evidenc limit smoke relat knowledg baselin report provid extens detail hitherto unknown particip limit intervent prise quit advic train yogic breath exercis effect specif intervent compon disso ciat prioriti stage identifi potenti cost effect scalabl commun outreach intervent includ effect research base compon futur factori studi isol impact dif ferent intervent compon outcom number event trial small uncommon low intens intervent replic find warrant lastli whilst effort made select random sampl find necessarili limit sampl depriv tobacco user delhi outcom compar studi evalu similarli session tobacco intervent rural india 39 result generalis geograph locat lmic nonetheless work confirm type opportunist quit advic yogic breath exercis equal effect relev set school work place maximis potenti impact conclus shown substanti effect poten tialli inexpens scalabl physician depend cultur sensit intervent aid cessat tobacco lmic number need treat gain addit quitter high 48 low intervent cost eas implement limit addit resourc protocol detail 20 mean offer credibl altern effect expens intens treatment pharmacotherapi low coverag tackl enorm tobacco problem face disadvantag user poorest countri world small effect observ minim tobacco clinic signific 3 intervent roll india result million fewer tobacco user year research need confirm find set current trial consist result hic underlin great potenti low intens intervent improv public health specif context lmic acknowledg author field investig staff ngo hridai hard work excel support field work data collect tobacco user consent particip studi contributor bk ls rw conceiv origin idea rct bk obtain fund bk ls rw wrote studi protocol rct report manuscript bk manag dai dai run trial includ particip follow bk rw ls undertook data analys wrote initi draft input ma jsa ksr bk guarantor articl author read review approv final version research list author independ funder final decis research constraint investig bk rw ls full access data studi bk final respons decis submit public fund studi support wellcom trust uk capac strengthen strateg award public health foundat india phfi consortium uk univers award 6936 addit fund cancer research uk c1417 a14135 uk nation centr smoke cessat train funder studi role studi design data collect data analysi data interpret write report author full access data studi final respons decis submit public compet interest ls report person fee pharmaceut compani make smoke cessat product grant pfizer submit work rw report grant person fee compani develop manufactur smoke cessat medic submit work addit dormant patent nicotin cannon nicotin deliveri devic issu ethic approv studi approv ucl 3051 002 public health foundat india trc iec 122 11 ethic committe proven peer review commiss extern peer review open access open access articl distribut accord term creativ common attribut cc 4.0 licens permit distribut remix adapt build work commerci provid origin work properli cite http creativecommons.org licens 4.0
articl www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 1 neuropsychiatr safeti efficaci vareniclin bupropion nicotin patch smoker psychiatr disord eagl doubl blind randomis placebo control clinic trial robert anthenelli neal benowitz robert west lisa st aubin thoma mcrae david lawrenc john ascher cristina russ alok krishen eden evin summari background substanti concern rais neuropsychiatr safeti smoke cessat medic vareniclin bupropion efficaci rel nicotin patch larg reli indirect comparison limit inform safeti efficaci smoker psychiatr disord compar rel neuropsychiatr safeti risk efficaci vareniclin bupropion nicotin patch placebo smoker psychiatr disord method randomis doubl blind tripl dummi placebo control activ control nicotin patch 21 mg dai taper trial vareniclin 1 mg dai bupropion 150 mg dai 12 week 12 week treatment follow 140 centr clinic trial centr academ centr outpati clinic 16 countri nov 30 2011 jan 13 2015 particip motiv quit smoker psychiatr disord receiv cessat counsel visit randomis comput gener 1 1 1 1 ratio particip investig research personnel mask treatment assign primari endpoint incid composit measur moder sever neuropsychiatr advers event main efficaci endpoint biochem confirm continu abstin week 9 12 particip randomli assign includ efficaci analysi receiv treatment includ safeti analysi trial regist clinicaltrials.gov number nct01456936 close find 8144 particip randomli assign 4116 psychiatr cohort 4074 includ safeti analysi 4028 psychiatr cohort 3984 includ safeti analysi psychiatr cohort 13 1 3 990 particip report moder sever neuropsychiatr advers event vareniclin group 22 2 2 989 bupropion group 25 2 5 1006 nicotin patch group 24 2 4 999 placebo group vareniclin placebo bupropion placebo risk differ rd moder sever neuropsychiatr advers event 1 28 95 ci 2 40 0 15 0 08 1 37 1 21 rd comparison nicotin patch 1 07 2 21 0 08 0 13 1 19 1 45 psychiatr cohort moder sever neuropsychiatr advers event report 67 6 5 1026 particip vareniclin group 68 6 7 1017 bupropion group 53 5 2 1016 nicotin patch group 50 4 9 1015 placebo group vareniclin placebo bupropion placebo rd 1 59 95 ci 0 42 3 59 1 78 0 24 3 81 rd versu nicotin patch 1 22 0 81 3 25 1 42 0 63 3 46 vareniclin treat particip achiev higher abstin rate placebo odd ratio 3 61 95 ci 3 07 4 24 nicotin patch 1 68 1 46 1 93 bupropion 1 75 1 52 2 01 bupropion nicotin patch achiev higher abstin rate placebo 2 07 1 75 2 45 2 15 1 82 2 54 cohort frequent advers event treatment group nausea vareniclin 25 511 2016 particip insomnia bupropion 12 245 2006 particip abnorm dream nicotin patch 12 251 2022 particip headach placebo 10 199 2014 particip efficaci treatment comparison differ cohort interpret studi show signific increas neuropsychiatr advers event attribut vareniclin bupropion rel nicotin patch placebo vareniclin effect placebo nicotin patch bupropion help smoker achiev abstin bupropion nicotin patch effect placebo fund pfizer glaxosmithklin publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 onlin comment http dx.doi.org 10.1016 s0140 6736 16 30294 univers california san diego ca usa prof anthenelli md univers california san francisco ca usa prof benowitz md univers colleg london uk prof west phd pfizer york ny usa st aubin dvm mcrae md lawrenc phd russ md gsk research triangl park nc usa ascher md parexel intern behalf gsk research triangl park nc usa krishen ms massachusett gener hospit harvard medic school boston ma usa prof evin md correspond prof robert anthenelli depart psychiatri univers california san diego health scienc 9500 gilman drive la jolla ca 92093 0603 usa ranthenelli ucsd.edu articl 2 www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 introduct prescript medic vareniclin bupropion shown substanti improv smoker chanc stop long term randomis trial real world observ studi 1 substanti concern rais safeti regard neuropsychiatr advers event suicid aggress 2 meta analys randomis trial larg compar observ studi support safeti concern inform food drug administr fda requir maker medic conduct suffici larg randomis trial provid greater clariti potenti safeti risk 3 addition smoke cessat efficaci medic rel nicotin replac therapi smoker psychiatr disord remain uncertain depend larg indirect comparison limit number studi small sampl size 4 present studi sought address issu larg doubl blind tripl dummi activ control placebo control randomis trial smoker psychiatr disord issu crucial import urgenc surround smoke cessat smoker respiratori cardiovascular smoke relat diseas provid maximum research context evid studi search pubm cochran databas systemat review websit food drug administr fda european medicin agenc relev report publish march 26 2016 review refer list document languag restrict search term includ vareniclin bupropion nicotin replac therapi safeti advers event suicid case report analys post market pharmacovigil data europ usa countri detect signal vareniclin neuropsychiatr advers event concern eventu extend bupropion result fda issu post market requir maker vareniclin bupropion randomis control trial assess risk neuropsychiatr advers event contrast studi author varieti control group broad rang studi popul larg sampl size detect signific increas neuropsychiatr advers event smoker prescrib vareniclin bupropion compar nicotin replac therapi placebo result control studi consist show vareniclin bupropion greater incid neuropsychiatr advers event activ placebo compar studi exclud smoker psychiatr ill group smoke larg proport cigarett consum worldwid vulner neuropsychiatr advers event smoke cessat efficaci perspect data compar efficaci vareniclin versu nicotin replac therapi summaris cochran network meta analys find vareniclin superior singl formul nicotin replac therapi reli indirect comparison recent open label trial compar vareniclin singl formul combin nicotin replac therapi detect signific differ treatment 26 week previou studi compar smoke cessat efficaci line smoke cessat aid head head smoker smoker current past psychiatr disord ad studi studi address prospect studi adequ size rigour assess potenti vareniclin bupropion neuropsychiatr advers event find show highli vareniclin bupropion contribut neuropsychiatr advers event moder sever intens rate 1 5 smoker psychiatr disord 4 smoker disord result consist increas incid event studi definit evid rel effect smoke cessat medic special popul smoker psychiatr disord fact odd ratio efficaci differ function psychiatr statu crucial inform treat popul smoke rate time gener popul disproportion affect smoke relat ill find medicin regul clinician smoker make inform choic life preserv treatment implic evid find studi largest kind meta analys previou randomis control trial larg observ cohort studi make highli vareniclin bupropion increas risk moder sever neuropsychiatr advers event smoker psychiatr disord evid sourc clear smoker psychiatr disord increas risk group expect small evid substanti boost studi show efficaci line smoke cessat medic vareniclin largest effect smoker psychiatr disord articl www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 3 support smoker achiev abstin base accur risk benefit analysi clinic practic guidelin recommend effect moder heavi smoker quit combin smoke cessat medic counsel 4 smoke cessat support underus 5 part due smoker clinician concern medic safe risk develop neuropsychiatr symptom concern reflect packag insert line agent vareniclin bupropion warn precaut countri box warn countri includ usa high risk smoke induc ill death reluct clinician prescrib effect smoke cessat medic place smoker risk concern neuropsychiatr safeti vareniclin bupropion aros case report 6,7 post market surveil analys 2,8 initi dearth studi smoker psychiatr disord report event 9 studi activ placebo compar publish past 4 year report medic increas neuropsychiatr symptom risk randomis placebo control trial vareniclin smoker psychiatr disorders10,11 identifi neuropsychiatr safeti signal worsen underli psychiatr condit independ meta analys trial report evid associ varenicline12,13 bupropion14 neuro psychiatr advers event observ studi examin sever outcom suicid behaviour admiss hospit larg cohort smoker comorbid psychiatr disord found heighten risk neuropsychiatr advers event varenicline9,15 bupropion 16 studi limit 3 studi includ meta analys prospect systemat probe neuropsychiatr advers event interest recent observ studi suffer channel bia sicker patient shunt nicotin smoke cessat aid concern side effect 3 remain determin neuropsychiatr safeti profil vareniclin bupropion randomis doubl blind activ control placebo control trial smoker psychiatr disord systemat probe neuropsychiatr advers event particip treatment treatment smoke cessat attempt addit safeti issu smoke cessat efficaci nicotin medic rel nicotin replac therapi plai role determin benefit risk ratio studi head head trial smoker psychiatr disord network meta analysi independ cochran databas systemat review recommend direct comparison singl combin form ulat nicotin replac therapi vareniclin valuabl 1 recent open label trial lighter smokers17 highlight doubl blind placebo control head head parison evidenc studi result inconsist previou find meta analys vareniclin efficaci singl formul nicotin replac therapi 1 rel efficaci line smoke cessat medic differ function smoker psychiatr histori previou compar efficaci trial directli compar medic smoker psychiatr disord gap literatur mind describ result largest trial pharmacotherapi smoke cessat date object compar rel safeti efficaci medic smoker psychiatr disord studi request design consult fda studi post authoris safeti studi european union method studi design particip evalu advers event global smoke cessat studi eagl multin multicentr randomis doubl blind placebo control activ control trial 140 centr 16 countri contin appendix studi site includ clinic trial centr academ centr outpati clinic treat patient psychiatr disord elig particip smoker ag 18 75 year prespecifi psychiatr diagnos diagnost statist manual mental disord fourth edit text revis dsm iv tr 18 smoke averag ten cigarett dai previou year exhal carbon monoxid concentr greater 10 part million ppm screen motiv stop smoke evidenc sign inform consent trial enrol target quit date set potenti particip recruit investig clinic newspap radio televis advertis flier poster particip includ psychiatr cohort met dsm iv tr diagnost criteria mood disord includ major depress disord bipolar disord anxieti disord includ panic disord agoraphobia post traumat stress disord obsess compuls disord social phobia generalis anxieti disord psychot disord includ schizophrenia schizoaffect disord onlin appendix articl 4 www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 psychiatr cohort 3984 psychiatr cohort 4074 vareniclin 990 bupropion 989 nicotin patch 1006 placebo 999 vareniclin 1026 bupropion 1017 nicotin patch 1016 placebo 1015 demograph characterist sex male 510 52 503 51 497 49 489 49 392 38 387 38 384 38 387 38 femal 480 48 486 49 509 51 510 51 634 62 630 62 632 62 628 62 ag year 45 8 13 0 46 0 13 0 46 1 12 8 45 9 12 8 47 2 11 8 46 7 12 2 47 6 11 5 46 9 11 5 race white 819 83 820 83 837 83 817 82 849 83 816 80 804 79 822 81 black 135 14 116 12 127 13 126 13 145 14 165 16 176 17 155 15 asian 14 1 16 2 13 1 19 2 5 1 10 1 11 1 7 1 22 2 37 4 29 3 37 4 27 3 26 3 25 2 30 3 unspecifi 0 0 0 0 0 0 0 1 1 weight kg 80 0 19 5 80 4 20 1 81 6 19 6 80 6 19 3 83 0 21 5 82 5 21 3 80 8 20 1 82 7 21 3 region usa 464 47 466 47 476 47 469 47 590 58 586 58 575 57 581 57 western europ countri 322 33 320 32 322 32 326 33 297 29 292 29 303 30 297 29 eastern europ 111 11 112 11 112 11 111 11 94 9 92 9 93 9 93 9 south middl america 93 9 91 9 96 10 93 9 45 4 47 5 45 4 44 4 smoke characterist ftcd score 5 5 2 0 5 5 2 0 5 6 2 0 5 5 2 0 6 0 1 9 6 1 1 9 6 0 2 0 5 9 2 0 durat smoke year 27 8 12 8 28 2 13 0 28 2 12 8 28 2 12 6 28 9 11 8 28 2 12 4 28 9 11 9 28 3 11 6 cigarett smoke dai past month 20 8 8 3 20 6 7 8 20 8 8 2 20 5 7 9 20 6 8 0 20 5 8 2 20 8 9 1 20 7 8 2 previou quit attempt 3 3 13 8 3 4 10 3 3 1 4 2 3 2 7 4 3 4 7 7 3 5 6 9 3 3 5 3 3 6 10 9 particip previou quit attempt 809 82 808 82 832 83 795 80 855 83 843 83 851 84 854 84 psychiatr characterist primari diagnosi scid unipolar bipolar mood disord 731 71 716 70 713 70 722 71 anxieti disord 193 19 200 20 195 19 194 19 psychot disord 95 9 96 9 99 10 96 9 person disord 7 1 5 1 9 1 3 1 had total score 4 4 4 4 0 28 4 1 4 1 0 24 4 2 4 1 0 25 4 5 4 3 0 22 8 3 6 5 0 30 8 7 6 9 0 36 8 4 6 6 0 31 8 2 6 2 0 36 anxieti subscal score 2 8 2 8 2 7 2 6 2 7 2 6 2 9 2 8 5 1 3 8 5 3 4 0 5 2 4 0 5 2 3 8 depress subscal score 1 6 2 1 1 4 2 0 1 5 2 0 1 6 2 1 3 2 3 3 3 4 3 5 3 2 3 3 3 1 3 2 lifetim suicid relat histori ssr ideat 48 5 43 4 50 5 49 5 338 33 357 35 333 33 349 34 behaviour 6 1 9 1 7 1 6 1 137 13 143 14 111 11 123 12 receiv psychotrop medic enrol 75 8 72 7 85 8 96 10 534 52 471 46 491 48 500 49 antidepress 22 2 21 2 26 3 36 4 384 37 318 31 334 33 341 34 anxiolyt hypnot sed 53 5 49 5 61 6 61 6 160 16 141 14 186 18 136 13 antipsychot 2 1 2 1 2 1 7 1 165 16 160 16 167 16 159 16 mood stabilis 6 1 1 1 3 1 10 1 16 2 22 2 22 2 22 2 1 1 2 1 3 1 0 1 1 6 1 1 1 3 1 data mean sd mean sd rang state ssr columbia suicid sever rate scale ftcd fagerström test cigarett depend applic had hospit anxieti depress scale scid structur clinic interview diagnost statist manual mental axi ii disord treat popul australia canada denmark finland germani zealand south africa spain bulgaria russia slovakia argentina brazil chile mexico psychostimul aminoacid herbal botan tabl 1 baselin characterist articl www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 5 borderlin person disord qualifi primari psychiatr disord exclud psychiatr comorbid secondari allow diagnos prespecifi exclud destabilis psychiatr condit alcohol drug disord previou 12 month particip consid clinic stabl inclus exacerb condit preced 6 month stabl treatment 3 month treatment chang anticip studi consid investig high risk injuri suicid behaviour gaug particip respons suicid behavior questionnair revis 19 columbia suicid sever rate scale ssr 20 administ screen profession mental health assess particip psychiatr cohort confirm histori dsm iv tr axi ii disord complet inclus exclus criteria appendix written consent form studi procedur approv institut review board ethic committe particip institut studi adher declar helsinki21 intern confer harmonis good clinic practic guidelin 22 independ data monitor committe review safeti data prespecifi timepoint ensur particip safeti sampl size adequaci particip sign inform consent receiv financi compens studi particip time travel expens standard set trial site randomis mask elig particip stratifi psychiatr cohort cohort psychiatr cohort base psychiatr primari diagnosi site figur 1 trial profil psychiatr cohort 11 186 assess elig 3042 exclud 2482 meet inclus criteria 282 declin particip 278 reason 8144 particip randomli assign 4116 psychiatr cohort figur 2 4028 psychiatr cohort 1005 randomli assign vareniclin 990 treat 15 treat 7 lost follow 1 longer met elig criteria 4 longer particip 3 reason 787 complet studi 203 discontinu treatment start 139 treatment phase 44 lost follow 12 advers event 3 insuffici clinic respons 64 longer particip 1 withdrawn due pregnanc 15 reason 64 follow phase 24 lost follow 2 advers event 1 longer met elig criteria 30 longer particip 7 reason 1005 includ efficaci analys 990 includ safeti analys 1001 randomli assign bupropion 989 treat 12 treat 1 longer met elig criteria 9 longer particip 1 protocol violat 1 reason 783 complet studi 206 discontinu treatment start 130 treatment phase 39 lost follow 10 advers event 2 insuffici clinic respons 3 longer met elig criteria 64 longer particip 1 medic error 1 particip di 10 reason 76 follow phase 28 lost follow 2 advers event 1 insuffici clinic respons 39 longer particip 1 protocol violat 5 reason 1001 includ efficaci analys 989 includ safeti analys 1013 randomli assign nicotin patch 1006 treat 7 treat 7 longer particip 767 complet studi 239 discontinu treatment start 157 treatment phase 37 lost follow 21 advers event 5 insuffici clinic respons 1 longer met elig criteria 82 longer particip 3 protocol violat 8 reason 82 follow phase 35 lost follow 1 advers event 3 insuffici clinic respons 1 longer met elig criteria 36 longer particip 6 reason 1013 includ efficaci analys 1006 includ safeti analys 1009 randomli assign placebo 999 treat 10 treat 3 lost follow 1 longer met elig criteria 4 longer particip 2 reason 787 complet studi 212 discontinu treatment start 154 treatment phase 39 lost follow 8 advers event 3 insuffici clinic respons 2 longer met elig criteria 91 longer particip 2 protocol violat 1 withdrawn due pregnanc 1 particip di 7 reason 58 follow phase 20 lost follow 2 longer met elig criteria 33 longer particip 1 particip di 2 reason 1009 includ efficaci analys 999 includ safeti analys articl 6 www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 region base prespecifi geograph group tabl 1 stratif particip randomis receiv maxim target dosag vareniclin 1 mg dai bupropion sustain releas 150 mg dai transderm nicotin patch 21 mg dai taper placebo 1 1 1 1 ratio tripl dummi design 12 week treatment phase 12 week treatment phase appendix particip ask complet 15 face face visit 11 telephon visit 24 week trial tripl dummi design featur requir particip studi medic mask tablet dispens separ vareniclin bupropion pill bottl match placebo appli activ placebo patch daili basi particip receiv activ treatment placebo medic condit instruct treatment dai activ treatment phase enrol equal 4000 1000 treatment group cohort treatment group balanc diagnost group psychiatr cohort psychiatr cohort mood psychiatr cohort anxieti psychiatr cohort psychot psychiatr cohort person disord region randomis administr independ clinic studi team prepar comput gener randomis schedul assign particip treatment block size 8 1 1 1 1 ratio 20 diagnosi region combin investig obtain particip identif number web base telephon call drug manag system studi figur 2 trial profil psychiatr cohort 1032 randomli assign vareniclin 1026 treat 6 treat 1 lost follow 5 longer particip 811 complet studi 215 discontinu treatment start 154 treatment phase 48 lost follow 20 advers event 1 insuffici clinic respons 2 longer met elig criteria 65 longer particip 4 protocol violat 14 reason 61 follow phase 19 lost follow 1 longer met elig criteria 36 longer particip 5 reason 1032 includ efficaci analys 1026 includ safeti analys 1033 randomli assign bupropion 1017 treat 16 treat 3 lost follow 1 advers event 1 longer met elig criteria 8 longer particip 1 protocol violat 2 reason 803 complet studi 214 discontinu treatment start 151 treatment phase 39 lost follow 16 advers event 1 insuffici clinic respons 4 longer met elig criteria 81 longer particip 1 protocol violat 1 particip di 8 reason 63 follow phase 20 lost follow 1 longer met elig criteria 34 longer particip 1 particip di 7 reason 1033 includ efficaci analys 1017 includ safeti analys 1025 randomli assign nicotin patch 1016 treat 9 treat 1 advers event 5 longer particip 1 protocol violat 1 particip di 1 reason 790 complet studi 226 discontinu treatment start 146 treatment phase 38 lost follow 12 advers event 5 insuffici clinic respons 3 longer met elig criteria 72 longer particip 1 protocol violat 15 reason 80 follow phase 34 lost follow 1 advers event 1 insuffici clinic respons 1 longer met elig criteria 34 longer particip 1 protocol violat 1 particip di 7 reason 1025 includ efficaci analys 1016 includ safeti analys 1026 randomli assign placebo 1015 treat 11 treat 3 lost follow 8 longer particip 765 complet studi 250 discontinu treatment start 181 treatment phase 44 lost follow 17 advers event 8 insuffici clinic respons 1 longer met elig criteria 90 longer particip 1 medic error 3 protocol violat 1 particip di 16 reason 69 follow phase 24 lost follow 1 advers event 2 insuffici clinic respons 34 longer particip 8 reason 1026 includ efficaci analys 1015 includ safeti analys 11 186 assess elig 3042 exclud 2482 meet inclus criteria 282 declin particip 278 reason 8144 particip randomli assign 4116 psychiatr cohort 4028 psychiatr cohort figur 1 articl www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 7 product kit code deciph randomis treatment block size particip investig research personnel mask treatment assign procedur particip set target quit date 1 week randomis coincid end titrat vareniclin bupropion initi nicotin patch treatment smoke cessat counsel 10 min base agenc healthcar research qualiti guidelines4 clinic visit particip encourag complet studi visit treatment discontinu studi visit pill patch count document measur medic complianc complianc defin partial full daili dose studi drug 80 plan treatment period minimum 68 dai metric treatment complianc 80 treatment condit tobacco nicotin assess structur questionnair clinic visit telephon contact clinic visit includ expir air carbon monoxid measur emerg advers event assess open end question direct observ semi structur neuropsychiatr advers event interview naei studi visit train interview fulli captur neuropsychiatr advers event interest appendix naei compris 25 question probe psychiatr symptom clinic trial 10 posit respons consid neuropsychiatr advers event assess train interview inquir symptom frequenc durat sever gener psychiatr advers event met fda requir advers event result death admiss hospit substanti disabl life threaten event classifi addition investig instruct assess posit respons ssr 20 proxi report particip famili member physician neuropsychiatr advers event psychiatr diagnosi assess screen structur clinic interview dsm iv tr axi ii disord scid scid ii 23,24 aspect psychiatr symptom sever assess baselin visit ssr 20 hospit anxieti psychiatr cohort 3984 psychiatr cohort 4074 vareniclin 990 bupropion 989 nicotin patch 1006 placebo 999 vareniclin 1026 bupropion 1017 nicotin patch 1016 placebo 1015 primari composit neuropsychiatr endpoint 13 1 3 22 2 2 25 2 5 24 2 4 67 6 5 68 6 7 53 5 2 50 4 9 estim primari composit neuropsychiatr advers event 95 ci 1 25 0 60 1 90 2 44 1 52 3 36 2 31 1 37 3 25 2 52 1 58 3 46 6 42 4 91 7 93 6 62 5 09 8 15 5 20 3 84 6 56 4 83 3 51 6 16 differ risk composit primari endpoint 95 ci versu placebo 1 28 2 40 0 15 0 08 1 37 1 21 0 21 1 54 1 12 1 59 0 42 3 59 1 78 0 24 3 81 0 37 1 53 2 26 versu nicotin patch 1 07 2 21 0 08 0 13 1 19 1 45 1 22 0 81 3 25 1 42 0 63 3 46 versu bupropion 1 19 2 30 0 09 0 20 2 34 1 95 compon primari neuropsychiatr composit endpoint anxieti 0 1 0 1 0 3 0 3 5 0 5 4 0 4 6 0 6 2 0 2 depress 1 0 1 0 0 0 6 0 6 4 0 4 7 0 7 6 0 6 feel abnorm 0 0 0 0 0 1 0 1 0 0 hostil 0 1 0 1 1 0 1 0 0 0 0 0 agit 10 1 0 11 1 1 19 1 9 11 1 1 25 2 4 29 2 9 21 2 1 22 2 2 aggress 3 0 3 3 0 3 2 0 2 3 0 3 14 1 4 9 0 9 7 0 7 8 0 8 delus 0 0 1 0 1 0 1 0 1 1 0 1 1 0 1 0 hallucin 1 0 1 0 0 0 5 0 5 4 0 4 2 0 2 2 0 2 homicid ideat 0 0 1 0 1 0 0 0 0 0 mania 0 1 0 1 2 0 2 2 0 2 7 0 7 9 0 9 3 0 3 6 0 6 panic 0 4 0 4 1 0 1 3 0 3 7 0 7 16 1 6 13 1 3 7 0 7 paranoia 0 1 0 1 0 0 1 0 1 0 0 2 0 2 psychosi 0 0 1 0 1 0 4 0 4 2 0 2 3 0 3 1 0 1 suicid behaviour 0 1 1 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 suicid ideat 0 1 0 1 2 0 2 3 0 3 5 0 5 2 0 2 3 0 3 2 0 2 complet suicid 0 0 0 1 0 1 0 0 0 0 tabl 2 continu page articl 8 www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 depress scale had 25 particip report sever neuropsychiatr advers event consid increas suicid risk substanti worsen psychiatr condit underw psychiatr evalu risk assess visit mental health profession made specif treatment intervent recommend includ particip continu studi fagerström test cigarett depend ftcd 26 assess cigarett depend sever baselin outcom primari endpoint composit measur base post market report neuropsychiatr advers event smoker take vareniclin bupropion compris 16 neuropsychiatr symptom categori includ 261 medic dictionari regulatori activ version 18.0 meddra 18.0 deriv prefer term primari endpoint captur volunt observ solicit neuropsychiatr advers event event increas sever ongo symptom 16 compon irrespect site studi physician assess causal relat studi medic primari endpoint met particip report event code 261 meddra deriv prefer term 16 symptom categori treatment 30 dai treatment discontinu met pre establish sever criteria advers event rate train investig mild interfer particip psychiatr cohort 3984 psychiatr cohort 4074 vareniclin 990 bupropion 989 nicotin patch 1006 placebo 999 vareniclin 1026 bupropion 1017 nicotin patch 1016 placebo 1015 continu previou page primari composit neuropsychiatr endpoint sever intens 1 0 1 4 0 4 3 0 3 5 0 5 14 1 4 14 1 4 14 1 4 13 1 3 compon primari neuropsychiatr composit endpoint sever intens anxieti 0 1 0 1 0 3 0 3 5 0 5 4 0 4 6 0 6 2 0 2 depress 1 0 1 0 0 0 6 0 6 4 0 4 7 0 7 6 0 6 feel abnorm 0 0 0 0 0 1 0 1 0 0 hostil 0 1 0 1 1 0 1 0 0 0 0 0 agit 0 0 2 0 2 0 1 0 1 1 0 1 4 0 4 2 0 2 aggress 1 1 0 1 0 1 0 0 1 0 1 1 0 1 0 1 0 1 delus 0 0 0 0 0 0 0 0 hallucin 0 0 0 0 0 1 0 1 0 0 homicid ideat 0 0 0 0 0 0 0 0 mania 0 0 0 0 2 0 2 1 0 1 0 0 panic 0 1 0 1 1 0 1 1 0 1 0 1 0 1 0 1 0 1 paranoia 0 0 0 0 0 0 0 0 psychosi 0 0 0 0 0 1 0 1 1 0 1 0 suicid behaviour 0 1 0 1 0 0 1 0 1 1 0 1 0 1 0 1 suicid ideat 0 0 0 1 0 1 1 0 1 0 1 0 1 0 complet suicid 0 0 0 1 0 1 0 0 0 0 event primari endpoint advers event 0 1 0 1 2 0 2 3 0 3 6 0 6 5 0 5 3 0 3 3 0 3 result perman treatment discontinu 1 0 1 5 0 5 7 0 7 3 0 3 16 1 6 15 1 5 12 1 2 15 1 5 lead intervent 0 2 0 2 1 0 1 3 0 3 7 0 7 12 1 2 7 0 7 11 1 1 combin advers event sever advers event lead treatment discontinu intervent 2 0 2 8 0 8 8 0 8 10 1 0 28 2 7 28 2 8 21 2 1 29 2 9 data state base squar mean analysi point estim 95 ci estim risk differ base gener linear model term treatment cohort region treatment cohort interact region level classif usa usa advers event report treatment 30 dai dose particip count row report multipl event particip count multipl row risk differ treat popul addit particip nicotin patch group psychiatr cohort report moder suicid ideat advers event identifi clinic databas lock particip includ analysi primari studi endpoint sever intens advers event moder sever intens advers event advers event psychiatr cohort bupropion suicid attempt 1 nicotin patch suicid attempt 1 panic 1 placebo suicid ideat 2 complet suicid 1 psychiatr cohort vareniclin suicid ideat 2 depress 1 auditori hallucin 1 exacerb bipolar disord 1 anxieti injuri behaviour 1 bupropion suicid attempt schizoaffect disord 1 exacerb bipolar disord 2 bipolar ii disord 1 emot disord neuropsychiatr symptom 1 nicotin patch anxieti 2 depress 1 placebo suicid attempt 1 suicid ideat 1 aggress 1 intervent includ psychotrop medic psychotherapi counsel admiss hospit tabl 2 summari primari neuropsychiatr composit safeti endpoint compon articl www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 9 usual daili function moder interfer function sever substanti interfer pre sever criteria primari neuropsychiatr advers event endpoint requir advers event compon expect report commonli anxieti depress feel abnorm hostil rate sever neuropsychiatr advers event remain 12 categori agit aggress delus hallucin homicid ideat mania panic paranoia psychosi suicid ideat behaviour complet suicid met sever criteria rate moder sever simplifi scheme primari composit safeti endpoint shown appendix secondari safeti endpoint includ subset neuropsychiatr advers event rate sever occurr individu compon safeti assess includ psychiatr rate scale advers event vital sign select laboratori valu cardiovascular safeti data report separ complet 28 week treatment extens phase primari efficaci endpoint smoke cessat continu abstin rate week 9 12 particip consid abstin report tobacco abstin period conjunct exhal carbon monoxid concentr greater 10 ppm miss report week 12 imput backward carri method miss week 12 deem smoker miss carbon monoxid measur imput 10 ppm sensit analysi imput miss valu smoke accord recommend practic 27 particip lost follow consid smoker pre design secondari efficaci endpoint carbon monoxid confirm continu abstin week 9 24 defin similarli 7 dai point preval abstin visit contact prespecifi outcom statist analysi sampl studi driven requir estim size increas rate neuropsychiatr advers event rel placebo group pre level precis base pool data previou randomis control trial 28 underli placebo rate neuropsychiatr advers event psychiatr cohort psychiatr cohort postul 3 5 7 0 sampl size 2000 treatment group determin suffici estim 75 increas neuropsychiatr advers event rate 1 59 1 59 sampl size suffici detect fold increas odd abstin rate placebo group point interv estim risk differ rd differ percentag incid neuro psychiatr advers event obtain generalis linear regress term account treatment cohort psychiatr cohort psychiatr cohort region reduc region usa usa interact differ consid signific 95 ci logist regress analysi analysi abstin endpoint estim odd ratio or 95 ci obtain linear contrast particip randomis studi medic compris popul efficaci analys particip treat studi medic compris popul analysi safeti vareniclin bupropion comparison versu placebo prespecifi primari treatment comparison deem psychiatr cohort 3984 psychiatr cohort 4074 vareniclin 990 bupropion 989 nicotin patch 1006 placebo 999 vareniclin 1026 bupropion 1017 nicotin patch 1016 placebo 1015 treatment 30 dai dose assess 988 983 996 995 1017 1012 1006 1006 suicid behaviour ideat 7 1 4 1 3 1 7 1 27 3 15 1 20 2 25 2 suicid behaviour 0 0 1 1 1 1 0 1 1 0 2 1 suicid ideat 7 1 4 1 3 1 6 1 27 3 15 1 20 2 25 2 follow 30 dai treatment dose end studi assess 807 816 800 805 833 836 824 791 suicid behaviour ideat 3 1 2 1 3 1 4 1 14 2 4 1 9 1 11 1 suicid behaviour 0 1 1 0 0 1 1 0 1 1 1 1 suicid ideat 3 1 2 1 3 1 4 1 14 2 4 1 9 1 11 1 data treat popul suicid behaviour sever particip posit answer ssr treatment psychiatr cohort nicotin patch suicid attempt 1 placebo complet suicid 1 psychiatr cohort bupropion suicid attempt 1 placebo suicid attempt 2 complet suicid follow psychiatr cohort bupropion suicid attempt 1 psychiatr cohort vareniclin suicid attempt 1 nicotin patch abort attempt 1 placebo abort attempt 1 tabl 3 columbia suicid sever rate scale ssr articl 10 www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 secondari adjust multipl test made trial regist clinicaltrials.gov number nct01456936 close role fund sourc studi post market requir usa pfizer glaxosmithklin studi design sponsor employe input ak lsa dl cr academ author rma input nlb aee rw lead academ author prepar initi draft manuscript author involv acquisit analysi interpret data critic revis manuscript import intellectu content lead academ author full access data studi final respons decis submit public author assum respons complet integr data fidel studi protocol statist analysi plan result nov 30 2011 jan 13 2015 11 186 smoker screen 8144 73 randomli assign psychiatr cohort 4028 psychiatr cohort 4116 figur 1 2 treat particip psychiatr cohort 3984 psychiatr cohort 4074 3145 79 3023 74 complet treatment 3124 78 3169 78 particip complet studi figur 1 2 reason discontinu similar cohort treatment group baselin demograph smoke psychiatr characterist treat particip present tabl 1 studi popul includ 3549 44 men averag ag 46 5 year 6584 82 particip white race ethnic particip usa 4207 52 particip smoke averag 21 cigarett dai averag ftcd 5 8 6647 82 particip made previou attempt quit treatment group similar baselin characterist cohort smoker psychiatr cohort femal resid usa higher ftcd score tabl 1 smoker psychiatr cohort met dsm iv tr criteria primari mood 2882 71 particip anxieti 782 19 particip psychot 386 9 particip borderlin person disord 24 1 particip 1996 49 particip take psychotrop medic baselin psychiatr cohort psychiatr cohort 3984 psychiatr cohort 4074 vareniclin 990 bupropion 989 nicotin patch 1006 placebo 999 vareniclin 1026 bupropion 1017 nicotin patch 1016 placebo 1015 psychiatr disord 315 32 332 34 301 30 259 26 405 39 435 43 420 41 354 35 abnorm dream 83 8 47 5 111 11 39 4 118 12 84 8 140 14 53 5 agit 32 3 29 3 28 3 25 3 47 5 56 6 39 4 41 4 anger 3 1 1 1 1 1 3 1 11 1 4 1 4 1 5 1 anxieti 46 5 64 6 45 4 57 6 86 8 105 10 93 9 63 6 depress mood 31 3 13 1 27 3 29 3 47 5 47 5 52 5 52 5 depress 17 2 13 1 8 1 15 2 49 5 45 4 47 5 46 5 depress symptom 5 1 3 1 2 1 2 1 11 1 8 1 12 1 13 1 initi insomnia 7 1 6 1 10 1 4 1 15 1 8 1 10 1 2 1 insomnia 95 10 126 13 91 9 73 7 94 9 119 12 104 10 66 7 irrit 34 3 29 3 47 5 37 4 48 5 42 4 61 6 67 7 major depress 3 1 0 1 1 3 1 7 1 10 1 4 1 2 1 middl insomnia 7 1 15 2 13 1 6 1 11 1 16 2 13 1 8 1 nervous 14 1 18 2 11 1 9 1 21 2 19 2 17 2 27 3 nightmar 9 1 7 1 26 3 3 1 13 1 9 1 30 3 14 1 panic attack 2 1 7 1 2 1 3 1 9 1 19 2 13 1 11 1 restless 14 1 14 1 15 1 14 1 17 2 20 2 14 1 9 1 sleep disord 31 3 37 4 17 2 19 2 34 3 36 4 28 3 23 2 tension 2 1 10 1 2 1 2 1 9 1 5 1 10 1 6 1 data classifi medic dictionari regulatori activ meddra version 18.0 system organ class categori psychiatr disord deriv prefer term occur treatment 30 dai dose treat popul meddra version 18.0 prefer term anxieti differ anxieti compon primari composit endpoint cluster meddra version 18.0 prefer term relat anxieti disord note appli prefer term tabl depress agit tabl 4 mild moder sever advers event code meddra categori psychiatr disord report 1 particip treatment group articl www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 11 1377 34 particip histori suicid ideat 514 13 particip histori suicid behaviour base ssr incid neuropsychiatr advers event endpoint similar treatment group vareniclin 4 0 80 2016 particip bupropion 4 5 90 2006 particip nicotin patch 3 9 78 2022 particip placebo 3 7 74 2014 particip neuro psychiatr advers event psychiatr cohort 5 8 238 4074 particip psychiatr cohort 2 1 84 3984 particip 0 0001 cohort effect tabl 2 treatment cohort interact 0 0652 analys neuropsychiatr advers event treatment assign present cohort separ psychiatr cohort risk composit safeti endpoint lower particip assign vareniclin assign placebo 1 28 95 ci 2 40 0 15 signific differ neuropsychiatr advers event assign bupropion versu placebo 0 08 1 37 1 21 differ vareniclin nicotin patch bupropion nicotin patch signific psychiatr cohort psychiatr cohort signific pairwis treatment differ 95 ci includ fewer particip treatment group psychiatr cohort ten 17 psychiatr cohort met primari safeti endpoint report neuropsychiatr advers event appendix particip report primari neuropsychiatr endpoint percentag report neuro psychiatr advers event sever met advers event criteria led treatment discontinu intervent clinic signific event lower psychiatr cohort psychiatr cohort similar treatment group tabl 2 number particip report suicid ideat behaviour ssr greater psychiatr cohort psychiatr cohort similar treatment group tabl 3 figur 3 continu abstin rate week 9 12 9 24 analys base randomis popul odd ratio 38 0 26 1 26 4 13 7 25 5 18 8 18 5 10 5 29 2 19 3 20 4 11 4 18 3 13 7 13 0 8 3 33 5 22 6 23 4 12 5 21 8 16 2 15 7 9 4 psychiatr cohort 4028 vareniclin 1005 bupropion 1001 nicotin patch 1013 placebo 1009 psychiatr cohort 4116 vareniclin 1032 bupropion 1033 nicotin patch 1025 placebo 1026 8144 vareniclin 2037 bupropion 2034 nicotin patch 2038 placebo 2035 95 ci primari comparison vareniclin placebo bupropion placebo secondari comparison nicotin patch placebo vareniclin nicotin patch bupropion nicotin patch vareniclin bupropion week 9 12 week 9 24 week 9 12 week 9 24 week 9 12 week 9 24 week 9 12 week 9 24 week 9 12 week 9 24 week 9 12 week 9 24 4 00 3 20 5 00 0 0001 2 26 1 80 2 85 0 0001 2 30 1 83 2 90 0 0001 1 74 1 43 2 10 0 0001 0 98 0 80 1 20 0 8701 1 77 1 46 2 14 0 0001 2 99 2 33 3 83 0 0001 2 00 1 54 2 59 0 0001 1 96 1 51 2 54 0 0001 1 52 1 23 1 89 0 0001 1 02 0 81 1 28 0 8645 1 49 1 20 1 85 0 0003 3 24 2 56 4 11 0 0001 1 87 1 46 2 39 0 0001 2 00 1 56 2 55 0 0001 1 62 1 32 1 99 0 0001 0 94 0 75 1 16 0 5467 1 74 1 41 2 14 0 0001 2 50 1 90 3 29 0 0001 1 77 1 33 2 36 0 0001 1 65 1 24 2 20 0 0007 1 51 1 19 1 93 0 0008 1 07 0 83 1 39 0 5824 1 41 1 11 1 79 0 0047 3 61 3 07 4 24 0 0001 2 07 1 75 2 45 0 0001 2 15 1 82 2 54 0 0001 1 68 1 46 1 93 0 0001 0 96 0 83 1 11 0 5797 1 75 1 52 2 01 0 0001 2 74 2 28 3 30 0 0001 1 89 1 56 2 29 0 0001 1 81 1 49 2 19 0 0001 1 52 1 29 1 78 0 0001 1 04 0 88 1 24 0 6002 1 45 1 24 1 70 0 0001 0 5 10 15 20 25 30 35 40 nt uo bs tin en ce ra te vareniclin bupropion nicotin patch placebo articl 12 www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 complet suicid studi placebo treat particip psychiatr cohort averag total had score improv baselin treatment phase 2 point psychiatr cohort 3 point psychiatr cohort effect similar treatment group appendix tabl 4 list advers event mild moder sever psychiatr disord meddra categori occur 1 treatment group cohort irrespect met criteria primari neuropsychiatr advers event endpoint psychiatr cohort report neuropsychiatr advers event type psychiatr cohort profil advers event exhibit abnorm dream common vareniclin nicotin patch compar placebo consist previou report incid gener advers event advers event death treatment discontinu advers event observ 5 particip summaris appendix treatment toler cohort frequent advers event treatment group nausea vareniclin 25 511 2016 particip insomnia bupropion 12 245 2006 particip abnorm dream nicotin patch 12 251 2022 particip headach placebo 10 199 2014 particip studi protocol analysi undertaken assess treatment efficaci vari psychiatr cohort psychiatr cohort abstin rate lower psychiatr cohort versu psychiatr cohort figur 3 evid found interact 0 6237 continu abstin rate week 9 12 9 24 treatment or pairwis comparison present combin sampl cohort figur 3 vareniclin show superior efficaci placebo nicotin patch bupropion end treatment week 9 12 follow week 9 24 bupropion show similar efficaci nicotin patch show superior efficaci versu placebo imput miss carbon monoxid measur occur 72 particip report continu abstin week 9 24 smoke significantli affect result appendix 7 dai point preval abstin week 1 24 show result consist continu abstin rate appendix discuss larg multin trial show signific increas rate moder sever neuropsychiatr advers event vareniclin bupropion rel nicotin patch placebo psychiatr disord find treatment valid longitudin assess ment suicid ssr mood anxieti symptom had convent assess neuropsychiatr advers event includ treatment discontinu vareniclin show superior efficaci bupropion nicotin patch cohort bupropion similar efficaci nicotin patch show superior efficaci placebo cohort interpret ci primari outcom measur find make highli vareniclin bupropion increas moder sever neuropsychiatr advers event 1 5 percentag point smoker psychiatr disord 4 percentag point smoker psychiatr disord base upper bound 95 ci consist increas neuropsychiatr advers event popul smoker studi detect 4 percentag point signific differ rate neuropsychiatr advers event psychiatr psychiatr cohort observ incid close postul valu 2 psychiatr cohort 6 psychiatr cohort failur detect medic effect attribut lack sensit measur select smoker unusu good mental health result add substanti previou meta analys randomis control trials12 14 observ studi 9,15,16,29 rigor experiment design detail proactiv assess treatment emerg post treatment neuropsychiatr symptom address limit previou studi provid import inform regul prescrib smoker make inform choic decid address nicotin depend find show time efficaci medic term or similar smoker psychiatr disord smoker psychiatr cohort achiev lower abstin rate psychiatr cohort absolut effect size smaller psychiatr disord substanti inspect 7 dai point preval abstin curv reveal similar recruit abstin effect previous psychiatr ill smoker vareniclin analys help assess evid differenti effect function sever psychiatr disord diagnost categori studi evid compar efficaci main pharmacolog treatment aid smoke cessat doubl blind tripl dummi trial size differ similar predict cochran network meta analysi 1 fact studi centr countri wide attitud tobacco confirm generalis conclus cultur articl www.thelancet.com publish onlin april 22 2016 http dx.doi.org 10.1016 s0140 6736 16 30272 0 13 result differ recent open label studi compar vareniclin combin nicotin replac therapi nicotin patch lozeng singl formul nicotin replac therapi nicotin patch 17 compar outcom measur prolong abstin 26 week studi found 1 1 small sampl size 95 ci 0 7 1 7 overlap point estim found present studi 1 52 estim cochran network meta analysi 1 57 present studi limit includ smoker psychiatr disord stabl treat previou psychiatr condit major depress disord remiss select effect affect find result generalis untreat symptomat unstabl psychiatr ill similarli restrict scope psychiatr cohort smoker major diseas categori mood anxieti psychot borderlin person disord exclud particip current substanc disord immin risk suicid limit generalis 24 week durat studi frequent monitor mirror real world smoke cessat attempt largest doubl blind placebo control safeti efficaci trial pharmacotherapi smoke cessat date cohort psychiatr cohort smaller studi power detect differ rare event complet suicid rule base upper bound 95 ci increas neuropsychiatr advers event defin 4 psychiatr cohort fourth recruit individu smoke averag ten cigarett dai moder nicotin depend find generalis lighter sever depend smoker analys potenti moder effect sex depend sever depress anxieti symptom cohort pre statist analysi plan consid com.ibm.drl.hbcp.predictor variabl subsequ public final attrit occur treatment group cohort miss data affect outcom limit lack signal neuropsychiatr advers event randomli control trial 10 14,30 combin grow number studi find associ larg cohort smoker psychiatr disord 9,15,16,29 make improb medic psychiatr stabl smoker causal heighten neuropsychiatr safeti risk summari context evid clinic trial observ cohort studi larg multin trial evid vareniclin bupropion safe psychiatr stabl smoker vareniclin appear effect singl pharmacotherapi line medic vareniclin bupropion nicotin patch efficaci compar placebo contributor rma dl full access data studi respons integr data accuraci data analysi rma lsa nlb aee ak dl cr rw input studi design dl ak statist analys lsa dl tm involv studi supervis author involv acquisit analysi interpret data rma draft manuscript author involv critic revis manuscript import intellectu content declar interest rma report receiv grant pfizer alkerm provid consult advisori board servic pfizer arena pharmaceut cerecor rma write manuscript support part nation institut alcohol abus alcohol grant number u01 aa013641 r01 aa019720 nation institut drug abus veteran affair cooper studi number 1031 1032 veteran affair merit award number neua 003 08 nlb report provid consult advisori board servic pfizer glaxosmithklin paid expert wit litig tobacco compani rw report receiv grant pfizer johnson johnson glaxosmithklin receiv person fee advisori board servic pfizer glaxosmithklin rw salari fund cancer research uk aee report receiv grant pfizer forum pharmaceut receiv person fee advisori board servic pfizer reckitt benckis aee write manuscript support nation institut drug abus career award patient orient research number k24 da030443 lsa tm dl cr employe stockhold pfizer ja employe glaxosmithklin stockhold compani ak parexel employe work behalf glaxosmithklin opinion express articl author necessarili reflect view employ acknowledg investig studi site personnel involv studi institut compens contribut pfizer glaxosmithklin editori support form creat tabl figur format refer collat review comment proof format submiss provid ann jakobsen abegal templar engag scientif horsham uk fund pfizer
author 2014 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com doi 10.1093 ntr ntu036 origin investig preliminari random control trial behavior exercis intervent smoke cessat ana abrant phd1,2 erika litvin bloom phd1,2 david strong phd2,3 deborah rieb phd4 bess marcu phd2,3 juli desaulni ms1 kathryn foka bs1 richard brown phd1,2 1butler hospit provid ri 2depart psychiatri human behavior alpert medic school brown univers provid ri 3depart famili prevent medicin univers california san diego la jolla ca 4depart kinesiolog univers rhode island kingston ri author ana abrant phd butler hospit 345 blackston boulevard provid ri 02906 usa telephon 401 455 6440 fax 401 455 6685 mail ana_abrant brown.edu receiv august 26 2013 accept februari 13 2014 abstract introduct previou exercis intervent studi smoke cessat challeng number methodolog cal limit confound potenti efficaci aerob exercis smoke cessat method preliminari efficaci behavior exercis intervent incorpor featur design address prior limit test random control trial rct sixti smoker 65.6 femal mean ag 47.3 year smoke mean 19.7 cigarett dai random receiv 12 week exercis intervent 12 week health educ contact control particip condit receiv 8 week telephon deliv standard smoke cessat protocol transderm nicotin patch follow up conduct end treatment eot 6 12 month timepoint result differ condit respect number weekli exercis health educ session attend 9.3 2.8 9.3 3.0 statist signific particip exercis condit demonstr higher verifi abstin rate eot 40 22.6 odd ratio 2.28 6 12 month follow up 26.7 12.9 2.46 irrespect treatment condit higher level moder vigor exercis lower level depress symptom intervent conclus result small rct point benefit behavior exercis intervent design address previou methodolog limit smoke cessat potenti public health impact demonstr efficaci exercis smoke cessat continu develop optim exercis intervent smoker larger rct merit pursuit introduct role regular aerob exercis ae potenti aid smoke cessat reduc relaps risk receiv increasingli greater attent ussher taylor faulkner 2012 practic exercis routin recommend cessat aid smoke profession everson taylor ussher 2010 endors current clinic practic guidelin treat tobacco depend fior al 2008 smoker identifi exercis potenti quit strategi everson hock taylor ussher 2010 smoker engag regular exercis lower level nation popul emmon marcu linnan rossi abram 1994 french hennriku jefferi 1996 exercis regularli mak ing quit attempt achiev long term abstin abrant al 2009 recent updat cochran review ussher colleagu 2012 conclud insuffici evid determin regular exercis effect intervent strategi promot smoke cessa tion note exist random control trial rct signific methodolog limit includ small sampl intervent insuffici intens lack effort increas adher lack contact control condit lack object measur physic activ fit insuffici attent tempor sequenc exercis quit import issu adher rate vari gener consist low studi argu actual engag exercis efficaci exercis fairli determin find marcu al 2005 found treatment effect exercis health educ control advanc access public 8 2014 1094 nicotin tobacco research volum 16 number 8 august 2014 1094 1103 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload mailto:ana_abrant brown.edu subject http ntr.oxfordjournals.org nicotin tobacco research condit smoker engag higher level moder intens ae week smoke abstin significantli higher effort address issu adher william colleagu 2010 conduct small random studi 8 week exercis program femal smoker design featur ensur complianc enrol highli motiv women complet 2 week run requir exercis supervis financi incentiv attend anc compar control particip exercis con dition time abstin end treatment eot abstin 1 month follow studi emploi featur limit potenti translat real world context e.g 2 week run exercis supervis studi facil addit limit recent year exercis intervent studi incorpor physic activ vigor intens vigor intens exercis current smoker due compromis respiratori capac ussher nunziata croplei west 2001 found smoker exercis moder intens measur heart rate perceiv exert high intens rang measur rate perceiv exert rpe vigor intens exercis difficult sedentari smoker ultim affect exercis adher addit moder intens oppos vigor inten siti ae consist higher level exercis adher vari popul perri al 2002 studi fewest methodolog limit kinnunen al 2008 marcu al 1999 marcu al 2005 prapavessi al 2007 conduct femal smoker exercis introduc mean decreas post cessat weight gain weight gain relaps risk male smoker borrelli spring niaura hitsman papandonato 2001 higher rate smoke male cdc 2011 design studi examin effect exercis intervent male smoker addit men women intervent introduc exercis manner extend weight manag includ benefit relat fit mental health function e.g improv mood cope import examin current studi test preliminari efficaci ae intervent smoker specif design address identifi methodolog limit generaliz dissemin intervent inter vention includ featur moder intens exercis sequenti approach adopt exercis 1 month prior quit date combin supervis home base exercis inclus femal male smoker conting base financi incent compon increas exercis adher inclus cognit behavior group intervent promot exercis adopt adher notabl aspect telephon counsel smoke cessat face face counsel consid er futur dissemin ae intervent adjunct tobacco quitlin e.g segan al 2011 initi rct ae compar health educ contact control hec intervent design includ level con tact treatment provid ae hec group receiv telephon counsel intervent smoke cessat transderm nicotin patch tnp hypothes abstin rate significantli higher ae group rel hec ae group show evid decreas crave withdraw symptom neg affect rel hec method procedur particip recruit newspap radio adver tisement particip screen telephon cur rent smoke level 10 cigarett dai extent physic inact particip regularli ae 20 min dai 3 dai week past 6 month particip appear meet studi criteria schedul comprehens baselin assess exclus criteria includ current dsm iv axi criteria alcohol drug abus depend bipolar disord eat disord psychot disord current suicid homicid physic disabl medic problem prohibit engag ae i. deni medic clearanc primari care physician current pregnanc intent pregnant 3 month i. treatment current pharmacotherapi smoke cessat includ nicotin replac therapi research staff obtain inform consent par ticip evalu diagnost screen measur detail confirm elig receiv medic clearanc exercis particip assign condit urn random stout 1988 bodi mass index bmi level nicotin depend gender ag includ block variabl 12 session group ae intervent hec equat therapist partici pant contact time particip condit receiv 8 session telephon counsel smoke cessat intervent includ tnp assess occur baselin 3 eot 6 12 month follow up 85 80 74 pletion rate particip compens 50 follow assess particip total 707 smoker express interest particip studi particip exclud reason physic activ 22 axi psychiatr disord 15.4 attend group ae hec session 8.2 medic condit 5.7 smoke 10 cigarett dai 4.1 reason 3.1 e.g ag take medi cation cessat phone smoke studi english speaker addit 32.7 par ticip lost interest studi initi contact 204 point baselin assess procedur 29 sixti particip 65.6 femal mean ag 47.3 year recruit random ae 30 hec 31 figur 1 consort figur tabl 1 baselin demograph characterist ae intervent ae compon particip ae condit attend ae session super vise exercis physiologist week research fit facil addition particip exercis prescript engag exercis minimum 1095 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org s04aw6 highlight exercis smoke cessat depend week intervent addit time week context environ e.g home commun resourc goal pro gress 100 min moder intens exercis week midwai intervent 150 min week week 12 week intervent particip instruct monitor exercis complet weekli exercis log includ type durat rpe activ exercis session began 20 min session weekli gradual increas heart rate monitor exercis physiologist ensur train moder intens rang 55 69 ag predict maxim heart rate type exercis equip par ticip includ treadmil recumb bicycl ellipti cal machin cognit behavior counsel exercis promot compon demonstr efficaci behavior modif strategi increas physic activ meta analysi dishman buckworth 1996 behavior techniqu incorpor exercis intervent condit 20 min weekli group session held dai prior exercis session weekli group particip guid increas physic activ behavior daili live group session focus topic design increas motiv improv exercis adopt maint nanc e.g psycholog physic health benefit exer cise barrier time manag maintain motiv goal set social support financi incent compon order maxim adher particip entitl incent level complianc exercis pro gram particip receiv 5 attend combin exercis cognit behavior group session 5 return ing complet exercis monitor form prior week irrespect actual exercis complet addi tion drew prize fish bowl rang 10 50 attend weekli exercis counsel exercis session consecut week hec intervent particip hec condit ask attend weekli hour long health educ session topic oral health heart diseas cancer sleep hygien secondhand figur 1 consort figur 1096 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research smoke relat effect smoke health infor mation convei lectur handout group exercis internet resourc particip encour ag make behavior physic activ discuss particip hec condit decid begin exercis particip hec condit provid incent deliveri schedul ae condit includ fish bowl draw paid full 10 attend session monitor form return telephon counsel smoke cessat treatment particip ae hec intervent receiv ident smoke cessat treatment consist recent clinic practic guidelin treat tobacco depend fior al 2008 treatment deliv 8 20 min weekli telephon counsel session begin week 1 intervent session conduct prior quit dai week 1 4 focus identifi high risk situat develop behavior cognit strategi cope high risk situat remain session conduct quit dai week 5 8 focus discuss quit ting experi provid support develop relaps pre vention strategi particip standard 8 week nicoderm cq 24 hr tnp 21 mg strength week 5 8 14 mg strength week 9 10 7 mg strength week 11 12 educ patch prior quit date smoker laps treatment encourag set quit date continu attempt quit wear nicotin patch exercis increas absorpt nicotin bloodstream particip instruct remov patch 1 hr prior engag exercis supervis home base session measur phone screen enrol addit screen smoke exercis behavior determin preliminari eligi biliti demograph inform date birth gender ethnic race marit statu educ collect structur clinic interview dsm iv axi disord patient version spitzer gibbon william 1995 relev section mood anxieti psychot screen substanc disord administ confirm diagnost elig smoke histori interview measur design research gather smoke relat inform includ limit ag smoke initi number year smoke previou quit attempt timelin followback smoke brown al 1998 report smoke statu gather baselin 3 6 12 month follow assess timelin follow back tlfb method adapt smoke behavior valid procedur previou studi brown al 1998 smoke statu report smoke statu 7 dai point preval abstin collect particip week 5 12 treatment 3 6 12 month follow up report abstin verifi expir carbon monoxid com.ibm.drl.hbcp.util 10 ppm cutoff srnt subcommitte biochem verif 2002 case signific report common valid approach corrob orat report absenc biochem verif emont collin zywiak 1991 ossip klein al 1991 fagerstrom test nicotin depend heatherton kozlowski frecker fagerström 1991 con tinuou measur nicotin depend center epidemiolog studi depress scale ce radloff 1977 assess depress symptom 20 item instrument demonstr good reliabl valid radloff 1977 posit neg affect scale pana watson clark tellegen 1988 20 item report scale demonstr good reliabl valid assess mood bodi mass index bmi consist american colleg sport medicin guidelin bmi calcul divid bodi weight kilogram height meter squar height weight obtain com.ibm.drl.hbcp.util detecto medic scale nicotin withdraw symptom withdraw sever categor crave neg affect somat sleep symptom baselin weekli treatment 12 week follow point patch discontinu monitor minnesota withdraw scale reliabl sensit scale hugh hatsukami 1986 level physic activ smoke tlfb interview particip report estim daili physi cal activ includ durat intens report rpe borg 1970 level moder vigor physic activ mvpa calcul sum activ rpe level 11 higher borg 1970 tlfb approach shown good reliabl valid com.ibm.drl.hbcp.util assess exercis behavior panza weinstock ash pescatello 2012 cardiorespiratori fit rockport 1 mile walk test measur cardiorespiratori fit adult valid treadmil pober freedson kline tabl 1 baselin demograph smoke exercis fit characterist ae 30 hec 31 demograph gender femal 63.3 67.7 ag mean year sd 47.1 8.5 47.5 10.7 hispan white 93.3 83.9 marri cohabit 51.7 37.9 colleg graduat 34.6 31.0 household incom 30,000 year 21.4 44.4 emploi 72.4 58.6 smoke smoke ag onset 15.1 3.5 15.9 5.6 year regular smoke 27.4 9.1 27.5 11.1 number lifetim quit attempt 3.2 2.8 4.4 3.1 cigarett dai 20.3 9.9 19.4 8.1 nicotin depend ftnd 5.9 2.1 5.6 1.6 exercis fit bodi mass index 28.5 4.2 28.9 7.0 peak vo2 ml kg min 27.8 5.8 26.2 9.6 percent bodi fat 33.0 6.9 32.1 8.5 note ae aerob exercis ftnd fagerstrom test nicotin depend hec health educ control 1097 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org exercis smoke cessat mcinni ripp 2002 durat walk test heart rate complet com.ibm.drl.hbcp.util calcul estim vo2peak measur peak aerob capac indic cardiorespiratori fit data analysi development natur project difficulti com.ibm.drl.hbcp.util effect size obtain small pilot studi power larger trial kraemer kupfer 2006 loscalzo 2009 goal studi examin ini tial effect ae intervent understand confid interv potenti larg import inform evalu intervent inform design futur larg scale trial noneth obtain current studi pri ori power analysi conduct obtain sampl size 61 30 ae 31 hec stabl group mean depend measur interest main outcom analys base 7 dai point preval abstin i. report abstin 7 dai prior schedul follow intent treat sam ple primari outcom report overridden object verif conserv direct smok ing shumak 1986 miss report count smoke test effect treatment primari outcom variabl biochem verifi 7 dai point preval absti nenc eot i. 3 month follow 6 12 month follow up conduct gener estim equa tion liang zeger 1986 zeger liang 1986 compar level posit affect neg affect depress symptom crave withdraw symptom level mvpa cardior piratori fit assess weekli quit dai week 5 end 12 week treatment linear mix model adjust gender level nicotin depend corr spond baselin measur similar model evalu posit affect neg affect depress symptom drawal symptom intervent conduct examin time vari effect mvpa irrespect treat ment condit analys assum alpha 0.05 result program complianc thirti particip random hec start intervent total 28 attend hec session thirti particip random ae initi intervent total 29 attend ae session initi interven tion 57 differ ae hec extent program complianc particip group attend similar number group session 9.3 2.8 9.3 3.0 12 session ae hec male femal significantli differ number session attend abstin end intervent significantli greater number group session attend intervent condit 10.8 7.8 session ae 3.18 df 22 01 11.6 7.5 session hec 4.84 df 25 001 addit weekli supervis exercis session particip engag type physic activ home remaind week activ includ walk 79.3 treadmil 51.7 bicycl 41.4 sport 31.0 housework 31.0 ellipti cal trainer 31.0 resist train 20.7 calisthen 20.7 aerob 17.2 yoga 17.2 run 3.2 program complianc high telephon deliv er smoke cessat session nicotin patch total phone call particip complet averag 6.95 session 6.9 1.5 7.0 1.8 ae hec men women differ number complet phone call expect complianc nicotin patch higher earlier week cessat decreas 8 week particip resum smoke percentag sam ple compliant nicotin patch week 5 quit week 82.3 week 6 85.7 week 7 77.2 week 8 76.3 week 9 65.8 week 10 65.1 week 11 59.6 week 12 25.9 state method section particip instruct remov nicotin patch 1 hr prior engag ae instruct receiv report advers event com.ibm.drl.hbcp.util nicotin patch context exercis program cessat outcom tabl 2 abstin rate odd ratio time point verifi 7 dai point preval abstin end 12 week treatment 6 month follow 12 month follow 40.0 26.7 26.7 ae compar 22.6 12.9 12.9 hec continu abstin end 12 week treatment 6 month fol low 12 month follow 30.0 23.3 13.3 ae compar 25.8 9.7 3.2 hec abstin primarili verifi verifi cation occur particip 6 month follow particip 12 month follow tabl 2 verifi 7 dai point preval continu abstin rate assess timepoint 7 dai point preval continu abstin ae 30 hec 31 95 ci ae 30 hec 31 95 ci end treatment 8 week postquit date 40.0 22.6 2.28 0.75 6.96 30.0 25.8 1.23 0.4 3.78 6 month follow 21 week postquit date 26.7 12.9 2.46 0.65 9.26 23.3 9.7 2.83 0.66 12.18 12 month follow 47 week postquit date 26.7 12.9 2.46 0.65 9.26 13.3 3.2 4.64 0.48 44.5 note ae aerob exercis hec health educ control odd ratio ci confid interv 1098 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research gener estim equat model evalu eot 6 12 month verifi abstin includ gender level depend plan covari linear effect time particip ae averag 2.02 95 ci 0.71 6.04 time abstin rel hec entir year effect statisti calli signific 0.72 se 0.55 18 effect ae reduc examin continu abstin 0.59 se 0.60 33 examin potenti moder effect gender interact term treatment sta tistic signific point preval 0.74 se 1.23 55 continu abstin 1.24 se 1.48 40 mood depress symptom quit tabl 3 mean sd depress symptom affect withdraw symptom condit week 5 12 intervent ce valu squar root transform due posit skew benefici normal effect residu prior quit dai signific differ level posit affect 0.60 se 2.40 80 nega tive affect 0.09 se 1.08 93 depress symp tom 1.93 se 1.97 33 signific decreas neg affect 0.23 se 0.09 01 depress symptom 0.06 se 0.03 02 quit dai detect chang averag level posit affect quit dai consider variabl observ 0.03 se 0.14 80 sig nific differ level posit affect 0.65 se 1.65 69 neg affect 0.45 se 1.58 78 depress symptom 0.13 se 0.35 72 indic ae hec particip crave nicotin withdraw symptom quit signific decreas crave 0.16 se 0.03 00 affect 0.04 se 0.01 00 somat 0.03 se 0.01 00 sleep disturb tabl 3 mean sd depress symptomatolog affect withdraw symptom treatment condit ae 30 hec 31 effect size cohen ce score baselin 6.3 6.3 8.2 7.2 week 5 quit date 7.3 7.2 8.0 6.2 0.09 week 7 2 week postquit date 6.7 9.7 10.9 8.9 0.45 week 12 week treatment 1.5 9.1 9.4 7.4 0.95 pana posit affect baselin 3.6 0.9 3.5 0.8 week 5 quit date 3.6 0.9 3.7 0.7 0.11 week 7 2 week postquit date 3.9 0.9 3.3 1.0 0.39 week 12 week treatment 4.1 0.8 3.7 0.8 0.53 pana neg affect baselin 1.2 0.3 1.3 0.5 week 5 quit date 1.4 0.7 1.4 0.3 0.00 week 7 2 week postquit date 1.4 0.8 1.4 0.5 0.09 week 12 week treatment 1.1 0.2 1.2 0.3 0.59 withdraw symptom neg affect week 5 quit date 5.1 2.5 4.5 1.5 0.29 week 7 2 week postquit date 4.2 2.0 5.6 2.0 0.70 week 12 week treatment 3.1 0.3 4.6 2.0 1.05 withdraw symptom crave week 5 quit date 4.9 1.7 4.8 1.3 0.07 week 7 2 week postquit date 4.0 1.6 4.4 1.4 0.27 week 12 week treatment 3.5 1.2 3.9 1.7 0.27 withdraw symptom sleep week 5 quit date 4.9 1.5 5.5 1.6 0.35 week 7 2 week postquit date 5.8 2.0 6.9 2.5 0.46 week 12 week treatment 4.7 1.2 5.7 1.7 0.68 withdraw symptom somat week 5 quit date 4.8 1.6 4.8 1.3 0.00 week 7 2 week postquit date 4.3 1.8 5.4 1.7 0.63 week 12 week treatment 3.7 0.8 4.4 1.3 0.65 minut mvpa week baselin 77.3 112.5 60.3 99.5 week 5 quit date 138.3 77.5 62.7 104.8 0.82 week 7 2 week postquit date 146.2 96.5 78.2 115.0 0.64 week 12 week treatment 134.0 99.4 70.1 105.2 0.62 note ae aerob exercis ce center epidemiolog studi depress scale hec health educ control mvpa moder vigor physic activ pana posit neg affect scale 1099 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org exercis smoke cessat withdraw symptom 0.12 se 0.05 02 8 week quit dai week 5 12 particip ae rel hec similar level crave 0.15 se 0.30 62 affect withdraw 0.10 se 0.09 27 significantli lower somat 0.14 se 0.07 049 sleep disturb withdraw symp tom 1.01 se 0.49 04 treatment level physic activ fit data miss baselin minut mvpa vo2peak adjust baselin level mvpa particip ae significantli higher level physic activ hec 4 week prior 1.18 se 0.40 01 8 week quit dai 1.37 se 0.43 01 differ decreas significantli treatment treatment time 0.04 se 0.04 31 treatment 60 ae condit compar 25.8 hec achiev averag 100 min mvpa 12 week intervent target level exercis midwai ae intervent trend higher fit level estim vo2peak eot particip ae rel hec 1.22 se 0.76 12 vo2peak ae 30.0 ml kg min vo2peak hec 27.3 ml kg min level mvpa affect depress withdraw symptom cessat outcom evalu time vari effect mvpa irrespec tive treatment condit chang intervent pattern higher posit affect lower neg affect observ exercis achiev averag 100 min mvpa 12 week intervent statisti calli signific relationship level exercis lev el posit 0.28 se 0.24 24 neg affect 0.14 se 0.19 46 crave 0.10 se 0.06 08 affect withdraw 0.09 se 0.07 24 treatment interact term mvpa time signific evalu relationship posit 99 neg affect 19 crave 23 affect drawal 0.26 higher level mvpa treatment significantli lower level depress symp tom 0.12 se 0.06 04 exercis report rang 3.1 7.2 depress symptom week quit date compar averag 8.0 12.0 exercis 100 min week observ sig nific interact mvpa time evalu level depress symptom treatment evalu time vari effect mvpa irr spectiv treatment condit relat ce sation outcom increas level mvpa significantli higher odd abstin 0.001 se 0.002 361 discuss current studi develop conduct prelimi nari rct ae intervent adult smoker design specif address methodolog limit previou studi area improv generaliz futur dissemin commun set notabl featur ae intervent inclus male smoker moder intens exercis engag home super vise set began month prior quit date compo nent increas adher e.g conting base financi incent cognit behavior group session exercis adopt telephon base smoke cessat counsel tnp result studi demonstr feasibl accept intervent compon good adher observ ae hec inter vention session similarli complianc telephon deliv cessat session nicotin patch high safeti instruct remov nicotin patch prior engag exercis bout advers event report nicotin patch engag ing ae program approxim interest particip lost interest declin studi involv prior complet studi enrol base line assess strategi increas engag earli stage studi recruit reach larger number individu motiv quit rap idli fluctuat preliminari natur project cessat outcom promis indic particip assign ae averag achiev abstin 7 dai point preval hec differ statist signific health inform provid hec condit suffici motiv produc chang anecdot partici pant report enjoi hec session state appreci novelti us inform receiv hec condit activ intervent contribut ce sation outcom increas physic activ particip smoke cessat trial relaps smok ing year treatment high studi extend intervent compon initi 12 week intervent period mitig declin abstin posttreat incorporat ing featur intervent e.g activ monitor ae facilit monitor mvpa health relat web site hec easili translat independ continu complet 12 week intervent decreas smoke relaps addit increas number telephon deliv cessat session current phone call equal 12 ae hec session potenti afford particip addit relaps prevent plan addit booster telephon session found improv long term cessat rate studi e.g rabiu pike hunter wiatrek mcalist 2007 consid strategi decreas relaps postintervent futur studi previou studi demonstr consist benefi cial effect ae crave withdraw symptom affect smoker haasova al 2012 robert maddison simpson bullen prapavessi 2012 taylor ussher faulkner 2007 ussher al 2012 vari abl examin potenti mediat relat ship group assign ae hec smoke cessat outcom analys group differ 1100 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research trajectori crave affect withdraw symptom neg affect posit affect depress symptom quit date eot effect size promis larger sampl signific achiev compar particip hec condit ae partici pant report lower somat fewer sleep disturb drawal symptom sleep previous examin context exercis intervent smoker sleep potenti restor factor improv resili stress earli cessa tion consider support benefit exercis nonpharmacolog intervent improv sleep driver taylor 2000 futur studi examin role ae improv sleep smoker undergo quit attempt current studi quarter hec particip increas physic activ conduct addit analys examin effect exercis affect depress withdraw symptom cessat outcom independ group assign find reveal particip exercis frequent report fewer depress symptom intervent period effect depress symptom consist systemat meta analyt review demonstr consist posit impact exercis clinic depress symptomolog e.g mead al 2009 increasingli attent paid import role neg affect depress plai imped effort smoke cessat e.g pratt brodi 2010 exer cise help risk subpopul smoker effort quit smoke potenti kei aspect ae intervent similarli implement prior exercis intervent smoke cessat studi inclus cognit behavior compon promot exercis engag ussher al 2012 studi includ exer cise counsel includ 5 min psychoeduc content studi incorpor structur cognit behavior strategi challeng neg think exercis goal set reward identi fy problem solv barrier develop exercis focus cope strategi manag mood affect cognit behavior approach impact experi depress symptom cessat smoke cessat counsel provid tele phone person effort increas dissemina biliti counsel similar typic provid tobacco quitlin u. state 2004 preval worldwid anderson zhu 2007 receipt multipl session proactiv telephon counsel smoker initi contact quitlin demonstr efficaci fior al 2008 stead perera lancast 2007 ultim quitlin plai kei role improv system integr abram graham levi mabri orlean 2010 futur studi explor int gration exercis counsel cognit behavio ral session content com.ibm.drl.hbcp.util studi context telephon deliv smoke cessat treatment preliminari trial sampl size small power detect statist signific effect smoke cessat outcom limit sampl rigor medic psychiatr screen caucasian higher educ level gener popul smoker hugh calla 2010 futur tri al target multimedia campaign boost recruit minor low educ popul strategi includ advertis newspap serv minor commun announc church bulletin placement inform materi commun center ambulatori care clinic predominantli minor neighbor hood materi tailor low literaci popul addit cigarett smoke highli comorbid medi cal psychiatr substanc disord grant hasin chou stinson dawson 2004 lasser al 2000 usdhh 2004 addit research need determin efficaci exercis intervent divers popula tion signific proport smoker psychiatr disord physic activ gener popul daumit al 2005 studi test preliminari efficaci ae interven tion smoke cessat attempt address previous identifi methodolog limit promis result suggest larger trial ae intervent warrant futur research explor potenti adapt ae intervent supervis exercis e.g local health club gym nonsupervis e.g primari care ven ue futur dissemin approach high public health signific decreas preval cigarett smoke reduc smoke relat morbid mortal fund work support nation institut drug abus fund grant k23 da019950 award dr ama declar interest declar
young adult quit smoke form evalu pack program lorien abrom richard windsor bruce simon morton receiv 29 novemb 2006 accept 9 june 2007 lack promis smoke cessat intervent target young adult recogn public health problem studi design determin feasibl young adult orient program pack program administ colleg student smoker estim effect smoke cessat particip n583 random enrol receiv moder intens mail base young adult intervent pack group intens program aim gener adult audienc clear air group particip assess baselin 3 6 month enrol particip pack group rate treatment favor engag program activ quit consecut dai 3 6 month follow up compar clear air group differ quit rate favor pack group follow up differ signific find offer support pack program administ colleg smoker introduct estim 23.6 young adult ag 18 24 year current smoker center diseas control prevent cdc 2005 smoke rate continu declin adult remain steadi young adult increas subgroup cdc 2005 lantz 2003 wechsler rigotti gledhil hoyt lee 1998 high level smoke young adult partial attribut target market tobacco product young adult ling glantz 2004 sepe ling glantz 2002 smoke cessat program aim young adult abram al 2003 curri al 2007 nation repres survei smoke cessat program serv adolesc young adult 5.6 found serv primarili young adult curri al 2007 young adult program evalu am al 2005 escofferi mccormick bateman 2004 klesg al 2006 obermay rilei asif jean mari 2004 o’neil gillispi slobin 2000 rutter 1990 hand success promot smoke cessat klesg al 2006 obermay al 2004 rutter 1990 studi limit relianc inform design lack random control group obermay al 2004 rutter 1990 report smoke statu biochem valida tion klesg al 2006 o’neil al 2000 studi limit generaliz particip consist larg colleg student except includ am al 2005 klesg al 2006 lack promis intervent target young adult recogn public health problem abram al 2003 backing fagan matthew grana 2003 curri 2003 lantz 2003 orlean al 2003 young adulthood repres distinct develop mental period life arnett 2000 young adult face uniqu challeng transit independ live job career select partner select parenthood arnett 2000 goldscheid goldscheid 1999 young issn 1462 2203 print issn 1469 994x onlin 2008 societi research nicotin tobacco doi 10.1080 14622200701767852 lorien abrom sc.d richard windsor ph.d georg washington univers school public health health servic washington dc bruce simon morton ph.d nation institut health bethesda md correspond lorien abrom georg washington univers school public health health servic 2175 street nw 7th floor washington dc 20037 usa tel 1 202 416 0482 mail lorien gwu.edu nicotin tobacco research volum 10 number 1 januari 2008 27 33 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org adulthood mark period life risk behavior tend increas includ ing increas cigarett smoker johnston o’mallei bachman 2003 young adult distinct smoke pattern characterist compar younger smo ker young adult higher preval smoke regular smoker smoke cigarett dai cdc 2003 johnston al 2003 compar older adult smoker young adult smoke similar rate smoke fewer cigarett dai addict nicotin express interest quit quit recent cdc 2003 higher level quit attempt young adult succe quit attempt compar older adult cdc 2006a garvei boss glynn rosner 1983 differ stage develop smoke characterist suggest young adult benefit smoke cessat program develop prefer andreasen 1995 belief motiv develop ment 2001 smoke cessat kit aim young adult smoker call pack abrom winickoff lowel moblei 2003 popul servic intern unpublish date 20,000 pack distribut young adult smoker unit state studi design determin feasibl young adult orient program base pack estim effect smoke cessat specif studi investig colleg popul pack program includ pack kit seri counsel mail result higher level program particip engag higher level particip satisfact favor smoke cessat outcom compar intens gener program method sampl particip 83 smoker 18 23 year undergradu student univers washington d.c metropolitan area elig studi includ student full part time smoke 1 cigarett dai past 7 dai ag 18 24 year interest quit smoke 6 month colleg student select repres signific proport young adult lantz 2003 smoke preval high 28 wechsler al 1998 univers access mail escofferi al 2005 recruit conduct fall spring 2004 2005 studi receiv institut review board approv georg washington univers nation institut health recruit includ flyer ad colleg newspap studi staff tabl student center total 243 student express interest particip provid contact inform 135 student 55.6 recontact recontact 83 enrol 61.5 44 32.5 longer inter est particip 8 5.9 inelig smoke 1 cigarett dai student particip offer financi compens complet 3 month 6 month assess survei 10 15 complet baselin survei particip report 7 dai abstin 6 month follow paid addit 10 saliva sampl cotinin analysi procedur measur particip random enrol receiv moder intens young adult orient intervent pack program intens program aim gener adult audienc clear air cta program counselor assign list identif number enrol particip randomli assign particip condit enrol particip assess person baselin phone 3 6 month postenrol particip report 6 month follow interview quit smoke met research staff 2 week interview provid saliva sampl primari smoke cessat outcom studi past 7 dai abstin smoke 6 month measur report verifi salivari cotinin analysi 10 ng ml cotinin etzel 1990 secondari outcom includ report reduct quantiti frequenc smoke nicotin depend mea sure fagerström test nicotin depend ftnd heatherton kozlowski frecker fagerström 1991 depress measur center epidemiolog studi depress ce scale radloff 1991 process measur assess part 3 month survei includ measur treatment rate e.g program rate 5 point likert scale strongli disagre strongli agre measur particip quit process e.g call friend famili member urg rate 28 form evalu pack program nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 4 point scale process measur item specif pack program e.g mail read ask particip pack group specif pack program measur mail respons receiv counselor respons tabul comput record count number instanc particip repli counselor receiv counsel mail data analyz calcul mean percentag kei measur pack cta group test chi squar test determin differ group statist signific intervent pack program pack program consist person counsel session last 15 min kit pack seri counsel mail goal person counsel session place public space colleg campu introduc particip pack kit review kei inform relat smoke cessat present kit encourag particip set quit date month 6 month person counsel session particip 10 12 counsel mail intervent compon person counsel kit mail promot common step cognit behavior program quit smoke base social cognit theori bandura 1986 step involv increas posit outcom expect quit enlist quitpal friend social support set quit date develop skill overcom crave quit prevent relaps pack kit resembl overs pack cigarett includ smoke cessat guid book wallet size quit card motiv slide rule product substitut cigarett gum toothpick putti figur 1 pack kit develop specif young adult involv intens year form research young adult abrom al 2003 popul servic intern unpublish counsel mail written staff counselor particip base set templat develop content pack guidebook tailor particip reason smoke smoke trigger chosen quit date inform collect baselin particip encourag repli mail counselor question comment updat counselor cessat progress mail weekli month monthli 5 month addit mail particip quit date 1 dai prequit quit date 4 dai postquit 2 week postquit mail counsel prefer phone counsel young adult consist rank phone counsel low list prefer assist option abrom al 2003 lawranc 2001 univers access mail colleg student escofferi al 2005 result feasibl mail compon pack intervent report abrom windsor simon morton unpublish counselor undergradu master public health student underw 8 hr train smoke cessat counsel requir write seri mail hypothet particip review studi supervisor accuraci content conform studi protocol month counsel particip counselor requir supervisor approv mail send counselor met weekli basi supervisor discuss issu pertain particip counsel clear air program cta program con sist person counsel session last 15 min materi clear air develop nation cancer institut u. depart health human servic 2003 similar pack program goal person counsel session introduc particip materi kei inform figur 1 pack smoke cessat kit content pack quit booklet pack quit card success meter ick lator slide card show harm chemic cigarett side monei save health benefit quit side wriglei orbit chew gum hotlix cinnamon toothpick preoccup putti nicotin tobacco research 29 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org relat smoke cessat present materi encourag particip set quit date month person counsel ing session particip provid addit assist quit result preliminari analys conduct identifi pre exist differ group signific differ found group baselin demograph characterist smoke characterist tabl 1 particip averag 19.8 year major 77.1 white ethnic smoke averag 9.1 cigarett dai low level nicotin depend slightli male 54.2 enrol femal follow rate sampl 86.7 3 month 68.7 6 month fifti percent 17 report quitter 6 month provid cotinin sampl found signific differ follow rate group time point cotinin sampl hypothes pack program result higher level program particip engag cta program found true particip variabl examin group 3 month follow tabl 2 partici pant group report made quit attempt high level pack group report made quit attempt 05 pack group rang cognit behavior techni que cope urg smoke call friend famili member urg crave 05 4d techniqu deal crave delai smoke deep breath 10 breath drop piec gum mouth distract 001 read reason quit smoke 01 signific differ enc found set quit date nicotin replac therapi readership guidebook addit activ cut group particip assess activ specif pack program 3 month follow vast major particip 91.6 read mail pack counselor addit half repli counselor mail time intervent period half particip report compon pack kit regularli gum popular follow hand putti toothpick slide rule particip rate pack intervent favor 5 point likert scale partici pant group rate neutral 3 agre 4 statement program recommend program friend particip pack group gave higher rate program like 3.8 pack 3.3 cta 05 willing recom mend program friend 4.1 pack 3.5 cta 01 tabl 3 present cessat outcom 3 6 month postenrol intent treat analysi conduct lost follow imput smoke dai smoke smoke cessat outcom favor pack condit result significantli 3 month base report past 7 dai smoke 31.3 pack group 20.0 cta group quit smoke odd report quit great tabl 1 baselin characterist particip characterist total particip n583 pack group n548 cta group n535 mean ag year sd 19.8 1.3 19.8 1.3 19.8 1.2 gender femal 45.8 47.9 42.9 male 54.2 52.1 57.1 race ethnic white 77.1 72.9 82.9 asian 3.6 4.2 2.9 black 2.4 0.0 5.7 hispan 1.2 2.1 0.0 15.7 20.8 8.6 live smoker 37.4 37.5 37.1 mean cigarett dai sd 9.1 6.2 9.9 6.5 8.0 5.6 mean past quit attempt sd 2.4 1.5 2.5 1.6 2.3 1.4 mean depress total score ce sd 11.4 7.4 11.8 8.5 10.9 5.6 mean baselin nicotin depend ftnd sd 1.9 1.8 2.1 1.8 1.5 1.6 note signific differ found group variabl includ tabl 30 form evalu pack program nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org pack group or51.81 95 ci 0.65 5.09 6 month 25.0 pack group 14.3 cta group quit smoke or52.00 95 ci 0.63 6.32 base biochem verif cotinin level report quitter provid saliva sampl 6 month 58.8 report quitter analysi lost follow assum smoke quit rate reduc 10.2 pack group 5.7 cta group or51.92 95 ci 0.35 10.52 ns base cotinin analysi decept rate found 28.6 pack group 33.3 cta group ns 3 month particip pack group quit consecut dai compar cta group 05 6 month particip pack group quit time consecut dai compar cta group 05 particip pack group report 3 month time dai pass cigarett compar cta group 05 6 month differ declin time dai smoke cigarett differ statist signific individu pack group experienc greater declin cigarett smoke week baselin 3 6 month follow up result reach signific discuss studi design document feasibl moder intens young adult orient smoke cessat program pack program particip pack group found engag program activ rate treatment favor quit consecut dai 3 6 month follow up differ quit rate group favor pack program signifi member pack group made quit attempt adopt cognit behavior techniqu cope urg smoke techniqu mention set guidebook set person counsel session greater adopt techniqu pack group relat favor rate pack tabl 2 exposur particip cessat program pack group n541 cta group n531 valuea set quit date 91.7 95.1 87.1 made quit attempt 87.5 95.1 77.4 call friend famili member urgeb 40.3 53.7 22.6 4d deal cravingb 57.0 78.1 29.0 nicotin replac therapi 15.3 19.5 9.7 read reason quittingb 77.8 90.2 61.3 read guidebook 58.3 56.1 61.3 read mail 91.6 repli mailsc 48.0 content pack regularli gum 80.7 hand putti 65.1 toothpick 63.9 slide rule 59.0 note acalcul chi squar test bpercent ctabul comput record mail respons receiv counselor 05 01 001 tabl 3 smoke cessat outcom 3 6 month group outcom 3 month follow 6 month follow pack group n548 cta group n535 valuea pack group n548 cta group n535 valuea quit rate report past 7 dai smoke 31.3 20.0 25.0 14.3 quit rate cotinin verifi 10.2d 5.7 dai cigarett sd 13.7 22.9 4.5 9.1 20.0 47.6 7.7 23.1 consecut dai quit sd 16.3 17.7 8.1 10.0 34.0 49.3 13.4 24.4 chang number cigarett smoke week baselin sd 241.9 45.0 229.8 35.8 235.9 36.4 223.0 28.2 note acalcul test chi squar test bmiss assum smoke cmiss assum dai cigarett d59.0 report quitter provid saliva sampl cotinin analysi 05 01 001 nicotin tobacco research 31 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org program predispos particip follow program prescrib quit activ altern higher level adopt techniqu result addit mention techniqu mail pack group receiv particip report read mail higher rate guidebook 92 pack particip read mail 58.3 particip read guidebook differ group signific find evid mail platform reach colleg student health inform promis platform standard print materi quit rate group significantli 3 6 month trend encourag 6 month base report biochem valid quit rate high pack group quit rate 10.2 compar minim invas intervent adult phone counsel multipl mail tailor materi strecher al 2005 high estim natur quit rate youth 4 cdc 2006b encourag pack program averag number consecut dai quit high pack group 3 month 05 time high pack group 6 month 05 surpris magnitud differ increas 3 6 month pack intervent mail month 3 6 month minim mail work sustain particip motiva tion quit find impli monthli counsel mail help prolong effect intens smoke cessat intervent e.g physician advic phone counsel ing quitlin time work conduct applic mail promot smoke cessat except includ etter le houezec landfeldt 2003 lenert muñoz perez bansod 2004 research area recommend present studi limit studi design unclear aspect pack program target young adult inclus mail compon increas contact time led favor outcom interven tion futur studi evalu effect mail compon effect variat sourc mail counselor written versu comput gener frequenc mail studi limit small sampl size inclus colleg student limit generaliz studi young adult smoke cessat colleg student sampl escofferi al 2004 obermay al 2004 o’neil al 2000 rutter 1990 futur studi need focu young adult colleg set strength studi includ test theori base program aim popul high smoke preval find studi program target young adult includ sequenti mail kit feasibl accept effect smoke cessat gener intens program monthli mail post quit date effect sustain ing quit attempt prevent relaps intens intervent acknowledg studi support order 263 md 510757 georg washington univers nichd author studi staff dedic project lisa ramirez ilana dickman jennif gill
random trial text2quit text messag program smoke cessat lorien abrom scd ashlei boal phd samuel simmen phd judith mendel mph richard windsor phd milk ton univers address school pub hampshir nw 0749 3797 http dx.do 242 background text messag program mobil phone shown promis help peopl quit smoke text2quit autom person interact mobil health program send text messag offer advic support remind quit smoke purpos evalu effect text2quit biochem confirm repeat point preval abstin context rct conduct u. method particip 503 recruit internet random receiv text2quit materi 2011 2013 particip survei baselin 1 3 6 month post enrol assess smoke statu saliva collect particip report smoke past 7 dai 6 month follow intent treat analysi lost follow categor smoker analys complet 2013 result biochem confirm repeat point preval abstin favor intervent group 11.1 abstin compar 5.0 control group rel risk 2.22 95 ci 1.16 4.26 po0.05 similarli report repeat point preval abstin higher intervent group 19.9 control group 10.0 po0.01 effect found uniform analyz demograph subgroup suggest larger effect white white conclus result provid initi support rel efficaci text2quit program prev med 2014;47 3 242 250 2014 american journal prevent medicin introduct tobacco lead prevent ofdeath disabl diseas burden u. 1,2smoke cessat program mobil phone text messag found effect smoke cessat health behavior 3 5 recent meta analysi studi text messag program smoke cessat conclud program increas long term quit rate 3 u. number text messag program smoke cessat publicli includ nation servic call smokefreetxt launch nation cancer institut nci en institut school public health georg wash washington district columbia rrespond lorien abrom scd milken institut lic health georg washington univers 950 washington dc 20052 mail lorien gwu.edu 36.00 i.org 10.1016 j.amepr 2014.04.010 rev med 2014;47 3 242 250 2014 am smokefree.gov 2011 addit caller nation quitlin number 1 800 quit offer text program state 25 state quitlin 2012 offer text program addit phone counsel 6 state quitlin caller offer program call text2quit 50,000 caller enrol text2quit servic 2011.7 number peopl enrol text messag program smoke cessat increas studi program conduct u. popul 5 exist studi u. popul consist pilot studi small sampl size short term follow 8,9 control group 8 biochem verif report smoke statu 8,9 form studi ybarra colleagu 9 intervent particip significantli control particip quit 4 week quit date find sustai ned 3 month 9 rican journal prevent medicin publish elsevi mailto:lorien gwu.edu mailto:lorien gwu.edu dx.doi.org 10.1016 j.amepr 2014.04.010 dx.doi.org 10.1016 j.amepr 2014.04.010 dx.doi.org 10.1016 j.amepr 2014.04.010 abrom al prev med 2014;47 3 242 250 243 studi aim build earlier pilot study8 evalu u. sampl recruit internet text2quit effect control materi promot biochem confirm repeat point preval abstin 6 month follow result studi inform long term studi text smoke cessat u. conduct text2quit highli subscri bed u. method studi procedur studi approv georg washington univers gwu irb recruit occur 19 2011 juli 10 2012 recruit enrol place internet individu search googl keyword relat quit smoke studi ad conjunct search result studi ad offer quit smoke possibl earn amazon gift card exchang partic ipat research studi individu click studi ad direct studi websit interest particip screen survei elig ask provid inform consent onlin baselin survei set quit date 30 dai individu random comput system intervent control group complet baselin survei elig studi particip requir 1 agedz18 year 2 smoke cigarett dai 3 u. mail address 4 mail address 5 cell phone number unlimit short messag servic sm plan 6 interest quit smoke month 7 pregnant particip complet onlin survei follow up 1 3 6 month post enrol particip return onlin survei repeat mail remind survei conduct studi staff phone mail sm saliva collect mail particip report smoke past 7 dai 6 month follow 10,11 saliva collect particip weremail kit instruct salivett pre paid postag envelop sampl return sampl return research team refriger mail batch j2 lab tucson az cotinin analysi particip receiv 15 amazon gift card complet survei 25 amazon gift card provid saliva sampl enrol procedur modifi group enrol particip detect fraudul disqualifi 57 incid addit procedur put place august 2011 discourag fraudul enrolle plete autom public ture test comput human captcha code requir individu type letter number shown imag ad elig form prevent comput bot enrol 12 particip requir confirm interest studi particip sm random final studi staff manual check cell phone number mail 3 dai enrol individu found cell phone mail address work regist disqualifi septemb 2014 measur follow survei 1 3 6 month enrol includ measur abstin smoke measur report 7 30 dai past smoke 13 primari outcom biochem confirm repeat point preval abstin 13 defin report smoke past 30 dai 3 6 month survei cotinin level r15 ng ml14,15 6 month measur abstin 1 month survei includ measur repeat point preval abstin quit date set 30 dai enrol particip reach quit date wrongfulli exclud secondari outcom consist 7 30 dai abstin 1 3 6 month follow up13 biochem confirm abstin 6 month follow baselin survei includ item assess demograph e.g ag gender race ethnic educ smoke charact istic particip e.g live smoker household cigarett smoke dai past quit attempt nic otin depend measur fagerstrom test nicotin depend ftnd 16 number text messag particip receiv prior enrol studi assess 1 month follow survei item inadvert omit baselin survei addition measur assess recommend smoke cessat aid studi enrollment17 call quitlin counsel physician clinic servic u. food drug administr fda approv quit smoke medic particip code recommend cessat aid repli recommend aid follow survei particip intervent group text2quit engag ment assess record interact text messag comput system report survei data number text messag particip comput system includ repli text2quit programmat survei kei word total averag calcul particip total includ keyword stop keyword unsubscrib program percentag particip keyword serv indic program disengag report data 1 3 6 month survei assess particip text2quit websit intervent group particip random intervent group receiv text2quit text2quit facilit text messag program design peopl quit smoke 8 text2quit develop 20108 gwu technic support provid voxiva washington dc program consist primarili autom bidirect text messag compris central compo nent program mail web portal offer support featur text messag time user quit date provid advic quit smoke messag base social cognit theory8,18 consist u. public health servic clinic practic guidelin 17 recommend call quitlin approv quit smoke medic messag interact prompt user track smoke report crave provid smoke statu abrom al prev med 2014;47 3 242 250244 particip report quit rout separ relaps messag protocol includ option set quit date messag tailor factor includ quit date top reason quit monei save quit quit smoke medic 17 studi text2quit offer 6 month enrol 3 month offer outgo messag quit smoke demand keyword outgo messag stop particip text time keyword sm keyword includ abil reset quit date date crave tip trivia game crave summari quit statist stat smoke smoke outgo messag peak period prior quit date particip receiv smss quit date approxim smss dai week quit date frequenc declin subsequ week app roxim smss week 2 month week remain portion outgo phase smss supplement person web portal text2quit.com mail websit provid access particip quit inform tool chang sm set gener resourc quit smoke mail weekli period quit date week 3 month mail gener reiter expand kei messag text particip repli mail updat inform mail control group particip random control group initi receiv web link smokefree.gov lead websit quit smoke inform run nci septemb 15 2011 smokefree.gov launch text program smokefreetxt control group materi chang avoid contamin control group similar text program point 135 26.8 particip recruit studi 66 control group consid erat chang lead quit smoke websit concern websit adopt text messag program trial period decis made offer futur control group particip guidebook quit smoke develop nci extens previou trial control materi e.g prokhorov al 19 guidebook clear air offer web link led particip document similar advic inform smokefree.gov 20 addit control group materi control group receiv studi relat remind text sm 2 week prior follow survei data analysi analys conduct intent treat approach demograph differ intervent control group test test chi squar test primari secondari outcom examin imput miss data respond survei return saliva sampl assum smoke 14 chi squar analys conduct compar proport particip treatment control group report quit addition logist regress unadjust adjust rel risk rr quit intervent group compar control group calcul primari secondari outcom determin smoke outcom treatment control group differ predetermin demograph categori chi squar anali se complet unadjust rr comput demograph subgroup primari outcom final identifi subgroup particip benefit intervent exact logist regress test condit subgroup interact predict primari outcom separ logist model construct subgroup analys conduct 2013 sa version 9.3 sa institut cari nc result shown figur 1 7,247 particip elig survei total 1,745 individu consent fill baselin survei random 503 241 control 262 intervent provid hand set verif sm phone number mail confirm valid work remain 1,242 exclud provid handset verif sm 502 valid cell phone number 460 cell phone number wrong number 268 analys detect differ enc group exclud reveal similar condit baselin demograph variabl except race partic ipant assign control group exclud white po0.05 follow rate 1 3 6 month survei 85.7 82.9 75.7 follow rate similar group 1 month survei slightli lower intervent group po0.01 elig provid saliva sampl i. report smoke past 7 dai 6 month follow 133 86 64.7 provid saliva sampl proport elig particip return saliva sampl significantli differ group 21 24.4 found high level cotinin saliva 415 ng ml particip code smoker analys biochem confirm quit time point vast major particip complet survei web 1 month 91.0 3 month 90.2 6 month 91.1 remain phone text mail mode survei complet similar intervent control group particip follow survei www.ajpmonline.org s04aw6 highlight abrom al prev med 2014;47 3 242 250 245 particip demograph particip characterist present tabl 1 particip averag 35.70 sd 10.66 year predominantli white 78.5 femal 65.6 colleg trade school educ 78.1 averag particip began smoke 17 sd 5.60 year smoke 18.48 sd 11.25 year time enrol particip smoke averag 17.29 sd 8.08 cigarett dai ftnd nicotin depend score 5.33 sd 2.30 averag particip receiv 29.32 sd 51.20 text messag dai prior enrol studi intervent control group particip similar variabl educ po0.01 7,247 assess 1,745 complet 1,745 rand 893 control group 144 verifi 498 valid cell phone 9 invalid mail address 1 unintention enrol 241 receiv alloc intervent 1 month follow 218 contact 90.5 23 lost follow 3 month follow 207 contact 85.9 34 lost follow 6 month follow 189 contact 78.4 52 lost follow 241 includ analys en ro llm en llo ca tio fo llo na ly si saliva follow 32 contact 64.0 18 lost follow 191 inelig saliva verif figur 1 enrol overview septemb 2014 primari secondari outcom unadjust adjust logist regress model conduct examin outcom group model adjust educ variabl found significantli group result similar unadjust adjust model unadjust model present tabl 2 examin primari smoke cessat outcom biochem confirm repeat point prev alenc abstin show intervent group likelihood quit compar control group intervent group 11.1 particip biochem confirm repeat point preval abstain compar 5.0 control group rr 2.22 95 ci 1.16 4.26 po0.05 elig 4,233 meet inclus criteria 1,269 declin particip baselin omiz 852 intervent group 358 verifi 230 valid cell phone 2 invalid mail address 262 receiv alloc intervent 1 month follow 213 contact 81.3 49 lost follow 3 month follow 210 contact 80.2 52 lost follow 6 month follow 192 contact 73.3 70 lost follow saliva follow 54 contact 65.1 29 lost follow 262 includ analys 179 inelig saliva verif tabl 1 demograph characterist particip note 503 intervent group 262 control group 241 ag sd 35.7 10.7 35.9 10.7 35.5 10.6 gender male 172 34.2 82 31.3 90 37.3 femal 330 65.6 180 68.7 150 62.8 race ethnic white 395 78.5 210 80.2 185 76.8 african american 54 10.7 24 9.2 30 12.5 latino 19 3.8 9 3.4 10 4.2 asian 12 2.4 7 2.7 5 2.1 23 4.6 12 4.6 11 4.6 educ high school lower 110 21.9 43 16.4 67 27.8 colleg trade school 254 50.5 146 55.7 108 44.8 colleg degre higher 139 27.6 73 27.9 66 27.4 presenc z1 smoker household 233 46.3 121 46.2 112 46.5 cigarett dai sd 17.29 8.08 17.68 8.13 16.86 8.02 past quit attempt sd 6.09 12.30 5.34 7.07 6.89 16.14 baselin nicotin depend ftnd sd 5.33 2.30 5.36 2.28 5.30 2.33 text receiv dai sd 29.32 51.20 25.09 46.36 33.58 55.43 note boldfac statist signific po0.01 test compar mean intervent control group χ2 test compar proport intervent control group ftnd fagerstrom test nicotin depend abrom al prev med 2014;47 3 242 250246 similar result higher quit rate obtain report repeat point preval abstin 19.9 intervent group report abstin compar 10.0 control group rr 1.99 95 ci 1.27 3.13 po0.01 secondari outcom explor 6 month follow report quit favor intervent group past 7 dai smoke rr 1.53 95 ci 1.13 2.07 po0.01 signific differ proport biochem confirm quitter intervent 15.7 control group 11.2 rr 1.40 95 ci 0.89 2.20 0.15 6 month follow past 30 dai quit 24.8 intervent group report smoke compar 15.8 control group particip rr 1.57 95 ci 1.10 2.26 po0.05 subgroup analyz tabl 3 higher percentag particip quit interven tion group compar control group rr statist signific categori subgroup e.g ag o35 year femal ftnd score r5 po0.05 intervent group subgroup interact test reach statist signific po0.05 level indic clear evid differenti effect examin subgroup trend white particip benefit intervent white particip 0.06 program engag particip intervent group 262 program engag assess base comput record particip 85.1 text messag comput system trial exclud keyword stop particip interact system averag 28.47 sd 25.81 interact 6 month program total keyword higher biochem confirm repeat point preval abstain mean 35.21 sd 26.66 abstain mean 22.87 sd 25.51 po0.05 abstai ner approxim 12 keyword www.ajpmonline.org tabl 2 comparison intervent control group outcom measur time period 503 follow survei measur intervent 262 se control 241 se rel risk 95 ci primari outcom biochem confirm repeat point preval abstin 11.1 0.02 5.0 0.01 2.22 1.16 4.26 report repeat point preval abstinenceb 19.9 0.02 10.0 0.02 1.99 1.27 3.13 secondari outcom 6 month biochem confirm abstin 15.7 0.02 11.2 0.02 1.40 0.89 2.20 smoke past 7 dai 31.7 0.03 20.8 0.03 1.53 1.13 2.07 smoke past 30 dai 24.8 0.03 15.8 0.02 1.57 1.10 2.26 3 month smoke past 7 dai 33.2 0.03 19.9 0.03 1.67 1.23 2.26 smoke past 30 dai 27.5 0.03 16.2 0.02 1.70 1.20 2.41 1 month smoke past 7 dai 30.5 0.03 14.5 0.02 2.10 1.47 3.00 smoke past 30 dai 11.8 0.02 7.5 0.02 1.58 0.91 2.76 note boldfac statist signific aχ2 analys conduct examin outcom intervent control group unadjust risk ratio present miss data imput smoke bself report repeat point preval abstin defin smoke past 30 dai 3 6 month follow up npo0.05 nnpo0.01 nnnpo0.001 abrom al prev med 2014;47 3 242 250 247 addit 30.1 particip 79 keyword stop unsubscrib program 6 month intervent period unsub scribe particip unsubscrib averag 61.22 dai enrol sd 58.23 proport biochem confirm repeat point preval abstain differ significantli keyword stop 5 6 24 13 χ2 1 262 2.58 0.11 intervent group particip provid access text2quit websit base report particip report log websit past 7 dai 1 64 3 month 81 follow up discuss studi evalu efficaci facilit text messag program aim smoker search quit smoke inform internet studi result encourag particip random iz receiv text2quit greater likelihood biochem confirm repeat point preval abstin 6 month post enrol primari outcom studi biochem confirm quit rate 11.1 intervent group 5.0 control roughli similar report previ ousli text messag studies21 studi popul base cessat method quitlin phone septemb 2014 counsel 22 statist signific differ demograph subgroup found trend suggest larger effect white compar white result secondari outcom larg support efficaci intervent report 7 30 dai point preval estim 6 month significantli favor inter vention group quit rate bio chemic confirm abstin 6 month higher intervent group differ statist signific lack signific find outcom futur studi warrant posit result conclus studi strength studi address gap literatur identifi commun prevent servic task forc applic mobil technolog smoke cessat u. 5 repres studi text messag smoke cessat u. long term follow biochem confirm smoke statu report consid adequ measur popul base studi low particip involv ment 23 25 decis biochem confirm smoke statu made natur intervent free colleagu 21 biochem ver ific report quitter reveal signific discrep report biochem con firm smoke statu quarter tabl 3 intervent control group abstin rate particip subgroupsa intervent control subgroup rel risk 95 ci subgroup quit se quit se ag year o35 151 14.6 0.03 132 5.3 0.02 2.75 1.21 6.22 z35 111 6.3 0.02 109 4.6 0.02 1.38 0.45 4.20 gender male 82 4.9 0.02 89 3.4 0.02 1.45 0.33 6.27 femal 180 13.9 0.03 150 6.0 0.02 2.32 1.12 4.81 race white 52 13.5 0.05 56 0.0 0.00 white 210 10.5 0.02 185 6.5 0.02 1.62 0.82 3.17 educ high school lower 43 7.0 0.04 67 3.0 0.02 2.34 0.41 13.42 colleg trade school 146 12.3 0.03 108 8.3 0.03 1.48 0.69 3.17 colleg degre higher 73 11.0 0.04 66 1.5 0.02 7.23 0.93 6.30 fagerstrom score r5 125 16.0 0.03 117 6.0 0.02 2.67 1.17 6.09 45 137 6.6 0.02 124 4.0 0.02 1.63 0.56 4.73 frequenc text o25 dai 122 13.8 0.03 145 4.1 0.02 3.37 1.30 8.70 z25 dai 52 13.5 0.05 74 9.5 0.03 1.42 0.53 3.81 live smoker live smoker 121 12.4 0.03 112 2.7 0.02 4.63 1.38 15.56 live smoker 97 11.3 0.03 89 7.9 0.03 1.44 0.59 3.56 cessat aid recommend cessat aid 111 15.3 0.03 118 5.9 0.02 2.58 1.11 5.99 recommend cessat aid 62 17.7 0.05 59 8.5 0.04 2.09 0.77 5.66 note boldfac statist signific po0.05 aχ2 analys conduct examin outcom intervent control group unadjust risk ratio present outcom biochem confirm repeat point preval abstin miss data imput smoke bp valu signific test condit subgroup interact term logist regress model present studi condit race margin signific 0.06 abrom al prev med 2014;47 3 242 250248 provid saliva sampl misrepres smoke statu design strength includ particip recruit real world condit studi ad shown moment googl search quit smoke inform 26 addit except educ baselin demograph smoke relat factor balanc group studi noteworthi test program wide offer u. quitlin combin phone counsel 7 find suggest text2quit improv quit quitlin caller studi need quitlin caller repres distinct popula tion recruit internet text messag confer addit benefit receiv quitlin phone counsel text2quit slightli modifi quitlin particip enrol onlin random comput intervent group repres strength weak repres strength autom enrol procedur subject recruit bias gener real world program enrol condit peopl initi express interest studi declin particip peopl enrol studi subsequ disqualifi enrol internet approach caution studi eventu benefit safeguard set 3 month trial includ manual check phone number handset verif captcha code publish recruit ment method internet except includ graham al 27 addit studi requir advanc scienc internet recruit futur www.ajpmonline.org abrom al prev med 2014;47 3 242 250 249 studi addit safeguard remov inform financi compens studi ad mail verifi contact partic ipant inform interview call verifi particip contact inform note particip suspect fraudul remov studi remov confound random process misrepr sentat particip differenti explain signific result analys reveal disqualifi larg similar studi group weak studi nation text program studi period impli effort contamin control group partic ipant control group independ sign smoke cessat text program 13 particip control group 5 3 month survei text program smoke cessat enrol studi suggest low level contamin control group text program magnitud effect larger report limit includ low respons rate 64.7 elig provid saliva sampl biochem verif respons rate differ intervent group addition smoker recruit studi repres distinct group specif attribut studi result limit generaliz smoker recruit studi motiv quit smoke digit connect access internet work cell phone unlimit text messag conclus mobil phone widespread u. part world quarter adult global access mobil phone 28 result trial motiv smoker recruit inter net preliminari evid rel efficaci facilit text messag intervent smoke cessa tion studi need compar text messag pro gram establish smoke cessat treatment evalu efficaci text messag program context health system includ quitlin research support grant 5k07 ca124579 02 american recoveri reinvest act supplement dr lorien abrom nation cancer institut nih support award septemb 2014 depart prevent commun health georg washington univers school public health health servic dr lorien abrom dr abrom research staff georg washington univers dedic studi includ amanda davi mph meenakshi ahuja mph dr abrom dr amanda graham colleagu schroeder institut tobacco research polici studi legaci initi guidanc conduct trial georg washington univers dr lorien abrom licens text2quit program voxiva dr lorien abrom stock option voxiva ashlei boal dr samuel simmen judith mendel dr richard windsor financi disclosur
research report doi 10.1111 1360 0443.2006.01461 2006 author journal compil 2006 societi studi addict addict 101 883 891 blackwel publish oxford uk addaddict 0965 2140 2006 author journal compil 2006 societi studi addict 2006 101 origin articl nicotin gum counsel african american light smoker jasjit ahluwalia al correspond jasjit ahluwalia execut director offic clinic research univers minnesota academ health center mayo mail code 451 420 delawar street se minneapoli mn 55455 usa mail jahluw umn.edu submit 22 june 2005 initi review complet 31 august 2005 final version accept 10 januari 2006 research report effect nicotin gum counsel african american light smoker 2 2 factori design jasjit ahluwalia 1,4 kolawol okuyemi 2,4 nicol nollen 5 won choi 5 harsohena kaur 3 kim pulver 5 matthew mayo 5 depart intern medicin 1 depart famili medicin 2 depart pediatr 3 univers minnesota cancer center 4 univers minnesota academ health center minneapoli mn usa depart prevent medicin 5 univers kansa medic center kansa citi ks usa abstract aim approxim 50 african american smoker light smoker smoke 10 cigarett dai preva lenc light smoke unit state increas singl smoke cessat clinic trial target light smoker purpos 2 2 factori random clinic trial evalu efficaci nic otin gum 2 mg versu placebo counsel motiv interview versu health educ african american light smoker design particip assign randomli studi arm 2 mg nicotin gum health educ 2 mg nicotin gum motiv interview mi placebo gum pla cebo gum mi particip set total 755 african american light smoker 66 femal mean ag 45 enrol commun health center 16 month period intervent measur particip receiv 8 week suppli nicotin gum counsel session 26 week studi biochem measur includ expir carbon monoxid serum salivari cotinin find dai quit rate nicotin gum placebo group 14.2 versu 11.1 0.232 6 month counsel effect emerg perform significantli mi 16.7 versu 8.5 0.001 result consist outcom time point week 1 8 26 conclus result highlight potenti posit impact direct inform advic orient counsel smoke cessat studi need assess intervent improv quit rate african american light smoker motiv quit keyword african american health educ motiv interview nicotin replac smoke introduct cigarett smoke remain lead prevent diseas unit state effort decreas preval 1 preval ciga rett smoke decreas past decad proport maintain low level ciga rett consumpt light smoker grow evid subpopul unit state teen young adult women ethnic minor group 2,3 phenomenon light smoke understood poorli number reason research varieti term describ smoker maintain low level cigarett consumpt 2 includ chipper 4 low rate smoker 5 5 cigarett dai cpd 5 dai week occasion smoker 6 smoke 25 30 dai light smoker 2 defin light smoker nation survei pre viousli cut 15 cpd 7 definit white smoke averag 17 cpd 8 cut 15 cpd inappropri appli popul african american smoke averag 12 cpd 8 consensu phe nomenon light smoke light smok ing transit state lead heavier smoke cessat 2,9,10 hold light smoke stabl pattern low consumpt maintain long period time 2,5,11 previous cross section 2006 author journal compil 2006 societi studi addict addict 101 883 891 884 jasjit ahluwalia al data shown major low rate smoker 88 exhibit stabl pattern cigarett consumpt 5 recent longitudin data suggest proport light smoker maintain stabl pattern low consumpt time 10 popul base prospect studi reveal major low rate smoker regular smoker 40.0 smoker 24.6 occasion smoker 13.4 prevail percept smoker light smoke present reduc minim risk health consequ studi shown light smoker suffer signific smoke relat morbid mortal compar smoker 12,13 addit approxim 50 african american light smoker african american experi disproportion share tobacco relat morbid mortal 14 prefer high tar nicotin menthol cigarett 15 tend inhal deepli 16 slow rate nicotin metabol 16 higher serum cotinin level cigarett smoke 17,18 greater difficulti quit smoke compar ethnic group 19 smoke characterist african american suggest possibl contribut excess smoke relat morbid experienc african american grow preval light smoke health risk clinic trial focus exclus light smoker 20 secondari analysi larger clinic trial found lozeng efficaci white smoke 15 cpd 21 notwithstand high preval light smoke african american disproportion high smoke relat morbid popul smoke cessat clinic trial target african american popul smoke 10 cpd 20 propos evalu efficaci nicotin gum 2 mg versu placebo counsel motiv interview versu health educ random clinic trial african american light smoker nation survei defin light smoke 15 cpd defin light smoke 10 cpd lower level smoke african american rel gener popul 7,8 combin counsel pharmacotherapi chosen light evid counsel enhanc long term success smoke cessat 22,23 ad pharma cotherapi counsel significantli boost quit rate 24 method studi design studi placebo control random trial 755 african american light smoker 10 cpd enrol commun health center period 16 month 2 2 factori design particip assign randomli placebo activ nicotin gum health educ motiv inter view mi group receiv smoke cessat guid develop studi particip provid writ ten inform consent visit studi pro cedur approv monitor univers kansa medic center human subject committe particip screen random elig individu identifi african american black 18 year ag smoke 10 fewer cigarett dai 6 month prior enrol smoke 25 30 dai interest quit 2 week spoke english perman home address work telephon smoker household allow enrol particip exclud contraind nicotin gum jaw problem irregu lar heartbeat recent myocardi infarct stroke pharmacotherapi smoke cessat 30 dai form tobacco 30 dai pregnant plan preg nant 6 month breast feed plan move local area 6 month individu demonstr mark inappro priat affect behavior exclud studi smoker recruit clinic media muniti outreach effort includ radio televis ga pump billboard advertis commun health fair post sign minor own busi mail referr letter physician particip ran domiz march 2003 june 2004 6 month follow session complet januari 2005 1933 peopl screen 1012 elig studi invit particip fig 1 enrol continu 755 particip ran domiz random code gener block 36 investig pharmaci univers kansa medic center packag studi medic code maintain blind random visit seal envelop pre assign random number drawn determin form counsel ing particip receiv envelop box gum match random number particip order ran domiz studi staff particip blind particip receiv activ gum placebo assign mi counsel versu blind elig particip 1012 older 44.7 ver su 42.4 year 0.001 smoke fewer cigarett dai 7.5 versu 13.3 0.001 nicotin gum counsel african american light smoker 885 2006 author journal compil 2006 societi studi addict addict 101 883 891 inelig 921 elig women 78.5 women versu 67.8 men 0.0001 smok ing fewer cigarett dai 7.4 versu 7.8 0.05 return random visit baselin characterist particip treat ment group shown tabl 1 treatment period prior random visit particip receiv ki ii quit smoke guid ki ii smoke guid 36 page booklet develop african american light smoker cultur sensit guid devel op project investig iter process expert feedback cultur relev anali si suitabl assess materi sam instrument develop assess difficulti suit abil educ materi patient low liter aci skill 25 final guid rate superior sam standard written 7th grade read ing level random visit particip assign randomli receiv 8 week suppli activ 2 mg nicotin gum placebo instruct gum usag depend number cigarett smoke base line individu smoke 8 10 cpd told 10 piec gum dai 4 week piec week 5 6 piec week 7 8 smoke cpd prescrib piec gum initi piec week 5 6 piec 2 week treatment smoke fewer cpd told piec gum dai 4 week piec week 5 6 piec week 7 8 dose regimen arriv expert consensu review manufactur recommend usag particip assign randomli figur 1 studi flowchart 1933 person screen 921 elig 1012 elig 257 return 755 random 189 assign receiv activ nicotin gum mi schedul visit window 175 week 1 166 week 3 160 week 6 171 week 8 142 week 16 168 week 26 189 assign receiv placebo gum mi schedul visit window 154 week 1 140 week 3 131 week 6 134 week 8 137 week 16 150 week 26 189 includ primari analysi 189 includ primari analysi 189 assign receiv activ nicotin gum 188 assign receiv placebo gum schedul visit window 159 week 1 152 week 3 145 week 6 145 week 8 145 week 16 157 week 26 schedul visit window 165 week 1 154 week 3 152 week 6 153 week 8 156 week 16 162 week 26 189 includ primari analysi 188 includ primari analysi 32 lost follow week 26 2 schedul visit window 28 return 2 withdrew consent 21 lost follow week 26 0 schedul visit window 20 return 1 withdrew consent 39 lost follow week 26 0 schedul visit window 39 return 0 withdrew consent 26 lost follow week 26 0 schedul visit window 25 return 1 withdrew consent s04aw6 highlight 2006 author journal compil 2006 societi studi addict addict 101 883 891 886 jasjit ahluwalia al receiv mi counsel gener partici pant receiv counsel person counsel session person visit randomiza tion week 1 week 8 telephon week 3 week 6 week 16 visit consist approxim 20 minut counsel session particip encourag set target quit date dai random visit addit particip complet batteri assess health educ standard counsel approach base current treatment guidelin 26 focus provid inform advic session train counselor ki ii quit smoke guid semistructur script review addict natur nicotin health consequ smoke benefit quit provid concret strategi develop quit plan identifi alter nativ trigger smoke motiv interview ing mi counsel approach initi develop addict behavior appli recent nicotin depend detail 27 mi se sion studi conduct train counselor semistructur script explor pro con smoke quit motiv confid quit valu clarif strategi base work miller rollnick 27 mi counselor particip separ weekli super vision studi period ensur integr respect counsel protocol maintain addit session tape record maintain fidel consist studi retent particip call postcard appoint remind mail visit particip miss appoint call reschedul visit studi promot item partic ipant visit complet e.g tote bag magnet pen drink cup shirt coffe mug wal mart voucher 40 baselin week 26 20 weeka 1 3 6 8 16 voucher earn complet ing telephon visit dispers person visit measur questionnair item read particip train research assist baselin measur assess demograph health relat infor mation smoke behavior psychosoci variabl tabl 1 baselin characterist particip characterist nicotin gum placebo gum mi 189 189 mi 189 188 ag year mean sd 45.2 10.7 43.5 11.8 46.5 10.0 45.2 10.0 femal 125 66.1 129 68.3 123 65.1 128 68.1 marri live partner 82 43.4 77 41.0 72 38.1 53 28.2 monthli famili incom 1,800 111 60.7 106 57.0 117 63.2 99 54.7 high school graduat 28 14.8 32 17.0 40 21.2 24 12.8 cigarett smoke dai mean sd 7.8 3.5 7.5 2.9 7.5 3.5 7.3 2.8 durat smoke year mean sd 23.5 12.1 22.8 12.8 25.1 11.4 24.2 11.5 smoke menthol cigarett 153 81.4 156 83.0 158 83.6 148 78.7 fagerström score mean sd 4.1 2.16 4.3 2.0 4.2 2.2 4.5 2.2 quit attempt year mean sd 2.8 4.4 2.8 5.1 4.0 10.0 3.4 5.6 serum cotinin ng ml mean sd 241.8 140.0 229.9 147.1 256.6 171.5 248.6 157.2 exhal carbon monoxid p.p.m mean sd 13.7 9.0 14.2 9.8 14.0 8.5 13.5 8.4 smoke cessat pharmacotherapi year 24 12.7 25 13.2 20 10.6 20 10.6 smoker household 65 34.4 71 37.6 87 46.0 71 37.8 weight kg mean sd 86.1 22.9 85.7 23.0 84.6 25.0 89.1 24.7 bodi mass index kg 2 mean sd 30.7 8.1 30.4 7.4 29.8 8.3 31.6 8.5 ce mean sd 3.4 2.8 3.5 2.6 3.4 2.5 3.5 2.5 clinic depress 84 44.4 89 47.1 83 43.9 90 47.8 motiv quit mean sd 9.1 1.6 9.0 1.7 9.0 1.8 9.1 1.6 confid quit mean sd 7.3 2.6 7.0 2.5 7.2 2.6 7.0 2.7 fagerström test nicotin depend rang 0 10 score 7 higher greater level nicotin depend 10 item center epidemiolog studi depress scale score rang 0 10 score 4 higher likelihood clinic depress nicotin gum counsel african american light smoker 887 2006 author journal compil 2006 societi studi addict addict 101 883 891 biolog measur tabl 1 nicotin depend assess item fagerstrom test nicotin depend ftnd 28 withdraw symptom measur random week 1 3 6 8 26 visit valid scale develop hugh hatsukami 29 psychosoci measur includ 10 item center epidemiolog studi depress scale ce 30 singl item assess motiv quit smoke confid quit smoke 10 point continuum rang motiv con fident extrem motiv confid 31,32 serum cotinin assess random expir carbon monoxid random week 1 8 26 salivari cotinin assess week 26 salivari cotinin cut 20 ng ml verifi abstin 26 week cut 10 part million p.p.m 33 primari outcom variabl studi cotinin verifi 7 dai abstin week 26 defin smoke cigarett puff previou 7 dai sec ondari outcom 7 dai abstin week 8 process measur includ counsel attend random week 1 3 6 8 16 counsel ing visit report gum usag past 7 dai week 1 3 8 end gum treatment data analysi statist consider sampl size determin priori assum tail type error 0.05 power 80 6 month biochem verifi carbon monoxid quit rate 7 placebo 16 placebo mi 16 gum 24 gum mi sampl size calcul base detect margin effect gum counsel base assumpt expect random placebo 11.5 cessat rate compar 20 random iz gum cessat rate expect mi margin test result 378 particip margin result 80 power detect differ control type error rate power calcul perform assum type error rate 2.5 test priori assumpt interact effect test endpoint primari outcom studi cotinin ver ifi 7 dai abstin 26 week quit date primari analys comparison verifi absti nenc rate 6 month descript purpos summar report verifi 7 dai absti nenc week 1 8 26 cotinin verifi 7 dai abstin week 26 group summar primari end point cotinin verifi 7 dai abstin 2 2 tabl assess margin joint effect treatment inferenti analys conduct logist regress smoke statu code 1 quitter 0 smoker logist regress model includ main effect term nicotin gum activ placebo counsel mi term interact gum counsel adjust odd ratio quit confid interv comput main effect interact term primari secondari end point interact term signific drop subsequ model secondari anal yse includ report verifi 7 dai absti nenc week 1 8 26 logist regress model primari end point subsequ com.ibm.drl.hbcp.util gener estim equa tion longitudin model report verifi 7 dai abstin statist analys perform intent treat basi lost follow imput smoker primari analys classifi ing lost follow smoker conserv approach perform sensit analys assess effect assumpt conclus mix linear model assess longitudin effect nicotin gum activ placebo counsel mi interact withdraw symptom score result 755 random particip 603 79.9 week 8 637 84.4 week 26 fig 1 118 particip lost follow 26 week studi window 112 return withdrew consent assess differenti attrit due counsel nicotin gum multipl logist regress model counsel gum main effect predict patient return adjust odd ratio calcul 95 confid interv differen tial attrit analys particip ran domiz return person visit week 1 1.9 95 ci 1.2 2.9 0.003 week 8 2.2 95 ci 1.5 3.2 0.001 week 26 1.6 95 ci 1.1 2.4 0.02 addi tional assign activ gum return week 8 1.6 95 ci 1.1 2.3 0.01 interact gum counsel signific includ model report biochem confirm abstin rate group time point shown tabl 2 hundr nineti particip report quit week 26 95 49.0 confirm quitter salivari cotinin 20 ng ml rate discrep report coti verifi quit logist regress model conduct examin demograph psychosoci 2006 author journal compil 2006 societi studi addict addict 101 883 891 888 jasjit ahluwalia al factor relat misreport result par ticip higher baselin cotinin report smoke statu accur week 26 0.995 95 ci 0.993 0.998 lower baselin cotinin demograph ag gen der baselin cpd educ marit statu presenc smoker household alcohol previou quit attempt past year nicotin depend psychosoci factor motiv quit depress counselor particip relationship relat mi report smoke statu tabl 3 show salivari cotinin verifi cessat rate week 26 counsel gum margin examin effect gum type counsel interact cessat logist regress verifi cessat week 26 perform tabl 4 interact counsel gum signific 0.6227 drop model result model main effect gum counsel result chang analyz complet imput miss val ue smoker com.ibm.drl.hbcp.util gener estim equat gee assess longitudin main effect gum counsel interact verifi report 7 dai abstin analys signific gum counsel interact signific effect due drug remain sig nific effect due counsel withdraw symptom order evalu withdraw symptom affect efficaci nicotin gum counsel assess longitudin withdraw symptom time adjust baselin level current smoke statu main effect gum counsel interact effect variabl drawal time mean withdraw score differ type counsel gum present withdraw score relaps remain abstin process evalu counsel gum particip assign return assign mi χ 2 17.4 0.004 68.8 particip random mi return session 80.9 particip random iz return session smoke 8 10 cpd baselin 387 particip report chew mean 6.3 sd 4.8 4.4 sd 4.2 piec gum dai 7 dai recommend 10 piec dai week 1 8 smoke 5 7 cpd baselin 253 partici pant report chew mean 5.1 sd 3.6 3.3 sd 3.7 piec gum dai 7 dai recommend 8 4 piec dai week 1 8 smoke 5 cpd baselin 115 partic ipant report chew mean 4.1 sd 3.8 2.7 sd 3.0 piec gum dai 7 dai recommend piec dai week 1 8 differ found gum usag random activ placebo gum addition tabl 2 report biochem verifi 7 dai abstin rate gum 189 gum mi 189 placebo 188 placebo mi 189 report imput quit week 1 48 25.4 29 15.3 41 21.8 24 12.7 quit week 8 62 32.8 45 23.8 55 29.3 33 17.5 quit week 26 67 35.5 35 18.5 60 31.9 32 16.9 carbon monoxid verifi 10 p.p.m quit week 1 43 22.8 29 15.3 39 20.7 24 12.7 quit week 8 58 30.7 40 21.1 47 25 32 16.9 quit week 26 55 29.1 29 15.3 45 23.9 28 14.8 saliva cotinin verifi 20 ng ml quit week 26 34 18.0 19 10.1 29 15.4 13 6.9 lost follow schedul visit window treat smoker tabl 3 joint margin salivari cotinin verifi cessat rate week 26 counsel nicotin replac ther com.ibm.drl.hbcp.api nrt counsel nrt placebo gum activ gum margin 15.4 18.0 16.7 mi 6.9 10.1 8.5 margin 11.1 14.2 nicotin gum counsel african american light smoker 889 2006 author journal compil 2006 societi studi addict addict 101 883 891 differ found gum usag random mi discuss current studi test efficaci 2 mg nicotin gum conjunct counsel smoke cessa tion african american light smoker contrari expect receiv activ gum higher quit rate receiv placebo gum 2 mg nicotin gum effect smoke cessa tion sampl african american light smoker studi control research set shown nicotin gum effect smoke cessat number studi primari care set fail find signific effect gum pla cebo 34 37 reason lack effect gum real world versu control trial set poor adher dose instruct lower motiv quit 35 37 present studi failur find effect gum due inadequ usag dose specif sampl light smoker chose 2 mg oppos 4 mg gum prescrib maximum 10 piec gum dai averag particip chew 5.5 3.8 3.9 piec gum dai week 1 3 8 provid adequ nicotin replac consid context high mean baselin serum cotinin level 244.2 ng ml found partic ipant sampl compar previou work sampl heavier african american smoker mean cotinin level 292 38 suggest popul african american light smoker cessat outcom treat phar macotherapi dosag heavier smoker group light smoker report baselin cigarett smoke dai particip report smoke averag 7.4 sd 2.4 cpd baselin cotinin valu con sistent significantli higher rate smoke closer nation averag african american smoker 12 cpd 8 consid possibl report factor discrep report cigarett smoke dai cotinin level explor factor discrep anci statist signific find higher serum cotinin level report smoke accur differ odd 0.995 1 ng unit differ clinic signific futur studi mean assess smoke statu cigarett smart pack timelin follow back procedur baselin cotinin level adjunct report studi found withdraw symptom affect treatment find surpris reason lack effect nicotin gum abstin due dose gum inad equat nicotin replac explana tion withdraw symptom chang time studi subset light smoker call chipper smoke fewer cigarett dai show group light smoker report withdraw symptom abstin smok ing find present studi respect drawal symptom consist earlier studi chipper 4,39 regard counsel studi found african american light smoker random return counsel visit random mi addition particip receiv advic orient health educ higher quit rate receiv motiv interview counsel differenti return rate explain higher effect result remain analyz complet find sug gest counsel perceiv relev sampl highli motiv smoker common notion light smoker interest quit hypothes group smoker counsel tech niqu design enhanc reinforc motiva tion baselin data show major particip studi highli motiv quit receiv intervent find favor outcom mi consist studi shown mi work peo ple resist angri demonstr low motiva tion chang health behavior 40 contraind patient tabl 4 logist regress model verifi cessat rate 26 week variabl estim se odd ratio 95 ci intercept 2.00 0.12 0.0001 counsel 1 mi 0 0.39 0.12 2.17 1.38 3.41 0.0008 nrt gum 1 placebo 0 0.12 0.11 1.31 0.84 2.02 0.2318 signific interact nrt counsel 0.6227 drop logist regress model 2006 author journal compil 2006 societi studi addict addict 101 883 891 890 jasjit ahluwalia al readi action hand favor outcom advic orient health educ encourag find practic implic health care provid health educ requir type special train mi approxim close type cessat advic deliv health care set studi limit wide varieti commun base recruit strategi reach potenti particip entir kan sa citi metropolitan area random follow activ occur singl commun health center find generaliz african american light smoker natur intervent particip requir home address access telephon result peopl access telephon homeless thirdli simi lar previou studi popul third sampl femal result lower quit rate sampl studi report women lower quit rate nrt 41 fourthli case smoke ce sation clinic trial particip select group motiv quit smoke limit gen eraliz reflect group smoker pharmacotherapi final discuss earlier instruct gum usag incongru patient serum cotinin lev el led signific underdos turn contribut lack efficaci nicotin gum sum current studi found advic orient health educ effect motiv interview counsel smoke cessat african american light smoker motiv quit 2 mg nicotin gum effect popul encourag larg number african american light smoker enrol cessat clinic trial contrari belief easier light smoker quit smoke quit rate african american light smoker studi lower expect low quit rate grow preval light smoke associ at health risk effort continu develop test intervent enhanc smoke cessat light smoker extend smoke cessat inter vention african american light smoker impor tant contribut reduc tobacco relat health dispar unit state acknowledg project support nation cancer institut nation institut health r01 ca091912 glaxo smithklin provid studi medica tion plai role design conduct studi interpret analysi data author staff swope parkwai health center tricia snow raegan bond sierra buff ington alicia brown angela banitt nichol freeman mona la flore robin liston brian man thui tran effort project grate volunt particip research
author 2014 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com doi 10.1093 ntr ntu095 origin investig smoke reduct increas efficaci random control trial smoke abstin conting incent residenti substanc abus treatment patient sheila alessi phd nanci petri phd depart medicin univers connecticut health center farmington ct author sheila alessi phd depart medicin univers connecticut health center 263 farmington avenu farmington ct 06030 usa telephon 860 679 1849 fax 860 679 1312 mail salessi uchc.edu receiv octob 16 2013 accept 11 2014 abstract introduct individu substanc disord sud experi increas smoke relat morbid mortal sever compromis smoke treatment benefit residenti sud treatment set posit target smoke increas smoke ban cultur shift smoker continu smoke studi examin effect conting manag cm increas smoke abstin residenti patient method smoker interest quit recruit residenti sud program men random frequent smoke monitor behavior support monitor 21 smoke abstin conting expir carbon monoxid 6 ppm urinari cotinin 30 ng ml incent cm 24 4 week set quit date proce dure includ daili behavior support smoke report 2 sampl a.m p.m mondai fridai cotinin test mondai cm particip receiv escal draw prize 1 20 100 valu neg test posit miss sampl reset draw follow up involv sampl report smoke efficaci week 4 8 12 24 result percent dai neg higher cm median interquartil rang 51.7 62.8 compar monitor 0 32.1 002 cigarett dai declin point preval abstin increas follow 01 signific group time effect 05 abstin efficaci increas intervent cm compar monitor abstin condit follow conclus cm improv measur respons smoke treatment residenti sud patient introduct cigarett smoke remain lead prevent morbid mortal lost product world health organ 2011 individu addit nicotin substanc disord sud disproportion affect higher smoke rate 90 kalman 1998 compar 19 u. adult schiller luca peregoi 2012 30 1.2 billion smoker worldwid world health organ smoke heavili lasser al 2000 die smoke relat complic sud problem hurt al 1996 mortal rate time higher nonsmok sud hser mccarthi anglin 1994 barrier treat smoke sud perceiv lack demand 80 sud smoker con templat quit smoke richter gibson ahluwalia schmelz 2001 barrier concern treat smoke jeopard sud recoveri smoke abstin decreas illicit drug alcohol baca yahn 2009 25 decreas likelihood sud relaps prochaska delucchi hall 2004 address smoke sud prescrib wide effort rise guydish al 2012 sherman 2008 william al 2005 smoke quit rate sud smok er low behavior pharmacolog smoke treatment grant hasin chou stinson dawson 2004 hai croghan schroeder ebbert hurt 2011 lasser al 2000 richter mccool catlei hall ahluwalia 2006 stein al 2006 residenti sud treatment set posi tion address smoke context high intens sud treatment servic similarli support intens quit smok ing servic act synergist effect smok ing intervent improv smoke outcom acceler pace smoke ban relat polici creat advanc access public june 16 2014 1436 nicotin tobacco research volum 16 number 11 novemb 2014 1436 1445 mailto:salessi uchc.edu subject nicotin tobacco research press identifi effect smoke treatment patient date research smoke ban set focus predominantli attitud pre post pol ici report examin smoke behavior indi cate patient continu smoke ban callaghan al 2007 guydish al 2012 quit counsel pharmacotherapi precipit return smok ing sud treatment guydish al 2012 prochaska al 2004 intens multimod strategi need tackl dispar smoke relat harm treatment efficaci effect treat smoke popul conting manag cm effect psy chosoci treatment sud dutra al 2008 improv smoke outcom sud smoker cm involv identifi clinic relev object defin target behavior e.g expir carbon monoxid read 6 ppm indic smoke abstin frequent monitor behavior provid tangibl incent voucher prize occur cm improv abstin alcohol cocain marijuana opioid maintain treatment patient higgin silverman heil 2008 petri 2012 evi denc support cm smoke tightli con troll quasi laboratori base studi nontreat seeker e.g roll higgin badger 1996 stitzer bickel bigelow liebson 1986 research cm treat smoke sud patient focus primarili opioid mainten set part clinic attend daili coincid abil assess smoke test reinforc abstin dunn al 2010 dunn sigmon thoma heil higgin 2008 shoptaw al 2002 shoptaw jarvik ling rawson 1996 demonstr project examin cm smoke absti nenc nonopioid medic set robl al 2005 invit 16 women residenti sud treatment continu smoke 10 cigarett daili smoke cessa tion counsel receiv educ support 4 week thrice daili test mondai fridai urinari cotinin cot test mondai abstin conting reinforc ment abstin increas cm compar pre postintervent alessi petri urso 2008 recruit 24 men residenti sud treatment receiv monitor time weekli random cot test weekli behavior support abstin conting incent 12 incent 12 4 week test ing taper base abstin increas cm rel control condit studi promis wide variabl respons cm number construct efficaci bandura 1977 explain variabl treatment respons abstin efficaci mediat relat smoke treatment increas abstin hendrick delucchi hall 2010 mccarthi al 2010 stanton lloyd richardson papandonato de dio niaura 2009 abstin increas efficaci perkin parzynski mercincavag conklin font 2012 studi partici pant receiv cm smoke abstin efficaci posit relat amodei lamb 2010 lamb morral galbicka kirbi iguchi 2005 romanowich mintz lamb 2009 cm differenti impact efficaci affect abstin evalu cm condit purpos studi conduct random clinic trial cm smoke abstin residenti sud treatment patient interest quit popul increasingli requir adher smoke free polici low smoke cessat rate set daili test schedul critic success cm smoke abstin hypothes cm increas smoke abstin compar behavior port monitor cm assess relat treatment efficaci abstin method particip set particip 45 men enter long term 6 month adult ag 18 minimum residenti sud treatment southern connecticut inclus criteria smoke 10 cigarett dai minimum studi intak 8 ppm biochem confir mation smoke statu report interest quit smoke individu receiv expect smoke treatment uncontrol psychiatr ill e.g acut schizophrenia suicid risk substanti cog nitiv impair 23 mini mental state examin mmse folstein folstein mchugh 1975 exclud patholog gambler recoveri exclud concern prize cm jeopard gambl recoveri petri alessi 2010 petri al 2006 research staff refer inelig patient connecticut quitlin residenti treatment servic includ individu group therapi psychoeduc group 12 step meet resourc need treatment includ opiat substitut medic treat sud substanc monitor urin test instant swab breathalyz posit test typic handl clinic staff studi particip affect stand ard treatment servic smoke prohibit indoor smoke break occur hour treat ment program residenti program includ smoke cessat treatment program studi provid smoke cessat medic bachelor level train research assist administ studi proce dure complet univers massachusett onlin workshop basic skill work smoker direct supervis princip investig sma univers institut review board approv studi recruit follow occur june 2008 octob 2010 fund cycl procedur baselin written inform consent determin elig particip complet quit smoke prepar session studi visit dai 1 involv submit sampl 5 hr minimum complet 30 min counsel session base clinic practic guidelin consum guid quit agenc health care polici research 1996 quit plan develop includ anticip potenti 1437 smoke reduct increas efficaci challeng identifi emot environment social support cope strategi 4.8 3.9 dai visit dai 2 progress obstacl discuss quit plan updat target quit date schedul 1 week intervent baselin random condit occur urn procedur stout wirtz carbonari del boca 1994 stratifi 6 ppm baselin 73.3 submit baselin 6 ppm monitor 21 start quit date sampl collect daili 5 hr minimum mondai fridai week 1 4 research staff discuss test result particip 5 min behavior support deliv encourag achiev maintain ing smoke abstin topic discuss includ person reason quit skill base item crave control tip individu discuss occur challeng success cigarett smoke alcohol drug medica tion track session cot test occur mondai breath alcohol urinari cocain marijuana opiat test occur weekli random dai monitor cm cm 24 cm particip addit procedur abstin conting incen tive week 1 4 test 6 ppm cot 30 ng ml week 1 smoke neg test rein forc encourag short period abstin critic initi dai e.g romanowich lamb 2010 guarante prize bowl contain 70 card 64 worth prize 1 e.g toiletri sport drink gum 5 worth 20 prize exercis weight portabl game barn nobl gift card 1 worth 100 prize linen tv dvd player draw neg test start increas consecut neg test cap 40 draw maximum week 1 posit test unexcus miss sampl reset draw neg test miss sampl clear advanc court appear doctor appoint reset draw se sion particip receiv prize earn written remind draw time standard prize bowl week 2 4 bowl neg test contain 500 card 50 worth prize 219 1 prize thirti 20 prize 100 prize bonu draw cot neg test total patient earn 150 draw prize bowl week 2 4 sampl submit neg 15 draw cot neg test transit guarante standard prize bowl affect number draw patient cap draw neg test continu draw time neg test proceed week 2 follow follow interview occur week 4 8 12 24 rela tive quit date assess smoke efficaci substanc medic complet cot breath alcohol urin drug test conduct figur 1 consolid standard report trial consort diagram particip flow recruit follow supplementari tabl 1 consort checklist assess intak case report form captur sociodemograph smoke histori mmse folstein al 1975 evalu at cognit impair diagnost statist manual mental disord fourth edit tr criteria american psycholog associ 2000 determin alcohol cocain marijuana opiat abus depend norc dsm screen gambl problem nod gerstein al 1999 nation opinion research center 1999 identifi patholog cal gambl question recoveri statu fagerström test nicotin depend heatherton kozlowski frecker fagerström 1991 complet score rang 0 10 sever relaps situat efficaci questionnair rseq gwaltnei al 2001 timelin followback sobel sobel 1992 administ intak follow rseq ask confid abil abstain spe cific context item rate 1 4 confid extrem confid total score rang 1 4 timelin followback captur daili frequenc intens ciga rett smoke alcohol cocain marijuana opiat sed benzodiazepin smoke cessat medic test calibr picosmokerlyz monitor bedfont scientif urinari cot site result accutest nicalert jant pharmac corpor urinari cocain opiat mari juana test conduct ontrak teststick varian breath alcohol test alco sensor iv altomet intoximet compens particip receiv 15 intak 25 follow 1 gift certif item snack gum cot sampl independ result cm particip earn 190 draw neg test averag expect maximum earn 426.56 prize 15 draw cot neg test expect addit 46.43 prize averag data analysi intent treat analys 45 conduct primari secondari outcom 43 case contribut efficaci time analysi due miss week 4 follow up initi baselin data examin differ enc condit found effect cm smoke intervent outcom percent dai neg report cigarett dai percent dai neg comput numera tor number dai test 6 ppm analyz dai sampl code posit denomin 20 dai sampl dai omit denomin dai point preval abstin ppa defin cot verifi report smoke report cigarett dai examin follow associ efficaci abstin outcom examin 1438 http ntr.oxfordjournals.org lookup suppl doi 10.1093 ntr ntu095 dc1 nicotin tobacco research mediat test due distribut abstin outcom secondari outcom frequenc drug alcohol posit test report nicotin stanc studi attend treatment retent analys differ condit singl timepoint outcom examin analysi varianc anova mann whitnei pearson chi squar test variabl past 30 dai work incom u. dollar number voluntari quit attempt percent dai neg dai report substanc examin nonparametr test transfor mation correct nonnorm distribut time intak week 4 examin repeat measur anova report cigarett dai efficaci remain time model hierarch mix model dichotom ppa continu cigarett dai outcom subject enter random effect condit time dai nest person condit time interact fix effect sampl size suffici detect effect size 80 primari neg outcom effect size estim relat magnitud accompani signifi canc test statist signific determin α 05 hierarch linear nonlinear model hlm v6.01 hierarch mix model ibm spss statist v19 remain analys result demograph baselin characterist demograph baselin characterist differ sig nificantli condit tabl 1 particip cocain opiat depend particip 20 year smoke histori smoke 15 cigarett daili major previou voluntari quit attempt attend adher averag cm monitor particip attend 27.0 8.8 28.1 9.3 studi session week 1 4 40 total 1 43 0.17 69 cohen 00 studi withdraw individu condi tion discharg sud residenti treatment prior end studi particip χ2 df 1 0.03 86 cm monitor particip differ num ber cot sampl submit averag sd 26.8 8.2 28.1 8.6 sampl 1 43 0.27 61 02 3.5 1.0 3.6 1.1 cot sampl 1 43 0.27 61 02 smoke behavior percent dai neg greater cm ver su monitor dai sampl code monitor behavior support 21 exclud 89 depart correct 42 elig criteria 38 left treatment miss recruit window 7 declin particip 2 intent treat analys 21 lost week 24 follow 1 unabl locat lost week 24 follow 1 unabl locat monitor behavior support cm 24 intent treat analys 24 alloc analysi follow random 45 enrol assess elig 134 figur 1 flow particip point initi contact data analysi consolid standard report trial consort guidelin cm conting manag 1439 smoke reduct increas efficaci smoke posit 137.0 008 η 0.75 omit ting sampl dai denomin 119 002 η 0.92 figur 2 cm monitor condit median interquartil rang iqr percent dai neg 32.5 45 0.0 25 miss dai code posit 51.7 55.2 0.0 30.8 miss dai omit denomin report cigarett dai decreas intak 28 dai period 1 41 54.04 00 32 differ condit 38 0004 condit time 30 0009 cot neg sampl rare occurr monitor condit instanc cm particip 28 hlm analys examin smoke outcom week 4 intak week 24 follow studi condit signific increas odd cot verifi 7 dai ppa slope coeffici 0.019 se 0.003 ratio approx df 43 4.95 00 odd ratio 1.02 ci 1.012 1.028 15.6 7 indi vidual smoke week 24 condit time interact signific 84 follow period cigarett smoke dai decreas slope coeffi cient 0.017 se 0.007 ratio approx df 43 2.59 01 differ condit time 83 supplementari figur 1 depict tra jectori time studi condit efficaci signific interact studi condit time intak week 4 abstin efficaci 1 41 5.70 02 24 efficaci increas pre posttreat greater extent averag sd cm 2.0 0.39 2.59 0.61 compar monitor 2.1 0.4 2.3 0.5 week 4 efficaci significantli correl percent dai neg intervent 60 001 efficaci ppa measur follow significantli correl rb valu 52 59 001 ppa significantli correl cigarett smoke dai follow up 05 nicotin substanc dai report substanc rare differ condit 192.0 219.5 17 1.00 number drug posit urin test χ2 df 1 0.06 0.90 34 81 number drug posit test 3 43 test week 4 6 41 test week 8 8 39 week 12 6 32 week 24 tabl 1 demograph baselin characterist variabl monitor 21 monitor cm 24 signific test df ag averag sd 37.4 9.8 38.4 9.9 1 43 0.13 73 year educ averag sd 11.3 2.7 11.5 2.1 1 43 0.04 84 marri 81.0 17 58.3 14 χ2 df 1 2.67 10 emploi full time 66.7 14 58.3 14 χ2 df 1 0.33 57 incom work past 30 dai median iqr 0 1060 0 0 218.50 33 ethnic χ2 df 1 0.50 83 hispan 14.3 3 16.7 4 hispan 85.7 18 83.3 20 race χ2 df 3 7.44 06 black 42.9 9 16.7 4 european american 47.6 10 79.2 19 nativ hawaiian pacif island 9.5 2 0 0 race 0 0 4.2 1 cigarett smoke ag smoke averag sd 16.1 9.0 14.0 3.1 1 43 1.23 27 cigarett dai averag sd 18.1 7.5 19.2 5.2 1 43 0.65 42 fagerström score averag sd 3.7 1.1 3.9 97 1 43 0.68 42 minnesota nicotin withdraw scale averag sd 8.5 6.3 8.3 5.8 1 43 01 92 1 baselin 6 ppm 28.6 6 25.0 6 χ2 df 1 0.07 79 averag sd 18.3 6.2 15.1 5.0 1 43 3.78 06 salivari cotinineb median iqr 6 0 6 0 245.00 81 quit number voluntari attempt median iqr 1.0 0 1.0 1 251.5 99 abstin efficaci averag sd 2.1 0.4 2.0 0.4 1 43 0.76 39 substanc depend alcohol 0.0 0 8.3 2 χ2 df 1 1.83 18 cocain 4.8 1 12.5 4 χ2 df 1 0.83 36 opiat 23.8 5 12.5 3 χ2 df 1 0.98 32 marijuana 0 0 0 0 poli depend 71.4 15 58.3 14 χ2 df 1 0.84 36 note cm conting manag carbon monoxid iqr interquartil rang astratif variabl bcotinin equival test stick result 6 2,000 ng ml manufactur insert 1440 http ntr.oxfordjournals.org lookup suppl doi 10.1093 ntr ntu095 dc1 nicotin tobacco research intervent reinforc exposur cm patient earn median iqr 28 draw 89.5 draw neg test result 96.46 162.26 prize constitut 20.5 42.4 maximum expect earn ing earn 0.0 0.0 draw 0.0 0.0 prize cot neg test advers event advers event involv cm particip ho pital experienc alcohol diseas relat heart liver lung problem event deem unrel studi particip discuss examin 4 week abstin base reinforc inter vention reduc smoke residenti sud treatment patient frequent monitor feasibl except incent period smok ing abstin increas cm efficaci increas group cm examin follow condit observ smoke reduct gener par effect psychosoci phar macotherapi smoke cessat sud popul efficaci abstin statu residenti sud treatment program approach smok ing set unit state partial smoke ban smoke treatment ser vice staff resid smoke smoke break occur dai nonetheless individu screen elig elect par ticip complet rate high studi withdraw pattern reflect increas accept treat smoke sud consist current guidelin achiev full dai neg test common cm particip rare monitor partici pant condit engend sustain absti nenc cessat goal histori abstin benefit attempt ceas smoke falba jofr bonet busch duchovni sindelar 2004 gourlai forb marrin pethica mcneil 1994 kenford al 1994 smoke reduct increas likelihood futur ce sation hugh carpent 2006 effect cm modest unclear explan relat reinforc exposur critic effect cm low forti percent cm patient earn 5 draw cap achiev 2.5 dai neg read miss session reason lost reinforc expect feasibl daili session exceed observ individu programmat circumst restrict person monitor ing technolog monitor reinforc smoke abstin remot alessi petri 2013 ongo clinic trial nct01484717 dalleri glenn raiff 2007 glenn dalleri 2007 stoop al 2009 smoke posit test reason miss rein forcement escal reinforc schedul roll al 1996 reset condit roll higgin 2000 higher reinforc densiti critic week ferguson gitchel shiffman sembow 2009 kenford al 1994 romanowich lamb 2010 paramet includ import improv cm outcom higher magnitud reinforc improv outcom cm substanc abus meta analysi lussier heil mongeon badger higgin 2006 cm smok ing abstin stitzer bigelow 1983 1984 incent smoke neg test substanti reduc pare report literatur alessi badger higgin 2004 donatel prow champeau hudson 2000 higgin al 2004 robl al 2005 shoptaw al 2002 higher reinforc magnitud increas respons cm 0 20 40 60 80 100 monitor cm ay iv figur 2 box whisker plot percent dai neg 6 ppm monitor 21 cm 24 condi tion monitor condit median end whisker minimum bottom maximum top valu save outlier defin 1.5 time length box end box open circl visual purpos data includ analys mean signific differ enc studi condit 002 analysi omit dai miss sampl 008 analysi code dai miss sampl smoke posit cm conting manag carbon monoxid 1441 smoke reduct increas efficaci understand process variabl underli effect cm point modifi target improv treatment respons previou work demonstr mediat effect efficaci relat tradit smoke ce sation counsel pharmacotherapi abstin knowledg random control trial cm smoke abstin examin relat result support previou find consist prior work efficaci assess prequit date predict abstin gwaltnei metrik kahler shiffman 2009 romanowich mintz lamb 2009 importantli evid extern reinforc abstin jeopard efficaci addit method enhanc efficaci quit attempt improv outcom cm treatment interestingli contrari expect reduct smoke intervent follow occur condit amount 15.6 particip abstin month 6 direct contrast observ increas smoke residenti sud treatment kelli al 2012 level abstin control condit par abstin rate achiev sud smoker smoke cessat pharmacotherapi kalman al 2011 kalman kahler garvei monti 2006 pole rounsavil gonsai severino sofuoglu 2010 present studi includ medic unlik studi observ increas smoke abstin time uncertain smoke restrict effect smoke polici occur extent frequent monitor behavior support activ ingredi requir investig studi nontreat control condit restrict abil attribut abstin time monitor condit detect group differ small sampl size test ing feasibl limit abil detect effect sampl limit men outcom differ enc sex report cm differ smok ing becker hu 2008 smoke relat morbid mucha stephenson morandi dirani 2006 respons smoke treatment perkin scott 2008 exist strength studi random clinic trial cm smoke abstin residenti sud treatment patient elig criteria liber increas generaliz result collect report biochem test smoke statu allow comprehens analysi smoke fewer measur measur cot follow import limit report test sud treatment program increas demand address cigarett smoke intervent enhanc smoke treatment respons rate need result sug gest intens monitor standard smoke ce sation counsel conjunct cm smoke abstin reduc smoke subset residen tial sud treatment patient supplementari materi supplementari tabl 1 figur 1 found onlin http www.ntr.oxfordjournals.org fund studi prepar report fund nation institut health grant r21 da021836 r21 da029215 r01 da013444 r01 da027615 r01 da024667 p30 da023918 p50 da092410 declar interest declar acknowledg patient staff liber program clinic research center univers connecticut health center support involv project grate urso tymoszczuk implement studi procedur ciesielski sierra leblanc assist studi administr report requir
express write smoke cessat treatment adjunct young adult smoker steven am christi patten chudlei werch darrel schroeder susanna steven paul fredrickson dan echol jame pennebak richard hurt receiv 3 octob 2005 accept 17 march 2006 investig evalu efficaci express write treatment adjunct offic smoke cessat intervent nicotin patch therapi young adult particip ag 18 24 year random offic intervent n599 express write offic intervent n597 condit receiv individu visit 6 week nicotin patch therapi began quit date week 2 visit particip express write intervent condit wrote 2 consecut dai 3 consecut dai quit date offic intervent group complet control write assign end treatment week 8 biochem confirm 7 dai point preval abstin express write offic intervent condit significantli greater offic condit 33 20 p5.043 or52.0 95 ci51.0 3.7 logist regress adjust gender 24 52 week abstin rate similar offic intervent versu express write offic intervent 12 11 24 week 11 11 52 week result suggest express write promis smoke cessat treatment adjunct young adult lengthier intervent booster test extend treatment effect particip report low level enthusiasm express write barrier implement longer time frame mode deliv express write young adult cigarett smoker explor introduct preval cigarett smoke declin adult ag group unit state 1983 smoke preval young adult ag 18 24 year remain stabl current preval rate 24 center diseas control prevent 2005 1991 1999 preval smoke colleg student rose 23 31 johnston o’mallei bachman 2003 smoke colleg student declin year 2000 2001 remain stabl current preval rate 27 johnston al 2003 high preval smoke young adult intervent trial design specif ag group review past 25 year tobacco relat research involv adol cent young adult sussman 2002 conjunc tion literatur review reveal publish intervent studi involv young adult am al 2005 hellman o’shea kunz schimpfhaus 1988 rutter 1990 suedfeld landon pargament epstien 1972 rutter 1990 uncontrol investig conduct 24 univers student com.ibm.drl.hbcp.util behavior smok ing reduct intervent yield signific result 7 24 particip abstin smoke 1 year 8 particip report reduc rate smoke approach young adult cigarett smoker intervent smoke cessat issn 1462 2203 print issn 1469 994x onlin 2007 societi research nicotin tobacco doi 10.1080 14622200601078525 steven am ph.d paul fredrickson m.d mayo clinic jacksonvil fl christi patten ph.d darrel schroeder m. susanna steven m. richard hurt m.d mayo clinic rochest mn chudlei werch ph.d univers florida gainesvil fl dan echol m.d mayo clinic scottsdal az jame pennebak ph.d univers texa austin tx correspond steven am ph.d mayo clinic divis hematolog oncolog mayo clinic cancer center 4500 san pablo road jacksonvil fl 32224 usa tel 1 904 953 6822 fax 1 904 953 2315 mail ames.steven mayo.edu nicotin tobacco research volum 9 number 2 februari 2007 185 194 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org includ treatment compon focus reduc stress theoret model initi mainten relaps cigarett smoke includ psycholog stress import factor e.g kassel shiffman 1997 pomerleau pomerleau 1990 smoker report smok ing lead reduct stress spielberg 1986 stress found prospect predict smoke initi byrn byrn reinhart 1995 failur achiev smoke abstin koval peterson 1999 altern tradit form stress manag e.g relax train express write emot experi pennebak 1997 techniqu signific advantag stress manag intervent requir particip train portabl wide rang ag mobil young adult uncompl portabl intervent advantag eas dissemin date studi evalu express write intervent smoke cessat evalu effect perceiv stress affect individu attempt quit smoke research found express write posit effect physic mental health specif mechan action express write influenc health understood sloan marx 2004a propos mechan reduct stress reduct activ mental inhibit klein 2002 pennebak 1997 activ mental inhibit occur byproduct individu effort inhibit thought feel pennebak 1997 inhibit requir physiolog effort reflect autonom central nervou system activ conceptu long term low level stressor pennebak 1997 inhibit thought feel noxiou event produc stress write event reduc psycholog stress caus activ inhibit pennebak 1997 klein 2002 expand propos mechan action suggest individu work memori avoid stress thought result attent solv problem stress life event work memori problem solv deficit perpetu higher level stress recent research support hypothes mechan action research explor mechan action express write ongo review klein 2002 present investig extens earlier work am al 2005 examin feasibl magnitud effect stress manag intervent involv express write adjunct offic smoke cessat young adult particip ag 18 21 year rando mize offic intervent express write offic intervent condit express write adjunct found effect evid statist nonsignific trend particip express write treatment adjunct condit poorli control group 10 20 tobacco abstin result earlier studi rais addit question methodolog present investig design address issu wonder time intervent affect tobacco abstin particip instruct complet express write prior quit date present investig particip ask complet express write quit date treatment prior investig 4 week includ nicotin replac therapi nrt current guidelin recommend phar macotherapi smoke cessat intens behavior treatment e.g greater number session enhanc success fior al 2000 longer behavior intervent includ nrt express write effect intervent includ present investig expand includ nicotin patch therapi primari aim investig evalu efficaci express write treatment adjunct offic smoke cessat intervent nicotin patch therapi mechan action express write exert effect ari aim examin impact express write propos mediat chang includ psycholog stress posit neg affect hypothes treatment effect mediat perceiv stress affect particip express write treat ment condit show greater reduct perceiv stress neg affect increas posit affect compar control treatment condit method particip studi approv mayo clinic institut review board particip includ 196 young adult cigarett smoker inter est stop cigarett smoke particip 186 express write smoke cessat treatment nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org recruit northeastern florida gener commun inclus criteria provis written inform consent ag 18 24 year histori smoke 10 cigarett dai past 6 month exclus criteria behavior pharmacolog cal treatment tobacco depend past 30 dai nicotin medic tobacco product cigarett past 30 dai pregnant breast feed alcohol depend past 3 month nicotin drug depend marijuana past 12 month clinic depress medic condit preclud transderm nicotin patch procedur particip recruit advertis post local colleg campus print colleg newspap citywid public target young adult particip paid total 95 particip studi random group design repeat assess ment baselin treatment session week 1 8 follow week 16 24 52 block random stratifi gen der baselin particip rando mize treatment condit offic intervent n599 express write offic intervent n597 treatment deliv research staff prior train deliv behavior smoke cessat interven tion staff receiv regular supervis ensur treatment fidel target quit date particip dai treatment session 2 particip receiv offic intervent base u. depart health human servic usdhh clinic practic guidelin treat tobacco depend fior al 2000 particip met research counselor weekli treatment session 4 week studi session last 30 40 min approxim 10 15 min devot control write assign initi session week 1 counselor assess factor determin content intervent stage chang social influenc famili friend cigarett psycholog factor includ presenc emot distress result cigarett cope method addict presenc physic psycholog depend content intervent restrict gener area addition research counselor com.ibm.drl.hbcp.util motiv inter view approach particip receiv 6 week 21 mg 24 hr transderm nrt i. nicotin patch begin target quit date dai treatment session 2 addit 4 week offic intervent 6 week nicotin replac particip random offic intervent condit receiv control write treatment compon express write offic intervent condit receiv express write treatment compon content write condit detail summari visit schedul outlin tabl 1 full verbatim instruct express write treatment compon control write condi tion obtain author request offic intervent control write assign ment consist instruct particip treat ment session 1 write e.g home total 20 min dai 2 consecut dai treatment session 2 i. target quit date 3 consecut dai time manag control write assign emphas partici pant describ specif object event detail describ thought feel assign found prior studi relat health outcom recommend control condit express write studi pennebak kiecolt glaser glaser 1988 petri booth pennebak davison thoma 1995 particip ask bring write assign treatment session complianc evalu particip ask turn write assur content read write assign collect effort enhanc partici pant emot disclosur activ write condit make methodolog control write condit consist expr sive write condit control write assign ment collect express write offic intervent particip random condit receiv express write treatment compon express write compon consist instruct ing particip treatment session 1 write e.g home total 20 min dai 2 consecut dai treatment session 2 i. target quit date 3 consecut dai deepest thought feel relat smoke stop smoke smoke relat problem conflict life particip ask bring write assign treatment session nicotin tobacco research 187 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org complianc evalu ask turn write outset treatment assur content read complianc express write evalu research counselor scan write sampl evalu text written written content write sampl scrutin particip standard line paper complet write assign aid research counselor review emot disclosur para mount import express write para digm write assign collect effort enhanc particip emot disclosur maxim complianc assur partici pant confidenti measur descript data basic demograph inform tobacco histori assess report form evalu similar treatment group stage chang prochaska diclement 1983 assess evalu particip interest discontinu cigarett smoke sever nicotin depend evalu fagerström test nicotin depend ftnd heatherton kozlowski frecker fagerström 1991 tobacco particip 7 dai point preval tobacco evalu week 8 16 24 52 evalu tobacco treatment phase particip 7 dai point preval tobacco evalu treatment session held week 1 4 particip consid abstin tobacco report smoke i. puff form tobacco previou 7 dai time period expir air carbon monoxid level 8 ppm biochem confirm abstin particip unavail attend follow appoint week 12 24 52 obtain salivari cotinin return mail expir air 8 ppm salivari cotinin level 15 ng ml wide accept cutoff level nonsmok recent guidelin issu societi research nicotin tobacco srnt subcommitte biochem verif recommend cutoff level benowitz al 2002 individu provid report smoke statu e.g miss visit lost follow biochem verif smoke obtain classifi smoke averag number cigarett smoke dai past 7 dai assess time point psycholog stress life experi survei le sarason johnson siegel 1978 wide report measur major life event administ baselin assess potenti treatment group differ major life event past 12 month le list 60 item design repres major life stressor experienc gener popul respond ask rate perceiv posit neg impact item occur exampl stressor list le includ event death spous experienc ill fire job le score calcul sum neg perceiv impact rate item endors occur past 12 month item rate occur perceiv posit impact includ calcul score addition perceiv stress scale 10 pss cohen 1988 10 item report instrument design measur extent situat individu life apprais stress prior 7 dai administ treatment process measur time point 10 item scale shorter version 14 item perceiv stress scale posit neg affect posit neg affect scale pana watson clark tellegan 1988 administ baselin week 8 treatment process measur assess posit neg affect tabl 1 schedul baselin treatment follow assess week 0 1 2 3 4 5r7 8 16 24 52 schedul visit screen baselin treatment phase target quit date express write nicotin patch follow phase visit attend number boi 99 95 90 79 73 61 50 46 55 ew boi 97 92 90 76 78 67 56 53 62 note boi offic intervent ew express write 188 express write smoke cessat treatment nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org treatment complianc accept unus nicotin patch collect expr sive write assign visual inspect evalu complianc treatment treatment complianc defin complet visit treatment phase complet write assign visit treatment complet defin remain enrol studi 8 week treatment phase evalu treatment accept partici pant group administ semistruc ture interview end treatment visit week 8 interview collect feedback particip perceiv help intervent data analys biochem confirm 7 dai point preval tobacco abstin end treatment assess ment week 8 identifi priori primari efficaci endpoint sampl size requir determin base endpoint baselin demo graphic particip treatment group summar compar rank sum test continu variabl chi squar test fisher exact test categor variabl gender includ stratif variabl studi base evid gender differ smoke cessat treatment outcom adult smoker e.g ward klesg zbikowski bli garvei 1997 wetter al 1999 stratif ensur treatment alloc balanc gender addit potenti reduct error varianc gender includ covari analys tobacco abstin outcom analyz logist regress assess treatment efficaci adjust gender case initi analysi perform treatment6gend interact term includ assess effect treatment moder gender particip includ analys abstin endpoint analys partici pant miss inform visit reason e.g withdraw studi relat miss visit classifi tobacco addit secondari analys perform assess treatment effect moder level stress 12 month le neg impact score level nicotin depend ftnd 5 ftnd 6 analys perform includ moder variabl covari logist regress analysi moderator6treat interact effect assess potenti mechan chang pss pana score week 8 end treatment compar treatment group analysi covari ancova baselin gender includ covari vicker altman 2001 addit analys perform ancova assess chang baselin end treatment variabl differ treatment group adjust smoke statu result particip characterist present studi approv mayo clinic institut review board conduct juli 2001 june 2005 total 196 particip enrol clinic trial random offic intervent n599 express write offic intervent condit n597 treatment group balanc demograph baselin smoke histori characterist tabl 2 tabl 2 baselin subject characteristics.a characterist offic n599 express write offic n597 ag year sd 20.8 2.0 20.9 2.0 gender femal 55 56 55 57 male 44 44 42 43 race caucasian 93 94 90 93 black african american 1 1 1 1 hispan 0 0 3 3 asian pacif island 2 2 1 1 nativ american alaskan nativ 2 2 1 1 1 1 1 1 cigarett dai sd 18.2 5.9 18.1 6.3 year regular smoke year sd 4.9 2.8 5.3 2.4 stage readi chang contempl 3 3 11 11 prepar 94 97 86 89 ftnd score 6 greater 22 22 15 16 number smoke friend 2 2 2 2 15 15 14 14 28 29 29 30 46 47 43 44 7 7 9 9 previou stop attempt 8 8 13 13 1 39 39 31 32 2 52 53 53 55 longest abstin past year 24 hr 22 22 29 30 1 7 dai 36 36 26 27 8 14 dai 10 10 12 13 15 dai 31 31 29 30 note adata report mean standard deviat sd continu variabl categor variabl bthe number smoke friend report subject control group stage readi chang miss control subject longest abstin past year report stress manag subject year regular smoke miss control stress manag particip chi squar p5.026 nicotin tobacco research 189 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org tobacco abstin biochem confirm 7 dai point preval continu tobacco abstin rate shown figur 1 treatment end treatment phase point preval abstin rate particip receiv express write offic intervent significantli higher receiv offic intervent 33 20 p5.043 or52.0 95 ci51.0 3.7 separ analys perform assess effect treatment depend gender level stress 12 month le neg impact score level nicotin depend ftnd 5 ftnd 6 analys signific moder effect identifi gen der6treat interact p5.448 ftnd6 treatment interact p5.502 les6treat interact p5.610 percentag particip continu ousli abstin target quit date end treatment phase 14 express write offic intervent group 9 offic intervent group p5.249 or51.7 95 ci50.7 4.1 report smoke end treatment assess week 8 mean chang smoke rate baselin 213.4 cigarett dai sd57.8 control group 213.8 cigar ett dai sd58.9 express write offic intervent group treatment group demonstr statist signific reduct smoke rate baselin chang smoke rate differ treatment group p5.84 6 month 1 year point preval abstin rate similar treatment group 6 month 12 11 express write offic offic 1 year 11 11 percentag particip continu abstin target quit date 1 year 2 express write offic group 2 offic group potenti mechan chang perceiv stress ps posit affect pa neg affect na hypothes reflect potenti mechan chang smoke treatment particip data baselin end treatment found evid suggest variabl chang significantli time treatment group pair test 09 case ancova found evid suggest variabl differ treatment group end treatment p5.944 p5.156 p5.300 ps pa na chang measur baselin end treatment week 8 differ smoke abstin abstin particip favor chang ps pa na p5.020 p5.031 p5.014 adjust figur 1 biochem confirm 7 dai point preval tobacco abstin treatment group write assign complet week dai week 2 visit target quit date tqd nicotin patch therapi continu end week 8 eot p5.043 week 8 abstin rate subject assign express write offic intervent ew boi significantli higher subject assign offic intervent boi 190 express write smoke cessat treatment nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org differ found differenti chang perceiv stress affect base treatment group valu 217 result pa na similar week 16 24 52 assess found end treatment week 8 chang ps differ smoke versu abstin week 16 assess p5.449 signific chang observ ps baselin week 24 express write offic partici pant p5.032 result ps similar week 52 found end treatment week 8 treatment complianc accept 196 particip 56 29 discontinu studi particip prior end 8 week treatment phase 25 express write offic 32 offic p5.240 89 50 56 particip report smoke studi visit prior discontinu number visit attend differ significantli group mdn58 express write offic 7 offic rank sum test p5.209 tabl 1 detail number particip attend studi visit percentag particip compliant treatment 68 69 express write offic 67 offic p5.718 regard particip complianc nicotin patch percentag patch 58 59 express write offic 57 offic p5.623 number dai express write complet differ significantli smoke versu abstin week 4 8 median number write assign complet 5 abstin 5 smoke week 4 rank sum test p5.707 median number write assign complet 5 abstin 5 smoke week 8 rank sum test p5.682 particip rate help consid er smoke cessat treatment gener specif help express write ponent 5 point scale 5 indic maximum perceiv benefit 1 indic benefit item smoke cessat treatment gener 123 particip complet item gave rate rang 3 5 94 rate 4 5 item ask perceiv help express write compon 66 particip express write condit complet item gave rate rang 1 5 76 rate 1 2 3 particip respons open end question aspect treatment help summar theme identifi major particip random treatment condit 75 offic condit 65 express write offic condit report support research counselor structur weekli treatment session help aspect treatment ask help aspect studi common respons particip write help treatment compon 49 offic condit 39 express write offic condit common respons help 30 offic condit 39 express write offic condit discuss publish investig explor express write smoke cessat extens prior investig i. am al 2005 point preval abstin rate particip receiv express write treatment adjunct significantli higher control condit treatment effect persist end treatment assess point 24 52 week follow assess point preval smoke abstin rate similar treatment group long term smoke abstin rate produc present studi lower produc studi adult standard form treatment meta analysi pre sent usdhh clinic practic guidelin fior al 2000 intervent nicotin patch adult yield averag smoke abstin rate 17.7 prior smoke cessat treatment studi publish specif pertain young adult difficult compar treatment outcom previou research involv specif ag group prior smoke cessat intervent adolesc produc mean treatment abstin rate 12 versu 7 control group 3 12 month follow sussman 2002 signific treatment group differ end treatment suggest young adult benefit longer express write warrant addit attent optim number write assign booster express write assess sustain signific earli treatment effect addition nicotin tobacco research 191 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org find treatment effect fade rapidli end treatment suggest young adult benefit gener intervent longer durat evid suggest express write assign space longer period time effect smyth 1998 particip enthusiast express write compon barrier implement longer time frame avenu deliv express write internet appeal young adult decis collect particip write affect outcom prior research investig particip belief write read affect outcom futur research explor issu limit studi particip instruct write specif topic i. smoke cessat prior research found instruct set particip affect treatment outcom particip allow choos topic write favor outcom smyth 1998 futur research explor allow individu choos write topic effect smoke cessat investig includ control condit deliv smoke cessat typic deliv real world set inclus sort write assign ment express write compar treatment usual control write assign prompt thought smoke cessat result weaker find futur research investig issu futur research explor express write smoke cessat includ wait list control condit find particip express write offic condit initi lower abstin rate particip offic condit reminisc prior investig i. am al 2005 particip complet express write cessat earlier studi 6 month abstin lower express write condit control condit 10 20 differ statist signific express write found creat short term avers mood state pennebak 1997 specul time quit date immedi at express write intervent earlier studi pair quit attempt peak advers mood state unwittingli hinder quit attempt present investig indic pattern lower percentag particip initi abstin express write condit present studi includ post quit date express write spec ulat account improv rate tobacco abstin express write condit quit date continu end treatment futur research explor optim time point initi express write durat treatment hypothes mechan chang includ perceiv stress ps posit affect pa neg affect na found chang significantli time variabl differ treatment group end treatment assess degre chang ps pa na baselin end treatment differ significantli absti nent versu abstin abstin favor chang consid collec tive result suggest impact express write tobacco abstin mediat affect perceiv stress hypothes propos effect express write mediat stress klein 2002 pennebak 1997 present limit amount research explor mechan action express write recent research identifi emot arous assess salivari cortisol report arous mediat variabl express write exert posit effect sloan marx 2004b sloan marx epstein 2005 cognit process promot assimil develop understand event hypothes mediat effect express write pennebak mayn franci 1997 exist hypoth size mechan action investig assess futur research examin mediat chang respons gather particip regard ing percept aspect intervent help versu help benefit support structur weekli offic intervent treatment session weekli structur futur studi intervent popul recommend lack enthusiasm express write treatment compon unfor tunat investig ask particip specif reason perceiv express write help aspect treatment help particip indic write perceiv help aspect treatment complianc write superior complianc nicotin patch 192 express write smoke cessat treatment nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org similar investig involv younger popul smoker present investig difficulti particip retent adher enc unabl compar particip retent complianc investig involv young adult studi conduct involv ag group rate present studi similar find studi examin retent treatment complianc rate adolesc involv smoke cessat intervent comprehens review treatment program adolesc smoker found retent rate rang 33 100 mean 78 sussman 2002 regard treatment complianc inv tigat found approxim 50 adolesc complet smoke treatment interven tion sussman dent lichtman 2001 sussman lichtman ritt pallonen 1999 studi examin complianc transderm nicotin patch adolesc found complianc rate rang 41 84 alterman gartit cook cnaan 1998 hanson allen jensen hatsukami 2003 relat shortcom present studi includ 6 week 21 mg dai nicotin patch therapi taper dose nicotin patch methodolog accept research grant applic investi gation written consist current usdhh clinic practic guidelin fior al 2000 advers effect particip adher nicotin patch complianc improv length treatment longer taper dose schedul consist current guidelin final limita tion collect express write assign inform content investig continu line research collect write sampl futur studi express write provid insight individu experi smoke cessat suggest mechan action express write exert effect acknowledg studi fund grant bm004 jame esther king biomed research program author edgar covil jame cragg judi olmo invalu assist complet investig
addict behavior 39 2014 848 853 content list sciencedirect addict behavior integr smoke cessat bing drink intervent young adult pilot efficaci trial steven am steven pokorni darrel schroeder winston tan chudlei werch abpp mayo clinic jacksonvil fl usa alachua counti health depart gainesvil fl usa mayo clinic rochest mn usa mayo clinic jacksonvil fl usa preventionpluswel jacksonvil fl usa integr intervent young adult smoker bing drinker examin integr intervent produc greater tobacco abstin 6 month integr intervent bing drink 6 month author abpp mayo clinic divis 4500 san pablo road jacksonvil fl 32224 usa tel 953 2315 mail address ames.steven mayo.edu s.c am http dx.doi.org 10.1016 j.addbeh 2014.02.001 0306 4603 2014 elsevi right reserv onlin 12 februari 2014 keyword smoke cessat bing drink young adult alcohol alcohol consumpt strongli cigarett smoke young adult primari aim investig complet pilot evalu efficaci integr intervent target cigarett smoke bing drink cigarett smoke bing behavior young adult 6 month follow particip 95 young adult 24.3 sd 3.5 year smoker 1 cigarett dai bing drink 1 time month randomli assign standard treatment 47 involv individu treatment visit week nicotin patch therapi ident smoke cessat treatment integr bing drink intervent integr intervent 48 intent treat analysi tobacco abstin 3 month end treatment 6 month follow particip receiv integr intervent biochem confirm abstin tobacco receiv standard treatment 3 month 19 9 0.06 6 month 21 9 0.05 6 month particip complet studi andwho receiv integrat ed intervent consum fewer drink permonth 0.05 number bing drink episod permonth 0.05 receiv standard treatment preliminari data support integr intervent enhanc smoke cessat reduc bing drink compar standard treatment 2014 elsevi right reserv 1 introduct cigarett smoke singl import prevent morbid mortal excess health cost u. account 443,000 prematur death year center diseas control prevent 2012 young adult ag 18 24 year high preva lenc cigarett smoke 23 pattern smoke tend dif fer consider older adult greater proport young adult smoke daili basi smoke low number hematolog oncolog 1 904 953 6822 fax 1 904 cigarett dai solberg boyl mccarti asch thoel 2007 de spite high preval smoke young adult distinctli pattern tobacco intervent trial de sign specif group recent systemat review young adult smoke literatur identifi 14 prior investig evalu intervent specif orient young adult villanti mckai abram holtgrav bowi 2010 base limit exist literatur preval problem young adult stand benefit greatli develop effect tobacco cessat intervent bing drink u. defin consumpt 5 standard iz alcohol drink i. 1 standard drink 14 pure alcohol row formal 4 drink row femal healthi peopl 2020 goal establish u. surgeon gener seek achiev http dx.doi.org 10.1016 j.addbeh 2014.02.001 mailto:ames.steven mayo.edu http dx.doi.org 10.1016 j.addbeh 2014.02.001 http www.sciencedirect.com scienc journal 03064603 849s.c am al addict behavior 39 2014 848 853 10 reduct bing drink year 2020 year 2008 prev alenc bing drink highest young adult ag 18 25 year comparison ag group preval 41.0 substanc abus mental health servic administr 2009 concern preval bing drink young adult remain stabl comparison preval report prior 2007 survei addit risk factor poor treat ment outcom smoke cessat intervent murrai istvan voelker rigdon wallac 1995 numer advers health consequ bing drink includ uninten tional accid injuri suicid interperson violenc unintend pregnanc child neglect lost product alcohol poison hyperten sion acut myocardi infarct gastriti pancreat sexual tran mit diseas mening uncontrol diabet naimi al 2003 consider evid suggest alcohol consumpt strongli cigarett smoke heavi alcohol user ag 12 older 58.0 smoke cigarett thepastmonth contrast 19.2 bing drinker 16.1 person drink alcohol past month current smoker substanc abus mental health servic administr 2009 higher level alcohol con sumption sever level tobacco depend poorer smoke treatment outcom adult smoker current past alcohol problem cook al 2012 final smoke alcohol independ risk factor cancer cardiovascu lar diseas interact synergist elev diseas risk risk pose substanc individu turati al 2013 publish earlier investig am al 2010 serv foundat current studi develop exper iment integr invent approach focu present manuscript earlier studi found integr intervent highli accept young adult particip receiv integr intervent biochem confirm abstin tobacco receiv standard treatment 36 21 fisher exact test 0.28 week 12 23 11 0.30 week 24 addition week 24 particip receiv integr intervent report fewer bing drink episod compar receiv standard treatment treatment effect 1.4 fewer bing drink episod 30 dai 0.37 ancova number episod report baselin includ covari base preliminari data proceed pilot efficaci trial primari aim investig pilot test efficaci integr intervent target cigarett smoke bing drink cigarett smoke bing behavior young adult 6 month follow hypothes integr inter vention significantli higher biochem confirm 7 dai point preval tobacco abstin rate fewer bing drink episod standard treatment 6 month follow integr intervent base rational decreas smoke improv mainten abstin result behavior intervent reduc bing drink hypothesi turn support line evid includ condit mechan crave smoke elicit higher level alcohol consumpt burton tiffani 1997 king epstein 2005 environment factor parent peer influenc con current cigarett engag bing drink hoffman welt barn 2001 wish examin effect integr intervent mediat chang correspond mediat mechan includ crave smoke perceiv similar typic smoker efficaci smoke abstin hypothes integr intervent decreas crave smoke decreas perceiv similar typic smoker increas efficaci smoke abstin 2 method 2.1 particip studi approv mayo clinic institut review board particip includ 95 young adult smoker bing drink inclus criteria includ ag 18 30 year smoke 1 ciga rett dai past 6 month bing drank 1 occa sion month past 3 month bing drink defin consumpt 5 standard alcohol drink row male 4 drink row femal exclus criteria includ cur rent alcohol depend assess structur clinic inter view dsm iv axi disord alcohol depend modul spitzer gibbon william 2004 drug depend determin drug abus screen test 20 skinner 1982 score 6 current clinic depress score 20 beck depress inventori ii beck steer brown 1996 current nicotin con tain medic tobacco product cigarett current smoke cessat treatment involv behavior pharmacolog intervent medic condit pre clude nicotin patch pregnant breast feed ing pregnant nicotin patch phase 2.2 procedur particip interest quit smoke recruit studi site north florida particip recruit gener commun local colleg campus local busi activ i. intercept sampl passiv method i. advertis ment colleg newspap citi wide public target young adult intercept sampl consist young adult research sistant approach young adult public place observ smoke interest learn particip smoke cessat studi interest individ ual provid flyer studi contact telephon num ber ask call complet screen studi emploi random groupdesignwith repeat assess baselin end treatment week 12 end studi week 24 particip paid 270 complet assess ment block random stratifi gender baselin assess particip random treatment condit 1 6 session individu behavior base smoke cessat intervent 8 week nicotin patch therapi i. standard treatment 2 ident smoke cessat treatment integr bing drink intervent i. integr intervent treatment condit match total contact time nicotin patch therapi treatment protocol condit particip level cigarett smoke particip smoke 10 cigarett dai treat 21 mg 24 4 week 14 mg 24 2 week 7 mg 24 2 week particip smoke 9 fewer cigarett dai treat 14 mg 24 6 week 7 mg 24 2 week target quit date particip set dai week 4 treatment visit nicotin replac therapi initi dai particip treatment manual master degre level search coordin whohad receiv train princip inv tigat smoke cessat intervent deliv treatment condit studi coordin whowa blind particip treatment condit assign respons complet assess treatment session audio record 25 session review entireti princip investiga tor correct feedback research counselor need ensur fidel discrimin treatment deliveri fidel receipt intervent particip assess end treatment visit correct feedback provid s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight 850 s.c am al addict behavior 39 2014 848 853 need fidel treatment enact i. particip daili life learn instruct wasmonitor par ticip complianc treatment assign nicotin patch therapi content treatment condit detail 2.2.1 standard treatment standard treatment consist 6 individu base semi structur counsel session consist unit state depart health human servic usdhh clinic practic guidelin treat tobacco depend fior jaén baker al 2008 8 week nicotin patch therapi treatment session consist behavior treatment 30 min durat final treatment session visit schedul dispens nicotin patch assess complianc nicotin patch monitor particip safeti address difficulti patch 10 min durat 2.2.2 integr intervent integr intervent consist session individu base semi structur behavior base intervent integr usdhh clinic practic guidelin treat tobacco depend fior al 2008 alcohol screen inter vention colleg student dimeff baer kivlahan marlatt 1999 particip random condit receiv 8 week nic otin patch therapi standard treatment treatment session consist behavior treatment 30 min durat final treatment session visit schedul dispens nicotin patch assess complianc nicotin patch monitor particip safeti address difficul ti patch 10 min develop integr intervent prior public treatmentmanu correspond ing author request am al 2010 integr intervent design smoke cessat approach focus alcohol relat smoke behavior seek concur rentli elimin tobacco bing drink high risk form alcohol consumpt exampl behavior treatment strat egi includ provid person feedback alcohol includ comparison person level peer norm identifi role high risk drink plai inmaintain smoke applic failur prior quit attempt quit smoke monitor relat alcohol tobacco alcohol modera tion train includ discuss goal set relat particip drink limit set count drink con sume monitor drink behavior alter drink learn skill manag drink situat alcohol moder train integr intervent approach high light rational focus reduc heavi drink aid stop smoke behavior aspect treatment includ develop relaps prevent plan implement relaps prevent strategi need overcom difficulti sustain abstin smoke high risk drink 2.3 measur 2.3.1 demograph data basic demograph informationwa assess evalu similar iti particip treatment condit 2.3.2 treatment accept conclus treatment particip ask rate help treatment 5 point likert scale 1 5 help lot 2.3.3 tobacco biochem confirm 7 dai point preval tobacco evalu week 12 24 particip consid abstin tobacco report smoke i. puff form tobacco previou 7 dai report tobacco abstin biochem confirm pire air carbon monoxid b8 ppm indic abstin end treatment week 12 salivari cotinin test b15 ng ml indic ativ abstin end studi week 24 2.3.4 alcohol consumpt quantiti frequenc alcohol consumpt assess timelin followback interview tlfb sobel sobel 1995 comput number bing drink episod past 30 dai tlfb report instrument assess quantiti alcohol consum standard drink standard drink defin 10 oz wine cooler 5 oz wine 12 oz beer 6 oz malt liquor 2.5 oz fortifi wine cocktail 0.5 oz 150 proof distil spirit 1 oz 100 proof distil spirit 1.25 oz 80 proof distil spirit bing drink defin consumpt 5 standard alcohol drink row male 4 drink row femal 2.3.5 measur evalu mediat chang evalu effect integr intervent mediat chang includ crave smoke perceiv similar typic smoker efficaci smoke abstin questionnair smoke urg cox tiffani christen 2001 perceiv similar typic smoker gerrard gibbon lane stock 2005 confid inventori revis velic diclement rossi prochaska 1990 mediat relat condit environment mechan pro pose account relationship cigarett smoke consumpt alcohol hypothesi rate smoke cessationwould enhanc integr behavior inter vention elimin bing drink smoke cessat intervent drobe 2002 littleton 2002 mediat assess time point baselin end treatment week 12 2.4 statist analysi present studi com.ibm.drl.hbcp.util random phase ii studi design object phase ii trial determin studi experiment intervent warrant provid preliminari data design larger trial debat formal statist comparison phase ii trial agre propos formal comparison qualif phase ii studi expect provid defin itiv comparison convent side type error rate 0.05 ratain sargent 2009 rubinstein al 2005 random phase ii trial side test fals posit type error rate 0.20 suggest primari comparison assess addit studi experiment intervent warrant ratain sargent 2009 rubinstein al 2005 analysi adher intent treat approach intent treat approach includ random particip statist analysi group randomli assign regard adher treatment withdraw treatment deviat studi protocol intent treat analysi avoid overestim efficaci intervent sult remov complier accept noncompli protocol deviat commonplac actual clinic practic baselin demograph particip treatment condit summar compar rank sum test continu variabl chi squar test fisher exact test categor variabl tobacco abstin outcom analyz logist s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight 851s.c am al addict behavior 39 2014 848 853 regress alcohol outcom evalu analysi covari baselin measur includ covari primari endpoint 7 dai point preval smoke abstin 6 month analyz logist gression endpoint tail 0.20 consid er suffici evid recommend pursu addit studi integr intervent consist tail valu present tobacco outcom analys tail valu report 3 result total 463 individu screen studi elig 220 exclud pre screen 96 phone screen 124 phase pre screen conduct inter cept sampl assess gener studi elig requir e.g ensur met ag requir particip exclud phasewer due inelig combin reason 1 target ag rang 2 frequenc smoke 3 regular form tobacco 4 resid studi area 5 pregnant 6 unwil nicotin replac therapi nrt 7 unwil counsel 8 drink alcohol 9 deni bing drink intercept particip pass pre screen gave contact inform research assist upwith amor depth phone screen whichwa similar pre screen questionnair detail passiv recruit flyer advertis word mouth cruit intercept phone screen particip exclud phase combin reason mention screen 243 particip elig baselin appoint 148 exclud due reason 1 unabl contact schedul baselin 89 2 show schedul baselin unabl contact 41 3 exclud due studi elig requir 18 e.g drug psycholog questionnair remain 95 individu includ 42 femal 53maleswith mean sd ag 24.3 3.5 year individu enrol studi random standard treatment 47 integr intervent 48 demograph tobacco histori alcohol tabl 1 baselin subject characteristics.a characterist standard trea ag year 24.4 3.3 gender femal 20 43 male 27 57 race ethnic caucasian hispan 40 85 caucasian hispan 0 0 black african american 4 9 asian pacif island 1 2 multipl race 2 4 cigarett dai 13.4 6.1 ag began regular smoke 18.0 2.3 smoker household 23 49 number drink month mean sd 60.3 50.6 median 25th 75th 44 27 82 number drink dai month mean sd 11.9 6.7 median 25th 75th 11 7 16 bing drink episod month mean sd 5.9 5.9 median 25th 75th 4 2 9 ag began regular alcohol 18.1 2.2 alcohol user household 37 79 data report mean sd continu variabl histori significantli differ intervent group tabl 1 47 particip assign standard treatment 23 49 attend 8 treatment session 35 74 attend 6 8 session similar attend observ 48 partici pant assign integr intervent group 18 38 tend 8 session 32 67 attend 6 8 session 13 28 particip standard treatment 20 42 integr intervent group discontinu studi particip prior schedul behavior treatment session treatment group complet studi con sider intervent help 100 integr intervent 92 standard treatment pro vide rate 4 5 5 point likert scale smoke abstin rate 3 end treatment 6 month present tabl 2 6 month random bio chemic confirm 7 dai point preval tobacco abstin rate primari endpoint 21 integr intervent 9 standard treatment odd ratio 2.8 90 c.i 1.0 8.0 tail 0.050 similar result obtain secondari smoke abstin endpoint biochem confirm 7 dai 30 dai point preval abstin 3 month 30 dai point preval abstin 6 month alcohol baselin 6 month summar tabl 3 particip attend 6 month follow visit 25 standard treatment 17 integr intervent averag report alco hol lower 6 month compar baselin analysi covari adjust baselin integr intervent found associatedwith fewer drink permonth 6 month treat ment effect 20.6 95 c.i 37.5 3.7 drink month fewer bing drink episod month treatment effect 2.4 95 c.i 4.6 0.2 episod month mediat variabl confid score distanc score crave score analyz particip attend end treat ment visit 22 standard treatment 17 integr interven tion particip potenti mediat variabl found signific chang anticip direct baselin end treatment treatment group effect evalu potenti mediat analysi covari base line measur includ covari analys tment 47 integr intervent 48 24.1 3.7 22 46 26 54 40 83 4 8 0 0 1 2 3 6 13.3 6.6 16.8 2.7 28 58 60.6 46.2 47 27 88 12.3 7.4 10.5 6 17 5.8 5.2 5 2 8 17.5 2.5 40 83 categor variabl tabl 2 tobacco abstin outcomes.a standard treatment integr intervent odd ratio 47 48 estim 90 c.i pb end treatment 7 dai point preval 4 9 9 19 2.5 0.9 7.1 0.078 30 dai point preval 3 6 8 17 2.9 0.9 9.5 0.065 6 month 7 dai point preval 4 9 10 21 2.8 1.0 8.0 0.050 30 dai point preval 3 6 8 17 2.9 0.9 9.5 0.065 particip met criteria point preval tobacco abstin report tobacco 7 dai 30 dai expir 8.0 ppm end treatment salivari cotinin 15.0 ng ml 6 month case particip miss inform assum tobacco tail chi squar test 852 s.c am al addict behavior 39 2014 848 853 signific treatment group effect identifi confid score estim 2.1 se 5.6 0.71 distanc score estim 3.1 se 7.5 0.68 crave score estim 1.8 se 3.2 0.57 4 discuss publish preliminari efficaci trial int grate smoke cessat bing drink intervent young adult studi extend prior work am al 2010 eval uat accept estim themagnitud effect size intervent approach significantli greater number partici pant receiv integr smoke cessat bing drink intervent abstin tobacco 6 month follow regard alcohol particip attend 6 month follow visit integr intervent found significantli fewer drink bing drink epi sode month standard treatment find extend particip includ lost follow prior 6 month end studi assess explan find particip fail complet studi continu com.ibm.drl.hbcp.util alcohol moder strategi learn engag treatment outset futur studi investig issu studi complet collect find provid preliminari tabl 3 alcohol baselin 6 month standard treatment integra mean sd studi complet drink dai month baselin 25 13.4 6.7 17 6 month 25 10.8 7.5 17 number drink month baselin 25 66.6 48.2 17 6 month 25 49.7 38.5 17 bing drink episod month baselin 25 7.3 6.3 17 6 month 25 5.0 4.8 17 particip drink dai month baselin 47 11.9 6.7 48 6 month 47 10.5 6.9 48 number drink month baselin 47 60.3 50.6 48 6 month 47 51.3 45.6 48 bing drink episod month baselin 47 5.9 5.9 48 6 month 47 4.7 4.9 48 assess treatment effect measur 6 monthswer analyz analysi cov independ variabl baselin characterist includ covari 6 month visit analysi perform includ random participan month assum chang alcohol consumpt baselin i. baselin support efficaci integr treatment approach suggest larg scale efficaci trial warrant divers sampl investig mediat chang studi complet correspond mechan propos account relationship cigarett smoke alcohol includ crave smoke perceiv similar typic smoker efficaci smoke abstin signifi differ found mediat variabl treatment condit studi complet mediat found chang significantli anticip direct baselin end treatment explor common variabl account occurr cigarett smoke alcohol remain fertil area research futur investig continu explor encount challeng recruit retain partici pant proven notori difficult investiga tion involv older adolesc young adult ramo hall prochaska 2010 recruit strategi consist passiv method includ advertis young adult orient public group mail student local univers addit activ intercept sampl recruit involv approach young adult observ smoke public place retent strategi consist flexibl appoint schedul monetari incen tive remind phone call mail prefer particip ted intervent treatment effecta mean sd coeffici 95 c.i 12.7 7.7 7.4 6.2 3.2 7.1 0.8 0.122 57.9 49.4 25.5 23.0 20.6 37.5 3.7 0.022 5.7 6.2 2.1 2.9 2.4 4.6 0.2 0.039 12.3 7.4 10.4 7.3 0.2 2.6 2.2 0.878 60.6 46.2 49.2 42.3 2.3 12.9 8.2 0.665 5.8 5.2 4.5 4.4 0.2 1.5 1.1 0.703 arianc ancova treatment 0 standard treatment 1 integr intervent ne analysiswa perform includedonli participantswhohad inform ts analysi includ random particip miss data 6 imput 6 month 853s.c am al addict behavior 39 2014 848 853 collect extens contact inform e.g home phone cell phone mail signific provid contact informa tion spite effort encount difficultywith particip retent follow period plagu vestig involv ag group result caution draw conclus integr intervent addi tional focu includ innov recruit retent strate gi futur studi need 4.1 conclus find provid preliminari support efficaci treatment approach target cigarett smoke bing drink young adult preliminari data present paper encourag suggest larg scale efficaci trial warrant ed futur research need clarifi mediat efficaci intervent innov recruit retent strategi includ overcom challeng work ag group role fund work support jame esther king biomed research program contributor dr am design studi wrote protocol creat integr invent focu studi dr pokorni devis intercept sampl recruit method import aspect methodolog princip inv tigat studi site direct dai dai oper studi site mr schroeder wrote conduct statist method dr tan serv studi physician oversaw monitor particip safeti dr werch contribut design research method recruit method author contribut approv final manuscript conflict interest author work conflict interest disclos acknowledg authorswish acknowledg edgar covil andrea tavlarid m.a parkerhinson mph jodian blake mph blair coleman mph assistancewith complet investig
prevent medicin 47 2008 194 199 content list sciencedirect prevent medicin ourna homepag www.e lsev r.com locat ypmed realu onlin cessat intervent colleg smoker random control trial lawrenc colleen klatt cheryl perri emili lein deborah hennriku pallonen robin bliss harri lando dana farlei jasjit ahluwalia edward ehling univers minnesota depart intern medicin 717 delawar street minneapoli mn 55455 usa univers texa austin school nurs usa univers minnesota school public health usa univers texa health scienc center houston usa univers minnesota cancer center usa univers minnesota boynton student health servic usa univers minnesota offic clinic research usa author fax 1 612 625 2695 mail address lcan umn.edu l.c 0091 7435 front matter crown copyright 20 doi 10.1016 j.ypm 2008.04.011 articl histori object determin onlin 2 2008 keyword smoke smoke cessat univers young adult internet random trial efficaci provid onlin cessat intervent colleg smoker method group random control trial intervent group receiv 10 weekli incent visit onlin colleg life magazin provid person smoke cessat messag peer email support evalu assess occur baselin 8 20 30 week enrol primari outcom report 30 dai abstin week 30 carbon monoxid breath test perform particip report 30 dai abstin week 30 result hundr seventeen colleg smoker univers minnesota enrol internet health screen control 260 intervent 257 fall 2004 intervent particip complet averag 18.9 sd 2.5 20weekli websit visit studi rate 30 dai abstin week 30wa higher intervent compar control group 41 23 pb0.001 test show low rate report differ report 6 month prolong abstin measur week 30 conclus provid person smoke cessationmessag part gener interest onlin colleg life magazin increas 30 dai abstin end semest intervent crown copyright 2008 publish elsevi right reserv introduct young adulthood critic transit period cigarett life adolesc experi cigarett young adult year escal cig arett consumpt establish regular smoke kandel chen 1995 chassin al 1996 orlando al 2004 studi rais concern increas initi smoke young adult wechsler al 1998 rigotti al 2000 husten 2007 recent studi tercyak al found 25 individu report smoke high school initi smoke 1 year tercyak al 2007 encourag cessat young adult nation health prioriti smokerswhoquit ag 30 avoidmuch harm relat cigarett doll al 2004 smoker ag quit compar older 08 publish elsevi rig smoker lee al 2007 recent work curri al offer explan find curri al 2007 young adult smoker make attempt quit compar older smoker effect assist studi cessat program design young adult shown mix result quinlan mccaul found benefit provid stage match manual colleg smoker quinlan mccaul 2000 am al found benefit express write inter vention am al 2005 travi lawrenc found provid stage tailor booklet increas abstin 3 month travi lawranc 2004 prokhorov al found provid computer feedback lung ag show amargin trend increas quit rate prokhorov al 2003 analysi rabiu al found increas short term abstin young adult smoker receiv phone counsel rabiu al 2004 addit work need develop attract effect program young peopl quit smoke internet promis channel improv deliveri smoke cessat servic young adult grow bodi literatur ht reserv mailto:lcan umn.edu http dx.doi.org 10.1016 j.ypm 2008.04.011 http www.sciencedirect.com scienc journal 00917435 195l.c al prevent medicin 47 2008 194 199 support modest effect onlin cessat program schneider al found improv abstin 3 month provid person stop smoke tip onlin discuss group schneider al 1990 etter found tailor onlin program increas quit help maintain short term abstin etter 2005 swartz al found provid tailor onlin cessat video increas abstin 3 month swartz al 2006 munoz al compar result studi conclud individu email remind increas abstin rate munoz al 2006 pike al found modest benefit interact site higher lower com.ibm.drl.hbcp.util pike al 2007 strecher al found significantli higher abstin rate result tailor tailor onlin feedback individu purchas nicotin patch strecher al 2005 result encourag note studi focus specif young adult smoker report result realu studi random trial test web assist cessat intervent colleg smoker primari object studi determin onlin intervent colleg smoker increas report 30 dai abstin rate end semest intervent smoke rate higher young adult attend colleg green al 2007 solberg al 2007 colleg univers u. enrol 14 million student import venu reach larg number young adult smoker u. censu 2006 featur realu intervent cessat messag deliv part gener interest onlin colleg life magazin narrowli focus smoke cessat websit method set studi conduct univers minnesota twin citi fall 2004 undergradu enrol 28,740 preval past 30 dai cigarett campu 26.6 lust 2005 studi procedur review approv univers minnesota institut review board particip recruit random studi recruit occur internet health screen octob 2004 detail al 2007 random sampl 25,000 undergradu invit email complet 46 item onlin health screen survei respond elig studi 1 smoke cigarett past 30 dai 2 ag 18 older 3 intend school semest elig individu identifi health screen survei ask complet 90 item onlin baselin survei 10 gift card compens prior studi enrol particip complet baselin survei provid onlin consent enrol random real time block random number sequenc gener studi statistician particip investig blind group assign control intervent condit particip random control group receiv confirm email con tain link onlin health academ resourc quitnet.com smoke cessat websit boynton student health servic websit student academ servic websit april 2005 univers health servic sponsor campu wide quit win contest student smoke sign person onlin smoke free month april chanc win 3000 prize contest promot advertis student newspap campu poster direct mail email univers student studentswer inform smoke statu prize winner verifi testimoni smoke free friend urin cotinin test particip random realu intervent group ask make 20 weekli visit studywebsit 30 week period visit thanksgiv winter spring break final exam develop realu intervent strategieswa base social cognit bandura 1986 problembehavior theori jessor 1991 al 2006 start week particip receiv email invit visit studi websit 1 report health lifestyl habit priorweek e.g dai smoke drink stress 2 interact quiz tailor feedback learn smoke relat e.g nicotin depend gener interest topic 3 view student author gener interest onlin colleg life magazin articl articl address smoke quit colleg particip receiv 10 gift card week plete studi activ smoke cessat content andmessageswer introduc gradual intervent period interact quiz 5 week explicitli address smoke final quizz particip encourag weeklong break smoke intervent period ask quit longer time final month intervent april 2005 intervent site activ promot campu wide quit win contest includ link onlin sign contest intervent group particip receiv weekli email written peer coach email messag content base templat develop studi investig person peer coach inform provid particip weekli visit websit particip encourag write back peer coach question week contest topic question week encourag particip reason quit e.g thing smoke cigarett identifi smoke trigger cope strategi e.g tempt smoke smoke individu wrote back peer coach contest enter draw 50 prize email exchang occur confidenti nicknam base studi email program prevent view actual email address allow central monitor messag content evalu measur baselin measur includ particip demograph smoke relat char acterist nicotin depend assess particip report time morn cigarett haddock al 1999 high proport daili smoker administ hook nicotin checklist honc develop assess loss autonomi cigarett younger adolesc difranza al 2002 wellman al 2005 measur includ proport friend smoke readi quit recent quit attempt prior pharmaco logic e.g nicotin patch nicotin gum nicotin lozeng zyban bupropion behavior e.g person counsel phone counsel smoke cessat websit assist quit smoke outcom determin onlin survei 8 20 30 week enrol week 30 evalu occur 1 week end campu wide quit win contest email announc contest winner 10 gift card offer compens survei respond primari outcom report 30 dai abstin atweek 30 individualswho report 30 dai abstin final evalu offer 50 complet person exit interview whichexh carbonmonoxid wasmeasuredus standard techniqueswith bedfont micro ii smokerlyz devic cut 8 pper mwa definit confirmedabstin jarvi al 1987 sato al 2003 secondari outcomeswer 7 dai point preval abstin 8 20 30 week quit attempt 30 week evalu studi particip ask report durat smoke cigarett puff informationwa calcul preval 6 month prolong abstin measur 30 week evalu correspond individu quit maintain abstin week end studi secondarymeasur continu smoker includ frequenc smoke readi quit process measur includ assist quit sampl size 250 particip group 85 power detect 12 absolut differ abstin rate treatment group i. control 20 inter vention 32 side alpha 0.05 statist analysi logist regress model compar rate 30 dai 7 dai abstin adjust particip baselin characterist analysi intent treat respond classifi continu smoker particip campu wide quit win contest examin mediat intervent effect includ quit win particip indic variabl logist regress model examin moder intervent effect perform logist regress includ level interact intervent group candid moder variabl baron kenni 1986 frazier al 2004 result particip flowchart evalu studi particip shown fig 1 email invit 25,000 undergradu led complet 6492 screen survei 26 respons rate respond 1857 report smoke prior 30 dai 29 preval 1618 87 studi elig reason inelig ag 18 8 greater 24 126 intent leav school complet academ year tabl 1 characterist studi particip univers minnesota twin citi 2004 5 control 260 realu 257 demograph characterist mean ag sd 19.8 1.6 20.1 1.6 0.03 femal 196 75.4 181 70.4 0.21 year school 0.56 freshman 80 30.8 67 26.1 sophomor 64 24.6 63 24.5 junior 67 25.8 68 26.5 senior 49 18.9 59 23.0 white 24 9.2 20 7.8 0.56 employ 0.85 work 84 32.3 81 31.6 part time 159 61.2 161 62.9 full time 17 6.5 14 5.5 resid 0.48 dormitori 84 32.3 71 27.6 fratern soror 9 3.5 10 3.9 parent 15 5.8 22 8.6 hous apart 152 58.5 154 60.0 internet 0.38 1 5 dai week 26 10.0 32 12.5 6 7 dai week 233 90.0 225 87.6 onlin dai 0.64 b15 min 17 6.5 13 5.1 15 30 min 65 25.0 56 21.8 31 60 min 94 36.2 98 38.1 61 120 min 43 16.5 53 20.6 n120 min 41 15.8 37 14.4 past 30 dai mean dai alcohol sd 8.4 5.8 8.3 6.0 0.82 mean dai 5 drink sd 4.8 4.4 4.6 4.4 0.79 smoke rrelat characterist averag dai smoke past 30 dai sd 14.7 11.8 13.4 11.8 0.21 number dai smoke past 30 dai 0.67 1 4 dai 87 33.5 97 37.7 5 10 dai 40 15.4 42 16.0 11 20 dai 37 14.2 35 13.6 21 30 dai 96 36.9 83 32.3 averag cigarett smoke dai sd 4.2 5.0 3.8 4.7 0.36 number cigarett smoke dai 0.21 1 2 cigarett 144 55.4 134 52.1 3 5 cigarett 56 21.5 75 29.2 6 10 cigarett 35 13.5 29 11.3 n10 cigarett 25 9.6 19 7.4 time morn cigarett 0.96 b30 min 23 9.5 21 8.9 31 60 min 27 11.2 25 10.6 n60 min 192 79.3 189 80.4 ag 1st 0.38 12 45 17.6 33 13.2 13 15 87 34.0 80 31.9 16 17 73 28.5 75 29.9 18 older 51 20.0 63 25.1 honc scorea sd 3.7 3.3 3.4 3.3 0.27 proport smoke friend 0.48 16 6.5 19 7.5 92 35.4 104 40.1 half 70 26.9 57 22.4 43 16.5 45 17.7 39 15.0 30 11.8 live smoker 0.33 live 17 6.5 26 10.2 124 47.7 118 46.1 119 45.8 112 43.8 intent quit 0.72 6 month 66 25.5 70 27.5 6 month 133 51.4 133 52.2 30 dai 60 23.2 52 20.4 quit attempt past year 136 52.9 120 46.9 0.17 prior pharmacotherapi 23 8.9 17 6.6 0.34 prior behavior program 17 6.5 16 6.2 0.88 hook nicotin checklist score rang 0 10 fig 1 studi flow univers minnesota twin citi 2004 5 196 l.c al prevent medicin 47 2008 194 199 105 elig smoker 517 32 complet baselin survei enrol studi 260 random control condit 257 random intervent condit individu withdrew studi follow survei respons rate exceed 90 differ group time point baselin characterist studi group similar term demograph smoke relat characterist tabl 1 small differ ag tween studi group control 19.8 sd 1.6 year intervent 20.1 sd 1.6 year 0.03 statist signific major particip occasion light smoker mean smoke 14.1 sd 11.8 dai prior 30 dai report smoke cigarett 1 wake morn deliveri intervent weekli check interact quiz link weekli visit realuwebsit particip intervent group complet theweekli check interact quiz averag 18.9 sd 2.5 time 20 activ week studi tervent group particip 227 88 complet task 18 20 week 172 67 visit week view onlin magazin content track individu level hit portion websit averag 1038 sd 371 week 149 sd 47.8 uniqu ip address result suggest drop particip check quiz view magazin content respons weekli peer coach email particip wrote back peer coach averag 4.6 sd 3.6 time rang 0 15 intervent thirti particip 14 write back occas twenti particip 8 wrote back 60 23 wrote back 2 3 time 69 27 wrote back 4 6 time 70 27 wrote back 7 time smoke outcom result report 7 dai 30 dai abstin present tabl 2 week 30 40.5 individu realu intervent group 104 257 report smoke cigarett prior 30 dai compar 23.1 60 260 usual care group odd ratio 2.26 95 confid interv 1.55 3.32 differ studi group rate tabl 3 quit attempt assist quit univers minnesota twin citi 2004 5 control realu break smoke 236a 232a 0.006 123 52.1 86 37.1 1 33 14.0 58 25.0 2 23 9.8 30 12.9 3 14 5.9 15 6.5 4 43 18.2 43 18.5 quit attempt 235 238 0.43 119 50.6 101 42.4 1 40 17.0 50 21.0 2 28 11.9 34 14.3 3 10 4.3 14 5.9 4 38 16.2 39 16.4 pharmacotherapi 237 239 24 10.1 27 11.3 0.68 behavior program 237 239 14 5.9 33 13.8 0.004 join quit win 237 239 29 12.2 91 38.1 b0.001 number particip due item respons 197l.c al prevent medicin 47 2008 194 199 report prolong abstin 6 month measur 30 week evalu point 6 participationwith test group control 46 60 76.7 intervent 88 104 84.6 0.21 individu record greater 8 ppm control 2 46 4.5 intervent 3 88 3.4 0.79 studi particip higher rate valid abstin intervent 85 257 33.1 compar control group 44 260 16.9 2.43 95 ci 1.60 3.68 individu report smoke prior 30 dai end studi control 168 intervent 126 greater decreas number dai smoke baselin final evalu intervent 18.1 12.3 dai month differ 5.8 dai compar control particip 16.6 14.9 dai month differ 1.7 dai 0.001 differ studi group averag number cigarett smoke smoke dai continu smoker readi quit increas final evalu 51 continu smoker intervent group 64 126 report intend perman stop smoke 30 dai compar 27 continu smoker control group 46 168 pb0.001 result forquit attempt anduseof assist inquittingar shown tabl 3 intervent groupparticipantsweremor report take break smoke 1 week longer small increas behavior program primarili due greater stop smoke websit intervent compar control group particip campu wide quit win contest stantial higher intervent group 91 239 38 compar control group 29 237 12 pb0.001 inclus quit win particip logist regress model potenti mediat realu intervent effect demonstr increas particip quit win account increas abstin realu group model particip quit win 2.98 95 ci 1.90 4.67 random realu intervent group 1.76 95 ci 1.16 2.66 signific independ com.ibm.drl.hbcp.predictor 30 dai abstin week 30 inter action term intervent group quit win particip signific examin potenti moder intervent effect seri logist regress model includ interact term intervent group particip baselin characterist e.g ag gender year school readi quit dai smoke baselin dai bing drink baselin time morn cigarett signific main effect found baselin number dai smoke 30 dai abstin week 30 0.92 95 ci 0.91 0.95 addit dai smoke baselin number dai bing drink 0.92 95 ci 0.88 0.97 addit episod bing drink time morn cigarett 3.05 95 ci 1.65 5.62 individu smoke greater 1 wake 1 interact term tabl 2 report abstin rate 8 20 30 week univers minnesota twin citi 2004 2005 control 260 realu 257 unadjust odd ratio adjust odd ratioa 7 dai abstin week 8 65 25 110 42.8 2.24 1.54 3.26 2.36 1.62 3.45 week 20 86 33.1 108 42.0 1.47 1.03 2.10 1.53 1.06 2.20 week 30 100 38.5 152 59.1 2.32 1.63 3.30 2.43 1.70 3.48 30 dai abstin week 8 42 16.2 41 16.0 0.99 0.62 1.58 1.03 0.64 1.66 week 20 51 19.6 62 24.1 1.30 0.86 1.98 1.34 0.88 2.04 week 30 60 23.1 104 40.5 2.26 1.55 3.32 2.31 1.58 3.40 bold valu specif 95 confid interv cross 1.0 i. statist 1.0 adjust baselin differ ag signific suggest differ efficaci realu intervent relat baselin characterist discuss studi show provid web base cessat interven tion part onlin colleg life magazin increas rate 7 dai abstin intervent period increas 30 dai abstinencebi theendof academ year addit todemonstr feasibl internet health screen recruit strategi studi identifi promis strategi e.g incorpor gener interest content onlin peer support weekli incent increas adher onlin health promot intervent abstin rate report intervent control group studi higher typic found studi enrol older smoker high rate occasion smoke baselin contribut find find consist result hook nicotin checklist report particip higher adolesc limit prior exposur tobacco lower report establish adult smoker difranza al 2002 wellman al 2005 report abstin rate control group consist declin cigarett amongoccasion smoker report observ studi colleg student wetter al 2004 kenford al 2005 colder al 2006 increas 30 dai 6 month prolong abstin rate measur 30 week enrol result intervent surpris inclus particip plan quit gradual introduct smoke cessat content intervent initi emphasi encourag shorter break smoke prolong abstinencemai contribut find futur studi earlier emphasi abstin longer term follow intervent period valuabl studi limit limit interpret result studi import acknowledg studi conduct singl campu therewa level contamin studi group contamin limit case size campu rel low proport student smoker i. estim 7 base survei respons elig enrol enrol studi 198 l.c al prevent medicin 47 2008 194 199 mean prevent studi particip intervent group share tobacco relat inform member control group unabl quantifi degre contamin occur studi futur studi explicit assess contamin campu random design address issu import note studi test multi compon intervent weekli monitor behavior inter activ quizz tailor feedback onlin magazin format peer email support control ascertain rel contribut intervent compon studi multipl arm need identifi contribut intervent compon clear carbon monoxid test perform insensit measur occasion smoke dolcini al 2003 cotinin measur limit occasion smoker benowitz 1983 futur studi interest biochem assess measur tobacco specif carcino gen persist longer period time hecht al 1999 addit studi high level incent 10 week particip encourag adher reassur note provis incent ti particip report smoke statu gratif receiv weekli incent intervent group convers disappoint receiv weekli incent control group influenc abstin outcom high level incent pose barrier broader dissemin effort futur studiesmight examin lower level incent altern incent structur e.g prize draw monetari incent e.g video music download influenc ad herenc intervent effect final intervent test campu predominantli white undergradu popul follow studi involv multipl campus divers student bodi great interest uniqu featur campu environ studywa occurr campu widequit win contest presenc incent rais question onlin intervent financi incent increas short term quit rate subsequ analys suggest increas particip contest contribut observ intervent effect futur ran domiz studi need identifi independ effect factor conclus realu studi demonstr provid onlin multi compon smoke cessat intervent financi incent particip feasibl increas short term abstin rate program particip colleg smoker innov work need improv long term quit rate determin efficaci context lower cost incent addit work need determin similar approach effect higher risk group young adult attend colleg frequent internet user acknowledg work support grant rc 2002 0025 clearwai minnesota addit support suppli provid univers minnesota transdisciplinari tobacco research center nih p50 013333
short term effect random comput base school smoke prevent trial aim elementari schoolchildren1 marlein ausem m.p.h 2 ils mester ph.d gerard van breukelen ph.d hein de vri ph.d maastricht health research institut prevent care netherland school primari care research depart health prevent medicin 34 581 589 2002 doi 10.1006 pmed 2002.1021 maastricht health research institut prevent methodolog statist faculti psycholog maastricht background smoke prevent program run school hour studi school program develop consist comput tailor intervent aim ag group school transit 11 12 year elementari schoolchildren aim studi evalu addit effect school smoke preven tion method hundr fifti particip school randomli alloc research con dition school condit exist lesson program school condit comput tailor letter student home school school condit bine approach control condit pretest 6 month follow data smoke initi continu data psychosoci variabl collect 3,349 student result control school condit dif fere posttest smoke initi 18.1 10.4 posttest smoke continu 23.5 13.1 multilevel logist regress anali se show posit effect school program signific effect found school program combin approach show stronger effect singl method ap proach 1 studi made grant european commiss dutch cancer foundat studi part european countri project call octopu unit kingdom univers birmingham spain univers oviedo netherland maastricht univers partic ipat grate coproject leader m.l lope 581 netherland school primari care research depart ivers p.o box 616 6200 md maastricht netherland conclus find studi suggest smoke prevent trial elementari schoolchil dren effect school comput tailor intervent 2002 american health foundat elsevi scienc usa kei word smoke prevent smoke initi smoke continu elementari school comput tailor intervent school as model rct netherland introduct 1997 approxim 50 dutch popul ag 10 19 year cigarett 22 occa sional daili smoker 1 smoke dutch youth case cigarett ag 11 12 year 2 netherland 27 36 11 12 year youth smoke cigarett 1 author state smoke prevent program aim prevent delai tobacco 3 6 impli effect prevent pro gram target youngster ag 11 year grade dutch elementari school focu program pre vent youngster start smoke prevent youngster experi continu ing smoke recent decad effect school base smoke prevent program secondari school stu dent develop worldwid special empha si social influenc 7 repres import determin smoke initi 8 10 similar school base smoke prevent program educ promot faculti health scienc maastricht thoma colleagu cooper project berben softwar construct school health educ local depart particip project 2 reprint request address fax 31 43 3671032 mail m.ausem gvo.unimaas.nl versiti p.o box 616 6200 md maastricht netherland elementari school appear success reduc ing tobacco 11,12 prevent pro gram 11 12 year netherland evalu ni 0091 7435 02 35.00 2002 american health foundat elsevi scienc usa right reserv advantag school set smoke prevent reach wide audienc health educ part curriculum countri opportun interp sonal commun school set optim evalu studi 13 potenti draw back school base smoke prevent program implement subject limit time untrain personnel 11 overcom disad vantag school intervent labori reach youngster disaffect school reject health messag regard unsympathet author figur 14 school program develop consist ing person tailor letter mail stu dent home idea person tailor letter orig inat unit state 15 18 develop test year netherland 19,20 goal studi de scribe effect comput base tailor school smoke prevent program ist dutch school smoke prevent program combin approach school school program combin approach includ research multipl prevent strategi produc result reduct tobacco 3,21 report describ effect school school smoke pre vention smoke initi smoke smoke continu smoke method design procedur spring 1997 414 school south ern eastern central part netherland approach assist local health depart local health depart 54 exist netherland time ask particip agre assist recruit school princip elementari school local health depart region receiv intro ductori letter telephon call discuss particip smoke prevent project school princip netherland 1997 entitl decid student particip ed ucat program provid school repr sent advisori bodi consist parent staff author particip june 1997 156 school final approv particip randomli assign region alli defin block school condit school condit school condit control group condit teacher condit train volunt instruct school program volun teer suppli school school materi pretest questionnair assess proce dure school particip condi tion distribut consent form student parent children select receiv educ materi home address twenti parent refus particip school alloc condit receiv pretest questionnair mail juli 1997 letter instruct regard ing assess procedur includ teach er instruct schedul 1 complet pretest questionnair septemb 1997 collect questionnair student complet class level put postag paid envelop seal return envelop research object valid appli young ag group method detect recent weekli smoke fam ili member smoke induc elev read 13,22 report result accur confi dential assur identif code sy tem 23 27 procedur studi front page pretest posttest questionnair provid inform confid identif code data file research replac student name fore data entri school program implement octo ber decemb school program start novemb 1997 end earli februari 1998 posttest mid februari 1998 time student treatment condit teacher implement school program complet pro cess evalu questionnair tabl 1 present time line sampl approach follow intervent school intervent consist school base social influenc program call don’t plai fire develop dutch foundat smoke health packag includ essenti compon success social influenc pro gram 28 instanc direct pressur discuss train refus skill awar smoke behavior influenc peopl enhanc short term physic social con sequenc smoke discuss packag studi contain teacher manual student workbook intervent consist lesson 45 60 min length lesson prise gener explan teacher class room discuss workbook task prepar part creativ activ sing song 582 ausem al pal highlight 20 instruct perform behaviour pal highlight 26 inform social environment consequ pal highlight 20 instruct perform behaviour 30 demonstr behaviour 41 behaviour practic rehears pal comment text link infer 20 26 social norm school intervent consist tai lore letter smoke prevent messag mail student home 3 week interv seal envelop address student procedur ensur optim confidenti letter includ aforement essenti compon success social influenc program content letter fine tune individu characterist mean pretest questionnair attitud social norm efficaci smoke intent behavior databas file creat person inform pilot test revis concept result creation messag file content messag base social inocul theori 29 suggest provid pupil informa tion skill make resist pressur smoke theori reason action 30 assum behavior result attitud cial norm bandura social cognit theori 31 describ operation model ing efficaci comput program develop maastricht univers combin databas file messag file com.ibm.drl.hbcp.core comput program consist decis rule provid translat student answer person me sage success messag combin letter format letter append pictur puzzl cartoon increas attent attract foster elabor stor ag knowledg 32 order increas elabo ration argument smoke competit includ children win cd voucher answer question don’t cigarett letter version contain inform student belief smoke gener short term consequ smoke irrit ey nausea bad smell social consequ smoke feel tough matur letter 32 version focus influenc social environ student smoke behavior intent smoke futur includ discuss smoke preval dutch popul boi girl receiv messag cartoon letter version base score efficaci scale low high refus tech niqu includ exercis cigarett fusal instanc student pretest questionnair doubt ca paciti refus cigarett messag select comput program explain cigarett refus capac improv carri simu lation exercis subsequ exercis de scribe student stimul practic cigarett refus step step child equip high efficaci receiv messag capac reinforc simul exercis explan cigarett refus ca paciti improv practic measur outcom measur student updat version as questionnair attitud social influenc efficaci assess pre dictor smoke attitudin belief social influ enc efficaci expect intent outcom measur smoke behavior 27,33,34 demograph variabl ag gender religion fam ili composit pocket monei parent work includ com.ibm.drl.hbcp.predictor sume influenc smoke attitud social influ enc efficaci expect attitud assess concept disadvantag smoke 11 item cronbach 0.80 rang posit 1 neg smoke 5 refer nausea cough irrit ey breath problem unwis expens bad health disturb passiv smoke regret bad smell advantag smoke 5 item 0.63 rang ing neg 1 posit smok ing 5 refer grow reliev boredom reliev tension tast good feel tough social accept 3 item 0.75 rang posit 3 neg smoke 3 refer receiv attent friend accep tanc friend make contact tabl 1 number school approach follow total 97 approach 414 approv random 39 39 38 40 156 septemb 97 pretest 36 36 37 34 143 septemb 97 februari 98 intervent februari 98 posttest 34 36 36 34 140 note school intervent school intervent school school intervent control 583tailor school smoke prevent pal highlight 51 materi incent pal highlight 24 informatio health consequ pal highlight 26 inform social environment consequ pal highlight 31 social comparison pal highlight 41 behaviour practic 20 instruct perform behaviour long term physic consequ 2 item 0.57 rang posit 3 nega tive smoke 3 refer risk cancer heart diseas social influenc measur indic model nuclear network 4 item rang smoke 2 absent 1 smoke 0 refer perceiv smoke behavior stu dent father mother brother sister friend model diffus network 4 item rang smoker 4 smoker 0 measur number smoke friend peer teacher famili member social norm 6 item rang posit 3 neg smoke 3 measur perceiv belief student father mother brother sister friend friend social pressur 10 item rang ten 5 0 measur perceiv pre smoke student father mother brother sister friend friend peer teacher famili advertis efficaci scale consist 6 item 0.91 rang uncertain 3 3 item refer student expect refrain smoke situa tion increas magnitud smoke friend smoke cigarett offer parent friend call coward intent smoke measur item rang ing 3 intent smoke 3 smoke behavior base report categoriz ing student 1 smoker student smoke puff cigarett 2 current smoker student smoke past past month 3 current smoker student smoke past month outcom effect smoke initi assess percentag pretest smoke pupil categori 1 initi smoke posttest categori 2 3 outcom effect smoke continu assess percentag pretest smoker categori 2 3 posttest smoke past month categori 3 process measur student process evalu assess exposur appreci expo school condit measur 35 question point scale 1 0 assess lesson stu dent receiv explan prepar class di cussion workbook task creativ activ end lesson appreci lesson evalu at bad 0 excel 10 exposur school condit record student receiv letter 1 0 extent read letter complet 4 1 student time read letter appreci letter score 4 point scale read 4 1 student judg visual appear letter nice 4 nice 1 order find student perceiv essenc tailor ing person approach degre sonal approach assess complet person direct 4 person direct 1 stu dent parent sibl friend allow read letter process measur teacher teacher questionnair assess perform mention element lesson 2 point scale 1 0 addit teacher appreci lesson bad 0 excel 10 analys student nest school school randomli assign treatment condit ignor nest lead type error narrow confi denc interv treatment effect 35 al analys carri multilevel gression model i. program mixreg linear regress continu outcom 36 mixor logist regress dichotom outcom 37 check random success treatment condit compar ag gen der pretest smoke pretest psychosoci variabl dropout check attrit post test outcom pretest demograph pretest smoke psychosoci variabl treatment condit com.ibm.drl.hbcp.predictor program effect line design studi factor condit dummi code compar main effect school school intervent interact test school intervent effect factor school comput school condit 1 versu school condit 0 test school intervent effect factor school comput school condit 1 versu school condit 0 test addit effect school intervent school intervent interact term school school includ analys run larg regress model mixor problem logist regress 584 ausem al conduct spss 9.0 38 determin final model signific covari interact term predict posttest current smoke strategi posttest current smoke predict treat ment factor school school inter action pretest psychosoci measur demograph variabl enter covari previou research show com.ibm.drl.hbcp.predictor smoke 27 nonsignific com.ibm.drl.hbcp.predictor interac tion delet stepwis 0.05 restric tion com.ibm.drl.hbcp.predictor remov model involv interact term model treatment factor school school remov effect focu studi final model enter multilevel analys test intervent effect result process measur calcul student teacher averag letter lesson subs quentli school averag student teacher result sampl characterist pretest questionnair return 143 school 91.7 frequent reason nonpar ticip teacher percept inexperi student smoke tabl 2 show pretest characterist student con dition pretest differ found condit respect demograph psy chosoci variabl posttest questionnair return 140 school 843 student 807 984 715 attrit student level pretest posttest 10.3 school return questionnair absente difficulti match pretest posttest data main attrit logist regr sion attrit depend variabl suggest younger children drop compar older student 0.82 95 ci 0.68 0.98 student school condit significantli drop compar student school condit 0.80 95 ci 0.64 1.01 program effect smoke smoke preval posttest shown tabl 3 pretest smoke sampl smoke initi lowest school condit 10.4 highest con trol condit 18.1 smoke sampl lowest rate smoke continu found school condit 13.1 highest rate control group 23.5 spss logist regress analys assess model nuclear network pressur attitud disadvantag intent ag signific com.ibm.drl.hbcp.predictor post test smoke initi signific interact tween school school factor tabl 2 pretest demograph psychosoci rang characterist student treatment condit 1,002 871 1,068 793 total 3,734 male 49 48 50 51 49 smoker 34.0 35.0 36.3 38.4 35.8 mean mean mean mean total mean ag 11.6 11.7 11.6 11.6 11.6 attitud disadvantag 11 3 55 36.3 36.2 36.4 36.0 36.2 advantag 5 3 25 10.6 10.5 10.3 10.9 10.6 social accept 9 3 9 0.2 0.3 0.4 0.3 0.3 long term consequ 6 3 6 2.5 2.6 2.5 2.7 2.6 social influenc model nuclear 8 3 0 0.9 1.0 0.9 1.0 1.0 model diffus 16 3 0 3.1 3.1 2.9 2.9 3.0 social norm 18 3 18 10.0 10.3 10.1 10.3 10.1 pressur 50 3 0 2.7 2.4 2.1 2.6 2.4 efficaci 18 3 18 9.4 9.5 9.6 8.8 9.4 intent 3 3 3 2.0 2.0 2.0 1.9 2.0 note school intervent school intervent school school intervent control 585tailor school smoke prevent found tabl 4 present result multilevel anal yse final regress model posttest smoke initi school program tend prevent pretest smoker initi smok ing posttest 0.08 student posit intent smoke student felt stronger pressur smoke older student significantli increas risk initi smoker posttest 0.05 student perceiv fewer disadvantag smoker environ tend higher risk initi smoker posttest 0.1 spss logist regress analys assess model nuclear network pressur attitud disadvantag attitud advantag intent ag signif icant com.ibm.drl.hbcp.predictor posttest smoke continu ta ble 5 show result multilevel analys final regress model posttest smoke contin uation interact treatment factor turn school treatment effect prevent pretest smoker continu smoke 0.05 school treatment effect signific student perceiv advantag smoke continu smoke posttest 0.05 school intraclass correl coeffici reflect proport unexplain outcom varianc account school regard post test smoke initi intraclass correl 0.07 posttest smoke continu 0.14 obtain regress model tabl 4 5 attrit posttest predict ag possibl treatment select dropout influenc result check effect analys repeat wai 39 miss data dropout replac pretest observ call observ carri ward analys dropout treat smoker worst case analys analys perform student 3,734 relev differ compar previou analys found process evalu intervent school 91 64 return teacher process questionnair school implement school program realiz teacher 69 questionnair return respons rate student process question nair ident outcom mea surement questionnair data collect bine respect school exposur 87 teacher carri explan activ tabl 4 signific com.ibm.drl.hbcp.predictor posttest smoke initi final regress model pretest smoker student 2,130 school 140 odd ratio 95 ci ag year 1.31 1.04 1.64 pretest attitud disadvantag 11 3 55 0.99 0.97 1.01 pretest model nuclear 8 3 0 0.93 0.86 1.01 pretest pressur 50 3 0 0.96 0.93 0.99 pretest intent 3 3 3 0.79 0.71 0.88 school program ref school program 1.09 0.77 1.56 school program ref school program 0.73 0.50 1.03 0.10 0.05 0.01 0.001 tabl 5 signific com.ibm.drl.hbcp.predictor posttest smoke continu final regress model pretest smoker student 1,190 school 137 odd ratio 95 ci ag year 1.01 0.77 1.32 pretest attitud advantag 5 4 25 1.06 1.01 1.12 pretest attitud disadvantag 11 3 55 0.99 0.97 1.01 pretest model nuclear 8 3 0 0.96 0.87 1.04 pretest pressur 50 3 0 1.01 0.99 1.03 pretest intent 3 3 3 0.95 0.86 1.06 school program ref school program 0.86 0.57 1.30 school program ref school program 0.65 0.42 0.99 0.05 tabl 3 smoke initi percentag 95 confid interv pretest smoker smoke continu ation percentag 95 confid interv pretest smoker treatment condit school unit analysi 34 36 36 34 smoke initi pretest smoker 14.9 11.2 18.7 10.4 6.8 14.0 15.2 10.2 20.3 18.1 12.5 23.7 smoke continu pretest smoker 21.6 15.4 27.8 13.1 9.2 19.3 14.2 7.4 18.9 23.5 17.0 30.1 note school intervent school intervent school intervent control group 586 ausem al lesson prepar activ impl ment 72 teacher 80 teacher class discuss 87 workbook task creativ end session activ car ri 55 teacher student respons similar teacher rate lesson grade 7.5 95 ci 7.3 7.6 scale bad 0 excel 10 student gave 7 95 ci 6.8 7.2 respect school exposur 85 student receiv letter student read averag 1.3 time 70 read complet 51 read letter 48 appear letter 59 student felt person address letter 58 mother 41 father 12 student sibl 6 friend allow read letter discuss goal studi describ effect ness smoke prevent dutch elemen tari schoolchildren 11 12 year comput tailor school program school program combin approach school school program school program effect prevent smoker continu ing smoke posttest pretest smoker school program resist smoke initi effect borderlin signific signific effect found school program smoke initi continu combin approach result addit effect smoke initi combin approach compar school condit specif school program prevent effect school program run simultan compar tailor school intervent tar gete elementari school children exist intervent target adult smoker receiv tailor letter smoke cessat inform tailor intervent aim promot healthi fat fruit veget intak show success result 20,40 compar disappoint result school smok ing prevent intervent found studi show british studi 12 aim schoolchil dren ag 11 12 year studi fulli compar schoolchildren netherland ag 11 12 year made school transi tion contrast british children ag pass stress school transit assum com.ibm.drl.hbcp.predictor smoke 13 school school interven tion compar theoret basi resist skill social norm pressur short long term consequ smoke tailor aspect school program import com.ibm.drl.hbcp.predictor success assess determin target group educ fine tune determin modif phase regard great import azjen fishbein conclud proper individu base instruc tion includ educ session greater level success expect 30,41 school intervent made computer tailor person fine tune instrument confirm recommend school aspect reason posit effect letter mail stu dent home method direct person approach result higher person involv ment messag stronger attitud behavior relationship half student 59 school group felt person ad dress letter involv rate undoubtedli improv inform letter tune student smoke behavior option studi order prevent argument student famili school program lack individu fine tune lower person involv result weaker attitud behavior relationship 42 ter address student half mother father allow read letter sponta neou parent involv stimul discu sion home smoke ag 11 12 year parent influenc domin compar older children peer turn influ ential effect impact parent influenc demonstr famili link program 43 studi show tailor letter parent influenc smoke prevent activ relationship found ag treatment posttest attrit attrit attrib ut school school school condit send back que tionnair absente difficulti match pretest posttest data analys includ drop out posttest smoker pre test smoke score yield result obtain exclud dropout analys limit studi time posttest measur 2 month end school intervent immedi end school intervent influenc result studi letter fresh student memori effect 587tailor school smoke prevent school intervent ar gument substanti time need show signific effect make sult comput tailor letter notabl vali dation report smoke behavior studi object measur 11 12 year old unreli measur de tect recent smoke smoker select ag group experi smoke report demon strate accur confidenti assur identif code system 23 26 studi precaut process evalu result school school program room implement improv school intervent attract regard content appear refin result discuss studi base short term assess elementari schoolchildren ag 11 12 year find confront stress life event school transit puberti smoke preval 11 12 year low litera ture strong increas smoke initi ation expect year follow 2 long term assess determin tailor school program remain promis strument prevent smoke initi continu prevent capac school program evid
articl 1934 psychiatri 163 11 novemb 2006ajp.psychiatryonline.org articl subject cme random control trial smoke cessat intervent peopl psychot disord amanda baker ph.d robyn richmond ph.d melani hail m.psych appl terri lewin b.com psych hon vaughan carr m.d f.r.a.n.z.c.p rachel taylor m.clin.psych sylvia janson r.n kai wilhelm m.d f.r.a.n.z.c.p object extrem high rate smoke individu psychot disord financi health cost studi investig efficaci smoke cessat interven tion group purpos studi compar integr psy cholog nicotin replac ther com.ibm.drl.hbcp.api intervent peopl psy chotic disord routin care method author recruit 298 regu lar smoker psychot disord side commun randomli assign routin care compari son condit 151 se sion individu administ smoke cessat intervent 147 consist nicotin replac ther com.ibm.drl.hbcp.api motiv interview cog nitiv behavior therapi outcom vari abl includ continu point preval abstin rate smoke duction statu symptom function result dif ferenc treatment group comparison group abstin rate significantli higher proport smoker complet treatment se sion stop smoke fol low occas point preval rate 3 month 30.0 versu 6.0 6 month 18.6 versu 4.0 12 month 18.6 versu 6.6 smoker complet treatment session achiev continu abstin 3 month 21.4 versu 4.0 strong dose respons relationship treatment session attend smoke reduct statu half complet interven tion program achiev 50 greater reduct daili cigarett consumpt follow up rel comparison subject evid deterior symptom function conclus find demon strate com.ibm.drl.hbcp.util nicotin replac therapi motiv interview cognit behavior therapi smoke ce sation intervent individu psychot disord devel opment efficaci intervent requir respond exist intervent psychiatri 2006 163 1934 1942 individu psychot disord consist shown high rate smoke rang 70 88 1 3 compar approxim 50 psychiatr disord schizophrenia 25 gener popul 4 concern financi health cost estim smoker schizophrenia unit state spend weekli incom cigarett 5 smoker psychiatr ill stop smoke compar individu psychiatr ill higher level nicotin depend 1 smoke relat diseas contribut reduc tion life expect common death peopl schizophrenia ischem heart diseas 6 smoker psychot disord smoke cigarett order allevi neg symptom cognit dysfunct medic side effect 7 ad dition smoke reason smok er psychiatr ill 3 paradox smoker psychot disord report experi enc increas psychiatr symptom number hospi taliz higher medic dose 8 small trial conduct smok er schizophrenia combin nico tine replac therapi 9 10 bupropion group intervent 11 13 intervent shown smoker mental ill ness 14 treatment trial smoker schizophrenia critic methodolog cal ground includ heterogen sampl small sampl size lack defin intervent parison group cessat achiev particip recommend futur smok psychiatri 163 11 novemb 2006 1935 baker richmond hail al ajp.psychiatryonline.org ing cessat intervent evalu rigor ou methodolog 15 assess smok ing outcom cessat 16 primari purpos studi evalu effect individu administ motiv inter view cognit behavior therapi nicotin placement therapi smoke cessat reduct individu psychot disord evalu impact psychiatr symptom hy pothes greater proport particip ceiv motiv interview cognit behavior therapi nicotin replac therapi report smoke cessat reduct rel routin care control condit method studi design particip provid written inform consent assess pretreat 3 month 15 week initi assess ment 6 12 month initi assess partici pant met inclus criteria randomli alloc group 1 treatment condit includ individu 1 hour session motiv interview cog nitiv behavior therapi nicotin replac therapi ad dition treatment usual provis booklet smoke cessat 17 support 18 2 comparison condi tion includ treatment usual booklet assess schedul treatment usual includ access gener practition publicli fund commun mental health team letter particip gener prac tition case manag treat psychiatrist notifi involv patient follow assess conduct member research team blind group allo cation particip reimburs 20 time travel particip assess occas particip procedur particip 298 smoker nonacut psychot disor der recruit sydnei australia newcastl region nsw australia referr receiv commun health agenc 82.2 inpati psychiatr unit 8.3 neurosci institut schizophrenia alli disord schizophrenia regist 7.0 particip recruit inpa tient unit contact 2 month postdischarg invit part inclus criteria 18 year ag smoke 15 cigarett dai icd 10 diagnosi psy chotic disord particip requir express inter est quit smoke exclus criteria medic condit preclud nicotin patch acut psy chotic case particip reassess 1 month postscreen acquir cognit impair particip inform randomli sign condit end initi assess ment interview achiev simpli draw seal envelop set envelop initi equal distribut treatment control alloc site prefer treatment session conduct search center nearbi commun clinic par ticip unabl attend center session con duct particip home pretreat assess last 1.5 hour 2 hour follow assess last approxim 1 hour research approv relev gional univers ethic committe sydnei newca tle particip miss consecut treatment se sion consid treatment dropout measur kei demograph clinic outcom measur port articl assess instrument report articl 19 briefli studi diagnost measur diagnosi determin di agnost interview psychosi 20 semistructur interview confirm diagnosi oper criteria psycho si 21 produc diagnost classif accord icd 10 diagnost categori obtain col laps match psychosi categori report low preval disord studi 22 addit provid clini cal diagnosi diagnost interview psychosi gather format sociodemograph characterist premorbid ad justment current symptom medic social function servic com.ibm.drl.hbcp.util antipsychot medic catego rize atyp versu typic subtyp smoke outcom measur primari smoke outcom measur continu abstin point preval absti nenc smoke reduct statu evalu intent treat program effect basi 23 ari smoke outcom analys base amount treat ment receiv select basi continu absti nenc refer proport particip report smoke nomin quit date current assess ment point 3 6 12 month point preval abstin refer proport particip abstin 7 figur 1 recruit attrit profil bracket number refer assess complet design time period subject refer screen 473 exclud 175 inelig sydnei 82 newcastl 31 refus sydnei 32 newcastl 30 includ 298 sydnei 152 newcastl 146 assign treatment motiv interview cognit behavior therapi cbt nicotin replac therapi 147 number motiv interview cbt session complet 5 35 23.8 5 7 42 28.6 8 70 47.6 follow assess completeda 3 month 131 4 6 month 128 1 12 month 127 follow assess completeda 3 month 121 4 6 month 116 4 12 month 120 2 assign comparison group 151 1936 psychiatri 163 11 novemb 2006 smoke cessat psychot disord ajp.psychiatryonline.org dai preced follow assess 16 smoke reduct statu base assess particip reduc daili consumpt cigarett 50 greater includ abstin rel baselin 16 index individu psychot disord 11 current abstin smoke confirm ing micro 11 smokerlys assess breath level carbon monoxid carbon monoxid level 10 ppm signifi particip smoke 8 hour nico tine depend measur fagerstrom test nicotin depend 24 motiv stop smoke measur 11 item readi motiv quit smoke question nair elabor stage readi scale rang ing 0 precontempl level 1 contempl quit cut 4 prepar stage measur psychopatholog qualiti life psychiat ric symptom assess 24 item psychiatr rate scale 26 beck depress inventori ii 27 state trait anxieti inventori 28 gener function mea sure 12 item short form survei 29 produc mental compon score physic health compon score lower score indic greater disabl therapi motiv interview cognit behavior therapi tervent deliv individu particip train therapist treatment manual written au thor specif popul 30 regular supervis senior clinic psychologist a.b provid therapist complet therapist checklist treatment session ensur treatment protocol consi tenci treatment maintain intervent consist weekli session 1 hour durat booster se sion week 8 10 session total summari session list week 1 conduct motiv interview 31 compri ing feedback initi assess assess good good aspect smoke identifi concern smoke com.ibm.drl.hbcp.util sane smokefre booklet 17 18 set goal outlin treatment plan assign home work week 2 review week homework exercis assess ment person trigger high risk situat plan stop smoke introduct cope urg devis crav ing plan provis inform withdraw symptom homework assign week 3 manag withdraw cognit restructur review withdraw symptom set quit date discuss nicotin replac therapi engag support person request discuss absti nenc rule violat effect identifi challeng unhelp neg thought suppli nicotin patch 7 dai 21 mg week 4 review cognit strategi skill enhanc ment discuss seemingli irrelev decis develop person skill problem solv skill suppli nico tine patch 7 dai 21 mg week 5 review consolidat ing cope skill train cigarett refus skill train asser tive commun skill develop stress manag suppli nicotin patch 7 dai 21 mg week 6 relaps prevent lifestyl modif includ rational relaps prevent identifi high risk situat tabl 1 continu point preval abstin rate smoke reduct statusa measur group phase 3 month 6 month 12 month odd ratio 99 ci odd ratio 99 ci odd ratio 99 ci continu abstin comparison group 151 4.0 1.00 2.0 1.00 0.7 1.00 treatment group 147 10.9 2.95 0.83 10.53 5.4 2.84 0.48 16.67 3.4 5.28 0.31 90.20 attend 5 session 35 0.0 0.0 0.0 attend 5 7 session 42 2.4 0.59 0.04 9.88 2.4 1.20 0.06 24.38 0.0 attend session 70 21.4 6.59 1.78 24.41 10.0 5.48 0.89 33.81 7.1 11.54 0.67 198.97 point preval abstin comparison group 151 6.0 1.00 4.0 1.00 6.6 1.00 treatment group 147 15.0 2.78 0.96 8.07 9.5 2.54 0.70 9.28 10.9 1.72 0.58 5.09 attend 5 session 35 0.0 0.0 0.0 attend 5 7 session 42 2.4 0.39 0.03 6.04 2.4 0.59 0.04 9.88 7.1 1.09 0.19 6.30 attend session 70 30.0 6.76 2.23 20.55 18.6 5.51 1.45 20.91 18.6 3.22 1.01 10.22 smoke reduct 50 greater rel baselin comparison group 151 16.6 1.00 18.5 1.00 17.9 1.00 treatment group 147 43.5 3.89 1.91 7.89 29.9 1.88 0.92 3.82 31.3 2.09 1.03 4.27 attend 5 session 35 20.0 1.26 0.37 4.29 14.3 0.73 0.19 2.84 11.4 0.59 0.14 2.59 attend 5 7 session 42 40.5 3.43 1.28 9.19 23.8 1.37 0.47 4.03 21.4 1.25 0.41 3.81 attend session 70 57.1 6.72 2.90 15.56 41.4 3.11 1.36 7.09 47.1 4.10 1.80 9.34 miss data classifi nonabstin fail achiev requir 50 reduct undefin confid interv 0.01 0.001 s04aw6 highlight s04aw6 highlight psychiatri 163 11 novemb 2006 1937 baker richmond hail al ajp.psychiatryonline.org regul consequ suppli nicotin patch 14 dai 21 mg week 8 booster session 1 review previou 2 week relaps prevent plan discuss taper nicotin replac therapi suppli nicotin patch 7 dai 21 mg 7 dai 14 mg week 10 booster session 2 review previou 2 week relaps prevent plan suppli ing remain patch 7 dai 14 mg 14 dai 7 mg statist analysi data analyz spss window version 12.0 kei smoke relat outcom variabl intent treat analys 23 conduct treatment group 147 ver su comparison group 151 subgroup analys base pattern treatment session attend analys miss data classifi nonabstin fail achiev requir rate reduct odd ratio confid interv ci report comparison group refer point odd ratio 1.00 continu outcom variabl e.g current tobacco symptom plan comparison assess phase repeat measur analys varianc anova examin group differ pattern chang par tial control number statist test threshold statist signific set 0.01 result recruit attrit profil present figur 1 473 individu refer studi 113 inelig 23.9 addit 62 13.1 de cline leav recruit sampl 298 regular smoker icd 10 psychot disord characterist particip pretreat assess detail 19 156 men 142 women recruit studi averag ag 37.24 year sd 11.09 year typic particip au tralian born 84.9 singl 65.8 receiv welfar port 95.6 complet senior high school 64.8 half studi group 56.7 diagnosi schizophrenia schizoaffec tive disord extens pretreat sampl charac terist report earlier articl 19 examin smoke characterist rea son smoke quit attend treatment session follow shown figur 1 approxim half 47.6 treatment group attend treatment session quarter 23.8 attend session pattern follow attend consid prepar data set analysi particip complet follow assess design time period i. half time interv tween follow up classifi continu smoker intent treat analys complet tabl 2 tobacco relat variabl smoker phase group phase nicotin dependencea stage changeb mean sd mean sd comparison group baselin 151 8.21 2.05 3.02 1.04 3 month 113 6.62 1.93 2.56 1.15 6 month 107 6.14 2.32 2.42 1.23 12 month 109 6.43 2.09 2.23 1.32 treatment group baselin 147 7.90 2.11 3.28 0.73 3 month 107 5.63 2.52 2.75 1.22 6 month 110 6.15 2.45 2.49 1.27 12 month 108 6.22 2.35 2.31 1.31 signific time effect baselin versu 3 month 152.11 df 1 211 0.001 6 month 140.04 df 1 215 0.001 12 month 303.47 df 1 215 0.001 signific group time interact 3 month versu 6 month 15.48 df 1 174 0.001 3 month versu 12 month 7.44 df 1 174 0.01 signific time effect baselin versu 3 month 27.92 df 1 211 0.001 6 month 58.21 df 1 215 0.001 12 month 75.56 df 1 215 0.001 3 month versu 12 month 11.56 df 1 174 0.001 figur 2 chang daili cigarett smoke smoker routin care cessat intervent signific time effect baselin versu 3 month 43.00 df 1 211 0.001 6 month 59.50 df 1 215 0.001 12 month 38.85 df 1 215 0.001 sd ig tt ya time month comparison group treatment group baselin 3 6 12 baselin 3 6 12 0 5 10 15 20 25 30 35 40 45 1938 psychiatri 163 11 novemb 2006 smoke cessat psychot disord ajp.psychiatryonline.org follow design time period tain nonintent treat analys basi peopl complet 3 6 12 month follow evalu nonconform data exclud relev noninten tion treat analys result pattern attend similar phase 84.6 252 3 month 81.9 244 6 month 82.9 247 12 month third 65.1 particip attend follow session major intent treat analys involv comparison pair time point signific differ group follow attend pattern smoke tabl 1 displai continu point preval absti nenc rate smoke reduct statu 3 6 12 month follow assess intent treat analys found signific differ tween treatment group comparison group con tinuou abstin point preval abstin rate measur 3 6 12 month sig nific differ smoke reduct statu 3 month 43.5 treatment group reduc cigarett consumpt 50 rel baselin rel 16.6 comparison group odd ratio 3.89 0.001 subsequ follow session approxi mate 30 treatment group 18 compari son group report compar reduct differ signific 12 month tabl 1 tabl 1 report comparison compari son group treatment subgroup defin basi pattern attend baselin differ enc group kei sociodemo graphic clinic variabl particip complet treatment session significantli comparison group improv 3 month follow smoke outcom measur i. continu ou point preval abstin reduct sta tu rel comparison group particip complet treatment session significantli abstin 6 12 month follow session point preval reduc consumpt 50 particip complet session significantli decreas smoke half 3 month differ abstin rate smoke reduct pattern medic sta tu entri studi atyp versu typic antip sychot medic medic statu impact effect observ treatment session attend follow assess particip report abstin 31 3 month 20 6 month 24 12 month produc carbon monoxid level 10 ppm except person 12 month report continu high level cannabi circumst person classifi abstin analysi keep accept practic tabl 2 figur 2 present profil select smok ing relat variabl current smoker phase nicotin depend fagerstrom test nicotin depen denc score daili cigarett consumpt signific reduct baselin follow session treatment group displai increas fagerstrom test nicotin depend score 3 month subsequ follow session rel smoker comparison group nicotin depen denc tend declin stage chang continu smoker report signific decreas motiv stop smoke follow up rel baselin signific decreas 3 month 12 month pattern nicotin replac therapi follow particip report nico tine replac therapi preced period tabl 3 symptom function profil phase group phase psychopatholog psychiatr rate scale 24 global score anxieti state trait anxieti inventori statea depress beck depress inventori iia mean sd mean sd mean sd comparison group baselin 150 35.25 11.47 108 42.61 12.55 141 17.94 14.73 3 month 121 34.17 9.18 106 39.57 12.22 119 14.41 11.16 6 month 116 35.27 9.95 103 39.83 12.76 115 14.30 11.45 12 month 120 34.18 7.89 103 39.81 12.99 119 12.66 11.27 treatment group baselin 147 32.85 7.99 84 39.81 11.91 132 14.42 12.08 3 month 131 33.05 8.31 106 38.94 13.19 127 12.99 10.49 6 month 128 31.84 7.15 114 37.25 12.47 127 10.75 10.59 12 month 127 32.16 7.80 94 37.31 12.34 126 12.27 11.28 late addit studi protocol account variat sampl size signific time effect baselin versu 6 month 10.87 df 1 147 0.001 signific time effect baselin versu 3 month 14.05 df 1 228 0.001 6 month 17.98 df 1 219 0.001 12 month 19.74 df 1 224 0.001 signific time effect baselin versu 3 month 7.30 df 1 250 0.01 6 month 8.52 df 1 242 0.01 12 month 9.06 df 1 241 0.01 psychiatri 163 11 novemb 2006 1939 baker richmond hail al ajp.psychiatryonline.org includ patch method 3 month 29.8 comparison group 84.0 treat ment group report nicotin replac therapi preced 3 month member treatment group attend session 58.6 report nicotin replac therapi pare 89.2 92.3 tend session treatment session larg reflect link nicotin replac ment therapi provis treatment attend 6 month 22.4 comparison group 37.5 treat group report nicotin replac therapi preced period 12 month report rate converg 28.3 comparison group 31.0 treat group report nicotin replac ment therapi preced 6 month port nicotin replac therapi 3 month net reduct 8.14 cigarett dai nicotin replac therapi user 137 report reduct 12.25 sd 16.96 cigarett dai compar 4.11 sd 10.6 nonus 106 0.001 group subs quentli report nicotin replac therapi 6 month show net reduct 8.28 cigarett dai nicotin replac therapi user 12 report reduct 10.42 sd 13.29 compar 2.14 sd 9.15 continu nonus 76 0.01 particip shift nonus nicotin replac therapi 6 month nicotin replac therapi 12 month 20 reduct 4.10 sd 14.34 cigarett dai compar creas 0.49 sd 8.46 particip nonus occas 131 net differ 4.59 cigarett dai signific 0.04 symptom function tabl 3 present symptom function profil phase signific differ tween group occas psychiatr rat ing scale 24 global score short form survei 12 physi cal compon score state trait anxieti inventori state anxieti score reduc significantli baselin 3 month beck depress inventori ii depress score significantli lower follow session rel baselin similarli baselin sf 12 mental compon score significantli lower follow occas indic gener improv mental function signific group time interact noninten tion treat analys suggest improv current function sf 12 mental compon scoresd sf 12 physic compon score mean sd mean sd 151 46.09 8.24 151 46.80 7.43 121 47.62 7.59 121 46.69 8.34 116 47.08 9.34 116 47.83 7.45 119 47.45 8.94 119 47.66 8.16 147 46.25 8.46 147 47.30 7.64 131 47.78 8.38 131 48.76 7.57 128 49.06 7.82 128 48.16 7.54 124 48.02 7.61 124 47.10 7.52 patient perspect jame 37 year man schizophrenia refer local commun mental health team take antipsychot medic smoke 50 cigarett dai attempt quit previou 12 month jame surpris found 45 minut assess session arduou comment ask smoke i’v thought randomli alloc activ treatment condit combi nation cognit behaviour therapi motiv terview nicotin replac therapi initi session spent discuss wai jame nicotin placement therapi rang behavior techni que e.g cope crave activ schedul work initi goal total abstin cigarett jame manag remain abstin tween week 5 8 longest time cigarett time show interest benefit cognit focuss treatment strategi e.g cognit restructur ing note patch good stop smoke social event led relaps strategi manag situa tion focu remain session end treatment jame longer nicotin replac therapi reduc smok ing 15 cigarett dai reflect posit treatment experi comment monei 20 assess se sion free stuff nicotin replac therapi patch good good talk i’v jame maintain reduct subsequ 12 month includ addit seri ou attempt quit last approxim 20 dai 1940 psychiatri 163 11 novemb 2006 smoke cessat psychot disord ajp.psychiatryonline.org symptom function attribut specif aspect treatment program discuss abstin result discuss consider smoke reduct find potenti intervent effect major find ing follow occas significantli higher proport smoker psychot disord complet treatment session ab stinent rel comparison group point preval rate 3 month 30.0 versu 6.0 6 month 18.6 versu 4.0 12 month 18.6 versu 6.6 smoker complet treatment session achiev continu abstin 3 month 21.4 versu 4.0 particip attend fewer treatment session report abstin follow point partici pant attend session report abstin appear smoker psychot disord complet counsel session smoke cessat intervent nicotin patch distribut stop smoke smoker complet intervent session similar relationship report small uncontrol studi smoker schizo phrenia 9 therapi procedur enhanc complet smoke cessat intervent e.g intervent complet contract reinforc conting enhanc cessat rate futur studi studi e.g 9 10 12 cessat rate achiev end treatment modest low report smoker psychiatr ill ness 33 lower cessat rate observ current sampl unexpect peopl chronic mental ill higher nic otin depend 1 smoke dai made previou attempt stop smoke 19 methodolog perspect research seek higher degre certainti assess current smoke abstin requir lower car bon monoxid threshold e.g 3 ppm 32 arguabl mark treatment dose spons relationship evid smoke reduct find tabl 1 approxim half 41.4 57.1 particip complet interven tion reduc smoke 50 rel base line compar comparison group 16.6 18.5 extend complet session 3 month reduc smoke mine futur cessat effort increas motiv 34 potenti import find recent view publish nicotin replac therapi studi primarili involv smoker quit hugh carpent 16 report 12 35 partici pant receiv activ treatment reduc daili cigarett consumpt 50 greater includ ab stainer compar 3 22 particip control condit 12 month data studi 31.3 versu 17.9 gener consi tent find attest target reduct abstin high number cigarett smoke level nicotin depend report studi 19 highlight earlier smoke intervent young peopl mental health problem heavi smoker current practic guidelin psychia trist recommend nicotin replac therapi earli cessat attempt individu psy chiatric disord withdraw symptom stop smoke 35 studi nic otin replac therapi commenc associ at net reduct cigarett dai suggest higher dose longer durat nico tine replac therapi obtain addit benefit gener plore deliveri uptak smoke intervent primari care set potenti barrier 36 urgent develop efficaci intervent smoker se vere mental ill respond intervent evalu studi pharmacolog ap proach give consider bupropion e.g 13 rimonab cannabinoid receptor 1 antagonist 37 combin nicotin replac therapi motiv interview cognit behavior therapi intervent worthi investig al studi report benefit atyp versu typic antipsychot medic smoke e.g 10 studi find signific benefit futur studi address issu worth ing specif intervent start regimen clozapin decreas crave 38 studi need evalu long term nicotin replac therapi extend cognit behavior therapi intervent allow resumpt treat ment relaps suggest smoker reduc number cigarett smoke inform stop smoke unabl short term reduc smoke help increas likelihood quit 11 hugh 34 mcchargu colleagu 15 sug gest reduct focus smoke intervent smoker schizophrenia ab stain cigarett evalu take account medic impact find individu continu smoke report signifi decreas motiv stop smoke tabl 2 odd recommend hugh mc chargu al reflect high level psychiatri 163 11 novemb 2006 1941 baker richmond hail al ajp.psychiatryonline.org motiv point recruit neg expect ongo studi particip import financi health benefit smoke reduct individu sever mental ill 34 import find signific improv studi group mental health measur worsen psychot symptom time tabl 3 consist studi e.g 9 10 evid suggest particip smoke cessat studi asso ciat worsen symptom studi largest random control trial smoke intervent individu psychot disord control therapi time possibl exist superior outcom smoke intervent particip ad dition therapist attent support specif motiv interview cognit behavior ther com.ibm.drl.hbcp.api nicotin replac therapi intervent level depend studi evid support efficaci bine nicotin replac therapi motiv terview cognit behavior therapi nonpsychi atric popul 14 16 ubiquit natur smoke peopl psychot disord heavi cost smoke group modest en courag find random control trial amin comprehens intervent requir assess long term outcom smoke cessat reduct intervent receiv june 7 2005 revis receiv oct 31 2005 accept dec 28 2005 centr mental health studi hunter england mental health univers newcastl newcastl au tralia neurosci institut schizophrenia alli disord nisad sydnei australia school public health muniti medicin school psychiatri univers south wale south wale australia address correspond reprint request dr baker centr mental health studi univers newcastl univers dr callaghan nsw 2308 austra lia amanda.bak newcastle.edu.au mail studi joint project conduct centr mental health studi univers newcastl hunter england mental health univers south wale fund provid nation health medic research council grant number 141708 rotari commun health tuberculosi australia nicotin replac therapi provid free charg glaxosmithklin booklet provid di count price sane australia author particip agenc health profession assist recruit includ neurosci institut schizophrenia alli disord nisad schizophrenia research regist author paul constabl angelin dalmau renai greig franc kai lambkin kristen moeller saxon cme disclosur author report compet interest apa polici requir disclosur cme author unapprov vestig product discuss cme program label medic individu physician permit mon decis label guid scientif litera ture clinic experi
bmj collabor jstor digit preserv extend access tobacco control http www.jstor.org particip popul base physic activ programm aid smoke cessat randomis trial author raphaël bize carol willi arnaud chiolero rebecca stoianov sylvi payot isabella locatelli jacqu cornuz sourc tobacco control vol 19 6 decemb 2010 pp 488 494 publish bmj stabl url http www.jstor.org stabl 40997793 access 03 02 2016 11 27 utc refer link refer jstor articl http www.jstor.org stabl 40997793 seq 1 cid pdf refer references_tab_cont log jstor access link refer jstor archiv accept term condit http www.jstor.org page info polici terms.jsp jstor profit servic help scholar research student discov build wide rang content trust digit archiv inform technolog tool increas product facilit form scholarship inform jstor contact support jstor.org content download 137.120.4.50 wed 03 feb 2016 11 27 15 utc subject jstor term condit http www.jstor.org http www.jstor.org publish bmj http www.jstor.org stabl 40997793 http www.jstor.org stabl 40997793 seq 1 cid pdf refer references_tab_cont http www.jstor.org page info polici terms.jsp http www.jstor.org page info polici terms.jsp http www.jstor.org page info polici terms.jsp particip popul base physic activ programm aid smoke cessat randomis trial raphaël bize 1'2 carol willi 1 arnaud chiolero 1'2 rebecca stoianov 3 sylvi payot 2 isabella locatelli 1 jacqu cornuz1'3 depart ambulatori care commun medicin univers lausann switzerland institut social prevent medicin univers lausann switzerland depart intern medicin univers hospit center lausann switzerland correspond dr raphaël bize depart ambulatori care commun medicin univers lausann rue du bugnon 44 ch 1011 lausann switzerland raphael.b hospvd.ch receiv 6 march 2009 accept 10 june 2010 publish onlin 25 august 2010 abstract object exercis combin nicotin therapi smoke cessat minimis weight gain quit low particip vigor intens physic activ programm preclud popul wide applic randomis control trial test popul base moder intens physic activ programm increas quit rate sedentari smoker receiv nicotin therapi method particip 481 57 male mean ag 42.2 year sd 10.1 mean cigarett consumpt 27 sd 10.2 dai offer week smoke cessat programm consist weekli 15 minut counsel session prescript nicotin replac therapi addit particip physic activ group 229 part programm moder intens physic activ implement nation level offer weekli 60 minut session physic activ ensur equal contact condit particip control group 252 attend weekli 60 minut health behaviour educ session unrel physic activ primari outcom continu verifi smoke abstin rate 1 year follow result continu smoke abstin rate high similar physic activ group control group end intervent 47 versu 46 0.81 1 year follow 27 versu 29 0.71 mean weight gain year 4.4 kg 6.2 kg sustain quitter physic activ control group 0.06 conclus particip popul base moder intens physic activ programm 9 week addit comprehens smoke cessat programm significantli increas smoke cessat rate signific reduct weight gain observ particip quit smoke physic activ group trial registr clinicaltrials.gov nation institut health onlin http clinicalthals.gov clinic trial registr number nct00521391 smoke sedentari behaviour lead death diseas western countri 1 2 evid base smoke cessat intervent includ counsel line pharmacotherapi nicotin replac therapi nrt 7 bupropion vareniclin 3 smoke abstin rate remain low clinic intervent innov approach smoker quit prevent relaps call 4 5 initi vigor intens physic activ defin 60 80 maxim oxygen uptak sedentari smoker stop smoke increas chanc quit reduc nicotin withdraw symptom neg mood perceiv stress weight gain 6 smoke cessat rate higher address simultan behaviour 14 increas physic activ contribut prevent cardiovascular diseas ind pendent smoke cessat advis healthcar profession 15 moder intens physic activ defin 40 60 maxim oxygen uptak physic activ counsel facil itat smoke cessat controversi 16 19 initi vigor intens physic activ difficult smoker replic effect moder intens physic activ programm need 8 16 20 trial assess particip programm moder intens physic activ implement popul level increas smoke cessat rate ad comprehens evid base smoke cessat programm offer individu coun sell nicotin replac therapi design randomis control trial evalu effect programm smoke cessa tion sedentari smoker stop smoke method research protocol approv 15 januari 2002 lausann medic school ethic committe regist clinicaltrials.gov clinic trial registr number nct00521391 data collect june 2002 januari 2006 recruit particip particip sedentari smoker gener popul want quit smoke recruit public advertis daili lai press interest smoker ask call studi centr trial explain phone pre screen inter view undertaken time candid met initi screen criteria schedul pre inclus visit candid inform agre particip 488 tobacco control 2010 19 488 494 doi 10.1136 tc 2009.030288 content download 137.120.4.50 wed 03 feb 2016 11 27 15 utc subject jstor term condit http www.jstor.org page info polici terms.jsp detail smoke medic histori obtain confirm elig inclus criteria ag 18 65 year smoke 10 cigarett dai regularli smoke averag 10 cigarett dai 3 year quit smoke classifi insuffici activ base swiss health enhanc physic activ survei 1999 screen instrument candid consid insuffici activ report 150 minut moder intens physic activ mpa week 60 minut vigor intens physic activ vpa week 21 22 exclus criteria current pharmacolog agent quit smoke medic problem alter exercis toler place particip risk physic activ relat cardiovascular event 23 includ heart diseas current recent major cardiovascular event recent myocardi infarct 12 month stroke angina pectori major arrhythmia presenc unstabl medic condit arthriti orthopaed problem psychiatr ill current diagnosi dsm iv axi risk alcohol consumpt 4 drink dai men 3 drink dai women psychotrop substanc cannabi current plan pregnanc systemat skin diseas preclud prescript transderm nicotin patch elig candid schedul pre inclus visit consist baselin medic examin blood pre anthropométri measur assess standard laboratori test haematolog blood chemistri urinalysi conduct studi design procedur studi design arm randomis control trial sequenc alloc arm physic activity7 group control7 group remot randomli gener comput conceal alloc secur mean seal envelop particip alloc studi arm studi nurs end pre inclus visit facilit interact interven particip programm deliv success wave 20 25 particip studi arm minimis potenti imbal success batch particip block randomis procedur block size 50 randomli permut treatment assign particip group attend 9 week programm weekli 15 minut session includ individu base smoke cessat intervent combin nicotin replac product counsel intervent cover standard cognit behaviour topic enhanc moti vation 24 25 highlight relev health benefit identifi barrier cope crave high risk situat socialis parti relaps prevent programm base swiss intern clinic guidelin smoke cessat 4 26 ensur standardis administr programm provid written manual tutor underw smoke cessat train healthcar profession 27 particip prescrib nrt past experi request consid nrt product 16 hour transderm patch 2 mg 4 mg gum 10 mg inhal 1 mg lozeng particip ask set quit date session smoke cessat programm week particip consid smoker fail quit relaps follow visit tobacco control 2010 19 488 494 doi 10.1136 tc 2009.030288 plan 10 26 52 week begin smoke cessat programm data collect studi centr locat depart ambulatori care commun medicin univers lausann switzerland improv retent reimburs travel expens particip complet follow visit 26 52 week physic activ programm addit comprehens smoke cessat programm physic activ group 9 week physic activ intervent includ structur lifestyl compon structur compon physic activ interven tion provid swiss allez hop7 programm implement popul base programm recommend adult gener popul 28 allez hop programm consist 60 minut group session week particip practis moder intens physic activ supervis train monitor session perform open recreat centr specif exercis relat equip session divid part interact discuss physic activ 5 minut aim posit influenc participants7 attitud physic activ percept easi perform behaviour be29 warm period 45 minut physic activ session intend target 40 60 maxim aerob power dedic brisk walk slow jog cool period debrief 5 10 minut intens physic activ moni tore borg rate perceiv exert scale base participants7 subject percept physic activ effort exert maxim exert 30 target intens physic intervent 11 easy7 13 hard7 31 lifestyl compon physic activ intervent consist encourag particip practis physic activ commut foot bicycl leisur recreat hike danc occup physic activ work household activ lawn move moder intens equival 30 minut time week 32 33 activ plan unplan activ part everydai life interven train applic motiv interview principl part standard profession curriculum 34 particip group told regular physic activ increas chanc successfulli quit weight withdraw symptom manag healthi lifestyl programm addit comprehens smoke cessat programm ensur equal contact condit group 9 week particip control group weekli 60 minut supervis group session receiv standard health educ programm session includ lectur handout discuss address prevent issu healthi diet prevent cardiovascular diseas cancer screen programm detect breast colon cancer group session base previous publish protocol adapt swiss epidemiolog situat 12 qualit test set ensur accept part studi design provid practic advic initi physic activ adher group session encourag 489 content download 137.120.4.50 wed 03 feb 2016 11 27 15 utc subject jstor term condit http www.jstor.org page info polici terms.jsp free provis educ counsel written health educ materi outcom primari outcom smoke cessat 1 year follow 52 week smoke cessat defin report abstin smoke confirm carbon monoxid concentr expir air 10 ppm measur micro smokerlys bedfont7 kent7 uk threshold consid reflect abstin smoke past 24 hour studi particip count continu abstin declar uninterruptedli smoker week 2 partici pant quit date week 107 26 52 concentr exhal air concomitantli 10 ppm abstin dai confirm consid secondari outcom follow visit 10 26 52 week criteria compli common standard outcom definit smoke cessat trial 35 physic activ quantifi administr physic activ frequenc questionnair questionnair develop valid random sampl 919 adult swiss resid heart rate monitor 36 37 respond number dai 7 dai number hour dai perform 70 activi ti group activ includ sedentari 20 minut requir complet questionnair sedentari lifestyl defin 10 total daili energi expenditur spent perform moder intens vigor intens physic activ defin activ requir 4 metabol equival task met questionnair complet baselin week 10 26 52.37 bodi weight record nearest 0.1 kg particip wear underwear sock height measur nearest 0.5 cm bodi mass index kg calcul nicotin withdraw assess wisconsin withdraw scale 38 confid sustain smoke cessat assess 10 cm visual analogu scale report symptom depr sion assess center epidemiologi studi depress scale 39 perceiv stress level assess 4 item perceiv stress scale demonstr good valid reliabl randomis clinic trial 40 statist method sampl size calcul base assumpt estim smoke cessat rate 52 week follow 20 control group 30 physic activ group differ consid relev clinic public health perspec tive assum error 5 target statist power 80 hundr particip includ arm studi account assumpt proport group compar x2 test differ continu variabl arm studi analys sampl test mann whitnei test variabl show asymmetr distribut conduct multipl logist regress model relat continu smoke abstin year studi group adjust ag sex educ daili cigarett consumpt baselin appli longitudin approach base generalis estim 490 equat model relat 7 dai point prev alenc abstin follow visit 10 26 52 week studi arm adjust previous mention potenti confound factor 41 inter action test stratif assess effect intervent differ respect sex ag particip provid inform smoke behaviour lost follow consid persist smoker intent treat analysi secondari outcom analys basi data statist analys perform stata statist softwar releas 9 statacorp lp result 1069 smoker screen phone pre inclus visit randomis 543 smoker 51 agre particip reason exclus detail figur 1 thirti particip arm studi attend group session consid major protocol violat turn prior regular exercis marijuana user counsel session particip exclud analys result particip rate 45 physic activ control group compos 229 252 particip figur 1 52 week follow visit complet 127 particip physic activ group follow rate 55 155 control group follow rate 62 adult smoker screen 1o69 ag 18 65 9 pregnant 3 regular exercis 1o9 somat health condit 116 2 cardiovascular risk factor 8o muscular problem 42 substanc abus 48 psychiatr disord 88 reason 31 adult smoker random 543 physic activ group 26o control group 283 major protocol major protocol violat 20 violat 28 substanc abus substanc abus regular exercis regular exercis attend attend group session 11 group session 2 pregnanc 1 physic activ group 229 control group 252 ii 1 year 127 1 year 155 figur 1 flow chart studi particip tobacco control 2010 19 488 494 doi 10.1136 tc 2009.030288 content download 137.120.4.50 wed 03 feb 2016 11 27 15 utc subject jstor term condit http www.jstor.org page info polici terms.jsp differ baselin group sex age7 marit statu educ level number cigarett smoke dai durat smoke nicotin depend weight bodi mass index weekli volum physic activ tabl 1 particip arm report high baselin confid sustain smoke cessat 7.0 visual analogu scale rang 0 10 particip randomis physic activ group 7.1 randomis control group end intervent particip arm studi report increas weekli volum moder intens vigor intens physic activ activ requir 4 met compar baselin valu 0.01 differ arm physic activ group report median 1606 met min week iqr 595 3165 control group median 1275 metsxmin week iqr 164 2236 differ group statist signific 0.04 fifti cent particip physic activ group 40 particip control group 0.12 consid sedentari end intervent spent 10 total daili energi expenditur perfor manc moder intens vigor intens physic activ requir 4 met 1 year follow weekli volum moder intens vigor intens physic activ higher baselin arm 0.01 differ physic activ arm 0.04 differ control arm higher physic activ group median 1419 met min week iqr 694 3094 control group 987 metsxmin week iqr 93 2749 0.03 group 75 particip prescrib combin nrt product 13 receiv monotherapi 12 declin nrt product quit felt confid deal withdraw symptom pharmacotherapi continu verifi smoke abstin rate high similar group end intervent 47 physic activ group versu 46 control group 0.81 rate decreas regularli period remain similar group 26 week 34 35 0 77 52 week 27 29 0.71 tabl 2 third relaps 59 physic activ group 66 control group occur week smoke cessat multipl logist regress analysi model rela tion continu verifi smoke abstin 1 year alloc physic activ group adjust ag gender educ daili cigarett consumpt baselin gave similar result compar crude analysi crude 0.93 95 ci 0.62 1.38 adjust 0.93 95 ci 0.62 1.39 generalis esti mate equat model take account 7 dai point preval abstin follow visit 10 26 52 week gave compar result respect cross section multipl logist regress model 0.92 95 ci 0.67 1.27 10 week score withdraw depress stress scale show trend amplitud direct favour physic activ group compar control group tabl 3 differ statist signific rare case skin intoler transderm patch replac oral form nrt clinic relev advers event report studi particip statist signific interact ag studi arm found multipl logist regress model interact term 0.02 split subgroup base median ag particip younger ag subgroup show higher rate continu verifi smoke abstin physic activ group control group revers observ older particip tabl 4 statist signific interact gender studi arm particip complet weight data year weight gain mean se baselin end 52 week follow 3.1 0.5 kg 127 physic activ group 3.7 0.3 kg 155 control group 0.27 mean weight gain 4.4 0.9 kg 59 6.2 0.5 kg 70 verifi sustain quitter 52 week physic activ control group respec tive 0.06 half weight gain sustain quitter 52 week occur 10 week visit 2.5 0.4 kg 2.7 0.2 kg 0.57 tabl 1 baselin characterist particip 481 physic activ group 229 control group 252 characterist ag mean sd year 42.2 10.0 42.5 9.5 0.76 men 128 56 144 57 0.78 1 marri cohabit 129 56 156 62 0.21 1 high school educ higher 86 37.6 92 36.7 0.84f previou smoke cessat attempt mean sd 2.5 2.7 2.7 3.8 0.46 year smoke mean sd 17.1 2.8 17.5 3.5 0.12 cigarett smoke dai mean sd 26.6 10.1 27.0 10.1 0.71 fagerström score mean sd 5.3 2.1 5.5 2.3 0.44 weekli volum physic activ 4 met median iqr metsxmin week 659 74 2085 694 105 1665 0.63 weight mean sd kg 73.1 16.5 71.7 13.1 0.28 bodi mass index mean sd kg m2 24.7 4.4 24.3 3.6 0.40 wisconsin smoke withdraw scale mean sd 45.2 175 16.0 42.8 178 14.3 0.15 center epidemiologi studi depress scale mean sd 11.4 180 8.1 9.0 195 7.3 0.07 4 item perceiv stress scale mean sd 4.3 186 2.6 4.2 208 2.8 0.79 side unpair test tx2 test mann whitnei rank sum test tobacco control 2010;19 488 494 doi 10.1 136 tc 2009.030288 491 content download 137.120.4.50 wed 03 feb 2016 11 27 15 utc subject jstor term condit http www.jstor.org page info polici terms.jsp tabl 2 continu verifi smoke abstin quit date week 10 26 52 physic continu smoke activ group control group abstin 229 252 10th week 107 46.7 115 45.6 0.81 26th week 78 34.1 89 35.3 0.77 52nd week 62 27.1 72 28.6 0.71 x2 test discuss particip weekli popul base programm moder intens physic activ 9 week suffi cient increas smoke cessat rate ad comprehens smoke cessat programm offer indi vidual counsel nicotin replac therapi observ high rate continu verifi smoke abstin group exceed found vareniclin arm 23 1 year recent smoke cessat trial compar efficaci vareniclin bupropion placebo smoke cessat 42 reason account high cessat rate trial smoker volun teer high expect studi se illustr high baselin confid sustain smoke cessat group import involv request candid particip studi result select highli moti vate particip studi particip posit influenc qualiti smoke cessat counsel provid group train motiv healthcar profession 26 27 ow high baselin motiv particip counsellor ceil effect limit potenti moder intens physic activ inter vention increas smoke cessat rate physic activ group report higher weekli volum physic activ control group half particip control group report increas weekli volum physic activ 9 week programm help remain abstin tendenc control particip increas physic activ practic absenc intervent dedi cate object trial studi impact intervent promot physic activ 43 45 attribut mechan previou health belief physic activ benefici smoke cessat behaviour chang induc frequent assess physic activ practic contamin studi arm social desir bia 44 increas physic activ control group reduc abil trial demonstr intervent effect partial blind studi particip research hypothesi physic activ measur reduc increas physic activ particip control group approach applic current studi incompat motiv interview principl underli behaviour interven tion 34 object measur physic activ electron devic reduc risk misclassifica tion account appar paradox increas physic activ contribut prevent cardiovascular diseas independ smoke cessat potenti particip integr programm smoke cessat increas physic activ practic regard interest find 15 marcu al conduct smoke cessat trial respect vigor intens moder intens physic activ part intervent femal smoker 13 16 vigor intens physic activ intervent effect increas smoke cessat 13 moder intens trial particip achiev 110 minut week moder intens physic activ abstain smoke end treatment achiev amount physic activ 16 recent trial suggest physic activ session vigor intens higher frequenc longer durat propos studi facilit smoke cessat 17 46 47 ag interact found trial invit futur research ag potenti moder physic activ intervent test explanatori mechan lower complianc physic activ intervent lower abil address behaviour time older individu futur trial benefit physic activ smoke cessat aim understand char acterist physic activ type activ intens durat frequenc isometr versu aerob exercis context practic relev shape dose respons relat 48 49 secondari outcom found signifi trend favour physic activ group smaller weight gain reduc withdraw symptom ow high exclus rate screen smoker includ fewer particip origin plan sampl size calcula tion 300 arm studi respons type ii error fals neg potenti physic activ clinic relev effect weight gain smoke cessat find call addit investig studi limit exclud randomis particip major protocol violat acknowledg holli campbel contribut paper consort statement exclus particip fals enrol randomis control trial justifi strict condit 50 51 cardin condit reascer tainment entri criteria appli ident group assess impact exclus find tabl 3 wisconsin smoke withdraw scale center epidemiologi studi ce depress scale 4 item perceiv stress scale score baselin week 1 0 smoke cessat intervent physic activ group control group mean sd ño mean sd ño wisconsin smoke withdraw scale score chang 3.9 16.7 88 1.5 16.7 85 0.36 ce depress scale score chang 2.0 7.9 87 0.1 7.9 96 0.08 4 item perceiv stress scale score chang 1.3 2.7 115 1.0 3.2 127 0.43 note neg score time correspond improv symptom side unpair test 492 tobacco control 2010;19 488 494 doi 10.1136 tc 2009.030288 content download 137.120.4.50 wed 03 feb 2016 11 27 15 utc subject jstor term condit http www.jstor.org page info polici terms.jsp tabl 4 continu verifi smoke abstin quit date week 52 ag group continu smoke abstin 52nd week physic activ group control group ag 42 year 40 118 33.9 32 126 25.4 0.15 ag 42 year 22 111 19.8 40 126 31.7 0.04 x2 test duplic analys includ randomis partici pant estim studi outcom remain ident sensit analysi data physic activ practic base report object measur physic activ strengthen assess actual dose7 physic activity52 physic activ frequenc questionnair valid heart rate monitor acceleromet record sociodemograph compar popul sampl switzerland 21 36 complianc compon physic activ programm assess indirectli weekli volum physic activ chang health behaviour simultan physic activ group hamper success rate 8 relev chang multipl health behaviour simultan que tion 14 53 call research field final investig conduct follow assess blind particip alloc 35 smoke absti nenc confirm object biochem test limit potenti inform bia conclud particip popul base moder intens physic activ programm provid increment benefit smoke cessat rate 1 year follow sedentari smoker ad comprehens evid base smoke cessat intervent offer indi vidual counsel nrt product acknowledg author full access data studi respons integr data accuraci data analysi nanci rigotti michael ussher advic studi design fund trial support grant swiss nation scienc foundat snsf 3200 067085 funder swiss nation scienc foundat compet interest ethic approv research protocol approv 15 januari 2002 lausann medic school ethic committe contributor author particip suffici work fulfil criteria authorship public respons portion content fulfil criteria includ author proven peer review commiss extern peer review
blebil al bmc public health 2014 14 460 http www.biomedcentral.com 1471 2458 14 460 research articl open access impact addit counsel session phone call smoke cessat outcom smoker penang state malaysia ali qai blebil1,2 sy azhar sy sulaiman1 moham azmi hassali3 juman abdulelah dujaili1 alfian moham zin4 abstract background studi world report smoke relaps occur week quit date current studi aim assess impact addit phone call counsel month abstin rate 3 6 month quit date smoker penang malaysia method studi conduct quit smoke clinic major hospit penang malaysia elig smoker attend clinic februari 1st octob 31st 2012 invit particip randomli assign urn design method receiv usual care clinic control usual care procedur extra counsel session phone call month quit attempt intervent result particip cohort smoke 14 cigarett dai averag mean 13.78 7.0 3 month control group quit smoke compar intervent group 36.9 46.7 verifi smoke statu reach statist signific 0.669 95 ci 0.395 1.133 0.86 6 month 71.7 intervent group successfulli quit smoke bio chemic verifi compar 48.6 control group 0.001 control group significantli quit smoke 0.375 95 ci 0.217 0.645 0.001 conclus smoke cessat intervent consist phone call counsel deliv month quit attempt reveal significantli higher abstin rate compar standard care approach addit counsel week stop smoke promis treatment strategi evalu trial registr tctr20140504001 keyword load counsel smoke cessat malaysia background specif method techniqu confirm improv abstin rate smoke numer studi find effect feasibl method assist port smoker quit smoke malaysia correspond aliblebil yahoo.com 1disciplin clinic pharmaci school pharmaceut scienc univers sain malaysia 11800 penang malaysia 2depart clinic pharmaci faculti pharmaceut scienc ucsi univers jalan menara gade ucsi height 56000 kuala lumpur malaysia full list author inform end articl 2014 blebil al license biom central common attribut licens http creativec reproduct medium provid dedic waiver http creativecommons.or state major 80.3 tobacco user stop smok ing assist 9 pharmacotherapi counsel 4.4 quit line 7.6 tradit medicin switch smokeless tobacco 1 studi report 70 tobacco user quit smoke cigarett relaps week quit date 2 4 initi week consid window period prior achiev long term abstin critic era curv relaps treatment con trol group intervent studi parallel 5 7 td open access articl distribut term creativ ommons.org licens 2.0 permit unrestrict distribut igin work properli credit creativ common public domain publicdomain 1.0 appli data made articl http www.clinicaltrials.in.th index.php tp regtrial menu trialsearch smenu fulltext task search task2 view1 id 1068 mailto:aliblebil yahoo.com http creativecommons.org licens 2.0 http creativecommons.org publicdomain 1.0 figur 1 schemat present studi design blebil al bmc public health 2014 14 460 page 2 9 http www.biomedcentral.com 1471 2458 14 460 prevent relaps week enhanc probabl success long term abstin 8 major smoker prefer ceas tobacco product avoid attend counsel session group programm person person contact 9 11 counsel phone call paid tention altern deliveri servic 12 15 numer potenti benefit smok ing cessat telephon counsel includ eas requir tobacco user locat cost effect deliveri scalabl larg number peopl locat abil tailor messag kei user characterist ag sex ethnic provid content distract smoker crave link smoker social support 16 order provid comfort feasibl intervent assess addit counsel session month quit date interest evalu effect type counsel telephon call result explor assess benefit load coun sell session telephon call support peopl quit compar method usual provis malaysian health care set gard abstin rate method set particip studi carri quit smoke clinic major hospit penang state pulau pinang seberang jaya hospit elig cigarett smoker attend clinic februari 1st octo ber 31st 2012 invit inclus exclus criteria individu attend clinic period review invit particip search inclus criteria involv 1 regist smoker attend quit smoke clinic walk refer outpati clinic hospit refer primari clinic 2 male femal ag 18 year 3 stop smoke addit outpati clinic hospit contact refer smoker patient stop smoke quit smoke clinic exclus criteria consist 1 patient refer quit smoke clinic 2 recent month histori cardiac arrhythmia angina pectori myocardi infarct medic condit research view particip commit studi 3 nrt smoke cessat treatment bupropion vareniclin 12 month studi enrol 4 tobacco prod uct cigarett 5 pregnant lactat intend pregnant 6 psychoact drug 7 su pect drug alcohol abus 8 patient continu bui nicotin gum 2 week treatment normal polici hospit patient suppli free nicotin gum 2 week patient continu nrt bui studi design particip randomli assign urn design receiv usual care combin nicotin gum cognit behaviour therapi control group previou combin extra counsel se sion phone call month quit attempt intervent group figur 1 pur pose requir adher studi protocol explain particip sign consent obtain particip expert counsellor expert counsellor quit smoke clinic hospit specialist deliv smoke ce sation servic charg provid counsel support part nation health ser vice accept cooper present studi blebil al bmc public health 2014 14 460 page 3 9 http www.biomedcentral.com 1471 2458 14 460 sampl size minimum sampl size 123 subject group power detect differ 11 intervent group control group allow 20 dropout final sampl size 148 subject arm base data studi ron borland al compar effect telephon call back counsel intervent provis resourc quit smoke 17 total target sampl size 296 subject randomis select method randomis patient treatment group import statist sue compar trial target sampl size current trial determin actual number particip recruit trial advanc urn design randomis abil impos small trial balanc act complet ran domis size trial increas cons quentli assign treatment sequenc creat urn design predict type restrict randomis process suscept bia likewis reduc 18 procedur assess elig particip randomis alloc specif group particip baselin visit interview expert counsellor counsellor interview intens counsel approach 20 30 mi nute studi particip ask socio demograph ag sex race marit statu educa tion level medic background smoke relat inform histori ag start smoke number ciga rett smoke dai previou quit attempt level nicotin depend malai version fager strom test nicotin depend ftnd 19 confid quit report efficaci i. rate chanc stop smoke perman entli current attempt 5 point likert scale high high neutral low low exhal carbon monoxid level higher intens counsel refer intervent involv extend contact patient clinician 10 mi nute 20,21 exhal level measur smokerlyz microco meter micro medic limit compani concentr breath measur cut point level 7 part million ppm indic smoke smoker learnt neg effect smok ing effect health posit effect stop addit particip receiv free nicotin gum supplement 2 week gener regul polici min istri health malaysia learnt nrt gain knowledg smoke withdraw symptom control withdraw symptom crave cigarett smoke week quit smoker receiv materi form brochur booklet stop smok ing malai chines languag view learnt counsellor materi develop publish health educ divis ministri health malaysia report harm effect health cons quenc smoke addit booklet displai object quit smoke clinic clude clinic process achiev goal activ particip randomis control group receiv usual care recommend ministri health malaysia malaysian clin ical practic guidelin treatment tobacco depend counsellor conduct individu coun sell smoker quit provid support advic materi 22 figur 1 counsel session 20 30 minut counsellor emphasis review problem solv train procedur particip support quit 22 usual care group month studi particip attend quit smoke clinic time gap week tween visit month particip ask attend clinic week total 2 visit month receiv extra phone call week visit total 2 phone call month month partici pant receiv phone call ask attend clinic end month intervent group smoker receiv care procedur receiv extra proactiv phone call week attend clinic month i. visit extra phone call procedur month control group extra phone call counsel session counsellor encourag smoker endur tempt quit concentr success provid inform harm effect smoke provid posit feedback empha sise benefit stop smoke encourag par ticip ceas usag cigarett lighter ashtrai avoid environ smoke counsellor prompt blebil al bmc public health 2014 14 460 page 4 9 http www.biomedcentral.com 1471 2458 14 460 smoker identifi obstacl difficulti stop smoke strategi overcom counsellor talk 10 15 minut par ticip proactiv extra phone call main object studi determin report point preval abstin previou 4 week verifi exhal level 3 6 month follow point end month bacco user ask smoke statu ask attend quit smoke clinic 3 month 6 month baselin visit assess smoke statu 4 week point preval abstin particip chose attend visit end month visit end sixth month consid smoker point end month 7 particip control group 3 par ticip intervent lost follow 6 month follow point 13 control group 5 intervent group lost outcom data collect research member connect counsel data analysi statist analysi collect data analys spss version 18.0 spss chicago il level signific set 0.05 descript statist displai baselin characterist sam ple popul includ socio demograph smoke relat inform continu variabl shown mean standard deviat fre quenci proport order describ categor variabl compar demo graphic smoke relat inform control group intervent group assess independ sampl test mann whitnei test continu variabl pearson chi squar χ2 fisher exact test categor variabl smoke cessat outcom compar intervent group control group mann whitnei test fisher exact test sixth month nonparametr statist test perform compar smoke abstin rate 4 week point preval abstin group 3 6 month follow point addit binari logist regress emploi pre dict impact extra phone call integr intervent smoke cessat outcom effect addit counsel month quit attempt compar usual care preval smoke abstin assess odd ratio binari logist regress control effect confound ethic approv present studi approv institut public health iph nation institut health nih medic research ethic committe mrec ministri health malaysia result baselin characterist studi particip 283 subject identifi februari 1st octob 31st 2012 231 smoker accept par ticip studi recruit procedur prematur stop time financi striction involv clinic larg project organis ministri health malaysia 231 particip 111 48.1 smoker ran domli assign usual care group rest 120 smoker alloc intervent group mean ag standard deviat sd particip time enrol studi 48.26 13.7 year rang 18 77 year tabl 1 major cohort chines 114 231 vast major studi particip male 96.1 67.5 marri addit 67.5 ject refer outpati clinic hospit major studi partic ipant low level educ 90 fin ish primari secondari school hundr twenti 95.7 studi par ticip histori chronic diseas hyper tension diabet mellitu asthma heart diseas highest frequenc comorbid hypertens 98 patient diabet mellitu dyslipidaemia 66 patient mean ag start smoke studi popula tion 17.38 3.9 year rang 8 35 year tobacco user smoke 14 cigarett dai aver ag mean 13.78 7.0 rang 3 50 cigarett dai addit mean ftnd score 3.79 1.2 consid low addict score rang ftnd major studi particip quit smoke past 87.9 signific differ tween control intervent group baselin socio demograph smoke histori data tabl 2 group type control versu intervent group significantli particip categori 0.025 i. walk refer outpati clinic hospit refer primari clinic major subject group refer patient clinic hospit baselin differ group control subsequ analys tabl 1 demograph smoke relat characterist tobacco user 231 quit smoke clinic penang malaysia characterist particip categori refer hospit clinic 70 30.3 refer outpati clinic 156 67.5 walk 5 2.2 ag mean sd year 48.26 13.7 weight mean sd kg 62.09 8.4 sex femal 9 3.9 male 222 96.1 race malai 88 38.1 chines 114 49.4 indian 29 12.5 marit statu singl 42 18.2 divorc widow 33 14.3 marri 156 67.5 educ statu primari 109 47.1 secondari 100 43.2 collag univers 21 9.1 formal educ 1 0.6 smoke habit histori ag start smoke mean sd 17.38 3.9 durat smoke mean sd 31.03 13.7 cigarett smoke dai mean sd 13.78 7.0 breath level ppm mean sd 14.45 4.9 ftnd score mean sd 3.79 1.2 previou smoke attempt 203 87.9 28 12.1 smoker household 150 64.9 81 35.1 note sd standard deviat carbon monoxid ppm part million ftnd fagerström test nicotin depend blebil al bmc public health 2014 14 460 page 5 9 http www.biomedcentral.com 1471 2458 14 460 smoke cessat intervent outcom monitor particip monitor follow visit sixth month smoke statu 4 week point preval abstin exhal level marker verifi quit number cigarett smoke dai case particip smoke smoke cessat outcom compar tween studi group present tabl 3 month follow visit quit date particip receiv addit counsel moth significantli higher rate success quit smoke compar ceiv usual care depend report 4 week point preval abstin 57.5 44.1 0.049 smoke statu particip verif exhal level significantli differ studi group addit 6 month quit date report 4 week point preval significantli higher intervent group compar con trol group 74.2 51.4 0.001 simi larli verifi smoke statu significantli usual care combin usual care extra phone call 48.6 71.7 0.001 risk estim integr intervent smoke cessat outcom month follow point particip usual care group quit smoke reach statist signific 0.669 95 ci 0.395 1.133 0.86 tabl 4 addit intervent cohort group 1.209 time quit smoke compar control group 95 ci 0.945 1.545 similarli month control group 0.375 time quit smoke 95 ci 0.217 0.645 0.001 control effect confound partici pant categori binari logist regress usual care group report smoke 3 6 month follow point 3 month result fail reach statist signific adjust 0.732 0.255 discuss demograph characterist studi particip tobacco user current studi predomin antli male 96.1 reflect previous report statist nhm iii cigarett smoke tremend rare malaysian femal 23 fur thermor report global adult tobacco survei gat malaysia report 22.9 individu ag 15 year older 43.6 male 1 femal current smoker cigarett includ manufac ture hand roll kretek 1 numer studi port cigarett smoke remain accept male smoke women social sanction malaysia asian countri gener 24 26 suggest quit femal smoker reveal truth smoke statu studi domin men major studi particip histori chronic diseas hypertens diabet mellitu tabl 2 demograph smoke relat characterist control versu intervent group characterist group type valuea control intervent 111 120 particip categori 0.025 refer hospit clinic 40 36.0 30 25.0 refer outpati clinic 71 64.0 85 70.8 walk 0 0 5 4.2 ag mean sd year 48.30 13.6 48.22 13.8 0.964b weight mean sd kg 62.77 6.6 61.46 9.8 0.499c sex 0.502d femal 3 2.7 6 5.0 male 108 97.3 114 95.0 race 0.063 malai 49 44.1 39 32.5 chines 53 47.7 61 50.8 indian 9 8.1 20 16.7 marit statu 0.086 singl 22 19.8 20 16.7 divorc widow 10 9.0 23 19.2 marri 79 71.2 77 64.2 educ statu 0.718 primari 54 48.6 55 45.8 secondari 46 41.4 54 45.0 collag univers 11 9.9 10 8.3 formal educ 0 0 1 0.8 chronic diseas 0.519 6 5.4 4 3.3 105 94.6 116 96.7 smoke habit histori cigarett smoke dai 14.54 7.6 13.08 6.3 0.111c ag start smoke 17.52 4.07 17.24 3.8 0.931c durat smoke 31.09 13.5 30.97 13.9 0.946b breath level 14.93 5.2 14.00 4.4 0.300c ftnd score 3.88 1.2 3.71 1 0.323c smoker household 0.214d 77 69.4 73 60.8 34 30.6 47 39.2 previou smoke attempt 0.105d 102 91.9 101 84.2 9 8.1 19 15.8 chanc rate quit 0.916 high 0 0 0 0 high 28 25.2 33 27.5 tabl 2 demograph smoke relat characterist control versu intervent group continu neutral 67 60.4 71 59.2 low 16 14.4 16 13.3 low 0 0 0 0 achi squar χ2 test bindepend sampl test cmann whitnei test dfisher exact test blebil al bmc public health 2014 14 460 page 6 9 http www.biomedcentral.com 1471 2458 14 460 support gener thought major tobacco user intend stop smoke en counter medic health problem 2011 gat malaysia report popula tion current smoker smoker abstin year visit health care provid 68 ask health care provid smoke 53 recommend stop smoke clinician 1 attent extra effort focus increas health awar program smoke risk smoke healthi individu major particip refer outpati clinic clinic surprisingli tuber culosi patient refer quit smoke clinic data collect current studi tabl 3 smoke cessat outcom control versu intervent condit outcom group type valuea control intervent 111 120 month monitor report 4 week point preval abstin 0.049 49 44.1 69 57.5 62 55.9 51 42.5 breath level 7.75 3.9 7.24 3.6 0.334b smoke statu verifi 0.144 smoker 41 36.9 56 46.7 smoker 70 63.1 64 53.3 sixth month monitor report 4 week point preval abstin 0.001 57 51.4 89 74.2 54 48.6 31 25.8 breath level 7.12 4.3 5.73 3.5 0.005b smoke statu verifi 0.001 smoker 54 48.6 86 71.7 smoker 57 51.4 34 28.3 afish exact test bmann whitnei test tabl 4 risk estim quit smoke group type 3 6 month follow point outcom group type 95 ci control intervent 111 120 3 month smoke statu 0.669a 0.395 1.133 0.86 smoker 41 36.9 56 46.7 smoker 70 63.1 64 53.3 smoke statu 0.732b 0.420 1.512 0.26 smoker 41 36.9 56 46.7 smoker 70 63.1 64 53.3 6 month smoke statu 0.375a 0.217 0.645 0.001 smoker 54 48.6 86 71.7 smoker 57 51.4 34 28.3 smoke statu 0.376b 0.224 0.671 0.001 smoker 54 48.6 86 71.7 smoker 57 51.4 34 28.3 note odd ratio ci confid interv acrud odd ratio badjust odd ratio particip categori blebil al bmc public health 2014 14 460 page 7 9 http www.biomedcentral.com 1471 2458 14 460 local studi report smoke preval tu berculosi patient high rang 40.3 53.4 state penang malaysia 27,28 smoke independ com.ibm.drl.hbcp.predictor poor tuberculosi treatment outcom prognosi 28 integr tobacco cessat intervent tuberculosi care confer advantag outcom tuberculosi treatment 29 attent group patient effect integr intervent smoke cessat outcom find current studi demonstr report point preval abstin intervent arm significantli higher control arm 3 6 month biochem verifi ab stinenc rate particip experienc load counsel phone call higher subject intervent group 74.2 versu 51.4 statist signific end 6 month quit date 0.001 believ object iviti biochem measur provid gold standard perfect accuraci assess smoke statu 30 smoke product short half life bodi biochem assess smoke statu smokerlyz verifi time specimen collect i. 24 48 hour 31 particip didn’t pass biochem assess end 3 6 month consid smoker suggest smoke valid chemic bio marker result evalu conform report accuraci addit subject intervent group abstin verifi 4 week point preval abstin end month statist signific end 6 month 1.644 95 ci 1.222 2.212 find suggest intens counsel dur ing critic period quit attempt i. month benefici impact long term similarli studi conduct unit state peopl live hiv aid rando mise usual smoke cessat treatment cell phone intervent intervent group phone call span period 3 month front load major phone call time schedul quit date end month patient intervent group 4.3 95 ci 1.9 9.8 time quit smoke 7 dai point preval abstin compar usual care particip 32 studi compar efficaci front load versu weekli haviour smoke cessat counsel schedul increas likelihood success earli abstin subsequ long term abstin 278 adult tobacco user 33 end 12 month post quit intervent particip blebil al bmc public health 2014 14 460 page 8 9 http www.biomedcentral.com 1471 2458 14 460 abstin compar particip weekli counsel schedul regard continu abstin 7 consecut dai 7 consecut episod point preval abstin enc signific continu abstin 11.7 6.3 0.007 33 studi report strength motiv quit smoke depend predict success abstin 34 rais possibl countri malaysia earlier stage tobacco epidem 35 motiv plai vital role success quit depend hap pen larg number tobacco user find easi quit potenti limit current studi rela tive small sampl size suppos target sampl size 296 subject collect sampl size 231 subject urn design ran domis problem resolv ensur ran domis group limit 96 recruit particip male fore generaliz result counter part femal compromis appli singl biomark verif smoke statu result misclassif analyt method involv biomark cotinin plasma saliva urin thiocyan plasma saliva expir air distinguish object tween smoker smoker recommend 36 collect sampl involv contact particip usual field studi result creas refus 37 due financi restrict exhal level biochem assess ment research demonstr spous impact behaviour smoke rate malaysian women low major cohort male affect decis quit smoke male spous extern factor influenc subject decis quit smoke increa ing cost live price good includ cigarett factor contribut differ observ abstin rate 3rd 6th month follow period fulli stand effect factor current data conclus summari smoke cessat intervent consist extra session phone call counsel month quit attempt result significantli higher ab stinenc rate compar standard care approach result current studi encourag 12 month outcom analys need evalu effect kind load approach long term studi evid addit counsel week quit date promis treatment strategi evalu compet interest author declar compet interest author contribut aqb contribut design studi wrote draft amz contribut collect outcom measur data aqb jad contribut data analysi review manuscript sass mah review manuscript sass supervis write contribut discuss author read approv final manuscript acknowledg author grate staff quit smoke clinic pulau pinang seberang jaya hospit support cooper data collect period studi author detail 1disciplin clinic pharmaci school pharmaceut scienc univers sain malaysia 11800 penang malaysia 2depart clinic pharmaci faculti pharmaceut scienc ucsi univers jalan menara gade ucsi height 56000 kuala lumpur malaysia 3disciplin social administr pharmaci school pharmaceut scienc univers sain malaysia 11800 penang malaysia 4quit smoke clinic penang gener hospit jalan residensi 10990 penang malaysia receiv 2 decemb 2013 accept 12 2014 publish 16 2014
author 2013 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com doi 10.1093 ntr ntt166 origin investig tobacco cessat low incom smoker motiv enhanc nicotin patch treatment beth bock phd1 georg papandonato phd2 marcel de dio phd3 david abram phd4 munawar azam md5 mark fagan md5 patrick sweenei md phd6 michael stein md2,5 raymond niaura phd4 1depart psychiatri human behavior alpert medic school brown univers provid ri 2center statist scienc brown univers provid ri 3depart health dispar research divis cancer prevent popul scienc univers texa md anderson cancer houston tx 4schroeder institut tobacco research polici studi american legaci foundat washington dc 5depart medicin alpert medic school brown univers provid ri 6depart obstetr gynecolog alpert medic school brown univers provid ri author beth bock phd center behavior prevent medicin miriam hospit 164 summit avenu provid ri 02906 usa telephon 401 793 8020 fax 401 793 8059 mail beth_bock brown.edu receiv march 14 2013 accept septemb 10 2013 abstract introduct decad tobacco declin gener popul unit state tobacco low incom popul continu major public health concern smoke rate higher individu high school educ health insur individu live feder poverti level dispar smoke cessat treatment low incom popul extens test cur rent studi efficaci 2 adjunct smoke cessat intervent evalu low incom smoker primari care set method total 846 particip randomli assign motiv enhanc treatment physician advic 8 week nicotin replac therapi nrt standard care consist physician advic 8 week nrt tobacco smoke abstin 1 2 6 12 month baselin result nicotin patch telephon counsel posit decision balanc predict increas abstin rate elev stress level temptat smoke social habit neg affect situat decreas abstin rate time analys show intervent effect smoke temptat length patch number telephon contact direct intervent effect abstin rate signific adjust model com.ibm.drl.hbcp.predictor select bia due perirandom attrit conclus integr therapeut approach promot adher medic quit smoke target stress manag reduc neg affect enhanc smoke cessat low incom smoker background tobacco approxim 438,000 death annual lead prevent morbid mortal health expens unit state cdc 2012 declin tobacco slow recent year declin ing 20.9 2005 19.3 2010 meet healthi peopl 2010 object reduc cigarett smoke adult 12 cdc 2011a broad gap socioeconom statu se group respect tobacco smoke preval remain highest high school educ 28.4 health insur 28.6 live feder poverti level 27.7 cdc 2011a 2011b 2012 respons dispar public polici effort made increas state medicaid insur coverag evid base tobacco cessat treatment cdc 2008 2009 46 state district columbia offer insur anc coverag tobacco cessat treatment medicaid recipi cdc 2010 degre coverag servic vari wide typic underutil coat al 2012 intervent deliv health care set physician potenti reach wide rang smoker 70 smoker physi cian year goldstein al 1998 wadland stoffelmayr iv 2001 intervent combin behavior intervent effect pharmacolog agent nicotin replac therapi nrt address advanc access public octob 30 2013 nicotin tobacco research volum 16 number 4 april 2014 413 422 413 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload mailto:beth_bock brown.edu subject http ntr.oxfordjournals.org cessat low se smoker exist medic condit lifestyl relat factor wadland al 2001 physician deliv smoke cessat intervent effect significantli increas smoke abstin rate aveyard begh parson west 2012 20 smoker report receiv smoke cessat assist physician ferketich khan wewer 2006 barrier report physician lack motiv quit smoke patient fact 60 smoker report desir quit unwil make quit attempt 6 month motiv lowest low se group reid hammond boudreau fong siahpush 2010 smit fidler west 2011 motiv enhanc intervent shown moder effect substanc abus relat treatment smedslund al 2011 meta analyt review found intervent smoke cessat effect heckman egleston hofmann 2010 hettema hendrick 2010 result vari wide depend popul studi persson hjalmarson 2006 found significantli higher quit rate 12 month follow diabet smok er primari care set inter vention compar physician advic similarli smoker bupropion abstin 6 12 month follow up compar bupropion physician advic soria legido escolano lópez yest montoya 2006 pregnant smoker young parent evi denc effect intervent lumlei al 2009 empir support smoke ce sation intervent psychiatr popul baker al 2006 substanc user haug sviki diclement 2004 stein al 2006 gener sampl primari care hospit patient heckman al 2010 estab lish date limit number studi specif focus test smoke cessat intervent low se smoker okuyemi al 2007 2013 identifi deliv treatment low incom popul primari health care center current studi test rel efficaci adjunct intervent low se smoker uninsur medicaid primari care set inter vention consist 8 week prescript nicotin patch combin physician advic educ patch follow telephon call health educ standard treatment intervent consist 8 week prescript nicotin patch physician advic intervent deliv counsel session includ behavior skill train hypothes intervent increas cessat rate compar standard treatment condit method adult smoker recruit routin health care visit hospit base primari care clinic locat separ citi hospit southern england elig studi patient 18 year ag current regular smoker 10 cigarett dai past 3 month speak english spanish uninsur medicaid recipi follow particip agre quit smoke enrol individu exclud medic condit preclud nicotin patch e.g unstabl angina uncon troll hypertens psoriasi smoke tobacco nrt smoke cessat treatment pregnant nurs maxim enrol smoker divers level readi quit smoke proactiv recruit strategi emploi smoker identifi clinic person nel registr check physician visit invit particip studi smoke pat tern smoke cessat recruit procedur empha size patient quit smoke interest quit smoke enrol studi research assist ra screen interest individu eligibil iti administ inform consent procedur approv miriam hospit institut review board immedi provid consent enrol particip 846 complet baselin survei laptop comput complet question item comput random number program assign particip random treatment condit standard care sc sc intervent design provid smoke cessat assist guidelin current practic standard care fior hatsukami baker 2002 hour train session held prior begin recruit ment attend resid physician fellow intern train session provid introduct studi purpos procedur educ materi al smoke cessat treatment guidelin agenc health care polici research ahcpr clinician guid train appli assess advis assist arrang follow studi protocol requir physician implement point model patient enrol studi arrang follow handl studi health educ part intervent protocol sc subject ask smoke statu assess nicotin depend advis quit smoke physician offer assist quit nicotin patch pamphlet referr ri state quit line smoker interest quit particip condit receiv compon sc intervent 45 min individu counsel session studi health educ smoke cessat spe cialist fluent english spanish counsel se sion motiv interview mi techniqu miller rollnick 1991 particip readi quit se sion includ behavior skill train smoke cessa tion particip intervent arm decid quit baselin visit follow telephon counsel call quit dai call 2 week choos quit call 2 4 week follow counsel content call focus review topic discuss person counsel session particip thought quit smoke reevalu readi quit particip elect quit smoke set quit date person counsel session follow telephon call 414 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research provid nicotin patch behavior skill train addit follow phone call quit date 2 week protocol particip chosen quit baselin visit content follow call elect quit review pro gress current quit attempt provid posit reinforc effort sustain quit problem solv barrier issu aris quit interventionist train supervis licens clinic psychologist ongo fidel monitor select session observ weekli clinic supervis counsel session tape record 20 tape select random review studi intervent coordin phd psychologist certifi mi number durat counsel call log studi counselor includ anali se regular weekli meet conduct review intervent procedur result counsel tape audit enhanc treatment fidel particip assess baselin follow assess 1 2 6 12 month baselin studi ra made minimum attempt reach particip telephon conduct follow assess respond phone call mail remind letter addit attempt made week measur particip complet questionnair assess sociod mograph inform smoke histori psycholog cal variabl assess instrument consent form manual studi materi english spanish achiev linguist conceptu equival spanish english ver sion assess instrument back translat method becerra shaw 1988 english languag instru ment translat spanish bilingu staff member translat back english bilingu staff member origin english instrument discrep mean english version clarifi remov modif made nece sari english spanish version arriv equival ethnic accultur addit standard demograph question assess ag gender marit statu educ level particip ask identifi ethnic group born unit state degre lan guag fluenci languag fluenci assess singl question particip describ spoke english spanish 5 point scale english english bet ter spanish languag equal spanish english spanish prior research hispan white popul shown languag fluenci highli correl extens measur accultur kaplan nápole springer stewart pérez stabl 2001 indic accultur larg scale epidemiolog studi e.g kerner breen tefft silsbi 1998 languag fluenci separ hispan subject accultur group 138 exclus primarili spanish speak highli accultur group 60 fluent english highli accultur hispan smoke variabl nicotin depend assess fagerström test nicotin depend ftnd heatherton kozlowski frecker fagerström 1991 report tobacco previou 7 dai assess timelin followback tlfb sobel sobel 1992 tlfb calendar base interview ask particip recal frequenc stanc tlfb extens assess varieti substanc health behavior sobel sobel 1992 tlfb report tobacco abstin confirm expir carbon monoxid test bedfont microsmokerlyz machin 5 ppm cutoff indic posit smoke result benowitz bernert caraballo holidai wang 2009 nicotin patch measur follow point interview particip studi provid patch previou contact particip purchas quit smoke medic includ nrt provid studi motiv quit smoke assess contempl ladder biener abram 1991 perceiv benefit barrier smoke cessat assess smoke decision balanc scale short form item measur perceiv benefit posit decision balanc perceiv barrier neg decision balanc smok ing pro con subscal high intern consist enci α 0.88 0.89 velic diclement rossi prochaska 1990 efficaci smoke cessat assess item short form smoke temptat questionnair velic diclement prochaska brandenburg 1985 demonstr good valid intern consist α 0.80 0.90 includ subscal assess temptat smoke prompt social mood habit cue base factor analysi data hand emploi item subscal measur tempta tion smoke neg affect situat α 0.80 item subscal measur temptat smoke social habit situat α 0.84 perceiv vulner smok ing relat ill assess sum item particip thought symptom ill ness caus made wors smoke rate health rel nonsmok ag 1 wors 5 extent health affect smoke 1 5 believ quit smoke improv health 1 5 depress symptom assess 20 item center epidemiolog studi depress scale demonstr good reliabl valid radloff 1977 english spanish item perceiv stress scale cohen kamarck mermelstein 1983 assess degre particip perceiv environ experi stress scale correl score life event measur demonstr adequ reliabl stress implic problem quit smoke cohen lichtenstein 1990 415 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org cessat low se smoker analyt plan primari outcom biochem verifi 7 dai point preval abstin p.p.a follow point 1 2 6 12 month primarili interest differ 7 dai ppa rate studi condit sc adjust studi dropout tail α 0.05 80 power estim 6 versu 12 abstin rate minim intervent motiva tional intervent base 360 subject cell 6 month follow 15 project attrit rate translat 423 subject arm baselin gener estim equat gee model liang al 2002 account repeat measur aspect studi robust se base work ing independ correl matrix calcul proc genmod sa stat 9.2 sa institut 2010 correct naiv se produc logist regress gee model tend sensit attrit bia requir miss ing follow complet random mcar nomenclatur rubin 1987 minim bia studi particip group strata accord ing follow visit intermitt missing assum mcar separ model fit group result subsequ combin pattern mixtur methodolog park lee 1999 complic aros presenc periran domiz attrit refus follow follow assess intervent point project successfulli complet baselin assess random studi arm contrast po trandom attrit tradit notion studi dropout follow assess treatment par ticip studi particip contribut follow observ accommod distinct group pattern mixtur model induc select bia dealt stage instrument variabl iv techniqu popular econometr literatur heckman 1979 requir hazard perirand omiz attrit estim logist regress techniqu appli baselin data covari de bia regress coeffici outcom model leigh ward fri 1993 select hazard invers mill ratio deriv ratio probabl densiti survivor function logit link equal select probabl simplifi interpret result model choic note provid parsimoni descript perirandom attrit primari studi goal chose retain selec tion model com.ibm.drl.hbcp.predictor stringent signific level customari 5 d’agostino 1998 hand impetu fit comprehens model tem pere fact covari missing limit number subject select hazard estim reduc effect sampl size analyz pri mari outcom stage iv approach adjust se outcom model fact select hazard estim error cross section procedur inflat se stata 13.0 statacorp 2013 extens longitudin data implement iv approach simul subject base line data subject specif select hazard simul 10,000 time joint sampl distribut enter covari outcom model result ci gee regress coeffici center simul averag length reflect simul variabl converg monitor correct decim place log odd ratio scale result particip characterist summar tabl 1 sampl 68.7 581 femal mean ag 39.6 sd 11.4 racial ethnic divers substanti 52.8 447 particip identifi white european american 23.4 198 identifi latino hispan 13.1 111 african american 10.6 90 identifi racial ethnic background major particip unemploi 75.9 204 41.4 350 singl marri 27.7 234 divorc separ dropout miss data particip random 406 sc 440 arm studi dropout rate studi visit attend shown tabl 2 consort diagram figur 1 appear 16 subject studi arm 66 sc 71 drop immedi baselin visit cumul dropout month 12 reach 58.6 sc 238 52.7 232 result highlight perirandom postrandom attrit account model abstin rate tabl 1 demograph characterist 846 variabl gender male 264 31.2 femal 581 68.7 ethnic european american 447 52.8 hispan latino 198 23.4 african american 111 13.1 90 10.6 ag sd 39.6 11.4 employ statu unemploi 642 75.9 emploi 204 24.1 marit statu singl 350 41.4 divorc separ 234 27.7 marri 160 18.9 live partner 59 7 widow 42 5 condit motiv 440 52 standard care 406 48 416 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research logist regress analys racial ethnic back ground treatment site motiv readi quit smoke size composit household marit emploi ment statu temptat smoke neg affect situat previou nrt potenti signific predic tor perirandom attrit studi arm sc includ default fail attain statist signific final select model shown tabl 3 covari tabl 2 abstin rate time dropout pattern studi arm studi arm visit attend abstin rate 1 month 2 month 6 month 12 month sc 440 baselin 71 16.1 1 month 30 6.8 40 2 month 68 15.5 38 33 6 month 63 14.3 37 37 20 12 month 208 47.3 39 40 30 28 406 baselin 66 16.3 1 month 38 9.4 37 2 month 60 14.8 35 32 6 month 74 18.2 42 37 24 12 month 168 41.4 38 45 33 29 note valu ital show studi complet motiv enhanc sc standard care 1,001 particip screen 155 exclus 83 longer interest 36 unabl schedul appoint 12 nonsmok 24 transport follow up 846 random 440 assign standard care sc intervent group 406 assign motiv enhanc group 302 68.6 complet 1 month follow 282 64.1 complet 2 month follow 222 50.5 complet 6 month follow 276 68.0 complet 1 month follow 251 61.8 complet 2 month follow 204 50.2 complet 6 month follow 168 41.4 complet 12 month follow 208 47.3 complet 12 month follow figur 1 consort diagram particip flow 417 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org cessat low se smoker standard baselin odd perirandom attrit odd ratio 1 10 95 ci 1 20 1 5 appli refer group white particip sc recruit miriam hospit full time part time employ widow hous hold median size compris adult singl child plan quit 30 dai neg affect score equal sampl median previous nicotin patch neg affect scale regress coeffici captur effect increas sampl median 3rd quartil smoke outcom due miss covari baselin select model allow calcul perirandom attrit hazard 810 846 subject gee pattern mixtur model 7 dai p.p.a follow control select bia found statist signific differ longitudin trajec tori abstin rate stratifi subject follow visit attend decid treat postrandom missing complet random estim singl gee model smoke abstin 810 subject adjust perirandom attrit aim studi evalu effect 7 dai p.p.a physician advic bine nrt enter report patch 8 week set target quit date covari at center sc end treatment median 4 week addit patch adjust differ num ber telephon contact receiv center sc end treatment median call refer group compos sc subject report 4 week ply patch 1 month follow receiv tel ephon call therapi design treatment effect narrowli circumscrib target estim procedur select haz ard rate standard coeffici estim effect increas propens earli dropout subject attend follow visit po trandom sampl median 0.15 char acterist studi particip baselin predict 15 probabl drop immedi con tribut follow measur whatsoev final race ethnic enter model highli accultur hispan retain potenti distinct group effect baselin variabl subsum select hazard term remain covari pre dominantli time vari natur cumul report patch cumul number phone contact posit deci sional balanc perceiv stress temptat smoke social habit neg affect situat aid inter pretat chose standard variabl regress coeffici captur effect increas baselin median baselin 3rd quartil posit decision balanc median 10 3rd quartil 12 social habit median 13 3rd quartil 15 neg affect median 23 3rd quartil 26 perceiv stress median 8 3rd quartil 10 show threshold effect linear effect median effect low level posit part enter regress low valu replac result shown tabl 4 gee ci valu correct estim uncertainti simul tabl 4 odd abstin refer group approxim reduc half follow visit stabil 6 month convert odd abstin rate find declin 22 1 month follow 95 ci 0.12 0.65 12 2 month follow 95 ci 0.05 0.24 drop 7 tabl 3 logist regress model perirandom attrit model term pe lcl ucl odd refer group 0.10 0.05 0.20 001 rhode island hospit 1.99 1.15 3.45 014 st joseph hospit 1.72 0.93 3.15 077 accultur hispan latino 1.45 0.84 2.51 194 highli accultur hispan latino 2.41 1.24 4.69 009 african american 1.14 0.61 2.13 675 1.06 0.58 1.95 834 plan quit 30 dai 1.57 1.06 2.32 027 number minor household 1.13 0.98 1.29 085 number adult household 1.09 0.97 1.23 162 motiv enhanc group 0.97 0.66 1.44 889 temptat smoke neg affect 0.84 0.69 1.03 080 unemploi 0.82 0.52 1.29 390 previou patch 0.47 0.23 0.95 033 widow 0.25 0.06 1.04 054 note refer group regress model tabl 3 hispan white particip sc full part time employ widow household median size compris adult singl child plan quit 30 dai neg affect score equal sampl median previous nicotin patch odd ratio pe point estim lcl 95 lower confid limit ucl 95 upper confid limit valu ital odd experienc outcom refer group 418 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research 6 month follow 95 ci 0.03 0.17 stabil level 12 month follow 95 ci 0.03 0.15 increas patch 8 week set ting target quit date rais odd abstin 1 month 1.70 95 ci 1.29 2.24 2 month follow up 1.58 95 ci 1.33 1.89 effect di sipat time weaken mainten period borderlin signific result 6 month 1.19 95 ci 1.01 1.39 posit nonsignific result 12 month 1.14 95 ci 0.95 1.36 con trast effect addit telephon contact remain constant studi period increas odd abstin quarter 1.26 95 ci 0.96 1.66 clinic signific effect size attain border line statist signific 09 quartil increas posit decision balanc rais odd abstin 1.19 95 ci 1.01 1.39 follow point increas smoke temptat stronger com.ibm.drl.hbcp.predictor continu smoke quartil increas neg affect situat halv odd abstin 0.47 95 ci 0.40 0.55 quar tile increas social habit situat reduc sixth 0.83 95 ci 0.71 0.97 final high ceiv stress level follow 10 unit cohen scale reduc odd abstin quarter 0.72 95 ci 0.52 0.99 increas earli dropout hazard 0 typic subject deem attend follow sampl median 0.15 typic subject estim 15 drop immedi random end attend follow advers affect smoke outcom reduc odd abstin 28 0.72 95 ci 0.37 1.40 sc subject statist signific 32 inclus hazard rate covari calcul margin benefit ad compon standard nicotin replac treatment regimen individu judg attend follow visit receiv po itiv dose random group subject estim hazard earli dropout appar deriv direct benefit intervent adjust covari model 0.97 95 ci 0.36 2.64 subject appear benefit intervent indirectli effect psycholog con struct predict abstin treatment dose receiv experienc larger decreas sc subject smoke temptat social habit 029 neg affect 021 situat differ dissip past 1 month follow complet counsel call dur ing intervent phase median 3 sc 2 0001 report week patch median 4 sc 3 6 month 032 12 month 083 follow up discuss studi sought test efficaci smoke cessat intervent sc low se smoker uninsur medicaid primari care set studi find indi cate effect intervent psycholog com.ibm.drl.hbcp.predictor tabl 4 logist regress model 7 dai point preval abstin adjust covari correct select bia due perirandom attrit model term pe lcl ucl odd refer group 1 month 0.28 0.12 0.65 003 2 month 0.13 0.05 0.31 001 6 month 0.07 0.03 0.15 001 12 month 0.07 0.03 0.17 001 accultur latino hispan 1.99 0.95 4.20 070 highli accultur latino hispan 2.01 0.80 5.06 139 patch week 1 1.70 1.29 2.24 001 patch week 2 1.58 1.33 1.89 001 patch week 6 1.19 1.01 1.39 042 patch week 12 1.14 0.95 1.36 180 number telephon contact 1.26 0.96 1.66 087 posit decision balanc 1.19 1.01 1.39 036 perceiv stress scale 8 0.72 0.52 0.99 045 temptat smoke posit affect habit 0.83 0.71 0.97 021 temptat smoke neg affect 0.47 0.40 0.55 001 motiv enhanc group 0.97 0.36 2.64 952 earli dropout hazard 0.72 0.37 1.40 322 earli dropout hazard motiv enhanc group 0.68 0.31 1.48 327 note refer group regress model tabl 4 hispan white african american subject sc report 4 week suppli patch receiv telephon call 1 month follow report median valu baselin psycholog measur includ model baselin covari profil 15 chanc drop immedi baselin visit odd ratio pe point estim lcl 95 lower confid limit ucl 95 upper confid limit valu ital odd experienc outcom refer group 419 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org cessat low se smoker abstin transient effect smoke effi caci 1 month follow dissip time find limit effect compon smok ing intervent consist meta analysi clinic trial adapt mi found low efficaci mi approach smoke gener popul burk arkowitz menchola 2003 addition find consist work okuyemi al 2007 test motiv focus smoke cessat trial conduct low incom hous develop 83 african american fail find addit mi compon nrt effec tive smoke cessat okuyemi al 2007 2013 find current studi highlight import factor relat tobacco cessat sampl low se smoker current studi ethnic racial minor particip significantli higher level attri tion compar nonminor individu highli accultur hispan highest level studi dropout find suggest develop innov retent strategi treatment intervent specif target address ethnic divers individu involv smoke cessat treatment strategi intervent enhanc account level accultur stress accultur smoke respons neg affect treatment retent predict continu smoke follow previou stud i note relationship neg affect state depress success tobacco cessat benjet wagner borg medina mora 2004 berlin covei 2006 blalock robinson wetter cinciripini 2006 catlei al 2005 integr psychotherapeut approach design manag decreas neg affect enhanc smoke cessat intervent improv treat ment retent outcom current studi provid techniqu manag stress includ behavio ral skill compon intervent pronounc target emphasi requir fulli address role neg affect state smoke ce sation patient plan quit smoke screen depress symptom refer special ist addit therapi quit smoke medica tion antidepress effect i. zyban consid studi greater nicotin patch significantli increas odd abstin 1 month 2 month follow assess protect effect extend patch 8 week period choic target quit date attenu 6 month follow significantli rais odd abstin 12 month follow find weaken relationship increas patch treatment abstin mainten period patch critic com.ibm.drl.hbcp.predictor abstin earlier quit ting process withdraw crave relat symptom promin mainten period behavio ral relaps prevent skill critic fac tor maintain abstin altern provid strong rational continu nicotin replac prolong period initi cessat addit behavior method prevent relaps futur studi examin impact includ behavior skill train compon specif target mainten period account extend trajectori quit process low incom smoker present numer challeng offer implement smoke cessat intervent practic barrier includ cost access health care ser vice set provid smoke cessa tion aid counsel continu care smoker challeng daili basi find sustain emploi ment stabl hous arrang compet activ prioriti clear low incom smoker motiv quit smoke compar socioeconom disadvantag okuyem al 2013 low incom smoker suffer addit burden relat depress alcohol substanc abus complic seek smoke cessat adher treatment access prehens health care set address multipl health care integr smoke cessat servic requir complet address problem limit current studi women rep resent sampl unclear find balanc distribut gender recruit studi experienc sig nific attrit baselin multipl attempt reach particip phone mail analyt strategi account miss data high level studi attri tion reduc precis estim 6 month 12 month follow up dropout select differenti dropout treatment condi tion awar studi encount similar issu perirandom attrit 16.3 sc 16.1 found present studi analyt strategi com.ibm.drl.hbcp.util address issu 12 month postrandom attrit rate addit 42.4 sc 36.6 higher typic encount clinic smoke ce sation studi attribut larg part high residenti mobil low incom primari care popula tion entir year studi okuyemi al 2013 homeless popul achiev follow rate 72 78 6 month higher observ 60 62 follow partici pant 12 month limit studi find continu relev intervent low se smoker recent public polici initi aim increas medicaid coverag tobacco cessat conclus studi highlight import number pretreat ment variabl affect studi retent includ accultura tion statu account transient effect smoke efficaci addit compon standard care smoke cessat substanti improv potenti psycholog com.ibm.drl.hbcp.predictor abstin follow motiv intervent addit telephon person contact effect altern individu interest join studi motiv quit addit motiv inter vention pois effect 420 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research impact nicotin replac medic studi shown motiv intervent effect help earlier stage readi e.g contempl move readi quit 90 particip studi prepar stage readi quit 30 dai stage iv approach studi help overcom problem perirandom attri tion common problem intervent target low incom hospit recruit popul e.g neuner al 2009 okuyemi al 2013 final method studi hold promis research applic com.ibm.drl.hbcp.util low contact method fund work support nation institut health nation institut drug abus r01da010860 dr niaura declar interest declar acknowledg bcb rn dba develop studi design bcb rn dba pj mf md mma implement studi recruit particip deliv intervent assist data organ gdp conduct statist analys mad gdp rn primari writer manu script author involv edit manuscript
evier.com locat ypmed prevent medicin 41 home health care nurs channel smoke cessat treatment outcom project care commun nurs assist research educ smoke belinda borrelli ph.d scott novak ph.d jacki hecht r.n m.s.n karen emmon ph.d georg papandonato ph.d david abram ph.d center behavior prevent medicin brown medic school miriam hospit coro west build suit 500 hoppin street provid ri 02903 usa harvard school public health boston ma 02215 usa center statist scienc brown univers provid ri 02912 usa onlin 22 septemb 2005 abstract background clinic guidelin smoke cessat suffici help subgroup smoker quit incorpor smoke cessat home base medic care proactiv reach high risk smoker access spontan seek smoke cessat method home health care nurs 98 randomli assign deliv motiv enhanc motiv interview carbon monoxid feedback standard care ahcpr guidelin smoke cessat patient seventi percent patient elig particip 273 54 femal mean ag 57 year 83 caucasian 41 high school educ studi conduct provid ri usa 1998 2003 result biochem verifi continu abstin rate 12 month follow 4.2 sc 8.7 intent treat analys 5.2 sc 11.8 case 0.05 report quit attempt significantli greater reduct number cigarett smoke dai follow up 12 month post treatment valu 0.05 conclus exist public health channel home health care reach smoker vari motiv quit potenti larg public health impact 2005 elsevi right reserv keyword smoke cessat motiv interview nurs medic ill smoker older smoker ahrq guidelin ahcpr guidelin introduct home health care servic grow exponenti due cost consciou manag care environ attempt made conduct research incorpor clinic theori health behavior chang home health care home health care ideal channel promot smoke cessat 1 access hard reach difficult treat popul highest risk smoke relat diseas 2 proactiv reach access spontan seek smoke cessat servic 3 foster motiv chang repeat 0091 7435 front matter 2005 elsevi right reserv doi 10.1016 j.ypm 2005.08.004 author fax 1 401 793 8078 mail address belinda_borrelli brown.edu borrelli contact 4 capit teachabl moment induc medic visit 5 dissemin approxim 30 patient discharg hospit home care 6 patient counsel home environ receiv cue smoke 7 access patient requir chronic diseas manag home requir acut care post hospit discharg prior paper survei 98 home health care nurs found train intervent 36 spent 1 3 min counsel patient smoke 55 spent 3 10 min borrelli al 2001 2 nurs report discuss smoke patient major home health care nurs prime readi deliv smoke cessat counsel home health care nurs promot 2005 815 821 www.el fig 1 patient flow 1998 2003 provid ri usa borrelli al prevent medicin 41 2005 815 821816 health behavior dougherti al 1999 brooten al 2001 old al 1997 borrelli al 2002 greenberg al 1994 knowledg publish random control trial exist com.ibm.drl.hbcp.util home health care nurs deliv smoke cessat adult receiv medic home care current studi random home health care nurs deliv smoke cessat intervent home health care patient smoke regular home base medic care medic ill older smoker face uniqu barrier quit 1 heavier smoker smoke longer time rimer andorlean 1993 2 decreas confid abil quit kviz al 1994 rimer al 1994 3 depress lack social support preval 4 quit improv health orlean al 1991 fail connect smoke current ill 5 longer risk smoke relat diseas depart health human servic 1989 hypothes intervent motiv enhanc target motiv quit barrier quit outperform intervent base guid line develop agenc health care polici research ahcpr standard care method treatment set nurs characterist nurs employe visit nurs associ vna rhode island ri acut chronic medic care patient unabl visit physician requir frequent daili care randomli select 104 160 nurs particip studi manageri support mandatori nurs particip 6 nurs particip anticip medic leav nineti nurs ag 44 year sd 9.5 educ 16 year sd 1.4 19 year nurs sd 11.2 93 caucasian random deliv smoke cessat intervent medic ill patient smoke 31 smoker 100 cigarett lifetim 13 report current smoke addit detail nurs attitud belief counsel behavior found borrelli al 2002 particip studi receiv ethic approv human subject review board miriam hospit approxim 11.8 vna patient identifi smoker compar nation data center diseas control 1999 smoker want quit refer nurs project care screen identifi smoker 83.5 484 refer contact 82.4 399 elig screen fig 1 elig studi patient vna servic 18 year smoke 3 cigarett dai past year english speak nicotin replac receiv treatment smoke mini mental state score 20 receiv hospic care approxim 70 278 screen elig agre particip 7.2 29 elig refus particip 23.1 92 inelig reason inelig smoker 26.1 discharg home care 22.8 smoke cigarett dai 14.1 alert orient 12.0 pipe cigar smoker 8.7 english speak 3.3 nurs recommend 2.2 278 smoker remov analys quit smoke screen nurs visit sampl tabl 1 consist 54.3 femal mean ag 57.2 year sd 14.3 ethnic composit 83.5 caucasian 12.2 african american 2.2 hispan 1.4 american indian 0.7 cape verdian forti percent high school educ 91 unemploi sixti percent earn 10,000 year incom 24 earn 10,000 24,000 marit statu 27 marri 22 widow 19 marri 3 live 29 divorc separ approxim 36 sampl plan quit baselin 5 contempl scale remaind think quit futur baselin mean number dai vna servic 103 sd 207 median 23dai themediannumberof homecar visitswas14 themedian number dai hospit discharg 24 medic diagnos lung diseas 38.3 hypertens 34.9 cardiovascular diseas 41.7 diabet 28.1 cancer 11.9 depress 12.3 mental disord 13.4 approxim 61.9 report health fair poor treatment overview visit patient group receiv quit smokingmanu tailor older medic ill smoker clear horizon consist 3 intervent visit follow telephon call sc deliv singl visit treatment integr regular medic visit patient exclus smoke cessat content smoke portion visit deliv 20 30min threem session 5 15 min singl sc session tabl 2 tabl 1 demograph characterist studi particip total sampl standard care motiv enhancementvari mean rang median sd mean sd mean sd ag 273 57.2 21 89 58 14.3 57.5 13.9 56.9 14.8 smoke rate cigarett dai 271 21.1 3 100 20 13.9 21.6 14.1 20.5 13.8 fagerstrom 273 6.3 1 11 6.0 3.1 6.4 2.0 6.3 4.0 year smoke 273 41.8 3 74 42 13.6 42.4 13.4 41.2 13.8 24 life quit life 273 8.5 0 150 3.0 20.2 8.1 20.9 9.0 19.6 quit year 272 1.4 0 25 0 3.1 1.5 3.2 1.3 3.2 contempl ladder 273 5.9 1 10 6 1.7 5.7 1.8 6.2 1.6 mini mental state 272 26.5 21 30 27.0 3.0 26.8 2.9 26.2 3.2 efficaci 273 84.6 15 150 86 31.9 79.0 31.7 90.8 31.1 sf 12 physic health 260 32.0 15.4 56.1 30.9 9.0 32.2 9.1 31.7 8.9 sf 12 mental health 260 44.6 11.9 67.9 45.9 11.6 44.7 11.5 44.5 11.7 0.002 borrelli al prevent medicin 41 2005 815 821 817 motiv enhanc treatment intervent develop focu group home care nurs supervisor tailor older medic ill smoker sensit degre readi chang base principl motiv interview miller rollnick 1991 2002 deliv client center manner focus explor resolv ambival quit smoke focus build intrins motiv chang 1 explor patient perspect concern consequ smoke 2 discuss good thing good thing smoke 3 help patient perceiv smoke discrep valu goal 4 explor patient belief cigarett affect health nurs obtain expir air patient discuss level relat specif diseas qualiti life peopl gener ask patient interpret result inform appli experi includ discuss physiolog damag diseas risk smoke attenu quit smoke older smoker lower efficaci repeat unsuccess quit attempt grembowski al 1993 includ build efficaci 1 set patient determin proxim subgoal 2 refram past quit attempt learn experi failur 3 affirm small behavior attitud 4 evoc patient stori confid build experi 5 vicari experi e.g success stori older smoker consist cognit behavior strategi enhanc mood social support includ discuss feel loss wai obtain pleasur live standard care treatment sc sc patient clear horizon ahcpr guidelin counsel 5 smoke assess motiv quit advis quit assist quit arrang follow counsel provid visit nurs provid support subsequ visit smoker tabl 2 treatment compon standard care motiv enhanc 1 visit 3 visit 5 min follow call clear horizon manual clear horizon manual ahcpr guidelin 5 quit smoke assess motiv quit advis quit assist quit arrang follow motiv interview explor ambival quit clarifi goal valu relat smoke carbon monoxid feedback increas risk percept build efficaci confid quit readi quit desir assist consist clinic guidelin fior al 2000 train evalu skill acquisit nurs 46 sc 52 train group 10 determin acquisit counsel skill pre post test nurs knowledg skill simul patient interview nurs booster session studi minim drift maintain counsel skill trainer licens clinic psychol ogist borrelli master level oncolog nurs educ hecht train motiv interview nurs train mi intern valid monitor deliveri intervent 1 live audiotap supervis sampl counsel session 2 patient exit interview conduct research assist 3 nurs document time spent discuss smoke compon deliv 4 monthli meet nurs measur research assist blind condit administ measur telephon patient compens 25.00 complet follow assess end treatment end nurs smoke cessat counsel 2 6 12 month end treatment sociodemograph smoke histori sociodemograph smoke histori assess report tabl 1 nicotin depend assess fagerstrom test nicotin depend heatherton al 1991 intern consist alpha 0.70 pomerleau al 1994 biochem marker nicotin depend pomerleau al 1990 mental statu 11 itemmini mental state examin folstein al 1975 part elig patient score 20 elig rang 0 30 psychosoci variabl motiv quit assess contempl ladder ordin measur 10 answer choic correspond level readi quit smoke demonstr reliabl valid found cognit behavior indic readi quit smoke biener abram 1991 abram biener 1992 herzog al 1999 efficaci quit smoke assess 15 item confid questionnair baselin good reliabl alpha 0.85 valid condiott lichtenstein 1981 item measur confid resist smoke varieti situat likert scale 0 confid 10 confid rang score 0 150 tabl 3 smoke outcom case 1998 2003 provid ri usa time sc sc 95 ci continu abstin end treatment 131 110 0.7 1.8 2.4 0.2 26.9 2 month follow 123 104 2.4 6.7 2.8 0.7 11.4 6 month follow 110 98 3.6 6.1 1.7 0.4 6.3 12 month follow 96 76 5.2 11.8 2.4 0.7 7.6 7 dai point preval abstin end treatment 131 110 8.4 10.04 1.2 0.5 2.3 2 month follow 125 104 10.4 10.5 1.0 0.4 2.3 6 month follow 110 99 11.8 13.1 1.1 0.4 2.5 12 month follow 96 76 10.4 17.1 1.7 0.7 4.3 motiv enhanc sc standard care odd ratio ci confid intern borrelli al prevent medicin 41 2005 815 821818 smoke statu expir air carbon monoxid assess report abstin 7 dai abstain defin obtain 10 ppm bedfont ecolyz particip avail 60 report smoke assess verifi report inform call verifi smoke statu examin continu abstin defin subject refrain smoke recent prior wave data collect qualiti life qualiti life assess shorten version medic outcom studi mo short form gener health survei sf 12 mchornei al 1993 scale measur physic health mental health function demonstr good valid reliabl alpha 0.85 popul mean scale physic 50.12 sd 9.45 rang 13 69 mental 50.04 sd 9.59 rang 10 70 intervent dose nurs record time spent discuss smoke compon deliv visit analyt plan nurs averag 4 particip rang 1 13 patient nurs cross section correl primari outcom 0.05 time point extens multilevel model account cluster patient nurs repeat measur aspect design deem affect signific find estim influenc treatment code 0 standard care 1 motiv enhanc smoke outcom 1 abstin 0 smoke logist regress hosmer lemeshow 1989 continu outcom differ score calcul baselin follow posit valu repres desir improv outcom motiv efficaci neg valu chang smoke reduct number cigarett smoke dai baselin test differ condit amount chang differ score calcul e.g t2 t1 regress ordinari squar estim procedur treatment assign baselin outcom covari grand mean center includ control initi baselin differ treatment group mean standard error present tabl 5 deriv intercept separ model differ code refer categori treatment assign result intercept interpret averag amount chang group report mean level variabl baselin result retent rate 89.5 end treatment 87.0 2 month 80.4 6month 70.5 12 month follow fig 1 rate exclud 39 subject di random dropout reach consid smoker intent treat analys dropout significantli 0.05 male white younger dropout differ condit rate attrit time primari smoke outcom statist comparison conduct baselin vari abl order test equival condit bonferroni correct number test alpha 0.05 20 0.0025 statist signific variabl number dai hospit discharg 0.009 efficaci 0.002 conduct sensit analys includ effect condit assign e.g unadjust replic analys covari e.g control balanc appreci differ enc observ set analys present unadjust effect particip report past week abstin level 10 ppm assess data recod reflect affirm past week smoke statu data top portion tabl 3 4 case intent treat approxim particip continu abstin sc end treatment 2 month 12 month follow up continu abstin rate 6 month higher sc bottom half tabl 3 4 achiev higher rate 7 dai point preval abstin sc time point group differ signific gee analys continu abstin 2.2 95 ci 0.4 11.5 point preval abstin 1.01 95 ci 0.4 2.2 sc demonstr signific increas rate contin uou abstin end treatment 12 month follow 2.5 1 df 0.05 intent treat analys time time analys signific time point continu abstin outcom secondari smoke outcom number quit attempt dichotom 1 quit attempt quit attempt previou wave data collect includ report smoke prior week make quit attempt sc time point tabl 5 signific differ achiev 2 month 12 month follow up 2 month 57.1 sc 43.1 1.7 95 ci 1.01 3.0 12 month 75.8 sc 54.8 2.5 95 ci 1.2 5.4 addition report significantli greater reduct number cigarett smoke dai sc time point tabl tabl 4 smoke outcom analys intent treat 273 1998 2003 provid ri usa time sc 95 ci continu abstin end treatment 0.7 1.6 2.2 0.2 25.0 2 month follow 2.2 5.9 2.7 0.7 10.9 6 month follow 3.1 5.2 1.7 0.4 6.2 12 month follow 4.2 8.7 2.1 0.6 6.6 7 dai point preval abstin end treatment 7.9 8.8 1.1 0.4 2.6 2 month follow 8.8 9.3 1.0 0.4 2.5 6 month follow 10.1 11.2 1.1 0.4 2.5 12 month follow 8.5 12.6 1.5 0.6 3.6 motiv enhanc sc standard care odd ratio ci confid intern borrelli al prevent medicin 41 2005 815 821 819 5 collaps time point 1.98 1 df 0.05 adjust averag number cigarett smoke dai baselin test possibl treatment differenti impact level motiv efficaci quit main effect gee model treatment exposur 57 74 129 particip receiv full treatment 3 visit follow phone call 26 34 129 receiv visit 8 receiv visit percent 12 129 receiv addit session full adher sc visit 94 136 144 18.7 receiv addit session 27 144 condit receipt full intervent extra contact smoke outcom receipt follow phone call condit unrel outcom discuss studi demonstr home health care feasibl effect channel nurs deliv smoke cessat counsel intervent outperform sc time point intent treat analys case analys show amount continu abstin sc 12 month continu abstin rate achiev intent treat 4.2 sc 8.7 case 5.2 sc 11.8 light tabl 5 secondari smoke outcom 1998 2003 provid ri usa end treatment 2 mon sc sc attempt quita 52.1 56.8 43.1 mean reduct cigarett smokeda 3.8 6.9 4 se 0.84 se 0.93 se 1.0 motiv enhanc sc standard care report smoke previou week calcul chang number cigarett smoke baselin e.g interest baselin averag number cigarett smoke dai fact provid nicotin replac popul number risk factor difficulti quit i. high level depress mood averag 42 year smoke high nicotin depend low educ low incom achiev group differ comparison group sc stronger minim contact intervent treatment control signifi differ group emerg smoke reduct group smoke significantli cigarett dai sc time point lack statist signific quit rate group find signific public health implic approxim 36 sampl plan quit baselin patient receiv counsel nurs exce number patient low intent enrol reactiv program bias select sampl high motiv quit rose theorem rose 1992 abram al 1996 state impact reach efficaci consid evalu smoke cessat interven tion impact efficaci intervent multipli reach reach defin percent penetr intervent popul result multipli 10 obtain impact rate clinic intervent high efficaci 40 reach 5 popul impact rate 0.20 40 5 10 public health intervent modest efficaci 5 reach 80 popul doubl impact clinic approach 0.40 appli equat current result find 11.8 efficaci 12 month case 0.70 reach particip rate elig patient 0.83 popul impact reach compon evalu efficaci popul base intervent studi glasgow al 1999 2001 extend model reaim framework reach efficaci adopt organiza tion implement provid mainten institution time combin determin public health impact explan differ sc nurs requir provid counsel visit follow call sc nurs requir provid counsel visit intention design studi confound equat contact time condit sc longer th 6 month 12 month sc sc 57.1 56.9 62.2 54.8 75.8 0 7.5 3.0 6.2 3.1 7.8 4 se 1.13 se 1.05 se 1.10 se 1.1 se 1.3 ti tb averag number cigarett smoke time point borrelli al prevent medicin 41 2005 815 821820 usual standard care analyz effect number contact contact time smoke outcom relationship intervent intens smoke outcom higher quit rate achiev due intervent content plausibl explan lack signific differ group 1 insuffici group differ enc intervent intens 2 lack statist power 18.7 sc patient receiv intervent contact prescrib studi protocol 9.3 patient receiv addit session 3 session phone contact prescrib studi protocol intervent dosag intens unrel smoke outcom studi power 1000 subject dichotom primari outcom smoke possibl high intra class correl nurs intra class correl low suffici amount subject detect effect due organiz upheav occur vna ceo layoff 1 3 train nurs fortun vna ri achiev greater stabil leadership strength studi includ excel retent rate random nurs proactiv patient outreach uniqu intervent channel deliveri theori base interven tion public health context intervent integr ongo medic care increas extern valid futur studi attempt dismantl activ ingredi provis biomark feedback relat smoke outcom cognit process underli acknowledg author visit nurs associ particip support project special karen enright rn phd sandra hooper rn susan bell rn patricia fleme rn mari linn hamilton rn nurs field deliv intervent dedic patient inspir author dr michael goldstein consult project research support grant nation cancer institut ca74553 dr borrelli p.i r25 ca7972 dr novak ca84719
1 titl happi end ii random control trial digit smoke cessat program nicotin replac type paper origin paper author håvar brendryen filip drozd pål kraft affili depart psycholog univers oslo correspond håvar brendryen depart psycholog postbok 1094 blindern 0317 oslo norwai phone 47 99 52 17 14 fax 47 22 84 51 58 email haavabr psykologi.uio.no total page count 19 word count abstract 402 word count bodi text 4,886 tabl exclud number tabl 5 number figur 1 2 abstract background happi end intens year smoke cessat program deliv internet cell phone consist 400 contact email web page interact voic respons ivr short messag servic sm technolog includ crave helplin relaps prevent system provid time therapi compon program fulli autom object object describ rational design assess 12 month efficaci sampl smoker attempt quit nicotin replac therapi nrt explor potenti effect cope plan cp efficaci se prior quit cp se mediat treatment effect method arm random control trial subject recruit internet advertis 290 randomli assign condit inclus criteria willing quit prescrib dai nrt ag 18 year older intervent group receiv control group receiv 44 page booklet abstin defin puff smoke dai assess mean internet survei telephon interview 1 3 6 12 month postcess main outcom repeat point abstin i. abstin measur point cp se measur baselin end prepar phase i. week treatment prior cessat dai result intent treat analysi particip intervent group report clinic statist significantli higher repeat point abstin rate control particip 20 versu 7 3.43 95 ci 1.60 7.34 002 differ observ baselin end prepar phase significantli higher level cp 261 3.07 002 precess se 261 2.63 01 observ intervent group compar control group increas se improv cp mediat long term treatment effect point abstin month quit cp se show partial mediat treatment effect conclus studi 12 month trial document long term treatment effect fulli autom smoke cessat intervent nrt studi add promis digit media support behavior chang keyword smoke cessat behavior chang internet cell phone ivr sm 3 introduct review 1 2 total 29 random control trial rct comput base intervent smoke cessat testifi effect form intervent review discuss depth differenti success intervent unsuccess intervent addition insuffici report intervent contribut lack pattern regard com.ibm.drl.hbcp.predictor intervent efficaci 2 aim studi describ rational intervent scrutini design complex smoke cessat intervent requir multitud choic made point kei principl assumpt guid design happi end hope convei inform intervent work work theori research happi end psycholog process quitter experi time point follow chronolog 3 15 smoke cessat intervent follow chronolog program content organ psycholog process peopl experi time point difficult achiev adjust static hierarch organ web page solv practic organ program content multipl piec made client sequenti restrict period client progress predetermin sequenc modul i. iter degre freedom restrict refer tunnel 16 com.ibm.drl.hbcp.core organ principl start 14 dai prepar phase morn client receiv email hyperlink activ link smoker access dai websit tabl 1 detail number contact point distribut program period order websit base reason chronolog model psycholog process peopl experi time point process therapi support regul 3 15 dai construct establish confid treatment provid therapeut allianc provid receiv treatment 17 addition major focu ensur client understand awar monitor activ particip engag crucial ingredi person goal attain 18 19 particip educ psycholog profil respons person smoker smoker awar learn thing smoke behavior nicotin depend reason previou failur quit motiv basi quit gener task specif efficaci problem peopl experi quit stress weight regul import com.ibm.drl.hbcp.predictor outcom chang process se extent person confid succe 20 pre postcess se shown plai import role smoke cessat 21 construct instil high realist level se particip crucial ingredi program educ particip cognit affect behavior reaction smoker experi slip occur i. smoke cigarett quit attempt particip told administr expect experi number slip 8 comment rc1 se moa 4 particip told critic experi slip react emotion behavior slip prevent devast cognit emot consequ snowbal break toler rule 19 prepar reaction recogn occur specif skill support system master setback probabl regul process success increas significantli 19 appli principl cognit behavior therapi 22 com.ibm.drl.hbcp.core assumpt client learn master life problem solv problem difficult situat smoke successfulli client recogn understand chang inappropri pattern thought occur relat acut problem experienc attempt instil capabl give particip small practic problem solv behavior task issu cognit emot task dai particip ask write note relat previou dai issu interact diari prepar phase element behavior skill train consist techniqu relat acquisit skill stop substitut monitor foresight 19 cp 23 relat high risk relaps situat addit activ place websit particip stai touch text messag sm interact voic respons ivr purpos twofold import particip commun cell phone plai crucial role rest program cell phone support activ process initi websit prepar phase 30 dai activ quit phase initi actual cessat attempt number activ includ ensur particip activ involv attempt quit numer contact point dai particip particip receiv email morn link dai specif websit differ websit prepar phase web activ focu motiv conflict smoker experi smoke free dai temptat impuls smoke motiv conflict impli effect expect consequ smoke versu smoke chang short posit short term consequ smoke e.g feel relax irrit tend inflat long term neg consequ smoke e.g health deflat dai week quit attempt 4 10 19 prevent particip receiv ivr messag short term posit consequ quit inform resembl type biofeedback e.g todai blood pressur reduc nonsmok topic elabor websit dai ivr messag receiv morn activ quit phase client log program log mean particip call messag inform client read topic websit dai quitter log remind automat activ program purpos log procedur ensur quitter activ involv awar monitor websit activ quit phase element activ collect social cognit learn theori 20 regul theori 9 24 emphasi comment hw2 20 instruct perform behaviour 41 behaviour practic comment hw3 42 behaviour substitut 12 monitor behaviour 2 problem solv 5 import postcess se 20 identifi kei com.ibm.drl.hbcp.predictor outcom smoke cessat attempt 21 regard type se expect import gener expect successfulli quit success expect expect manag difficult situat temptat smoke major aim program strengthen particip postcess se prepar quitter tempt situat i. cognit emot experi learn masteri experi remind quitter number tool overcom crave client encourag make concret implement intent cope plan stai smoke free futur 23 25 final dai quitter continu follow activ relat diari read perform write phase task base principl cognit behavior therapi behavior skill learn e.g problem focus masteri stop 20 26 effect program account fact larg proport quitter relaps import rememb relaps typic follow pattern intermitt episod smoke follow clean start 7 case relaps preced laps laps increas risk relaps 7 experi laps subsequ laps relaps occur 1 4 dai 3 12 intervent purpos lesson relev address smoke cessat intervent prevent occurr gener risk factor program offer time therapi remov prevent escal process increas risk subsequ relaps effect intervent aim reduc number cigarett smoke slip variabl predict probabl abstin 27 shorten period smoke reduc amount smoke client slip prepar implement intent 28 resum quit attempt e.g continu quit attempt tomorrow morn autom i. ivr base relaps prevent system incorpor entail particip call night quitter ask smoke dai particip smoke dai report press 2 activ therapi regimen i. regimen activ depend slip quitter previous report purpos regimen induc particip attribut slip situat factor prevent neg emot full blown relaps import element make quitter accept relaps smoke part deliber decis person powerless prevent quitter experi close call situat smoker brought brink smoke 12 13 point occurr smoke nonsmok influenc quitter acut cope respons particip cope close call situat ivr base crave helplin particip instruct call helplin time tempt cigarett make principl implement intent cp call ask report feel kind push button client pick emot regul ii motiv boost iii stress regul client hear therapeut messag specif design solv problem messag call comment rc4 link 29 87 2 4 efficaci comment rc5 29 inform emot consequ comment rc6 87 verbal persuas capabl comment hw7 4 action plan 2 problem solv comment hw8 4 action plan comment hw9 2 problem solv comment rc10 63 reduc neg emot comment hw11 63 reduc neg emot comment rc12 2 problem solv 17 social support unspecifi 6 final offer 11 month follow phase phase log procedur continu daili week week week week remain follow period system regist slip activ relaps prevent system period particip access crave helplin follow phase final quitter receiv number encourag sm ivr messag phase summari compar digit smoke cessat program 1 2 30 33 appear uniqu featur combin media approach email web ivr sm distinct reli tunnel 16 broad structur principl final includ compon time therapi i. crave helplin relaps prevent system commonli observ field 29 previou trial appli similar design investig digit multimedia smoke cessat intervent studi earlier rct 30 12 month rct digit smoke cessat intervent trial short term effect i. month quit document 31 33 i. restrict comparison rct appli intent treat principl provid direct test efficaci fulli autom digit deliv smoke cessat intervent target smoker motiv quit trial repres signific contribut potenti appli digit media smoke cessat intervent studi 30 import shortcom address current trial previou trial 30 nrt part recruit induc final sampl 10 subject experiment condit nrt quit attempt result appli nrt problem gener find smoker current trial aim recruit subject quit adjac nrt previou trial 30 fail document mediat effect program relev psycholog variabl technic complet mediat effect found 30 efficaci month smoke cessat conclud analysi confound variabl smoke statu avoid confound variabl investig effect obtain cessat lead aim studi explor psycholog effect caus intervent eventu mediat treatment effect variabl hypothes test hypothesi digit fulli autom smoke cessat intervent produc increas 12 month abstin rate compar control condit booklet expect digit intervent increas precess level cope plan efficaci final expect hypothes increas precess cope plan efficaci partial mediat treatment effect 7 tabl 1 overview potenti contact point program user entir intervent period compon week 1 2 week 3 6 week 7 8 week 9 10 week 11 15 week 16 54 email º º º º º º º º º º º º º º web page text messag log call log call note tabl show daili contact point sampl week sampl week repeat form entir 54 week intervent period cell repres intend contact except text messag dash repres messag depend week number i. week 1 2 messag week 3 6 messag week 7 8 number messag gradual reduc dai week 9 54 dash repres text messag 8 method subject subject recruit mean onlin banner advertis norwegian region newspap 6 10 februari 2006 banner displai 947,059 time result 2,595 hit give hit rate 0.3 click banner potenti subject rout websit studi inform inform consent baselin questionnair inform consent process particip inform arbitrarili split group receiv tool smoke cessat tool includ form medic particip studi requir attend face face meet consult inform provid whatsoev intervent condit i. happi end booklet mention stage peopl quit 6 march 2006 ag 18 year smoke cigarett daili basi quit nicotin replac therapi own mobil phone norwegian regist phone number postal address daili access internet email elig candid inclus studi 427 uniqu registr 23 fulfil inclus criteria 82 subject exclud miss valu 19 subject exclud suspect base share famili postal address email ip address worksit reduc risk commun experiment condit final subject exclud randomli requir number particip 296 power analysi materi control group receiv 44 page booklet issu norwegian director health social affair booklet gener cessat inform quit calendar 10 dai quit log phone number nation quit line link relev open onlin tobacco cessat resourc booklet recommend 10 dai prepar prior quit reader encourag map smoke habit quit log addition ten prepar dai booklet suggest exercis aim rais awar person smoke habit 48 dai quit calendar compos small encourag daili messag improv health quit e.g risk cardiovascular diseas reduc food tast treatment group receiv digit multimedia intervent happi end previou section tabl 1 detail number contact point distribut program period stress contact point includ telephon call helplin 100 autom intervent side procedur base comput gener random digit 296 peopl randomli alloc happi end intervent group control condit booklet group stratifi block random appli ensur equal number male femal group random perform experiment name ident subject conceal experiment random 9 random subject receiv email inform tool provid i. happi end booklet subject group told intervent begin 20 februari design quit date 6 march subject control group told booklet encourag read booklet design cessat date i. 6 march activ quit attempt inform type treatment provid group withheld subject experiment condit data collect mean onlin questionnair baselin precess 1 3 6 12 month cessat email link questionnair subject data collect point email remind nonrespond postcess follow up telephon interview conduct subject respond remind telephon interview structur standard person person counsel face face contact experiment subject point attempt made contact nonrespond telephon condit data collect point variabl abstin defin complet smoke free past dai subject miss valu abstin data code smoker abstin data base report biochem verif assess 1 3 6 12 month cessat main outcom trial repeat point abstin abstin postcess measur point nicotin depend assess fagerström test nicotin depend ftnd 34 cronbach alpha 68 se measur item rate point scale averag cronbach alpha 82 cp measur item rate point scale cp refer behavior cognit strategi connect anticip barrier suitabl cope respons 23 cronbach alpha 86 program adher continu automat regist comput trial end user initi activ tabl 1 web ivr servic regist present studi intend evalu effect happi end adjunct nicotin replac therapi nrt elig candid studi inform agre attempt quit nrt import note subject receiv inform recommend nrt condit technic reason modifi featur program booklet control nrt subject ask month nrt quit attempt data analysi alpha level 05 chosen statist test test tail check differ experiment condit baselin test scale χ test perform categor data χ test base 2 2 conting tabl appli yate continu correct outcom examin intent treat itt principl i. miss count smoker repeat point abstin 12 month point abstin 1 3 6 12 month cessat odd ratio 95 confid interv ci χ test experiment condit carri hierarch logist regress 10 appli 35 test cp se mediat effect experiment condit abstin analys base complet case approach 11 result program attrit subject characterist tabl 2 baselin sampl characterist treatment control 144 146 femal 72 50 73 50 colleg degre 70 49 76 52 ag 39.5 11.0 39.7 10.8 ftnd 4.5 2.3 4.6 2.2 cigarett dai 16.6 7.2 17.6 7.0 precess efficaci 5.1 1.4 5.1 1.3 precess cope plan 2.3 0.6 2.4 0.7 note number repres mean standard deviat continu variabl number observ percentag observ parenthes dichotom variabl baselin variabl treatment control subject differ significantli tabl 2 flow particip depict figur 1 296 subject exclud random discov fulfil inclus criteria sign person intend quit subject report quit smoke point random subject refer erron alloc figur 1 final number particip 290 12 figur 1 flowchart note cumul loss loss follow previou follow up shown bracket note particip discontinu intervent approach data collect assess elig 427 random 296 exclud 131 meet inclus criteria 23 reason 108 alloc happi end 148 receiv alloc intervent 144 receiv alloc intervent 4 erron alloc alloc booklet group 148 receiv alloc intervent 146 receiv alloc intervent 2 erron alloc lost follow cumul 1 month 5 3 month 9 10 6 month 20 22 12 month 13 26 discontinu intervent 57 lost follow cumul 1 month 19 3 month 15 24 6 month 26 36 12 month 23 38 discontinu intervent 0 analyz 144 exclud analysi 4 erron alloc analyz 146 exclud analysi 2 erron alloc ly si ll ll ca ti ro ll en 13 computer log routin reveal subject treatment condit larg extent accomplish action intend program design i. 10 case tabl 3 detail program adher tabl 1 detail contact point client crave helplin 80 subject 56 call helplin 45 subject 31 call 19 subject 13 call time tabl 3 mean number activ client action compon happi end activ client action rang mean sd log call 0 42 26 16 62 open web page 0 44 26 13 59 respond log call 0 102 53 37 52 note tabl show extent subject adher compon intervent 144 log call initi program respond mean answer abstin question theoret rang observ rang coincid except theoret maximum log call 104 hand column show averag percentag action complet total 57 subject discontinu intervent 36 week subject web page give reason withdraw program data collect program withdraw approach web telephon interview program particip subject control group month 17 subject 12 report found help 74 subject 51 found help 46 subject 32 report help miss 5 i. 7 subject shown tabl 4 respons rate found studi gener high experiment condit time note tabl 4 respons rate web survei fell sharpli total respons rate time correspondingli proport respons gather mean telephon interview increas suggest import combin web survei telephon interview long term follow month cessat significantli subject treatment condit control condit respond survei 7.5 006 select attrit problem point abstin month group differ total respons rate prepar 3 6 12 month signific cumul dropout rate 12 month i. loss follow 1 3 6 12 month significantli differ treatment control condit select attrit problem interpret 12 month repeat point abstin 14 tabl 4 web phone total respons rate condit time point web phone total time cessat treat contr treat contr treat contr prepar 132 131 132 131 1 month 128 119 11 8 139 127 3 month 119 110 16 21 135 131 6 month 101 97 23 23 124 120 12 month 101 89 30 34 131 123 note nonrespond web survei approach telephon column head repres abbrevi treatment condit 144 control condit 146 abstin main find trial particip intervent condit 29 20 report clinic statist significantli higher repeat point abstin rate control particip 10 7 3.43 95 ci 1.60 7.34 290 002 efficaci help smoker achiev long term abstin equal effect sampl subgroup defin sex ag nicotin depend interact effect experiment condit baselin characterist found agre quit nrt 34 subject 24 treatment condit report nrt 14 subject 10 control condit report nrt proport nrt user significantli higher treatment condit compar control condit 9.3 002 ad nrt experiment condit logist regress model odd ratio decreas 2.86 95 ci 1.31 6.24 290 008 summari hypothesi produc increas abstin rate compar control group receiv booklet support nrt control tabl 5 show point abstin repeat point abstin rate follow up odd ratio confid interv abstin rate significantli higher treatment condit control condit 1 3 6 month 12 month differ reach margin signific level reason effect size report month abstin inflat select attrit note tabl 5 proport abstain gradual decreas month fact increas 12 month control condit lack signific differ group 12 month point part due subject control condit perform quit attempt subject treatment condit relaps smoke 15 tabl 5 point abstin repeat point abstin rate condit time point treatment control 144 146 time cessat 95 ci point abstin 1 month 60 42 25 17 3.46 2.01 5.95 001 3 month 51 35 23 16 2.93 1.67 5.14 001 6 month 42 29 20 14 2.59 1.43 4.69 002 12 month 47 33 33 23 1.66 0.99 2.79 07 repeat point abstin 1 3 month 43 30 17 12 3.23 1.74 6.00 001 1 3 6 month 34 24 10 7 4.24 1.99 8.89 001 1 3 6 12 month 29 20 10 7 3.43 1.60 7.34 002 note point abstin base dai point preval intent treat precess cope plan cp efficaci se pearson baselin precess cp 32 001 level precess cp significantli higher treatment condit 3.0 sd 0.5 control condit 2.8 sd 0.5 261 3.1 002 hypothes pearson baselin precess se 54 001 level precess se significantli higher treatment condit 5.5 sd 1.2 control condit 5.1 sd 1.3 261 3.0 003 hypothes group differ cp se small standard deviat cp se test formal 35 mediat treatment effect experiment condit baselin cp se enter block pre cp enter block pre se enter block point abstin month depend variabl pre cp show small signific mediat effect block pre se show small signific mediat effect block block pre cp longer predict abstin significantli mean increas pre cp add explanatori power pre se correl cp se lower baselin 26 001 compar precess 49 001 mediat analysi repeat repeat point abstin 12 month depend variabl mediat effect whatsoev summari slightli increas level cp se week prepar phase program increas se explain initi success gain abstin i. month cessat ancillari analysi complet case analysi show repeat point abstin rate 12 month 25 16 29 118 subject treatment group versu 9 10 108 subject control group 8.22 3.19 95 ci 1.47 6.92 226 0.004 compar intent treat analysi repres small increas abstin rate group small decreas effect size look happen peopl intervent minim level exclud exclud subject perform fewer action categori log call open web page answer log call result abstin rate treatment condit 26 111 inclus intervent minimum level appli complet case approach increas quit rate 29 100 17 discuss trial demonstr efficaci digit deliv fulli autom smoke cessat intervent happi end booklet condit combin nrt produc increas repeat point abstin 12 month abil increas precess efficaci explain success gain earli abstin quitter nrt promis result inflat effect size compromis conclus main effect experiment condit clinic statist signific control nrt success explain psycholog support provid program mechan plai caus treatment effect fulli clear stage instil higher level precess efficaci compar control condit explain initi success gain abstin previou trial intervent similar design 30 nrt part recruit induc potenti influenc repres sampl result trial appli smoker nrt contrast current trial recruit smoker quit nrt subject nrt treatment effect main outcom impress control nrt trial significantli add generaliz find trial find appli nrt user nonus generaliz concern trial recruit select trial verifi report claim abstin bio chemic due geograph spread sampl fiscal practic concern fals report consid minim person contact treatment provid subject 36 current trial amount person contact experiment subject equal condit restrict data collect i. telephon follow respond misreport compromis conclus summari trial extend public health signific digit multimedia intervent smoke cessat show psycholog support effect mediat modern distanc commun technolog autom support stand intervent fact suffici signific effect long term behavior chang 18 acknowledg trial made cooper fund univers oslo happi end norwegian research council result own univers oslo contractu constraint sponsor public declar interest author financi interest intervent scrutini sharehold happi end

bupropion cognit behavior treatment depress smoke cessat richard brown raymond niaura elizabeth lloyd richardson david strong christoph kahler ana abrant david abram ivan miller receiv 20 octob 2005 accept 18 septemb 2006 studi random doubl blind placebo control clinic trial examin effect intens cognit behavior mood manag treatment cbtd bupropion singularli combin smoke cessat adult smoker extens previou work plan examin synergist effect cbtd bupropion smoke cessat outcom gener smoker depress vulner factor particip 524 smoker 47.5 femal mage544.27 year random 12 week treatment standard cognit behavior smoke cessat treatment st bupropion bup st placebo plac standard cessat treatment combin cognit behavior treatment depress cbtd bup cbtd plac follow assess conduct 2 6 12 month treatment report abstin verifi biochem consist previou studi bupropion comparison placebo result smoke outcom intens group treatment ad cbtd standard intens group treatment result improv smoke cessat outcom addit cbtd bupropion combin differenti effect smoker singl past episod major depress disord mdd recurr mdd elev depress symptom find regard recurr mdd elev depress symptom interpret caution low rate recurr mdd low level depress symptom sampl priori test treatment effect smoker depress vulner factor warrant futur clinic trial introduct major depress disord mdd psychiatr disord frequent cigarett smoke adult glassman 1993 grant hasin chou stinson dawson 2004 imped smoke cessat effort covei 1999 glassman 1993 conflict evid exist relationship histori mdd smoke cessat outcom covei 2004 hall 2004 hitsman borrelli mcchargu spring niaura 2003 depress symptom niaura al 2001 neg mood cinciripini al 2003 ginsberg hall reu muñoz 1995 killen al 1996 kinnunen doherti militello garvei 1996 consist poorer smoke outcom cessat treatment provid strategi manag depress symptom neg mood develop examin studi hall colleagu examin group cognit behav ioral mood manag treatment attent smoker histori mdd yield mix find hall muñoz reu 1994 issn 1462 2203 print issn 1469 994x onlin 2007 societi research nicotin tobacco doi 10.1080 14622200701416955 richard brown ph.d raymond niaura ph.d david strong ph.d ana abrant ph.d ivan miller ph.d brown medic school depart psychiatri human behavior butler hospit provid ri elizabeth lloyd richardson ph.d brown medic school depart psychiatri human behavior miriam hospit provid ri christoph kahler ph.d brown medic school depart psychiatri human behavior brown univers center alcohol addict studi david abram ph.d offic behavior social scienc research nation institut health bethesda md correspond richard brown ph.d brown medic school butler hospit 345 blackston boulevard provid ri 02906 usa tel 1 401 455 6254 fax 1 401 455 6424 mail richard_brown brown.edu nicotin tobacco research volum 9 number 7 juli 2007 721 730 nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org hall al 1996 hall al 1998 studi pharmacotherapi incorpor studi design studi 10 session mood manag treatment compar 5 session control condit smoker past mdd smoke outcom mood manag condit hall al 1994 hall al 1998 studi treatment condit equat contact time 10 session mood manag condit outperform control condit smo ker past mdd hall al 1996 studi suggest addit contact time specif mood manag skill benefit past mdd smoker studi smoker histori mdd alcohol depen denc group cognit behavior mood manag ment program significantli higher rate smoke abstin compar behavior skill control group patten martin myer calfa william 1998 examin efficaci cognit behavior depress skill treatment brown al 2001 recruit sampl smoker past mdd examin 8 session group treatment equat therapist particip contact time standard smoke cessat st st cognit behavior treatment depress cbtd find signific main effect treatment secondari analys reveal smoker recurr mdd receiv cbtd significantli abstin receiv st find replic pool data previous cite studi hall colleagu haa muñoz humfleet reu hall 2004 find suggest recurr mdd marker smoke cessat failur histori mdd appear smoker lifetim mdd episod benefit target mood manag skill smoke cessat treatment interestingli cbtd shown significantli improv smoke cessat outcom smoker higher level depress symptom brown al 2001 neg mood haa al 2004 addit develop cognit behavior mood manag treatment depress smoker efficaci antidepress pharmacotherapi examin major focu bupropion hydrochlorid bupropion select inhibitor noradrenalin dopamin hypothes bupropion effect reduc reuptak dopamin mesolimb system result reduc crave reduc reuptak nora drenalin locu coeruleu reduc nicotin withdraw symptom hai ebbert 2003 bupropion consist outperform placebo acut smoke cessat studi gonzal al 2001 hall al 2002 hurt al 1997 jorenbi al 1999 simon duncan carmodi hude 2004 tonnesen al 2003 relaps prevent studi cox al 2004 hai al 2001 vari subpopul smoker cardiovascular diseas tonstad al 2003 post traumat stress disord hertzberg moor feldman beckham 2001 schizophrenia evin al 2001 georg al 2002 hospit employe dalsgaro al 2004 african american ahluwalia harri catlei okuyemi mayo 2002 veteran dual diagnos saxon al 2003 adolesc attent deficit hyperact disord upadhyaya bradi wang 2004 bupropion antidepress studi examin differenti impact depress symptom smoke cessat depress symptom measur beck depress inventori found chang smoke cessat treatment bupropion last 7 week hurt al 1997 9 week jorenbi al 1999 find consist efficaci bupropion examin cessat smoker histori mdd studi find bupropion efficaci past mdd smoker hall al 2002 smith al 2003 studi find differenti efficaci cox al 2004 hayford al 1999 import question remain efficaci cognit behavior mood manag treatment bupropion smoker depr sive vulner unclear intens cognit behavior mood manag treatment robust effect sever vulner mood man agement treatment bupropion primarili studi independ smoke cessat effort previou studi explor therapeut approach concert improv smoke cessat outcom combin approach syner gistic influenc mood smoke depress smoker review cont plutchik wild karasu 1986 friedman al 2004b studi keller al 2000 miller al 2005 suggest combin psychotherapi pharmacotherapi effect treatment mdd similarli clinic practic guidelin treatment tobacco depend recommend pharmacotherapi combin intens treatment fior al 2000 722 treatment depress smoke cessat nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org present studi examin effect intens cognit behavior mood manag treatment bupropion singularli combin achiev mainten smoke cessat adult smoker random placebo control clinic trial studi build previou work brown al 2001 increas intens cbtd 8 session 12 session incorpor test efficaci bupropion made depress treatment literatur typic cognit behavior treatment mdd 16 20 session derubei al 2005 hollon al 1992 benefit combin psychotherapi phar macotherapi demonstr friedman al 2004a hollon al 2005 interest studi synergist effect cbtd bupropion smoke cessat outcom gener risk smoke subpopul base depress vulner factor smoke cessa tion failur histor i. smoker singl past episod recurr mdd current i. elev depress symptom method particip particip 524 smoker recruit new paper radio televis advertis particip random doubl blind placebo control 262 clinic trial compar standard cognit behavior smoke cessat treatment bupropion sr st bup standard cogni tive behavior smoke cessat treatment placebo st plac standard cessat treat ment combin cognit behavior treatment depress bupropion sr cbtd bup standard cessat treatment combin cognit behavior treatment depress placebo cbtd plac phone call potenti particip gener hospit base health well referr phone line staf hospit volunt time potenti particip inform natur studi requir particip studi exclus criteria concurr psycholog psychiatr treatment unstabl medic condit e.g hypertens seizur disord invit attend inform meet prior studi particip extens divers demand health well volunt staff unabl systemat collect inform particip attend inform meet meet potenti particip inform studi procedur random hospit studi site schedul intak interview assign site confirm elig intak interview particip sign statement inform consent approv butler hospit miriam hospit institut review board particip studi smoke 10 cigarett dai past year exclus criteria current axi disord diagnost statist manual mental disord 4th edit dsm iv american psychiatr associ 1994 dsm iv diagno si past year psychoact substanc abus depend nicotin current psychotrop medic medic interact advers bupropion current weekli frequent psychotherapi tobacco product particip screen studi physician rule unstabl medic condit hypertens preg nanci lactat refus contracept studi medic histori seizur disord head injuri loss conscious eat disord panic disord particip agre studi suppli medic smoke cessat durat studi particip initi telephon screen particip met preliminari criteria invit attend inform meet outlin studi detail invit schedul initi assess interview particip provid written inform consent prior studi particip particip randomli assign treatment site receiv manual group treatment st cbtd initi assess interview particip screen exclus criteria current dsm iv diagnos structur clinic interview administ train research assist super vise ph.d level investig train clinic psycholog particip complet medic examin studi physician assess medic exclus criteria particip randomli assign receiv medic condit bupropion placebo urn random techniqu wei 1978 assign base gender current depress symptom level nicotin depend figur 1 detail inform treatment cell size particip complet group medic therapi 12 week measur assess complet baselin follow 2 6 12 month post treatment nicotin tobacco research 723 nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org descript diagnost measur particip provid demograph background inform ag gender year educ marit statu number year regular smoke averag number cigarett dai current past axi diagnos determin structur clinic interview dsm iv nonpati ent edit scid np spitzer gibbon william 1995 sever nicotin depend assess fagerström test nicotin depend ftnd heatherton kozlowski frecker fagerström 1991 item measur higher score indic higher level nicotin depend measur smoke statu withdraw report smoke statu obtain treatment session quit date end treatment telephon 2 6 12 month outcom analys base 7 dai point preval abstin particip report abstin verifi biochem method alveolar carbon monoxid cmd carbon monoxid monitor spiro metric auburn main salivari cotinin assai 2 ml saliva sampl collect treatment 6 12 month follow assai american health foundat valhalla york follow biochem measur obtain person particip report 7 dai abstin abstin con firm combin 10 ppm cotinin 15 ng ml cum richard 1988 srnt subcommitte biochem verif 2002 case biochem verifica tion obtain 8.2 report abstin verifi interview signific measur depress symptom center epidemiolog studi depress scale ce radloff 1977 assess depress symp tom prior treatment scale demonstr good reliabl valid radloff 1977 found significantli current smoke statu inabil iti quit gener popul anda al 1990 histori mdd assess scid np covari analys treatment medic particip random receiv medic bupropion sr placebo figur 1 particip enrol bup bupropion cbtd cognit behavior therapi depress plac placebo st standard treatment 724 treatment depress smoke cessat nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org particip receiv ident packag bupropion placebo pill prepar manufactur zyban glaxo smith kline bupropion deliv er standard therapeut dose 150 mg dai 3 dai 300 mg dai total 12 week particip studi staff blind medic condit studi medic side effect monitor weekli basi 5 4.8 sampl discon tinu medic treatment rash high blood pressur anxieti sto mach problem chest pain swollen tongu difficulti concentr psychosoci intervent particip random receiv intens group counsel intervent standard smoke cessat treatment st standard cessat treatment combin cognit behavior group therapi depress cbtd group treatment condit provid twelv 90 min session equat therapist contact time session initi occur weekli weekli monthli session total 12 week quit date began awaken morn seventh session 3 week session 1 st condit comprehens program includ monitor manag nicotin fade relaps prevent social support enhanc cbtd condit consist standard smoke cessat skill cognit behavior cope skill depress includ daili mood rate pleasant event schedul cognit restruc ture assert train treatment detail brown al 2001 particip random treatment condi tion 157 st plac 112 cbtd plac 147 st bup 108 cbtd bup balanc drug placebo condit individu basi behavior treatment random group suscept fluctuat recruit avail site pair senior junior therapist train cbtd fluctuat prevent fulli implement studi plan assign group cohort st cbtd group averag particip attend 9.19 sd52.53 session session atten danc significantli treatment group 05 tabl 1 list demo graphic smoke characterist treat ment condit therapist group led ph.d level psychologist experienc cbt total 13 therapist 8 male 5 femal conduct treatment session therapist provid treatment condit richard brown provid therapist train oversight junior therapist pair senior therapist train extens treatment protocol group session audiotap purpos supervis assess therapist adher protocol data analys examin effect treatment point preval abstin post treatment follow up conduct repeat measur analys categor outcom gener estim equat gee liang zeger 1986 zeger liang 1986 gee analysi inclus categor continu ind pendent variabl model covari structur observ corr late time analys conduct sa proc genmod logit link func tion unstructur correl matrix speci fi covari gee analys gender averag daili smoke rate baselin ce score histori mdd dichotom simpli histori posit histori neg extrem low number individu histori recurr mdd addit variabl carri linear effect time includ model initi model includ term treatment site interac tion treatment site treatment tabl 1 baselin characterist particip treatment condition.a characterist st plac n5157 cbtd plac n5112 st bup n5147 cbtd bup n5108 ag 45.16 10.98 44.40 9.89 43.89 9.95 43.36 10.57 femal 47.10 44.60 51.0 46.30 cigarett dai 25.54 9.62 25.40 11.34 24.46 9.88 24.06 9.30 ce score 6.31 5.99 5.44 6.70 6.53 6.73 5.77 6.09 ce score 16 7.7 7.2 8.8 11.1 mdd histori 22.9 23.4 19.0 16.8 note bup bupropion cbt cognit behavior therapi depress ce center epidemiolog studi depress scale mdd major depress disord plac placebo st standard treatment avalu mean standard deviat percentag nicotin tobacco research 725 nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org signific effect found valu 25 term drop analys test main effect treatment test interact treatment condit time determin treatment effect weaken follow up test simultan interact cbtd covari test interact bupropion covari final test interact cbtd bupropion inter action cbtd bupropion measur depress vulner mdd histori ce primari analys individu smoke abstin confirm follow consid abstin miss data consid nonabstin report abstin rate correspond report abstin smoke cessat trial cross studi comparison gee analys ran analys assumpt made miss data data particip analys exclud 12 particip provid follow data result assumpt miss data highli concord worst case assumpt detail result 524 particip random treatment 249 47.5 women 322 61.4 marri mean ag sampl 44.27 year sd510.38 mean number year educ 13.61 sd52.25 major particip 92 identifi white n5482 3.8 african american n520 2.3 hispan n512 1.9 n510 identifi come racial ethnic origin prior treatment particip report smoke averag 24.6 cigarett dai sd510.0 smoke averag 26.0 year sd510.64 sampl mean ftnd 6.41 sd51.90 major particip 94.5 made quit attempt last 12 hr sampl baselin mean ce radloff 1977 6.08 sd56.37 particip 79.0 n5414 histori mdd 17.6 particip n592 singl past episod mdd 3.1 parti cipant n516 recurr mdd inform past histori mdd miss particip 0.4 rate histori substanc disord high 43.7 specif 39.5 met criteria lifetim alcohol abus n5120 depend n587 19.1 met criteria lifetim drug abus n541 depend n559 524 particip began treatment 426 particip signific 81.3 provid complet outcom data follow up post treatment 2 month 6 month 12 month total 64 particip 12.2 lack complet outcom data follow up 13 2.5 lack data follow up 9 1.7 lack data follow up 12 2.3 lack data follow up odd complet follow up significantli relat treatment condit dai point preval abstin rate end treatment 2 month 6 month 12 month follow up cell 262 design st plac 24.8 21.0 17.8 15.3 cbtd plac 25.9 25.9 15.2 17.9 st bup 49.7 42.9 27.9 22.5 cbtd bup 38.9 25.0 23.2 17.6 outcom shown figur 2 rate continu abstin confirm abstin post treatment 2 month 6 month 12 month 8.9 11.6 17.7 11.1 initi gee model time covari gender smoke rate baselin ce score mdd histori main effect treatment show signific effect time b520.31 se50.04 or50.73 0001 reflect strong tendenc abstin rate decreas treatment main effect cigarett smoke week signific greater smoke relat lower odd abstin b520.02 se50.09 or50.98 p5.03 effect covari nonsignific main effect bup signific b50.68 se50.17 or5 1.97 0001 receiv bup greater odd abstin receiv plac main effect cbtd nonsignific b520.21 se50.17 or50.81 p5.22 step analysi interact bup cbtd ad interact bup time cbtd time bup6tim interact signific b520.20 se50.07 or50.82 p5.009 result decreas rate abstin post treatment 12 month significantli steeper receiv bup receiv plac post treatment main effect bup compar plac highli robust b50.88 se50.19 or52.41 0001 effect weaker 2 month post treatment b50.61 se50.20 or51.84 p5.002 6 month post treatment b50.54 se50.22 or51.72 p5.01 substanti weaker nonsignific 12 month b50.26 se50.23 or51.30 p5.26 remain model bup6tim interact retain interact drop model 726 treatment depress smoke cessat nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org step variabl carri interac tion cbtd covari gender smoke rate baselin ce score mdd histori ad simultan model interact signific valu 19 remov interact ad interact bup covari interac tion signific valu 07 correl covari gener weak valu 10 correl femal gender smoke rate 522 52.20 0001 correl mdd histori baselin ce score 519 5.18 0001 multicollinear covari test covari interact treatment individu interact effect test nonsignific final test potenti synergist effect bup cbtd depress risk factor ran model ad interact mdd histori ce bup cbtd bup6cbtd mdd history6bup6cbtd interac tion ce d6bup6cbtd interact signific valu 30 found evid synergist effect smoker depress vulner discuss studi examin efficaci bupropion combin intens group smoke cessat treatment context random doubl blind placebo control clini cal trial strength studi includ larg sampl size 12 month follow high retent rate biochem verifi smoke outcom primari aim studi examin efficaci bupropion combin intens cognit behavior smoke cessat treatment addit cbtd consist previou studi bupropion compar placebo result smoke outcom intens group treatment bupropion asso ciat higher rate abstin end treatment follow time point ad cbtd standard intens group treatment result improv smoke cessat outcom addit cbtd bupropion differ ential effect smoker depress vulner abil factor mdd histori elev depress symptom treatment effect bupropion signific present studi expect addit cbtd offer extra benefit smoker depress vulner factor previou work brown al 2001 hall colleagu haa al 2004 demonstr ad cbtd smoke cessat treatment efficaci smoker recurr mdd effort extend efficaci treatment smoker depress vulner abil factor singl past episod mdd elev depress symptom increas dosag cbtd studi 8 session 12 session contrari hypothesi ad cbtd standard cognit behavior smoke figur 2 rate confirm 7 dai point preval abstin end treatment period 2 6 12 month treatment end bup bupropion cbtd cognit behavior therapi depress plac placebo st standard treatment nicotin tobacco research 727 nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org cessat treatment significantli improv outcom smoker histori mdd elev level depress symptom preval past episod mdd low end rang found previou smoke cessat studi 16 particip recurr mdd prohibit conduct analys specif subgroup result speak primarili effect cbtd singl episod mdd consist previou find ing brown al 2001 hall al 1996 increas dosag found evid benefici effect cbtd smoke cessat predominantli singl past episod mdd smoker 108 smoker histori mdd limit statist power find effect cbtd group 108 particip power approxim 80 find signific effect cbtd follow assum true effect size h5.50 e.g 20 abstin 43 abstin or53.0 effect medium size cohen 1988 effect cbtd past mdd smaller odd ratio 1.30 gee analysi find regard vulner factor recurr mdd elev depress symptom note small sampl size prohibit test effect cbtd recurr mdd similarli smoker sampl low level depress symptom cbtd differenti effect smoker clinic elev level depress symptom strong bodi literatur support bupropion smoke cessat result point wane effect bupropion smoke cessat treatment 12 month discontinu bupropion abstin rate declin treatment bupropion longer show advantag placebo continu prescrib bupropion follow ing discontinu intens group smoke cessat treatment maintain smoke abstin prevent smoke relaps support suggest found multicent random doubl blind placebo control studi smoker abstin 7 week open label bupropion randomli assign 45 week placebo bupropion hai al 2001 studi 52 week point preval smoke abstin significantli higher bupropion group placebo group median time relaps continu abstin higher treatment group continua tion bupropion smoke cessat promis mainten strategi intens group treatment low preval smoker signific depress vulner limit abil test hypothes impact bupropion cbtd risk subpopul smoker explan low rate depress vulner exclud particip take prescrib psychotrop medic engag psychotherapi individu signific depress vulner receiv form treatment addition exclus individu type medic comorbid iti result lower particip depress vulner smoker high rate medic morbid individu depr sion well al 1989 present studi sampl homo geneou regard racial composit particip white sampl reflect racial characterist prevail local popul white individu respond differ treatment caution make direct gener izat result popul studi featur intens group smoke cessat treatment equat contact time limit design lack inclus control condit estim efficaci intens treatment final imbal exist particip assign group treatment lack group differ confid studi conclus differ group balanc summari studi shown bupropion effect rang depress vulner factor present studi support previous observ lack effect cbtd smoke cessat smoker histori mdd singl past episod mdd cbtd appear promis smoke cessat smoker recurr mdd brown al 2001 haa al 2004 present studi unabl evalu effect cbtd risk popul regard elev depress symptom cbtd bupropion appear differenti efficaci low moder rang depress symptom futur studi evalu effect treatment smoker clinic elev level depress symptom priori test cbtd smoker recurr mdd warrant effect cbtd popul found post hoc test 728 treatment depress smoke cessat nivers berdeen arch 3 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org interact studi design specifi calli test cbtd smoker vulner factor acknowledg research support nation institut health grant da08511 richard brown hl32318 raymond niaura author suzann sale melani poisson donna delanei adrien mcparlen contribut
author 2013 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com doi 10.1093 ntr ntt093 origin investig develop preliminari random control trial distress toler treatment smoker histori earli laps richard brown phd1 kathleen palm reed phd2 erika litvin bloom phd1 haruka minami phd1 david strong phd3 carl lejuez phd4 christoph kahler phd5 michael zvolenski phd6 elizabeth gifford phd7 steven hay phd8 1depart psychiatri human behavior butler hospit alpert medic school brown univers provid ri 2depart psycholog clark univers worcest ma 3depart famili prevent medicin univers california san diego la jolla ca 4depart psycholog univers maryland colleg park md 5brown univers center alcohol addict studi provid ri 6depart psycholog univers houston houston tx 7center health care evalu va palo alto health care system menlo park ca 8depart psycholog univers nevada reno nv author richard brown phd butler hospit alpert medic school brown univers 345 blackston boulevard provid ri 02906 telephon 401 455 6254 fax 401 455 6424 mail richard_brown brown.edu receiv februari 20 2013 accept june 10 2013 abstract introduct inabl toler distress signific com.ibm.drl.hbcp.predictor earli smoke laps cessat attempt conduct preliminari random control trial compar distress toler dt treatment incorpor element exposur base therapi accept commit therapi standard smoke cessat treatment st method smoker histori earli laps prior quit attempt receiv dt 27 9 2 hr group 6 50 min individu session st 22 6 90 min group 1 20 min individu session 8 week transderm nicotin patch result end behavior treatment odd abstin particip receiv dt 6.46 time greater particip receiv st 66.7 31.8 equival medium larg effect size odd abstin dt 1.73 time greater 8 week small medium effect size differ 13 26 week statist signific laps smoke week postquit dt particip 4 time greater odd abstin st particip end treatment rel st dt particip report larger decreas experienti avoid hypothes dt treatment mediat prior quit dai trajectori neg mood withdraw symptom dt differ st larg consist hypothes conclus reason decreas abstin dt treatment discontinu suggest futur research discuss introduct distress toler earli smoke laps structur plan prepar prior quit date particip smoke cessat program unabl sustain quit attempt matter dai anecdot evid emerg find suggest common experi earli lapser substanti risk subsequ relaps shiffman al 2006 propos mileston process success smoke cessat initi abstin 24 hr smoke avoid laps instanc smoke initi abstin recent investig mileston reveal smoker unabl sustain quit attempt matter dai larg studi 1,429 smoker 44 fail quit consecut dai includ 12 achiev initi abstin i. 24 hr abstin japuntich al 2011 studi report similar outcom studi 3,000 smoker receiv telephon assist smoke cessat treatment zhu al 1996 approxim 50 smoke week postquit earli lapser substanti risk subsequ relaps gener defin smoke 7 consecut dai advanc access public juli 24 2013 2005 nicotin tobacco research volum 15 number 12 decemb 2013 2005 2015 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload mailto:richard_brown brown.edu http ntr.oxfordjournals.org treatment earli laps smoker definit 60 lapser relaps experienc laps averag 3 4 dai shiffman al 1996 50 relaps occur 2 week crucial develop treat ment strategi smoker histori repeat earli laps past decad research highlight cen tral role respons neg affect smoke laps subsequ relaps relatedli recent studi shown primarili sever intens distress predict smoke laps degre individu toler discomfort i. distress tol eranc dt brown lejuez kahler strong 2002 brown al 2009 exhibit task persist brandon al 2003 quinn brandon copeland 1996 brown al 2002 found current smoker fail sustain previou quit attempt 24 hr imm diat relaps compar current smoker quit smoke past period 3 month delai relaps higher level depress symptom greater tendenc react stress neg affect shorter latenc termin physic psycholog challeng task data subsequ prospect studi confirm combin psycholog physic dt index limit persist laboratori challeng task underli smoke laps import impli cation smoke cessat treatment trace figur mirror brandon al 2003 breath hold breath carbon monoxid rich air brown al 2009 paradigm manag dt behavior exposur therapi e.g barlow crask cerni klosko 1989 accept commit therapi act hay strosahl wilson 1999 current studi describ outcom behavior therapi develop project incorpor element exposur act increas dt high risk popul smoker histori earli smoke laps detail descript treat ment preliminari find small uncontrol sampl earli laps smoker brown al 2008 behavior exposur act smoke cessat recent neg reinforc model smoke baker piper mccarthi majeski fior 2004 parrott 1999 similar establish learn theori account anxi eti disord describ anxieti maintain avoid escap behavior mowrer 1960 treatment anxieti disord research consist found confront previous avoid distress absenc avoid escap behavior lead greater respons flex ibil eventu decreas distress meuret wolitzki taylor twohig crask 2012 extend find anxieti literatur behavior smoke cessat intervent address dt com.ibm.drl.hbcp.core sy temat repeat exposur increasingli lengthi period smoke abstin predict rela tive smoker engag exposur prior quit smoker expos nicotin withdraw neg affect increas period abstin engag avoid escap behavior exp rienc sever withdraw neg affect prior quit date report eventu decreas withdraw neg affect quit accumul evid suggest order expo treatment maxim effect individu fulli engag exposur attempt distract engag avoid strategi crask street barlow 1989 grayson foa stekete 1982 propos prospect quitter need demonstr willing remain uncomfort state work desir goal quit smoke end act hay al 1999 strategi incorpor treatment act place central focu accept defin behavior approach psycholog avers troubl intern stimuli behav adapt gifford 1994 gifford hay 1997 distress intoler individu benefit act base approach teach accept uncomfort symptom sensat commit achiev valu goal abstin smoke previou studi provid support applic act smoke cessat gener popula tion adult smoker bricker mann marek liu peterson 2010 gifford al 2004 hernández lópez luciano bricker roal nieto montesino 2009 previou studi compar accept base smoke ce sation treatment standard cognit behavior treatment hernández lópez al 2009 previou studi except small uncontrol studi brown al 2008 focus specif treatment smoker histori earli smoke laps present studi evalu result preliminari random control trial compar dt treatment standard smoke cessat treatment combin 8 week transderm nicotin patch select sampl earli laps smoker defin regular smoker tori quit attempt past 10 year attempt last longer 72 hour expect earli laps smoker assign dt treatment higher point preval abstin rate short long term follow compar standard treatment st predict abstin mediat decreas gener smoke specif experienti avoid defin unwilling remain contact uncomfort bodili sensat emot thought involv effort control suppress experi addition predict compar st smoker dt experi greater neg affect withdraw symptom group session preced quit dai neg affect withdraw quit dai line previou research expect abstin predict neg affect withdraw experienc quit dai method particip adult smoker recruit newspap radio advertis target smoker previou difficulti quit short period time inclus criteria ag 18 65 year smoke 15 cigarett dai past 3 year motiv quit smoke 2006 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research month past 10 year made quit attempt remain abstin 72 hr particip exclud current diagnost statist manual mental disord dsm iv axi disord psychoact substanc abus depend exclud nicotin depend past 6 month current psychotrop medic histori signific medic condit e.g cardiovascular neurolog gastrointestin system ill deem unhealthi context complet physic examin pregnanc breast feed current pharmacotherapi smoke cessat tobacco product met preliminari criteria initi phone screen schedul comprehens baselin assess includ inform consent structur clinic interview dsm iv patient version scid np spitzer gibbon william 2002 complet report measur conduct 1,047 phone screen 12 month period 118 potenti particip schedul baselin assess 59 show complet baselin assess 10 rule base scid np result 49 particip clinic trial consort flow diagram shown figur 1 institut review board butler hospit provid ethic approv studi treatment particip receiv 8 week nicotin replac ther com.ibm.drl.hbcp.api form nicotin patch nicoderm cq begin quit dai includ 4 week 21 mg patch 2 week 14 mg 2 week 7 mg anticip number size behavior treatment group determin advanc i. group treatment condit 10 group member group treatment assign ment randomli select fix pool assign detail therapist manual ensur standard deliveri content condit doctor level psychologist traine psycholog intern postdoc toral fellow deliv treatment senior author rab author kmpr train therapist con duct weekli group supervis session ensur standardi zation protocol deliveri standard smoke cessat treatment st protocol studi base standard behavior protocol publish previous brown 2003 yield posit outcom control trial brown al 2001 st compon includ monitor identifi trigger develop manag strategi cope trigger e.g avoid alter assess elig phone 1,047 exclud 998 meet inclus criteria 917 quit attempt longer 72 hour past 10 year 648 scid diagnosi baselin assess 10 259 lost interest declin particip 22 complet baselin assess 59 random 49 alloc dt 27 receiv dt 27 alloc st 22 receiv st 22 lost follow 8 week 2 lost follow 13 week 1 lost follow 26 week 2 lost follow 8 week 0 lost follow 13 week 1 lost follow 26 week 1 analyz 27 analyz 22 phone call receiv 1,136 unabl contact screen 89 figur 1 consort flow diagram 2007 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org treatment earli laps smoker substitut relaps prevent skill e.g identifi plan high risk situat st deliv 6 week period includ 90 min group session 20 min phone session quit week occur begin week 3 dt treatment descript specif dt treatment compon detail brown al 2008 dt element drawn exposur base accept base act hay al 1999 treatment approach treatment compris 50 min individu session 2 hr group session 8 week period quit dai occur begin week 5 treatment session particip engag exercis aim increas tol eranc distress maintain focu valu life goal quit smoke exampl strategi emphas treatment includ nicotin fade foxx brown 1979 schedul abstin valu clarif accept defus exercis manag skill rational choic st comparison condit consid compar dt comparison condit equat contact time provid stringent comparison dt treatment treatment effect attribut differ treatment content development natur project limit power detect signific differ enc power analysi decid restrict consist development goal project decid compar compari son fulli equat contact time expecta tion larger random control trial fulli equat contact time major addit treat ment contact dt treatment specif devot deliv train act dt skill front load session prior quit date treatment session intend individu learn skill measur assess occur baselin prior group treat ment session 8 13 26 week follow postquit date 96 96 92 complet rate particip paid 25 complet end treat ment 8 13 week assess 50 complet 26 week assess addition receiv 20 pro vide saliva sampl cotinin analysi verifi abstin 13 26 week assess smoke statu report smoke past 7 dai 7 dai point preval collect particip group treatment session 8 13 26 week follow up particip report abstin verifi expir carbon monoxid 5 ppm 8 13 26 week cotinin verif cotinin 10 ng ml 13 26 week unavail assess 6 week 8 12 week 13 9 week 26 absti nenc verifi inform identifi particip prior quit unverifi report absti nenc consid smoke smoke histori pattern smoke histori pattern assess standard smoke histori questionnair brown al 2002 fagerström test nicotin depend ftnd heatherton kozlowski frecker fagerström 1991 continu measur nicotin depend mediat process experienti avoid gener accept action questionnair aaq cronbach α 70 hay al 2004 9 item question nair design measur tendenc engag exp riential avoid gener natur item rate 7 point likert scale 1 true 7 true sampl item includ i’m afraid feel feel depress anxiou unabl care respons high score experienti avoid low score greater psy cholog accept willing smoke specif avoid inflex scale ai cronbach α 93 gifford antonuccio kohlenberg hay piasecki 2002 13 item measur design assess likelihood smoke relat intern experi thought smoke feel crave smoke stress boredom enjoy bodili sensat physic withdraw symptom lead smoke degre believ reduct frequenc intens intern experi i. avoid order smoke respons likert scale rang 1 5 weekli measur group treatment neg mood withdraw symptom tension depress anger subscal profil mood state pom mcnair lorr droppleman 1971 sum creat total neg mood score withdraw symptom assess item minnesota nicotin withdraw scale hugh hatsukami 1986 piasecki al 2000 divid scale affect irrit frustrat anger anxieti nervou ness sad depress difficulti concentr physic symptom restless appetit increas crave singl item sleep disturb troubl wake troubl fall ing asleep dream usual disrupt wake frequent treatment integr dt condit adher rate modifi version act tape rate scale gifford hay 1998 develop map close dt treatment manual specif therapist behavior consid prescrib proscrib waltz addi koerner jacobson 1993 rater assess presenc absenc behavior separ st treatment rate scale develop similar manner treatment session condit videotap approxim 40 st dt tape randomli select rate independ rater rater research assist treatment deliveri receiv approxim 10 hr adher code train weekli supervis kappa coeffici comput 2008 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research ascertain reliabl estim disagr code rater conserv assess behavior direct nonadher power analysi development natur project main con cern determin sampl size obtain reason esti mate effect size power effect size valu effect size estim present odd ratio or smoke abstin chinn 2000 suggest or 1.44 2.47 4.25 equival cohen valu 0.2 small 0.5 medium 0.8 larg respec tive cohen 1992 group mean continu variabl typic begin stabil 15 particip dichotom variabl point preval abstin sam ple size 50 25 condit provid stabl group proport effect size estim estim sampl size 50 evalu potenti dt intervent budgetari constraint development project recogn larg larg effect cohen 0.80 power 80 alpha 05 attain statist signific sampl size cohen 1988 data analysi primari aim examin dt earli lapser led higher abstin rate behavior treatment improv long term smoke cessat outcom 8 13 26 week quit dai test effect dt treat ment verifi 7 dai point preval abstin behavior treatment weekli assess quit date 4 week quit date long term fol low period 8 13 26 week assess con duct gener estim equat gee gee method repeat measur analys categor outcom model absti nenc observ time particip random treatment includ intent treat analysi analys assum α 05 note previous effect size greater interest absolut signific level small sampl size explor potenti mechan chang oper dt treatment conduct seri success regr sion analys relat dt treatment experi ential avoid gener smoke specif prior quit dai propos mediat prior quit dai biochem verifi abstin 4 week behavior treatment quit dai control treatment regress analys compar lev el neg mood pom subscal drawal symptom week prior quit dai quit dai dt versu st treatment differ neg mood withdraw symptom quit dai examin gee control baselin level variabl time week quit dai plan covari ag level nicotin depend neg mood withdraw symptom assess quit dai 1 2 4 week end group treatment quit includ analys st group complet assess week 3 result preliminari analys treatment assign final sampl 49 particip 27 receiv dt treatment 22 receiv st treatment dt st group differ characterist prior random tabl 1 particip mean ag 47.68 sd 10.31 year 49 femal 32.7 high school educ 4.1 hispan latino 90 caucasian particip moder level nicotin depend mean ftnd 6.3 sd 1.73 mean cigarett dai 21.65 sd 8.33 enter treatment mild level depress symptom mean ce 9.32 sd 7.70 49 particip 14 28.6 report prior major depress episod dsm iv criteria 50 7 endors recurr major depress episod treatment integr treatment integr rate 99.9 prescrib element present dt tape rate 100 prescrib behavior present st tape proscrib behavior observ st dt session tape good treatment integr treatment condit averag kappa coeffici rater code treatment tape 99 dt treatment 1.0 st indic excel agreement smoke outcom behavior treatment gee model examin ag gender year cation potenti covari addit plan inclus level nicotin depend linear effect time propos covari ag adjust odd ratio aor 1.04 95 ci 0.99 1.10 11 includ level depend aor 0.81 95 ci 0.62 1.07 14 linear effect time primari set covari gender year educ show relationship outcom ps 5 control primari set covari verifi abstin rate 1 2 3 4 week quit dai significantli smok er dt st evidenc signific treatment time interact aor 1.76 95 ci 1.24 2.50 002 end behavior treatment 4 week quit dai smoker dt significantli abstin st 66.7 31.8 aor 6.46 95 ci 1.58 26.50 001 equival larg effect size 1.03 chinn 2000 end nicotin patch treatment 8 week follow abstin rate smoker dt st 40.7 31.8 differ longer significantli dif ferent aor 1.73 95 ci 0.46 6.48 reflect small medium effect size 30 figur 2 long term smoke outcom evalu 7 dai point preval abstin rate 4 end group treatment 8 end patch treatment 13 26 week postquit assess gee analysi covari main effect treatment condit sig nific statist aor 1.83 95 ci 0.46 7.34 39 step interact covari 2009 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org treatment earli laps smoker treatment condit enter block term model signific interact treatment condit time covari ps 10 verifi 7 dai point preval abstin rate assess point dt st group shown figur 2 recoveri laps secondari analys conduct examin group dif ferenc rate recoveri earli laps laps week quit date 51.0 particip dt condit time 5.55 particip st condit abstin end group treatment 4 week postquit date reflect larg effect size 95 fulli abstin week 49.0 100 particip dt condit 54.6 partici pant st condit abstin end group treatment mediat process decreas experienti avoid order evalu propos treatment mechan sequenti process evalu degre smoker dt rel st larger decreas experienti avoid anc gener smoke specif baselin quit date examin aaq index gener experienti avoid ai index smoke specif exp riential avoid dt treatment hypoth esiz chang experienti avoid prior quit attempt examin prequit experienti avoid mediat examin postquit experienti avoid media tor confound smoke outcom regress analys signific differ aaq 1.61 se 1.97 42 score smok er dt st treatment signifi differ ai score 5.16 se 2.46 04 smoker dt treatment averag larger decreas level smoke specif experienti avoid smoker st logist regress model examin experienti avoid relat success cessat end behavior treatment logist model control standard covari treatment condit success model includ aaq ai measur assess baselin margin relationship aaq score prior cessat odd abstin 0.17 tabl 1 demograph smoke characterist final sampl distress toler treatment standard treatment 27 22 femal 12 44.4 12 54.5 race ethnic hispan 2 7.4 0 0.0 white 24 88.9 20 90.9 african american 3 11.1 2 9.1 educ high school graduat 2 7.4 4 18.2 high school graduat 4 14.8 6 27.3 colleg 14 51.9 9 40.9 colleg degre 3 11.1 2 9.1 master degre 4 14.8 1 4.5 marit statu marri 15 55.6 8 36.4 engag 0 0.0 1 4.5 divorc 8 29.6 6 27.3 separ 0 0.0 1 4.5 marri 2 7.4 5 30.8 live 1 3.7 0 0.0 widow 1 3.7 1 4.5 employ emploi 23 85.2 17 77.3 depress histori depress episod 18 66.7 17 77.3 singl depress episod 3 11.1 4 18.2 recurr depress episod 6 22.2 1 4.5 sd sd ag 47.19 11.4 48.30 9.01 fagerström test nicotin depend 6.33 1.52 6.27 2.00 averag cigarett dai 22 7.26 21 9.65 2010 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research se 0.09 059 decreas gener experienti avoid anc prior cessat margin greater rate abstin end treatment sig nific relationship ai score prior cessat odd abstin end treatment 0.02 se 0.07 80 mediat requir treat ment affect mediat mediat relat outcom control treatment full mediat anali se conduct aaq chang ai relat outcom neg mood withdraw symptom prior quit dai consist predict effect exposur base intervent regress analys show smoker dt rel st report significantli greater increas neg mood pom immedi prior group session occur 2 week quit dai i. directli engag prescrib exposur exercis 7.75 se 2.40 003 immedi prior group session occur week quit dai 17.09 se 5.22 002 control baselin level neg mood support effect exercis particip dt report significantli lower level neg mood quit dai rel st control neg mood report week prior quit dai 8.73 se 3.65 02 figur 3 differ withdraw subscal score affect physic symptom crave sleep condit baselin observ ps 05 control level withdraw subscal baselin dt particip report significantli higher affect 0.44 se 0.21 047 physic symptom 0.51 se 0.22 026 week prior quit dai quit dai ps 05 compar st crave score increas significantli prior quit dai condit ps 2 consist hypothesi dt particip lower crave quit dai receiv st control crave week quit dai 0.54 se 0.25 04 figur 4 differ condit level sleep disturb week prior quit dai ps 05 neg mood withdraw symptom quit dai expect gee model reveal particip dt treatment rel st maintain significantli lower level crave 0.63 se 14 19.22 01 affect withdraw 0.26 se 13 3.97 046 end group treatment quit dai differ neg mood pom physic symptom sleep distur banc condit observ ps 05 figur 3 4 discuss find preliminari random con trol trial dt treatment smoker histori earli laps encourag complet behavior treatment 4 week quit date odd verifi 7 dai point preval abstin 6.46 time greater receiv dt 66.7 abstin receiv ing st 31.8 abstin particip equival medium larg effect size differ statist clinic signific noteworthi studi particip unabl quit smoke 72 hr past 10 year figur 2 abstin rate 7 dai point preval distress toler dt standard treatment st condit week 4 end group treatment abstin rate dt 66.7 significantli higher st 40.9 049 71 verifi 7 dai point preval abstin rate 8 13 26 week quit dai significantli differ dt versu st 40.7 22.2 14.8 31.8 27.3 9.1 2011 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org treatment earli laps smoker figur 4 weekli affect withdraw crave score distress toler standard treatment st condit withdraw symptom includ affect crave assess week 3 st condit includ figur week quitdai 5 63 10 7 8 9 8 40 4 5 5 0 5 5 6 0 6 5 baselin week 2 week 1 quit dai week 1 week 2 week 4 distress toler standard end group figur 3 weekli neg mood score distress toler standard treatment st condit pom profil mood state neg mood assess week 3 st condit includ figur particip receiv dt treatment show tendenc recov earli smoke laps regain abstin pattern characterist smok ing cessat treatment outcom research studi examin directli treatment outcom find sug gest smoker laps treatment drop treatment shortli borrelli al 2002 patterson al 2003 shiffman al 2006 current find suggest particip receiv dt treatment studi continu stai treatment smoke laps success effort persist face smoke laps regain abstin statu end 2012 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org nicotin tobacco research behavior treatment session laps smok ing week quit date dt particip time st particip abstin end treatment correspond larg effect size similar pattern shown previou act base smoke cessat research studi gifford al 2004 gifford al 2011 show higher quit rate 1 year follow versu 6 month particip laps regain abstin final dt treatment produc evid exposur act compon result hypothes particip reaction discomfort quit smoke evid gener tendenc experienti avoid measur aaq dt particip report decreas smoke specif experienti avoid i. avoid smoke withdraw relat thought feel bodili sensat prior quit dai find reflect fact primari emphasi dt intervent reduc attempt avoid smoke specif gener distress consist rational exposur base dt intervent particip dt rel st report significantli greater increas neg mood prior group session 2 week quit dai expect observ increas week dt particip prescrib exposur exercis engag prior arriv group e.g refrain smoke increasingli longer period time support effect exercis particip dt report significantli lower level neg mood crave quit dai rel st particip exposur base procedur hold signific promis strong relationship level neg mood reaction quit dai earli laps kenford al 2002 mccarthi piasecki fior baker 2006 piasecki kenford smith fior baker 1997 piasecki al 2000 hypothes chang reaction discomfort quit mechan effect dt improv cessat outcom odd abstin 1.73 time greater favor dt 8 week follow end nicotin patch treatment roughli small medium effect size differ maintain behavior treatment patch discontinu 13 26 week larg decreas abstin occur dt 4 week end behavior treat ment 8 week end patch postquit 8 week 13 week postquit reflect sudden di continu intens behavior treatment pharmacolog treatment earli laps popu lation requir extend activ treatment phase reduc intens gradual succe maintain long term abstin support extend treatment increas long term abstin rate begin ning accumul hall colleagu conduct studi indic extend pharma colog behavior treatment full year result significantli higher long term abstin rate 40 typic observ smoke cessat studi hall al 2011 hall al 2009 hall humfleet reu muñoz cullen 2004 limit current studi limit merit discuss respect particip smoker current psychi atric substanc comorbid exclud rel gener popul smoke preval individu condit substanti higher cdc 2013 lasser al 2000 result treatment stud i involv popul gener produc low abstin rate prochaska delucchi hall 2004 futur research need evalu efficaci dt approach popul expect dt approach directli target emot vulner com.ibm.drl.hbcp.core psychiatr substanc disord respect methodolog sampl size small obtain stabl estim effect size power detect signific group differ abstin rate relationship hypothes mediat outcom limit possibl group effect smoke outcom exist small sampl size construct stabl model treat group level anal ysi total contact time greater dt st differ observ treat ment attribut addit time differ treatment content futur studi need compar dt st equat contact time respect treatment content combin dt treatment nicotin patch convei inconsist me sage reduc particip opportun exposur practic dt skill purpos nicotin patch decreas discomfort intens nicotin withdraw crave line possibl previou smoke cessat studi found higher quit rate act act combin pharmaco therapi e.g compar gifford al 2004 gifford al 2011 half individu schedul base line assess show random treatment final sampl esp cialli motiv commit quit smoke rel popul smoker histori earli laps final particip histori earli laps result gener gener popul treatment seek ing smoker histori longer durat quit attempt futur research need determin dt approach suit smoker histori earli laps benefit gener popul smoker conclus summari conclud dt treatment signific clinic impact earli laps smoker dur ing treatment particip futur research need develop evalu innov method assist earli laps smoker extend maintain treatment gain extend time period method develop longer term success outcom achiev dt treatment hold promis import clinic smoke cessat resourc treatment resist subpop ulat addit larger studi determin 2013 nivers berdeen ovem ber 27 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org treatment earli laps smoker stabil effect size estim observ cur rent studi find applic broader popul smoker fund nation institut drug abus da017332 r.a.b declar interest declar
nicotin tobacco research volum 14 number 4 april 2012 443 447 443 doi 10.1093 ntr ntr233 advanc access publish decemb 21 2011 author 2011 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com higher post stroke mortal rate kammersgaard olsen 2006 myint al 2006 base observ studi estim 43 patient quit smoke stroke transient ischem attack tia stroke prevent annual hankei warlow 1999 smoke cessat wide recommend secondari stroke prevent recommend minor smoker give smoke stroke previou follow studi found 22 current smoker gave smoke month stroke bak al 2002 report smoke cessat rate 11 83 month year stroke gall dewei thrift 2009 iv heuschmann wolf redfern 2008 mouradian majumdar senthilselvan khan shuaib 2002 ovbiagel al 2004 redfern mckevitt dunda rudd wolf 2000 sappok al 2001 sienkiewicz jarosz zatorski baranowska ryglewicz bienkowski 2009 factor includ gender post stroke function statu sociodemograph characterist extent nicotin depend depress increas risk persist smoke stroke bak al 2002 iv al 2008 redfern al 2000 sienkiewicz jarosz al 2009 efficaci smoke cessat intervent ischem stroke tia perform random clinic trial compar efficaci minim smoke cessat intervent intens smoke cessat intervent patient acut ischem stroke tia subject method period februari 2005 octob 2006 cur rent daili smoker ag 76 admit depart neurolog univers hospit odens acut ischem stroke tia invit particip studi stroke tia defin world health organ criteria stroke 1989 recommend stroke abstract background smoke cessat wide recommend secondari stroke prevent efficaci smoke cessat intervent stroke tran sient ischem attack tia method nineti smoker ag 76 admit ischem stroke tia random minim smoke cessat intervent intens smoke cessat interven tion patient attend 30 min individu counsel studi nurs patient random intens smoke cessat intervent particip 5 session outpati smoke cessat program author smoke cessat instruc tor 30 min outpati visit 6 week 5 telephon counsel session studi nurs free sampl nicotin replac therapi offer part intens smok ing cessat program smoke cessat rate 6 month determin report verifi measur exhal carbon monoxid fewer patient expect recruit render report pilot studi result 6 month report smoke cessat rate 37.8 minim intervent group 42.9 intens intervent group smoke cessat rate verifi exhal level minim intervent group inten sive intervent group 28.9 32.7 differ found group c2 0.16 69 conclus smoke cessat rate moder compar result studi intens smoke cessat intervent superior short smok ing cessat intervent factor intens smoke cessat intervent influenc smoke cessat rate stroke tia introduct smoke recogn risk factor stroke ischem heart diseas persist smoke stroke origin investig smoke cessat intervent ischem stroke transient ischem attack random control pilot trial nicol brunner frandsen m.d margit sørensen r.n tanja kirstin hyldahl r.n rikk mitzi henriksen r.n søren bak m.d ph.d depart neurolog odens univers hospit odens denmark author brunner frandsen m.d depart neurolog odens univers hospit sdr boulevard 29 5000 odens denmark telephon 45 65 41 24 75 fax 45 65 41 33 89 mail nbrunner80 hotmail.com receiv april 18 2011 accept septemb 7 2011 nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload mailto:nbrunner80 hotmail.com http ntr.oxfordjournals.org 444 smoke cessat intervent ischem stroke prevent diagnosi therapi report task forc stroke cerebrovascular disord 1989 total number potenti particip admit studi period regist patient sever stroke e.g continu impair conscious aphasia symptom make impo sibl smoke patient sever concomit diseas decreas life expect patient wise unabl particip smoke cessat program exclud scandinavian stroke scale multicent trial hemodilut ischem stroke background studi protocol scandinavian stroke studi group 1985 assess stroke sever admiss inform previou stroke previou myocardi infarct alcohol consumpt stroke sever admiss retriev medic record patient comput tomographi scan ad mission establish diagnosi train studi nurs daili check record patient admit depart neurolog written inform consent elig patient random minim intens smoke cessat interven tion patient random comput gener list odd number number repres mini mal intens smoke cessat intervent creat consecut number seal envelop obtain inform consent studi nurs open random envelop patient inform intervent assign patient complet short structur interview includ question smoke habit marit statu daili tobacco consumpt calcul equat cigarett 1 cheroot 3 cigar 5 tobacco patient categor moder smoker 1 14 dai heavi smoker 14 dai weekli alcohol consumpt 21 drink men 14 drink women classifi high alcohol consump tion particip live current smoker regist baselin inform length hospit stai depress symptom degre nicotin addict regist intervent patient includ studi receiv 30 min individu counsel studi nurs studi nurs advis patient quit smoke hand booklet inform smoke cessat free nicotin replac therapi nicotin patch offer hospit stai patient request order physician patient minim smoke cessat intervent group receiv smoke cessat advic part studi patient random intens smoke cessat intervent offer session outpati smoke ce sation program discharg smoke cessat author smoke cessat instructor free sampl nicotin replac therapi gum patch tablet nasal sprai offer part program patient invit 30 min outpati visit week telephon counsel session studi nurs dai week week month month discharg session patient complet short structur interview current smoke habit includ daili consumpt cigarett nicotin replac therapi persist smoker repeat advis stop smoke initi sampl size estim studi 300 patient 150 patient group alpha 05 90 power detect differ approxim 18 cessat rate 22 minim intervent group versu 40 intens intervent group fewer patient expect recruit inclus period render report pilot studi follow patient group invit follow visit month discharg smoke cessat rate month determin report verifi measur exhal carbon monoxid micro smokerlyz bedfont scientif measur amount exhal equip studi calibr recom mendat manufactur patient instruct exhal complet fulli inhal hold breath exhal slowli fulli equip amount exhal report part million ppm studi patient 8 ppm classifi current smoker christensen al 2004 patient lost follow patient refus par ticip measur final visit consid persist smoker random patient includ final analysi smoke cessat rate patient di follow period chi squar test odd ratio compar smoke cessat rate group physician involv patient recruit smok ing cessat intervent follow visit studi approv ethic committe southern denmark danish registri board result total 94 patient stroke tia accept partici pate studi patient 45 47.9 random iz minim smoke cessat intervent 49 52.1 random intens smoke cessat intervent baselin characterist present tabl 1 patient random minim smoke cessat intervent 41 91.1 particip month follow visit patient left studi consid current smoker seventeen patient initi 45 patient 37.8 report smoke cessat patient report smoke cessat 13 patient accept measur exhal patient level nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 445 nicotin tobacco research volum 14 number 4 april 2012 8 ppm patient refus particip measur ment classifi persist smoker patient 17.8 nicotin replac therapi time month report smoke cessat forti 87.8 patient random tensiv smoke cessat intervent program complet studi patient left studi dai left month month patient left month consult patient consid er current smoker patient complet studi particip rate 98.9 person counsel session studi nurs 95.9 telephon con sultat twenti 67.4 patient complet studi gum nicotin patch time month 12 report smoke cessat visit 21 initi 49 42.8 report smok ing cessat patient 16 level 8 ppm ten 62.5 nicotin replac therapi time month 16 patient 50 level 8 ppm end follow period report smoke cessat dai discharg hospit smoke cessat rate verifi exhal level minim intervent group intens intervent group 28.9 32.7 differ found group c2 0.16 69 odd ratio smoke cessat due intens smoke cessat intervent 1.19 95 ci 0.45 3.17 discuss present studi random patient stroke tia minim intens smoke cessat intervent found differ smoke cessat rate group month follow major advantag present studi random design standard advic smoke cessat exhal level valid smoke statu previous smoke cessat rate stroke assess intervent studi studi 112 patient refer stroke prevent clinic stroke tia mouradian al 2002 identifi 38 smoker baselin clinic visit patient inform import risk factor modif report smok ing cessat rate year follow 11 popul base stroke regist 363 current smoker stroke aliv year follow forti percent report smoke cessat month 48 report smoke cessat year pattern smoke cessat relaps complex iv al 2008 johnson rosewel jame 2007 studi 98 patient undergo carotid endarterectomi 198 patient refer rapid access stroke clinic tia nondis stroke advic risk factor modif part usual treat ment report smoke cessat rate month 22 follow studi popul base stroke inci denc studi gall al 2009 trace 51 stroke survivor current smoker stroke onset 19 patient 37 stop smoke year stroke sistent smoker 40 recal receiv advic smoke cessat recent sienkiewicz jarosz al 2009 report result prospect month follow studi 98 current smoker stroke report smoke cessat 37 patient 38 confirm measur level exhal prospect studi specif aim improv sec ondari prevent stroke tia ovbiagel al 2004 found report smoke cessat rate 83 24 patient month admiss patient receiv advic secondari prevent includ smoke cessat diet exercis person stroke risk factor telephon interview discharg part prevent program compar smoke cessa tion rate intervent follow studi studi focus smoke cessat intervent major import lifestyl modif stroke studi potenti limit primari limit small sampl size made imposs demonstr small moder differ group sampl size prior studi calcul 150 patient group tabl 1 baselin characterist characterist minim smoke cessat intervent 45 intens smoke cessat intervent 49 ag year 25 49 10 22.2 10 20.4 50 65 21 46.7 29 59.2 65 14 31.1 10 20.4 femal 22 48.9 17 34.7 sssa admiss mean 51.6 54.4 high alcohol consumptionb 2 4.4 5 10.2 previou stroke 4 8.9 8 16.3 previou myocardi infarct 3 6.7 1 2.0 smoke admiss moder 1 14 dai 14 31.1 9 18.4 heavi 14 dai 31 68.9 40 81.6 year smoke 0 9 3 6.7 1 2 10 19 2 4.4 2 4.1 20 40 88.9 46 93.9 partner smoke daili 20 44.4 13 26.5 live 14 31.1 10 20.4 note valu ascandinavian stroke scale femal 14 unit week men 21 unit week nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 446 smoke cessat intervent ischem stroke
hypnosi smoke cessat random trial timothi carmodi carol duncan joel simon sharon solkowitz joi huggin sharon lee kevin delucchi receiv 16 februari 2007 accept 15 august 2007 purpos studi determin hypnosi effect help smoker quit standard behavior counsel intervent combin nicotin patch np total 286 current smoker enrol random control smoke cessat trial san francisco veteran affair medic center particip treatment condit 60 min session receiv follow phone call 2 month np 6 month 29 hypnosi group report 7 dai point preval abstin compar 23 behavior counsel group rel risk rr 51.27 95 confid interv ci 0.84 1.92 base biochem proxi confirm 26 particip hypnosi group abstin 6 month compar 18 behavior group rr51.44 95 ci 0.91 2.30 12 month report 7 dai point preval quit rate 24 hypnosi group 16 behavior group rr51.47 95 ci 0.90 2.40 base biochem proxi confirm 20 particip hypnosi group abstin 12 month compar 14 behavior group rr51.40 95 ci 0.81 2.42 particip histori depress hypnosi yield significantli higher valid point preval quit rate 6 12 month standard treatment conclud hypnosi combin np compar favor standard behavior counsel gener long term quit rate introduct hypnosi peopl quit smoke year green 1996 1999 consid expert form complementari altern medicin smoke cessat sood ebbert sood steven 2006 recent studi green 1999 hypnosi shown yield quit rate compar multi compon treatment combin counsel nicotin replac evid consid strong includ hypnosi evid base intervent recent smoke cessat clinic practic guidelin abbott stead white barn ernst 2000 fior al 2000 rannei melvin lux mcclain lohr 2006 control studi efficaci hypnosi smoke cessat lack lynn neufeld rhue matorin 1993 studi investig efficaci hypnosi smoke cessat biochem ical method cotinin assai verifi abstin smoke conduct follow evalu 6 month holroyd 1980 addit clinic report hypnosi smoke cessat provid detail inform characterist partici pant e.g smoke histori hypnotiz treat ment procedur long term outcom inform withdraw symptom reason relaps green 1999 hypnosi continu view great interest smoker ing treatment option smoke cessat sood al 2006 recent theoret advanc field hypno si involv applic social cognit learn theori kirsch capafon cardena buelna amigó 1999 gener renew interest treatment modal smoke issn 1462 2203 print issn 1469 994x onlin 2008 societi research nicotin tobacco doi 10.1080 14622200802023833 timothi carmodi carol duncan joel simon sharon solkowitz joi huggin sharon lee kevin delucchi san francisco veteran affair medic center univers california san francisco ca correspond timothi carmodi mental health servic 116b veteran affair medic center 4150 clement street san francisco ca 94121 usa tel 1 415 221 4810 x2344 fax 1 415 750 6987 mail timothy.carmodi ucsf.edu nicotin tobacco research volum 10 number 5 2008 811 818 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org cessat provid theoret foundat empir research effect hypnosi mechan chang respons expect motiv factor nonhypnot suggest thought import mechan ism determin effect hypnot nonhypnot suggest braffman kirsch 1999 mill kirsch allen reutenau 2005 undertook present studi determin specif hypnosi intervent prove effect help smoker quit compar standard behavior counsel treatment combin np select hypnosi treatment design promot commit sustain abstin regula tori cope respons enhanc smoke cessat relaps prevent capafon amigó 1995 lynn al 1993 incorpor suggest guid imageri procedur develop spiegel 1994 lynn al 1993 green 1996 1999 gorassini spano 1986 hypnosi intervent prove superior roughli equival behavior counsel offer option smoker quit method particip septemb 2001 decemb 2003 enrol 176 men 110 women san francisco veteran affair medic center figur 1 particip current smoker interest quit report smoke 10 cigarett dai pre enrol week patient contraind nicotin replac n59 exclud local institut review board approv obtain particip provid written inform consent assess readi quit stage chang model prochaska diclement 1983 recruit particip contempl action stage quit total 81 22 elig smoker declin enrol sixteen 6 random attend session treatment receiv nicotin patch np yield baselin 270 particip 141 hypnosi arm 129 behavior counsel attend session 12 random behavior figur 1 particip flow chart 812 hypnosi smoke cessat nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org counsel 4 random hypnosi 270 particip attend session receiv np 16 6 lost follow 3 1 withdrew 5 particip 2 di analys consid lost follow particip smoker includ 5 particip di 246 subject 125 hypnosi arm 121 behavior arm complet final follow assess 12 month data 265 subject 137 hypnosi arm 128 behavior arm analys consid lost follow particip smoker intervent randomli assign particip studi arm intervent equival term amount contact time counselor particip treatment arm month suppli np initi dose 21 14 mg base number cigarett smoke dai enrol intervent particip studi arm receiv follow telephon counsel call week 3 4 6 telephon intervent session last 20 min continu skill train initi initi counsel session particip relaps encourag set quit date hypnosi intervent hypnosi intervent administ public health educ receiv intens train ing ongo supervis author hypnosi intervent script audio tape particip random hypnosi treatment group particip 60 min face face session hypnosi train provid audiotap train daili home hypnosi intervent com.ibm.drl.hbcp.util suggest guid imageri procedur develop spiegel 1994 lynn al 1993 green 1996 1999 gorassini spano 1986 learn practic emploi hypnot skill resist urg smoke com.ibm.drl.hbcp.core compon intervent goal treatment particip master hypnosi skill skill increas motiv efficaci resist temptat smoke hypnosi view set skill direct respons suggest aim facilit control smoke behavior motiv quit continu abstin smoke particip provid menu skill cope withdraw symptom urg smoke hypnot suggest encourag relax commit quit imag nonsmok abil resist urg smoke mood manag devel opment healthi lifestyl suggest involv anchor gestur includ partici pant gener adapt cope respons sustain abstin smoke high risk situat hypnosi suggest se sion provid audiotap partici pant practic techniqu hypnot suggest train audio tape reinforc follow phone call behavior intervent smoker random evid base beha vioral intervent counsel face face session last 60 min 20 min follow phone call week 3 4 6 session danger smoke benefit quit review particip knowledg belief potenti barrier smoke cessat assess counter argument belief barrier provid behavior man agement techniqu counter relaps trigger discuss rehears behavior inter vention administ public health educ base social learn theori bandura 1997 stage chang model prochaska diclement 1983 data collect measur histori alcohol drug histori depress measur singl item particip report presenc absenc histori measur hypnot depth ask particip rate experi depth hypnosi session scale 1 lowest level depth 40 highest level depth measur expect intervent help baselin particip ask rate expect help intervent 3 point scale 1 help 3 help end treatment assess perceiv help strategi includ hypnosi treatment particip ask specif strategi help found strategi 3 point scale 1 help 3 help strategi includ repeat kei phrase anchor cue feel stress imagin special place listen hypnosi audiotap practic hypnosi regularli hypnot assess help quit strategi taught nicotin tobacco research 813 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org behavior treatment particip ask specif quit strategi help found techniqu 3 point scale 15not help 35veri help strategi includ remind reason quit oral substitut plan respons difficult situat exercis relax chang daili routin reward smoke measur nicotin withdraw symptom modifi version minnesota nicotin withdraw scale hugh hatsukami 1986 hurt al 1997 studi bupropion smoke cessat consist item crave depress mood difficulti fall asleep awaken night irrit anxieti difficulti concentr restless increas appetit particip respond item 5 point scale 05absent 45sever total nicotin withdraw score calcul rang 0 36 measur administ week 2 3 9 collect baselin data ag race sex marit statu presenc smoker household level educ histori drug alcohol abus histori depress bodi mass index weight kg divid height meters2 calcul report data medic pro blem record base particip interview obtain report data pre enrol level smoke pack year smoke number prior quit attempt estim level tobacco addict base fagerström test nicotin depend ftnd fagerström heatherton kozlowski 1992 20 item efficaci questionnair prochaska velic diclement fava 1988 administ baselin assess depress symptom beck depress inventori bdi beck steer brown 1996 bdi measur total score rang 0 63 divid level depress 0 13 minim 14 19 mild 20 28 mod erat 29 63 sever follow phone call inform obtain smoke statu nicotin withdraw symptom np 6 month telephon follow addit data obtain quit attempt enrol current level smoke date cigarett smoke 12 month telephon follow collect data report smok ing statu alcohol consumpt presenc smoker household quit attempt previou 6 month date cigarett smoke longest period tobacco abstin durat nicotin therapi tobacco product smoke cessat biochem valid record report point preval tobacco abstin defin smoke puff 7 dai 6 12 month particip report quit smoke obtain saliva sampl cotinin test level 15 ng ml indic current tobacco report quitter cotinin level 15 ng ml ascertain telephon interview nicotin replac follow date particip 6 month particip 12 month analyz smoker consid particip stop smoke cigarett tobacco product smoker saliva sampl store 221uc assai cotinin report quitter provid saliva specimen accept statement spous signific smoke statu 6 month 17 particip 7 hypnosi group 10 behavior group 12 month 11 6 hypnosi group 5 behavior group proxi report shown reliabl chen renni dosman 1995 statist analysi compar baselin variabl sampl test wilcoxon rank sum test continu variabl chi squar test categor variabl compar treatment calcul rel risk rr 95 confid interv ci randomiza tion hypnosi intervent standard formula multipl logist regress model control treatment assign examin baselin variabl independ com.ibm.drl.hbcp.predictor quit calcul addit logist regr sion model includ interact treatment assign baselin variabl result signific differ baselin characterist treatment group 05 tabl 1 particip predominantli unmarri white middl ag smoke tori similar group particip moder heavi smoker mean 29 pack year smoke smoke pack cigarett daili time enrol histori depress highli preval group 33 hypnosi group 40 behavior group mean expect help rate similar 814 hypnosi smoke cessat nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org intervent group 4.20 sd50.76 hypnosi group 4.12 sd50.85 behavior group p5.329 comparison studi medic log intervent treatment group differ np mean number np particip 33 se51.9 hypnosi group 36 se51.8 behavior group p5.354 addit sever nicotin withdraw symptom compar treatment group week 2 3 9 sever nicotin withdraw symptom significantli higher behavior group m513.5 sd57.3 hypnosi group m510.9 sd55.7 week 2 p5.03 significantli treatment condit week 3 9 follow data particip 6 month assess 7 dai point preval quit rate base report includ dropout smoker 29 40 140 hypnosi group 23 29 129 behavior counsel group rr51.27 95 ci 0.84 1.92 p5.27 base biochem proxi confirm point preval quit rate 26 36 140 hypnosi group versu 18 23 129 behavior group rr51.44 95 ci 0.91 2.30 p5.14 12 month report point preval quit rate includ dropout smoker 24 33 137 hypnosi group 16 21 128 behavior group rr51.47 95 ci 0.90 2.40 p5.13 base biochem proxi confirm point preval quit rate 20 27 137 hypnosi group 14 18 128 behavior group 12 month rr51.40 95 ci 0.81 2.42 p5.25 result similar particip lost follow exclud analys tabl 2 rate report quit higher confirm biochem magnitud benefit intervent 1 year similar statist model variabl point preval quit examin addit logist regress model measur smoke statu report valid absti nenc 6 12 month variabl point preval quit includ gender ethnic histori alcohol abus histori depress number smoker hous hold expect help treatment nicotin depend measur ftnd number quit strategi addit examin inter action treatment assign gender ethnic alcohol histori depress histori number quit strategi logist regr sion model predict report valid tabl 1 baselin characterist studi particip n5286 characterist hypnosi group n5145 behavior group n5141 ag year 45 12 45 13 90 white 101 70 96 68 80 women 61 42 49 35 23 marri 37 26 34 24 70 veteran 47 32 54 38 32 level educ year 15 2 14 2 25 current tobacco cigarett dai 20 8 20 10 63 smoke pack year 29 21 30 24 66 beck depress inventori score 11 9 10 9 39 fagerström score 5 2 5 2 75 expect help scale 1 5 4 0.8 4 0.9 42 coronari diseas 8 6 10 7 63 vascular diseas 10 7 6 4 40 copd 15 10 18 13 58 histori tobacco relat cancer 3 2 2 1 1.00 diabet mellitu 9 6 9 7 1.00 hypertens 29 20 25 18 65 alcohol abus 30 21 28 20 1.00 drug abus 22 15 25 18 63 histori depress 47 33 55 40 27 valu mean sd valu denot number percentag subject n5286 level educ achiev n5285 beck depress inventori n5285 fagerström score current tobacco defin averag number cigarett smoke dai tabl 2 smoke cessat rate rel risk quit hypnosi group quit behavior group quit rel risk 95 ci report 1 week 77 141 55 73 129 56 0.97 0.79 1.20 81 report 2 week 64 141 45 68 129 53 0.87 0.68 1.11 28 report 8 week 54 141 38 47 129 36 1.06 0.78 1.44 80 report 6 month 40 140 29 29 129 23 1.27 0.84 1.92 27 valid 6 month 36 140 26 23 129 18 1.44 0.91 2.30 14 valid 6 month 36 133 27 23 124 19 1.44 0.90 2.28 14 report 12 month 33 137 24 21 128 16 1.47 0.90 2.40 13 valid 12 month 27 137 20 18 128 14 1.40 0.81 2.42 25 valid 12 month 27 125 22 18 121 15 1.45 0.85 2.50 19 ci confid interv valid saliva cotinin level spousal proxi particip lost follow consid smoker valid saliva cotinin level spousal proxi particip lost follow exclud nicotin tobacco research 815 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org quit 6 month statist signific wald x2526.58 02 wald x2526.75 02 interact examin interact treatment assign histori depress signific predict valid quit 6 month 01 shown figur 2 6 month hypnosi condit particip histori depress greater valid quit rate histori depress relationship revers behavior condit particip assign hypnosi group examin relationship perceiv depth hypnosi outcom mean perceiv depth averag hypnosi intervent session significantli relat valid quit 12 month m514.7 sd58.7 valid quitter m513.4 sd58.4 smoker p5.50 investig relationship specif quit strategi valid outcom group combin dropout count smoker abstin particip report averag 4 quit strategi sd52.8 compar mean 2.8 sd52.8 smoker 001 shown figur 3 valid point preval quit rate 6 12 month significantli higher particip quit strategi 6 month jonckheer terpstra test53.36 001 12 month jonckheer terpstra test53.20 002 addit partici pant hypnosi group regular practic hypnosi i. listen audiotap week significantli valid quit 12 month r5.33 01 valid quit 12 month posit rate help kei phrase r5.35 01 anchor feel stress r5.31 05 discuss found hypnosi combin np yield long term smoke cessat rate slightli higher behavior counsel np measur primari outcom emploi definit smoke cessat cessa tion find base report valid biochem analysi proxi report compar logist model control com.ibm.drl.hbcp.predictor cessat treatment assign ment statist signifi differ probabl cessat interestingli group smoker histori depress valid point preval quit rate 6 12 month higher particip hypnosi intervent number dropout treat ment higher behavior group hypnosi intervent result consist observ peopl commonli view hypnosi popular viabl method achiev smoke cessat result support efficaci hypnosi smoke cessat treatment smoker histori depress recent studi hypnosi shown gener quit rate compar standard treatment combin counsel nicotin replac green 1999 recent review green lynn 2000 conclud hypnosi yield higher quit rate wait list control group gener compar intervent involv hypnosi design assess methodolog studi determin hypnosi achiev effect number quit strategi found predict success outcom figur 3 valid point preval quit rate number quit strategi treatment figur 2 valid point preval quit rate treatment assign histori depress 816 hypnosi smoke cessat nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org treatment group differ variabl particip hypnosi group perceiv depth hypnot respons found predict success outcom particip report practic hypnosi techniqu regularli i. week found higher quit rate addit particip hypnosi treatment condit report significantli sever nicotin withdraw symptom behavior group week 2 futur studi investig impact hypnosi withdraw close mechan underli com.ibm.drl.hbcp.util hypnosi smoke cessat unknown involv factor includ expect placebo factor enhanc respons sugg tion alter unconsci impuls serv maintain smoke enhanc abil focu attent treatment strategi green 1999 mill al 2005 cognit behavior model hypnosi hypnot treatment affect behavior chang mean cognit behavior educ aspect suggest therapist schwartz 1992 reinforc moti vation regul messag facilit initi cessat resist temptat smoke mainten abstin lynn al 1993 altern respons expect posit causal mechan hypnosi placebo intervent kirsch 1997 mill reardon carosella 2006 perspect hypnosi thought achiev effect chang person expect nonvoli tional reaction hypnot suggest expert view hypnosi nondecept placebo creat cognit set anticip nonvolit respons kirsch 1999 effect hypnosi partial fulli relat role respons expect present studi treatment group differ baselin rate expect help intervent assign regul theori hypnosi consid state recept attent concentra tion design facilit respons suggest behavior chang capafon amigó 1995 individu learn prac tice appli hypnot suggest cope strategi daili basi initi maintain desir behavior chang hypnot suggest present studi includ visual imageri aim increas motiv efficaci quit remain abstin smoke peopl ad hypnot induct imagin suggest yield increas respond braffman kirsch 1999 mill al 2005 interpret find studi limit consid instanc hypnosi combin np unabl draw conclus efficaci hypnosi singl treatment modal limit fact research assist conduct follow assess phone call blind treatment condit particip addit comparison group includ placebo control unabl comment hypnosi behavior counsel group compar placebo control larger studi demonstr statist signific differ studi arm quit rate hypnosi arm higher behavior group prematur draw conclus hypnosi smoker histori depr sion measur histori depress base diagnost interview differenti major singl episod recur rent form depress final unabl determin mechan treatment success achiev hypnosi treatment group argu unabl determin degre np treatment condit respons achiev recent meta analys form empir basi current practic guid line fior al 2000 rannei al 2006 np effect treatment nicotin depend counsel ad np significantli increas valid long term quit rate present studi treatment group differ np quit rate gener hypnosi treatment group present studi pare favor achiev beha vioral counsel condit provid support hypnosi addit smoke cessat inter vention conclus valid point preval quit rate hypnosi treatment arm exceed behavior counsel arm 6 12 month follow particip histori depress hypnosi yield significantli higher point preval quit rate 6 12 month behavior treatment particip random behavior group quit rate particip histori depress consider lower 6 month quit rate particip histori depress nicotin tobacco research 817 nivers berdeen ovem ber 26 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org slightli higher 12 month research need replic explor mean post hoc find result studi support hypnosi evid base intervent smoke cessat combin np acknowledg studi fund california tobacco relat diseas research program 10rt 0061 fund agenc role conduct research prepar manuscript
1 0 drug alcohol depend 122 2012 186 194 content list scivers sciencedirect drug alcohol depend ourna ho pag www.elsev ier locat drugalcdep ntensiv intervent alcohol depend smoker earli recoveri random trial imothi carmodya kevin delucchib carol duncana peter banysa joel simonb haron solkowitza joi hugginsa sharon leea sharon hallb mental health servic san francisco va medic center 4150 clement street san francisco ca 94121 usa treatment research center univers california san francisco 401 parnassu street san francisco ca 94143 usa gener intern medicin section medic servic san francisco va medic center 4150 clement street san francisco ca 94121 usa depart medicin epidemiolog biostatist univers california san francisco 505 parnassu street san francisco ca 94143 usa rticl histori eceiv 24 june 2011 eceiv revis form 4 septemb 2011 ccept 22 septemb 2011 vailabl onlin 19 octob 2011 eyword moke cessat obacco lcohol depend oncurr intervent arli recoveri introduct purpos studi investig efficaci intens tobacco cessat intervent alcohol depend smoker earli recoveri method total 162 alcohol depend smoker random intens intervent smoke cessat usual care intens intervent consist 16 session individu cogni tive behavior therapi cbt combin nicotin replac therapi last 26 week usual care involv referr free stand smoke cessat program provid smoke cessat counsel vari durat guidelin concord medic primari cessat outcom verifi 7 dai point preval abstin ppa 12 26 38 52 week result 12 26 week verifi 7 dai point preval quit rate significantli higher intens intervent group usual care group 0.03 quit rate treatment group significantli 38 52 week verifi 30 dai alcohol abstin rate significantli treatment group follow assess conclus intens smoke cessat intervent yield higher short term smoke quit rate jeopard sobrieti chronic care model facilit mainten smoke cessat year alcohol treatment longer period time hope studi inform develop effect intervent concurr alcohol tobacco disord introduct half individu receiv treatment alco ol disord aud includ alcohol abus depend tobacco relat diseas hurt al 1996 advers ealth effect chronic alcohol tobacco shown synergist castellsagu al 1999 pelucchi al 2006 combin alcohol tobacco multipli risk er upper respiratori digest tract includ cancer mouth throat larynx esophagu pelucchi al 2006 urthermor chronic smoke shown author mental health servic 116b veteran affair medic enter 4150 clement street san francisco ca 94121 usa el 1 415 221 4810x6344 fax 1 415 750 6987 mail address timothy.carmodi va.gov t.p carmodi 376 8716 front matter publish elsevi ireland oi 10.1016 j.drugalcdep 2011.09.026 publish elsevi ireland slow neurocognit recoveri abstin alcohol patient durazzo al 2007 individu aud compar gener pop ulat preval tobacco higher quit rate lower fertig 2002 niaaa 1998 sobel al 2002 rate tobacco nicotin depend higher individu drink heavili highest rate occur tobacco user aud falk al 2006 grant al 2004 genet neurobiolog behavior factor hypothes explain relationship aud tobacco kalman al 2009 convers alcohol abus preval smoker nonsmok breslau 1995 le 2002 preval cigarett smoke declin unit state diminish individ ual aud fertig 2002 kozlowski al 1986 niaaa 1998 sobel al 2002 grow evid support smoke cessat con current abstin alcohol drug dx.doi.org 10.1016 j.drugalcdep 2011.09.026 http www.sciencedirect.com scienc journal 03768716 http www.elsevier.com locat drugalcdep mailto:timothy.carmodi va.gov dx.doi.org 10.1016 j.drugalcdep 2011.09.026 ohol 2 fi 2 2 t.p carmodi al drug alc lcohol depend smoker earli recoveri e.g baca yahn 009 kalman 1998 prochaska al 2004 sobel al 2002 recent public health servic clinic practic guidelin smoke cessat fior al 2008 encourag substanc isord program address tobacco patient owev time smoke cessat earli recoveri ontinu subject debat propon concurr reatment point studi show smoke cessat arli recoveri enhanc long term recoveri sobrieti friend agano 2005 prochaska al 2004 smoker earli stage ubstanc abus treatment gener awar health con equenc tobacco interest receiv uit smoke baca yahn 2009 joseph al 2004a xpert point evid question strategi ncourag smoke cessat concurr initi reatment alcohol substanc disord joseph al 2004a viewpoint support data show hat quit rate higher individu longer period ecoveri sobrieti kalman al 2006 smoke cessat intervent conduct concurr ithin context substanc disord sud treatment av shown yield variabl quit rate kalman al 2009 oint preval quit rate tobacco 6 month rang rom 2 18 baca yahn 2009 modest uit rate clinic signific major health gain hat result smoke cessat west 2007 gener ntervent modal greater intens ield higher quit rate fior al 2008 clinic trial roduc highest smoke abstin rate date com.ibm.drl.hbcp.util ntensiv level counsel nicotin replac medic fulli integr residenti sud treatment program burl al 2001 present studi investig efficaci inten iv intervent smoke cessat compar usual care intens intervent consist 16 session individ al cognit behavior therapi cbt combin nicotin eplac therapi nrt last 26 week onent cbt design facilit short term long term quit rate includ motiv enhanc skill train mood manag behavior activ acilit social support weight manag usual care nvolv referr free stand smoke cessat program hat provid smoke cessat counsel guidelin oncord medic hypothes intens ntervent yield significantli higher biochem veri ed 7 dai point preval quit rate tobacco 26 week end treatment 52 week end studi usual care econd hypothes alcohol abstin rate ntensiv intervent condit significantli higher 26 52 week usual care group oth theoret support empir evid dispel belief hat smoke cessat jeopard sobrieti earli recoveri studi condit stimulu effect result rom repeat pair smoke cue drink behav coonei al 2003 suggest discontinu smoke ould elimin cue trigger desir drink method 1 design present studi com.ibm.drl.hbcp.util parallel unblind random design reatment arm consort flow chart studi present fig 1 assess ent conduct baselin week 12 26 38 52 ntervent implement baselin 26 week assess hu assess visit week 12 schedul mid treatment end reatment eot assess conduct week 26 follow assess epend 122 2012 186 194 187 schedul week 38 12 week eot 52 end studi 26 week eot 2.2 particip particip 162 veteran 157 male 5 femal recruit drug alcohol treatment dat program san francisco veteran affair medic center sfvamc martinez va outpati clinic local institut review board approv obtain particip provid written inform consent time enrol clinic trials.gov identifi nct00217984 2.2.1 elig criteria sought includ lighter smoker studi sampl exclud dat patient week sobrieti reduc risk earli dropout dat patient consid elig particip 18 year report alcohol primari drug abus smok ing 5 cigarett dai abstin alcohol 7 dai report interest quit smoke exclus criteria includ contraindi cation nicotin patch adjuv nicotin medic e.g unstabl angina recent myocardi infarct skin allergi nicotin patch sever cardiova cular diseas lactat pregnanc report posit serum pregnanc test pre menopaus women unstabl psychiatr disord sever cognit impair 2.2.2 random particip randomli assign particip intens intervent usual care comput gener random assign ment list random stratifi basi number cigarett dai baselin 20 dai 20 dai depress past current abus drug cocain 2.2.3 studi intervent intens intervent consist 16 session individu cognit behavior therapi cbt smoke cessat includ mood manag 16 week nicotin patch 26 week nicotin lozeng intervent protocol base treatment protocol develop hall al 2009 5 session focus health consequ smoke prepar quit date final 11 session includ treatment modul address skill train mood manag cognit restructur behavior activ social support weight manag 12 session sched ul weekli basi session 13 14 conduct altern week final session schedul week usual care involv referr medic center smoke cessat clinic intervent period last 26 week randomli select subset treatment session audio tape assess ther apist compet skill level adher intervent protocol adher compet skill level checklist adapt valli colleagu 1986 adher compet skill level percentag score calcul therapist intervent session mean percentag score 86 adher 82 compet skill level 2.3 measur 2.3.1 smoke abstin outcom abstin outcom conform guid line societi research nicotin tobacco hugh al 2003 valid 7 dai point preval abstin serv primari outcom defin report smoke puff 7 dai prior assess visit combin carbon monoxid level 10 ppm hugh al 2003 compar cotinin method bio chemic verif point preval abstin assess cigarett smoke statu baselin point preval abstin follow assess particip ask 1 smoke cigarett past 7 dai 2 averag cigarett smoke dai sustain abstin sa prolong abstin pa secondari smoke cessat outcom sa defin verifi point preval abstin assess ment 90 dai timelin follow back tlfb brown al 1998 assess tobacco alcohol 12 26 38 52 week pa defin report smoke abstin greater 7 dai row time cover tlfb verifi exhal 10 ppm follow assess occur pa report period 2.3.2 alcohol drug alcohol drug subsect addic tion sever index asi mclellan al 1980 1985 1992 character substanc pattern substanc treatment relat variabl asi shown valid reliabl measur substanc abus mclellan al 2006 applebi al 1997 report standard cronbach alpha 0.89 alcohol scale verifi 30 dai point preval abstin serv primari alcohol outcom measur defin report drink 30 dai prior assess combin neg breath analysi 90 dai tlfb conduct 12 26 38 52 week includ assess alcohol 2.3.3 nicotin depend nicotin depend measur compo it intern diagnost interview cidi world health organ 1997 188 t.p carmodi al drug alcohol depend 122 2012 186 194 344 scree ned eli gibilit reason in gibil 41 time al cohol 28 methad 17 lcoho 17 trea tment 13 5 igar tte dai 8 locatio 7 patch nrt 6 sych 4 phone 3 ot interest 2 statu 2 varen icli ne 148 in gibl 196 eli gibl 162 rando mize 34 elig fuse 82 rand omiz ed int nsive care 80 rand omiz ed ual ca 22 lost follow 60 assess 12 ek 62 assess 12 week 17 lost followu 1 assess 3 lost follow 1 death 56 assess 26 ek 63 assess 26 week 0 lo st follo wup 1 lost follow 2 ass ess 53 assess 38 ek 56 assess 38 week 6 lost follow 1 assess ed 0 lost follow 55 assess 52 ek 57 assess 52week 0 lo st follo wup sort fl 2 1 2 2 fig 1 con agerström test nicotin depend ftnd heatherton al 1991 ftnd intern consist construct valid payn al 1994 3.4 abstin thought thought abstin taa form hall al 990 1991 wasserman al 2001 assess desir quit tobacco alcohol expect success quit expect difficulti quit absti enc goal total perman abstin versu restrict goal taa administ baselin subsequ assess visit espons item valid com.ibm.drl.hbcp.predictor abstin ubstanc abus treatment hall al 1990 1991 wasserman al 2001 3.5 emot distress composit score psychiatr statu index addict sever index asi psi mclellan al 1980 1985 1992 serv lobal measur emot distress asi psi shown valid eliabl measur psychiatr problem substanc abus mclellan al 2006 level sever depress symptom assess beck epress inventori bdi beck al 1961 reliabl valid bdi demonstr numer studi sampl psychiatr patient nternal consist bdi shown strong mean cronbach coeffi ient alpha 0.86 beck steer 1984 measur emot distress dminist assess visit 3.6 lifetim histori mood disord composit intern diagnost nterview cidi world health organ 1997 identifi lifetim ow chart diagnos mood disord includ bipolar disord major depress dy thymic disord cidi comprehens fulli structur diagnost interview assess mental disord successfulli larg epi demiolog studi nation comorbid survei kessler al 1994 chosen psychiatr diagnost instrument nation institut drug abus nida clinic trial network maxim effici minim cleric error section cidi auto 2.1 robin al 2000 recent revis computer cidi gener dsm iv lifetim diagnos mood disord 2.3.7 quit attempt smoke cessat treatment modal follow visit week 12 26 38 52 particip treatment group ask quit attempt level withdraw discomfort attempt smoke cessat treatment modal includ nrt medic receiv studi particip ask recal number quit attempt treatment modal associ at quit attempt withdraw discomfort assess 10 point likert scale 2.3.8 intens intervent attend particip intens intervent group attend averag 8 session 16 particip 27 attend 16 session t.p carmodi al drug alcohol depend 122 2012 186 194 189 tabl 1 baselin characterist variabl respons usual care 80 intens 82 sex male 76 95.0 81 98.8 femal 4 5.0 1 1.2 hispan 6 7.5 9 11.0 73 91.3 73 89.0 unsur 1 1.3 race african american black 33 41.3 27 32.9 caucasian white 36 45.0 42 51.2 11 13.8 13 15.9 marit statu marri 9 11.3 6 7.3 widow 6 7.5 3 3.7 65 81.3 73 89.0 degre hs ged 46 57.5 52 63.4 post secondari 28 35.0 23 28.1 miss 6 7.5 7 8.5 employ unemploi 69 86.3 62 75.6 emploi retir 11 13.8 20 24.4 live situat hous apart 14 17.5 10 12.2 hous apart 5 6.3 11 13.4 halfwai hous 34 42.5 36 43.9 sro room hotel motel 2 2.5 5 6.1 homeless 24 30.0 18 22.0 institut 1 1.2 1 1.2 miss 1 1.3 incom 10,000 43 53.8 52 63.4 10,000 37 46.3 30 36.6 quit smoke forev 56 70.0 54 65.9 24 30.0 28 34.2 quit drink forev 53 66.3 49 59.8 27 33.8 33 40.3 mean sd mean sd ag 48.0 7.75 52.0 7.35 cigarett 24 17.1 10.24 16.5 10.76 year smoke 29.3 10.01 34.3 10.45 time quit 5.2 11.56 4.8 14.20 ftnd 4.2 2.24 4.2 2.51 bdi 14.0 9.37 14.3 11.6 asi alcohol dai 30 dai 3.2 5.24 3.8 5.78 alcohol year 25.6 11.43 30.6 11.20 cocain dai 30 dai 1.5 3.6 0.7 2.65 cocain year 9.5 10.57 9.2 10.72 1 drug dai 30 dai 2.0 4.31 2.1 5.35 1 drug year 13.1 10.7 14.4 13.12 asi alcohol 0.2 0.24 0.2 0.24 asi drug 0.1 0.09 0.1 0.08 asi psychiatr 0.2 0.26 0.3 0.25 taa cigarett desir quit 9.1 1.48 9.1 1.41 expect difficult 6.4 3.04 6.4 2.67 expect success 8.1 1.93 7.7 2.24 taa alcohol desir quit 9.5 1.00 9.0 1.68 expect difficult 5.3 2.88 5.6 2.95 si 2 expect success tnd fagerström test nicotin depend bdi beck depress inventori 4 data analysi gener estim equat gee assum miss data occur andomli violat assumpt lead bias estim schneider al 2010 test evid outcom elat random missing includ percentag assess po tive smoke model particip complet assess number assess attend assum miss ess complet random mix effect regress model proc lmix sa version 9.2 compar verifi point preval abstin at post baselin assess term model treatment ondit intens usual care week assess 12 26 38 52 heir interact model estim allow full observ data lso includ number assess attend covari preliminari odel 9.0 1.33 8.6 2.02 ddiction sever index taa thought abstin secondari analys model assess number cigarett reportedli smoke prior 7 dai level mix effect model proc mix sa includ term treatment condit time interact comparison particip made quit attempt quit modal e.g nrt similarli test proc nlmix proport achiev sustain prolong abstin compar pearson chi squar test investig potenti moder effect measur assess point studi intak level sever depress symptom mea sure bdi total score ftnd total score lifetim histori mood disord expect success investig accomplish estim test model point preval abstin vari abl interact treatment condit ad main model includ treatment condit assess week interact term 190 t.p carmodi al drug alcohol depend 122 2012 186 194 tabl 2 estim test model paramet paramet estim se df pr intercept 8.11 1.8030 139 4.50 0.0001 condit 3.77 1.6399 139 2.30 0.0229 3 3 6 4 1 2 3 6 0 5 10 15 20 25 30 week 12baselin week 26 week 38 week 52 pe rc en bs ne nt usual care intens time 0.041 0.0259 139 1.57 0.1183 cond time 0.066 0.0322 139 2.06 0.0416 result 1 studi sampl characterist studi sampl characterist present tabl 1 sam le consist veteran 97 male 48 identifi aucasian 37 identifi african american mean ag 50 year marit statu predominantli singl 91 9 sampl high school educ total 81 er unemploi 83 annual incom 21,000 43 report live half hous therapeut ommun 26 homeless mean total score 1 sd 2.37 ftnd averag smoke rate 17 cigarett er dai reflect rang smoke behavior studi sam le due elig criteria includ lighter smoker ho cut smoke anticip quit ing mean score 0.25 sd 0.25 asi psi exceed mean score 0.10 gener popul mclellan al 985 1992 mean score 0.19 sd 0.23 total ation repres sampl 8429 patient recruit ver 300 substanc abus program mclellan al 2006 addi ion alcohol cocain cannabi rug compar report studi smok ng cessat dat set e.g burl al 2001 joseph al 004a 2 tobacco outcom shown fig 2 verifi point preval abstin reater intens intervent compar usual care post baselin assess week 12 26 absolut differ approxim 15 ffect treatment condit interact treatment ondit time assess reach statist signific stimat mix effect regress model summa iz tabl 2 inclus number assess ttend alter result signific pre ictor shown fig 3 left panel averag number cigarett moke 7 dai prior assess averag 5 73 usual care condit intens treatment fig 3 mean number cigarett left panel fig 2 verifi point preval abstin rate treatment condit time condit mean lower week 12 26 38 52 week test time 0.0001 condit time 0.04 signific level lower inten sive condit signific effect condit 0.04 group differ found sustain prolong abstin compar treatment condit assess particip made quit attempt quit modal iti e.g nrt similar pattern found measur significantli particip intens treatment report quit attempt week 12 40 18 0.003 quit modal week 12 39 18 0.005 compar usual care group differ found subsequ assess moder analysi lifetim mood disord signific 0.0008 interact 0.07 histori mood disord achiev verifi abstin intens con dition fig 4 week 12 26 quit rate particip histori mood disord intens intervent slightli higher quit rate histori mood disord usual care condit trend revers week 38 52 number particip absti nent subgroup depend treatment condit time histori mood disord low rang 1 8 note model treatment condit longer signif icant model signific covari bdi level treatment condit time t.p carmodi al drug alcohol 0 5 10 15 20 25 30 35 wee week12 week26 week38 52 pe rc en bs en hx md usual care 39 hx md inten iv 42 hx md usual care 41 hx md inten iv 40 fig 4 verifi point preval abstin rate treatment condit time histori mood disord 50 60 70 80 90 100 pe rc en bs en usual care intens 3 weekbaselin week12 week26 week38 52 fig 5 percent abstin alcohol treatment condit otal score ftnd total score expect success treatment ondit remain signific investig associ histori mood isord verifi smoke abstin compar group ith histori mood disord baselin bdi total com.ibm.drl.hbcp.core bdi total score baselin 12 week result reveal group histori mood di rder significantli higher bdi total score baselin group histori bdi total score ecreas baselin 12 week significantli otal score group histori mood disord addi ion group significantli ftnd otal score number cigarett smoke week aselin 3 alcohol outcom treatment condit comparison proport abstin rom alcohol assess present fig 5 treat ent condit differ signific 0.08 im effect 0.001 result declin rate abstin treatment condit time interact 0.03 illustr ross line signific abstin rate epend 122 2012 186 194 191 usual care group drop abstin rate inten sive condit 12 week abstin rate group equival 78 week 26 differ condit virtual 7 8 week 38 52 4 discuss find partial confirm primari hypothesi 12 26 week verifi 7 dai point preval quit rate significantli higher intens intervent group usual care group quit attempt treatment modal iti nrt significantli higher particip intens intervent usual care group combin extend cbt combin nrt appear facilit effort quit success quit end treatment 26 week intens smoke cessa tion intervent yield significantli higher quit rate usual care end treatment significantli particip intens condit report quit attempt treatment modal week 12 particip usual care group quit rate achiev intens intervent group 26 week end treatment compar favor result previou studi alcohol depend smoker earli recoveri kalman al 2009 benefit intens intervent short live differ quit rate treatment condit attenu longer signific 38 52 week number factor contribut lack main tenanc higher quit rate intens intervent intens intervent fulli integr dat program conduct train research assist program staff follow period suffici support program staff sustain abstin tobacco short term quitter intens inter vention group intens intervent particip attend session learn skill need maintain abstin end treatment differ observ earlier assess reflect effect due nonspecif differ therapeut support 27 inten sive intervent particip attend 16 session post hoc analysi reveal number intervent se sion attend quit rate follow assess intens intervent con duct period 26 week intervent last longer tobacco cessat treatment long prevent relaps durat num ber type intervent modal form counsel deliveri e.g group versu individu face face versu individ ual telephon deliv consid studi pharmacolog behavior form extend treatment shown promis improv sustain smoke cessat outcom hall al 1998 2004 2009 chronic care model telephon deliv counsel support mainten sobrieti drug alcohol treatment set mckai al 2010 hypothes alcohol abstin rate significantli treatment condit result show particip intens intervent interfer alcohol recoveri sobrieti report 30 dai alcohol abstin rate decreas similar trend treatment group 52 week studi major empir evid support view initi at smoke cessat earli recoveri enhanc outcom tobacco substanc friend pagano 2005 1 ohol 1 1 92 t.p carmodi al drug alc rochaska al 2004 except larg scale joseph al 2004a studi militari veteran aud con urrent cessat tobacco alcohol month substanc abus treatment lower alcohol bstinenc rate 12 month surprisingli histori mood disord higher smoke quit rate present studi group nclude particip histori major depress bipolar dysthym disord associ histori mood isord quit rate stronger intens interven ion group occur treatment condit egardless particip histori mood disor er expos intens intervent includ ood manag success quit smok ng stai quit particip histori mood isord post hoc analys reveal group ori mood disord significantli higher bdi total score baselin group histori mood disord heir level depress symptom decreas baselin 2 week significantli group histori mood disord particip histori mood di rder benefit structur sud rogram frequent contact counselor dat ver histori mood disord number ntensiv intervent session attend confirm nexpect find requir futur analys studi onsider variabl pattern depress symptom uit smoker histori major depress disor er burgess al 2002 smoker depress disord av shown experi signific improv ymptom crave nicotin particip intens moke cessat intervent blalock al 2008 explain particip histori mood di rder present studi assign usual care ondit quit higher rate histori mood isord occur psychiatr disord major depress ommon alcohol depend smoker burl al 1997 covei al 1993 kodl al 2008 kranzler al 1996 miller al 997 histori depress disord nece arili mean individu experi signific emot istress time earli recoveri smoke cessat effort odl al 2008 recent examin effect depress ymptom abstin tobacco alcohol treatment alcohol nicotin depend found depress ymptom prospect relat alcohol elat subsequ tobacco mood manag ent recommend critic compon tobacco se treatment alcohol depend smoker occur ajor depress patten 2002 steinberg al 2004 result present studi suggest histori mood disord tself indic mood manag alcohol depend smoker earli recoveri prognost oorer outcom addit presenc psychiatr morbid lcohol depend tobacco smoker ackground socioeconom disadvantag daeppen al 2000 lack effect cope skill manag dysphor mood tate substanc relat urg burl al 1997 steinberg al 2004 demograph characterist particip present studi level socioeconom disadvan ag consist observ veteran enrol va substanc abus treatment program ocat urban center burl al 1997 alcohol depend obacco smoker emploi educ rink alcohol greater earlier onset alcohol epend 122 2012 186 194 problem alcohol depend nonsmok daeppen al 2000 challeng margin hous poverti social alien repres addit obstacl concurr cessat tobacco alcohol tobacco alcohol cessat outcom enhanc intervent techniqu mini mize impact socioeconom disadvantag adjust read literaci level educ materi expand social support cessat link intervent hous employ resourc gordon al 1988 number limit present studi par ticip male militari veteran find gener veteran women sam ple size larg test primari hypothes power optim investig moder mediat treatment outcom complet rate follow assess lower anticip exten sive cohort mainten effort fourth alcohol breath test verif abstin tobacco alcohol limit us assess sustain prolong abstin assess focus efficaci assess accept abil practic cost feasibl need determin suitabl intervent specif dat clinic set increas number empir studi aim develop effect smoke cessat treatment smok er aud successfulli integr intervent substanc abus treatment set burl al 2001 drake al 1998 thompson al 1988 burl al 2001 pare efficaci intens smoke cessat intervent context residenti drug alcohol treatment treatment condit focus exclus smoke cessat smoke cessat experi opportun gener train cigarett drug alco hol daili relaps prevent train particip treatment condit identifi high risk situat smok ing learn practic cope skill session vivo situat particip intervent continu examin similar successfulli quit smoke drug alcohol learn smoke cessat techniqu e.g conting contract appli quit drug alcohol identifi high risk situat common smoke drug alcohol learn cope skill prevent relaps cigarett drug alcohol intervent yield significantli higher smoke abstin rate 12 month usual care residenti drug alco hol treatment set lend high intens integr smoke cessat intervent integr model treatment deliveri show promis demonstr success incorpor smoke cessa tion mental health substanc abus program hall prochaska 2009 integr smoke cessat inter vention va specialti mental health clinic provid treatment veteran post traumat stress disord mcfall al 2005 2006 2007 2010 research treatment efficaci move ward consider interact specif intervent compon process factor patient attribut imel al 2008 design futur treatment outcom studi cigarett smoker alcohol substanc disor der role fund sourc work compon ucsf treatment research cen ter support nida grant p50 da09253 nida role studi design collect analysi ohol t.p carmodi al drug alc nterpret data write report decis submit paper public ontributor author list qualifi authorship par icip suffici work respons ublic timothi carmodi kevin delucchi carol duncan haron hall made substanti contribut design data col ection analysi literatur review write manuscript haron solkowitz joi huggin sharon lee made substanti ontribut data collect literatur review peter ani made substanti contribut design data collect literatur review joel simon made substanti contribut data collect analysi write manuscript uthor final approv submiss onflict interest disclosur author cknowledg expertis guidanc senior staff treatment esearch center invalu appreci ata collect effort sharon mozgai norma rey ppreciat efer pplebi dyson altman luchin d.j 1997 assess substanc multiproblem patient reliabl valid addict sever index mental hospit popul nerv ment disord 185 159 165 aca c.t yahn c.e 2009 smoke cessat substanc abus treatment subst abus treat 36 205 219 eck a.t steer r.a 1984 intern consist origin revis beck depress inventori clin psychol 40 1365 1367 eck a.t ward c.h mendelsohn mock erbaugh 1961 inventori measur depress arch gen psychiatri 4 561 571 lalock j.a robinson j.d wetter d.w schreindorf l. cinciripini p.m 2008 nicotin withdraw smoker current depress disord undergo intens smoke cessat treatment psychol addict behav 22 122 128 reslau 1995 psychiatr comorbid smoke nicotin depend behav genet 25 95 101 rown r.a burgess e. sale s.d whitelei j.a evan d.m miller i.w 1998 reliabl valid smoke timelin follow back interview psychol addict behav 12 101 112 urgess e. brown r.a kahler c.w niaura abram d.b goldstein m.g miller i.w 2002 pattern chang depress symptom smoke cessat risk relaps consult clin psychol 70 356 361 url t.a burl a. latini 2001 control smoke cessat trial substanc depend inpati consult clin psychol 69 295 304 url t.a ramsei t.g seidner a.l kondo c. 1997 issu relat smoke cessat substanc abus subst abus 9 27 40 astellsagu munoz de stefani victora c.g catelletto rolon p.a quintana m.j 1999 independ joint effect tobacco smoke alco hol drink risk esophag cancer men women int cancer 82 657 664 oonei j.l coonei n.l pilkei d.t kranzler h.k oncken c.a 2003 effect nicotin depriv urg drink smoke alcohol smoker addict 98 913 921 ovei l. glassman a.h stetner becker 1993 effect histori alcohol major depress smoke cessat psychiatri 150 1546 1547 aeppen j.b smith t.l danko g.p gordon landi n.a nurnberg bucholz k.k raimo schuckit m.a collabor studi group genet alcohol 2000 clinic correl cigarett smoke nicotin depen denc alcohol depend men women alcohol alcohol 35 171 175 rake r.e mercer mcfadden mueser k.t mchugo g.j bond g.r 1998 review integr mental health substanc abus treatment patient dual disord schizophren bull 24 589 608 urazzo t.c rothlind j.c gazdzinski bani meyerhoff d.j 2007 chronic smoke differenti neurocognit recoveri abstin alcohol patient preliminari investig alcohol clin exp re 31 1114 1127 alk d.e yi hiller sturmhöfel 2006 epidemiolog analysi occur alcohol tobacco disord alcohol re health 29 162 171 epend 122 2012 186 194 193 fertig j.b 2002 overview alcohol tobacco mechan treatment alco hol clin exp re 26 1909 1910 fior m.c jaen c.r baker t.b 2008 treat tobacco depend 2008 updat clinic practic guidelin depart health human servic public health servic rockvil md friend k.b pagano m.e 2005 smoke cessat alcohol consumpt individu treatment alcohol disord addict disord 24 61 75 gordon s.m kennedi b.p mcpeak j.d 1988 neuro psycholog impair alcohol assess treatment consider rehabilit subst abus 5 99 104 grant b.f hasin d. chou s.p stinson f. dawson d.a 2004 nicotin depen denc psychiatr disord unit state arch gen psychiatri 61 1107 1115 hall s.m havassi b.e wasserman d.a 1990 commit abstin acut stress relaps alcohol opiat nicotin consult clin psychol 58 175 181 hall s.m havassi b.e wasserman d.a 1991 effect commit absti nenc posit mood stress cope relaps cocain consult clin psychol 59 526 532 hall s.m humfleet g.l munoz r.f reu v.i robbin j.a prochaska j.j 2009 extend treatment older cigarett smoker addict 104 1043 1052 hall s.m humfleet g.l reu v.i munoz r.f cullen 2004 extend nortripti line psycholog treatment cigarett smoke psychiatri 161 2100 2107 hall s.m prochaska j.j 2009 treatment smoker occur disord emphasi integr mental health addict treatment set ann rev clin psychol 5 409 431 hall s.m reu v.i munoz r.f see k.l humfleet hartz d.t frederick triffleman 1998 nortriptylin cognit behavior therapi treatment cigarett smoke arch gen psychiatri 55 683 690 heatherton kozlowski frecker fagerström 1991 fagerström test nicotin depend revis fagerström toler questionnair br addict 86 1119 1127 hugh j.r keeli j.p niaura r. ossip klein d.j richmond r.l swan g.e 2003 measur abstin clinic trial issu recommend nicotin tob re 5 13 25 hurt r.d offord k.p croghan i.t gomez dahl kottk t.e mors r.m melton l.j 1996 mortal inpati addict treatment jama 275 1097 1103 imel z.e wampold b.e miller s.d fleme r.r 2008 distinct differ direct comparison psychotherapi alcohol disord psychol addict behav 22 533 543 joseph lexau willenbr nugent nelson 2004a factor readi stop smoke patient treatment alcohol disord addict 13 405 417 joseph willenbr nugent nelson 2004b random trial con current versu delai smoke intervent patient alcohol depend treatment stud alcohol 65 681 691 kalman 1998 smoke cessat treatment substanc misus earli recoveri review literatur recommend practic subst misus 33 2021 2047 kalman kahler garvei a.j monti p.m 2006 high dose nicotin patch ther com.ibm.drl.hbcp.api smoker past histori alcohol depend 36 week outcom subst abus treat 30 213 217 kalman kim digirolamo smelson ziedoni 2009 address tobacco disord smoker earli remiss alcohol depend case integr smoke cessat servic substanc disord treatment program clin psychol rev 30 12 24 kessler r.c mcgonagl k.a zhao nelson c.b hugh eshleman wittchen kendler k. 1994 lifetim 12 month preval dsm iii psychiatr disord unit state result nation comorbid survei arch gen psychiatri 51 8 19 kodl m.m fu s. willenbr m.l grave nelson d.b joseph a.m 2008 impact depress symptom alcohol cigarett consumpt treatment alcohol nicotin depend alcohol clin exp re 32 92 99 kozlowski l.t jelinek l.c pope m.a 1986 cigarett smoke alcohol abus continu neglect problem pub health 77 205 207 kranzler h.r del boca f.k rounsavil b.j 1996 comorbid psychiatr diagno si predict year outcom alcohol posttreat natur histori studi stud alcohol 57 619 626 le a.d 2002 effect nicotin alcohol consumpt alcohol clin exp re 26 1915 1916 mcfall m.e saxon a.j thompson c.e yoshimoto malt strait troster kanter zhou h.a dougherti c.m steel 2005 improv rate quit smoke veteran posttraumat stress disord psychiatri 162 1311 1319 mcfall m.e atkin d.c yoshimoto thompson c.e kanter malt saxon a.j 2006 integr tobacco cessat treatment mental health care patient posttraumat stress disord addict 15 336 344 mcfall saxon a.j malt c.a chow bailei baker d.g beckham j.c boardman k.d carmodi t.p joseph a.m smith m.w shih yu holodnii lavori p.w 2010 integr tobacco cessat mental health care posttraumat stress disord random control trial jama 304 2485 2493 mcfall saxon a.j thaneemit chen smith m.w joseph a.m carmodi t.p beckham j.c malt c.a vertre j.e boardman k.d lavori p.w 2007 1 ohol 94 t.p carmodi al drug alc integr smoke cessat mental health care post traumat stress disord clin trial 4 178 189 ckai j.r van horn d.h.a oslin d.w lynch k.g ivei ward drapkin m.l becher j.r coviello d.m 2010 random trial extend telephon base continu care alcohol depend treatment substanc outcom consult clin psychol 78 912 923 clellan a.t cacciola j. alterman a.i rikoon s.h caris 2006 addic tion sever index 25 origin contribut transit addict 15 113 124 clellan a.t kushner metzger peter smith grissom pettinati argeri 1992 edit addict sever index subst abus treat 9 199 213 clellan a.t luborski cacciola griffith evan barr h.l o’brien c.p 1985 data addict sever index reliabl valid center nerv ment disord 173 412 423 clellan a.t luborski woodi g.e o’brien c.p 1980 improv diagno tic evalu instrument substanc abus patient addict sever index nerv ment disord 168 26 33 iller n. hoffmann n.g ninonuevo astrachan b.m 1997 lifetim diagnosi major depress multivari com.ibm.drl.hbcp.predictor treatment outcom inpa tient substanc disord abstin base program ann clin psychiatri 9 127 137 ation institut alcohol abus alcohol 1998 alcohol tobacco nation institut alcohol abus alcohol niaaa rockvil md atten c.a 2002 treat alcohol smoker histori depress alcohol clin exp re 26 1947 1949 ayn smith p.o mccracken l.m mcsherri w.c antoni m.m 1994 assess nicotin depend comparison fagerström toler questionnair ftq fagerström test nicotin depend ftnd clinic sampl addict behav 19 307 317 epend 122 2012 186 194 pelucchi gallu garavello bosetti la vecchia 2006 cancer risk alcohol tobacco focu upper aero digest tract liver alcohol re health 29 193 198 prochaska j.j delucchi hall s.m 2004 meta analysi smoke cessat intervent individu substanc abus treatment recoveri con sult clin psychol 72 1144 1156 robin cottler bucholz compton north rourk 2000 comput iz diagnost interview schedul dsm iv di manag group ottawa ontario canada schneider k.l hedek bailei k.c cook j.w spring 2010 comment analyz addict behavior time nicotin tob re 12 445 448 sobel l.c sobel m.b agraw 2002 chang dual recoveri individu alcohol tobacco problem current knowledg futur direct alcohol clin exp re 26 1936 1938 steinberg h.r hall rustin 2004 psychosoci therapi tobacco depen denc mental health substanc popul psychiatr ann 33 470 478 thompson r. michnich m.e friedland gilson grothau l.c storer 1988 effect smoke cessat intervent integr primari care practic med care 26 62 76 valli t.m shaw b.f dobson k. 1986 cognit therapi scale psychometr properti consult clin psychol 54 381 385 wasserman d.a stewart a.l delucchi 2001 social support abstin opiat cocain opioid mainten treatment drug alcohol depend 65 65 75 west 2007 clinic signific small effect smoke cessat treat ment addict 102 506 509 world health organ 1997 composit intern diagnost inter view cidi research manual american psychiatr press washington dc intens intervent alcohol depend smoker earli recoveri random trial 1 introduct 2 method 2.1 design 2.2 particip 2.2.1 elig criteria 2.2.2 random 2.2.3 studi intervent 2.3 measur 2.3.1 smoke abstin outcom 2.3.2 alcohol drug 2.3.3 nicotin depend 2.3.4 abstin thought 2.3.5 emot distress 2.3.6 lifetim histori mood disord 2.3.7 quit attempt smoke cessat treatment modal 2.3.8 intens intervent attend 2.4 data analysi 3 result 3.1 studi sampl characterist 3.2 tobacco outcom 3.3 alcohol outcom 4 discuss role fund sourc contributor conflict interest acknowledg refer
5 smoke cessat adher intervent chines patient erectil dysfunct sophia s.c chan phd dori y.p leung phd abu s.m abdullah phd sue s.t lo md andrew w.c yip md wai ming kok md sai yin ho phd tai hing lam md background associ smoke erectil dysfunct causal uncertain.norct previous conduct cessat counsel addit nicotin replac therapi nrt adher counsel smoker erectil dysfunct purpos aim studi determin smoke cessat counsel conjunct nrt increas quit nrt adher compar usual care stop smoke improv erectil function chines erectil dysfunct patient smoke design rct conduct data collect 2004 2007 analyz 2008 set particip sampl includ 719 chines adult erectil dysfunct patient smoke 1 cigarett dai intend quit smoke 7 dai nrt intervent group a1 receiv 15 minut smoke cessat 3 minut nrt adher counsel baselin 1 week 4 week free nrt 2 week group a2 receiv treatment adher counsel group receiv 10 minut quit advic subject receiv quit booklet fırst contact main outcom measur report 7 dai tobacco abstin 6 month 4 week nrt adher 1 month improv erectil dysfunct condit 6 month result intervent group a1 a2 achiev higher rate abstin report 23 12.8 rr 1.79 95 ci 1.22 2.62 biochem valid 11.4 5.5 rr 2.07 95 ci 1.13 3.77 control group nrt adher rate differ group a1 a2 13.7 12.7 rr 1.08 95 ci 0.69 1.69 improv erectil dysfunct statu baselin 6 month report quit 6 month intervent statu conclus quit smoke improv erectil dysfunct studi found signifıc outcom differ themean achiev smoke cessat trial registr isrctn13070778 prev med 2010;39 3 251 258 2010 american journal prevent medicin rom depart nurs studi chan leung depart commun medicin ho lam univers hong kong hong ong famili plan associ hong kong lo kok hong kong epart surgeri yip kwong wah hospit hong kong boston nivers school public health abdullah boston massachusett address correspond tai hing lam md depart uniti medicin school public health univers hong kong williammwmong block lk faculti ofmedicin 21 sassoon road okfulam hong kong mail hrmrlth hkucc.hku.hk 0749 3797 17.00 doi 10.1016 j.amepr 2010.05.006 2010 american journal prevent medicin publish el ntroduct igarett smoke lead public health chal leng global preval smoke greater amongmen thanwomen increas mong adolesc young adult 1 erectil dysfunc ion preval health problem consider mpact qualiti life middl ag men 2 4 ecent data5 9 suggest independ dose espons relationship smoke risk rectil dysfunct cross section study5 show sevier prev med 2010;39 3 251 258 251 mailto:hrmrlth hkucc.hku.hk 2 2 252 chan al prev med 2010;39 3 251 258 hat chines men hong kong smoke 20 igarett daili 50 higher risk erectil ysfunction smoker 30 lower risk av erectil dysfunct smoke 20 cigarett daili cross section study7 hina show increas trend risk rectil dysfunct cigarett smoke improv ent erectil dysfunct smoker top smoke observ prospect study10 iran motiv male smoker stop smoke im ortant public health challeng asian coun ri men make major smoke opul china largest smoke popul world cardiovascular diseas number ne killer account 22.5 death 2000.11 china preval smoke inmen 57 002,12 11.8 million erectil dysfunct case er attribut smoke associ ausal 7 patient erectil dysfunct high risk oronari heart diseas 13 disagre ent relationship smoke erectil dysfunct causal 14,15 erectil dysfunc ion import smoke relat health problem potenti command attent creat tronger motiv quit young peopl diseas govern introduc ealth warn smoke erectil dysfunct cigarett pack state smoke erec il dysfunct 16 state smoke ay erectil dysfunct 17 nicotin replac therapi nrt doubl uit rate smoker nrt adher rec mmend treatment regimen 18 20 studies18,21 eport posit relationship nrt adher cessat study22 examin reason onadher smoker attempt quit av report intervent design increas rt adher rct conduct studi effect moke cessat intervent test effıcaci ounsel adher nrt examin osit effect quit smoke erectil dysfunc ion chines patient hypothes 1 ercentag quit higher inter ention group usual minim care group 2 adher nrt greater group eceiv smoke cessat nrt adher ounsel group receiv smoke essat counsel 3 smoke cessat mprove erectil function ethod articip al subject recruit viamassmedia public referr rom hospit clinic physician januari 2004 april 007 inhongkong subject elig inclus theywer hines male ag 18 year report erectil dysfunc ion smoke 1 cigarett dai intend quit smoke ithin 7 dai fırst contact nrt contraindi ation nrt smoke cessat regi ens.subjectswhodidnotmeet thesecriteria werepsychologicallyor hysic unabl commun take regular psychotrop edic health problem render nsuitabl nrt recent stroke palpit ther life threaten condit exclud fıve item nternat index erectil function iief 5 measur ool screen object est confırm erectil dysfunct doctor accept elf report erectil dysfunct order establish case linic set addit author believ men ot report erectil dysfunct symptom tudi design hiswa singl blindedrct approv ethic committe univers hong kong februari 19 2003 articip clinic hospit subject provid written orm consent prior random subject randomli ssign intervent group a1 a2 ontrol group member intervent group andomli assign group a1 a2 ntervent ntervent group a1 receiv 15 minut face face smok ng cessat counsel session 3 minut nrt adher ounsel session train male counselor addit 1 eek freenrt nicotin gumor patch fırst contact ntervent group a2 receiv intervent group 1 3 minut nrt adher counsel patient enter approach com.ibm.drl.hbcp.util motiv interview ng techniques23 recommend ahcpr clinic practic uidelin smoke cessat 24 smoke cessat coun el 4r approach24 boostmotiv quit includ nformat health consequ smoke emphas enefıt quit encourag smoker quit identifı arrier provid suggest overcom spe ifıc counsel relationship smoke quit moke erectil dysfunct nrt adher interven ion develop guidelines25 adher ntervent emphas import adher rescrib nrt dosag assess discuss wai om barrier deliv problem orient intervent mprove adher control group receiv 10 minut face face counsel session simpl advic quit smoke ubject group test exhal carbon monoxid level receiv quit pamphlet titl easi tep quit produc hong kong council smok ng health 26 subject group a1 a2 receiv elephon hotlin number counselor need www.ajpm online.net 3 6 7 chan al prev med 2010;39 3 251 258 253 counsel test exhal provid 1 eek and4week intervent groups.atweek 1 total week addit free nrt plan 1 week free rt offer nrt sponsorship btain total 2 week fırst contact 1 week ollow freenrtwa provid nicotin patch nico in gumwer offer particip allow choos prefer group a1 group a2 check rtusag receiv addit adher counseling.at 4week oth group check nrt receiv smoke essat counsel need check nrt usag includ heck patch bodi level nuse nrt report quitter report stop smoke past 7 dai invit biochem valid urinari otinin exhal level 1 4 week counsel ntervent complet onmai 13 2007 subject ingroupsa1 anda2 3month subject includ ng group 6 month receiv follow telephon contact rain interviewerswhowereblind interventionassign attempt weremad time period ubject categor lost follow 3 month detail nformat nrt 8 week collect ntervent group 6 month inform smoke statu icotin depend measur fagerström test nicotin epend ftnd 27 quit attempt cessat method psy hosoci factor erectil function measur iief 528 obtain standard questionnair report quit er invit biochem valid urinari cotinin xhale level travel allow hk 200 1 hk 7.8 offer subject present valid utcom measur primari outcom measur 1 report 7 dai oint preval tobacco abstin 6 month 2 continu se nrt 4 week 4 week adher rate 1 month eport quit valid exhal urinari cotinin evel subject consid current smoker lost ollow exhal level 8 ppm urinari cotinin oncentr 115 ng ml 29 main secondari outcom hang iief 5 score baselin 6 month secondari utcom includ valid quit rate report reduct 50 cigarett consumpt 6 month 8 week nrt ad erenc rate 3 month tatist analysi requir sampl size calcul base primari utcom order provid conserv 90 power ith 5 signifıc level total 1210 subject 422 a1 422 a2 366 need detect 10 differ imultan 1 report 7 dai point preval quit at intervent group a1 a2 control group 26 16 2 4 week adher rate 29 19 3 report quit rate 31 21 group a1 2 assum 70 particip goal set recruit ng 1729 subject test effect smoke cessat intervent ith counsel nrt intervent group a1 2 combin compar control group test effect nrt adher intervent inter eptemb 2010 ention group compar tobacco abstin reduct nrt adher group compar pear chi squar test exploratori analysi conduct ief 5 score group smoke statu 6 month gener inear regress binomi distribut log link function examin effect intervent smoke tatu improv stage iief 5 score 6 onth tabl 1 miss iief 5 score xclude analysi rel risk rr 95 ci eport applic baselin group differ er test chi squar test categor variabl nova distribut continu variabl nalys perform spss version 16.0 2008 esult nrollment total 1469 male smoker screen studi ligibl figur 1 438 subject eet inclus criteria 66 erectil ysfunction 24.9 nonsmok 999 elig ubject 719 72 agre particip underw andom result 249 smoke cessat nrt adher group a1 252 smoke essat group a2 218 control group ll 345 subject 48 recruit public hrough mass media 242 33.7 men health linic famili plan associ 107 14.9 rom kwong wah hospit erectil dysfunct linic 25 3.5 physician referr signifıc differ group 1 a2 retent rate time point 1 eek 84.3 80.2 0.29 1 month 66.3 3.9 0.64 3 month 77.9 72.6 1.00 6 month group a1 76.3 a2 0.2 71.5 0.28 subject 719 nclude analys intent treat 523 ubject 73 complet 6 month follow 6 onth noncomplet younger complet ag 47 49 year 0.02 differ signifıcantli ag start smoke year smoke number igarett smoke daili nicotin depend sever rectil dysfunct baselin demograph characterist istori smoke quit erectil dysfunct ondit similar group ubject group a1 fewer subject group a2 aken erectil dysfunct medic past month han control group tabl 1 obacco abstin reduct igarett consumpt ubject receiv smoke cessat counsel rtweremor quit 23 control roup 12.8 6 month primari outcom report 7 9 1 9 0 1 thera 254 chan al prev med 2010;39 3 251 258 dai point preval uit rate rr 1.79 5 ci 1.22 2.62 0.003 ry outcom bio hemic confırm uit rate ignifıcantli rr 2.07 95 ci 13 3.77 0.02 heoveral level ofpar icipationforvalid 60.1 86 143 ith 62.6 72 115 heinterventiongroup 50.0 14 28 control group pectiv rr 1.25 5 ci 0.84 1.86 0.27 72 ubject partici at valid est intervent roup 57 79.2 ad urinari nicotin evel 115ng mland xpire level 9 pm compar ith 12 85.7 14 ubject control roup rr 0.92 95 0.72 1.79 52 includ quit er subject intervent roup ontrol group uc daili ciga ett consumpt 50 aselin 6 month rr 1.52 95 ci 20 1.92 0.001 result simi ar remain sig ifıcant eport quitter exclud analysi rr 1.46 95 ci 1.03 2.08 0.04 dherenc nicotin eplac therapi intervent group differ signifıcantli tabl 1 baselin characterist sd characterist ag year marit statu marri cohabit educ level primari secondari tertiari ag start smoke year year smoke cigarett smoke dai dai ftnd scorea quit attempt 1 2 5 6 10 10 take medicin erectil dy month iief 5 score stage sever 0 7 moder 8 11 mild moder 12 16 mild 17 21 erectil dysfunct 22 25 aposs rang 1 10 b33 subject group a1 20 miss data ftnd fagerström test nicotin version nrt nicotin replac adher nrt 4 week 13.7 12.7 1.08 95 ci 0.69 1.69 0.75 1 month rimari outcom 8 week 3 month secondari outcom 7.2 3.6 rr 2.02 95 0.93 4.42 0.08 tabl 2 analysi show hat report 7 dai abstin rate group a1 26.1 higher group a2 21.0 3 onth differ nonsignifıc patient smoke erectil dysfunct smoke cessat nrt adher counsel a1 249 smoke cessat counsel a2 252 materi 218 48.9 11.8 48.7 11.2 49.2 11.4 200 80.6 194 77.0 180 82.6 48 19.4 58 23.0 38 17.4 54 21.7 49 19.4 45 20.6 162 65.1 162 64.3 150 68.8 33 13.3 41 16.3 23 10.6 18.3 4.6 18.6 5.2 18.7 5.0 30.4 12.1 30.1 11.5 30.5 11.5 st 30 20.4 10.0 21.1 12.3 20.1 9.7 4.6 2.5 4.6 2.4 4.4 2.5 70 28.5 76 30.3 53 24.8 51 20.7 46 18.3 56 26.2 95 38.6 109 43.4 85 39.7 12 4.9 11 4.4 9 4.2 18 7.3 9 3.6 11 5.1 tion 74 29.7 50 19.8 56 25.7 77 35.6 90 38.8 72 37.5 32 14.8 31 13.4 28 14.6 58 26.9 68 29.3 47 24.5 39 18.1 32 13.8 35 18.2 10 4.6 11 4.7 10 5.2 score indic greater depend nicotin a2 26 group exclud analysi endenc iief 5 intern index erectil function item py ic pa func igher gro dep rr 1.24 95 ci 0.90 1.71 0.18 www.ajpm online.net 1 2 chan al prev med 2010;39 3 251 258 255 rectil function score 6 month 77 143 quitter 53.8 report im rovement erectil dysfunct compar 62 576 nonquitt 28.1 rr 2.10 95 ci 1.64 70 0.001 gener linear model redictor report smoke statu 6 month nterventiongroupstatusatbaselin quittingsmokingwasa ignifıc com.ibm.drl.hbcp.predictor improv erectil dysfunct rr 2.07 95 ci 1.61 2.67 0.001 interven ion effect observ rr 1.10 95 ci 0.82 1.47 0.53 iscuss author knowledg fırst rct evalu te patient center counsel conjunct ith nrt lead improv outcom smoke essat erectil dysfunct subject quit moke com.ibm.drl.hbcp.predictor improv erectil dy unction current rct result show risk sever erectil dysfunct reduc quit moke provid evid potenti causal ationship smoke erectil dysfunct differ intervent type fınding hould strong impact chines asian opul erectil dysfunct preval sian western popul 4,5,30 erectil dysfunc ion patient smoke expect concret bene ıt readili appreci mmediat notic effect patient person live han abstract delai benefıt reduc igur 1 consort chart risk heart diseas cancer eptemb 2010 plai month year quit smoke directli compar lo cal studi nurs deliv intervent current intervent achiev quit rate 23 slightli lower smoke cessat clinic 27 counsel 1 week free nrt 18 higher quitlin 12 nrt 31 fact quit rate studi face face coun sele addit free nrt higher hose result telephon counsel consist ith previou fınding quit rate increaseswith ntensiti intervent 32 result present ct previou studi provid strong evi enc base plan launch similar moke cessat servic china asia men ealth clinic erectil dysfunct clinic smoke essat integr part treatment hose client smoke erectil ysfunction goal trial assess effıcaci counsel session nrt adher signif differ found nrt adher rate ween group a1 a2 1 3 month diffıculti subject recruit encount aggr iv outreach effort public campaign subject ecruit discontinu april 2007 ad ic independ data monitor committe interimmeet advic base nterim analysi show signifıc differ report quit rate 6 month subject eceiv smoke cessat intervent group a1 nda2 control effect nrt adher nce intervent 6 month stop recruit studi ntroduc harm subjectswith erectil dysfunct ho smoke theywould receiv simpl cessat advic regular clinic care chines men ith erectil dysfunct seek medic rectil dysfunct stigma conserv chi es cultur calcul complet studi how total 1762 subject requir 3 2 256 chan al prev med 2010;39 3 251 258 rder achiev esir power 90 detect ob erv differ secondari om adher at 8 week adher nce rate 3 onth 7.2 6 low ad erenc rate mall absolut differ nce confırm ruit ect im ould cost ef ectiv addit nlike earlier tudi 22 cost ort main eason discontin ation nrt 4 eek trial33 urther studi ad erenc intervent sing method provis ull nrt need fınding substanti discrep elf report biochem valid quit rate 6 onth noteworthi due themodest level particip 60 biochem valid elf report quitter 6 month evidenc act 20 misreport quit elf report quit rate inflat oth group incorrect report quit level particip higher ther local studi 10 compar tudi conduct 50 34 36 alid major reason refus particip relaps major reason misreport alid test addit investig alter ativ method encourag particip valida ion test smoke cessat research need trength limit major strength studi 72 ligibl patient enrol refer var ou sourc commun repres tabl 2 abstin reduct rate abstin rate 6 month report 7 dai point preva quit rate biochem valid quit ra reduct rate 6 month reduct daili cigarett consumpt 50 includ subject reduct daili cigarett consumpt 50 exclud report quitt total adher rate 4 week adher rate nrt month 8 week adher rate nrt month aquit confirm carbon ng ml nrt nicotin replac therapi ang divers popul studi dd generaliz current fınding 64 interventiongroupa1 62 interventiongroup 2 compli intervent counsel base in 1 week 1 month 13 group 1 17 ingroupa2 receiv counsel ng 1 week 1 month complianc rate er consid high studi conduct nonclini al set clinic erectil dysfunct patient studi limit 24 28 ubject lost follow 6 month ultipl call attrit level resembl 20 5 loss trial counsel hospit smok rs37,38 exceed 15 lost follow 12 onth rct stage match intervent ardiac patient hong kong 39 percentag lost ollow introduc substanti bia aus percentag similar studi arm omplet larg resembl noncomplet cessa ion rate studi underestim ecaus subject whower lost follow upwer count continu smoker guidelin rt prescrib quit date set 40 adher rate studi group intervent a1 a2 501 control 218 rel risk 95 ci 115 23.0 28 12.8 1.79 1.22 2.62 57 11.4 12 5.5 2.07 1.13 3.77 213 42.5 61 28.0 1.52 1.20 1.92 98 386 25.4 33 190 17.4 1.46 1.03 2.08 smoke cessat nrt adher counsel 249 smoke cessat counsel 252 34 13.7 32 12.7 1.08 0.69 1.69 18 7.2 9 3.6 2.02 0.93 4.42 oxid level expir air 9 ppm urinari cotinin level 115 lenc tea rs 1 3 mon current studi restrict erectil dysfunct www.ajpm online.net 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 chan al prev med 2010;39 3 251 258 257 atient readi quit 7 dai whichmai av explain high cessat rate limit ligibl subject recruit inclus criterion ean fınding gener motiv moker erectil dysfunct gener moke popul inhongkong themajor moker 51 readi quit smoke 41 31 subject 4 classifı rectil dysfunct iief 5 score small entag similar studi arm hat subject erectil dysfunct refer physician espond honestli questionnair ormai eri mild symptom iief 5 sensit nough detect nrt 6 month heck subject whichmight affect valid esult report quitter somewer usingnrtat time test affect urinari cotin ne exhal possibl nlike usag low earli rolong usag costli smoker believ effect nrt usag smoker nhongkongwa low evenwhen provid cost 18 studi fund competit earmark esearch grant hku7428 03m research rant council rgc hong kong princip investiga lam nicotin patch gum provid free harg subject provid free pfızer indebt particip patient todr hak law lok sang leung fromkwongwahhospi al anddr pak ling liu fromprincessmargaret hospit subject recruit allan lau counsel ata acquisit assist indepen ent data monitor committe prof harri lando nivers minnesota prof johan karlberg daniel y.t fong univers hong kong fınancial disclosur report author paper efer 1 warrencw jonesnr eriksenmp asma pattern global tobacco young peopl implic futur chronic diseas burden adult lancet 2006;367 749 53 2 laumann eo paik rosen rc sexual dysfunct u. preval com.ibm.drl.hbcp.predictor jama 1999;281 537 44 3 parish wl laumann eo pan hao sexual dysfunct urban china popul base nation survei men women sex med 2007;4 1559 74 4 laumann eo nicolosi flasser db al sexual problem women men ag 40 80 preval correl indentifı eptemb 2010 global studi sexual attitud behavior int impot re 2005;17 39 57 5 lam abdullah asm ho lm yip awc fan smoke sexual dysfunct chines male fınding men health sur vei int impot re 2006;18 364 9 6 fungmm bettencourt barrett connor heart diseas risk factor predict erectil dysfunct 25 year coll cardiol 2004;43 1405 11 7 reynold chen al cigarett smoke erectil dysfunc tion chines men clinic vascular diseas epi demiol 2007;166 803 9 8 millett wen lm rissel al smoke erectil dysfunct fınding repres sampl australian men tob control 2006;15 136 9 9 gade nm nehra jacobson dj al associ smoke erectil dysfunct popul base studi epidemiol 2005;161 346 51 0 pourmand alidaeemr rasili makeki mehrsai cigarett smoker erectil dysfunct benefıt stop prospec tive studi bju int 2004;94 1310 3 1 gud wux al major death amongmen women china engl med 2005;353 1124 34 2 yangg ma linn zhoul smoke passiv smoke inchines chin epidemiol 2005;26 78 83 3 kirbi jackson betteridg friedli erectil dysfunct marker cardiovascular diseas int clin pract 2001;55 9 614 8 4 british medic associ smoke reproduct life impact smoke sexual reproduct child health www bma.org.uk imag smoking_tcm41 21289 pdf 5 usdhh cdc nation center chronic diseas prevent health promot offıc smoke health health cons quenc smoke report surgeon gener atlanta ga usdhh 6 health canada graphic health warn www.hc sc.gc.ca hl tobac tabac legisl label etiquett graph impot impuissant4 eng.phpcanada 7 tobacco control offıc depart health hksar govern smoke public health amend bill 2005 guidelin health warn packet retail contain tobacco product www.tco.gov.hk english download fıle pictorial_health_warning_ bklet_eng.pdf 8 lam abdullah asm chan ssc hedlei aj hong kong council smoke health smoke cessat health centr schc steer group adher nicotin replac therapi versu quit smoke amongchines smoker preliminari investig psychopharmacolog berl 2005;177 400 8 9 shiffman hugh jr di marino sweenei ct pattern counter nicotin gum persist concurr smoke addict 2003;98 1747 53 0 johnston brown saunder al level nicotin replac quit smoke attempt nicotin tob re 2004;6 377 9 1 killen jd fortmann sp davi strausberg varadi heavi smoker benefıt higher dose nicotin patch therapi exp clin psychopharmacol 1999;7 226 33 2 burn ek levinson discontinu nicotin replac therapi smoke cessat attempt prev med 2008;34 3 212 5 3 emmon km rollnick motiv interview healthcar set ting opportun limit prev med 2001;20 68 74 4 fior mc bailei wc cohen sj al clinic practic guidelin treat tobacco depend washington dc usdhh 2000 5 adher long term therapi evid action geneva 2003 6 hong kong council smoke health good reason quit www.smokefree.hk cosh cc detail.xml lang en fldrid 221 http www.bma.org.uk imag smoking_tcm41 21289 pdf http www.bma.org.uk imag smoking_tcm41 21289 pdf http www.hc sc.gc.ca hl tobac tabac legisl label etiquett graph impot impuissant4 eng.phpcanada http www.hc sc.gc.ca hl tobac tabac legisl label etiquett graph impot impuissant4 eng.phpcanada http www.hc sc.gc.ca hl tobac tabac legisl label etiquett graph impot impuissant4 eng.phpcanada http www.tco.gov.hk english download file pictorial_health_warning_bklet_eng.pdf http www.tco.gov.hk english download file pictorial_health_warning_bklet_eng.pdf http www.smokefree.hk cosh cc detail.xml lang en 26fldrid 221 2 2 2 3 3 3 3 3 3 3 3 3 3 4 4 258 chan al prev med 2010;39 3 251 258 7 heatherton tf kozlowski lt frecker rc fagerström ko fag erström test nicotin depend revis fagerström toler questionnair br addict 1999;6 1119 27 8 rosen rc cappelleri jc smithmd lipski pena bm develop evalu abridg 5 item version intern index erectil function iief 5 diagnost tool erectil dysfunct int impot re 1999;11 319 26 9 jarvismj tunstal pedoeh feyerabend vesei salooje parison test distinguish smoker smoker public health 1987;77 1435 8 0 ng eml cheng jyw preval biopsychosoci correl erectil dysfunct hong kong popul base studi urolog 2007;70 131 6 1 abdullah asm lamth chan ssc hedlei a.which smoker smoke cessat quitlin hong kong effect quitlin tob control 2004;13 415 21 2 fior mc jaén cr baker tb al treat tobacco depen denc 2008 updat rockvil md usdhh 2008 www.ahrq gov path tobacco.htm clinic 3 chanssc leungdyp abdullahasm al reason complianc nicotin replac therapi chines smoke patient erectil dysfunct present 7th annual confer inter nation societi prevent tobacco induc diseas isptid tobacco free futur forward 2008 sept 26 28 kyoto japan 4 smith pm burgess smoke cessat initi hospit stai patient coronari arteri diseas random control trial med 5 rigotti na arnsten jh mckool km wood reid km pasternak rc singer de effıcaci smoke cessat program hospit pa tient arch intern med 1997;157 22 2653 60 6 prokhorov av yost mullin jone al health outcom comput assist smoke ce sation counsel intervent commun colleg student addict behav 2008;33 757 71 7 hennriku dj lando ha mccarti mc al team project effect smoke cessat intervent hospit patient prev med 2005;40 249 58 8 quist paulsen gallefoss randomis control trial smoke cessat intervent admiss coronari heart diseas bmj 2003;327 1254 7 9 chan ssc chan sc lau cp lam effect stage match smoke cessat intervent cardiac patient ran domiz control trial poster present 13th world confer enc tobacco health 2006 juli 12 15 washington dc 2006 confex.com uicc wctoh techprogram p8926 htm 0 nation institut clinic excel guidanc nicotin replac therapi nrt bupropion smoke ce sation technolog apprais guidanc 39 london nation institut clinic excel 2005 1 social survei section themat household survei report 26 pattern smoke hong kong censu statist depart june 2006 www.censtatd.gov.hk products_and_servic product public statistical_report social_data index_cd_b1130226_dt_ ssoc 2009;180 13 1297 303 latest.jsp latest ajpm new onlin visit www.ajpm online.net announc section homepag www.ajpm online.net http www.ahrq.gov path tobacco.htm 23clinic http www.ahrq.gov path tobacco.htm 23clinic http www.censtatd.gov.hk products_and_servic product public statistical_report social_data index_cd_b1130226_dt_latest.jsp http www.censtatd.gov.hk products_and_servic product public statistical_report social_data index_cd_b1130226_dt_latest.jsp http www.censtatd.gov.hk products_and_servic product public statistical_report social_data index_cd_b1130226_dt_latest.jsp http 2006 confex.com uicc wctoh techprogram p8926 htm smoke cessat adher intervent chines patient erectil dysfunct introduct method particip studi design intervent outcom measur statist analysi result enrol tobacco abstin reduct cigarett consumpt adher nicotin replac therapi erectil function score discuss strength limit refer
random control trial stage match intervent smoke cessat cardiac patientsadd_3733 829 837 sophia chan1 dori leung1 david wong1 chu pak lau2 vivian wong3 tai hing lam4 school nurs univers hong kong lk faculti medicin pokfulam hong kong 1depart medicin univers hong kong hong kong 2hong kong buddhist hospit lok fu kowloon hong kong3and school public health univers hong kong lk faculti medicin pokfulam hong kong4 abstract aim examin effect stage match smoke cessat counsel intervent smoker cardiac diseas method total 1860 chines cardiac patient smoke cigarett past 7 dai ag 18 year recruit cardiac patient clinic hong kong hospit alloc randomli intervent group control group intervent group 938 receiv counsel match stage readi quit train counsellor baselin 1 week 1 month control group 922 receiv counsel healthi diet baselin primari outcom report 7 dai 30 dai point preval pp tobacco abstin 12 month baselin secondari outcom measur includ biochem valid abstin 12 month follow report 7 dai 30 dai pp abstin reduct cigarett consumpt 50 3 6 month result intent treat analysi interven tion control group show signific differ report 7 dai pp abstin intervent 26.5 versu control 25.5 0.60 30 dai pp intervent 25.4 versu control 24.2 0.55 biochem valid abstin intervent 6.6 versu control 4.9 0.14 quit attempt 24 hour intervent 40.3 versu control 34.3 0.007 12 month follow adjust baselin stage readi quit smoke conclus intervent base stage chang model promot smoke cessat cardiac patient china fail find long term benefit keyword behaviour counsel cardiac patient chines popul random control trial tobacco abstin transtheoret model chang correspond sophia chan school nurs li ka shing faculti medicin univers hong kong 4 william mw mong block li ka shing faculti medicin 21 sassoon road pokfulam hong kong 852 mail nssophia hkucc.hku.hk submit 21 april 2011 initi review complet 15 june 2011 final version accept 16 novemb 2011 introduct smoke major recurr event patient coronari heart diseas chd smoke cessat coronari event reduc cardiovascular mortal 35 45 5 year 1 fatal myocardi infarct occur smoker quit cardiac event 2 smoke cessat treatment highli cost effect recommend clinic guidelin secondari cardiovascular diseas prevent 3 behaviour intervent treat tobacco rec ommend cardiac patient gener 3 5 studi smoke cessat intervent chd patient provid mix result meta analys random iz control trial show behaviour smoke cessat intervent includ target increas efficaci develop risk percept cope skill appear effect 6,7 meta analysi 12 studi conclud limit effect promot tobacco abstin chd patient 8 studi includ review mix particip popul divers intervent method good evid need promot intervent secondari prevent chd patient studi research report doi 10.1111 1360 0443.2011.03733 2011 author addict 2011 societi studi addict addict 107 829 837 target patient disappoint result wigger al report ad minim behaviour smoke cessat intervent nicotin replac therapi nrt provid addi tional effect quit 12 month 9 hart al test health counsel intervent multipl behaviour risk factor report signific reduc tion fat consumpt signific chang proport smoker 4 month 10 cardiac event requir medic atten tion regard teachabl moment excel opportun initi smoke cessat patient motiv make improv health condit smoke behaviour patient receiv limit attent health care profession smoke cessat inter vention proper follow up rare part routin clinic care hong kong mainland china countri frequent report reason includ lack time counsel skill 11,12 stage match cessat counsel routin cardiac patient treatment nicotin depend wide method smoker gener public quit smoke recent meta analysi 14 random trial smoke cessa tion show psychosoci intervent gener effect compar usual advic deliv gener practition train counsellor 7 conduct random control trial test effect nurs deliv stage match smoke intervent chines cardiac outpati hong kong specif aim studi examin effect stage match smoke cessat counsel intervent tobacco abstin reduct cigarett consumpt half compar control group ii stage match counsel intervent enhanc make quit attempt clinic set cardiac patient method particip set chines cigarett smoker attend cardiac patient clinic 10 major hospit hong kong routin follow visit recruit march 2002 decemb 2004 patient ag 18 year smoke cigarett daili past 7 dai elig particip patient exclud clinic ill suitabl complet questionnair receiv intervent commun chines studi design procedur singl blind multi centr random con troll trial approv ethic committe studi site li ka shing faculti medicin univers hong kong patient provid written consent prior random cardiac patient smoke refer physician regular consult meet nurs smoke cessat counsellor room clinic screen elig patient invit join trial baselin data includ demograph health statu smoke quit histori obtain patient structur questionnair administ face face interview nurs counsellor prior random nicotin depend assess fagerström test 13 stage readi quit pre contempl contempl prepar action assess algorithm adapt diclement al 1991 base quit attempt past year intent quit futur 14 appendix s1 show stage algorithm readi quit studi baselin interview assess nurs counsellor patient assign intervent control group open serial number seal opaqu envelop ing print instruct group allo cation sequenc intervent control gener sequenti project coordin base simpl random sampl procedur replac ms excel intervent patient assign intervent group receiv 30 minut individu face face smoke cessat counsel match stage readi quit baselin visit receiv telephon call nurs counsellor 1 week 1 month baselin visit reassess stage readi quit addit counsel smoke cessat match updat stage phone call telephon counsel session last 15 minut individu stage match smoke cessat counsel develop base transtheoret model chang 14 standard stage match proto col provid intervent match patient stage readi quit pre contempl contempl prepar action mainten smoker pre contempl stage readi quit goal intervent patient seri ousli quit 6 month nurs 830 sophia chan al 2011 author addict 2011 societi studi addict addict 107 829 837 counsellor assess smoker knowledg misconcept base knowledg gap mi concept nurs counsellor increas smoker percept risk problem smoke offer inform resourc final discuss possibl chang behaviour smoker contempl stage think quit goal tip balanc pro quit outweigh con express confid patient abil quit order achiev goal nurs counsellor give advic reason chang clarifi misconcept provid support identifi barrier offer potenti solut addit nurs counsellor encourag small step quit action i. delai cigarett cut number cigarett smoker prepar stage readi make chang goal intervent patient plan quit attempt nurs counsellor strengthen smoker commit motiv quit help smoker set quit date develop action plan smoker action stage make chang goal intervent provid support nurs counsellor discuss smoker remov cue relaps develop ing cope skill referr smoke cessat programm support group detail counsel provid patient intervent group appendix s2 control group receiv 15 minut face face counsel healthi diet nurs counsellor baselin visit page a4 size leaflet highlight import healthi diet cardiac patient patient telephon counsel ling patient arm receiv standard care provid routin respect hospi tal drug nicotin replac therapi nrt form gum patch provid due lack resourc stage match medic counsel ling nrt discuss patient contem plation action stage intervent group deem fidel intervent deliveri intervent conduct regist nurs complet 2 dai train workshop smoke cessat counsel pass written practic test train includ health hazard smoke tobacco epidem stage readi quit smoke stage match smoke cessat treat ment counsel techniqu nurs counsellor decision balanc review tool intervent compon checklist ensur treatment fidel document deliveri intervent compon total time spent counsel session record qualiti counsel intervent moni tore qualiti assur mechan regular meet counsellor held 2 month case share evalu counsellor audio tape counsel session month tape audit experienc nurs supervisor perfor manc assess feedback improv pro vide individu counsellor share regular meet train nurs counsellor random alloc procedur strictli provid inter vention patient instruc tion seal opaqu envelop contamin intervent observ follow outcom measur patient telephon 3 6 12 month initi contact train interview blind group assign follow patient ask cigarett tobacco product contact past 7 dai 30 dai attempt made consid patient lost follow primari outcom measur report 7 dai 30 dai point preval pp tobacco absti nenc 12 month initi contact 12 month follow patient report total abstin smoke puff past 7 dai 30 dai consid report quitter secondari outcom includ report 7 dai 30 dai pp tobacco abstin 3 6 month bio chemic valid tobacco abstin 12 month exhal carbon monoxid level 8 part million ppm measur smokerlyz urin cotinin level 100 ng ml measur nicalert strip 15 quit attempt stop smoke last 24 hour 12 month quit attempt rate reduct cigarett consumpt 50 compar baselin follow reduct rate biochemi calli valid tobacco abstin 12 month outcom measur base report patient report stop smoke 7 dai 12 month invit attend centr health promot univers hong kong biochem valid travel allow hkd 50 1 hk 7.8 increas hkd 100 hkd 200 offer patient present valid lost follow refus particip valid test treat smoker stage match smoke cessat intervent 831 2011 author addict 2011 societi studi addict addict 107 829 837 sampl size calcul base previou studi 12 month tobacco ab tinenc patient receiv nurs deliv behaviour orient counsel baselin post discharg telephon follow up 27 versu 20 control group receiv usual care 16 detect differ 7 group base primari outcom side 5 signifi canc level power 90 1550 patient requir account loss 15 patient 12 month follow total 1824 patient need statist analysi data analysi perform statist packag social scienc spss chicago il usa version 14.0 window compar baselin characterist patient c2 test categor variabl test continu variabl intervent control group c2 test assess effect intervent calcul crude odd ratio 95 confid interv ci primari secondari outcom logist regress perform adjust baselin stage readi quit smoke 1860 patient includ analysi intent treat appli cabl i. consid respond follow patient current smoker made quit attempt follow period chang smoke behaviour compar baselin 5 level signific set analys result patient enrol march 2002 decemb 2004 60 588 patient cardiac diseas screen 58 479 96.5 smoker lower smoke rate 3.5 cardiac patient current studi compar popul daili smoke preval 11 2007 unexpect 17 cardiac patient quit smoke diseas cardiac patient smoke di 2109 elig patient 1860 88.2 consent particip assign randomli intervent 938 control group 922 gener intervent control group similar demograph characterist smoke cessat histori clinic histori heart diseas rang 0.21 0.71 patient intervent group higher stage readi quit smoke control group contempl prepar stage 37 versu 27 0.001 tabl 1 intervent studi complet loss follow figur 1 show consolid standard report trial consort chart 938 patient intervent group receiv baselin face face stage match smoke cessat counsel 54.4 510 938 receiv 1 week 1 month telephon follow counsel 35.4 332 938 receiv 1 week 1 month telephon counsel ling 10.2 96 938 receiv telephon counsel initi counsel session patient control group receiv face face 15 minut healthi diet counsel leaflet healthi diet baselin 3 month telephon follow 87.4 820 938 intervent 87.7 809 922 control group contact 86.5 811 938 intervent 86.1 794 922 control group retain 6 month 12 month follow 85.5 802 938 intervent 84.3 777 922 control group provid data statist signific differ retent rate found group total 25 patient intervent 16 versu control 9 0.23 di studi period exclud deceas case base line characterist similar 1579 1835 respond 12 month lost follow 256 1835 patient singl widow baselin lost follow control group primari secondari outcom primari outcom intervent group control group similar report 7 dai pp tobacco abstin intervent 26.5 versu control 25.5 0.60 report 30 dai pp abstin intervent 25.4 versu control 24.2 0.55 12 month follow secondari outcom intervent group higher report 7 dai pp abstin 3 month intervent 22.9 versu control 17.8 0.006 6 month intervent 27.8 versu control 21.7 0.002 similarli intervent group higher report 30 dai abstin 3 month intervent 19.6 versu control 15.3 0.01 6 month intervent 25.8 versu control 20.3 0.005 telephon follow statist signific differ found biochem valid quit rate 12 month intervent 6.6 control 4.9 832 sophia chan al 2011 author addict 2011 societi studi addict addict 107 829 837 group 0.14 tabl 2 484 report abstin 7 dai 12 month 130 26.9 particip biochem valid particip rate differ interven tion 28.5 71 249 control group 24.7 58 235 0.34 fig 1 misreport rate slightli significantli lower intervent group intervent 12.7 71 versu control 22.4 13 58 0.14 includ report quitter 37.1 348 938 intervent group report reduct cigarett consumpt 50 baselin 3 month compar 26.9 248 922 control group 0.001 signific differ smoke reduct rate sustain 6 month intervent 41.3 versu control 33.1 0.001 12 month intervent 40.7 versu control 37.6 0.17 addit intervent group higher proport quit attempt tobacco abstin 24 hour 12 month studi period compar control group intervent 40.3 versu control 34.3 0.007 tabl 2 adjust baselin group differ stage readi quit smoke intervent effect diminish secondari outcom except 7 dai pp tobacco abstin 6 month adjust 1.28 95 ci 1.03 1.59 0.03 smoke reduct rate 3 month adjust 1.62 95 ci 1.22 2.17 0.001 tabl 2 discuss effect quit smoke reduct 3 6 month differ sustain 12 month adjust baselin stage readi quit cardiac patient tabl 1 baselin characterist particip interventionc 938 controld 922 sex 0.22 male 859 91.6 834 90.5 femal 79 8.4 88 9.5 ag mean sd year 58.0 14.1 58.6 14.1 0.38 educ levela 0.40 primari 445 48.0 460 50.1 secondari 396 42.7 365 39.7 tertiari 86 9.3 94 10.2 marit statu 0.45 singl 103 11.0 84 9.1 marri cohabit 710 75.7 699 75.8 divorc 54 5.8 61 6.6 widow 71 7.6 78 8.8 fagerström nicotin depend score mean sd 2.62 2.1 2.51 2.1 0.21 year regular smoke mean sd 38.9 15.5 39.8 15.4 0.25 daili cigarett consumpt mean sd 12.0 8.3 11.6 8.1 0.26 previou quit attempt 0 214 22.8 224 24.3 0.24 1 724 77.2 698 75.7 stage readi quit 0.001 pre contempl stage 591 63.0 673 73.0 contempl stage 232 24.7 179 19.4 prepar stage 115 12.3 70 7.6 type heart diseasea 0.71 coronari heart diseas 459 51.5 460 52.0 othersb 441 48.5 425 48.0 durat cardiac diseasea 0.26 1 year 238 26.3 227 25.5 1 year 3 year 299 33.1 263 29.5 3 year 6 year 207 22.9 228 25.6 6 year 160 17.7 173 19.4 amiss data exclud binclud congenit heart diseas arrhythmia cardiovascular diseas cstage match smoke cessat counsel ling dhealthi diet educ programm sd standard deviat stage match smoke cessat intervent 833 2011 author addict 2011 societi studi addict addict 107 829 837 figur 1 consort chart studi 834 sophia chan al 2011 author addict 2011 societi studi addict addict 107 829 837 short term effect diminish intervent group quit smoke 6 month follow reduc smoke con sumption 3 month follow explan lack long term effect stage match counsel intervent studi 54.4 510 938 patient intervent group complet 1 week 1 month telephon remind session weaken effect inter vention abstin rate estim biochem valid abstin rate 12 month low compar report measur major reason larg discrep low particip rate valid test 30 misreport rate studi substan tial abstin rate report inflat abstin rate higher control group reduc effect size find deviat recent systemat review studi suggest behaviour psy choeduc therapi posit effect help smoker heart diseas stop smoke 7,16,18 20 review combin studi mix behaviour intervent approach pharmacotherapi intens behaviour support vari huttunen lenz colleagu review random control trial rct smoke cessat intervent cardiac patient 7 identifi rct appli stage chang theori experiment group versu usual care 21,22 studi found counsel increas rate abstin cardiac patient addit intervent approach smoker heart diseas direct add complementari pharmacotherapi behaviour intervent 7,18 20 previou studi demonstr smoke cessat intervent base behaviour therapi pharmacotherapi nrt bupropion vareni cline higher rate smoke absti nenc cardiac patient compar placebo usual care 19,23,24 medic advic sought nrt pharmacolog pro duct buproprion patient sever cardio vascular diseas includ heart failur stabl angina occlus peripher arteri diseas rare case nrt advers event includ heart palpit chest pain 25 bupropion increas rate ischaem heart diseas 26 potenti option smoke reduc tion programm ultim goal complet tabl 2 abstin tobacco reduct smoke 3 6 12 month follow quit attempt 12 month perioda interventionb 938 controlc 922 absolut differ pt 95 ci 95 ci adjust ord 95 ci primari outcom 12 month report 7 dai pp quit rate 249 26.5 235 25.5 1.06 2.93 5.05 1.06 0.86 1.30 0.95 0.77 1.18 report 30 dai pp quit rate 238 25.4 223 24.2 1.19 2.74 5.11 1.07 0.86 1.32 0.96 0.77 1.19 secondari outcom report 7 dai pp quit rate 3 month 215 22.9 164 17.8 5.13 1.47 8.80 1.37 1.09 1.73 1.22 0.97 1.55 6 month 261 27.8 200 21.7 6.13 2.21 10.06 1.39 1.13 1.72 1.28 1.03 1.59 report 30 dai pp quit rate 3 month 184 19.6 141 15.3 4.32 0.87 7.78 1.35 1.06 1.72 1.19 0.93 1.53 6 month 242 25.8 187 20.3 5.52 1.69 9.35 1.37 1.10 1.70 0.87 0.70 1.07 biochem valid quit rate 12 month 62 6.6 45 4.9 1.73 0.39 3.85 1.35 0.91 2.00 1.26 0.85 1.87 report reduct daili cigarett consumpt 50 3 month 348 37.1 248 26.9 10.2 5.96 14.44 1.60 1.32 1.95 1.62 1.22 2.17 6 month 387 41.3 305 33.1 8.18 3.78 12.57 1.42 1.18 1.72 1.21 0.92 1.60 12 month 382 40.7 347 37.6 3.09 1.35 7.53 1.14 0.95 1.37 1.20 0.91 1.57 quit attempt 24 hour 12 month period 378 40.3 316 34.4 6.03 1.63 10.42 1.29 1.07 1.56 1.18 0.97 1.43 0.05 0.01 0.001 abi intent treat analysi assum respond follow patient current smoker made quit attempt period chang smoke behaviour compar baselin bstage match smoke cessat counsel chealthi diet educ programm dodd ratio adjust baselin stage readi quit smoke ci confid interv pp point preval stage match smoke cessat intervent 835 2011 author addict 2011 societi studi addict addict 107 829 837 cessat shown effect smoker quit 27 studi limit cardiac patient clinic provid rehabilit programm includ health talk advic smoke cessat usual standard care stage match counsel plausibl interven tion overlap usual standard care patient control group receiv inter vention patient set effect 28 usual care bias effect null time usual care vari hospit hospit advic specif partli explain higher 7 dai pp quit rate reduct rate observ intervent group interv follow up insignific differ 12 month follow proport patient posit outcom control group caught intervent group mul tipl attempt financi incent manag encourag quarter report quitter attend biochem valid rigotti al report low particip rate hospit patient financi incent offer sampl collect made easi particip 29 studi major reason quitter attend valid unreach 39.4 140 355 unavail 26.2 93 355 smoke heart diseas cardiac patient hide smoke statu pare smoker smoke relat diseas 27 conclus larg sampl size pare relev studi stage match counsel ling intervent result earlier cessat reduct smoke compar control group 3 6 month follow benefit su tain 12 month studi smoke cessat intervent relaps prevent cardiac patient warrant clinic trial registr clinic trial registr number http www control trials.com number isrctn32840413 declar interest studi fund competit earmark research grant hku7224 01m research grant council rgc hong kong connec tion research tobacco alcohol phar maceut game industri fund substanti organ acknowledg studi fund competit earmark research grant hku7224 01m research grant council rgc hong kong rgc involv design conduct studi collect manag analysi interpret data prepar review approv manuscript indebt particip patient miss sarbina chan coordin project miss cora bow assist edit format ting manuscript interim data analys present 13th world confer tobacco health 8 15 juli 2006 washington dc usa 8th asian asia pacif confer tobacco health 17 21 octob 2007 taipei taiwan
experiment therapeut medicin 7 716 720 2014716 abstract studi examin effect individu counsel smoke cessat china present studi evalu efficaci individu counsel patient chronic obstruct pulmonari diseas copd asymp tomat smoker prospect random studi evalu 85 smoker copd 105 asymptomat smoker normal lung function individu randomli alloc intervent control group subject intervent group provid individu cognit counsel base face face individu consult materi telephon follow up subject control group provid simpl smoke cessat advic smoke statu subject st georg respiratori questionnair sgrq copd patient assess baselin week 4 month 6 copd patient exacerb 6 month record total studi popul individu counsel result higher absti nenc rate compar control intervent control 23.4 10.4 0.007 similar result observ smoker copd intervent control 40.5 18.6 0.027 asymptomat smoker effect individu counsel identifi statist insignific intervent control 9.6 3.8 0.230 sgrq score copd exacerb significantli improv patient abstain smoke compar patient fail stop smoke airwai obstruct quit motiv individu counsel com.ibm.drl.hbcp.predictor smoke cessat airwai obstruct signific com.ibm.drl.hbcp.predictor smoke cessat odd ratio 4.215 95 confid interv 2.215 7.865 result present studi show individu counsel effect method smoke cessat copd patient efficaci asymptomat smoker requir confirm studi introduct smoke lead mortal worldwid half long term smoker succumb tobacco relat diseas 1 2010 estim 28.1 adult china 301 million 52.9 male 2.4 femal current smoker 91.8 smoker attempt quit method assist smoke cessat 2 2.5 male 3.5 femal success remain abstin 24 month 3 male popul china succumb tobacco relat mortal high smoke rate persist 4 specif smoke cessat medic china smoker 5.6 concern regard health effect smoke 5 identifica tion effect method aid smoke cessat china urgent cognit intervent chronic obstruct pulmonari diseas copd global health crisi smoke caus factor 50 older smoker develop copd 6 preval copd resid 40 year 8.2 china 7 smoke cessat signific intervent copd manag ment recommend global initi chronic obstruct lung diseas gold 8 slow diseas progress 9 studi develop countri show cognit counsel cost effect treatment motiv behavior base smoke cessat 10 12 effect shown group individu remain ambigu specif individu cognit counsel effect smoker airwai obstruct 13 effect 14 studi individu counsel smoke cessat effect individu counsel smoke cessat smoker chronic obstruct pulmonari diseas asymptomat smoker juan chen1 yan chen2 ping chen2 zhijun liu2 hong luo2 shan cai2 1depart radiolog 2depart intern medicin divis respiratori diseas xiangya hospit central south univers changsha hunan 410011 p.r china receiv juli 29 2013 accept decemb 6 2013 doi 10.3892 etm 2013.1463 correspond dr ping chen depart intern medicin divis respiratori diseas xiangya hospit central south univers 139 renm road changsha hunan 410011 p.r china mail pingchen0731 sina.com contribut equal kei word smoke cessat individu counsel chronic obstruct pulmonari diseas chen al quit smoke copd asymptomat smoker 717 conduct china patient copd present prospect random studi evalu efficaci individu counsel smoke cessat copd patient asymptomat smoker china materi method particip smoke subject copd recruit residenti area advertis pulmonari outpati clinic physic examin center xiangya hospit changsha china month period march 2010 septemb 2010 subject underw standard lung function test measur forc vital capac fvc forc expiratori volum 1 sec fev1 copd defin gold criteria fev1 fvc 70 bronchodilat 8 asymptomat smoker defin smoker respiratori symptom i. cough sputum product dyspnea normal lung function enrol subject 18 year smoke cigarett dai minimum 100 dai subject experi smoke cessat medic histori asthma asbestosi silicosi bronchiectasi lung cancer exclud studi subject provid inform consent approv medic ethic committe xiangya hospit studi design gener accept motiv quit signific factor smoke cessat 15 smoker copd asymptomat divid categori motiv quit desir quit indiffer hope quit hope quit smoker categori assign intervent control group random digit tabl quit motiv compar group intervent group provid individu cogni tive counsel base face face individu counsel perform baselin materi telephon call week 1 2 3 4 6 8 month 3 4 5 face face individu counsel last 20 min base method relat harm smoke benefit smoke cessa tion method quit method handl withdraw symptom prevent relaps 16 smoker copd counsel content focus correl smoke habit copd materi includ specif smoke cessat handbook smoke cessat tip telephon call last 10 min design promot smoke cessat smoker conquer issu occur smoke cessa tion control group provid smoke cessat advic intervent conduct doctor experi profession smoke cessat treatment main assess perform baselin week 4 month 6 nicotin depend assess fagerström test nicotin depend ftnd st georg respiratori questionnair sgrq measur health relat qualiti life exacerb time 6 month record copd patient exacerb defin gold paramet specif acut event character worsen patient respiratori symptom normal dai dai variat lead chang medic 8 absti nenc defin report sustain abstin week 4 month 6 report abstin week 4 month 6 verifi exhal carbon monoxid level 10 ppm statist analysi minimum total sampl 152 particip expect success rate 25 intervent group compar 5 control group tail signific level 0.05 power 80 statist analys perform spss 17.0 statist softwar spss chicago il usa 0.05 consid statist signific differ enc distribut quantit data analyz test distribut data wilcoxon mann whitnei test categor variabl data χ2 test com.ibm.drl.hbcp.predictor outcom analyz multinomi logist regress result baselin characterist total 85 copd patient 105 asymptomat smoker includ studi twelv smoker 5 copd 7 asymptomat withdrew 6 month period common reason withdraw attribut poor complianc withdraw regard smoker includ outcom analys tabl list baselin characterist subject baselin characterist balanc intervent control group balanc intervent control group copd asymptomat smoker signific differ enc baselin characterist copd patient asymptomat smoker ag pack year quit motiv significantli higher copd patient asymptomat smoker educ level copd patient lower asymptomat smoker sever copd classifi predict fev1 percentag percentag observ term copd grade 11 subject mild fev1 80 predict 46 moder fev1 50 80 predict 33 sever fev1 30 50 predict 10 sever fev1 30 predict full represent shown tabl ii smoke cessat outcom fig 1 list smoke cessat outcom smoker copd consid abstin rate higher intervent group control group 23.4 10.4 0.007 result similar base exclus smoker copd 40.5 18.6 0.027 effect individu counsel asymptomat smoker statist insignific 9.6 3.8 0.230 tabl ii list abstin rate smoker spirometr result smoker copd quit smoke 29.4 normal spirometri 6.7 0.001 higher copd grade correl experiment therapeut medicin 7 716 720 2014718 higher abstin rate differ abstin rate mild moder sever sever copd group statist insignific 22.2 25.6 31.0 50.0 0.540 health outcom analysi base copd particip proport patient improv sgrq score unit calcul group show signific clinic qualiti life copd patient abstain smoke 36.0 signific improv sgrq total score significantli higher 13.3 patient fail stop smoke 0.037 month period averag 0.61 exacerb tabl particip characterist copd asymptomat smoker intervent control intervent control intervent control characterist group 94 group 96 group 42 group 43 group 52 group 53 ag year 50.8 13.9 50.3 13.2 61.4 8.6 61.6 7.7 41.7 10.1a 41.6 9.8b male:femal 91 3 93 3 41 1 41 2 50 2 52 1 pack year 31.6 18.8 32.6 20.4 40.2 18.2 44.3 15.9 23.7 15.4a 24.0 19.4b daili cigarett 19.0 10.3 20.6 12.7 17.5 8.4 17.2 9.6 22.4 10.6 23.6 13.9 carbon monoxid ppm 15.1 8.2 16.1 8.2 14.2 7.3 14.1 8.5 17.5 8.4 18.3 9.2 ftnd point 4.1 2.4 4.2 2.3 4.0 2.0 4.1 2.5 4.2 2.1 4.3 2.4 educ junior high school 40 34 28 20 12 14 senior high school 23 23 10 14 13 9 colleg 31 39 4 9 27 30 quit motiv desir quit 17 18 3 3 14 15 indiffer 27 26 5 5 22 21 hope quit 37 39 23 24 14 15 hope quit 13 13 11 11 2 2 ap 0.05 copd intervent group bp 0.05 copd control group pack year calcul multipli number pack cigarett smoke dai number year individu smoke copd chronic obstruct pulmonari diseas ftnd fagerström test nicotin depend tabl ii abstin rate stratifi baselin spirometr result copd variabl normal mild moder sever sever subject 105 85 9 39 29 8 abstain 7 25 2 10 9 4 abstin rate 6.7 29.4 22.2 25.6 31.0 50.0 0.001a 0.540b ap compar abstin rate asymptomat smoker copd patient bp compar abstin rate grade copd patient copd chronic obstruct pulmonari diseas figur 1 abstin rate group 0.05 tc total smoker control ti total smoker intervent cc copd control ci copd intervent ac asymptomat control ai asymptomat interven tion copd chronic obstruct pulmonari diseas chen al quit smoke copd asymptomat smoker 719 copd patient abstain smoke compar 1.21 exacerb patient continu smoke 3.32 0.001 com.ibm.drl.hbcp.predictor smoke cessat outcom multinomi logist regress analyz abstin outcom com.ibm.drl.hbcp.predictor tabl iii individu counsel copd quit motiv found independ com.ibm.drl.hbcp.predictor abstin copd signific odd ratio 4.215 95 confid interv 2.215 7.865 factor includ ag gender daili cigarett pack year ftnd educ background sgrq includ initi regress model found statist signific associ abstin discuss present studi knowledg random control trial china demonstr efficaci individu counsel smoke cessat smoker copd asymptomat smoker signific observ individu counsel effect method smoke cessat true smoker copd result present studi correl previou studi evalu effici individu counsel smoke cessat develop countri bednarek al 13 poland recruit 4,494 smoker smoker receiv simpl smoke cessat advic 1,177 subject airwai obstruct inform copd smoke cessat halt lung diseas progress year sustain smoke cessat rate airwai obstruct 16.3 compar 12.0 normal spirometr paramet 0.0003 12 strate al 17 sweden obtain similar result studi 512 smoker enrol receiv annual spirometri smoke cessat advic person letter physician year 25 smoker copd smoke free 1 year compar 7 smoker normal lung function 0.001 studi result present studi individu counsel efficaci help smoker quit effi cienci copd patient mark studi willems al 14 netherland group meet smoke cessat report 42 16 38 abstin rate copd patient smoker comparison 68 17 25 abstin rate healthi smoker author offer statist analysi result explan healthi smoker recruit higher motiv smoke cessat author assess motiv subject toljamo al 15 finland enrol 584 smoker studi provid individu coun sele individu studi report 5.4 sustain abstin rate smoker copd compar 10.6 patient copd 0.125 success quit identifi airwai obstruct clear differ studi present studi spirometri conduct end studi copd patient inform ill comparison patient present studi receiv counsel found awar correl smoke habit copd smoke cessat improv cessat rate found smoker copd factor lead result includ compon quit motiv higher copd patient gener smoker major patient copd suffer cough dyspnea wide consid harm effect smoke concern person health popular reason smoke cessat china 5 posit spirometr result copd diagnosi show patient harm effect smoke necess smoke cessat unit state nation lung health educ program previous recommend spirometr test increas motiva tion smoker quit 18 park al 19 ʻlung ag spirometr result order encourag smoke cessat studi report independ verifi rate quit 12 month intervent control group 13.6 6.4 0.005 addit smoke social behavior china individu share cigarett make difficult asymptomat smoker stop smoke smoker copd reject cigarett offer due diseas goal clinic control copd patient includ improv exercis toler emot function prevent diseas progress minim symp tom lead increas qualiti life 8 continu airwai inflamm smoker copd 20 smoke cessat effect method reduc progress diseas slow annual fev1 declin rate 9 result increas qualiti adjust life year copd patient 10 dyspnea cough symptom copd patient exp rienc improv smoke cessat 21 tabl iii com.ibm.drl.hbcp.predictor smoke cessat logist regress model com.ibm.drl.hbcp.predictor 95 ci airwai obstruct 1.652 0.000 4.217 2.215 7.865 individu counsel 1.133 0.007 3.104 1.369 7.042 quit motiv 1.146 0.000 3.145 1.780 5.557 odd ratio ci confid interv experiment therapeut medicin 7 716 720 2014720 health outcom present studi demonstr statist signific improv sgrq total score copd exacerb patient copd abstain smoke demonstr smoke cessat result increas health benefit copd patient number factor involv smoke cessat studi western countri shown health statu econom reason commonli factor 22,23 addit smoke abstin associ at ag male gender high incom high level educ low nicotin depend smoke free famili polici 15,24 studi south africa show clinic intervent smoke free famili polici increas rate smoke cessat 25 previou studi china observ interest quit smoker affect past quit experi nicotin depend health concern attitud smoke 26,27 observ present studi confirm previou observa tion show motiv health statu signific factor affect result smoke cessat found individu counsel signific factor demograph characterist nicotin depend identifi independ factor smoke cessat possibl ow small sampl size limit present studi major copd patient recruit outpa tient clinic possibl sever clinic symptom typic patient copd patient motiv quit smoke addit major subject studi hunan provinc china studi popul true represent smoker china conclus individu smoke cessat counsel effect method help copd patient quit result increas health benefit health profession provid cognit counsel smoker quit smoke quit motiv healthi statu factor individu counsel signific factor smoke cessat result individu counsel effici asymptomat smoker remain uncertain nationwid multicent studi requir investi gate futur acknowledg studi support grant chines nation natur scienc foundat no 81070039 81270100 chronic respiratori diseas research fund chines medic associ 08020520130
nurs research juli august 2005 vol 54 4 243 nurs research juli august 2005 vol 54 4 243 254 effect nurs inpati smoke cessat program individu cardiovascular diseas maud christin chouinard sylvi robichaud ekstrand background smoke import risk factor cardio vascular diseas cvd quit highli beneficial.yet 30 cvd patient stop smoke relaps prevent strategi effect initi exacerb diseas object nurs deliv inpati smoke cessat pro gram base transtheoret model telephon follow tailor level readi quit smoke evalu smoke abstin progress ulterior stage chang method particip 168 randomli assign cohort inpati counsel telephon follow inpati counsel usual care inpati interven tion consist 1 hr counsel session tele phone follow includ 6 call 2 month discharg nurs intervent tailor individu stage chang end point 2 6 month includ actual continu smoke cessat rate biochem marker increas motiv progress ulterior stage chang result assum surviv patient lost follow smoker 6 month smoke abstin rate 41.5 inpati counsel telephon follow group compar 30.2 20 inpati coun sele usual care group 05 progress ulterior stage chang 43.3 32.1 18.2 02 stage chang base line intervent predict smoke statu 6 month discuss tailor smoke cessat program telephon follow significantli increas smoke cessa tion 6 month progress ulterior stage chang telephon follow import adjunct recommend includ comprehen sive smoke cessat program hospit set individu cvd kei word cardiovascular diseas smoke cessat transtheoret model smoke major public health problem theworld fior al 2000 report import risk factor cardiovascular diseas cvd american associ cardiovascular cardiopul monari rehabilit 2004 pipe 1999 smoke cessa tion highli benefici person suffer cvd critchlei capewel 2003 wilson gibson willan cook 2000 30 stop smoke advic health care profession van berkel boersma roo hesselink erdman simoon 1999 report exacerb diseas motiv individu stop smoke rich mond 1999 hospit smoke free environ ment import contribut factor rigotti 2000 taylor houston miller killen debusk 1990 report 61 smoke cessat rate 12 month patient particip nurs inpati smok ing cessat program telephon follow 01 compar group patient hospit acut myocardi infarct ami 32 smoke ce sation dornela sampson grai water thomp son 2000 found 67 smoke cessat rate 6 month compar 43 usual care group ami patient particip psychologist led inpati intervent telephon follow base stage chang transtheoret model 05 intervent evalu person ami report smoke abstin confirm biochem analys contribut telephon follow evalu inpati environ nurs health care profession contact patient smoke prohibit ward hospit maud christin chouinard phd rn assist professor modul de scienc infirmièr de la santé université du québec à chicoutimi québec canada sylvi robichaud ekstrand phd rn associ professor faculti nurs université de montréal québec canada 244 nurs inpati smoke cessat program nurs research julyaugust 2005 vol 54 4 environ ideal set individu stop smoke gain skill need remain nonsmok discharg cote 2000 anticip individu acquir initi smoke relaps prevent skill particip inpati smoke cessat program tele phone follow nurs famili support requir prevent relaps readi ness stop smoke level interven tion adapt particip characterist con tribut effect intervent andersen keller 2002 introduc tailor program reach consider number patient cvd hospit environ effec tive discharg johnson budz mackai miller 1999 increas particip rate improv effect creat greater impact smoke cessat popul level abram al 1996 studi led nurs yield anticip result bolman de vri van breukelen 2002 hajek taylor mill 2002 reid al 2003 lack tailor smoke cessat program short durat span limit sampl size contribut factor controversi result nurs led smoke cessa tion program methodolog issu con sider warrant investig sebregt falger bär 2000 wigger smet de hae peter lege mate 2003 purpos studi evalu effect nurs inpati smoke cessat program telephon follow transtheoret model addit studi design delin effect ad telephon follow theoret framework studi conceptu transtheoret model prochaska diclement 1983 smoke cessat intervent develop integr el ment model multipl attempt nonsmok smoke cessat consid process end product smoker nonsmok believ progress higher level chang requir cognit behavior process chang com.ibm.drl.hbcp.util specif process chang reflect individu readi smoker stage chang reflect readi evalu effect smoke cessat program rustin tate 1993 propos smoke cessat nurs intervent con sider effect smoker progress stage chang quit smoke peopl follow linear path modifi behavior transtheoret model schemat repres spiral attempt modifi maintain healthi behavior individu regress previou stage learn eventu reach mainten stage stage chang identifi transtheoret model prochaska red ever 2002 precontempl stage intent modifi behavior 6 month contempla tion signifi individu awar smoke problemat feel ambival quit quit smoke 6 month month state hav ing attempt quit smoke 24 hr past year prepar stage combin intent behavior effort individu stage initi action stop smoke month back intent attempt quit past year action 6 month time frame individu alter environ experi relationship stop smoke high risk relap ing habit establish mainten 6 month time frame individu remain nonsmok requir motiv skill prevent relaps number scientif articl aim health care pro fession underlin import integr infor mation gener transtheoret model smok ing cessat program cole 2001 cote 2000 coward 1999 effect smoke cessat program base model remain controversi andersen keller mcgowan 1999 riemsma al 2003 spencer pagel hallion adam 2002 studi smoke cessat 6 month desir outcom subtl cognit occur normal process quit smoke occur abram 1993 velic rossi diclement prochaska 1996 progress stage chang chosen secondari outcom object studi test hypothes smoker cvd receiv nurs deliv er inpati smoke cessat counsel intervent base stage chang telephon follow group 1 group 2 present higher point preval smoke abstin higher rate con tinuou abstin smoke progr sion ulterior stage chang 2 6 month hospit discharg usual care group group 3 inpati smoke cessat counsel intervent telephon follow group 1 expect produc significantli result inpati smoke cessat counsel intervent group 2 point preval smoke abstin refer smoke past 7 dai obtain neg ativ biochem result time measur continu smoke abstin refrain smoke hospit discharg anticip initi stage chang predict smoke cessat method sampl select criteria inclus criteria requir particip studi adult 18 year older hospit cvd myocardi infarc tion angina heart failur peripher vascular diseas smoker smoke cigarett past nurs research juli august 2005 vol 54 4 nurs inpati smoke cessat program 245 month abil commun french local resid telephon home plan ho pital discharg home mental physic disabil iti imped particip sampl size sampl size determin pass 2000 softwar chi squar pearson test unilater proport differenti set 25 smoke ce sation progress stage chang group receiv inpati counsel telephon follow receiv usual care critic alpha set 5 type error power 1 80 type ii error sampl size establish 52 particip group procedur research protocol consent form approv scientif ethic committe patient admiss medic record review potenti particip identifi verifi medic diagnosi smok ing statu studi explain elig partici pant condit stabl famili member present studi explain patient wish particip studi sign consent form data collect inpati period includ stage chang data nicotin depend clinic sociodemograph data level psycholog distress compari son purpos particip nonparticip patient agre provid basic clinic sociodemo graphic inform sign respect consent form conveni sampl particip creat prevent contamin group cluster randomiza tion hauck gilliss donner gortner 1991 randomli assign individu predetermin cluster subject group assign inpati counsel telephon follow inpati counsel usual care ran domli assign cluster individu familiar studi charg randomiza tion procedur includ insert inform envelop seal open investig time recruit experiment group inpati counsel telephon follow inpati counsel met intervent nurs durat session var i individu health statu specif usual care group receiv gener advic smoke cessat discharg individu inpa tient counsel telephon follow group receiv total phone call 2 month fol low sequenc call week call week 2 week call 2 week nurs research assist met particip home 2 6 month hospit discharg par ticip complet instrument question nair baselin particip declar smoke past week underw biochem vali dation test smoke cessat intervent principl pertain smoke cessa tion intervent appli experiment group smoke cessat intervent adapt individu health condit signific famili member prefer live particip involv explan stage chang accord ing transtheoret model present particip signific famili member infor mation relat famili member concret provid support cvd patient provid cohen 1992 import remain smoker emphas nurs agenc health care polici research 1996 inpati counsel telephon follow base transtheoret model prochaska diclement norcross 1997 precontem plation stage smoke cessat intervent focus increas perceiv con smoke decision balanc encourag experienti process chang cognit affect process contempl stage intervent aim increa ing con smoke diminish pro experi ential behavior process chang incorpor action undertaken smoker prepar stage principl target rever sal decision balanc con pro smok ing extens behavior process chang reinforc efficaci acquisit relaps prevent skill action stage focus increas behavior process rein forc efficaci provid relaps prevent skill reinforc smoke cessat attempt congratu late individu decid stop smoke remain nonsmok telephon interview intervent tailor actual stage chang smoke habit inpati counsel session last 40 min averag sd 8.1 rang 10 60 min famili member spous 44 84.6 accom pani patient 46.4 52 interview seventi percent 56 particip inpati cessat program telephon follow receiv telephon call case prefer interrupt call desir continu studi case fewer call made particip difficult reach patient physic depend nicotin physic condit allow orient pharmacolog aid 29 particip nicotin patch 6 chew nicotin gum 6 prescrib bupropion zyban significantli partic ipant inpati counsel telephon follow group pharmacolog aid 22 39.2 inpati counsel 13 23.2 usual care 6 10.7 group 01 patient 22 complet 3 month pharmacolog treatment nurs patient cvd inform nicotin cessat drug adjunct fact 17 29 particip 246 nurs inpati smoke cessat program nurs research julyaugust 2005 vol 54 4 nicotin cessat drug adjunct cost issu i. pharmacolog aid cover univers medic insur plan main retic doctor patient nicotin cessat drug adjunct safeti effect smoke cessat instrument instrument gather inform relat smoke includ smoke stage chang short form admini tere baselin 2 6 month fagerström test nicotin depend l’indic de détress psy chologiqu de l’enquêt santé québec idpesq quebec health survei psycholog distress index complet baselin smoke statu evalu report particip declar nonsmok er confirm biochem test addit clinic sociodemograph questionnair admin ister baselin 2 6 month stage chang stage chang identifi french version smoke stage chang short form instrument compos question evalu person intent quit smoke spe cific time interv identifi specif stage chang transtheoret model figur 1 questionnair psycholog evalu psychometr properti report literatur stage chang predict smoke ce sation relaps diclement prochaska 1985 analyz movement stage chang score 1 patient progress higher stage remain stage relaps previou stage score 0 nicotin depend nicotin depend mea sure french version fagerström test nicotin depend heatherton kozlowski frecker fagerström 1991 scale compris question sum reflect sever physic depend nicotin score rang 7 10 strong nicotin depen denc score 4 6 signifi moder depend 4 reflect depend cronbach alpha coeffici 61 scale displai moder intern reliabl instrument extens clinic practic studi intern reliabl 59 psycholog distress sever preval symptom depress anxieti measur 14 item instrument provincewid survei quebec canada provid suffici data establish psycho metric properti instrument regard con struct valid criterion relat valid reliabl prévill boyer potvin perrault legar 1992 mean cronbach alpha coeffici 89 studi cronbach alpha coeffici 90 smoke statu report smoke cessat valid home health test urinari contin test immuno test detect activ smoke element urin person smoke previou 4 dai 5 error rate event particip con junctli nicotin substitut smoke statu valid bedfont carbon monoxid exhal test smokerlys earlier studi biochem measur enhanc valid report indi vidual high risk relaps patrick al 1994 studi repres similar situat figur 1 interpret algorithm smoke behavior stage chang scale nurs research juli august 2005 vol 54 4 nurs inpati smoke cessat program 247 data analysi chi squar analys analys varianc anova com.ibm.drl.hbcp.util determin random provid equiv alent group i. particip sociodemograph clinic characterist baselin significantli similar analys compar patient consent particip studi declin agre provid inform smoke cessat rate calcul avail follow data record particip lost follow discontinu particip restart smoke cluster analys form small number particip cohort 3 6 particip prevent contamin group i. avoid patient group benefit similar smoke cessat inform probabilist sampl method com.ibm.drl.hbcp.util conting tabl 2 3 chi squar analys di crete variabl point preval smoke abstin continu smoke abstin stage progress 2 6 month signific differ found group inpati counsel tele phone follow inpati counsel usual care 2 2 chi squar analys perform particip 168 nonparticip 57 pa gender women 45 26.8 20 35.1 23 men 123 73.2 37 64.9 marri 124 73.8 38 66.7 30 educ year 0 12 131 78 53 93 01 13 37 22 4 7 work statu emploi 60 35.7 12 21.1 12 retir 65 38.7 28 49.1 unemploi 43 25.6 17 29.8 famili incomeb 14,999 29 18.1 19 34.5 01 15,000 59,999 104 65.0 33 60 60,000 27 16.9 3 5.5 princip diagnosi myocardi infarct 40 23.8 11 19.3 37 angina 61 36.3 26 45.6 heart failur 11 6.5 1 1.8 peripher vascular diseas 56 33.3 19 33.3 previou quit attempt 141 83.9 44 77.2 25 medic advic 124 73.8 38 66.7 30 stage chang precontempl 20 11.9 18 31.6 01 contempl 18 10.7 4 7 prepar 121 72 30 52.6 action 9 5.4 5 8.8 sd ag 55.9 10.4 60.0 11.7 01 length stai dai 7.15 11.2 7.72 10.4 74 ag smoke initi year 15.21 4.5 14.14 5.0 05 agroup comparison test continu 2 nomin categor variabl bthe total number particip equal 225 refus answer tabl 1 characterist particip versu nonparticip 225 248 nurs inpati smoke cessat program nurs research julyaugust 2005 vol 54 4 multipl logist regress analys identifi vari abl predict smoke abstin progr sion ulterior stage chang 21 variabl baselin enter includ durat inpati smok ing cessat intervent famili member particip forward method signific variabl incorpor regress analys enter method result particip conveni sampl compos 168 patient cvd recruit cardiolog unit region tertiari hospit provinc quebec canada decemb 2001 august 2002 1,354 consecut patient hospit cvd screen 267 19.7 identifi smoker figur 2 data obtain person declin fulli particip studi inform compar particip tabl 1 declin particip older educ lower famili incom start smoke younger ag particip found precontem plation stage i. envis quit smoke 6 month compar analys baselin particip experiment group present similar sociodemograph clinic charact istic tabl 2 similar smoke characterist tabl 3 valid 2 month 61 individu state nonsmok biochem confirm obtain 55 3 test reason relat investig 3 inpati counsel inpati telephon counsel follow usual care total 56 56 56 168 pa gender women 13 23.2 11 19.6 21 37.5 45 26.8 08 men 43 76.8 45 80.4 35 62.5 123 73.2 marri 40 71.4 44 78.6 40 71.4 124 73.8 61 educ year 0 12 45 80.4 41 73.2 45 80.4 131 78.0 57 13 11 19.6 15 26.8 11 19.6 37 22.0 work statu emploi 23 41.1 24 42.9 13 23.2 60 35.7 13 retir 18 32.1 22 39.3 25 44.6 65 38.7 unemploi 15 26.8 10 17.9 18 32.1 43 25.6 famili incom 14,999 10 18.2 6 11.1 13 25.5 29 18.1 10 15,000 59,999 32 58.2 38 70.4 34 66.7 104 65.0 60,000 13 23.6 10 18.5 4 7.8 27 16.9 princip diagnosi myocardi infarct 16 28.6 12 21.4 12 21.4 40 23.8 68 angina 22 39.3 22 39.3 17 30.4 61 36.3 heart failur 4 7.1 3 5.4 4 7.1 11 6.5 peripher vascular diseas 14 25.0 19 33.9 23 41.1 56 33.3 sd ag 54.0 10.8 56.5 10.3 57.25 9.9 55.9 10.4 22 length stai dai 7.6 13.1 7.5 13.0 6.4 6.5 7.2 11.2 82 psycholog distress 1.50 0.48 1.46 0.45 1.54 0.48 1.50 0.47 67 agroup comparison anova continu 2 categor variabl tabl 2 sociodemograph clinic characterist sampl baselin nurs research juli august 2005 vol 54 4 nurs inpati smoke cessat program 249 refus undergo test consid smoker 55 particip test 38 69.1 underw urin test present neg result confirm nega tive carbon monoxid test 51.5 20 14 25.5 underw carbon monoxid test show neg result final 3 person 5.5 show posit result reclassifi smoker 6 month 55 individu declar nonsmok 6 refus undergo test classifi smoker 49 remain individu 42 85.7 neg result urin test 13 31 confirm carbon monoxid test 5 10.2 underw carbon monoxid test neg result 2 individu test point preval smoke abstin 2 month individu inpati counsel telephon follow group significantli abstain smoke compar inpati counsel usual care group 44.4 24 compar 33.3 23.6 2 2 163 5.28 07 6 month differ slightli higher 41.5 22 30.2 16 20.0 11 point preval smoke abstin respect group 2 2 161 5.90 05 tabl 4 continu smoke abstin 2 month 42.6 23 inpati counsel telephon follow group quit smoke figur 2 flow chart particip recruit follow cvd cardiova cular diseas ainclud smoker bexclud follow analysi 250 nurs inpati smoke cessat program nurs research julyaugust 2005 vol 54 4 remain nonsmok compar 29.6 16 inpati counsel group 21.8 12 usual care group tabl 4 differ appear clinic signific statist signifi 2 2 163 5.57 06 6 month continu abstin rate high inter vention group usual care group 24.5 24.5 12.7 differ signific 2 2 161 3.01 21 progress ulterior stage chang 2 month 48.1 26 inpati counsel telephon follow group progress ulterior stage chang compar 29.6 16 inpati counsel group 27.3 15 usual care group 2 2 163 6.23 04 6 month differ greater exist smaller number usual care group progress ulterior stage chang 2 2 161 8.05 02 tabl 4 data analys precontempl contempl receiv usual care progress subs quent stage chang 6 month 25 3 inpati intervent group progress 2 2 36 6.36 04 signific differ level distribut stage chang appar group 2 month 2 6 135 9.71 inpati counsel inpati telephon counsel follow usual care total 56 56 56 168 pa previou quit attempt 47 83.9 47 83.9 47 83.9 141 83.9 1.00 medic advic smoke cessat 47 83.9 38 67.9 39 69.6 124 73.8 11 stage chang precontempl 6 10.7 5 8.9 9 16.1 20 11.9 86 contempl 5 8.9 7 12.5 6 10.7 18 10.7 prepar 43 76.8 40 71.4 38 67.9 121 72.0 action 2 3.6 4 7.1 3 5.4 9 5.4 sd ag smoke initi 15.8 5.9 15.6 3.6 15.1 3.6 15.5 4.5 74 addict 5.6 2.3 4.5 2.8 5.1 2.1 5.1 2.5 07 agroup comparison anova continu 2 categor nomin variabl tabl 3 smoke characterist sampl baselin inpati counsel inpati telephon counsel follow usual care 2 point preval smoke abstin 2 month 24 44.4 18 33.3 13 23.6 5.28 07 6 month 22 41.5 16 30.2 11 20.0 5.90 05 continu smoke abstin 2 month 23 42.6 16 29.6 12 21.8 5.57 06 6 month 13 24.5 13 24.5 7 12.7 3.01 21 progress stage chang 2 month 26 48.1 16 29.6 15 27.3 6.23 04 6 month s23 43.4 17 32.1 10 18.2 8.05 02 tabl 4 smoke cessat result 2 6 month nurs research juli august 2005 vol 54 4 nurs inpati smoke cessat program 251 14 6 month 2 8 112 13.68 09 inpati counsel telephon follow group remain relaps precontempl stage 2 6 month figur 3 telephon follow adjunct inpati smoke counsel intervent signific differ exist inpati coun sele telephon follow group inpati counsel group progress ulterior stage chang 2 month 2 1 108 3.90 05 signific differ exist group point preval smoke abstin 2 1 106 1.48 22 stage progress 2 1 106 1.45 23 6 month baselin variabl com.ibm.drl.hbcp.predictor smoke cessat stage progress 6 month initi stage readi chang 1 21 baselin variabl predict point preval smoke abstin 6 month r2 08 03 initi stage chang enter regress analysi group assign variabl explain 13 varianc smoke absti nenc 6 month tabl 5 individu inpati counsel telephon follow group 2.75 time nonsmok 6 month individu receiv usual care group assign factor pre dict progress ulterior stage chang tabl 5 initi stage chang group assign forc equat result compar abstin 6 month explain 13 varianc discuss studi patient cvd nurs led inpati smoke cessat program telephon follow group quit smoke 6 month significantli fre quentli inpati counsel usual care group 41.5 point preval smoke abstin rate 6 month lower observ taylor al 1990 61 1 year dornela al 2000 67 6 month present studi design individu suffer type cvd exclud cerebrovascular diseas ami patient sever diseas plai role particip motiv level quit smoke particip inpati smoke cessat counsel telephon follow group quit smoke compar usual care group inpa tient smoke cessat counsel tele phone follow encourag partici pant remain nonsmok 6 month hospit discharg 9 22 patient inpati counsel telephon follow group relaps 2 6 month learn smoker 6 month trend observ 2 month point preval continu smoke abstin 6 month similar trend notic continu ou abstin knowledg research figur 3 stage chang group baselin 2 6 month posthospit discharg 252 nurs inpati smoke cessat program nurs research julyaugust 2005 vol 54 4 studi effect smoke cessat program individu peripher vascular diseas clark aish 2002 galvin webb hillier 2001 power brown makin 1992 smoke cessat studi highli motiv individu recruit particip includ studi level motiv readi quit smoke explain rela tive lower smoke abstin rate pierc farka gilpin 1998 import note particip present lower level readi quit smoke baselin progress readili stage chang studi particip inpati counsel telephon follow group precontempl stage baselin progress ult rior stage chang 2 6 month indi vidual smoke think quit 6 month prepar ing environ seek support quit stage chang made particip progress ulterior stage chang chanc quit smoke 6 month hospi tal discharg higher prochaska al 2002 confirm stage chang baselin predic tive point preval smoke abstin 6 month similar result current studi taylor al 1990 found high intent quit smoke ho pital discharg predict smoke cessat 12 month particip studi influenc stage chang 28 hospit patient declin enrol studi predominantli precontempl stage result observ clark aish 2002 report earlier signific increas smoke abstin result inpati smoke ce sation program includ telephon follow dornela al 2000 taylor al 1990 studi tele phone follow benefici partici pant restart smoke hospit discharg point preval smoke abstin continu absti nenc telephon follow permit pro gression ulterior stage chang ultim led higher smoke cessat rate doubl point preval smoke abstin rate 21.5 usual care 11.3 inpati counsel result support hajek al 2002 obtain signific result short inpati smoke inter vention individu heart diseas mi angina pattern suggest smoker benefit continu support health care profession hospit discharg smoker attempt perman nonsmok reinforc logic repres transtheoret model spiral refer multipl attempt undertaken behavior modif studi nurs encourag famili member particip inpati smoke cessat counsel session famili member involv main reason short hospit stai analys famili member particip com.ibm.drl.hbcp.predictor smoke abstin progress ulterior stage chang intens sustain smoke cessat intervent influenc social support dispens famili member addit dura tion inpati smoke cessat counsel tele phone follow com.ibm.drl.hbcp.predictor suggest smoke cessat intervent effect result studi gener french speak canadian popul cvd quarter sampl men result gener women effec tive random method contamin group occur point preval smoke progress stage abstin 6 month chang 6 month variabl 95 ci 95 ci stage chang baselin precontemplationa 1.00 1.00 contempl 58 0.05 6.46 2.13 0.25 18.44 prepar 2.27 0.61 8.40 3.87 0.84 17.97 action 11.16 1.69 73.68 11.07 1.48 82.68 group assign usual carea 1.00 1.00 inpati counsel telephon follow 2.75 1.13 6.71 3.32 1.35 8.17 inpati counsel 1.56 0.62 3.90 1.94 0.77 4.85 note odd ratio ci confid interv arefer group 05 01 tabl 5 logist regress enter method nurs research juli august 2005 vol 54 4 nurs inpati smoke cessat program 253 rehospit period particip cardiac rehabilit program restrict exist patient seek inform smoke cessat discharg hospit transtheoret model tailor smoke cessat program select cog nitiv behavior compon result studi nurs inpati smoke cessat program tailor patient readi chang increas point preval smoke abstin 6 month addit patient cvd smoke 6 month hospit discharg demon strate higher level motiv quit smoke futur accept public decemb 14 2004 articl written conform requir degre phd nurs scienc author univers montreal author maud christin chouinard phd rn mod ul de scienc infirmièr de la santé université du québec à chicoutimi 555 boul de l’université chicoutimi québec canada g7h 2b1 mail maud christine_chouinard uqac.ca
nicotin tobacco research volum 13 number 8 august 2011 756 760 756 doi 10.1093 ntr ntr068 advanc access publish april 18 2011 author 2011 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com treatment smoke cessat adequ power trial warrant introduct evid suggest exercis smoke cessat ussher taylor faulkner 2008 exercis shown reduc neg experi accompani quit cigarett crave withdraw symptom neg mood state weight gain parson shraim ingli aveyard hajek 2009 taylor ussher faulkner 2007 vast major studi fo cuse femal smoker aerob exercis taylor al 2007 ussher al 2008 resist train i. weight lift ing form exercis increas muscular strength offer smoker strategi quit type exercis resist train rt potenti moder at postcess weight gain american colleg sport medicin acsm 2009b neg mood state arent lander matt etnier 2005 resist train typic facil base effect home equip ment bodi weight research individ ual prefer rt type exercis center diseas control prevent 2006 studi sess rt smoke cessat studi shown singl resist exercis isometr contract i. static muscl contract effect reduc tobacco crave perceiv help quit attempt al chalabi al 2008 ussher croplei playl mohidin west 2009 abstract introduct research exercis help smoke cessat major studi fo cuse women aerob exercis pilot studi explor resist train rt i. weight lift adjunct strategi quit smoke men women method sampl 25 smoker receiv smoke ce sation counsel session nicotin patch prior random 12 week rt contact control cc group assess conduct baselin 3 month 6 month follow result particip 52 femal averag 36.5 year sd 12.0 ag 19.1 year sd 12.0 smoke 3 month assess object verifi 7 dai point preval abstin ppa rate 46 rt group 17 cc prolong abstin rate 16 8 6 month assess object verifi 7 dai ppa rate 38 rt group 17 cc prolong absti nenc rate 15 8 mean bodi weight decreas 0.6 kg sd 1.7 rt group increas 0.6 kg sd 2.8 cc group mean bodi fat decreas 0.5 sd 1.8 rt group increas 0.6 sd 0.7 cc conclus studi report rt program aid smoke cessat treatment find ing suggest program feasibl adjunct report resist train aid standard smoke cessat treatment pilot studi joseph ciccolo ph.d 1 shira dunsig ph.d 2 david william ph.d 3 john bartholomew ph.d 4 ernestin jen ph.d 5 michael ussher ph.d 6 william kraemer ph.d 7 bess marcu ph.d 8 1 depart commun health center behavior prevent medicin alpert medic school brown univers miriam hospit provid ri 2 center behavior prevent medicin miriam hospit provid ri 3 depart commun health brown univers provid ri 4 depart kinesiolog health educ univers texa austin tx 5 depart psychiatri human behavior center behavior prevent medicin alpert medic school brown univers miriam hospit provid ri 6 divis commun health scienc st georg univers london uk 7 neag school educ univers connecticut storr ct 8 depart famili prevent medicin univers california san diego ca author joseph ciccolo ph.d miriam hospit alpert medic school brown univers provid ri 02903 usa telephon 401 793 8089 fax 401 793 8078 mail joseph_ciccolo brown.edu receiv januari 7 2011 accept march 16 2011 guest januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 757 nicotin tobacco research volum 13 number 8 august 2011 ussher west doshi sampuran 2006 rt pro gram offer smoker aid quit purpos pilot studi obtain initi estim effect rt adjunct smoke cessat counsel smok ing abstin bodi weight composit test feasibl research method futur adequ power efficaci trial method particip male femal smoker 5 cigarett dai 1 year ag 18 65 year recruit newspap internet televis adver tisement volunt exclud particip regular exercis 60 min week presenc chronic health condit pregnanc smokeless tobacco current smoke cessat treatment safeti reason requir obtain physi cian consent particip prior provid inform consent measur session particip ask smoke smoke smoke puff past 24 hr past 7 dai par ticip report smoke past 7 dai ask dai smoke puff cigarett carbon monoxid concentr assess micro 4 smokerlyz bedfont scientif baselin nicotin depend heatherton kozlowski frecker fagerström 1991 nicotin withdraw symptom west hajek 2004 perceiv abil quit etter bergman humair perneg 2000 assess baselin 3 month assess includ bodi composit determin dual energi rai absorptiometri technolog upper lower bodi strength i. chest press leg press acsm 5 repetit maximum test estim maxim strength acsm 2009a base line 3 month 6 month assess includ bodi weight 3 month physic activ recal questionnair kohl blair paffenbarg macera kronenfeld 1997 procedur enrol particip attend 30 min pre random session includ baselin assess 2 week run period particip ask quit smoke begin exercis run strategi exclud individu adher studi requir cipriani gedd 2010 prior random particip receiv 15 20 min smoke cessat counsel session american lung associ freedom smoke manual addition box 8 week suppli nicotin patch patch suppli need nicotin patch dose tailor cigarett consumpt particip told appli patch morn quit dai random comput gener list number rt contact control cc condit occur immedi counsel resist train condit particip engag 60 min rt session week 12 week full bodi routin acsm 2009b involv 10 exercis set intens volum adjust 3 week 3 week particip complet set 10 repetit exercis 65 75 estimat ed maxim strength week 4 12 particip complet ed set exercis weight systemat increas research match gain strength maintain inten siti week 7 10 research monitor exercis safeti interact minim smoke discuss particip exercis attend se sion week make miss session prior week session dai ask engag rt supervis session chang exercis contact control condit particip watch 25 min video week room film cover health relat issu e.g nutrit shown accept similar research marcu al 2005 assess frequenc session identi cal rt condit interact staff mini mize particip ask chang current exercis smoke assess incent smoke statu assess week 12 week tervent follow particip achiev 7 dai point preval abstin ppa posttreat follow report smoke past 7 dai obtain read 10 ppm report smoke rate 9 ppm assess previou dai west hajek stead stapleton 2005 particip achiev prolong abstin posttreat follow report smoke begin week 3 allow week grace period quit ob tain rate 10 ppm session particip paid 15 complet week 1 6 25 week 7 12 10 6 month follow data analysi group differ baselin variabl number se sion attend studi attrit rate follow 3 month 6 month assess analysi varianc chi squar test logist regress model examin effect treatment assign odd quit 3 month 6 month follow effect size present odd ratio odd ratio 95 ci unadjust quit rate present treatment arm timepoint 3 month 6 month analys intent treat exclud particip diagnos lung cancer particip miss ing smoke outcom consid quit final sess differ mean chang bodi weight baselin 3 month 3 month 6 month bodi composit base line 3 month chest leg strength baselin 3 month total physic activ baselin 3 month baselin 6 month result total 306 individu screen telephon 173 elig 51 gain access physician medic consent forti volunt remain interest studi consent particip 2 week run guest januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 758 resist train aid standard smoke cessat treatment period 26 random rt cc includ 13 women 12 men exclud particip develop lung cancer obtain physician consent factor relat drop prior random figur 1 summa rize particip flow mean ag 36.5 sd 12.0 53 caucasian 31 hispan 12 black 4 asian signific group differ baselin measur averag durat smoke 19.1 year sd 12.0 averag fagerström test nicotin depend score 4.0 sd 2.6 mean 18.0 sd 10.1 cigarett smoke daili averag bodi weight baselin 81.8 kg sd 16.1 averag bodi fat 35.1 sd 7.0 rt particip attend averag 18.8 sd 6.1 se sion cc attend 18.2 sd 5.7 attrit rate rt cc 8 3 month 38 50 figur 1 consort flow diagram 6 month nicotin patch similar group rt particip report 73.1 sd 21.9 dai 8 week period cc report 71.1 sd 21.0 3 month object verifi 7 dai ppa rate 46 rt 17 cc 4.3 95 ci 0.7 27.8 pro long abstin 16 8 2.0 95 ci 0.2 25.4 6 month object verifi 7 dai ppa 38 rt 17 cc 3.1 95 ci 0.5 20.1 prolong abstin 15 8 2.0 95 ci 0.2 25.4 3 month rt particip show mean reduct bodi weight 0.6 kg sd 1.7 fat 0.5 sd 1.8 cc particip show mean increas bodi weight 0.6 kg sd 2.8 fat 0.6 sd 0.7 3 6 month rt particip mean reduct bodi weight 0.1 kg sd 1.8 cc mean increas 0.5 kg sd 2.0 tabl 1 summari effect size 3 month rt group increas averag chest 9.7 kg sd 12.0 leg 67.8 kg sd 50.6 strength cc decreas chest 0.2 kg sd 4.4 increas leg 3.5kg sd 6.5 strength aver ag physic activ complet increas rt 3 month 9.1 metabol equival met wk sd 3.0 decreas cc 0.02 met wk sd 0.6 increas rt 5.2 met wk sd 7.8 cc 3.8 met wk sd 3.3 6 month discuss studi explor rt aid smoke cessa tion result show particip attend approxim 75 intervent session retent 92 group 3 month 62 rt 50 cc 6 month 3 month assess 16 rt particip achiev prolong abstin versu 8 cc 15 rt condit sustain prolong abstin 6 month treatment follow versu 8 cc result suggest rt program viabl adjunct smoke cessat treatment strength pilot investig men women recruit previous whelm major exercis base smoke cessat studi focus women ussher al 2008 smoke cessat treatment singl 15 20 min counsel session comparison treatment e.g cognit behavior therapi counsel poten tialli generaliz lower cost larg effect size differ group 3 month 6 month follow small amount time par ticip ask engag intervent rt particip requir attend 60 min session week compar time intens pro gram exercis base smoke cessat interven tion produc similar result e.g william al 2010 fourth studi report bodi composi tion quit 3 month medium effect size differ bodi weight bodi compo sition condit suggest rt prevent weight gain importantli preserv mu cle mass quit recruit sampl divers half particip identifi racial ethnic minor guest januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 759 nicotin tobacco research volum 13 number 8 august 2011 limit investig similar exercis base smoke cessat research ussher al 2008 recruit approxim 10 duce extern valid barrier enrol access physician medic consent import compon ensur particip safeti 2 week run pe riod reduc enrol increas like hood enrol particip compliant attempt increas intern valid cipriani gedd 2010 differenti time requir group limit number contact assess ident group differen tial drop final carbon monoxid biologi cal measur smoke sensit indic e.g cotinin yield definit result limit larg effect size differ group abstin medium effect size differ bodi weight composit success adher rate suggest rt feasibl smoke cessat inter vention adequ power trial rt smoke cessa tion includ comparison type physic activ e.g aerob exercis cost effect analys requir tabl 1 summari effect size differ group resist train 13 contact control 12 effect size 7 dai point preval abstin 3 month 46 17 4.3a 6 month 38 17 3.1a prolong abstin 3 month 16 8 2.0a 6 month 15 8 2.0a mean chang bodi weight baselin 3 month 0.6 1.7 0.6 1.7 0.7b 3 month 6 month 0.1 1.8 0.5 2.0 0.3b mean chang bodi fat baselin 3 month 0.5 1.8 0.6 0.7 0.8b aeffect size summar odd ratio beffect size summar cohen declar interest declar acknowledg phil stanforth staff fit ness institut texa dixi stanforth patti coffman tam metzger murtaza aziz nina dibenedetto anna hugh maegan william mattdavi dr john ivi support research assist addit research particip devot time effort studi
lung cancer 2004 44 13 21 effect smoke cessat materi lung cancer screen popul matthew clarka lisa sanderson coxg jame jettc christi pattena darrel schroederd liza nirelli kristin vickersa richard hurtb stephen swensenf depart psychiatri psycholog mayo w11a mayo clinic 200 street sw rochest mn 55905 usa nicotin research center mayo clinic rochest mn usa depart oncolog mayo clinic rochest mn usa divis biostatist mayo clinic rochest mn usa section patient educ mayo clinic rochest mn usa depart radiolog mayo clinic rochest mn usa lombardi cancer center georgetown univers rochest mn usa receiv 30 june 2003 receiv revis form 29 septemb 2003 accept 2 octob 2003 keyword smoke intervent chest ct screen internet resourc motiv counsel summari random control trial smoke intervent document lung cancer screen popul studi randomli sign 171 current smoker undergo low dose fast spiral chest ct sct lung cancer screen receiv standard written materi written list internet resourc smoke cessat 1 year follow subject receiv internet base resourc report make stop tempt 68 versu 48 0.011 statist signific differ 7 dai point preval quit rate 5 versu 10 advanc motiv readi stop smoke 27 versu 30 group investig warrant tailor smoke interven tion cancer screen particip 2003 elsevi ireland right reserv 1 introduct propos cancer screen present uniqu opportun provid nicotin de pendenc counsel 1 cancer screen provid teachabl moment moti vation chang health behavior enhanc assist stop smoke provid author tel 1 507 284 3985 fax 1 507 284 4345 mail address clark.matthew mayo.edu m.m clark 2 limit investig effect provid nicotin depen denc counsel individu undergo cancer screen 3 studi found 86 smoker undergo low dose chest ct screen earli detect lung cancer report receiv smoke cessat treatment part lung cancer screen program 4 indic high level interest term char acterist 55 women undergo lung cancer earli detect screen report high level nico tine addict low confid abil 0169 5002 front matter 2003 elsevi ireland right reserv doi 10.1016 j.lungcan 2003.10.001 14 m.m clark al quit smoke high perceiv risk develop lung cancer 5 random singl arm studi receiv physician advic quit smoke 9 16 55 women report quit smoke 1 month follow clinic base treatment nicotin depen denc produc highest abstin rate 5 smoker gener popul advantag clinic program 6 intervent wide access easili distribut reach larger proport smoker smoker interact briefli health care provid period basi e.g annual exam screen import stop smoke treatment easili distribut smoker conveni manual develop provid written inform assist individu stop smoke inform assist smoker advanc readi stop smoke make stop attempt improv likelihood futur success abstin 7 evalu cer screen popul provis written materi gener sampl smoker slightli increas smoke abstin rate 13 8 rate spontan smoke ce sation 1 year period 7 9,10 studi com.ibm.drl.hbcp.util materi report benefit larg random field trial 843 3.5 subject receiv standard guid report 7 dai absti nenc 6 month follow multipl tailor materi yield similar abstin rate 3.2 5.5 control subject report 7 dai abstin 11 efficaci method creat altern mean dissemin informa tion com.ibm.drl.hbcp.util potenti provid internet result nation repres survei approxim 40 indi vidual internet access report internet seek health relat inform fur ther internet health inform report af fect decis health health care 12 web site vast divers inform smoke relat health issu specif strategi stop smok ing internet base inform smoker access multipl sourc inform direct learn tool base interest circumst quali tativ studi individu internet resourc smoke cessat suggest conveni timeli anonym unmet inform primari reason seek onlin smoke cessat resourc 13 evalu written materi direct smoker web site smoke cessat versu standard condit inform smoke absti nenc provid guidanc develop effect mode interven high risk individu undergo cancer screen 1999 initi low dose fast spiral chest ct studi sct 14 determin screen small cell lung cancer reason likelihood decreas mortal increas diagnosi earli stage tumor sctc particip 20 pack year smok ing histori high risk smoke relat morbid moti vate engag lung cancer screen degre particip low dose fast spiral chest ct screen influ enc chang smoke behavior context receiv materi smoke ce sation undergo screen i. acknowledg increas cancer risk interact health care provid obtain screen result promot smok ing abstin studi shown ceiv feedback health consequ smoke enhanc motiv stop 15 plausibl receiv posit screen sult strong influenc increas smoke abstin altern potenti current smoker receiv neg screen result con tinu restart smoke possibl result perceiv reduct cancer risk interest ingli survei 172 current smoker respond express high interest receiv chest ct screen 62 54 smoker quit smoke receiv posit scan 52 16 19 quit receiv neg scan author note studi measur intent action recent report sampl 1475 chest ct screen particip low dose fast spiral chest ct screen rec ommend smoke abstin 1 year follow 17 note 14 abstin rate higher expect spontan rate stop ping smoke chest ct screen result enhanc intent quit deliv eri tailor time intervent quit rate improv primari goal studi examin effect standard written materi smoke cessat 15 materi nicotin depend compar written materi consist internet base sourc smoke abstin rate lung cer screen popul hypothes internet base resourc provid rang resourc benefici improv smoke abstin 2 method 2.1 particip 20 januari 15 decemb 1999 1520 partic ipant enrol sct underw baselin preval low dose fast spiral chest ct scan particip includ 785 men 735 women 1508 99 white 12 african american nativ american hispan 50 year ag mean ag 59 year rang 50 85 year sixti percent current smoker 39 smoker median number pack year smoke 45 rang 20 230 pack year 1520 partici pant enrol sct 738 particip return annual follow visit time period subject recruit current investig report baselin ct screen recommend smoke abstin 1 year follow 17 25 declin screen tobacco 315 report absti nenc cigarett 398 report smoke cigarett 398 current smoker 162 42 elig studi access internet addit 65 elig smoker i. smoker internet access declin particip random smok ing cessat intervent current studi includ total 171 current smoker random receiv written materi consist internet base resourc 85 standard smoke cessat inform 86 commun inform low dose fast spiral chest ct screen studi local region televis newspap coverag carri inform gener outlin studi elig requir fund nation cancer institut larger sct trial particip enrol provid written inform consent includ asymptomat men women 50 year ag older current quit 10 year ago cigarett smoker 20 pack year histori smoke inelig histori cancer year melanomat skin cancer cervi cal cancer situ local prostat cancer particip requir mental comp tent consid healthi potenti undergo pulmonari resect i. congest heart failur disabl dyspnea time enrol individu ill decreas life expect 5 year exclud sixti individu inelig due ill current investiga tion particip recruit annual follow visit addit inclus criteria current studi current cigarett smoker access comput internet servic written inform consent particip 3 measur 3.1 smoke statu stage readi stop smoke evalu stage readi chang 18 assess interest chang smoke behavior base item assess individu classifi transtheoreti cal model 19 stage chang precontempla tion think stop smoke contempl stop smoke 6 month prepar plan stop smoke month action stop smoke past 6 month mainten abstin smoke 6 month 3.2 smoke histori assess cigarett smoke dai stop tempt past year smoker hous hold item fagerström test nicotin de pendenc ftnd 20 measur degre sever nicotin depend annual follow visit particip ask smoke cigarett ask cigarett smoke dai ask quit date collect expir air car bon monoxid level biochem confirm point preval smoke abstin 98 biochem confirm abstin 4 procedur scan perform multislic spi ral comput tomographi scanner comput tomographi imag view cine mode 16 m.m clark al format comput workstat investig radiologist 4.1 smoke cessat intervent subject random receiv written materi consist standard smoke cessat inform 86 list internet resourc smoke cessat 85 current smoker internet access random provid standard written materi 4.2 standard materi particip condit receiv copi clear air quit smoke quit public nation cancer insti tute 21 clear air 24 page manual describ multipl behavior strategi stop smoke topic includ prepar quit smoke social support reduc temptat practic habit avoid weight gain reward success includ address telephon number addit sourc includ american heart associ american cancer societi american lung asso ciation addit particip condit american lung associ booklet quit smoke action plan date inform pharmacotherapi nicotin depend 4.3 internet base resourc particip condit receiv handout list 10 internet site relat stop ping smoke descript site web site includ american heart associa tion american cancer societi nation cancer institut cancer inform servic center diseas control cdc tip tobacco informa tion prevent sourc mayo clinic nicotin de pendenc center quit nation tobacco campaign smoke café massachusett quitlin nicotin anonym american lung associ site includ inform health risk relat tobacco benefit stop smoke specif behavior strategi support stop review stop smoke medi cation refer local resourc 5 follow month enrol smoke intervent particip mail questionnair assess current smoke statu tobacco current stage readi stop smoke 18 extent com.ibm.drl.hbcp.util inform provid studi ask return questionnair postag paid mail annual visit cor respond 1 year follow studi par ticip ask current tobacco statu expir air measur addit particip ask complet seri question assess stage readi ness stop smoke number tobacco stop attempt past year tobacco 6 statist analysi data present mean s.d con tinuou variabl percentag categor variabl respons 1 month follow survei tobacco variabl collect 1 year follow compar treat ment group chi squar test 1 year smoke abstin outcom subject miss visit fail provid tobacco inform classifi smoke analys perform data imput miss valu biochem confirm 7 dai smoke abstin exact bi nari confid interv calcul treatment group logist regress analysi perform smoke abstin depend variabl treatment group depend variabl addit logist regress assess screen recommen dation 1 year tobacco outcom separ analys perform depend variabl biochem con firm 7 dai smoke abstin attempt stop smoke year advanc stage chang baselin 1 year screen ing recommend analyz binari indic variabl addit follow versu addit follow treatment group includ covari analysi case side test perform valu 0.05 statist signific 7 result baselin subject characterist time en rollment current investig similar treatment group tabl 1 mean s.d ag enrol 57.4 5.3 year rang 51 74 year major materi smoke cessat 17 tabl 1 baselin subject characterist treatment condit internet resourc 85a standard materi 86a mean s.d mean s.d ag year 57.8 5.2 57.0 5.3 50 54 27 32 35 41 55 59 33 39 30 35 60 64 16 19 13 15 65 9 11 8 9 femal gender 39 46 45 52 stage chang precontempl 14 16 22 26 contempl 51 60 50 58 prepar 20 24 14 16 cigarett dayb 10 13 15 10 12 11 20 41 48 38 44 21 30 23 27 25 29 31 8 9 13 15 attempt stop smoke year 53 70 47 60 smoker household 31 37 32 38 fagerstrom test nicotin depend score 5 56 66 51 59 6 29 34 35 41 recommend chest ct screen addit follow 68 80 70 81 follow 6 month 6 7 8 9 follow 3 month 8 9 6 7 follow 2 2 2 2 1 1 0 0 data stop attempt year miss subject internet group subject written materi group data smoker household miss subject written group addit cigarett tobacco product report subject internet group cigar pipe subject written materi group cigar chew tobacco subject 60 smoke 20 cigarett dai larg proport subject 65 report attempt stop smok ing year plan initi stop attempt 30 dai 20 59 21 subject prepar contem plation precontempl stage chang 1 month follow survei return 61 72 subject internet base inform group 59 69 standard condit tabl 2 respond survei report 7 dai point preval abstin smoke differ significantli group 13 versu 7 internet versu standard materi 0.248 group similar respect percentag subject found advanc baselin stage chang 1 month follow 29 versu 14 internet versu stan dard materi 0.632 signific differ 0.001 group percent amount provid written infor mation subject review respond ceiv internet base resourc 26 materi 51 look 23 look standard group percentag 17 27 56 subject receiv standard inform report review materi subject receiv internet base resourc report materi amount internet materi greater content written materi group major 80 subject report 18 m.m clark al tabl 2 com.ibm.drl.hbcp.util intervent materi 30 dai follow internet resourc standard materi na na pb inform provid wai stop smoke 61 59 0.001 haven’t chanc 16 26 10 17 look part 31 51 16 27 look 14 23 33 56 help inform look 45 49 ns help 5 11 4 8 help 35 78 38 78 help 5 11 7 14 share inform friend rel 54 56 ns 36 67 46 82 18 33 10 18 stop smoke studi visit 61 59 ns 38 62 39 66 23 38 20 34 smoke puff 7 dai 61 59 ns 8 13 4 7 53 87 55 93 stage chang 58 58 ns precontempl 10 17 8 14 contempl 28 48 38 66 prepar 11 19 8 14 action 9 16 4 7 ct visit time spend internet websit internet group pamphlet written materi group relat stop smoke 61 59 ns 1 39 64 29 49 1 2h 12 20 25 42 2 5h 8 13 5 8 5 2 3 0 0 web site relat health stop smoke internet group 49 16 33 3 6 6 12 8 16 6 12 6 12 4 8 30 dai follow survei return 61 72 subject internet group 59 69 written group number provid correspond number subject respond item chi squar test materi smoke cessat 19 spent 2 hr inform relat stop smoke 1 year follow statist significantli higher percentag subject receiv internet base resourc compar standard con dition group report made attempt stop smoke year 68 versu 48 0.011 tabl 3 percent ag subject biochem confirm abstin smoke 1 year follow 5 95 ci 1 12 internet group versu 10 95 ci 5 19 standard condit group 0.166 0.4 95 ci 0.1 1.4 group similar respect proport subject advanc baselin stage chang 27 versu 30 internet versu writ ten materi 0.704 multipl logist regress analysi adjust treatment group recommend addit follow chest ct screen exam found abstin 0.5 0.267 make quit attempt 0.8 0.412 advanc stage chang baselin 1 year 0.6 0.222 8 discuss studi report result random con troll trial nicotin depend intervent lung cancer screen popul found high risk individu undergo lung cer screen signific differ smoke abstin rate 1 year receiv standard written materi smoke cessat provid list 10 ternet site consist inform strategi smoke cessat 0.166 0.4 95 ci 0.1 1.4 internet versu standard materi similar percentag subject advanc readi stop smoke 1 month follow similar advanc readi stop smoke 1 year follow biochem confirm smoke abstin rate 5 internet 10 stan dard materi 1 year follow similar rate spontan cessat 1 year period gener popul 7 9 particip interact physician receiv direct inform specif health factor relat cigarett usag futur research design efficaci intervent sampl size investig limit statist power detect dif ferenc abstin rate group upper limit 95 confid interv odd ratio upper limit 1.4 odd ratio internet versu standard materi suggest modest benefit internet base mate rial approach similar vestig plausibl explan lack efficaci tailor web base materi web base materi educ materi focus manag ed ucat interact combin program 22,23 discuss format web base materi partici pant make inform decis web site assess learn prefer consider tailor web site recommend help subject web site investig health behavior weight manag iden tifi import includ interact counsel segment web base intervent assist particip health behavior chang 24 initi suggest mail commun help smoker 25 attent interact counsel aspect web base intervent futur studi includ web base health resourc criteria evalu qualiti internet health program 26 efficaci intervent improv limit particip ran domiz receiv print web base format resourc match perceiv learn prefer learn ing style prior research demonstr individu vari term favor learn modal iti prefer access health relat inform 27 29 order meet individu inform learn rec ommend health educ inform deliv varieti learn modali ti technolog 30 match smoke cessat inform modal print versu web base materi individu pref erenc style impact smoke cessat rate limit sampl internet ac cess potenti current smoker 58 inter net access higher gener popul 42 nonetheless characterist subject limit gener studi find result studi limit lack ethnic divers sampl gener propos undergo cer screen present teachabl moment 20 m.m clark al tabl 3 year smoke statu outcom outcom internet resourc standard materi pa biochem confirm smoke abstin 85 4 5 86 9 10 ns cigarett dai 80 78 ns 0 4 5 9 12 1 10 15 19 9 12 11 20 43 54 41 53 21 30 13 16 10 13 31 5 6 9 12 attempt stop smoke year 73 50 68 79 38 48 0.011 method past year quit smokingb 50 38 28 56 24 63 formal program 0 0 1 3 nicotin replac 17 34 10 26 nicotin medic 17 34 10 26 3 6 1 2 stage chang 74 79 ns precontempl 15 20 19 24 contempl 37 50 35 44 prepar 18 24 15 19 action 3 4 9 11 mainten 1 1 1 1 chi squar test subject method intervent integr screen result intervent pro vide baselin chest ct screen educ materi written internet base direct int grate screen result perceiv risk cancer smoke cessat strategi efficaci increas long term smoke absti nenc high risk individu undergo lung cer screen acknowledg studi support grant ca 79935 nation cancer institut
cremer al bmc public health 2012 12 277 http www.biomedcentral.com 1471 2458 12 277 studi protocol open access web base comput tailor smoke prevent programm primari school children intervent design studi protocol henricu paul cremer liesbeth mercken ank oenema hein de vri abstract background number smoker declin decad smoke major health problem youngster adolesc reason effect smoke prevent programm target primari school children web base comput tailor feedback programm effect intervent stimul youngster start smoke increas knowledg advers effect smoke attitud efficaci smoke method design paper describ develop evalu protocol web base school smoke prevent programm primari school children ag 10 13 year entitl fun smoke transform postal mail intervent web base intervent transform effect prompt examin web base intervent evalu 2 year cluster randomis control trial rct studi arm intervent intervent prompt condit evalu effect smoke behaviour compar inform control condit inform pupil smoke statu factor relat smoke obtain web base questionnair complet questionnair pupil intervent condit receiv comput tailor feedback letter person mail box attitud social influenc efficaci expect content personalis feedback letter pupil intervent prompt condit addit personalis feedback letter receiv mail sm messag prompt revisit fun smoke websit main outcom measur smoke utilis fun smoke websit measur carri baselin 12 month 24 month follow discuss present studi protocol describ purpos intervent design studi protocol fun smoke expect pupil receiv tailor advic smoke 24 month contrast pupil control condit tailor feedback letter prompt expect effect provid tailor feedback letter trial registr dutch trial regist ntr3116 background smoke children young adolesc remain public health problem caus ill chronic di eas cancer cardiovascular diseas older ag 1 3 recent nation preval rate show 12 12 year children smoke cigarett correspond p.cremer maastrichtuniversity.nl equal contributor depart health promot school public health primari care caphri maastricht univers p.o box 616 6200 md maastricht netherland 2012 cremer al license biom centra common attribut licens http creativeco reproduct medium provid orig ag 13 percentag doubl 4 smoke ag group recognis com.ibm.drl.hbcp.predictor regular smoke addict occur 60 90 smoke cigarett 5,6 earlier peopl start smoke higher chanc regular smoker diffi cult quit 7 author state smoke prevent programm aim prevent delai start tobacco 8 impli target children ag 10 12 year 9 children increasingli start open access articl distribut term creativ mmons.org licens 2.0 permit unrestrict distribut inal work properli cite mailto:p.crem maastrichtuniversity.nl cremer al bmc public health 2012 12 277 page 2 10 http www.biomedcentral.com 1471 2458 12 277 experi smoke transit period pri mari secondari school 10 prevent programm focu increas knowledg posit attitud smoke anti smoke attitud efficaci skill refus cigarett children smoke prevent experi ment continu smoke 11,12 primari prevent programm design discourag experiment cigarett deter regular deliv school set ting 13 result relat effect school programm mix found effect report small reduct smok ing behaviour 13 15 addition school programm drawback limit time insuffi cientli train unmotiv personnel 16,17 school intervent youngster articul studi 9,18,19 school approach provid altern strategi youth health promot 20,21 ausem colleagu 9,22,23 compar effect school smoke pre vention programm school programm children ag 10 13 year octopu studi school intervent pupil ask complet questionnair school receiv print deliv comput tailor advic target ing attitud social influenc efficaci home school intervent show signific short term prevent effect smoke initi continu 9 print deliv programm web base programm popular flexibl appeal children adolesc lack web base smoke prevent intervent present studi adapt effect school intervent octopu studi translat web base school version entitl fun smoke web base comput tailor intervent benefit easi access fill question nair suitabl time read tailor advic particip choos cost effect 24 high drop discontinu rate observ web base intervent 25,26 repetit messag multipl tailor import enhanc effect comput tailor intervent gener smoke prevent specif 9,22,27,28 fore import find wai stimul particip promot multipl exposur educ content mean promot repeat exposur prevent ing drop programm prompt remind peopl particip encourag revisit websit gather inform topic interest 29 prompt deliv wai mail mail short text messag sm prompt support adher health interven tion shown effect increas participa tion rate 30 mail sm prompt chosen method promot repeat interven tion websit evalu effect programm smoke relat outcom articl describ intervent develop evalu protocol fun smoke method design intervent intervent object object intervent prevent smoke primari school children ag 10 13 year achiev children provid personalis feedback includ inform smoke posit attitud smoke nega tive attitud smoke skill plan fuse cigarett feedback prepar children refus cigarett make transit sec ondari school prevent regu lar smoker mail sm messag prompt promot visit intervent websit children expos smoke relat format receiv repeat tailor feedback letter intervent framework procedur fun smoke school smoke pre vention programm children receiv puter tailor feedback letter visit websit addit inform smoke websit section children complet assess questionnair receiv puter tailor feedback access addit inform smoke watch short movi consequ smoke plai game question smoke section regularli updat stimul pupil revisit fun smoke websit children visit websit complet assess ment questionnair assess place class room base questionnair sonalis feedback letter gener post websit password protect area pdf attach particip mail address children read personalis feedback letter pdf attach fun smoke websit feedback letter consecut dai letter appear hour complet assess question nair mail websit order flexibl adapt children live pupil intervent pal highlight 11 feedback behaviour pal highlight 26 inform social environment consequ pal highlight 11 feedback behaviour cremer al bmc public health 2012 12 277 page 3 10 http www.biomedcentral.com 1471 2458 12 277 condit opportun complet add ition questionnair measur period return fun smoke web site choos option complet questionnair receiv addit feedback letter particip choos set question fill i. attitud social influenc efficaci smaller questionnair complet feedback letter gener pdf attach respond mail address post websit prompt children revisit websit particip intervent prompt condit receiv sm mail messag figur 1 show design fun smoke studi measur peri od intervent trial particip invit complet full sessment questionnair 12 24 month baselin questionnair complet receiv repeat feedback letter smoke statu kei determin e.g attitud social influenc figur 1 design fun smoke efficaci expect tailor advic account answer pupil previ ou measur increas probabl intervent attract 87 pupil grade 7 8 10 12 year old involv develop process group inter view perform select colour scheme design intervent websit develop ing lai out websit logo pre sent children ask choos favourit fun smoke popular addition short anim develop make complet questionnair attract anim consequ smoke depict anim children appreci anim theoret background tailor feedback messag provid fun smoke programm develop base int grate model explor motiv behaviour pal highlight 33 prompt cue pal highlight 25 salienc consequ figur 2 chang model cremer al bmc public health 2012 12 277 page 4 10 http www.biomedcentral.com 1471 2458 12 277 chang chang model model compos int gration social cognit theori model 31 33 chang model figur 2 haviour determin peopl motiv intent perform behaviour barrier decreas chanc intent translat action individu abil plan specif action reach target behaviour i. action plan increas chanc intent translat action motiv factor attitud social influ enc efficaci expect determin person intent chang motiv factor influ enc awar factor knowledg cue action inform factor messag qualiti predispos factor behaviour psycholog biolog social cultur factor 32 chang model studi develop questionnair comput tailor advic content tailor feedback letter pupil intervent group receiv comput tailor feedback letter complet baselin sessment questionnair main determin chang model attitud social influenc efficaci expect intent behaviour address tailor feedback letter theoret method promot determin 34,35 tailor feedback letter focuss ledg attitud improv knowledg knowledg quiz smoke includ questionnair score quiz fed back letter pupil high score knowledg quiz receiv compliment good knowledg correct swer provid clarifi elabor question answer incorrectli addition advic pupil attitud smoke provid tailor feedback letter attitud address confirm smoke attitud belief provid ing argument counter pro smoke belief tailor feedback letter address subject norm social influenc feedback ceiv norm actual smoke behaviour signific mother father sibl inform approv letter provid inform number peopl smoke netherland smoke norm strat egi provid deal unsupport cial circumst e.g parent sibl smoke mobil support smoke stimul commun mobilis social support efficaci focu final tailor feedback letter pupil confid stick smoke intent refus cigarett difficult situat e.g friend offer cigarett feedback fo cuss strengthen confid pupil lower efficaci expect feedback provid strategi tip trick deal difficult situat verbal persuas exhort addit inform format action plan pupil motiv form plan refus cigarett situat thought pal highlight 73 frame refram pal highlight 11 feedback behaviour 32 info approv pal highlight 20 instruct perform behaviour pal highlight 4 action plan 2 problem solv pal comment text link 73 24 attitud 73 24 intent indirect pal comment text 31 social comparison pal comment text 67 restructur social environ pal comment text link 11 31 32 67 17 social influenc norm 11 31 32 67 17 intent indirect pal comment text 17 social support unspecifi pal comment text link 20 2 4 efficaci 20 2 4 intent indirect cremer al bmc public health 2012 12 277 page 5 10 http www.biomedcentral.com 1471 2458 12 277 difficult cue identif form action plan difficult situat overview determin theoret method exampl fun smoke intervent shown tabl 1 pre test intervent start intervent pre final version programm pre test small group children target group pre test perform de termin usabl websit access questionnair complet procedur primari school techsmith mora softwar 36 test usag fun smoke websit web base questionnair 5 children ag 10 11 year 2 teacher examin bottleneck school level fun smoke programm pilot test perform primari school 26 chil dren complet procedur school test log websit search question nair complet questionnair read perso nalis advic qualit quantit interview carri obtain detail inform durat complet questionnair proce ur classroom readabl personalis tabl 1 overview method comput tailor messag determin method exampl fu knowledg elabor yo smoke smoker attitud argument yo smoke social influenc norm model inform approv mum parent arrang stimul commun mobil social support efficaci verbal persuas exhort frie friend start ta game plan cope respons format action plan cue identif form action plan difficult situat smart unexpect happ frie difficult tip thin imagin make plan ignor peopl talk intent chang evalu intent chang behavior don’t wise advic base result minor adjust made improv readabl personalis advic simplifi log procedur websit evalu design object design version fun smoke programm intervent intervent prompt condit evalu cluster randomis control trial inform control condit aim test effect iv programm prevent smoke initi ation cognit favour smoke 12 24 month post baselin addit effect prompt usag websit outcom measur school unit randomis assess smoke behaviour smoke relat cognit baselin 12 24 month mean web base questionnair smoke chosen primari outcom measur preval rate monthli smoke gener low ag 13 8 ag 2010 4 addit alli level utilis websit primari outcom measur outcom operation number visit fun smoke websit smoke intervent smoke give score 7 od start read didn’t harm smoke av cough rid toxic substanc bodi won’t nauseou smoke oxygen blood make nauseou dad smoke don’t listen ut support smoke nice present decid smoke nd offer cigarett difficult smoke don’t smoke press smoke lking movi nice comput elevis show recent don’t smoke en instanc parti sociabl nd light cigarett offer fuse cigarett advanc unexpect situat plan smoke exampl ith smoke offer cigarett riend offer cigarett friend obtrus start smoke cigarett futur excit read letter smoke pal highlight 26 inform social environment consequ pal highlight 24 inform health consequ pal highlight 32 inform approv 17 social support unspecifi pal highlight 2 problem solv pal highlight 20 instruct perform behaviour 88 mental rehears success behaviour pal comment text link 26 knowledg 26 motiv factor indirect 26 intent indirect cremer al bmc public health 2012 12 277 page 6 10 http www.biomedcentral.com 1471 2458 12 277 expect significantli higher intervent prompt condit compar intervent condi tion secondari outcom measur attitud social influenc efficaci intent smoke monthli smoke hypothes studi 1 provid children comput tailor feedback smoke prevent smoke initi 2 children receiv comput tailor feedback smoke stronger cognit favour smoke 3 comput tailor feedback smoke prompt children mail sm revisit websit result stronger effect prevent smoke initi cognit favour smoke tailor feedback 4 children receiv comput tailor feedback sm mail visit websit children receiv comput tailor feedback sampl size calcul base sampl size calcul 81 school 3,240 pupil includ studi calcul base assumpt 15 intervent con dition 8 intervent prompt condit smoke 24 month baselin control condit nation preval rate smok ing expect 24 ag 13 od optim design method raudenbush 37 side signific level 0.05 target power 0.80 icc 0.04 base studi ausem al 38 calcul sampl size calcul sampl size utilis web site 300 children condit need 600 children total assum pupil intervent prompt condit revisit fun smoke websit mean usag 5.5 sd 0.8 contrast children intervent condit visit websit time baselin 12 month 24 month mean usag 3.5 expect randomis school unit randomis ran domli assign studi condit comput determin sequenc cluster ran domis scheme utilis websit fun smoke websit monitor web log intervent intervent prompt condit particip person code usernam base usernam web log identifi date particip visit websit websit compon e.g read tailor feedback letter read addit inform plai game complet questionnair click recruit procedur fun smoke implement primari school programm offer region health author rha netherland total 31 rha netherland invit mail telephon particip recruit primari school region rha decid particip activ recruit infor mation telephon school visit recruit primari school passiv manner infor mation mail newslett maastricht univers perform method region particip rha school region netherland includ reach divers sampl pupil intervent present school programm main part intervent take place school system 3,500 dutch primari school contact particip 175 school part studi effect rate 5.0 procedur illustr detail figur 3 criteria inclus primari school final grade pupil ag 10 12 year particip studi children comput internet access school home special cation school school prevent programm don’t smoke ik ook niet exclud school interest particip receiv invit letter inform brochur rha programm explain telephon school princip week contact member research team discuss particip effect studi school interest particip agreement inclus criteria check parent children inform proce ur goal studi mean letter chil dren home parent student grade particip school includ studi parent refus involv sign inform consent letter return research team parent children deni particip start studi addition withdraw participa tion moment mail telephon person entir studi period procedur baselin questionnair screen instrument tailor feedback messag plete school hour supervis figur 3 recruit primari school cremer al bmc public health 2012 12 277 page 7 10 http www.biomedcentral.com 1471 2458 12 277 teacher distribut particip children person log detail seal envelop particip children instruct teacher procedur emploi year follow assess year fol low questionnair complet home time children left primari school year follow particip contact mail mail invit complet web base questionnair complet baselin 12 month question nair children intervent group receiv short summari tailor feedback comput screen extend tailor advic hour complet web base questionnair pdf attach ment respond mail address post websit 12 month children inter vention group visit websit obtain informa tion receiv advic time year particip intervent prompt condit pro activ prompt mail sm revisit fun smoke web site prompt 1 2 3 month baselin measur prompt 5 7 9 month baselin accord prompt content websit refresh address topic relev smoke prevent procedur repeat year evalu studi particip intervent condit receiv me sage revisit websit 2 year follow period view inform shown particip inter vention prompt condit particip con trol condit access fun smoke websit questionnair web base questionnair fun smoke program adapt version octopu question nair assess com.ibm.drl.hbcp.predictor smoke 9,22,23,38 demograph assess term ag gender locat school religion ethnic famili composit pocket monei school perform mobil phone number mail address socioeconom statu se se measur famili affluenc scale fa scale measur famili wealth base cial econom marker 39,40 fa includ question car ownership number holidai trip year number comput home respond bedroom answer combin index knowledg smoke assess question smoke cough answer categori includ don’t attitud assess advantag pro ten disadvantag con smoke particip complet question smoke answer feel matur feel matur pro ill ill con point scale procedur support previou studi reliabl scale 41 social influenc measur concept social norm model social norm assess belief smoke parent famili friend particip complet question mother think point answer scale rang smoke smoke model includ smoke behaviour parent famili friend total question includ mother smoke point answer scale rang number smoker environ assess cremer al bmc public health 2012 12 277 page 8 10 http www.biomedcentral.com 1471 2458 12 277 question friend smoke point scale answer op tion efficaci expect assess ten item order determin easi difficult smoke situat question answer point scale rang easi diffi cult smoke 42 smoke smoke parent offer cigarett smoke exampl efficaci question intent measur differ smoker smoker question assess smoker intent stop smoke smoker ask start experi smoke question intent measur point scale answer option rang action plan differenti smoker smoker smoker assess action plan stop smoke smoker assess wai refus cigarett group action plan measur item throw cigarett lighter smoker refus cigarett smoker que tion complet point scale rang total agre total disagre smoke behaviour assess report question statement describ behaviour internation accept algorithm 9,11,43,44 answer scale rank item smoke puff smoke smoke anymor quit smoke smoke week quit smoke smoke week smoke smoke month smoke weekli month smoke daili week smoke dai children categoris smoker smoke puff smoke anymor stop smoke smoke week stop smoke smoke week smoker smoke smoke month smoke month smoke week smoke dai smoke 24 hour smoke dur ing 24 hour past 7 dai smoke past 7 dai past month smoke past month assess question assess answer scale addition qualit assess made number cigarett smoke past week weekend cigarett smoke week weekend process evalu pupil intervent condit receiv process evalu questionnair assess tailor feedback letter invit fill web base questionnair mail dai receiv feedback letter children ask letter read give rate 1 low 10 high individu feedback letter process evalu que tionnair assess aspect appr ciation attract pleasur comprehens thought provid feedback question answer point scale exampl answer option level attract nice nice comprehens clear clear level personalis person person 12 24 month pupil intervent condit ask prompt receiv sm mail opinion prompt assess amount vi qualit assess pupil visit fun smoke websit notic updat websit addit 12 24 month baselin telephon depth interview held assess qualit evalu programm pupil statist analys multilevel logist regress analys mlwin examin differ studi group smoke statu cognit favour smoke mediat moder analys perform identifi cognit factor mediat intervent effect explor differenti effect group base demo graphic characterist data process evalu inter view held 12 24 month pupil analys nvivo ethic approv studi approv medic ethic committe atrium orbi zuyd hospit nl32093.096.11 mec 11 25 regist dutch trial regist ntr3116 discuss paper design intervent evalu ation protocol fun smoke programm present present studi aim develop comput tailor smoke prevent programm primari school chil dren provid attitud knowledg skill plan refus cigarett make transit primari secondari cremer al bmc public health 2012 12 277 page 9 10 http www.biomedcentral.com 1471 2458 12 277 school programm adapt translat exist comput tailor intervent previ ousli print deliv content comput tai lore feedback similar origin print deliv version messag shorter compli requir messag internet long time interv send feedback letter made shorter dai oppos week print deliv version prefer pupil web base deliv eri allow creation comprehens web site children find inform smoke game addit movi smoke websit facilit multipl exposur smoke inform provid multipl feedback structur approach involv pupil medium prefer pupil pre test programm good basi effect intervent increas likelihood web base approach attract pupil version intervent test group cluster randomis control trial hypothesis pupil intervent con dition start experi smoke compar control condit smoke rate lower intervent prompt condit intervent condit strength limit previou school smoke prevent programm requir invest time particip primari school 45 lead frustrat higher drop rate particip school fun smoke programm web base intervent requir limit input time teacher meet school lower workload involv implement smoke prevent programm strength design ef fectiv studi assess effect imm diat 12 24 month test short long term effect fun smoke programm limit studi smoke haviour factor relat smoke base report youngster lead mea urement error i. social desir answer avoid social desir answer guarante full confiden tialiti particip valid adolesc report smoke shown high accord anc biolog indic measur assur confidenti 46 approxim 60 expect drop final measur pupil connect primari school drop percentag account sampl size calcul larg sampl size guarante power evalu studi programm proven effect valuabl tool smoke prevent readili implement primari school netherland studi provid valuabl informa tion usabl addit effect sm mail remind combin comput tailor feedback programm compet interest hdv scientif director vision2 health compani licens evid base innov comput tailor health commun tool acknowledg studi fund zonmw netherland organis health research develop grant number 200110011 author contribut hdv design wrote origin propos hpc lm ao hdv develop smoke prevent programm execut studi hpc significantli contribut write paper lm ao hdv involv revis manuscript critic author read approv final version manuscript receiv 8 march 2012 accept 10 april 2012 publish 10 april 2012
smoke cessat intervent femal prison address urgent public health karen cropsei psyd gloria eldridg phd michael weaver md gabriela villalobo bs maxin stitzer phd al phd smoke lead prevent death unit state 1 smoke preva lenc morbid mortal decreas gener popul smoke preval remain 3 4 time higher prison nonincarcer adult popul 2 common medic problem prison smoke relat includ heart circulatori respiratori kidnei liver problem diabet 3 medic care prison consum 11 correct budget expect doubl in10 year part high rate smoke medic condit 4 continu high preval smoke prison import public health implic increas incar cerat rate unit state 5 high prev alenc comorbid psychiatr substanc abus disord nicotin de pendenc low natur rate smoke cessat prison incarcer men 70 80 current smoker 2,6 11 smoke preval incarcer women rang 42 91 2 4 time higher women gener popul 2,12,13 prison comorbid condi tion psychiatr disord substanc depend greater nicotin depend likelihood smoke cessat absenc intens interven tion 14 past 10 year concern secondhand smoke threat litig desir protect employe prison health reduc prison health care expenditur limit prison amen correct facil iti implement smoke ban striction smoke ban prison differ smoke ban set prison confin legitim opportun smoke durat sentenc recours quit smoke cold turkei smoke cessat treatment nicotin replac obtain cigarett tobacco underground prison econ omi prison smoke ban unin tend consequ prison continu smoke thrive contraband economi grow meet demand cigarett 8,9,15,16 public health perspect temporari cessat smoke punit smoke restrict quit smoke 17 97 peopl smoke free jail return smoke 6 month releas suggest smoke ban restrict incarcer mark effect lifetim preval smoke 18 nation commiss correct health care 2002 report health statu releas inmat recommend inmat provid smoke free environ smoke cessat program offer staff member inmat offer smoke cessat program smoke restrict increas likelihood tobacco control prison environ sustain smoke cessat releas 19 smoke cessat intervent shown effect correc tional set remain virtual de spite enorm human health eco nomic cost smoke prison 13,19,20 burgeon literatur smok ing cessat popul locat 2 publish paper smoke cessat intervent prison eding al conduct 2 small studi control procedur smoke cessat male prison 21 studi methodo logic limit includ small sampl size 14 28 signific treatment attrit lack biolog verif treatment outcom richmond al report pilot studi 30 male prison receiv 2 session cognit behavior counsel nicotin replac therapi buproprion materi 22 report smoke verifi level expir carbon monoxid assess 6 month intervent 6 month 26 verifi point preval abstin object test efficaci combin pharmacolog behav ioral smoke cessat intervent women state prison southern unit state method studi design random control trial 6 month waitlist control group intervent 10 week group intervent combin nicotin replac therapi hundr fifti particip receiv intervent 289 control group assess occur baselin end treatment 3 6 12 month treatment weekli session particip intervent group result intervent efficaci compar waitlist control group point preval quit rate intervent group 18 end treatment 17 3 month follow 14 6 month follow 12 12 month follow quit rate consist outcom commun smoke cessat intervent conclus femal prison interest smoke cessat interven tion achiev point preval quit rate similar commun sampl augment tobacco control polici prison smoke cessat inter vention potenti address signific public health public health 2008;98 1894 1901 doi 10.2105 ajph 2007.128207 research practic 1894 research practic peer review cropsei al american journal public health octob 2008 vol 98 10 22 continu abstin studi notabl small sampl size focu male prison knowledg studi random clinic trial smoke cessat femal prison examin effi caci combin behavior pharma colog intervent compar waitlist control group studi design overcom limit previou studi focu femal prison antici pate group expos interven tion superior quit rate time point compar waitlist control group method procedur june 2004 june 2006 particip recruit flyer hous unit announc larg prison hous femal offend southeastern unit state inclus criteria adult smoker smoke 5 cigarett dai interest smoke cessat treatment abil particip group psychotherapi contraind nicotin replac e.g 6 month myocardi infarct hous gener popul e.g segreg hous acut mental health wing least1year left serv releas date confirm prison record particip receiv medic clearanc nicotin replac prison physician studi design studi design random con troll trial 6 month waitlist control group 6 month control group cross activ intervent particip receiv intervent par ticip complet baselin assess consist demograph inform height weight smoke histori weekli measur daili smoke number ciga rett smoke previou dai type ciga rett smoke concentr part million ppm expir air measur vitalograph breathco vitalo graph lenexa ks expir read ing 3 ppm higher indic current smoke 2 total 364 particip provid inform consent 360 complet baselin assess ment 250 start intervent fig ur 1 intervent descript behavior intervent base mood manag train prevent smok ing relaps 23 intervent select focu mood manag skill standard behavior intervent smoke cessat mood manag train combin pharmacotherapi shown 1 year smoke cessat rate approxim 30 nonincarcer popul 23 10 session group intervent modifi deliveri prison includ exampl smoke trigger encount prison cope strategi feasibl appro priat environ final standard mood manag intervent deliv 8 week 4 session 2 week prison intervent deliv 10 week 1 session week eas prison schedul burden studi nicotin replac nortryptylin pharmacoth com.ibm.drl.hbcp.api adjunct origin studi 23 choic medic base part prison regul made antid pressant medic smoke cessat feasibl intervent particip receiv nicoderm cq nicotin replac patch glaxosmithklin london england start week 3 intervent manufactur suggest dose side effect assess patch distribut weekli group session particip ask make quit attempt week 3 4 immedi receiv suppli nicotin replac patch random hundr fifti particip enrol intervent 289 control group 2 cohort ran domiz intervent control group subsequ particip assign waitlist control group waitlist particip complet baselin assess follow assess 10 week 3 month 6 month end treatment 3 month 6 month follow point intervent group 6 month follow waitlist partici pant cross intervent group figur 1 waitlist particip instruct advic quit reduc smoke data collect intervent particip complet baselin assess 10 weekli assess follow assess 3 6 12 month particip smoke 10 cigarett dai baselin start 21 mg nicotin patch 1 addit contact end treat ment 3 month follow assess receiv addit patch assess side effect medic problem primari outcom measur smoke sta tu abstin smoke time point abstin defin report con tinuou abstin previou week con firm exhal 2 ppm 2 data analysi group compar demograph smoke characterist c2 test 1 analys varianc repeat measur analysi varianc procedur examin long term effect inter vention smoke rate gener iz estim equat method gener estim equat robust procedur longitudin dichotom data provid estim relat time variabl interest analysi model includ treatment group inter vention waitlist time 15 time point base line week 1 10 group treatment postin tervent week 11 medic check 3 6 12 month follow treat ment time interact term outcom variabl interest smoke cessat time point smoke abstin partic ipant withdrew intervent code smoke particip transfer facil releas intervent end 42 assess 6 abstin 36 smok ing carri forward subsequ follow point particip miss data e.g return court segreg follow code smoke research practic octob 2008 vol 98 10 american journal public health cropsei al peer review research practic 1895 result comparison treatment drop group analys baselin smoke demo graphic variabl conduct particip enter intervent 250 particip withdrew transfer intervent began 110 signific differ variabl note group similarli comparison particip complet intervent 116 particip drop interven tion 134 show differ ag race ethnic number cigarett dai time cigarett rate difficulti quit attempt treatment drop out singl 05 start daili smoke younger ag 05 signific differ found baselin demograph smoke charac terist treatment complet 116 control particip 289 signific differ found complet 116 control particip start intervent 110 particip start inter vention smoke fewer cigarett dai 14.0 17.1 rate quit attempt difficult complet 4.4 5.2 05 signific differ demograph smoke behavior found group demograph characterist hundr fifti particip enter intervent sampl divid white 44 white 56 particip mean ag 33.8 year sd 9.0 year twenti percent report high school cation 41 complet high school graduat equival degre 32 greater high school educ figur 1 flow chart particip smoke cessat intervent femal prison southeastern unit state june 2004 june 2006 research practic 1896 research practic peer review cropsei al american journal public health octob 2008 vol 98 10 report histori treatment mental ill 67 substanc abus 58 smoke characterist smoke characterist displai tabl 1 smoke pattern chang dramat enter prison 14.2 start smoke time 50.8 creas smoke 15.8 decreas smoke 0.4 quit smoke enter prison particip smoke menthol 72.3 regular tar 20.1 cigarett 0.9 smoke unfilt hand roll cigarett enter prison 61.2 smoke mentho late cigarett 15.9 smoke regular tar cigarett 22.8 smoke unfilt hand roll cigarett comparison treatment control group gener estim equat anali si show the10 week group intervent combin nicotin replac effi caciou compar waitlist control group support primari hypothesi time intervent interact signific 001 time point 5 week 4 intervent week target quit date 29 intervent particip verifi abstin abstin declin subsequ week point preval quit rate intervent group 18.4 end treatment 16.8 3 month follow 14.0 6 month follow figur 2 signific differ point preval quit rate intervent control group present 6 month follow 14.0 2.8 c2 23.0 df 1 001 12 month follow point control comparison waitlist group cross activ intervent 6 month 11.6 intervent particip abstin the12 month follow relaps rate half intervent particip 125 1 week verifi abstin 50 intervent particip 20.0 4 week sustain verifi abstin 10 week treatment 1 year follow partic ipant 1 week verifi tabl 1 smoke characterist women 250 state prison southeastern unit state june 2004 june 2006 mean sd ag smoke initi 13.7 4.8 ag daili smoke 16.2 4.9 averag chronic pulmonari diseas 16.5 8.7 time cigarett min 55.2 82.4 carbon monoxid concentr ppm 14.4 8.4 total year smoke 18.3 9.6 past quit attempt 2.4 2.8 longest quit mo 12.9 16.8 time quit mo 29.3 53.0 difficulti quit attempta 5.3 2.0 percentag famili smoke 49.0 36.1 percentag friend smoke 77.0 26.8 averag amount spent weekli cigarett prison 19.49 12.74 likelihood continu smoke releaseb 3.7 2.2 think quit smoke 30 dai 48.3 6 month 47.5 quit 4.2 famili member medic problem relat smoke 38.6 32.7 don’t 28.7 famili member di smoke 34.3 39.0 don’t 26.7 person medic problem smoke 31.1 44.2 don’t 24.7 chang smoke behavior come prison start smoke 14.2 increas 50.8 decreas 15.8 stai 18.8 quit 0.4 type cigarett smoke come prison regular 20.1 light 6.7 menthol 72.3 unfilt roll 0.9 type cigarett smoke come prison regular 15.9 menthol 61.2 unfilt roll 22.8 note percentag add 100 round adetermin respons likert scale 1 7 1 easi 7 difficult bdetermin respons likert scale 1 7 1 7 research practic octob 2008 vol 98 10 american journal public health cropsei al peer review research practic 1897 abstin 125 26 20.8 remain abstin 79.2 relaps studi approxim half 45.5 relaps 1 week verifi abstin 14.1 relaps 2 week 11.1 relaps 3 week 2 particip relaps 24 week verifi abstin attend medic complianc particip attend mean 6.7 sd 3.1 of10 group therapi session examin effect group attend smoke cessa tion end treatment 3 6 12 month follow point number session attend significantli relat success smoke cessat time point tabl 2 similarli examin complianc nicotin replac calcul percentag dose treatment particip drop treatment code nicotin replac fewer half 43.3 sd 33.7 dose nicotin replac treatment complianc nicotin replac ment significantli relat smoke cessat outcom end treatment 3 month follow outcom 6 12 month outcom tabl 2 medic complianc strongli relat group attend partici pant attend intervent group receiv nicotin replac examin complianc nicotin replac particip 1 week placement 203 continu attend weekli session divid total number dose number dose durat time particip remain treatment women nicotin replac 1 week continu attend weekli session 80.47 dose tabl 2 present result adjust medic complianc outcom adher enc nicotin replac improv quit rate end treatment 89.7 77.9 3 month follow 89.3 78.5 relat outcom final examin medic complianc note eot end treatment med medic check week 4 6 month valu 001 baselin week 3 valu signific c2 analysi calcul valu figur 2 smoke quit rate verifi abstin women 539 state prison time treatment group southeastern unit state june 2004 june 2006 tabl 2 attend medic complianc treatment outcom smoke cessat intervent femal prison southeastern unit state june 2004 june 2006 abstin mean sd smoke mean sd number session attend 250 end treatment 8.9 1.5 6.2 3.1 30.6 001 6 month follow 7.9 2.6 6.5 3.1 5.9 02 12 month follow 7.9 2.6 6.5 3.1 4.7 03 medic complianc 250 end treatment 60.9 29.0 39.3 33.5 16.3 001 3 month follow 53.1 32.2 41.3 33.7 4.3 04 6 month follow 48.3 30.4 42.5 34.2 0.9 34 12 month follow 50.5 31.2 42.4 34.0 1.5 22 adjust medic complianc 203 end treatment 89.7 16.6 77.9 25.0 8.8 003 3 month follow 89.3 16.7 78.5 24.9 6.3 02 6 month follow 86.9 20.7 79.4 24.3 2.6 11 12 month follow 88.5 16.6 79.3 24.6 3.3 07 weekli medic complianc week 4 183 97.3 8.5 80.3 28.4 18.4 001 week 5 182 92.2 19.8 77.1 30.9 12.9 001 week 6 146 93.0 19.4 79.2 30.5 9.0 003 week 7 105 90.5 20.6 74.4 32.4 7.8 006 week 8 106 85.9 29.8 81.4 31.0 0.5 48 week 9 109 89.6 24.9 72.8 35.9 6.8 01 week 10 86 80.1 35.0 81.3 31.8 0.0 89 note statist test perform 1 analysi varianc research practic 1898 research practic peer review cropsei al american journal public health octob 2008 vol 98 10 determin nicotin replac relat weekli outcom tabl 2 gener weekli medic complianc relat weekli abstin rate the10 week treatment effect weak en week studi attrit medic complianc rate converg smoke cessat rate 10 ppm carbon monoxid cutoff examin point preval abstin rate 10 ppm cutoff cut gener smoke cessat treatment studi stringent cutoff greatli increas abstin rate pare stringent 2 ppm cutoff abstin rate 37.2 end treat ment 40.4 3 month follow 30.8 6 month follow 23.0 12 month follow standard cutoff misclassi fi 25.0 smoker nonsmok end treatment 20.8 12 month follow discuss combin behavior pharmaco logic intervent efficaci compar waitlist control group promot smoke cessat femal prison studi random clinic trial smoke cessat prison pop ulat show femal prison interest quit smoke prison quit rate absenc intervent low femal prison success achiev sustain smoke cessat provid state art smoke cessa tion treatment stringent cutoff verifi abstin point preval quit rate commensur nonprison sampl expos similar smoke cessat intervent 2,24,25 stringent cutoff commonli smoke cessat trial quit rate doubl rate report suggest cessat studi liber cutoff overesti mate effect intervent similar clinic trial smoke cessat intervent particip relaps coupl week quit ap proxim 20 particip initi smoke cessat achiev smoke absti nenc relaps approxim 12 particip remain abstin 12 month follow relaps rate similar studi nicotin replac therapi 26 group session attend nico tine patch problemat partic ipant averag particip attend 6.7 10 group session half drop intervent particip drop report longer interest quit smoke attrit rate similar smoke cessat trial commun 27 consist pre viou studi particip attend group session remain abstin 12 month follow 27,28 nicotin patch posit late smoke abstin weekli session 3 month follow long term abstin 6 month relat greater nicotin replac ment intervent partici pant drop treatment includ analysi gener complianc nicotin replac poor half dose medic complianc nicotin placement approxim 80 women remain treatment nicotin replac provid free charg distribut group session puzzl consist previou studi peopl remain treatment nicotin patch 28 30 previou studi found medic adher relat high level nicotin depend medic side effect low mo tivat provid give inadequ instruc tion nicotin patch inadequ dose 28,30 32 factor relat medic nonus studi studi document smoke prison riskier smoke prison women studi start smoke time increas smoke enter prison women smoke unfilt cigarett incarcer quarter smoke hand roll unfilt cigarett enter prison 99 cigarett sold unit state filter smoke unfilt cigarett uncommon gen eral popul 33 unfilt cigarett increas risk cancer chronic obstruct pulmonari di eas heart diseas mortal 34,35 compar youth popul mean ag approxim 34 year fact report medic problem caus wor en smoke concern limit studi limit enrol adult femal prison result appli male prison juvenil offend pre viou studi document respons nicotin replac therapi smoke cessat intervent femal smoker compar male smoker 36,37 pattern hold true correct environ structur environment demand correct facili ti prison uniqu environ gener alli long term confin similar result observ correct set final inter vention studi intens attrit high suggest addit studi determin efficaci shorter intens intervent correc tional popul conclus prison repres import neglect venu address smoke cessat select hypothesi suggest smoke local peopl struggl poverti psychiatr disord high level nicotin depend abus substances38,39 attribut common prison spons high preval smoke correct system unit state implement smoke ban smoke restrict 16 ban restrict address short term problem smoke correct sy tem evid short term sanction smoke translat long term smoke cessat releas research practic octob 2008 vol 98 10 american journal public health cropsei al peer review research practic 1899 evid suggest virtual prison return smoke releas 18 studi examin impact smoke ban smoke prison 76 male prison continu smoke1month ban 9 effect public health respons high preval smoke associ at health problem prison augment prison tobacco control polici effect smoke cessat intervent 17,19 studi smoke cessat intervent femal prison popul feasibl accept effect similar intervent de liver commun public health import address smoke ce sation correct popul subsequ research address effect smoke cessat intervent cor rection venu import futur research address pro cess relaps smoke sustain cessa tion smoke releas prison author karen cropsei depart psychiatri univers alabama birmingham gloria eldridg depart behavior health research servic univers alaska anchorag michael weaver gabriela villalobo depart ternal medicin virginia commonwealth univers richmond maxin stitzer depart psychiatri bayview medic center john hopkin uni versiti baltimor md al depart biostatist virginia commonwealth univers rich mond request reprint karen cropsei univers alabama birmingham substanc abus center 401 beacon parkwai west birmingham al 35209 mail kcropsei beapsy1 his.uab.edu articl accept januari 30 2008 contributor cropsei contribut studi design data collect write eldridg weaver stitzer contribut studi design write villalobo contribut data collect write contribut statist analys data acknowledg studi fund nation institut drug abus nation institut health grant k23da15774 product support provid glaxo smithklin portion paper present societi research nicotin tobacco confer februari 27 march 1 2008 portland oregon note glaxosmithklin input studi result studi design human particip protect studi receiv institut review board approv virginia commonwealth univers vir ginia depart correct
journal consult clinic psycholog 1991 vol 59 2,318 324 copyright 1991 american psycholog associ 0022 006x 9i s3.00 evalu intrins extrins motiv intervent smoke cessat program susan curri edward wagner center health studi group health cooper puget sound seattl washington depart health servic univers washington loui grothau center health studi group health cooper puget sound seattl washington person feedback financi incent develop intrins extrins motiv framework evalu adjunct materi smoke cessat ss 1,217 random 4 treatment group 3 12 month consist hypothes deriv motiv framework financi incent increas materi increas cessat rate program user higher relaps rate manag quit person feedback increas smoke cessat materi 3 month distribut materi continu abstin abstin 3 12 month group receiv person feedback rate group intervent smoke cessat promis cost effect easili dissemin part larg scale health promot effort studi dem onstrat cessat rate smoker materi compar smoker partici pate intens group treatment program davi faust ordentlish 1984 glasgow 1978 glasgow schafer o'neil 1981 particip usag rate program consider lower group program curri marlatt gordon baer 1988 schneider benya saeger 1984 data particip rate smoker request program rang 21 59 compar 80 90 smoker sign group program compar outcom program user develop effect method increas proport individu program lead signific increas proport ultim achiev long term cessat cum emont jaen scian dra 1988 evalu effect intervent aim creas smoke cessat materi devel op intrins extrins motiv framework curri wagner grothau 1990 harackiewicz sanson portion articl present 97th annual conven tion american psycholog associ orlean loui siana august 1989 research support nation institut drug abus grant r01 da04447 susan curri princip investig deborah dickstein brian russel bonner reink assist conduct research russel glasgow help consult correspond articl address su san curri center health studi 1730 minor avenu 16th floor seattl washington 98101 blair epstein manderlink 1987 intrins extrins mo tivat refer origin desir engag particu lar behavior intrins motiv reflect desir achiev intern reward e.g sens compet trinsic motiv reflect desir receiv extern reward e.g monei enhanc intrins motiv smoker receiv written person feedback design bolster confid abil successfulli materi extrins moti vation approach financi prize draw centiv materi relat intervent evalu smoke cessa tion financi incent increas particip pro gram smoke cessat worksit commun intervent e.g king flora fortmann taylor 1987 klesg vasei glasgow 1986 attempt tailor content smoke cessat program individu characterist shown dramat improv smoke cessat 1975 owen ewin lee press intervent fit intrins extrins conceptu frame work specif design perspect studi cite compar type inter vention singl design research behavior smoke cessat shown extrins motiv strong incen tive offer gain detriment long term outcom undermin intrins motiv deci ryan 1985 similarli recent work relationship intrin sic extrins motiv smoke cessat shown higher level extrins rel intrins motiv lower probabl achiev abstin curri al 1990 basi find hypoth size group receiv extrins strategi show highest program smoke cessa tion highest subject receiv intrins strategi clear theoret perspect 318 feedback incent 319 effect combin strategi facto rial design assess individu combin impact motiv enhanc strategi point cessat process includ program initi cessat long term abstin target popul individu request materi smoke cessat method set studi conduct group health cooper puget sound ghc profit consum govern health maint nanc organ serv 350,000 enrolle western wash ton state ghc publish health orient magazin view mail charg contract holder bimonthli basi readership survei subject recruit 70 adult enrolle read part magazin subject recruit subject recruit 4 month period 1987 consecut full page advertis view magazin cruitment involv step process smoker mail coupon advertis mail descript studi consent statement baselin questionnair 1,555 son initi return coupon 1,217 78 return sign consent statement complet questionnair enrol studi major subject women 65 averag ag 44.1 year sd 14.02 59 marri live partner 90 high school graduat 68 emploi wage subject smoke averag 24.7 cigarett dai sd 10.9 smoke averag 25.4 year sd 13.0 averag 2.9 prior attempt quit sd 3.3 total 33 subject receiv prior treatment smoke cessat random subject stratifi basi gender number cigarett smoke dai dichotom 30 cigarett dai random receiv intrins motiv strategi intrins 304 extrins motiv strategi extrins 304 strategi 304 strategi control 305 signific differ baselin characterist studi group tabl 1 intervent smoker enrol studi receiv break program smoke cessat curri gordon marlatt 1987 program consist unit complet week week basi postag paid progress report unit includ particip return studi offic plete program motiv strategi kei compon intrins extrins motiv strate gi summar tabl 2 intrins motiv strategi written person feedback base previou research enhanc ing efficaci bandura schunk 1981 bandura cervon 1983 work show intrins motiv stop smoke focus dimens health concern control curri al 1990 enhanc confid motiv quit ap proach highlight similar smoker previou experi reason quit experi motiv success quitter subject receiv total set feedback materi subject receiv set consist person analysi item baselin questionnair smoke quit histori number earlier quit attempt longest previou abstin previou partici pation cessat program health concern desir control intrins motiv dimens copi reason quit section baselin questionnair highli rate intrins motiv quit highlight yel low set person feedback materi subject return progress report unit 1 2 feed back reinforc subject activ complet di cuss benefit activ subject find complet subject return report unit 3 4 ceiv set feedback materi similar set subject elig receiv feedback 12 week materi extrins motiv intervent prize incent conting materi defin return unit progress report incent link directli smoke cessat subject receiv secret gift ceram coffe mug entri prize draw return progress report tabl 1 subject characterist characterist gender femal ag educ 12 year incom lok year marri emploi white baselin smoke cigarett dai year smoke previou quit 2i 1 month smoke 1 5 min awaken previou attempt desir quit 1 10 total 1,217 65 44.1 90 93 59 68 94 24.7 25.4 52 56 2.9 7.3 intrins 304 64 43.3 90 93 58 70 95 25.0 25.1 56 56 2.9 7.2 extrins 304 64 44.2 90 90 54 69 93 24.2 25.0 54 56 3.1 7.4 304 65 44.3 92 95 64 67 92 25.1 25.6 51 56 2.6 7.3 control 305 65 44.7 89 93 58 67 94 24.5 25.8 49 56 3.1 7.3 pal highlight 11 feedback behaviour pal highlight 93 vicari consequ pal highlight 11 feedback behaviour pal highlight 51 materi incent pal comment text link 11 12 intrins motiv 320 curri wagner grothau tabl 2 compon intrins extrins motiv strategi time intrins person feedback extrins financi incent random program mail subject mail unit 1 2 progress report week materi progress report receiv subject mail unit 3 4 progress report person analysi baselin data highlight copi reason quit questionnair person analysi progress report remind postcard send progress report person analysi progress report set record keep form recycl unit smoke descript prize draw secret gift gift draw entri remind postcard send progress report bonu entri draw set record keep form recycl unit smoke program unit draw main prize expens paid week trip hawaii prize expens paid weekend resort san juan island prize weekend delux hotel downtown seattl bonu entri draw subject return progress report unit 3 4 subject elig enter prize draw 12 week materi prize draw conduct 12 week subject random assess baselin baselin questionnair assess demograph ag sex educ marit statu employ statu incom smoke histori ag smoke onset numberofyear smoke baselin smok ing rate number prior quit attempt number prior treatment program longest prior period abstin cigarett physi cal depend variabl inclus separ anali se smoke cessat process social support perceiv stress health lifestyl motiv follow materi smoke statu assess mail questionnair telephon follow subject respond mail 2 week 3 12 month random obtain follow data 98 partici pant 3 month follow 95 particip 12 month follow subject ask rate 8 program unit 5 point scale read 0 read unit activ 1 read unit half activ 2 read unit activ 3 read unit activ 4 track subject return unit progress report break booklet saliva cotinin 12 month mail telephon follow up began subject arrang saliva speci men assess physic nicotin level dai time call attempt obtain saliva sampl subject report abstin live 25 mile ra diu defin basi zip code center health studi week report abstin sampl ic cooler collect transfer laboratori freezer 4 hr frozen sampl ship dry ic ameri health foundat analysi statist analysi outcom analyt step chi squar test differ proport treatment group test 05 pairwis comparison intervent group control group conduct logist regress analysi addit logist model construct compar intervent group control group con troll ag sex baselin smoke rate number cigarett smoke dai intervent effect estim adjust analys replic estim unadjust model result report unadjust analys result materi impact motiv strategi materi examin behavior report measur behavior measur defin return progress report unit 1 dichotom report measur particip report ac tiviti program unit mea intend reflect signific commit program unit exclud measur order assess impact intervent program independ requir enter prize draw group receiv extrins intervent signifi cantli higher rate return unit progress report tabl 3 compar control group subject receiv ing extrins motiv strategi return unit progress report report compl tion program activ program pal comment text 12 monitor behaviour feedback incent 321 tabl 3 proport odd ratio confid interv ci outcom measur treatment group outcom intrins 304 extrins 304 304 control 305 return unit 1 progress report ci report complet activ unit ci report 24 hr cessat 3 month follow dai abstin 3 month ci dai abstin 12 month dai abstin 3 12 month ci 17 1.1 0.7 1.6 31 1.4 1.1,2.1 51 13 1.8 1.1,3.1 17 32 2.5 1.7,3.7 34 1.7 1.2,2.4 53 1.1 0.8 2.4 13 10 4 2.0 0.7 1.1,3.7 0.4,1.6 29 2.1 1.4 3.2 31 1.4 1.1,2.1 49 9 1.0 0.9 1.3 12 4 0.7 0.4 1.6 16 1.0 24 1.0 43 1.0 15 5 1.0 0001 039 06 32 004 note odd ratio 95 confid interv logist regress analysi pairwis compari son control group present chi squar test 05 7 dai abstin 3 month 06 x2 3 1,217 test proport group equal unit higher intervent group compar control group subject receiv person feedback financi incent 1.5 time report complet activ program unit subject receiv motiv intervent result replic addit analys continu mea calcul sum rate program unit smoke cessat proport subject group report smoke abstent 24 hr 3 month period receiv program report tabl 3 signific differ group 3 month margin signific 06 differ 7 dai abstin group pairwis comparison control group confirm predict intrins group significantli higher rate cessat subject receiv person iz feedback 1.8 time achiev abstin control group member contrast group receiv financi incent control subject 12 month follow signific differ enc 7 dai abstin group highli signific differ continu absti nenc defin 7 dai abstin 3 12 month follow up pairwis comparison subject ceiv person feedback report continu abstin compar control group time odd ratio 2.67 95 confi denc interv 1.34 5.31 report continu abstin group receiv financi incent saliva cotinin tabl 4 summar result saliva collect cotinin analys 12 month follow nonconfirma tion abstin defin report smoke refus cooper subject contact make appoint obtain saliva sampl presenc 10 ng ml cotinin analyz sampl estim nonconfirm rate 12 month abstin preval 11 control 16 intrins 30 31 extrin sic reduc 12 month abstin preval rate 322 curri wagner grothau tabl 4 summari collect analysi saliva sampl 12 month follow intervent variabl intrins extrins control subject report abstin 12 month subject geograph area saliva collect number subject relaps phone obtain specimen number refus specimen obtain specimen cotinin 10 ng ml cotinin valu ng ml report confirm saliva cotinine8 58 32 55 1 3 28 88 1 121 16 44 29 66 3 4 22 76 2 87 180 31 43 30 70 5 4 21 70 0 30 51 38 75 1 1 36 95 2 89 145 11 note dash applic calcul divid sum number relaps number refus number sampl cotinin valu 10 ng ml number subject elig saliva test i. number subject live geograph boundari collect disconfirm rate treat ment group differ significantli x2 3 129 6.29 05 total sampl proport yield esti mate intrins 14 extrins 9 9 control 13 x2 3 1,217 7.11 05 estim nonconfirma tion rate subject report abstin 3 12 month follow up 0 intrins extrins group 10 1 10 control group outcom percentag 12 month continu abstin chang adjust program cessat relaps relat program 3 month cessat laps 3 12 month follow up studi group summar tabl 5 pattern result suggest effect motiv intervent primarili subject program mate rial program significantli higher absti nenc rate 3 month x2 3 1,217 17.85 001 appear higher long term abstin rate subject receiv person feedback result higher abstin rate 3 month lower laps rate 3 12 month program user appear program user receiv financi centiv abstin 3 month highest relaps rate small sampl size preclud statist compari son outcom subject characterist program continu abstin intrins extrins intervent combi nation significantli increas program materi tabl 5 summari relationship program smoke cessat relaps treatment group percentag intervent intrins 304 extrins 304 304 control 305 program 31 34 31 24 dai abstin 3 month 22 10 12 6 15 6 12 6 relaps 3 1 2 month 24 30 67 38 64 42 44 27 total abstin 3 12 month 17 7 4 4 5 3 7 5 note defin complet activ program unit feedback incent 323 intrins intervent significantli higher rate continu abstin find type smoker respond intervent kind smoker respond intervent address que tion multivari logist regress model test interact treatment group variabl list tabl 1 gender ag educ incom marit statu em ployment baselin smoke rate year smoke smoke 15 min awaken number previou quit attempt desir quit separ set logist model test materi continu abstin depen dent variabl signific interact baselin sociodemograph smoke histori desir quit variabl treatment group outcom subject char acterist predict materi continu absti nenc treatment group particip materi post high school educa tion 32 versu 26 x2 1 1,217 4.40 04 report significantli previou quit attempt 3.28 versu 2.76 183 2.48 02 express significantli higher desir quit smoke 7.84 versu 7.08 1208 5.54 001 continu abstain significantli lower rate baselin smoke 19.97 versu 24.97 cigarett dai 1204 3.67 001 previous abstain month 78 versu 51 x2 1 1,217 20.74 001 express significantli higher desir quit 7.81 versu 7.27 1208 1.20 05 discuss studi repres applic intrins extrins motiv conceptu framework design interven tion aim improv effect smoke cessat program increas smoker request consist hypothes deriv motiv framework extrins orient financi centiv increas materi increas cessat rate program user higher relaps rate man ag quit compar receiv manual result effect long term ce sation rate intrins orient person feedback increas materi higher rate smoke cessat 3 month distribut materi user nonus program continu ou abstin 12 month rate group receiv person feedback 10 higher initi cessat rate substanti lower rate laps continu abstin rate repres improv current state art median rate 10 prospect studi unaid smok ing cessat 4.3 cohen al 1989 appear financi incent diminish posit impact person feedback im pact diminish unclear data obtain 3 month follow subject receiv person aliz feedback receiv fi nancial incent equal awar receiv feedback equal posit evalu us explan lower quit rate higher relaps rate subject receiv financi incent repres social psychologist call overjustifi cation effect lepper green nisbett 1973 subject receiv ing financi incent attribut earli behavior i. materi initi cessat desir enter prize draw desir abil quit smoke reduc sens commit quit ting confid cope difficulti avoid relaps cessat find research suggest clich lead hors water make drink found simpli increas materi automat result higher cessat rate interpret stage model cessat process pro chaska diclement 1983 financi incent push contempl action stage develop resourc achiev cessat hand highlight smoker intrins motiv quit ting provid confid boost feedback appear enhanc materi improv chanc suc cess find support concern leader health promot rais generaliz dura biliti incent health behavior green wilson lo vato 1986 neg effect financi incen tive found studi odd studi report posit effect quit motiv financi centiv winett king altman 1989 po sibl explan discrep notabl financi incent studi conting smok ing behavior materi sug gest incent appli directli major outcom interest i. smoke cessat intermedi behavior i. booklet addit alli studi demonstr effect finan cial incent appli worksit set factor social support norm pre e.g group contest buddi system pool monei oper time extrins orient motiv strategi work persona lize context mail materi impact extrins intrins interven tion differ evid differ sociodemograph characterist smoke histori level motiv smoker respond inter vention consist process analys lighter smoker previous success cessat attempt higher motiv quit success e.g curri thompson sexton omenn 1989 pomerleau ad kin pertshuk 1978
internet base conting manag promot smoke cessat random control studi jess dalleri univers florida bethani raiff rowan univers michael grabinski red 5 group llc york evalu internet base conting manag intervent promot smoke cessat particip conting group 39 earn voucher conting video confirm breath carbon monoxid 4 part million ppm earn particip nonconting group 38 independ level goal feedback smoke statu provid particip homepag median percentag neg sampl intervent nonconting conting group 25 66.7 signific differ absolut level abstin 3 6 month follow up compar baselin particip group reduc estim 15.6 ppm intervent phase result suggest conting neg co promot higher rate abstin treatment element system feedback frequent monitor goal reduc smoke kei word cigarett smoke conting manag delai discount internet inform technolog permeat dai live recent research clinician har internet mobil phone deliv behavior health intervent rang problem boyer smelson fletcher ziedoni picard 2010 gainsburi blaszczynski 2011 goodwin velic intil 2008 marsch dalleri 2012 includ smoke cessat e.g cobb graham byron niaura abram 2011 japuntich al 2006 mcdaniel stratton 2006 seidman al 2010 dalleri colleagu develop test internet base conting manag ment intervent promot smoke cessat dalleri glenn 2005 dalleri glenn raiff 2007 dalleri meredith glenn 2008 dalleri raiff 2011 glenn dalleri 2007 stoop al 2009 breath carbon monoxid verifi observ particip provid sampl web camera monetari voucher exchang good servic internet deliv conting neg breath sampl excel adher sampl dai breath collect schedul studi particip provid 97 1,120 total sampl schedul 4 week studi dalleri al 2007 compar dan neal statist analysi matthew locei program delai discount procedur alana rojewski steven meredith rachel cassidi philip erb data collect particip manag ment zadai sanchez patrick kurdila data entri research prepar paper support nation institut health grant p30da029926 r01da019580 address correspond jess dalleri depart psycholog univers florida box 112250 gainesvil florida 32611 mail dalleri ufl.edu doi 10.1002 jaba 89 journal appli behavior analysi 2013 46 750 764 number 4 winter 2013 750 monitor baselin condit 3 breath sampl neg recent smoke 65 400 breath sampl collect treatment neg 7 part million ppm breath serv object index smoke statu conting manag intervent smoke cessat sigmon lamb dalleri 2008 breathcoha half life 6 8 hr sampl collect dai increas valid measur smoke statu crowlei macdonald zerb petti 1991 javor hatch lamb 2005 cf yoon higgin bradstreet badger thoma 2009 sampl collect sustain period initi possibl maintain abstin e.g week initi abstin gourlai forb marrin pethica mcneil 1994 kenford al 1994 yoon al 2009 requir person method collect sampl particip home treatment clinic constitut signific barrier treatment internet base system appear obviat barrier treatment entail frequent monitor dalleri raiff 2011 internet base conting manag shown promot abstin heavi dalleri glenn raiff 2007 adolesc reynold dalleri shroff patak leraa 2008 rural stoop al 2009 smoker stoop al 2009 conduct small group random studi evalu impact conting voucher rel voucher deliv statu nonconting group sampl rural smoker particip earn nonconting group yoke match particip con tingent group total amount earn group equival differ group voucher con tingent smoke abstinence.dur 6 week treatment period 36.6 sampl neg 4 ppm conting group 11.3 neg noncon tingent group group differ abstin maintain 12 week follow primari object current studi evalu efficaci internet base conting manag promot smoke cessat stoop al 2009 studi particip random conting nonconting group conduct follow assess 3 6 month main treatment phase longer previou internet base contin genci manag studi factor treatment respons intervent explor secondari object assess com.ibm.drl.hbcp.predictor outcom treatment base demograph smok ing characterist individu differ tempor discount i. impuls choic bickel al 2010 carrol anker mach newman perri 2010 dalleri raiff 2007 yoon al 2007 method particip particip healthi smoker recruit print media word mouth north central florida particip characterist present tabl 1 includ studi smoker ag 18 60 year smoke 10 cigarett dai blow intak 10 ppm report minimum 2 year smoke histori comput internet access express desir quit smoke score 8 greater scale 1 10 respons question quit smoke applic exclud show evid current alcohol depend drug verifi report urinalysi cocain benzodiazepin opiat report smoke marijuana month report histori medic psychiatr ill internet base cm smoke cessat 751 judgment interfer studi resid smoker smoke insid home women disqualifi pregnant assess urin test local institut review board approv studi procedur materi particip loan monitor web camera need case laptop comput loan particip comput work properli monitor initi calibr manufactur 6 month manufactur recommend cali bration kit provid distributor copi particip driver licens obtain ask sign campu properti certif contract state return equip screen interest person screen phone basic qualifi criteria smoke sever desir quit smoke ag qualifi applic schedul person screen screen particip underw inform consent process member research team studi procedur detail particip inform earn maximum 530.00 voucher earn studi voucher exchang good gift certif purchas internet e.g amazon.com point studi particip inform purchas desir item earn monei cover cost item ship handl particip inform environment sourc elev read particip instruct avoid hand environment smoke avoid smoke substanc e.g marijuana read 4 ppm consid er posit particip believ sampl fals posit contest result sampl contest sampl neg contest sampl consid er neg voucher award purpos data analysi sampl consid posit addit particip complet psychosoci histori questionnair psychosoci histori contain question relat demograph smoke histori prior drug abus gener health medic fagerstrom test nicotin depend ftnd fagerstrom schneider 1989 6 item questionnair assess nicotin depend score rang 0 10 0 repres low depend 10 repres high depend urin sampl collect urin sampl analyz presenc cocain benzodiazepin opiat weight measur regularli calibr electron scale particip complet univers rhode island chang assess urica prochaska diclement 1983 report measur assess stage chang precontempl contempl tabl 1 demograph smoke characterist particip characterist conting group 39 nonconting group 38 ag year 39.3 13.20 40.1 13.28 femal 49 47 caucasian 74.4 81.6 cigarett dai 20.4 8.74 20.6 9.65 weight kg 80.4 16.7 79.3 19.1 intak ppm 25.1 15.82 25.2 13.14 year smoke 19.64 12.37 19.68 12.74 nicotin depend ftnd 5.13 1.90 5.24 2.54 readi chang urica 9.9 1.27 10.1 1.52 delai discount auc 0.421 0.270 0.454 0.228 note valu mean sd 752 jess dalleri al action andmainten particip respond 5 point likert scale 1 strongli disagre 5 strongli agre subscal combin arithmet yield continu score assess report readi chang final particip complet delai di count task comput task base prior research similar procedur dalleri raiff 2007 johnson bickel 2002 particip click respons button present comput screen left button correspond adjust amount monei immedi button correspond 100.00 delai 1 week 2 week 1 month 4 month 8 month 1 year 5 year 10 year present random order algorithm adjust adjust amount monei indiff enc point point option approxim equat term determin delai detail informa tion comput algorithm support inform contact author choic discount task hypothet sens particip receiv amount chose instruct task locat respons altern choos option prefer base feel summari measur delai discount area curv auc calcul normal delai indiffer point sum area pair indiffer point specif auc calcul sum result equat x2 x1 y1þ y2 2 x1 x2 success delai y1 y2 present valu delai auc measur rang 0 maximum discount 1 discount auc yield distribut measur discount myerson green warusawitharana 2001 detail design studi group random design primari differ group voucher deliv conting conting group conting nonconting group base smoke abstin particip inform avail voucher sampl sampl basi conting group intervent particip assign conting group ensur partic ipant yoke procedur remain particip randomli assign conting nonconting group screen phase signorini al 1993 particip stratifi base smoke sever 30 cigarett dai gender borrelli spring niaura hitsman papandonato 2001 particip nonconting group yoke singl particip select randomli conting group yoke particip receiv voucher hermatch particip conting group e.g higgin wong badger ogden dantona 2000 silverman al 1998 nonconting particip told earn voucher submit video voucher deliv unpredict schedul earn voucher told earn voucher base report smoke cotinin level meet goal voucher deliv immedi video submit amount voucher determin particip yoke conting counterpart internet base monitor conting manag softwar engin develop web base applic call otiv8 manag contin genci manag program collect video sampl studi particip log internet base cm smoke cessat 753 otiv8 websit usernam password complet video sampl collect simpl screen print instruct web base sampl collect process explain detail progress particip homepag bandwidth selec tor video post result entri voucher displai back homepag particip homepag ac cess secur encrypt connect consist graph particip sampl result show cumul smoke absti nenc voucher earn histori box show messag system administr post video button displai show previou sampl date time earliest date time provid sampl figur 1 procedur 8 hr interv elaps sampl particip click post video button program direct bandwidth selector interfac particip select high speed connect digit scriber line cabl modem satellit low speed connect dial phone line video post interfac guid particip process upload video sampl post result video post screen particip instruct click button turn webcam box 320 240 pixel displai webcam allow user orient camera properli captur result user instruct click record readi leav sampl figur 1a particip wish stop record instruct click stop button video stream webcam directli studi server secur encrypt connect tamper particip properli record video contain compon particip reset comet show zero particip hold breath meter count 15 particip exhal meter particip show result digit displai meter camera record sampl procedur particip enter numer result meter post result text box result fed voucher program process otiv8 incent track system result voucher amount store voucher interfac gener partici pant automat direct voucher displai voucher displai screen displai messag base posit neg result group assign particip conting group particip earn account balanc displai amount earn neg sampl inform potenti earn sampl includ particip nonconting group user click continu button return homepag latest graph account summari earliest date time provid sampl displai averag time upload video access otiv8 websit approxim 90 video review dai train staff result enter particip compar result shown video staff made step submit video properli particip attempt fake video visual cue watch chest expand initi deep breath exhal audio cue hear exhal meter verifi authent submiss process concern authent particip contact 754 jess dalleri al figur 1 top panel show video submiss screen particip requir input final result text box order earn voucher bottom panel show particip homepag displai graph voucher account balanc post video button video post button deactiv minimum intersampl interv 8 hr met internet base cm smoke cessat 755 case ask turn head sidewai exhal show lip mouthpiec meter exhal 4,774 sampl 39 problemat technic reason discrep user input video confirm read discrep result voucher award erron procedur group assign research staff met particip home provid equip instruct phase studi sampl procedur particip complet quiz demonstr read understood instruct group assign silverman chutuap bigelow stitzer 1999 baselin 3 dai particip ask submit video clip show valu dai cut requir ment phase averag calcul end phase taper particip conting group reduct breath requir voucher deliveri submiss 4 dai phase particip group reduct goal determin base averag baselin level end phase final cutpoint 4 ppm averag baselin 36 ppm success sampl 4 ppm lower previou sampl goal eighth sampl 4 ppm.meet cut submiss result 3.00 voucher particip conting group particip nonconting group earn voucher base match contin gent counterpart conting submit video independ meet goal particip quantit progress graph particip homepag show person taper goal horizont dash line graph respect sampl number figur 1 addit particip leav sampl goal sampl text box final dai taper dai 7 design quit date abstin induct remaind voucher procedur 21 dai sampl particip conting group judg posit neg sampl 4 ppm consid neg evid continu abstin result increas schedul voucher magnitud conting particip initi voucher 3.00 increas 0.25 addit consecut neg result 5.00 bonu neg sampl result 3.00 voucher 3.25 8.50 fourth 3.75 particip nonconting group earn voucher base match voucher counterpart conting video mission independ abstin end abstin induct phase partic ipant complet treatment accept scale result report raiff jarvi turturici dalleri 2013 thin 21 dai thin phase main treatment phase monitor possibl voucher deliveri decreas week sampl mondai sampl thursdai time 12 00 p.m 12 00 a.m voucher valu simpli continu base previou schedul conting group previou phase particip noncon tingent group earn voucher base match counterpart conting video mission independ abstin counsel support counsel provid person taper phase phone quit dai week 4 person session end ofweek 7 counselor semistructur script base public health servic guidelin fior 756 jess dalleri al 2000 blind group assign ident script phase counselor train licens psychologist follow follow visit schedul complet thin phase 3 6 month complet thin ning phase research assist visit partici pant home particip clinic visit particip provid urin sampl ask report smoke cigarett puff past 7 dai abstin defin 4 ppm urin cotinin 80 ng ml answer smoke past 7 dai urin cotinin assess highli sensit ga chromatographi techniqu cotinin exclud point preval measur particip report nicotin replac e.g patch occur particip 4 week particip 3 6 month conting group particip nonconting group 6 month result main depend variabl studi breath level miss sampl consid er posit figur 2 show individu subject data group phase studi row repres particip posit sampl thin line neg sampl repres thick line miss sampl blank space sampl neg baselin suggest monitor promot smoke abstin taper slightli sampl met 4 ppm cutpoint abstin compar baselin visual analysi suggest higher rate neg sampl treatment phase group compar baselin averag level sd baselin taper abstin induct thin phase conting group 25.4 ppm 17.4 13.9 ppm 12.3 6.8 ppm 11.8 7.7 ppm 13.8 averag co nonconting group 23.5 ppm 12.4 16.3 ppm 11.3 8.0 ppm 7.5 9.3 ppm 9.3 mix effect linear model assess effect group assign treatment phase level respons variabl level ppm fix factor group conting nonconting phase baselin taper absti nenc induct thin group phase interact subject weight ag race gender ftnd score urica score auc model random intercept subject assum order autoregress correl structur phase mix model analysi show signific effect group group phase interac tion indic group statu reliabl com.ibm.drl.hbcp.predictor daili co.howev level vari significantli phase treat ment group model estim level taper phase averag 9.0 ppm lower baselin 0001 95 ci 11.2 6.8 level abstin induc tion 15.6 ppm lower baselin 0001 95 ci 17.8 13.4 level thin 14.5 ppm lower baselin 0001 95 ci 16.7 12.2 averag level thin estim 5.5 ppm lower taper 0001 95 ci 7.7 3.2 level abstin induct 6.6 ppm lower taper 0001 95 ci 8.8 4.4 averag level thin significantli abstin induct 3339 patient demograph variabl includ ed mix model ag weight race gender ftnd urica auc level significantli ftnd margin alli auc group internet base cm smoke cessat 757 averag daili level estim increas 1.80 ppm addit point ftnd score 95 ci 0.501 3.090 0072 level estim decreas 1.02 ppm addit increas 0.1 auc 95 ci 2.111 0.713 0685 conting dichotom outcom smoke abstain assess group differ percentag abstin treatment abstin induct thin phase combin figur 3 top show median percentag neg sampl group shade bar percentag neg sampl particip fill circl median percentag neg sampl nonconting conting group 25 66.7 048 side mann whitnei test figur 3 bot tom show median number dai sustain abstin convent figur 2 smoke statu assess breath particip studi phase line repres particip neg result thick horizont line posit result thin horizont line miss sampl space miss sampl count posit final point graph result 3 6 month follow visit 758 jess dalleri al top panel median dai sustain abstin nonconting conting group 2.25 5.50 0731 side mann whitnei test adher video submiss protocol high group median percentag submit sampl nonconting conting group 89.5 91.9 addit partici pant return equip monitor laptop webcam high rate laptop collect monitor return total maximum earn 530.00 continu smoke abstin averag amount earn conting group 245.70 particip yoke samemagnitud earn receiv individu nonconting group 223.88 3 month follow 18 particip conting group abstin 7.7 nonconting group abstin base definit abstin 6 month follow 8 conting group abstin 15.8 nonconting group abstin x2 test differ statist signific particip lost follow consid posit smoke blank space figur 3 3 6 month time point note figur 3 show data abstin defin point preval definit note discuss present studi suggest internet base conting manag promot higher rate neg sampl treatment rel group voucher deliv level stoop al 2009 sampl 67 neg smoke conting group 25 neg nonconting group differ relat group differ adher video base sampl procedur group provid equival high rate mission otiv8 system main procedur differ group conting abstin group receiv ident instruct goal feedback base smoke statu conting nonconting 0 20 40 60 80 100 conting nonconting 0 5 10 15 20 ed ia er ce nt ag iv pl es ed ia ta ed bs tin en ce ay group figur 3 top panel show median percentag neg sampl submit abstin induct thin phase individu dot repres percentag neg sampl submit individu particip bottom panel show median number dai consecut abstin abstin induct phase individu dot repres number dai sustain abstin particip internet base cm smoke cessat 759 differ percentag neg co group treatment signific differ sustain abstin treat ment figur 3 signific differ group absolut level neverth level decreas substanti group rel baselin figur 2 show baselin condit monitor virtual particip continu smoke meaning number particip group achiev sustain period abstin treatment result suggest factor conting abstin influenc smoke specul behavior chang due frequent monitor daili goal base instruct reduc auto mate feedback graph progress figur 1 implicit social conting abstin combin factor studi nonconting comparison group includ factor e.g higgin wong badger ogden dantona 2000 silverman al 1998 particu larli frequent monitor feed back quantit graph goal particip studi found featur help promot abstin report raiff al 2013 procedur nonconting comparison group entail number activ ingredi promot behavior chang addit adher video submiss protocol high group suggest monetari consequ conting plai role promot abstin extent monetari consequ increas engag monitor feedback goal set procedur increas abstin monetari consequ adventiti reinforc abstin cf schroeder gupman epstein umbricht preston 2003 pattern result suggest conting base abstin se import factor oper gener neg co find group differ neg co parallel group mean differ enc absolut level point preval measur follow consist stoop al 2009 studi find suggest frequent monitor internet captur smoke abstin record fals neg desir character smoke statu fulli biochemi cal measur salivari cotinin studi futur research internet base method obtain salivari cotin in result process obtain salivari cotinin rapid afford nanomateri electrochem biosensor develop e.g nian al 2012 cotinin combin earli treatment initi abstin salivari cotinin mainten higgin colleagu person conting manag procedur preg nant smoker e.g higgin al 2004 combin procedur optim chanc detect reinforc earli abstin cotinin longer half life 20 hr compar higher rate delai discount i. auc margin smoke statu treatment consider interest relat discount smoke statu e.g dalleri raiff 2007 koffarnu jarmolowicz mueller bickel 2013 yoon al 2007 discount ing tailor treatment stanger budnei bickel 2012 weak associ present studi suggest delai discount limit com.ibm.drl.hbcp.util condit 760 jess dalleri al contrast measur nicotin depend ftnd significantli level studi dalleri al 2007 kozlowski porter orlean pope 1994 measur nicotin depen denc tailor conting manag incorpor addit inter vention grai al 2011 await research present studi includ taper shape period abstin induct condit studi similar procedur initi abstin gradual hard treat smoker lamb kirbi morral galbicka iguchi 2010 lamb morral kirbi iguchi galbicka 2004 heavi smoker dalleri al 2007 unclear shape improv cessat outcom rel abrupt transit abstin research cocain depend individu shape procedur found meaning differ abstin particip expos shape expos correia sigmon silverman bigelow stitzer 2005 context smoke cessat studi suggest shape enhanc outcom rel abrupt transit abstin hard treat smoker lamb al 2010 plausibl frequent assess smoke rel cocain daili time week enhanc effect shape popul base measur procedur detect small smoke reinforc shortli occur correia al 2005 lamb al 2010 studi differ respect differ success result factor durat shape period particular shape schedul emploi lack group differ point preval follow surpris absolut level durat sustain abstin significantli differ group treatment factor respect enhanc maintain treatment gain consid durat current treatment period 7 week short durat shorter conting manag intervent target drug abus higgin al 2000 silverman higgin brooner montoya 1996 shorter psychosoci pharmacolog intervent target cigarett smok ing fior 2000 treatment durat relat effect abstin conting manag ongo lussier heil mongeon badger higgin 2006 longer durat translat greater long term mainten magnitud voucher earn low gener high sustain rate abstin treatment higher earn greater long term success rate petri roll 2011 counsel session 3 week thin period voucher weekli abstin intervent includ explicit procedur maintain abstin prevent relaps interven tion remov futur research investig potenti intermitt sched ul maintain abstin long durat month desir includ random schedul monitor prevent possibl time smoke provid measur period abstin predict schedul monitor present studi addit method enhanc treatment gain consid combin internet base conting manag pharmacotherapi cognit behavior ther com.ibm.drl.hbcp.api carrol rounsavil 2007 cavallo al 2007 fior 2000 krishnan sarin al 2006 addit meredith grabinski internet base cm smoke cessat 761 dalleri 2011 develop group conting model small group smoker work team initi abstin earn voucher commun member enabl discuss board integr otiv8 architectur group contin genci model sustain voucher withdrawn permit low cost method maintain social conting abstin present studi add grow literatur internet base method promot smoke cessat dispar exist access internet base health care evid access gap reduc internet base method mcdaniel stratton 2006 video enabl mobil phone emploi futur version intervent narrow access gap hertzberg al press advent lower cost method detect smoke schepi al 2008 method fund conting manag intervent amass kamien 2008 dalleri al 2008 internet base conting manag increasingli practic scalabl method inform technolog continu mitig barrier evid base behavior treatment promot smoke cessat healthi lifestyl choic
full term condit access found http www.tandfonline.com action journalinform journalcod isum20 download nh educ scotland date 14 decemb 2015 04 12 substanc misus issn 1082 6084 print 1532 2491 onlin journal homepag http www.tandfonline.com loi isum20 random trial mind train smoker target disadvantag popul jame davi simon goldberg maggi anderson alison manlei steven smith timothi baker cite articl jame davi simon goldberg maggi anderson alison manlei steven smith timothi baker 2014 random trial mind train smoker target disadvantag popul substanc misus 49 5 571 585 link articl http dx.doi.org 10.3109 10826084.2013.770025 publish onlin 11 mar 2014 submit articl journal articl view 156 view relat articl view crossmark data http www.tandfonline.com action journalinform journalcod isum20 http www.tandfonline.com loi isum20 http dx.doi.org 10.3109 10826084.2013.770025 http www.tandfonline.com action authorsubmiss journalcod isum20 page instruct http www.tandfonline.com action authorsubmiss journalcod isum20 page instruct http www.tandfonline.com doi mlt 10.3109 10826084.2013.770025 http www.tandfonline.com doi mlt 10.3109 10826084.2013.770025 http crossmark.crossref.org dialog doi 10.3109 10826084.2013.770025 domain pdf date_stamp 2014 03 11 http crossmark.crossref.org dialog doi 10.3109 10826084.2013.770025 domain pdf date_stamp 2014 03 11 substanc misus 49 571 585 2014 copyright 2014 informa healthcar usa issn 1082 6084 print 1532 2491 onlin doi 10.3109 10826084.2013.770025 origin articl random trial mind train smoker target disadvantag popul jame davis1 simon goldberg2 maggi anderson1 alison manley1 steven smith1 timothi baker1 1center tobacco research intervent univers wisconsin madison school medicin public health madison wisconsin usa 2depart counsel psycholog univers wisconsin madison madison wisconsin usa report result random trial compar smoke cessat treatment mind train ing smoker mt usual care therapi con trol includ avail tobacco quit line nicotin patch data collect 196 low socioeconom statu smoker 2010 2011 madison wisconsin particip random mt telephon quit line primari outcom 6 month smoke abstin measur carbon monoxid breath test time line follow back treatment initi random particip particip intervent ab stinenc rate significantli mt 38.7 control 20.6 05 group studi limit discuss result suggest studi warrant keyword smoke tobacco mind medit altern disadvantag introduct smoke long recogn major public health concern nation depart health educ welfar 1964 internation world health organ 2002 decad basic research treatment develop smoke remain greatest prevent death unit state center diseas control prevent 2008 decad research made signific progress identifi effect phar macolog treatment tobacco addict m.c fior al 2008 stead perera bullen mant lancast 2008 convers innov behavior smoke cessat therapi develop fund provid nation institut drug abus nida grant k23da022471 address correspond jame davi md center tobacco research intervent univers wisconsin madison school medicin public health 1930 monro street madison wi 53711 mail jjamesdavi hotmail.com late 1980 niaura abram 2002 piasecki fior mccarthi baker 2002 schwartz 1987 shiffman 1993 except motiv interview lai cahil qin tang 2010 accept commit therapi gifford al 2004 gifford al 2011 behavior smoke cessat treatment modali ti enjoi greatest clinic popular empir support remain todai 20 year ago skill train intratreat social support fior al 2008 research develop smoke cessat therapi todai benefit compel evid causal substrat smoke laps includ emot regul chamber gullon allen 2009 johnson farri schmidt zvolenski 2012 attent control moor malinowski 2009 water al 2003 find suggest therapi improv emot regul attent control benefit smoker attempt cessat public mind increas rapidli number decad brown ryan creswel 2007 grow num ber studi show mind base therapi diminish neg affect state grossman niemann schmidt walach 2004 addition ma teasdal 2004 found mind base cognit therapi effect reduc depress laps rate comparedwith control receiv treatment usual studi decad shown mind train program improv emot regul report biophi iolog neuroimag studi farb anderson se gal 2012 hill updegraff 2012 hofmann sawyer witt 2010 mar abbei 2010 studi emploi test mind train therapi includ mind base stress reduct 571 ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 572 davi al mbsr kabat zinn 1994 dialect behavior ther com.ibm.drl.hbcp.api linehan 1993 accept commit ther com.ibm.drl.hbcp.api hay al 2004 mind base cog nitiv therapi teasdal segal william 1995 addit cognit neurosci research demon strate train mind increas tention control increas activ attent neural network brefczynski lewi lutz schaefer levinson davidson 2007 lutz al 2009 slagter lutz greischar nieuwenhui davidson 2009 recent function imag studi found mind ful attent decreas report crave smoker decreas activ brain region associatedwith crave westbrook al 2011 note studi provid singl mind train session effect extend mul tisess mind program yield find ing find suggest addit search mind base intervent smoker warrant research benefit test emot regul attent control mind train enjoi consider recent scientif enquiri research mind base intervent smoker limit pilot studi mbsr modif smoker yield biochem confirm point preval abstin 6 week post cessat 56 demonstr correla tion practic time abstin davi flem ing bonu baker 2007 conclus studi limit due sampl size 18 lack control group studi mind skill call urg surf test col lege student show subsequ decreas smok ing 7 dai period compar control ceiv nomind instruct simpli ask techniqu natur cope urg bowen marlatt 2009 recent random trial 88 mind intervent compar match control american lung associ freedom smoke demonstr sig nificantli higher biochem confirm point preva lenc abstin 17 week follow brewer al 2011 gifford al show accept base ther com.ibm.drl.hbcp.api act incorpor mind train bupropion found effect bupropion smoke cessat 2011 evid pro vide initi studi mind smoke limit small number studi small sam ple size emploi divers program test present remain uncertainti efficaci mind intervent smoker mecha nism mind train impact smoke cessat method provid mind train optim accept adher enc smoker import consider develop mind base therapi smoker smoker substant differ popul choos class mind 20 year smoke increasingli problem low socioeconom statu se individu hiscock bauld amo fidler munafo 2012 law whitman bowser krech 2002 stoddard johnson bolei cruz sussman 1997 28.9 poverti smoke compar 18.3 poverti center di eas control prevent 2011 present 25.1 high school nongradu smoke compar 9.9 percent colleg degre center di eas control prevent 2011 shown research gener enrol low se pop ulat possibl due high rate trition matthew chatfield brayn 2006 nevid javier moulton 1996 recent studi shown low se addict popul moder complianc mind train program urban commu niti bowen al 2006 therapeut communi ti substanc abus garland al 2010 garland schwarz kelli whitt howard 2012 complianc attrit issu disadvantag smok er smoke highest rate continu consider research develop ther com.ibm.drl.hbcp.api ideal mind base therapi smoker smoker larg disadvantag smoker current trial develop seri program develop studi compar smoke cessa tion rate mt usual care therapi moder low se popul studywa intention design compar higher intens intervent mt lower intens usual care intervent telephon quit line order answer function question mt intervent effect kind programsmost commonli inmanymed facil current studi design test mt usual care intervent match con trol design experiment isol mind ness therapeut agent make compel conclu sion mechan primari aim studi test treatment accept ofmt low se smoker class attend medit time mea sure time line follow back tlfb compar mt usual care treatment rate smoke ce sation measur 7 dai point preval abstin tlfb 4 24 week post quit attempt explor mediat effect mind interven tion report measur primari outcom variabl defin biolog confirm 7 dai point preva lenc abstin 4 24 week post quit attempt method studi recruit subject recruit advertis televis newspap flyer madison dane counti area ad placement low se neighbor hood print televis advertis displai headlin quit smoke studi larg print studi ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 mind train smoker 573 mind smoker smaller print approach intent recruit sampl popul princip want quit smoke oppos princip interest learn mind phone screen clusion exclus criteria requir caller 18 year ag smoke cigarett dai tobacco product claim high motiv quit state willing attend 10meet 2 month period pilot research mt sug gest high attrit heavi drinker particip exclud consum alco holic drink night week caller met phone base inclus exclus criteria invit orient visit final exclusionari test suicid major depress perform patient health questionnair phq 9 kroenk spitzer william 2001 score statement suicid intent exclud individu studi trigger referr medic practition screen emploi exclud particip homeless psychiatr disord comorbid drug potenti particip attend studi orient meet arm studi blind particip work odd hour transport issu temporari hou ing declin partic ipat prior random make mt schedul consent individu ask plete baselin assess visit carbon monoxid breath test report measur undergo random random draw control group quit line 4 week nicotin replac therapi nrt mt mt 4 week nrt final particip ask make 5 minut observ inform intak call wisconsin tobacco quit line complet call particip includ design promot feel procedur uniform particip studi center control particip instruct make appoint call quit coach dai quit coach smoke cessat therapi mt particip hand instruct mt smoke cessat therapi control consid treatment initi call quit coach made time trip studi center pick nicotin patch mt particip consid treatment initi made time trip arriv mt class intervent current studi design test intervent mind train smoker mt mod erat low se popul mt design meet low se smoker provid instruct video simpl languag read understand abstract concept mind train addit mind train mt integr wide test therapeut modal includ medic skill train group support program develop mt emploi nation institut health nih endors research method stage 1 behav ioral therapi program develop rounsavil carrol onken 2001 target outcom establish stabl effect size identifi potenti outcom medi ator collect data accept adher guid intervent develop futur research mt design structur similar establish mbsr program kabat zinn 1994 consist 7 week weekli class provid instruct mind mt similar intens mind base train program multipl weekli meet defin intens smoke cessat therapi depart health human servic treat bacco depend clinic practic guidelin fior bailei cohen 2000 mt instruct gener mind ful practic medit mind walk mind eat target train appli mind smoke relaps determi nant smoke trigger strong emot addic tive thought urg withdraw symptom develop ment mt iter trial davi al 2007 davi al unpublish data provid feedback low se smoker typic join anmt intervent prin cipal quit smoke interest learn practic medit mind reason addition low se smoker typic read manual express frustrat ab stract instruct subtl conceptu distinct period year mt adapt popul mind instruct clear goal smoke cessat deliv essen tial instruct instruct dvd present com.ibm.drl.hbcp.core skill train concret exercis everydai exampl quit line control intervent control receiv smoke cessat counsel wisconsin tobacco quit line run aler amer ica largest telephon smoke cessat corpor control encourag make repeat call quit line assign quit dai weekend approx imat 2 week orient ask return studi center pick 4 week 21 mg nicotin patch data quit line collect assess visit follow phone survei mt intervent mt taught instructor formal addict train success complet 2 dai mt instructor train train provid instruct mt instruct dvd manual teachmind skill target smoke laps challeng mt schedul tabl 1 gan 7 hour introductori class ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 574 davi al tabl 1 schedul activ mt particip week hour activ 1 sun 7 class 1 skill train mind medit walk talk listen 1 wed 3 class 2 mind trigger automat behavior medit group 2 wed 3 class 3 mind emot stress situat medit group 3 wed 3 class 4 mind urg withdraw symptom medit group 4 wed 3 class 5 mind addict thought eat medit group 5 sun 7 class 6 mt quit dai retreat weekend start 4 week patch 5 wed 1.5 medit group 6 wed 1.5 medit group 7 wed 1.5 medit group 8 wed 1.5 medit group note mt class incorpor instruct video progress skill train mind instructor quit dai retreat dai abstin 7 hour silent retreat instructor guid mind practic medit group run class mt facilit open previou class member class group includ 30 minut guid medit 30minut ofmind talk listen amind skill share pai close attent comment advic themedit groupwa integr program provid long term safe intim group support andmotiv support daili medit practic weekdai class 90minut instruct class instructor plai 15 20 minut mt instruct dvd instruct provid addict expert mind instructor physician past particip mt instruct dvd pro vide basic instruct mind practic medit mind walk mind talk li tene target mind skill mind ful manag smoke trigger urg withdraw symptom addict thought neg emot plai section dvd mt instruc tor approxim hour provid sonal instruct answer question conduct exer cise dvd 90 minut weekli class hour long meet medit group long term support group open current past mt particip themedit group consist 30 minut guid medit 30 minut support group practic call mind talk listen themt intervent particip ask prac tice 30 minut guid medit dai home 30 minut guid medit cd cd pro vide guidanc mind skill specif target manag relaps challeng includ exercis attent physic sensat mind emot mind thought particip receiv copi mt manual devel op provid expand version concept exercis provid dvd particip pro vide access materi mt web site www.sittoquit.com 4 week class partici pant attend quit dai retreat attempt smoke cessat initi 4 week 21 mg nico tine patch quit dai retreat compris 7 hour instructor guid mind practic con duct silenc includ quit dai retreat medit group total 24 hour class time quit dai retreat graduat par ticip invit continu attend medit group addit 4 week return group support time particip complet intervent remain abstin 4 week en courag advoc advoc return class sporad provid encourag particip summari mt compris kei element tradit mind train taught mbsr kabat zinn 1994 provid mind train ing target specif relaps challeng provid integr nicotin replac therapi long term group support smoke assess visit smoke abstin questionnair data col lect assess visit baselin 4 week 24 week post smoke cessat 4 24 week particip assign quit date particip paid 30 attend 4 week post quit assess visit 60 attend 24 week post quit assess visit smoke statu primari studi 7 dai point preval abstin 4 24 week schedul quit dai confirm breath test tlfb contemporari stringent cutoff 7 ppm 10 ppm defin abstin minim possibl fals posit outcom middleton moric 2000 continu abstin measur order pro vide greater breadth understand smoke havior 24 week studi assess tlfb monitor tlfb cover long pe riod consid reliabl account partic ipant defin continu abstin 24 week met tlfb criteria state smoke quit dai fi nalli emploi recent develop measur smoke abstin number dai smoke 2 week post quit measur correl close 24 week abstin continu variabl ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 mind train smoker 575 greater statist power correl continu report measur baker al 2011 questionnair measur report measur obtain time point intervent 1 medita tion calendar mt particip record daili minut medit intervent 1 month quit dai 2 demograph smoke histori questionnair administ particip baselin 3 fagerstrom test nicotin depend ftnd α 0.61 heatherton kozlowski frecker fagerstrom 1991 complet baselin 4 wisconsin inventori smoke depend motiv wisdm α 0.69 smith al 2010 complet baselin 5 mt evalu administ quit dai design mt particip provid feedback experi intervent 6 difficulti emot regul scale der α 0.93 gratz roemer 2004 complet assess visit 7 attent control scale ac α 0.88 derryberri reed 2002 measur abil direct maintain attent complet assess visit 8 facet mind questionnair ffmq baer smith hopkin kriet meyer tonei 2006 α subscal 0.75 0.91 baer al 2008 lykin baer 2009 provid assess visit assess acquisit mind skill particip ffmq 39 item compos subscal observ involv notic intern extern experi describ involv la bele experi word act awar involv attend moment moment activ nonjudg experi refer make make neg assess thought feel nonreact exp rienc involv allow thought feel persever baer al 2008 subscal analyz individu ffmq composit score brewer al 2009 lykin baer 2009 assess instructor fidel materi minim materi standard instruct dvd provid com.ibm.drl.hbcp.core conceptu materi class miss data manag data analysi manag miss data recommend method schlomer bauman card 2010 depend ing data miss complet random mcar miss complet random nmar determin point preval abstin outcom adher intent treat nmar principl failur attend 4 24 week post quit assess ment visit result code particip relaps visit data analyz repeat report mea sure time group interact analyz port complet analysi exclud particip miss 4 24 week post quit assess vi analysi miss data conduct spss 19 report measur visit complet determin scale contain 2 miss data data miss primarili due particip error item left blank paper survei classifi mcar 5 cutoff consid problem atic schafer 1999 effort imput miss data made independ group test chi squar test conduct compar baselin characterist group chi squar test perform alyz group differ dichotom outcom e.g point preval abstin attrit logist regress comput odd ratio estim confi denc interv ci pearson correl comput identifi associ secondari outcom mea sure continu smoke outcom mix anali se covari ancova comput identifi time group interact report measur cova control abstin statu due po sibil abstin bia rate report measur ancova test met homogen iti regress slope assumpt relev baselin dif ferenc group covari analys appli bonferonni correct test secondari outcom tabl 4 5 control possibl increas type decis error occur multipl test result recruit recruit effort 12 month led 943 caller 730 reach phone screen declin exclus phone screen orient session 196 particip random mt partici pant 105 control 91 118 particip initi treatment 59 mt particip 59 control figur 1 recruit flyer low se neigh borhood effect instrument obtain random particip demograph studi particip reflect moder low se subpopul madison recruit area analysi baselin data random particip show mean ag 41.65 year sd 13.29 50 male 50 femal tabl 2 half particip educ high school statist signific baselin differ mt particip control regard ag gender race ethnic year smoke cigarett dai previou quit attempt sampl distribut contain high percentag smoker african american low educ level compar volunt popul typic recruit smoke studi madison wisconsin area univers wisconsin madison center tobacco research intervent uw ctri unpublish data signific baselin differ mt ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 576 davi al assess elig 730 declin screen 174 19 madison area 97 studi fit schedul 8 studi pai 3 mind group 10 quit line group 11 quit 6 nicotin patch 20 cite reason total declin add 174 particip declin reason random 196 mt intervent 105 53.6 ll oc io nr ol lm en control intervent 91 46.4 ol lo 4 wk assess visit 44 41.9 4 wk assess visit 60 65.9 na ly si intent treat 105 treatment initi 59 intent treat 91 treatment initi 59 exclud screen 126 12 smoke 5 cig dai 53 consum alcohol 12 form tobacco 37 motiv quit 43 unabl attend class 1 ag 18 total exclus add 126 particip exclud reason exclud orient 27 9 due depress phq 18 due schedul conflict schedul orient 430 initi treatment 59 56.2 initi treatment 59 64.8 24 wk assess visit 23 21.9 24 wk assess visit 32 35.2 attend orient 207 figur 1 consort diagram particip control treatment initi 118 baselin differ observ mt group contain heavier smoker 130 2.08 039 racial ethnic minor χ2 1 130 5.32 02 larger proport particip post high school educ χ2 1 130 4.17 041 attrit preintervent attrit rate dropout immedi random 43 mt particip 37.2 control 22 commonli report reason preintervent attrit group lack phone imperman hous transport issu commonli report reason preintervent attrit mt schedul conflict control desir mt analys conduct identifi baselin particip characterist predict preinterven tion attrit includ ag gender educ level cigarett smoke dai number prior quit attempt ftnd repeat report measur der ac ffmq preintervent attrit predict mt particip fewer number cigarett smoke dai 0.28 001 higher educ level 3.52 01 control greater number cigarett smoke dai 0.25 02 higher ftnd score 0.36 001 indic higher level addict appear predict stai mt drop control baselin characterist signific com.ibm.drl.hbcp.predictor preintervent attrit baselin characterist predict intraintervent attrit treatment accept treatment accept control treatment initi determin part report call quit ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 mind train smoker 577 tabl 2 particip baselin characterist total sd baselin characterist 196 gender male 50 femal 50 race american indian 2.04 asian 0.00 african american 11.73 latino 1.53 white 77.04 1.53 unknown 6.12 ethnic hispan 1.53 educ high school 49.49 high school 45.41 unknown 5.10 ag 41.65 13.92 number cigarett dai 15.75 8.64 number year smoke 22.34 13.11 number quit attempt 6.51 11.39 recruit materi english target english speak popul unknown data case due error fill data packet line mean number report call particip home quit coach treatment period 1.71 sd 1.89 rang 1 10 call comparison call wisconsin resid wiscon sin tobacco quit line wtql time period 1.2 call caller unpublish wtql data 2012 indic accept thewtql control signific differ attrit studi visit group treatment accept mt inter vention starter determin class attend inter vention complet medit time evalu content materi class attend defin particip sign daili attend sheet class complet defin attend quit dai retreat mean number class attend 4.7 78.8 sd 1.57 tervent complet 74.6 sd 0.44 pletion defin attend quit dai retreat common reason provid miss class clude schedul conflict ill weather de termin particip commun instructor mean minut dai medit mt 21.6 sd 11.15 30 minut request vast major particip report guid medit cd portion 13.6 graduat decid mt advoc return regularli intent help group advoc 100 maintain abstin 6 month complet cours advoc present class evalu patch post treatment veal 78.8 particip patch 4 week 21.2 patch stop dai start report medica tion reaction signific differ ab stinenc 4 24week patch versu twenti particip port addit medic studi request margin significantli lower abstin rate protocol 24 evalu evalu provid studi visit complet clude numer likert scale open end writ ten respons particip rate aspect mt effect aspect teach mind ness help quit smoke likert scale 0 3 0 1 2 moder amount 3 lot particip provid mean spons mt class teach mind 2.85 sd 0.36 mt class help particip quit smoke 2.80 sd 0.41 quit dai retreat teach ing mind 2.78 sd 0.48 quit dai retreat help quit smoke 2.73 sd 0.55 support group remain abstin 2.48 sd 0.79 written qualit feedback effect mt result respons posi tive includ help awar emot desir pass made awar smoke made feel mind help lesson anxieti worri futur situat help act integr react abstin rate primari outcomemeasur studi 7 dai point preva lenc abstin 4 24 week post quit reach statist signific intent treat analysi reach statist signific compar treat ment initi 4 week mt particip 45.8 control 25.4 24 week mt particip 38.7 control 20.6 2.33 05 tabl 3 figur 2 3 continu abstin rate signific group treatment initi tabl 3 group treatment initi analysi differ baselin educ cigarett smoke dai analys provid adjust or control fac tor adjust chang signifi canc statu analysi repeat report measur mix effect ancova conduct assess group time interact time point baselin 4 week 24 week post quit particip respons der ac ffmq composit measur subscal ancova control abstin statu possibl smoke abstin affect report rate ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 578 davi al tabl 3 abstin rate mt versu control 4 24 week intent treat analysi 196 mt control odd ratio ci odd ratioa ci valuea 4 week point preval 25.7 17.6 1.62 81 3.25 17 1.41 0.68 2.91 35 24 week point preval 22.7 14.5 1.68 80 3.55 17 1.56 0.72 3.38 26 4 week continu 21.9 11.0 2.27 1.02 5.07 05 2.00 0.88 4.54 10 24 week continu 10.5 5.5 2.01 67 6.03 21 1.71 0.56 5.24 35 treatment initi analysi 118 mt control odd ratio ci odd ratioa ci valuea 4 week point preval 45.8 25.4 2.48 1.14 5.39 02 2.43 1.04 5.64 04 24 week point preval 38.7 20.6 2.33 1.02 5.31 05 2.86 1.11 7.35 03 4 week continu 39.0 15.3 3.55 1.47 8.57 01 3.32 1.31 8.41 01 24 week continu 18.6 6.8 3.15 0.94 10.55 06 2.92 0.80 10.58 10 note intent treat mt 105 control 91 treatment initi analysi mt 59 control 59 point preval abstin 7 ppm cigarett 7 dai tlfb continu abstin 7 ppm cigarett tlfb statement cigarett quit dai odd ratio ci logist regress exponenti coeffici calcul odd ratio 95 confid interv ci odd ratioa adjust odd ratio control race educ level cigarett smoke dai figur 2 analysi 7 dai point preval abstin 4 24 week post quit treatment initi valu reflect test time group effect figur 3 intent treat analysi 7 dai point preval abstin 4 24 week post quit valu reflect test time group effect ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 mind train smoker 579 ta 4 na ly si ha ng se lf ep tm ea su ve im gr ou 38 tr ol gr ou 43 od el ef fe ct ea su el ea 4 ee ea 24 ee ea el ea 4 ee ea 24 ee ea ro ta ti tic si gn im ta ti tic si gn im gr ou ta ti tic ig fic ul ty ith ot io ul io sc al 2 18 0 5 7 1 96 0 5 1 1 90 0 6 3 1 95 0 5 0 2 00 0 5 3 1 98 0 5 6 1 7 8 0 41 5 2 2 7 8 4 89 0 1 2 7 8 5 65 0 01 tte nt io na lc tr ol sc al 2 52 0 3 7 2 76 0 4 2 2 76 0 4 1 2 77 0 3 6 2 78 0 3 9 2 73 0 3 9 1 7 8 0 69 4 1 2 7 8 7 29 0 01 2 7 8 8 4 3 0 01 fi ve ac df ul ne ss ue st io nn ai fm 3 30 0 5 0 3 65 0 5 4 3 62 0 5 8 3 52 0 4 6 3 56 0 5 6 3 49 0 4 5 1 7 8 0 15 7 0 2 7 8 7 34 0 01 2 7 8 10 2 2 0 01 ff su bs ca le ju dg 3 20 0 9 1 3 87 0 7 9 3 62 0 9 0 3 74 0 7 5 3 82 0 7 5 3 54 0 7 3 1 7 8 0 33 5 7 2 7 8 2 55 0 8 2 7 8 7 19 0 01 ff su bs ca le bs er vi ng 3 51 0 7 5 3 68 0 6 5 3 72 0 6 5 3 33 0 7 4 3 15 0 7 2 3 38 0 7 2 1 7 8 5 51 0 2 2 7 8 2 83 0 6 2 7 8 3 52 0 3 ff su bs ca le ac tiv iti 3 15 0 6 1 3 51 0 5 6 3 51 0 6 3 3 31 0 5 8 3 35 0 7 7 3 42 0 6 3 1 7 8 0 09 7 7 2 7 8 7 96 0 01 2 7 8 3 59 0 3 ff su bs ca le es cr ib 3 54 0 8 1 3 69 0 8 7 3 76 0 8 2 3 75 0 9 0 3 77 0 7 2 3 64 0 7 0 1 7 8 0 47 4 9 2 7 8 2 45 0 9 2 7 8 4 57 0 1 ff su bs ca le ct ith aw ar en es 3 08 0 7 9 3 40 0 7 0 3 38 0 6 8 3 54 0 6 6 3 63 0 6 6 3 47 0 6 6 1 7 8 4 58 0 4 2 7 8 3 50 0 3 2 7 8 5 49 0 1 1 ix ed er pu te nt ro lli ng fo ab st en ce st al ys cl ud es pa rt ic ip ts ith da ta fr om al lt hr ee se ss en tv al ue ith te ri sk ar st tic al ly si gn ifi ca nt af te fe rr ic ct io al ue ith ou ta st er ar ts ig ni fic ta ft er fe rr ic ct io ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 580 davi al tabl 5 report data correl minut medit smoke abstin minut meditateda dai smoke post quitb measur 4 week attent control scale 0.01 95 0.20 04 4 week difficulti emot regul scale 0.32 04 0.36 00 4 week facet mind questionnair ffmq composit 0.39 01 0.34 00 4 week ffmq subscal observ 0.26 08 0.31 00 4 week ffmq subscal describ 0.18 24 0.19 06 4 week ffmq subscal act awar 0.39 01 0.20 04 4 week ffmq subscal nonjudg 0.32 0.04 0.21 0.03 4 week ffmq subscal nonreact 0.36 0.02 0.33 0.00 adata report mt group control medit measur minut medit 4 week post quit studi visit bdata report mt control group smoke abstin measur number dai smoke 2 week statist signific remain statist signific bonferroni correct independ sampl test show stati tical signific differ mt particip control baselin report measur tabl 4 mt particip score higher der 2.14 sd 0.57 control 1.99 sd 0.48 intent treat 187 3.02 049 intervent initi mt 2.15 sd 0.58 control 2.02 sd 0.50 115 2.78 19 baselin differ ac intent treat control demonstr higher score 2.77 sd 0.40 thanmt 2.60 sd 0.40 187 3.02 004 treatment initi control 2.76 sd 0.39 mt 2.58 sd 0.39 115 0.80 02 baselin differ ffmq intent treat control score higher 3.51 sd 0.46 mt 3.36 sd 0.51 187 0.58 044 intervent initi control 3.49 sd 0.46 mt 3.31 sd 0.51 115 0.32 044 compar expect direct random mt correl greater emot control greater attent control greater report mind subscal substant occur treatment period correl report measur medit abstin mt particip record number minut medit dai daili calendar bon ferroni correct signific time group omnibu teract found compar mt particip control time point baselin 4 week 24 week der ac ffmq composit measur nonjudg subscal ffmq tabl 4 correl examin baselin post treatment differ score minut medit associ remain expect direct fail reach statist signifi canc bonferroni correct der 0.32 04 ac 0.01 95 ffmq 0.39 01 post test score der ac ffmq subscal correl number dai smoke 2 week shown tabl 5 found sig nific correl bonferroni correct number dai smoke 2 week score der 0.36 00 ffmq observ 0.31 00 ffmq nonreact 0.33 00 subscal discuss studi design answer function que tion mt intervent show reason accept low se smoker determin quit rate mt compar usual care tervent summari relev discuss point studi includ 1 treatment accept abil complianc requir themt program popul encourag reason complet daili medit time starter 2 attrit high attrit group typ ical low se popul data suggest heavier smoker drop mt group drop control group 3 primari outcom point preval abstin 4 24 week post quit attempt reach signific intent treat analysi reach signific analysi treatment initi analysi or show stabl effect size analys 4 potenti chang pro cess mt group compar control group show signific improv report measur emot regul attent control mind ness treatment period post treatment score measur significantli correl medita tion time smoke abstin complianc requir mt pro gram accept treatment initi mean class attend 71 mean complet 74.6 mean medit time 21.6 minut dai improv previou studi conduct mt laboratori mind train fulli target smoke cessat com.ibm.drl.hbcp.core concept provid manual instruct video prior studi particip read manual mean medit ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 mind train smoker 581 time lower davi al unpublish data find suggest present iter mt appear provid improv term approach materi treatment low se popul studi show high preintervent attrit high 24 week post quit assess visit attrit consid import recruit disadvantag smoker studi higher attrit rate antic ipat attrit level studi mind train low se popul includ design studi garland 2010 result 69 complet post intervent assess similarli univers washington group establish work mind ness train alcohol low se popul pro vide mind intervent low se incarcer substanc user experienc high attrit rate 305 enrol 87 month assess pleter research chang primari measur 6 month 3 month studi demonstr attrit rule except studi low se popul addict involv provid ing intens intervent mind train discredit necess develop effect intervent popul simpli provid understand attrit occur studi popul de sign account particip studi drop primarili due issu relat temporari hous disconnect phone lack transport difficulti continu treatment drop high rate evalu secondari reason dropout show strong prefer particip arm studi mt particip pri marili cite schedul conflict reason earli dropout control cite desir mt stai mt heavier smoker higher ftnd drop heav ier smoke predict dropout control suggest indic higher level addict fact pre dict stai intens mt intervent drop intens control intervent observ rais question possibil iti mt valu subpopul smoker greater depend possibl valu depend interest find low educ level deterr tomt particip impor tant conclus attrit data suggest effort made make mt palat low se dividu fact success regard low educ individu attrit data suggest smoker sever addict schedul conflict seek intens therapi standard length mind train program mbsr 8 week length deterr smoker find ing suggest futur research mind base therapi smoker benefit target smoker interest intens therapi sever depend suggest benefici test intens mind intervent suit wider por tion smoke popul creat low intens variant mt dvd counsel session dvd web base format model investiga tion ongo develop program intent treat analysi show point preval abstin 24 week post quit attempt mt particip 22.7 versu control 14.5 1.68 17 analysi treatment initi show abstin mt particip 38.7 versu control 20.6 2.33 05 definit conclus efficaci mt intervent limit small effect size high attrit treatment differ suggest mt intervent lead mean ing increas benefit usual care therapi futur research determin promis abstin rate found treatment initi studi replic attrit cull subject initi particip pool addit inform conduct mt intervent research disadvantag popul yield lower attrit higher abstin rate import consider particip mt intervent daili medit practic led demonstr inmind emot attent skill result suggest mt partici pant report emot regul attent con trol mind improv substanti pletion mt intervent compar control remain elev till 24 week post treatment addit number minut medit mt particip significantli post treatment score measur correl associ suggest acquisit mind ful skill relat amount time partici pant devot medit altern time medita tion simpli amark formotiv whichwould lead higher abstin rate final smoke ab stinenc predict post treatment report mea sure emot regul attent control andmind ful find suggest acquisit mind skill smoker quit smoke princip limit studi design compar mt intens usual care therapi lack time intens match control differ treatment hour treatment effect favor mt condit occur due greater treatment exposur state initi studi design address function question treatment mt compar treatment commonli seri studi studi demonstr reason efficaci effect size mt usual care therapi treatment starter potenti limit particip blind respect intervent blind ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 582 davi al perform due function necess provid particip inform mt schedul enrol ethic prefer al low particip ampl inform intervent prior put time effort smok ing cessat attempt smoker orient session demonstr strong prefer high intens mt low intens quit line interven tion lack blind ethic motiv creat potenti baselin differ particip characterist orient session substan tial effort made provid posit impress control intervent nonetheless resent demor shadish cook campbel 2002 led lower rate abstin control attitud treatment questionnair borkovec nau 1972 provid understand potenti studi effect addition baselin differ report measur mt particip control specif control score higher mt particip measur ac ffmq mt particip score higher der suggest random fail creat group equal measur initi differ mt particip move desir direct measur intervent control remain compar stabl final high attrit studi reduc power generaliz attrit winnow sampl recept mt train artifici increas effect size convers high rate nonattend 4 24 week post quit assess visit figur 1 inappropri suppress abstin report intent treat analys nonattend count relaps relatedli attri tion visit mean success ful motiv particip provid data report measur bias result favor mt con dition studi design test accept di advantag smoker expect attrit rate high attrit rate studi simi lar intervent disadvantag popul frack woodruff candelaria elder 1997 goldad al 2011 matthew al 2006 postel al 2011 zeller al 2004 futur studi mind base smoke intervent benefit term statist power recruit disadvantag popul potenti exclus smoker tempo rari hous cell phone limit mean transport nih endors protocol behavior interven tion develop recommend stage 1 develop studi test emerg therapi estim effect size suggest potenti mediat guid program develop rounsavil al 2001 primari find studi suggest mt compar usual care therapi produc signific increas abstin treatment initi show reason treatment accept disadvantag popul studi suggest mt particip lead emot regul attent control mind increas smoker chanc obtain abstin high attrit popul limit statist power generaliz suggest futur studi mt benefit design fea ture recruit smoker particip intens intervent addit futur studi benefit explor intens form mt palat wider popul hope find design futur studi evalu mind base treatment smoker declar interest dr baker serv investig research project sponsor pharmaceut compani includ ing pfizer glaxo wellcom sanofi nabi biophar maceut dr smith serv past 5 year investig research studi univers wisconsin madison fund wholli part glaxosmithklin pfizer dr davi mr goldberg ms anderson ms manlei conflict inter est declar author respons content write articl author jame davi md physician intern medicin assist professor center tobacco research intervent univers wisconsin madison director merit hospit smoke cessat program univers wisconsin tobacco scholar program dr davi practic medit 20 year medicin 10 year princip interest medit mind medic ill conduct research full time mind smoke cessat guidanc dr timothi baker michael fior richard davidson simon goldberg ba doctor student depart counsel psycholog univers wisconsin madison primari research interest psychotherapi special interest mind base intervent addit research mind addict involv project center investig healthi mind univers wisconsin madison waisman center ow nl oa de du ca tio fo sc ot la 0 4 12 1 4 ec em 20 15 mind train smoker 583 incorpor mind practic public educ conduct research direct dr william hoyt bruce wampold lisa flook richard davidson maggi anderson bs medic student univers wisconsin madison school medicin public health work studi coordin mind train smoker research studi 2010 2011 univers wisconsin madison center tobacco research intervent univers wisconsin madison tobacco scienc scholar supervis dr jame davi alison manlei ba hold bachelor degre psycholog univers wisconsin madison studi coordin mind train smoker laboratori center tobacco research intervent madison wisconsin involv project wisconsin center educ research wisconsin studi famili work research interest mood disord addict cognit process intend practic psychotherapist steven smith ph.d associ professor depart medicin univers wisconsin madison school medicin public health addit clinic investig univers wisconsin madison center tobacco research intervent uw ctri 1992 complet ph.d psycholog 1990 univers wisconsin madison dr smith complet research fellowship nation institut drug abus nida addict research center arc baltimor maryland arc conduct psycholog molecular genet research vulner addict uw ctri dr smith involv numer studi investig behavior medic treatment nicotin depend measur nicotin withdraw depend develop cultur smoke cessat treatment american indian smoker efficaci telephon tobacco quit line addit conduct clinic research dr smith maintain outpati clinic practic licens psychologist timothi baker ph.d professor medicin univers wisconsin madison school medicin public health director research uw ctri incept 1992 dr baker princip investig transciplinari tobacco research tturc grant began 2004 serv senior scientist panel produc public health servic clinic practic guidelin treat tobacco depend 2008 interest motiv factor addict publish multipl paper subject dr baker editor journal abnorm psycholog recipi jame cattel award american psycholog societi glossari mind cognit skill pai close attent moment moment experi encount ing sensat emot thought nonreac tiviti accept mind train smoker smoke ce sation therapi train mind smoker manag relaps challeng includ smok ing trigger urg withdraw symptom stress situat
www.elsevier.com locat pateduc patient educ counsel 63 2006 177 187 effect smoke cessat counsel midwiv dutch pregnant women partner hein de vri martijntj bakker 1 patricia dolan mullen gerard van breukelen depart health educ univers maastricht p.o box 616 6200 md maastricht netherland municip institut public health hagu netherland center health promot prevent research univers texa houston school public health usa depart methodolog statist univers maastricht netherland receiv 14 june 2005 receiv revis form 14 octob 2005 accept 19 octob 2005 abstract object smoke pregnanc import problem netherland test effect health counsel method midwiv rct method provinc 42 practic includ 118 midwiv randomli assign experiment control condit midwiv experiment group provid health counsel materi smoke cessat pregnanc earli postpartum partner booklet control receiv routin care main outcom measur 7 dai abstin continu abstin partner smoke 6 week post intervent t1 6 week postpartum t2 result multi level analysi reveal signific differ condit t1 t2 intent treat analysi nineteen percent experiment group report 7 dai abstin compar 7 control group t1 21 12 t2 continu abstin percentag 12 experiment group 3 control group partner intervent success conclus intervent result signific effect smoke behavior pregnant women partner smoke practic implic program realiz short term effect import precondit midwiv proper train 2005 elsevi ireland right reserv keyword smoke cessat counsel pregnanc spous 1 introduct smoke cessat pregnanc significantli reduc risk growth retard fetal death sudden infant death syndrom problem 1 5 continu abstin postpartum reduc children exposur environment tobacco smoke asso ciat health risk 6,7 sustain abstin postpartum reduc women lifetim risk smoke relat diseas 8 essenti develop program enabl women effect quit smoke author tel 31 43 3882410 fax 31 43 3671032 mail address hein.devri gvo.unimaas.nl de vri 1 time studi m.j bakker emploi depart health educ univers maastricht 0738 3991 front matter 2005 elsevi ireland right reserv doi 10.1016 j.pec 2005.10.002 earli pregnanc reduc high relaps rate occur month post deliveri 9 11 studi smoke cessat pregnant women show mix result effect rang 2 20 12 prenat smoke cessat trial deliv intervent usual prenat care practition 10,13,14 favor result found interven tion deliv specif train health care profe sional deliveri routin care success 15 19 intervent effect implement routin antenat care due difficulti midwiv experi implement intervent intend 15,18 effec tive studi need test program result signific effect test real life de vri al patient educ counsel 63 2006 177 187178 context program realiz public health dutch pilot studi suggest pregnant women smoke pregnanc inform advantag smoke babi inform increas efficaci quit partner support 20 studi reveal implement program feasibl 21 review smoke pregnant women suggest includ partner smoke program smoke statu partner chief com.ibm.drl.hbcp.predictor postpartum relaps 10,13 previou studi netherland test effec tive health counsel protocol group smoker 22 24 strategi refer minim intervent strategi mi mi base chang model previous refer attitud social influenc efficaci model 25 27 int grate insight social cognit model 28 30 model distinguish motiv chang phase pre motiv phase peopl awar health problem phase knowledg risk percept cue prompt peopl awar import determin motiv phase peopl motiv chang behavior phase attitud social influenc percept efficaci expect import post motiv phase peopl translat intent action preparatori action plan need aim studi adapt evalu mi smoke cessat protocol pregnant women partner hypothes women experiment condit quit smoke pregnanc remain smoke free deliveri stimul awar posit attitud efficaci develop action plan quit provid inform smoke cessat partner hypothes significantli partner experiment condit control condit give smoke 2 analysi account nest patient practic assum random practic cluster varianc 0.37 impli intraclass correl 0.10 2 method 2.1 studi design studi pre test post test random control group design pre test post test 6 week post intervent t1 6 week postpartum t2 women nest midwif practic practic nest provinc provinc unit random experiment control condit random practic plan turn imposs practic provinc share personnel women experiment condit receiv intervent consist video manual partner booklet smoke health counsel midwiv women control condit receiv usual care gener folder dutch smoke health foundat specif counsel 2.2 particip power analysi run identifi respond need studi find signific differ 15 smoke cessat rate condit analysi power 0.80 0.05 tail base estim quit rate 20 experiment condit versu 5 control condit reveal 38 practic 8 patient condit need result total 304 respond 31 sampl consist 318 patient 42 practic 21 condit 2 2.3 procedur approach 62 chair provinci network midwif practic receiv letter inform brochur project 15 chair 24.2 provinci network agre particip repres 60 practic 157 midwiv reason refus includ time constraint particip studi midwif smoker midwif pregnant forti practic 118 midwiv randomli select repres netherland regard geograph distribut east west level urbaniza tion provinc match locat level urban provinc result pair assign experiment control group condit throw dice fig 1 2.4 identif pregnant smoker women elig studi pregnant assum women smoke pregnanc chang smoke behavior speak understand dutch smoke cigarett dai time recruit approxim 12 week gestat women includ studi februari 1996 decemb 1996 particip midwiv ask client smoke consult client report smoke ask particip studi smoke health inform studi requir de vri al patient educ counsel 63 2006 177 187 179 fig 1 flow particip dropout rate reason dropout 1n dropout unreach express interest count smoker includ possibl urin test cotinin product nicotin recommend collect 13 woman consent studi complet baselin questionnair 2.5 intervent develop intervent guid program matrix base mcguir 32,33 persuas de vri al patient educ counsel 63 2006 177 187180 commun model step inform process strategi messag sourc method develop fig 2 detail video guid post deliveri booklet develop women video direct rais awar consequ smoke pregnanc import women previou studi reveal motiv quit 20 pilot test show video attract women contempl contempl quit guid stage match base smoke cessat guid gener practi tioner 23,24 guid adapt pregnant women addit pregnanc relat specif informa tion illustr increas women awar danger relaps deliveri booklet written posit effect remain smoke free post deliveri consequ environment tobacco smoke young children pregnant women motiv stop smoke encount difficulti quit presenc smoke partner 34 booklet made smoke partner fig 2 health communica booklet outlin import commit father pregnanc explain quit make substanti differ health babi health father mother provid suggest quit smoke 2.6 health counsel mi protocol experiment condit health counsel mi protocol base protocol earlier studi 22,24 consist step step 1 midwiv identifi smoke behavior woman partner number cigarett smoke dai motiv quit assess order classifi stage chang 30 women want quit smoke 30 dai identifi prepar women want quit smoke pregnanc 30 dai identifi contempl women quit smoke identifi precontempl step 2 midwif attempt enhanc motiv quit precontempl contempl provid tion persuas matrix pal highlight 26 inform social environment consequ link 26 awar pal highlight 26 inform social environment consequ link 26 awar pal highlight 18 social support practic pal highlight 24 inform health consequ pal sticki note 24 inform health consequ pal sticki note 26 inform social environment consequ pal sticki note 17 social support unspecifi pal sticki note 2 problem solv 4 action plan pal sticki note 41 behaviour practic rehears pal sticki note 2 problem solv pal sticki note link 26 attitud pal sticki note link 2 4 efficaci pal sticki note link 17 social influenc pal sticki note 67 restructur social env de vri al patient educ counsel 63 2006 177 187 181 inform short term advantag smoke step 3 relev women prepar stage midwif discuss barrier success quit mobil social support quit step 4 address goal set set action plan women prepar agre quit date regist midwif women invit contact 8 month pregnanc order discuss motiv quit smoke women wish quit relaps prevent women set quit date step 5 addit materi tailor motiv stage provid women stimul women read advantag quit women unmotiv immedi quit smoke develop action plan quit cope potenti problem women motiv quit smoke midwiv request invit women read booklet watch video step 6 address women prefer aftercar e.g telephon contact consulta tion initi woman step 7 8 month gestat midwif hand booklet smoke post deliveri smoker quit statu consequ passiv smoke young children discuss quitter invit make commit remain smoker 2.7 materi train midwiv pregnant women receiv prenat care dutch midwif visit midwif regular basi approxim 12 week gestat 6 week deliveri midwiv client 4 week month pregnanc experiment group midwiv talk client smoke schedul contact approxim 3 month pregnant 8 month regularli schedul consult manual intervent card step protocol facilit effect counsel develop midwiv experiment condit intervent card design midwiv record progress commit client midwiv dedic approxi mate 10 min consult cessat counsel 21,35 offer 3 train address topic smoke smoke cessat client 21 train base earlier work mi protocol 22 24 2.8 questionnair questionnair base previou work smoke cessat pregnant women 20 data present paper deriv measur ment written questionnair complet intak t0 telephon interview conduct train interview 6 week t1 intervent 6 week postpartum t2 2.8.1 pre test questionnair pre test questionnair assess socio demograph characterist ag year educ level regular partner paid job pregnanc pariti number week gestat entri care smoke item number cigarett dai pregnanc entri care number minut cigarett wake ag regular smoker anticip partner quit weekli alcohol consumpt week glass measur time point 2.8.2 post test questionnair outcom assess point preval abstin assess respond smoke cigarett puff past 7 dai t1 t2 continu abstin defin report 7 dai abstin time point assess t2 partner smoke measur women report partner smoke daili amount cigarett addition quit attempt assess women quit attempt 24 measur contact increas report reliabl bogu pipelin procedur women particip cotinin assess valid women report smoke behavior 36 random sampl 30 particip midwiv ask collect urin sampl urin cotinin measur ga chromatographi mass spectrometri cut point set 25 mg 37 program evalu question assess satisfact content appear materi ask post test question earlier studi 34,38,39 women ask receiv video watch receiv guid read extent 0 4 watch video guid rate credibl understand interest attract length scale 1 low 7 high final rate video guid rang 1 bad 10 excel 2.9 analysi multilevel logist regress analys patient nest practic run test differenti attrit post test 1 post test 2 test effect intervent mlwin 40 outcom analys conduct dropout women miscarri particip due languag difficulti treat smoker dropout pal highlight 48 credibl sourc 17 social support unspecifi 2 problem solv pal highlight 1 goal set behaviour 4 action plan pal highlight 70 ad object environ 26 inform social environment consequ 4 action plan 2 problem solv pal highlight 26 inform social environment consequ pal highlight 9 committ de vri al patient educ counsel 63 2006 177 187182 tabl 1 baselin characterist percentag mean s.d studi group socio demograph pregnanc smoke histori smoke network experiment 141 miss control 177 miss ag s.d 28.6 4.32 9 28.4 4.39 5 level educ 5 13 low 47.1 61.6 medium 38.2 23.8 high 14.7 14.6 steadi partner 99.3 2 97.2 1 paid job woman 68.4 5 65.2 13 number prior pregnanc 5 13 0 55.1 51.8 1 29.4 30.5 2 15.4 17.7 number week pregnant intak s.d 12.4 1.91 1 13.4 3.67 3 number cigarett dai pregnanc s.d 17.4 8.46 1 18.4 8.51 0 number cigarett dai visit midwif s.d 9.1 6.83 0 7.7 5.01 0 ag began smoke s.d 14.9 2.28 5 15.4 2.51 13 minut cigarett 6 16 5 8.9 6.8 6 30 18.5 22.4 31 60 20.0 13.7 60 52.6 57.1 drink alcohol 14 5 11 13 partner smoke 71.2 10 72.5 18 anticip effort quit partner 6 12 lot 31.1 28.5 averag 32.6 32.1 14.1 16.4 22.2 23.0 pql2 rigl estim method assess intervent effect 31 com.ibm.drl.hbcp.predictor baselin variabl list tabl 1 steadi partner variabl varianc interact treatment covari predict post test smoke test provinc includ model fix effect multilevel logist regress outcom post test conduct method method 1 includ baselin com.ibm.drl.hbcp.predictor 0.10 quit attempt point preval analysi nt1 289 nt2 286 method result reduct sampl size due miss valu com.ibm.drl.hbcp.predictor analys rerun com.ibm.drl.hbcp.predictor signific 0.05 quit attempt abstin post test nt1 313 nt2 310 refer method 2 collinear com.ibm.drl.hbcp.predictor found vif 1.5 41 2.10 ethic approv medic ethic board maastricht univers grant ethic approv studi 3 result 3.1 recruit result midwiv instruct invit pregnant woman smoke invit 80 elig women minut meet process evalua tion reveal compli studi recommend busi women invit 72 agre particip reason refus women quit smoke fear confront smoke statu young mother regard studi intrus privaci anticip feel guilt shame burden particip research studi total 318 smoker includ studi 141 experiment condit 177 control condit post test 85.1 88.7 group elig studi fig 1 multilevel logist regress dropout 1 0 post test treatment group provinc number cigarett smoke com.ibm.drl.hbcp.predictor baselin variabl miss dropout show dropout vari practic intraclass correl 0.35 0.05 com.ibm.drl.hbcp.predictor significantli relat dropout point time ps 0.10 3.2 characterist respond baselin characterist studi group present tabl 1 major women lower educ steadi partner paid job pregnant time reduc number cigarett smoke onset pregnanc drink alcohol smoke partner 3.3 implement midwif experiment practic train mi result 71 midwiv train total 96 women experiment group report receiv video 91 report receiv guid women de vri al patient educ counsel 63 2006 177 187 183 tabl 2 evalu video guid relaps booklet experiment intak smoke group video 92 mean s.d guid 112 mean s.d crediblea 5.76 1.30 5.91 1.03 understandablea 6.30 0.87 6.32 0.54 interestinga 5.08 1.66 5.78 1.10 attractivea 4.40 1.81 5.35 1.41 lengtha 5.20 1.59 3.19 1.65 overallb 6.66 1.36 7.39 0.96 scale 1 7 1 lowest rate scale 1 10 1 lowest rate tabl 3 mix logist regress quit attempt 7 dai abstin treatment covari 6 week intervent dropout includ smoker 289 s.e 95 ci quit attempta treatment group1 0.92 0.40 2.51 1.14 5.54 0.023 provinceb 0.32 0.39 1.37 0.64 2.94 0.42 cigarett dayc 0.36 0.14 0.70 0.53 0.91 0.008 ag onset smokingc 0.39 0.29 1.48 0.84 2.58 0.17 smoke partnera 0.18 0.31 0.84 0.46 1.53 0.57 educ leveld 0.58 0.28 1.79 1.02 3.12 0.041 constant 2.25 1.03 0.028 cluster variance 0.35 0.24 0.077 point preval abstinencea treatment groupa 1.90 0.67 6.67 1.81 24.59 0.004 provinceb 0.74 0.63 2.10 0.61 7.25 0.24 cigarett dayc 0.95 0.27 0.39 0.23 0.66 0.000 ag onset smokingc 0.08 0.45 1.08 0.44 2.64 0.86 smoke partnera 0.72 0.43 0.49 0.21 1.12 0.091 educ leveld 0.13 0.43 1.14 0.49 2.66 0.77 constant 2.08 1.64 0.20 cluster varianc 0.82 0.55 0.069 code 1 0 provinc 1 west 0 east result ag onset number cigarett dai report effect 5 unit increas i. 5 year ag onset smoke 5 cigarett educ level 1 medium high 0 low ag year tail cluster varianc neg receiv video 68 report watch video 82 receiv guid report read part averag 2.82 scale 0 4 s.d 1.40 gener women rate materi credibl understand interest attract gave good rate tabl 2 guid perceiv long 3.4 result 6 week intervent dropout includ smoker found 27 treat women report quit attempt 6 week intervent oppos 24 control group detail fig 1 addition 19 experiment group report 7 dai abstin compar 7 control group dropout exclud analysi percentag experiment group control group markedli tabl 3 summar result multilevel logist regress analysi quit attempt 7 dai abstin method 1 i. includ com.ibm.drl.hbcp.predictor 0.10 outcom time point method treatment provinc number cigarett dai intak covari 0.05 analys produc similar result tabl complet case analysi exclud dropout produc similar result line fact dropout rate modest significantli relat com.ibm.drl.hbcp.predictor test interact treatment pro provinc treatment number cigarett dai intak signific interact found 6 week intervent ps 0.30 3.5 result 6 week postpartum t2 6 week postpartum quit attempt report 38 experiment group 23 control group dai abstin report 21 experiment group versu 12 control group dropout exclud percentag group notic tabl 4 show effect signific method 1 method treatment provinc number cigarett dai intak com.ibm.drl.hbcp.predictor complet case analysi produc similar result tabl test interact treatment provinc treatment number cigarett dai intak found interact treatment number cigarett smoke dai intak respect outcom tail 0.05 treatment effect increas number cigarett smoke dai intak odd ratio tabl 4 correspond treatment effect patient smoke cigarett dai intak suggest smoke statu intak import maintain gener benefici treatment effect smoke behavior tabl 4 reveal signific treatment effect continu abstin 12 experi mental group 3 control group test interact treatment provinc number cigarett dai intak found interact 0.30 combin result outcom post test tabl 3 4 show treatment number cigarett dai intak consist predict smoke cessat educ level ag onset smoke smoke partner predict provinc east versu west predict 0.20 outcom signific cluster varianc found estim icc vari 0.06 0.23 depend outcom de vri al patient educ counsel 63 2006 177 187184 tabl 4 mix logist regress quit attempt 7 dai abstin continu abstin treatment covari 6 week postpartum dropout includ smoker 286 s.e 95 ci quit attempta treatment groupa 1.17 0.39 3.21 1.50 6.85 0.003 provinceb 0.13 0.38 1.14 0.55 2.38 0.73 cigarett dayc 0.72 0.16 0.52 0.36 0.67 0.000 ag onset smokingc 0.57 0.31 1.76 0.97 3.20 0.064 smoke partnera 0.48 0.31 0.62 0.33 1.14 0.12 educ leveld 0.65 0.30 1.92 1.07 3.42 0.03 constant 2.08 1.08 0.05 cluster variance 0.22 0.22 0.16 point preval abstinencea treatment groupa 1.08 0.54 2.94 1.03 8.40 0.044 provinceb 0.58 0.52 0.56 0.20 1.54 0.26 cigarett dayc 0.80 0.23 0.45 0.29 0.71 0.001 ag onset smokingc 0.76 0.40 2.13 0.97 4.66 0.06 smoke partnera 1.22 0.39 0.29 0.14 0.64 0.002 educ leveld 1.17 0.41 3.21 1.42 7.22 0.005 constant 3.06 1.43 0.03 cluster varianc 0.60 0.44 0.09 continu abstinencea treatment group 1.83 0.86 6.25 1.16 33.61 0.033 provinc 0.51 0.78 0.60 0.13 2.76 0.52 cigarett dai 0.80 0.35 0.45 0.23 0.89 0.022 ag onset smoke 0.15 0.64 1.16 0.33 4.07 0.82 smoke partner 1.26 0.56 0.28 0.10 0.84 0.023 educ level 0.48 0.60 1.61 0.50 5.24 0.43 constant 2.60 2.27 0.25 cluster varianc 0.98 0.83 0.12 code 1 0 provinc 1 west 0 east result ag onset number cigarett dai report effect 5 unit increas i. 5 year ag onset smoke 5 cigarett educ level 1 medium high 0 low ag year tail cluster varianc neg 3.6 biochem valid biochem valid result unus due problem experienc transport 47 sampl pre test report smoker avail analysi 17 experiment 30 control group result reveal pre test report smoker pre test smoker experiment control group 17 urin sampl valid urin sampl 6 week postpartum sampl confirm report smoke statu 3.7 partner smoke total 76.2 women experiment condit report hand partner booklet partner receiv booklet 48.4 read intak post test group 72 patient report partner smoker percentag vari 70 74 depend time point group group differ signific time point ps 0.30 intervent effect smoke behavior partner 4 discuss conclus 4.1 discuss dutch midwiv uniqu posit pregnant women smoke quit goal studi test smoke cessat intervent pregnant women midwiv studi reveal effect program hinder implement routin antenat care 15,18 multilevel analysi reveal 7 dai abstin criterion intervent result fold increas chanc quit pregnanc experiment group 19 compar control group 7 dai abstin 6 week postpartum increas fold experiment group 21 compar control group 12 signific effect found t2 continu abstin 12 experiment group 3 control group european studi show signific result 12,42 result support review melvin al 43 suggest cessat counsel session 5 15 min deliv train provid effect found averag risk ratio 1.7 lumlei al review 64 trial found signific reduct smoke intervent group rel risk rr 0.94 author conclud strategi consist reward social support result significantli greater smoke reduct strategi trial includ relaps prevent show statist reduct relaps suggest effect relaps prevent strategi develop 14 result tabl 3 4 smoke fewer cigarett dai intak higher educ predict quit attempt 6 week post intervent 6 week postpartum factor significantli predict smoke statu 6 week post intervent 6 week postpartum smoke partner higher educ predict smoke statu 6 week postpartum social support import determin success quit smoke smoke statu pregnant smoker partner influenc chanc quit 44 intervent consist guid chang partner smoke behavior similar result found multi compon program lower socio econom african american 6 month follow 45 park al 19 conclud studi effect persist 6 month longer found de vri al patient educ counsel 63 2006 177 187 185 stanton al find a16.5 quit rate father intervent group versu 9.3 control group intervent group receiv 18 min video nicotin patch inform pack newslett author attribut success free distribut nicotin patch 46 research need reveal effect compon motiv husband quit smoke studi pharmacotherapi allow netherland conclus pharmacotherapi smoke cessat pregnant women mix efficaci nrt pregnanc fulli nrt pregnanc safer smoke 47 evid requir 48 choic pharmacotherapi smoke cessat made jointli pregnant smoker health care provid 49 studi subject limit problem conduct research routin care standard practic disrupt women requir complet pre test midwif offic consult start intervent women complet questionnair consult finish variabl attitud intent quit com.ibm.drl.hbcp.predictor recommend collect cotinin sampl 13 assess fail logist problem transport sampl order prevent treatment contamin provinc practic random includ 4 12 provinc studi fact fix effect provinc predict outcom 0.20 suggest provinc influenc result differ provinc respect baselin variabl list tabl 1 adjust includ baselin variabl covari model fourth respons rate chair region network midwif practic low reflect respons bia final reli women report partner smoke report partner futur research 4.2 conclus intervent easi routin prenat midwiferi care appreci women midwiv result cessat pregnanc 6 week postpartum recommend investig possibl requir implement nation wide implement precondit public health impact realiz research need strengthen intervent improv partner intervent identifi element mi protocol effect instanc donatel al 50 suggest posit effect social support direct financi incent high risk pregnant women recent find motiva tional interview attract unmotiv women 51,52 final prevent relaps long term postpartum intervent requir 4.3 practic implic program realiz short term effect import precondit midwiv proper train program implement nation wide futur studi reveal factor facilit hinder nation implement nation implement level 53 addit research need test effect approach combin recent approach comput tailor 54 56 telephon counsel 57 60 motiv interview 61 63 acknowledg studi financ mean grant dutch cancer societi dutch heart foundat prevent fund jonathan van riet alexandra dummert assist saadhna pandai correct english review construct critic earlier version
194 annal pharmacotherapi 2009 februari volum 43 www.theannals.com access healthprofession healthcar system 1 pharmacist kei posi tion assist individu tobacco cessat servic pharma cist ideal situat interact individu obtain medic smoke relat ill pharmacist tobacco cessat import activ interest provid counsel 2,3 phar macist formal train provid bacco cessat counsel 4 op portun pharmacist receiv train increas 5 7 shown increas confid qualiti provis counsel 4 autom technolog certif technician free pharmacist tradit dispens respons 8 addit updat pharmaci practic law allow collabor practic agreement physician empow pharmacist initi modifi drug therapi pa tient includ tobacco cessat 9 pharmacist wide varieti set ting begun provid direct pa tient care includ smoke cessa tion 10,11 grow inter est expand pharmacist role tobacco treatment 15 studi assess effect pharmacist deliv tobacco cessat intervent 12 studi controlled13 17 10 uncontrol 18 27 fourteen studi target smoking14 27 1 target chew tobacco 13 8 studi smoke intervent conduct ed includ control group19 21,23 27 2 biochem measur confirm report cessat 19,20 studi tobacco intervent deliv random trial assess effect pharmacist deliv program smoke cessat larri dent kari jo harri curti noonan drug alcohol substanc abus author inform provid end text background train access healthcar profession pharmacist ideal posit provid tobacco cessat intervent 15 studi identifi literatur assess effect tobacco cessat intervent deliv pharmacist random control trial conduct pharmacist deliv program smoke cessat biochem confirm object assess effect smoke cessat face face group program conduct pharmacist team compar standard care session deliv pharmacist telephon method open label prospect random control trial conduct veteran health administr commun base outpati clinic rocki mountain region particip randomli assign receiv 3 session face face group program conduct pharmacist team 5 10 minut standard care session deliv pharmacist team telephon particip group offer releas bupropion nicotin patch cost primari outcom report abstin biochem confirm urinari cotinin 6 month quit date result hundr smoker random octob 3 2005 march 30 2007 6 month follow survei complet novemb 6 2007 analysi data complet decemb 2007 intent treat procedur confirm abstin rate end 6 month 28 pharmacist deliv face face treatment group 11.8 standard care telephon session control group 0.041 conclus studi demonstr pharmacist effect provid tobacco cessat intervent greater com.ibm.drl.hbcp.util pharmacist tobacco cessat effort signific impact smoke rate prevent tobacco relat diseas improv public health kei word nicotin addict pharmacist role pharmaci smoke cessat intervent tobacco cessat ann pharmacoth 2009;43 194 201 publish onlin 27 jan 2009 www.theannals.com doi 10.1345 aph 1l556 librari period dept januari 20 2016aop.sagepub.comdownload http aop.sagepub.com er pharmacist suggest feasibl effect pharmacist deliv intervent 12 rigor design studi emploi control group biochem verif smoke cessat conduct studi assess effect biochem confirm report smoke cessat face face group program conduct pharmacist team versu telephon assist deliv pharmacist team biochem verif report cessat im portant establish accuraci studi high intensi ty intervent suffer inflat quit rate base report 28 method studi design prospect open label random trial compar effect 7 dai point preval quit rate face face 3 session group program conduct phar macist team versu 5 10 minut standard care se sion deliv pharmacist team telephon intervent team consist licens clinic phar macist advanc pharmaci practic experi app student physician veteran affair va commun base outpati clinic rocki mountain region refer patient smoke clinic pharma cist electron computer patient record system particip random octob 3 2005 march 30 2007 6 month follow survei complet novemb 6 2007 analysi data complet decemb 2007 particip group offer choic releas bupropion tablet nicotin patch va provid medic cost particip 6 month establish quit date report cessat biochem con firm test urinari cotinin visit schedul 3 dai particip provid urinari sampl clinic particip treatment control group set quit date 10 14 dai intervent contact elect set quit date assign dai 12 intervent contact quit date trial procedur approv monitor uni versiti montana institut review board screen elig criteria flow particip studi appear figur 1 patient electron medic record system identifi exclud patient diagnosi schizophrenia requir approach quit smoke prior particip pharmaci group program script questionnair conduct telephon pharmaci team screen patient refer studi individu plan leav area 6 month pharmacotherapi smoke cessat 30 dai form tobacco cigarett cigar pipe tobacco spit tobacco 30 dai exclud elig patient smoke cigarett daili 7 dai readi quit 2 week 4 10 point motiv scale capabl attend 3 schedul session clinic interest particip studi 26 patient exclud particip trial treat studi studi enrol random baselin assess success complet screen pro cedur elig particip copi ap prove consent form address return en velop return consent materi recontact 2 addit time consent form collect particip invit particip sign consent form receiv particip se quential enrol trial random treatment control group clinic pharmacist ran domiz code assign particip puter gener studi statistician stratifi sex block 6 pharmacist team conduct base line assess telephon notifi partici pant group assign particip assign face face treatment group inform de tail group session particip sign control group standard care smoke ce sation compon deliv telephon treatment group particip assign treatment group particip face face 3 session group program clinic de liver pharmacist app student 6 hour program consist 3 person session 3 hour se sion 1 2 hour session 2 1 hour session 3 de liver 2 week interv 5 week small group smoker vari size 3 10 particip program group form 3 4 month depend number referr treatment pro gram adapt vet cigarett pro gram29 develop va montana veteran health ad ministr multipl theori behavior chang clude transtheoret model change30 health belief model 31 program previous peer support goal set behavior strategi cognit techniqu elicit support chang 26 session 1 facilit prepar quit assist medica annal pharmacotherapi 2009 februari volum 43 195www.theannals.com librari period dept januari 20 2016aop.sagepub.comdownload http aop.sagepub.com tion establish quit date cope trigger teach habit bust behavior strategi appli period prior quit date particip select quit date 2 3 dai prior session session 2 address problem quit stage immedi quit date manag withdraw symptom cope crave manag fear weight gain stress reduct session 3 focus mainten chang strategi prevent slip relaps reward system follow particip instruct call clinic question receiv addit support need control group baselin assess complet phar macist app student structur script deliv intervent particip receiv time 5 10 minut session telephon includ ponent standard care recommend clinic prac tice guidelines32 practic va inter vention deliv healthcar provid refer 5 tobacco advis quit assess willing make quit attempt assist quit attempt arrang follow standard care deliv telephon similar telephon quit line servic 33 follow particip instruct call clinic que tion receiv addit support need studi medic particip group offer choic releas bupropion 100 mg tablet 3 time daili nicotin patch dose 21 mg daili 4 week 14 mg daili 2 week 7 mg daili 2 week smoke 10 cigarett daili 14 mg daili 4 week 7 mg daili 2 week smoke fewer 10 cigarett daili va formulari option guidelin particip ceiv bupropion receiv 30 dai suppli 2 refil complet 12 week therapi particip receiv nicotin patch receiv quantiti suffici complet 8 week step therapi smoke 10 cigarett daili 6 week fewer 10 cigarett daili dosag regimen similar group prior prescrib medic clinic pharmacist view patient medic record contraind contraind bupropion includ histori seizur disord histori eat disord form bupropion monoamin oxidas 196 annal pharmacotherapi 2009 februari volum 43 www.theannals.com la dent al figur 1 particip flow pharmacist deliv smoke cessat program 308 person screen 120 invit particip 188 elig 156 meet inclus criteria 32 unabl contact 50 assign pharmacist deliv program 28 attend 3 session 36 attend 2 session 45 attend 1 session 5 attend session 51 assign standard care session telephon 51 particip 3 lost follow 6 month 2 declin complet follow assess 1 di unrel studi 0 withdrew consent 1 lost follow 6 month 1 unabl contact 0 withdrew consent 50 includ primari analysi 51 includ primari analysi 19 declin particip 101 random librari period dept januari 20 2016aop.sagepub.comdownload http aop.sagepub.com hibitor past 14 dai precaut nicotin patch includ myocardi infarct 2 week se riou arrhythmia worsen angina pectori studi particip select drug receiv va medic mail deliveri system measur month quit date particip tele phone research assist complet assess ment particip report smoke previ ou 7 dai puff invit clinic provid sampl test urinari cotinin 34 particip invit provid urin sampl reim burs 20 time travel cost primari outcom variabl studi bio chemic confirm 7 dai point preval smoke cessat 6 month defin smoke cigarett puff previou 7 dai sec ondari outcom includ 30 dai point preval absti nenc continu abstin 6 mo thirti dai point preval defin smoke cigarett puff 30 dai continu ou abstin defin cigarett puff quit dai questionnair assess form tobacco nicotin replac therapi posur secondhand smoke time urin test labcorp analyz urin sampl immunoassai solarcar technolog corp bethlehem pa consid er longest cotinin half life typic initi coti concentr patient neg test result assum tobacco free 7 dai period 28 particip urin cotinin concentr 0.3 µg ml higher consid smoker sociodemograph inform smoke behavior measur efficaci motiv health informa tion assess baselin survei question adapt prior studi 35 37 nicotin depend assess 6 item fagerstrom test nicotin de pendenc scale baselin 6 month smok ing 38 4 item perceiv stress scale base line 6 month measur degre situa tion past month apprais stress 4 item rate 0 4 high er score perceiv stress 39 10 item cen ter epidemiolog studi short depress scale score measur baselin 6 month 40 score 10 higher rang 0 30 likelihood clini cal depress efficaci motiv quit smok ing assess separ baselin 6 month particip ask scale 1 10 motiv confid quit smoke 1 motiv confid 10 mo tivat confid particip report quit phrase item alter assess motiv con fidenc stai quit 41,42 withdraw symptom includ depress mood troubl fall asleep irrit frustrat anger anxieti difficulti concentr restless increas ap petit weight gain crave smoke assess 6 month 8 symptom rate 0 3 sever 35,43 particip choos medic adher assess 6 month statement scale 1 10 close follow recommend dose schedul 1 10 44 studi record assess number program session complet particip treatment group data manag particip data test result record microsoft sql server 2000 databas microsoft corp redmond wa data doubl enter check rang valu regular interv intern consi tenci valid program check data entri error duplic statist analysi priori sampl size calcul assum 7 dai point preval abstin 10 control group base previou studi standard medic care32 35 intervent group base previou pilot studi pharmacist deliv interven tion 26 sampl size 100 particip 50 treat ment yield 86 power detect differ tween group α 0.05 baselin categor vari abl summar frequenc percentag quantit variabl summar mean sd treatment regimen baselin categor variabl treatment group compar χ2 test 2 sampl test χ2 test compar point preval smoke cessat continu abstin rate base intent treat analysi treat ment control group primari outcom smoke cessat subject lost follow report abstin 6 month post quit date fail return urin cotinin test classifi smoker primari analys data analysi conduct sa version 9.0 cari nc result result particip flow studi ap pear figur 1 common reason exclus inabl attend 3 session 54 188 due barri effect pharmacist deliv smoke cessat program annal pharmacotherapi 2009 februari volum 43 197www.theannals.com librari period dept januari 20 2016aop.sagepub.comdownload http aop.sagepub.com er cost transport travel distanc ly area schedul conflict work activ 19 elig patient declin particip common reason readi quit avers group differ ag number cigarett smoke dai declin particip readi quit 2 week lower 10 point moti vation scale 0.004 baselin characterist particip sig nificantli treatment group tabl 1 major particip male 93 panic white 96 colleg educ 61 retir 56 marri member unmarri coupl 55 baselin 57 particip consid good excel health characterist equal distribut treatment group 0.34 6 month quit date biochem con firm 7 dai point preval quit rate 28 14 50 pharmacist deliv face face treatment group 11.8 6 51 standard care group 0.041 tabl 2 report quit rate significantli higher treatment group time period 14 bio chemic confirm quitter treatment group 93 13 14 attend 3 counsel session particip attend 3 session 46 13 28 main tain continu abstin compar 5 1 22 attend 2 session fewer suggest impor tanc attend 3 session program 23 particip report abstin invit provid urin sampl biochem verif 88 15 17 treatment group 100 6 6 control group complet test particip report ab stinenc treatment group control group test posit urinari cotinin bupropion chosen 66 67 101 subject nicotin patch chosen 25 25 101 subject 9 9 101 subject select drug differ treatment group type medic chosen 0.37 signific differ quit rate type medi cation chosen treatment group 0.41 83 particip opt studi medica tion assess adher 6 month fol low survei 63 52 83 repli recommend dose schedul equal distribut treatment control group recommend do ing schedul 0.98 patient report medic problem clinic pharmacist advers effect medic mild patient report develop dizzi possibl relat nicotin toxic wear 21 mg patch requir ing reduct dosag patient discontinu bupro pion rash follow particip report experienc 8 withdraw symptom common ly smoke cessat 96 particip report withdraw symptom discuss random control trial conduct assess effect pharmacist deliv program smoke bio chemic verif 28 biochem confirm quit rate obtain studi higher quit rate 2 biochemi calli confirm random control trial conduct uk australia port intent treat quit rate 14.7 15 18.5 14 6 month intens ponent group program account differ quit rate studi report studi 2 prior control studi group intervent intent treat port tobacco cessat rate 34 45 36.5 26 similar report quit rate 34 obtain current studi high retent follow studi contribut higher quit rate choic pharmacotherapi group equival primari strength studi complianc recogn standard 198 annal pharmacotherapi 2009 februari volum 43 www.theannals.com la dent al tabl 1 baselin characterist treatment control groupsa group pharmacist deliv standard program care characterist 50 51 ag time studi enrol 56.7 9.8 55.0 9.5 0.378 ag began smoke 17.2 5.5 17.3 5.6 0.975 year smoke 35.2 12.9 36.2 12.1 0.685 cigarett dai 18.9 11.2 20.1 9.3 0.563 quit attempt 8.7 10.6 7.9 9.5 0.677 ftnd score 4.2 2.5 4.4 2.1 0.648 chronic health condit 2.4 1.6 2.2 1.5 0.505 pss 4 4.7 3.9 4.9 3.5 0.785 cesd 10 score 8.9 6.9 8.9 6.7 0.966 motiv quit 8.9 1.4 8.5 1.6 0.159 confid quit 7.6 2.3 7.5 2.2 0.860 cesd 10 10 item center epidemiolog studi short depress scale ftnd fagerstrom test nicotin depend pss 4 perceiv stress scale amean sd librari period dept januari 20 2016aop.sagepub.comdownload http aop.sagepub.com effect pharmacist deliv smoke cessat program annal pharmacotherapi 2009 februari volum 43 199www.theannals.com methodolog design measur efficaci tobacco cessat intervent includ random con troll trial durat follow intent treat analysi account attrit biochem veri ficat studi success recruit ment retent particip import prerequisit conduct rigor evalu smoke cessat program applic studi greatest impact va sy tem manag care set similar ambulatori care site larg number pharmacist practic empow expand scope practic al low abil meet patient prescrib bacco cessat medic pharmacist commun practic develop collabor practic agre ment physician commun pre scribe tobacco cessat medic exclud nicotin gum patch counter de pend pharmaci practic law vari dif ferent state studi addit evi denc effect releas ver su sustain releas formul bupropion smoke cessat 46,47 pharmacist suit provid bacco cessat intervent acc sibil abil assist counsel initi drug therapi easi follow support medica tion relat problem studi support find report clinic practic guideline32 strong dose respons relationship inten siti counsel cessat success intens treatment intervent length number treatment session deliv greater rate smoke cessa tion intens pharmacist intervent greater impact abstin rate intervent limit abil reach smoker inelig studi inabl attend group program tobacco user interest lack avail access abil afford intens group program studi number limit standard care model deliv telephon control group determin addit time ef fort requir propos intervent result significantli outcom compar inter vention deliv healthcar provid limit design deliveri time atten tion differ significantli treatment con trol group gener studi find ing smoker gener popul studi particip predominantli white male middl ag reproduc studi patient popul unknown research suggest men women racial ethnic mi noriti benefit similar smoke cessat inter vention deliv studi 32 strength studi long 6 mo follow period delai tween treatment follow assess introduc error particip recal distal event accur medic withdraw symptom pharmacist team deliv intervent condit knowledg studi hypothesi influenc studi outcom detail protocol checklist step complet contact point help systemat intervent deliveri minim concern screen process select individu time avail transport attend group program sourc bia limit studi rigor evalu effect pharmacist deliv tobacco cessat intervent ultim intervent serv model widespread effect phar macist provid tobacco cessat servic esp cialli va similar ambulatori care set addition establish effect pharmacist de liver tobacco cessat servic provid justifica tion compens parti payer impor tantli greater pharmacist tobacco cessat ef fort signific impact smoke rate prevent tobacco relat diseas improv public health larri dent pharmd bcp associ professor clinic phar maci specialist depart pharmaci practic skagg school pharmaci univers montana missoula mt kari jo harri phd mph associ professor school public commun health scienc univers montana curti noonan phd assist professor depart phar maci practic depart biomed scienc skagg school pharmaci univers montana tabl 2 point preval continu abstin rate base intent treat analysi group pharmacist deliv standard program care pp ca rate cotinin confirm 14 28.0 6 11.8 0.041 7 dai pp report 1 dai pp 20 40.0 8 15.7 0.006 7 dai pp 17 34.0 6 11.8 0.008 30 dai pp 16 32.0 6 11.8 0.014 6 mo ca 14 28.0 6 11.8 0.041 ca continu abstin pp point preval 50 bn 51 librari period dept januari 20 2016aop.sagepub.comdownload http aop.sagepub.com reprint dr dent depart pharmaci practic skagg school pharmaci univers montana 32 campu dr 1522 mi soula mt 59812 fax 406 243 4353 larry.d umontana.edu studi sponsor prevent cancer foundat platform present find made annual meet ing american colleg clinic pharmaci louisvil ky oc tober 20 2008 kathren conwai casei ruggiero univers montana school public commun health scienc assist conduct fol low survei data entri databas manag
dickson spillmann al bmc public health 2013 13 1227 http www.biomedcentral.com 1471 2458 13 1227 research articl open access group hypnosi relax smoke cessat adult cluster randomis control trial maria dickson spillmann severin haug michael schaub abstract background popular hypnotherapi smoke cessat efficaci method unclear aim investig efficaci singl session group hypnotherapi smoke cessat compar relax swiss adult smoker method cluster randomis parallel group control trial singl session hypnosi relax smoke cessat deliv group smoker median size 11 particip 223 smoker consum 5 cigarett dai quit cessat aid 47.1 femal 37.5 year sd 11.8 86.1 swiss nicotin withdraw smoke abstin efficaci advers reaction assess 2 week follow main outcom report 30 dai point preval smoke abstin assess 6 month follow abstin valid salivari analysi secondari outcom includ number cigarett smoke dai smoke abstin efficaci nicotin withdraw result 6 month follow 14.7 hypnosi group 17.8 relax group abstin intervent effect smoke statu 73 number cigarett smoke dai 56 smoke abstin efficaci differ intervent 14 2 week follow smoker hypnosi group experienc reduc withdraw 02 intervent produc advers reaction 81 conclus singl session group hypnotherapi effect smoke cessat group relax session trial registr current control trial isrctn72839675 keyword smoke cessat cigarett smoke hypnosi group therapi cluster randomis control trial background smoker give smoke studi 40 80 quit 1 3 80 quit smoke assi tanc 4,5 long term success cold turkei method low 7 8 5,6 smoker hold mispercept nicotin replac therapi nrt smoke cessat method 7 11 smoker ce sation assist motiv nrt medic smoke cessat rang correspond maria.dickson isgf.uzh.ch swiss research institut public health addict isgf univers zurich konradstrass 32 postfach 8031 zürich switzerland 2013 dickson spillmann al license biom creativ common attribut licens http distribut reproduct medium domain dedic waiver http creativecom articl state cessat method includ hypnotherapi avai labl quarter smoker intend quit interest hypnotherapi 12,13 markabl interest swiss smoker 14 efficaci hypnosi smoke cessat method investig 15 26 heterogen studi design review meta analys hy pnotherapi smoke cessat undertaken 27 31 except 32,33 support efficaci hypnoth rapi smoke cessat method paper report find cluster randomis trial investig efficaci hypno therapi smoke cessat compar relax ed central open access articl distribut term creativecommons.org licens 2.0 permit unrestrict provid origin work properli cite creativ common public mons.org publicdomain 1.0 appli data made http www.control trials.com isrctn72839675 isrctn72839675 mailto:maria.dickson isgf.uzh.ch http creativecommons.org licens 2.0 http creativecommons.org publicdomain 1.0 dickson spillmann al bmc public health 2013 13 1227 page 2 9 http www.biomedcentral.com 1471 2458 13 1227 trial stand previou research char acteris larg sampl size comparison made activ control group report smoke abstin biolog valid trial repres substanti addit small power bodi research hypnosi smoke cessat intend evalu hypnotherapi afford time save therapi smoker quit intent intervent trial conduct singl session group format method trial design protocol studi previous pub lish 34 trial design diverg tween protocol present articl note protocol announc simpl rando mise trial recruit studi start awar recruit ment procedur unit randomis cluster individu individu result particip cluster fea ture common particip cluster e.g case work colleagu tend therapi session effect cluster randomis parallel group con troll trial cluster refer group partici pant attend therapi session week intervent particip contact telephon follow interview month intervent follow inter view conduct telephon relax condit intend activ control group oppos wait list control match experiment group regard therapist contact time 29 choos type control group want evalu hypnotherapi ef fect addit specif effect therapist contact social support relax includ wait list control group anticip partici pant kind control group feel mo tivat quit follow period bias month abstin rate particip recruit perform advertis onlin print newspap individu 18 year report smoke cigarett dai cessat method time studi intend quit elig particip contrast studi protocol appli upper ag limit older individu ag 78 ful fill inclus criteria antici pate methodolog ethic reason exclud individu exclus criteria acut alcohol substanc nicotin manifest sign psychot symptom observ therapist start therapi session interest individu mail inform studi inclus cri teria cost particip anonym confiden tialiti inform efficaci hypnosi relax smoke cessat clear low risk intervent randomli assign intervent particip ask smoke cessat aid studi period ensur commit smoke cessat studi particip particip paid 40 swiss franc ca 37 usd therapi session potenti particip provid calendar show therapi date group 8 15 elig smoker avail date project leader assign group cluster intervent sequenc therapi session place confer room hotel institut involv zurich citi small town northwest switzerland 8 10 pm weekdai 10 12 saturdai intervent therapi session conduct swiss german languag 37 year male hypnosi relax therapist therapi session consist part psycho educ part 40 minut actual tervent 40 min debrief 20 min con tent part record script therapist instruct follow psycho educa tional part consist discuss benefit smoke cessat equal condit part actual intervent place dim light soft background music hypnosi induc guid imageri calm tone voic therapist invit particip travel bodi progress feel heavier warmer comfort par ticip ask feel toe heel ankl calv knee thigh heavier heavier final experi comfort heavi leg sink deeper deeper state exercis repeat bodi cover induct hypnosi requir ten minut extens minut compar protocol set suggest made disconnect pleasant experi socia lise act smoke hypnosi dickson spillmann al bmc public health 2013 13 1227 page 3 9 http www.biomedcentral.com 1471 2458 13 1227 deepen repeat statement involv relax associ anchor result state deep relax kei word subsequ repeat maintain state deep relax particip suggest target switch ing imag smoker smoker suggest contain element cognit behav ioural approach hypnotherapi smoke cessat 21,35,36 suggest made particip power resist smoke tempt situat deal symptom mood swing en hanc appetit smoke cessat set suggest refer evok posit commit smoke cessat assum respons bodi reduc physiolog psycholog effect smoke withdraw 16,17,24,37 end session particip led back full awar relax condit particip ini tialli invit make comfort relax repetit statement made chor reinforc deepen relax particip ask listen music ten mi nute suggest sentenc hypnosi group particip debrief intervent end session debrief includ infor mation intervent undergon respond open question particip particip receiv compact disc cd home includ content actual intervent ensur fidel intervent script pro ject leader perform random unannounc visit therapi session indic breach script therapist outcom primari outcom trial rate smo king abstin month hypnotherapi compar relax secondari outcom compar nicotin withdraw symptom smoker intervent evalu intervent differ efficaci advers reaction week intervent compar daili cigarett consumpt quitter intervent week month therapi session part therapi session partici pant fill rang baselin questionnair questionnair assess sociodemograph inform nicotin depend fagerström test nico tine depend ftnd 38,39 smoke histori smoke abstin efficaci 40,41 histori substanc mental health beck depress inventori bdi 42,43 beck anxieti inven tori bai 44,45 mental compon score mc 12 12 item short form health survei sf 12 46,47 physic health bodi mass index bmi physic compon score pc 12 sf 12 46,47 lifetim diagnos anxieti depress lung diseas cancer heart diseas assess 48 addit particip provid baselin saliva sampl quantis saliva collect devic nal von min den regensburg germani sampl determin concentr cotinin metabolit nicotin liquid chromatographi mass spectrometri mass spectrometri lc ms ms ana lysi institut forens medicin univers zurich week follow interview dai point preval smoke abstin frequenc cd therapi session smoke abstin efficaci withdraw symptom minnesota nicotin withdraw scale mnw 49 potenti ad vers event result intervent bai bdi assess advers event includ mon symptom typic ni cotin withdraw symptom assess 4 point scale rang 1 present 4 sever month follow interview 30 dai point preval smoke abstin cd previou 30 dai cessat aid bai bdi advers event investig particip report smoke abstin previou 30 dai cessat aid saliva collect devic post result bmi baselin bai bdi follow up advers event month follow report present paper sampl size cluster random design trial requir recalcul sampl size compar studi protocol 34 recalcul sampl size basi group hypnosi studi nicotin replac therapi absenc recent investig refer earli trial group hypnotherapi smoke cessat 18,26,50 conserv result 25 abstin month 18 studi observ 0 abstin enc attent placebo control group assum rate cessat aid 7 6 control group aim statist power 80 accept alpha level 5 individu trial target sampl size current trial 142 individu power univers kiel germani assum icc 0.05 averag dickson spillmann al bmc public health 2013 13 1227 page 4 9 http www.biomedcentral.com 1471 2458 13 1227 cluster size 10 individu design effect 1 10 1 0.05 1.45 51 requir minimum sampl size present trial 142 1.45 206 actual sampl size 257 implement sequenc gener assum averag 10 individu group project leader gener random sequenc 20 se sion onlin program criterion occurr intervent balanc i. 10 session intervent partici pant sign trial session ran domli alloc onlin program hypnosi intervent ethic approv inform consent cluster randomis trial perform compli anc declar helsinki review ethic committe canton zurich declar object kek stv nr 16 10 particip inform consent form prior therapi session ask sign form therapi session blind hypnosi relax therapist inform text messag project leader part therapi session intervent perform particip remain blind regard assign intervent end therapi session statist method chi squar test compar baselin characterist hypnosi relax group data analysi conduct intent treat itt principl parallel ana lyse data complet case basi analys perform subsampl check base line differ primari outcom analys logist regress analysi hypnotherapi rela xation independ variabl smoke depend variabl variabl signifi baselin differ covari secondari analys linear ordin regress analysi generalis estim equat gee origin intend 34 procedur suitabl present outcom logist regr sion analysi stata 12 se colleg station texa usa regress analys account cluster random survei svy command calcul outcom command accur estim standard error sampl method simpl random sampl result flow particip figur 1 show flow particip trial recruit particip recruit constantli start mid april 2011 end begin februari 2012 follow interview place continu week month therapi date cruitment end reach intend sampl size data prepar data imput undertaken pasw 18.0 ibm corp armonk ny baselin variabl miss valu variabl 9 miss ing valu data imput linear regr sion method scale mean ftnd efficaci pc 12 mc 12 mnw advers event bai bdi calcul baselin data tabl 1 show characterist sampl relax ation group significantli educ compar hypnosi group turn show higher ftnd valu slightli higher mean bai relax group intervent retent follow up delai follow up reach 92.2 107 particip hypnosi group 94.4 101 partici pant relax group follow differ retent group signific x2 0.41 df 1 52 follow reach 85.3 99 hypnosi group 81.3 87 relax group differ signific x2 0.655 df 1 42 differ group gard delai target effect follow date signific week 0.32 df 193 75 month follow 1.37 df 163 17 return rate salivett biolog valid nicotin abstin report smoker return salivett particip return salivett count smoker biochem analys confirm nicotin abstin defin randomis therapi session 21 particip includ baselin analys 116 particip includ 2 week follow analys complet case protocol 107 itt protocol 116 particip includ 6 month follow analys complet case protocol 99 itt protocol 116 complet 107 lost follow respons 7 discontinu intervent declin provid reason 2 median number particip session 11 8 15 total particip 116 exclud 15 sick emerg 5 problem date 3 unexcus absenc 7 enrol hypnosi session 11 alloc baselin 2 week follow 6 month follow analysi relax session 10 median number particip session 11 7 14 total particip 107 exclud 19 sick emerg 4 problem date 5 unexcus absenc 10 complet 101 lost follow respons 5 discontinu intervent disappoint receiv intervent 1 complet 87 lost follow respons 18 discontinu intervent sever mental problem declin provid reason 2 complet 99 lost follow respons 17 particip includ baselin analys 107 particip includ 2 week follow analys complet case protocol 101 itt protocol 107 particip includ 6 month follow analys complet case protocol 87 itt protocol 107 figur 1 particip flow trial dickson spillmann al bmc public health 2013 13 1227 page 5 9 http www.biomedcentral.com 1471 2458 13 1227 5 ng ml 36 report smoker show slightli higher valu typic ob serv occasion smoker evalu particip count smoker outcom estim primari outcom time follow 17 14.7 95 ci 0.08 0.21 particip hypnosi group 19 17.8 95 ci 0.10 0.25 relax group report nicotin abstin previou 30 dai effect intervent signific tabl 2 unadjust analysi control variabl show baselin group differ led similar result 0.80 se 0.29 0.62 95 ci 0.37 1.72 54 cc analysi 0.84 se 0.37 0.40 95 ci 0.34 2.09 69 secondari outcom week follow 38 33.3 partici pant hypnosi group 26 24.5 relax group report smoke abstin tabl 1 baselin characterist hypnosi relax group total sampl variabl hypnosi 116 relax 107 total 223 test sd sd sd x2 demograph femal 52 44.8 53 49.5 105 47.1 0.50 ag 116 38.0 13.2 107 36.9 10.1 223 37.5 11.8 0.71 swiss 102 87.9 90 84.1 192 86.1 0.68 civil statu 2.04 singl 49 42.2 51 47.7 100 44.8 marri 45 38.8 43 40.2 88 39.5 divorc separ 22 19.0 13 12.1 35 15.7 educ 11.22 basic educ 13 11.2 4 3.7 17 7.6 apprenticeship 56 48.3 40 37.4 96 43.0 matur 24 20.7 24 22.4 48 21.5 univers 23 19.8 39 36.4 62 27.8 smoke relat variabl ftnd 115 5.0 2.2 107 4.4 2.0 222 4.7 2.1 2.13 efficaci 115 3.3 0.9 106 3.3 0.8 221 3.3 0.9 0.43 cotinin ng ml 115 336.6 119.3 107 326.3 124.6 222 331.6 121.7 0.63 ag cigarett 93 16.2 3.3 85 17.2 3.6 178 16.7 3.5 1.89 smoke cohabit 11 24.4 16 38.1 27 31.0 1.89 cessat attempt number 37 3.3 3.4 43 3.7 5.2 80 3.5 4.5 0.37 nrt 38 40.9 34 40.0 72 40.4 0.01 altern therapi 18 19.4 16 18.8 34 19.1 0.01 physic health pc 12 116 51.5 6.5 106 52.7 5.6 222 52.1 6.1 1.56 lung diseas life 11 10.1 8 8.2 19 9.2 0.23 heart diseas life 6 5.5 3 3.1 9 4.3 0.74 cancer life 4 3.7 1 1.0 5 2.4 1.54 mental health mc 12 116 50.0 8.4 106 50.1 7.5 222 50.1 7.9 0.10 bdi 116 0.9 0.7 107 0.9 0.7 223 0.9 0.7 0.95 bai 116 0.4 0.4 106 0.3 0.3 222 0.4 0.4 2.23 substanc consumpt alcohol 30 dai 116 7.2 6.6 106 8.6 6.7 222 7.9 6.7 1.59 alcohol 7 dai 116 1.8 1.8 106 2.2 1.6 222 2.0 1.7 1.61 cannabi life 66 56.9 73 68.9 139 62.6 3.39 cocain life 13 11.2 13 12.3 26 11.7 0.06 note mean sd standard deviat 0.05 tabl creat basi intent treat dataset dickson spillmann al bmc public health 2013 13 1227 page 6 9 http www.biomedcentral.com 1471 2458 13 1227 previou dai effect intervent signific 1.73 se 0.60 95 ci 0.84 3.57 1.58 13 week intervent mean number cigarett smoke previou dai similar group tabl 3 linear regress show effect intervent number daili cigarett smoke signific 38 β 03 se 94 0.40 95 ci 1.58 2.33 69 0.07 95 ci 0.26 0.40 icc hypnosi 00 tabl 2 logist regress model predict 30 dai point preval smoke abstin month follow com.ibm.drl.hbcp.predictor 95 ci se intervent 0 relax 1 hypnosi 0.86 0.36 2.06 0.36 0.35 73 ftnd 0.89 0.72 1.12 0.09 1.03 32 bai 1.21 0.45 3.26 0.57 0.41 69 educ apprenticeship elementari school 1.20 0.20 7.27 1.03 0.21 84 matur elementari school 2.18 0.31 14.96 2.01 0.85 41 univers elementari school 1.42 0.24 8.37 1.21 0.41 68 constant term 0.22 0.0 1.54 0.20 1.62 12 note odd ratio ci confid interv se standard error dickson spillmann al bmc public health 2013 13 1227 page 7 9 http www.biomedcentral.com 1471 2458 13 1227 relax 00 month intervent group show higher cigarett consumpt compar week follow hypnosi 13.6 sd 8.6 laxat 14.3 sd 7.3 type intervent significantli predict number daili cigarett smoke month follow 0.75 β 0.05 se 1.27 59 95 ci 3.39 1.89 56 0.09 95 ci 0.42 0.24 icc hypnosi 03 relax 00 hypnosi group member show lower mnw score relax group member linear regress analysi reveal intervent pre dict mnw score effect small 36 β 31 se 14 2.54 95 ci 0.66 0.06 02 0.05 95 ci 0.58 0.48 icc hypnosi 00 relax 42 member intervent group show similar efficaci tabl 3 tabl 3 mean standard deviat sd secondari outcom week follow intervent group secondari outcom hypnosi relax sd sd daili cigarett previou 7 dai 9.40 7.70 8.90 7.00 mnw 0.60 0.63 0.63 0.55 smoke abstin efficaci 4.31 0.67 4.22 0.80 advers event 1.22 0.30 1.19 0.24 headach 1.30 0.61 1.33 0.67 dry mouth 1.41 0.78 1.32 0.67 nausea vomit 1.06 0.28 1.08 0.34 tast disord 1.14 0.40 1.11 0.38 visual problem 1.19 0.55 1.10 0.39 abdomin pain 1.23 0.57 1.22 0.52 constip 1.30 0.65 1.21 0.52 skin rash 1.13 0.42 1.11 0.43 itch 1.18 0.58 1.18 0.48 abnorm dream 1.34 0.76 1.26 0.68 symptom 1.13 0.51 1.20 0.61 intervent type effect efficaci 37 β 37 se 24 1.55 95 ci 0.13 0.86 14 0.12 95 ci 0.41 0.65 icc hyp nosi 33 relax 00 advers event index assess week follow show similar mean inter vention group linear regress analys confirm absenc intervent effect 00 β 02 se 04 0.24 95 ci 0.08 0.07 81 0.11 95 ci 0.17 0.39 icc hypnosi 01 relax 00 report cessat aid cd particip abstin month follow hypnosi group relax group cessat method therapi session month follow hypnosi group cd averag 1.01 sd 4.32 time previou 30 dai relax group averag 0.32 sd 1.54 time differ signific 1.43 df 115.86 se 0.48 15 95 ci 0.26 1.64 0.21 95 ci 0.09 0.50 icc hypnosi 00 relax 00 discuss studi investig efficaci sin gle session group hypnosi smoke cessat larg sampl smoker quit find group hypnosi effect smoke cessat group relax abstin rate result trial parabl figur lower end stu di singl session group hypnosi 18.5 25 abstin 15,18,25 studi report higher ab stinenc rate 45 50 26,50 abstin rate superior previous report 7 8 success rate cessat aid explain particip strong quit intent 52 experienc social support 53 56 contact therapist dickson spillmann al bmc public health 2013 13 1227 page 8 9 http www.biomedcentral.com 1471 2458 13 1227 undergo psycho educ part receiv sug gestion relax state relax hypnosi advers event week intervent group differ hypnosi su perior relax regard attenu withdraw symptom smoke cessat psycho logic hypnosi lead enhanc smoke ab stinenc efficaci compar relax larg sampl size support generaliz find popul similar socio demo graphic cultur background strong intent quit neg side generaliz lower fact studi therapist conduct session quantifi therapist intervent effect trial present limit ad dress debrief particip studi condit want prevent specul condit behav accord ing specul particip disappoint receiv de sire intervent lower mo tivat stai abstin follow period retrospect eleg leav particip blind follow assess guess condit expect condit absenc group effect lead idea particip hypnosi condit state compar particip relax condit check induct hypnosi success report instrument suffici discrimi nant valid differenti hypnosi relax ation futur research deal question easili applic econom manipul check hypnotherapi studi conduct conclus conclus studi attend singl smoke cessat session psycho educ part relax group highli mo tivat smoker yield success rate 15 18 hypnosi effect specif effect therapist contact social support relax foster smoke abstin compet interest author declar compet interest author contribut md coordin studi perform statist data analysi wrote manuscript sh gave substanti input data analysi critic review manuscript ms develop studi design author contribut approv final manuscript receiv 26 septemb 2013 accept 20 decemb 2013 publish 23 decemb 2013
journal consult clinic psycholog copyright 1998 american psycholog associ 1998 vol 66 3 549 557 0022 006xp98 3.00 tailor intervent commun stage match inform smoker motiv stage ari dijkstra hein de vri jolanda roijack gerard van breukelen maastricht univers smoker stage low readi quit immot precontempl smoker stage high readi quit contempl prepar randomli alloc 1 4 tailor intervent condit offer outcom inform efficaci enhanc inform sort inform inform data 1,540 smoker stratifi stage analyz primari outcom measur stage transit hypothes regard stage match informa tion immot precontempl verifi regard contempl pre parer found compar control group contempl benefit sort inform prepar benefit efficaci enhanc inform comparison contempl prepar assign match treatment contempl prepar assign mismatch treatment support find intervent smoke cessat lower percentag smoker popul lich tenstein glasgow 1992 smoker interest intervent direct peopl intend quit smoke netherland 70 smoker plan quit 6 month mudd dolder de vri 1994 conceiv impact intervent smoke rate popul enhanc target larg group smoker stage chang model prochaska diclement cross 1992 explicitli recogn group smoker low readi chang model view behavior chang process readi chang behavior intern izat behavior distinguish discret stage behavior chang regard intervent stage match principl deriv stage chang model intervent direct stage aim intervent stage transit theoret point view stage match intervent direct chang cognit determin respons transit stage basi earlier cross section studi suggest smoker low readi quit informa tion outcom progress stage smoker ari dijkstra hein de vri jolanda roijack depart health educ maastricht univers maastricht netherland gerard van breukelen depart methodolog statist maa tricht univers maastricht netherland research support grant dutch cancer societi correspond articl address ari dijkstra depart clinic health psychol ogi leiden univers p.o box 9555 2300 rb leiden nether land electron mail adijkstra rulfsw.leidenuniv.nl high readi quit efficaci enhanc ing inform de vri backbier 1994 dijkstra de vri bakker 1996 similarli jani mann 1977 sound decis make process peopl process inform consequ chang chang behavior process inform chang behavior miller rollnick i991 literatur search reveal studi differenti im pact outcom inform efficaci enhanc infor mation behavior chang develop stage match intervent data impact sort inform interact stage chang present studi extend version origin stage chang model dijkstra bakker de vri 1997 group smoker plan quit 6 month smoker stage recogn immot plan quit 5 year plan quit precontempl plan quit 5 year 6 month precontempl consid er stage immot consid er stuck low readi smoker plan quit 6 month smoker stage recogn contempl plan quit 6 month month prepar plan quit month diclement al 1991 contempl consid er quit prepar decid quit short term group smoker increas readi quit distinguish immot precontempla tot contempl prepar regard stage match intervent find de vri backbier 1994 dijkstra de vri bak ker 1996 extrapol stage model regard extrem group immot prepar 549 550 dijkstra de vri roijack van breukelen expect immot benefit outcom inform reason quit efficaci enhanc inform quit prove detriment trigger defens inform process strong behavior chang appeal sort inform larg mismatch smoker low readi quit prepar benefit effi caci enhanc inform outcom inform highli redund inhibit inform process expect smoker intermedi roup recon templa con templa wou ld benefit combin sort inform type inform stimul stage transit goal studi practic assess sort inform smoker stage offer smoke cessat intervent effect experiment condi tion compar stage informa tion control condit condit offer outcom format efficaci enhanc inform sort inform addit experiment condit compar goal studi assess principl stage match format ion smoker stage sort fo rma ion cou ld demon strate smoker assign stage match condit compar smoker sign stage mismatch condit primari outcom measur stage transit measur definit outcom measur smoker stage velic rossi prochaska dicl ment 1996 valid result obtain measur convent measur intent quit point preval abstin measur part ic ipant recrui tment smoker recruit advertis local newspap netherland group smoker explicitli invit particip studi smoker plan quit 6 month high readi chang smoker plan quit next6 month low readi chang ask volunt research project minim intervent smoke cessat includ possibl control group member particip complet question nalr offer opportun l0 bonu prize amount 100 particip phone univers regist 1,733 pretest questionnair return prepaid envelop 2 week 1,540 88.9 pretest questionnair return exclud 60 questionnair pipe cigar smoker fill incomplet smoker randomli assign condit inform outcom quit oc condit 384 efficaci enhanc inform se condit 385 sort inform bo condit 386 inform condit 385 participa4at experiment condit intervent materi mail control condit receiv letter told receiv informa tion t2 10 week t3 intervent particip posttest questionnair articl pre sent data t1 t3 data evalu intervent t2 tailor feedback intervent consist comput gener individu tai lore intervent letter condit specif sort inform computer system gener tailor letter adapt previou evalu minim intervent smoker plan quit dijkstra de vri roijack press present intervent consist page individu report base pretest questionnair score decis rule develop relat question answer questionnair lead inform intervent combin potenti part messag coher messag report experiment condit contain specif sort inform mention design section tailor individu stage chang perceiv outcom situat effi caci level smoke behavior person letter men tion individu time letter specif measur guarante standard prevent number page exceed program expert system shorter messag condit content messag part vari depend individu score topic address letter oc condit introduct tailor letter state readi crucial smoke cessat letter meant enhanc readi stress pro quit letter contain inform outcom smoke quit ring includ person health consequ social consequ nonsmok partner appreci smoke cessat consequ smoke peopl environ amount inform present depend individu score item assess expect outcom monetari cons quenc amount monei save 1 month 1 year quit comput respond restructur inform offer neg outcom quit weight gain loss function smoke relax expect withdraw symptom smoker anticip strong withdraw symptom tempor charact symptom explain letter se condit introduct tailor letter state activ skill quit crucial smoke cessat letter meant enhanc individu confid abil quit offer skill prove help smoker letter contain inform skill cope social emot addict situat depend indi vidual confid score skill cope crave stress anger depress mood withdraw symp tom social pressur address smoker report lot confid refrain smoke specif situat smoker told increas chanc success quit smoker moder confid refrain smoke specif situat cognit behav ioral skill offer bo condit introduct tailor letter rational offer stress import sort inform topic address letter oc se condit address condit pal highlight 24 inform health consequ 26 inform social environment consequ pal highlight 32 inform approv pal highlight 73 frame refram pal highlight 20 instruct perform behaviour pal highlight 87 verbal persuas capabl pal comment text 63 reduc neg emot pal comment text link 20 63 87 efficaci stage match smoke cessat intervent 5 5 1 stage chang stage transit stage chang sess confront smoker plan regard smok ing cessat quit plan ask quit plan fit intent quit smoker plan quit month consid prepar smoker plan quit 6 month consid contempl smoker plan quit year 5 year consid precontempl smoker plan quit futur 5 year smoke indefinit cut smoke indefinit cut consid immot primari outcom measur stage transit assess dichotom stage forward transit score 1 transit backward transit score 0 particip consid action state engag quit attempt time measur intent verifi result obtain stage transit measur common outcom measur intent quit measur composit 10 point scale intend quit smoke respons rang 1 10 quit smoke 1 10 intent score averag item score point preval abstin conserv criterion assess smoke cessat smoke dai pu biochem verif report quit behavior conduct pect announc biochem verif creas nonrespons dropout smoker plan quit 6 month velic procbaska rossi snow 1992 lead highli select group immot precontempl half sampl consist smoker 3 month follow plan quit smoke consid import outcom measur velic etal 1992 pro con quit twenti item assess anticip physic social evalu monetari outcom quit item rate 0 expect 3 strong expect outcom item deriv questionnair assess pro con quit earlier studi stage chang dijkstra ta 1996 studi pattern pro con quit stage ident pattern found decision balanc measur velic diclement prochaska brandenburg 1985 present scale assess pro quit compos 15 item refer posit outcom behavior chang cron bach alpha 87 scale assess con quit compos 6 item refer neg outcom behavior chang 57 averag item score scale score correl scale signific low 24 efficaci expect item assess particip abil refrain smoke situat item deriv questionnair studi predict power efficaci smoke cessat mudd kok strecher 1995 factor analys reveal factor efficaci cope social situat item 81 efficaci cope neg emot item 86 efficaci expect measur 7 point scale 3 refrain smoke 3 refrain smoke averag item score scale score smoke behavior demograph smoke behavior mea sure smoker year smoke cigarett smoke averag engag 24 hr quit attempt preced 12 month heavi smoke measur fagerstrtm test nicotin depend ftnd heatherton kozlowski frecker fagerstrtm 1991 assess smoke habit item item score ad minimum score 0 maximum 10 71 demograph measur gender ag educ level categor low medium high tailor intervent check extent primari condit effect met particip ask t2 extent read letter respons rang 1 read 10 read tat ical ana ly se outcom measur binari multivari test multivari analysi varianc binari measur stage transit 7 dai cessat logist regress quantit outcom measur intent quit linear regress sex ag level educ routin includ covari analys increas power reduc unexplain varianc robinson jewel 199 condit dummi code test tail alpha set 05 test tailor intervent condit effect compar condit group smoker analys stratifi stage stage experiment condit compar inform group expect stage hypothes stage match condit effect condit experiment condit compar match mismatch test conduct test smok er receiv stage match inform made stage transit quit 7 dai greater intent quit compar smoker receiv inform mismatch stage expect explain introduct depict tabl 1 manipul check assess extent condit led cognit final determin extent smoker read intervent materi par ipan characteri ic check ion 1,540 sponden 59 ema le av rage ag 39.7 sd 12 2 level educa ion 2 2 lass i low 4 3 3 5 igh av rage 20.3 igar te pe sd tabl 1 hypothes stage match mismatch inform provid smoker motiv stage mismatch particip group inform inform immot 310 oc 107 bo se precontempl 226 bo 63 oc se contempl 197 bo 64 se oc prepar 116 se 37 bo oc note oc outcom inform se efficaci enhanc inform bo type inform 552 dijkstra de vri roijack van breukelen 9.1 smoke averag 21.8 year sd 11.8 averag ftnd score 4.6 sd 2.5 respond 44.9 engag quit attempt year 32.6 categor immot 26.6 precontempl 24.2 contempl 16.6 prepar cognit measur mean score pro con quit 1.59 sd 0.6 1.26 sd 0.6 efficaci regard emot state social situat 0 97 sd 1.3 0.19 sd 1.2 final mean score intent quit 5.9 sd 2.8 check random success pare condit sex ag level educ stage ftnd score number cigarett smoke dai number year smoke quit attempt 12 month pro con quit efficaci factor intent quit measur t1 addit check condi tion compar score quit plan chi squar test discret variabl test continu variabl reveal signific differ condit variabl attrit pretest t1 posttest 2 t3 28.8 440 logist regress analysi attrit depend variabl t1 variabl involv random izat check com.ibm.drl.hbcp.predictor reveal signific 05 rela tion dropout male drop fre quentli condit oc bo condi tion contempl prepar tabl 2 percentag dropout stage condit attrit relat condit pretest stage analys dropout led bias result check bia addit analysi perform dropout includ miss t3 replac record t1 t2 analys test tailor intervent condit effect compar condit group smoker analys show experiment condit led signific 05 increas compar condit outcom measur ception receiv outcom inform lead 7 dai cessat receiv inform con trast analys experiment condit led sig nificantli result tabl 3 4 show effect condit stage contrast experiment condit immot hypothes immot bene fit oc condit stage transit intent quit condit outcom inform oc bo condit led signific creas compar condit regard 7 dai smoke cessat experiment condit led significantli quit condit contrast analys experiment condit differ significantli precontempl hypothes precontempla tor benefit bo condit stage transit condit efficaci en hanc inform se bo condit led signifi cantli stage transit condit experiment condit led significantli higher intent regard cessat smoke week experiment condit led signifi cantli quit contrast analys experiment condit significantli differ contempl hypothes contempl precontempl benefit bo condit stage transit intent quit experi mental condit present sort inform bo condit led signific increas compar condit regard refrain smoke 7 dai experiment condit led significantli quit contrast analys contrast signific 05 contempl bo condit report greater intent contempl se condit prepar hypothes prepar benefit se condit condit effi caci enhanc inform se condit led sig nificantli stage transit significantli 7 dai cessat condit experiment tabl 2 percentag dropout t1 t3 condit transit stage transit stage immot precontempl contempl prepar condit t1 1,540 502 409 374 255 att3 1,540 28.7 20.1 26.9 33.5 40.6 outcom inform 384 23.4 19.5 20.8 29.4 26.4 efficaci enhanc inform 385 29.6 25.9 21.6 31.5 46.4 type inform 386 26.4 12.7 33 30.4 39.4 control inform 385 34.8 23.5 32.4 43.3 47.1 t3 1,100 401 299 248 152 1,100 295 272 284 251 note t1 time 1 intervent t3 time 3 10 week intervent stage match smoke cessat intervent tabl 3 intent quit t3 stage condit mean raw beta adjust sex ag educ oc oc se se bo bo particip group 5 8 9 0.61 5 8 2 0.60 6.18 0.89 5.27 immot 3.80 0.74 3.61 0.53 3.94 0.88 3.04 precontempl 6.38 0.73 6 6 6 1.00 6.79 1.14 5.66 contempl 7.92 0.54 7.57 0.18 8.22 0.84 7.38 prepar 7.60 0.18 7.55 0.12 7.98 0.61 7.40 note particip t3 state refrain smoke 7 dai exclud outcom analysi intent quit smoke condit dummi code posit beta effect experiment group exceed control group column beta mean adjust sex ag educ t3 time 3 10 week intervent oc outcom inform se efficaci enhanc inform bo sort inform control inform contrast analys experiment condit comput stage contempl bo condit significantli higher intent quit contempl se condit 05 01 001 553 condit led significantli higher intent quit contrast analys contrast signific 05 prepar se condit report 7 dai cessat prepar oc condit match mismatch test smoker assign stage match condit compar assign stage mismatch con dition outcom measur tabl 2 show size match group small test binari outcom variabl analys smoker low readi quit immot pre contempl combin match smoker im motiv oc condit precontempl bo condit compar mismatch smoker immo tive bo se condit precontempl oc se condit binari match mismatch variabl comput enter regress analys outcom measur smoker high readi quit contempl bo condit prepar se condit match compar contempl oc se condit prepar oc bo condit mismatch match mismatch test show result smoker low readi quit percentag smok er made forward stage transit ceiv stage match inform differ significantli receiv mismatch inform 32.9 31.9 faa'thermor nonsignific differ found regard 7 dai cessat 2.9 4.1 intent quit 5.10 4.94 smoker high readi quit percentag stage transit receiv stage match inform borderlin significantli 10 higher receiv mismatch inform 44.8 34.7 regard 7 dai cessat match smoker quit borderlin significantli mismatch smoker 17.8 10.3 intent quit differ significantli smoker match 7.80 7.99 post hoc analys set post hoc analys concern distinct immot precontempl match mismatch test smoker low readi quit signific argu present distinct tween immot precontempl smoker justifi place post hoc analys comput immot precontempl smoker pool group smoker plan quit 6 month contrast analys test group benefit experiment condi tion match mi match analys comput data pool group oc condit match condit mismatch bo condit match condit mismatch se condit match condit mismatch contrast analys match mismatch analys reveal signific effect regard stage transit 7 dai cessat intent quit compar pool group data refut justifi distinct immot precontempl set post hoc analys concern data backward stage transit tabl 4 perform posit effect intervent neutral backward stage transit immot back ward transit con trast condit contempl experiment condit lead significantli fewer backward transit control group match mi match analys hypothes fewer match smoker 5 5 4 dijkstra de vri roijack van breukelen tabl 4 stage transit point preval abstin 7 dai cessat t3 stage condit percentag odd ratio stage transit oc oc se se bo bo dai cessat odd ratio odd ratio odd ratio stage transit sampl forward 31.2 1.89 36.5 2.42 35.6 2.34 19.1 backward 11.5 10.2 8.4 17.4 immot forward 32.0 2.11 27.5 1.85 30.6 2.09 17.4 precontempl forward 28.8 1.90 40.7 3.23 34.5 2.50 17.1 backward 5.5 4.9 1.7 15.7 contempl forward 29.0 1.71 32.2 1.91 39.3 2.64 20.0 backward 14.5 18.6 16.4 28.9 prepar forward 37.8 1.70 54.3 3.49 45.9 2.60 25.7 backward 48.6 31.4 30.6 48.6 dai cessat sampl 4.8 1.52 8.5 2.91 8.1 2.71 3.2 immot 1.9 1.2 3.4 1.1 precontempl 5.3 2.03 7.0 2.73 4.8 2.7 contempl 6.9 1.84 8.2 2.11 10.9 2.94 3.9 prepar 7.7 29.7 5.00 22.0 2.81 8.3 note odd ratio 5 depict signific odd ratio greater 1.00 mean percentag experiment condit significantli higher percentag control condit column odd ratio percentag adjust sex ag educ t3 time 3 10 week intervent oc outcom inform se efficaci inform bo sort inform inform contrast analys experiment condit comput stage prepar se condit quit smoke 7 dai significantli prepar oc condit 0 5 01 001 mismatch smoker make backward transit veal differ manipul check read letter expect intervent outcom inform increas expect posit intervent efficaci enhanc inform increas efficaci sort informat ion decreas expect neg outcom dijkstra al press tabl 5 show mean cognit measur condit particip refrain rom smoke week exclud analys leav 1,032 particip 393 immot 284 precontempl 229 contempl 126 prepar receiv outcom inform oc condi ion outcom efficaci enhanc inform condi ion led anticip pro receiv informat ion condi ion contrast analysi reveal receiv outcom inform led anticip significantli pro receiv combinat ion inform receiv efficaci enhanc inform se condi ion led increas efficaci cope social situat signific effect found regard con quit efficaci cope emot extent smoker report hav ing read tailor letter effect stage condit mean score 10 point scale rang 9.27 9.85 analys includ dropout attrit ion t3 predict condit sex stage t1 present result influenc select dropout studi problem measur t1 t2 dropout substitut t3 measur repeat analys heyt ing tolboom esser 1992 t3 data miss 440 particip drop miss partici pant 145 replac t2 data 295 t1 data regard 7 dai smoke cessat outcom measur dropout consid smoke 7 dai analys signific result chang qualita tive minor beta odd ratio valu emerg goal studi assess sort informa ion smoker stage offer smoke cessa stage match smoke cessat intervent tabl 5 manipul check mean raw beta cognit variabl t3 condit adjust pretest score sex ag educ 555 oc se bo 281 oc 249 se 261 bo 243 variabl scale rang pro quit 0 3 1.72 0.16 1.58 0.02 1.64 0.08 1.56 con quit 0 3 1.19 0.01 1.20 0.01 1.22 0.03 1.19 efficaci social situat 3 3 0.00 0.14 0.06 0.19 0.05 0.09 0.013 emot efficaci 3 3 0.74 0.16 0.77 0.13 0.81 0.08 0.89 note particip t3 state refrain smoke 7 dai exclud analys condit dummi cede posit beta mean score experiment group exce control group t3 time 3 10 week intervent oc outcom inform se efficaci enhanc inform bo sort inform inform 05 01 001 tion intervent test practic pare experiment condit inform condit stage transit measur stage result obtain immot condit pre sent outcom inform led transit condit precontempl condit present efficaci enhanc inform led tran sition contempl condit present ing type inform led transit condit prepar condit present efficaci enhanc inform led transit hypothes contempl prepar verifi immot precontempl partli case contrast experiment group regard stage transit signific result permit preliminari recommend intervent direct stage practi calli intervent need intervent outcom inform efficaci enhanc format direct immot precontempl contempl intervent efficaci en hanc inform direct prepar goal studi assess principl stage match inform demonstr match mismatch test reveal smoker high readi quit assign match treatment made borderlin significantli stage transit stop smoke week borderlin significantli smoker assign mismatch treatment addit contrast analys reveal contempl condit offer type information.had greater intent quit condit offer efficaci enhanc inform prepar condit offer efficaci enhanc inform stop smoke week condit offer outcom inform result comparison inform group result contrast analys match mismatch analys strongli contempl combin outcom inform efficaci enhanc ing inform prepar efficaci enhanc format earlier research show effect smoke cessat intervent lower smoker contempl stage smoker prepar stage diclement al 1991 prochaska 1991 find strongli support distinct stage high readi quit smoker low readi quit result partli unexpect smoker assign match treatment benefit treatment smoker assign mismatch treatment mean matter kind informa tion smoker low readi offer long offer inform smoke smoke cessat esp cialli immot condit led small differ percentag smoker made forward stage transi tion largest differ experi mental condit 4.5 immot 11.9 precontempl 10.3 contempl 16.5 pre parer precontempl data intent quit show experiment condit led signific creas compar condit data stage transit immot intent quit pre contempl support notion type inform present studi specif match mismatch smoker low readi quit explan consid lack match mismatch inform relat exist smoker subtyp velic hugh fava prochaska diclement 1995 smoker low readi quit includ group immot precontempl benefit inform benefit efficaci enhanc inform pre ent inform condit manipul match mi match inform relev smoker low readi quit smoker variabl frame inform length intervent messag match mismatch smoker low readi quit messag smoke smoke cessat chang target 556 dijkstra de vri roijack van breukelen cognit smoker stage process informa tion smoke smoke cessat diclement al 1991 prochaska al 1992 prochaska velic diclement fava 1988 tailor intervent lead intervent understood tailor intervent cue action al explan plausibl present find support hypothes match immot precontempl respect smoker contempl prepar stage differ smoker low readi quit support distinct smoker high readi quit low readi quit data reveal addit relev result exam ple result obtain stage transit primari measur support convent measur intent quit reveal pattern effect immot precontempl contempl 7 dai cessat measur reveal pattern prepar fact stage transit outcom measur bine convent outcom measur earli stage defin term similar measur intent stage action stage defin term behavior effect tailor intervent consid mediat cognit expect outcom efficaci expect basic condit cognit met experi mental condit smoker stage report read letter averag score 10 point scale 9 high figur explain person relev tailor letter smoker recogn smoke behavior psycho logic profil intervent expect cognit partli detect receiv inform outcom smoke cessa tion led anticip pro quit receiv efficaci enhanc inform led confid abil cope social situat receiv type inform time result antici pation pro quit effect small anticip con quit perceiv efficaci cope emot significantli chang intervent result cognit underestim exclus 7 dai quitter analys promis exclus page individu inform chang relev cognit 10 week limit present studi short follow smoker stage time develop addit extent result influenc select dropout particip intent treat analys suggest influ enc differ small sampl select immot precontempl psycholog defens confront smoke behavior join studi hand appro priat sampl draw conclus futur applica tion tailor inform direct kind smoker futur research present stage match result replic group smoker low readi quit address map popul smoker match mismatch manipul develop group smoker low readi quit compris signific proport smoke popul netherland 70 mudd al 1994 unit state 40 velic al 1995 justifi continu effort target group
full term condit access found http www.tandfonline.com action journalinform journalcod nhyp20 download univers aberdeen date 22 januari 2016 03 42 intern journal clinic experiment hypnosi issn 0020 7144 print 1744 5183 onlin journal homepag http www.tandfonline.com loi nhyp20 intens hypnotherapi smoke cessation:a prospect studi gari elkin joel marcu jeff bate hasan rajab teresa cook cite articl gari elkin joel marcu jeff bate hasan rajab teresa cook 2006 intens hypnotherapi smoke cessation:a prospect studi intern journal clinic experiment hypnosi 54 3 303 315 link articl http dx.doi.org 10.1080 00207140600689512 publish onlin 29 oct 2010 submit articl journal articl view 524 view relat articl cite articl 11 view cite articl http www.tandfonline.com action journalinform journalcod nhyp20 http www.tandfonline.com loi nhyp20 http dx.doi.org 10.1080 00207140600689512 http www.tandfonline.com action authorsubmiss journalcod nhyp20 page instruct http www.tandfonline.com action authorsubmiss journalcod nhyp20 page instruct http www.tandfonline.com doi mlt 10.1080 00207140600689512 http www.tandfonline.com doi mlt 10.1080 00207140600689512 http www.tandfonline.com doi citedbi 10.1080 00207140600689512 tabmodul http www.tandfonline.com doi citedbi 10.1080 00207140600689512 tabmodul intl journal clinic experiment hypnosi 54 3 303 315 2006 copyright intern journal clinic experiment hypnosi issn 0020 7144 print 1744 5183 onlin doi 10.1080 00207140600689512 303 nhyp0020 71441744 5183journal clinic experiment hypnosi vol 54 03 april 2006 pp 0 0intl journal clinic experiment hypnosisintens hypnotherapi smoke cessat prospect study1 intens hypnotherapi smoke cessationgari elkin al gari elkin joel marcu jeff bate hasan rajab2 scott white memori hospit clinic templ texa usa teresa cook baylor univers waco texa usa abstract studi report prospect pilot trial intens hypnotherapi smoke cessat hypnotherapi involv mul tipl individu session 8 visit approxim 2 month indi vidual hypnot suggest support therapeut relationship twenti subject randomli assign intens hypnotherapi condit wait list control condit target quit date 1 week begin treatment patient evalu smoke cessat end treatment week 12 26 report abstin confirm carbon monoxid concentr expir air 8 ppm rate point preval smoke cessat confirm carbon monoxid measur intens hypnotherapi group 40 end treatment 60 12 week 40 26 week 05 cigarett smoke major prevent diseas major prematur death smoke lead risk factor chronic obstruct pulmonari diseas cancer vascular diseas mortal u. depart health human servic 1990 peopl smoke awar fact smoke associ at health risk 80 current smoker express desir stop smoke usdhh 1990 smoker success quit smoke assist giovino henningfield tomar escobedo slade 1995 manuscript submit 20 2005 final revis receiv august 29 2005 1the author paul cinciripini univers texa m.d anderson cancer center guidanc select outcom measur studi design appreci express matthew ridlei jennif gibbon rameriz serv studi coordin 2address correspond gari elkin ph.d abpp abph scott white clinic 2401 south 31 street templ tx 76508 usa mail gelkin swmail.sw.org ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 304 gari elkin al retrospect clinic studi hypnotherapi shown encourag promis smoke cessat crasilneck 1990 elkin rajab 2004 outcom studi hypno therapi smoke cessat date fail achiev random izat includ biolog marker smoke cessat fior al 1996 2000 result potenti effect hyp nosi remain larg unknown green lynn 2000 random studi hypnosi examin minim approach hypnotherapi involv session group intervent berkowitz ross townsend kohberg 1979 cornwel burrow mcmurrai 1981 hyman stanlei burrow horn 1986 javel 1980 neufeld lynn 1988 pederson scrimgeour lefco 1975 rabkin boyko shane kaufert 1984 spano mondoux burgess 1995 spano sim defay mondoux gabora 1992 spiegel frischholz fleiss spiegel 1993 spiegel 1970 stanton 1978 william hall 1988 find minim approach hypnosi smoke cessat outcom 20 25 cessat cornwel al rabkin al recent green lynn 2000 complet comprehens review studi com.ibm.drl.hbcp.util hypnosi smoke cessat conclud appar minim hypnot intervent develop spiegel 1970 group hypnosi intervent lynn neufeld rhue matorin 1993 achiev abstin rate 20 hypnosi shown effect treatment smok ing intens treatment approach hyp nosi greater benefit smoke cessat green lynn 2000 suggest intens intervent contact gener result higher cessat rate fior al 2000 develop innov intens approach hypnosi smoke cessat consist recommend purpos present studi establish benefici effect intens approach hypnotherapi smoke cessat prospect random pilot studi biolog marker abstin hypothes intervent result smoke cessat rate 30 higher sustain 6 month follow visit method subject subject recruit physician referr advertis ment total 28 volunt interest stop smoke evalu 20 met studi criteria studi approv scott white clinic hospit institut review board initi screen subject ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 intens hypnotherapi smoke cessat 305 attend inform meet studi explain questionnair complet written inform consent provid subject elig inclus 18 year ag report smoke 10 cigarett dai inter est quit smoke 30 dai abil attend weekli session spoke english exclus criteria includ regular noncigarett tobacco product report current abus alcohol psychoact drug current smoke cessa tion treatment report histori borderlin person disor der hypnotherapi reason baselin characterist particip shown tabl 1 averag ag particip earli mid 40 major femal caucasian marri high school cation smoke 20 cigarett dai fagerstrom score slightli greater 10 tabl 1 baselin characterist subject characterist control hypnotherapi ag 41.7 10.2 43.7 8.4 femal gender 80 60 caucasian race 100 90 cigarett smoke dai 25.7 9.6 22.2 6.1 fagerstrom score 10.9 1.2 10.7 8 marit statu marri live partner 70 90 singl 0 10 divorc 30 0 educ hs ged 60 80 1 3 yr coll 20 0 coll degre 10 1 post grad degre 10 1 reason want stop smoke health 100 100 expens 50 80 spous famili request 30 30 job requir 10 0 insur cost 40 10 smell bad 80 40 30 20 ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 306 gari elkin al measur baselin data assess complet demograph inform smoke behavior reason want stop smoke perceiv benefit smoke cessat baselin nicotin depend assess 8 item fagerstrom test nicotin depend ftnd scale ftnd wide mea nicotin depend score rang 0 11 score 6 greater higher level depend fagerstrom schneider 1989 report abstin confirm expir carbon monoxid measur baselin end treatment week 8 week 12 26 subject classifi abstain report smoke 7 dai prior assess valu 8 ppm cinciripini al 2003 inconsist report valu note 7 measur inconsist report valu resolv saliva cotinin analysi 20 ng ml procedur baselin visit subject randomli assign receiv intens hypnotherapi smoke cessat wait list control group subject wait list control group receiv materi nation cancer institut glynn manlei 1990 encourag set date quit smoke assess smoke cessat complet week 8 12 26 particip receiv 25 follow appoint attend research staff provid support phone call particip 3 dai target quit date week 2 4 5 support phone call last 5 10 minut intens hypnotherapi intervent provid doc toral clinic psychologist psyd physician md therapist complet 40 hour train hypnotherapi provid pri mari investig train guidelin learn object outlin public standard train clinic hypnosi hammond elkin 1994 therapist receiv addi tional train hypnotherapi treatment studi subject assign intens hypnotherapi intervent met research therapist visit prepar visit provid discuss myth misconcept hypnosi process hypnot induct elkin handel 2001 visit prepar visit subject receiv materi nation cancer institut glynn manlei 1990 subject receiv 30 minut counsel session includ explor ambival quit prepar quit problem solv difficult situat commit semi tructur counsel script subject ask set target quit ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 intens hypnotherapi smoke cessat 307 date approxim 7 dai subject intens hypno therapi group provid hypnosi tape record tape player instruct daili practic hypnosi collect report averag number cigarett smoke dai 7 dai prior assess abstin subject unavail assess count abstain allow particip miss person visit prior assess 26 week outcom period chosen evid suggest cessat rate 26 52 week differ substanti fagerstrom 1989 hjalmarson 1984 hugh gust keenan fenwick healei 1989 hurt al 1994 kornitz boutsen dramaix thij gustavsson 1995 russel al 1993 fee stewart 1982 sach saw leischow 1993 tonnesen norregaad simonsen saw 1991 subject intens hypnotherapi intervent group receiv session session last approxim 1 hour counsel session occur visit time subject receiv encourag practic hypnosi hypnot induc tion complet session 1 2 4 7 standard transcript suggest deepen relax ation absorpt relax imageri commit stop smoke decreas crave nicotin posthypnot suggest practic hypnosi visual posit benefit smoke cessat subject ask session prefer specif imageri relax dissoci suggest fol low transcript specif imageri relax posit benefit smoke cessat individu base question determin patient prefer imageri hypnot induct summar ey focu induct begin focus attent spot wall concentr begin feel relax concentr intens thing begin fade background occur notic relax heavi feel allow ey lid close relax notic wave relax begin top head spread forehead face neck shoulder muscl fiber bodi complet relax notic feel let deepli relax comfort remain relax find feel ing comfort feel safe secur peac feel calm secur feel calm bother interfer feel comfort mental imageri relax hear voic part mind part place feel safe ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 308 gari elkin al secur place deepli relax respond suggest feel feel experi commit smoke cessat todai smoker free nicotin free cigarett smoke cigarett tobacco dai passesh commit remain free cigarett stronger time enter relax state rememb reason stop smoke dissoci crave enter deeper level hyp nosi notic float sensat awar bodi float space bodi float feel comfort mind awar pleasant place individu imageri pleasant place bodi float bother crave nicotin mind block consciou awar crave feel detach bodi relax posthypnot suggest remain free nicotin free cigarett find sens satisfact accomplish find sleep sens smell improv sens tast improv eat excess find amount food satisfi hypnosi time practic hypnosi listen tape record provid todai enter deep state relax deep todai relax state find feel control deepli relax comfort feel dissoci consciou awar excess crave nicotin relax state commit ment remain free cigarett stronger find kind strength practic hypnosi posit imageri benefit smoke cessat futur nonsmok free nicotin cigarett notic good thing healthi feel individu imageri introduc depend patient perceiv benefit smoke cessat feel smoke matter time stress difficult remain calm relax futur result efficaci intervent smoke cessat evalu weekli point preval abstin rate rate continu abstin case intent treat analysi perform point preval rate subject classifi ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 intens hypnotherapi smoke cessat 309 abstin report smoke previou 7 dai report confirm expir carbon monoxid 8 ppm classifi continu abstin subject confirm smoke basi carbon monoxid measur visit biochem confirm point preval smoke cessat rate shown tabl 2 fisher exact test com.ibm.drl.hbcp.util compar intervent wait list control respect point preval smoke cessat rate intens hypnotherapi intervent wait list control condit end treatment 12 week 26 week 40 10 15 60 0 005 40 0 043 rate continu abstin target quit date end treatment shown figur 1 result 30 continu abstin end treatment period subject control group achiev continu abstin averag number cigarett smoke dai assess ment point shown figur 2 week 26 averag number cigarett smoke intens hypnotherapi group comparison averag number cigarett smoke wait list control group remain stabl 20 cigarett dai discuss result present studi reveal intens hypno therapi intervent effect mean achiev smoke cessat rate smoke cessat 26 week follow 40 confirm expir carbon monoxid 8 ppm rate smoke cessat compar higher achiev pharmacolog nonhypnot behavior intervent small sampl hypnosi intervent accept result present studi support effi caci intens approach hypnotherapi adult smoker tabl 2 point preval smoke cessat rate confirm carbon monoxid measur time target quit date subject smoke valuecontrol intens hypnotherapi 8 week 10 40 15 12 week 0 60 005 26 week 0 40 043 fisher exact test ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 310 gari elkin al hypothesi intervent result smoke cessa tion rate 30 higher sustain 26 week follow visit confirm consist previou observ suggest intervent involv consider patient contact extend longer period time effect minim intervent rate fior al 2000 holroyd 1980 suggest likelihood success hypnosi treatment tobacco depend increas approach includ multipl session individu hyp notic suggest individu counsel follow intens interperson relationship present intervent consist observ add support approach hypnotherapi smoke cessat present studi limit includ small sampl size lack measur hypnotiz addit research larger sampl size enhanc confi denc generaliz result explor potenti variabl relat success intervent import assess subject level figur 1 percentag subject maintain continu abstin smoke week 1 week 7 ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 intens hypnotherapi smoke cessat 311 hypnotiz previou studi suggest hypno tizabl respons hypnot intervent smoke cessat marcovitch gelfand perri 1980 perri mullen 1975 effect hypnosi reduc withdraw symptom tobacco cessat determin hugh hatsukami 1986 investig intens hypnotherapi smoke ce sation warrant provid innov focu behavior research fior al 2000 recent observ innov develop nonpharmaco logic intervent smoke cessat past 20 year niaura abram 2002 shiffman 1993 innov behavior intervent smoke cessat need pharmacolog intervent bupropion nicotin replac yield cessat rate 35 combin jorenbi al 1999 combin behavior intervent cinciripini cinciripini walfisch van vunaki haqu 1996 30 smoker reject pharmacolog intervent unpleas unaccept side effect jorenbi al reason discontinu pharmacolog bine intervent ineffect hurt al 1997 figur 2 averag number cigarett smoke dai baselin 26 week intens hypnosi group control group ow nl oa de ni ve rs iti ee 0 3 42 2 2 ja nu ar 20 16 312 gari elkin al smoker prefer seek nonpharmacolog interven tion intens hypnotherapi conclus intens hypnotherapi intervent effec tive smoke cessat result cessat rate higher previous achiev minim approach random iz prospect studi base result initi pilot studi intens hypnotherapi inno vativ behavior intervent signific benefit smoker larger random studi integr state art method achiev high follow rate scott 2004 warrant fulli determin effect intervent studi reveal potenti cost save mediat factor hypnot suscept expect
effect vari level diseas manag smoke cessat random trial edward ellerbeck md mph jonathan mahnken phd paula cupertino phd lisa sanderson cox phd allen greiner md mph laura mussulman ma mph niaman nazir mbb mph theresa shireman phd kenneth resnicow phd jasjit ahluwalia md mph ms background cigarett smoke chronic relaps ill inadequ address primari care practic object compar cessat rate smoker receiv pharmacotherapi combin moder high intens diseas manag includ counsel provid feedback design random clinic trial june 2004 decemb 2007 set 50 rural primari care practic particip 750 person smoke 10 cigarett dai intervent pharmacotherapi 250 pharmacotherapi supplement 2 counsel call moder intens diseas manag 249 pharmacotherapi suppl ment 6 counsel call high intens diseas man agement 251 intervent offer 6 month 2 year particip offer free pharmacotherapi moder intens high intens diseas manag recipi ent postcounsel progress report fax physician measur report point preval smoke absti nenc 24 month primari outcom 0 24 month analys smoke abstin com.ibm.drl.hbcp.util pharmaco therapi discuss smoke physician secondari outcom research assist blind treatment signment conduct outcom assess result pharmacotherapi com.ibm.drl.hbcp.util similar treatment group 473 741 63.8 302 739 40.9 175 732 23.9 179 726 24.7 particip request pharmaco therapi fourth 6 month treat ment cycl particip physician treatment cycl 37.5 59.5 report discuss smoke cessat physician differ treatment group abstin rate increas studi 0 24 month analys dem onstrat higher abstin high intens diseas man agement group moder intens diseas manag group odd ratio 1.43 95 ci 1.00 2.03 combin diseas manag group pharmaco therapi group 1.47 ci 1.08 2.00 report abstin 24 month 68 244 27.9 56 238 23.5 particip high moder intens diseas manag group 1.33 ci 0.88 2.02 56 244 23.0 particip pharmacotherapi group 1.12 ci 0.78 1.61 combin diseas manag ment pharmacotherapi limit effect pharmacotherapi manag separ provis free pharmacotherapi cessa tion valid 58 report quitter conclus smoker make repeat pharmacotherapi assist quit attempt lead progress greater smoke abstin point preval abstin differ 24 month analys incorpor assess full 24 month treatment suggest higher intens diseas man agement increas abstin primari fund sourc nation cancer institut ann intern med 2009;150 437 446 www.annals.org author affili end text clinicaltrials.gov registr number nct00440115 cigarett smoke chronic ill character byrep cycl quit attempt relaps model address smoke cessat base sin gle short term intervent last week month 1 smoker quit singl intervent studi address chronic natur nicotin depend provid systemat petit treatment opportun 1 provid treatment smoker prepar quit limit reach current smoke cessat intervent 2 model chronic diseas care provid altern approach expand reach effect ness smoke cessat effort 3 physician direct contact approxim 70 smoker year 4 5 potenti role promot smoke cessat delin print editor note 438 editori comment 496 relat articl 447 summari patient 36 web appendix tabl convers graphic slide audio summari annal intern medicin articl 2009 american colleg physician 437 download http annals.org univ aberdeen user 02 15 2016 incorpor current clinic practic guidelin 1 develop effect prescript pharmacotherapi smoke cessat role pri mari care practic promot smoke cessat import half smoker physician ask smoke 6 fewer receiv advic health care provid quit receiv pharmacotherapi follow 4 7 smoke cessat counsel compet press clinic task advic physician feel busi routin repeatedli counsel particip smoke 8 10 assist primari care physician treatment rural smoker develop kanquit smoke cessat program base chronic care model 4 int grate principl diseas manag treatment smoker rural primari care object enrol smoker willing quit diseas registri compar cessat rate smok er receiv pharmacotherapi combin moder intens high intens diseas manag ment includ counsel provid feedback method design overview random singl blind trial vari lev el diseas manag smoke cessat cruit particip smoke 10 cigarett dai rural primari care clinic kansa randomli assign receiv pharmacotherapi pharmacotherapi supplement 1 2 counsel call 6 month moder intens diseas manag pharmacotherapi supplement 6 counsel call 6 month high intens diseas manag recipi moder intens high intens di eas manag fax period progress report physician offer particip free pharmaco therapi bupropion transderm nicotin patch 6 month enrol particip june 2004 octob 2005 24 month plete follow decemb 2007 particip pro vide written inform consent univers kansa medic center human subject committe approv studi set particip conduct studi 50 rural primari care prac tice kansa physician engag prevent search network 11 part rural primari care search experi train medic student systemat screen particip identifi smoker recruit studi interest quit 12 consid smoker elig primari care physician particip studi older 18 year smoke 10 cigarett dai 1 year 25 past 30 dai spoke english telephon exclud smoker pregnant plan pregnant plan move studi area sign dementia men tal ill preclud particip live smoker enrol studi 1827 smoker screen 61 met criteria studi entri figur 1 enrol 67 random intervent particip random random occur particip level comput gener random number tabl gener alloc card block 24 alloc equal distribut treatment group conceal al locat card sequenti number opaqu seal envelop research assist verifi particip elig complet baselin assess ment project director open sequenti seal envelop determin particip treatment alloc 9 counselor train smoke cessat motiv interview 12 conduct intervent singl central site assign particip counselor regard practic site pharmacotherapi baselin smoker receiv health educ mail consist letter inform bupropion nicotin patch smoke cessat copi quit smoke consum guid 13 smoker quit health benefit time 14 baselin 6 12 18 month particip receiv mail offer free pharmacotherapi consist 6 week nicotin patch 21 mg 7 week context smoke cessat difficult requir repeat intens intervent contribut multicent trial 750 primari care patient smoke 10 cigarett dai randomli sign pharmacotherapi nicotin patch bupropion pharmacotherapi supplement 2 call train counselor pharmacotherapi supplement 6 counsel call com.ibm.drl.hbcp.util interven tion offer 6 month 2 year declin time smoke abstin rate 2 year 23 24 28 3 group caution pharmacotherapi free smoke abstin report editor articl diseas manag smoke cessat 438 7 april 2009 annal intern medicin volum 150 number 7 www.annals.org download http annals.org univ aberdeen user 02 15 2016 sustain releas bupropion 150 mg daili par ticip interest medic turn postag paid postcard call toll free number screen particip request pharmaco therapi potenti contraind 15 partici pant absolut contraind drug inelig receiv drug offer option receiv drug particip contraind drug elig ceiv medic studi particip aspect intervent particip request bupropion rel con traindic nicotin patch research staff fax prescript request primari care physician figur 1 studi flow diagram includ primari analysi 238 includ primari analysi 244 declin particip 305 unabl contact 58 inelig 714 randomli assign 750 smoker screen elig 1827 includ primari analysi 244 mdm 249 hdm 251 pm 250 2 4 complet 217 lost follow 33 deceas 5 incarcer 1 nonrespons 27 complet 199 lost follow 50 deceas 9 incarcer 2 nonrespons 39 complet 204 lost follow 47 deceas 7 incarcer 0 nonrespons 40 1 8 complet 220 lost follow 30 deceas 2 incarcer 1 nonrespons 27 complet 196 lost follow 53 deceas 7 incarcer 2 nonrespons 44 complet 190 lost follow 61 deceas 6 incarcer 0 nonrespons 55 1 2 complet 226 lost follow 24 deceas 2 incarcer 1 nonrespons 21 complet 212 lost follow 37 deceas 3 incarcer 2 nonrespons 32 complet 205 lost follow 46 deceas 3 incarcer 0 nonrespons 43 6 complet 230 lost follow 20 deceas 2 incarcer 1 nonrespons 17 complet 221 lost follow 28 deceas 2 incarcer 2 nonrespons 24 invit particip 1113 complet 220 lost follow 31 deceas 2 incarcer 0 nonrespons 29 hdm high intens diseas manag mdm moder intens diseas manag pm pharmacotherapi manag articlediseas manag smoke cessat www.annals.org 7 april 2009 annal intern medicin volum 150 number 7 439 download http annals.org univ aberdeen user 02 15 2016 prescript request delin rel contra indic potenti drug interact par ticip physician made final assess appropri bupropion patch particip contraind nicotin patch receipt fax sign prescript bupropion patch mail particip instruct diseas manag addit pharmacotherapi moder intens high intens diseas manag group receiv ed ucat support telephon counsel period progress report counsel suggest fax physician 6 month receiv kanquit new letter address tip quit smoke talk physician smoke pharmacoth com.ibm.drl.hbcp.api cessat newslett person clude studi updat counselor photograph physician fea ture stori testimoni particip quit smoke offer particip assign moder intens diseas manag 2 telephon base counsel session 6 month 1 session promot quit tempt 1 addit follow session made quit attempt offer particip assign high intens diseas manag 6 counsel call 6 month promot quit prevent laps schedul call particip conveni vari particip quit plan rough schedul call 1 3 6 9 16 week onset 6 month treatment cycl counselor motiv interview techniqu semistructur protocol promot cessat attempt abstin smoker encourag relaps prevent counsel call case manag mind particip avail pharmaco therapi interest particip provid immedi at support acquir nicotin patch bupropion previous fax person progress report sugg tion intervent particip physician counsel call moder intens high intens diseas manag particip counsel call high intens diseas manag particip 6 month cycl fax addit progress report particip physician moder intens high intens diseas manag particip set quit date outcom measur follow research assist blind treatment group assign conduct assess telephon baselin 6 12 18 24 month primari outcom primari outcom measur report 7 dai abstin 24 month defin smoke cigarett previou 7 dai report abstin consid suffici pop ulat base smoke cessat studi 16 test report bia treatment group valid tabl 1 baselin characterist studi particip characterist total particip 750 pm group 250 mdm group 249 hdm group 251 mean ag sd 47.2 13.1 47.1 13.4 48.2 12.4 46.4 13.5 women 439 58.5 144 57.6 144 57.8 151 60.2 educ high school 385 51.3 128 51.2 129 51.8 128 51.0 mean cigarett smoke dai sd 23.7 10.4 24.3 11.0 23.8 10.3 22.9 10.0 mean fagerström score sd 5.2 2.2 5.2 2.2 5.2 2.2 5.0 2.1 previou bupropion 245 32.7 83 33.2 74 29.7 88 35.1 previou nicotin replac 397 52.9 128 51.2 128 51.4 141 56.2 smoker household 345 46.0 119 47.6 116 46.6 110 43.8 mean motiv quit sd 8.7 2.1 8.7 2.0 8.6 2.2 8.6 2.0 mean confid quit sd 6.1 2.7 5.9 2.7 6.1 2.8 6.3 2.6 stage chang precontempl 65 8.7 22 8.8 20 8.0 23 9.2 contempl 457 60.9 158 63.2 153 61.5 146 58.2 prepar 228 30.4 70 28.0 76 30.5 82 32.7 medic condit hypertens 258 34.4 95 38.0 78 31.3 85 33.9 hyperlipidemia 269 35.9 91 36.4 86 34.5 92 36.7 diabet 101 13.5 43 17.2 30 12.1 28 11.2 chronic lung diseas 202 26.9 65 26.0 73 29.3 64 25.5 heart diseas 73 9.7 24 9.6 29 11.7 20 8.0 histori depress 304 40.5 107 42.8 96 38.6 101 40.2 hdm high intens diseas manag mdm moder intens diseas manag pm pharmacotherapi manag fagerström test score nicotin depend rang 0 10 score 6 greater level nicotin depend motiv confid quit smoke score rang 0 10 articl diseas manag smoke cessat 440 7 april 2009 annal intern medicin volum 150 number 7 www.annals.org download http annals.org univ aberdeen user 02 15 2016 report abstin month 12 24 salivari cotinin level 15 ng ml mail saliva sampl 17 high resist particip provid salivari sampl month 12 conduct valid proxi report signific month 24 quit ter return salivari sampl 18 secondari outcom secondari outcom includ report 7 dai ab stinenc 6 12 18 month assess com.ibm.drl.hbcp.util pharmacotherapi basi particip request bupropion transderm nicotin patch 6 month treatment cycl conclu sion 6 month cycl ask particip physician previou 6 month discuss smoke cessat measur baselin assess ag sex educ level major comorbid condit smoke histori includ number cigarett smoke dai previou bupropion previou nicotin replac stage readi ness stop smoke 19 assess nicotin depen denc fagerström test nicotin depen denc 20 assess import confid quit separ 11 point likert scale rang ing import confid 0 point treme import confid 10 point monitor procedur kansa univers medic center institut view board approv data safeti monitor plan explicitli particip ad vers effect counselor record spontan report advers event intervent call research assi tant semiannu assess advers port report kansa univers medic cen ter human subject committe data qualiti monitor effort includ dual data entri examin frequenc distribut rang check identif ver ific miss valu statist analysi power calcul 250 particip group 80 power compar high intens diseas manag moder intens diseas man agement 95 power compar combin high intens diseas manag moder intens diseas manag pharmacotherapi basi 10 15 25 report quit rate pharmaco therapi moder intens diseas manag high intens diseas manag conduct data analys speci fi sa softwar version 9.1 sa institut cari north carolina gener descript statist baselin measur assess imbal treatment group gener linear mix model primari end point report abstin 24 month 0 24 month report abstin pharmacotherapi particip physician discu sion smoke 21 2 primari test kan quit studi comparison report cessat rate high intens diseas manag moder intens diseas manag high moder intens diseas manag combin pharmacotherapi addit consid 2 sen sitiv analys imput miss data smoker imput miss data quit gener linear mix model includ term main effect treatment group time interact fit model proc nlmix procedur sensit analys imput data particip di incarcer averag gener iz linear mix model estim particip ran dom effect arriv margin estim effect intervent 21 22 compar valid abstin 12 24 month uncondit logist gression model administ intervent central locat assess cluster treatment effect particip primari care practic gener linear mix model test clu tere logist regress model random intercept term facil effect 21 basi tabl 2 com.ibm.drl.hbcp.util pharmacotherapi nicotin patch bupropion treatment period month particip odd ratio 95 ci pm mdm hdm hdm mdm hdm mdm pm 0 6 142 247 57.5 160 245 65.3 171 249 68.7 1.19 0.81 1.76 1.53 1.10 2.13 6 12 114 247 46.2 93 244 38.1 95 248 38.3 1.01 0.69 1.48 0.71 0.51 0.99 12 18 65 247 26.3 49 240 20.4 61 245 24.9 1.28 0.83 1.96 0.82 0.57 1.17 18 24 55 244 22.5 65 238 27.3 59 244 24.2 0.84 0.55 1.28 1.18 0.82 1.70 hdm high intens diseas manag mdm moder intens diseas manag pm pharmacotherapi manag denomin time particip di incarcer margin odd ratio estim gener linear mix model presenc treatment time interact 0.01 articlediseas manag smoke cessat www.annals.org 7 april 2009 annal intern medicin volum 150 number 7 441 download http annals.org univ aberdeen user 02 15 2016 24 month outcom found evid cluster effect 23 comput cost provid perspect includ direct variabl cost ecut intervent princip intervent cost counsel pharmacotherapi counselor time time pharmacotherapi manag record computer track log valu local hourli wage fring benefit phar macotherapi valu prevail onlin price mail ing cost telephon fax charg valu long distanc rate cost valu 2005 u. dollar reflect intervent began role fund sourc studi fund nation cancer insti tute glaxosmithklin provid studi medic sourc role design conduct analysi studi decis submit manu script public result random result group similar base line characterist tabl 1 addit smoke 427 57 particip 1 major risk factor cardiovascular diseas particip report physician median 3.5 time 12 month studi particip smoke averag 24 cigarett dai 30.4 prepar stage quit 60.9 contempl stage 8.7 pre contempl stage 24 month follow 24 particip di incarcer 750 particip loss follow due nonrespons vari treatment group figur 1 22.0 pharmacotherapi group 31.3 moder intens diseas manag group 31.1 high intens diseas manag group lost follow 1 assess peri od 0.03 com.ibm.drl.hbcp.util counsel 24 month intervent high intens diseas manag particip complet averag 8.2 counsel call rang 0 24 moder intens diseas manag particip plete averag 3.6 call rang 0 7 engag counsel declin interven tion 90.9 67.9 57.3 54.3 high intens diseas manag particip 90.0 68.2 60.3 59.2 moder intens diseas manag ment particip particip 1 counsel se sion fourth treatment cycl appendix tabl 1 www annals.org averag number call complet 3.2 1.8 1.6 1.7 high intens diseas manag ment recipi 1.3 0.9 0.7 0.7 moder tabl 3 smoke statu particip time statu begin cycl total particip statu complet cycl pm group total particip statu complet cycl mdm group smoke quit nonrespons dead incarcer smoke quit nonrespons dead incarcer month 6 month 6 baselin smoke 250 204 81.6 26 10.4 17 6.8 3 1.2 249 185 74.3 36 14.5 24 9.6 4 1.6 month 12 month 12 month 6 smoke 204 172 84.3 21 10.3 11 5.4 185 154 83.2 16 8.7 14 7.6 1 0.5 quit 26 9 34.6 16 61.5 1 3.9 36 2 5.6 33 91.7 1 2.8 nonrespons 17 7 41.2 1 5.9 9 52.9 24 7 29.2 17 70.8 month 18 month 18 month 12 smoke 188 163 86.7 15 8.0 10 5.3 163 132 81.0 10 6.1 17 10.4 4 2.5 quit 38 16 42.1 18 47.4 4 10.5 49 15 30.6 30 61.2 4 8.2 nonrespons 21 6 28.6 2 9.5 13 61.9 32 9 28.1 23 71.9 month 24 month 24 month 18 smoke 185 151 81.6 26 14.1 7 3.8 1 0.5 156 120 76.9 21 13.5 13 8.3 2 1.3 quit 35 4 11.4 28 80.0 1 2.9 2 5.7 40 8 20.0 32 80.0 nonrespons 27 6 22.2 2 7.4 19 70.4 44 15 6.8 3 6.8 26 59.1 hdm high intens diseas manag mdm moder intens diseas manag pm pharmacotherapi manag articl diseas manag smoke cessat 442 7 april 2009 annal intern medicin volum 150 number 7 www.annals.org download http annals.org univ aberdeen user 02 15 2016 intens diseas manag recipi fourth treatment cycl com.ibm.drl.hbcp.util pharmacotherapi identifi treatment time interact utiliza tion pharmacotherapi 0.01 comparison tween treatment group pharmacotherapi de rive survei period tabl 2 pharmacotherapi uptak differ pool diseas manag group compar pharmacotherapi group increas uptak 6 month odd ratio 1.53 95 ci 1.10 2.13 lower uptak diseas manag group 6 month 0.71 ci 0.51 0.99 request pharmacotherapi de cline 6 month particip 63.8 40.9 23.9 24.7 request pharmacotherapi dur ing fourth treatment cycl spectiv end studi 23 33 23 12 9 particip request total 0 1 2 3 4 cycl pharmacotherapi 41.1 pharmacotherapi cycl bupropion 58.9 nicotin patch differ choic pharmacoth com.ibm.drl.hbcp.api treatment group support health care provid 3 treatment group 635 84.7 particip report 1 offic visit physician median 5 visit 2 year studi particip physician treatment cycl 37.5 59.5 report discuss smoke ce sation physician appendix tabl 2 www.annals.org proport vari high intens moder intens diseas manag ment group 1.03 ci 0.75 1.41 pool diseas manag group versu pharmaco therapi group 0.92 ci 0.70 1.19 ap pendix tabl 2 www.annals.org smoke cessat studi smoker move differ ent transit state smoke statu tabl 3 primari 24 month analysi miss valu im pute equal smoke 7 dai point preval report abstin 27.9 23.5 high intens moder intens diseas manag group 1.33 ci 0.88 2.02 tabl 4 cessat rate diseas manag group bine similar 23.0 report cessat rate pharmacotherapi manag group 1.12 ci 0.78 1.61 sensit analysi show effect similar method handl miss data nonrespons imput quit smoke secondari analys 0 24 month show report abstin rate higher high intens moder intens diseas manag ment group studi 1.43 ci 1.00 2.03 imput higher combin diseas manag ment group pharmacotherapi group 1.47 ci 1.08 2.00 imput tabl 4 figur 2 find sensit analysi similar classifi miss valu smoke rate valid report abstin similar 3 treatment group 12 24 month indic appar bia report abstin intens treatment cotinin confirm abstin rate 12 month 11.3 9.8 high intens moder intens diseas manag group respec tive 1.24 ci 0.69 2.22 tabl 4 cotinin confirm abstin rate pool diseas manag group higher 5.3 absti nenc rate pharmacotherapi group 2.33 ci 1.24 4.38 confirm abstin rate 24 month cotinin valid proxi similar 3 treatment group tabl 4 cost analysi pharmacotherapi cost significantli differ 3 treatment group 209 particip pharmacotherapi moder intens diseas manag 225 high intens diseas manag ment 0.64 studi time devot phar macotherapi diseas manag 0.5 3.8 7.7 hour particip pharmacotherapi tabl 3 continu total particip statu complet cycl hdm group smoke quit nonrespons dead incarcer month 6 251 179 71.3 41 16.3 29 11.6 12 0.8 month 12 179 130 72.6 27 15.1 21 11.7 1 0.6 41 9 22.0 31 75.6 1 2.4 29 6 20.7 2 6.9 21 72.4 month 18 145 107 73.8 22 15.2 14 9.7 2 1.4 60 14 23.3 37 61.7 8 13.3 1 1.7 43 10 23.3 33 76.7 month 24 131 109 83.2 17 13.0 5 3.8 59 13 22.0 44 74.6 1 1.7 1 1.7 55 14 25.5 7 12.7 7 61.8 articlediseas manag smoke cessat www.annals.org 7 april 2009 annal intern medicin volum 150 number 7 443 download http annals.org univ aberdeen user 02 15 2016 moder intens high intens diseas manag group differ counselor time led signific differ 3 group mean total intervent cost particip 231 sd 222 pharmacotherapi 348 sd 236 moder at intens diseas manag 460 sd 289 high intens diseas manag 0.001 discuss studi demonstr feasibl treat smoke chronic diseas group smok er offer repeat intervent support quit attempt treat relaps kanquit larg pro portion rural smoker particip 24 month smoke cessat program smoker offer free pharmacotherapi accompani modest effort coordin prescript primari care physician result high level pharmacotherapi uti lizat repeat pharmacotherapi assist quit tempt 3 treatment group abstin 24 month differ treatment group 0 24 month data analys suggest intens diseas manag higher rate smoke abstin studi kanquit intens counsel consi tentli higher com.ibm.drl.hbcp.util pharmacotherapi fax physician provid particip specif counsel treatment suggest frequent discuss physician particip smoke cessat effect intens diseas manag smoke cessat 18 month intervent direct result counsel mediat greater utiliza tion pharmacotherapi frequent discuss tween physician particip tabl 4 report valid abstin time point report 7 dai point preval pm mdm hdm month 6 26 247 10.5 36 245 14.7 41 249 16.5 month 12 38 247 15.4 49 244 20.1 60 248 24.2 month 18 35 247 14.2 40 240 16.7 59 245 24.1 month 24 56 244 23.0 56 238 23.5 68 244 27.9 valid 7 dai point preval month 12 13 247 5.3 24 244 9.8 28 248 11.3 month 24 33 244 13.5 35 238 14.7 36 244 14.8 hdm mdm hdm mdm pm 95 ci 95 ci statist comparison month 24 imput 708 1.31 0.85 2.02 0.22 1.19 0.82 1.73 0.35 month 24 miss smoker 741 1.33 0.88 2.02 0.18 1.12 0.78 1.61 0.54 month 24 miss quit 741 1.23 0.84 1.66 0.30 1.42 1.01 1.99 0.04 month 12 valid 643 1.24 0.69 2.22 0.47 2.33 1.24 4.38 0.01 month 24 valid 620 1.00 0.60 1.68 0.99 1.19 0.76 1.87 0.44 baselin 24 month imput 708 1.43 1.00 2.03 0.05 1.47 1.08 2.00 0.02 hdm high intens diseas manag mdm moder intens diseas manag odd ratio pm pharmacotherapi manag miss valu classifi smoke valid salivari cotinin measur 15 ng ml valid salivari cotinin measur 15 ng ml signific gener linear mix model report abstin provid evid treatment time interact 0.19 case saliva sampl provid 33.3 34.7 31.6 report quitter 12 month 39.7 33.9 30.3 24 month hdm mdm pm group figur 2 popul averag estim probabl quit smoke 3 studi group pr ob ab ili ty month hdm mdm pm 6 12 18 24 0.0 0.2 0.4 0.6 error bar repres 95 ci popul estim hdm high intens diseas manag mdm moder intens diseas manag pm pharmacotherapi manag articl diseas manag smoke cessat 444 7 april 2009 annal intern medicin volum 150 number 7 www.annals.org download http annals.org univ aberdeen user 02 15 2016 critic element success clinic intervent abil reach popul risk 2 intervent smoke cessat sult high abstin rate particip program low 1 10 24 program result high smoke cessat rate 30 pro gram ultim affect 3 total popula tion smoker free pharmacotherapi substan tialli increas number smoker make quit attempt 25 passiv offer free pharmacotherapi offer state quitlin reach 3 elig smoker 26 27 kanquit creation di eas registri allow enrol smoker smoke cessat intervent interest quit high rate particip studi suggest approach reach third smoker encount primari care practic proactiv engag ment smoker kanquit modest level provid pharmacotherapi manag group com.ibm.drl.hbcp.util pharmacotherapi fourth smoker registri medlin search studi publish english octob 2008 reveal studi smoker 6 12 month attempt reengag relaps smoker treatment small earli studi relaps smoker discourag 28 29 larger studi demonstr activ treatment relaps smoker transderm nicotin patch 30 nicotin lozeng 31 bupropion 32 higher cessat rate studi extend previou find show progress higher rate absti nenc smoker reengag treatment 4 time 2 year studi joseph colleagu 33 fu worker 34 shown smoker quit attempt fail interest vet eran affair studi partin colleagu 35 smoker relaps receiv telephon call physician receiv computer remind 32 advantag smoke cessat pharmacotherapi studi suggest smoker engag pharmacolog treatment smoke cessat proac tive offer treatment repeat time strength studi includ random design popul base recruit prolong interven tion follow high rate particip follow studi limit substanti variabl smok ing cessat rate time discrep 0 24 month find 24 month point preval abstin relat larg creas abstin report pharmacotherapi manag group 18 24 month sudden unexplain increas smoke cessat increas pharmacotherapi di cussion smoke cessat particip physician repres delai effect pharmacotherapi manag intervent late forc extern studi releas vareniclin 2006 smoke restric tion rural hospit rural commun neverth extern forc uniqu affect pharmacotherapi group hard understand addit limit studi lack blind particip inabl isol ef fect pharmacotherapi manag offer free pharmacotherapi conduct assess tele phone mail reli mail saliva sampl biochem verif valid report smoke cessat 58 particip 24 month rate valid similar 3 treat ment group suggest bia report absti nenc treatment assign occur studi reli transderm nicotin patch bupropion newer effect agent result 36 37 final provis free pharmacotherapi part studi limit generaliz abil find current practic financi support pharmacotherapi highli variabl studi demonstr diseas manag approach reach high proport smoker primari care practic smoker initi quit engag treatment 2 year follow presenc free pharmacoth com.ibm.drl.hbcp.api pharmacotherapi manag smoker make 1 pharmacotherapi assist quit attempt intens diseas manag sociat differ smoke abstin 24 month 0 24 month analys illustr associ intens intervent smoke cessat rate address discrep addi tional long term studi diseas manag smok ing cessat need univers kansa medic center kansa citi kansa uni versiti michigan ann arbor michigan univers minnesota medic school minneapoli minnesota acknowledg author research assist case manag support design implement studi carla berg phd geneviev casei olivia chang andrea elya char tresza hutcheson shawn jeffri phd terri tapp harri lando phd univers minnesota school public health scientif contribut studi concept design grant support nation cancer institut grant r01 101963 studi medic provid glaxosmithklin potenti financi conflict interest disclos reproduc research statement studi protocol statist code data set institut approv dr ellerbeck mail eellerb kumc.edu request singl reprint edward ellerbeck md mph de partment prevent medicin public health univers kan articlediseas manag smoke cessat www.annals.org 7 april 2009 annal intern medicin volum 150 number 7 445 download http annals.org univ aberdeen user 02 15 2016 sa medic center msn 1008 3901 rainbow boulevard kansa citi ks 66160 mail eellerb kumc.edu current author address author contribut www annals.org
abstract background tobacco cessat acut myocardi infarct ami substanti improv outcom effect individu programm established.to date studi examin factor aim assess outcom smoke cessa tion programm ami method hundr nineti current smoker admit coronari care ami particip random control studi compar outpati tobacco intervent stanford heart attack stai free sf programm usual care uc programm result log rank analys reveal patient sf programm retain longer 0.001 higher cotinin valid abstin rate 0.001 compar patient uc programm twelv month intervent 39 sf programm compar 2 uc programm demonstr cotinin valid tobacco cessat repres signific reduc relaps rate sf programm χ2 0.001 conclus sf smoke cessat programm initi hospit significantli reduc smoke rate 12 month myocardi infarct superior uc quit programm australian outcom lower american programm origin publish outcom intern med 2001 31 470 475 kei word acut myocardi infarct random iz trial smoke cessat treatment programm origin articl random control trial cigarett quit programm coronari care patient acut myocardi infarct feenei 1 mcpherson 1 connor 1,2 mcalist 1 m.young1,2 garrahy3 1alcohol drug assess unit 3depart cardiolog princess alexandra hospit 2depart psychiatri univers queensland royal brisban hospit brisban queensland australia introduct cancer ischaem heart diseas frequent death 22.5 death australia 1 declin smoke preval previou australian survei plateau confirm sustain commit anti smoke programm 2 approxim 26 australian smoke tobacco 2,3 episod hospit identifi present valuabl opportun patient stop smoke 4,5 realiti remain hospit inpati quit smoke feel encour ag seek support 6 5 year comprehens guidelin review smoke cessat publish 4,5,7 widespread profession endors limit publish studi base curtail us consid erabl heterogen effect trial tobacco cessat recogn 8 difficulti achiev similar outcom programm appli health care set patient popu lation reflect distinct efficaci effect studi directli compar treatment difficult recommend approach 7 evid rel effect psycholog ical approach 7 profession group achiev correspond gerald feenei director alcohol drug assess unit princess alexandra hospit brisban qld 4102 australia email gerald_feenei health.qld.gov.au receiv 6 decemb 2000 accept 6 june 2001 intern medicin journal 2001 31 470 475 471smoke cessat programm ami intern medicin journal 2001 31 470 475 similar outcom appli ident programm 9 benefit smoke cessat 50 reduct risk recurr myocardi infarct cardiovascular death success quit gener accept wide appli programm cardiac patient hospit 10 current studi evalu compar hospit tobacco intervent acut myocardi infarct ami addit report urinari cotinin estim valid measur usual care uc programm local devel op didactic.th stanford heart attack stai free sf programm origin usa incorpor recent techniqu found achiev behaviour chang 11 method subject hundr nineti patient sequenti admit coronari care unit ccu iden tifi nurs staff current cigarett smoker tobacco week hospit suffer ami document elev serum creatin phosphokinas histori prolong ischaem chest pain appear wave evolv st segment chang electrocardiogram patient offer tobacco quit programm recruit occur ccu particip randomli assign receiv nurs manag programm sf uc programm 11 random list odd number gener sequenc 200 seal envelop created.with patient consent envelop open assign programm ethic approv ethic approv present project obtain princess alexandra hospit research ethic committe procedur present studi accord ethic standard helsinki declar 1975 revis 1993 treatment programm patient advis stop smoke staff cardiologist involv care nicotin replac ment queensland hospit standard drug list unavail hospit pharmaci offer part programm group inform avail hospit patient ask notifi clinic nicotin replac treatment alcohol drug assess adau clinic appoint 3 6 12 month interv treatment aim smoke abstin primari goal differ term content deliveri usual care uc programm includ verbal print advic tobacco cessat primarili didact patient watch educ video ccu stai review adau nurs outpati adau support coun sell follow offer 3 6 12 month interv patient advis attend cardiologist stop smoke stanford heart attack stai free programm nurs manag sf programm began transfer ccu transfer attend cardiologist advis patient stop smoke 11 addit sf patient interview adau physician medic implic tobacco cessat aim programm discuss programm includ number behaviour compon patient programm manual stai free design identifi high risk situat relaps contain simpl exercis develop plan manag situat manual review patient complet 28 item questionnair assess confid maintain cessat patient report 70 confid resist identifi high risk relaps situat counsel specif cope strategi audiotap home review programm princip point includ exercis progr sive muscl relax manual work patient 2 week period inpati outpati target earli stage recoveri hospit discharg adau nurs initi tele phone contact weekli 4 week 2 3 6 12 month includ inquiri relaps confid remain abstin addit support advic consid feenei al 472 data collect instrument patient tobacco cigarett nicotin content low 0.4 mg medium 0.4 1.2 mg high 1.2 mg report daili usag nicotin depend level nicotin depend measur fagerstrom toler questionnair ftq 12 rate rang 0 2 low depend 8 high depend maximum score 10 efficaci resist smoke patient complet sf programm efficaci measur record patient confid resist urg smoke 28 identifi high risk situat e.g feel stress smoke drink alcohol beverag rate rang 0 confid quit 100 absolut confid smoke cessat smoke cessat statu record direct question follow adau outpati clinic biochem valid involv urinari cotinin long live metabolit nicotin estim visit adau 13 level 400 ng ml probabl return smoke patient report nicotin supplement data analysi examin potenti bias group random izat kei subject demograph independ test emploi interv i. ftq efficaci rate χ2 analys nomin data i. gender cigarett strength log rank analys carri compar attrit relaps treatment group pro gramm analys carri spss statist packag window version 9 result patient characterist 198 cigarett smoker 145 64 male 53 36 female.ther 73 male 23 femal sf treatment 72 male 30 femal uc treatment repres equal gender proport treatment group χ2 1 200 0.7 0.24 ns random administr error result 96 patient sf programm 102 patient uc programm omiss mean ag subject 53.9 11 differ significantli treatment programm 1 198 1.44 0.15 ns patient programm report similar cigarett brand strength χ2 2 176 0.37 0.82 ns daili smoke frequenc χ2 3 171 1.10 0.78 ns level nicotin depend ftq 1 133 0.68 0.68 ns efficaci quit estim differ treatment group 1 154 0.63 0.53 ns data report tabl 1 attend treatment group programm attend 198 patient discharg ccu 141 71 attend tobacco outpati clinic 1 month 118 60 3 month 68 34 12 month period studi patient di includ death sf programm uc programm attend programm durat treatment group log rank surviv analysi examin differ observ expect event case attrit treatment programm 12 month studi period.ther differ enc treatment group programm durat log rank 1 198 17.99 0.001 indic significantli higher retent sf treatment group 12 month attend figur summar fig 1 urinari cotinin statu treatment group patient programm report abstin conflict elev urinari cotinin level studi purpos record continu smoke tobacco relaps studi durat log rank analysi examin smoke relaps patient 12 month studi period result patient uc group relaps earlier frequent sf group log rank 1 198 21.18 0.001 figur 1 summar urinari cotinin statu treatment group programm durat intern medicin journal 2001 31 470 475 smoke cessat programm ami 473smoke cessat programm ami abstin 12 month 68 patient remain studi 12 month 47 32 68 record neg urinari cotinin estim 1 3 12 month session term treatment group differ 39 31 79 sf group 2 1 62 uc group commenc programm remain abstin durat studi period χ2 1 68 28.03 0.001 discuss present random studi compar smoke cessat programm ami patient long establish older smoker mean ag 54 years.thei unabl quit tobacco independ patient treat ment group compar number indic addict medicin physician addit attend cardiologist individu review sf patient programm deliv nurs problem inher smoke intervent research accur classifi smoke statu patient fail attend programm sf studi base absti nenc rate calcul categor studi particip lost follow relaps smoke programm attend urinari cotinin estim outcom measur programm complianc clear weak studi absenc follow data 66 particip drop 12 month pronounc uc programm higher drop rate uc 79 sf 51 find confirm sf group consi tentli programm attend 12 month intern medicin journal 2001 31 470 475 tabl 1 ag gender cigarett strength daili usag fagerstrom score quit efficaci group measur total sampl sf group standard ccu group 198 96 102 subject ag mean year sd 53.9 10.95 52.89 10.39 55.13 11.51 0.15 gender male 145 64 73 76 72 70 femal 53 36 23 24 30 29 0.24 cigarett strength low 63 32 35 37 28 28 0.83 medium 55 27 29 30 26 27 high 58 30 29 30 29 28 miss 22 11 3 3 19 19 daili cigarett usag 10 68 34 33 34 35 33 0.78 11 20 49 25 27 28 22 22 21 30 53 27 31 33 22 22 31 2 1 1 1 1 1 miss 26 13 4 4 22 22 report measur mean fagerstrom sd 4.62 1.78 4.61 1.82 4.8 1.81 0.68 mean efficaci sd 66 22.5 65.03 22.44 67.35 23 0.52 sf stanford heart attack stai free ccu coronari care unit sd standard deviat figur 1 tobacco programm attend abstin group acut myocardi infarct sf stai free uc usual care feenei al 474 sf patient attend outpati programm session urinari cotinin level group consist report abstin quit rate group consider higher present paper report verifi patient outcom structur quit smoke programm manag health profession demonstr benefit retain smoker ami treatment chronic relaps condit nicotin depend improv retent treatment programm offer greater opportun interven effect approach assist patient quit tobacco chang decad design sf programm distinguish process stop smoke maintain absti nenc recogn psycholog compon nicotin depend appli cognit behaviour cbt techniqu treat ment direct modifi maladapt behaviour engend sens person control problem solv develop respons deal high risk relaps situat minim relaps contact form telephon support includ significantli improv treatment outcom 7,11,14 develop sf programm replic find 4 year broader case manag system coronari risk factor modif ami 14 sf programm outcom mark contrast estim 21 smoke intervent efficaci biochem unvalid report 1980 earlier trial men high risk ischaem heart diseas 8 ident sf programm achiev 32 verifi quit rate 12 month ami repres encourag outcom report australian studi emploi inter vention result significantli sf group 71 report quit rate11 70 report follow studi incorpor broader risk factor modif 14 magnitud outcom differ difficult explain educ occup neg attitud smoke factor identi fi import tobacco quit cardiac patient 15 american relationship employ health insur hospit access identifi patient respons cbt base programm health care system resourc patient demograph differ impor tant factor financi reward attend outpati follow origin sf studi effect heterogen effect trial tobacco cessat demon strate evid hospit base smoke inter vention deliv profession primarili respons intervent readili identifi outcom 9 health care profession clinic nurs deliv programm minim therapist effect programm hospit base intervent cardiac popul produc substan tialli inferior result report quit rate 17 reduc 8 base cotinin verif report rigotti16 steven publish report outcom 20 9 interestingli sf programm biochem verifi cessat rate 12 month higher 27 cardiac patient 17 began sf uc trial nicotin replac ment wide patient cardiac diseas studi patient elect purchas evid improv outcom safeti nicotin replac therapi mandat patient agent complement programm 18,19 bupropion atyp antidepress improv outcom 20 potenti reduc commun burden ami secondari prevent consider tobacco cessat remain import element effort direct secondari prevent modest poorli fund comparison care acut ischaem episod gener inadequ evalu health administr success oversea origin programm translat effect australia oversea outcom appli benchmark present report demonstr mislead belief highlight import australian benchmark valid australian outcom data area acknowledg gratefulli acknowledg stanford cardiac rehabilit programm dr debusk nanci houston miller rn access stanford heart attack stai free programme.w dr alan clagu director chemic patholog royal brisban hospit carri urinari cotinin begin studi intern medicin journal 2001 31 470 475 smoke cessat programm ami 475smoke cessat programm ami intern medicin journal 2001 31 470 475
issu pulmonari nu rsing combin commun participatori research random clinic trial protect hood tobacco phat smoke cessat studi erika sivarajan froelich rn ma mph phd daniel doolan rn phd valeri yerger carol mcgruder ba def ruth malon rn phd faand ing ment univ univ behavi san fr sa cisco medici 50 background articl describ process result smoke cessat intervent ran domiz clinic trial rct conduct commun base participatori research project rct test outcom improv ad social justic tobacco industri target me sage smoke cessat program conduct african american adult low incom commun san francisco california studi lesson futur similar research project focu urban low incom popul method particip randomli alloc receiv smoke cessat program control group cg cg care tobacco industri media iam messag primari intervent behav ioral intak particip report sever withdraw smoke 25 cigarett daili offer free nicotin replac therapi baselin data person interview outcom measur includ report smoke statu valid quit salivari cotinin assai result 87 particip provid baselin data 31 27 join rct proport quitt ing cg iam group 11.5 13.6 6 month 5.3 15.8 12 month conclus african american underserv citi neighborhood recruit rct commun participatori approach differ cg iam proport quit 2.1 10.5 6 12 month 3 year adequ fund high staf ratio intens outreach follow schedul need achiev recruit studi goal heart lung 2010;39 50 63 nation institut health md 07 003 html laudabl goal shift tfund agenc encourag researchersto partner commun conduct commun base participatori research interven tion studi aim address health dispar http grants.nih.gov grant guid rfa file rfa adepart physiolog nurs school nur ivers california san francisco california bdepart epidemiolog biostatist school medicin siti california san francisco california csan francisco siti san francisco california ddepart social oral scienc school nurs univers california ancisco california epolari research develop francisco african american tobacco free project san fran alifornia finstitut health polici studi school ne univers california san francisco california ww.heartandlung.org research paradigm research communi ti research commun relev respons commun concern conduct studi exception challeng ing articl report process studi support fund california tobacco relat diseas research program grant 11bt 1701 12at 1700 author erika froelich rn ma mph phd de partment physiolog nurs 2 koret room n631 uni versiti california san francisco san francisco ca 94143 0610 0147 9563 front matter 2010 elsevi right reserv doi 10.1016 j.hrtlng 2009.06.004 januari februari 2010 heart lung http grants.nih.gov grant guid rfa file rfa md 07 003 html http grants.nih.gov grant guid rfa file rfa md 07 003 html froelich al protect hood tobacco phat result smoke cessat intervent clinic trial conduct commun base par ticipatori research project lesson futur similar research project studi focus urban low incom popul background racial ethnic group unit state african american worst outcom tobacco relat diseas 1 ag adjust mortal iti rate tobacco relat cancers2 7 cardiova cular diseas stroke8 higher african american hispan white high light import develop effect smoke cessat intervent popul benefit quit smoke document includ major reduct risk tobacco late diseas 9,10 african american pare white heavi smoker research suggest african ameri can higher intak nicotin cigarett metabol nicotin slowli 11 quit smoke 12 race ethnic percentag smoker quit 2000 lowest african american 13 review 2000 smoke cessat studi african american conclud specif strategi optim african ameri can 14 feder guidelin suggest tai lore intervent effect 15 smoke cessat studi test interven tion tailor african american descript studi experimen tal design 16 commun studi show success reduc smoke preval rate 27 34 low incom african american popul 17 author conclud research need identifi effect smoke cessat method suit african american previou work suggest racial identif accultur bear success quit 16,18 previou muniti capac build studi african american made tobacco industri document media deconstruct train conjunct tobacco industri effort promot smoke african american pervas ti african american commun ganiz exploit ti thwart public health polici 19 low incom african american commun subject tensiv geograph target market bacco product 20,21 previou work suggest african american smoker mobil heart lung vol 39 1 quit review tobacco industri document racial target industri 22 protect hood tobacco phat random clinic trial rct conduct part commun base participatori project investi gate includ tobacco industri docu ment cessat program contextu social justic implic tobacco promot african american quit smoke ar ticl describ characterist sampl african american adult low incom urban commun enrol enrol phat rct 23 studi design method intervent protocol result rct lesson learn experi combin commun participatori rct research materi method rct design assess efficaci evid base smoke cessat program control group cg compar program supplement tobacco indu media iam relat smoke cessat intervent phat project engag neighborhood resid tobacco control en courag smoke cessat includ commun resid plan research paid volunt program staff set studi place southeast health center establish public clinic geograph accessi ble resid bayview hunter point bvhp neighborhood san francisco california predominantli african american neighborhood includ larg proport smoker earlier survei show 48 bvhp hous hold includ smoker 24 resid commu niti document health dispar includ higher averag rate tobacco late diseas prevent hospit 25 addit 50 african american neighbor hood report peopl smoke indoor pare 25 asian pacif island live commun 24 ear lier survei 55 bvhp african american believ health ill control compar 15 bvhp white 24 25 rct focus empower social ju tice address factor smoke cessa tion program african american www.heartandlung.org 51 tabl industri media intervent program kei activ curriculum content purpos object week 1 priorit commun issu problem tobacco 101 tidbit game introduct commun capac build process refram tobacco grave commun concern group bond introduct tobacco industri fact commun empower capac build week 2 continu commun capac build process introduct tobacco industri tactic target african american commun case studi naapi uptown cigarett commun empower capac build week 3 deconstruct tobacco advertis media campaign media literaci week 4 tobacco industri document review smoke enemi person loss exercis letter write exercis commun educ empower true natur breadth tobacco dustri predatori behavior educ scope impact bacco relat death african american commun week 5 finish letter write exercis complic african american leadership group tobacco industri deput studi particip tobacco control advoc commun empower build commun tobacco control capac naapi nation associ african american posit imageri protect hood tobacco phat froelich al sampl recruit resid bvhp neighbor hood inclus criteria identif african american ag 21 year tobacco past month ness quit smoke assess intak inter view agreement telephon follow review 6 12 month inter vention provid salivari cotinin sampl clusion criteria inabl read speak english preclud particip intervent compon depend addict substanc marijuana 52 www.heartandlung.org peopl depend substanc requir dual intervent referr resourc disabl health condit prevent tend involv rct 1 year follow review potenti subject affirm area part studi 12 month basi sampl size calcul approxi mate 270 particip requir accommo date 25 attrit rate obtain approxim 200 particip 100 group sampl size suffici 80 power detect differ group 05 level januari februari 2010 heart lung froelich al protect hood tobacco phat recruit phat commun research partner bvhp commun resid part pilot phase phat project26 conduct outreach muniti organ express interest phat effort reduc tobacco 27 recruit ment flyer wide distribut commu niti content flyer advertis local bvhp newspap flyer distribut commun event well fair cultur event beauti sa lon barber shop librari venu work local commun member creat websit invit particip program public servic announc featur muniti resid air local public access televis radio station facilit recruit ment retent incent offer includ ing free child care free nicotin replac therapi nrt free cessat program materi 5 pai ment session attend bonu complet program session entri quit win 28,29 draw 500 end studi addit confirm smoke free 6 12 month enter quit win draw addit 500 recruit conduct period 25 month start april 21 2004 end 31 2006 initi contact method potenti enrolle initi at contact suggest recruit flyer telephon project director v.b.y manag elig screen random group consent process document project director explain studi caller answer question screen elig person elig want particip person enrol appoint schedul conveni inform consent explain written sign consent obtain procedur approv univers california san francisco institut review board 26 random procedur random random permut block group particip group equal chanc assign cg iam intervent group true blind behavior intervent base line data collect random alloc blind data collector subsequ group assign 30 37 heart lung vol 39 1 group assign cg receiv 1 hour pre class orient session standard 5 week smoke ce sation intervent includ establish evid base behavior intervent program deliv commun health nurs train smoke cessat techniqu provid educa tional cognit behavior smoke cessat tervent base establish guidelin 15,30,31 time smoke cessat pro gram offer neighborhood program free includ lectur written handout prepar quit smoke discuss quit strategi relaps prevent strategi particip receiv edit version pathwai freedom ptf smoke cessat guid center diseas control prevent specifi calli tailor african americans38 group set home edit consist remov section ptf focus social justic messag conceptu compon kei part intervent deliv iam group prepar particip group relaps prevent 39 refer cal ifornia smoker helplin encourag make call session familiar telephon support servic iam intervent group program includ featur cg program tailor commu niti develop iam intervent tabl partici pant schedul attend 1 hour pre class orient session total 2 hour group session includ presen tation reinforc previous discuss ed ucat behavior strategi avoid relaps iam compon 40,41 iam group ceiv unedit ptf smoke cessat guid 38 iam program consist denorm deconstruct educ intervent pretest 42 deliv iam group se sion convei reinforc kei messag tobacco industri target commun empow ment social justic compon includ content tabl shown particip weekli intern tobacco industri document reveal industri target psychograph studi african american provid didact content african american disproportion harm tobacco advertis analysi exer cise show tobacco industri african market african american vice versa provid exposur guest speaker includ suc cess quitter commun discuss www.heartandlung.org 53 tabl ii demograph health problem african american enrol enrol rct rct rct demograph ag mean sd 46.62 10.3 60 47.53 9.4 27 women 71.7a 43 44.4a 12 educ high school 1.7 1 0 0 high school 16.7 10 29.6 8 high school graduat 23.3 14 25.9 7 colleg 45.0 27 29.6 8 colleg graduat 11.7 7 14.8 4 post graduat 1.7 1 0 0 marit statu singl 41.75 25 40.1 11 marri 13.3 8 25.9 7 widow 6.7 4 11.1 3 divorc 25.0 15 14.8 4 separ 10.0 6 7.4 2 employ emploi full time 20.0 12 7.4 2 emploi part time 11.7 7 7.4 2 unabl work 15.0 9 14.8 4 unemploi 18.3 11 33.3 9 annual incom 0 4999 23.3 14 29.6 8 5000 14,999 35.0 21 37.0 10 15,000 24,999 11.7 7 0 0 25,000 50,000 18.3 11 22.2 6 refus 11.7 7 11.1 3 health problem hypertens 43.3 26 25.9 7 heart diseas 11.7 7 3.7 1 diabet mellitu 16.7 10 18.5 5 psychiatr problem hx 21.7 13 11.1 3 hospit 60.0 36 66.7 18 life threaten ill 38.3 23 44.4 12 sd standard deviat rct random clinic trial astatist signific 02 protect hood tobacco phat froelich al quit experi felt smoke free commun partner help final select document advertis pre sent iam protocol standard phat rct deliv experienc muniti tobacco control advoc c.mcg serv commun princip investig particip complet iam program refer telephon support servic relaps pre vention session feder guidelin suggest advic health profession enhanc 54 www.heartandlung.org smoke cessat health care practition provid initi smoke cessat educ counsel establish guidelin group pre class orient session 15 educ counsel ing behavior intervent focus relaps trigger plan situat cope challeng recruit retain particip experienc commun tobacco control advoc assist health profession initi pre class orient deliv social justic teaser motiv particip pre class session januari februari 2010 heart lung tabl iii smoke pattern rct rct 60 rct 27 instrument mean sd rang mean sd rang efficaci 50.63 24.6 0 100 60 56.39 24.8 1 100 27 pack year smoke 14.21 10.8 0.2 38 56 11.30 11.1 0.2 38 27 daili cigarett 11.35 7.1 1 35 58 8.40 6.2 1 20 27 year smoke regularli 24.4 11.2 0.5 50 58 25.28 12.0 1.5 50 27 durat longest quit attempt 351.3 614 0 3650 54 452.6 775 0 3650 26 rct random clinic trial sd standard deviat alongest quit year skew 2 particip report quit 10 tabl iv health percept knowledg rct rct rct health excel good 25.0 15 22.2 6 good 41.7 25 40.7 11 fair poor 33.3 20 37.0 10 avoid futur health problem quit smoke 80.0 48 81.5 22 uncertain 20.0 12 18.5 5 smoke 20 benefit quit strongli disagre disagre 75.0 45 59.3 16 disagre agre agre strongli agre 16.7 10 25.9 7 smoke harm health strongli disagre disagre 20.0 12 14.8 4 disagre agre agre strongli agre 75.0 45 74.0 20 rct random clinic trial froelich al protect hood tobacco phat pharmacolog compon offer group primari treatment pro gram behavior nicotin patch lozeng made particip highli addict nicotin request partici pant offer nrt cost report se vere withdraw symptom crave previou attempt quit report 25 cigarett daili pregnant lactat women heart lung vol 39 1 offer pharmacolog portion tervent nrt patch ap prove popul elig primari behavior compon intervent african american regist nurs commun instruct particip proper includ caution smoke patch lozeng taper schedul manufactur guidelin 39 procedur data collect initi phase studi consist step www.heartandlung.org 55 tabl smoke practic belief african american rct frequent brand rct rct newport 51.7 31 59.3 16 gener 10.0 6 14.8 4 kool 8.3 5 3.7 1 30.0 18 22.2 6 nicotin depend measur a.m cigarett 30 min 60.0 36 44.4 12 smoke a.m 28.3 17 25.9 7 smoke ill 36.7 22 25.9 7 smoke unrestrict home 25.0 15 29.6 8 live 31.7 19 25.9 7 hous smoke 48.3 29 29.6 8 closest person smoke 38.3 23 40.7 11 rct random clinic trial protect hood tobacco phat froelich al particip recruit inform consent base line data collect random con trol program iam intervent program baselin data obtain directli particip person interview random cg iam intervent group data collect clude question demograph smoke tori knowledg belief health addict screen confid quit smoke childrear statu smoke practic home fea ture provid baselin data unbias respect subsequ group assign baselin procedur complet begin ning group intervent session partici pant randomli assign cg iam group particip contact follow data collect telephon interview 6 12 month random measur data assess ob tain ident group baselin assess includ report demo graphic data ag ethnic educ marit statu employ statu incom clinic data clude risk factor prior admiss hospit life threaten condit smoke histori consist 22 item instru ment origin develop women initi nonsmok win trial30,31 assess level addict quit smoke year smoke av erag number cigarett smoke daili intent 56 www.heartandlung.org stai cigarett confid remain cigarett includ question secondhand smoke stanford depend index32,33 measur degre addict nicotin instrument deriv fagerstrom toler questionnair 20 classifi addict basi 5 question score rang 0 25 test retest correl 5 question rang 0.71 0.90 belief knowledg benefit smoke cessation34 ascer tain 3 standard questionnair item develop test 4000 smoker 20 commun unit state 1989 nation cancer institut commun inter vention trial smoke cessat 7 item 4 respons choic 1 avoid decreas health problem smoke quit 2 smoke 20 year benefit quit respons option strongli agre strongli disagre 3 smoke harm health strongli agre strongli disagre efficaci assess confid questionnaire35 scale 1 10 35,36 list 14 high risk situat relaps smok ing particip ask rank confid resist urg smoke sit uation scale 0 confid 100 confid score 70 denot high risk relaps januari februari 2010 heart lung iam 26 note complet data end telephon call 203 met criteria studi 191 agre consent 87 complet baselin data collect 85 random 60 start cg 34 start iam 26 finish cg 12 finish iam 10 data 6 mo 26 4 lost 4 refus data 6 mo 22 4 lost data 12 mo 19 4 lost 11 date project end data 12 mo 26 4 lost 4 refus cg 34 note complet data end rct 27 fig 1 recruit enrol retent statist sampl rct random clinic trial cg control group iam industri media froelich al protect hood tobacco phat primari outcom measur 6 12 month particip group report smoke past 7 dai puff ask saliva sampl analyz cotinin verifi nonsmok statu 37 cotinin test tempt verifi smoke statu partici pant famili friend particip cotinin level 14 ng dl consid smoker latest follow period 37 port smoke contradict cotinin test particip famili friend assum particip resum smoke cotinin verif verifica heart lung vol 39 1 tion famili friend obtain particip statu consid miss qualiti assur establish ini tial 8 hour train session data collector interventionist initi biweekli subsequ monthli meet research group inter ventionist regist nurs ensur consist protocol protocol modif commun studi staff oral write measur aim ensur high qualiti consist data collect integr intervent data manag analysi statist packag social scienc spss chicago il data entri man agement analysi report describ tention treat analysi approach conform consort43,44 guidelin report result rct studi execut issu studi team initi impress bvhp public clinic smoke cessat tervent program patient particip intervent serv usual care cg plan studi evolv appar program longer viabl control program medic nurs team public clinic request ethic ground research team provid cessat program cg condit clinic particip addit unbudget quirement result divers half interven tion program fund mount cg addit fund sought grant analyz implic circumst issu aros discuss section result sampl characterist basi sampl size calcul plan studi sampl approxim 200 particip 100 group total 203 call receiv phat project pro gram 196 particip obtain inform agre screen studi number 191 met elig criteria recruit 87 afri american adult part baselin data collect april 21 2004 31 2006 87 particip 60 part rct 27 part baselin data www.heartandlung.org 57 tabl vi demograph health problem african american group assign cg iam demograph mean mean sd ag 46.7 46.5 10.8 women 64.7 80.8 21 educ high school 17.6 19.2 5 high school graduat 23.5 23.1 6 colleg 50.0 38.5 10 colleg graduat 8.8 19.2 5 marit statu singl 44.1 38.5 10 marri 11.8 15.4 4 widow 5.9 7.7 2 divorc separ 38.2 38.4 10 employ emploi full time 8.8a 34.6a 9 emploi part time 11.8 11.5 3 unabl work 14.7 15.4 4 unemploi 23.5 11.5 3 annual incom 0 14,999 55.9 61.5 16 15,000 24,999 11.8 11.5 3 25,000 14.7 23.5 7 refus 17.6 3.8 1 health problem hypertens 44.1 42.3 11 heart diseas 8.8 15.4 4 diabet mellitu 23.5 7.7 2 psychiatr problem hx 23.5 19.2 5 hospit 58.8 61.5 16 life threaten ill 41.2 34.6 9 cg control group iam industri media astatist signific differ 01 protect hood tobacco phat froelich al collect enrol rct tabl ii describ characterist particip rct rct inform futur research assess number person approach screen obtain desir sampl size evalu particip part rct reveal minor differ 2 group tabl ii 55 particip women 71.7 rct 44.4 rct statist signific 02 differ averag ag educ mar ital statu employ incom similar 58 www.heartandlung.org rct versu rct simi larli descript chronic health problem life threaten ill previou hospit perceiv gener health statu knowledg titud belief smoke signifi cantli 2 group tabl ii smoke pattern tabl iii health percept tabl iv smoke practic tabl differ particip rct figur 1 show number proport gard studi sampl recruit baselin data collect enrol rct ran domiz result assign 34 januari februari 2010 heart lung tabl vii smoke pattern group assign cg iam instrument mean sd rang mean sd rang efficaci 50.5 25.1 10 100 34 50.8 24.4 0 89 26 pack year smoke 16.5 10.7 0.3 38 31 11.4 10.3 0.2 37 25 cigarett 11.9 6.0 2 30 32 10.7 8.3 1 35 26 year smoke 26.1 10.8 0.5 50 33 22.2 11.5 2 40 25 quit attempt 2.2 2.1 0 10 30 2.6 1.6 0 7 22 durat longest quit attempt 345.6 692 0 3650 30 358.3 515 1 1825 24 cg control group iam industri media sd standard deviat aon outlier remov group report 20 tabl viii health percept knowledg group assign cg iam health excel good good 58.8 20 77.0 20 fair poor 41.2 14 23.1 6 avoid futur health problem quit smoke 85.3 29 73.1 19 uncertain 14.7 5 26.9 7 smoke 20 benefit quit strongli disagre disagre 76.5 26 73.1 19 disagre agre agre strongli agre 14.7 5 19.2 5 refus 8.8 3 7.7 2 smoke harm health strongli disagre disagre 14.7 5 26.9 7 disagre agre agre strongli agre 82.4 28 65.4 17 2.9 1 7.7 2 cg control group iam industri media froelich al protect hood tobacco phat particip cg 26 particip iam group tabl vi compar cg iam group 2 group similar regard import ciodemograph smoke pattern health percep tion knowledg variabl tabl vi ix 8.8 cg versu 34.6 iam group emploi statist signific differ 01 follow data provid heart lung vol 39 1 80 particip cg 75 iam group 6 month 12 month fol low data collect point tabl show intent treat analys 6 12 month 11.5 cg 13.6 iam group smoke free 6 month 5.3 cg 15.8 iam group remain smoke free 12 month smoke www.heartandlung.org 59 tabl ix smoke practic belief african american group assign frequent brand cg iam newport 50.0 17 53.8 14 gener 8.8 3 11.5 3 kool 14.7 5 0 0 26.5 9 34.6 9 nicotin depend measur a.m cigarett 30 min 58.8 20 34.6a 9 smoke morn 35.3 12 80.8a 21 smoke ill 35.3 12 38.5 10 smoke unrestrict home 29.4 10 19.2 5 live 23.5 8 42.3 11 hous smoke 58.8 20 34.6a 9 closest person smoke 47.1 16 26.9 7 cg control group iam industri media statist signific 01 ap 06 tabl comparisonof smoke cessationdiffer group assign follow time cg iam 6 mo 11.5 3 26 13.6 3 22 ns 12 mo 5.3 1 19 15.8 3 19 ns cg control group iam industri media ns signific protect hood tobacco phat froelich al cessat outcom significantli low number group discuss phat project combin commun partic ipatori random trial smoke cessat intervent african american resid low incom urban commun design test efficaci evid base smoke cessat program compar efficaci program supplement tobacco iam social justic intervent suc cess sustain commun partnership 4 year trial unsuccess enrol suffici sampl size particip 60 www.heartandlung.org research approach limit fail includ measur chronic obstruct pulmonari diseas highli cor relat tobacco serv moti vation quit social justic teaser decid recruit dif ficulti appar made difficult find differ group achiev suffici sampl size primari limit studi inabil iti recruit enrol suffici number partic ipant result inabl answer research question care preliminari work con duct commun principl muniti participatori research actual particip recruit complet inter vention follow fell short higher degre estim plan phase view document challeng enrol suffi cient number african american clinic search inabl reach recruit goal bvhp commun unusu obviou explan inadequ particip rate challeng face commun studi signific includ poverti violenc drug prob lem compet everydai demand face commun member long term partic ipat health promot activ luxuri afford sincer januari februari 2010 heart lung froelich al protect hood tobacco phat express desir gain assist smok ing cessat effort multipl incent offer 27 31 87 particip pro vide baselin data subsequ unabl part phat rct evalu data provid estim sampl size calcu lation futur particip level commit greater enrol suggest enrol rct year educ accur knowledg potenti health benefit quit smoke shown answer correctli question achiev health benefit smoke 20 year enrol rct higher frequenc hypertens diagnosi motiv quit time frame limit fund studi contributor failur recruit suffi cient particip achiev sampl size adequ statist power undertak mount control intervent program budget design handl inter vention program challeng term staff resourc number particip propos time frame 270 number actu alli recruit 60 repres shortfal 73.7 find suggest tervent unabl answer research question inadequ sampl size preclud intend intent treat statist analysi studi sim ilar studies16 19 provid guidanc futur research field understand characterist african american resid underserv urban area seek quit smoke seek conduct similar studi inabl achiev adequ sam ple size trial yield import observa tion particip singl widow divorc separ small proport marri research suggest social support promot health behavior chang lit eratur smoke cessat appli provid social support smoke 31 half sampl emploi part time full time approxim 60 report annual incom 15,000 suggest ing group social financi resourc medic histori sam ple medic problem includ hyper tension approxim 43 high proport particip histori psychiat heart lung vol 39 1 ric problem prior hospit life threaten ing ill anticip young cohort knowledg harm smoke belief benefit quit substanti smoke histori low level efficaci suggest low report cigarett intak level addic tion smoker socioeconom margin circumst requir aggress interven tion possibl recent approach offer pre cessat pharmacolog therapi 45 interest find high level knowledg harm effect bacco high preval tobacco late diseas hypertens particip rate health good excel lent find rais question par ticip accur translat gener knowledg tobacco harm risk ap praisal consist find studi suggest smoker vulnera ble denial risk inform suffici fulli inform smoker 46 50 suggest lack specif knowledg diseas caus tobacco find suggest studi pro gram provid comprehens approach warrant high proport particip histori hypertens 43.3 es tablish risk reduct smoke cessat comprehen sive health assess intervent low urban african american commun addit limit studi affect outcom underus nrt initi adjuv evid base behavior educ counsel skill build interven tion reason clear topic address public 23 conclus view increas interest commun base participatori approach research 46,47 worth note lesson learn studi prove import investiga tor commun worker studi show engag recruit african ameri can live poorest citi neigh borhood clinic research commun participatori approach experi enc show popul identifi smoke cessat import prioriti search intervent research involv www.heartandlung.org 61 protect hood tobacco phat froelich al commun urgent need address persi tent health dispar public studi meet primari end point test efficaci im portant futur research learn experi anticip need studi low incom communi ti compet prioriti experi suggest studi period 3 year prolong durat recruit acquisit addit site establish sourc fund suffici achiev complet studi object need achiev recruit goal margin commun reliabl high staf ratio greater intens commun outreach intens follow schedul olivia boudreaux harri ernestin daniel marian field marion fisher vera harrel anthoni holm edna jame walter johnson lashawnda thoma marcia wertz pamela jone catherin water contribut project
www.thelancet.com psychiatri vol 2 2015 395 articl lancet psychiatri 2015 2 395 402 publish onlin april 1 2015 http dx.doi.org 10.1016 s2215 0366 15 00091 7 comment page 364 depart health scienc univers york york uk prof gilbodi frcpsych peckham phd mitchel phd li msc becqu phd hewitt phd parrott msc school social commun medicin univers bristol bristol uk man phd centr primari care knowl phd planner msc school nurs midwiferi social work bradshaw phd univers manchest manchest uk depart clinic educ health psycholog univers colleg london london uk michi dphil faculti health social care univers hull hull uk shepherd mnur correspond prof simon gilbodi depart health scienc univers york york yo10 5dd uk simon.gilbodi york.ac.uk bespok smoke cessat peopl sever mental ill health scimitar pilot randomis control trial simon gilbodi emili peckham mei man natasha mitchel jinshuo li taeko becqu catherin hewitt sarah knowl tim bradshaw clair planner steve parrott susan michi charl shepherd summari background peopl sever mental ill health time smoke typic access convent smoke cessat servic contribut widen health inequ reduc life expect aim pilot intervent target smoker sever mental ill health test method recruit randomis follow implement full trial method smoke cessat intervent sever mental ill health trial scimitar pilot randomis control trial smoke cessat strategi design specifi calli peopl sever mental ill health deliv mental health nurs consist behaviour support drug compar convent smoke cessat servic usual care adult ag 18 year older bipolar disord schizophrenia current smoker recruit nh primari care mental health set uk york scarborough hull manchest elig particip randomli alloc usual care control group usual care bespok smoke cessat strategi intervent group randomis central telephon system comput gener random number mask particip famili doctor research treatment alloc primari outcom smoke statu 12 month verifi ed carbon monoxid measur report particip provid exhal measur report smoke statu 12 month includ primari analysi trial regist isrctn.com number isrctn79497236 find 97 peopl recruit pilot studi 51 randomli alloc control group 46 assign intervent group particip engag bespok smoke cessat strategi individu assign usual care access nh smoke cessat servic 12 month 35 69 control 33 72 peopl assign intervent group provid measur report smoke statu smoke cessat highest individu receiv bespok intervent 12 33 36 8 35 23 adjust odd ratio 2 9 95 ci 0 8 10 5 interpret shown feasibl recruit randomis peopl sever mental ill health trial natur level engag bespok smoke cessat strategi higher convent approach eff ectiv safeti smoke cessat programm design peopl sever mental ill health test fulli power randomis control trial fund nation institut health research health technolog assess programm introduct peopl sever mental ill health includ schizophrenia bipolar disord smoke smoke heavili gener popul 1,2 point preval smoke individu sever mental ill health estim 58 90 3 peopl sever mental ill health begin smoke earlier ag higher incidence4,5 sever mental ill health compar gener popul individu sever mental ill health smoke cigarett intens deeper inhal extract greater level nicotin cigarett 6 depend nicotin develop smoke relat diseas receiv quit 7 smoke part cultur mental health servic staff patient 8 peopl sever mental ill health misinform health profession risk benefi ts smoke versu treatment nicotin dependence9 fear overestim medic risk nicotin replac treatment 10 individu smoke reliev depress anxieti 11 nicotin fact increas anxieti smoke contribut gener poor physic health individu sever mental ill health cohort studi show peopl disord schizophrenia die averag 20 25 year earlier sever mental ill health smoke import modifi risk factor health inequ 12 recent public health guidanc issu uk nation institut health care excel nice http crossmark.crossref.org dialog doi 10.1016 s2215 0366 15 00091 7 domain pdf articl 396 www.thelancet.com psychiatri vol 2 2015 stress mental health servic complet smoke free peopl mental health servic full access smoke cessat intervent 13 specifi guidanc scarc smoke cessat servic provid smoke cessat intervent adapt individu sever mental ill health trial base evid suggest peopl sever mental ill health give smoke behaviour pharmacolog intervent aid quit eff ectiv peopl sever mental ill health gener popul 14 individu sever mental ill health gener access convent smoke cessat servic 15 gener popul rate smoke fall chang happen peopl sever mental ill health 16 address widen health inequ design smoke cessat intervent strategi specifi calli peopl sever mental ill health base evid support behaviour chang techniqu eff ectiv pharmacotherapi 17,18 strategi repres mean organis deliv smoke cessat servic respons peopl sever mental ill health boost chanc engag evid support smoke cessat method smoke cessat intervent sever mental ill health trial scimitar aim compar clinic eff ec tive cost eff ectiv bespok smoke cessat intervent convent uk nation health servic nh smoke cessat method peopl sever mental ill health sought preliminari evid clinic eff ectiv popul fulli power trial inform prematur method studi design particip scimitar pilot pragmat arm parallel group randomis control trial test recruit retent randomis peopl sever mental ill health recruit particip nh primari care mental health servic uk base york scarborough manchest hull judg peopl elig trial ag 18 year older sever mental health disord smoke express interest cut smoke necessarili quit defi nition sever mental ill health agre adopt pragmat defi nition19 includ peopl document diagnosi schizophrenia delusion psychot ill categori f20 f22 10th revis intern classifi cation diseas icd 10 bipolar disord f31 icd 10 specifi ed diagnosi sever mental ill health made recruit clinician work specialist psychiatr servic report primari care psychiatr note exclud peopl pregnant breastfeed comorbid drug alcohol problem ascertain famili doctor mental health worker english speaker capac consent particip provid written inform consent part trial ethic approv sought grant oct 29 2010 leed east research ethic committe 10 h1306 72 randomis mask simpl randomis comput gener random number sequenc secur telephon randomis servic run york trial unit gener random sequenc make random alloc research telephon servic particip provid inform consent complet baselin assess randomli alloc individu usual care control group usual care bespok smoke cessat strategi intervent group random alloc made research immedi inform particip alloc letter particip famili doctor mental health specialist detail alloc subsequ smoke cessat manag natur intervent mask particip famili doctor treatment alloc mask research treatment alloc inform particip baselin appoint alloc achiev mask subsequ follow assess diff erent research peopl sever mental ill health diffi cult follow decid maximis particip engag studi subsequ follow visit research baselin interview complet subsequ interview procedur particip consent part trial ask complet baselin questionnair height weight measur calcul bodi mass index bmi obtain exhal carbon monoxid read monitor telephon randomis servic alloc particip studi group randomis particip 12 month obtain data 1 month 6 month 12 month particip trial receiv usual care consist advic access full rang smoke cessat servic er local nh servic famili doctor provid articl www.thelancet.com psychiatri vol 2 2015 397 direct cost told particip free telephon helplin nh quitlin er advic smoke cessat particip remain care famili doctor continu receiv usual servic mental health team trial addit usual care er particip alloc intervent group bespok structur smoke cessat programm individu tailor servic deliv skill mental health practition work conjunct particip particip famili doctor mental health specialist intervent met nice guidelin smoke cessat servic time trial 20 deliv servic manual smoke cessat 21 alter cater peopl sever mental ill health adapt includ make assess set quit date recognis reason smoke context individu mental ill provid home visit give addit face face support unsuccess quit attempt relaps inform particip famili doctor psychiatrist success quit attempt clinician review antipsychot drug dose case metabol chang outcom measur primari outcom smoke cessat 12 month randomis valid outcom measur exhal monitor defi ned smoke cessat read 10 ppm obtain measur accept particip report abstin secondari outcom number cigarett smoke report patient score fagerstrom test nicotin depend 22 motiv quit 23 patient health questionnair 9,24 short form 12 physic mental compon 25 screen primari care note record detail nicotin replac treatment product smoke cessat prescrib particip comparison group ask particip drug misus baselin 12 month follow investig nicotin substitut final calcul bmi assess weight chang initi smoke cessat intervent classifi ed advers event serious relat intervent trial regist isrctn.com number isrctn79497236 control group 51 intervent group 46 97 women 25 49 14 30 39 40 men 26 51 32 70 58 60 ag year 46 4 35 2 53 5 47 3 40 6 56 9 47 2 37 0 56 3 bodi mass index kg m2 29 3 25 1 32 5 27 3 24 1 32 0 28 6 17 9 43 1 cigarett smoke dai 23 3 13 2 26 5 12 0 24 8 12 7 smoke durat year 25 8 12 2 28 5 13 5 27 1 12 9 exhal ppm 24 7 14 1 22 9 13 2 23 8 13 6 alcohol consumpt 32 63 23 50 55 57 19 37 23 50 42 43 feel smoke aff ect state health 43 84 40 87 83 86 8 16 6 13 14 14 advis quit smoke doctor 30 59 31 67 61 63 21 41 15 33 36 37 report drug misus 10 20 5 11 15 15 41 80 41 89 82 85 data number particip median iqr mean sd data miss peopl control group data miss particip control group data miss control peopl intervent group data miss individu group tabl 1 baselin characterist smoke histori figur 1 trial profi le 26 exclud 6 meet inclus criteria 6 give consent 13 unabl contact 1 reason 123 return consent contact 97 randomis 51 usual care control group 46 bespok smoke cessat strategi intervent group 35 includ primari analysi 12 month 16 return questionnair 5 withdrawn studi 11 unknown reason 33 includ primari analysi 12 month 13 return questionnair 10 withdrawn studi 3 unknown reason control group intervent group exhal measur 33 31 quit smoke verifi ed exhal 8 24 10 32 exhal measur report smoke statu 35 33 total quit smoke 8 23 12 36 data number particip tabl 2 smoke cessat 12 month articl 398 www.thelancet.com psychiatri vol 2 2015 statist analysi design extern pilot trial complex intervent primari aim test feasibl intervent method recruit randomis follow popul sever mental ill health ahead full trial aim recruit 100 particip pilot trial assum loss follow 30 particip sampl size 100 95 ci level attrit 21 39 26,27 extern pilot trial 100 particip ensur robust estim recruit follow popul likelihood low small sampl size result eff ectiv establish nonetheless test primari outcom mimic practic full scale trial emphasis result analysi preliminari interpret caution 28,29 compar treatment group logist regress adjust prognost variabl sex ag number cigarett smoke baselin alcohol consum tion calcul odd ratio 95 ci model summaris secondari outcom descript mean sd median iqr continu outcom number particip categor data report number patient complet case includ primari secondari analys treatment group sensit analysi assum peopl miss data smoke role fund sourc studi commiss uk nation institut health research health technolog assess programm project refer hta 07 41 05 funder role studi design data collect data analysi data interpret write report author full access data studi fi nal respons decis submit public result 2011 2012 recruit 97 plan 100 particip trial fi gure 1 51 alloc usual care control group 46 assign usual care bespok smoke cessat programm intervent group group balanc term prognost socio demograph characterist tabl 1 median ag particip 47 2 year iqr 37 0 56 3 mean durat smoke 27 1 year sd 12 9 rang 3 60 mean 24 8 cigarett sd 12 7 rang 5 60 smoke dai 12 month 64 particip measur peopl report smoke statu group 23 35 individu alloc control group stop smoke compar 12 36 33 peopl assign intervent group tabl 2 logist regress adjust sex ag baselin number cigarett smoke baselin alcohol consumpt likelihood stop smoke intervent group time higher control group odd ratio 2 9 95 ci 0 8 10 5 assum miss inform meant individu smoke 16 51 particip stop smoke control group compar 12 26 46 peopl assign intervent group odd ratio 2 5 95 ci 0 8 7 7 control group intervent group baselin 51 1 month 41 6 month 33 12 month 35 baselin 46 1 month 42 6 month 36 12 month 33 number cigarett 23 3 13 2 49 19 4 12 3 37 17 1 11 6 30 18 4 11 6 30 26 5 12 0 43 18 4 9 6 38 16 8 9 6 31 20 1 10 6 26 score fagerstrom test nicotin depend 6 1 2 2 51 5 5 2 4 40 4 8 2 1 32 4 9 2 2 29 6 0 2 6 45 5 2 2 1 38 5 2 2 3 30 5 3 2 0 27 score motiv quit 13 4 2 4 51 11 8 2 4 40 12 3 3 1 34 11 1 3 1 32 14 3 2 3 46 14 2 2 5 41 12 6 3 2 33 12 1 4 0 33 score patient health questionnair 9 8 7 6 6 49 8 3 6 5 39 8 7 7 0 32 7 7 7 3 34 9 8 7 1 45 9 2 7 1 41 9 6 6 5 33 11 2 7 0 33 score short form 12 physic compon 45 3 10 9 51 45 4 10 1 40 46 9 11 4 34 45 8 9 1 33 45 0 10 9 45 45 4 11 2 42 47 8 11 1 35 46 2 11 1 33 score short form 12 mental compon 40 8 11 8 51 42 6 10 2 40 41 6 10 7 34 41 8 11 0 33 40 8 13 1 45 39 9 13 3 42 37 1 12 9 35 39 1 11 2 33 bodi mass index kg m2 29 3 25 1 32 5 50 28 5 25 2 31 7 34 27 3 24 1 33 0 46 27 8 24 4 32 0 33 drug misus 10 20 50 4 12 34 5 11 46 2 6 33 data mean sd median iqr number patient tabl 3 summari secondari outcom articl www.thelancet.com psychiatri vol 2 2015 399 tabl 3 present analysi secondari outcom number cigarett smoke dai fell slightli fi rst 6 month group rose 12 month score fagerstrom test nicotin depend show slight initi decreas group indic diminish nicotin depend remain stabl 12 month follow score motiv quit show similar small reduct group 12 month suggest particip motiv stop smoke high score patient health questionnair 9 augment level depress score fairli stabl fi rst 6 month group escal 12 month intervent group fell control group tabl 3 physic compon short form 12 score rose slightli 6 month group suggest physic health fell 12 month control group score 12 month similar baselin score slightli higher baselin intervent group score mental compon short form 12 fell slightli fi rst 6 month intervent group 12 month slightli lower baselin usual care group score rose mental compon 1 month decreas 12 month slightli higher baselin bmi chang 12 month group 12 month drug misus report 6 particip intervent arm 12 control arm individu assign control group face face nh stop smoke servic 6 particip alloc intervent group report nh quitlin trial period 22 48 peopl assign intervent group pharmacotherapi smoke cessat note primari care record compar ten 19 control fi gure 2 mainstai pharmacotherapi nicotin replac 4 peopl assign intervent record receiv vareniclin 21 advers event record 17 particip trial tabl 4 12 event class relat studi patient advers event admit deterior mental health patient admit separ occas surgeri exist problem admit ill unrel studi chest infect patient di lung cancer advers event judg defi nite relat intervent event side eff ect nicotin replac product burn mouth feel sleepi headach minor side eff ect smoke cessat drug headach nightmar partici pant deterior mental health admiss individu unrel complaint ear infect patient diagnos parasomnia discuss main fi nding scimitar smoke cessat achiev peopl sever mental ill health bespok smoke cessat intervent increas engag servic boost chanc sustain quit observ odd success quit 12 month time higher individu assign bespok smoke cessat intervent compar peopl alloc receiv usual care cautiou interpret result base pilot trial data 68 particip 95 ci odd ratio wide clinician peopl sever mental ill health desir quit smoke ensur onward referr suitabl local smoke cessat servic bespok smoke cessat intervent test scimitar repres organis enhanc figur 2 smoke cessat treatment trial period data obtain analysi primari care record inh ala tor pa tch gu mo uth sp rai lo zen ge na sal sp rai mi cro tab va ren icli ne 0 type treatment 5 10 15 pa tie nt usual care bespok smoke cessat strategi control group 51 intervent group 46 total advers event defi nite relat 0 0 0 relat 0 0 0 relat 1 4 5 unrel 0 6 6 unclassifi ed 1 0 1 advers event defi nite relat 1 0 1 relat 2 3 5 relat 0 0 0 unrel 1 2 3 total 6 15 21 data number advers event tabl 4 relat advers event studi articl 400 www.thelancet.com psychiatri vol 2 2015 model care ensur peopl sever mental ill health access benefi evid support strategi quit smoke knowledg trial fi rst uk bespok smoke cessat intervent design peopl sever mental ill health deliv staff work mental health servic compar convent nh stop smoke servic panel present usual nh practic refer peopl sever mental ill health exist nh stop smoke servic adapt made accommod specifi individu bespok strategi entail face face time convent stop smoke servic compon intervent deliveri mental health profession understand peopl sever mental ill health import role eff ectiv 17,18 smoke cessat intervent rare deliv mental health profession repres role staff stop smoke programm centr nh servic model care accord recommend made nice recent guidanc 13 note nice recommend made robust evid clinic eff ectiv cost eff ectiv drawn trial base evid design scimitar intervent adapt enhanc evid support nh smoke cessat strategi er cut quit nicotin preload approach 30 result pilot trial alongsid data systemat review 14 repres accumul evid eff ectiv smoke cessat peopl sever mental ill health ultim clinic eff ectiv cost eff ectiv bespok smoke cessat intervent individu test fulli power randomis control trial note bespok smoke cessat programm expens usual nh servic invest justifi ed basi cost eff ectiv analysi fi nding show deterior mental health peopl assign intervent group compar control fi nding accord evid gather smoker gener popul cessat smoke improv mental health 31 fi nding mood monitor clinic practic safeti smoke cessat examin scimitar particip sever mental ill health encourag choos form smoke cessat treatment collabor famili doctor famili doctor reluct prescrib product aid smoke cessat nicotin replac treatment choic accord recent guidanc 32 pilot trial limit biochem verifi endpoint test smoke cessat short medium term futur trial captur outcom obtain biochem verifi ed outcom particip remain trial unabl biochem verifi outcom retain particip result trial alter substanti analys report smoke data particip import gold standard biochem verifi ed outcom obtain prefer report data follow good popul 30 particip lost follow 12 month panel research context systemat review design smoke cessat intervent sever mental ill health trial scimitar fi rst systemat review 14 search kei databas medlin embas cinahl psycinfo hmic central dare smoke cessat studi extract data independ includ randomis control trial countri care set adult smoker sever mental ill health identifi ed ten small scale trial potenti eff ectiv highlight nicotin replac bupropion behaviour chang techniqu enabl peopl sever mental ill health quit smoke 14 eff ect size accord broadli estim eff ect popul sever mental ill health systemat review show smoke cessat deterior mental health data inform content design pilot trial bespok intervent systemat review highlight absenc research show servic organis deliv exist mental health servic clarifi peopl sever mental ill health refer exist smoke cessat servic bespok servic need identifi ed larg scale trial studi longer term biolog verifi ed smoke cessat outcom interpret fi nding scimitar show feasibl deliv bespok smoke cessat intervent peopl sever mental ill health recruit randomis retain trial particip sever mental ill health pilot trial power show clinic eff ectiv cost eff ectiv peopl alloc bespok intervent time stop smoke particip control group 95 ci wide research need ascertain gener smoke cessat servic bespok programm design peopl sever mental ill health eff ectiv effi cient confi gurat articl www.thelancet.com psychiatri vol 2 2015 401 loss follow diff er group 16 31 51 control lost follow 13 28 46 peopl intervent group strategi enhanc follow small payment particip futur trial reduc attrit potenti bia final pragmat evalu complex intervent combin case manag pharmacotherapi evid support behaviour chang techniqu disaggreg rel contribut element context assess remain topic futur consider face substanti health inequ peopl sever mental ill health smoke import modifi risk factor poor health reduc life expect 13,32 shown peopl sever mental ill health engag readili bespok intervent translat increas number peopl stop smoke ensur equit provis smoke cessat servic popul import invest bespok smoke cessat servic result defi nitiv clinic trial prematur research aim establish clinic eff ectiv cost eff ectiv bespok smoke cessat servic peopl sever mental ill health fulli power trial commenc juli 2015 isctrn72955454 contributor sg sm jl ch tbr sk sp sm design studi sm nm ep cs cp sk collect data tbe ch jl sp analys data ch contribut present data ch sg tbe jl sp ep interpret data sg ep tbe ch jl sk wrote report sm nm tbr cp sp sm cs critic review report declar interest declar compet interest acknowledg smoke cessat intervent sever mental ill health trial scimitar fund nation institut health research nihr health technolog assess hta programm project number 07 41 05 publish full health technolog assess inform http www.nets.nihr.ac.uk project hta 074105 report present independ research nihr collabor leadership appli health research care yorkshir humber commiss nihr view opinion express author necessarili refl ect nation health servic nihr nihr evalu trial studi coordin centr hta programm depart health particip part trial famili doctor secondari tertiari care staff recruit particip studi complet trial document member trial steer committe data monitor ethic committe overse studi helen hartlei leed stop smoke servic provid train mental health smoke cessat practition fabiana lorencatto andi mcewen director nation centr smoke cessat train advic evid support smoke cessat intervent adapt peopl sever mental ill health scimitar support northeast northwest hub mental health research network north east yorkshir north lincolnshir comprehens local research network trial dedic memori prof helen lester 1961 2013 celebr work contribut care wellb peopl sever mental ill health work abid passion last contribut
gonseth al bmc public health 2014 14 911 http www.biomedcentral.com 1471 2458 14 911 research articl open access leptin smoke cessat secondari analys random control trial assess physic activ aid smoke cessat semira gonseth1,2,3 isabella locatelli2,3 raphaël bize2 sébastien nusslé4 carol clair3 françoi pralong5 jacqu cornuz3 abstract background smoker lower bodi weight compar smoker smoke cessat weight gain case hormon mechan action implic weight variat relat smoke leptin implic made secondari analys rct hypothesi free exploratori approach studi dynam leptin smoke cessat method measur serum leptin level 271 sedentari smoker quit particip random control trial assess 9 week moder intens physic activ intervent aid smoke cessat adjust leptin bodi fat level perform linear regress test associ leptin level studi group time result year smoke cessat mean serum leptin chang 3.23 mg sd 4.89 control group 1.25 mg sd 4.86 intervent group differ 0.05 adjust bodi fat level leptin higher control group intervent group differ 0.01 mean weight gain 2.91 sd 6.66 kg intervent 3.33 sd 4.47 kg control group signific conclus serum leptin level significantli increas smoke cessat spite substanti weight gain leptin dynam chronic tobacco user quit smoke physic activ impact dynam leptin situat clinic trial registr number nct00521391 keyword smoke smoke cessat physic activ leptin weight gain background tobacco world lead prevent death 1 smoker smoke view mean weight control 2 5 smoke cessat deed 2.6 kg mean weight gain year quit men 3.6 kg women 6 effici treatment prevent intervent avoid weight gain smoke cessat lack correspond semira.gonseth gmail.com 1depart epidemiolog biostatist univers california san francisco 1450 3rd street san francisco ca usa 2institut social prevent medicin univers lausann hospit 1010 lausann switzerland full list author inform end articl 2014 gonseth al license biom centra common attribut licens http creativec reproduct medium provid dedic waiver http creativecommons.or state 7 promis evid ward physic activ pa solut instanc cochran review found year regular pa fol low smoke cessat decreas weight gain 8 numer studi argu hormon mechan action implic post cessat weight gain leptin involv 9 12 leptin cytokin releas adipos tissu act central suppress food intak increas metabol rate 13 leptin decreas appetit eat leptin rise food intak modifi balanc appetit stimul inhibit hypothalamu action involv open access articl distribut term creativ ommons.org licens 2.0 permit unrestrict distribut igin work properli credit creativ common public domain publicdomain 1.0 appli data made articl http www.clinicaltrials.gov mailto:semira.gonseth gmail.com http creativecommons.org licens 2.0 http creativecommons.org publicdomain 1.0 gonseth al bmc public health 2014 14 911 page 2 8 http www.biomedcentral.com 1471 2458 14 911 neuropeptid lead consecut decreas food intak 14 16 leptin consid potenti mediat weight gain smoke cessat 10,17,18 differ bodi weight observ smoker nonsmok 13 crude serum leptin level lower smoker comparison nonsmok 9,19 21 associ disappear lep tin adjust bodi mass index bmi 22 prospect studi small sampl size short follow explor variat leptin follow ing smoke cessat result contradictori 13,22 25 studi effect physic activ serum lep tin level scarc review studi design manipul energi balanc show serum leptin level chang physic activ mark energi deficit occur 26,27 publish studi leptin variat physic activ assess intens physic activ com.ibm.drl.hbcp.util small sampl size short time intervent scarc inform exist biodynam leptin smoke cessat plausibl leptin good candid explain weight gain follow ing smoke cessat attempt describ biodynam serum leptin level smoke ce sation analyz variat insulin secr tion sensit impact leptin level influenc smoke cessat physic activ 28,29 perform secondari analys random control clinic trial rct assess moder physic activ aid smoke cessa tion sedentari subject exploratori hypothesi free approach method analyz data popul base random control trial assess moder pa aid smoke cessat main outcom rct year continu smoke abstin rate high statist inter vention group control group 27 versu 29 0.71 result discuss detail 30 mean weight gain year follow significantli group 31 full inclus exclus criteria studi design procedur detail 30 smoke cessat program particip randomli divid group intervent group control group sequenc alloc group remot randomli gener comput conceal alloc secur mean seal envelop partici pant attend 9 week program weekli 15 minut individu base smoke cessat intervent combin counsel prescript nicotin placement therapi 16 hour transderm patch 1 2 mg gum 1 mg lozeng 10 mg inhal program base intern guidelin smok ing cessat 32 subject stop smoke 5th week inclus visit relaps consid er smoker continu abstin defin smoke week 5 week 52 base report valid carbon monoxid measur 10 ppm subject enrol intervent group attend 9 week weekli 60 minut exercis intervent base nationwid implement moder intens pa pro gram allez hop pa facilit 33 group session divid part discu sion pa 45 minut moder pa debrief intervent target reach score 11 easi 13 hard borg rate perciev exert scale 34 particip encourag practic 30 minut moder intens pa time week subject enrol control group attend 9 week weekli 60 minut health educ program en equal contact condit control subject partici pate group session healthi lifestyl includ lectur distribut handout discuss diet prevent cardio vascular diseas cancer screen program breast colon cancer adapt valid program swiss popula tion 35 serum fast leptin insulin glucos level assess baselin 3 6 12 month data collect report smoke abstin confirm car bon monoxid exhal air 10 ppm measur micro smokerlys bedfont pa quantifi administr physic activ frequenc questionnair pafq 36,37 volum pa calcul met min week pa achiev 4 met american heart associ 38 particip wear underwear weight nearest 0.1 kg height measur nearest 0.5 cm bmi calcul formula weight kg height2 cm proport lean fat mass assess leg arm bioelectr imp anc analysi 39 plasma leptin measur radio immuno assai kit linco research st charl m.o serum sampl remov morn overnight fast cost reason gonseth al bmc public health 2014 14 911 page 3 8 http www.biomedcentral.com 1471 2458 14 911 leptin measur 271 total 481 includ particip percentag bodi fat bmi leptin analyz continu variabl order investig leptin level control chang adipos tissu defin ratio leptin bodi fat level ratio leptin level mg percentag bodi fat differ serum leptin level men women de scribe 40 estim insulin secret insulin sensit particip homeostasi model assess insulin resist homa ir cal culat formula fast insulin mu fast glucos mmol 22.5 41 result pre sent particip stratifi sex statist analys perform comparison baselin char acterist intervent control group sampl test normal distribut variabl parametr wilcoxon test skew variabl test binari variabl follow time abstin durat total physic activ proport continu ab stinent 12 month compar group wilcoxon test twelv month weight bmi bodi fat homa ir leptin ratio leptin bodi fat ratio leptin bodi fat compar sampl test leptin variabl baselin subsequ visit estim perform simpl linear regress studi group smoke statu perform multivari linear regress esti mate impact potenti confound variabl associ leptin level studi group individ ual miss data exclud analys polynomi longitudin model order compar dynam time ratio leptin bodi fat group random method addit file 1 system statist comput graphic 2.11.1 http www.r project.org func tion lme librari nlme result studi popul includ 271 particip 136 control group 135 intervent group statist signific differ observ base line characterist control intervent group tabl 1 follow median durat 55 iq 11 59 week similar intervent control group 271 particip 81 29.9 continu abstin verifi entir durat studi follow particip show median durat abstin 11.9 iq 4 52.3 week control group median abstin 16.5 iq 4.5 51.7 week intervent group 11.4 iq 3.5 53.5 week differ 0.95 12 month follow abstin rate 50.96 control group 50.76 intervent group differ 0.97 total physic activ 4 met 12 month 879 203 2240 met min week control group 1642 758 3084 met min week intervent group differ 0.01 tabl 2 show metabol relat vari abl 3 6 12 month baselin visit studi group chang leptin signifi cantli higher control group 6 month 0.08 significantli higher 12 month 0.014 chang ratio leptin bodi fat higher control group visit strongli signifi 6 12 month follow 0.024 0.001 0.008 3 6 12 month illu trate figur 1 variabl show signific chang group tabl 3 show variabl smoke statu independ entli studi group signific associ observ multivari linear regress chang ratio leptin bodi fat significantli studi group lower intervent group visit tabl 4 fast insulin glucos level impact associ signific valu expect insulin 6 month 0.011 smoke statu appli longitudin model found mean ratio leptin bodi fat increas 35 week decreas quadrat curv 0.001 linear quadrat term addit file 2 figur s1 found signific interact studi group time 0.04 attest pattern ratio leptin bodi fat follow control intervent group intervent group show attenu dynam ratio leptin bodi fat time maximum gain 0.04 ml 0.07 ml 35 week final gain 0.02 ml 0.04 ml median follow durat 55 week final piecewis longitudin model appli 234 particip stop smoke give separ estim ratio leptin bodi fat chang abstin relaps episod follow addit file 2 figur s2 physic activ influenc leptin dynam abstin period import increas control intervent group 0.03 model show signific effect sex ratio leptin bodi fat initi level dynam time http www.r project.org tabl 1 baselin characterist studi group control 136 intervent 135 men 81 59.6 77 57.0 0.674 ag year mean sd 42.7 9.3 41.7 9.7 0.419 number cig median iqr 25 20 30 25 20 30 0.697 year educ mean sd 12.6 1.8 12.5 1.8 0.782 physic activ 4 met median iqr 936 188 2047 866 190 2403 0.942 weight kg mean sd 70.7 12.9 71.8 15.9 0.526 bmi mean sd 23.8 3.23 24.1 4.12 0.526 percent bodi fat mean sd 25.6 5.7 25.8 7.0 0.876 homa ir 2.22 1.13 2.45 1.39 0.17 leptin mg median iqr 6.4 4.2 11.7 7.2 4.3 12.2 0.376 ratio leptin bodi fat mg median iqr 0.26 0.17 0.43 0.28 0.19 0.48 0.290 135 133 115 111 gonseth al bmc public health 2014 14 911 page 4 8 http www.biomedcentral.com 1471 2458 14 911 women baselin ratio leptin bodi fat level signifi cantli larger men 0.48 ml 0.20 ml 0.001 import dynam follow relaps smoke modifi quadrat pattern adjust leptin lead abrupt linear de creas mean adjust leptin relaps epi sode start 0.001 discuss found level leptin significantli increas studi period studi particip ind pendent studi group increas serum leptin greatest 5.27 mg sd 5.59 continu ou abstin particip control group constitut increas 82 compar mean control group baselin leptin level level adjust bodi fat leptin increas 12 month control group interven tion addit particip group gain substanti weight e.g 6.04 kg sd 3.87 tabl 2 chang follow variabl 3 6 12 month group 3 month intervent control interven bodi weight kg 2.31 2.72 2.15 2.48 0.665 2.84 5 bmi kg m2 0.8 0.91 0.73 0.89 0.57 1.01 1 bodi fat 1.76 4.43 1.09 2.13 0.269 2.53 5 homa ir 0.1 1.16 0.04 1.22 0.735 0.33 1 fast leptin ug 1.78 3.79 2.37 3.61 0.273 1.73 5 ratio leptin bodi fat 0 0.19 0.06 0.1 0.024 0.04 0 bmi bodi mass index homa ir homeostasi model assess insulin resistan assess univari linear regress analysi valu express mean standard deviat 0.05 0.01 control abstin group 4.66 kg sd 4.18 inter vention abstin group 12 month find bring solid evid post cessat leptin dynam previous found smaller studi shorter follow subject 13,22 25 probabl leptin level increas smoke cessat studi particip increas food intak increas food intak wide observ smoke cessat 42 caus compensatori eat behav ior respons tobacco withdraw 43 accord ing previou studi nonsmok leptin increas increas food intak instanc studi conduct weigl al over rapidli increas serum leptin level 40 percent 44 observ increas leptin independ major influenc insulin secret sensit strictli leptin pathwai find counter intuit expect baselin visit particip studi 6 month 12 month tion control intervent control 99 3.02 3.51 0.822 2.91 6.66 3.33 4.47 0.633 83 1.03 1.21 0.928 1 1.98 1.14 1.53 0.624 75 1.86 3.19 0.477 2.49 5.24 2.53 2.95 0.957 08 0.24 1.03 0.596 0.67 1.56 0.78 1.92 0.731 77 3.2 4.42 0.08 1.25 4.86 3.23 4.89 0.014 23 0.08 0.12 0.001 0.02 0.22 0.07 0.12 0.008 ce figur 1 ratio leptin bodi fat studi group studi period baselin visit 3 6 12 month gonseth al bmc public health 2014 14 911 page 5 8 http www.biomedcentral.com 1471 2458 14 911 effect increas leptin level con secut decreas appetit food intak weight gain aris situat 45 unlik observ studi hypoth es made explain appar contradict instanc particip present ing resist leptin i. rise leptin pro duce decreas appetit food intak bodi weight expect chronic tobacco induc leptin resist similar produc insulin resist de scribe willi al 46 stage mechan action metabol effect smoke leptin hypothes instanc chronic tabl 3 chang follow variabl 3 6 12 month statu continu abstin relaps 3 month smoke abstin smok bodi weight kg 2.25 2.35 1.99 2.83 0.584 3.05 bmi kg m2 0.78 0.89 0.68 0.95 0.539 1.08 1 bodi fat 1.49 3.19 1.23 4 0.784 2.18 3 homa ir 0.1 1.56 0.03 1.03 0.763 0.27 1 fast leptin ug 1.8 4.3 2.03 3.67 0.734 1.88 6 ratio leptin bodi fat 0 0.15 0.03 0.17 0.513 0.02 0 valu express mean standard deviat inflamm induc smoke metabolit damag leptin receptor reason ap parent contradictori result involv hor mone pathwai insulin instanc increas eat behavior due tobacco withdraw strong influ enc action leptin research subject need addit moder physic activ tenuat increas serum leptin level smoke cessat found particip intervent group underw 9 week smoke cessat program consist 60 minut week moder physic activ lower increas serum fter baselin visit particip smoke 6 month 12 month ing abstin smoke abstin 4 2.45 6.15 0.599 2.45 3.64 3.2 7.42 0.520 44 0.86 1.87 0.535 0.84 1.2 1.1 2.29 0.468 1 2.09 6.01 0.955 2.5 2.84 2.57 5.47 0.948 2 0.27 0.93 0.977 0.99 2.32 0.83 1.54 0.681 82 2.63 4.59 0.505 1.83 4.14 2.56 5.44 0.455 18 0.02 0.22 0.529 0 0.11 0.03 0.24 0.564 tabl 4 multivari linear regress analysi ratio leptin bodi fat 3 6 12 month baselin visit 3 month 124 6 month 95 12 month 101 rc rc rc intercept 0.084 0.469 0.072 0.609 0.145 0.579 intervent 0.238 0.040 0.426 0.002 0.115 0.030 smoke statu 0.062 0.602 0.122 0.417 0.018 0.749 fast insulin mu 0.204 0.084 0.466 0.008 0.005 0.174 fast glucos mmol 0.091 0.429 0.057 0.705 0.023 0.655 rc regress coeffici 0.05 0.01 gonseth al bmc public health 2014 14 911 page 6 8 http www.biomedcentral.com 1471 2458 14 911 leptin level year follow control group interest note theoret expect increas weight gain intervent group compar control group de pite fact intervent group lower serum leptin level underli mecha nism action effect remain unknown hypothes stage accord interpret benefici impact physic activ leptin resist exist induc smoke i. physic activ reduc leptin resist physic activ benefici impact type 2 diabet insulin resist 47 produc similar action leptin potenti benefici action physic activ leptin resist confirm occur instanc chang balanc muscular fat mass favor muscl model found smoke cessa tion trigger increas serum leptin level group physic activ attenu increas lead substanti recov initi leptin level end follow interpret de creas leptin resist time smoke cessa tion similar heal process reflect eat behavior due tobacco drawal attenu time incident model show smoke relaps trigger abrupt de creas leptin level fall leptin con secut effect relaps occur smoke act substitut food food intak decreas decreas serum leptin level limit studi mention physic activ program studi moder intens underestim potenti effect physic activ metabol homeostasi discuss 30 sec ond vast major particip inter vention control group relaps stage studi longitudin model supplementari analys allow counteract ing limit take account inform particip independ begin durat smoke abstin relaps conclus found serum leptin level significantli increas smoke cessat studi particip gain substanti weight time period find discord theoret effect leptin hypothes explain find includ instanc leptin resist smoker hypothes investig found moder physic activ tenuat potenti leptin resist studi bring addit argument hypothesi leptin implic weight gain smoke cessat addit file addit file 1 supplementari materi 31,48 54 addit file 2 figur s1 ratio leptin bodi fat mean pattern year follow random group mix effect model figur s2 ratio leptin bodi fat mean pattern abstin relaps episod follow sex random group adjust piecewis polynomi longitudin model compet interest author declar compet interest author contribut sg particip data collect design studi perform analys wrote manuscript il perform analys contribut redact methodolog section manuscript rb particip data collect particip design studi supervis analys critic review manuscript jc design conduct primari studi particip design studi supervis analys critic review manuscript sn cc fp provid gener guidanc critic review manuscript import conceptu scientif content author read approv final manuscript http www.biomedcentral.com content supplementari 1471 2458 14 911 s1 pdf http www.biomedcentral.com content supplementari 1471 2458 14 911 s2 pptx gonseth al bmc public health 2014 14 911 page 7 8 http www.biomedcentral.com 1471 2458 14 911 acknowledg author prof joseph wiemel read comment version manuscript fund studi fund ambulatori care commun medicin depart lausann univers hospit sg benefit grant swiss cancer leagu bil kl 3124 02 2013 sicpa foundat entiti support scientif work sn benefit grant swiss nation scienc foundat earli post doc mobil fellowship author detail 1depart epidemiolog biostatist univers california san francisco 1450 3rd street san francisco ca usa 2institut social prevent medicin univers lausann hospit 1010 lausann switzerland 3depart ambulatori care commun medicin univers lausann 1011 lausann switzerland 4depart environment scienc polici manag univers california mulford hall berkelei ca usa 5depart endocrinolog diabetolog metabol univers lausann 1011 lausann switzerland receiv 9 septemb 2013 accept 29 august 2014 publish 3 septemb 2014

long term outcom cell phone deliv intervent smoker live hiv aid ellen gritz 1 heather danysh 1 faith fletcher 1 iren tami mauri 1 michel cororv fingeret 1 rachel mark king 2 roberto arduino 3 damon vidrine1 1depart behavior scienc 2cancer prevent center univers texa md anderson cancer center houston 3divis infecti diseas univers texa health scienc center houston medic school background peopl live human immunodefici viru hiv aid plwha substanti higher preval cigarett smoke compar gener popul addit plwha suscept advers health effect smoke primari object design test efficaci 12 month smoke cessat intervent target plwha method particip enrol urban hiv clinic multiethn econom disadvan tage patient popul particip receiv smoke cessat treatment usual care uc coun sele deliv cell phone intervent cpi 7 dai point preval abstin evalu 3 6 12 month logist regress gener linear mix model result random 474 hiv posit smoker uc cpi group evalu treatment effect 7 dai abstin outcom 3 6 12 month follow up particip cpi group 2.41 time 049 demonstr abstin compar uc group treatment effect strongest 3 month follow odd ratio 4.3 001 diminish 6 12 month 05 conclus cell phone deliv smoke cessat treatment posit impact abstin rate pare usual care approach futur research focu strategi sustain treatment effect long term keyword hiv aid smoke cessat cell phone intervent disproportion burden cigarett smoke person live human immunodefici viru hiv aid plwha repres press public health problem contrast document preva lenc smoke gener unit state popul substanti evid smoke preval 2 3 time higher plwha estim rang 45 70 1 plwha suscept advers health cons quenc tobacco elev risk major cardiovascular diseas cancer bacteri pneumonia mortal 2 fact recent evid larg cohort studi 60 death plwha attribut smoke 3 compel evid suggest plwha suffer disproportion neg health consequ relat smoke andwould benefit con sider smoke cessat treatment larg scale smoke cessat random control trial rct conduct exclus plwha 4 rct target plwha yield stat istic signific treatment effect long term smok ing abstin 5 6 small pilot demonstr trial shown promis result develop intervent combin support counsel nicotin replac therapi nrt enhanc smoke abstin plwha 7 10 current larg scale rct 474 usual care approach compar innov cell receiv 8 march 2013 accept 11 2013 electron publish 23 2013 correspond ellen gritz phd depart behavior scienc uni versiti texa md anderson cancer center po box 301439 unit 1330 houston tx 77030 1439 egritz mdanderson.org clinic infecti diseas 2013;57 4 608 15 author 2013 publish oxford univers press behalf infecti diseas societi america right reserv permiss mail journals.permiss oup.com doi 10.1093 cid cit349 608 cid 2013 57 15 august hiv aid nivers berdeen ovem ber 26 2015 http cid.oxfordjournals.org ow nload mailto:egritz mdanderson.org mailto:journals.permiss oup.com http cid.oxfordjournals.org phone counsel base smoke cessat intervent sampl low incom multiethn hiv posit smoker knowledg largest smoke cessat interven tion studi exclus target plwha conduct date focu uniqu econom ical disadvantag popul plwha 3 month trial show particip receiv cell phone base smoke cessat intervent 4.3 time abstin compar individu receiv ing usual care 001 11 report long term smoke relat outcom intervent trial 12 month follow method particip screen studi particip recruit thoma street health center counti oper hiv clinic serv predominantli low incom medic indig patient popul total 474 particip recruit februari 2007 de cember 2009 research staff screen clinic patient eligi biliti arriv primari care appoint inclus criteria hiv posit ag 18 year current smoker 5 cigarett daili expir carbon monoxid level 7 ppm set quit date 7 dai abil speak english spanish exclus criteria clude current enrol smoke cessat program physician deem inelig base medic psychiatr condit studi design procedur obtain inform consent particip complet audio comput assist interview acasi receiv provid advic quit smoke subsequ particip random 1 2 treatment group usual care uc cell phone intervent cpi uc cpi treatment inform recommend treat tobacco depend clinic practic guidelin 12 particip assign uc group provid tar gete written smoke cessat materi tip sheet de sign address concern hiv posit smoker instruct obtain nrt form nicotin patch clinic particip assign cpi group receiv uc ponent cell phone deliv counsel intervent 3 month access support hotlin cpi design 1 reduc access care barrier 2 provid intens level support 3 meet special target popul counsel content drawn cog nitiv behavior motiv interview techniqu empir support literatur smoke cessat 12 descript counsel session content call schedul call complet rate pre viousli publish 11 particip cpi group pro vide prepaid cell phone counselor train supervis licens clinic psychologist follow assess conduct 3 6 12 month postenrol includ acasi biolog confirm smoke statu expir research protocol approv institut review board univers texa md anderson cancer center univers texa health scienc center houston addi tional detail treatment studi design follow sessment procedur previous publish 11 baselin follow assess includ measur assess demograph behavior psychosoci characteri tic tobacco relat item administ baselin includ ag smoke initi number cigarett smoke dai quit attempt histori follow item administ assess smoke abstin 24 hour 7 dai 30 dai number quit attempt length abstin dai nrt cessat treatment exposur form tobacco smoke relat measur includ fagerström test nicotin depend ftnd 13 reason quit scale intrins extrins quit motiva tion 14 9 item quit efficaci scale 15 de pressiv symptom assess 20 item center epidemiolog studi depress scale ce 16 current anxieti assess state compon state trait anxieti inventori stai 17 qualiti life qol assess medic outcom studi hiv health survei mo hiv provid mental physic function statu summari score 18 alcohol measur alcohol disord identif test audit 19 singl item assess illicit drug past month statist analysi descript statist comput separ uc cpi group includ gener mean standard devia tion frequenc demograph psychosoci tobacco relat alcohol illicit drug variabl baselin seri univari regress model evalu baselin differ potenti confound 2 treatment group statist signific test χ2 test categor variabl test continu vari abl report 7 dai point preval abstin primari outcom measur smoke abstin 24 hour 30 dai abstin assess secondari outcom expir level biochem verifi report smoke statu particip report absti nenc level 7 ppm code smoker hiv aid cid 2013 57 15 august 609 nivers berdeen ovem ber 26 2015 http cid.oxfordjournals.org ow nload http cid.oxfordjournals.org smoke abstin outcom express dichoto mou variabl gener linear mix model glmm evalu treatment effect abstin outcom primari outcom smoke absti nenc repeatedli measur time point 3 6 12 month particip glmm uti lize analysi accommod repeat measur subject correl 20 glmm handl miss data imput valu glmm model analysi logit link function binomi error vari anc gener odd ratio or confid interv ci model includ variabl follow time point ag fix effect subject random effect teract term follow visit treatment group evalu treatment effect vari statisti calli time analys conduct intent treat itt approach lost follow code smoker repeat complet case cc approach clude data particip complet 1 follow assess 21 analys conduct stata softwar version 10.1 statacorp colleg station texa result screen total 1372 individu studi 553 exclud due failur meet studi inclus criteria figur 1 total 474 particip random uc group 238 cpi group 236 particip follow rate 3 6 12 month postenrol 73.8 76.4 77.0 statisti calli signific differ follow rate treat ment condit baselin characterist treatment group present tabl 1 treatment group balanc regard demograph psychosoci tobacco relat alcohol illicit drug variabl baselin figur 1 consolid standard report trial consort diagram show screen studi enrol retent 12 month follow 610 cid 2013 57 15 august hiv aid nivers berdeen ovem ber 26 2015 http cid.oxfordjournals.org ow nload http cid.oxfordjournals.org except ag statist signific differenc es baselin variabl treatment condit sampl 70.0 male 76.2 african american 17.7 marri live signific major sampl unemploi baselin 78.9 primarili due health reason 49.2 38.4 high school educ primari mode report hiv ac quisit heterosexu contact 45.6 particip report hiv transmiss men sex men 25.2 inject drug 17.2 mean ag base line 44.8 sd 8.1 year mean ag baselin variabl statist signific differ 2 treatment condit uc 45.7 sd 7.8 cpi 43.9 sd 8.3 017 ag adjust regr sion model evalu smoke abstin outcom half sampl 67.3 report high level depress symptom baselin ce 16 studi sampl report poor physic mental function statu assess qol mo hiv physic health summari ph score mental health summari mh score summari score popul mean 50 particip report averag ph score 40.0 sd 10.8 mh score 42.1 sd 11.2 baselin approxim 31 particip classifi harm hazard level alcohol audit score 8 40.1 report illicit drug past 30 dai baselin particip report smoke mean 19.2 sd tabl 1 baselin characterist studi particip treatment group characterist cell phone intervent group 236 usual care group 238 demograph variabl ag mean sd 43.9 8.3 45.7 7.8 women 68 28.8 74 31.1 race ethnic white 30 12.7 29 12.2 black african american 176 74.6 185 77.7 latino hispan 24 10.2 19 8.0 6 2.5 5 2.1 year formal educ mean sd 10.9 2.7 10.8 2.5 educ level high school 94 39.8 88 37.0 high school equival 89 37.7 91 38.2 high school 53 22.5 59 24.8 current employ statu work full part time 53 22.5 47 19.7 work due health 143 60.6 157 66.0 unabl find work 20 8.5 16 6.7 work reason 20 8.5 18 7.6 hiv transmiss male homosexu contact 62 26.4 57 24.1 heterosexu contact 108 46.0 107 45.2 inject drug 34 14.5 47 19.8 31 13.2 26 11.0 marri live partner 39 16.5 45 18.9 psychosoci variabl depress ce score mean sd 22.0 11.2 21.5 11.4 ce score 16 167 70.8 152 63.9 anxieti stai state score mean sd 43.6 13.6 43.0 13.2 physic health summari mo hiv ph score mean sd 39.8 11.2 40.3 10.4 mental health summari mo hiv mh score mean sd 41.9 11.4 42.3 11.1 tobacco relat variabl ag smoke initi mean sd 18.2 9.0 17.4 6.8 cigarett smoke dai mean sd 18.6 11.3 19.7 11.8 nicotin depend ftnd score mean sd 5.73 2.3 5.82 2.3 previou quit attempt 137 58.1 145 60.9 tabl 1 continu characterist cell phone intervent group 236 usual care group 238 smoker home 133 56.3 113 47.5 smoke efficaci mean sd 24.9 9.1 25.8 8.4 intrins quit motiv mean sd 38.4 9.1 38.7 8.7 extrins quit motiv mean sd 27.3 8.7 28.1 9.4 alcohol illicit drug alcohol audit score mean sd 5.8 8.2 6.1 8.3 audit score 8 68 28.8 78 32.8 illicit drug past 30 99 42.0 91 38.2 data present abbrevi audit alcohol disord identif test ce center epidemiolog studi depress scale ftnd fagerström test nicotin depend hiv human immunodefici viru mh mental health survei mo hiv medic outcom studi hiv health survei ph physic health survei sd standard deviat stai state trait anxieti inventori 05 hiv aid cid 2013 57 15 august 611 nivers berdeen ovem ber 26 2015 http cid.oxfordjournals.org ow nload http cid.oxfordjournals.org 11.5 cigarett dai 51.9 report live smoker mean ftnd score 5.8 sd 2.3 indic moder high level nicotin depend 13 treatment effect smoke abstin outcom present tabl 2 primari outcom 7 dai point preval abstin 12 month follow result itt analysi particip cpi group 2.41 time 95 ci 1.01 5.76 abstin compar uc group result similar evalu 7 dai abstin cc approach 2.46 95 ci 1.03 5.94 evalu secondari smoke ab stinenc outcom 24 hour abstin 30 dai abstin yield similar or 7 dai abstin or rang 2.20 2.47 inclus interact term follow time point treatment group glmm model yield statist signific chang slope 0001 dicat treatment effect vari follow time point illustr figur 2 pre sent preval 7 dai abstin individu follow time point treatment group particip ran domiz cpi group 4.3 time 95 ci 1.9 9.8 report smoke abstin 3 month studi enrol compar uc group itt analysi cc analysi result similar yield 4.5 95 ci 2.0 10.3 treat ment effect evid 3 month time point diminish evalu abstin 6 12 month follow time point 05 discuss purpos studi develop implement smoke cessat intervent intend address complex medic social encount plwha low incom multiethn background end provid particip prepaid cell phone lack resourc unstabl telephon servic popul proactiv telephon call design tabl 2 primari secondari smoke abstin outcom particip random cell phone intervent group usual care group smoke abstin data 12 mo follow intent treat 474 complet case 423 95 ci 95 ci primari 7 2.41 1.01 5.76 049 2.46 1.03 5.94 044 secondari 24 2.36 1.28 4.38 006 2.47 1.31 4.64 005 30 2.20 83 5.83 114 2.29 85 6.15 133 estim gener gener linear mix model regress logit link function model adjust fix effect time follow time point ag random effect subject abbrevi ci confid interv odd ratio figur 2 smoke abstin treatment group show percent ag particip treatment condit usual care cell phone intervent report 7 dai smoke abstin 3 6 12 month follow period bar repres standard error mean percentag abstin intent treat complet case approach 612 cid 2013 57 15 august hiv aid nivers berdeen ovem ber 26 2015 http cid.oxfordjournals.org ow nload http cid.oxfordjournals.org address hiv specif issu treatment respons risk hiv relat diseas cognit behavior compo nent design modifi thought behavior serv barrier quit smoke remain absti nent final motiv compon design address fluctuat quit motiv promot greater efficaci quit smoke treatment deliveri phase object success demonstr signific treatment effect cpi group compar uc group attest target person tervent plwha combin focu deliv empir valid treatment strategi smoke cessa tion find show absolut quit rate low cpi uc group diminish time substanti work remain accomplish assist derserv popul tobacco cessat aspect studi deserv comment particip select base demonstr level smoke 5 cigarett dai expir breath 7 ppm lead exclus 40.3 smoker screen figur 1 particip reach screen cutoff appli studi stantial level nicotin depend popul level data dicat african american hispan individu smoke fewer cigarett dai compar white individu remain nicotin depend 22 exact reason trend lighter smoke lack eco nomic resourc purchas cigarett daili contribut factor hiv aid disproportion affect racial ethnic minor low incom popul 23 futur smoke cessat effort inclus lighter nondaili smoker previous mention absolut quit rate cpi uc treatment group low due low nrt com.ibm.drl.hbcp.util high nicotin depend sampl plwha smoker particip receiv inform obtain free nrt actual com.ibm.drl.hbcp.util rate low due requir impos counti clinic particip addit class receiv nrt characterist studi sampl moder high level nicotin depend includ mean ftnd score 5.8 high rate alcohol illicit drug 24 26 substanti rate poli tobacco 21.6 includ cigar smokeless tobacco 27 28 greater utiliza tion nrt posit affect quit rate de pendent sampl smoker 12 29 import nrt support find lloyd richardson col leagu report nrt adher predict ab stinenc plwha enrol cessat trial 5 import descriptor sampl baselin high level depress symptom poor mental physic health function statu substanti burden mental ill smoker plwha person suffer depress lower quit rate nondepress individu 30 33 pharmacolog cal support shown differenti benefit person 34 35 final intervent featur person counsel address barrier cessat directli connect studi particip social servic mental health counselor drug abus counselor specialti address real world problem develop intervent incorpor featur futur research strength studi includ larg sampl size urban multiethn popul repres plwha 2 element prior studi match expir breath verifi report smoke abstin classifi meet criterion smoker rigor measur abstin studi report subject report bia limit includ singl hiv clinic albeit counti site larg patient popul studi design test intervent effect deliv stage hiv diagnosi treatment initi diagnosi success antir trovir treatment defin cd4 count viral load diseas progress research address point optim smoke cessat treatment fur thermor design permit nuanc efficaci assess specif counsel treatment compon expir valid smoke statu po tential limit misclassif smoke statu occur due marijuana marijuana user incorrectli classifi smoker altern rela tive short half life result misclassifi cation smoker code abstin due low level relat misclassif nondifferenti impact treatment effect outcom absenc evid base cessat program plwha hiv specif clinic smoke guidelin recent recommend call clinic behavior system base research tailor uniqu medic social plwha 4 36 recogn plwha eco nomic disadvantag background face signific barrier subsequ prevent popul particip smoke cessat program barrier german econom disadvantag plwha includ transport difficulti lack resourc includ telephon compet medic social high frequenc household move limit access smoke cessat program 37 39 studi hiv aid cid 2013 57 15 august 613 nivers berdeen ovem ber 26 2015 http cid.oxfordjournals.org ow nload http cid.oxfordjournals.org uniqu aim address barrier cell phone technolog deliv treatment futur studi impera tive make pharmacolog behavior support readili target popul continu tailor tervent address specif plwha larg scale rct smoke cessa tion intervent plwha proactiv cell phone base intervent combin support counsel ing motiv intervent materi topic target plwha success compar uc intervent includ physician advic quit tip sheet intervent effect declin time greatest impact occur 3 month follow find efficaci cpi effect sustain 3 month treatment period suggest extend inter vention approach benefici futur studi address sustain intervent effect rais absolut quit rate reduc real life barrier cessat psychiatr comorbid environment life style characterist underserv popul note acknowledg work support nation cancer institut nation institut health r01ca097893 p30ca16672 depinho potenti conflict interest author report conflict author submit icmj form disclosur potenti conflict interest conflict editor relev content manuscript disclos
full term condit access found http www.tandfonline.com action journalinform journalcod wjdd20 download univers aberdeen date 07 decemb 2015 06 41 journal dual diagnosi issn 1550 4263 print 1550 4271 onlin journal homepag http www.tandfonline.com loi wjdd20 preliminari evalu adjunct motiv interview psychiatr complex smoker suzi bird gulliv phd barbara kamholz phd ami helstrom phd sandra morissett phd christoph kahler phd cite articl suzi bird gulliv phd barbara kamholz phd ami helstrom phd sandra morissett phd christoph kahler phd 2008 preliminari evalu adjunct motiv interview psychiatr complex smoker journal dual diagnosi 4 4 394 413 doi 10.1080 15504260802086149 link articl http dx.doi.org 10.1080 15504260802086149 publish onlin 12 dec 2008 submit articl journal articl view 35 view relat articl cite articl 2 view cite articl http www.tandfonline.com action journalinform journalcod wjdd20 http www.tandfonline.com loi wjdd20 http www.tandfonline.com action showcitformat doi 10.1080 15504260802086149 http dx.doi.org 10.1080 15504260802086149 http www.tandfonline.com action authorsubmiss journalcod wjdd20 page instruct http www.tandfonline.com action authorsubmiss journalcod wjdd20 page instruct http www.tandfonline.com doi mlt 10.1080 15504260802086149 http www.tandfonline.com doi mlt 10.1080 15504260802086149 http www.tandfonline.com doi citedbi 10.1080 15504260802086149 tabmodul http www.tandfonline.com doi citedbi 10.1080 15504260802086149 tabmodul preliminari evalu adjunct motiv interview psychiatr complex smoker suzi bird gulliv phd barbara kamholz phd ami helstrom phd sandra morissett phd christoph kahler phd abstract hundr psychiatr complex militari veteran 97 male 201 recruit part studi investig dif ferenti efficaci session motiv interview mi intervent yield smoke behavior particip ran domli assign mi intervent mi mi breath instruct mi incent spirometri tool feedback lung suzi bird gulliv affili center excel research return war veteran waco tx barbara kamholz ami helstrom sandra morissett affili at va boston healthcar system boston ma suzi bird gulliv barbara kamholz ami helstrom sandra morissett affili boston univers boston ma christoph kahler affili center alcohol addict studi brown univers provid ri work support va research enhanc award program reap grant ronald goldstein md princip investig nida grant da11088 award author nida grant da016138 award author nida grant k23da016376 award fourth author grant fund award author depart veteran affair csp 725 address correspond suzi bird gulliv visn 17 center excel research return war veteran ctxvhc waco campu build 7 4800 memori drive waco tx 76711 mail suzy.gulliver2 va.gov 394 journal dual diagnosi vol 4 4 2008 onlin http www.haworthpress.com 2008 haworth press right reserv doi 10.1080 15504260802086149 ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 395 function inexpens form biofeedback result suggest smoke behavior measur report number cigarett dai confirm expir carbon monoxid level decreas group time differ treatment condit cigarett dai measur tobacco depend implic harm reduct challeng popul discuss keyword motiv interview smoke tobacco spirometri 2 decad motiv interview techniqu de scribe develop miller rollnick 1991 2002 gen erat enorm clinic research interest effort area culmin paradigm shift addict treatment field care provid disciplin treatment foci seek receiv train adapt motiv interview ami o’leari tevyaw monti 2004 meta analys publish date examin effect ami burk arkowitz menchola 2003 dunn deroo rivara 2001 noonan moyer 1997 bien miller tonigan 1993 support paradigm shift result meta analys demonstr ami outcom supe rior treatment placebo control addit ami compar activ treatment cognit behavior therapi cbt effect size report differ close burk al 2003 base meta analys surmis ami superior treatment effect inten sive costli cbt burk al 2003 dunn deroo rivara 2001 noonan moyer 1997 bien al 1993 number research look close data com.ibm.drl.hbcp.util ami tobacco cessat specif literatur equivoc e.g hecht borrelli breger defrancesco ernst resnicow 2005 modest result pregnant smoker ershoff quinn boyd stern gregori wirtschaft 1999 stott diclement dolan mullen 2002 teenag smoker polysubst mccam bridg strang 2004 tait huls 2003 smoker schizophrenia steinberg ziedoni krejci 2004 cancer patient wakefield olver whitford 2004 adolesc psychiatr patient brown al 2003 methadon maintain pregnant smoker haug sviki diclement 2004 explan data ami tobacco cessat gold standard outcom treatment tobacco depend ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 396 journal dual diagnosi i. biochem verifi sustain tobacco abstin unnec essarili conserv outcom fact smoke cessat measur outcom motiv inter view mi true target mi engag chang effort independ profession techniqu motiva tional intervent effect foster attend smoke cessat program steinberg al 2004 reduc num ber cigarett smoke wakefield al 2004 move individu stage chang tobacco hecht al 2005 moder effect size com.ibm.drl.hbcp.util ami smoke cessat remain area interest prematur drop ami clinic research agenda ami individu psychiatr comorbid research focus efficaci ami popul increas vulner tobacco depend appear pri mari import problem tobacco depend inflat patient mental ill lasser boyd woolhandl himmelstein mccormick bor 2000 clinic trial typic includ psychiatr condit exclus criteria addit smoke cessa tion trial individu psychiatr comorbid gener at mix result trial report discourag outcom e.g dalack meador woodruff 1999 observ promis result test efficaci singl session mi motiv smoker schizophrenia mi intervent compar standard psychoeduc counsel advic led greater proport particip contact treatment provid receiv session counsel compar condit steinberg al 2004 find challeng assist smoker psychiatr comorbid quit smoke dalack meador woodruff 1999 elev rate smoke veteran sampl hankin spiro miller kazi 1999 dobi kivlahan maynard bush davi bradlei 2004 sought examin efficaci adjunct mi popul militari veteran psychiatr comorbid clinic research experi veteran multipl psychiatr comorbid suggest reinforc schedul avail altern adapt reinforc limit interest ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 397 ad low cost behavior task serv increas power person feedback compon mi goal intervent studi evalu effect enhanc mi incorpor pulmonari function test feedback daili biofeedback practic design focu patient concret manner pulmonari function chose evalu rel efficaci incent spirometri breath instruct bi ad platform mi chose incent spiromet low cost rela tive simpl portabl biofeedback devic exercis diaphragm patient surgeri bastin morain bardocski kahn mélot 1997 expressli adjunct tobacco depend treatment function practic control breath ing provis feedback progress hypothes increas salienc person feed back pulmonari function test mi conceptu ideal contrast prescrib instruct deep breath bi chosen face valid clear demonstr benefit pulmonari function smoke cessat e.g payn unpublish manual mi bi includ comparison mi mi includ mi bi hope control breath compon mi understand mi led success mi bi evalu rel com.ibm.drl.hbcp.util type mi psychiatr medic complex popul hypothes psychiatr complex popul patient present smoke cessat treatment express motiv smoke cessat patient treat practic enhanc mi mi bi mi evid chang pa tient treat mi chang largest patient receiv incent spiromet anticip reduct smoke condit depend variabl includ measur report smoke rate nicotin depend expir carbon monoxid method particip hundr militari veteran 97 male 201 cruit part studi investig differenti efficaci ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 398 journal dual diagnosi session mi intervent facilit engag smoke cessat effort yield smoke behavior particip recruit flyer post va boston healthcar system flyer made mention quit smoke solicit dividu smoke cigarett curiou lung function studi approv va boston healthcar system intern review board particip provid inform consent initi studi procedur criteria studi particip aim maxim inclus facilit generaliz veteran individu elig particip 18 year smoke cigarett daili basi report plan remain boston area 6 month exclus criteria relat psychiatr condit substanc abus histori physic condit veteran contact contact research staff telephon complet initi elig screen subset veteran present research staff offic appoint express interest partic ipat veteran screen elig person de termin elig studi particip individu schedul baselin assess baselin assess gener place 3 week telephon screen person baselin assess clinic base laboratori particip complet form consent process report measur smoke cope mood relat variabl time complet physiolog cal measur includ expir pulmonari function test includ lung capac volum air expir rest heart rate particip voluntari veteran compens 40 time complet assess conclus baselin assess ment particip randomli assign intervent condit appoint time 1 2 week return clinic particip told appoint feedback assess speak doctor concern relat smoke follow period includ follow assess monthli interv research assist last 30 minut particip complet abbrevi report assess packet physiolog measur baselin assess particip ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 399 provid written appoint card indic follow assess ment time telephon remind call night preced appoint follow appoint schedul previou meet phone letter previou meet miss partic ipant opportun complet follow assess telephon exclud physiolog measur intervent intervent meet particip met clinic psychologist deliv treatment condit 1 mi 2 mi instruct deep breath mi bi 3 mi instruct incent spiromet prac tice breath diaphragmat control mi singl mi session develop base miller rollnick 1991 2002 mi manual inform project match motiv enhanc manual project match research group 1994 singl session mi shown effect studi adult young ado lescent e.g colbi al 1998 mccambridg strang 2004 studi therapist doctor level psychologist minimum 3 year experi treat addict includ nicotin depend train motiv interview profession train seri miller rollnick 1998 therapist conduct intervent order minim potenti confound therapist effect mi se sion last 40 50 minut includ elicit idiograph smok ing histori patient percept smoke elicit motiv statement present discuss person feedback includ smoke mood cope relat variabl pulmonari function test discuss benefit concern smoke develop chang plan provis smoke cessat referr addit mi portion intervent particip mi bi condit train deep breath particip told breath deepli slowli 5 minut clinician demonstr diaphragmat deep breath techniqu patient demonstr understand techniqu session mi portion intervent particip mi condit train incent spiromet particip shown incent spiromet devic goal devic exhal moder continu explain particip instruct exhal ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 400 journal dual diagnosi gaug rise mid region goal practic control gaug exhal clinician demonstr incent spiromet gave particip incent spiromet demonstr understand practic session post session instruct deep breath practic time daili measur demograph questionnair report measur assess ag sex educ employ statu intim partnership statu incom ethnic particip ask current prescrib medic fagerstrom test nicotin depend ftnd ftnd heatherton kozlowski frecker fagerstrom 1991 assess sever nicotin depend intern consist sampl adequ α 64 ftnd demonstr good converg valid biochem indic heavi smoke heatherton al 1991 smoke quantiti frequenc smoke quantiti measur baselin follow item cigarett smoke dai smoke past month report smoke abstin verifi assess ppm 10 point preval abstin defin cigarett smoke dai report dai assess stage chang questionnair inventori prochaska diclement 1983 evalu psycholog ical readi chang smoke behavior base prochaksa diclement 1982 model behavior chang perceiv impor tanc quit smoke assess 0 import 10 extrem import rate scale psychometr data support stage chang questionnair stabil rang 88 98 morera johnson freel 1998 ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 401 expir expir measur bedfont ec50 micro smokelyz breath carbon monoxid monitor monitor calibr manufactur guidelin increas stabil measur measur particip expir level 10 ppm higher consid consist statu regular smoker perkin 1996 follow assess assess follow includ measur mention except demograph questionnair ftnd stage chang questionnair follow assess includ assess engag smoke cessat treatment includ entri smoke cessat program line nicotin replac therapi medic bupropion unaid effort reduc smoke quit cold turkei data analysi plan test treatment effect point preval abstin number cigarett smoke dai level 6 month follow assess gener estim equat gee liang zeger 1986 zeger liang 1986 compound symmetr covari anc matrix gee offer extens linear logist regress analys repeat measur data correct standard error model coeffici account cluster correl depen dent measur analys includ linear effect time i. month control baselin level nicotin depend assess ftnd perceiv import quit smoke analys cigarett dai cpd level includ respect variabl baselin covari treatment condit dummi code mi bi refer group allow test differ mi mi bi mi mi gee inclus analysi individu miss depend obser vation chose primari analysi analyz data conduct worst case analys assum miss equal smoke point preval abstin substitut baselin level cpd miss data variabl case data compar worst case analys lead ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 402 journal dual diagnosi conclus treatment effect step anal ysi enter interact treatment condit dummi code time determin differ condit remain constant follow power approxim 80 depend degre correl time point outcom detect differ condit medium size 50 gee primari analys rochon 1998 effect small 40 detect power 80 analys miss data i. worst case analys result total 208 particip recruit period 1 year random condit mi 67 mi 67 mi bi 74 particip complet assign intervent monthli follow data obtain occa sion 149 particip 71.6 miss data common provid follow data 83 39.9 provid data 6 monthli follow up condit differ significantli mean number complet follow up percentag provid follow data particip complet assess significantli older 001 complet complet 1 6 follow up 149 differ significantli complet attend follow up 59 sex marit statu annual incom ethnic data demograph variabl 190 208 partici pant depend variabl tabl 1 mean ag particip 49 year half sampl caucasian 140 67.3 averag level educ sampl 12.7 year sd 2.1 major particip unemploi disabl 155 75.2 particip modal annual incom 10,000 major 86.5 marri separ divorc particip smoke averag 23 cpd sd 12.3 report mean durat smoke histori approxim 32 year sd 9.1 averag 6.5 sd 14.1 quit attempt averag expir 17.1 ppm sd 10.15 78.7 particip baselin baselin score 10 ppm expect sampl complic substanc psychiatr comorbid chart review ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 403 tabl 1 particip demograph data mi mi bi mi test variabl 67 74 67 differ male sex 100 95.9 94 χ2 2 1 ns ag year mean 49.06 49.64 47.5 1.13 ns marit statu marri 26 23 22 χ2 10 1 ns separ 5 11 6 marri live 6 10 6 divorc 29 29 4 widow 3 1 3 highest grade complet mean 12.5 13.0 12.5 χ2 26 1 ns 10,000 10,000 10,000 χ2 8 1 ns annual incom median 14,999 14,999 14,999 employ statu emploi 13.4 13.5 15.4 χ2 10 4.7 ns full time student 0 2.7 3.0 disabl 44.8 45.9 40.0 full time homemak 0 0 1.5 retir 9.0 8.1 7.7 unemploi 32.8 29.8 32.4 ethnic white 74.6 66.2 61.2 χ2 8 11.5 ns american indian alaskan nativ 0 0 6.0 black 22.4 27.0 28.4 hispan 0 1.4 1.5 3.0 5.4 2.9 note bi breath instruct mi motiv interview incent spirometri 96 particip 199 histori mental health care deliv va specif 66 particip carri diagnosi substanc disord 137 62 129 carri substanc axi psychiatr diagnosi forti percent particip 93 carri substanc axi psychiatr diagnos 30 62 carri diagnos major 71 particip axi psychiatr diagnosi mood disord diagnos 91 particip axi psychiatr diagnosi addit diagnos includ post traumat stress disord ptsd 54 42 ptsd anxieti disord 33 26 psychot disord 48 37 addit high percentag particip present va care provid lung relat diseas ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 404 journal dual diagnosi previou 3 month includ 14.9 31 chronic obstruct pulmonari diseas 1.0 2 lung cancer 3.8 8 emphysema 6.3 13 asthma addit 13.5 28 present bronchiti baselin comparison treatment condit signific differ treatment condit baselin smoke relat variabl includ ftnd motiv quit smoke spirometri cpd addit group test baselin characterist conduct group differ significantli ag sex marit statu employ statu incom tabl 1 group slightli unbalanc sex women mi condit 3 4 women mi mi bi condit addit signific differ psychiatr comorbid condit smoke outcom point preval abstin point preval abstin rate mi condit 4.5 4.7 8.6 8.8 12.5 10.3 1 2 3 4 5 6 month abstin rate mi bi condit 9.0 8.6 14.7 14.3 15.1 16.6 follow point abstin rate mi condit 0 0 7.6 9.4 6.6 13.3 follow point worst case assumpt made miss data treat continu smoke abstin rate mi condit 3.0 3.0 4.5 4.5 6.0 4.5 follow point worst case assumpt abstin rate mi bi condit 5.4 4.0 6.8 6.8 6.8 6.8 abstin rate mi condit 0 0 4.5 4.5 3.0 6.0 gee model predict point preval abstin follow up linear effect time significantli posit 22 se 09 odd ratio 1.25 018 indic odd abstin increas 25 subsequ month greater import quit greater odd abstin 46 se 14 1.58 001 ftnd treatment dummi code approach signific 30 interact treatment dummi code time nonsignific ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 405 figur 1 report smoke motiv inter view mi incent spirometri mi breath instruct bi mi treatment group 6 month follow period mean cpd treatment condit 0 5 10 15 20 25 ba se lin 1 2 3 4 5 6 time mi mi mi bi cpd figur 1 show averag cpd baselin month follow treatment condit cpd gener decreas 20 baselin mid low teen follow analysi purpos squar root transform conduct correct posit skew initi analysi conduct pair test compar baselin cpd cpd follow result cpd significantli lower baselin follow 0001 true worst case assumpt result gee analysi predict follow cpd con troll baselin show effect time signif icantli neg 10 se 03 0006 indic cpd decreas significantli 6 month follow greater ftnd score higher cpd 11 se 05 026 greater import quit lower cpd 15 se 04 0002 treatment condit differ significantli cpd 65 interact treatment dummi code time nonsignific analys ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 406 journal dual diagnosi figur 2 carbon monoxid motiv inter view mi incent spirometri mi breath instruct bi mi treatment group 6 month follow period mean treatment condit 0 5 10 15 20 25 ba se lin 1 2 3 4 5 6 time mi mi mi bi worst case assumpt render effect time ftnd nonsignif icant effect import quit remain signific 12 se 03 0001 level mean level obtain baselin follow up treatment condit shown figur 2 cpd correl mod erat highli follow averag 67 rang 64 73 level consist mid teen baselin follow up mi bi condit level consi tentli 13 month follow analysi purpos squar root transform conduct correct posit skew conduct pair test compar baselin follow month 5 significantli lower base line 009 result alter worst case assumpt result gee analysi predict follow control baselin level tend decreas follow 05 se 03 059 greater nicotin depend score higher 09 se 03 01 greater ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 407 import quit lower 11 se 03 0004 dummi code mi versu mi bi comparison significantli neg 57 se 19 003 indic receiv mi bi significantli lower level follow up receiv mi dummi code mi versu mi comparison direct nonsignific 29 se 19 12 interact treatment dummi code time nonsignific analys worst case assumpt render effect ftnd nonsignific effect signific remain smoke cessat intervent involv particip evalu 1 month follow point regard ing particip smoke cessat effort includ attend smoke cessat group quit line quit cold turkei effort nicotin replac therapi 55.3 1 month follow 39.4 6 month follow report modifi smoke behavior method differ group type treatment seek involv discuss mi receiv consider attent past 2 decad equivoc find studi rais question com.ibm.drl.hbcp.util tobacco cessat reason debat relat dispari ti outcom assess research stringent criterion document meaning chang i. abstin current studi evalu gold standard outcom variabl i. cigarett abstin includ addit outcom variabl i. chang cpd level fulli control trial conduct result current studi support previou find adapt mi ful assist psychiatr complex veteran chang tobacco respect abstin outcom biochem verifi quit rate follow period rang 0 16.6 treatment condi tion collaps group linear increas abstin ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 408 journal dual diagnosi subsequ month abstin greater import chang data support hypothes practic enhanc mi particip mi condit report sig nificantli lower cpd produc significantli lower valu follow particip condit fact contrari hypothes particip mi bi condit perform significantli particip mi condit differ enc remain signific abstin time point remov reason find unclear late difficulti incorpor instruct particip smoke behavior word provid feedback patient session knowledg lung function carri forward meaning smoke behavior chang session possibl spiromet unusu instrument particip familiar altern spiromet exercis suffici prompt particip smoke behavior relationship perform contrast bi led greater chang repres simpler intervent lent daili practic respect reduct cpd worst case scenario miss data cpd significantli lower follow compar baselin argu statisti calli signific reduct treatment condit signific effect time 6 month follow period specif treatment condit particip reduc daili cigarett pack dai approxim 23 cpd half pack dai approxim 13 cpd level tobacco consid er safe particip consid treatment failur gener standard chang repres approxim 57 reduct cigarett smoke translat improv func tion potenti health benefit chaudhuri al 2006 reduct cigarett consumpt import public health im plicat virtu secondhand smoke exposur gilpin pierc 2002 notabl smoker achiev maintain reduc smoke level colletti supnick rizzo 1982 glasgow klesg klesg vasei gunnarson 1985 evid reduct decreas undermin interest cessat carpent hugh keeli 2003 reduct correspondingli reduc exposur ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 bird gulliv al 409 harm toxin includ hurt al 2000 recent meta analysi reduct cigarett predict tobacco cessa tion unmotiv smoker carpent hugh solomon 2004 data suggest motiv interven tion import clinic effect disappoint smoke cessat outcom type popul glassman al 1990 hurt al 1994 joseph nichol anderson 1993 i. complic psychiatr substanc comorbid step direct limit number limit current studi warrant men tion foremost studi fulli control mi condit control therapist time attent unabl parcel effect treatment versu treatment psycholog placebo promis find report consid preliminari therapist adher mi procedur systemat evalu trial high level ed ucat train experi treat nicotin depen denc addict assuag concern futur fulli control trial benefit systemat formal monitor therapist adher strength studi repeat assess time recogn 6 month follow durat data speak point preval abstin versu sustain abstin import longitudin assess highlight data suggest increas likelihood abstin subsequ month fourth follow period report data collect level practic mi mi bi procedur evalu data incon sistenc 9 particip mi condit report conduct daili deep breath found decreas confid valid degre veteran activ engag treatment initi dose mi provid clear note partic ipant condit contact research staff administ smoke assess follow point contact effect particip motiv quit smoke contribut outcom final studi includ primarili male sampl previou find sex differ respons nicotin ow nl oa de ni ve rs iti ee 0 6 41 0 7 ec em 20 15 410 journal dual diagnosi replac munafò bradburn bow david 2004 differ smoke cessat male femal veteran specif sherman fu joseph lanto yano 2005 addit research need evalu mi differenti effect men versu women point true veteran sampl increas enrol women militari conclus preliminari natur result suggest motiv intervent benefici patient smoke struggl multipl psychiatr issu futur research need evalu com.ibm.drl.hbcp.util mi tobacco cessat includ pulmonari function feedback patient psychiatr comorbid find fur ther argu critic research assess report multipl outcom systemat studi order provid derstand clinic meaning abstin true focu mi increas motiv engag effort chang abstin se reduct palat achiev start point recalcitr psychiatr smoker note 1 copi manual obtain author
2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 1 21 origin articl journal a­z archiv gener psychiatri 55 8 august 1998 nortriptylin cognitive­behavior therapi treatment cigarett smoke archiv gener psychiatri issu volum 55 8 august 1998 pp 683­690 copyright copyright 1998 american medic associ right reserv applic far dfar restrict appli govern american medic associ 515 state st chicago il 60610 public type origin articl issn 0003­990x access 00000756­199808000­00001 keyword behavior therapi cognit therapi depress disord nortriptylin smoke cessat nortriptylin cognitive­behavior therapi treatment cigarett smoke hall sharon phd reu victor md munoz ricardo phd see karen humfleet gari phd hartz dian ma frederick sydnei phd triffleman elisa md author inform depart psychiatri univers california san francisco dr hall reu munoz see humfleet frederick triffleman ms hartz san francisco veteran affair medic center psychiatri servic san francisco dr hall see triffleman dr triffleman depart psychiatri yale univers haven conn abstract background histori major depress disord mdd predict failur quit smoke determin effect nortriptylin hydrochlorid cognitive­behavior therapi smoke treatment outcom smoker histori mdd studi address effect diagnosi treatment condit dysphoria quit smoke effect dysphoria abstin method 2 nortriptylin placebo 2 cognitive­behavior therapi control 2 histori mdd histori random trial particip 199 cigarett smoker outcom measur biolog verifi abstin cigarett week 12 24 38 64 mood withdraw depress measur 3 5 8 dai smoke quit date result nortriptylin produc higher abstin rate placebo independ depress histori cognitive­behavior therapi effect particip histori depress nortriptylin allevi neg affect occur smoke cessat increas level neg affect baselin 3 dai smoke quit date predict abstin assess mdd history­neg smoker sex­by­depress histori interact mdd history­posit women abstin mdd history­neg women depress histori predict abstin men conclus nortriptylin promis adjunct smoke cessat smoker histori depress aid intens psychosoci treatment mood diagnosi interact predict relaps increas neg affect quit smoke attenu nortriptylin arch gen psychiatri 1998;55 683­690 http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 brows toc 1 http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 brows toc children 7cye 7cs.sh 22.23.27.31.39.40 7c1 7c60 http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 toc s.sh 22.23.27.31.38 7c1 7c60 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 2 21 link cigarett smoke depress mood establish popul studi 1­4 evid diagnos depress major depress disord mdd diagnosi nicotin depend correl gener popul 5 individu current histor depress disord overrepres seek smoke treatment 6,7 smoker histori mdd experi sever mood­rel symptom quit smoke 8,9 studi investig efficaci antidepress therapi smoke treatment mdd history­posit smoker antidepress studi smoke cessat includ imipramin hydrochlorid 10 doxepin hydrochlorid 11 bupropion hydrochlorid 12,13 fluoxetin hydrochlorid 14 result imipramin 10 doxepin 11 studi mix difficult interpret methodolog problem bupropion shown short­term efficaci small trial 12,13 recent large­ scale pharmaceut industry­sponsor studi suffici convinc drug receiv feder drug administr indic treatment cigarett smoke 15 result multisit pharmaceut industry­sponsor studi fluoxetin publish secondari analysi part data set suggest particip report depress symptom studi enrol show significantli improv cessat rate administr activ drug 14 nortriptylin hydrochlorid adrenerg activ smoke cessat nortriptylin inexpens gener drug therapeut serum level treatment depress 190­532 nmol 16 provid initi treatment paramet studi hall colleagu 7 found smoker histori depress abstin treat 10 session cognitive­behavior cb therapi treat 5 session health educ therapi zelman colleagu 17 found dysphor smoker help support treatment greater extent nondysphor smoker hall colleagu 18 control equival contact time cognitive­behavior therapi fail replic origin find purpos propos studi attempt recaptur find origin studi compar 10­session cb intervent smoke cessat 5­session health educ control intervent origin studi present studi 2 2 2 factori design medic nortriptylin placebo cross cb intervent presenc absenc histori mdd hypothes 1 particip histori mdd show higher abstin rate administr nortriptylin administr placebo differ hypothes mdd history­ neg particip 2 particip histori mdd show higher abstin rate cb intervent intervent differ hypothes mdd history­neg smoker 3 major depress disord history­posit particip show greater increas dysphoria quit smoke mdd history­neg particip 4 nortriptylin effect placebo reduc dysphoria occur quit smoke mdd history­posit particip differ predict mdd history­neg particip 5 independ mdd histori particip smaller increas dysphoria immedi quit smoke abstin assess particip greater increas dysphoria quit smoke particip method particip 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 3 21 studi approv institut review board univers california san francisco particip recruit public servic newspap announc give written inform consent 248 individu complet diagnost interview schedul 19 condit evalu studi enrol withdrew person reason random assign exclud 46 patient 27 electrocardiograph abnorm 11 current mdd 8 reason 199 particip randomli assign 1 2 psycholog treatment cb therapi 1 2 drug treatment activ nortriptylin placebo men 89 women 110 ag 21 65 year smoke 10 cigarett dai want quit smoke individu met criteria mdd 3 month baselin exclud refer depress treatment individu take prescrib psychotrop drug show evid alcohol nonnicotin drug exclud individu monoamin oxidas inhibitor 2 week exclud take drug histori mdd diagnos 65 32.7 particip fifti particip report recurr episod procedur nortriptylin dispens week 1 week 12 psycholog treatment occur week 4 week 12 smoke quit date week 5 therapeut nortriptylin level reach particip assess baselin demograph variabl mood depress withdraw symptom current histor mdd addit assess held week 12 24 38 64 psycholog measur complet smoke statu determin assess particip ask smoke puff week expir air carbon monoxid level 10 ppm urin sampl analyz cotinin cotinin level 341 nmol particip code abstin addit serum sampl nortriptylin level complianc assess capsul count capsul allotted­capsul return determin side effect checklist administ baselin week 1 4 6 particip complet profil mood state pom 20 withdraw scale 21 3 5 8 dai smoke quit date beck depress inventori 22 complet 8 dai smoke quit date particip stratifi mdd histori mdd histori number cigarett smoke randomli assign stratif block 4 experiment condit computer random program measur bachelor master level survei worker train r.f.m administ computer diagnost interview schedul 23 base diagnost interview schedul particip classifi mdd histori posit mdd histori neg neg affect assess pom total mood disturb tmd score assess depress symptom past week beck depress inventori trait anxieti state­trait anxieti inventori trait scale 24 administ 2 smoke scale shiffman tobacco withdraw scale 21 wide scale show score function time cigarett smoke differenti partial total abstin fagerstrom toler questionnair 25,26 measur tobacco depend high score predict smoke treatment failur correl physiolog smoking­induc treatment intervent 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 4 21 drug treatment medic placebo control doubl blind placebo activ drug ident appear particip met studi physician week 1 begin administr medic week 2 3 administr medic review side effect drug dose titrat therapeut level depress particip receiv nortriptylin hydrochlorid 25 mg 3 dai dose increas 50 mg 4 dai serum level assess week 2 dose increas 75 mg therapeut level reach serum level reassess week 4 dose increas 100 mg week 6 dosag titrat downward modal dose 100 mg titrat occur particip receiv activ drug dose titrat particip receiv placebo cohort particip continu receiv mainten dose medic week 12 medic taper week 13 psycholog treatment cb treatment central premis cb treatment detail 7 thought activ mood interact influenc smoke session focus mood manag skill manag dysphoria maintain nonsmok includ method increas frequenc pleasant activ decreas relapse­rel thought thought stop increas pleasant thought rational­emot techniqu techniqu increas posit social contact decreas neg contact improv relationship develop particip met ten 2­hour group session 5­11 member 8 week therapist manual s.m.h r.f.m organista phd unpublish data 1992 intervent intervent detail 7 provid health­rel inform facilit discuss com.ibm.drl.hbcp.core element develop plan quit smoke weekli modif plan method includ paper­and­pencil exercis inform handout didact present homework assign smoke monitor particip met 90­minut session 5­11 member 8 week provid therapist 3 doctoral­level clinic psychologist experi cb psychoeduc intervent therapist treat particip 4 experiment condit therapist supervis weekli r.f.m g.h adher protocol monitor situat aros protocol audiotap review standard respons develop medic prescrib 1 2 psychiatr resid supervis v.i.r k.l. statist method princip data analysi method gener linear model com.ibm.drl.hbcp.glm gener classic linear model estim likelihood function squar 27 gener linear model repeat measur miss data exclud particip data miss imput valu 28,29 comput program proc mix sa institut cari nc estim test com.ibm.drl.hbcp.glm abstin depend variabl comput program glmmix macro sa institut 30 interact program mention proc mix modifi dichotom data evalu 3 hypothes hypothes 1 2 5 predict abstin abstin statu week 12 24 38 64 depend variabl hypothes 1 2 test 2 activ placebo drug 2 cb intervent 2 mdd mdd histori model hypothesi 5 test model includ baselin poms­tmd score dai 3 poms­tmd score 3 design variabl drug psycholog treatment condit diagnost statu interact independ variabl 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 5 21 hypothes 3 4 predict dysphoria quit date complet 3 parallel analys analysi depend variabl poms­tmd score baselin dai 3 5 8 smoke quit date analysi withdraw score replac pom score analysi depend variabl beck depress inventori score baselin dai 8 3 design variabl interact independ variabl provid comparison recent antidepress studi 15 present continu abstin rate abstin assess chi squar test evalu univari variabl evalu effect sex interact 3 design variabl abstin rate week 12 64 3 com.ibm.drl.hbcp.glm model comput macro glmmix parallel model determin therapist effect effect nortriptylin level capsul ingest abstin rate 4 assess evalu 2 com.ibm.drl.hbcp.glm analys nortriptylin independ variabl serum level diagnost categori interact capsul independ variabl activ drug placebo capsul count interact com.ibm.drl.hbcp.glm analys effect signific post hoc contrast complet comput program proc mix macro glmmix effect size express odd ratio or confid interv ci student test chi squar test determin differ particip particip miss data assess baselin demograph smoke mood psychiatr variabl 05 comparison analysi varianc chi squar test evalu baselin differ treatment condit chi squar test evalu rate occurr side effect test 2 tail 05 comparison result particip characterist demograph smoke psychiatr characterist particip experiment group tabl 1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 6 21 tabl 1 data variabl psycholog treatment drug condit demograph smoke psychiatr characterist mdd history­posit mdd history­ neg particip tabl 2 http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7ctt1 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 7 21 tabl 2 baselin mood­ withdrawal­rel variabl particip histori major depress disord mdd attrit http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7ctt2 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 8 21 forty­seven 24 particip report complet treatment particip 23 drop person reason 5 drop medic side effect 4 activ drug group 1 placebo group 11 drop program issu dislik group format 1 particip move 1 unrel medic problem 6 gave reason drop differ psycholog intervent chi squared1 199 1.51 22 diagnost categori chi21 199 63 dropout rate particip placebo group higher dropout rate 30 particip activ drug group 17 chi 2 1 199 4.54 04 2.07 95 ci 1.05­4.06 no­show rate assess follow week 12 19 week 24 17 week 38 20 week 64 17 signific differ number assess miss design variabl psycholog treatment condit t197 42 drug treatment condit t197 1.63 25 diagnosi t197 72 abstin rate main effect drug signific chi21 199 4.34 04 2.42 95 ci 1.75­3.35 treatment condit diagnosi interact chi21 199 3.84 05 main effect assess week 12 24 38 64 signific chi23 199 10.33 02 0.78 95 ci 0.68­0.90 indic declin abstin rate condit week 12 week 64 signific effect 05 includ hypothes diagnosi drug interact chi21 199 92 psycholog treatment condit drug interact chi21 199 98 diagnosi psycholog treatment condit drug interact chi21 199 59 abstin rate assess shown figur 1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 9 21 figur 1 abstin rate time particip receiv activ nortriptylin hydrochlorid 99 placebo 100 effect drug signific week 12 64 depend variabl abstin assess 04 continu abstin year 02 signific main interact effect diagnosi 05 comparison activ drug condit 24 particip achiev continu abstin placebo drug condit 12 achiev continu abstin chi21 199 5.03 02 2.3 95 ci 1.1­5.0 conclud evid superior nortriptylin placebo cigarett smoker mdd history­neg mdd history­posit smoker abstin rate psycholog treatment condit diagnost group shown figur 2 figur 2 mdd history­posit particip assign cb intervent achiev abstin rate compar mdd history­neg particip mdd history­posit subject assign intervent abstin assign cb intervent http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7cff1 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 10 21 figur 2 abstin rate time cognitive­behavior cb 100 health educ 99 intervent major depress disord mdd history­neg 134 mdd history­posit 65 diagnosi signific interact effect 05 reflect significantli poorer abstin rate mdd history­posit subject 31 mdd history­neg subject 68 intervent group chi21,68 6.44 01 1.70 95 ci 1.00­2.98 signific differ 91 mdd history­ posit 34 mdd history­neg 66 particip cb intervent group conclud achiev support hypothesi particip histori mdd benefit cb therapi particip histori mdd abstin rate diagnosi psycholog treatment condit activ placebo drug tabl 3 http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7cff2 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 11 21 tabl 3 abstin rate assess baselin diagnosi psycholog treatment drug dose http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7ctt3 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 12 21 abstin rate differ therapist interact therapist drug psycholog treatment drug psycholog treatment condit 05 comparison predict abstin nortriptylin serum level net capsul count nortriptylin serum level particip assign receiv activ nortriptylin abstin week blood draw predict abstin week 12 24 38 64 chi21 86 14.28 001 1.02 95 ci 1.01­1.03 abstin particip select smoke result lower nortriptylin level 31 particip receiv nortriptylin obtain serum sampl week 6 44 51 achiev serum level consid therapeut treatment mdd mean week 6 nortriptylin serum level abstin smoke subject week tabl 4 tabl 4 mainten nortriptylin serum level abstin statu assess 86 particip receiv activ nortriptylin provid blood sampl week 6 capsul ingest differ condit chi21 199 1.43 23 capsul interact drug chi21 199 68 control 2 variabl drug abstin placebo remain signific chi21 199 4.32 04 3.03 95 ci 1.07­8.57 side effect 14 potenti side effect dry mouth rash weight gain lightheaded shaki hand constip blurri vision sexual problem difficulti urin race heart swollen leg chest pain pressur short breath postbaselin endors rate differ drug condit 4 1 dry mouth activ 78 placebo 33 chi squared1 198 39.6 001 7.00 95 ci 3.73­ 13.17 2 lightheaded activ 49 placebo 22 chi squared1 198 16.01 001 2.42 95 ci 1.85­6.35 3 shaki hand activ 23 placebo 11 chi squared1 198 5.11 02 2.42 95 ci 1.11­5.29 4 blurri vision activ 16 placebo 6 chi squared1 198 5.11 02 3.00 95 ci 1.12­7.99 sex effect http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7ctt4 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 13 21 sex interact diagnost categori chi21 199 9.08 002 drug chi21 199 3.33 07 psycholog treatment condit chi21 199 1 93 post hoc analys poorer abstin rate mdd history­posit women mdd history­neg women chi21,110 9.82 002 2.05 95 ci 1.32­3.23 mdd history­posit men chi21,89 1.66 20 women abstin rate follow week 12 mdd histori posit 38 mdd histori neg 53 week 24 mdd histori posit 22 mdd histori neg 47 week 38 mdd histori posit 29 mdd histori neg 39 week 64 mdd histori posit 20 mdd histori neg 37 men abstin rate follow week 12 mdd histori posit 61 mdd histori neg 52 week 24 mdd histori posit 45 mdd histori neg 37 week 38 mdd histori posit 47 mdd histori neg 36 week 64 mdd histori posit 37 mdd histori neg 31 neg affect state function diagnost drug condit poms­tmd score signific drug activ placebo assess baselin dai 3 5 8 interact effect f3,359 3.30 02 figur 3 show poms­tmd score particip placebo increas baselin dai 3 score activ drug decreas signific main effect assess f3,359 6.77 001 hypothes diagnost statu assess interact fail meet tradit level signific f3,359 2.47 06 poms­tmd score tend decreas time mdd history­posit particip baselin dai 8 baselin mean 45.93 sd 36.83 dai 3 mean 38.36 sd 36.08 dai 5 mean 24.71 sd 26.85 dai 8 mean 22.72 sd 33.52 mdd history­neg particip poms­tmd score tend increas baselin dai 3 baselin mean 21.37 sd 29.03 dai 3 mean 28.11 sd 33.37 decreas dai 5 mean 17.67 sd 28.03 dai 8 mean 15.53 sd 27.39 signific effect beck depress inventori 05 total withdraw symptom 05 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 14 21 figur 3 profil mood state total mood disturb score particip receiv activ nortriptylin hydrochlorid placebo baselin 192 dai 3 139 5 119 8 130 smoke quit date signific drug assess interact 02 reflect downward slope particip receiv activ drug f3,181 8.38 001 upward slope particip receiv placebo f3,178 2.55 06 predict abstin postquit mood hypothes increas poms­tmd score occur baselin smoke quit date predict lower rate abstin dai 3 score show greatest chang baselin control baselin poms­tmd score dai 3 score interact diagnost histori chi21 199 5.26 02 poms­tmd score baselin dai 3 diagnost condit subject smoke abstin week 12 64 tabl 5 2 week select clariti present data week 24 38 show similar pattern magnitud chang http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7cff3 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 15 21 tabl 5 poms­tmd score particip histori major depress disord smoke abstin week 12 64 tabl 5 postquit increas poor mood predict abstin mdd history­neg particip comment outcom data suggest nortriptylin adjunct smoke cessat effort support correl serum level abstin statu reflect complianc sustain signific nortriptylin dose net capsul ingest activ placebo treatment enter statist model differ side effect activ placebo group perceiv suffici troublesom high dropout rate fact dropout rate particip activ drug group particip placebo group http ovidsp.uk.ovid.com sp 3.18.0b ovidweb.cgi hmgipdfgcjhfldmlfnjkjhegmpkbaa00 view imag 00000756 199808000 00001 7ctt5 ovft width 700 height 400 weblinkreturn full text 3dl 7cs.sh 22.23.27.31.37 7c0 7c00000756 199808000 00001 resultset s.sh 22.23.27.31 7c1 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 16 21 industry­sponsor studi garner feder drug administr indic bupropion nortriptylin gener drug expens contrari hypothes differenti abstin effect smoker histori mdd nortriptylin find parallel report bupropion 13,14 2 antidepress drug similar effect smoke cessat effect noradrenerg transmiss effect neurotransmitt system differ 2 drug independ diagnosi nortriptylin allevi increas poor mood occur dai smoke cessat find implic antidepress amelior neg mood smoke cessat non­clin depress patient drug instanc poor mood part diagnos disord argu differ rate smoke cessat 4 experiment cell confound observ differ mood activ placebo drug condit collect smoke data dai 3 5 98 refut argument effect observ easili explain differ cessat rate dysphoria decreas baselin dai 3 particip nortriptylin treatment group increas particip placebo group increas dysphoria frequent note quit smoke 8,9 observ differ drug condit due confound smoke quit rate replic origin find mdd history­posit particip differenti help 10­ session cb intervent compar 5­session intervent 7 result contrast lack signific enhanc outcom mdd history­posit particip therapeut contact time held equival control condit 17 increas psychotherapeut contact differenti benefit smoker depress histori interpret data support failur psychotherapeut condit differenti alter cessation­induc mood histori mdd predict poor treatment outcom studi 6 7,17 report sex differ lack analysi differ explain inconsist literatur 6,32 result support hypothesi mdd history­posit particip greater increas neg affect quit smoke mdd history­neg smoker mdd history­neg smoker show increas poor mood quit smoke mdd history­posit smoker show nonsignific decreas data consist earlier investig earlier investig difficult compar current studi lack baselin data 8 failur includ subject successfulli quit 33 small sampl size 9 failur current data agre exist literatur literatur imperfect troubl current find consid tent replic similarli increas poms­tmd score baselin 3 dai quit date predict failur maintain abstin mdd history­neg particip mdd history­posit particip particip greater decreas poor mood baselin dai 3 relat abstin significantli limit studi outcom report repres expect nortriptylin typic medic set psycholog intervent studi provid contact time intens provid physician volunt sampl particip sought treatment motiv chang smoker encount physician practic particip independ condit smoke 64­week follow­up accept public march 24 1998 2 17 2016 ovid nortriptylin cognitive­behavior therapi treatment cigarett smoke http ovidsp.uk.ovid.com sp­3.18.0b ovidweb.cgi 17 21 studi support grant r01 da 23652 p50 da 09253 t32 da 07250 nation institut drug abus rockvil md career research scientist award veteran administr washington dc dr hall scott walter chri hobart manuscript prepar kevin delucchi statist consult reprint sharon hall phd univers california san francisco box 0984trc treatment research center 401 parnassu av san francisco ca 94143­0984 articl web site www.ama­assn.org psych
psycholog intervent antidepress treatment smoke cessat sharon hall phd gari humfleet phd victor reu md ricardo muñoz phd dian hartz phd roland maud griffin ba background sustain releas bupropion hydrochlo ride nortriptylin hydrochlorid shown efficaci treatment cigarett smoke psycholog intervent creas efficaci antidepress studi compar drug placebo examin efficaci 2 drug placebo psycholog intervent method 2 medic manag psycho logic intervent 3 bupropion nortriptylin pla cebo random trial particip 220 cigarett smoker outcom measur biolog verifi ab stinenc cigarett week 12 24 36 52 result psycholog intervent produc higher 7 dai point preval rate biochem verifi ab stinenc medic manag point preval abstin nortriptylin bupropion efficaci placebo rate 1 year continu abstin 2 drug dif fer placebo psycholog tervent differ medic manag rate 1 year continu abstin conclus nortriptylin bupropion ef ficaci produc abstin cigarett smoker similarli psycholog intervent produc ab stinenc rate simpl medic manag drug psycholog intervent limit ef ficaci produc sustain abstin data suggest combin psycholog intervent tidepress drug treatment effect antidepress drug treatment arch gen psychiatri 2002;59 930 936 antidepress bupro pion hydrochorid triptylin hydrochlorid areus adjunct treat ment tobacco depen denc multicent bupropion trial port 1 year continu abstin rate 24 300 mg 18 150 mg 14 100 mg 10 placebo differ placebo signific 150 300 mg group 1 trial pare bupropion nicotin patch port 1 year continu abstin rate 36 bupropion nicotin patch 33 bupropion 16 nico tine patch 15 placebo bu propion nicotin patch sult insignificantlyhigherabstin rate patch placebo 2 group report 1 year continu abstin rate 24 nortriptylin 12 pla cebo 3 studi report 14 patient receiv nortriptylin 3 patient receiv placebo abstin 6 month treatment 4 nicotin replac treatment nrt effect pro vide psychosoci treatment 5,6 impact psychosoci intervent tidepress treatment cigarett smok ing unknown antidepress nrt differ eas mode administra tion advers effect effect mood withdraw symptom contribut differ role psychosoci intervent antidepress studi volv psychotherapi counsel ing extens contact project staff includ physician reinforc quit ting smoke 1,2 multipl episod counsel research staff 1,2 group meet 3,4 psychotherapi 3 accord ing agenc health care polici research guidelines7,8 time studi conduct typi cal practic base medic manag protocol entail physician ad vice quit smoke 1 3 follow visit refer origin articl depart psychiatri univers california san francisco dr hall humfleet reu muñoz hartz edina minn mr maud griffin reprint arch gen psychiatri vol 59 oct 2002 www.archgenpsychiatry.com 930 2002 american medic associ right reserv download http archpsyc.jamanetwork.com univers aberdeen user 11 25 2015 ral smoke cessat group antidepress efficaci context differ obtain extens psychotherapi import question effect psycholog intervent pi ad antidepress therapi question rel efficaci 2 drug basi extant literatur deem differ efficaci bupropion nortrip tylin predict differ tween 2 expect produc higher abstin rate placebo hypothes propos 1 abstin rate higher particip receiv activ antidepress treatment bupropion nortriptylin 52 week period ceiv placebo 2 independ drug abstin rate higher particip receiv pi receiv 3 activ drug condit bine pi efficaci periment condit produc abstin subject method subject smoker 10 cigarett dai recruit ad vertis public servic announc flyer tele phone screen potenti particip invit ori entat meet interest individu complet inform consent invit baselin assess includ physic examin electrocardiogram blood draw section structur clinic interview dsm iv 9 diagnos depress dysthymia bipolar disord ad minist master level clinician particip sess demograph variabl mood paper pencil measur interview administ research staff exclusionari criteria includ cardiovascular diseas hy perthyroid seizur bulimia monoamin oxi dase inhibitor 2 week sever allergi includ aller gi experiment drug life threaten diseas bipolar diseas current major depress disord mdd pregnanc lactat levodopa migrain previou treatment cigarett smoke nortriptylin bupropion treatment alcohol drug 6 month psychiatr ho pital 1 year psychiatr medic suicid psychot symptom current nrt procedur particip stratifi number cigarett smoke sex histori depress histori randomli sign 1 6 experiment cell 3 bupropion triptylin placebo 2 pi assess baselin week 12 end treat ment 24 36 52 particip code nonsmok report smoke cigarett puff previou 7 dai expir carbon monoxid level 10 ppm urinari cotinin level 60 ng ml 10 ad vers effect assess checklist baselin week 1 2 3 6 52 week particip drug believ receiv perceiv help measur neg affect assess profil mood state pom 11 basi structur clinic interview dsm iv particip classifi posit neg mdd administ fagerstrom test nicotin dependence12 advers effect scale develop includ advers effect report bupropion nortriptylin counsel intervent medic manag medic manag develop 1996 agenc health care polici research guidelines7 condit collabor depress trial 13 medic man agement includ advic stop smoke antidepress medi cation advers effect monitor educ materi introduc complex time consum interven tion impract primari care physician 5 licens psychiatr intern medi cine resid particip provid written inform smoke cessat freedom smoke 14 week 1 physician review treatment rational pre scription instruct discuss behavior factor import smoke cessat establish quit date week 5 session last 10 20 minut minut visit schedul week 2 6 11 particip queri cessat progress physician spond briefli question provid encourag ad vice specif quit strategi offer psycholog intervent particip particip session previous de scribe addit particip 5 group session provid 3 master level counselor mon smoke treatment provid health care organiza tion consult group intervent adapt intervent detail elsewhere3,15 17 avail author s.m.h 90 minut se sion week 4 session 2 3 week 5 session 4 5 week 7 11 group size rang 3 11 intervent provid health relat inform mood manag smoke ce sation discuss cessat com.ibm.drl.hbcp.core element de velop quit smoke plan weekli modif method includ monitor cigarett af fectiv state paper pencil exercis focus health relat inform motiv quit decreas relaps relat thought inform handout didact present pharmacolog intervent medic placebo control doubl blind su tain releas properti bupropion rest formula tion tablet coat placebo bupropion avail encapsul drug maintain patenc bupropion formul provid blind drug particip receiv capsul ident number appear univers california san francisco drug prod uct servic prepar medic capsul nortriptylin lactos placebo activ drug encapsul pow dere form bupropion wellbutrin sr tablet glaxo research triangl park nc similar size pla cebo tablet insert lactos fill capsul capsul secur gelatin mixtur prevent open nortriptylin drug dose titrat particip therapeut serum level 50 150 ng ml obtain reprint arch gen psychiatri vol 59 oct 2002 www.archgenpsychiatry.com 931 2002 american medic associ right reserv download http archpsyc.jamanetwork.com univers aberdeen user 11 25 2015 particip assign activ nortriptylin hydrochlorid receiv 25 mg 3 dai 50 mg 4 dai end week serum level nortriptylin sess dosag increas 75 mg therapeut se rum level reach week 4 serum level assess drug dosag increas 100 mg week 6 serum level assess determin final dose end week 12 drug dose decreas 25 mg 2 dai final drug administr 25 mg 3 dai dose titrat partici pant receiv activ drug dose titrat partici pant receiv placebo titrat perform physi cian contact particip clinic staff mean nortriptylin blood level particip abstin week 6 59.9 ng ml sd 25.2 ng ml report blood lev el abstin particip nicotin result lower nortriptylin level 18 daili nortriptylin hydro chlorid dosag week 7 50 mg 2 75 mg 26 100 mg 25 125 mg 5 bupropion hydrochlorid dosag began 150 mg 3 dai dosag increas 300 mg remain week 12 dose decreas 150 mg 3 dai discontinu dose reduct occur particip report unpleas advers effect mean bupro pion blood level abstin subject 36.0 ng ml week 7 particip receiv bupropion receiv 300 mg particip return pill bottl clinic visit pill count number pill record pa tient fail return bottl ask call clinic staff pill count statist method princip data analysi method gener linear model com.ibm.drl.hbcp.glm gener classic linear model comput estim mean likelihood function squar com.ibm.drl.hbcp.glm repeat measur miss data drop particip data miss assum miss data equat smok ing 19 21 sa proc mix version 6.12 softwar sa institut cari nc abstin depend variabl glimmix macro sa sa stitut interact proc mix modifi dichotom data 22 singl com.ibm.drl.hbcp.glm evalu 3 hypothes abstin statu week 12 24 38 52 depend variabl design 2 activ drug placebo 2 pi 2 mdd histori histori model assess enter peat variabl interact assess depend variabl predict interact drop final model signific effect emerg perform singl test hypoth esi hypothesi wise error rate held 05 evalu effect sex interact 3 design variabl abstin rate week 12 52 mean 3 com.ibm.drl.hbcp.glm model comput glimmix macro parallel procedur compar 3 drug condit bupro pion nortriptylin placebo effect size express odd ratio confid interv analysi varianc 2 test evalu base line differ treatment condit continu ab stinenc rate rate occurr advers effect test 2 tail 05 comparison result particip characterist demograph smoke psychiatr characterist particip experiment condit tabl 1 signific differ tween condit baselin attrit figure1 show particip flow telephon con tact week 52 smoker 220 randomli sign 1 3 pharmacolog treatment nortripti line bupropion placebo 1 2 counsel treatment pi histori mdd present 33 particip medic emer genci break blind 1 partici pant receiv placebo drug usabl sampl 219 consist 122 men 97 women thirti particip 17 fail complet treatment 15 person reason 12 ceiv medic advers effect bupropion 6 triptylin 3 placebo 3 1 unrel medi cal condit 9 undisclos reason signific differ psycholog treat ment condit 21 219 1.37 24 diag tabl 1 baselin variabl psycholog intervent drug condit variabl placebo 37 placebo pi 36 nortriptylin hydrochlorid 38 nortriptylin pi 35 bupropion hydrochlorid 36 bupropion pi 37 ag 43.4 11.8 39.3 10.2 37.8 11.8 40.9 12.1 37.1 9.7 37.9 11.4 usual cigarett 23.0 10.6 22.2 9.5 20.9 9.3 20.2 7.9 19.8 7.5 22.5 9.0 fagerstrom scale score 5.4 2.3 4.7 2.0 4.6 2.1 4.7 2.3 4.1 2.2 5.1 2.3 year regular smoker 24.7 11.8 21.2 9.9 19.6 11.3 23.1 12.6 19.7 10.2 21.2 11.6 carbon monoxid ppm 27.8 10.9 25.6 12.4 26.0 9.2 25.7 12.4 25.4 10.2 31.2 15.3 previou quit attempt 7.0 11.9 6.8 9.9 9.0 13.8 5.3 7.1 6.3 8.0 4.6 4.1 pom total mood score 29.8 33.2 27.1 33.7 27.3 32.2 29.0 34.7 28.7 29.9 21.5 34.1 histori mdd 14 37.8 11 30.6 12 31.6 12 34.3 12 33.3 12 32.4 sex 15 40.5 17 47.2 17 44.7 16 45.7 15 41.7 17 46.0 race white 26 70.3 31 86.1 33 86.8 31 88.6 30 83.3 28 75.7 marri partner 10 27.0 14 38.9 15 39.5 11 31.4 8 22.2 16 44.4 medic manag pi psycholog intervent pom profil mood state mdd major depress disord mean sd reprint arch gen psychiatri vol 59 oct 2002 www.archgenpsychiatry.com 932 2002 american medic associ right reserv download http archpsyc.jamanetwork.com univers aberdeen user 11 25 2015 nostic categori 21 219 3.19 07 treat ment dropout signific differ drug condit 22 219 7.29 03 bupro pion 15.1 11 nortriptylin 10.0 7 pla cebo 26.0 19 rate placebo signifi cantlygreat rate fornortriptylin 21 219 6.74 009 bupropion 21 219 2.69 10 2 activ drug differ 21 219 1.01 31 mean number counsel session attend 3.58 sd 1.61 percentag number particip unabl collect smoke data week 12 15 33 week 26 16 35 week 36 17 38 week 52 19 42 signific differ drug psycholog treatment diagnost categori abstin main effect drug psycholog treatment condi tion assess time signific 05 tabl 2 signific effect nei ther main effect mdd diagnosi interact variabl variabl signific hypothes activ drug effect placebo figur 2 pi effect figur 3 support lack signific interact drug pi condit lack support hypothesi activ medic pi efficaci condit hypothes differ efficaci tween 2 activ drug found 21 126 1.88 17 interact bupropion nortriptylin diagnosi fell short tradit level signific 21 126 3.39 07 differ enc 2 drug particip histori depress higher abstin rate bupropion nortriptylin particip histori depress disord miss data omit 52 week abstin rate particip histori mdd 27 triptylin 24 bupropion 20 miss data code smoke drug par ticip histori mdd 52 week absti nenc rate 16 nortriptylin 13 miss data code relaps 38 bupropion 33 miss data code relaps continu absti nenc rate 1 year period 20.7 bupro pion 13.2 nortriptylin 11.8 placebo 22 162 1.96 38 2 psychosoci condit 13 18 pi 22 162 1 main effect sex approach signific 21 189 2.68 10 favor abstin rate men compar women abstin rate men week 12 44 week 24 29 week 36 26 week 52 24 women rate week 12 41 week 24 20 week 36 28 week 52 23 analys differ sig nific data reanalyz miss data code smoke miss data code smok ing continu abstin rate bupro pion 16.4 nortriptylin 9.6 placebo 8.2 22 219 2.80 25 10 pi 13 22 219 1 36 bupropion hydrochlorid 36 placebo pi 35 nortriptylin pi 37 bupropion pi 38 nortriptylin hydrochlorid 37 placebo 32 assess week 12 30 assess week 1231 assess week 1232 assess week 1234 assess week 12 27 assess week 12 31 assess week 24 29 assess week 2430 assess week 2433 assess week 2430 assess week 24 31 assess week 24 32 assess week 36 30 assess week 3627 assess week 3633 assess week 3631 assess week 36 28 assess week 36 31 assess week 52 28 assess week 5226 assess week 5231 assess week 5230 assess week 52 31 assess week 52 2373 patient screen telephon 1889 elig invit orient meet 178 attend meet random 70 follow 40 exclud ecg 36 medic reason 11 psychiatr reason 21 illicit drug past 30 398 attend pretreat assess 220 random figur 1 attrit flow chart ecg electrocardiogram medic manag pi psycholog intervent asterisk 219 blind broken 1 femal subject group receiv placebo pi reprint arch gen psychiatri vol 59 oct 2002 www.archgenpsychiatry.com 933 2002 american medic associ right reserv download http archpsyc.jamanetwork.com univers aberdeen user 11 25 2015 fifti particip 25 sampl port studi nrt 34 bupropion dur ing follow 15 bupropion group 14 triptylin group 25 placebo group placebo recipi activ drug recipi nonstudi pharmacolog therapi 21 219 5.42 20 54 subject report extrastudi medic 14 abstin time report distribut fairli equal treatment condit week 24 1 partici pant report studi medic absti nent nortriptylin condit week 36 1 abstin particip antidepress condit 2 placebo condit studi medi cation week 52 studi medic count 4 bupropion group 2 nortriptylin group 3 placebo group mainten blind part inform consent procedur partici pant inform advers effect drug surpris particip receiv activ drug tabl 2 percent abstin number assess number abstin assess time treatment condit drug week 12 week 24 week 36 week 52 medic manag bupropion 36 abstin 47 42 26 22 34 31 29 25 assess 32 31 32 31 abstin 15 8 11 9 nortriptylin 38 abstin 38 34 23 18 26 21 23 18 assess 34 30 31 30 abstin 13 7 8 7 placebo 37 abstin 15 11 10 8 18 14 13 11 assess 27 31 28 31 abstin 4 3 5 4 psycholog intervent bupropion 37 abstin 56 49 30 27 30 27 29 24 assess 32 33 33 31 abstin 18 10 10 9 nortriptylin 35 abstin 58 51 30 26 33 26 23 17 assess 31 30 27 26 abstin 18 9 9 6 placebo 36 abstin 40 33 31 25 20 17 21 17 assess 30 29 30 28 abstin 12 9 6 6 main effect drug 21 189 10.76 001 odd ratio 4.3 95 confid interv ci 1.83 10.00 psycholog treatment condit 21 189 8.53 004 3.32 95 ci 1.31 8.41 assess time 23 189 20.46 001 0.98 95 ci 0.97 0.99 signific 05 number parenthes repres percentag subject abstin miss data code smoke 100 60 80 90 70 50 30 10 40 20 0 12 24 36 52 assess week bs tin en nortriptylin hydrochlorid bupropion hydrochlorid placebo figur 2 dai point preval abstin rate pharmacolog intervent 100 60 80 90 70 50 30 10 40 20 0 12 24 36 52 assess week bs tin en placebo drug placebo pi drug pi figur 3 dai point preval abstin rate psycholog intervent pi drug medic manag reprint arch gen psychiatri vol 59 oct 2002 www.archgenpsychiatry.com 934 2002 american medic associ right reserv download http archpsyc.jamanetwork.com univers aberdeen user 11 25 2015 guess receiv activ drug 87 placebo particip receiv activ drug 67 21 160 9.06 003 odd ratio 3.29 95 confid interv 1.48 7.30 activ drug particip correctli guess assign activ placebo drug 49 nortriptylin recipi 58 bupropion recipi correctli guess drug assign ment 21 96 1 35 bupropion recipi ent nortriptylin particip correctli identifi drug receiv advers effect potenti advers effect dry mouth rash weight gain light headed shaki hand constip blurri vision sexual problem difficulti urin race heart swollen leg chest pain pressur short breath weight loss headach agit nausea vom it dizzi difficulti sleep sweat post baselin endors rate differ nortripti line placebo 1 dry mouth nortriptylin 72 placebo 33 21 131 19.71 001 odd ratio 5.16 95 confid interv 2.45 10.86 2 constip nortriptylin 32 pla cebo 14 21 131 5.91 02 odd ratio 2.87 95 confid interv 1.20 6.85 bupropion differ placebo item comment predict bupropion nortriptylin ef ficaci placebo produc abstin mea sure point preval abstin year similarli pi efficaci hypothesi pi add antidepr sant treatment support case recent studi hall al3 mdd pre dict failur quit smoke equival effect bupropion nortriptylin gener drug nortriptylin lower cost suggest altern bupropion smoker drug differ ent advers effect risk profil nortripti line shown relat increas rate cardiac event patient ischem heart diseas 23 present studi content pi increas contact increas ab stinenc visual inspect data valu figur 3 sug gest potenti differ placebo remain 3 condit activ drug pi placebo pi activ drug week 12 24 52 pi increas abstin rate ad activ drug bring abstin rate placebo condit level activ drug addit research role psycholog treat ment antidepress warrant interac tion drug histori mdd reach statisti calli signific level 07 inspect data suggest potenti superior bupropion smoker histori mdd virtual differ pa tient histori mdd effect warrant examin studi design address question abstin rate present studi lower report earlier work nortriptyline3 bupropion 1,2 differ reflect chang ing natur particip enter smoke treatment trial smoker present studi smoke fewer ciga rett partner spous blue collar servic worker white recent study24 shown decreas abstin rate smoke cessat studi past 25 year author studi attribut increas difficulti quit ciga rett individu continu smoke current pressur nortriptylin bupropion signifi cantli efficaci placebo point preval rate compar case 1 year continu abstin rate evalu at modest week 24 52 abstin rate field continu seek effica ciou treatment recent clinic trial ac ceptabl rigor publish 199625 1999,2 fail find differ placebo activ nrt recent review nrt effect sug gest decreas efficaci nicotin patch nico tine gum introduc 1980 26 popul smoker intervent experi declin efficaci inform provid particip part inform consent procedur sur prise correctli guess drug receiv studi drug detect effect report mainten blind particip correctli guess drug receiv 27 29 complex blind procedur placebo bupropion sustain releas capsul unavail reassur bupropion recipi nortriptylin recipi guess drug knowledg clinic trial report studi medic fol low period found high rate 54 pa tient 25 sampl 14 54 par ticip abstin recod abstin particip smoke chang find ing repres 6 sampl fairli equal distribut condit neverth increas avail smoke cessa tion medic recommend studi routin report data understand outcom process abstin relaps result present studi limit select natur sampl result meet criteria complet research avail year medic exclusionari criteria submit public juli 20 2001 final revis ceiv novemb 12 2001 accept decemb 11 2001 reprint arch gen psychiatri vol 59 oct 2002 www.archgenpsychiatry.com 935 2002 american medic associ right reserv download http archpsyc.jamanetwork.com univers aberdeen user 11 25 2015 studi support grant r01 da02538 2 p50 da09253 nation institut drug abus bethesda md grant r01 ca71378 nation cancer institut bethesda kevin delucchi phd statist con sultat heather kenna manuscript prepar author reprint sharon hall phd univers california san francisco 401 parna su av box 0984 san francisco ca 94143 0984 mail smh itsa.ucsf.edu
articl 2100 psychiatri 161 11 novemb 2004http ajp.psychiatryonline.org extend nortriptylin psycholog treatment cigarett smoke sharon hall ph.d gari humfleet ph.d victor reu m.d ricardo muñoz ph.d jennif cullen ph.d object accept treatment ciga rett smoke rare achiev abstin rate 35 1 year low rate flect failur provid extend multi focal treatment complex chronic addict chronic diseas model smoke author undertook studi determin effect long term antidepress psycholog treatment method hundr sixti smoker 10 cigarett dai randomli sign treatment condi tion nortriptylin versu placebo versu extend treat ment design subject receiv 8 week transderm nicotin patch group counsel session activ placebo treatment intervent subject treatment end point subject extend treatment continu take drug placebo week 52 receiv addit 9 monthli counsel session checkup tele phone call midwai se sion subject assess baselin week 12 24 36 52 princi pal outcom variabl repeat ab stinenc assess 1 year period point preva lenc 7 dai abstin result week 52 point preval abstin rate miss subject imput smoker 30 pla cebo treatment 42 placebo extend treatment 18 activ treatment 50 activ extend treatment miss subject omit rate 32 57 21 56 conclus comprehens extend treatment combin drug psy cholog intervent produc con sistent abstin rate substan tialli higher literatur psychiatri 2004 161 2100 2107 cigarett smoke recogn addict long term abstin rate poor averag 20 35 intens wide accept treatment 1 4 addict drug recognit addict chronic relaps led treatment extend durat follow support feasi ble easi reentri treatment cigarett smoke promulg model inexpens time limit includ larg scale commun inter vention trial commit 5 cours medic limit psycholog contact 1 6 extend treatment test tobacco depen denc met success hai al 7 treat subject 7 week open label bupropion end open label treatment 59 subject abstin enter 52 week relaps preven tion phase phase subject receiv monthli individu counsel research staff ei ther activ placebo bupropion point preval absti nenc significantli higher bupropion group placebo group week 52 week 78 condit differ week 104 median time relaps significantli greater bupropion group placebo group lung health studi provid intens psycholog cal treatment 2 mg nicotin gum subject con tinu gum 3 6 month attain absti nenc gum obtain physician assent 1 year point preval absti nenc rate 35 28.6 sampl sustain nonsmok 1 year 8 22 5 year 9 collabor european anti smoke evalua tion 15 25 mg nicotin patch cross 8 versu 22 week drug administr condi tion compar placebo differ enc activ patch condit found highest sustain abstin rate 15.4 1 year 25 mg patch administ 22 week 10 present studi gener inexpens drug efficaci treatment nicotin addic tion nortriptylin 2 4 11 provid psycholog ical intervent design factori treatment length 12 versu 52 week dose activ drug versu placebo factor primari hypothesi tend nortriptylin produc peat 7 dai point preval abstin week 24 36 52 remain treatment condit psychiatri 161 11 novemb 2004 2101 hall humfleet reu al http ajp.psychiatryonline.org secondari hypothes 1 activ drug efficaci placebo produc 7 dai point preval abstin 52 week period 2 extend treatment efficaci treatment produc 7 dai point preval ab stinenc 52 week period method subject studi treatment approv institut review board univers california san francisco cruit initi hundr sixti subject smoke 10 cigarett dai stratifi baselin number ciga rett histori nicotin replac therapi versu histori major depress disord versu randomli assign experiment cell subject cruit advertis public servic announc flyer telephon screen invit orient meet complet written inform consent invit baselin assess includ physic exam inat ecg blood draw basic blood chemistri anal yse section structur clinic interview dsm iv scid 12 diagnos depress dysthymia bipolar di order administ master level clinician exclusionari criteria includ cardiovascular diseas histori seizur sever allergi life threaten diseas bipolar disor der current major depress disord dopa migrain headach current psychiatr medic includ bupropion suicid psychot symptom current nico tine replac therapi previou treatment cigarett smok ing nortriptylin treatment drug alcohol 6 month psychiatr hospit 1 year pregnanc lactat assess measur assess repeat week 12 24 36 52 expir carbon monoxid urinari cotinin assess confirm smoke statu week 24 36 52 carbon monoxid assess week 12 dai point preval abstin assess primari outcom measur subject consid abstin answer question past 7 dai smoke puff cigarett carbon monoxid level 10 ppm cotinin level 50 ng ml recommend 13 side effect assess checklist week 1 7 11 12 subject monthli contact week 12 subject assign tend treatment base scid subject classifi posit neg histori major depress disord baselin administ fagerstrom test nicotin de pendenc 14 minnesota nicotin withdraw question nair valid instrument yield total withdraw discomfort score 15 16 administ demograph questionnair subject reimburs 25.00 return assess week 24 36 52 summari treatment procedur subject particip 12 week treatment time particip group counsel session ject began activ placebo nortriptylin week 1 con tinu take activ drug placebo week 12 quit date set week 5 therapeut blood level achiev fore cessat quit date subject began 8 week transderm nicotin patch patch treatment contin u week 12 week 12 subject told receiv extend treatment subject treatment therapeut contact subject extend treatment continu take activ nortriptylin placebo assign remain treat ment period particip monthli psycholog counsel ing telephon counsel 2 week session final studi place univers affili smok ing cessat clinic treatment intervent nicotin replac therapi subject receiv 4 week 21 mg transderm nicotin patch 2 week 14 mg patch 2 week 7 mg patch nicotin patch began quit date week 5 continu week 12 activ nortriptylin versu placebo nortriptylin drug dose titrat subject therapeut serum level 50 150 ng ml obtain subject assign activ nortrip tylin receiv 25 mg dai 3 dai 50 mg dai 11 dai dose increas 75 mg dai week 3 week 4 serum level assess therapeut serum level reach drug dose increas 100 mg dai week 6 serum level assess determin final dose dose titrat subject receiv activ drug dose titrat randomli select subject cohort receiv placebo titrat perform physician contact subject front line staff front line medic staff intern medicin physician licens nurs practition blind drug assign subject met clinician week 1 start medi cation treatment week 2 3 12 review complianc side effect subject relaps refer counselor versu extend treatment previou studi nortriptylin 2 4 treatment place 12 week subject assign treatment condi tion told assign treatment week 12 began 5 7 dai taper activ drug placebo extend treatment place week 52 week 12 subject extend treatment condit told assign extend treatment subject continu drug dose reach end titrat period week 52 subject choos discontinu drug week 52 subject take drug week 52 taper drug time subject blind drug assign studi inform drug assign week 52 assess psycholog treatment deliv master level psy chologist health educ treatment condit activ activ extend placebo placebo extend subject initi receiv behavior group treatment pro vide health relat inform facilit group discuss develop continu modif person plan quit smoke method includ monitor ciga rett paper pencil exercis focus health late inform motiv quit decreas relaps relat thought inform handout didact present 90 minut session held week 4 5 se sion 7 11 total 7.5 hour counsel time extend condit subject receiv group treatment treatment condit activ pla cebo extend treatment condit individu counsel se sion held month subject receiv 20 30 minut session 4 week week 16 20 24 28 32 36 40 44 48 total 3 4.5 hour counsel session coun selor continu review reinforc behavior chang 2102 psychiatri 161 11 novemb 2004 treatment smoke http ajp.psychiatryonline.org strategi discuss initi group therapi ject relaps quit date establish relaps situa tion review determin strategi develop overcom similar situat week session subject contact telephon assess smoke provid reinforc nonsmok subject relaps schedul face face session telephon contact approxim 5 10 minut long approxim 40 80 minut telephon counsel provid counselor train multistep process read treatment manual observ supervisor g.l.h provid treatment intervent cohort observ supervisor treat cohort train procedur telephon contact coun selor met weekli supervis g.l.h r.f.m extend intervent detail manual author data analysi plan group size base set power 80 type error rate 0.05 estim effect size hall al 2 factor anticip attrit rate logist regress test effect drug placebo dose treatment durat repeat 7 dai abstin design durat dose independ variabl primari hypothesi evalu test dose durat interact gener estim equat gener classic linear model quasi like hood estim test hypothes point preval abstin week 24 36 52 17 18 sa ver sion 8.02 analys 19 ensur random compromis compar experiment cell baselin variabl tabl 1 analysi varianc anova continu variabl chi squar analysi categor variabl identifi potenti covari correl baselin vari abl point preval abstin week 12 24 36 52 abstin assess versu abstin point biseri correl includ preliminari hy pothesi test model variabl signific correla tion abstin variabl elimin contribut significantli final model determina tion com.ibm.drl.hbcp.predictor attrit assess low attrit rate week 12 2 week 24 4 week 36 14 week 52 9 provid comparison ear lier studi complet chi squar test activ nortripti line versu placebo week 12 differ week medic placebo dispens determin anova individu comparison tukei test test prove signific dif ferenc withdraw symptom activ placebo condit week 12 determin repeat measur anova baselin level symptom covari control gener tendenc endors symptom dif ferenc side effect report 12 week treat ment determin compar number subject report effect activ placebo condit week 12 52 includ subject extend treatment analys advers event set analys seri chi squar test fisher exact test cell size small test analys sec tion tail result subject characterist demograph smoke psychiatr characterist subject experiment condit shown tabl 1 signific differ tervent condit attrit figur 1 show data flow contact program week 52 assess condit differ percentag subject collect smoke data week 12 df 3 160 0.28 fisher exact test week 24 df 3 160 0.42 fisher act test week 52 χ2 7.40 df 3 160 0.06 week 36 signific differ follow rate df 3 160 0.02 fisher exact test attend rate placebo extend condit lower condit number percentag ject contact assess shown figur 1 subject consid complet treat ment condit particip week 12 extend condit treatment compl tion attend session tabl 1 baselin variabl smoker 10 cigarett dai treatment condit variabl treatment placebo 40 extend placebo 41 nortriptylin 39 extend nortriptylin 40 mean sd mean sd mean sd mean sd ag year 38.8 9.5 38.9 10.4 36.1 9.1 40.2 10.8 usual number cigarett smoke dai 18.8 6.8 18.7 7.0 20.4 7.5 18.8 7.4 fagerstrom test nicotin depend score 4.6 2.1 4.5 1.9 4.6 2.1 4.7 1.9 year regular smoke 20.3 10.5 21.3 11.2 18.4 9.2 22.7 10.8 carbon monoxid level ppm 23.8 9.3 21.5 7.2 21.4 8.9 22.7 9.3 number previou attempt quit 3.5 3.7 5.3 6.9 5.3 6.7 7.1 13.6 posit histori major depress disord 11 27.5 8 19.5 7 17.9 7 17.5 femal 17 42.5 19 46.3 15 38.5 15 37.5 white 33 82.5 32 78.1 29 74.4 30 75.0 marri live partner 22 55.0 19 46.3 18 47.4 15 37.5 psychiatri 161 11 novemb 2004 2103 hall humfleet reu al http ajp.psychiatryonline.org differ activ treatment placebo ei ther activ 30 39 76.9 placebo 29 40 72.5 χ2 0.20 df 1 79 0.65 extend ac tive 27 40 67.5 placebo 20 41 48.8 χ2 1.16 df 1 81 0.28 condit abstin primari hypothesi subject activ tend condit report repeat abstin week 24 36 52 subject remain condit confirm lo gistic regress analysi test signific dose durat interact durat dose teract signific χ2 6.90 df 1 160 0.009 main effect major depress disord χ2 5.02 df 1 160 0.03 posit histori major de pressiv disord predict abstin figur 2 indi cate effect extend durat obtain consi tent abstin greater subject receiv activ drug receiv placebo test hypothesi comput gener iz estim equat analysi miss data omit ted model recommend lon gitudin analys 20 21 durat dose time assess signific χ2 11.90 df 3 0.008 160 comparison paramet estim activ condit differ signifi cantli placebo extend condit odd ratio 0.47 95 confid interv ci 0.30 0.75 0.001 placebo condit odd ratio 0.69 96 ci 0.49 0.95 0.02 extend activ condit differ significantli extend placebo condi tion odd ratio 0.81 95 ci 0.60 1.09 0.17 model histori major depress disord pro duce main effect interact treatment condit replic gener estim equat figur 1 flow chart show attrit smoker 10 cigarett dai assign treatment condit 52 week assess week 52 34 87 assess week 52 37 93 assess week 52 36 90 assess week 52 30 73 assess week 36 36 92 assess week 36 39 98 assess week 36 38 95 assess week 36 32 78 assess week 24 37 95 assess week 24 39 98 assess week 24 40 100 assess week 24 38 93 assess week 12 38 97 assess week 12 37 93 assess week 12 40 100 assess week 12 41 100 nortriptylin 39 placebo 40 extend nortriptylin 40 extend placebo 41 randomli assign 160 invit attend orient meet 848 caller termin 322 contraind medic 203 smoke 10 cigarett dai 185 reason 69 psychiatr medic problem 69 randomli assign 232 attend meet fail complet laboratori test ecg 129 exclud ow ecg 36 exclud medic reason 30 exclud psychiatr reason 37 patient screen telephon 1,671 invit orient meet 823 attend orient meet 440 elig patient agre attend pretreat assess 392 2104 psychiatri 161 11 novemb 2004 treatment smoke http ajp.psychiatryonline.org miss data code smoke alter signifi canc level markedli abstin rate condit assess shown figur 3 miss data miss data figur 4 miss data smoke earlier studi activ drug produc higher absti nenc rate placebo week 12 miss data omit χ2 4.91 df 1 157 0.03 odd ratio 2.29 95 ci 1.10 4.80 code smoke χ2 5.05 df 1 160 0.03 odd ratio 2.27 95 ci 1.10 4.70 nortriptylin adher differ experiment cell week nortriptylin dispens particip 11.5 df 3 156 0.0001 expect condit differ significantli extend condit 0.007 tukei test tukei test differ tween activ drug placebo condit pla cebo mean 9.45 week sd 3.50 activ drug mean 8.87 sd 3.75 activ drug placebo tend condit placebo mean 18.48 sd 15.34 ac tive drug mean 21.15 sd 16.56 expect signific differ tween subject extend activ nortripti line treatment nortriptylin blood level week 6 subject mean 58.9 sd 34.3 extend subject mean 69.3 sd 60.1 10 df 56.3 n. withdraw symptom repeat measur anova signific differ drug condit baselin 5.92 df 1 94 0.02 activ drug mean 7.32 sd 5.76 pla cebo mean 4.83 sd 4.10 baselin level variat differ 12 week signific 3.93 df 1 94 0.05 activ drug mean 4.84 sd 4.60 placebo mean 6.45 sd 5.14 subject smok ing baselin differ point reflect ten denci endors symptom mean symptom pla cebo condit increas 4.8 6.5 baselin 12 week symptom activ drug condi tion decreas mean 7.3 4.8 side effect week 0 12 subject activ drug condi tion endors 22 side effect subject placebo ef fect dry mouth 85 versu 40 lightheaded 44 versu 22 shaki hand 30 versu 14 consti pation 38 versu 15 blurri vision 23 versu 7 difficulti urin 13 versu 2 sexual difficulti 19 versu 2 0.01 comparison diffi culti urin 0.02 week 12 52 subject extend treatment condit activ drug subject report skin red 2.5 versu 0 df 1 0.03 fisher exact test sexual difficulti 8.9 versu 1.2 df 1 0.03 fisher exact test placebo subject sever ad vers event fourteen subject receiv activ drug termin medic side effect end respect treatment period activ treatment 10 activ extend treatment subject receiv placebo termin treatment side effect placebo treatment placebo extend treat ment activ versu placebo 0.18 fisher exact test figur 2 interact drug placebo treatment length consist abstin rate week 24 36 52 smoker 10 cigarett dai 45 40 35 30 25 st 20 15 10 extend placebo activ treatment length figur 3 abstin rate treatment group smoker 10 cigarett dai 52 week miss data omit 80 70 60 50 40 st 30 20 10 week 12 week 24 week 36 week 52 placebo placebo extend activ activ extend psychiatri 161 11 novemb 2004 2105 hall humfleet reu al http ajp.psychiatryonline.org knowledg drug part inform consent procedur partici pant inform side effect drug surpris particip activ drug guess receiv activ drug 63 placebo particip take activ drug 37 df 1 0.0001 fisher act test odd ratio 5.75 95 ci 2.45 13.49 extra studi medic abstin subject report extra studi medic rare abstin subject greatli affect suggest recent consensu paper 22 includ individu medic treatment success week 24 abstin subject report ing extra studi medic placebo extend subject activ extend subject nicotin replac ment therapi week 36 abstin subject port nicotin replac therapi placebo extend subject activ subject absti nent subject week 36 activ extend condit report combin nicotin replac therapi bupropion week 52 abstin ject report nicotin replac therapi placebo extend condit abstin subject placebo condit report bupropion discuss studi repres model intervent treatment view time event session ongo process extend time period befit chronic diseas combina tion pharmacolog psycholog intervent produc highest abstin rate report literatur 1 year point preval rate 50 activ extend condit unparallel compar rate report approxi mate 20 year ago uncontrol trial rapid smok ing 23 24 factor contribut rate intervent includ low moder depend evidenc fagerstrom test nicotin depend score select trial intervent current studi differ report literatur bine modal extend time period independ subject abstin sta tu time period analys point preval data suggest extend counsel placebo differ significantli extend counsel ac tive drug activ drug extend counsel superior help smoker achiev repeat abstin repeat abstin consid outcom singl point preval outcom suggest tend counsel import attain absti nenc reliabl abstin attain combin drug counsel nortriptylin u. food drug ad ministr indic cigarett smoke interest attempt replic find current studi sustain releas bupropion differ activ drug placebo number side effect 12 week treatment 22 symptom includ sexual difficulti report 20 ject receiv nortriptylin extend treat ment period fewer differ subject activ placebo condit ac tual number particip report low condit number pattern side effect experi enc worth note barrier nortriptylin nortriptylin inexpens gener drug safe smoker extend treatment provid addit aid maintain abstin high abstin rate achiev week 12 reflect combin pharmacolog treatment nortriptylin nicotin replac ther com.ibm.drl.hbcp.api psycholog intervent contribut high rate extend treatment appear duce rate relaps attribut high abstin rate obtain psycholog counsel regular phone con tact extent level counsel nece sari cost effect studi argu expens time extend treat ment preclud widespread implement expens smoke treatment figur 4 abstin rate treatment group smoker 10 cigarett dai 52 week miss data imput smoke 80 70 60 50 40 st 30 20 10 week 12 week 24 week 36 week 52 placebo placebo extend activ activ extend 2106 psychiatri 161 11 novemb 2004 treatment smoke http ajp.psychiatryonline.org cost effect medic intervent high health care cost tobacco 25 data show chronic smoker provid er effort need success cessat question rais data dif ferenc observ maintain longer follow period question relev chronic diseas model extend treatment con tinu benefici effect provid prolong period indefinit histori major depress disord correl signif icantli consist abstin magnitud correl small 0.15 repres chanc find signific differ nortriptylin placebo week 12 inspect data sug gest endur contrast earlier find group indic signific effect point preval abstin nortriptylin 2 4 psycholog intervent treatment period compar studi nicotin patch swamp effect due nortriptylin puzzl effect evid week 12 immedi termin nicotin replac therapi argu smoker engag intens long term treatment pro pose public data need convinc practition smoker substanti abstin rate achiev treatment commen surat tobacco addict properti requir generaliz move target assess result wide dissemin studi unusu result blind report report usual subject guess treatment rule except behav ioral activ drug 2 4 26 present part ninth annual meet societi search nicotin tobacco orlean feb 19 22 2003 65th annual meet colleg problem drug depen denc miami beach fla june 15 19 2003 receiv nov 10 2003 revis receiv feb 9 2004 accept march 10 2004 univers california san francisco address reprint request dr hall univers california san francisco 401 parnassu av box 0984 san francisco ca 94143 0984 smh itsa.ucsf.edu mail support nation institut drug abus grant r01 da 002538 r01 da 015732 k05 da 016752 p50 da 9253 author juli gorecki data analys liza partlow lorel hiramoto assist manuscript prepara tion john hugh comment earlier version articl
american journal public health octob 2006 vol 96 101808 research practic peer review hall al research practic object contact control test efficaci stage care intervent reduc cigarett smoke psychiatr patient patient treatment depress method conduct random clinic trial includ assess baselin month 3 6 12 18 hundr twenti patient mental health outpati treatment diagnos depress smoke 1 cigarett dai particip desir quit smoke prerequisit particip stage care intervent particip receiv puter motiv feedback baselin 3 6 12 month offer 6 session psycholog counsel pharmacolog cessat treatment program contact control particip receiv guid referr list local smoke treatment provid result hypothes abstin rate stage care interven tion particip exceed contact control particip month 12 18 signific differ favor stage care intervent found occurr quit attempt stringenc abstin goal conclus data suggest individu psychiatr treatment de pression aid quit smoke stage care interven tion smoke cessat intervent gener popul implement psychiatr outpati set public health 2006;96 1808 1814 doi 10.2105 ajph 2005.080382 treatment cigarett smoke depress mental health outpati random clinic trial sharon hall phd janic tsoh phd judith prochaska phd mph stuart eisendrath md joseph rossi phd colleen red phd ami rosen psyd marc meisner md gari humfleet phd juli gorecki ma smoke cessat treatment identifi effect smoker gener skill train pharmacotherapi clinic support import note rec ommend implement mental health treatment set 1 clinic trial articl test efficaci stage care interven tion implement mental health outpati set design chang smoke behavior smoker clude unmotiv quit target popul interest patient outpa tient treatment depress stage care intervent inter vention smoker enrol depress treatment smoke cessat primari goal individu presenc mental health treat ment set provid opportun inter vene smoke behavior stage care intervent oper iz recommend agenc health care polici research american psychiatr associ practic guidelin 8,9 integr computer feedback system base tran theoret model provid feedback smoke provis face face individu psycholog counsel pharmacolog treatment stage readi 10 stage care interven tion compar educ mate rial referr list control contact control control condit design model current practic mental health clinic practic ceed provid propos 4 hypothes 1 stage care intervent particip abstin cigarett month 12 18 particip contact control group observ effect size inter vention smoker readi quit smoke observ lit eratur 11,12 light find mental health system reluct identifi treat tobacco depend exhort diagnos treat fatal disord 1,2 phenomenon link belief part mental health profession skill provid smoke treatment failur derstand mental health patient suc ceed quit smoke reimburs con cern fear exacerb symptom nicotin withdraw 2,3 time assum individu mental ill ness distract demor disor ganiz benefit smoke treatment larg scale recent studi estim 44.3 cigarett smoke coun smoke individu psychiat ric disord substanc abus de pendenc schizophrenia bipolar disord major depress disord mdd 4 de press smoker numer largest group comorbid smoker consider occurr high incid preval depress 5 compel argument provis smoke treatment psychi atric outpati set argu ment high preval cigarett smok ing set 6,7 smoke cessat exacerb psychiatr disord quit smoke treatment provid safeti net 3 mental health provid view skillfulli provid nicotin depend treatment possess basic tool need provid treatment includ interview behavior chang method knowledg psychopharmacolog agenc health care polici search guidelines8 american psychi atric associ practic guidelines9 time studi initi 1999 suggest smoker comorbid mental health condit offer octob 2006 vol 96 10 american journal public health hall al peer review research practic 1809 research practic expect signific differ absti nenc rate month 3 6 2 stage care intervent particip report 1 attempt quit smoke contact control partici pant month 3 6 12 18 3 month 3 6 12 18 stage care inter vention particip stringent smoke abstin goal contact control particip 4 independ treat ment condit sever depress symp tom measur baselin beck de pression index bdi ii predict abstin cigarett month 3 6 12 18.13 method site conduct trial 4 mental health outpati clinic april 2000 june 2003 site univers base train focus clinic 103 3 part larg health mainten organ hmo 219 locat urban area provid rang ser vice includ group individu psy chotherapi pharmacotherapi particip particip recruit provid ferral invit letter flyer par ticip clinic recruit materi state particip quit smoke particip paid maximum 150 particip need enrol 1 particip clinic inclus criteria diagnosi current unipolar depr sion primari care evalu men tal disord prime md 14 smoke 1 cigarett dai week recruit enrol pa tient particip clinic site exclus criteria ag younger 18 year inabl speak english histori bipolar disord presenc condit contraind pharmacolog treatment presenc dementia disord interfer compr hension materi patient met screen criteria dur ing telephon interview includ prime md invit orient meet project staff studi particip provid baselin data includ psychometr instrument shown figur 1 585 smoker screen 431 found elig invit particip studi hundr twenti accept random contact referr control 159 step care intervent 163 random alloc list comput gener statist staff basi list complet baselin assess interview randomli assign particip condit stratifi block num ber cigarett smoke dai particip stage chang stage care intervent model compon computer motiv feedback compon stage care interven tion model computer system provid individu feedback motiv smoker quit system includ feed back smoke behavior readi quit individu characterist smoker 12,15 system base stage chang model 10 model conceptu smoker 1 5 stage respect cessat precontempl intent chang contempl intend quit 6 month prepar ing quit month 1 quit attempt year action quit smoke 6 month maint nanc quit smoke 6 month stage chang model assum dividu readi ad vantag treatment intervent 18 present studi design test stage chang model con ceptual model tool intervent smoker rang tention quit smoke computer system pre ent studi detail 15 particip met counselor spond question comput cognit behavior process chang percept pro con smoke temptat smoke system made norm ips comparison produc report design optim movement stage report particip current stage decis cogni tive behavior process compar earlier port tempt situat strategi movement stage readi provid individu report tempt situat propos strategi move stage readi counselor particip review written report treatment session base computer feedback report last 15 minut held baselin month 3 6 12 cessat treatment program compon stage care intervent model cessat treatment program particip reach contempl stage basi puter feedback report cessat treat ment consist psycholog counsel adapt publish intervent 16,17 nico tine patch sustain releas bupropion entranc studi particip assign 1 2 counselor master degre psy chologi doctor clini cal psycholog counselor provid moti vation counsel cessat treatment particip supervis weekli project coordin author particip reach contempl stage offer cessat treatment ethic concern particip request ce sation treatment stage ceiv studi period 34 53 stage care intervent partici pant enter cessat treatment 19 counsel provid 6 session 30 minut 8 week focus complet ce sation agre quit date tervent includ develop mitment abstin quit plan iter revis quit process select quit date particip seri test pertain reason smoke discuss inform american journal public health octob 2006 vol 96 101810 research practic peer review hall al research practic tabl 1 continu baselin variabl smoke cessat treatment condit random clinic trial depress patient mental health treatment contact control stage care intervent mean sd mean sd particip 159 163 ag 42.2 12.8 41.5 12.4 ag cigarett 14.8 3.8 14.8 4.4 ag began smoke regularli 17.1 4.4 18.0 6.1 fagerström test nicotin depend total score 4.2 2.6 3.8 2.4 beck depress inventori scorea 21.4 10.9 20.6 11.7 expir air carbon monoxid concentr ppm 15.2 10.2 15.5 9.9 prior quit attempt 6.2 15.6 5.0 10.0 usual cigarett smoke dai 15.3 10.3 15.8 10.0 ascor 21 moder depress 4 part categor scheme minim mild moder sever 13 verifi expir air carbon monoxid 10 ppm risk smoke benefit quit ting discuss inform nutri tion exercis intervent clude mood monitor discuss wai increas pleasant mood decreas neg behavior skill duce relaps risk relax social support skill manual senior author request particip smoke 10 ciga rett dai receiv 21 mg nicotin patch 6 week 14 mg patch week 7 8 7 mg patch final 2 week particip smoke fewer 10 cigarett dai start 14 mg patch 6 week switch 7 mg patch remaind treatment patient fail quit smoke nicotin replac therapi resum smoke time initi cessat treatment elig request bupropion project staff request relai patient mental health provid project staff agreement reach appropri bupropion particip contact control intervent contact control intervent con sist provid particip visit folder list referr smoke cessat program stop smoke guid 20 therapeut contact particip studi staff measur biolog verifi report quit tempt primari outcom variabl 7 dai abstin cigarett verifi expir air carbon monoxid 10 ppm particip test cut report smoke puff 7 dai code abstin cigarett collect data 24 hour quit attempt questionnair interview inform system data commit abstin measur thought abstin questionnair 20,21 assess endors ment 1 6 categori abstin goal vari degre commit ment complet abstin 1 quit 2 quit slip 3 occasion 4 abstin time 5 control 6 clear goal respons robust com.ibm.drl.hbcp.predictor abstin tobacco depend substanc abus treatment 20,22 questionnair admin ister assess instrument remain instru ment wide psychi atric nonpsychiatr popul stage chang question admini tere particip experiment control condit 18 depress symp tom measur total score bdi ii 13 level nicotin depend assess fagerström test nico tine depend ftnd 23 instru ment administ assess ftnd analys restrict baselin assess studi depress dysthymia mania hypomania nicotin depend section computer diagnost interview schedule24 ftnd23 administ baselin assess shown figur 1 assess held baselin 3 6 12 18 month particip paid 25 assess receiv 50 bonu complet assess particip reimburs 10 valid address facilit futur contact assess administ interview held bach elor master degre psycholog public health interview inform particip experiment condit data analysi method sampl size requir base type error rate 05 2 tail test minim power level 80 estim rang effect size base studi computer motiv feed back stage chang model clinic trial compar cessat treatment gener popul studi design compar studi outpati psychiatr popul estim suggest total sampl size rang 300 400 test hypothes compar treatment condit baselin variabl comput propens score predict sessment attrit dichotom score base complet assess versu noncomplet assess 25,26 propens score estim effect miss data outcom nonsignific contribu tion suggest miss data pattern proba bly bia result score elimin final model signifi score miss data pat tern affect result retain model correct contri bution 27 score contribut signifi cantli model 05 drop analys test site differ found data combin 4 site test hypothes prototyp model gener estim equat gee baselin variabl tabl 1 2 octob 2006 vol 96 10 american journal public health hall al peer review research practic 1811 research practic tabl 2 categor baselin variabl smoke cessat treatment condit random clinic trial depress patient mental health treatment contact stage care control intervent femal 113 71.1 111 68.1 white 103 64.8 117 71.8 marri partner 47 70.4 42 74.2 dsm iv posit mdd 155 97.5 152 93.3 current mdd 133 83.7 135 82.8 dsm iv recurr mdd 89 57.4 79 52.0 depress disord 4 2.5 11 6.8 dsm iv nicotin withdraw 74 46.8 68 42.0 dsm iv nicotin depend 118 74.7 104 64.2 stage chang precontempl 34 21.4 36 22.1 contempl 90 56.6 81 49.7 prepar 35 22.0 46 28.2 educ level achiev high school graduat 39 24.5 27 16.6 colleg 56 35.2 76 46.6 colleg graduat 51 32.1 45 27.6 graduat degre 13 8.2 15 9.2 employ statu emploi full part time 83 52.2 87 53.4 unemploi 42 26 46 28.2 retir 15 9.4 17 10.4 homemak 6 3.8 3 1.9 student 13 8.2 10 6.1 psychiatr medic 131 82.4 122 74.9 bupropion nortriptylin 19 12.3 27 17.8 note mdd major depress disord dsm iv diagnost manual mental disord 4th revis 29 05 correl depend variabl sampl sampl partit treatment condit depress statu discret singl episod life long singl episod recurr enter data indic cognit havior intervent effect individu recurr depress 28 30 variabl correl consist depend variabl enter initi analysi gee time treatment condit variabl fail contribut model drop final analysi hypothesi 1 ab stinenc statu month 12 18 depend variabl analysi strategi hypothes 2 4 quit attempt abstin goal depress symptom parallel strategi test hypothesi 1 gee analyt method hypothesi 2 depend vari abl presenc absenc 24 hour quit attempt report month 3 6 12 18 hypothesi 3 depend variabl categori endors thought abstin questionnair month 3 6 12 18 hypothesi 4 depen dent variabl abstin month 3 6 12 18 record miss ing data indic smoke consist current statist prac tice25,26 concern put cent societi research nicotin tobacco task forc 31 order increas generaliz clini calli recogn diagnost categori replic test 4 hypothes clude smoker diagnosi major depress disord 307 χ2 compar enrolle versu nonenrolle cessat treatment stage care intervent attain abstin assess result descript statist particip recruit follow rate shown figur 1 demograph smok ing mental health medic variabl shown tabl 1 2 signific differ condit baselin variabl percentag particip meet criteria lifetim nicotin depend diagnosi puter diagnost interview schedul di control group higher percentag experiment 74.7 versu 64.2 nicotin depen denc diagnosi correl significantli abstin assess hypothesi test gee test hypothesi effect treatment time abstin main effect treatment condit χ2 4.05 df 1 0441 odd ratio 4.549 95 confid inter val ci 1.04 19.93 propens score contribut model abstin rate treatment condit time particip shown figur 2 comparison earlier report code miss data indic smoke report abstin rate obtain miss data code indic smoke rate stage care interven tion month 3 13.5 month 6 14.11 month 12 14.11 month 18 18.40 contact control month 3 9.43 month 6 15.73 month 12 9.43 month 18 13.21 gee assess hypothesi stage care intervent particip report quit attempt contact control particip indi cate signific treatment cigarett american journal public health octob 2006 vol 96 101812 research practic peer review hall al research practic note mdd major depress order di computer diagnost interview schedul figur 1 recruit follow depress patient mental health treatment particip smoke cessat treatment program smoke baselin interact χ2 6.54 df 1 01 3.44 ci 1.36 8.69 signific main effect treatment con dition χ2 4.42 df 1 03 3.52 ci 1.10 11.29 number cigarett baselin χ2 8.12 df 1 004 2.01 95 ci 1.25 3.23 previou quit tempt χ2 7.23 df 1 007 1.03 95 ci 1.01 1.06 propens score signific contributor treatment condit number cigarett smoke baselin interact shown figur 3 particip smoke 20 ciga rett dai contact control report quit attempt smoke fewer 20 cigarett dai particip smoke 20 cig arett dai stage care intervent differ particip smoke fewer 20 cigarett dai condit stage care intervent appear increas probabl heavier lighter smoker tempt quit test hypothesi stage care intervent particip stringent smoke cessat goal collaps 6 respons categori thought abstin question nair taq 3 categori small sampl size categori ask que tion control occasion quit forev 101 control occasion 146 chang goal 62 gee signific effect propen siti score χ2 8.36 df 1 004 7.67 95 ci 1.99 29.63 time χ2 6.72 df 1 01 1.14 95 ci 1.03 1.25 treatment χ2 4.50 df 1 03 1.46 95 ci 1.03 2.06 spection mean differ percentag particip chang goal time point differ experiment 15.1 control condit 14.7 signific treatment condit effect suggest stage care intervent particip endors goal complet continu abstin control particip 43.9 34.4 con vers stage care intervent particip endors goal control 41.4 contact control partici pant 50.5 hypothesi 4 support signific relationship ab stinenc bdi main inter action effect assess replic test hypothes subsampl particip diagnos mdd 307 produc result parallel report entir sampl 322 examin effect opt cessa tion treatment offer part stage care intervent abstin enrolle ce sation treatment report abstin 1 4 follow assess ment χ2 6.77 df 1 009 2.51 95 ci 1.24 5.05 48.1 enrolle 26 nonenrolle discuss smoker treatment depress help intervent integr moti vation feedback medic psy cholog intervent abstin make 1 quit octob 2006 vol 96 10 american journal public health hall al peer review research practic 1813 research practic figur 2 smoke abstin rate treatment condit figur 3 percentag particip made 1 quit attempt treatment condit cigarett baselin attempt heavier smoker stringent abstin goal intervent enhanc 3 import compon abstin intent chang attempt chang success chang index patholog bdi ii predict abstin find suggest depress symptoma tologi respons smoke inter vention independ mental health outpati smoke cessa tion program offer symptom sever popul dif ferenc condit found month 12 18 find par allel found compar intervent gener population12,15 find concert evid efficaci lack correl depress sever abstin buttress com.ibm.drl.hbcp.core conclus eman studi smoker mental health treatment depress respon sive wide implement intervent behavior respons tervent parallel found gen eral popul smoker earlier paper examin applic stage chang model sampl baselin found pattern relat ship parallel gener popula tion support conclus 32 limit limit studi sampl repres privat pai hmo mental health patient result gener public sector mental health clinic differ 2 experiment condit modest note sampl consist mental health patient express intent quit smoke gain entranc studi result directli compar studi smoker motiv quit seek addict creas potenc cessat intervent offer repeatedli american journal public health octob 2006 vol 96 101814 research practic peer review hall al research practic long term doubt increas abstin rate advis interven tion work equal individu mental health disord anxieti disord unknown col lect data comorbid disord potenti predict variabl pre enc smoker home variabl interact treatment condit unknown conclus current studi test stage care tervent base inter vention therapi outpati mental health clinic 2 import implica tion studi psychiatr patient enter smoke intervent mental health treatment al studi yield data proport elig smoker implic pare baselin treatment exce offer psychiatr clinic patient stage care intervent quit higher rate intens con trol condit author sharon hall janic tsoh judith prochaska stuart eisendrath gari humfleet juli gorecki univers california san francisco joseph rossi colleen red univers rhode island cancer prevent research center kingston ri marc meisner kaiser permanent san rafael calif time studi ami rosen univers california san francisco request reprint sharon hall phd univers california san francisco treatment research center 401 parnassu avenu box 0984 san francisco ca 94143 mail lppi.ucsf.edu articl accept januari 20 2006 contributor hall design supervis studi perform data analysi tsoh assist conceptu im plement computer system studi serv therapist prochaska assist conceptu izat studi serv therapist volv interpret data eisendrath lead clinician supervis antidepress treatment univers california san francisco site pro vide administr support rossi red de velop expert system work tsoh im plement univers california san francisco site rosen supervis implement studi site serv therapist meisner lead investig kaiser permanent hmo site provid gener clinic oversight humfleet involv conceptu provid clinic guid anc execut gorecki design plete data analys acknowledg studi support nation institut drug abus grant p50 da09253 t32 da07250 k05 da016752 author kevin delucchi constanc weisner consult clinic staff kaiser permanent northern california langlei porter psychiatr institut assist lorel hiramoto manuscript prepar edit human particip protect studi approv univers califor nia san francisco institut review board partici pant gave written inform consent
extend treatment older cigarett smoker sharon hall gari humfleet ricardo muñoz victor reu juli robbin judith prochaska univers california san francisco ca usa abstract aim tobacco depend treatment achiev abstin rate 25 30 1 year low rate reflect failur conceptu tobacco depend chronic disord aim present studi determin efficaci extend cognit behavior pharmacolog intervent smoker 50 year ag determin gender differ efficaci exist design open random clinic trial set free stand smoke treatment research clinic particip total 402 smoker 10 cigarett dai 50 year ag older intervent particip complet 12 week treatment includ group counsel nicotin replac therapi nrt bupropion particip independ smoke statu assign randomli follow condit standard treatment st treatment ii extend nrt nrt 40 week nicotin gum avail iii extend cognit behavior therapi cbt 11 cognit behavior session 40 week period iv cbt nrt combin 11 cognit behavior session 40 week nicotin gum avail measur primari outcom variabl 7 dai point preval cigarett abstin verifi biochem week 24 52 64 104 find clinic import find signific main effect treatment condit time treatment time interact cbt condit produc high cigarett abstin rate maintain 2 year studi period week 24 58 52 55 64 55 104 55 significantli effect nrt st period treatment condit significantli st effect gender found conclus extend cognit behavior treat ment produc high stabl cigarett abstin rate men women nrt add efficaci extend cbt hamper efficaci research need determin result replic sampl greater rang ag improv addit medic nrt keyword bupropion chronic disord cigarett smoke nrt older adult tobacco depend correspond sharon hall univers california san francisco 401 parnassu avenu box 0984 san francisco ca 94143 0984 usa mail lppi.ucsf.edu submit 30 juli 2008 initi review complet 24 octob 2008 final version accept 23 januari 2009 introduct goal studi evalu extend ciga rett smoke treatment program group chronic heavi smoker adult 50 year ag older studi guid concept tobacco depen denc addict chronic relaps 1,2 smoker quit time gener quit attempt fail relaps norm 3,4 addict recognit addict disord chronic relaps led servic includ treatment extend durat follow support encourag treatment entri describ usual provis servic cigarett smoker part intervent model inexpens time limit cours treatment corollari chronic disord model pharmacolog treat ment physic symptom predomin smoke serv divers function smoker weight mood regul modal preliminari version paper present annual meet societi research nicotin tobacco 21 24 februari 2007 austin tx 27 februari 1 march 2008 portland usa research report doi 10.1111 1360 0443.2009.02548 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 mailto:shal lppi.ucsf.edu overcom multipl deficit present loss function provid thirdli independ content intervent model tobacco depen denc chronic disord suggest long term treatment treatment occur life time intervent account implic model failur explain low long term cigarett abstin rate expect tobacco depend treatment 25 30 1 year combin pharmacotherapi behavior therapi 2,5 studi extend treatment litera ture earli studi assess effect extend bine nicotin replac therapi nrt versu singl modal nrt kornitz al 6 compar activ patch activ nicotin gum activ patch placebo gum placebo patch placebo gum 6 month found signific differ favor activ patch activ gum recent studi address effi caci extend bupropion administr mix result hai al treat particip 7 week open label bupropion assign randomli cigarett abstin particip 59 initi sampl activ placebo bupropion 45 week cigarett abstin significantli higher bupropion group placebo group 1 year drug therapi condit differ 2 year 7 studi group smoker treat nicotin patch calibr level cigarett intak cigarett abstin particip assign randomli activ placebo bupropion 6 month abstin rate differ condi tion 8 cox al 9 random abstin smoker treat bupropion 7 week continu bupropion remaind 1 year placebo bupropion produc higher cigarett absti nenc end medic treatment pare placebo differ 1 year follow killen al 10 treat smoker 12 week open label bupropion nicotin patch weekli relaps prevent train particip independ smoke statu offer relaps prevent session continu activ placebo bupropion addit 14 week differ abstin rate condit 1 year nortriptylin complet studi smoker assign treatment condi tion 2 2 nortriptylin versu placebo treatment versu extend treatment design partici pant extend treatment continu take drug placebo receiv monthli individu counsel se sion week 52 telephon call session week 52 found 50 cigarett abstin rate smoker extend nortriptylin counsel 1 year period 42 cigarett abstin rate 1 year receiv counsel placebo 11 exceed effect short term treat ment studi assess effect extend vareni cline administr drug enhanc abstin tonstad al 12 random abstin smoker treat 12 week vareniclin continu vareniclin treatment placebo addit 12 week continu ciga rett abstin rate higher vareniclin group placebo group week 13 24 13 52 william al 13 administ vareni cline placebo 1 year period found vareniclin superior placebo 12 52 week studi assess effect cognit behav ioral therapi cbt promot long term abstin 14 particip receiv bupropion nicotin patch cbt 8 week assign randomli receiv 12 week cbt voic mail monitor ing telephon counsel telephon base gener support investig report signific differ 20 week favor cbt condit differ 52 week signific predict gender treatment interact found histori depress treatment moder individu posit histori show respons assign intens condit summari exist data present mix pictur respect efficaci extend treatment follow up end treatment complet modest evid mainten treatment effect diffi cult interpret cigarett abstin rate studi cigarett abstin smoker continu extend treatment portion studi present studi particip continu extend treatment phase studi allow comparison cigarett abstin rate report literatur intervent direct spe cific compon relaps follow conduct 1 year end extend treatment cbt base intervent address area 2000 practic guidelin import relaps 2 select smoker 50 year ag older par ticip reason survei 15 descrip tive data random control trial conduct mid 1990 suggest older smoker long term heavi smoker depend nicotin motiv quit 15 19 older american fastest grow popul segment growth increas sheer number older smoker 20 thirdli smoke risk factor 1044 sharon hall al 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 14 major death older peopl 21 fourthli smoker physician assum quit smoke older limit benefit ag group ag group risk heart diseas stroke lung cancer declin quit 22,23 fifthli recent treatment studi older smoker random control trial tobacco depen denc intervent older smoker report lit eratur past 14 year ag 50 select definit older smoker 2000 practic guidelin 2 experiment condit standard treatment st extend nrt nrt extend cognit behavior treatment cbt extend cognit behavior treatment extend nrt combin combin hypothes propos week 24 52 64 104 cbt condit combin condit nrt condit produc higher point preval cigarett abstin rate st condit ii week 24 52 64 104 combin higher point preval cigarett abstin rate remain condit iii men women highest point preval cigarett abstin rate combin condit differ enc condit condi tion greater women men hypothesi formul public killen al 2008 paper 14 base frequent voic supposit women help social support men quit smoke 1 method procedur particip consolid standard report trial consort 24 chart fig 1 show particip recruit attrit contact program week 104 assess studi treatment approv univers california san fran cisco ucsf institut review board recruit initi particip sign written inform consent enter treatment particip 2314 individu screen telephone2314 individu screen telephon 985 invit orient meet 620 attend orient meet 518 elig agre attend pre treatment assess week 12 week 24 week 52 429 elig pre treatment assess 60 exclud medic reason 29 exclud psychiatr reason 402 random 26 decid particip 1 deceas prior random 99 extend nrt 104 extend combin 99 extend cbt 1 deceas st 94 assess 95.0 98 assess 99.0 97 assess 93.3 99 assess 100 92 assess 92.9 96 assess 97.0 99 assess 95.2 98 assess 99.0 2 deceas 1 cbt 1 nrt 90 assess 90.9 91 assess 92.9 95 assess 91.4 95 assess 96.9 92 assess 93.9 94 assess 90.4 88 assess 89.8 89 assess 89.9 week 64 week 104 87 assess 89.7 87 assess 84.5 85 assess 86.7 3 deceas 1 st 1 combin 1 nrt 84 assess 85.7 1210 inelig 119 caller termin 100 treatment figur 1 recruit follow chart st standard treatment cbt cognit behavior therapi nrt nico tine replac therapi extend treatment older cigarett smoker 1045 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 recruit advertis public servic announc flyer telephon screen particip invit orient meet complet inform consent invit baselin assess ment includ physic examin electrocardio graphic ekg blood sampl basic blood chemistri analys particip complet depress alcohol nicotin section computer diag nostic interview schedul dsm iv cdi 25 admin ister research staff particip 50 year ag smoke 10 cigarett dai exclusionari criteria includ cardiovascular diseas histori seizur sever allergi life threaten diseas life time bipolar disord current major depress disord mdd current psychiatr medic suicid psy chotic symptom treatment drug alcohol 6 month psychiatr hospit 1 year pregnanc lactat hundr particip complet base line test screen consent particip particip di week 5 random reduc sampl random 402 death occur studi death unrel studi procedur mean ag 56.7 year standard deviat sd 5.87 mean year regular smoke 37.8 sd 8.23 mean number cigarett smoke dai 20.5 sd 8.72 mean score fagerström test nicotin depend ftnd 4.8 sd 2.1 women compris 40 sampl caucasian compris 76.9 divid equal marri live partner 42.5 separ divorc widow 39.7 12.1 high school graduat 35.5 colleg 30.5 colleg graduat 21.9 graduat degre term diagnosi 21.1 histori mdd 63 diagnosi life time nicotin depend 38.6 diagnosi life time nicotin withdraw 18.1 diagnosi life time alcohol depend variabl marit statu marri live partner versu significantli condit marit statu correl cigarett abstin assess week 8 402 particip stratifi gender histori mdd posit histori mdd versu current cigarett abstin statu assign randomli experiment condi tion computer alloc list project statistician ms robbin contact particip assign individu particip subject number transmit electron clinic staff condit differ percentag partici pant collect smoke data week 12 24 52 64 104 determin com.ibm.drl.hbcp.predictor attrit assess due low attrit rate rate suffici low attrit bia concern week 12 3.2 week 24 4.0 week 52 7.0 week 64 9.0 week 104 13.4 assess data collect baselin week 12 24 52 64 104 particip contact assess independ con tinu treatment particip paid 25.00 complet assess week 12 24 52 64 104 biochem verifi 7 dai point preval absti nenc cigarett report cigarett abstin smoke puff expir air carbon monoxid level 10 part million p.p.m anatabin anabasin level 2 mg ml primari depend variabl anatabin ana basin alkaloid present tobacco present nicotin medic measur concentr alkaloid detect tobacco peopl treat nrt 26 cotinin verif product nicotin tobacco nrt anatabin anabasin assai partici pant report level consist ciga rett abstin particip code abstin anatabin anabasin assai fell cut point 27 administ questionnair assess gender educ ethnic marit statu profil mood state pom 28 measur treatment partner support quit adapt mermelstein 1983 29 ftnd 30 measur drug alcohol develop thought abstin questionnair 31 medic outcom scale short form sf 36 32 geriatr depress scale 33 perceiv stress scale 34 treatment condit standard treatment st particip provid 12 week sustain releas bupropion 10 week 2 mg 4 mg nico tine gum receiv counsel base clear hori zon 35 manual design origin aid smoker 50 year ag coun selor guid smoker step quit particip guid possibl ag relat slower drug clearanc 1046 sharon hall al 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 account modifi standard bupropion dose pro tocol dose 150 mg dai week advers effect note dose increas 300 mg week remain rest 12 week period bar advers event period particip provid 10 week nicotin gum begin quit date week 3 particip smoke 25 cigarett dai receiv 6 week 4 mg gum 4 week 2 mg gum particip smoke 25 cigarett dai receiv 10 week 2 mg gum 12 piec dai report withdraw symptom 4 mg gum week 8 meet par ticip instruct begin taper gum taper complet week 12 particip receiv group counsel session held week 1 3 se sion immedi quit date 5 8 par ticip assign st receiv treatment week 12 extend nrt nrt condit provid evid efficaci cost effect long term nrt relaps prevent strategi bupropion nrt counsel ing provid 12 week provid st particip taper nrt nrt week 52 particip receiv instruct week 8 oral counselor write nicotin gum extend treatment period counsel provid remaind studi specif particip instruct shelf nicotin gum urg smoke occur extend nrt extend bupropion concern accumul bupropion older individu 36 long term clinic trial older patient publish studi initi cbt bupropion nrt group counsel provid 12 week treatment st con dition cbt intervent base cognit behavior model content area 2000 practic guidelin recommend relaps prevent motiv social support dysphoria depend withdraw weight gain 2 version inter vention tailor older smoker design direct coach instruct therapist motiv motiv compon intervent identifi cue elicit motiv decision balanc chart emphas benefit quit cost smoke particip make repeat commit cigarett abstin signific ii mood manag particip receiv administ mood manag guid materi chart number cigarett smoke number pleasant activ mood level distribut 37,38 particip instruct increas pleasant activ note correspond activ mood mood number cigarett smoke idea increas pleasant activ provid iii weight control physic activ control weight decreas depress 39,40 goal activ program particip complet 30 minut moder exercis dai week particip receiv pedomet form pro vide record time spent activ assess pedomet studi counselor convert step esti mate goal 10 000 step dai corr spond public health activ guidelin 30 minut moder physic activ dai 41 sequent session devot assist particip gradual increas activ order reach goal computer graph feedback counselor encourag iv social support social support intervent includ manag current support network build larger smoke network determin smoke statu network member identifi support cessat smoke infor mation particip counselor practis method elicit posit support handl nega tive support provid particip list group activ develop commun sourc internet withdraw depend counselor alert report symptom crave weight gain work particip develop strategi deal emerg symptom remind par ticip strategi taught interven tion help prevent emerg symptom eleven individu extend treatment session provid group session includ st protocol week 10 52 time session frequent earli extend treatment period increas gradual studi 2 week week 10 16 4 week week 20 36 8 week week 44 52 session last 20 40 minut copi extend treatment older cigarett smoker 1047 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 treatment manual senior author extend cbt extend nrt combin bupropion nrt group counsel provid 12 week treatment st con dition relaps prevent intervent ident provid cbt condit nrt parallel nrt condit nrt reinforc counselor counselor train monitor counselor train dr humfleet muñoz clinic psychologist initi train consist read studi manual observ individu treat cohort particip couns lor observ cohort dr humfleet dr muñoz project coordin counselor met weekli dr humfleet muñoz review previou week session review progress clinic difficulti handl therapeut issu effect theoret confin studi address meet statist method plan sampl size base primari hypothesi test differ 7 dai point preval cigarett abstin rate week 24 104 estim effect size hall al 42 factor anticip attrit rate gener iz estim equat gee test hypothesi point preval cigarett abstin follow period power analys base method analysi power set 80 type error rate 0.05 method rochon 43 sa version 9.1 analys 44 ensur random compro mise compar experiment condit baselin variabl tabl 1 analysi vari anc anova continu variabl pearson c2 test categor variabl identifi potenti cova riat correl baselin variabl point preval cigarett abstin week 12 24 52 64 104 includ preliminari hypothesi test model variabl signific correl cigarett abstin variabl elimi nate contribut significantli final model differ number dai studi nrt test analysi varianc differ condit studi pre scription medic studi nrt assess determin pearson c2 analysi categor variabl test tail result cigarett abstin anatabin anabasin correct cigarett absti nenc rate treatment condit assess ment tabl 1 shown graphic fig 2 initi analys covari reveal ftnd score ag number year regular smoke ethnic social particip score pom total score baselin variabl correl signifi cantli outcom baselin variabl enter covari full gee model ing variabl treatment condit time po sibl interact treatment condit interact treatment condit covari ag number year regular smoke ethnic hispan caucasian versu social particip score pom total score contribut signifi cantli drop final model signific main effect found treatment condit c2 3 402 8.12 0.0435 time c2 1 402 48.78 0.0001 baselin ftnd c2 1 402 19.45 0.0001 ag c2 1 402 3.91 0.0481 tabl 1 number percentag abstin cigarett treatment condit treatment condit week 12 24 52 64 104 week 12 week 24 week 52 week 64 week 104 st 59 63 50 54 30 33 30 34 31 36 cbt 63 64 56 58 50 55 48 55 46 55 combin 64 66 58 59 46 48 48 51 39 45 nrt 62 63 55 56 39 41 42 46 35 40 st standard threatment cbt extend cognit behavior treatment nrt extend nicotin replac therapi combin extend cognit behavior treatment extend nrt combin 1048 sharon hall al 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 signific interact treatment time c2 3 402 8.35 0.0392 treatment ftnd score c2 3 402 8.17 0.0427 respect main effect treatment younger ag lower ftnd score greater probabl cigarett abstin interact ftnd score treatment reflect consist neg correl ftnd score cigarett abstin st combin condit relationship cbt nrt condit test individu hypothes follow hypothesi 1 period week 24 52 64 104 cbt condit combin condit nrt con dition produc higher point preval cigarett abstin rate st condit hypothesi partial support cbt condit signifi cantli higher cigarett abstin rate st odd ratio 1.27 95 confid interv ci 1.52 1.05 0.0122 nrt 1.22 95 ci 1.45 1.03 0.0211 time nrt c2 1 402 0.37 0.7104 combin c2 1 402 0.73 0.4683 differ significantli st hypothesi 2 period week 24 52 64 104 combin higher point preval cigarett abstin rate remain condit contrari predict cbt effect combin 1.18 95 ci 1.40 0.99 0.0618 differ enc achiev tradit level signific note combin significantli effect st effect nrt c2 1 402 0.38 0.7031 hypothesi 3 men women highest point preval cigarett abstin rate combin condit differ condit condit greater women men main interact effect gender studi medic nrt signific differ treatment group studi medic consid adjunct tobacco depend treatment i. bupro pion nortriptylin vareniclin assess rate report low week 12 0.8 week 24 3.1 week 52 4.2 week 64 5.2 week 104 8.4 number dai studi provid nrt nrt condit significantli higher 85 31 sd 103.62 combin condit 48 23 sd 78.74 1,201 8.21 0.0046 cbt condit report minim number dai studi nrt week 12 52 1 33 sd 10.1 st condit 1 22 sd 7.73 differ observ indic behavior techniqu extend treatment condit extend treatment condi tion differ significantli number coun sele session attend xrp 5 5 xrp nrt 5 9 pedomet part physic activ compon cbt 42.2 combin 50 discuss import find studi high stabl cigarett abstin rate produc cbt condit rate strikingli higher report recent literatur impor 0 10 20 30 40 50 60 70 80 90 100 week 12 week 24 week 52 week 64 week 104 assess week er ce ta st en st cbt combin nrt figur 2 carbon monoxid anatabin anabasin correct abstin rate treatment condit week 12 24 52 64 104 extend treatment older cigarett smoker 1049 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 tant cigarett abstin rate main tain 1 year end extend treatment critic question due content intervent aim provid skill maintain abstin result due continu long term support question resolv control group equival time cbt treatment content result maintain end treatment suggest content thera peutic contact plai import role outcom expect specif portiv content provid skill result cigarett abstin withdrawn find ing differ killen al 14 found 12 week extend cbt facilit abstin long term follow present studi killen differ extend intervent differ length 40 week present studi 12 killen al studi content ag subject sampl addit work need determin variabl result differ studi import find failur ad nrt cbt increas cigarett abstin rate reason lack increas cigarett abstin clear avail pharmaceu tical adjunct particip attent cognit behavior intervent skill provid learn combin particip attribut abil quit nrt newli acquir skill 45 nrt modest condit avail significantli dai nrt condit combin condit argu low rate nrt combin condi tion render comparison combin cbt tent combin condit fare nrt higher condit consid term clinic com.ibm.drl.hbcp.util rememb lower rate reflect particip chose nrt context condit find accur reflect efficaci cbt combin condit present studi nrt increas cigarett abstin rate provid extend period time consist grow literatur suggest nrt effect increas increas durat 46 strength studi includ larg sampl size manual treatment model driven intervent biochem verif assai limita tion studi includ generaliz popula tion treat educ particip research attend multipl treatment session predominantli caucasian read speak english expect lower ftnd score baselin predict cigarett abstin younger ag predict cigarett abstin suggest difficult oldest smoker quit smoke interact ftnd score treatment condit puzzl due chanc find larg scale tobacco abstin treatment studi anatabin anabasin assai biochem verif studi assai modest effect outcom 905 assai complet 17 chang function anatabin anabasin analys vari treatment condit st nrt cbt combin present studi suggest cost obtain urin assai weigh carefulli increas accuraci provid older smoker rapidli increas segment popul gener neglect smoke treatment intervent set 50 year ag lower limit recruit mean ag smoker studi 56 year ag younger anticip studi initi partici pant studi substanti older individu al particip recent publish clinic trial averag ag 38.6 year 11 high cigarett abstin rate obtain current studi suggest provis smoke treatment servic older adult effici valuabl health care resourc suggest extend intervent studi gener popul smoker simpli 50 year ag argu intens extend treat ment preclud adopt wide due constraint impos insur compani restrict provid time cost provid ing long term treatment cardiovascular diseas cancer emphysema consid cost extend tobacco abstin treatment trivial clinic trial registr clinic trials.gov nct00086385 http www clinicaltrials.gov declar interest acknowledg public made grant number r01 da02538 k05 da016752 k23 da018691 1050 sharon hall al 2009 author journal compil 2009 societi studi addict addict 104 1043 1052 http www p50 da 09253 content sole respons author necessarili repres offi cial view nih nida author dr kevin delucchi univers california san francisco statist consult wynni wong help data analysi jennif morri manu script prepar dr ronald pilato clinic contribut
extend cognit behavior treatment medic treat depend smoker sharon hall phd gari humfleet phd ricardo muñoz phd victor reu md judith prochaska phd mph juli robbin ma research clinician expect low rate long term cigarett abstin sequent tobacco depend treatment 25 1 year binat therapi 1,2 low rate attribut failur conceput tobacco depend addict chronic laps implic chronic diseas model suggest longer tend cours tobacco depend treatment result higher long term cigarett absti nenc rate studi examin efficaci extend administr sustain releas bupropion bupropion sr hai al treat particip 7 week open label bupropion sr randomli assign cigarett abstin particip 59 sampl activ placebo bupropion sr addit 45 week cigarett absti nenc significantli higher activ drug condit 55.1 placebo drug condit 42.3 1 year therapi condit differ 2 year follow 41.6 activ drug 40.0 placebo 3 studi smoker treat nicotin patch calibr dividu cigarett intak abstin particip 31 sampl randomli assign activ placebo bupropion sr 6 month abstin rate differ condit 6 month 25 placebo 28 activ drug 4 cox al 5 random abstin smoker treat 7 week bupropion sr continu bupropion sr remaind 1 year placebo activ drug produc greater cigarett abstin end treat ment compar placebo 55.89 43.58 differ 1 year follow 42.34 42.95 appear extend bupropion sr pro vide increas abstin rate administ effect lost medic termin extend administr vareniclin studi william al administ vareniclin placebo 1 year found vareniclin superior placebo 12 week 76.5 72.2 52 week 37.8 34.1 6 tonstad al 7 ran domiz abstin smoker treat 12 week vareniclin continu vareniclin placebo addit 12 week continu cigarett absti nenc rate higher vareniclin group placebo group week 13 24 70.5 49.6 weeks13 52 43.6 36.9 ther apeut effect extend vareniclin past period administr earlier work group studi extend administr nortriptylin assign smoker 1 4 treatment condit 2 2 factori design nortriptylin placebo treatment extend treatment partic ipant extend treatment continu take drug placebo receiv monthli indi vidual counsel session week 52 week 52 abstin rate 56 extend nortriptylin 57 extend placebo condit produc abstin rate exceed short term treat ment studi investig effect extend cognit behavior treatment cbt killen al 8 treat smoker 12 week open label bupropion sr nicotin patch weekli relaps prevent train particip independ smoke statu offer 4 relaps prevent session continu activ placebo drug addit 14 week dif ferenc abstin rate condit at1year study9 particip receiv bupropion sr nicotin patch cbt 8 week randomli assign receiv 12 week cbt voicemail monitor telephon counsel tele phone base gener support investig report signific differ 20 week 45 29 52 week 31 27 recent studi 402 peopl smoke 10 cigarett dai object evalu smoke cessat efficaci extend sustain releas bupropion bupropion sr cognit behavior treatment cbt method particip smoke 10 cigarett dai smoke 30 minut aris 406 complet 12 week smoke cessat treatment includ group counsel nicotin replac therapi bupropion sr particip randomli assign 1 5 condit 1 treatment 2 activ bupropion sr 40 week 3 placebo 40 week 4 activ bupropion sr 11 session cbt 40 week cbt 5 placebo 11 session cbt 40 week particip assess baselin week 12 24 52 64 104 result cbt superior 3 extend treatment week 12 104 extend treatment condit superior standard treatment week 64 104 2 cbt condit produc significantli higher abstin rate 3 condit conclus contact provid increas abstin treatment cbt increas long term abstin extend treatment termin public health 2011;101 2349 2356 doi 10.2105 ajph 2010 300084 research practic decemb 2011 vol 101 12 american journal public health hall al peer review research practic 2349 50 year older 10 complet 12 week treatment includ group coun sele nicotin gum bupropion sr randomli assign 1 4 follow condit 1 standard treatment treatment 2 extend nicotin replac therapi nrt 40 week nicotin gum avail 3 extend cbt 11 cognit havior session 40 week period 4 extend cbt extend nrt 11 cbt session 40 week nicotin gum avail abil extend cbt condit produc high cigarett abstin rate main tain 2 year studi period week 24 58.3 week 52 55.0 week 64 54.6 week 104 54.8 extend cbt condit significantli effect extend nrt standard treatment period treatment condit significantli standard treat ment find suggest extend cbt produc high stabl cigarett abstin rate medic plai major role maintain abstin combin cbt current studi evalu cbt intervent similar hall al 10 evalu efficaci long term bupropion sr versu placebo propos hypothes 1 assess baselin activ bupropion extend cbt cbt condit produc higher point preval abstin rate placebo extend cbt cbt placebo activ bupropion standard treatment primari hypothesi 2 assess end extend treatment 2 condit includ cbt combin activ placebo bupropion produc abstin rate superior produc 3 condit includ cbt method activ versu placebo bupropion sr cross extend cbt versu medic manag 2 2 factori design 4 condit compar standard 12 week treatment sessment conduct baselin week 12 24 52 64 104 design summar figur 1 particip particip recruit advertis public servic announc flyer cruitment began februari 2003 end novemb 2005 telephon screen particip invit orient meet sign written state ment inform consent invit baselin assess includ physic examin ekg blood draw basic blood chemistri analys par ticip complet depress alco hol nicotin section computer diagnost interview schedul dsm iv 11 administ research staff research activi ti place univers california san francisco individu elig particip ag 18 year smoke 10 cigarett dai smoke 30 minut aris exclusionari criteria includ cardiovascular diseas histori seizur sever allergi life threaten di eas lifetim bipolar disord current major depress disord current psy chiatric medic suicid psychot symptom treatment drug alcohol prior 6 month psychiatr hospi taliz prior year pregnanc lactat total 407 particip consent particip complet test screen ing particip di randomiza tion treatment condit remain 406 particip randomli assign 1 5 experiment condit stratif variabl cigarett dai gender smoke statu week 12 assess data collect baselin week 12 24 52 64 104 particip con tact assess continu treatment particip paid 25 assess complet week 12 24 52 64 104 complet assess ment receiv bonu 50 week104 primari depend variabl bio chemic verifi 7 dai point preval abstin cigarett report abstin expir air carbon mon oxid level 10 ppm lower urinari cotinin level 60 ng ml lower 12 administ standard demo graphic questionnair profil mood state pom 13 fagerström test nico tine depend measur drug alcohol develop author thought abstin questionnaire14,15 social particip index size respond social network center epidemiolog studi depress scale16 minnesota nicotin withdraw question nair 17,18 measur identifi covari assess treatment attend studi medic nonstudi prescript medic approv treatment nicotin depend nonstudi nrt tobacco product e.g cigar snu smokeless tobacco analyz effect blind procedur particip thought receiv bupropion placebo 6 respons option 1 absolut receiv bupropion 2 pretti good idea receiv bupropion 3 receiv bupropion 4 absolut receiv placebo 5 pretti good idea receiv placebo 6 receiv placebo standard treatment condit particip provid 12 week worth bupropion sr 10 week worth nicotin patch receiv counsel base standard treatment author earlier studi 1 bupropion sr dose 150 milligram dai days1 3 300 milligram dai dai 4 7 week treatment advers effect patient continu 300 milligram dai remaind 12 week period advers effect occur week dose reduc 150 milligram dai remaind 12 week period partic ipant provid 10 week worth nicotin patch begin quit date research practic 2350 research practic peer review hall al american journal public health decemb 2011 vol 101 12 week 3 group counselor instruct particip nicotin patch particip smoke 25 cigarett dai receiv 6 week 21 milligram patch 4 week 14 milligram patch particip smoke fewer 25 cigarett dai receiv 10 week 7 milligram patch week 11 meet particip instruct discontinu patch week 12 particip receiv 5 group counsel session held week 1 3 2 session held week 3 1 quit date 1 immedi 5 11 particip assign standard treatment st condit receiv treatment week 12 extend treatment condit drug activ placebo bupropion 12 week standard treatment particip random activ drug placebo extend treatment condit receiv activ placebo drug week 52 activ placebo condit particip 2 ident appear capsul dai particip met monthli nurs practition studi clinic approxim 5 to10 minut check side effect report smoke statu activ drug dose 300 milligram dai patient extend treatment period dosag reduc to150 milligram dai initi 12 week remain dose durat studi condit particip termin drug reason includ lack proven efficaci particip percept stabl abstin achiev drug longer need cognit behavior treatment eleven indi vidual extend cbt session provid weeks12 52 space frequent earlier extend treatment period 2 week week 12 20 4 week week 20 52 session 20 40 minut long 5 session introduc content remain ing 6 session reinforc materi learn provid support ap propriat particip smoke statu counselor complet telephon check in counsel session particip midwai face face meet cbt content area evid base recommend relaps prevent contain public health servic 2000 practic guidelin treat tobacco depend 1 content area motiv social support dysphoria depend withdraw weight gain detail descript cbt intervent present hall al 10 briefli motiv compon intervent focus provid cue elicit motiv smoker decision balanc chart emphas posit effect quit cost smoke particip remind continu commit abstin make commit signific social support compo nent 2 part manag current port network attempt build larger nonsmok network suggest particip activ includ larger popul nonsmok provid direct interven tion depress mood develop basi earlier work 19,20 administ mood manag guid partici pant instruct increas pleasant activ note correspond pleasant activ mood note correspon denc mood number cigarett smoke idea increas pleasant activ provid respect withdraw symptom counselor work particip develop strategi deal emerg note cbt activ cognit behavior treatment activ medic manag nrt nicotin replac therapi cbt placebo cognit behavior treatment placebo medic manag st standard treatment figur 1 design studi evalu smoke cessat treatment san francisco ca februari 2003 novemb 2007 research practic decemb 2011 vol 101 12 american journal public health hall al peer review research practic 2351 symptom address weight control increas physic activ attempt restrict calori smoke cessat intak shown increas probabl relaps 21 goal activ program particip complet equival 30 minut moder exercis dai week particip studi provid pedomet goal 10000 step dai correspond public health activ guidelin 30 minut moder physic activ dai medic manag particip medic manag condit receiv behavior intervent extend treatment period meet monthli nurs practition report side effect smoke statu counsel offer visit statist method sampl size determin basi requir impli primari hy pothesi test differ 7 dai point preval abstin rate week 12 through104 power set 80 type error rate 0.05 estim effect size hall al 22 factor anticip attrit rate gener estim equat gee gener classic linear model quasi likelihood estim test hypothes 7 dai point preval abstin week 12 24 52 64 104 base power analys method analysi sa version 9.1.3 sa institut cari nc analys 23 analys includ data identifi potenti covari corr late baselin variabl point prev alenc abstin week 12 24 52 64 104 point biseri correl includ preliminari hypothesi test model variabl signific correl abstin variabl elimin contribut final model ensur random compromis examin baselin variabl 5 experiment con dition analysi varianc anova continu variabl pearson c2 test categor variabl sig nific differ condit 28 variabl 1 anova test differ number week bupropion placebo drug extend treat ment condit differ 5 condit nonstudi prescript medic nonstudi nrt assess determin pearson c2 analysi categor vari abl belief drug receiv test 6 2 c2 test belief drug categori cross actual drug test analys 2 tail result demograph smoke psychiatr characterist particip baselin experiment condit shown tabl 1 attrit consort flow diagram figur 2 show particip recruit attrit contact program week 104 assess percentag particip successfulli collect smoke data week 12 24 52 64 104 differ significantli treatment condit assess week 104 attrit suffici small week 12 1.7 week 24 3.4 week 52 7.1 week 64 9.3 week 104 16.2 creation pattern mixtur model feasibl week 104 signific differ attrit rate treatment condit week 104 data variabl significantli corr late attend correl abstin statu assess abstin hypothesi 1 activ bupropion extend cbt condit higher abstin rate 4 condit assess hypothesi port initi analys covari pom total score number cigarett smoke dai gender eth niciti baselin significantli correl main abstin outcom weeks12 104 variabl enter covari gee model con tain variabl treatment condit time treatment time interact interact gender treatment ethnic treatment contribut significantli drop final model cigarett dai pom total score retain final model includ cigarett dai pom total score covari treatment condit time interact treatment condit covari signific effect found treatment condit c2 4 406 9.69 046 time odd ratio 0.764 week 95 confid interv ci 0.715 0.817 001 cigarett smoke dai 0.951 pom total score treatment interact 0.983 1 point increas 95 ci 0.967 0.999 037 cbt condit significantli higher abstin rate st condi tion time 13.97 95 ci 3.03 64.37 001 significantli dif ferent compar remain 3 treatment condit 3 extend condit produc higher abstin rate time st condit placebo cbt cbt 7.22 95 ci 1.80 29.00 005 activ 10.30 95 ci 2.56 41.45 018 placebo 7.06 95 ci 1.40 35.62 001 cbt condit produc consist high absti nenc rate week 24 49.4 52 40.5 64 40.6 104 47.6 dai biochem correct point preval abstin rate condit shown figur 3 fewer cigarett dai predict absti nenc high pom total mood disturb score st condit correl abstin week 52 abstin week 12 abstin week 104 cbt hypothesi 2 end extend treatment 2 condit includ cbt produc superior abstin rate produc 3 condit includ cbt hypothesi support hy pothesi 2 elimin covari contribut model social particip score retain final model includ social particip score time treatment condit social particip score treatment condit teract gee model point research practic 2352 research practic peer review hall al american journal public health decemb 2011 vol 101 12 preval abstin week 64 104 signific effect found cbt versu cbt 1.54 95 ci 1.05 2.26 029 social particip score baselin 1.15 1 point increas 95 ci 1.02 1.30 023 receiv extend cbt week 12 52 associ at higher probabl abstin week 64 104 higher social particip score counsel session bupropion 2 cbt condit significantli differ mean number counsel session attend cbt 4.2 sd 3.8 cbt 5.0 sd 3.7 1 163 1.84 176 attend counsel session correl significantli abstin statu week 52 0.384 001 104 0.397 001 cbt condit week 52 cbt condit 0.303 007 cbt content provid 5 session addit session extend treatment reinforc content support abstin 83 particip cbt condit 34 41.0 attend 5 session 39 80 48.8 cbt condit differ signific c2 1 163 1.00 318 differ treat ment condit number week studi drug prescrib cbt 20.4 sd 15.0 cbt 18.3 sd 17.0 18.8 sd 13.7 17.2 sd 13.6 4 condit consid separ anova 1 323 0.65 586 compar particip receiv activ drug placebo drug extend treatment activ 19.6 sd 14.4 placebo 17.7 sd 15.4 anova 1 324 1.25 264 nonstudi medic signific differ treatment group nonstudi medi cation smoke cessat properti i. bupropion nortriptylin vareniclin assess rate report low week 12 0.6 week 24 2.8 week 52 6.5 week 64 10.5 week 104 11.0 signific differ nonstudi nrt treatment group point cbt particip report highest percentag week 24 8.8 week 52 12.7 week 64 19.3 effect blind procedur week 104 particip receiv activ placebo drug differ belief drug ceiv function actual drug assign c2 5 152 2.35 812 receiv placebo 65.3 believ receiv bupropion receiv bupropion 64.9 believ receiv bupropion c2 1 perceiv drug assign ment signific predict perceiv help medic particip effort quit smoke c2 3 150 23.7 001 actual drug assign tabl 1 baselin variabl studi popul adult smoker san francisco ca februari 2003 novemb 2007 variabl mean 6sd continu particip 406 ag 40.7 69.8 ag start smoke regularli 17.8 64.5 year regular smoke 22.9 610.1 cigarett smoke 19.0 67.4 carbon monoxid ppm 21.6 611.3 fagerström total score 4.9 62.1 center epidemiolog studi depress scale 7.7 66.1 profil mood state total score 21.9 629.2 mo sf 36 physic compon score 50.6 67.9 mo sf 36 mental compon score 48.8 68.9 perceiv stress scale 20.7 67.6 minnesota nicotin withdraw scale crave score 2.7 60.9 withdraw score 6.0 65.4 michigan nicotin reinforc questionnair posit reinforc score 7.9 62.9 neg reinforc score 12.5 64.8 categor posit dsm iv diagnos histori mde 113 28.0 nicotin depend 324 80.4 nicotin withdraw 208 51.7 alcohol depend 89 22.1 femalea 159 39.2 white hispan 281 69.7 educ level achiev high school graduat 64 16.0 colleg 156 39.1 colleg graduat graduat school 135 31.3 graduat degre 54 13.5 marri live partner 152 37.9 note dsm iv diagnost statist manual mental disord fourth edit mde major depress episod mo sf 36 medic outcom studi short form 36 item questionnair percentag total 100 round afour particip report transgend 2 request random male 2 request random femal research practic decemb 2011 vol 101 12 american journal public health hall al peer review research practic 2353 signific com.ibm.drl.hbcp.predictor perceiv help c2 3 149 1.34 727 discuss hypothesi cbt condi tion produc highest abstin rate week 24 104 support cbt result significantli higher abstin rate st produc significantli higher rate cbt hypothesi week 52 104 2 extend treatment condit produc higher abstin rate remain 3 condit support result present interest pictur long term mainten strategi hand extend treatment pro duce long term abstin rate standard treatment differ implic find intrigu cbt differ suggest simpl period check in effect activ drug coun sele fact differenti cost 2 intervent consider avail placebo drug complic interpret result drug offer particip attend session result differ obtain import blind studi appear maintain cbt effi caciou maintain abstin treat ment termin find temper fact effect evid cbt condit cbt con dition week 104 difficult explain addit medic cbt enhanc abstin current studi earlier studi particip older 50 year 2 studi differ sampl characterist class drug provid examin abstin data smoker older 50 year current studi subsampl cbt effect medic manag treatment gardless combin activ drug placebo find close parallel earlier find particip older 50 year suffici focus motiv quit smoke make expend effort learn skill present cbt session fa vorabl outcom cbt treatment termin extend cbt superior intervent includ cbt suggest primari prem is cbt particip tool manag smoke correct inspect data suggest effect result primarili effect activ cbt condit fairli sizabl literatur efficaci extend treatment note earlier result mix favor result occur studi particip includ extend treatment achiev abstin end initi treatment period find suggest extend treatment work recruit note cbt activ cognit behavior treatment activ medic manag cbt placebo cognit behavior treatment placebo medic manag figur 2 recruit follow evalu smoke cessat treatment san francisco ca februari 2003 novemb 2007 research practic 2354 research practic peer review hall al american journal public health decemb 2011 vol 101 12 individu laps laps back abstin maintain abstin hand studi found effect extend treatment provid counsel 2 pharmacolog intervent initi treatment period find sug gest extend treatment effica ciou provid strong foundat abstin intervent cbt session medic modest approxim 40 partici pant attend session ceiv cbt content particip request medic prescript half time period underutil particip abil determin longer intervent success fulli termin activ involv question offer long term treatment cigarett smoker increa ingli import proport popul smoke shrink po tential chronic depend inter vention differ cost effect studi resolv issu contribut public health import step develop modal provid intervent feasibl larger proport smoke popul adapt content internet intervent plete onlin combin internet modal modal telephon intervent requir travel time part particip import step determin subpopul smoker provid cost effect match extend multimod intervent intervent possibl particip fail achiev prolong abstin shorter unimod treatment intervent current studi accept particip smoke 10 cigarett dai report smoke 30 minut aris criteria establish work definit depend smoke intervent equal benefici lighter smoker evid physic depend question resolv analys larger data set accru singl studi secondari analys data varieti sourc author author depart psychiatri uni versiti california san francisco correspond sharon hall phd depart psychiatri univers california san francisco 401 parnassu av box 0984 san francisco ca 94143 mail sharon.hal ucsf.edu reprint order http www.ajph.org click reprint eprint button articl accept novemb 22 2010 contributor hall supervis conduct studi humfleet supervis dai dai oper studi collabor muñoz design supervis clinic intervent reu medic respons led design impl mentat pharmacolog intervent pro chaska contribut studi design collabor g.l humfleet muñoz design clinic intervent robbin respons data analysi acknowledg studi support nation institut drug abus award r01 da02538 k05 da016752 k23 da018691 p50 da09253 author kevin delucchi stati tical consult jennif morri articl prepar ronald pilato clinic contribut melissa bartman statist analysi note content sole respons author necessarili repres offici view nation institut drug abus nation institut health human particip protect studi protocol approv univers california san francisco institut review board particip provid written inform consent
ngl na dic engl med 372;22 nejm.org 28 20152108 depart medicin s.d.h d.a.a k.g.v biostatist epidemiolog s.d.h b.f k. m.o.h medic ethic health polici s.d.h k.g.v psychiatri j.a center health incent behav ioral econom leonard davi stitut health econom s.d.h b.f d.s. k. j.a g.l d.a.a k.g.v perelman school medicin uni versiti pennsylvania depart statist d.s. health care manag d.a.a k.g.v wharton school univers pennsylvania cen ter health equiti research pro motion philadelphia veteran affair medic center d.a.a k.g.v center health care innov uni versiti pennsylvania health system d.a.a k.g.v philadelphia center behavior decis research carnegi mellon univers pittsburgh g.l cv caremark woonsocket ri t.a.b address reprint request dr halpern perelman school medicin univers pennsylvania 719 blocklei hall 423 guardian dr phila delphia pa 19104 6021 shalpern exchang upenn articl publish 13 2015 nejm.org engl med 2015;372 2108 17 doi 10.1056 nejmoa1414293 copyright 2015 massachusett medic societi background financi incent promot health behavior effect wai deliv health incent remain uncertain method randomli assign cv caremark employe rel friend incent program usual care smoke cessat incent program target individu target group partici pant individu orient program group orient program entail reward approxim 800 smoke cessat oth er entail refund deposit 150 650 reward payment success ful particip usual care includ inform resourc free smoke cessat aid result 2538 particip enrol assign reward base pro gram 90.0 accept assign compar 13.7 assign deposit base program 0.001 intent treat analys rate su tain abstin smoke 6 month higher incent program rang 9.4 16.0 usual care 6.0 0.05 comparison superior reward base program sustain 12 month group orient individu orient program sociat similar 6 month abstin rate 13.7 12.1 0.29 reward base program higher abstin rate deposit base program 15.7 10.2 0.001 instrumen tal variabl analys account differenti accept rate absti nenc 6 month 13.2 percentag point 95 confid interv 3.1 22.8 higher deposit base program reward base program estim 13.7 particip accept particip type program conclus reward base program commonli accept deposit base program lead higher rate sustain abstin smoke group orient incent program effect individu orient program fund nation institut health cv caremark clinicaltrials.gov number nct01526265 bs tr ac random trial financi incent program smoke cessat scott halpern m.d ph.d benjamin french ph.d dylan small ph.d kathryn saulsgiv ph.d michael harhai m.p.h janet audrain mcgovern ph.d georg loewenstein ph.d troyen brennan m.d j.d david asch m.d m.b.a kevin volpp m.d ph.d origin articl england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 2015 2109 financi incent progr am smoke cessat financi incent shown promot varieti health behavior 1 8 random clinic trial involv 878 gener electr employe bundl incent worth 750 smoke cessat tripl quit rate 5.0 14.7 8 led program adapt gen eral electr u. employe 9 centiv program increasingli gov ernment employ insur motiv health behavior 10,11 design base tradit econom sumption size incent deter mine effect contrast behavior econom theori suggest incent similar size effect de pend design 12 deposit commit con tract particip put monei risk recoup suc cess chang behavior varieti onlin employ base behavior chang program peopl typic motiv avoid loss seek gain 13 deposit contract success reward program make deposit deter peopl particip effect deposit reward program pare 14,15 incent target group effect incent target individu peopl strongli motiv social comparison 16 18 collabor incen tive payment success group member increas success group add dimens interperson ac countabl teamwork 19 competit de sign pari mutuel scheme monei deposit group member chang behavior distribut group member amplifi peopl aver sion loss highlight regret feel benefit failur chang 20,21 evalu incent program smoke cessat base ward deposit contract deliv er individu group level compar intervent measur accep tanc defin proport peopl accept incent program offer effect assess proport peopl offer program stop smok ing efficaci assess proport peopl stop smoke accept incent program thod trial design conduct group random con troll trial compar usual care centiv program aim promot sustain abstin smoke protocol avail full text articl nejm.org approv institut review board univers pennsylvania au thor vouch accuraci complet data fidel studi protocol studi popul multifacet recruit scheme fig s1 supplementari appendix avail nejm.org enrol cv caremark em ploye rel friend unit state elig particip 18 year ag report smoke 5 ciga rett dai internet access indi cate interest learn wai stop smoke recruit occur februari 2012 octob 2012 health web base research portal creat studi 22 particip open account electron sign inform consent document complet baselin questionnair particip told paid complet questionnair submit sampl confirm smoke abstin studi test wai provid financi incent pro mote cessat dissuad nonsmok enrol inform potenti particip randomli screen baselin smoke random particip learn detail assign intervent ask accept declin intervent chose target quit date 1 90 dai enrol select random sampl 5 enrol particip undergo baselin cotinin screen offer 100 complet cotinin assai quick summari nejm.org england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 20152110 ngl na dic random intervent particip randomli assign indi vidual basi group fig 1 ran domiz stratifi di chotom variabl particip full health care benefit cv caremark annual household incom 60,000 cv caremark workforc median 60,000 develop adapt random algorithm23 26 date assign probabl group enrol particip updat probabl reflect invers proport particip assign group accept intervent rel total accept group 26 approach bal anc recruit accept particip group increas odd random izat intervent previou particip declin particip offer usual care consist inform local smoke cessat resourc cessat guid produc american cancer societi 41 particip receiv health benefit cv caremark free access behavior modifi cation program nicotin replac therapi particip assign individu incen tive group elig receiv 200 biochem confirm abstin time 14 dai 30 dai 6 month target quit date particip addit 200 bonu 6 month total 800 fig s2 supplementari appendix individu deposit group sum includ 150 deposit fund particip quit smoke collabor reward competit deposit group cohort smoker form roll basi link particip figur 1 assess elig random 2538 underw random 4629 person creat health account 612 exclud 10 18 yr ag 84 smoke 5 cigarett dai 54 smoke 6 mo 38 internet access 426 cv caremark employe rel friend 4017 elig 1479 complet enrol 52 provid consent 55 give social secur number 1372 complet baselin survei 468 assign usual care 468 includ primari analysi 471 assign competit deposit 471 includ primari analysi 582 assign individu deposit 582 includ primari analysi 519 assign collabor reward 519 includ primari analysi 498 assign individu reward 498 includ primari analysi england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 2015 2111 financi incent progr am smoke cessat select quit date nearest collabor reward group payment success ful group member time point increas increas group success rate 100 time point particip quit 600 time point particip quit sought foster collabor particip web base chat room commun studi competit deposit group 150 depo group member 450 match reward member 3,600 total redistribut member quit time point particip group quit 14 dai return smok ing 30 dai particip receiv 600 14 dai payout member group member competit cohort receiv accu rate anonym descript petitor make vivid possibl benefit lack change21 enabl particip undermin competitor effort particip group incent group 200 bonu sustain abstin 6 month intervent differ incent accru disburs fig s2 suppl mentari appendix payment schedul bonu ident basi anticip success rate estim intervent carri expect 800 outcom primari outcom sustain abstin smoke 6 month target quit date 27 achiev sustain abstin quir submit saliva sampl coti concentr 10 ng milli liter28 14 dai 30 dai 6 month user nicotin replac therapi urinari sampl anabasin concentr 3 ng millilit consid show sustain abstin 29 particip submit sampl code activ smoke secondari outcom includ initi quit rate 14 dai sustain abstin 30 dai sustain abstin 12 month i. 6 month final incent disburs ment incent accept rate reflect pro portion particip assign incent agre contract group requir deposit consid particip accept intervent made 150 deposit credit debit card 60 dai enrol select quit date whichev consent partici pant declin assign program remain assign group intent treat analys treat ident usual care group statist analysi analys aim studi logist gression compar accept interven tion adjust variabl random stratifi 30 sec ond conduct intent treat analys logist regress compar effec tive incent program ran domli assign particip pare efficaci intervent conduct tradit protocol analys pare group particip accept dif ferent intervent analys subject select bias 31 primari approach measur efficaci model random group instrument variable32,33 analys complier averag treatment effect 34 36 analys detail supplementari appendix data randomli assign particip estim treatment effect particip accept intervent estim sampl 2185 partici pant provid 80 power detect abso lute differ 7.5 percentag point rate sustain abstin incent program individu reward program detail calcul provid supplementari appendix esult patient characterist 2538 particip enrol demograph smoke relat characterist particip balanc studi group tabl 1 england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 20152112 ngl na dic characterist usual care 468 individu reward 498 collabor reward 519 individu deposit 582 competit deposit 471 demograph characterist ag yr median 34 32 32 33 33 interquartil rang 26 47 25 46 25 45 25 48 25 45 femal sex 300 64 312 63 322 62 367 63 293 62 race white 365 78 409 82 387 75 452 78 376 80 black 43 9 44 9 58 11 54 9 49 10 60 13 45 9 74 14 76 13 46 10 year educ median 13 13 13 13 13 interquartil rang 12 14 12 14 12 15 12 15 12 15 annual household incom 60,000 346 74 375 75 382 74 403 69 358 76 60,000 122 26 123 25 137 26 179 31 113 24 health insur cv caremark employe enrol cv caremark health care plan 152 32 174 35 177 34 213 37 168 36 enrol cv caremark health care plan 139 30 136 27 151 29 180 31 146 31 rel friend cv caremark employe enrol cv caremark health care plan 36 8 33 7 26 5 29 5 36 8 enrol cv caremark health care plan 141 30 155 31 165 32 160 27 121 26 smoke histori cigarett smoke dai median 15 15 15 15 15 interquartil rang 10 20 10 20 9 20 10 20 10 20 durat regular smoke yr median 15 12 13 14 14 interquartil rang 6 26 6 25 6 25 6 25 7 25 ag smoke yr median 17 17 17 17 17 interquartil rang 15 19 15 19 15 19 15 19 15 19 level nicotin depend low 101 22 111 22 118 23 122 21 95 20 low moder 148 32 155 31 152 29 185 32 141 30 moder 194 41 210 42 229 44 251 43 215 46 high 25 5 22 4 20 4 24 4 20 4 stage chang prepar 300 64 312 63 327 63 372 64 312 66 contempl 168 36 186 37 192 37 210 36 158 34 successfulli quit 24 hr period past year 300 64 307 62 328 63 361 62 294 62 tabl 1 particip characterist intent treat popul england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 2015 2113 financi incent progr am smoke cessat accept intervent 2070 particip assign intervent group 1060 51.2 accept intervent particip accept reward base incent pro gram combin accept rate 90.0 deposit base program combin ac ceptanc rate 13.7 0.001 fig 2 partici pant similarli accept individu al incent combin accept rate 50.6 group incent combin accept rate 51.9 0.55 effect cost intervent median payout particip stop smok ing incent group similar tabl s1 supplementari appendix intent treat analys program yield greater rate sustain abstin smoke 6 month rang 9.4 16.0 usual care 6.0 0.05 comparison fig 3 tabl s2 suppl mentari appendix 12 month 6 month cessat incent roughli half par ticip abstin 6 month group submit neg cotinin assai reward base incent program remain superior usual care fig 3 proport report quitter submit ted cotinin sampl lower 12 month 30 dai 6 month group tabl s3 supplementari appendix secondari analys report abstin 12 month relaps smoke common analys requir biochem confirm incent group remain superior usual care tabl s2 supplementari ap pendix 6 month proport particip sustain abstin greater ward base incent 15.7 deposit base incent 10.2 0.001 tabl s4 supplementari appendix similar particip assign individu incent program assign group incent program 12.1 13.7 0.29 tabl s5 supplementari appendix par ticip access free pharmacolog ce sation aid cv caremark benefit higher abstin rate partici pant benefit tabl s6 supplementari appendix total cost spent particip sustain abstin lower deposit base group reward base group fig s3 supplemen tari appendix efficaci intervent similar effect individu ward collabor reward individ characterist usual care 468 individu reward 498 collabor reward 519 individu deposit 582 competit deposit 471 nrt assist quit smoke 340 73 384 77 384 74 421 72 350 74 method quit smoke 65 14 51 10 71 14 73 13 47 10 intent treat popul includ particip underw random studi group sig nific differ studi group baselin characterist list 0.05 nrt denot nicotin replac therapi race report year educ rang grade 1 17 17 repres graduat school 13 16 repres 1 4 year colleg cv caremark health care plan includ free access behavior modif program nrt level depend base score fagerström test nicotin depend score rang 1 10 higher score indic intens physic depend nicotin low depend correspond score 1 2 low moder de pendenc score 3 4 moder depend score 5 7 high depend score 8 10 particip ask think quit smoke option select 30 dai prepar stage 6 month contempl stage think quit precontempl stage valu contempl stage includ 10 particip precontempl stage 2 particip usual care group 2 particip individu reward group 2 particip collabor reward group 3 particip individu deposit group 1 particip competit deposit group data miss 1 particip competit deposit group particip nrt behavior therapi prescript medic method quit smoke tabl 1 continu england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 20152114 ngl na dic ual deposit competit deposit group reward base incent de posit base incent efficaci analys standard protocol analys 52.3 accept deposit versu 17.1 accept reward sustain abstin 6 month 0.001 similarli larg differ enc observ time point tabl s7 supplementari appendix analys complier averag treatment effect ad select effect inher proto col analys rate abstin 6 month 13.2 percentag point 95 confid terval 3.1 22.8 higher deposit base program reward base program 13.7 smoker accept type incent tabl 2 approach deposit superior reward assum particip accept deposit 12.5 time greater underli propens stop smoke particip accept reward analys account enrol potenti nonsmok 150 particip ask submit coti assai baselin confirm smoke sta tu 9 6.0 submit neg assai 21 14.0 return assai rate similar group tabl s8 suppl mentari appendix sensit analys ad just possibl 20 particip smoker reveal ident estim effect tabl s9 supplementari appendix discuss 50 year releas surgeon gener report harm effect smoke nation polici behavior pro gram pharmacolog approach help reduc smoke rate unit state 37 approach clear smoke remain lead prevent ill death 38,39 larg random trial unit state found centiv program expect valu 800 effect promot sustain ab stinenc smoke im portant find incent program requir peopl deposit 150 monei effect reward base program similar peopl accept deposit program true 650 reward offer deposit arm particip addit return origin 150 deposit analys account accept rate intervent show deposit base incen tive substanti efficaci reward base incent peopl accept robust result larg potenti select effect sug gest incent build particip loss aversion13 meaningfulli chang behavior found group orient reward program significantli effect individu orient program result larg trial consist small random control trial incent weight loss group orient figur 2 accept rate financi incent structur accept rate adjust stratifi variables30 partic ipant receiv health insur cv caremark annual household incom 60,000 60,000 bar denot 95 confid interv parenthes numer indi cate number particip accept intervent denomi nator number particip assign intervent usual care group shown option declin usual care cc ep ta nc ss ig ne te rv en tio 100 80 90 70 60 40 30 10 50 20 0 assign intervent individu reward 472 498 collabor reward 442 519 individu deposit 75 582 competit deposit 71 471 94.8 85.3 12.6 15.1 england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 2015 2115 financi incent progr am smoke cessat payment compar individu orient payment produc small earli benefit sustain time 19,22 final find individu reward 800 compar usual care tri pled rate smoke cessat cv caremark employe friend fam ili confirm extend generaliz find previou trial involv gen eral electr employe 8 addit pub lic health effect smoke reduct find import employ emploi smoker estim cost 5,816 year emploi smoker 40 800 payment born employ paid quit highli cost save studi limit low rate accept deposit program requir protocol modif restrict propor tion particip randomli assign group implement limit preserv balanc particip char acterist group preserv power effect analys limit precis analys compar efficaci reward deposit group 41 particip access free pharmaco logic behavior cessat aid employe benefit smoke cessat rate higher access aid find suggest superior incent hold popula tion univers access trial group half smoker quit end intervent 6 month document sustain abstin 12 month suggest similar durabl fi nancial incent nicotin replac ther com.ibm.drl.hbcp.api bupropion relaps complet treatment occur roughli 50 particip 41,42 secondari analys suggest true relaps rate trial lower reduc tion submiss sampl 12 month group tabl s3 supplementari appendix studi strength ad dition compar financi incent smoke cessat larg number partici pant trial measur specif contribu tion accept efficaci interven tion effect trial compar multipl incent program de sign featur base behavior econom theori includ repeat payment reinforc target behavior 43 bonu payment end intervent offset smoker tendenc discount import futur event 44,45 provis ongo feedback particip accru gain loss contin gent report smoke statu maxim effect regret avers 20,21 fi nalli trial randomli select particip screen cotinin test prevent nonsmok er enrol robust find ing analys account potenti par ticip nonsmok strong evid effect incen tive figur 3 rate sustain abstin smoke 6 12 month target quit date primari outcom sustain abstin 6 month aster isk valu 0.05 0.01 0.001 comparison intervent group usual care adjust ment stratifi variables30 particip receiv health insur cv caremark annual hous hold incom 60,000 60,000 bar 95 confid interv su st ai ne bs tin en ce ar tic ip ts 20 10 15 5 0 6 12 month select quit date usual care individu reward collabor reward individu deposit competit deposit random group england journal medicin download nejm.org univers aberdeen novemb 30 2015 person permiss copyright 2015 massachusett medic societi right reserv engl med 372;22 nejm.org 28 20152116 ngl na dic summari trial show financi incent program smok ing cessat reward smoke cessat effect deposit base contract ow higher rate ac ceptanc addit efficaci deposit base contract cost effect contract em ployer suggest futur innov em ploye benefit design seek establish effect smoke cessat program requir deposit smaller 150 trial support grant nation cancer institut r01 ca159932 dr halpern grant nation institut ag rc2 ag036592 dr asch volpp cv caremark disclosur form provid author full text articl nejm.org
66 doi 10.1177 0022034509350867 receiv decemb 7 2007 revis june 23 2009 accept juli 22 2009 hanioka1 ojima2 tanaka3 naito4 hamajima4 matsuse5 1depart prevent public health dentistri fukuoka dental colleg 2 15 1 tamura sawara ku fukuoka 814 0193 japan 2depart prevent dentistri graduat school dentistri osaka univers suita osaka japan 3divis epidemiolog prevent aichi cancer center research institut nagoya aichi japan 4depart prevent medicin biostatist medic decis make nagoya univers graduat school medicin nagoya aichi japan 5depart research develop kyoto medic scienc laboratori kyoto japan author haniokat colleg fdcnet.ac.jp dent re 89 1 66 70 2010 abstract smoke exert detriment effect dental treat ment oral health goal evalu effec tive term abstin rate smoke cessat intervent deliv dental profession individu quit smoke randomli assign inter vention intervent group intens inter vention provid consist 5 counsel session includ addit nicotin replac ment regimen report abstin verifi salivari cotinin level thirti person intervent 23 intervent group start trial intent treat basi 3 6 12 month continu abstin rate inter vention group 51.5 39.4 36.4 rate intervent group consist 13.0 adjust odd ratio 95 confid interv logist stepwis regress analys 7.1 1.8 28.5 8.9 1.7 47.2 6.4 1.3 30.7 intens smoke cessat intervent dental set effect kei word smoke cessat dentist dental hygienist random control trial introduct causal associ smoke oral diseas establish oral cancer periodont diseas depart health human servic 2004 smoke form oral symptom prematur tooth loss smoke krall al 1997 hanioka al 2007a smoke impair effect dental treat ment smoke decreas effect periodont treatment preber bergström 1990 kaldahl al 1996 grossi al 1997 root canal treatment krall al 2006 wound heal tooth extract larsen 1992 dental implant failur chuang al 2002 shown affect smoke smoke cessat decreas risk tooth loss dietrich al 2007 dental implant failur lambert al 2000 increas speed recoveri periodont treatment preshaw al 2005 smoke cessat import measur preven tion oral diseas symptom ensur effect dental treatment sustain dental organ world recommend ce sation tobacco chart mucos lesion dissemin earli detect oral cancer mecklenburg al 1994 smoke cessa tion manual dental team develop govern mecklenburg al 1991 british dental associ beaglehol watt 2004 global level advocaci guid oral health profession includ smoke cessat practic fdi 2005 clinic trial physician dentist involv conduct comprehens tobacco control strategi cohen al 1994 effec tive smoke cessat intervent dental set highlight standard evalu difficult due vari eti intervent regimen carr ebbert 2007 japan smoke rate male femal adult 39.9 10.0 2006 rate men high develop countri young femal increas smoke cessat guidelin introduc cooper 7 medic 2 dental academi 2005 includ role dental profession inform smoke cessat practic japan 2006 japan smoke cessat treatment physician approv government health insur recognit nicotin depend diseas pro tocol intens intervent includ diagnosi nicotin depend counsel smoke behavior modif prescript nicotin patch intens smoke cessat intervent conduct dental hygienist success binni al 2007 dental set ting smoke cessat intervent implement ensur effect treatment dental diseas aim feasibl studi evalu potenti effect intens smoke cessat inter vention deliv dental profession outcom measur term abstin rate intens smoke cessat intervent dental set research report clinic librari period dept novemb 25 2015 person permission.jdr.sagepub.comdownload 2010 intern american associ dental research http jdr.sagepub.com dent re 89 1 2010 smoke cessat dental set 67 method local dental associ hiroshima prefectur nagasaki citi agre recruit dental clinic dentist dental hygienist 30 dental clinic particip 3 hour train intens smoke cessat inter vention consist counsel lectur addit pharmaceut regimen role plai exer cise organ achiev goal experiment protocol detail protocol intervent studi approv ethic committe fukuoka dental colleg adult screen mean questionnair ask willing stop smoke 1 mo pregnant breast feed histori diseas exclud angina pectori myocar dial infarct arrhythmia heart diseas cerebr hem orrhag subarachnoid hemorrhag cerebr diseas patient clinic assign intervent intervent group free nicotin transderm patch provid intervent group similar benefit intervent group intervent group partici pant disappoint find offer benefit disappoint led select dropout unwant behavior fore modifi random consent design kaper al 2005 particip blind exist counter part experiment group particip verbal inform studi ask interest take part agre particip assign intervent intervent group assign card envelop provid priori clinic random assign intervent group told detail studi examin effect intens smoke cessat intervent intervent group told salivari test particip group gave written inform consent particip inter vention protocol recommend previous tomar 2001 gordon al 2005 protocol intervent group consist 5 visit visit particip counsel set quit date includ major regimen prevent relaps consist behavior pharmaceut approach materi nicotin patch nicotinel tt novarti pharma k.k tokyo japan consist 3 dosag level pro vide 6 wk inform nicotin gum nicorett johnson johnson k.k consum compani tokyo japan particip purchas drug store pharmaceut approach reduc withdraw symptom counsel visit perform 2 consecut visit inform consent obtain visit ordin dental treatment counsel dur ing visit requir longer time visit visit approxim 2 4 8 wk 3 mo quit date smoke cessat counsel conduct similar concis manner assist particip overcom withdraw symptom prevent relaps daili cigarett durat smoke data collect questionnair nicotin depend esti mate mean tobacco depend screener td consist 10 question kawakami al 1999 smoker td score 5 estim nicotin depend particip time start end intervent dentist dental hygienist record verifi smoke cessat saliva determin level cotinin metabolit nico tine saliva collect 3 mo visit particip group 6 12 month follow saliva collect individu report smoke cessat particip chew cotton plug salivett sarstedt nürnbrecht germani 1 2 min ensur fulli satur saliva cotton plug store sampl tube mail laboratori laboratori sampl centrifug harvest saliva plate petit enzym link immunosorb assai solut rabbit polyclon anti goat igg dako glostrup denmark cut 20 ng ml verifi report abstin etzel 1990 particip count smoker lost follow fail provid saliva sampl intent treat analysi differ averag group assess tail test differ distribut group evalu χ2 test effect smoke cessa tion intervent evalu comparison 3 6 12 month continu abstin rate intervent intervent group continu abstin rate defin intent treat analysi number indi vidual continu stop smoke observa tion period divid particip studi adjust odd ratio 95 confid interv ci continu abstin intervent group rel intervent group calcul logist regress analysi backward stepwis select elimin signific factor 0.10 sex ag daili cigarett td score statist analys conduct spss softwar spss japan tokyo signific level set 5 result facil particip train 19 clinic 63.3 began trial 47 44 particip assign intervent intervent group 33 23 individu consent particip fig intervent period 15 person lost studi 56 particip intervent group person nicotin patch particip report nicotin gum patch ceas 6 month period advers event smoke cessat report signific differ group respect sex ag cigarett smoke daili smoke yr tabl 1 td score lower intervent group intervent group differ signific librari period dept novemb 25 2015 person permission.jdr.sagepub.comdownload 2010 intern american associ dental research http jdr.sagepub.com 68 hanioka al dent re 89 1 2010 train receiv 30 clinic recruit intervent group intervent group patient 19 clinic intervent group 33 intervent group 23 8 lost studi salivari test 3 month salivari test 6 month report quitter 7 lost studi salivari test 1 year report quitter 47 assign intervent group 44 assign intervent group 14 declin particip 21 declin particip 33 includ intent treat analysi 23 includ intent treat analysi figur train intens smoke cessat intervent flow particip salivari test chemic valid abstin intervent intervent group tabl 1 comparison characterist smoker intervent intervent group characterist intervent group 33 intervent group 23 number particip male 26 14 femal 7 9 nsa ag yr 48.0 43.4 52.6 46.7 41.2 52.3 ns cigarett smoke daili 24.3 19.5 29.0 20.6 14.9 26.3 ns yr smoke 26.7 22.2 31.2 24.1 18.7 29.5 ns td scorec 7.3 6.5 8.1 6.0 5.1 6.9 ns signific intervent intervent group 95 confid interv tobacco depend screener td consist 10 question smoker td score 5 assess nicotin depend smoker dentist dental hygienist contact time dentist 1.7 time longer dental hygienist particip 63.6 complet maximum visit 5 6 visit effect intervent evalu 33 partici pant intervent group 23 particip intervent group continu abstin rate intent treat basi tabl 3 3 month period 75.8 69.6 evalu smoke statu intervent intervent group abstin rate 51.5 13.0 abstin rate intervent group follow assess 6 12 mo consist 3 mo rate decreas 39.4 6 mo 36.4 1 yr intervent group adjust 95 ci continu abstin intervent rel intervent group 3 6 12 mo 7.1 1.8 28.5 8.9 1.7 47.2 6.4 1.3 30.7 discuss present studi demonstr intens smoke cessat intervent effect dental set term long term abstin rate verifi chemic present studi particip limit smoker quit 1 mo intervent individu ing quit 1 mo 3 time effect attempt quit hanioka al 2007b dental clinic independ facil smoker motiv help quit effect nation survei conduct time verifi effect smoke cessat treatment medic set 279 facil respons rate 61.2 japan time present studi report 6 12 month continu absti nenc rate 2546 smoker 40.8 32.6 number similar intervent group present studi number particip complet maximum visit lower medic set 30.0 present studi 63.6 75 particip examin 3 month period intervent intervent group particip complet maximum intervent good complianc dental set due necess continu dental treatment dental profession train smoke cessat intervent influenc smoke behavior intervent group interven unconsci type bia bia due lower td score intervent group intervent group tabl 2 characterist intervent practic intervent group 33 intervent dentist dental hygienist total mean time particip min 73.7 53.9 93.5 42.3 27.9 56.8 116.2 86.8 145.6 mean number particip 4.4 3.8 5.0 4.3 3.7 4.9 4.6 4.0 5.1 record incomplet 95 confid interv total intervent time intervent group particip 116.2 min averag tabl 2 mean number interven tion person 4.6 63.6 particip complet intervent number intervent receiv similar librari period dept novemb 25 2015 person permission.jdr.sagepub.comdownload 2010 intern american associ dental research http jdr.sagepub.com dent re 89 1 2010 smoke cessat dental set 69 tabl 3 abstin ratio intervent intervent group adjust odd ratio logist stepwis regress analysi period assess intervent group intervent group registr 33 100 23 100 3 mo daysa 107.7 100.3 115.1 103.1 93.9 112.4 ns examin 25 75.8 16 69.6 ns quitc 17 51.5 3 13.0 0.004 crude 7.1 1.8 28.5 0.006 adjust ord 7.1 1.8 28.5 0.006 6 mo dai 196.5 181.8 211.1 204.3 176.3 232.3 ns quit 13 39.4 3 13.0 0.039 crude 4.3 1.1 17.6 0.040 adjust or 8.9 1.7 47.2 0.010 1 yrf dai 433.2 402.2 464.2 453.3 388.8 517.9 ns quit 12 36.4 3 13.0 ns crude 3.8 0.9 15.5 ns adjust or 6.4 1.3 30.7 0.021 base dai intervent set quit dai 1 wk visit recommend intervent group period approxim 7 dai shorter tabl 95 confid interv report abstin verifi salivari cotinin level 20 ng ml 3 6 12 mo salivari test 6 12 mo perform reportedli quit variabl enter ag daili cigarett enter assess delai approxim 2 mo due extens financi support underestim effect current intervent adjust ag daili cigarett group contrib ut increas crude odd ratio random consent minim overestim effect due particip bia method inspir debat controversi ethic issu homer 2002 method appropri at studi examin effect respect behavior chang kaper al 2005 avoid parallel design particip assign intervent intervent clinic particip bia occur group studi design assess efficaci smoke cessat program dental set vari greatli warnakulasuriya 2002 carr ebbert 2007 includ abstin rate treatment intent treat base intervent gener popu lation dental patient lack exist control group intens intervent regimen short long term observ period report abstin chemic verif intervent singl profession team approach team approach recommend differ inter vention approach identifi dental physician set cohen al 1994 strength present studi confirm evalu intervent trial comparison abstin verifi chemic control group intent treat basi limit studi note number particip intervent group third intervent group imbal anc due greater benefit free nicotin patch intervent intervent group expect effect abstin individu particip trial nicotin patch counter japan 2008 influenc avail drug store effect ness intervent dental set clarifi smoke cessat counsel dentist dental hygienist requir time commit efficaci practic consid approv smoke cessat practic health insur system improv efficaci dental set discuss requir medic econom dental profession intervent save dental expenditur prevent dental diseas improv dental treatment effect sourc dental patient receiv intens smoke cessat intervent referr servic gordon al 2007 present studi dental profession briefli train smoke cessat intervent dental profession potenti behavior pharmaceut approach dental visit opportun smoker effect help quit smoke train profession acknowledg studi support fukuoka dental colleg grant grant aid cancer research japanes ministri health labor welfar 13 3 17 1
complementari therapi medicin 2014 22 1 8 onlin www.sciencedirect.com sciencedirect jo ur nal home ag www.elsev ierhea journa ls im hypnotherapi effect nicotin replac therapi smoke cessat result random control trial faysal hasana sofija zagarinsc karen pischkea shamila saiyeda ann mari bettencourta laura beala dian macysa sanjai auroraa nanci mcclearyb divis pulmonari critic care sleep medicin north shore medic center salem hospit salem ma unit state depart medicin massachusett gener hospit boston ma unit state depart psychiatri tuft univers school medicin boston ma unit state depart behavior medicin research baystat medic center springfield ma unit state onlin 6 januari 2014 keyword smoke cessat hypnosi nicotin replac random control trial hospit summari background efficaci pharmacotherapi smoke cessat document due relaps rate side effect hypnotherapi gain attent altern treatment option aim center random studi compar efficaci hypnotherapi hypnotherapi nicotin replac therapi nrt convent nrt patient hospit cardiac pulmonari ill method evalu report biochem verifi 7 dai preval smoke abstin rate 12 26 week post hospit patient 164 random counsel base treatment group nrt 30 dai nrt 41 90 min hypnotherapi session 39 nrt hypnotherapi hnrt 37 treatment group compar quit group 35 patient refus intervent result hypnotherapi patient nrt patient nonsmok 12 week 43.9 28.2 0.14 26 week hospit 36.6 18.0 0.06 smoke abstin rate hnrt group similar group differ smoke abstin rate 26 week quit particip treatment group multivari regress analysi adjust diagnosi demograph characterist hnrt time nrt particip abstain 26 week post discharg rr 3.6 0.03 rr 3.2 0.04 author depart behavior medicin research baystat medic center 140 high street room 223 springfield ma 01105 unit state tel 1 4137942876 fax 1 4137943890 mail address sofija.zagarin baystatehealth.org s.e zagarin 0965 2299 front matter 2014 elsevi right reserv http dx.doi.org 10.1016 j.ctim 2013.12.012 dx.doi.org 10.1016 j.ctim 2013.12.012 http www.sciencedirect.com scienc journal 09652299 www.elsevierhealth.com journal ctim http crossmark.crossref.org dialog doi 10.1016 j.ctim 2013.12.012 domain pdf mailto:sofija.zagarin baystatehealth.org dx.doi.org 10.1016 j.ctim 2013.12.012 2 f.m hasan al conclus hypnotherapi effect nrt improv smoke abstin patient hospit smoke relat ill asset post discharg smoke re 4 2 blind modal intervent cessat program 2014 elsevi ntroduct igarett smoke remain lead mor iditi mortal recogn remedi global health hazard 1 3 5 million american continu smoke hird smoker express desir stop 4 moke cessat program ost effect measur improv health decreas ortal gener popul 5 7 reatli enhanc rapid gain understand psychopharmacolog nicotin recognit icotin addict 8 highli addict natur nicotin continu pose signific challeng uit 9,10 process regul develop moti ation stop smoke complex life event evelop motiv patient illion smoker hospit year hospi aliz smoke relat ill rank high teach moment barrier reduc moti ation counsel modal access nhanc treatment accept 11,12 medic moke cessat doubl odd achiev abstin fter hospit discharge13,14 accep anc pharmacotherapi limit common side ffect 15,16 complementari therapi supplant practic onvent medicin increas sought ypnotherapi continu view great inter st smoker treatment option 17,18 hrough suggest intens attent hypnoth py abstin build motiv egul 19,20 hypnosi claim effect current evid efficaci nconclus 21,22 studi role hypnotherapi behavior ounsel base smoke cessat program patient ospit cardiac pulmonari ill ompar convent treatment nicotin eplac therapi nrt hypothes sug estiv power hypnosi encourag behavior cope echan enhanc motiv increas ikelihood smoke cessat hospit moke relat ill ethod studi random control trial limit enter conduct north shore medic cen er salem massachusett octob 2006 009 institut review board north shore med cal center partner healthcar organ approv protocol patient provid written consent articip erv et particip ll current smoker ag 18 75 year dmit cardiac pulmonari ill elec ronic identifi patient termin ill histori substanc abus major psychiatr disord xclude psychiatr diagnos identifi edic histori includ schizophrenia bipolar onal disord exclud patient regnant patient ho ital discharg due cognit languag barrier atient receiv hypnotherapi nrt past ix month fig 1 nicotin depend assess num er cigarett smoke daili pack year smoke rior quit attempt hospit discharg summari eview determin diagnosi respons ospit admiss smoke specif efficaci easur questionnair assess patient sens mportanc quit confid biliti stop smoke ntervent random particip treatment roup nrt nrt hypnotherapi group eceiv hypnotherapi nrt hnrt treatment odal detail random ssignment perform permut block ratio 1 1 1 assign sequenti number chedul maintain independ studi roject coordin random assign con eal patient research staff patient ad sign inform consent document nroll studi elig patient receiv hypnotherapi nrt random er observ fourth quit group enrol patient receiv materi ounsel hospit quit group eceiv standard counsel admit atient receiv contact 26 week ost hospit treatment group receiv hypnoth py nrt intens counsel 30 min ospit follow telephon call addi ional counsel 1 2 4 8 12 week hospit ischarg telephon counsel session standard last 15 min call counselor nforc abstin assess nrt adher due natur intervent condit counselor icotin replac therapi atient receiv nrt free month suppli nicotin patch initi dose base num er cigarett smoke prior hospit rct hypnotherapi smoke cessat 3 wing figur 1 flow chart sho patient smoke 10 20 cigarett dai receiv dose 21 mg dai 24 nrt patient nicotin gum lozeng administ need control crave reduc withdraw symptom quit date establish week discharg patient encourag continu nrt month hypnotherapi patient random hypnotherapi receiv time person hypnotherapi session 1 2 week ho pital discharg consist 90 min individu session certifi hypnotist tobacco treatment specialist kp session began interview assess motiv trigger smoke hypnotherapi introduc collabor posit relationship particip enrol happen patient consent concern bout power control address repeti iv statement deep breath state relax focus attent achiev patient achiev tranc state hypnosi set suggest isual imageri made emphas good health heal dissoci pleasant experi moke suggest made creat neg ffectiv nicotin build worth urg ontrol resist smoke session individu reinforc patient main reason trigger ant stop smoke patient train ypnosi standard tape smoke cessat elax end session contin ed home reinforc behavior modif bstinenc 4 f.m hasan al tabl 1 comparison intervent group hypnotherapi hypnotherapi nicotin replac therapi nrt treatment group quit nrt control group term baselin characterist follow statu characterist nrt hypnotherapi hypnotherapi nrt quit 39 41 38 37 mean sd mean sd mean sd mean sd ag year 55.3 12.2 55.0 10.6 54.4 8.9 56.0 10.7 femal 18 46.2 25 61.0 14 36.8 16 43.2 white race 32 82.1 38 92.7 31 81.6 36 97.3 year educ 12.6 2.0 13.0 2.0 13.2 1.8 13.2 1.9 marri live 22 56.4 17 41.5 17 44.7 17 46.0 live smoker 16 41.0 18 45.0 13 34.2 14 38.9 cardiac diagnosi enrollmenta 25 64.1 26 63.4 22 57.9 27 73.0 enrol cardiac rehab 6 15.4 3 7.3 5 13.2 2 5.4 averag number cigarett smoke dai 21.2 12.6 19.8 12.6 20.5 9.3 15.0 10.0 total year smoker 34.2 14.4 36.5 12.7 34.3 11.7 33.2 10.8 number attempt quit smoke 3.6 4.2 4.5 5.4 5.6 6.3 4.1 3.4 quit relat efficaci import scaleb 9.7 0.7 9.7 0.84 9.3 1.4 9.4 1.2 quit relat efficaci confid scaleb 7.6 2.1 8.2 2.1 7.6 2.0 8.2 1.9 lost follow 12 30.8 14 34.2 13 34.2 17 46.0 differ nrt control group 0.05 0.2 base anova continu variabl chi squar fisher exact test categor variabl aci 7 remain patient pulmonari diagnosi enrol scale rang 0 10 score 10 indic high effic ssessment primari outcom measur 7 dai preval obacco abstin 26 week post hospit etermin report verifi urinari cotinin evel level 15 ng ml consid indica iv abstin particip fail provid urin sampl abstin confirm contact ousehold proxi 23 secondari outcom report dai preval tobacco abstin smoke 12 eek post hospit treatment group omparison abstin rate 26 week inter ention group quit group influenc dmit diagnosi cardiac pulmonari abstin at 12 26 week discharg nalysi haracterist studi popul report mean standard deviat sd continu covari frequenc percent ge level categor covari report mean sd continu covari treatment roup smoke cessat statu 12 26 week ost hospit anova assess dif erenc mean categori statist ignific categor covari calcul differ treatment group smoke ce ation statu chi squar test fisher exact test tabl small cell frequenc conduct outcom analys intent treat consid particip reach follow continu smoker evalu associ etween treatment group smoke cessat statu nadjust multivari logist regress moke cessat variabl depend variabl onsid covari interven ion group statu smoke cessat statu 0.20 inclus final multivari model con uct analys covari includ final multivari model variabl hose remov result 10 chang beta oeffici smoke cessat statu variabl erform statist analys sa softwar version 9.2 2011 sa institut cari nc esult total 164 patient admit cardiac ulmonari diagnosi fulfil inclus criteria nroll studi fig 1 122 patient andom treatment group nrt hnrt 42 atient declin treatment nrt hypnotherapi er includ observ quit group andom treatment condit 33.9 lost ollow 26 week time point tabl 1 tatist signific differ baselin demograph ariabl group tabl 1 particip pre ominantli middl ag white 48 femal moke histori similar group cardiac iagnosi primari admiss 59.8 atient ischem heart diseas account 86.5 hese admiss evid myocardi njuri 33.7 cardiac patient exacerb chronic irwai obstruct pneumonia account 80 pul onari admiss efficaci relat smoke cessat high roup baselin differ base type diag osi hospit i. cardiac pulmonari data rct hypnotherapi smoke cessat 5 figur 2 comparison averag smoke relat efficaci i. perceiv import confid abil 0 2 2 stop smoke baselin smoke statu follow 12 26 week standard error shown smoke relat efficaci baselin smoke abstin follow smoke abstain follow time point report higher efficaci term import confid baselin 0.05 comparison fig 2 compar nrt group patient receiv hyp notherapi abstain smoke 12 26 week hospit 12 week 43.9 patient hypnotherapi group report smoker compar 28.2 patient receiv nrt 0.14 tabl 2 smoke abstin rate attenu 26 week post discharg group 36.6 nrt 18 0.06 smoke abstin rate group receiv hypnotherapi nrt simi lar observ receiv hypnotherapi tabl 2 multivari analysi particip interven tion condit i. hnrt time nrt group particip quit smoke base cotinin verifi 26 week smoke assess tabl 2 unadjust multivari rel risksa associati 26 week follow quit rate nrt control group quit rate intervent nrt hypnotherapi model 1 quit 12 week 11 28.2 18 43.9 model 2 quit 26 week 7 18.0 15 36.6 nrt nrt hypnotherapi model 1 quit 12 week 11 28.2 18 47.4 model 2 quit 26 week 7 18.0 13 34.2 model reflect quit rate intervent group rel quit adjust gender marit statu diagnosi enrol cardia adjust race white diagnosi enrol cardia adjust quit relat efficaci import scale diagn igur 3 comparison smoke abstin rate follow time point intervent statu rr 3.6 95 ci 1.1 11.4 rr 3.2 95 ci 1.04 9.7 espect tabl 2 multivari result base elf report 12 week data similar base 26 week data hnrt condit particip rr 3.4 95 ci 1.2 10.0 attenu par icip hypnotherapi condit rr 2.2 95 ci 8 6.2 particip random hypnotherapi group end higher smoke abstin rate 12 6 week follow compar random nrt control group 0.14 0.06 ig 3 similarli particip random nrt ypnotherapi group tend higher smoke absti enc rate 12 26 week follow compar hose random nrt control group 0.08 0.10 differ smoke bstinenc rate 26 week particip bserv quit group particip hree treatment group valu rang 0.34 0.50 atient quit cold turkei abstin rate 7.0 26 week compar 18.0 nrt group 0.34 36.6 group 0.37 34.2 nrt group 0.50 pre hospit smoke rate differ as admit diagnosi hospit 18.8 1.1 on intervent group smoke statu 12 group unadjust rel risk multivari rel risk 95 ci 95 ci 2.0 0.8 5.1 2.2b 0.8 6.2 2.6 0.9 7.4 3.6c 1.1 11.4 2.3 0.9 5.9 3.4d 1.2 10.0 2.4 0.8 6.8 3.2d 1.04 9.7 at control group pulmonari pulmonari osi enrol cardiac pulmonari 6 1 2 igur 4 comparison smoke statu follow time oint diagnosi statu cardiac pulmonari igarett dai patient cardiac diagnosi 19.9 1.5 patient pulmonari diagnosi 0.54 smoke abstin rate post discharg iffer admit diagnosi smoke abstin ignificantli higher 12 week post hospit par icip admit cardiac diagnosi compar admit pulmonari diagnosi 52.1 20.0 0.001 fig 4 patient admit ed cardiac diagnosi time ik abstain smoke 12 week patient dmit pulmonari diagnosi 4.3 95 ci 8 10.3 associ persist adjust ent attend cardiac rehabilit program 3.6 95 ci 1.5 8.8 significantli dif erent verifi smoke cessat rate 26 week ost hospit tend higher cardiac atient compar pulmonari patient 34.1 0.0 0.07 iscuss studi evid hypnotherapi ffectiv tradit pharmacotherapi nrt nhanc behavior modif increas smoke bstinenc rate discharg patient hospit zed cardiac pulmonari ill compar patient receiv treatment nrt counsel atient receiv hypnotherapi counsel ik nonsmok 26 week post hospit ur data show combin nrt hypnotherapi reatment enhanc smoke cessat at achiev hypnotherapi hypnosi highli individu mind bodi interac ion focus attent kei suggest phase hat reinforc healthi smoke free state 18,24,25 hile clear hypnosi facilit respons ess behavior chang benefici ffect hypnotherapi attribut increas onfid motiv weaken desir smoke 18 alter state conscious individu hemselv enter proper effect sug estion smoke abstin studi f.m hasan al ederson al 26 hypnosi shown effec iv simpl relax session suggest moke abstin hypnotherapi hown power adjunct tool cognit behavior herapi 27 clinic benefit patient ronchial asthma irrit bowel syndrom cancer 28,29 issu design blind andom control studi major limita ion confirm efficaci hypnotherapi smoke essat 21 heterogen methodolog made ifficult compar result exist studi xist random control trial suggest ess hypnotherapi promot smoke abstin armodi al compar hypnotherapi psycholog al treatment 256 subject nrt provid articip 30 abstin rate 12 month higher hypnotherapi group differ valid abstin elkin al found intens ypnotherapi superior smoker receiv ateri number particip small 31 owev studi 168 smoker rabkin al found hyp otherapi compar behavior treatment ealth educ hypnotherapi session 32 studi show natur ill time admiss influenc abstin rate discharg uch similar smoke rate prior hospi aliz patient admit cardiac diagnosi or quit smoke 12 week follow ompar patient admit pulmonari ill associ persist adjust attend cardiac rehabilit program data add videnc previou studi hospit pportun time intervent modifi behavior 11,12 ay due fact patient relat heir smoke hospit admiss otiv stop smoke 33 evid compa abstin rate note 26 week quit roup compar treatment group high com.ibm.drl.hbcp.core smoke cessat import confid cale group studi analysi limit fact ar vastli modal hypnosi harmacotherapi repres random challeng articip interventionist blind treat ent condit conduct intent treat nalysi address potenti unplan crossov poor treatment adher differ moke cessat rate observ analysi nderestim observ sig ific differ group limit nother limit analysi particip tudi differ particip declin partic pate repres sourc popul gener public compar bserv quit group refus random atient random treatment condit observ differ group term baselin char cterist conclus hypnotherapi combin counsel ng appear effect nrt combin ith counsel improv short term smoke cessa ion rate patient admit hospit 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 rct hypnotherapi smoke cessat smoke relat ill encourag result hypnotherapi specif highli motiv popula tion enhanc motiv effect smoke relat admiss short live 34 chronic relaps natur nicotin depend 35 import role ambulatori physician special ist extend teach moment maintain enhanc motiv hospit discharg 36,37,38 gen eral interest hypnotherapi desir patient modal smoke cessat di courag research divers popul need confirm efficaci hypnotherapi recommend mainstream therapi smoke cessat fund work support norman read charit trust foundat authorship statement author access data role write manuscript conflict interest statement author conflict interest declar acknowledg author dr susan regan data collect work support norman read charit trust foundat
famili practic oxford univers press 1994 vol 11 2 print great britain smoke intervent gener practic success pregnant pregnant women kjell haug fugellj leif edvard aar0 olav foss haug fugelli aar0 le foss op smoke intervent gener practic success pregnant pregnant women famili practic 1994 11 111 116 object studi evalu effect simpl smoke intervent programm carri larg number gener practition gp pregnant pregnant women group women defin dichotomi pregnant versu pregnant intervent versu control intervent semtstructur flip booklet implement ordinari sequenc consult studi involv 187 gp western norwai subject 350 daili smoke pregnant women 274 daili smoke pregnant women 18 34 year ag point preval abstin rate 18 month 15 20 pregnant pregnant women intervent group 7 control group pp 0.06 n̂on prefliwnt 006 twenti cent pregnant women 34 pregnant women report reduc cigarett consumpt stop smoke includ drop out smoker continu abstin rate 15 month 6 0 pregnant women intervent control 5 1 pregnant women stop smoke smoke partne'r 0.001 encourag partner 0.004 preval pregnant pregnant women stop smoke higher intervent control group pregnant women stop smoke frequent pregnant individu mean daili cigarett consumpt posit effect intervent observ pregnant women potenti women smoker period pregnanc child infanc gp receiv train specif health promot effort effect low cost smoke intervent programm design pregnant women explor introduct eighti cent norwegian women pregnant lifetim 1 con sult gener practition gp gynaecologist midwif averag 11 time pregnanc major women gp medic check up pregnanc women group frequent contact health care system pregnanc divis social medicin depart public health primari health care univers btrgen ulriksd 8c 5009 bergen research center health promot univers bergen qisteinsg 3 5020 bergen depart clinic chemistri uuevaal univers hospit 0407 oslo norwai 1987 16 daili smoke norwegian women stop smoke awar pregnant 2 thirti cent daili smoker consult gp medic check 2 success smoke intervent programm design pregnant women result impor tant consequ public health 3'4 1 reduc risk antenat perinat plicat 2 reduc health consequ passiv smok ing children 3 reduc futur chanc tobacco relat diseas women 111 nivers olleg ondon januari 13 2017 http fam pra.oxfordjournals.org ow nload http fampra.oxfordjournals.org 112 famili practic intern journal 4 increas smoke cessat rate male partner 5 parent smoker reduc chanc teenag smoker smoke intervent studi gener practic design small number gp particip 5 gener special select gp interest familiar patient educ counsel result studi optimist order warrant extern valid smoke tervent studi gener practic broader repr sentat particip gp prefer aim studi evalu extent simpl intervent programm gener practic daili smoke pregnant pregnant women result smoke abstin reduct daili cigarett consumpt 18 month materi method design studi order assur smoke intervent implement ordinari sequenc consult gener practic ii simpl realist regard time consumpt gener practic iii carri larg number gp select train studi 398 gp western norwai work half time gener practic invit mail particip studi 9 gp ask record pregnant women consult 12 month recruit pregnant pregnant women studi total 187 gp particip recruit start novemb 1986 last 1 year particip woman 18 month follow end april 1989 randomli alloc gp subgroup pregnant pregnant patient end control group third intervent group gp recruit pregnant women intervent group recruit pregnant women control group vice versa origin studi plan dif ferent intervent group pregnant pregnant women idea mobil social support partner order increas effect intervent studi realiz partner suffici motiv attend consult decid distinguish inter vention condit analysi data present result particip women 18 34 year ag daili smoker live partner indic social medic prob lem inclus particip studi voluntari women drop time daili smoke pregnant women consult gp check trimest pregnanc includ recruit 2379 pregnant women medic check particip gp recruit ment period 2 smoke cigarett dai 3 month pregnanc smoke cigarett dai check hundr seventi pregnant women fulfil inclus criteria hundr forti women refus particip studi remain 530 180 drop studi period spontan abort 24 complic 8 move district 31 drop unknown reason 117 350 pregnant women 98 control group 252 intervent group complet studi daili smoke pregnant women recruit consult gp complaint relat smoke smoke cigarett dai 3 month plan pregnant 18 month hundr thirti pregnant women includ lack inform pregnant women refus par ticip studi period 163 pregnant women drop pregnant 25 move district 23 drop unknown reason 115 leav 274 111 control group 163 intervent group complet studi consult women intervent group advis stop smoke communica tion last 15 minut 5 minut gp messag design provid inform health hazard smoke stop smoke avoid relaps addit pregnant women special inform problem relat smoke fetu flip page booklet page special prepar pregnant women intervent group equival set prepar pregnant women end con sultat fiip present booklet distribut women intervent group invit consult gp 1,6 12 18 month discuss smoke habit problem relat smoke cessat smoke relaps pregnant women control group ordinari control programm pregnanc year deliveri extra consulta tion organ pregnant pregnant women control group flip over booklet distribut nivers olleg ondon januari 13 2017 http fam pra.oxfordjournals.org ow nload http fampra.oxfordjournals.org smoke intervent pregnanc 113 inclus patient ask fill que tionnair smoke habit smoke histori smoke habit signific attitud smoke cessat blood test analysi serum thiocyan consult 12 month serum analys perform depart clinic chemistri ulleva univers hospit oslo blood test pregnant women control group blood test repres form intervent eighteen month inclus particip women receiv postal anonym question nair questionnair repeat que tion addit women ask smoke habit studi period end studi anonym question nair gp particip studi 9 gp question ask ag sex smoke habit mean number consult dai statist analys conduct statist packag social scienc spss pc version 4.0 method appli cross tabul squar test independ analysi varianc student mest multivari analysi varianc repeat measur manova signi ficanc accept 5 level 0.05 result account pregnant women includ studi assum drop out stop smoke calcul 10 pregnant women intervent group 5 control group stop smoke make assumpt pregnant women 12 6 stop smoke smoke cessat rate calcul continu abstin rate women report smoker 15 month studi period regard smoker condit includ drop out continu abstin rate pregnant women 6 0 intervent control pregnant women 5 pregnant smoker mean serum thiocyan fell 68.9 45.3 mol 1 pregnant smoker 80.0 35.1 jmola inclus signific differ tween particip drop out regard mean daili cigarett consumpt ag attitud smoke habit ag start smoke smoke habit partner par ticip consid present characterist present tabl 1 total 350 pregnant women 274 pregnant women studi repres 66 origin 530 pregnant women 63 origin 437 pregnant women women intervent group control group report stop smok ing point preval abstin rate shown tabl 2 com.ibm.drl.hbcp.predictor inclus smoker 18 month examin tabl 3 pregnant women stop smoke 18 month inclus report cigarett con sumption inclus pregnant women stop smoke stop smoke studi signific lower mean serum thiocyan inclus stop smoke 0.002 pregnant women stop smoke older 0.03 smoke partner 0.004 encourag stop smoke partner 0.02 older start smoke 0.02 compar pregnant women stop smoke associ lesser extent found pregnant women tabl 3 figur 1 show mean daili cigarett consump tion time group women defin dichotomi pregnant versu pregnant intervent versu control chang cigarett consumpt pregnant women signifi cantli pregnant women 0.001 pregnant women reduc consump tion 6 month deliveri creas consumpt 12 month pregnant women intervent group mean daili cigarett consumpt reduc 30 studi period main stabl control group dif ferenc trend intervent intervent found 0.05 posit effect intervent observ pregnant women 0.001 twenti cent pregnant women stop smoke report reduc cigarett consumpt end studi fifti cent increas consumpt pregnant women stop smok ing 34 report reduct cigarett consump tion 29 increas 187 gp particip studi 178 88 answer questionnair 33 femal 145 male sixteen cent report smoker 6 daili smoker 10 inclus relat smok ing habit gp cigarett consumpt patient studi twelv month preg nant women gp smoker report higher daili cigarett consumpt women attend smoke gp 9.2 versu 7.5 cigarett dai 0.02 equival trend found analysi serum thiocyan pregnant women nivers olleg ondon januari 13 2017 http fam pra.oxfordjournals.org ow nload http fampra.oxfordjournals.org 1 14 famili practic intern journal tabl 1 characterist particip pregnant pregnant women regist inclus characterist regist inclus pregnant women 350 95 ci pregnant women 274 95 ft ci signific mean ag women year mean ag start smoke year mean number cigarett smoke dai mean valu serum thiocyan anol 1 predict smoker 5 year percentag answer smoke big problem percentag partner smoke daili percentag encourag partner stop smoke 25.9 25.4 26.3 16.0 15.8 16.3 9.5 9.0 10.1 83.0 80.0 86.0 57 47.7 69.3 57.7 27.6 27.1 28.2 16.2 15.9 16.5 13.4 12.6 14.2 99.2 93.9 104.5 57 44.5 71.7 42.1 0.001 0.3 0.001 0.001 0.9 0.2 0.5 0.001 analys serum thiocyan perform pregnant women control group tabl 2 point preval abstin rate 6 12 18 month inclus 6 month 12 month 15 month 18 month pregnant intervent control pregnant intervent control 244 97 154 109 19 8 0.02 16 4 0.002 16 11 0.3 17 11 0.2 15 10 0.3 19 7 0.008 15 7 0.06 20 7 0.006 miss data pregnant 11 pregnant women tabl 3 smoke habit end studi characterist pregnant pregnant women regist inclus characterist regist inclus mean ag year mean ag start smoke year mean daili cigarett consumpt mean serum thiocyan anol 1 percentag partner smoke percentag partner encourag women stop smoke stop smoke 18 month 45 sd 27.0 4.0 16.7 2.0 9.1 4.7 71.0 25.7 51.1 73.3 pregnant women smoke 18 month 305 sd 25.7 4.1 15.9 2.1 9.5 4.8 84.7 28.7 71.9 55.4 signific 0.03 0.02 0.6 0.002 0.004 0.02 pregnant women stop smoke 18 month 43 sd 27.9 3.6 16.5 3.1 12.5 4.8 87.7 33.9 60.0 56.4 smoke 18 month 231 sd 27.6 4.5 16.2 2.6 13.5 6.8 102.2 33.9 73.8 39.5 signific 0.69 0.5 0.2 0.03 0.07 0.05 analys serum thiocyan perform pregnant women control group nivers olleg ondon januari 13 2017 http fam pra.oxfordjournals.org ow nload http fampra.oxfordjournals.org smoke intervent pregnanc 115 3 6 9 12 15 month intervent 18 figur 1 pregnant intervent pregnant intervent pregnant intervent pregnant intervent mean valu cigarett smoke dai 6 12 18 month inclus anol 1 0.16 106.0 versu 86.4 102.3 versu 93.1 pregnant women 0.04 pregnant women consult femal gp stop smoke consult male gp 19 versu 11 0.08 dif ferenc found pregnant women smoke cessat rate show correl ag gp number consult dai discuss regard point preval abstin rate pregnant women intervent group stop smoke studi period pare pregnant women control group 15 versu 7 result compar 10 smoke intervent studi pregnant women studi point preval abstin rate 12 month inclus vari 6 28 intervent group 2 14 control group 10 12 point preval abstin rate pregnant women studi 20 7 intervent control group corr spond intervent studi gener practic point preval abstin rate 12 month vari 17 19 intervent group 10 control group 58 found 1 year continu abstin rate 5 1 inter vention control group pregnant women close found russel al classic studi 5.1 3 5 studi demonstr differ enc 13 14 longer frequent intens consult result higher cessat rate 15 prior inclus gp screen 2379 preg nant women women smoke 3 month concept 16 report stop smoke check pregnanc 2 presum pregnant women studi belong select group smoker addict tobacco pregnant women agre particip studi end studi mean number cigar ett smoke dai pregnant pregnant women intervent group cigarett consumpt pregnant women inclus end studi previous report pregnant women reduc cigarett consumpt 31 check pregnanc 2 pregnant women 30 reduct cigarett consumpt studi period reduct virtual preg nant pregnant women intervent group gp recruit mean number 5.4 women argu result gp includ women studi receiv train specif health promo tion effort number daili smoke pregnant women reflect factual frequenc patient gener practic result realist regard gp involv ment time consumpt smoke cessat rate larg number daili smoke pregnant women consult gp year studi gp instruct includ consecut daili smoke pregnant women studi period expect number pregnant women recruit month recruit smoke women turn slow particip gp succe recruit expect women select place effect select posit neg regard cessat rate gp recruit heavi smoker hard com.ibm.drl.hbcp.core smoker particip cessat rate low hand women request smoke cessat includ highli motiv group women particip cessat rate high mechan place 398 gp initi invit particip studi 187 particip select gp posit specif studi ob nivers olleg ondon januari 13 2017 http fam pra.oxfordjournals.org ow nload http fampra.oxfordjournals.org 116 famili practic intern journal viousli place bind oneself par ticip studi 30 month challeng respond gp previous particip organ smoke tervent receiv specif educ smoke cessat techniqu patient counsel studi period awar smoke intervent studi clude particip gp result repres gener practic result publish conclus demonstr signific effect simpl smoke intervent programm carri larg number gp effect pregnant pregnant women regard stop smoke find promis pregnant women belong select group smoker mean daili cigarett consump tion posit effect intervent observ pregnant women convinc potenti women smoker period pregnanc child infanc suggest gp receiv train specif health promot effort addit effect low cost smoke intervent programm design pregnant women explor acknowledg grate particip women gp particip enthusiast 2 year studi studi financ norwegian cancer societi norwegian research council scienc human
effect voucher base incent abstin cigarett smoke fetal growth pregnant women sarah heil1,2 stephen higgins1,2 ira bernstein3 laura solomon2,4 randal rogers1 colleen thomas5 gari badger5 mari ellen lynch1 1 depart psychiatri univers vermont 2 depart psycholog univers vermont 3 depart obstetr gynecolog univers vermont 4 depart famili practic univers vermont 5 depart medic biostatist univers vermont abstract aim studi examin voucher base reinforc therapi vbrt conting smoke abstin pregnanc effect method decreas matern smoke pregnanc improv fetal growth design condit parallel group random control trial conduct set trial conduct univers base research clinic particip total 82 smoker enter prenat care particip trial intervent particip randomli assign conting conting voucher condit voucher exchang retail item pregnanc 12 week postpartum conting condit voucher earn biochem verifi smoke abstin conting condit voucher earn independ smoke statu measur smoke outcom evalu urin toxicolog test report fetal growth outcom evalu serial ultrasound examin perform trimest find conting voucher significantli increas point preval abstin end pregnanc 41 10 12 week postpartum assess 24 3 serial ultrasound examin significantli greater growth term estim fetal weight femur length abdomin circumfer conting compar conting condit conclus result provid evid vbrt substant contribut make effort decreas matern smoke pregnanc provid evid posit effect fetal health keyword voucher conting manag pregnant women smoke cessat fetal growth author sarah heil rm 1415 uhc 1 prospect st burlington vt 05401 usa sarah.heil uvm.edu nih public access author manuscript addict author manuscript pmc 2009 august 25 publish final edit form addict 2008 june 103 6 1009 1018 doi 10.1111 1360 0443.2008.02237 ih pa author anuscript ih pa author anuscript ih pa author anuscript introduct matern smoke lead prevent poor pregnanc outcom infant morbid mortal 1,2 effect intervent exist promot smoke cessat pregnanc cessat rate low 20 women smoke 10 cigarett dai educ 3 5 small grow literatur suggest voucher base reinforc therapi vbrt women earn voucher exchang retail item conting biochem verifi abstin promis promot smoke cessat pregnanc postpartum vbrt form conting manag began intervent outpati treatment cocain depend 6 result recent meta analysi 30 control studi support efficaci vbrt treatment wide rang substanc disord includ cigarett smoker 7,8 semin report vbrt pregnant postpartum smoker random trial involv low incom pregnant smoker assign vbrt usual care control condit 9 vbrt condit pregnant smoker receiv monthli 50 voucher conting biochem verifi smoke abstin pregnanc month postpartum biochem confirm smoke cessat rate end pregnanc 32 9 vbrt control condit 21 6 2 month postpartum assess magnitud treatment effect exceed result decad research topic warrant investig effort examin vbrt treat pregnant smoker pilot studi conduct low incom women smoke enter prenat care 10 research initi period sustain abstin import sustain abstin longer term 11 13 establish initi abstin pregnant smoker abstin monitor voucher base intervent begin high frequenc gradual taper downward antepartum period voucher base incent escal success drug neg specimen e.g 6.25 neg sampl 7.50 includ reset conting drug period abstin reset monetari voucher back initi low level 14 protect relaps postpartum 15 frequenc abstin monitor increas initi postpartum week taper downward 12 week postpartum treatment initi pilot studi group particip initi assign conting conting voucher condit consecut admiss randomli voucher antepartum 12 week postpartum earn biochem verifi smoke abstin conting condit independ smoke statu conting condit biochem verifi point preval abstin significantli greater conting conting condit end pregnanc 37 9 12 week postpartum 33 0 24 week postpartum 27 0 assess result provid evid efficaci voucher promot abstin pregnant smoker suggest effect continu discontinu vbrt postpartum result encourag temper fact major particip assign consecut admiss randomli current report present outcom complet random clinic trial addit rigor experiment design interest examin effect fetal growth 16,17 assess serial ultrasound examin heil al page 2 addict author manuscript pmc 2009 august 25 ih pa author anuscript ih pa author anuscript ih pa author anuscript method particip particip recruit larg group obstetr practic women infant children wic program greater burlington vt area studi inclus criteria report smoke puff past 7 dai prenat visit report estim gestat ag 20 week resid counti studi clinic locat plan remain geograph area 6 month deliveri speak english exclus criteria incarcer previous particip studi resid particip studi women receiv prenat care clinic complet questionnair basic sociodemograph smoke statu includ ag race year educ estim gestat ag ega smoke frequenc past 7 dai endors smoke past 7 dai subsequ contact studi staff studi particip total 182 women deem studi elig contact eighti 45 women agre particip enrol 43 24 express interest fail complet enrol process 57 31 contact refus particip characterist note compar enrol studi signific differ note mean sem gestat ag 9.1 0.4 studi particip 10.4 0.5 week particip 82 women agre particip 40 randomli assign conting voucher condit 42 conting condit random stratifi base clinic particip receiv prenat care criterion withdraw particip trial treatment assign pregnanc termin fetal demis 5 women 3 conting 2 conting withdrawn studi base criterion leav 77 women result analys studi outcom studi approv univers vermont institut review board particip provid written inform consent assess particip complet questionnair examin socio demograph current smoke statu histori smoke environ motiv confid intent quit smoke provid breath urin specimen studi intak assess appropri modifi version batteri complet month studi intak assess end pregnanc 28 week gestat 2 4 8 12 24 week postpartum assess abstin monitor period breath specimen analyz micro smokerlyz carbon monoxid monitor bedfont scientif kent uk onsit enzym immunoassai test emit microgen corp fremont ca run roch coba mira analyz distribut dade behr deerfield il determin urin cotinin level ga chromatographi perform laboratori labstat kitchen ontario canada confirm urin cotinin level urin specimen collect end pregnanc 12 end vbrt 24 week postpartum end studi assess treatment intervent abstin monitor schedul studi particip chose mondai quit date begin quit date particip report studi clinic met clinic staff site conveni provid breath urin sampl abstin monitor complet timelin follow back procedur assess smoke frequenc visit 18 monitor schedul particip conting conting voucher condit condit heil al page 3 addict author manuscript pmc 2009 august 25 ih pa author anuscript ih pa author anuscript ih pa author anuscript abstin monitor daili initi 5 dai mondai fridai cessat effort begin 2nd week monitor decreas weekli mondai thursdai 7 week week wednesdai 4 week wednesdai deliveri postpartum period monitor increas week wednesdai initi 4 week biweekli wednesdai 8 week abstin monitor end end week 12 monitor end intervent week 12 postpartum final 24 week postpartum assess conting voucher condit voucher redeem retail item earn conting submit breath specimen 6 ppm 19 initi dai cessat effort order detect reinforc initi cessat effort begin week 2 abstin monitor voucher deliv conting urin cotinin level 80 ng ml 19 criterion requir longer durat smoke abstin breath voucher deliveri independ report smoke statu base exclus meet biochem verif criterion voucher began 6.25 escal 1.25 consecut neg specimen maximum 45.00 remain bar posit test result miss abstin monitor visit posit test result miss visit reset voucher back origin low consecut neg test restor pre reset level cash particip voucher purchas made clinic staff conting voucher condit condit voucher deliv independ smoke statu voucher valu 15.00 visit antepartum 20.00 visit postpartum estim suffici sustain particip abstin monitor result payment amount compar averag earn conting condit conting voucher condit servic addit monitor voucher base incent mention particip receiv usual care smoke cessat provid obstetr clinic typic involv provid inquiri smoke statu discuss advantag quit pregnanc studi staff attempt influenc clinic practic part studi intervent studi staff review smoke cessat pamphlet particip initi intak assess design pregnant women 20 abstin end pregnanc assess receiv pamphlet highlight reason remain abstin postpartum 21 particip inform nicotin replac product urin sampl test posit cotinin ultrasound examin infant outcom deliveri ultrasound examin perform approxim 30 34 week gestat purpos estim fetal growth fifti women 29 conting 28 conting complet examin measur fetal growth includ estim fetal bipariet diamet head circumfer abdomin circumfer femur length obtain standard techniqu sonograph blind particip treatment condit smoke statu head circumfer abdomin circumfer femur length combin method hadlock 22 calcul estim fetal weight estim made lean bodi mass accret fetal thigh emploi previous report techniqu 23 fetal measur perform triplic mean assign estim specif paramet serial ultrasound assess fetal size obtain gener individu estim fetal growth mid trimest compar treatment condit examin factor influenc fetal growth significantli random heil al page 4 addict author manuscript pmc 2009 august 25 ih pa author anuscript ih pa author anuscript ih pa author anuscript condit record matern ag pre pregnanc bodi mass index bmi matern weight gain pregnanc 1 hour glucos screen result illicit drug exposur pariti infant gender infant birth weight gestat ag deliveri obstetr chart utero fetal growth fetal femur length lean bodi mass shown sensit marker effect matern smoke 24 28 gener analysi repeat measur gener serial ultrasound greater statist power rel relat measur collect singl time point e.g birth weight subject subject variabl estim growth paramet account initi ultrasound provid sensit analysi growth allow signific differ emerg smaller sampl infant outcom measur obtain matern medic record includ gestat ag deliveri birth weight nurseri admiss newborn neonat intens care unit nicu statist method primari analysi smoke abstin base particip random except women withdrawn due pregnanc termin fetal demis 77 conting conting treatment condit compar particip characterist chi squar test categor measur test continu measur fisher exact test compar condit assess complianc end pregnanc 12 24 week postpartum assess treatment condit compar point preval continu abstin smoke miss specimen treat smoke posit point preval abstin compar condit end pregnanc 12 24 week postpartum fisher exact test declar abstin assess particip 1 report smoke puff past 7 dai 2 urin cotinin level 80 ng ml test compar condit mean week continu abstin defin report smoke clinic visit neg biochem confirm test result percentag particip condit continu abstin entir trimest compar fisher exact test treatment condit compar fetal growth paramet subset particip serial ultrasound obtain 57 growth rate comput base number dai ultrasound convert weekli growth rate analys covari evalu treatment differ growth rate control particip pre pregnanc bmi variabl significantli treatment condit signific com.ibm.drl.hbcp.predictor growth outcom analys covari similar manner compar fetal growth abstain 15 smoker 42 independ treatment condit studi power detect differ treatment condit infant outcom deliveri conting conting treatment condit compar chi squar test categor measur test continu measur analysi covari treatment condit comparison birth weight order adjust group differ particip pre pregnanc bmi data set twin born particip conting condit set twin born particip conting condit exclud analys multipl gestat confound outcom addition data infant particip conting miss leav 34 39 infant born particip conting conting condit statist analys perform sa version 9.1 sa institut cari nc statist signific determin base α 05 heil al page 5 addict author manuscript pmc 2009 august 25 ih pa author anuscript ih pa author anuscript ih pa author anuscript result particip characterist signific differ socio demograph smoke characterist note women random conting conting voucher condit studi intak assess tabl 1 assess complianc complianc period assess high 83 95 significantli treatment condit assess point smoke abstin biochem confirm point preval abstin level significantli greater women conting conting condit end pregnanc assess 41 10 fisher exact test 003 12 week postpartum assess 24 3 fisher exact test 006 figur 1 point preval abstin 24 week postpartum assess conduct month discontinu voucher program significantli 8 3 mean week sem continu abstin antepartum period significantli greater conting conting condit conting condit achiev 9.7 1.9 week compar 2.0 8 week conting condit 75 3.90 001 figur 2 top panel addition greater percentag women conting compar conting condit sustain abstin trimest 24 conting condit maintain abstin trimest compar 3 conting condit fisher exact test 005 figur 2 bottom panel evid conting particip continu smoke reduc level smoke mean decreas urin cotinin level intak assess end pregnanc assess 39 33 ng ml conting conting condit voucher earn 12 week postpartum time voucher program end significantli treatment condit total mean sd voucher earn 461 456 rang 0 1,180 413 163 rang 75 670 conting conting condit report nicotin replac product studi particip conting condit report dai gum week studi abstin determin level fetal growth infant outcom deliveri demograph characterist smoke statu end pregnanc assess compar particip 57 20 complet ultrasound examin signific differ note complet ultrasound examin percentag women treatment condit abstin end pregnanc assess strikingli consist abstin differ observ total sampl conting condit 12 29 41 subset abstin compar 15 37 41 total sampl women treat condit conting condit 3 28 11 subset abstin compar 4 40 10 total sampl women treat condit heil al page 6 addict author manuscript pmc 2009 august 25 ih pa author anuscript ih pa author anuscript ih pa author anuscript significantli greater increas estim fetal weight conting compar conting condit 1,55 8.4 006 tabl 2 figur 3 top panel addit estim growth rate individu paramet comput estim fetal weight fetal femur length fetal abdomin circumfer significantli greater conting compar conting condit 1,54 4.4 4.1 ps 05 tabl 2 figur 3 bottom panel trend greater growth conting conting condit note lean thigh area tabl 2 statist differ head circumfer bipariet diamet tabl 2 fetal growth measur compar abstain smoker independ treatment condit significantli greater increas estim fetal weight 214.9 13.0 190.3 8.2 1,54 6.54 01 trend greater growth abstain smoker note abdomin circumfer statist differ head circumfer femur length lean thigh area bipariet diamet mean birth weight significantli treatment condit tabl 3 mean differ 253 greater estim ultrasound examin support pattern diverg growth rate condit trend outcom conting compar conting condit note percentag low birth weight infant preterm birth mean gestat ag deliveri tabl 3 expect statist differ percentag nicu admiss discuss antepartum abstin level observ conting condit present studi doubl abstin rate typic report efficaci intervent lower incom pregnant smoker 3 5 result coupl prior trial 9,10 provid compel evid support efficaci vbrt promot smoke cessat pregnant women conting incent effect establish biochem verifi period continu smoke abstin antepartum period averag 10 week durat compar 2 week conting condit time abstin differ import 24 women treat conting condit abstain trimest compar 3 treat conting condit previou research underscor import smoke statu trimest fetal growth 16,17,29 consist result smoke abstin result present studi document greater fetal growth trimest women conting compar conting condit growth effect observ present studi consist effect smoke fetal growth evid smoke disproportion affect femur length 26 28 result underscor benefit measur fetal growth collect serial ultrasound examin outcom measur type research note earlier opportun repeat measur afford ultrasound examin greater statist power smaller sampl size power detect differ outcom measur singl time point infant outcom deliveri birth weight show trend outcom conting compar conting condit statist heil al page 7 addict author manuscript pmc 2009 august 25 ih pa author anuscript ih pa author anuscript ih pa author anuscript extens correl evid show smoke abstin signific benefit fetal growth neonat birth weight limit experiment evid semin experiment studi smoke cessat pregnant women sexton hebel 30 report significantli greater matern smoke abstin neonat birth weight experiment compar control condit studi biochem confirm smoke abstin 43 20 end pregnanc neonat birth weight 3,278 3,186 92 mean differ consist 253 mean differ observ present studi awar experiment report literatur examin effect smoke cessat neonat birth weight report 71 31 218 32 increas experiment condit futur studi vbrt examin effect fetal growth neonat birth weight inform term examin replic present find gain understand quit smoke impact import outcom smoke abstin continu high level postpartum period magnitud effect consist compar result prior random trial 10 studi examin abstin discontinu voucher program 24 week postpartum smoke abstin rate significantli greater conting compar conting condit random trial present studi outcom point greater abstin conting condit studi investig larger sampl appear estim magnitud effect discontinu incent result antepartum period promis potenti com.ibm.drl.hbcp.util type intervent substant improv fetal growth observ present studi short term intervent direct smoke cessat durat pregnanc benefici potenti limit studi warrant comment rate enrol studi 45 lower report intervent literatur 9,33,34 enrol rate present studi artifact method recruit order enrol particip meet goal research protocol recruit multipl clinic introduc delai potenti particip contact dai prenat care appoint health care profession member prenat care practic ideal recruit occur part prenat visit member practic enrol rate observ present studi repres rate achiev program implement singl practic lower enrol rate present studi comparison demograph smoke characterist smoke attitud report literatur suggest sampl compar 9,33,34 cost obviou practic issu regard incent base intervent perform formal cost analysi cost incent averag 334 antepartum period appear reason consid cost care neonat advers affect cigarett smoke exposur recent studi u. 35 estim matern smoke result addit medic cost year birth rang 1,142 1,358 woman smoke pregnanc cost dramat underscor serious public health problem gener lack progress promot abstin rate 20 low cost intervent broad reach suggest treatment approach address recalcitr behavior intervent lower intens cost greater reach intervent higher intens cost reach voucher base intervent investig present studi approach typic approach address illicit drug abus pregnant women efficaci subset pregnant women smoker typic fare heil al page 8 addict author manuscript pmc 2009 august 25 ih pa author anuscript ih pa author anuscript ih pa author anuscript lower intens approach present result encourag potenti com.ibm.drl.hbcp.util voucher base incent increas smoke abstin improv fetal growth pregnant women acknowledg alissa dumeer paula glasmann natali jacuzzi luke mchale adrien preston ed reimann lauren shapiro lindsai simpson rachel vital jin yoon assist data collect entri research support research grant r01da14028 sth gcrc mo1rr109
www.elsevier.com locat ypmed prevent medicin 40 2005 249 258 team project effect smoke cessat intervent hospit patient deborah hennriku ph.d harri lando ph.d maribet mccarti ph.d m.p.h r.n david klevan m.d neal holtan m.d m.p.h jacquelyn huebsch ph.d r.n sharon jestu r.n paul pentel m.d donald pine m.d susan sullivan ph.d m.p.h karen swenson r.n m. a.o.c.n john vessei ph.d.g adivis epidemiolog school public health univers minnesota minneapoli mn 55454 usa bhealthpartn medic group michigan citi 46360 usa cst paul divis public health st paul mn 55101 usa dregion hospit st paul mn 55101 usa ehennepin counti medic center minneapoli mn 55415 usa fpark nicollet health system minneapoli mn 55440 usa gwheaton colleg wheaton il 60187 5593 usa onlin 8 juli 2004 abstract background studi evalu effect smoke cessat intervent popul 1 modifi usual care uc 2 advic 3 advic extend counsel hospit method smoker 2,095 patient hospit randomli assign condit smoke statu ascertain phone interview 7 dai 12 month post discharg 12 month report abstin valid analysi saliva cotinin intent treat analys perform result 7 dai follow 24.2 particip report abstin previou 7 dai differ condit 12 month follow report abstin significantli higher condit uc 15.0 15.2 19.8 signific differ condit cotinin valid abstin uc 8.8 10.0 9.9 conclus intervent hospit patient increas abstin rate featur studi contribut find inclus particip criteria fact pharmacolog aid provid stage match approach result intens counsel particip unwil set quit date 2004 institut cancer prevent elsevi right reserv keyword hospit smoke cessat valid report counsel introduct taliz repres good access point smoke hospit opportun reach larg number smoker time recept advic quit 1 4 smoker hospit servic nonsmok 5 hospi 0091 7435 front matter 2004 institut cancer prevent doi 10.1016 j.ypm 2004.05.030 author divis epidemiolog school public health univers minnesota 1300 south street suit 300 minneapoli mn 55454 fax 1 612 624 0315 mail address hennriku epi.umn.edu d.j hennriku cessat intervent experi impair health make smoker recept health relat messag 2 addit hospit smoke ban break routin occur hospit con dition aid cessat effort fact quit rate hospit significantli higher rate expect gener popul absenc smoke cessat intervent 6,7 grow literatur effect smoke cessat intervent hospit 8,9 franc elsevi right reserv d.j hennriku al prevent medicin 40 2005 249 258250 al 9 review studi perform 1999 found total 20 studi examin effect hospit base smoke cessat intervent includ con trol comparison condit result efficaci intervent mix found statist signific differ control intervent group note author review studi differ import dimens includ reach intens hospit counsel durat relaps prevent counsel discharg level train intervent staff explain differ find clear conclus relaps prevent program sustain 3 5 month period discharg import determin success hospit base smoke cessat intervent clear import high intens hospit interven tion perform staff highli train smoke cessat counsel effort dedic provid servic steven al 4 hajek al 10 found smoke cessat intervent perform hospit staff inconsist carri result cessat rate significantli control review studi limit reach group recept smoke cessat messag patient specif ill relat smoke 11 13 think quit 14 16 expect quit rate typic lower studi fewer exclus control trial exclud patient base readi quit type ill steven al 17 found signific differ intervent control group long term abstin rate abstin biochem valid find effect counsel interven tion long term abstin studi due featur intervent 4,18 relaps prevent compon studi briefer 3 5 month period identifi effect franc glasgow review rigotti al 18 provid counsel phone call month discharg hospit patient quit steven al 4 provid post discharg counsel phone call note respiratori therapist interventionist fail reach patient assign intervent condit present studi team teachabl moment project assess system base intervent implement hospit twin citi area low intens intervent provid doctor nurs regular patient care high intens intervent train staff motiv interview approach provid hospit counsel session counsel phone call 6 month discharg compar modifi usual care uc condit patient provid smoke cessat man ual advic counsel high intens con dition includ featur identifi effect previou studi strong relaps prevent compon train counselor dedic studi unlik previou studi smoke cessat hospit patient recruit limit specif medic condit readi quit question interest treatment condit includ compon relat success outcom studi effect larg unrestrict patient popul method hospit hospit particip studi counti facil downtown set privat suburb studi counti hospit purchas manag care organ studi approv institut review board univers minnesota particip hospit particip particip drawn gener admiss studi hospit patient potenti elig smoke cigarett week admiss consid regular smoker 1 month year admiss patient pregnant chemic depend psychiatr disturb primari reason admiss exclud studi elig requir includ ag 18 75 year length hospit stai 24 greater abil understand consent process avail telephon contact addit patient sever physic mental distress approach particip recruit hospit research assist obtain list admiss previou dai screen patient meet ag admiss diagnosi requir smoke statu elig criteria research assi tant approach elig patient inform consent ask consent patient complet baselin interview random treatment condit group assign list condit randomli order block 30 assign intervent treatment group vari intervent inten siti modifi usual care condit uc particip d.j hennriku al prevent medicin 40 2005 249 258 251 receiv smoke cessat manual tailor hospi tal patient 19,20 directori smoke cessat program resourc commun provid advic condit particip smoke cessat manual directori commun resourc research assist label patient record cue nurs physician provid medic care patient give 60 smoke cessat advic document advic label cue physician provid advic patient chart hospit locat label cue nurs advic determin consult nurs hospit act prompt label cu advic told provid patient smoker particip studi includ prompt provid advic quit mention quit posit health benefit hospit stai opportun quit direct patient cessat manual research assist enrol studi provid ask sign date label provid advic import featur provid advic condi tion activ frequent effort inform provid studi encourag provid smoke cessat advic team project label effort led team project physician nurs investig hospit vari hospit promot effort includ articl hospit staff newslett letter physician inform session nurs ward present physician group poster effect smoke nurs physician loung small incent provid advic e.g 2 gift certif hospit coffe shop entri monthli lotteri 50 gift certif nurs document advic snack team project provid desk ward addit research assist attempt alert nurs patient care random provid advic condit particip advic condit receiv letter discharg sign physician nurs investig hospit reiter health care provid quit ask read smoke cessat manual receiv hospit addit pamphlet enclos letter advic counsel condit particip receiv intervent deliv con dition e.g manual resourc directori provid advic letter discharg extend bedsid counsel session hospit telephon call research nurs 6 month discharg nurs provid counsel session hospit deliv phone discharg occur particip hospit stai short research nurs motiv interview 21 relaps prevent 22 approach assess factor affect particip abil ing quit includ stage chang efficaci relat quit counsel increas motiv discuss quit strategi depend particip current stage readi chang counselor encourag undecid particip examin ambival quit voic reason quit counsel decid quit focus review barrier cessat strategi cope urg smoke develop action plan quit maintain motiv stai cigarett gener strategi cope continu urg smoke focu particip succeed quit smoke nicotin replac therapi nrt counter period studi bupropion zyban prescript nrt bupropion free charg studi nurs counselor provid inform cessat aid help direct condit particip need smoke cessat program commun counsel session close space particip set quit date avoid relaps protocol call counsel session occur 2 3 dai 1 week 2 3 week 1 month 3 month 6 month quit date counsel call schedul roughli 1 month particip set quit date protocol time call base quit date counsel develop action plan initi particip set date particip set quit date 2 3 session desir session counsel discontinu flexibl counsel approach consist recommend 2000 clinic practic guidelin treat tobacco depend 23 research nurs receiv 12 initi train smoke cessat counsel provid detail manual includ counsel guidelin gener inform health effect smoke quit techniqu pharmacolog aid smoke cessat train session includ didact present role plai studi counselor met regularli review case discuss problem encount particip data collect baselin interview conduct hospit random treatment follow interview conduct divis epidemiolog tele phone survei center 7 18 dai median 9 dai mean 9.4 dai 12 month median 369 dai mean 373.1 d.j hennriku al prevent medicin 40 2005 249 258252 dai hospit discharg window 12 dai reach subject initi follow interview optim reach end window time quit relaps interview place estim quit rate affect problem signific differ condit time discharg follow interview measur demograph characterist measur baselin includ ed ag gender ethnic marit statu educ determin smoke statu baselin respond ask smoke cigarett regular basi 100 cigarett lifetim smoke regularli ask smoke cigarett current smoker ask smoke 7 dai hospit period 1 month past year gener smoke dai smoke variabl measur baselin includ number ciga rett smoke dai daili smoker week occasion smoker ag initi smoke number year smoker stage chang 24 level addict nicotin fagerstrom scale item time wake cigarett dai 25 percentag friend smoker level efficaci cessat measur singl item ask particip rate scale 0 10 confid quit perman decid main cessat outcom assess follow 7 dai point preval smoke particip ask smoke puff tobacco product previou 7 dai 26 12 month interview ask consid current smoker nicotin replac ment product 7 dai interview subject smoke tobacco product previou 7 dai consid abstin report 12 month interview subject report tobacco product previou 7 dai current smoker nicotin placement product consid abstin report particip report abstin 12 month interview ask provid saliva sampl test cotinin metabolit nicotin respond consent kit materi saliva collect 3 dai postcard remind return sampl fail return sampl 9 12 dai origin mail receiv telephon remind mail kit return sampl mail incent payment 25 method collect saliva sampl biochem vali dation previou studi 27 discharg diagnosi base inform abstract ed particip medic record hospit personnel train nosolog code inform primari secondari discharg diagnos form code base intern classif diseas 9th version clinic modif icd 9 cm 28 return univers particip primari discharg diagnosi classifi smok ing relat base classif surgeon gener report health consequ smoke 29,30 method classif lando al 31 particip provid advic condit chart nurs record audit determin provid document smoke cessat advic initi sticker prompt give advic research nurs complet form counsel session particip condit note time length counsel session analysi analys conduct sa statist packag version 8.1 32 outcom variabl absti nenc tobacco dichotom multivari analys conduct logist regr sion techniqu cotinin sampl inform nicotin replac product collect 7 dai interview analys data conduct report tobacco product outcom analys 12 month data conduct version outcom variabl report abstin report adjust result cotinin analys follow patient refus interview contact consid smoker intent treat anali si cotinin correct 12 month outcom cotinin valu greater equal 15 ng ml refus fail provid saliva sampl consid smoker subject di ill particip exclud analys mantel haenszel test homogen effect perform outcom determin result hospit pool chi squar analys relationship treatment condit outcom measur perform final effort examin effect outcom accept patient stage chang diagno si separ logist regress analys run exam in relationship stage chang presenc smoke relat ill 12 month cessat variabl d.j hennriku al prevent medicin 40 2005 249 258 253 result particip recruit follow rate fig 1 consort flowchart describ cruitment intervent follow rate 33 search assist screen 55,120 patient period januari 1997 june 1999 thirteen thousand hundr thirti 24.9 smoker 5,166 patient elig studi particip 3,988 approach consent enrol 2,095 patient 52.5 patient approach fig 1 flow patient consent major reason inelig identifi smoker admiss psychiatr problem chemic depend 18.7 subject approach consent unavail follow lack phone 6.4 ill particip 10.1 length stai 24 8.2 22.8 elig studi approach consent larg due breviti hospit stai studi staff made multipl attempt talk patient elig studi patient unavail e.g sleep test procedur busi visitor stage studi tabl 1 characterist particip random studi condit characterist modifi usual care uc 696 advic 703 advic counsel 696 male 323 46.4 331 47.1 335 48.1 mean ag sd year 47.1 13.2 47.9 13.1 47.5 13.2 educ high school 337 48.6 380 54.2 347 50.0 colleg 243 35.1 222 31.7 244 35.1 colleg graduat 113 16.3 99 14.1 105 15.1 marri 380 54.7 365 52.1 366 52.7 ethnic white 551 79.2 541 77.5 547 78.9 black 115 16.5 114 16.3 113 16.3 30 4.3 43 6.2 33 4.8 stage chang precontempl 113 16.4 139 20.0 106 15.3 contempl 298 43.1 301 43.4 335 48.5 prepar 280 40.5 254 36.6 250 36.2 cigarett dai 5 min 261 37.8 281 40.3 284 41.0 6 30 min 216 31.3 220 31.5 192 27.8 31 60 min 86 12.5 81 11.6 93 13.4 60 min 127 18.4 116 16.6 123 17.8 confid abil quit mean sd 0 10 scale 7.0 2.8 6.8 2.8 6.9 2.7 ag start smoke 14 year younger 185 26.7 180 25.8 181 26.0 15 16 year 180 26.0 188 26.9 189 27.2 17 18 year 137 19.8 154 22.0 137 19.7 19 year older 190 27.5 177 25.3 188 27.1 smoke relat diagnosi 217 31.5 182 26.2 208 31.0 percentag friend smoker 207 29.8 227 32.6 219 31.7 half 62 8.9 66 9.5 74 10.7 half 166 23.9 149 21.4 125 18.1 half 117 16.8 115 16.5 138 19.9 130 18.7 134 19.2 129 18.6 hospit 139 20.0 136 19.4 138 19.8 290 41.7 290 41.3 287 41.2 158 22.7 164 23.3 156 22.4 109 15.7 113 16.1 115 16.5 d.j hennriku al prevent medicin 40 2005 249 258254 2,095 particip enrol studi 1,812 86.5 complet follow interview 1,591 75.9 complet final follow complet rate similar studi condit 7 dai interview complet rate 12 month follow lower advic counsel group due higher rate refus failur reach particip separ logist regress analys follow occas interview complet depend variabl particip characterist includ covari show loss follow significantli relat studi condit 7 dai 12 month follow educ level greater high school gradua tion african american ethnic precontempl prepar stage chang significantli complet interview 7 dai 12 month follow up male signifi cantli complet 7 dai interview differ sex complet 12 month interview tabl 1 present characterist baselin partic ipant treatment condit outstand differ group baselin characterist intervent fidel fig 1 inform intervent rate patient enrol studi receiv smoke cessa tion manual medic record particip advic advic counsel condit audit determin provid docu ment provis smoke cessat advic initi advic remind label physician remind label audit 96.2 relev chart nurs remind label 93.3 document label 47.5 particip condit receiv advic physician 51.2 particip condit receiv advic nurs 72.0 receiv advic sourc differ condit provid advic rate signific differ rate hospit rate advic sourc rang 58.3 hospit 90.7 hospit chi squar 80.84 0.0001 examin counsel record 590 88.6 666 particip condit receiv counsel session 37.2 receiv median number session provid 4 half 43.5 initi counsel session conduct phone discharg hospit median length initi session 20 min 25 session 30 min longer median length phone session 10 min phone call rang durat 1 min 40 min quit rate mantel haenszel test homogen effect found differ hospit relationship treatment condit uc uc smoke outcom variabl indic result pool hospit hundr partici pant 27.9 complet interview 24.2 enrol particip report quit 7 dai survei 1,119 particip 61.8 complet tabl 3 relationship studi condit abstin 7 dai 12 month interview group group quit chi squar 7 dai follow report data intent treat analysi modifi usual care 673 175 26.0 advic 676 162 24.0 advic counsel 672 169 25.2 0.84 0.05 12 month follow report intent treat analysi modifi usual care 673 101 15.0 advic 678 103 15.2 advic counsel 666 132 19.8 7.17 0.05 12 month follow cotinin correct intent treat analysi modifi usual care 673 59 8.8 advic 678 68 10.0 advic counsel 666 66 9.9 0.75 0.05 d.j hennriku al prevent medicin 40 2005 249 258 255 interview 53.4 enrol particip report quit attempt last 24 total 336 particip 21.1 complet interview 16.0 enrol particip report tobacco nicotin replac product previou 7 dai 12 month survei 241 provid analyz saliva sampl tabl 2 detail rate saliva sampl return partic ipant report abstin 12 month interview small number particip refus provid sampl ask nicotin replac product larger number agre return sampl 241 sampl analyz 48 19.9 concentr cotinin consist smoker i. equal greater 15 ng ml number disconfirm greatest advic counsel condit analysi occur renc problem cotinin provis i. disconfirm refus failur provid sampl condit interview 12 month follow problem significantli relat studi condit chi squar 12.06 0.0015 problem significantli occur advic counsel ing condit 9.9 modifi usual care 6.1 advic 5.2 condit tabl 3 present result bivari analys 7 dai report quit rate 12 month report cotinin valid quit rate signific differ abstin studi group 7 dai follow interview abstin rate significantli higher advic counsel condit tabl 2 number particip follow studi condit modifi usual care uc advic advic counsel subject analysi 673 678 666 elig saliva sampl lost follow upa 122 18 139 21 165 25 elig smoke previou 7 dai 432 64 420 62 352 53 nrt 16 2 12 2 15 2 consid smoker 2 1 4 1 2 1 abstin elig 101 15 103 15 132 20 saliva sampl return analysi elig sampl provid refus provid sampl 4 1 2 1 4 1 return sampl 20 3 22 3 39 6 technic problemsb 4 1 2 1 4 1 return sampl 74 11 78 12 89 13 disconfirm report z15 ng ml cotinin 15 2 10 1 23 3 refus reach 12 month interview subject ask saliva error saliva analyz due technic problem 12 month follow report data differ enc signific cotinin correct analysi advic condit significantli usual care condit analysi pattern result found multivari analys control moder variabl logist regress analys examin relationship stage chang treatment condit 12 month outcom variabl found stage chang significantli relat report cotinin cor rect 12 month quit rate precontempl lower quit rate contempl prepar report quit rate precontempl contempl prepar 7.2 19.1 18.1 respec tive cotinin correct rate 2.9 12.6 9.2 interact stage chang treatment condit signific outcom variabl logist regress analys examin relationship smoke relat diagnosi treatment condit 12 month outcom variabl found signific interact diagnosi treatment condit outcom quit rate higher smoke relat diagnos treatment condit differ pronounc provid advic condit cotinin correct instanc quit rate smoke relat diagnosi diagnosi 13.0 7.0 modifi usual care condit 22.4 5.6 advic condit 14.2 8.4 advic counsel condit discuss advantag studi larg sampl patient divers set hospit biochem valid report cessat inclus comparison group receiv smoke cessat manual d.j hennriku al prevent medicin 40 2005 249 258256 intens condit includ element identifi effect previou studi long term relaps prevent compon train counselor dedicat ed studi strong test effect smoke cessat intervent gener admiss popul hospit patient result interview conduct 7 18 dai discharg hospit provid evid hospit iz patient engag smoke cessat program engag result effort quit 52.5 subject invit particip smoke cessat studi consent half attempt quit smoke period immedi discharg stai cigarett 24 quarter report tobacco period 7 dai true particip treatment group hospit stai promis recruit point smoke cessat intervent studi result provid support intervent present studi differ treatment group short term i. 7 18 dai discharg hospit abstin rate signific differ report abstin 12 month discharg cessat rate advic counsel condit 19.8 higher modifi usual care 15.0 advic 15.2 condit differ disappear report result correct result biochem valid difficult compar quit rate found studi studi differ enc studi elig criteria intens intervent extent loss follow factor greatli affect quit rate intent treat analysi valid long term quit rate present studi higher found rigotti al 18 i. 8.1 intervent group 8.7 control group studi unrestrict sampl weaker relaps prevent compon miller al 15 i. 20 22 27 usual care minim intervent intens intervent group studi restrict patient readi quit strong relaps prevent compon free nicotin replac therapi loss follow examin subgroup result present studi inclus depress quit rate precontempl patient smoke relat diagnosi lower 12 month quit rate part inclus group affect abstin rate condit factor led lower quit rate pharmacolog aid smoke cessat provid counselor provid informa tion nicotin replac product bupropion financi reach particip previou hospit base research suggest greater pharmacolog aid conjunct relaps prevent program produc result 8 final note counsel condit discontinu patient set quit date 3 4 counsel session consequ ly 63 particip advic counsel ing group receiv counsel session 13 receiv maximum number session reason approach particip select base readi quit multipl call patient interest make concret step quit counsel increas motiv warrant practic meant subject counsel condit receiv intens intervent discrep report cotinin cor rect result 12 month follow find condit higher rate disconfirm failur return sampl perplex studi smoke cessat hospit patient report low level biochem valid 15,18 rigotti al 18 confirm report nonsmok 54 82 patient request saliva sampl 6 month follow unlik present studi differ confirm rate studi condit signific miller al rigotti al studi differ expect direct 60 control group 48 inter vention group differ disconfirm condit present studi consist conclus velic al 34 valid report surveil studi test low intens treatment test intens intervent note disconfirm rate low intens modifi usual care uc condit 44 rate similar found control group rigotti al 18 studi studi hospit patient report differ disconfirm condit result present studi rais strong caution reli report determin outcom set note major reason disconfirma tion report present studi failur return saliva sampl report abstain ask provid saliva sampl 14 provid sampl test posit cotinin 3 refus provid sampl 25 agre provid sampl rigotti al 18 report major reason disconfirm report studi failur obtain sampl financi incent provid sampl collect made easi particip failur provid sampl present studi d.j hennriku al prevent medicin 40 2005 249 258 257 due reluct admit smoke time provid sampl complet accompani survei mail item constitut signific barrier relationship loss follow disconfirm report abstin treatment condit studi intent treat analysi valid report impor tant rememb provid conserv estim abstin rate pose signific problem larg popul base studi lengthi follow period true result studi report quit result cotinin correct intent treat result loss follow disconfirm rate found studi point import improv methodolog reach particip follow obtain sampl biochem valid report rigor review literatur conclud strong smoke cessat intervent hospit patient effect 6,8 reason lack effect present studi unclear result rais cautionari note hospit base smoke cessat intervent report evalu outcom hospit base program acknowledg research support grant hl54132 nation institut health
journal american colleg cardiolog vol 56 25 2010 2010 american colleg cardiolog foundat issn 0735 1097 36.00 peripher arteri diseas effect smoke cessat program peripher arteri diseas patient random control trial deborah hennriku phd ann joseph md mph harri lando phd sue duval phd lauri ukestad ms molli kodl phd alan hirsch md minneapoli minnesota object studi test effect smoke cessat program design patient peripher arteri diseas pad background tobacco lead risk factor pad incid progress ischem event tobacco ce sation reduc pad relat morbid mortal prospect clinic trial evalu smoke cessat intervent pad patient method recruit outpati lower extrem pad identifi medic record cigarett smoker partici pant randomli assign intens tailor pad specif counsel intervent minim inter vention particip complet survei baselin 3 6 month follow report 7 dai point prev alent smoke abstin confirm cotinin carbon monoxid assess result 687 outpati identifi probabl smoker lower extrem pad 232 met studi elig requir 124 53 elig enrol particip recept counselor contact median number session 8.5 rang 0 18 particip randomli assign intens intervent group significantli confirm abstin 6 month follow 21.3 versu 6.8 minim intervent group chi squar 5.21 0.023 conclus long term smoker pad initi quit attempt engag intens smoke cessat program intens intervent tobacco depend effect smoke cessa tion intervent minim care studi conduct examin long term effect tensiv smoke cessat program popul examin effect intervent clinic relat pad coll cardiol 2010;56 2105 12 2010 american colleg cardiolog foundat ublish elsevi doi 10.1016 j.jacc 2010.07.031 therosclerot peripher arteri diseas pad highli reval disord affect 5 10 u. dult 40 year ag 1 3 pad major isabl person decreas function apac exercis limb pain claudi ation untreat progress critic limb schemia defin ischem rest pain gangren mputat 4,5 rom divis epidemiolog commun health school public ealth univers minnesota minneapoli minnesota medic school uni ersiti minnesota minneapoli minnesota divis environment health cienc school public health univers minnesota minneapoli minnesota veteran administr medic center minneapoli minnesota roject support fund clearwai minnesota bloomington minnesota grant rc 2005 0039 dr duval receiv research grant abbott ascular author report relationship disclos manuscript receiv march 31 2010 revis manuscript receiv june 25 2010 ccept juli 6 2010 cigarett smoke singl import risk factor develop progress pad 1,2,6,7 eta analysi 17 studi found 2.2 fold greater preva enc symptomat pad smoker compar onsmok 7 continu smoke acceler pro ression stabl claudic limb ischem ad syndrom includ critic limb ischemia atal nonfat system cardiovascular ischem event e.g angina myocardi infarct transient ischem ack stroke pad patient achiev abstin rom smoke higher surviv rate 8 10 page 2113 import quit smoke person ith pad studi examin smoke cessat ad patient conduct 2 1 2106 hennriku al jacc vol 56 25 2010 smoke cessat program pad patient decemb 14 21 2010 2105 12 observ studi formal smoke cessa tion program provid 11,12 random studi conduct galvin al 13 test effect nurs conduct smoke cessat educ pro gram nicotin gum pharmacolog aid smoke essat sampl size small end point smoke reduct smoke cessat tudi found signific differ intervent control group report number cigarett moke test 2 biomark tobacco expir arbon monoxid urinari cotinin metabolit nico in provid conflict result 13 present studi test reach effect ntensiv comprehens smoke cessat program ad patient object examin ess pad patient enrol intens program econd object examin program effect ypothes 7 dai point preval abstin ould significantli higher patient randomli ssign intens pad specif intervent condi ion compar patient randomli alloc mini al intervent usual care control group ethod it particip particip recruit 2 edic center minneapoli abbott northwestern ho ital minneapoli veteran administr medic enter vamc particip provid written orm consent studi approv institut eview board univers minnesota vamc allina health system primari inclus criteria diagnosi lower xtremiti pad defin 1 nkle brachial index 0.90 1 lower extrem oe brachial index 0.60 object evid arteri cclusiv diseas 1 lower extrem duplex ultrasonog aphi magnet reson angiographi comput tomo raphic angiographi prior leg arteri revascular mputat due pad current smoke defin moke 1 cigarett dai 6 dai week ddition inclus criteria includ desir quit 30 dai ag 18 year older abil speak rite english particip smoke cessat rogram past 30 dai consumpt fewer 1 alcohol drink week rocedur juli 2006 2008 studi staff dentifi potenti elig patient schedul upcom visit recruit site appoint ent list electron medic record patient etter describ studi screen abbrevi acronym pad peripher arteri diseas vamc veteran administr medic center elephon upcom medic appoint erson visit determin elig studi nterest elig patient underw inform onsent process studi coordin clinic visit complet baselin survei random partici ant predetermin block random schedul tratifi medic center intens smoke essat intervent group minim intervent roup follow survei mail particip 3 month 6 month baselin survei complet mail copi survei remind letter articip return initi copi urvei return contact particip elephon request survei complet 6 month ollow particip return urvei contact 1 page version survei hat measur smoke outcom particip eport abstin cigarett 6 month ask ither provid saliva sampl test cotinin etabolit nicotin nicotin eplac product provid expir air sampl est carbon monoxid level verifi report saliva ollect mail mail saliva collect kit articip return saliva sampl 9 2 dai initi mail method collect aliva sampl biochem verif reviou studi 14 conduct carbon monoxid est person gener particip home ntervent intens intervent group ensiv smoke cessat intervent includ physician dvice quit smoke smoke cessat counsel rovid studi counselor vascular clinic care provid er cu provid cessat advic prompt partici ant medic chart addit particip ntensiv intervent group individu letter ascular healthcar provid site eceiv care advis quit smoke emphas import quit patient pad counsel intervent includ behavior phar acolog compon evid base gener opul smoker counsel consist combin educ link smoke onset progress pad motiv interview increas otiv quit 15 cognit behavior counsel evelop quit plan 16 provis inform harmacolog aid smoke cessat counselor ognit behavior problem solv skill train approach patient select target quit date prepar quit identifi person relev behavior cognit strat gi cope urg smoke 16 encourag articip stop smoke medic aid pro id inform type medic obtain health insur health provid ask patient select person heir social network activ support quit ffort patient nomin support person gave 7 6 1 3 2107jacc vol 56 25 2010 hennriku al decemb 14 21 2010 2105 12 smoke cessat program pad patient ermiss counselor contact support erson telephon earli counsel process discuss trategi provid effect support particip plan deliv minimum 6 counsel session ver period 5 month allow articip desir initi visit counselor ener occur person subsequ visit occur person telephon particip conveni counselor train studi includ educ bout tobacco addict counsel techniqu pharmaco ogic aid smoke cessat intervent rotocol culmin role plai counsel situat conduct monthli meet counselor ut studi discuss individu case inim intervent group intens con ition particip minim intervent receiv erbal advic quit smoke vascular provid rompt form medic chart studi oordin gave particip group list smoke essat program resourc commun hese particip receiv letter vascular rovid encourag quit smoke eet studi smoke cessat counselor easur smoke statu primari tobacco utcom measur 7 dai point preval smoke i. smoke cigarett puff past dai 17 3 month 6 month follow 6 month follow saliva sampl test icalert test strip nymox corpor hasbrouck eight jersei nicalert level 1 i. 10 ng ml consid disconfirm valu carbon onoxid level 8 ppm consid indic moke person provid report moke statu i. lost follow iochem verif smoke statu btain classifi smoker se pharmacolog aid smoke cessat survei particip ask sed 7 medic commonli sed pharmacolog aid smoke cessat nico in patch nicotin gum nicotin lozeng nicotin inhal icotin nasal sprai bupropion hydrochlorid zyban areniclin chantix particip ask ad medic hese medic studi enrol month follow dai ther smoke relat measur measur smok ng histori current attitud practic relat smok ng social context smoke administ aselin measur includ number cigarett moke dai daili smoker week nondaili moker ag initi smoke level addict icotin 18 previou particip formal smoke essat program reduct smoke number uit attempt last 24 previou year evel efficaci cessat measur singl item hat ask particip rate scale 0 10 onfid quit perman decid question particip belief includ 4 tem adapt number sourc 19 21 valuat subject level concern pad oncern circul problem peripher arteri iseas pad specif risk smoke circul roblem relat cigarett smoke con inu smoke harm long term ealth import quit health roblem quit smoke espons option question strongli disagre isagre agre strongli agre measur social ontext smoke number smoker ubject household smoke statu spous partner number close friend smoke respons option lmost half half half perceiv level support quit moke measur separ famili friend pons option scale 1 5 1 mean upport 5 mean extrem support emograph health relat measur de ograph characterist measur baselin includ ag ethnic marit statu educ level health elat measur includ measur depress 0 item version center epidemiolog studi epress scale ce 22 short form 36 ealth survei sf 36 item questionnair measur subject percept gener health respons ption excel good good fair poor 23 ntervent process studi counselor record umber counsel session complet length site session nalys examin differ studi roup factor potenti confound ain outcom analysi test continu variabl chi squar test categor variabl variabl est list tabl 1 found differ etween group potenti confound squar test relationship studi group moke statu follow pharmacolog aid smoke cessat studi period analys ollow smoke statu intent treat particip ho lost follow report valid mea ur provid sampl valid report abstin valid measur consid smoker adjust alpha level account test 6 month follow esult igur 1 overview recruit elig urvei complet 687 particip dentifi record patient pad py sf 2108 hennriku al jacc vol 56 25 2010 smoke cessat program pad patient decemb 14 21 2010 2105 12 urrent smoker 583 85 screen elig 232 34 identifi 40 screen elig criteria studi fifti percent ad tobacco studi baselin characterist intens interventt 1 pad tobacco studi baselin characterist inten site abbott northwestern vamc sociodemograph characterist mean sd ag sex male femal race white educ high school degre vocat train colleg colleg univers undergradu graduat degre marit statu marri live marri gener health depress ce 10 total score 10 gener health judg fair poor sf 36 item tobacco relat variabl mean sd ag start smoke mean sd cigarett dai cigarett morn 30 min wake mean confid quit 11 point scale pad relat smoke agre strongli agre continu smoke harm long term health agre strongli agre cut back smoke past year quit attempt past year previou particip quit program previou type nrt patch gum lozeng inhal nasal sprai previou bupropion previou vareniclin smoker household spous smoke number close friend smoke perceiv support quit famili extrem support support support perceiv support quit friend extrem support support support esult express mean sd ce center epidemiolog studi depress scale nrt nicotin replac thera hose elig studi consent particip onfirm smoker common reason ineligibil ty want quit 30 dai 171 171 patient includ calcul roup minim intervent control grouptervent group minim intervent control group nsive intervent 64 minim intervent 60 test differ group 0.91 23 36 21 35 41 64 39 65 59.8 7.1 60.7 9.0 0.53 0.38 53 83 53 88 11 17 7 12 0.27 58 92 58 97 5 8 2 3 0.33 18 28 17 28 38 59 40 67 8 13 3 5 0.29 27 42 31 52 37 58 29 48 19 32 15 28 0.61 34 54 32 54 0.98 15.7 3.5 15.8 3.3 0.87 18.8 10.7 17.5 12.8 0.74 59 92 53 88 0.47 6.1 2.6 6.4 2.5 0.53 45 74 41 72 0.82 59 97 57 97 0.38 44 69 39 65 0.66 47 73 39 65 0.31 16 25 9 15 0.17 52 81 52 87 0.41 30 47 26 44 0.76 11 20 14 27 0.40 28 65 28 62 0.78 17 27 15 25 0.55 0.61 13 20 14 24 35 55 27 46 16 25 18 31 0.20 39 65 44 76 14 23 12 21 7 12 2 3 0.48 30 48 25 45 23 37 26 46 9 15 5 9 36 short form 36 health survei vamc veteran administr medic center ion give int roport confirm smoker interest quit 9 6 2109jacc vol 56 25 2010 hennriku al decemb 14 21 2010 2105 12 smoke cessat program pad patient mmediat 31 confirm smoker 124 403 ndicat interest quit immedi 124 enrol studi 64 random intens intervent group 60 minim ntervent group particip di ours studi 3 intens intervent group 1 minim intervent group includ comput survei complet rate analys tudi outcom survei complet rate 2 group er similar 3 month follow complet rate minim intervent group higher 6 month ollow intens group 83 75 articip characterist tabl 1 present characteri ic particip displai differ baselin etween intens minim intervent group articip predominantli male 85 caucasian 94 mean ag 60 year rang 40 81 year hei smoke mean number 20 cigarett dai 0 smoke cigarett dai 30 min ak data suggest particip ad high level nicotin depend repons uestion belief smoke lmost particip believ smoke pose isk health import health uit smoke immedi major particip ri quit cut back smoke past ear pharmacolog aid smoke essat 20 particip formal moke cessat program confid figur 1 diagram recruit random survei patient identifi record diagnos peripher arteri diseas pa elig criteria studi fifti percent elig consent minim intervent group survei complet rate 2 group sim higher 6 month follow intens group 83 75 hei quit smoke major particip live 0 ith smoker close friend smoke hei report famili member extrem upport quit smoke ad support friend final half partici ant report fair poor health larg roport 30 score depress ce 10 found signific baselin differ vari ble particip randomli assign inten iv minim intervent group ntervent fidel particip recept coun elor contact 2 contact counsel median number session 8.5 rang 0 18 wenti percent session complet person remaind complet phone median length ession 20 min median total time counsel ession patient 3.2 total time ariabl rang 20 min 10.8 patient ho reach counsel edic tabl 2 describ differ ntensiv minim intervent group harmacolog aid smoke cessat studi eriod report 6 month follow survei inten iv intervent group particip report significantli or pharmacolog aid smoke cessat ur studi period 6 month follow 87 ntensiv intervent group particip report harmacolog aid smoke cessat eriod baselin 6 month survei 7 minim intervent particip rate smoker screen studi elig 232 40 screen met ipat 64 randomli alloc intens intervent group 60 3 month follow complet rate minim intervent group etur partic ilar 024 medic proport 0 fi 6 ot befor 2110 hennriku al jacc vol 56 25 2010 smoke cessat program pad patient decemb 14 21 2010 2105 12 ho nicotin replac product roughli similar etween 2 group intens intervent partici ant significantli vareniclin 54.4 30.6 minim intervent group 019 median number dai report medic se medic 47.5 intens ntervent particip 13.0 minim intervent articip moke abstin tabl 3 present 7 dai point preva ent abstin 3 6 month follow intent reat report data provid follow peri ds biochem verifi result provid nal follow particip lost follow ount smoker number 30 3 month follow 16 intens group 14 minim group 25 6 month follow 15 intens group 10 minim group particip report bstinenc 6 month follow survei 4 2 ondit provid sampl biochem confir ation report 5 3 intens condit 2 minim condit provid sampl er confirm biochem test partic pant count smoker analys 6 month follow intens intervent partici ant significantli abstin inim intervent particip verifi quit rate month follow 21.3 intens intervent roup versu 6.8 minim intervent group chi squar 5.21 0.023 effect evid oth studi site verifi quit rate minim ntensiv group 4.8 versu 13.7 percentag particip report ofor smoke cessat studi period 6tabl 2 percentag particip refor smoke cessat studi interv 46 medic 87.0 nicotin replac medic 45.6 bupropion 8.7 vareniclin 54.4 note 29 particip complet 6 month survei minim intervent group return survei 4 die elationship studi condit abstin 3 6 tabl 3 relationship studi condit abstin group 3 month follow report intent treat analysi intens 6 minim 5 6 month follow report intent treat analysi intens 6 minim 5 6 month follow biochem verifi intent treat analysi intens 6 minim 5 ot 4 particip di 6 month survei exclud analys bbott northwestern 7.8 versu 25.6 amc iscuss kei find studi patient ith pad current smoker interest uit recept formal smoke cessat rogram signific proport quit rovid resourc interest quit eflect high proport particip ut back amount smoke quit moke year studi fact ost particip previous pharmacolog id smoke cessat confirm moker group interest quit moke immedi particip respons question baselin survei bout belief smoke health onsist desir quit studi particip nivers understand risk smok ng health quit immedi inal desir quit demonstr high evel engag counsel assign intens intervent condit data reinforc import provid critic resourc isk highli motiv patient patient pad confront consid rabl obstacl smoke cessat includ high level addict smoke 90 particip studi report smoke cigarett dai rmacolog aidsth survei 95 pharmacolog aid iod 6 month survei 95 control 49 chi squar 67.4 5.127 0.024 32.7 1.686 ns 20.4 2.590 ns 30.6 5.484 0.019 clude analys 25 15 intens intervent group 10 survei follow 6 month follow abstin chi squar 13 21.3 4 6.8 5.21 0.023 19 31.2 6 10.2 8.00 0.005 13 21.3 4 6.8 5.21 0.023 pha monport ion montat 3 1 9 1 9 1 9 2111jacc vol 56 25 2010 hennriku al decemb 14 21 2010 2105 12 smoke cessat program pad patient ithin 30 min wake compar 50.8 minn ota smoker 2006 2007 tobacco supplement current popul survei 24 mean number igarett dai smoke particip 21.2 ar mean 13.9 cigarett dai report innesota smoker current popul survei 24 addit major particip live household ith smoker spous partner moke expos daili cue smoke result studi suggest provid intens moke cessat intervent patient pad ignificantli increas short term quit rate effect due increas medic patient ntensiv intervent group receipt counsel ntensiv intervent particip significantli ik pharmacolog aid smoke cessat longer period im particip intens intervent group lso significantli vareniclin newest medic smoke cessat moke cessat literatur report reluct moker pharmacolog aid smoke cessat frequent failur ong suffici quantiti 25,26 benefit or intens counsel encourag patient tart persever pharmacolog aid moke cessat tudi limit studi result interpret ight methodolog limit particip recruit rom 2 larg medic center provid specialti care atient pad patient popul ot repres patient pad rimarili manag primari care import limita ion short time frame studi relaps ccur 6 month includ measur or prolong abstin inform medic ight inaccur base recal ver 3 month period follow survei limit result implic medic practic research signific pro ortion patient diagnos pad identifi urrent smoker medic record initi eriou quit attempt particip intens smoke essat program import healthcar provid dvise pad patient quit smoke follow ecommend care effect ealthcar base intervent smoke cessat een establish reflect recent updat evid base public health servic clinic practic uidelin tobacco 27 u. intern ad evid base guidelin uniformli offer class ecommend clinician offer individu ad tobacco cessat intervent 28,29 augment standard treatment call group patient gritz al 30 suggest hronic ill patient continu smoke diag osi profit modif tailor stan ard smoke cessat treatment design healthi moker patient continu smoke iagnos chronic ill caus xacerb tobacco highli addict icotin face problem comorbid ack access care face healthi smoker ritz al 30 suggest modif treatment opul increas intens includ amili treatment improv access smoke cessat rogram provid special tailor materi ensur hat medic provid address tobacco medic lifestyl issu address treatment patient chronic ill research effect modif smoke essat treatment chronic ill patient need onclus long term smoker pad initi eriou quit attempt engag intens smoke essat program engag intens ad specif intervent signific ncreas smoke abstin result mportanc incorpor smoke cessat treatment nto medic manag pad high level ddiction signific barrier quit pad atient treatment includ tobacco depend anag rigor long term futur inv igat larger sampl longer follow onduct evalu impact intervent imb symptom system ischem event rate eprint request correspond dr deborah hennriku chool public health univers minnesota 1300 south econd street suit 300 minneapoli minnesota 55408 mail ennr001 umn.edu efer 1 agarw associ activ passiv smoke peripher arteri diseas result nhane 1999 2004 angi ologi 2009;60 335 45 2 criqui mh peripher arteri diseas epidemiolog aspect vasc med 2001;6 suppl 1 3 7 3 hirsch criqui mh treat jacobson al peripher arteri diseas detect awar treatment primari care jama 2001;286 1317 24 4 mcdaniel md cronenwett jl basic data relat natur histori intermitt claudic ann vasc surg 1989;3 273 5 imparato kim ge davidson crowlei jg intermitt claudic natur surgeri 1975;78 795 6 cole cw hill gb farzad al cigarett smoke peripher arteri occlus diseas surgeri 1993;114 753 7 7 willigendael em teijink jaw bartelink ml al influenc smoke incid preval peripher arteri diseas vasc surg 2004;40 1158 65 8 chi uw jaff mr optim risk factor modif medic manag patient peripher arteri diseas cathet cardiovasc interv 2008;71 475 89 mailto:hennr001 umn.edu 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 2112 hennriku al jacc vol 56 25 2010 smoke cessat program pad patient decemb 14 21 2010 2105 12 9 faulkner kw hous ak castleden wm effect cessat smoke accumul surviv rate patient symptom atic peripher vascular diseas med aust 1983;1 217 9 0 lassila lepantalo cigarett smoke outcom lower limb arteri surgeri acta chir scand 1988;154 635 40 1 ramirez tortosa mc urbano lopez jurado al lifestyl free live patient peripher vascular diseas fon tain stage ii relat plasma ldl lipid composit 15 month follow studi clin nutr 1999;18 281 9 2 smith frank pj greenhalgh rm poulter nr powel jt influenc smoke cessat hypertriglyceridaemia progress peripher arteri diseas onset critic ischaemia eur vasc endovasc surg 1997;11 402 8 3 galvin webb hillier assess impact nurs led health educ intervent peopl peripher vascular diseas smoke physiolog marker nicotin depen denc withdraw int nur stud 2001;38 91 105 4 mcbride cm curri sj lando ha piri pl grothau lc nelson jc prevent relaps women quit smoke pregnanc public health 1999;89 706 11 5 miller wr rollnick motiv interview prepar peopl chang addict behavior york guildford press 1991 6 fior mc jaén cr baker tb al treat tobacco depend 2008 updat clinic practic guidelin rockvil md u. depart health human servic public health servic 2008 7 hugh jr keeli jp niaura rs ossip klein dj richmond rl swan ge measur abstin clinic trial issu recommend nicotin tobac re 2003;5 13 26 8 heatherton tf kozlowski lt frecker rc fagerstrom ko fagerstrom test nicotin depend revis fagerstrom toler questionnair br addict 1991;86 1119 27 9 bloom rj stevick ca lennon patient perspect smoke peripher vascular diseas veteran popul survei surg 1990;56 535 9 0 kaufert jm rabkin sw syrotuik boyko shane health belief com.ibm.drl.hbcp.predictor success altern modal smoke cessat result control trial behav med 1986;9 475 89 1 marshal studi smoke attitud behaviour patient myocardi infarct int nur stud 1990;27 375 87 2 andresen em malmgren ja carter wb patrick dl screen depress older adult evalu short form ce prev med 1994;10 77 84 3 ware je snow kk kosinski gandek sf 36 health survei manual interpret guid boston ma nimrod press 1993 4 giovino ga chaloupka fj hartman al cigarett smoke preval polici 50 state era chang robert wood johnson foundat impacteen tobacco chart book buffalo ny univers buffalo state univers york 2009 5 etter jf perneg tv attitud nicotin replac therapi smoker smoker gener public clin pharmacol ther 2001;69 175 83 6 shiffman ferguson sg rohai al perceiv safeti efficaci nicotin replac therapi smoker smoker relationship complianc addict 2008;103 1371 8 7 fior mc jaén cr baker tb al treat tobacco depend 2008 updat clinic practic guidelin rockvil md u. depart health human servic public health servic 2008 8 hirsch haskal zj hertzer nr al acc aha guidelin manag patient peripher arteri diseas lower extrem renal mesenter abdomin aortic report american colleg cardiolog american heart associ task forc practic guidelin write committe develop guid line manag patient peripher arteri diseas lower extrem renal mesenter abdomin aortic cir culat 2006;113 1474 547 9 norgren hiatt wr dormandi ja nehler mr harri ka fowk fg tasc ii work group inter societi con sensu manag peripher arteri diseas tasc ii vasc surg 2007;45 suppl 5 67 0 gritz er vidrin dj fingeret mc smoke cessat critic compon medic manag chronic diseas popul prev med 2007;33 suppl 414 22 ey word clinic trial peripher arteri diseas smoke essat effect smoke cessat program peripher arteri diseas patient method site particip procedur intervent intens intervent group minim intervent group measur smoke statu pharmacolog aid smoke cessat smoke relat measur demograph health relat measur intervent process analys result particip characterist intervent fidel medic smoke abstin discuss studi limit conclus refer
author 2015 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com nicotin tobacco research 2015 1012 1021 doi 10.1093 ntr ntv034 origin investig 1012 introduct individu diagnos psychiatr disord higher preval cigarett smoke 36 21 greater nicotin depend epidemiolog studi likelihood quit compar smoker mental ill 1 3 smoker mental ill addict disord estim consum 44 46 cigarett smoke unit state 4,5 account 200 000 480 000 tobacco relat prematur death unit origin investig treat tobacco depend intersect divers poverti mental ill random feasibl replic trial norval hickman iii phd mph1 kevin delucchi phd2 judith prochaska phd mph3 1tobacco relat diseas research program univers california offic presid oakland ca 2depart psychiatri univers california san francisco san francisco ca 3stanford prevent research center depart medicin stanford univers stanford ca author norval hickman iii phd mph california tobacco relat diseas research program univers california offic presid 300 lakesid drive oakland ca 94606 usa telephon 510 987 9032 fax 510 587 6325 mail norval.hickman ucop.edu abstract introduct ethnic divers uninsur psychiatr sampl occur drug alco hol addict evalu feasibl reproduc tobacco treatment intervent intervent previous demonstr efficaci insur psychiatr nonpsychiatr sam ple 20.0 25.0 abstin 18 month method daili smoker recruit 2009 2010 psychiatr unit urban public hospit random usual care unit nicotin replac quit advic intervent ad transtheoret model tailor comput assist intervent stage match manual counsel 10 week post hospit nicotin replac result sampl 100 69 recruit rate ag 40 56 racial ethnic minor 65 male 79 unemploi 48 unstabl hous diagnos unipolar 54 bipo lar 14 depress psychot disord 46 77 report past month illicit drug prior hospit particip averag 19 sd 11 cigarett dai 23 sd 13 year 80 smoke 30 minut awaken 25 prepar quit encourag compara ble effect gener popul 7 dai point preval abstin intervent versu control 12.5 versu 7.3 3 month 17.5 versu 8.5 6 month 26.2 versu 16.7 12 month retent exceed 80 12 month odd abstin increas time predict higher efficaci greater perceiv social statu diagnosi psy chotic disord compar unipolar depress conclus find uninsur smoker mental ill engag tobacco treatment research quit rate compar gener popul larger investi gation warrant inclus divers smoker mental ill clinic trial support encourag nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http www.oxfordjournals.org mailto:norval.hickman ucop.edu subject http ntr.oxfordjournals.org 1013nicotin tobacco research 2015 vol 17 8 state annual 6,7 averag life expect individu mental ill 25 year shorter gener popul primarili due tobacco relat diseas cardiovascular di eas lung diseas type cancer 8 tobacco addict costli studi smoker schizophrenia estim 27 median incom 9 tobacco clinic practic guidelin recommend provid ce sation treatment smoker 10 joint commiss ban smoke hospit 1993,11 american psychiatr associ identifi psychiatr hospit ideal oppor tuniti treat tobacco depend 12 treatment tobacco psychiatri regular practic mental health profession smoker mental ill quit quit 13 tobacco believ form medic individu fear ban smoke psychiatr unit worsen symptom increas behavior problem publish review suggest 14 smoker mental ill motiv quit smoke gener population15 hospit smoker mental ill 65 interest quit 16 tobacco treatment ran domiz trial signific effect long term abstin found quit smoke worsen clinic symp tom unipolar depress bipolar disord posttraumat stress disord schizophrenia 17 21 treatment tobacco depend enc decreas likelihood rehospitaliza tion 22 review cessat treatment outpati mental ill conclud depress smoker cognit behavior nicotin replac therapi nrt doubl cessat rate reduc depress symptom 23 notabl combin nrt buproprion result abstin nrt smoker schizophrenia 24 evid suggest pharmacotherapi psycholog counsel effect ing peopl mental ill quit smoke increasingli psychiatr hospit adopt smoke ban 25 notabl treatment major hospit psychiatr patient return smoke shortli discharg smoke free unit 14,16 hospit set uniqu opportun initi tobacco depend treatment group vulner underserv smoker inpati psychiatr set rare focu cessat trial publish random trial examin efficaci tobacco depend treat ment adults22 adolescents26 hospit inpati psy chiatri trial enrol smoker intent quit provid counsel combin post hospit nrt rel advic adult trial com.ibm.drl.hbcp.util transtheoret model ttm tailor comput assist intervent unit repeat 3 6 month follow combin stage match manual individu unit counsel quit rate significantli increas time differ condit 20 treatment 8 usual care particip abstin 18 month follow 22 abstin rate compar prior evalu treatment approach depress patient 25 quit 18 month particip gener popul 22 25 quit 18 month 18,27 adolesc trial com.ibm.drl.hbcp.util motiv interview demonstr increas efficaci intent quit differ group abstin 26 trial conduct hospit affili academ medic center particip larg insur hispan caucasian accept efficaci tobacco treatment intervent divers repres sam ple requir evalu translat random clinic trial primari aim test ttm tailor comput assist intervent stage match manual unit counsel post hospit izat nrt racial ethnic divers sampl uninsur smoker mental ill recruit larg urban public hospit feasibl replic trial pow er detect signific differ due budgetari time constraint fund award primari aim examin treatment group differ abstin rate 12 month time hypothes treatment group greater 7 dai point preval tobacco abstin 12 month hospitali zation compar usual care group secondari aim character baselin sociodemograph clinic tobacco relat com.ibm.drl.hbcp.predictor abstin specif hypothes lower socioeconom statu unstabl hous greater nicotin depend reduc motiv quit poorer mental health racial discrimin experi predict smoke abstin 12 month period lastli examin predic tor acut psychiatr servic psychiatr rehospitaliza tion treatment emerg servic 12 month studi includ studi condit tobacco abstin sociodemo graphic clinic tobacco measur interest method set recruit adult smoker smoke free psychiatr unit acut acut unit san francisco gener hospit sfgh april 2009 april 2010 sfgh 100 smoke free juli 1 2008 sfgh largest public acut care hospit san francisco counti primarili serv citi uninsur indig unhous studi design sfgh arm random clinic trial extens replic larger trial 224 conduct langlei porter psychiatr institute22 enrol smoker intent quit compar enhanc usual care ttm tailor intervent http clinicaltrials.gov identifi nct00136812 sfgh usual care assess tobacco pro vide nrt tobacco user hospit manag nicotin withdraw trial usual care condit enhanc studi staff advis smoker quit provid quit smoke pam phlet 28 offer referr post hospit intervent condit ad ttm tailor comput deliv intervent print report stage match treatment manual unit individu cessat counsel avail 10 week nrt post hospit 6 month follow cessat counsel provid studi staff focus moti vation enhanc manag temptat decision balanc process chang 15 30 minut session indi vidual report direct particip relev exercis manual materi written sixth grade read level post hospit intervent contact 3 6 month repeat comput intervent rememb particip earlier respons provid ips feedback chang time recommend step quit smoke maintain abstin prevent loss misus studi nrt deliv instal 4 6 week increment previous report accept intervent evalu nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http clinicaltrials.gov http ntr.oxfordjournals.org 1014 nicotin tobacco research 2015 vol 17 8 insur psychiatr sampl 29 current studi treat ment adapt includ ethnic divers urban imag comput program treatment manual greater ref erenc menthol tobacco tobacco industri market cigarett black lower incom smoker greater outreach field ensur complet post hospit treatment session 30 randomli assign particip treatment enhanc usual care arm comput gener random assign program stratifi baselin cigarett dai 15 stage chang variabl predict quit smoke address intervent 27,31 research staff blind randomiza tion schedul research protocol approv committe human research univers california san francisco sfgh administr particip research staff medic record identifi potenti eligi ble patient clinic staff ask patient hear smoke studi interest introduc research staff provid greater descript studi assess elig trial inclus criteria smok ing cigarett daili prior hospit ag 18 year older fluenci written spoken english exclud patient physic threaten staff sedat point commun symptom resolv suffici hospit contraind nrt research staff review consent form particip assess understand purpos potenti risk ben efit particip capac screen instrument 32 particip compens 10 baselin assess 20 person follow 10 phone mail email 20 bonu complet assess 120 maximum measur descript measur assess ag gender race ethnic educ annual incom hous stabil employ statu marit statu macarthur scale subject social status33 particip place rung graphic ladder reflect perceiv social stand defin commun sss commun unit state sss broadli rate 1 10 tobacco characterist assess cigarett dai fagerström test cigarett depend 34,35 includ ing time cigarett smoke stage chang categor precontempl intent quit 6 month con templat intent quit 6 month prepar intent quit 30 dai past year 24 hour quit attempt 36 thought abstin scale assess desir quit anticip success quit perceiv difficulti quit ting singl item rate 10 point scale 37 assess form tobacco includ cigar smokeless menthol year smoke cessat advic mental gener health provid past year measur mental health statu substanc includ center epidemiolog studi depress scale cesd 10 38 behavior symptom identif scale basi 24 39 health statu survei short form sf12 physic mental health composit scores40 alcohol disord identif test41 drug abus screen test dast 10 42 addict sever index item past 30 dai substanc 43 clinic diag nose durat psychiatr hospit obtain medic record number prior hospit assess measur race relat stress administ 44 major experi discrimin yield count number major experi unfair treatment lifetim relat issu employ educ hou ing everydai discrimin scale assess exposur 10 chronic experi unfair treatment past month treat courtesi respect receiv poorer ser vice store patient popul ad 3 item everydai measur receiv poorer servic mental healthcar medic care 2 question deni mental health care cronbach alpha 22 item 0.90 singl discrimin frequenc score tabul outcom measur feasibl trial assess sampl recruit reten tion rate primari tobacco outcom 7 dai point preva lenc abstin form tobacco includ smokeless assess verifi 3 6 12 month follow up 45 report tobacco complet biochem verif expir air carbon monoxid sampl analyz bedfont smokerlyz 10 part million verifi abstin 46 particip lost follow unabl attend person confirm nonsmok statu call collater contact friend famili case manag provid baselin ask particip tobacco past 7 dai prior research smoker alcohol problem compar collater inform report confirm demonstr valid 47 clinic outcom interest acut psychiatr servic defin psychiatr treatment emerg servic rehospitaliza tion assess particip report follow hospit electron medic record 48 data analysi descript statist mean frequenc summar sampl characterist group analysi varianc pearson chi squar test group differ sampl retent 12 month examin test differ treatment condit baselin descript characterist test pri mari hypothesi estim test gener estim equat model logit link function proc genmod sa version 9.2 49 model examin abstin versu smok ing statu 3 12 month follow up condit account depend respons individu attribut repeat measur independ variabl inter vention versu usual care condit variabl differ condit baselin predict attrit depend variabl 7 dai point preval abstin model time 3 6 12 month test secondari hypothesi model build proceed step univari model examin baselin sociod mograph tobacco relat clinic characterist predict tobacco abstin 12 month studi variabl 05 enter final gener estimat ing equat base multivari logist model clinic acut psychiatr care servic point 12 month trial estim test logist regress model independ variabl treatment condit abstin statu nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 1015nicotin tobacco research 2015 vol 17 8 covari identifi relev psychiatr hospit literatur result total 145 adult smoker identifi studi elig medic record 40 declin particip pass capac screener trial 100 provid inform consent 69 recruit rate 49 particip random intervent arm 51 enhanc usual care arm figur 1 mean ag sampl 39.5 year sd 11.3 65 men 56 racial ethnic minor 20.0 identifi lesbian gai bisexu transgend 15 foreign born tabl 1 half 52 report live current resi denc 6 month 19 unhous 78 stanc disord diagnosi report medic record prior hospit particip smoke averag 19.3 cigarett dai sd 12.2 averag 23.1 year sd 12.7 80 smoke cigarett 30 minut wake 53 smoke menthol 33 precontempl 42 contem plation 25 prepar quit smoke particip hospit danger 73 danger 14 grave disabl 13 53 hospit week 30 dai hospit 77 illicit drug 67 consum alcohol 55 illicit drug alcohol major medicar medicaid 66 insur carrier term racial discrimin experi 36 report 32 report 1 3 26 report 4 cesd 10 score significantli higher particip experi enc racial discrimin 17.7 sd 7.0 13.7 sd 9.0 1,92 5.84 02 discrimin experi heavier smoke nicotin depend treatment deliveri studi retent intervent particip complet initi comput counsel session acut stai hospit 65 53 complet intervent con tact intervent particip complet figur 1 screen enrol studi particip nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 1016 nicotin tobacco research 2015 vol 17 8 tabl 1 sociodemograph tobacco clinic characterist sampl psychiatr inpati random control trial smoke cessat intervent san francisco ca recruit april 2009 april 2010 characterist full sampl 100 mean sd number sociodemograph characterist ag year 39.5 11.3 gender male 65 femal 32 transgend 3 race ethnic caucasian 44 black 27 hispan 9 asian american pacif island 11 multiraci nativ american 9 marit statu marri cohabit 10 divorc separ widow 28 singl marri 62 annual individu incom 10 000 67 10 000 33 hous stabil unstabl hous 48 stabli hous 6 month 52 educ year 12.8 2.5 employ statu unemploi 79 emploi 12 retir student homemak 9 macarthur scale subject social statu social statu commun 5.2 2.9 social statu unit state 4.4 2.8 tobacco characterist usual cigarett dai 19.3 12.2 menthol 53 ftcd total score 5.2 2.3 time cigarett dai 30 min 80 30 min 20 year smoke 23.1 12.7 thought abstin desir stop 5.9 3.2 expect success quit 5.7 3.0 difficulti stai abstin 6.9 3.1 stage chang precontempl 33 contempl 42 prepar 25 quit attempt past year 24 44 cessat advic mental health provid past year 45 cessat advic mental health provid past year 46 clinic characterist reason hospit danger 73 danger 14 grave disabilitya 13 length hospit stai dai 2 7 dai 47 8 13 dai 30 2 week longer 23 cesd 10 scoreb 16.0 8.1 diagnosi medic record unipolar depress 52 bipolar disord 15 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 1017nicotin tobacco research 2015 vol 17 8 follow comput contact due incarcer total 16 particip incarcer studi post hospit studi provid nrt request distribut 28 particip 57 treatment group 25 interven tion particip receiv full 10 week regimen studi patch abstin rate differ base distribut studi nrt 80 follow assess complet time point retent rate increas trial due greater outreach effort 30 retent 86 intervent group 94 usual care group 12 month follow nonsignific differ figur 1 measur characterist predict 12 month retent par ticip di trial suicid abstin statu verifi 7 dai point preval abstin rate 7.3 usual care 12.5 intervent 3 month follow 8.5 17.5 6 month 16.7 26.2 12 month figur 2 model abstin 12 month reveal signific differ quit time gener estim equat model 1.11 95 ci 1.02 1.20 02 differ enc treatment condit statist signific 1.80 95 ci 0.74 4.38 19 figur 2 collater report reli verifi smoke statu 6 6 9 particip 3 6 12 month assess particip code abstin expir confirm obtain major collater report 12.5 18.2 31.6 particip 3 6 12 month assess comparison literatur code particip lost follow smoke exclud deceas particip verifi 7 dai point preval abstin rate 6.0 usual care 10.4 intervent particip 3 month follow 8.0 14.9 6 month 16.0 23.4 12 month com.ibm.drl.hbcp.predictor condit abstin examin potenti covari treatment effect elu cidat com.ibm.drl.hbcp.predictor abstin clinic sampl univari at model baselin measur social stand sss commun sss quit efficaci thought abstin desir success anticip difficulti physic health sf12 substanc dast 10 psychiatr diagnosi predict abstin time valu 05 gender ag race ethnic marit statu incom employ cigarett dai menthol year smoke stage chang past quit attempt length hospi taliz reason hospit score fagerström test cigarett depend cesd 10 dast predict abstin random group differ base line educ level hous stabil alcohol alcohol disord identif test basi 24 summari score valu 05 sss commun highli correl sss 0.70 001 exclud model remain ing 11 variabl enter multivari analysi tabl 2 signific variabl final model time sss thought abstin desir success psychiatr diagnosi valu 05 odd abstin increas time predict greater baselin desir efficaci quit smoke greater perceiv social statu unit state psy chotic disord diagnosi compar unipolar depress psychiatr rehospit sampl 28 particip usual care 55 28 intervent 57 rehospit emerg ser vice psychiatr care 12 month follow acut psychiatr servic 12 month studi unrel model variabl includ abstin statu studi condit gender ethnic educ prior hospit sever psychiatr symptom baselin psychiatr diagnosi stabil live situat characterist full sampl 100 mean sd number psychot disord 29 diagnosi report 4 basi 24 summari scalec 1.9 0.8 audit total score 8.7 9.8 dast 10 total score 4.1 3.6 sf 12f physic compon summari 46.4 11.9 mental compon summari 33.5 14.7 previou psychiatr hospit 1 5 64 6 33 subject social statu refer macarthur scale subject social status33 ftcd fagerström test cigarett depend rang 0 10 0 2 low depend 3 4 low depend 5 medium depend 6 7 high depend 8 10 high dependence34,35 audit alcohol disord identif test41 basi behavior symptom identif scale39 cesd center epidemiolog studi depress scale 38 aa condit result mental disord render person unabl care basic obtain food cloth shelter brang 0 30 11 signific depress symptom crang 0 4 higher sever symptom drang 0 40 8 hazard harm drink erang 0 10 3 moder drug problem frang 0 100 nation averag 50 sd 10 lower score wors mental physic health tabl 1 continu nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 1018 nicotin tobacco research 2015 vol 17 8 discuss high level recruit retent support feasibl treat tobacco addict smoker public psychiatr hospit term replic found signific increas abstin time higher quit rate interven tion versu enhanc usual care group consist prior work psychiatr sampl research smoker gen eral popul increas abstin time charact istic stage tailor intervent smoker initi intend quit support cessat process time 18,22,27,50,51 pattern increas abstin time cessat induct trial 45 contrast characterist relaps curv tradit action orient treatment approach 52 repeat intervent contact provid opportun engag particip initi readi quit current studi 12 month abstin rate 26 compar prior investi gation similar ttm base approach inpati psychiatr smoker depress outpati smoker studi smoker mental ill 18,22,27 design demonstr feasibl project studi small sampl size 80 power detect odd ratio 2.67 continu com.ibm.drl.hbcp.predictor cesd score odd ratio 4.60 binari com.ibm.drl.hbcp.predictor treatment group covari bipolar disord statu 53 differ percent abstin 3 6 12 month assess translat number need treat 20 11 10.5 lack statist signific treatment group differ current trial due part short durat follow small sampl size quit rate 16.7 usual care group parent trial 7.7 particip usual care arm absti nent 18 month 22 vulner risk popul enhanc usual care group current studi support studi staff obtain nrt hospit provid commun cessat referr examin correl abstin found partial port hypothesi patient baselin report greater perceiv social statu unit state greater desir quit greater anticip success quit achiev abstin trial relationship expect success quit abstin consist earlier find 22 reitzel colleagues54 found ceiv social statu unit state predict abstin unhous smoker racial ethnic divers smoker seek treatment 55 unexpect find higher likelihood abstin particip psychot disord compar tabl 2 multivari model predict tobacco abstin 12 month studi period random control trial smoke cessat intervent psychiatr inpati san francisco ca recruit april 2009 april 2010 variabl 95 ci condit ref usual care 1.76 0.69 4.48 24 time 1.16 1.04 1.29 007 educ year 0.90 0.74 1.09 28 hous stabil 0.77 0.31 1.91 58 social statu unit state 1.25 1.04 1.50 02 desir quit 1.28 1.06 1.55 01 expect success quit 1.26 1.06 1.50 007 perceiv difficulti stai quit 0.92 0.79 1.06 25 sf 12 physic compon summari 1.03 0.99 1.09 17 basi 24 summari scale 0.89 0.38 2.06 78 psychiatr diagnosi unipolar depress ref 1.00 bipolar depress 0.73 0.12 4.53 73 psychot disord 5.16 1.76 15.07 03 ci confid interv odd ratio sampl size 100 figur upload peer review a.tif file format requir detail instruct author document figur 2 verifi point preval abstin rate treatment condit time random control trial smoke cessat intervent psychiatr inpati san francisco ca recruit april 2009 april 2010 nivers berdeen ovem ber 30 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org 1019nicotin tobacco research 2015 vol 17 8 unipolar depress earlier studi found differ abstin diagnosi 22 investig includ diag nostic heterogen sampl allow comparison type mental ill unrel abstin measur incom employ statu hous stabil nicotin depend mental health racial discrimin prior studi support link discrimin experi nicotin depend heavier smoke 56 58 kendzor colleagues59 found greater number racial discrimin experi predict lower tobacco abstin treatment seek latino fagerström test cigarett depend cigarett dai associ at discrimin sampl likelihood acut psychiatr servic differ condit model variabl greater cur rent sampl 56 studi insur smoker recruit academ psychiatr hospit 47 18 month follow window close studi start budget shortfal san francisco commun mental health system consider pressur sfgh psychiatri reduc length psychiatr visit direct patient chronic mental ill afford outpati commun mental health servic 60 system result increas acut psychiatr servic studi period divers chronic case make difficult identifi signific demograph clinic correl studi limit 12 month follow addit support time abstin rate continu increas 18 month observ sampl similar interventions18,22 relaps occur diagnos obtain medic record valid diagnost instrument particip recruit site find gener set urban sampl unhous cut point 10 part million abstin optim light smoker 61 promis find studi warrant larger trial low incom divers smoker mental ill assess cost deliv intervent return invest notabl parent trial intervent evalu inpati psychiatri found highli cost effect increment cost effect ness ratio 428 qualiti adjust life year 62 conclus translat trial 100 uninsur racial ethnic divers smok er mental ill successfulli enrol high reten tion year period sampl uniqu tobacco treatment trial represent patient popul seek acut mental healthcar public health safeti net system rel studi tobacco treatment smoker mental health problem current sampl high rate occur psychiat ric addict disord activ suicid time recruit ment clinic unstabl particip quit smoke particip notabl particip random ttm tailor comput assist intervent combin nrt achiev higher quit rate rel enhanc usual care afford care act inclus tobacco cessat servic improv access evid base tobacco treatment previous uninsur indi vidual 7 deliveri intervent 3 6 month fit con ceptual wagner colleagu chronic care model 63 emphas integr healthcar system build patient confid efficaci manag chronic health condit racial ethnic divers smoker mental ill low incom repres multipl prioriti group longstand tobacco relat dispar tran lation trial demonstr feasibl initi tobacco treatment vulner group smoker psychiatr ho pital replic treatment effect divers patient group fund work support grant nation institut drug abus k23 da018691 p50da09253 t32da007250 declar interest prochaska serv expert wit tobacco compani lawsuit receiv fee work provid consult pfizer make medic quit smoke hickman delucchi hold conflict interest acknowledg acknowledg jessica clifton kathleen gali mph jessica hamon romina kim anayansi lombardi maryam najafi nichola orozco amanda schweizer assist studi recruit assess
pilot studi voucher base incent promot abstin cigarett smoke pregnanc postpartum stephen higgin sarah heil laura solomon ira bernstein jennif plebani lussier rebecca abel mari ellen lynch gari badger receiv 15 august 2003 accept 28 june 2004 report result pilot studi examin voucher redeem retail item incent smoke cessat pregnanc postpartum 100 studi elig women smoke enter prenat care 58 recruit univers base commun obstetr practic particip smoke cessat studi particip assign conting nonconting voucher condit voucher pregnanc 12 week postpartum conting condit voucher earn biochem verifi smoke abstin nonconting condit voucher earn independ smoke statu abstin monitor voucher deliveri conduct daili initi 5 dai cessat effort gradual decreas week antepartum increas weekli initi 4 week postpartum decreas week remain 8 week postpartum intervent period conting voucher increas 7 dai point preval abstin end pregnanc 37 9 12 week postpartum 33 0 assess effect sustain 24 week postpartum assess 27 0 12 week discontinu voucher program total mean voucher earn antepartum postpartum 397 sd 414 313 sd 142 conting nonconting condit magnitud treatment effect exce level typic observ pregnant recent postpartum smoker mainten effect 24 week postpartum extend durat report previous introduct matern smoke lead prevent poor pregnanc outcom infant morbid mortal floyd rimer giovino mullen sullivan 1993 u. depart health human servic 2001 effect intervent exist promot smoke cessat pregnanc cessat rate low v20 women educ heavier smoker dolan mullen ramirez groff 1994 solomon secker walker skelli flynn 1996 addition major women successfulli quit smoke pregnanc relaps 3 6 month deliveri fingerhut kleinman kendrick 1990 mcbride piri curri 1992 recent report voucher base incent pregnant smoker note substanti increas usual cessat rate observ popul donatel prow champeau hudson 2000 trial 220 pregnant smoker randomli assign receiv smoke cessat kit kit voucher conting biochem verifi smoke absti nenc voucher condit design issn 1462 2203 print issn 1469 994x onlin 2004 societi research nicotin tobacco doi 10.1080 14622200412331324910 stephen higgin ph.d depart psychiatri psycholog sarah heil ph.d rebecca abel b. mari ellen lynch r.n depart psychiatri jennif plebani lussier m.a depart psycholog laura solomon ph.d depart psycholog famili practic ira bernstein m.d depart obstetr gynecolog gari badger m. depart medic biostatist univers vermont burlington vt correspond stephen higgin ph.d depart psychiatri univers vermont 38 fletcher place burlington vt 05401 usa tel z1 802 656 9615 fax z1 802 656 9628 mail stephen.higgin uvm.edu nicotin tobacco research volum 6 number 6 decemb 2004 1015 1020 nivers berdeen februari 19 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org signific particip trial pregnant women signific receiv voucher conting smoke statu pregnanc 2 month postpartum smoke statu assess monthli voucher worth 50 assess pregnant smoker 50 test 25 subsequ test signific cost voucher cover donat local health care organ busi foundat biochem confirm smoke cessa tion rate end pregnanc 32 versu 9 voucher control condit 21 versu 6 2 month postpartum assess ment abstin level voucher program discontinu 2 month postpartum report magnitud treatment effect exceed observ pregnant smoker decad research topic warrant investig present pilot studi conduct assess efficaci voucher promot absti nenc pregnant smoker extend assess period voucher discontinu voucher exchang retail item incent abstain substanc abus begun intervent outpati treatment cocain depend higgin al 1991 review higgin alessi dantona 2002 higgin heil lussier 2004 research area initi period sustain abstin import sustain abstin voucher discontinu higgin badger budnei 2000 higgin wong badger ogden dantona 2000 extend notion treatment pregnant smoker complic increas relaps risk postpartum establish initi abstin antepar tum protect relaps risk postpartum voucher base intervent present studi began high intens gradual taper downward antepartum period increas intens initi postpartum week taper downward 12 week postpartum treatment assess conduct 24 week postpartum 12 week di continu voucher base intervent method subject particip recruit larg group obstetr practic singl practition obstetr practic greater burlington vermont area studi inclus criteria report current smoker puff past 7 dai prenat visit resid citi limit studi clinic plan remain geograph area 6 month deliveri english speak exclus criteria incarcera tion previous particip studi resid particip studi pilot studi gestat ag inclus exclus criterion women receiv prenat care clinic complet questionnair basic sociodemograph inform smoke statu endors smoke past 7 dai contact subsequ studi staff person phone studi particip total 100 women deem studi elig 58 agre particip 42 declin 58 agre particip 31 assign conting voucher condit 27 nonconting con dition voucher condit criterion withdraw trial treatment assign pregnanc termi nation fetal demis women withdrawn studi base criterion conting condit nonconting condit leav 53 women result analys studi outcom 53 particip contribut analys 37 assign treatment condit consecut studi admiss 16 particip random condi tion assign particip consecut admi sion continu studi staff experienc comfort studi protocol time random assign experiment condit initi prepar fulli random trial schedul follow studi particip provid written inform consent studi approv univers vermont institut review board assess particip complet questionnair examin sociodemograph current smoke statu tori smoke environ motiv confi denc intent quit smoke provid breath carbon monoxid urin specimen cotinin analysi studi intak assess prenat visit enter studi visit end pregnanc 32 week gestat 2 4 8 12 24 week postpartum onsit enzym immunoassai test determin cotinin level purpos implement voucher program cutpoint 80 ng ml studi outcom purpos urin speci men collect end pregnanc 12 week end incent program 24 week end studi postpartum assess analyz laboratori ga chromatographi mass 1016 voucher base incentn promot perinat smoke abstin nivers berdeen februari 19 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org spectrometri 80 ng ml cutpoint smok ing abstin outcom result report defin report smoke puff past 7 dai confirm urinari cotinin level 80 ng ml point preval abstin rate report base women assign condit minu drawn pregnanc termin fetal demis 53 treatment intervent abstin monitor schedul enter studi particip chose subsequ mondai quit date begin quit date particip report studi clinic met clinic staff site conveni abstin monitor monitor schedul voucher deliveri particip conting nonconting voucher con dition condit voucher deliveri daili initi 5 dai cessat effort mondai fridai begin week monitor decreas weekli mon dai thursdai 7 week weekli 4 week wednesdai wednesdai deliveri postpartum period monitor increas weekli initi 4 week wednesdai wednesdai 8 week abstin monitor end end week 12 monitor occur end postpartum intervent week 12 final 24 week postpartum assess conting voucher condit voucher redeem retail item earn submit breath specimen level 6 ppm initi 5 dai cessat effort order detect reinforc initi cessat effort begin week 2 abstin monitor vou cher deliv conting urinari cotinin level 80 ng ml criterion requir longer durat smoke abstin compar breath voucher deliveri independ report smoke statu base exclus meet biochem verif criterion voucher began 6.25 escal 1.25 consecut neg specimen maximum 45.00 posit test result miss visit reset voucher back ori ginal low consecut neg test restor pre reset level cash particip voucher pur chase made clinic staff women assign condit attend 63.7 531 833 schedul antepartum postpartum abstin monitor session total mean voucher earn 397 sd 414 rang 0 1,135 nonconting voucher condit condit voucher deliv independ smoke statu voucher valu 11.50 visit ant partum 20.00 visit postpartum estim suffici sustain participa tion abstin monitor result pai ment amount compar averag earn conting condit conting voucher condit women assign condit attend 63.3 426 673 schedul antepartum postpartum abstin monitor session total mean voucher earn 313 sd 142 rang 35 517 servic addit monitor voucher base incent mention partici pant receiv usual care smoke cessat provid obstetr clinic typic involv provid inquiri smoke statu discuss advantag quit pregnanc studi staff attempt influenc clinic practic part studi intervent particip receiv pamphlet studi staff initi intak assess design pregnant women outlin reason quit smoke stra tegi quit secker walker solomon flynn skelli mead 1998a abstin end pregnanc assess receiv pamphlet highlight reason remain abstin postpartum secker walker solomon flynn skelli mead 1998b statist analysi conting nonconting treatment condit compar subject characterist chi squar test test fisher exact test test differ treatment condit proport subject meet biochem confirm abstin criterion end pregnanc 12 24 week postpartum breslow dai chi squar test homogen determin treatment differ abstin rate homogen method assign i. subject consecut assign random test homogen involv cell frequenc 0.5 ad cell order defin odd ratio prior comput breslow dai statist analys perform sa statist softwar statist signific determin base alpha level 05 nicotin tobacco research 1017 nivers berdeen februari 19 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org result signific differ sociodemograph smoke characterist attitud note women conting nonconting voucher condit studi intak assess tabl 1 limit amount inform characterist 42 women declin studi base inform avail detect signific differ studi particip declin compar studi particip declin found characterist race 94 versu 95 white x2 1 04 85 mean year educa tion 11.6 sd 2.0 versu 11.2 sd 2.3 93 2.90 37 mean ag 22.7 year sd 4.9 versu 24.6 year sd 4.7 93 1.92 06 gestat ag 14.0 week sd 7.4 versu 11.8 week sd 6.2 93 21.48 14 mean number cigarett smoke dai week prior prenat care visit 10.3 sd 8.6 versu 12.4 sd 9.6 93 1.12 27 loss follow low significantli treatment condit end pregnanc 12 week postpartum 24 week postpartum assess complet respec tive 90 27 30 87 26 30 87 26 30 particip conting voucher condit versu 100 23 23 91 21 23 87 20 23 nonconting voucher condit biochem confirm 7 dai point preval abstin level significantli greater conting nonconting condit end pregnanc 025 12 week postpartum 003 24 week 007 postpartum assess ment tabl 2 evid treatment differ abstin depend subject assign randomli con secut admiss pw 30 assess time subject assign randomli abstin level conting versu nonconting con dition 25 2 8 versu 0 0 8 25 2 8 versu 0 0 8 25 2 8 versu 0 0 8 end pregnanc 12 week postpartum 24 week postpartum assess assign consecut admiss abstin level con tingent versu nonconting condit 41 9 22 versu 13 2 15 27 6 22 versu 0 0 15 27 6 22 versu 0 0 15 assess discuss treatment effect observ voucher program place present studi replic report previous donatel al 2000 voucher base incent program donatel al studi involv monthli monitor tabl 1 subject characterist characterist contingenta noncontingenta 30 23 demograph ag year 22.8 4.9 22.5 4.9 83 educ year 11.7 2.1 11.6 1.9 92 white 93 96 72 marri 30 13 14 privat insur 10 13 73 pregnanc 57 48 52 week pregnant intak 15.6 7.5 11.8 6.8 06 smoke characterist cigarett dai prepregn 23.3 11.9 22.7 10.4 83 cigarett dai past 7 dai 9.9 8.8 10.8 8.5 70 ag start smoke year 14.1 2.6 13.7 1.7 47 intak carbon monoxid ppm 12.5 9.5 10.3 5.4 30 intak urinari cotinin ng ml 1070 712 1229 606 40 live smoker 83 65 13 smoke attitud amount quitb 3.9 0.3 3.9 0.4 96 confid quitb 3.1 0.8 2.9 0.7 40 intend quit pregnantc 4.5 0.8 4.6 0.6 47 note valu repres mean sd atreat group text bassess point scale 1 4 lot cassess point scale 1 5 tabl 2 biochem confirm 7 dai point preval abstin particip conting nonconting end pregnanc 37 11 30 9 2 23 12 week postpartum 33 10 30 0 0 23 24 week postpartum 27 8 30 0 0 23 pv 05 1018 voucher base incentn promot perinat smoke abstin nivers berdeen februari 19 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org smoke statu maximum 800 incent divid target smoker social support person contrast present studi intens greater monthli monitor maximum incent approxim 1,200 target exclus smoker magnitud abstin effect observ studi compar voucher program place 7 dai point preval abstin end pregnanc 32 versu 9 incent control condit donatel al 37 versu 9 present studi end incent period 8 week postpartum donatel al 12 week postpartum present studi 7 dai point preval abstin 21 versu 6 33 versu 0 donatel al report abstin discontinu voucher program present studi 7 dai point preval abstin 27 versu 0 6 month postpartum assess 12 week voucher discontinu abstin rate end pregnanc initi coupl month postpartum studi approxim doubl 15 18 abstin rate report efficaci intervent lower incom pregnant smoker dolan mullen al 1994 sustain treatment effect observ 6 month postpartum assess present studi knowledg observ previous interven tion low incom women effect report donatel al 2000 present report replic lower intens abstin monitor incent valu donatel al adequ intens intervent present studi need reliabl produc high abstin rate observ initi studi determin parametr studi voucher frequenc abstin monitor vari systemat incent studi involv illicit drug abus nonpregn smoker parametr factor influenc outcom higgin al 2004 complex notwith stand result studi suggest voucher base incent offer effect strategi increas smoke cessat rate low incom pregnant recent postpartum women cost obviou practic issu regard voucher incent base intervent specif identifi total cost patient present intervent voucher cost dissoci clinic cost research intervent substanti excess health care cost matern smoke intervent prove cost effect adam melvin 1998 center diseas control pre vention 1997 miller villa hogu sivapathasundaram 2001 estim matern smoke result addit medic cost year birth 1,142 1,358 smoke pregnant woman result observ nonconting voucher condit merit comment 9 abstin rate observ antepartum consist 7 9 abstin rate observ usual care prior smoke cessat studi conduct clinic particip present studi secker walker al 1994 1998a similarli 0 abstin rate observ postpartum present studi slightli lower 3 5 postpartum abstin rate observ prior studi secker walker al 1994 1998a consist 0 postpartum abstin rate report usual care studi conduct e.g gebaur kwo hayn wewer 1998 low balanda clare 1998 inform suggest nonconting voucher effect abstin rate consist result studi cigarett smoke type substanc abus noncon tingent voucher higgin al 2004 voucher incent improv absti nenc substanc abus conting relationship avail abstin essenti strikingli low rate abstin observ antepartum postpartum conting condit present studi provid evid recalcitr natur smoke popul result obtain conting voucher condit present studi encoura ging small number women studi fact major assign consecut admiss random respect treatment condit underscor caution replic small sampl size advers affect precis estim magnitud treatment effect compar abstin rate observ voucher period present studi donatel al 2000 studi suggest substant problem present studi assign particip treatment condit consecut admiss increas possibl subject characterist extern influenc chang time treatment intervent contribut differ ential treatment effect observ absenc signific differ subject characterist tween treatment condit present studi consist result subject rando mize treatment assign consecut nicotin tobacco research 1019 nivers berdeen februari 19 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org admiss argu likelihood present result artifact research design replic fulli random design adequ address possibl limit notwithstand present result donatel al 2000 encourag potenti com.ibm.drl.hbcp.util voucher base incent increas smoke abstin pregnanc postpartum low incom smoker acknowledg luke mchale lindsai simpson paula glasmann assist data collect joan mongeon assist statist analys lauriann verret assist prepar tabl melinda rouill assist manuscript prepar research support research grant r01da14028 nation institut drug abus
prevent medicin 68 2014 51 57 content list sciencedirect prevent medicin ourna homepag www.e lsev locat ypmed examin schedul financi incent smoke cessat pregnant women stephen higgin yukiko washio alexa lopez sarah heil laura solomon mari ellen lynch jennif hanson taram higgin joanm skelli ryan redner ira bernstein vermont center behavior health univers vermont usa depart psychiatri univers vermont usa depart psycholog univers vermont usa depart famili practic univers vermont usa depart medic biostatist univers vermont usa depart obstetr gynecolog reproduct scienc univers vermont usa clinicaltrials.gov nct01801384 author depart psychiatri univers vermont burlington vt 05401 usa fax mail address stephen.higgin uvm.edu s.t higgi http dx.doi.org 10.1016 j.ypm 2014.03.024 0091 7435 2014 elsevi right reserv onlin 2 april 2014 keyword financi incent voucher conting manag tobacco pregnanc smoke cessat fetal growth birth outcom object examin efficaci voucher base incent intervent decreas smoke pregnanc increas fetal growth improv increas cost strategi redistribut usual incent higher valu earli quit attempt method 118 pregnant smoker greater burlington vermont studi decemb 2006 june 2012 randomli assign revis conting voucher rcv usual conting voucher cv schedul abstin conting voucher conting voucher ncv control condit voucher provid independ smoke statu smoke statuswa biochem verifi serial sonograph es timat fetal growth obtain gestat week 30 34 result rcv cv condit increas point preval abstin ncv level earli rcv 40 cv 46 ncv 13 007 late pregnanc rcv 45 cv 36 ncv 18 04 assess abstin level differ rcv cv condit rcv intervent increas fetal growth control level cv condit 05 conclus trial support efficaci cv increas antepartum abstin fetal growth strategi e.g increas incent valu improv outcom 2014 elsevi right reserv cigarett smoke lead prevent poor pregnanc outcom u. industri countri increas risk catastroph pregnanc complic advers effect extend childhood cnattingiu 2004 cohen al 2010 kandel al 2009 roger 2008 stene larsen al 2009 advers effect medic ly econom drain health care system reason effect smoke cessat intervent pregnant women sore need reason improv ment need econom disadvantag women disproportion high rate smoke pregnanc higgin al 2009 kandel al 2009 effect cessat intervent aid effort decreas unsettl hc campu rm 3100bold hall 1 802 656 9628 ns problem health dispar e.g cdc 2010 higgin chilcoat 2009 intervent financi incent increas antepartum cessat rate fold control level increa ing fetal growth higgin al 2012 lumlei al 2009 incent base intervent promis ampl room improv prior trial 35 40 women treat incent achiev antepartum abstin heil al 2008 higgin al 2004a 2010 present trial conduct goal improv outcom achiev efficaci voucher base incent intervent increa ing cost incent 1180 maxim earn schedul incent revis provid higher monetari incent earli quit attempt earli suc cess predict late pregnanc abstin higgin al 2006 incent reduc usual level potenti maxim earn remain unchang counsel intens increas level prior incent trial rational improv http crossmark.crossref.org dialog doi 10.1016 j.ypm 2014.03.024 domain pdf http dx.doi.org 10.1016 j.ypm 2014.03.024 mailto:stephen.higgin uvm.edu http dx.doi.org 10.1016 j.ypm 2014.03.024 http www.sciencedirect.com scienc journal 00917435 52 s.t higgin al prevent medicin 68 2014 51 57 gener treatment respons fior al 2008 windsor al 1985 1993 method particip particip recruit obstetr practic women fant children wic offic burlington vt studi inclus criteria smoke past 7 dai gestat ag 25 week resid counti clinic locat plan remain geograph area 6 month deliveri english speak exclus criteria incarcer previou particip voucher base incent trial smoke cessat resid trial particip regular opioid psychomotor stimul antipsychot medic women receiv prenat care refer clinic complet questionnair smoke statu total 297womenwer deem potenti ly elig studi successfulli contact studi staff fig 1 hundr thirti 44 enrol 63 21 express interest fail complet enrol process 104 35 refus particip women agre particip 44 randomli assign revis conting voucher rcv condit 44 usual conting voucher cv condit 42 conting voucher ncv control condit criterion withdraw trial treatment signment pregnanc termin fetal demis 12 women 4 rcv 5 cv 3 ncv withdrawn base criterion leav 118 women result primari analysi smoke statu tabl 1 univers vermont institut review board approv studi particip provid written inform consent assess particip complet questionnair examin sociodemograph smoke psychiatr characterist provid breath urin specimen studi intak assess modifi version batteri complet month intak assess earli pregnanc assess end pregnanc 28 week gestat late pregnanc assess 2 4 8 12 24 week postpartum fig 1 flow particip studi particip pregnant assess abstin monitor period breath specimen analyz carbon monoxid monitor urin cotinin level determin onsit enzym immunoassai test consid smoker assess woman report smoke past dai meet urin cotinin abstin criterion treatment intervent abstin monitor schedul studi entri women chose twomondai quit date particip request attend clinic bemet staff member altern site initi 5 dai cessat effort week 2 mon itor decreas 2 weekli mondai thursdai 7 week weekli wednesdai 4 week week wednesdai deliveri cv ncv condit rcv condit schedul week week 12 week deliveri equat potenti earn condit deliveri condit back weekli monitor schedul 4 week week 12 week postpartum regular abstin monitor end save 24 week follow assess women fail achiev absti nenc relaps continu achiev abstin fre quenci monitor lean recycl back entir progress recycl option woman compar rcv cv ncv condit 40 46 41 women servic particip receiv usual care smoke cessat provid obstetr clinic studi staff provid addit cessat counsel particip visit week studi entri final antepartum visit postpartum studi visit women quit pregnanc counsel occur routin smoke statu monitor visit temptat smoke report counsel guid print booklet tailor pregnant smoker acog 2001 addit cessat counsel includ prior trial higgin al 2012 smoker greater burlington vt studi decemb 2006 june 2012 tabl 1 particip characterist revis conting voucher 40 conting voucher 39 conting voucher 39 demograph ag year 24.1 4.2 24.9 5.1 24.7 5.4 75 caucasian 90 100 89 11 educ 63 12 year educ 23 18 23 12 year educ 62 67 51 12 year educ 15 15 26 week pregnant baselin 10.0 4.2 10.1 4.1 10.7 4.5 74 primagravida 67 62 64 89 marri 10 18 21 41 privat insur 32 20 18 27 work pai home 70a 38b 56ab 02 smoke characterist ag start smoke cigarett 14.9 3.4 16.3 3.1 15.2 2.1 09 cigarett dai pre pregnanc 17.7 8.8 19.5 7.7 17.8 8.7 55 cigarett dai baselin 9.5 5.8 8.7 7.6 7.8 5.3 49 live smoker 82 85 77 66 smoke allow home 55 67 61 57 friend famili smoke 22 28 31 70 attempt quit pre pregnanc 80 77 62 14 number quit attempt pregnanc 0.8 1.6 0.6 1.3 0.5 1.1 54 minnesota nicotin withdraw scale total score 1.6 0.8 1.4 0.7 1.5 0.9 58 psychiatr symptom stress rate 6.3 2.8a 4.8 2.5b 5.8 2.5ab 04 beck depress inventori 11.1 7.0 9.8 7.4 10.8 7.1 38 histori depress symptom 42 36 46 65 note valu representmean sdunless indicated.mean percentageswith common letter differ significantli atα 05 pairwis comparison participantswer 118 pregnant smoker greater burlington vt studi decemb 2006 june 2012 53s.t higgin al prevent medicin 68 2014 51 57 usual conting voucher cv condit voucher redeem retail itemswer earn conting submit breath specimen 6 ppm initi dai cessat effort begin week 2 voucher deliv conting urin cotinin level 80 ng ml criterion requir longer durat smoke absti nenc breath higgin al 2007a voucher deliverywa independ report smoke statu base exclus meet biochem verif criterion unauthor failur complet sched ul assess treat posit test result consist intent treat approach friedman al 1998 voucher began 6.25 escal 1.25 consecut neg specimen maximum 45.00 remain bar posit test result miss abstin monitor visit posit test result miss visit reset voucher back origin low consecut neg test restor pre reset level revis conting voucher rcv condit voucher schedul outlin abovewa rcv con dition potenti earn reschedul move 296.25 ward bonus week 1 6 meet 4 ppm breath criterion week 1 test cotinin neg urin test 2nd mondai quit attempt submit cotinin neg specimen week week 6 specif bonus earn reach cutoff 4 ppm week 1 start 18.75 increas 3.75 success neg sampl reach maxi mum potenti bonu 33.75 5th consecut neg specimen meet 4 ppmco cutoff duringweek 1 women condit earn incent cv condit theymet 6 ppmcobut 4 ppm cutoff inweek 1 goal provid bonus achiev stringent criterion decreas likelihood low level smoke undermin longer term abstin higgin al 2006 assur woman receiv incent shemet slightli liber 6 ppm criterion effect prior trial higgin al 2012 test ing cotinin neg 2nd mondai result addit bonu 87.50 usual cv incent earn date bonus 15.50 thursdai 2nd test dai week week 2 6 woman test neg smoke earlier test conduct week set bonus design reinforc initi period continu abstin base result fromour prior studi higgin al 2006 2007a conting voucher ncv control condit condit voucher deliv independ smoke statu voucher valu 15.00 visit antepartum 20.00 visit postpar tum valu result payment amount compar averag earn cv condit prior trial heil al 2008 cv rcv condit serial ultrasound examin birth outcom serial ultrasound examin perform approxim 30 34 week gestat estim fetal growth serial ultrasound assess gener individu estim fetal growth mid trimest compar treatment condit analysi repeat measur afford serial ultrasound greater statist power relatedmeasur collect singl time point e.g birth weight sen sitiv incent base smoke cessat intervent heil al 2008 seventi women complet assess 25 rcv 25 cv 20 ncv mea sure includ estim bipariet diamet head circumfer abdomin circumfer femur length obtain obstetrician blind particip treatment condit smoke statu standard tech niqu head circumfer abdomin circumfer femur length combin themethod hadlock al 1985 calcul estimat ed fetal weight gain estim made lean bodi mass accret fetal thigh emploi previous report techniqu bernstein al 1997 measur perform triplic mean assign estim specif paramet infant birth outcom obtain matern medic record statist method primari analysi smoke statu base particip ran domiz except women withdrawn due pregnanc termina tion fetal demis 118 friedman al 1998 women deliv twin omit analys birth outcom fetal growth base 70 women deliv singleton complet ultrasound assess treatment condit compar particip characterist chi squar test categor measur analysi varianc continu measur outcom signific pairwis comparison examin signific differ lsd test continu outcom pairwis chi squar 54 s.t higgin al prevent medicin 68 2014 51 57 categor outcom logist regress compar treatment condit point preval abstin dichotom birth outcom analysi varianc compar antepartum neg smoke statu test gestat ag deliveri signific test pairwis comparison test effect size cohen 95 confid limit analysi covari compar treat ment condit birth weight pre pregnanc bmi covari compar treatment condit fetal growth fetal sex gestat ag ultrasound covari baselin characterist ag start smoke cigarett rate 0 10 stress past week includ covari analysi differ significantli treatment condit andwer correlatedwith fetal growth outcom anal yse perform sa version 9 statist softwar sa institut cari nc statist signific determin base 05 result particip characterist characterist differ significantli treatment conditions:mor assign rcv conditionwork home compar cv ncv condit assign rcv condit report higher mean rate stress past week assign cv ncv condi tion tabl 1 characterist significantli corr late smoke abstin birth outcom compar particip characterist women complet ultra sound assess tabl 2 differ mean stress rate note sampl remain signific subgroup ag smoke initi differ smoke abstin rcv cv incent condit increas antepartum 7 dai point preval abstin level observ ncv control condit fig 2 signific treatment effect earli pregnanc assess wald x2 2 9.8 007 40.0 46.1 12.8 women assign rcv cv ncv tabl 2 particip characterist complet ultrasound assess revis conting voucher 25 demograph ag year 24.5 4.7 caucasian 96 educ 12 year educ 29 12 year educ 54 12 year educ 17 week pregnant baselin 11.0 4.7 primagravida 60 marri 16 privat insur 32 work pai home 64 smoke characterist ag start smoke cigarett 14.6 2.6b cigarett dai pre pregnanc 17.2 8.0 cigarett dai baselin 9.8 5.7 live smoker 84 smoke allow home 44 friend famili smoke 20 attempt quit pre pregnanc 84 number quit attempt pregnanc 0.7 1.2 minnesota nicotin withdraw scale total score 1.9 0.8 psychiatr symptom stress rate 6.9 2.4a beck depress inventori 13.1 7.5 histori depress symptom 52 note valu repres mean sd mean percentageswith 70 pregnant smoker greater burlington vt studi decemb 2006 june 2012 condit abstin fig 2 upper panel pairwis parison women assign rcv condit differ assign ncv condit 01 4.5 95 ci 1.5 14.1 cv condit differ ncv 01 5.8 95 ci 1.9 18.0 assign incent condit differ 58 0.78 95 ci 0.3 1.9 abstin differ late pregnanc assess similar pattern wald x2 2 6.4 04 45.0 35.9 18.0 women assign rcv cv ncv condit abstin fig 2 lower panel pairwis comparison rcv con dition differ significantli ncv condit 01 3.7 95 ci 1.3 10.5 differ cv ncv trend direct 08 2.6 95 ci 0.9 7.3 incent condit differ 41 1.5 95 ci 0.6 3.6 compar treatment condit themean percentag antepartum toxicolog test neg smoke largest number consecut neg test fig 3 upper lower panel neg toxicolog test includ neg specimen 6 initi week treatment cotinin neg specimen 80 ng ml subs quent antepartum abstin monitor visit mean percentag neg test women assign rcv cv ncv condit averag 56.0 55.4 31.0 neg test spectiv 2,115 6.2 003 pairwis comparison assign rcv condit differ ncv con dition 01 cohen 0.70 95 ci 0.24 1.15 assign cv condit differ assign ncv condit 01 cohen 0.68 95 ci 0.22 1.13 incent condit differ 91 cohen 0.01 95 ci 0.43 0.45 mean sem consecut neg test assign rcv cv ncv con dition averag 10.9 1.3 14.8 2.0 5.8 1.1 consecut nega tive toxicolog test 2,115 8.5 001 pairwis comparison assign rcv differ assign ncv condit 1,115 2.4 02 cohen 0.53 95 ci 0.08 0.98 assign cv condit differ conting voucher 25 conting voucher 20 24.7 4.1 24.1 4.0 89 100 85 09 69 20 25 68 50 12 25 9.9 4.3 10.8 4.9 69 64 60 95 24 15 68 28 20 66 48 50 47 16.7 3.3a 14.7 2.2b 02 19.9 8.8 16.9 6.6 37 7.0 5.8 7.2 5.0 17 80 70 51 60 65 32 24 30 74 84 65 22 0.8 1.5 0.6 1.1 82 1.5 0.8 1.7 0.8 35 5.2 2.6b 5.6 2.4ab 05 10.9 8.5 12.0 7.1 62 52 40 66 mon letter differ significantli atα 05 pairwis comparison particip fig 2 upper panel 7 dai point preval abstin rate treatment condit antepartum assess conduct approxim month start intervent earli pregnanc assess lower panel 7 dai point preval abstin rate treatment condit antepartum assess conduct approxim 28 week gestat late pregnanc assess condit share common letter differ atα 05 participantswer 118 pregnant smoker greater burlington vt studi 2006 2011 fig 3 mean percent neg antepartum smoke statu test conduct treatment condit error bar repres 1 sem condit share common letter differ α 05 particip 118 pregnant smoker greater burlington vt studi decemb 2006 june 2012 55s.t higgin al prevent medicin 68 2014 51 57 ncv 1,115 4.1 001 cohen 0.93 95 ci 0.46 1.4 signific differ rcv cv condit trend favor cv condit note 1,115 1.8 08 cohen 0.40 95 ci 0.05 0.84 whenw repeat comparison subgroupofwomenwho complet ultrasound assess pattern larg remain notabl except measur consecut neg toxicolog test signific treatment effect 2,66 6.4 003 averag sem 11.2 1.9 17.5 2.0 7.2 2.2 consecut neg test rcv cv andncv con dition pairwis comparison differ rcv ncv condit longer signific 17 trend differ rcv cv larg er data set achiev signific 03 signific treatment effect note postpartum absti nenc level sampl tabl 3 24 week assess abstin level rcv cv condit 17.9 15.4 fold greater level ncv condit 7.7 differ statist signific rcv ncv 2.6 95 ci 0.6 11.0 cv ncv 2.2 95 ci 0.5 9.4 mean total voucher earn differ significantli treatment condit 557.08 64.54 443.65 73.69 383.59 32.46 rcv cv ncv condit 2,115 2.19 12 fetal growth signific treatment effect estim fetal weight 2,60 5.5 006 abdomin circumfer 2,61 4.2 02 femur length 2,61 3.3 04 tabl 4 pairwis comparison fetus mother treat cv condit greater increas weight gain fetus mother treat ncv 0.05 cohen 0.84 95 ci 0.22 1.45 rcv condit 0.05 cohen 0.20 95 ci 0.36 0.76 fetus mother cv condit greater increas abdomin circumfer ncv 0.05 cohen 0.74 95 ci 0.13 1.34 rcv 0.05 cohen 0.83 95 ci 0.25 1.4 lastli fetus mother cv condit show greater increas femur length rcv condit 0.05 cohen 6.60 95 ci 5.2 8.0 ncv condit sig nific treatment effect fetal head circumfer bipariet diam eter lean thigh area birth outcom signific treatment effect birth outcom tabl 5 outcom averag outcom slightli infant born mother assign cv pare ncv rcv condit tabl 3 biochem verifi 7 dai smoke abstin postpartum assess revis conting voucher 40 conting voucher 39 conting voucher 39 12 week 18 23 18 77 24 week 18 15 8 41 particip 118 pregnant smoker greater burlington vt studi decemb 2006 june 2012 56 s.t higgin al prevent medicin 68 2014 51 57 discuss result provid support efficaci financi centiv smoke cessat intervent pregnant women higgin al 2012 knowledg sixth control trial incent demonstr increas control level smoke cessat rate higgin al 2012 trial demonstr increas fetal growth heil al 2008 impor tant purpos present studi evid revi ing intervent includ larger incent earli abstin improv smoke abstin level rcv condit compar usual cv schedul evid suggest revis schedul effect protect fetal growth similar effort improv outcom voucher base interven tion cocain depend bymodifi usual schedul provid larger magnitud incent form bonus abstin earli treatment fail improv outcom usual arrang ment silverman al 1998 goal devis strategi increas proport women respond favor incent base intervent strategi strategi merit consider primari offer greater incent valu abstin intervent heavier smoker higgin al 2009 approach demonstr improv outcom incent base intervent illicit drug abus higgin al 2007b lussier al 2006 silverman al 1999 strategi combin incent smoke cessat pharmaco therapi repres viabl option explor oncken kranzler 2009 deserv comment strategi intensifi fre quenci backdrop counsel present studi effort increas gener treatment respons evid strategi increas abstin rate level achiev usual cv condit prior trial averag 36 18 18 late pregnanc 12 week postpartum 24 week postpartum assess present trial compar 34 24 14 assess prior trial higgin al 2012 abstin rate present rel prior trial ncv control condit prior trial point preval abstin rate condit 7 3 1 late pregnanc 12 week 24 week postpartum assess present trial 18 18 8 increas cessat rate ncv control condit tabl 4 estim fetal growth measur revis conting voucher 25 fetal weight gain week 191.0 9.5b abdomin circumfer cm week 1.03 0.04b femur length cm week 0.16 0.01b head circumfer cm week 0.68 0.05 bipariet diamet cm week 0.21 0.01 lean thigh area cm2 week 0.82 0.08 note mean sem common letter differ significantli 05 pairwis cember 2006 june 2012 attribut increas intens counsel due absenc low counsel intens ncv control condit potenti expla nation prior trial offer minim counsel offer provid part routin obstetr care higgin al 2012 result observ ncv con dition suggest earlier differ observ cv ncv condit elimin provid ing intens counsel group earli week intervent potenti practic drawback strategi overlook includ women attend addit counsel session absenc conting voucher provid women ncv condit present studi incent includ support attend make sens provid conting tendanc recent abstin superior outcom observ cv compar ncv condit present studi birth outcom cv condit present trial match close outcom observ previous condit underscor reli abil treatment outcom condit mean birth weight 3344.8 101.9 present trial compar 3295.6 63.8 prior trial higgin al 2010 reason differ cv ncv condit thesemeasur reduc present compar prior trial attribut creas abstin rate ncv condit mean birth weight ncv condit present trial 3188.6 105.0 compar 3093.6 67.0 prior trial birth outcom cv condi tion present trial match close observ prior trial low birth weight deliveri present prior trial 7.9 5.9 mean gestat ag 39.3 39.1 week preterm deliveri 5.3 5.9 nicu admiss 2.6 4.7 higgin al 2010 trial limit conduct small sampl larg rural caucasian young women u. state howwel approach treatment effect gener iz tomor divers sampl larg unansw question control trial conduct u. state oregon posit donatel al 2004 broad gener observ financi incent decreas substanc incent intervent base scientif principl reinforc higgin al 2004b lussier al 2006 optimist strategi conting voucher 25 conting voucher 20 valu 228.5 8.7a 196.5 7.1b 006 1.21 0.05a 1.05 0.05b 02 0.20 0.01a 0.19 0.01ab 04 0.62 0.04 0.63 0.04 63 0.21 0.01 0.19 0.02 67 0.88 0.05 0.91 0.05 55 omparison particip 70 pregnant smoker greater burlington vt studi de tabl 5 infant outcom deliveri measur revis conting voucher 37 conting voucher 38 conting voucher 36 birth weight 3284.9 105.8 3344.8 101.9 3188.6 105.0 56 low birth weight 11 7 11 87 gestat ag week 39.0 0.3 39.3 0.3 38.9 0.3 51 preterm birth 8 5 11 66 nicu admiss 8 2 11 41 note valu repres mean sem note fewer women treatment condit due avail birth outcom data nicu neonat intens care unit particip 111 infant greater burlington vt studi decemb 2006 june 2012 57s.t higgin al prevent medicin 68 2014 51 57 reduc smoke pregnanc efficaci divers sam ple set import futur challeng research effort larger proport women respond demon strate cost effect approach conflict interest statement declar acknowledg research support nation institut health nih research award r01da014028 r01hd075669 institut train grant t32da007242 center biomed research excel center award p20gm103644
evier.com locat ypmed prevent medicin 41 smoke cessat patient copd daili gener practic smocc month result sander hilberink m.sc johanna jacob m.sc ben j.a.m bottema ph.d hein de vri ph.d richard p.t.m grol ph.d centr qualiti care research wok univers medic centr nijmegen st radboud kwazo 229 p.o box 9101 6500 hb nijmegen netherland depart gener practic univers medic centr nijmegen st radboud netherland depart health promot health maastricht univers netherland centr qualiti care research wok maastricht univers netherland onlin 3 octob 2005 abstract background chronic obstruct pulmonari diseas copd form increas health problem smoke cessat improv prognosi diseas patient persist smoke present studi present result smoke cessat counsel protocol gener practic smoke cessat patient copd gener practic smocc method random control trial patient copd compar smoke cessat counsel intensifi minim intervent strategi usual care total 43 gener practic 392 patient particip nijmegen netherland 2001 2002 result significantli smoker experiment group made quit attempt 44.9 versu 36.5 quit smoke control group 16.0 versu 8.8 motiv stop smoke baselin smoke cessat conclus smocc strategi doubl report quit rate compli gener practition implement gener practic recommend 2005 elsevi right reserv keyword smoke cessat gener practic pulmonari diseas chronic obstruct guidelin implement introduct chronic obstruct pulmonari diseas copd life threaten disabl diseas increas health problem world health organis 2000 nation heart lung blood institut 2003 smoke domin risk factor smoke cessat remain major aspect treatment nation heart lung blood institut 2003 quit smoke reduc ongo deterior diseas improv prognosi copd relat complaint scanlon al 2000 anthonisen al 1994 willems al 2004 number smoke cessat intervent incorpor gener practic simpl physician advic quit silagi stead 2003 combin spirometri gorecka al 2003 pharmacolog therapi i. nicotin 0091 7435 front matter 2005 elsevi right reserv doi 10.1016 j.ypm 2005.08.003 author fax 31 24 3540166 mail address s.hilberink kwazo.umcn.nl s.r hilberink replac therapi nrt antidepress silagi al 2003 hugh al 2003 minim intervent counsel pieters al 2001 pro activ telephon counsel stead al 2003 case stop smoke support copd patient combin pharmacolog behavior strategi effect van der meer al 2003 stage chang prochaska diclement 1982 1983 central concept smoke cessat intervent divid process behavior chang step precontempl chang quit smoke month stage contempl intent quit smoke month prepar stage quit 1 month person prepar action stage action mainten relat actual chang behavior mainten chang minim intervent strategi mi call stage base smoke cessat intervent gener practi 2005 822 827 www.el s.r hilberink al prevent medicin 41 2005 822 827 823 tioner pieters al 2001 appli normal practic visit effect decreas smoke preva lenc applic protocol risk popul cardiac patient pregnant women show effect bolman al 2002 bakker 2001 approxim patient copd smoke 54 consid quit smoke month sooner hilberink al press emphasi treatment guidelin smoke cessat patient copd found difficult group smoke cessat treatment postma sluiter 1989 crow lei al 1995 pederson al 1991 daughton al 1980 copd patient visit gener practition gp 6 month regular control consult nation heart lung blood institut 2003 gp contribut smoke cessat process chang mi intensifi strategi smoke cessat copd gener practic smocc smocc program embed normal daili practic recommend copd treatment guidelin nation heart lung blood institut 2003 implement guidelin tune barrier stimuli make knowledg base effect implement strategi train health profe sional improv perform smoke cessat activ organiz factor address grol grimshaw 2003 implement research show interact educ profession effect suggest multifacet intervent outreach visit implement guidelin grol grimshaw 2003 thomson o’brien al 2004 design multifacet intervent includ profession train outreach visit implement smoke cessat counsel protocol present studi smocc strategi evalu effect report quit rate month method studi design studi arm random control trial gener practic intervent group receiv support implement smocc program control group practic deliv usual care random place practic level practic classifi class high low task deleg gp practic nurs experi smoke cessat counsel practic class randomli alloc group power analysi show group minimum 25 gener practic 150 patient copd group find statist signific differ 10 quit rate alpha 0.05 beta 0.20 intervent protocol profession direct intervent consist group train copd smoke smoke cessat individu support provid outreach visitor mean counsel feedback perform practic locat visit outreach visitor support materi deliv includ softwar detect patient copd inform copd smoke cessat letter patient questionnair assess smoke statu smoke cessat counsel protocol protocol request educ tool patient patient direct intervent smocc protocol consist extend version themi specif aim educ support patient gener practic patient intervent group invit control visit accordancewith copd treatment guidelin nation heart lung blood institut 2003 control visit focus symptom health statu treatment smoke behavior motiv stage quit smoke patient divid categori 1 prepar quit 1 month 2 contempl quit 6 month 3 precontempl quit hilberink al press smoker unmotiv quit receiv inform advantag quit smoker motiv quit receiv efficaci enhanc inform discuss cope barrier quit depend sever nicotin depend receiv addit inform nrt contempl invit 2 week patient prepar quit month consult schedul set quit date plan follow visit gp maximum follow visit proactiv telephon call practic nurs assist maximum telephon call patient educ tool consist booklet develop copd popul videotap materi patient motiv stage obtain reliabl report smoke bogu pipelin procedurewa appli jone sigal 1971 aguini al 1993 subject recruit practic place district netherland practic suitabl gener practic electron inform system forti practic enrol studi drop prior random mean softwar program anatom therapeut chemic atc prescript code intern classifica tion primari care icpc diagnosi code select made potenti copd patient select criteria 1 ag 35 year 2 diagnos copd 3 record medic icpc code r95 96 4 prescript time bronchodil past year atc code r03a bc 5 prescript time inhal anti inflammatori medic past year atc code r03 valid select result gp ask confirm diagnosi patient approach letter short questionnair assess smoke statu smoker request give inform consent instrument gp receiv questionnair assess baselin practic characterist polici copd smoke cessat contact person practic complet short questionnair telephon follow gp receiv evalu questionnair assess complianc part protocol patient receiv extens questionnair baselin 6 month follow main outcom measur studi report point preval smoke 7 dai collect data motiv quit smoke prochaska diclement 1983 nicotin depend measur fagerström test nicotin depend ftnd heatherton al 1991 number studi found support valid heatherton al 1991 pomerleau al 1994 efficaci measur eleven item point scale 0 4 cronbach alpha 90 scale develop base previou research de vri andmudd 1998 de vri al 1995 1998 dijkstra de vri 1999 dijkstra al 1996 1998 mudd de vri 1999 construct sever copd measur dutch version medic research council questionnair van der lend s.r hilberink al prevent medicin 41 2005 822 827824 ori 1972 1 sever dyspnoea sum score rang 0 3 2 chronic cough 3 chronic sputum product questionnair good psychometr properti toren al 1993 samet 1978 statist analys bivari analys describ group differ drop analys perform backward logist regress analysi effect analys carri intent treat basi hierarch structur studi patient nest practic perform multilevel analys spss 11.0 sa v8.2 proc mix glimmix macro result inclus gener practic twenti practic alloc control group 23 practic intervent group 5 practic drop fig 1 tabl 1 show baselin fig 1 consort figur studi nijmegen characterist practic gp differ arm observ inclus patient 406 copd patient includ patient di studi patient felt ill ongo particip inclus 14 patient exclud sampl total sampl consist 392 patient 148 control group 244 intervent group fig 1 differ group result drop larg group practic control group tabl 2 show baselin characterist patient group 50 sampl quit smoke month patient smocc group tend slightli motiv chi2 5.7 df 2 0.059 6 month questionnair return 323 patient 82.4 131 control group 192 intervent maastricht netherland 2001 2002 tabl 1 baselin characterist includ practic gp nijmegen maastricht netherland 2001 2002 variabl smocc control practic 21 22 practic form singl hand 43 37 dual practic 38 45 group practic 14 9 health centr 5 number patient median sd 2900.0 2946.0 2975.0 2291.0 number gp median sd 2.0 1.3 2.0 0.9 number practic assist median sd 2.0 1.3 2.0 1.0 experi research copd 24 14 experi smoke cessat intervent research 10 gp 25 30 male 72 87 ag mean sd 45.8 7.0 44.6 6.8 number work hour practic mean sd 42.5 13.7 41.8 11.1 familiar mi 36 37 attent smoke cessat patient copd recommend nrt 28 33 assess sever nicotin depend 60 57 assess motiv quit 80 80 note smocc smoke cessat patient copd intervent group gp gener practition mi minim intervent strategi nrt nicotin replac therapi copd chronic obstruct pulmonari diseas tabl 2 baselin characterist includ patient copd 392 nijmegen maastricht netherland 2001 2002 variabl smocc 244 control 148 demograph male 46.3 55.4 ag mean sd 58.0 12.1 60.1 11.5 partner 75.8 73.6 educ primari level 47.5 48.0 secondari level 41.4 38.5 advanc level 7.4 7.4 voluntari job 37.7 34.5 smoke stage chang prepar 25.8 17.6 contempl 32.0 28.4 precontempl 39.8 50.7 efficaci mean sd 21.5 10.5 19.5 9.3 nicotin dependencea mean sd 4.4 2.3 4.3 2.6 attempt quit smoke 75.0 71.6 copd dyspnoeab mean sd 1.5 1.2 1.6 1.2 chronic coughingb 33.2 35.1 chronic sputumb 34.8 28.4 note smocc smoke cessat patient copd intervent group fagerström test nicotin depend ftnd grol grimshaw 2003 medic research council mrc ecc dijkstra al 1996 sum score rang 0 3 tabl 3 quit rate point preval baselin motiv stop smoke nijmegen maastricht netherland 2001 2002 stage chang quit rate smocc 244 control 148 quit rate 16.0 8.8 prepar 63 26 quit rate prepar 20.6 15.4 contempl 78 42 quit rate contempl 16.7 7.1 precontempl 97 75 quit rate precontempl 13.4 8.0 note smocc smoke cessat patient copd intervent group due miss stage motiv patient total sampl greater sum patient categori s.r hilberink al prevent medicin 41 2005 822 827 825 group chi2 6.1 df 1 0.013 drop patient consid smoker control bias treatment effect due patient select fior al 2000 backward logist regress analysi show drop main effect complianc protocol 19 gp 18 practic return questionnair evalu smocc protocol report complianc aspect protocol good 70 80 smoke cessat patient intervent group attempt quit 6 month follow 44.9 versu 36.5 chi2 10.4 df 1 0.003 patient significantli quit attempt median 1.0 sd 1.6 versu 0.0 sd 1.3 8305.5 2.9 0.019 significantli patient smoke intervent group 16.0 control group 8.8 chi2 4.0 df 1 046 2.0 95 ci 1.0 3.9 differ quit rate motiv stage signific chi2 3.2 df 2 0.199 tabl 3 stage transit thirteen patient 5.3 intervent group made shift forward stage chang mean increas motiv quit smoke control group stage transit occur 10.9 patient 16 chi2 1.6 df 1 0.215 discuss protocol successfulli implement doubl quit rate compar usual care studi copd found continu abstin rate 6 month 33.3 15.7 versu 21.4 9.0 favor s.r hilberink al prevent medicin 41 2005 822 827826 intervent pederson al 1991 tashkin al 2001 intens intervent compar smocc strategi place control environ pederson al 1991 tashkin al 2001 patient sever lung diseas pederson al 1991 motiv patient tashkin al 2001 present studi report smoke cessat program predominantli sever patient motiv stage reflect real life effect gener practic differ quit rate motiv stage protocol success motiv patient recent critiqu stage base intervent riemsma al 2003 stage chang construct littel grivin 2002 sutton 2000 publish indic success stage base approach popul applic stage base protocol proven effect risk popul smoke form direct threat cancer patient bolman al 2002 pregnant women bakker 2001 present studi found intervent effect stage progress replic result cornuz al 2002 rais doubt us refin stage chang approach copd popul prepar contempl popul differ determin motiv hilberink al press simplifi stage chang model motiv stop smoke effect refin version implement method chosen appreci profession outreach visit small scale interact train deliv support materi effect contribut guidelin implement daili practic line find grol grimshaw 2003 hulscher al 1998 bero al 1998 implement nation scale benefit cost time consum implement strategi e.g person contact telephon helpdesk mail internet complement reduc number outreach visit implement strategi explor educ set methodolog consider made firstli size effect quit rate distort fact patient control group quit smoke 8.8 compar 6.5 gener smoke popul stivoro smoke free 2004 due influenc research set i. hawthorn effect roethlisberg dickson 1939 detect proce dure select practic level possibl affect quit rate 37 practic control group experi applic mi estim 28 dutch gener practition time drossaert al 1999 report complianc data gp protocol inform exact perform interact patient research method videotap consult need thirdli report smoke behavior reliabl popul smoke form increas risk pregnant women patient cardiovascular diseas perceiv pressur report smoke behavior klesg al 1995 secker walker al 1997 campbel al 2001 appli bogu pipelin procedur jone sigal 1971 brief patient report post treatment smoke statu check biochem analysi enhanc accuraci report measur smoke aguini al 1993 subject perceiv pressur hide smoke behavior gimen adam 2002 spite shortcom recommend larg scale implement smoke cessat counsel protocol gener practic preval copd netherland estim 1.4 femal 2.4 male research men environ 2002 approxim smoke hilberink al press implement protocol nation scale mean consider increas patient copd succeed smoke cessat acknowledg present studi financ dutch asthma foundat netherland organ health research develop zonmw pharmacia studi initi centr qualiti care research wok maastricht nijmegen data analys perform research
effect commun dna base risk assess crohn diseas smoke cessat randomis control trial open access gareth holland research fellow 1 sophia whitwel research associ 1 richard parker consult statistician 2 natali prescott research fellow 3 alastair forb professor gastroenterolog clinic nutrition4 jeremi sanderson consult gastroenterologist5 christoph mathew professor molecular genet 3 cathryn lewi professor genet epidemiolog statist 3 salli watt genet counsellor 6 stephen sutton professor behaviour scienc 2 david armstrong professor medicin sociolog 7 ann louis kinmonth foundat professor gener practic 2 tobi prevost professor medic statist 7 theresa marteau professor health psycholog 1 1depart psycholog gui section health psycholog king colleg london london se1 9rt uk 2depart public health primari care univers cambridg cambridg uk 3depart medic molecular genet king colleg london school medicin london uk 4depart gastroenterolog clinic nutrit univers colleg hospit london uk 5depart gastroenterolog st thoma hospit london uk 6clinic genet gui hospit london uk 7depart primari care public health scienc king colleg london london uk abstract object test hypothesi commun risk develop crohn diseas base genotyp stop smoke reduc risk motiv behaviour chang smoker famili risk design parallel group cluster randomis control trial set famili crohn diseas unit kingdom particip 497 smoker mean ag 42.6 sd 14.4 year degre rel proband crohn diseas outcom assess 209 251 base dna analysi 217 246 standard risk assess intervent commun risk assess crohn diseas postal booklet base famili histori diseas smoke statu addit dna analysi nod2 genotyp particip telephon nation health servic stop smoke counsellor review booklet deliv standard smoke cessat intervent call tape record random subsampl select assess fidel clinic protocol main outcom measur primari outcom smoke cessat 24 hour longer assess month result proport particip stop smoke 24 hour longer differ arm 35 73 209 dna arm versu 36 78 217 dna arm differ 1 95 confid interv 10 8 0.83 proport make quit attempt dna arm differ told mutat put increas risk 36 told 35 dna arm 36 conclus rel patient crohn diseas feedback dna base risk assess motiv behaviour chang reduc risk standard risk assess find accord rang popul behaviour support promulg commerci dna base test search gene variant confer increas risk common complex diseas basi effect motiv health relat behaviour chang trial registr current control trial isrctn21633644 introduct expect high commun estim diseas risk deriv genet test motiv chang behaviour reduc risk strongli type risk inform biomark 1 3direct consum test offer rang common complex disord expect motiv behaviour chang reduc identifi risk 23andm correspond marteau theresa.marteau kcl.ac.uk commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 1 12 research research http www.bmj.com permiss http www.bmj.com subscrib www 23andme.com navigen www.navigenics.com expect consist theori attitud chang predict greater salienc person inform dna make impact 4 test hypothesi randomis control trial assess com.ibm.drl.hbcp.util commun result predict genet test motiv quit smoker famili risk develop condit crohn diseas doubl smoking5 reduc stop 6 crohn diseas complex genet condit preval 1 1000 popul 7 degre rel 20 fold increas risk develop condit absolut risk 20 1000 popul addit increas risk mutat nod2 gene 40 1000 popul mutat nod2 gene 150 1000 popul 8 predict test crohn diseas serv time paradigm assess impact commun result predict genet test behaviour chang reduc risk case smoke cessat primari hypothesi commun risk estim crohn diseas incorpor dna analysi higher likelihood quit attempt smoke degre rel proband crohn diseas box test hypothes box predict dose respons effect receipt dna base risk inform peopl found risk enhanc mutat motiv chang behaviour found mutat comparison arm undergodna analysi 9the final hypothesi reflect concern commun dna analys reveal risk enhanc mutat lead lower rate risk reduc behaviour compar dna analysi possibl induc fals reassur box 10 method carri parallel group cluster randomis control trial unit kingdom 1 1 alloc particip famili cluster receiv type risk assess crohn diseas dna risk commun dna risk commun base dna analysi nod2 genotyp famili histori crohn diseas smoke statu base famili histori crohn diseas smoke statu elig particip degre rel proband crohn diseas ag 18 year diagnosi crohn diseas ulcer coliti smoke cigarett daili intervent risk assess crohn diseas trial coordin post booklet particip outlin explain result risk assess develop crohn diseas compris figur lifetim risk person risk reduct smoke cessat fig 1 natur risk assess differ arm risk estim calcul control dna arm person risk develop crohn diseas base residu famili risk proband parent sibl child estim effect unidentifi gene account contribut nod2 smoke statu twofold increas risk smoker previou research 8 risk estim particip arm rang 20 40 1000 popul median 30 mean 31.4 intervent dna arm person risk develop crohn diseas base residu famili risk smoke statu nod2 genotyp mutat confer gene dosag effect risk deriv mouthwash sampl return post particip calcul previou research 8 effect calibr risk commun dna arm high medium low control arm receiv averag genet risk base famili histori risk estim particip dna arm rang 20 350 1000 popul median 40 mean 45.2 83 188 226 particip receiv risk estim rang 20 40 1000 popul rang control group risk confin respect averag risk estim particip nod2 genotyp mutat median 30 mean 32.0 mutat median 50 mean 64.8 mutat median 200 mean 243.8 advic smoke cessat research counsellor train provis nation health servic stop smoke servic telephon particip receiv risk assess booklet counsellor reiter inform booklet ensur comprehens deliv smoke cessat intervent increas motiv stop smoke encourag nh stop smoke servic telephon call record subsampl assess determin fidel clinic protocol recruit follow procedur rout inform proband studi identifi degre rel met elig criteria firstli approach proband receiv care hospit servic obtain ethic approv local author obtain address proband crohn diseas databas 42 particip hospit detail member uk nation associ coliti crohn diseas crohn coliti uk final advertis newslett nation associ coliti crohn diseas chariti ostomi lifestyl procedur develop part feasibl studi 11 occas telephon elig degre rel consent contact initi telephon call check consent elig collect inform particip famili histori crohn diseas person smoke characterist telephon call elig particip receiv risk assess booklet research counsellor administ smoke cessat intervent amemb research team deliv intervent telephon particip week month assess primari secondari endpoint outcom primari outcom primari outcom quit attempt 24 hour durat made month commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 2 12 research http www 23andme.com http www.navigenics.com http www.bmj.com permiss http www.bmj.com subscrib hypothes test trial hypothesi 1 smoker attempt quit commun risk estim develop crohn diseas addition incorpor dna analysi compar equival commun base phenotyp famili histori heavi smoke arm comparison hypothesi 2 effect commun presenc risk increas mutat smoker risk assess includ feedback dna analysi smoke cessat attempt analysi reveal risk increas mutat compar undergo similar dna analysi reveal risk increas mutat versu mutat dna arm comparison risk assess incorpor dna analysi mutat versu dna arm hypothesi 3 effect commun absenc risk increas mutat smoker risk assess includ feedback dna analysi smoke cessat attempt analysi reveal risk increas mutat compar smoker undergo risk assess incorpor dna analysi mutat versu dna arm risk assess assess report month trial regist origin primari outcom particip engag quit relat behaviour includ quit attempt 24 hour durat behaviour contact stop smoke servic nicotin replac therapi start recruit data collect chang primari outcom report quit attempt measur predict eventu cessat 12 13 expert advic trial steer committe basi smoke cessat research approv data monitor committe secondari outcom assess report smoke cessat week receipt risk assess month follow russel standard procedur 14 assess abstin smoke preced dai particip classifi smoker biochem verifi smoker saliva sampl return post valid abstin requir report smoke cigarett previou dai cotinin concentr 15 ng ml addit measur recal genet test result week month receipt result particip ask recal genet test result receiv mutat sampl size sampl size origin set 540 particip 270 arm anticip follow 430 particip project 80 follow rate allow cluster particip famili assum intraclust correl greater 0.6 mean cluster size 1.13 deriv pilot studi 11 equival follow 400 particip randomis trial assess sampl size assumpt predetermin follow 50 particip confirm mean cluster size 1.14 higher follow rate 87 identifi intraclust correl trial steer committe support revis sampl size calcul base follow rate 85 effect cluster set final sampl size 470 randomis particip 400 15 side test 5 level signific primari outcom detect group effect size 80 power hypothesi odd ratio 1.75 49 35 dna arm 200 compar dna arm 200 hypothesi dna arm odd ratio 2.55 mutat 50 compar mutat 150 odd ratio 2.45 57 35 mutat 50 compar dna arm 200 hypothesi odd ratio 0.5 21 35 mutat dna arm 150 compar dna arm 200 randomis trial statistician prepar randomis sequenc randomli select block size 6 8 10 randomli permut alloc block equal alloc ratio particip randomis famili cluster particip alloc assign sequenc cluster particip requir alloc arm sequenc randomis independ trial coordin ensur trial coordin team suppli data requir randomis particip date birth confirm agreement gener sequenc trial blind research counsellor particip blind alloc studi arm randomis sequenc conceal trial coordin team research counsellor statist team studi data randomis group alloc conceal research team collect outcom data statist analysi compar primari outcom secondari cessat outcom arm estim differ proport odd ratio 95 confid interv provid χ2 test analys intent treat strategi common assumpt secondari cessat outcom particip classifi smoker biochem verifi smoker primari outcom intent treat strategi treat miss outcom miss analysi complet case analysi secondarili imput miss data 24 hour quit attempt made month recalcul differ proport test side assess 5 signific level sensit analysi confirm cluster made neglig differ result differ conclus interpret donner method 16 assess hypothes compar primari commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 3 12 research http www.bmj.com permiss http www.bmj.com subscrib outcom mutat statu subgroup dna arm dna arm detail trial method report 15 result figur 2 show flow particip studi contact 37 571 proband crohn diseas 1890 rel identifi smoker assess elig 497 agre particip randomis 251 risk assess basi dna analysi 246 control group receiv standard risk assess period recruit follow ran april 2007 septemb 2010 group similar baselin characterist tabl 1 number analys allow dropout primari endpoint particip provid outcom follow month analys complet case analysi plan analysi strategi conclus chang analysi undertaken randomis particip altern assum 24 hour quit attempt respond month secondari abstin outcom analys 497 randomis particip miss data regard indic smoke cessat tabl 2 3 present result outcom primari outcom month proport particip 24 hour quit attempt differ significantli arm 35 dna arm 36 dna arm differ 1 95 confid interv 10 8 0.83 subgroup analysi differ quit attempt observ particip dna arm feedback reveal increas risk frommut 36 mutat 35 particip dna arm 36 secondari outcom report smoke cessat week report smoke cessat week differ significantli dna dna arm 11 8 differ 3 3 8 0.32 differ arm subgroup analysi dna arm mutat 14 dna arm mutat 11 dna arm 8 dai smoke cessat month proport particip stop smoke dai report differ dna dna arm 17 20 differ 3 10 4 0.42 subgroup dna armwithmut 18 dna arm mutat 18 dna arm 20 biochem valid report smoke statu corrobor find show signific differ dna dna arm 4 5 differ 1 5 2 0.47 subgroup dna arm mutat 4 dna arm mutat 4 dna arm 5 ancillari analysi recal genet test result particip dna arm recal receiv dna test 97 212 219 week 93 195 209 month follow week 57 particip 124 219 accur rememb genotyp statu twomut 43 95 219 recal incorrectli know result recal test month 34 72 209 accur recal result 66 137 209 unabl harm particip dna arm mutat crohn diseas risk 40 1000 popul express signific worri health develop crohn diseas attribut particip studi discuss clinic member research team particip express concern complet month follow fidel protocol research gjh assess subsampl randomli select tape record determin fidel clinic protocol intervent deliveri deem accept case deliveri kei compon includ explan particip risk determin stop smoke reduc risk 15 discuss rel patient crohn diseas feedback dna base risk assess motiv behaviour chang reduc risk crohn diseas standard risk assess dna base risk assess signific effect primari secondari outcom trial hypothes support evid intervent caus harm individu report concern readili allevi strength weak studi paradigm crohn diseas offer distinct advantag relat previou studi effect inform genet risk health behaviour precis inform generalis disord recent advanc make offer peopl precis inform risk develop crohn diseas importantli specif effect smoke baselin risk estim risk crohn diseas confer common sequenc variants17wer rang expect observ common complex condit particip low risk increas possibl find generalis crohn diseas includ wide rang common complex condit test offer insid healthcar set trial design robust date area randomis undertaken central independ contact particip data person smoke characterist balanc arm limit method previou clinic trials18 larg overcom appropri power sampl achiev low level attrit 86 particip successfulli biochem valid smoke cessat effect recruit particip commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 4 12 research http www.bmj.com permiss http www.bmj.com subscrib genet risk chronic disord specif behaviour characterist inevit challeng achiev trial approach limit feasibl trial requir substanti resourc suggest addit recruit level viabl target popul messag offer trial generalis specif condit crohn diseas intervent includ advic base phenotyp particip show ad inform person genotyp addit impact chang behaviour intervent base feasibl health servic model commun risk common complex condit includ previous evalu evid base booklet commun risk emploi number percentag graphic represent risk highli standardis fig 1 particip telephon ensur understand 19 counsellor train nh standard smoke cessat provid quit attempt telephon shown effect motiv smoker quit 20 assess fidel deliveri exclud possibl find due deliveri type risk assess comparison observ data endpoint suggest intervent commun risk post counsel telephonewa effect increas number 24 hour quit attempt current studi 36 particip dna arm made quit attempt previou month addit effect ad dna risk inform compar rate 22 particip survei repres sampl 29 335 english adult smokers21 22 www.smokinginengland.info limit studi studi limit firstli magnitud risk commun dna arm greater commun dna arm unavoid due precis risk assess offer genotyp detect mutat inflat risk estim expect increas impact inform arm trial focus peopl low risk particip receiv inform indic high risk studi unabl assess impact genet risk inform higher magnitud case practic peopl receiv inform gene variant typic confer low risk develop common complex diseas natur recruit trial includ adequ number peopl high risk requir substanti greater resourc object trial assess motiv impact commun low reduct absolut risk thirdli larg number proband smoke rel contact respons rate low increas likelihood particip bia meant intern valid studi strongli assur extern valid uncertain fourthli primari endpoint base report smoke behaviour support biochem valid smoke cessat outcom fifthli mouthwash sampl trial arm increas similar procedur arm allow genotyp arm assess enabl adjust imbal take mouthwash sampl particip dna risk assess lead sens lost randomis small pilot studi trial found take sampl test dna led confus basi phenotyp risk estim judg consider outweigh advantag design final intervent deliv booklet form post telephon convers research counsellor present face face consult respons clinician bigger impact unawar evid suggest differenti dna dna condit stress genet basi risk consult alter patient respons find trial suggest postal commun common approach deliveri risk assess gener model specialist packag behaviour chang retain activ generalist specialist practition consult wide unit kingdom smoking23 increasingli weight loss 24 interpret studi result consist result prespecifi analys robust randomis control trial suggest null effect dna base estim diseas risk risk reduc behaviour chang compar phenotyp base estim accord find recent longitudin cohort studi assess behaviour impact genom wide profil 25 result add strength recent cochran review base rigor studi 18 reach similar conclus report behaviour chang commun genet risk inform 26 collinear commun risk estim genotyp prevent assess independ effect 9 weight current evid suggest commun dna base diseas risk estim impact health behaviour includ smoke high expect potenc commun chang behaviour unfound 27 equal concern commun risk estim diseas base dnamai demotiv behaviour chang support result 28 concern aris observ diseas consid genet basi perceiv control 29 genet risk assess engend fatalist respons receiv higher risk estim readili provid fals reassur receiv lower risk estim result current studi provid support hypothesi find recent systemat review fatalist respons genet risk inform accord lack effect 30 line previou studi show suboptim recal genet risk inform 31 32 found poor recal mutat statu 34 particip dna arm accur recal inform month find add weight suggest potenc genet risk inform overestim systemat impact recipi health relat behaviour particip trial arm receiv risk estim comment extent magnitud estim havemotiv quit attempt proven major particip receiv absolut risk estim 5 lower crohn diseas consist level genet risk commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 5 12 research http www.smokinginengland.info http www.bmj.com permiss http www.bmj.com subscrib gener complex chronic diseas evid suggest commun larger absolut risk higher perceiv risk 33 higher percept risk increas motiv chang behaviour 34 35 impact behaviour circumst small result keep control trial present smoker dna base estim risk lung cancer shown effect 36 38 implic public health polici result current trial provid strong addit support hypothesi commun risk assess base genotyp effect motiv smoke cessat commun phenotyp risk residu famili risk smoke statu result provid evid commun dna base risk assess induc fals reassur exist evid support claim receipt result dna base test gene variant confer increas risk common complex diseas motiv behaviour chang dna base risk estim role present risk reduct strategi aim improv popul health motiv behaviour chang 27thi studi individu level genotyp feasibl intervent model base postal commun risk telephon counsel generalist specialist complement wide rang effect tobacco control intervent deliv popul individu level 39 41 unansw question futur research research behaviour impact commun genet risk inform limit quantiti qualiti ongo advanc genet research reveal pattern find observ consist replic rang common chronic diseas middl life contribut genet characteris effect treatment cessat increas quit attempt research carefulli diseas behaviour health servic context involv primari secondari care practition face face distanc deliveri risk commun behaviour chang approach evalu conclus feedback dna base risk assess smoke rel patient crohn diseas motiv behaviour chang reduc risk type risk assess result trial accord carri popul target rang behaviour smoke research team counsellor sophi attwood samantha brummag ruth collin rachel crockett angela macfarlan recruit particip deliv intervent laboratori staff kasia blaszczyk diann soar pedro pessoa lope dna extract genotyp particip nh trust staff nation associ coliti crohn diseas ostomi lifestyl particip freeli gave time member trial steer committe phil hannaford chair sarah walker william newman rona moss morri carolin murphi robert west clair goodman contributor tmm da alk atp ss princip investig trial atp trial statistician rap provid addit statist input sclw gjh trial manag cgm njp cml respons dna analysi calcul risk figur af js provid method particip recruit sw develop counsel protocol author draft manuscript read approv final version guarantor tmm guarantor tmm princip investig confirm full access data studi take respons integr data accuraci data analysi accept full respons conduct studi control decis publish fund studi fund part grant medic research council uk risk commun prevent medicin optimis impact dna risk inform g0500274 njp cgm support nation institut health research nihr biomed research centr gui st thoma nh foundat trust partnership king colleg london af support nihr comprehens biomed research centr uclh ucl trial protocol peer review council funder role design conduct studi collect manag analysi interpret data prepar review approv manuscript compet interest author complet icmj uniform disclosur form www.icmje.org coi_disclosure.pdf request author declar support organis submit work financi relationship organis interest submit work previou year relationship activ influenc submit work ethic approv studi approv hertfordshir 1 research ethic committe 06 q0201 19 approv research develop obtain hospit proband contact south london andmaudslei trust cover academ depart psycholog institut psychiatri king colleg london employ research counsellor data share dataset author 1 collin fs green ed guttmach ae guyer ms vision futur genom research natur 2003;422 835 47 2 graml nash siren culpepp predict genet primari care expect motiv impact genet test affect import famili physician place screen famili cancer risk genet med 2003;5 172 5 3 collin revolut arriv natur 2010;464 674 5 4 chen chaiken heurist systemat model broader context chaiken trope ed dual process theori social psycholog guildford press 1999 73 96 5 calkin bm meta analysi role smoke inflammatori bowel diseas dig di sci 1989;34 1841 54 6 brant sr wang rawsthorn sargent datta lw nouvet al popul base case control studi card15 risk factor crohn diseas ulcer coliti gastroenterol 2007;102 313 23 7 forb inflammatori bowel diseas clinician guid 2nd ed arnold 2001 8 lewi cm whitwel scl forb sanderson mathew cg marteau tm estim risk common complex diseas genet environment factor crohn diseas med genet 2007;44 689 94 9 fanshaw tr prevost robert js green rc armstrong marteau tm explain behaviour chang genet test problem collinear test risk estim genet test 2008;12 381 6 10 marteau tm robert laruss green rc predict genet test alzheim diseas impact risk percept risk anal 2005;25 397 404 11 reid ep forb sanderson mathew cg lewi marteau tm recruit degre rel prevent research comparison clinician proband led method contact crohn diseas eur hum genet 2006;14 1263 8 12 west mcewen boll owen smoke cessat smoke pattern gener popul 1 year follow addict 2001;96 891 902 13 balmford borland burnei influenc quit date predict smoke cessat outcom health educ re 2010;25 698 706 14 west hajek stead stapleton outcom criteria smoke cessat trial propos common standard addict 2005;100 299 303 15 whitwel mathew lewi forb watt sanderson al trial protocol commun dna base risk assess crohn diseas randomis control trial assess impact stop smoke bmc public health 2011;11 44 16 donner birkett buck randomis cluster sampl size requir analysi epidemiol 1981;114 906 14 17 mathew link pathogenesi crohn diseas provid genom wide associ scan nat rev genet 2008;9 9 14 commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 6 12 research http www.icmje.org coi_disclosure.pdf http www.bmj.com permiss http www.bmj.com subscrib topic extent commun small individu risk diseas motiv chang kei behaviour smoke diet physic activ uncertain expect risk inform base genet motiv high exist trial limit reliabl support expect studi add commun dna base risk inform impact stop smoke reduc risk crohn diseas evid support central role dna base risk assess motiv behaviour chang lack 18 marteau tm french dp griffin sj prevost sutton watkinson al effect commun dna base diseas risk estim risk reduc behaviours.cochran databas syst rev 2010 10 cd007275 19 wright aj takeichi whitwel scl hankin marteau tm impact genet test crohn diseas risk magnitud graphic format motiv stop smoke experiment analogu studi clin genet 2008;73 306 14 20 stead lf perera lancast telephon counsel smoke cessation.cochran databas syst rev 2006 3 cd002850 21 fidler shahab west jarvi mcewen stapleton al smoke toolkit studi nation studi smoke smoke cessat england bmcpublic health 2011;11 479 22 west smoke england 2012 www.smokinginengland.info 23 depart health nh stop smoke servic 2012 http smokefree.nhs.uk 24 jolli lewi beach denlei adab deek jj al comparison rang commerci primari care led weight reduct programm minim intervent control weight loss obes lighten randomis control trial bmj 2011;343 d6500 25 bloss cs schork nj topol ej effect direct consum genomewid profil assess diseas risk engl med 2011;364 524 34 26 chao robert js marteau tm silliman cuppl la green rc health behavior genet risk assess alzheim diseas reveal studi alzheim di assoc disord 2008;22 94 7 27 evan jp meslin em marteau tm caulfield deflat genom bubbl scienc 2011;331 861 2 28 bate br templeton achter pj harri tm condit cm gene heart diseas mean focu group studi public understand genet risk factor wilei subscript servic 2003 156 61 29 shiloh rashuk rosenth benyamini ill causal attribut exploratori studi structur associ ill cognit percept control behav med 2002;25 373 94 30 collin wright marteau impact commun person genet risk inform perceiv control risk systemat review genet med 2011;13 273 7 31 meiser dunn dixon powel lw psycholog adjust knowledg hereditari hemochromatosi clinic base sampl prospect studi genet coun 2005;14 453 63 32 watson duvivi wade walsh ashlei davidson papaikonom al famili histori breast cancer women understand recal genet risk med genet 1998;9 731 8 33 cameron ld sherman ka marteau tm brown pm impact genet risk inform type diseas perceiv risk anticip affect expect consequ genet test health psychol 2009;28 307 16 34 floyd dl prentic dunn roger rw meta analysi research protect motiv theori appl soc psychol 2000;30 407 29 35 miln sheeran orbel predict intervent health relat behavior meta analyt review protect motiv theori appl soc psychol 2000;30 106 43 36 audrain boyd roth main caporaso lerman genet suscept test smoke cessat treatment year outcom random trial addict behav 1997;22 741 51 37 sanderson sc humphri se hubbart hugh jarvi mj wardl psycholog behaviour impact genet test smoker lung cancer risk phase ii exploratori trial health psychol 2008;13 481 94 38 hishida terazawa mamiya ito matsuo tajima al efficaci genotyp notif japanes smoker smoke cessat intervent studi workplac cancer epidemiol 2010;34 96 100 39 depart health healthi live healthi peopl tobacco control plan england depart health 2011 www.dh.gov.uk en publicationsandstatist public publicationspolicyandguid dh_124917 40 nation prevent health taskforc take prevent action respons australia healthiest countri 2020 australian govern 2010 www preventativehealth.org.au internet preventativehealth publishing.nsf content take prevent action 41 world health organ framework convent tobacco control 2003 www.who.int fctc text_download en index.html accept 13 june 2012 cite bmj 2012;345 e4708 open access articl distribut term creativ common attribut commerci licens permit distribut reproduct medium provid origin work properli cite commerci complianc licens http creativecommons.org licens nc 2.0 http creativecommons.org licens nc 2.0 legalcod commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 7 12 research http www.smokinginengland.info http smokefree.nhs.uk http www.dh.gov.uk en publicationsandstatist public publicationspolicyandguid dh_124917 http www.dh.gov.uk en publicationsandstatist public publicationspolicyandguid dh_124917 http www.preventativehealth.org.au internet preventativehealth publishing.nsf content take prevent action http www.preventativehealth.org.au internet preventativehealth publishing.nsf content take prevent action http www.preventativehealth.org.au internet preventativehealth publishing.nsf content take prevent action http www.who.int fctc text_download en index.html http creativecommons.org licens nc 2.0 http creativecommons.org licens nc 2.0 http creativecommons.org licens nc 2.0 legalcod http www.bmj.com permiss http www.bmj.com subscrib tabl tabl 1 person baselin smoke characterist valu percentag number particip state dna arm 246 dna arm 251 characterist sex 39 96 42 105 men 61 150 58 145 women 00.4 1 miss 43 14.8 42 14.0 mean sd ag year ethnic 98 241 96 240 white 0.4 1 2 5 black 0.4 1 1 2 asian 1 3 1 2 01 2 miss socioeconom statu 1 2 2 5 group 1 depriv 13 32 10 25 group 2 31 75 35 88 group 3 56 137 53 133 group 4 depriv 4 1.5 4 1.6 mean sd short form fagerström test nicotin depend commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 8 12 research http www.bmj.com permiss http www.bmj.com subscrib tabl 2 primari secondari outcom arm valu percentag number event total number particip state differ proport 95 ci valuenon dna arm 246 dna arm 251 outcom primari outcom 1 10 8 0.8336 78 217 35 73 209 1 24 hour quit attempt measur month secondari outcom 7 dai abstin 3 3 8 0.328 20 246 11 27 251 measur week report measur month 3 10 4 0.4220 48 246 17 42 251 report 1 5 2 0.475 12 246 4 9 251 biochem valid commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 9 12 research http www.bmj.com permiss http www.bmj.com subscrib tabl 3 comparison primari secondari outcom subgroup dna arm dna arm valu percentag number outcom number group state differ 95 ci valuedna arm dnaarm 246 outcom dna arm 1 2 mutat dna arm mutat dna arm 1 2 mutat dna arm dna arm mutat dna arm 1 2 mutat 50 mutat 182 primari outcom 1 15 17 0.92 0.4 16 15 0.96 1 11 9 0.8136 16 45 35 57 164 36 78 217 1 24 hour quit attempt measur month secondari outcom 7 dai abstin 3 8 14 0.566 4 16 0.193 3 9 0.3214 7 50 11 20 182 8 20 246 measur week report measur month 0.1 12 12 0.98 2 13 10 0.80 1 9 6 0.7218 9 50 18 33 182 20 48 246 report 0.2 6 6 0.96 1 7 5 0.79 1 5 3 0.614 2 50 4 7 182 5 12 246 biochem valid commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 10 12 research http www.bmj.com permiss http www.bmj.com subscrib figur fig 1 inform booklet commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 11 12 research http www.bmj.com permiss http www.bmj.com subscrib fig 2 flow particip studi commerci reus right reprint http www.bmj.com permiss subscrib http www.bmj.com subscrib bmj 2012;345 e4708 doi 10.1136 bmj.e4708 publish 20 juli 2012 page 12 12 research http www.bmj.com permiss http www.bmj.com subscrib
1 3 0 drug alcohol depend 111 2010 105 113 content list sciencedirect drug alcohol depend journa homepag www.e lsev ier locat drugalcdep random control trial nrt aid gradual abrupt cessat smoker activ quit ohn hugh laura solomon ami livingston peter calla erica peter nivers vermont burlington vt usa rticl histori eceiv 6 januari 2010 eceiv revis form 1 april 2010 ccept 1 april 2010 vailabl onlin 26 2010 eyword radual icotin icotin replac therapi smoke cessat program advis abrupt gradual cessation.w conduct random iz control trial gradual cessat 297 abrupt cessat 299 minim treatment 150 smoker want quit prefer quit gradual particip recruitedvianewspap radio advertis thegradu andabrupt condit receivedfivephon call total 90min minim treatment condit receiv call 25min total gradual condit receiv nicotin lozeng mail reduc smoke prior quit date quit dai particip receiv lozeng primari outcom prolong abstin 2 week post quit dai 6 month prior quit dai gradual condit decreas cigarett dai 54 condit decreas 1 5 prolong abstin rate 10ppm treatment educt moke cessat obacco herapi differ gradual abrupt minim treatment condit 4 7 5 7 dai point preval rate 7 11 11 fewer smoker gradual condit 48 made quit attempt abrupt 64 minim 60 condit 001 gradual condit week delai quit date increas probabl laps 19 001 conclud smoker stop gradual futur gradual cessat nicotin pre treatment produc higher quit rate abrupt cessat liabil gradual reduct thei smoker dela introduct alcohol illeg drug abus decid quit rgent drug relat problem occur urg top abruptli kleber al 2006 con rast urgent problem occur cigarett moker decid quit larabi 2005 result stop gradual cessat i. reduc number igarett dai cpd dai week prior quit ing recent survei 48 83 plan quit want quit gradual hugh al 2007 shiffman al 2006 9 51 reduc year meyer al 2003 shiffman al 2006 43 57 reduc quit meyer al 2003 west al 2001 common ratio al gradual cessat reduct intermediari tep quit skinner 1969 reduct increas fficaci bandura 1977 reduct break condit espons smoke bouton swartzentrub 1991 author univers vermont depart psychiatri uhc ampu mail stop 482 burlington vt 05401 usa tel 1 802 656 9610 ax 1 802 847 1446 mail address john.hugh uvm.edu j.r hugh 376 8716 front matter 2010 elsevi ireland right reserv oi 10.1016 j.drugalcdep 2010.04.007 quit date 2010 elsevi ireland right reserv reduct decreas nicotin depend hugh carpent 2006 current guidelin meta analys review explicitli recommend abrupt gradual cessat men tion gradual cessat potenti treatment fior al 2008 west al 2000 silagi al 2004 law tang 1995 stead al 2008 evid gradual cessat effect abrupt cessat unclear case control studi smokerswhoquit gradual lower abstin rate quit abruptli chose gradual cessat depend fail past peter al 2007 hugh 2007 cheong al 2007 random control trial rct compar gradual abrupt cessat smoker activ quit tabl 1 7 9 show numer superior absti nenc rate gradual cessat small sampl size show statist signific result cinciripini al 1994 studi varieti design method studi examin combin instruct gradual reduct nicotin replac therapi nrt pre treatment compar abrupt cessat i. design similar cur rent studi studi internet base treatment nicotin gum show advantag gradual abrupt etter al 2009 transderm nicotin report http www.sciencedirect.com scienc journal 03768716 http www.elsevier.com locat drugalcdep mailto:john.hugh uvm.edu dx.doi.org 10.1016 j.drugalcdep 2010.04.007 106 j.r hugh al drug alcohol depend 111 2010 105 113 tabl 1 prior random control trial gradual cessat nicotin pre treatment studi gradual condit psycho social tx pre cessat medic percent reduct activ control placebo control percent quit activ control ora 95 ci gradual abrupt etter al 2009 157 internet gum 4 week state 21 20 1.1 0.6 1.9 rezaishiraz al 2007 47 51 person patch 2 week denic cigarett state 28 21 1.4 0.6 3.6 cinciripini al 1994 17 person 75 26 41 6 11.2 1.2 105.1 cinciripini al 1995 63 65 person 76 47 31 27 1.2 0.6 2.6 cum al 1988 252 257 written state 9 6 1.6 1.0 2.5 flaxman 1978 16 person 23 13 38 56 0.8 0.3 2.2 gunther al 1992 55 person state 25 22 0.9 0.3 2.2 rose al 1998 40 person patch 4 week mecamylamin 57 13 30 15 2.4 0.8 7.3 rupt 1 2 2 schuurman al 2004 100 person patch 2 week confid interv denic denicotin odd ratio tx treatment 1.0 quit rate gradual quit rate abrupt 1.0 gradual ab advantag gradual studi confound se denicotin cigarett gradual cessat condit rezaishiraz al 2007 rct compar gradual abrupt essat smoker activ quit didnot usenrt aid reduct report wide vari result cinciripini al 1994 1995 cum al 1988 flaxman 1978 gunther al 1992 rct examin pre treatment nrt prior quit date instruct smoker reduc report om smoker spontan reduc prior quit date rose al 1998 becker al 2008 schuurman al 2004 hese smoker reducedmor prior quit date weremor ik achiev abstin smoker rose al 998 becker al 2008 contrast studi separ literatur exam ned smoke reduct smoker plan quit futur studi consist found reduct ncreas probabl make quit attempt ubsequ abstin hugh carpent 2006 studi suggest gradual cessat east efficaci abrupt cessat trial methodolog report problem e.g small sam le size match treatment contact time confound nclude intervent verif reduct radual condit reduct abrupt condit prior quit date biochem verif abstin believ larg stringent rct test gradual cessat brupt cessat indicated.w hypothes gradual ce ation produc higher quit rate abrupt cessat articip smoker want quit gradual rt aid pre treatment reduct method 1 design recruit smoker prefer quit gradual reason irst thought group benefit grad al cessat recent studi half smoker wish quit lan gradual peter al 2007 shiffman al 2006 necdot observ treatment program encourag smoker ish quit gradual quit abruptli wonder abrupt cessat ctualli efficaci group smoker smoker wish stop gradual randomli assign 2 2 1 ratio gradual cessat intervent abrupt cessat intervent minim reatment control condit includ minim treatment condit oth theoutcomesof gradual andabrupt conditionswereequival wecouldknow effect i. quit rate greater minim treatment ineffect quit rate similar minim treatment ounsel deliv phone gradual cessat condit nicotin ozeng aid reduct prior quit dai themajor outcomewa prolong bstinenc 2 week 6 month post quit dai 3 3 22 12 2.1 1.0 4.5 studi method gradual intervent design repres intervent clinic set telephon quit line gradual cessat intervent clinic set rct tabl 1 differ fromabrupt cessat intervent aspect gradual abrupt cessat gradual treatment extend treatment time start treatment quit date longer abrupt treatment gradual treatment session prior quit date involv treatment time current studi equat abrupt andgradu treatment total treatment timebecausewebeliev variabl confound outcom vari treat ment consid make time treatment entri quit date abrupt gradual treatment requir abrupt group wait week thought extern valid unfairli disadvantag abrupt treatment allow abrupt condit quit sooner studi entri gradual condit gradual condit nrt week prior quit date aid reduc tion consid abrupt group nrt prior quit date reduc approv standard nrt result design equat number session treat ment time abrupt gradual group allow abrupt gradual group distribut pre cessat post cessat session i. gradual condit call pre cessat post cessat call abrupt twopr post cessat theminim pre post cessat call result decis studi test reduc cigarett dai se comparison gradual cessat abrupt cessat treatment clinic quit line set 2.2 recruit obtain substanti number minor smoker recruit columbia sc albuquerqu nm florenc sc newspap radio ad state quit smoke gradual receiv free nicotin lozeng confidenti telephon support leav home major inclus criteria 18 year daili smoker 15 cigarett dai quit smoke 30 dai prefer quit gradual abruptli chang cigarett dai 20 ormor lastmonth nicotin lozeng fda caution lozeng requir physician contact includ smoke 15 cigarett dai believ smoke undertak reduct program includ wish quit 30 dai inten tion quit diclement al 2004 half screen elig 75 elig consent fig 1 studi approv univers vermont committe human research 2.3 particip compar popul base sampl smoker giovino 2002 etter perneg 2001 fagerstrom furgerg 2008 hugh 2004 smoker bewomen 54 48 older 48v 39 year african american 10 12 somewhatmor hispan 13 8 complet high school 91 79 mean cigarett dai entri greater 23 15 preval light ultra light cigarett lower 58 87 mean fagerstrom test nicotin depend ftnd score higher nation sampl 5.9 4.3 4.6 differ due inclus criteria fact smoker seek treatment heavier andmor depend smoker haviland al 2003 marit statu confid quit gradual reduct statist dif fere experiment condit tabl 2 whenweent covari j.r hugh al drug alcohol depend 111 2010 105 113 107 ion flo 3 7 fig 1 recruit retent analys result chang appreci extent present unadjust result intend sampl size 300 abrupt 00 gradual conditionwa base priori hypothesi abstin at 26 week 25 gradual condit 15 abrupt ondit 10 minim treatment condit rate base result tabl 1 belief nrt pre quit date gradual roup shiffman ferguson 2008 free nrt particip ost quit date stead al 2008 substanti increas quit rate receipt consent statistician gener conceal alloc equenc random particip gradual abrupt minim treat ent condit 2 2 1 ratio block random stratifi citi ounselor base sa procedur plan cari nc sa institut number session 5 treatment time 90min total ident gradual abrupt condit greater minim treat ent control condit 2 session 20min total schedul call time quit date intend mimic typic practic smoke cessat rogramsandareoutlin infig 2 mcewenet al 2006 abramset al 2003 par icip set aquitdayat thefirst sessionbut variedbetween thegradu ondit 3 5 week reduct abrupt minim treatment con ition 1 3week typic abrupt smokingcess treatment abram al 2003 mcewen al 2006 phone counsel deliv counselor bachelor degre npsychologyor counseling.al counselorsdeliveredal treatment andparticip ad counselor durat intervent counselor receiv train detail treatmentmanu intervent session er tape monitor ls listen randomli chosen all provid feedback counselorsmonthli studi treatment anual condit www.uvm.edu hbpl effect counselor counselor treatment condit interact ajor outcom chart itt intent treat 2.4 gradual cessat intervent werecommendedparticip thegradu condit reduceby25 thefirst week 50 week 75 week smoker chose goal rate progress reduct method particip choos schedul reduct sr smoker gradual increas time cigarett cinciripini al 1997 hierarch reduct easiest hr smoker elimin cigarett easiest hardest give levinson al 1971 hierar chal reduct hardest hr elimin hardest give cigarett sixti percent smoker chose sr 25 chose hr 11 chose hr 4 itwa unclearwhichmethod chose reduct abstin result differ initi chosenmethod clinic observ larg major smoker exclus chosen method reduct method reduc method initi choic method valid descrip tion actual behavior outcom method differ result pool result initi chosen reduct method mail smoker 2 4mg nicotin lozeng stead al 2008 commit glaxosmithklin consum healthcar recommend label abrupt cessat 4mg smoke 30min aris 2mg pre quit period recommend smoker substitut lozeng cigarett foregon lozeng bat urg smoke counsel data call ask advers event ae call focus reduct fourth call 2 dai prior quit dai discuss common prepar strategi e.g make difficult access cigarett review proper nicotin lozeng cessat call 2 dai post quit dai focus relaps prevent emphasi problem solv high risk smoke situat http www.uvm.edu hbpl 108 j.r hugh al drug alcohol depend 111 2010 105 113 tabl 2 particip characterist 746 condit statist df abrupt 299 gradual 297 minim treatment 150 recruit site columbia 36 35 36 35 2 4 0.06 1.00 albuquerqu 51 51 51 51 florenc 14 14 13 14 demograph gender male 46 45 46 47 2 2 0.21 0.90 ag mean sd 46 13 48 12 48 13 47 13 2,743 0.08 0.92 hispan 13 13 14 11 2 2 0.58 0.75 race white 82 79 85 81 2 4 3.57 0.47 black african american 10 12 8 12 8 9 7 8 marit statu marri 47 44 50 45 2 4 10.74 0.03 divorc widow separ 38 38 39 34 marri 16 18 10 21 highest educ high school 9 10 9 9 2 4 1.23 0.87 high school 60 61 58 60 colleg graduat 31 29 33 30 smoke histori cigarett dai mean sd 23 9 23 9 23 8 24 9 2,740 0.45 0.64 cigarett type regular 42 42 41 47 2 4 6.61 0.16 light 43 43 42 45 ultra light 15 15 17 8 ag start smoke mean sd 18 5 18 6 17 5 18 5 2,738 1.66 0.19 prior quit attempt mean sd 5.0 7.9 5.1 8.4 5.1 8.7 4.5 4.2 2,717 0.39 0.68 median 3 3 3 3 kw 2 2 0.58 0.75 prior treatment call quit line 6 5 6 6 2 2 0.42 0.81 medic 68 65 72 64 2 2 4.32 0.12 37 35 37 39 2 2 0.77 0.68 plan quit month 0 10 mean sd 8.3 2.2 8.1 2.4 8.4 2.1 8.4 2.0 2,734 1.70 0.18 prefer gradual abrupt 0 10 mean sd 4.0 2.5 4.0 2.6 3.9 2.4 4.3 2.4 2,717 1.09 0.34 confid stop gradual 1 5 mean sd 3.8 0.9 4.0 0.9 3.8 0.9 3.7 1.0 2,740 4.25 0.01 confid stop abruptli 1 5 mean sd 2.4 1.2 2.4 1.2 2.5 1.2 2.4 1.2 2,740 0.73 0.48 ftnd mean sd 5.9 1.8 5.8 1.8 5.9 1.8 5.9 1.7 2,717 0.09 0.91 minut cigarett mean sd 16 25 18 33 16 19 15 15 2,739 0.81 0.45 2 tnd fagerstrom test nicotin depend sd standard deviat chi squar test categor variabl anova mean kruskal walli test quit past 702 5 abrupt cessat intervent abrupt cessat intervent mimick typic behavior therapi abram al 2003 mcewen al 2006 call abrupt condit eview reason want quit prior quit attempt strategi nparametr barrier cessat particip explicitli instruct chang cigarett dai prior quit date call immedi prior quit dai content pre quit dai prepar call gradual condi tion fourth andfifth call quit dai focus relaps prevent e.g problem solv wai manag high risk smoke situat j.r hugh al drug alcohol depend 111 2010 105 113 109 tmen 2 2 7 1 3 fig 2 trea 6 minim treatment intervent treatment common condit conditionwa intend tomim aminim intervent primari practic fior al 2008 session review plan uit encourag set quit date advis nicotin lozeng ccord label instruct session 2 dai post quit at relaps prevent problem solv counsel ast session gradual condit condit particip nation cancer institut lear air booklet www.smokefree.gov pub clear air.pdf icotin lozeng start quit date particip advis se lozeng packag recommend 12 week post quit at conting abstin 7 assess descript data collect studi entri mail questionnair studi entri immedi pre quit date gradual abrupt condit examin gradual cessat benefici effect outlin introduct i. decreas depend disrupt pattern smoke ncreas efficacy.w examin nicotin depend total score item fagerstrom test nicotin depend ftnd time igarett previous valid singl item visual analog scale report ddiction hugh al 2004b 0 addict cigarett 00 extrem addict cigarettes.w examin disrupt regular ty smoke stereotypi subscal nicotin depend syndrom cale shiffman al 2004 smoker rate true extrem rue two5 point likert scale total score 0 10 statement moke number cigarett dai dai smoke affect thing examin efficaci short orm velic scale velic al 1990 ask abil resist smoke 9 ituat examin motiv quit 11 point motiv ladder revious valid hugh al 2005 0 plan quit nextmonth 10 plan quit month.w includ likert cale confid abil quit 1 5 confid eiv difficulti quit 1 quit imposs 5 quit easi examin prefer quittingmethod 11 point lad er 0 quit gradual reduct 5 quit ither gradual abruptli 10 quit abruptli verifi reduct andnon reduct wehir local research assist visit moker gradual abrupt condit studi entri immedi quit dai obtain breath carbon monoxid level research assist lso obtain level thosewho report abstin 6 month follow condit time dai collect uncontrol follow up ti set quit date post quit dai outcom ollect phone research assist blind studi condit ad role intervent assess occur 2 week 4 week 6 week month 6 month quit date set particip studi onset reach quarter particip 6 month follow fig 1 6 month call report smoke week visit schedul obtain sampl verifi abstin citi obtain sampl 52 gradual condit 66 abrupt condit 51 minim treatment condit 2.8 data analysi srnt recommend outcom clinic trial hugh al 2003 state analys base random found inelig i. modifi intent treat itt sampl smoke cessat trial typic count lost follow smoker hall al 2001 srnt subcommitte biochem verif 2002 sta tistic correct made number test statistician correct feis 2002 baselin characterist compar studi condit chi squar test categor variabl analysi varianc thekrusk walli test continu variabl siegel 1956 abstin outcom quit attempt analyz bivari chi squar test assess confound variabl inter action perform logist regress proport hazard model time laps analys 3 result 3.1 intern valid complianc 90 smoker gradual condit assign 4mg lozeng smoke 30min ari ing prior quit date 93 smoker gradual condit nicotin lozeng and86 lozeng 1week median 83 dai averag 18.6mg dai i. 4 5 lozeng dai week quit attempt mean number dai nrt 6.5 gradual 6.2 abrupt condit 6.0 minim treatment 2,419 2.01 0.14 incid ae rate sever small similar gradual abrupt minim treatment condit 3 5 3 incid discontinu due ae 1 group particip complet 4 5 treatment call gradual 79 abrupt 78 condit complet 2 2 call minim treatment 83 condit mean decreas cpd studi entri week prior quit date subset particip miss data 54 13 cpd gradual 1 0.3 cpd abrupt 5 1 cpd minim treatment condit decreas cowa 21 6ppm gradual 0 0ppm http www.smokefree.gov pub clearing_the_air.pdf 1 hol 3 3 5 10 j.r hugh al drug alco brupt condit expect mean time design uit date greater gradual abrupt minim reatment condit 27 15 15 dai 2,718 358.7 001 2 abstin condit differ statist measur abstin 6 month follow tabl 3 gradual ondit consist signific trend lower absti enc rate incid 6 month contact ampl differ group ran analys tabl 3 contact 6 month uit rate higher odd ratio group imilar result tabl 3 smoker gradual conditionwer tomak quit ttempt defin 1 dai smoke abrupt ndminim treatment condit 48 64 60 2 2 15.9 001 surviv analysi laps thefirst 6week time eriod collect daili data time laps significantli longer abrupt gradual condit pro ortion hazard ratio hr 1.2 2 1 3.35 07 abrupt s.minim treatment condit hr 1.2 2 1 2.52 11 id differ gradual minim treatment condit hr 1.0 2 1 0.00 96 fig 3 3 effect gradual reduct efficaci depend egular smoke measur gradual cessat prior quit date ad anticip effect efficaci depend reg lariti smoke examin result baselin quit questionnair outcom result nterpret cautious reason erifi pre quit questionnair complet immedi rior cessat rate complet aselin pre quit survei differ condit 57 omplet gradual 82 abrupt 70 mini al treatment condit 2 2 44.3 001 outcom eport base select subsampl anticip particip gradual condit increas elf efficaci mean score baselin 18 pre quit 23 han condit 18 pre cessat 19 pre uit 2,502 45.67 0001 similar effect occur ith 5 point confid quit scale 2,510 2.97 05 5 point perceiv difficulti quit scale 2,504 24.63 0001 particip gradual condit lso decreas depend i. increas time cigarett 15 28min particip condit ot 2,509 21.29 0001 similar outcom occur depend measur ftnd 2,487 12.15 0001 elf rate addict 2,512 62.13 0001 particip radual condit decreas regular smoke 6.9 3 1 10 scale indic smoke disrupt ut regular smoke chang particip ther condit 2,507 30.26 0001 crave decreas gradual condit 4.5 4.0 1 5 scale baselin quit condit 4.5 4.4 2,508 9.16 0001 gradual condit examin com.ibm.drl.hbcp.predictor time laps seri bivari analys redictor surviv time 6 week greater reduct cpd time cigarett confid quit motiv quit efficaci crave depend regular smok ng extra week studi entri uit dai gradual condit probabl laps epend 111 2010 105 113 increas 19 hr 1.19 2 1 4.80 03 grad ual condit amount nrt relat surviv time 3.4 moder test baselin characterist inter act effect gradual abrupt treatment surviv time ag sex race cpd ftnd rate addict confid abil quit intent quit month confid quit gradual confid quit abruptli ratio desir quit gradual abruptli efficaci reg ular smoke smoker rate depend low visual analog scale studi onset abrupt con dition outcom gradual condit i. longer time laps smoker rate highli depend abrupt condit outcom gradual condit 2 1 3.91 05 similar signific interact occur depend measur ftnd cpd smoker high efficaci abrupt condit perform gradual condit smoker low efficaci abrupt condit perform gradual condit 2 1 4.98 03 similar signific interact occur rate confid quit surprisingli rel prefer gradual abrupt cessat predict respons treat ment return pre quit questionnair relaps hr 1.23 1.01 1.49 effect interact experiment condit moder influenc point preval prolong outcom 4 discuss 4.1 summari result major find smoker prefer quit gradual gradual cessat superior abrupt ce sation minim treatment treatment fact signific trend outcom wors gradual ce sation condit fail confirm hypothes smoker prefer reduc quit receiv nrt reduc gradual cessat produc abstin abrupt cessat post hoc find suggest gradual cessat equival abrupt cessat depend smoker occur time relaps analys dichotom abstin outcom requir replic failur find statist differ condit interpret mean intervent effi caciou efficaci thatnrt phone counsel andminim treatment interven tion similar valid treatment deliv phone mail fior al 2008 addit incid 6 month prolong abstin higher expect quitter receiv treatment hugh al 2004a 4.2 studi asset limit asset studi includ sampl size larger prior studi particip abrupt gradual condi tion receiv amount counsel similar result occur outcom measur prior quit dai gradual condit nrt dai substanti amount larg biochem confirm declin cpd occur abrupt group decreas nicotin depen j.r hugh al drug alcohol depend 111 2010 105 113 111 tabl 3 abstin outcom 6 month follow upa percent abstin gradual condit percent abstin abrupt condit percent abstin minim treatment condit odd ratio gradual abrupt prolong abstinenceb 3 month report 13 10,18 20 16,25 11 7,18 0.6 0.4,1.0 6 month report 9 6,13 13 9,17 12 7,18 0.7 0.4,1.1 6 month verifi 4 2,7 7 4,10 5 2,9 0.6 0.3,1.2 7 dai abstin 3 month report 30 25,36 37 32,43 27 20,35 0.7 0.5,1.0 6 month report 24 19,29 31 26,36 31 24,39 0.7 0.5,1.0 15 4 6 month verifi 7 4,10 11 8 carbon monoxid mean 95 confid interv parenthes 2 week grace period enc increas efficaci disrupt smoke or abrupt condit studi limit discuss xperiment condit vari wai reduc ion pre quit date hypothes iffer prevent benefit gradual cessat e.g otmatch treatment time allow gradual treat ent spend time tradit behavior techniqu abrupt group gradual treatment shown benefit possibl paramet reduct er optim e.g patch ather lozengeorus longer reductionperiod pro ect incid abstin optimist owerwa expect comparison ow sixth row tabl 2 half articip report abstin agre est test high rais question alid report studi studi hone base treatment stead al 2006 obtain respons rate biochem verif 50 3 explan result recent retrospect survei smoker chose quit immedi outcom quit ater suggest smoker delai os motiv quit larabi 2005 west sohal 2006 ig 3 surviv curv time report laps quit attempt tho ero due time call inquir smoke esign believ observ carri backward accur mo 11 6,17 0.6 0.3,1.0 ferguson al 2009 find gradual con dition longer delai quit date laps consist find explan failur find gradual ce sation superior counsel time gradual condit spent teach gradual reduct problem solv wai cope high risk smoke situat deficit caus gradual condit wors number call similar gradual abrupt condit gradual condit receiv pre cessat call fewer post cessat call abrupt condit mass treatment session earli abstin smoker strug gling pre cessat import establish abstin prior studi found smoke reduct systemat increas time cigarett i. schedul reduct sr increas abstin compar abrupt cessat method reduc cinciripini al 1995 found differ abstin outcom sr method 4.4 failur replic efficaci pre treatment reduc quit indic studi suggest pre treatment nrt increas abstin shiffman ferguson 2008 quit relaps dai abstin assign ay studi post cessat smoke statu miss due studi conserv observ carri forward 1 hol 2 4 0 12 j.r hugh al drug alco tudi specif design test pre treatment urgradu conditionusednrtprior thequit date andour abrupt id andw foundnodiffer trial fail confirm benefici effect pre treatment prior stud es fail find pre treatment nrt increas quit rate er similar studi deliv treatment person i. provid treatment internet etter al 009 phone bullen al 2008 addit pre reatment studi nicotin patch trial ik studi oral nrt fail find posit result etter al 2009 herrera al 1995 result suggest person ontact transderm nicotin essenti increas uffici complianc observ benefici pre treatment effect reduc quit indic nrt approv sev ral countri smokerswho plan quit wang al 2008 esult inconsist find ver reduc quit indicationwasbasedon studi smoker ho plan quit futur smok rs reduct consist increas probabl quit ttempt abstin hugh carpent 2005 nterpret reduct efficaci ambival smok rs plan quit futur motiv moker quit 5 summari smoker quit gradual countri reduc quit indic ur studi unexpect neg result increas fur rct gradual abrupt cessat ol fund sourc conduct studi prepar manuscript fund grant da 017825 jh senior scientist award da 0490 jh institut traininggrantda 07242 ep nation institut drug abus sponsor role studi design data collect data analysi interpret data write report decis submit aper public studi regist prior onset ww.clinicaltrials.gov nct00297492 ontributor dr calla hugh solomon design studi btain fund dr hugh ms livingston dr peter par icip data collect dr calla hugh peter solomon articip data analysi author particip interpr ation result write paper approv final draft manuscript onflict interest 1 1 2007 dr hugh receiv research grant nation institut health pfizer pfizer develop ell smoke cessat medic time ccept honoraria consult fee profit profit organ compani develop sell pro ot smoke cessat product servic educ advoc bout smoke cessat abbot pharmaceut acrux aradigm merican academi addict psychiatri american psychiatr ssociat begbi traynor cambridg hospit cline davi mann constella group consult behavior chang ean foundat dla piper epi european respiratori societi votec exchang limit fagerstrom consult free clear epend 111 2010 105 113 glaxo smith kline golin harri healthwis insyght inform invivodata john hopkin univers jl reckner main medic center mcneil pharmaceut novarti pharmaceut oglivi health pr ottawa heart institut pfizer pharmaceut pinnei associ propag pharmaceut reuter scientia selecta templ univers health scienc univers arkansa universityofcalifornia sanfrancisco universityofcantabria uni versiti kentucki nation institut health wolter publish xenova author declar acknowledg karl fagerstrom saul shiffman robert west design analysi interpret result patti gannon vivian jordan rachel legendr joann lemir aaronmors maryroohan rebeccawhiteandmatthewwolff conduct studi
eur respir 1998 11 284 290 doi 10.1183 09031936.98.11020284 print uk right reserv copyright er journal 1998 european respiratori journal issn 0903 1936 effect postal smoke cessat advic random control trial young men reduc fev1 asbesto exposur humerfelt g.e eid kvåle l.e aarø gulsvik aa smoke cessat benefici effect morbid mortal obstruct lung diseas lung cancer 1 3 smoke cessat subject risk reduc rate declin forc expiratori volum fev1 smoker 4 5 respiratori symptom improv 6 7 quit smoke asbesto expos individu import due interact asbesto cig arett smoke develop lung cancer 8 9 minim smoke intervent includ written ver bal advic inform letter pamphlet book mainten programm individu group 10 13 commun base intervent trial random control group biochem valid outcom subject risk 14 15 respiratori physician great respons smok ing cessat individu patient commun 16 commun unknown postal smoke cessat advic respiratori physi cian success young adult male high risk lung cancer primari aim rand omiz control trial evalu effect advic male smoker attend spi rometri survei secondari aim evalu whe ther inform smoker presenc reduc fev1 harm effect asbesto addi tional effect smoke cessat ed identifi com.ibm.drl.hbcp.predictor smoke cessat subject method initi survei trial perform sampl men ag 30 45 yr live 34 rural municip western norwai particip cross section commun sur vei octob 1988 octob 1989 17 men ag 30 45 yr 22,392 area invit survei 73 attend 16,393 tabl 1 informa tion smoke habit previou occup asbesto effect postal smoke cessat advic random control trial young men reduc fev1 asbesto exposur humerfelt g.e eid kvåle l.e aarø gulsvik er journal 1998 abstract commun base random control inter vention trial cessat high risk smoker trial evalu effect postal smoke cessat advic smoker asbesto exposur reduc forc expiratori volum fev1 men ag 30 45 yr 22,392 live 34 municip western norwai invit cross section commun survei inform smoke habit occup asbesto exposur obtain administ question nair measur fev1 perform dry wedg bellow spirom ter 16,393 particip identifi group 2,610 smoker previou occup asbesto exposur adjust fev1 lowest quartil ran dom half 1,300 receiv mail person letter respiratori physician person specif health advic quit smoke pamphlet smoke ce sation remain smoker 1,310 act control receiv inform twelv month intervent inform smoke habit exam in postal questionnair respond 2,282 smoke cessa tion report altogeth 13.7 intervent group versu 9.9 control group 0.01 1 yr sustain quit rate smoke year 5.6 versu 3.5 0.05 measur carbon monoxid expir air ð10 part million confirm report nonsmok sampl group commun simpl postal smoke cessat advic respiratori physician base person specif risk factor improv 1 yr sustain success rate 60 identifi high risk smoker eur respir 1998 11 284 290 dept thorac medicin epidemiol ogi research centr health pro motion univers bergen norwai correspond humerfelt dept thorac medicin haukeland sykehu 5021 bergen norwai fax 47 55975149 keyword biochem valid commun survei random control trial smoke cessat receiv decemb 10 1996 accept revis octob 25 1997 trial support grant research council norwai norwegian cancer societi borregaard glaxo norwai confeder norw gian busi industri smoke cessat high risk smoker 285 exposur obtain administ question nair 18 measur perform height weight spirometri attend forc expira tion record dry wedg spiromet vitalo graph model vitalograph buckingham uk 17 19 highest fev1 valu analys correct bodi temperatur pressur satur btp condit ag height adjust fev1 level calcul regress coeffici ag bodi height base norwegian refer enc popul healthi asymptomat men citi oslo 20 regress coeffici 0.032 l·yr 1 5.742 l·min 1 con stant 4.540 residu standard deviat 0.549 ag height standard residu maximum valu fev1 sfev1 determin lung func tion level 5 sampl size end subject includ random con troll trial design trial calcul 1,300 ject respons rate 70 group order detect alpha 0.05 beta 0.20 21 signific differ 12 month 5 sustain chang intervent group versu 2.5 chang control group 22 base inform particip tend initi survei octob 1989 identifi trial popul 3,384 men high risk smoker tabl 1 includ current smoker previou occup asbesto exposur 1,558 ag height adjust fev1 lowest quartil reduc fev1 1,293 533 order obtain need sampl size random 77 3,384 subject drawn give 2,610 subject includ 1,186 1,014 410 subject subgroup respec tive includ random control trial individu 50 chanc drawn intervent group 1,300 control group 1,310 januari 15 1990 letter mail respiratori physician subject intervent group postal advic includ person specif health advic quit smoke pamphlet smoke cessat letter address recipi print ed qualiti rest letter subject remind specif answer smoke besto exposur attend initi survei result fev1 measur informa tion danger continu smoke expos asbesto reduc fev1 risk factor letter state recipi belong group subject increas risk smok ing relat lung diseas recipi strong ly advis quit benefici effect smoke cessat state recipi encourag read enclos pamphlet produc norwegian cancer societi letter individu person sign ed physician pamphlet exsmok size 10 cm 14 cm 15 page empha size behaviour modif techniqu smoke cess ation recommend earli quit date remain 1,310 subject act control receiv format trial approv region mitte medic research ethic follow valid survei januari 1991 subject intervent group 1,300 control group 1,310 receiv postal administ questionnair accompani ter mention letter intervent group 12 month previous subject ask return questionnair return remind letter 3 6 week word question smoke ident ini tial survei subject report nonsmok ask give month year quit success smoke cessat defin individu al follow deni daili smoke subject live 11 neighbour municip bergen clude 60 subject control group 73 intervent group 133 subject june 1991 tabl 1 ag height daili cigarett consumpt standard residu fev1 subject ag 30 45 yr particip initi cross section survei current smoker report previou occup asbesto exposur oae reduc fev1 3,384 particip current smoker 16,393 oae reduc fev1 1,558 oae reduc fev1 1,293 oae reduc fev1 533 ag yr height cm cigarettes·dai 1 1 9 10 19 š20 sfev1 38 4 179 6 1012 6 3871 24 2098 13 0.380 0.95 37 4 178 6 193 12 880 57 485 31 0.112 0.62 37 4 180 6 157 12 712 55 424 33 1.642 0.60 37 4 179 7 66 12 278 52 189 36 1.624 0.57 valu mean sd absolut number percentag parenthesi reduc fev1 defin ag height adjust fev1 lowest quartil attend particip includ 5,021 31 smoker 4,116 25 exsmok 275 2 subject miss inform smoke habit calcul 13,930 subject accept spirometr record fev1 forc expiratori volum sfev1 standard residu fev1 286 humerfelt al invit free charg consult respiratori physician invit random order physician blind respect group ject belong altogeth 114 subject 86 attend valid survei carbon monoxid expir air measur bedfont ec50 analyz bedfont technic instrument upchurch sittingbourn uk 23 24 subject claim nonsmok cut ð10 part million ppm distinguish nonsmok smoker 25 statist method analys perform biomed data program bmdp packag bmdp statist softwar lo angel usa 26 bivari associ bet ween respons com.ibm.drl.hbcp.predictor variabl test ed chi squar test odd ratio or stratifi tabl test mantel haenszel techniqu pair test compar mean valu signi ficanc level 0.05 tail pri mari respons variabl chosen smoke statu follow linear regress analysi relat daili cigarett consumpt follow cigarett con sumption initi survei multipl logist regress analysi appli relat smoke statu follow com.ibm.drl.hbcp.predictor interact postal advic result trial popul includ 21 particip cross section survei 47 attend smok er tabl 1 subject identifi subgroup trial popul similar ag bodi height particip initi survei similar daili cigarett consumpt observ subgroup mean sd 16 7 cigarettes·dai 1 averag ciga rett dai particip smoker mean sd 14 7 cigarettes·dai 1 0.05 preval report occup asbesto exposur muniti men ag 30 45 yr 25 19 low 5 medium end 1 high level exposur versu 62 trial popul tabl 1 subject intervent group control group balanc distribut inclus criteria ag ag smoke onset bodi height daili cig arett consumpt respiratori symptom fev1 level tabl 2 follow intervent control ject dead remain subject respons rate remind letter 87 2,282 lower 0.001 intervent group 83 control group 92 tabl 3 group respons rate invers relat daili cigarett consumpt initi survei 87 84 81 smoker 10 light 10 19 med ium š20 heavi cigarettes·dai 1 trend present control group respond follow 13.7 148 intervent group versu 9.9 119 control group report nonsmok 0.01 subject clude stop smoke run stop januari 1 1990 intervent period tabl 3 assum nonrespond follow stop smoke cessat rate intent treat 11.4 versu 9.1 0.05 exclud ject stop smoke run 32 subject group 12 month cessat rate main respond group 11.1 116 1049 versu 7.4 87 1169 0.01 effect postal advic higher subject reduc fev1 1.7 95 con fidenc interv 95 ci 1.2 2.5 asb to exposur 1.2 95 ci 0.8 1.7 differ effect statist signific chi squar test homogen 0.12 figur 1 illustr report month smoke ce sation group postal advic januari 1990 gradual increas cessat rate observ month februari april 1990 intervent group compar control group excess gain inter vention group maintain end follow 1 yr sustain success rate march 1991 smok ing preced 12 month 5.6 intervent group versu 3.5 0.05 control group fig 1 correspond 60 improv success postal advic cessat rate invers relat daili ciga rett consumpt initi survei tabl 3 quitter intervent control group smoke initi survei slightli older smoke onset 0.01 stop mean sd valu 13 7 versu 16 7 cigarettes·dai 1 18 4 versu 17 3 yr smoker follow mean sd daili cigarett consumpt intervent group reduc 14 9 versu 15 9 cigarett control group 0.05 subject linear regress coeffici initi daili cigarett consumpt com.ibm.drl.hbcp.predictor consumpt follow lower intervent group 0.69 se 0.03 0.001 control group 0.77 se 0.03 0.001 coeffici statist tabl 2 comparison random group base characterist initi survei 2,610 control group 1,310 intervent group 1,300 inclus criteria asbesto exposur reduc fev1 ag yr ag smoke onset yr height cm cigarettes·dai 1 morn cough morn phlegm sfev1 591 45.1 512 39.1 207 15.8 37 4 17.1 2.8 179 6 15.8 7.0 315 24.9 255 20.4 1.05 0.95 595 45.8 502 38.6 203 15.6 37 4 17.2 2.9 179 6 15.9 6.8 331 26.1 237 19.1 1.05 0.96 valu mean sd absolut number percentag parenthesi spirometri 1,158 1,154 subject control intervent group ag height adjust fev1 lowest quartil attend inform morn cough phlegm miss 114 77 subject text cal culat sfev1 definit legend tabl 1 smoke cessat high risk smoker 287 multipl logist regress analysi esti mate adjust smoke cessat follow adjust group ag ag smoke onset daili cigarett consumpt subgroup smoker ta ble 4 postal advic remain independ pre dictor smoke cessat similar effect observ subject inform presenc asbesto exposur reduc fev1 risk factor older ag smoke onset low daili cigarett consumpt observ independ com.ibm.drl.hbcp.predictor smoke cessat signific order interact found dep artur multipl model combina tion covari risk smoke cessat similar attend 86 valid survei observ sampl group deni nonsmok ing follow tabl 5 attend rate rel at length smoke cessat prior follow 100 intervent group 90 con trol group remain nonsmok š6 month long term quitter compar 69 83 re pectiv stop smoke 6 month short term quitter prior follow attend altogeth 24 subject relaps 90 subject report nonsmok tabl 5 higher relaps rate observ short term quitter 33 intervent group 38 control group long term quitter 13 18 0.01 claim nonsmok intervent group 50 control group 40 concen tration ð10 ppm expir air obtain 49 versu 38 subject tabl 5 base measur june 1991 cumul 18 month success rate januari 1990 exclud 14 17 subject quit smoke run 6.5 35 537 intervent group versu 3.6 21 589 control group 0.05 tabl 5 tabl 3 smoke statu respond follow march 1991 daili cigarett consumpt initi survei 1988 1989 control group intervent group 2,282 nonsmok follow smoker follow daili cigarett con sumption initi subject stop smoke dur ing run period stop smoke januari 1 1990 reduc daili cig arett consumpt š25 daili smoker survei cigarettes·dai 1 1 9 10 19 š20 total 137 666 378 1201 116 606 345 1081 7.3 2.4 1.6 2.7 6.9 3.1 1.4 3.0 8.7 8.3 4.0 7.4 17.6 10.6 7.9 11.1 9.4 7.4 23.1 12.7 13.9 12.1 28.2 17.6 81.9 84.3 72.9 79.9 68.5 77.3 63.9 71.3 inform cigarett consumpt initi survei miss 20 1.7 14 1.3 subject control interven tion group stop smoke prior januari 1 1990 reduct relat daili cigarett consumpt ini tial survei 0.01 0.001 signific differ observ outcom follow group relat remain smoker januari 1 1990 marchjan juli sept nov jan march 8 6 4 2 0 12 10 sm ce ss io 1990 1991 fig 1 smoke cessat particip intervent group control group report month quit ting retrospect march 1991 2,282 advic quit smoke post januari 15 1990 inform miss subject tabl 4 adjust odd ratio or 95 con fidenc interv 95 ci smoke cessat postal advic intervent group ag ag smo king onset daili cigarett consumpt subgroup smoker 2,166 nonsmok follow factor odd ratio 95 ci postal advic ag yr 30 34 35 39 40 45 ag smoke onset yr 5 cigarettes·dai 1 1 9 10 19 š20 subgroup smoker asbesto exposur reduc fev1 1 1.5 1 0.8 0.9 1 1.5 1 0.6 0.4 1 0.9 0.8 1.1 2.0 0.6 1.2 0.6 1.3 1.2 1.8 0.4 0.8 0.2 0.6 0.7 1.3 0.6 1.3 0.01 0.01 0.001 includ subject exclud miss infor mation covari signific ind pendent variabl model ag height adjust forc expiratori volum fev1 lowest quar tile attend 288 humerfelt al discuss random control trial show postal smok ing cessat advic respiratori physician im prove 1 yr sustain quit rate 60 identifi high risk smoker effect appear directli tribut intervent group match baselin assign intervent control group complet random group ident cessat rate 3 run period prior intervent differ cessat rate appear follow rate 80 group valid survei confirm ob serv higher cessat rate intervent group pare control group select bia affect result re pons rate initi survei 73 partici pant similar demograph characterist smoke habit respiratori symptom men ag 30 45 yr gener popul norwai 17 follow 87 respons obtain similar initi characterist ag ag smoke onset daili cigarett consumpt respiratori symptom asbesto exposur fev1 level observ respond nonrespon dent intervent control group agreement intervent studi male british civil servant 27 observ higher respons rate fol low control group intervent group explan differ fol low questionnair deliber made imperson standard avoid pressur intervent subject deni underestim continu smoke consist observ medium heavi smoker initi survei made effort answer follow questionnair intervent group control group higher smoker rate possibl pre nonrespond intervent group control group present reduc differ group spec ulat cessat rate nonrespond control group 109 9.9 ident observ success rate respond intervent group 219 third 6.6 success rate 9.9 versu 12.5 0.05 respons bia chang main conclus stati tical signific effect intervent previou intervent trial shown smoke cessat base report interpret con serv due high implicit demand subject report posit chang 28 bia outcom assess consider influenc result observ good agreement report smoke cessat object mea urement subject group similar observa tion previous observ asbesto expos wegian men ag 45 65 yr particip smok ing cessat programm 25 valid survei show proport subject claim ing smoke 21 nonsmok expir air 10 ppm 3 similar group tabl 5 men intervent group respond optimist follow questionnair subject control group result interpret caution short half life mea ur nonrepres sampl subject valid survei observ higher relaps rate short term quitter long term quitter explain acceler increas report ce sation rate observ short term quitter group fig 1 35 subsequ relaps smoke previou studi shown smoker make quit attempt year 1 95 relaps maximum 5 succe leav approxim 1.7 33 5 success sustain quitter 1 yr 29 observ late 1970 usa half 3.5 1 yr quit rate observ control group trial 1990 1991 fig 1 reason differ recent posit attitud smoke ce sation norwai observ effect postal advic difficult compar intervent studi due differ enc intervent programm trial popul length follow outcom measur minim intervent easili implement perform cross section survei high risk smok er postal advic appli geograph area due long distanc subject respiratori phy sician larg number subject risk commun inclus criteria trial pop ulat includ altogeth 47 smoker commun subject includ commun base intervent studi recruit highli motiv quit smoke trial tend smoker fulfil inclus criteria equal chanc select trial includ ing smoker motiv quit reflect modest 1 yr sustain abstin rate 5.6 postal advic futur commun stud i includ inform degre motiva tion quit order compar success rate dif ferent intervent trial criterion set tabl 5 valid report smoke cessat subject live 11 surround municip bergen report smoke cessat postal questionnair march 1991 control group intervent group invit valid june 91 attend valid test claim nonsmok expir air ð10 ppm expir air 10 ppm claim smoke telephon inform claim nonsmok claim smoke nonrespond 60 100 52 87 38 63 2 3 12 20 3 5 3 5 2 3 73 100 62 85 49 67 1 1 12 16 5 7 5 7 1 1 valu present absolut number percentag parenthesi answer obtain 589 subject control group 537 subject intervent group ppm part million smoke cessat high risk smoker 289 daili cigarett consumpt subject trial popul 58 subject smoke š15 ciga rettes·dai 1 contrast lung health studi 14 collabor european anti smoke evalu ation ceas trial 15 smoker š10 š15 cigarettes·dai 1 includ observ 1 yr sustain quit rate trial sim ilar result previou minim intervent studi 11 30 previou commun base studi media announc american lung associ recruit highli motiv smoker 12 month su tain cessat obtain 5 receiv postal cessat mainten manual versu 2 control 11 commun programm achiev mod est effect term percentag smoker quit substanti number consid smoker reach low cost 30 smoker attend local doctor verbal smoke cessat advic cessat leaflet warn follow effici advic advic 22 method gave 12 month sustain abstin rate 5 3 1 patient smoke relat lung diseas 5 1 yr success obtain verbal advic quit respiratori physician 31 subsequ ter encourag improv outcom 9 nurs conduct advic lung clinic gave 1 yr cessa tion rate 3 versu 1 control group 13 agreement previou intervent studi nicotin replac observ deg ree cessat invers relat daili cigarett consumpt 13 27 32 indic addict properti smoke psycholog nicotin depend make difficult heavi smoker quit light smoker 15 33 letter pamphlet trial includ infor mation nicotin replac attempt improv postal advic includ addit infor mation nicotin depend replac therapi possibl improv success rate 34 35 studi select group found impact presenc respiratori symptom smok ing cessat 36 studi 467 coal miner pre enc chronic respiratori symptom invers relat cessat 37 similarli observ respiratori symptom preval subject stopp ed smoke compar morn cough phlegm reach 5 level statist signific effect disappear adjust cigarett consumpt suggest subject respiratori symptom addict properti smoke import motiva tion abil stop contrast subject diseas diseas onset rapid dramat e.g myocardi infarct 36 respiratori physician great task care smoker high risk 38 commun trial simpl cheap postal smoke cessa tion advic respiratori physician men identifi increas risk smoke relat lung di eas base estim programm improv 1 yr sustain success rate 28 i. 60 improv 47 smoker commun acknowledg author staff nation health screen servic data collect make data file stensvold excel work random identif subject includ trial apollon grieg meidel nilssen technic assist i.a campbel help comment critic design studi prep arat manuscript grieg subsequ di
author 2013 publish oxford univers press behalf societi research nicotin tobacco right reserv permiss mail journals.permiss oup.com doi 10.1093 ntr ntt005 origin investig random clinic trial smoke cessat treatment provid hiv clinic care set gari humfleet phd sharon hall phd kevin delucchi phd jame dillei md depart psychiatri univers california san francisco ca author gari humfleet depart psychiatri univers california san francisco 401 parnassu avenu san francisco ca 94143 usa telephon 415 476 7674 fax 415 931 2926 mail ghumfleet lppi.ucsf.edu receiv march 10 2012 accept decemb 21 2012 abstract introduct identifi success smoke treatment intervent method deliveri critic smoke rate hiv posit popul medic implic smoke popul studi compar efficaci 3 smoke cessat intervent provid hiv clinic treatment set method baselin assess 209 hiv posit smoker randomli assign 1 3 condit parallel group design treatment condit individu counsel nicotin replac treatment nrt comput base internet smoke treatment nrt nrt smoke statu determin follow assess plete 12 24 36 52 week treatment initi result cessat rate rang 15 29 statist signific differ abstin found treatment condit time emploi report greater desir quit lower mood disturb score achiev abstin 01 number cigarett particip report smoke 24 hr prior assess significantli declin time 001 conclus found differ abstin rate group result integr smok ing cessat intervent feasibl hiv clinic treatment set cessat result promis absti nenc rate report compar found similar treatment studi multipl popul research warrant introduct identifi success smoke cessat treatment effec tive method treatment deliveri critic smoke rate hiv posit hiv popul medic implic smoke popul nation estim smoke approxim 21 adult popul smoke center diseas control 2007 higher rate 57 report numer hiv cohort burn al 1991 collin al 2001 gritz vidrin lazev amick arduino 2004 mamari bahr martinez 2002 research suggest hiv smoker smoke averag 15 20 cigarett dai moder level nico tine depend burkhalt springer chhabra ostroff rapkin 2005 gritz al 2004 mamari al 2002 vidrin arduino lazev gritz 2006 smoke found predict increas likelihood varieti hiv relat medic complic includ bac terial pneumonia hiv relat pulmonari emphysema hairi leukoplakia oral candidiasi aid dementia boulter al 1996 burn al 1996 conlei al 1996 diaz al 2000 greenspan barr sciubba winkler 1992 hirschtick al 1995 palacio hilton canchola greenspan 1997 reardon kim wagner koziel kornfeld 1996 addi tion daili tobacco attenu 40 immun virolog respons antiretrovir therapi cigarett smoke found neg impact health relat qualiti life person hiv turner al 2001 research smoke cessat hiv diagnosi limit data cessat rate low burkhalt al 2005 collin al 2001 gritz al 2004 major smoker continu tobacco hiv diagnosi uniqu factor influenc cessat hiv smoker includ perceiv compet manag health psycholog adjust hiv diseas diagnosi individu hiv face multipl treatment demand includ complex medic regimen regular medic monitor visit frequent visit alli health profession perceiv compet efficaci consist adher hiv treatment arnsten al 2007 barclai al 2007 johnson al 2007 perceiv compet manag health issu high level hiv qualiti advanc access public februari 19 2013 1436 nicotin tobacco research volum 15 number 8 august 2013 1436 1445 mailto:ghumfleet lppi.ucsf.edu nicotin tobacco research life wallston osborn wagner hilker 2011 perceiv abil manag multipl health demand relev smoke cessat popul relat psycholog adjust ill import dimens treatment engag ross hunter condon collin beglei 1994 psycholog respons hiv hopeless minim diseas inhibit health behavior respons activ cope fight spirit promot health behavior chang kellei al 2000 date clinic trial evalu smoke treatment hiv smoker report ingersol cropsei heckman 2009 conduct pilot studi 40 hiv smoker test treatment motiv interview nicotin patch versu guid read found dif ferenc cessat rate 3 month follow vidrin mark arduino gritz 2012 compar standard care intervent cell phone deliv proactiv counsel intervent sampl 474 hiv smoker found signific differ group 3 month 11.9 abstin smoker cell phone deliv inter vention compar 3.4 smoker usual care con dition twelv month follow data report lloyd richardson al 2009 compar se sion behavior intervent nicotin patch se sion motiv enhanc patch intervent found signific differ cessat rate group quit rate 10 6 month integr smoke treatment clinic treatment set ting effect individu chronic medic condit requir frequent medic vi extend period time tradition behavior treatment deliv face face counsel effect multipl barrier provid counsel clinic care set lack space lack time lack train valuabl resourc provid health relat inform dissemin behavior chang treatment comput technolog internet civljak sheikh stead car 2010 efficaci comput base smoke treatment easier integr clinic set ting tradit treatment primari aim studi determin effi caci target smoke treatment incorpor behav ioral intervent address uniqu hiv smoker target smoke treatment develop treatment deliv tradit manner face face individu counsel ic treat ment deliv nontradit manner comput technolog internet treatment compar sh condit treatment includ nico tine replac treatment nrt deliv hiv clinic care set primari hypothesi counsel internet base treatment condit result higher point preval abstin rate sh condit secondari hypothes level perceiv health compet predict outcom particip higher level compet quit smok ing particip lower level compet psycholog adjust hiv predict outcom particip higher level psycholog adjust hiv quit smoke particip low level psycholog adjust hiv method studi design baselin assess 209 hiv smoker stratifi base number cigarett dai greater 20 cigarett dai depress base composit intern diagnost interview cidi diagnosi gender strata random comput algorithm condit 1 1 1 fashion paral lel group design treatment condit includ tradit ic intervent target hiv smoker nrt comput base internet smoke treatment cbi target hiv smok er nrt sh nrt condit smoke statu determin follow assess complet 12 24 36 52 week treatment initi studi conduct june 2006 februari 2010 particip flow figur 1 particip hiv smoker recruit clinic serv hiv person san francisco ca eighti individu patient univers california san francisco aid health project organ hiv test counsel substanc abus treatment mental health ser vice hundr twenti particip patient posit health practic san francisco gener hospit sfgh public health care facil addit partici pant recruit tenderloin health commun base program provid case manag servic peopl hiv receiv medic care sfgh elig particip 18 year older smoke dai month regist patient facil iti individu exclud enrol smoke cessat treatment experienc signific sever cognit impair dementia neg impact treatment sampl size base effect size found studi condit similar sh cbi treatment condit work nrt group treatment similar ic intervent base find studi evalu sh intervent nrt daughton al 1998 joseph antonnucio 1999 solomon scharoun flynn secker walker sepinwal 2000 stapleton al 1995 expect 12 24 36 52 week abstin rate sh condit 20 14 12 11 lack previou research comput base intervent clinic set estim abstin rate cbi intervent result technolog base intervent telephon counsel nrt lando al 1997 reid pipe dafo 1999 solomon al 2000 expect 12 24 36 52 week abstin rate cbi condit 38 25 23 22 base work similar counsel intervent nrt expect 12 24 36 52 week abstin rate ic condit 56 30 28 28 hall al 2002 humfleet al 2002 recruit particip recruit site direct pro vider referr displai post card flyer clinic recruit letter home address patient 1437 smoke cessat treatment hiv clinic care set previous consent contact research purpos potenti particip provid overview studi screen briefli exclus criteria tel ephon interest elig schedul baselin assess studi procedur review inform consent obtain baselin assess interview data baselin interview particip complet cidi schedul structur computer interview dsm iv diagnos world health organ 1997 mod ul measur nicotin alcohol abus depend depress bipolar disord administ addict sever index mclellan al 1992 assess current past alcohol drug psychiatr histori treatment report inform demograph inform smoke histori current pattern obtain report questionnair devel op group multipl studi particip complet smoke relat measur includ figur 1 particip flow uneven sampl size condit function factor primari reach target time enrol ceas random return balanc recruit fewer particip strata expect smoke greater 20 cigarett dai exagger unbalanc 1438 nicotin tobacco research fagerström test nicotin depend item instru ment measur smoke behavior indic physic depend payn smith mccracken mcsherri antoni 1994 thought abstin scale item mea ur assess desir quit anticip success fulli quit anticip difficulti remain abstin abstin relat goal hall havassi wasserman 1990 stage chang measur item scale assess readi quit smoke diclement al 1991 particip complet psychosoci mea ur includ profil mood state pom 60 item measur mood disturb mcnair lorr droppleman 1992 perceiv health compet scale assess compet manag health condit smith wallston smith 1995 perceiv stress scale gener stress mea ur cohen kamarck mermelstein 1983 hiv risk behavior scale assess sexual drug risk relat hiv dark hall heather ward wodak 1991 adjust hiv scale ross al 1994 baselin assess elig smoker stratifi base gender male femal histori major depress disord mdd mdd number cigarett dai 20 20 elig smok er random arm ic comput base intervent sh arm pharmacolog treatment nrt particip smoke cigarett dai chose cigarett dai ensur level depend warrant nrt particip obtain 10 week nicotin patch nicotin gum counter nicotin replac medic week 1 visit particip receiv written view nrt medic includ chart compar nrt eas flexibl primari side effect particip written instruct specif form nrt chose initi 4 week suppli addit nrt schedul distribut week 5 9 particip experienc signific side effect difficulti form nrt option switch form nrt nrt dose base written instruct provid manufactur behavior treatment treatment provid clinic site incent provid complet treatment session individu counsel ic condit includ ic session intervent base cognit behavior treatment model previou work group hall al 2009 hall humfleet reu munoz cullen 2004 target hiv smoker target base research hiv individu indic import neg impact smoke hiv relat health condit high level stress high level depress low level social support intervent includ specif inform hiv relat health issu smoke stress manag compon mood manag compon social support compo nent intervent individu tailor develop written person quit plan discuss exercis homework assign individu al encourag topic appli live develop specif cessat strategi base discuss incorpor strategi quit plan counsel session held week 1 2 3 5 8 12 session 40 60 min length session 1 smoker reason quit identifi infor mation smoke hiv relat health condit di cuss quit date schedul dai session 2 strategi prepar quit review counselor review nrt medic initi suppli nrt provid direct review session 2 remain session began check includ report smoke statu review withdraw symptom crave difficulti success experienc particip abstin posit reinforc relaps discuss altern strategi encour ag set quit date content introduc subsequ session homework exercis base content assign content session 2 5 mood manag social support maintain motiv stress manag content area review dur ing session 6 long term nonsmok goal discuss counselor clinician master doctor degre social work psycholog previou exp rienc smoke cessat treatment prior treat studi particip counselor train studi protocol didact session role plai session observ pilot particip counselor train supervis lead author comput base internet treatment particip random cbi condit offer access web site intervent model counsel intervent content intervent content provid sixth grade read level web site home page includ overview treatment direct web site treatment compon structur step roughli session counsel intervent session 6 counsel intervent review previou session includ web site step interact specif inform topic introduc individu direct complet assess exercis homework assign individu encourag develop cessat strategi base read feedback exercis incorpor strategi onlin person quit plan pilot work develop intervent step 30 45 min complet averag web site contain step step 1 educ prepar step 2 manag mood quit step 3 social support quit step 4 stress manag step 5 increas maintain motiv recommend step sequenc particip access webpag time mirror real world applic particip access web site 12 month suggest specif schedul web site visit web site includ messag board partici pant commun studi particip 1439 smoke cessat treatment hiv clinic care set treatment condit bulletin board includ expert compon smoker obtain inform feedback project staff sixteen percent partici pant assign cbi messag board cbi orient meet held week 1 meet research staff determin particip sonal access internet establish usernam pass word web site provid overview web site usernam password requir limit access web site particip assign cbi condit overview staff guid particip assess exercis step 1 demonstr complet exercis strategi quit incorpor strategi person quit plan staff discuss quit date smoker enter date plan particip access web site comput station locat clinic public puter commun home individu limit access internet list altern free access locat voucher provid particip internet access home interest access internet busi locat cafe home particip packet materi includ written guid access navig web site map identifi locat free voucher base internet access copi printabl form web site particip provid contact inform experienc difficulti access web site addit cessat guidanc provid orient meet 45 60 min sh nrt particip random sh condit met briefli research staff particip receiv quit smoke fastmark 1998 lamin quick refer guid studi staff briefli review guid recommend establish ing quit date week 2 staff member review nrt medic provid direct nrt dispens initi suppli nrt particip schedul pick subsequ nrt suppli ce sation guidanc provid follow assess follow assess complet 12 24 36 52 week treatment initi retent rate 89 12 week 84 24 week 82 36 week 81 52 week cigarett biochem verifi 7 dai abstin cigarett primari outcom variabl smoke abstin includ report 7 dai point preval abstin sustain abstin obtain follow assess point preval abstin verifi level particip code abstin report cigarett puff 7 dai level 10 ppm particip report abstin unabl unwil clinic provid breath sampl accept confirmatori statement signific weekli contact lieu breath sampl proxi report implement particip measur sustain abstin base recent recommend smoke cessat literatur hugh al 2003 smoke defin cigarett 7 consecut dai previou assess particip report smoke con secut dai code posit sustain abstin definit requir repeat tobacco consid er relaps individu experi isol slip consid abstin chose supplement measur form biolog confirm base recent recommend expert panel srnt subcommitte biochem verif 2002 data analysi model gener estim equat assum miss data miss complet random violat assumpt lead bias estim schneider hedek bailei cook spring 2010 test evid outcom relat missing includ index complet assess result missing complet random i. complet abstin mix effect nonlinear regress model proc nlmix sa version 9.2 compar verifi point preval abstin rate postbaselin assess prior final analysi multivari model test set candid covari relationship outcom retain variabl 10 inclus final model candid variabl vari abl list tabl 1 2 term final model treatment condit ic cbi sh week assess 12 24 36 52 interact baselin mea ur emploi desir quit pom total mood disturb number cigarett smoke 24 hr model estim allow full observ data 76 particip complet assess complet statu complet assess includ model number assess complet secondari analys test treatment effect number cigarett reportedli smoke prior 24 hr mix effect model proc nlmix sa final data collect site effect site test result particip characterist detail particip characterist found tabl 1 2 retent rate treatment condit shown tabl 3 studi sampl predominantli male ethnic racial divers low socioeconom statu sampl emploi larg proport homeless live transit hous rate lifetim psychiatr disord illicit drug past month high signific differ treatment group found variabl smoker sh condit older 01 histori major depress episod 05 particip condit 1440 nicotin tobacco research smoker cbi condit met criteria bipolar disord condit 05 number cigarett smoke dai fagerström depend score moder level nicotin depend enc half sampl 44 endors smok ing treatment goal total cigarett abstin baselin characterist consist clinic censu data indic sampl repres clinic popul smoke outcom percentag smoke abstin rang 15 29 statist signific differ treatment condit figur 2 tabl 3 estim mix effect regr sion model summar tabl 4 emploi report greater desir quit lower mood disturb score achiev abstin tabl 2 baselin psychiatr drug treatment variabl 209 percentag lifetim psychiatr diagnosesa major depress episod 41 bipolar disord 22 alcohol depend 55 drug past 30 dai marijuana 37 cocain 8 amphetamin 8 heroin 1 mean standard deviat tobacco daili cigarett 19.8 10.5 ag smoke regularli 17.2 6.2 prior quit attempt 4.1 6.5 fagerström test nicotin depend score 4.9 2.4 percentag smoke treatment goal clear goal 5.1 control smoke 3.2 abstain time 5.5 smoke occasion 2.8 quit slip 26.6 quit forev 44.0 12.8 note asignific differ treatment condit smoker condit report histori major depress episod smoker condit 05 smoker comput base intervent report histori bipolar disord smoker condit 05 tabl 3 percent abstin mean number cigarett smoke treatment condit assess week week counsel cbi 12 24.36 25.93 29.17 24 15.07 15.09 26.67 36 18.92 21.28 20.93 52 19.72 20.41 25.58 baselin 17.5 18.4 17.2 12 6.1 7.1 6.4 24 7.4 7.7 11.0 36 8.7 7.5 10.5 52 8.4 8.4 10.5 note cbi comput base internet smoke treatment tabl 1 demograph characterist 209 categori data mean agea sd 45 8.0 sexual identif gai lesbian 61.5 straight 24.3 bisexu 7.4 gender male 81.7 femal 15.1 transgend 3.2 ethnic hispan 13.5 race african american 26.6 white 52.7 american indian 2.4 multipl 18.3 educ high school 20.6 high school gener equival degre 44.5 associ degre vocat 15.0 bachelor degre 15.9 graduat degre 3.7 marit statu marri 4.8 marri 73.4 separ divorc widow 21.3 live situat rent 51.2 halfwai hous therapeut commun 13.1 singl room occup hotel 16.9 homeless 5.8 13.4 employ emploi 14.0 unemploi 58.0 retir 10.6 17.5 incom 10,000 42.2 10,000 20,999 40.8 21,000 30,999 8.7 31,000 8.9 note asignific differ treatment condit smoker treatment older smoker treatment 01 1441 smoke cessat treatment hiv clinic care set differ sustain abstin found effect base recruit site number cigarett particip report smoke 24 hr prior assess significantli declin time 001 mean assess 17.8 8.7 10.5 11.1 11.5 treatment condit differ declin tabl 3 similar effect found particip ask number cigarett prior week nrt report nrt collect nrt distribut record surrog nrt complianc signific differ nrt distribut function treatment condit mean number patch distribut 51.5 44.7 47.0 particip sh cbi ic condit 172 mean piec gum di tribut 530.9 467.5 471.4 sh cbi ic condit 757 adjust hiv perceiv health control differ outcom function perceiv health control individu higher level activ cope posit outlook hiv quit smoke 05 conclus lack increment efficaci behavior treatment surpris combin behavior pharmacolog treatment result higher quit rate behav ioral pharmacolog treatment fior al 2008 lack differ relat minim behavior treatment mean number coun sele session attend 3.6 6 60 mean number visit cbi web site 3.2 figur 2 tabl 4 cbi condit demonstr higher initi quit rate promis odd ratio investig strategi optim internet base intervent telephon text messag prove lack intervent differ high quit rate report particip sh condit previou studi nrt hiv smoker found lower success rate ingersol al 2009 vidrin al 2012 base previou research expect 10 12 year quit rate smoker treat figur 2 analys point preval abstin rate treatment condit time signific differ enc treatment time tabl 4 estim test model paramet variabl estim odd ratio lower 95 confid interv upper 95 confid interv cbi 1.21 3.37 0.46 24.64 counsel 0.20 1.23 0.17 8.73 assess 0.01 0.99 0.96 1.02 complet 2.58 13.19 1.28 136.2 emploi 0.39 0.68 0.49 0.93 desir quit 0.54 1.72 1.11 2.68 pom mood disturb 0.02 0.98 0.96 1.00 usual cigarett dai 0.025 1.03 0.97 1.09 note cbi comput base internet smoke treatment 01 1442 nicotin tobacco research nrt sampl doubl rate particip sh condit slightli nrt particip intervent differ signific studi particip obtain nrt hiv clinic set requir di tant locat e.g pharmaci obtain medic po sibl conveni access nrt result increas particip control condit averag 7 week patch distribut treatment group suggest 70 adher fairli good level adher adher nrt rare report literatur reliabl refer group unavail ferguson shiffman gitchel 2011 research warrant treatment condit found emploi report greater desir quit lower mood disturb score achiev abstin strategi enhanc desir quit motiv intervent address mood disturb pharmacolog cal behavior treatment part smoke treatment consid employ variabl support behavior chang efficaci reduc stress financi hous stabil hiv popul employ indica tor health statu healthier hiv infect smoker motiv stai quit optimist benefit quit data examin possibl studi futur research explor contribut employ variabl found support secondari hypothes perceiv health control relat absti nenc found adjust hiv relat success ful quit individu higher level activ cope posit outlook hiv quit smok ing lower level individu posit outlook smoke signific health issu address activ cope skill deal hiv easili transfer gener smoke cessat strategi studi limit hiv relat health data impact smoke cessat motiva tion outcom sampl recruit public health set find gener individu higher socioeconom statu insur studi design examin differenti efficaci treatment function target content addit research area recommend find characterist sampl consist report hiv smoker describ ing complex medic group hiv smoker face varieti psycholog environment econom challeng high risk smoke lower level treatment success larg proport sampl unem ploi extrem low incom unstabl live situat addit signific proport sampl report current alcohol illicit drug smoke treatment failur humfleet munoz see reu hall 1999 particip high rate lifetim major depress episod bipolar disord alco hol depend tobacco smoke treatment failur futur research varia ble develop strategi assist group smoker find signific differ outcom experiment treatment condit abstin rate compar found studi nrt behavior intervent multipl popul fior al 2008 differ studi hiv smoker find lower cessat rate nrt mini mum result smoke cessat treatment feasibl potenti efficaci hiv clinic care set ting research critic understand smok ing cessat uniqu popul fund work support nida grant p50 da09253 r01 da15791 r01 da02538 california trdrp grant 15rt 0165 declar interest compet interest declar author acknowledg author acknowledg georg harrison m.d meg newman m.d kevin kellei m.a barb adler m.a jeanni m.s.w staff aid health project san francisco gener posit health program tenderloin health center assist support successfulli complet project
evalu minim contact smoke cessat intervent outpati set nanci janz phd rn marshal becker phd mph john kirscht phd stephen erak md john billi md jame 0 woolliscroft md abstract examin abil provid initi minim contact intervent modifi smoke behavior ambulatori clinic patient smoker outpati site assign group provid intervent pi provid intervent manual pi usual care control group physician messag emphas patient person su ceptibl physician concern patient abil quit efficaci nurs consult concentr benefit barrier stop strategi cessat introduct extens health educ effort 59 million adult unit state continu smoke cigarett percentag smoker declin heavi smoker 20 year ago fortun smoke cessat decreas risk lung cancer heart attack cardiovascular diseas reduct risk occur fairli quit 3 formal smoke cessat program labor intens time consum expens limit number reach attract motiv select group smok er evid high recidiv follow 7 9 contrast minim contact intervent com.ibm.drl.hbcp.util therapist consult comprehens booklet manual written pamphlet tape messag binat strategi compar formal program minim contact intervent simpl admin ister inexpens reach greater number appeal smoker prefer engag structur cessat program control evalu minim contact smoke cessat program 0'6 promis approach combin program smoke cessat antismok messag therapist practition 11 13 continu prefer smoker quit 8 9 outpati clinic ideal set offer minim contact health practition intervent booklet previou studi physician influenc intervent emploi broad advic quit smoke studi intervent attempt capit factor emerg import smoke cessat depart health behavior health educ school public health depart intern medicin school medicin univers michigan veteran administr medic center ann arbor michigan address reprint request nanci janz phd rn assist research scientist depart health behavior health educ school public health univers michigan 1420 washington height ann arbor mi 48109 paper submit journal august 19 1986 revis accept public novemb 17 1986 editor note relat articl 849 editori 782 issu 1987 american journal public health 0090 0036 87 1.50 telephon interview conduct 250 particip dai clinic visit month pi pi prove superior usual care motiv attempt quit month month follow up logist regress analys partici pant receiv manual addit health provid messag time quit smoke studi period particip studi group public health 1987 77 805 809 literatur person suscept untoward effect smoke belief smoke cessat undertaken successfulli efficaci concern express physician subsequ avail smoker written guidelin assist effort cessat research effort identifi sens sonal suscept ingredi decis attempt cessat smoker report quit health relat reason 17 18 link symptom cough short breath smoke report major precipit unaid quit 9 signific symptom ill occur minim physician counsel produc 30 cent 40 cent cessat long term relaps 2 bandura defin efficaci convict successfulli execut behavior requir pro duce outcom 22 respect smoke efficaci defin confid abil remain abstin situat 23 numer studi document import efficaci suggest innov strategi manipul efficaci expect integr part smoke cessat pro gram 2 28 recent studi document combin influenc health belief efficaci relat smoke cessat 14,29,30 nation survei found 70 cent smoke pack cigarett dai quit urg physician 25 cent smoker report receiv advic 3 russel colleagues32 estim potenti 200 fold annual increas number smoker quit physician provid smoke cessat advic recent survei 400 primari care physician found 58 cent prepar counsel patient 3 cent express confid fairli success counsel effort 33 final program offer smoker interest quit guid flexibl approach smoke cessat high degre individu involv enhanc manag 34 amount time physician devot counsel client nece sarili limit effort devot motiv decis quit smoke manual provid cognit behavior guid line process quit ajph juli 1987 vol 77 7 805 janz al present investig field trial provid base minim contact smoke cessat intervent effect health care provid consult emphasiz ing person suscept efficaci provid inter est manual contrast usual care abil modifi smoke behavior ambulatori clinic patient method client attend outpati medic clinic larg midwestern teach hospit 18 year ag smoke minimum cigarett dai particip studi health practic smoke enrol inform consent obtain outpati site studi group usual care group control 2 health care provid intervent group pi receiv smoke cessat messag physician consult cessat nurs 3 health care provid intervent manual group pi clinic site divid half dai clinic unit unit assign experiment control statu type alloc studi group select physician staf clinic assign half dai week limit contamin treatment control condit strictest sens random patient control experiment group reason bia introduc half dai classifi experiment control morn afternoon session includ group smoker clinic experiment half dai random experiment group i. manual experiment group physician 42 tutori research team emphas critic role primari care provid recommend smoke cessat compon includ physician messag person suscept efficaci physician interest point briefli state smoke studi marker patient record prior physician contact addit nurs 6 taught counsel patient regard difficulti encount attempt quit strategi avoid overcom problem physician schedul clinic control half dai 21 inform smoke studi manual studi step step quit kit modif booklet test earlier research 14 emploi diari format contain smoke awar test stop smoke contract suggest ed deep breath exercis monitor system number cigarett smoke daili advic wai quit basic design aim progress skill develop week period encourag reward complet task smoke cessat plan occur dai 8 dai 10 kit allow mode time frame quit month intak period 250 smoker recruit assign studi group pi 69 pi 75 106 subject interview telephon dai initi clinic visit baselin interview month month clinic visit dichotom depend variabl construct subject attempt quit tabl 1 sociodemograph characterist studi particip studi group 250 provid provid sociodemograph total control manual characterist 250 106 69 75 ag year 30 12 11 13 11 30 40 24 27 19 23 40 50 24 21 28 24 50 60 23 24 22 24 60 70 12 12 13 9 70 6 5 6 9 male 38 32 46 40 marri 55 55 54 56 unemploi 45 47 49 39 educ grade school 4 2 6 4 junior high 6 6 7 5 high school 18 14 20 21 high school 25 26 29 19 colleg 32 33 29 35 colleg graduat 15 19 9 16 famili incom 6,000 12 14 10 11 6,000 11,999 17 12 28 12 12,000 20,000 20 16 18 26 20,000 51 56 43 50 smoke cessat achiev addit measur chang smoke statu baselin month baselin month creat reduct 20 cent reduct number cigarett smoke reduct ii 50 cent reduct cut point select reduc tion 20 cent yield meaning smoke behavior produc 20 cent cut point felt alter behavior half repres signific modif yield 50 cent cut point assess smoke statu obtain partici pant report reason requir subject return laboratori test pose signific space personnel cost inconveni problem composit subject select alter includ permiss chemic assai part studi consent form effort made emploi survei research approach design assur valid report clear distinct made particip interview health care team interview identifi clinic assur subject answer strictli confidenti interview er train avoid make laden comment subject smoke statu final smoke behavior assess multipl question item model emploi nation survei smoke statu recent review compar chemic assai report measur conclud fact report accur determin number cigarett smoke 35 result particip characterist differ sociodemograph characterist group tabl 1 mean ag 46.3 year 62 cent femal reflect propor tion clinic popul 55 cent marri ajph juli 1987 vol 77 7806 evalu smoke cessat intervent 100 90 80 70 60 50 cr 40 30 20 10 0 control provtid qz prov ider 4 manual attempt quit reducl 20 reducl 500 quit figur smoke statu month studi group slightli half sampl emploi full time home subject evenli distribut term famili incom cut point 20,000 differ occur level educ control group subject score higher pi group index fortun extent differ affect studi outcom result conserv bia studi subject averag smoke 27 year smoke 24 cigarett dai previous attempt quit time data shown outcom month twelv subject 5 cent lost baselin interview month follow substanti ef fort particip locat continu reason unrel smoke statu differ drop rate studi group find subject smoke statu month follow interview present figur 1 figur figur 2 categori attempt quit includ categori greater reduct reduct 20 includ reduct 50 quit higher number smoker attempt quit intervent group control group pi pi intervent equal effect pi yield desir outcom control group categori pi superior pi group caus higher percentag smoker reduc level cigarett smoke quit outcom month addit 27 subject lost month month follow interview total drop rate baselin month 15.6 cent drop rate vari significantli studi group differ attempt quit smoke statu month follow studi group displai figur 2 intervent subject control subject made cessat attempt small addit increment 3 cent quit attempt achiev pi pi subject pi group quit smoke particip ceiv provid messag usual care indepen 100 90 80 70 60 50 40 30 20 10 0 attempt quit reducl reducil quit 20 250 figur 2 smoke statu month studi group tabl 2 logist regress smoke cessat month month follow up month month odd odd model ratio 95 cl ratio 95 cl model intervent control 3.15 1.02 9.68 1.96 0.91,4.22 model pi 3.23 1.27 8.13 2.18 1.05,4.52 model lntervent linear progress 2.12 1.12 3.80 1.57 1.03,2.40 model pi 1.94 0.50 7.49 1.36 0.51,3.66 pi 4.40 1.34,14.44 2.46 1.06,5.65 1 pi 2 pi 3 dent influenc studi intervent similar reduct process logist regress investig progress effect level intervent predict smoke cessat month follow up assess partit studi group model analyz placement provid intervent alter model combin pi pi repres intervent intervent model pair pi group control group model assum equal space linear relationship studi group pi pi model consid explanatori power intervent option enter separ model ad degre freedom previou model tabl 2 displai odd ratio confid interv model option month month fol low up independ test provid valid extent intens intervent result enhanc benefit smoker month follow data pi appropri intermedi intervent i. model pi definit effect usual care option effect pi smoker quit month follow evid outcom pi group similar ajph juli 1987 vol 77 7 807 janz al obtain control group prefer model partit group pi versu model show pi smoker studi particip quit month follow interview discuss smoker attempt quit suffici step cessat process reduct import light dose respons relationship number cigarett smoke untoward health outcom report literatur intervent effec tive fact pi group appreci pi group stimul individu quit smoke attest power health care provid physician nurs motiv decis quit find consist previou survei smoker claim attempt quit told physician 3 step step quit kit produc signific increment effect pi option regard attempt quit manual design focu decis quit provid behavior guidelin process quit studi intervent result attempt rate control group exhibit impress level attempt quit contributor phe nomenon smoke cessat regularli encourag public health mass media campaign advic signific environment restrict smoker frequent attempt quit absenc direct encourag health profession effort encourag smoke cessat albeit unsystemat underwai clinic prior research occur sporad group physician awar ofour studi counsel patient usual month control group particip interview extens smoke habit suffici stimul occurr quit attempt quit rate import outcom measur smoke intervent studi intervent complet month follow quit rate improv month unusu find literatur smoke cessat intervent 36 dimens cessat addit manual prove consist efficaci month quit rate pi particip control find influenc pi strategi cessat declin month intuit reason physician messag nurs consult suffici forc smoker attempt quit passag time impact provid messag begin dissip pattern consist literatur sourc credibl decai messag effect time 37 addit quit kit mechan sustain motiv drop baselin interview month follow 16 cent dispro portion studi group research argu particip includ drop out includ comput treatment effect approach repres conserv method examin efficaci treatment drop out consid smoker reanalysi condit show signific chang outcom find encourag deriv popul wide rang smoker visit medic care clinic reason ostens unrel smoke patient characterist found relat smoke behavior outcom suggest intervent gener attract ness type effort consider potenti natur recruit larg number smoker minim report disrupt routin care give pi intervent composit featur studi attempt assess efficaci compon physician patient interac tion tape record standard pi messag deliv impact pi due actual content messag opportun influenti health care team confront smoker set health heighten concern import attribut efficaci stress belief barrier involv quit continu educ physician nurs inclus issu counsel effort warrant smoke studi marker alert intervent group physician deliv standard messag help ensur inclus point logist regresison analysi reinforc addit benefit offer step step quit kit assist smoker achiev posit smoke outcom give smoker smoke cessat manual rou tine clinic appoint doubl chanc success quit compar expos standard messag health care team usual care practic worthi adopt longer term outcom requir period reinforc health care team supplementari materi focus difficulti commonli face smoker acknowledg research support grant hl 30566 divis lung diseas nhlbi veteran administr medic center health servic research fellowship
health educ research theori practic vol 12 no.l 1997 page 129 138 worksit smoke intervent 2 year assess group incent leonard jason doreen salina1 susan mcmahon donald hedeker2 mari stockton abstract sixti compani chicago area recruit particip worksit smoke cessat program particip work site receiv televis program new paper supplement part commun wide media campaign condit 1 manual 2 manual incent 6 month im 3 mainten manual incent cognit behavior support group 6 month gem result 2 year assess examin random effect regress model addit definit quit rate monli smoke cessat research explor advantag public health approach worksit examin introduct smoke link 400 000 death year repres 5 million year potenti life lost cdc 1993 smoke remain lead prevent death mcginni foeg 1993 cost approxim 100 billion annual term health care expenditur lost product mackenzi al 1994 mass media depart psycholog depaul univers 2219 kenmor avenu chicago il 60614 3504 depart psycholog behavior scienc northwestern univers chicago il 60611 2depart epidemiolog blostatlstlc univers illinoi chicago chicago il 60612 usa worksit approach smoke cessat repres modal reach entir commun includ smoker make effort attend formal clinic warneck al 1989 worksit intervent demonstr promis result produc higher quit rate recruit particip clinic base approach klesg al 1987a fischer al 1990 multicompon behavior worksit inter vention yield averag cessat rate 34.6 post test 20.8 follow klesg al 1987a 20 control worksit smok ing cessat studi examin particip worksit intervent 58 quit smoke control condit fisher al 1990 advantag worksit approach i. reduc cost opportun promot smoke norm major weak worksit approach inabl attract maintain larg number smoker klesg al 1987a worksit program incorpor structur port group yield mix result malott al 1984 glasgow al 1986 cohen al 1988 group potenti particu larli effect worksit set stress neg affect occur work thought precipit smoke relaps shiffman 1982 marlatt gordon 1985 social support encourag smoker make initi decis quit continu particip cessat program maintain abstin mermelstein al 1986 mass media intervent eco nomic reach larg number oxford univers press 129 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org jason al peopl contribut public percept social norm toler smoke warneck al 1989 specif cognit behavior strategi quit model media program flai 1987 manual method present smoke cessat strategi frac tion cost clinic approach manual practic major smoker prefer chang approach quit flai al 1989 combin manual media program found effect strategi flai 1987 monetari incent adjunct treatment number studi order motiv peopl quit remain quit e.g klesg al 1986 1987b jason al 1990 incent higher particip rate higher cessat rate worksit smoke cessat intervent larg studi com.ibm.drl.hbcp.util control group need confirm effect malon jason 1990 worksit smoke cessat studi conduct jason associ improv exist method facilit smoker process quit jason al 1987a 1989 salina al 1994 initi 3 week intervent involv group media manual compar media manual ng jason al 1987b larg differ post test 41 versu 21 maintain 12 month assess jason al 1987a subsequ studi ad incen tive 12 monthli support group result significantli higher quit rate ng 2 year assess salina al 1994 present larg scale worksit smoke cessa tion studi design examin effect combin manual monetari incent group session worksit increas quit rate reduc recidiv rate addit entir chicagoland area target media televis seri pre sent new newspap supplement distribut area order provid peopl commun strategi quit smoke order improv previou studi worksit recruit 63 frequent group booster session con duct earlier intervent expect particip greatest support hypothes group incent manual gim produc higher quit rate incent manual im turn produc higher quit rate manual initi find suggest quit rate particip gim significantli higher particip im post test 6 12 month assess subject im significantli higher quit rate post test 6 month assess quit rate group 12 month assess significantli jason al 1995 purpos paper examin data collect 2 year begin intervent compar find obtain definit quit rate fre quentli smoke cessat research method sampl director personnel 400 compani contact letter particip studi compani randomli select list obtain dun bradstreet standard poor metropolitan chicago guid 400 compani origin contact 63 express interest particip agre receiv compon intervent i. manual incent group approxim 21 compani size rang 100 199 200 299 300 400 employe particip compani categor iz type busi manufactur 18 financ 12 busi legal servic 11 commun 7 wholesal retail trade 6 health 6 130 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org worksit intervent hospit 3 compani match size type randomli assign condit gim im data 61 compani post test mcmahon ai 1994 58 pani 6 12 18 24 month compani drop reason i. busi ness difficult employe attend session compani time financi problem employe firm provid gener inform flyer distribut post specif intervent gim im implement worksit particip paid releas time particip intervent assess particip worksit charg intervent baselin percentag smoker firm similar condit 28 25 im 27 gim smoker recruit rate similar 58 59 im 55 gim media intervent particip condit ask watch 5 dai smoke cessat media program smoke free 90 air daili wgn televis chicago program discuss behavior chang strategi smoke law ordin effect hand smoke smoke workplac progress report quit program televis rate approxim 333 000 526 000 peopl watch middai new even new program approxim 50 000 copi 8 page new paper supplement design accompani program distribut chicago public librari particip worksit worksit affili illinoi chamber commerc worksit intervent worksit intervent implement worksit research team 18 leader hire train specif conduct orient session biochem verif procedur data collect group session distribut incent detail treatment manual develop intervent weekli meet held train plan addit coordin identifi firm serv liaison project team compani condit particip condit receiv media manual freedom smoke 20 dai american lung associ 1986b newspap supplement complet 14 eco lyzer read schedul session gim 6 month interven tion incent condit im particip incent condit receiv media manual american lung associ 1986b newspap supplement opportun earn 1 dai dai abstin 6 month total po sibl 175 report smoke statu verifi ecolyz read time payment 14 ecolyz read schedul session gim group condit gim particip group condit receiv media manual american lung associ 1986a new paper supplement opportun earn 1 dai 6 month group meet group meet held week initi 3 week phase intervent meet base manual american lung associ 1986b newspap supplement group particip present strategi identifi smok ing pattern trigger smoke chang pattern anticip cope urg smoke share experi buddi system emphas order foster group support 6 month initi 3 week intervent 14 booster meet held particip group condit meet held weekli held biweekli held monthli 131 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org jason al order provid support initi booster session topic includ identifi reason quit smoke buddi system build support network cope strategi deal encourag smoke live smoker weight control exercis stress manag group condit particip receiv mainten manual lifetim freedom smoke american lung associ 1986a addit receiv worksit support group group condit particip elig earn 1 dai dai abstin 14 booster session report smoke statu verifi ecolyz read booster session data collect report questionnair collect pre test data orient data collect immedi initi 3 week phase intervent post test 6 immedi end group booster session 12 18 24 month begin intervent lotteri system encourag complet survei assess ecolyz draeger measur carbon monoxid verifi report smoke statu cotinin sampl collect 6 month assess addit measur verifi smoke statu random effect model cluster data random effect probit regress analysi gibbon bock 1987 hedek 1992 assess effect worksit intervent quit rate assess studi post 6 12 18 24 month analys assess intervent effect perform concurr estimat ing adjust degre intraclass correl data due nest individu firm accomplish includ random firm effect model extent individu firm independ outcom random effect analysi effect handl unit analysi problem cluster data liber conserv ordinari individu level analysi aggreg level worksit level analysi typic alli bryk raudenbush 1992 hedek al 1994a result random effect analys addit previou analys jason al 1995 estim firm level influenc individu smoke outcom intervent effect longitudin data random effect probit model assess time relat trend repeat classi ficat particip smoke statu assess longitudin data ran dom effect model account depend data result repeat assess individu time includ random individu effect model random effect reveal degre variat exist term time relat trend model random effect model place restric tion number observ individu subject miss interview wave exclud wave exclud analysi assumpt model data subject repres subject deviat averag trend line estim sampl model character subject trend time base data subject complet incomplet augment time trend estim sampl laird 1988 inform respect miss data random effect model logist regress approach logist regress com.ibm.drl.hbcp.util examin quit rate varieti perspect smoke cessat literatur consist smoke literatur criteria defin cessat klesg al 132 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org worksit intervent 1987a approach recod miss data smoke com.ibm.drl.hbcp.util complet data examin continu quit rate order provid comparison techniqu assess intervent effect point preval tradition point preval rate number baselin smoker abstin point time report advantag approach li fact data com.ibm.drl.hbcp.util data valid extent sampl size vari time miss particip smoke miss data vari condit approach accur addit point preval rate problemat sampl particip assess time point peopl oscil quit abstin enc individu nest work site ordinari logist regress random effect regress cluster data order examin point preval recod miss data smoke smoke cessat research recom mend peopl miss assess conserv consid smoker particip miss data assess smoke abstin e.g klesg al 1987a curri al 1988 approach advantag miss particip smoke smoke smoke statu particip consid power lost techniqu problemat miss data rate typic differ group intens intervent higher rate attrit e.g control condit attrit intervent condit bias quit rate favor intens intervent complet data approach tradit alli research difficulti deal longitudin data number observ subject differ random effect model address issu addit peopl examin time mean abstin rate peopl interpret peopl includ rate select prob lem aris reli complet data sampl particip complet data necessarili repres popul particip began studi make infer addit power statist test reduc result throw data collect continu quit rate smoker cycl stage quit time success mainten anc prochaska diclement 1992 health consequ short term quit remain unclear trend report continu abstin rate klesg al 1987a complet data specif time point examin continu quit rate time point advantag disadv ag discuss appli method addi tion continu quit rate bia result intervent improv quit rate time studi condit produc quit rate initi fairli low increas time examin continu quit rate present dif ferent view phenomena peopl quit post test definit classifi continu quitter preliminari analys consider attrit occur pre test 24 month assess miss data rate condit significantli assess 6 month post test x2 2 844 7.50 0.024 12 month x2 2 844 13.13 0.002 18 month x2 2 844 28.99 0.001 24 month x2 2 844 15.53 0.001 order control potenti confound effect 133 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org jason al tabl pre test demograph characterist condit variabl 280 incent 281 group 283 gender femal male race black white employ unskil skill cleric technician manag profession mean ag sd mean year smoke sd mean cigarett dai sd mean year educ sd mean se sd 71.8 28.2 16.6 77.6 5.8 27.4 43.8 28.8 37.4 10.6 19.9 10.2 22.5 10.4 13.8 2.2 42.9 19.4 58.1 41.9 16.5 70.6 12.9 25.4 52.1 22.5 37.8 19.7 21.3 14.1 44.5 9.8 9.8 11.5 2.2 19.1 59.2 40.8 28.5 63.0 8.5 28.8 56.7 14.4 38.3 11.1 20.2 11.0 20.7 12.0 13.5 2.3 41.4 19.8 condit relat result baselin characterist relat attrit wave examin statist signific differ found baselin variabl drop out younger male heavier smoker report lower health rate effort quit smoke confid quit concern weight gain variabl control attrit subsequ analys addit sex race differ condit control subsequ analys tabl demograph inform result pre test data collect 844 particip 280 sh 2811 283 tabl list observ individu level quit rate assess ment studi point preval quit rate base data subject assess tabl ii list quit rate obtain miss data recod smoke point preval random effect model cluster data estim firm effect particip nest firm result report random effect regress model clu tere data equival result obtain ordinari logist regress term condit effect wave result signi ficant main effect condit post test x2 2 565 85.10 0.001 6 month fr2 2 465 34.67 0.001 12 month x2 2 441 13.27 0.002 assess signific main effect condit 18 month 2 2 496 2.76 24 month x2 2 501 4.28 specif condit comparison gim versu im post 6 12 month reveal signific effect 6.90 0.001 note neg repres smoke 3.53 0.001 2.70 0.01 condit parison im versu exhibit signific effect post test 6 month assess 2.50 0.02 2.45 0.02 12 month 0.68 ns longitudin data random effect model term longitudin analys smoke statu classif analys includ subject report smoke statu assess period miss sex race variabl attrit fit 134 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org worksit intervent tfcble ii quit smoke post 6 month 12 month 18 month 24 month rate time condit point preval rate includ group gim 193 283 179 283 178 283 208 283 203 283 quit 47.7 32.3 39.1 24.6 33.1 20.7 21.6 15.8 25.6 18.2 incent im 221 281 154 281 152 281 174 281 162 281 quit 12.2 9.4 19.5 10.4 18.4 9.7 19.0 11.5 23.5 13.2 data recod miss data 191 280 160 280 134 280 144 280 166 280 quit 5.2 3.5 7.5 4.3 15.7 7.4 14.6 7.4 17.5 10.3 includ term main effect time main effect condit im versu gim versu im random subject effect account depend data result repeat measur ject result analys signific main effect condit x2 2 746 56.04 0.01 turn specif condit comparison observ signific differ favor term greater abstin enc gim versu im 4.61 0.001 im versu 2.75 0.01 test effect condit vari assess interact condit time ad basic model inclus condit time interact model observ signific 2 2 746 61.44 0.01 inspect contrast reveal signific gim versu im comparison 6.25 0.001 signific effect im versu 1.97 0.05 inclus condit time interact model main effect condit reflect differ post test signific differ enc observ favor gim versu im 6.99 0.001 im versu 3.32 0.001 observ condit quit rate assess tabl ii depict condit differ wave condit time effect i. larg differ observ gim im post test 47.7 versu 12.2 significantli decreas time differ im post test 12.2 versu 5.2 significantli decreas time logist regress analys quit rate examin quit rate varieti approach analys com.ibm.drl.hbcp.util logist regress specif time point sex race variabl attrit includ model recod miss data smoke particip miss data assess ment recod smoke tabl ii quit rate effect intervent favor gim versu im signific time point post test x2 2 797 72.97 0.001 6 month x2 2 797 37.54 0.001 12 month x2 2 797 19.28 0.001 18 month x2 2 797 7.44 0.03 24 month x2 2 797 7.85 0.02 complet data particip complet data assess examin tabl iii quit rate result reveal main effect condit favor gim versu im post test 6 12 24 month x2 2 183 35.68 0.001 x2 2 183 18.64 0.001 x2 2 183 10.86 0.01 x2 2 af 183 6.57 0.04 18 month continu quit rate final continu quit rate examin utiliz ing complet data suggest curri al 135 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org jason al tabl hl quit rate time condit complet data point preval rate continu quit rate group gim incent im post 6 month 12 month 18 month 24 month 86 86 86 86 86 141 109 93 86 quit 59.3 52.3 38.3 47.7 31.2 31.4 19.4 38.4 19.8 60 60 60 60 60 133 91 71 60 quit 18.3 26.7 9.8 28.3 11.0 23.3 14.1 26.7 13.3 45 45 45 45 45 118 79 54 44 quit 11.1 13.3 5.1 17.8 5.1 22.2 3.7 22.2 4.5 1988 klesg al 1987a tabl iii analys main effect condit favor gim versu im 6 12 month x2 2 183 19.03 0.001 x2 2 183 10.90 0.01 18 24 month discuss result suggest interpret effect intervent smoke statu vari depend outcom vari den focus point preval rate specif time point group significantli enhanc quit rate incent post test 6 12 month 18 24 month incent increas quit rate manual post test 6 month 12 18 24 month random effect model examin trend time initi strong group effect diminish time quit rate incent condit increas time random effect model typic smoke cessat research quit rate defin differ definit compar purpos miss data recod smoke complet data examin particip gim significantli higher quit rate im 24 month point preval rate continu quit rate consid signific group effect 6 12 month expect direct 24 month longer signific examin condit effect varieti lens import implic smoke cessat intervent combin ation social support cognit behavior skill incent result higher quit rate incent manual 12 month effect 24 month clear pro con definit differ conclus result pre sent data perspect facilit comparison studi rigor statist approach model data random effect model differenti attrit rate condit control attrit term report quit rate percentag truth data point preval rate reced miss data smoke probabl miss particip smoke approach recod miss data repres accur approach probabl differ point preval rate accur long term focu studi random effect model enabl examin group trend time distribut manual enabl peopl quit smoke number peopl quirt program increas time public health perspect intervent illustr cost effect approach smoke cessat addit incent enhanc quit rate condit peopl quit time program frequent presenc smoke cessat leader worksit person feedback 136 nivers berdeen januari 22 2016 http her.oxfordjournals.org ow nload http her.oxfordjournals.org worksit intervent ecolyz read contribut increas quit rate im group intervent boost quit rate differ condit dimin ish time result suggest group benefici effect direct statist alli signific quit rate cost smoke societi 100 billion annual enorm cost benefit worksit program consid highli cost effect jason al 1995 converg natur data expens involv implement group intervent incent intervent con sider cost effect group intervent long term follow intervent uniqu benefit consid media intervent group repres effect method reach thousand smoker media addit benefit rais awar sensit gener public difficulti involv quit smoke incent increas respons rate particip rate group particip identifi cope strategi specif effect provid environ prepar practic support smoker benefit access varieti intervent method approach appeal indi vidual attrit rate limit studi multicompon worksit studi gener klesg al 1987a stand factor drop develop strategi improv particip long term mainten focus relaps prevent group session tailor materi match particip stage chang prochaska diclement 1983 reduc recidiv rate challeng research continu innov smoke cessat intervent order attain larger effect reduc attrit worksit provid ideal set test innovat iv intervent understand stage chang process quit promot smoke norm legisl smoke polici group conduct worksit increas awar encourag support worker inter action build exist support net work employe addition worksit intervent potenti reach high risk smoker i. heavi smoker women minor access tradit smoke cessat clinic american continu smoke center diseas control 1992 develop refin larg scale health promot effort repres import focu research public health offici commun leader acknowledg studi conduct connect research grant 5r01 hl42987 02 nation institut heart lung blood
address heavi drink smoke cessat treatment random clinic trial christoph kahler jane metrik brown univers heather lachanc nation jewish medic research center susan ramsei warren alpert medic school brown univers rhode island hospit david abram nation institut health peter monti provid va medic center brown univers richard brown warren alpert medic school brown univers butler hospit heavi alcohol frequent occur cigarett smoke imped smoke cessat clinic trial examin smoke cessat treatment incorpor alcohol intervent improv smoke cessat outcom 7 dai verifi point preval abstin reduc drink consum week heavi drinker seek smoke cessat treatment assign urn random receiv 8 week nicotin replac therapi 4 session standard smoke cessat treatment st 119 standard treatment equal intens incorpor alcohol intervent st bi 117 follow up 26 week particip st bi report approxim 20 fewer drink week 027 greater smoke abstin adjust odd ratio 1.56 95 confid interv 1.01 2.43 st effect smoke primarili evid 2 week quit date essenti absent 16 week effect st bi smoke outcom robust moder heavi drinker compar heavi drinker integr alcohol intervent smoke cessat treatment appear feasibl develop need yield last effect smoke keyword smoke alcohol alcohol intervent smoke cessat treatment posit associ cigarett smoke alcohol document e.g chiolero wietlisbach ruffieux paccaud cornuz 2006 dawson 2000 falk yi hiller sturmhofel 2006 friedman tekawa klatski sidnei armstrong 1991 20 current smoker consum drink occas month compar 6.5 nonsmok dawson 2000 combin neg effect excess drink smoke health outcom substanti smoke heavi drink ing combin produc neg consequ brain morpholog function durazzo cardena studholm weiner meyerhoff 2007 meyerhoff al 2006 smoke negat cardioprotect effect regular drink ebbert jannei seller folsom cerhan 2005 schroder marrugat elosua cova 2002 multipl effect op erat smoke combin heavi drink confer markedli greater risk oral pharyng laryng esoph ageal cancer rel smoke drink smoke drink pelucchi gallu garavello bosetti la vecchia 2006 greater alcohol decreas odd smok ing cessat hymowitz al 1997 osler prescott godtfredsen hein schnohr 1999 sorli kannel 1990 zimmerman warheit ulbrich buhl auth 1990 strong prospect com.ibm.drl.hbcp.predictor smoke relaps quitter garvei bliss hitchcock heinold rosner 1992 ocken al 2000 current christoph kahler jane metrik center alcohol addic tion studi brown univers heather lachanc nation jewish medic research center susan ramsei warren alpert medic school brown univers rhode island hospit david abram offic behavior social scienc research nation institut health peter monti provid va medic center center alcohol addict studi brown univers richard brown warren alpert medic school brown univers butler hospit studi support grant r01 da15534 nation institut drug abus christoph kahler peter monti effort support part depart veteran affair senior career research scientist award gratefulli acknowledg andrea resend jennif larenc dan belenki catherin costantino cheryl eaton tim othi souza kara szczesni assist project treatment provid john mcgeari gail schilk jame mackillop patricia relli moniz correspond articl address christoph kahler center alcohol addict studi brown univers box s121 5 provid ri 02912 mail christopher_kahl brown.edu journal consult clinic psycholog copyright 2008 american psycholog associ 2008 vol 76 5 852 862 0022 006x 08 12.00 doi 10.1037 a0012717 852 alcohol humfleet munoz see reu hall 1999 sherman wang nguyen 1996 smith kraemer miller debusk taylor 1999 current bing drink murrai istvan voelker rigdon wallac 1995 start smoke cessat treatment alcohol treatment humfleet al 1999 neg absti nenc except hugh oliveto 1993 treatment sampl approxim quar ter smoke laps occur context involv alcohol baer lichtenstein 1988 borland 1990 shiffman 1982 number recent clinic trial examin smoke cessat intervent initi alcohol treatment result dicat intervent harm treatment outcom drink outcom prochaska delucchi hall 2004 except e.g joseph willenbr nugent nelson 2004 attent devot smoker drink heavili alcohol depend u. depart health human servic guidelin treat tobacco depend recommend smoker reduc avoid drink alcohol make quit attempt fior bailei cohen al 2000 clinician guidanc address heavi drink smoke cessat treatment empir studi publish date area motivation focus behavior intervent shown reduc drink mccradi 2000 moyer finnei swearingen vergun 2002 whitlock polen green orlean klein 2004 drinker seek treatment alcohol problem sever alcohol problem moyer al 2002 incorpor inter vention smoke cessat treatment nondepend heavi drinker efficaci reduc drink improv smoke cessat outcom end aim current studi test efficaci smoke cessat treatment incorpor alcohol intervent focus risk smoke relaps drink neg effect continu heavi drink random clinic trial involv 236 alcohol depend heavi drink smoker recruit commun seek smoke cessat treatment partic ipant random standard smoke cessat treat ment st includ provis nicotin patch equival standard treatment incorpor alcohol intervent st bi treatment condit match amount contact time particip 26 week smoke quit date hypothes st bi compar st result higher rate point preval smoke abstin 2 8 16 26 week quit date lower number alcohol drink consum week addit hypothes st bi rel st result lower rate initi laps smoke involv alcohol treatment final examin potenti moder treatment effect smoke level drink prior treatment inten tion chang drink analys consid explor atori theoret reason expect stronger weaker effect st bi higher level variabl pretreat drink emphasi st bi alcohol relev heavier drinker hand heavi drinker chang drink smoke simultan prove overli difficult intent chang drink st bi effect intend chang drink reinforc expect smoker chang alcohol facilit smoke cessat hand st bi effect smoker inform st bi redund intent method particip particip 236 heavi drink smoker recruit commun includ particip 18 year ag smoke cigarett regularli 1 year smoke 10 cigarett dai tobacco product nicotin replac therapi drink heavili nation institut alcohol abus alcohol niaaa guidelin niaaa 1995 men 14 drink week 5 drink occas month past 12 month women 7 drink week 4 drink occas month particip clude met full dsm iv criteria alcohol depend past 12 month met criteria current psychoact substanc abus depend exclud nicotin depend alcohol abus past 12 month current past month affect disord psychot suicid unstabl medic condit suggest caution nicotin patch e.g unstabl angina arrhythmia recent congest heart fail ur pregnant lactat intend pregnant smoker agre 6 month seek smoke cessat treatment activ phase treatment i. 8 week quit date nicotin patch sampl size estim determin requir sampl size base effect st bi versu st smoke abstin equival odd ratio base priori estim abstin rate st rang 40 2 week 30 8 week 20 16 week 15 26 week repres small medium effect size believ clinic signific smoke outcom analyz peat measur procedur sampl size deter minat analys outlin rochon 1998 rochon geesiz program version 2.1 determin sampl size 212 particip need allow 10 attrit follow chose recruit final sampl 236 particip procedur particip recruit post commun bul letin board newspap radio advertis ask social drinker want quit smoke potenti particip screen telephon complet intak interview sign statement inform consent approv brown univers institut review board particip recruit octob 2003 juli 2006 follow up conduct januari 2004 853smoke cessat treatment heavi drinker june 2007 991 individu screen studi 428 meet preliminari inclus exclus criteria 216 elig show baselin 206 declin particip studi 10 347 elig screen 96 deem inelig baselin fifteen addit individu drop prior receiv treatment materi prior learn treatment condit includ outcom analys result base 236 particip enter treatment potenti intent treat sampl 251 figur 1 detail dia gram particip flow random particip assign treatment con dition urn random techniqu wei 1978 ensur balanc gender level nicotin depend fager ström test nicotin depend ftnd number drink consum week intent chang drink quit ting smoke hundr nineteen particip ran domiz st condit 117 random st bi data random research assist lead author christoph kahler conduct comput base urn random inform treatment provid treatment assign assess particip complet assess treatment session addit follow up conduct 8 16 26 week quit date prior assess particip provid breath sampl confirm alcohol neg ativ research assist conduct interview inform treatment condit assign treatment treatment consist individu counsel session 3 week quit date occur session 2 1 week session 1 manual request christoph kahler particip receiv treatment transderm nic otin patch initi dose start 21 mg 4 week 2 week 14 mg patch 2 week 7 mg patch st base recent clinic practic guidelin fior al 2000 focus problem solv high risk situat smoke relaps provid support treat ment encourag particip seek support quit smoke treatment particip st advic avoid reduc drink exclud 111 meet inclus criteria 96 reason medic rule 7 psychiatr rule 17 substanc abus depend rule 29 smoke criteria met 25 drink criteria met 20 pregnanc posit bal incomplet baselin 7 drop prior treatment 15 note multipl reason appli particip instanc smoke outcom 119 drink outcom 106 complet 2 week fup 111 complet 8 week fup 107 complet 16 week fup 106 complet 26 week fup 108 alloc st 119 complet 1 session 3 complet 2 session 13 complet 3 session 12 complet 4 session 91 complet 2 week fup 111 complet 8 week fup 112 complet 16 week fup 113 complet 26 week fup 107 2 particip di prior fup alloc st bi 117 complet 1 session 5 complet 2 session 5 complet 3 session 17 complet 4 session 90 smoke outcom 117 drink outcom 110 random 236 alloc follow analysi assess elig baselin 347 figur 1 consort flowchart elig random treatment follow fup inclus analys st standard smoke cessat treatment st bi standard smoke cessat integr alcohol intervent 854 kahler al quit smoke st bi condit discuss alcohol reserv half session 1 2 session rang length 70 min session 1 40 min session 2 20 min session 3 4 st st bi match treatment contact time st 40 min session 1 20 min session 2 dedic teach progress muscl relax shown improv smoke cessa tion outcom fior al 2000 session 3 4 contain 5 min check in relax skill st bi amount time dedic discuss partici pant alcohol session st bi includ open end discuss current drink smoke pattern norm feedback drink level risk smoke relaps drink preliminari goal set modul po tential role alcohol smoke relaps entri discuss short long term drink interest long term drink partici pant encourag abstain alcohol 2 week quit smoke prefer abstain drink nicotin patch provid recommend moder drink limit inform risk combin heavi drink smoke session focus final drink goal support efficaci chang 5 min check achiev drink goal includ session 3 4 session 4 recent benefit chang drink longer term drink goal review alcohol modul st bi conduct nonconfront therapeut style mo tivat interview miller rollnick 2002 tend minim patient resist stress person respons decid chang therapist treatment deliv male therapist femal therapist doctor degre master degre bachelor degre psychol ogi counsel relat field counselor provid treat ment condit audiotap session de tail therapist manual ensur standard treatment deliveri therapist complet minimum 20 hr train motiv interview specif intervent studi averag audiotap therapist rate supervisor christoph kahler heather lachanc biweekli basi modif yale adher compet scale carrol al 2000 therapist receiv adequ compet adher rate complet case regular individu supervis conduct therapist receiv 1 hr group supervis week measur baselin interview particip provid demograph background inform ag gender year educ marit statu number year regular smoke averag number cigarett dai dsm iv axi diagnos deter mine structur clinic interview dsm iv patient edit scid spitzer gibbon william 1995 sever nicotin depend assess ftnd heatherton kozlowski frecker fagerström 1991 valid item measur particip complet singl item quasi continu assess intend cut stop drink treatment rang 0 1 possibl 2 3 final commit quit smoke assess item commit quit smoke scale kahler al 2007 variabl covari outcom analys strong predict valid sampl kahler al 2007 smoke statu outcom analys base 7 dai point preval abstin i. report abstin 7 dai prior assess dai assess 2 end psychosoci treatment 8 end treatment nicotin patch 16 26 week particip quit date report abstin verifi alveolar carbon monoxid bed font scientif williamsburg va smokelyz breath moni tor 16 26 week follow up saliva sampl cotinin level determin enzym immunoassai collect report abstin abstin confirm binat 10 ppm cotinin 15 ng ml srnt subcommitte biochem verif 2002 signific report verifi smoke statu provid report data provid biochem veri ficat abstin total 4 assess complet smoke data verifi biochem signific report obtain 94.1 93.2 90.3 94.1 particip 2 8 16 26 week follow up particip st bi di 16 26 week follow up death deem unrel studi particip smoke statu 26 week follow left miss odd complet follow up significantli relat treatment condit primari anal yse individu smoke abstin confirm follow consid abstin miss data consid nonabstin 236 particip enter treatment includ smoke outcom anali se report abstin rate correspond report abstin smoke cessat trial ran analys assumpt made miss data data particip analys exclud 12 particip provid follow data result assumpt miss data highli concord worst case assumpt detail secondari smoke outcom continu smoke abstin defin report ing smoke quit date onward verifi abstin follow point preval abstin cho sen primari outcom biochem verif short window time analyz point preval abstin repeat measur context appropri captur variabl outcom time rel collaps outcom examin differ treatment condit time greater statist power compar singl measur outcom hall al 2001 alcohol timelin followback interview tlfb bell sobel 1996 valid daili calendar assist sessment alcohol baselin assess alcohol prior 8 week tlfb conduct session 3 4 follow interv period 855smoke cessat treatment heavi drinker administr smoke nicotin replac assess tlfb primari outcom variabl number drink consum week variabl chosen primari drink outcom appropri mir ror multipl target st bi stress avoid drink ing limit amount consum drink ing drink level consid medic riski 15 drink week men 8 drink week women drink week quit date aggreg thirteen 2 week block 2 week block reflect drink consum week 2 week quit date psychosoci treatment deliv total 216 91.5 106 st 110 st bi particip provid daili drink data quit date 207 87.7 provid complet data 8 week treatment 200 84.7 provid complet data 26 week analys conduct data 216 relaps interview relaps interview administ particip laps smoke determin circumst surround initi laps episod includ individu al drink alcohol time reliabl retrospect recal smoke laps question variabl retrospect recal alcohol consumpt occur laps episod appear fairli accur compar real time assess shiffman al 1997 treatment adher audiotap randomli select half particip sampl adher code research assist code topic treat ment protocol outlin cover number topic rate rang 28 topic session 1 14 topic session 4 10 tape code research assist discrep rate review ensur consist rate specif item includ element common treatment e.g direct patch behav ior specif st e.g describ progress muscl relax ation st bi e.g ask pro drink treatment evalu quit process assess discrimin treatment condit particip ask 8 week follow seri singl item question help counsel qualiti interact therapist extent treatment empha size import learn relax skill reduc drink quit smoke ask extent engag smoke cessat strategi e.g avoid high risk situat 78 degre avoid drink alcohol data analysi plan chi squar analys test examin group differ treatment complianc treatment fidel nicotin patch com.ibm.drl.hbcp.util particip evalu treatment particip report gener alcohol specif smoke cessat strategi expect indic equal condit dealt specif relax alcohol examin point preval smoke outcom primari drink outcom drink week examin effect treatment context covari impact outcom repeat measur analys conduct gener estim equat gee liang zeger 1986 proc genmod sa sa institut 1997 inclus covari relat outcom treatment condit maxim statist power cohen cohen west aiken 2003 covari inform kei com.ibm.drl.hbcp.predictor outcom popul smoke outcom point preval abstin follow up depend variabl binomi distribut logit link function drink week count distribut overdispers due posit skew neg binomi distribut logit link function analyz outcom model extens poisson distribut count data appro priat variabl count greater expect base mean similar odd ratio expon model coeffici reflect ratio number event drink expect occur condit rel number event expect occur condit covari gee analys potenti influenc outcom gender ftnd averag number drink consum week squar root transform correct posit skew intent chang drink mitment quit smoke continu variabl stan dardiz facilit comparison model coeffici variabl carri linear effect time includ correl covari gener weak rs 15 correl male gender drink week 236 42 0001 correl ftnd drink week 236 15 02 preliminari test effect code reveal smoke drink outcom therapist differ significantli averag remain therapist therapist treatment interact therapist effect includ primari outcom analys smoke drink outcom enter main effect treatment covari enter interact treatment condit drink week baselin intent chang drink final examin proport particip st st bi experienc initi laps smoke drink treatment effect variabl examin effect treatment reduc includ variabl gee analysi predict smoke outcom consist mediat mechan result sampl analys 45 106 femal 55 130 male 32.6 77 marri cohabit mean ag sampl 41.5 year sd 12.0 mean educ 14.0 year sd 2.6 vast major particip 214 90.7 identifi hispan white sampl 3.8 african american 3.4 hispan latino 0.8 asian american 1.3 identifi mix ethnic origin baselin par ticip smoke averag 21.3 sd 9.4 cigarett dai smoke averag 22.7 year sd 11.5 sampl mean ftnd 5.0 sd 2.2 major 856 kahler al particip 90.7 made quit attempt last 12 hr mean commit quit smok ing scale score 3.9 sd 62 5 particip report 8 week prior treatment drank 54.7 sd 27.3 dai consum averag 16.5 sd 11.9 drink week intent drink 31.4 possibl 33.5 17.8 reduc stop drink quit smoke remain 17.4 reduc stop drink ing base structur clinic interview dsm iv patient edit 19.5 particip met criteria current alcohol abus 17.4 past alcohol depend explor atori analys abus depend diagnos predict smoke drink outcom interact st bi predict outcom lifetim diagnos 26.5 past drug abus 20.9 past drug depend 33.6 past major depress disord treatment condit differ significantli baselin variabl ps 20 advers event note 2 particip st bi di follow particip condit hospit studi reason deem unrel particip block arteri recurr lung cancer advers event report treatment complianc fidel discrimin attend treatment session differ significantli condit figur 1 patch complianc differ significantli condit particip patch 73.7 sd 29.7 dai 8 week quit date base data 212 particip counselor adher protocol excel st con dition 96.7 st protocol topic session sampl complet compar 97.5 st bi topic specif relax train st 99.4 cover st versu 1.8 st bi alcohol compon specif st bi 97.6 cover st bi compar 3.5 st 8 week follow 207 particip complet post treatment evalu counsel report strat egi quit smoke consist expect rate help counsel therapist concern particip counselor differ significantli treatment condit ps 15 st bi compar st agre strongli counselor made clear relax skill quit smoke 35 01 agre strongli st counselor made clear chang alcohol quit smoke 59 0001 strategi quit particip st bi differ significantli st report gener smoke cessat strategi 75 agre significantli strongli avoid drink alcohol 49 0006 limit alcohol drank 31 03 smoke outcom dai point preval abstin rate 45.4 st versu 57.3 st bi 2 week odd ratio 1.61 95 confid interv ci 0.96 2.70 07 31.1 versu 39.3 8 week 1.45 95 ci 0.84 2.46 18 17.7 versu 18.0 16 week 1.02 95 ci 0.53 1.99 95 17.7 versu 19.1 26 week 1.10 95 ci 0.57 2.14 76 continu abstin rate differ significantli 12.6 st versu 13.7 st bi 1.09 95 ci 0.52 2.34 81 initi gee model chosen covari gender ftnd averag number drink consum week intent chang drink commit quit smoke main effect treatment present tabl 1 signific main effect st bi indic significantli higher odd abstin time compar st higher ftnd score lower odd abstin greater commit quit higher odd abstin men significantli women abstin effect drink week intent chang drink nonsignific gee model weigh time point equal assess effect treatment step analysi ad interact st bi time shown tabl 1 st bi time interact nonsignific adjust aor 0.85 95 ci 0.64 1.11 23 suggest signific differ treatment effect time nonetheless model base aor time period mirror wane effect treatment raw data 2 week aor 1.78 95 ci 1.05 3.02 03 8 week aor 1.57 95 ci 0.90 2.73 11 16 week aor 1.08 95 ci tabl 1 gener estim equat analys predict 7 dai point preval smoke abstin 2 8 16 26 week quit date variabl 95 ci main effect time 0.54 0.46 0.62 0001 male gender 1.71 1.05 2.81 033 fagerström test nicotin depend 0.73 0.58 0.93 009 drink week 1.03 0.80 1.32 83 intent chang drink 0.86 0.69 1.08 19 commit quit smoke scale 1.59 1.24 2.02 0002 st bi compar st 1.56 1.01 2.43 047 interact treatment st bi intent chang drink 1.39 0.89 2.18 15 st bi drink week 0.57 0.36 0.90 016 note 236 or 1 reduc odd abstin or 1 increas odd abstin continu variabl stan dardiz 0 sd 1 rel effect compar directli odd ratio ci confid interv 857smoke cessat treatment heavi drinker 0.53 2.20 84 26 week aor 1.17 95 ci 0.58 2.36 66 final step analysi time treatment interac tion remov model interact treatment condit drink week intent chang drink ad tabl 1 interact treat ment interact test bonferroni correct alpha 025 determin signific st bi intent interact reach signific st bi drink week interact signific indi cate effect st bi rel st attenu higher level drink illustr effect divid sampl half base median number drink consum week gender 18.4 drink week men 8.8 drink women raw unadjust point preval abstin rate treatment condit drink level shown figur 2 moder heavi drinker 119 effect st bi rel st robust signific aor 2.09 95 ci 1.15 3.81 015 heavi drinker 117 effect small nonsignific aor 1.27 95 ci 0.64 2.51 50 drink outcom spearman rank order point biseri correl point preval smoke abstin follow drink week 2 week prior follow small nonsig nific rang rs 06 02 indic abstin smoke drink significantli abstin result differ indic drink percent heavi drink dai percent dai abstin examin consist treatment recommend signif icantli particip st bi compar st abstain en tire drink 2 week quit 20.2 st bi 9.7 st 03 nicotin patch i. 8 week quit date 13.9 3.9 01 26 week follow virtual particip st bi 94.4 st 98.1 drunk effect condit longer signific 15 fewer particip st bi met niaaa criteria heavi drink past 2 week pare st differ signific 2 week 45.9 st bi 58.7 st 06 8 week 51.9 st bi 57.7 st 39 26 week 60.0 st bi 68.0 st 23 figur 3 show number drink consum week quit date treatment condit 26 week follow condit larg reduct weekli alcohol consumpt 42.3 drinker reduc drink 50 follow 1.9 increas drink 50 neg binomi gee model predict drink week quit date higher ftnd score exp 0.87 95 ci 0.79 0.96 005 greater intent chang drink exp 0.89 95 ci 0.80 0.98 01 significantli lower number drink consum week greater drink week baselin significantli greater number drink exp 1.84 95 ci 1.67 2.03 0001 st bi compar st drank significantli fewer drink week exp 0.81 95 ci 0.67 0.98 027 repres 20 reduct drink week rel st control baselin drink interact treatment condit time drink week baselin intent chang drink nonsignific alcohol involv laps total 217 particip 91.9 provid adequ data classifi slip smoke drink alcohol occur 8 week particip receiv activ treatment st 30.6 particip 33 108 report initi slip smoke treatment drink alcohol compar 22.0 st bi 24 109 2 1 217 2.04 15 moder heavi drinker 0 10 20 30 40 50 60 70 2 week 8 week 16 week 26 week week quit date rc ti st 59 st bi 60 heavi drinker 0 10 20 30 40 50 60 70 2 week 8 week 16 week 26 week week quit date er ce ab st st 60 st bi 57 figur 2 raw unadjust 7 dai point preval smoke abstin 2 8 16 26 week quit date treatment condit level drink particip classifi moder heavi heavi drinker gender base median split mean number drink consum week baselin median drink week men 18.4 women 8.8 st standard smoke cessat treatment st bi standard smoke cessat integr alcohol intervent 858 kahler al ran logist regress model predict alcohol involv smok ing laps includ covari gee model higher ftnd score lower odd alcohol involv smoke laps aor 0.62 95 ci 0.45 0.87 005 higher drink week greater odd alcohol involv smoke laps aor 1.61 95 ci 1.11 2.33 01 effect st bi nonsignific aor 0.56 95 ci 0.29 1.07 08 covari effect treatment signific examin alcohol relat slip mediat effect st bi point preval smoke outcom exploratori analysi interact treatment condit drink week enter logist regr sion model predict alcohol involv smoke laps signific aor 2.64 95 ci 1.31 5.32 006 drink gender base median level drink sampl 31.4 st particip report initi slip drink compar 12.3 st bi 2 1 108 5.85 016 drink median rate 29.8 st 32.7 st bi 2 1 109 0.10 75 examin effect account interact st bi drink week predict smoke abstin ad alcohol involv smoke laps variabl gee model smoke outcom alcohol involv smoke laps treatment significantli abstin follow aor 0.42 95 ci 0.24 0.76 004 variabl includ model interact st bi drink week reduc longer signific aor 0.70 95 ci 0.43 1.15 16 indic avoid alcohol involv slip account interact tween treatment drink week discuss result studi suggest integr alcohol intervent smoke cessat treatment heavi drinker feasibl detract smoke outcom lead reduc drink result differ smoker meet current criteria alcohol abus met lifetim criteria alcohol depend addit alcohol modul st affect particip willing attend counsel session particip st bi st differ evalu counselor smoke treatment report level nicotin patch smoke cessat strategi time st bi readili distinguish st term session topic cover particip evalu amount focu alcohol particip report effort avoid drink repeat measur analys point preval abstin covari relev com.ibm.drl.hbcp.predictor outcom provid maxi mal statist power particip receiv st bi signifi cantli abstin smoke receiv st magnitud effect small adjust 1.56 equival 0.25 chinn 2000 effect st bi smok ing approach signific time coun sele ongo 2 week quit date effect dimin ish 8 week essenti absent 16 week likewis effect st bi continu abstin smoke small convincingli argu effect size small differ 1 continu 6 month smoke abstin rate clinic meaning substanti health benefit stop smoke west 2007 differ continu abstin rate 1.1 st bi st approach statist signific present sampl size consid robust enhanc ment treatment approach need maxim total effect size treatment extend impact longer period time mainten treatment gain ongo challeng smoke cessat field e.g covei al 2007 lancast hajek stead west jarvi 2006 present studi behavior treatment provid 2 week quit date extend behavior treatment time nicotin replac provid maintain initi gain smoke abstin st bi mix person counsel session telephon counsel session provid practic cost effect mean maintain contact particip extend period time hall humfleet reu munoz cullen 2004 modest main effect st bi smoke emerg context interact st bi weekli drink level prior treatment moder heavi drinker i. bottom half sampl drink week gender median 18.4 men 8.8 women effect st bi compar st robust aor 2.09 0.41 heavi drinker effect st bi small aor 1.27 0.13 nonsignific surpri ingli moder heavi heavi drinker st poor smoke outcom effect st bi drink outcom small signific effect occur context larg reduct drink condit averag 40 previou studi yield equivoc 0 2 4 6 8 10 12 14 16 18 bl 2 4 6 8 ri 10 12 14 16 18 20 22 24 26 eek quit date st 104 st bi 109 figur 3 mean number drink consum week 26 week quit date drink week averag thirteen 2 week interv graph treatment condit raw unadjust data shown st bi compar st drank significantli fewer drink week exp 0.81 95 ci 0.67 0.98 027 st standard smoke cessat treatment st bi standard smoke cessat integr alcohol intervent bl baselin 859smoke cessat treatment heavi drinker evid quit smoke signific reduct drink carmelli swan robinett 1993 nothwehr lando bobo 1995 smoke cessat intervent shown affect alcohol fox sexton hebel 1987 murrai istvan voelker 1996 substanti reduct drink condit present studi found prior smoke cessat studi reflect fact sampl screen specif heavi drink room drink chang particip recent longitu dinal commun studi found quit smoke reduc odd heavi drink karlamangla zhou reuben greendal moor 2006 particip recruit studi specif focus alcohol drinker quit smoke inform studi examin type counsel help alcohol drinker quit smoke inform studi hypothes nonetheless due focu studi larg proport sampl believ chang drink import smoke cessat success intent chang drink relat greater reduct drink half sampl baselin cut drink make quit attempt final particip condit complet depth assess daili drink behavior baselin follow assess reactiv effect clifford maisto davi 2007 notabl find drink week quit attempt larg main tain follow mainten occur vast major particip return smoke benefici effect st bi reduc drink rel st appear larg maintain consist appar 2 week quit date data suggest initi smoke cessat opportun heavi drinker make last drink clinician reinforc moder drink level conduct diagnost interview follow determin studi particip experienc reemerg alcohol depend follow aggreg particip abstin smoke follow necessarili drink smoke heavier drinker sampl wors smoke outcom find surpri ing expect drink smoke outcom correl moder analys data set shown odd laps smoke significantli higher drink dai compar nondrink dai kahler al 2005 quarter particip sampl experienc initi laps smoke drink alcohol treatment alcohol relev risk factor smoke relaps smoke cessat occur absenc larg drink larg drink occur absenc success smoke ce sation clear addit intervent reduc drink necessarili impact smoke outcom popul nondepend heavi drinker indic st bi effect st reduc proport particip alcohol involv smoke laps effect reach signifi canc sampl moder heavi drink er st bi effect st bi significantli reduc odd alcohol involv smoke laps rel st inclus alcohol involv smoke laps reduc effect interact drink dai treatment condit 22 make nonsignific support reduc occurr alcohol involv smoke laps po tential mechan st bi produc superior smoke cessat outcom particip frequent tend contact particip earli stage quit smoke potenti telephon contact suggest act augment effect st bi reduc alcohol involv laps risk ultim lead robust effect st bi smoke outcom limit conclus studi kind test efficaci smoke cessat treatment heavi drinker specif incorpor detail alcohol specif intervent compon treatment equat contact time deliv intend control random clinic trial high follow rate adequ sampl size sampl recruit lack racial ethnic divers limit smoker heavi drinker alcohol depend result gener lighter drinker current alcohol depend replic result divers sampl warrant replic interact drink dai baselin st bi clarifi smoker benefit st bi investig potenti mechan action st bi need investig suggest direct refin intervent popul smoker present studi assess drink occur time smoke laps conduct retrospect number drink consum prior smoke laps record ecolog data collect tech niqu handheld comput elucid alcohol consumpt smoke relationship mechanist investig effort modifi st bi produc larger last effect smoke outcom
journal consult clinic psycholog copyright 1997 american psycholog associ 1997 vol 65 4 663 672 0022 006x 97 3.00 nicotin patch video cigarett smoke cessat joel killen stephen fortmann lauri davi ann varadi stanford univers school medicin total 424 smoker random 2 2 factori experi pharmacolog factor contain 2 level transderm nicotin patch tnp 21 mg placebo behavior treatment factor contain 2 level video enhanc treatment manual serf treatment manual 2 month tnp produc higher level abstin 36 placebo 20 001 comparison signific secondari analys 2 month complianc patch treatment regimen 2 6 12 month relaps nicotin replac therapi improv abil produc smoke cessat product sustain longer term abstin remain elus goal nicotin replac therapi nrt state art treatment nicotin addict growth interest nrt stem observ compuls tobacco involv physiolog behavior depend nicotin nicotin deliv tobacco produc effect nrt nicotin addict accomplish manner permit therapeut manag depend process lessen health risk user henningfield jasinski 1988 nonetheless addit behavior treatment nrt significantli increas long term smoke cessat rate hugh 1991 nrt shown effec tive combin intens clinic base behavior tervent design facilit develop regula tor skill hall tunstal ginsberg benowitz jone 1987 hall tunstal rugg jone benowitz 1985 kiuen mac cobi taylor 1984 kozak fagerstrom 1995 schneider al 1983 evid respect nicotin gum ng clinic base behavior treatment combin conclus standard meta analyt review conclud ng pharmacolog aid smoke cessat bine behavior treatment program deliv smoke cessat clinic hugh 1991 lam sack sze chalmer 1987 abstin rate impr joel killen stephen fortmann lauri davi ann varadi center research diseas prevent stanford univers school medicin research fund public health servic grant hl 47219 nation heart lung blood institut hoechst marion roussel provid nicotin placebo patch blue shield manag provid partial support develop relaps prevent video conni gibnei ronni field barbara elspa assist conduct studi michaela kiernan excel construct feedback correspond articl address joel killen center research diseas prevent stanford univ siti school medicin 1000 welch road palo alto california 94304 1885 electron mail internet kiilen scrdestanford.edu sive ng deliv gener medic practic con junction counsel intervent british thorac societi 1983 hugh gust keenan fenwick healei 1989 nicotin patch tnp studi examin efficaci minim contact treatment combin thor oughli recent meta analyt review fior smith jorenbi 1994 conclud 14 17 publish tnp studi includ signific degre counsel individu group fior al review high intens behavior treatment fold higher abstin rate end treatment ng tnp purchas prescript result psychologist health care profession involv smoke cessat treatment lose con trol nrt product consum addit advent manag care heavi emphasi cost contain erod clinician abil provid specif instruct proper nrt supervis applic behavior chang skill prudent focu resourc develop cost effect behavior intervent pro vide stand adjuv nrt treatment nicotin depend benowitz 1993 date compar publish report control trial examin nrt combin treat ment program balanc result studi support strong case us nrt behavior treatment combin studi lando colleagu found smoker ng booklet receiv ng coupl inform pamphlet lando kalb mcgovern 1988 similarli studi conduct group combin ng behavior procedur superior ng prevent smoke relaps fortmann killen 1995 killen fortmann man varadi 1990 recent placebo control investig smoker receiv tnp placebo coupl materi telephon counsel activ tnp produc abstin rate 20.5 6 month follow 663 664 killen fortmann davi varadi abstin rate placebo condit 2.5 westman levin rose 1993 com.ibm.drl.hbcp.core theoret proposit underli behavior treat ment smoke cessat smoker requir regula tori skill cope nonpharmacolog factor maintain cigarett smoke precipit relaps lich tenstein glasgow 1992 research smoker attempt quit treatment format fail acquir skill effect curri 1993 curri marlatt gordon baer 1988 glasgow schafer o'neil 1981 gritz al 1988 regulatori skill acquir effici model intervent promot enact masteri experi enc bandura 1986 ciinic base behavior treatment base social learn principl promot skill acquisit live model displai therapist guid rehears direct applic newli acquir skill bandura 1986 killen al 1984 lichtenstein glasgow 1992 ste ven holli 1989 contrast intervent includ earlier effort reli print base materi i. manual quit kit facilit train curri 1993 glynn boyd gruman 1990 poor perform treatment enabl acquisit regulatori skill reflect part weak method pro duce masteri behavior intervent cou pled nrt product counter market aim studi explor video aid skill train provid context smoke cessat program interest video deriv theori evid suggest visual media effect text format deliveri intervent base model principl rosenth bandura 1978 ro senthal zimmerman 1978 salomon 1979 human behavior learn observ mod el bandura 1986 live demonstr text video film displai varieti media model inform rule behavior behavior chang instruct effect process observa tional learn bandura 1986 visual media effect text format deliveri model intervent visual media effect activ subprocess govern observ learn rosenth bandura 1978 rosenth zimmerman 1978 salomon 1979 video enhanc attent motiv process model behavior function viewer portrai model interest retent model inform relat charac terist model perform inform pro cess strategi viewer retent enhanc model explain rule guid behavior complex behavior divid compon part divers creativ cope behavior model varieti situat respect retent inform product model behavior video mod el displai effect prompt viewer engag activ inform process enhanc retent model inform abil reproduc behavior maibach flora 1993 elect test video enhanc intervent studi hope operation social learn principl effect print base approach studi design explor primari hypothes hypothesi tnp produc significantli higher abstin rate placebo follow hypothesi video enhanc treatment manual produc higher abstin rate follow print base manual respect hypoth esi goal develop intervent coupl nrt compar easi dissemin includ theoret im portant compon difficult implement print base intervent examin treatment efficaci random 424 particip placebo control 2 2 factori design includ nrt behavior treatment factor method design total 424 smoker 214 men 210 women random 2 2 fulli cross factori experi pharmacolog factor contain level tnp 21 mg placebo patch treatment factor contain level video enhanc manual manual assign patch condit dou ble blind particip receiv print base treatment manual gener consensu nrt coupl behavior intervent counter market includ intervent recruit particip program announc local newspap interest smoker 18 year instruct telephon program offic locat san jose california baselin interview con duct time initi telephon contact collect background inform determin elig complet baselin telephon interview caller want particip schedul initi offic visit visit particip random treatment condit sign written consent form complet questionnair assess batteri receiv instruct tnp exclusionari criteria baselin telephon interview potenti particip ask seri medic question assess elig tnp treatment individu pregnant lactat receiv activ treatment cancer peptic ulcer diseas exclud studi report histori heart diseas recent chest pain diabet thyroid diseas ask obtain written permiss particip physician provid detail letter physician explain natur studi food drug administr caution transderm nicotin variabl measur initi baselin telephon interview addit basic demograph medic statu question inform obtain initi telephon contact cigarett smoke cessat 665 smoke histori aspect current past smoke behav ior assess i. cigarett smoke dai prior quit attempt number year smoke ag began smoke cigarett brand modifi fagerstrom toler questionnair fagerstrom tol eranc questionnair ftq fagerstrom 1978 recent revis fagerstrom test nicotin depend ftnd heatherton kozlow ski frecker fagerstrom 1991 develop research clinician categor smoker degre nicotin depend fagerstrom schneider 1989 modif ftq entail rescal item provid respons choic analyz daili cigarett consumpt separ killen al 1990 question includ modif refer aspect individu cigarett consumpt pattern difficulti refrain smoke forbidden smoke morn smoke bedridden ill depth inhal time awaken smoke cigarett score modifi ftq rang 5 25 good test retest reliabl establish modifi instru ment studi test retest correl question 78 71 83 79 90 previous document valid measur demonstra ting predict crave 8 week period magnitud relationship compar report biochem indic tobacco smoke intak killen fortmann newman varadi 1991 person characterist person characterist assess ag gender race marit statu employ statu educ reliabl telephon interview test retest reliabl telephon interview question medic histori smoke histori modifi ftq person characteri tic previous establish pilot studi 57 smoker killen al 1990 pearson correl calcul smoker respons item time 1 time 2 mean interv assess 15.5 dai adequ stabil survei respons 70 observ question subsequ drop interview treatment analys present articl hypothes concern ing variabl secondari primari hypothes fore examin futur report variabl measur 2 6 12 month follow up particip return studi center follow 2 month provid expir air sampl analysi carbon monoxid level saliva sampl cotinin determin addit estim number time watch video refer treatment manual intervent contact particip telephon 6 12 month follow up determin smoke statu puff cigarett 7 consecut dai preced phone contact ask visit survei center provid saliva sampl cotinin determin variabl measur treatment research staff contact particip telephon 24 hr 1 week 1 month treatment assess smoke statu side effect crave patch biochem assess nonsmok statu follow assess examin saliva cotinin concentr 2 month assess expir air measur wear patch measur perform ecolyz energet scienc york collect saliva sampl particip hold dental roll mouth satur luepker pechacek murrai 1981 cotinin concentr measur studi method jacob wilson benowitz 1981 definit abstin abstin defin report nonsmok puff 7 consecut dai contact saliva cotinin level 20 ng ml level 9 part million ppm variabl measur initi offic visit variabl assess initi offic visit crave nrt design promot smoke cessat relaps prevent prevent reduc crave abstin effect nicotin withdraw examin relat ship crave tnp measur crave baselin point treatment obtain crave score base item felt crave cigarett felt strong urg smoke averag item item particip rate 6 point scale upset crave urg depress symptom depress symptom measur 20 item center epidemiolog studi depress scale ce instrument develop studi epidemiolog depress symptomatolog gener popul scale high intern consist radloff 1977 bodi mass index bmi bmi gener consid prefer index rel bodi weight reflect adipos kraemer berkowitz hammer 1990 bmi comput kilo gram divid squar meter height weight record standard balanc beam scale particip remov shoe jacket addit heavi cloth measur depress symptom bmi includ respons definit relaps particip report date relaps return smoke relaps date defin dai particip smoke 7 consecut dai ossip klein bigelow curri hall kirkiand 1986 reclassif procedur particip area time assess report abstin fail provid breath saliva sampl relev biochem confirm classifi smoker treatment treatment particip receiv manual design develop regulatori skill resist urg smoke manual high risk situat typic en counter smoker coupl strategi cope successfulli urg smoke riski situat manual provid space particip record cope strategi situat depict high risk situat specif 666 killen fortmann davi varadi particip instruct complet manual quit smoke review treatment practic cope strategi leav studi center particip ask complet plan action detail situat expect riski cope strategi addit treatment manual half particip receiv 20 min video design enhanc efficaci manual present viewer charact model specif concret regulatori skill cope riski situat resort smoke give viewer opportun cognit rehears skill model video charact video fiction realist charact exp rienc dai struggl manag cigarett success model intervent depend part model similar target audienc care select repres charact place realist set situat viewer observ charact confront situa tion smoker identifi riski watch charact cope situat resort smoke viewer instruct place similar situat plan approach manag situat successfulli smoke freez frame viewer develop person scenario learn charact chosen react interspers program testimoni smoker present tip cope strategi work particip view video group 8 10 initi offic visit particip assign video group copi video instruct conjunct manual remaind studi tnp primari treatment phase half particip trial receiv 8 week suppli tnp 21 mg primari treatment phase half receiv placebo particip instruct appli patch 24 hr transderm system provid cost particip report irregular intermitt smoke quit dai allow continu medic provid continu quit smoke return regular smoke treatment instruct discontinu return patch particip remain studi ascertain respons variabl analyz intent treat tnp titrat phase titrat phase introduc begin week 9 particip tnp receiv 14 mg week 9 12 7 mg week 13 16 particip placebo condit wore placebo patch titrat phase concomit medic chronic medic studi drug permit ted drug document dose indica tion date initi discontinu dose record safeti side effect side effect assess telephon weekli basi report difficulti remind proper tnp applic skin respons mild irrit erythema prompt withdraw patch referr person physician primari statist analysi primari statist analysi direct test main hypothes studi tnp video enhanc behavior treatment manual improv abstin rate result lower relaps rate logist analysi test statisti cal signific differ abstin treatment group 2 6 12 month follow up separ model fit follow point biochem confirm smoke statu depend variabl patch tnp placebo video statu video manual manual independ variabl ana lyze 12 month relaps curv surviv analysi cox proport hazard model time relaps depend vari treatment condit independ variabl wald chi squar valu report logist analys sa logist cox proport hazard analys sa phreg log rank chi squar valu surviv curv analys sa lifetest reader note rate surviv analysi higher abstin rate design abstin particip report smoke 7 consecu tive dai surviv analysi particip consid relaps report smoke 7 consecut dai resu compar studi group tabl 1 compar treatment condit number baselin variabl show import differ al particip placebo group slightli younger treatment condit reclassif report nonsmok 75 69 provid bio chemic confirm 6 12 month rate differ reatment group note fail ing provid confirm reclassifi smoker 12 month exact number unverifi report group tnp video manual 14 tnp manual 17 placebo video manual 14 placebo manual 14 6 month follow 6 report nonsmok san francisco bai area unabl assess person 12 month follow 4 report nonsmok bai area logist analysi logist analysi patch video factor covari examin abstin rate 2 6 12 month follow up abst inenc rate treatment condit present tabl 2 2 month tnp produc higher level abstin 3 6 placebo 2 0 xe 1 424 13.57 001 odd ratio 2.26 95 confid interv ci 1.45 3.50 comparison signific video enhanc efficaci treatment manual follow video produc lower abstin rate 6 month 1 424 3.95 05 0.60 95 ci 0.36 0.99 surviv analysi cox proport hazard analysi examin im relaps dai particip smoke 7 consec cigarett smoke cessat 667 tabl 1 comparison baselin variabl treatment condit variabl placebo tnp placebo video tnp video sd cigarett smoke dai 22.52 7.78 23.05 8.33 23.69 9.71 24.84 10.23 27 modifi ftq 17.14 3.50 16.63 3.95 16.68 3.37 16.70 3.66 71 depress ce 13.59 9.66 11.87 8.61 12.30 9.67 13.62 9.44 41 bmi kg 2 26.14 4.48 25.85 5.03 26.22 5.30 27.33 6.10 18 ag year 42.21 10.36 44.84 10.87 46.89 12.34 47.47 11.21 002 educ year 13.66 2.28 14.46 2.35 14.45 2.74 14.10 2.24 06 gender male 48 50 51 52 94 marri 41 42 44 50 51 white 80 83 81 84 81 sampl size 104 103 108 109 note tnp nicotin patch ftq fagerstrom toler questionnair ce center epidemio logic studi depress scale bmi bodi mass index utiv dai 12 month patch condit video condit independ variabl short term receiv tnp significantli relaps receiv placebo x2 1 424 11.56 001 hazard ratio 1.45 95 ci 1.17 1.80 shown figur 1 tnp group separ placebo group earli surviv curv converg 6 month follow log rank x2 1 424 12.03 001 contrast relaps rate video manual group manual group significantli log rank x2 1 424 3.26 10 result surviv curv group present analysi complianc treatment instruct conduct secondari analysi examin effect treatment protocol complianc relaps assess complianc patch treatment protocol 24 hr 1 week 1 month 2 month research assist queri particip telephon patch particip consid fulli compli ant assess respond question wear patch definit 44 tabl 2 percentag particip report smoke 7 dai biochem confirm 2 6 12 month follow up treatment condit 2 6 12 6 12 condit month month month month tnp manual 41 25 20 15 tnp manual video 31 16 14 7 placebo manual 18 18 14 10 placebo manual video 21 12 10 10 note tnp nicotin patch 2 month logist model show signific main effect tnp x2 1 424 13.27 001 6 month logist model show signific main effect video condit x2 1 424 3.95 05 percent abstin 6 12 month particip tnp condit 22 particip placebo patch condit fulli compliant x2 1 424 23.47 001 2 month follow particip ask time watch video refer treatment manual mean number manual referr 5.08 sd 6.43 mean number addit tape view 2.64 sd 4.99 signific differ mean manual video group variabl highli correl 54 001 mean number manual referr index complianc manua video treatment instruct complianc analysi stepwis cox proport hazard analysi exam in time relaps treatment condit treatment pro tocol patch manual complianc statu includ indepen dent variabl 2 month patch complianc statu 2 1 410 37.0 001 patch treatment condit x2 1 410 13.68 001 enter model 6 month patch complianc statu enter model x2 1 410 39.40 001 12 month patch complianc statu enter model x2 1 410 33.64 001 surviv curv displai effect patch condit patch complianc statu present figur 2 curv significantli x2 3 424 40.84 001 evid complianc independ patch treatment condit import effect relaps effect tnp crave particip smoke tele phone call conduct 24 hr 1 week 1 month ask report current level crave crave level present figur 3 assess pare crave level tnp placebo condit crave level 24 hr 001 1 week 05 significantli lower assign receiv tnp signific differ report crave level group 1 month assess 668 killen fortmann davi varadi q3 13 1 o0 90 8 0 70 60 50 40 30 20 10 0 eoe activ patch ooii abeelp llw el ool mll e_ wllm mmmu wwmmee placebo patch 1 o0 200 300 401 dai figur 1 relaps regular smoke daili 1 week 1 year random compar activ nicotin patch placebo patch treatment group respons treatment analysi examin variabl predict respons treatment repeat relaps analysi data partici pant assign tnp group main effect video enhanc examin respons treatment group investig respons treatment stepwis multi variat cox proport hazard model 01 criterion entri independ variabl list tabl 1 level nicotin depend measur modifi ftq relaps higher nicotin depend score baselin relaps sig nificantli higher rate baselin 12 month follow x2 1 209 7.32 01 hazard ratio 1.05 95 ci 1.01 1.10 illustr surviv curv modifi ftq quartil present figur 4 12 month follow surviv nonrelaps rate quartil quartil 1 35 quartil 2 21 quartil 3 18 quartil 4 13 efficaci blind 6 month follow particip ask guess treatment assign seventi percent receiv tnp guess correctli compar 64 assign placebo condit x2 1 384 60.26 001 discuss studi design explor primari hypothes hypothesi tnp produc significantli higher abstin rate placebo follow hypothesi partial confirm 2 month follow abstin rate group receiv tnp 36 compar 20 assign placebo condit result statist signific abstin rate produc tnp placebo 6 12 month follow up significantli surviv analysi reveal common pattern relaps surviv curv separ earli relaps occur precipit tnp group superior tnp placebo promot smoke cessat strike earli treatment 14 particip tnp group relaps end week compar 30 placebo condit unlik earlier work ng surviv curv converg 6 month mark maintain degre separ result compar tnp studi fact perform smoker tnp group end treatment perform smoker number tnp trial similar 6 month follow fior al 1994 pool data 17 doubl blind placebo control tnp studi publish cigarett smoke cessat 669 100 90 8 0 70 6 0 50 40 activ compli placebo compli 30 20 activ compli 10 plocebo compli 0 1 o0 200 300 400 dai figur 2 relaps regular smoke daili 1 week 1 year random compar compli compli activ placebo patch ta'eat instruct septemb 1993 provid inform mag nitud effect tnp combin abstin rate activ group placebo group compar group end treatment 6 month follow mean biochem confirm abstin rate tnp user 5 4 3 2 chang level crave 24 hr 1 week 1 month figur 3 mean crave level assess telephon call complet 24 hr 1 week 1 month postrandom tnp nicotin patch 27 end treatment 22 6 month compar 13 9 placebo fior al 1994 figur studi 36 21 tnp versu 20 15 placebo gener abstin rate achiev tnp studi similar rate produc tnp studi appear particip placebo group studi counterpart investig complianc treatment instruct import medi ator treatment outcom obstacl success nicotin replac ng smoker fail compli instruct chew gum advent tnp promis higher complianc due part eas complianc analys frequent miss report ef ficaci studi evid complianc tnp proto col complet larg trial 1,600 smoker half discontinu patch fore end 12 week intervent imperi cancer search fund gener practic group 1993 investig report substanti deviat tnp treatment protocol kozak fagerstrom 1995 westman al 1993 studi complianc protocol govern patch incomplet full complianc 44 22 tnp placebo condit secondari analysi relationship complianc relaps produc interest result full complianc tnp 670 killen fortmann davi varadi 100 9 0 8 0 7 0 6 0 5 0 30 20 10 0 1st quartil ftq 4th 0 1 o0 200 300 oq dai figur 4 relaps regular smoke daili 1 week quartil modifi fagerstrom toler questionnair ftq score protocol produc lower short term relaps rate result lead reason conclus proper medica tion produc treatment effect 6 month mark perform particip placebo patch instruct match perform fulli compliant activ patch user find mean surpris remind psycholog factor effort commit hap expect import role plai effort alter behavior govern psycholog biolog factor gottlieb killen marlatt taylor 1987 question tnp address analys analysi focus effect nicotin replac crave scientif term crave fire primarili common languag origin addict research deem crave unsuit term scientif theori highli subject natur wise 1988 banish crave make strong case word describ strong desir drug kozlowski wilkinson 1987 critic tobacco research sert import crave mainten smok ing habit west schneider 1987 suggest crave potenti import featur cigarett withdraw 407 russel 1988 refer crav ing urg smoke fundament difficult problem smoker quit 68 work shown initi crave cessat import com.ibm.drl.hbcp.predictor smoke relaps killen fort mann kraemer varadi newman 1992 killen al 1991 rational nrt allevi crave abstin effect influenc relaps amin effect tnp crave studi compar report crave obtain period telephon call particip report abstin time tele phone contact previou work crave observ diminish trial refrain smoke assign receiv tnp report signifi cantli lower level crave call made 24 hr 1 week postrandom crave level tnp placebo group converg 1 month contact tnp produc signific short term effect conduct analysi determin variabl fluenc respons treatment tnp group modifi ftq com.ibm.drl.hbcp.predictor relaps studi 35 score lowest quartil surviv month 12 compar 13 score highest quartil ftq ftnd develop research clinician categor smoker degre nicotin depend fagerstrom schneider 1989 heath erton al 1991 instrument assum nicotin depen denc relat drug num ber cigarett dai nicotin yield brand effect drug smoke awaken sleep plasma nicotin level mini cigarett smoke cessat 671 mal degre cigarett dai judg satisfi result crave relief intern stimulu control rel extern control fag erstrom schneider 1989 find strong associ ftq score relaps add increas bodi evid reveal nicotin depend import media tor treatment respons rais question depen denc account gener smoke cessat treatment hypothesi guid research video enhanc intervent produc higher absti nenc rate follow print base treat ment manual hypothesi confirm account failur video intervent enhanc manual varieti secondari anali se examin complianc data report help materi fail provid conclus answer question work increa ingli clear skill train intervent suit intervent format elimin minim opportun guid problem identif train skill masteri achiev interven tion model guid rehears direct ap plicat newli acquir skill bandura 1986 accu rate identif problemat situat specif skill chosen train time allot train practic individu perceiv level person masteri adjust train schedul requir match individu perform accomplish variabl influenc skill acquisit perform video power medium provid model demonstra tion supervis guidanc afford intens clinic base skill train intervent unavail treatment format social learn perspect analysi treatment efficaci question treatment method induc behavior chang gener aliz situat respons system maintain time bandura 1969 analysi appli field smoke cessat nrt improv abil produc smoke cessat product sustain longer term abstin remain elus goal smoke cessat treatment program combin nrt intens clinic base behavior inter vention achiev measur success regard access intens program limit case smoker unwil commit treatment effort continu creativ research effort need develop gener intervent capabl produc generaliz durabl treatment effect
random trial smoke cessat intervent hospit patient yve lacass réjean lamontagn sylvi martin serg simard mari arsenault receiv 9 novemb 2006 accept 12 juli 2007 hospit time perceiv vulner danger smoke quit motiv peak aim determin smoke cessat intervent moder intens increas smoke cessat rate hospit smoker design random trial conduct univers affili cardio pulmonari tertiari care center particip hospit smoker ag 70 year intervent smoke cessat intervent consist educ psycholog support pharmacolog therapi follow phone call patient assign control group receiv usual care measur point preval cessat rate 1 year follow total 468 patient screen 196 random smoke cessat rate 12 month follow higher expect found signific differ studi group intervent 30.3 control 27.8 similar result obtain patient smoke statu valid urinari cotinin assai length stai depend nicotin signific com.ibm.drl.hbcp.predictor smoke cessat smoke cessat intervent moder intens deliv tertiari cardio pulmonari center increas smoke cessat rate 1 year follow result trial divert deliv care inpati deliv smoke cessat intervent introduct rational smoke cessat intervent inpati hospit window opportun emmon goldstein 1992 time perceiv vulner danger smoke quit motiv recept smoke cessat intervent peak smoker hospit condit caus complic smoke orlean kristel gritz 1993 trial smoke cessat intervent hospit patient result increas cessat rate specif popul acut myocardi infarct taylor houston miller killen debusk 1990 debusk al 1994 lesser extent undergo elect surgeri simon solkowitz carmodi browner 1997 result gener patient hospit tertiari care center remain uncertain report result random trial conduct cardiothorac hospit compar effect smoke cessat intervent moder intens usual care wish determin intervent consist educ psycholog support pharmacolog therapi follow phone call increas cessat rate 1 year follow hospit smoker ag 70 hypothesi intervent effect increas 1 year cessat rate 10 absolut differ issn 1462 2203 print issn 1469 994x onlin 2008 societi research nicotin tobacco doi 10.1080 14622200801979142 yve lacass m.d m.sc sylvi martin m.sc serg simard m.sc centr de recherch centr de pneumologi hôpit laval institut universitair de cardiologi de pneumologi de l’université laval québec canada réjean lamontagn m.a pavillon de prévent de maladi cardiaqu hôpit laval institut universi tair de cardiologi de pneumologi de l’université laval québec canada mari arsenault m.d centr de recherch institut de cardiologi hôpit laval institut universitair de cardiologi de pneumologi de l’université laval québec canada studi carri laval hospit correspond yve lacass centr de pneumologi hôpit laval 2725 chemin ste foi ste foi quebec g1v 4g5 canada tel 418 656 4747 fax 418 656 4762 mail yves.lacass med ulaval.ca nicotin tobacco research volum 10 number 7 juli 2008 1215 1221 nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org method clinic set studi popul random trial conduct laval hospit quebec heart lung institut referr 307 bed center tertiari care cardiolog respiratori medicin gener intern medicin cardiac surgeri thorac surgeri gener surgeri studi protocol receiv approv hospit research ethic committe patient recruit januari 1 2004 decemb 31 2005 fulfil criteria elig current smoker ag 70 anticip durat hospit 36 hr patient contempl prepar action stage chang prochaska diclement 1983 exclus criteria refus particip patient precontempl stage chang patient hospit alcohol drug abus critic termin ill patient disord sever short term prognosi intervent smoke cessat intervent tailor model assum smoke involv physiolog addict psycholog depend nicotin tobacco depend clinic practic guidelin panel 2000 basic compon includ strong quit smoke messag treat physician motiv quit relaps prevent materi cessat counsel ing pharmacolog adjunct follow support intervent typic involv step 5 smoke initi step involv 5 min assess smoke histori degre physic addict quit motiv i. patient stage chang determin prochaska definit item prochaska goldstein 1991 advis quit physician practic laval hospit instruct trial smoke cessat intervent ongo hospit remind fluoresc remind sticker chart patient assign intervent group advis stop smoke messag reinforc counselor interven tion session assess willing quit patient interview belief behavior relat smoke past experi smoke cessat assist smoker stop smoke conclud 10 20 min intervent session 15 min session counselor assist patient smoke cessat process intervent base bandura efficaci theori bandura 1982 efficaci refer person convict peopl feel successfulli execut behavior order produc outcom higher level induc efficaci higher formanc accomplish patient taught monitor smoke habit observ condit smoke occur reward success effort efficaci achiev guid practic correct feed back simul high risk situat hospit discharg creation social support desir person encourag nicotin replac therapi nrt transder mal nicotin patch offer patient level depend tobacco depend clinic practic guidelin panel 2000 nrt reduc nicotin withdraw symptom contempl prepar stage chang nrt continu discharg total 8 week jorenbi al 1999 enter action stage hospit nrt advers effect patient activ heart diseas joseph al 1996 work group studi transderm nicotin patient coronari arteri diseas 1994 consid risk benefit patient 4 week post myocardi infarct period arrhythmia sever worsen angina pectori tobacco depend clinic practic guidelin panel 2000 final decis nrt left treat physician initi dosag nicodermh glaxosmithklin 21 14 7 mg id sever depend arrang follow 6 week hospit discharg patient random intervent group contact tele phone time zhu al 1996 therapist deliv inpati smok ing cessat intervent provid continu support advic relaps prevent phone call schedul 7 14 30 45 dai discharg quit date time phone call last 10 min usual care patient group receiv usual care specif instruct stop smoke contact patient control group studi personnel limit 1216 smoke cessat intervent hospit patient nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org obtain measur baselin 6 month 1 year follow measur outcom primari outcom point preval abstin 1 year follow primari outcom trial report abstin record 6 month 1 year follow telephon contact report smoke statu 1 year follow valid urinari cotinin assai jarvi tunstal pedo feyerabend vesei salooje 1987 bramer kallung 2003 doubl antibodi nicotin metabolit diagnost product corpor markham ontario measur administ short que tionnair studi entri level nicotin depend measur fagerström test nicotin depend item intern consist questionnair close relat biochem indic heavi smoke heatherton kozlowski frecker fagerstrom 1991 order measur intens tobacco withdraw select questionnair smoke urg tiffani drobe 1991 32 item questionnair valid reliabl provid independ investig willner hardman eaton 1995 measur efficaci velic scale valid reliabl instrument specif smoke cessat area velic diclement rossi prochaska 1990 final limit scl 90 depress domain derogati cleari 1977 studi protocol patient admit hospit 24 hr locat hospit admiss servic elig accept particip immedi assign intervent control group hospit pharmacist tabl random number random intervent group cessat intervent began immedi baselin data collect except surgic patient intervent deliv pre postop time surgeri patient condit order minim bias 6 month 12 month follow outcom assess short standard close questionnair research assist patient group alloc urinari spot collect 1 year follow coincident visit treat physician mail studi offic seal test tube statist analysi primari analys baselin characterist pare unpair test continu variabl fisher exact test categor variabl weight kappa statist measur concord report smoke statu valid urinari cotinin kramer feinstein 1981 report cessat rate 6 month 1 year follow group absolut rate differ 95 confid interv ci absolut rate differ comput number need treat nnt i. number patient receiv intervent order obtain success event laupaci sackett robert 1988 provid 95 ci nnt altman 1998 separ analys conduct analysi involv patient follow analysi includ lost follow patient count continu smoker end trial analysi consid smoke statu valid urinari coti set statist signific 0.05 level side secondari analys com.ibm.drl.hbcp.predictor smoke cessat 1 year follow investig influenc demograph pretreat smoke characterist likelihood smoke cessat 1 year follow conduct logist regress analys depend variabl consist abstin rate 1 year follow sampl size order decid differ cessat rate trial detect introduc concept nnt health care provid patient smoke cessat clinic staff member agre nnt 10 correspond absolut differ smoke cessat rate 1 year follow intervent usual care group 10 comput sampl size 366 patient 183 group need plete trial expect smoke cessat rate 1 year follow control group 16 glasgow steven vogt mullooli lichtenstein 1991 side alpha error 5 power 80 analys run intent treat principl interim analysi plan interim analysi half need sampl size complet studi stop rule state priori trial stop treatment effect reach signific 0.001 level side haybittl 1971 95 ci observ nnt exclud target nnt 10 nicotin tobacco research 1217 nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org result patient trial profil depict figur 1 468 patient screen 335 deem elig 196 random found differ baselin characterist subject group except previou quit attempt intervent group higher smoke indic control group tabl 1 differ small clinic irrelev intervent 99 patient alloc intervent group receiv quit smoke messag treat physician motiv quit relaps prevent materi cessat counsel eighteen receiv nicotin replac therapi averag patient 1.4 follow phone call discharg follow call 1 month discharg median 37 dai primari analysi smoke cessat rate concord report smoke statu valid urinari cotinin good kappa 0.74 95 ci 0.60 0.88 tabl 2 12 month follow 30 99 patient alloc intervent group report stop smoke includ 11 18 patient receiv nrt hospit time 27 97 control patient quit intervent result signific increas smoke cessat rate 6 month 1 year follow tabl 3 differ cessat rate comput nnt exceed accept threshold 10 decid priori base find made decis stop trial interim analysi declar intervent ineffect com.ibm.drl.hbcp.predictor smoke cessat identifi signific com.ibm.drl.hbcp.predictor smoke cessat 1 year follow longer stai hospit higher likelihood abstin 1 year odd ratio dai hospit 1.06 95 ci 1.01 1.12 depend nicotin nonsmok 12 month follow unit fageström score 0.82 95 ci 0.71 0.96 com.ibm.drl.hbcp.predictor remain signific multivari analysi discuss random trial smoke cessat intervent moder intens deliv figur 1 trial profil 1218 smoke cessat intervent hospit patient nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org tertiari cardiopulmonari center increas smoke cessat rate 1 year follow stop trial plan interim analysi reveal nnt exceed accept threshold 10 decid priori width observ confid interv differ cessat rate relat threshold nnt clear indic sampl size trial explain neg result goodman berlin 1994 nrt offer patient allo cate intervent group import tabl 1 baselin characterist studi particip characterist intervent group n599 control group n597 ag year 52 9 52 10 0.4 gender male 64 68 0.3 educ year 10 3 10 3 0.5 live 31 36 0.2 work 59 58 1.0 smoke histori cigarett dai 20.4 12.6 22.8 9.4 0.04 pack year 35 24 41 22 0.02 number previou attempt quit smoke 2.4 2.2 2.0 2.2 0.04 stage chang contempl 7 6 prepar 90 94 action 2 0 0.6 hospit cardiolog 63 65 acut myocardi infarct 35 22 62 44 28 63 unstabl angina 47 29 62 33 21 63 heart failur 5 3 62 5 3 63 heart diseas 13 8 62 18 11 63 respiratori medicin 27 18 obstruct lung diseas 56 15 27 47 8 17 pneumonia 22 6 27 18 3 17 lung diseas 22 6 27 35 6 17 10 18 0.07 length stai dai 8 6 8 7 0.9 surgic procedur hospit 11 18 0.1 ftnd 0 10 5.1 2.2 5.5 2.2 0.1 efficaci 1 5 3.0 0.8 3.0 0.7 0.5 questionnair smoke urg 1 7 2.1 1.4 1.8 1.1 0.1 scl 90 depress 0 4 0.7 0.6 0.7 0.7 0.8 note ftnd fagerström test nicotin depend tabl 2 concord report valid smoke cessat rate valid smoke cessat rate totalsmok smoker report smoke cessat rate smoker 57 3 60 smoker 8 27 35 total 65 30 95 note cutoff point 200 ng ml discrimin smoker smoker bramer al 2003 tabl 3 comparison smoke cessat rate intervent usual care group time follow smoke cessat rate absolut differ 95 ci number need treat limit 95 ci intervent group usual care group 6 month follow report smoke cessat rate 29 90 32.2 27 90 30.0 2.2 24.0 8.5 45 12 report smoke cessat rate 29 99 29.3 27 97 27.8 1.5 24.3 7.2 69 14 1 year follow report smoke cessat rate 30 85 35.3 27 86 31.4 3.9 22.9 10.6 27 10 report smoke cessat rate 30 99 30.3 27 97 27.8 2.5 23.3 8.2 41 13 smoke cessat rate valid urinari cotinin measur 15 46 32.6 17 49 34.7 22.1 211.1 6.9 15 note analysi involv patient follow analysi involv patient lost follow patient count continu smoker nicotin tobacco research 1219 nivers berdeen januari 20 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org observ 18 patient 99 receiv patient refus nrt argu cope withdraw symptom adjunct therapi barrier prescript nrt reluct physician provid patient activ heart condit risk side effect substanti trial specif addr sing issu joseph al 1996 work group studi transderm nicotin patient coronari arteri diseas 1994 method fill gap evid practic belong knowledg transfer davi al 2003 intervent transfer evid practic studi grol grimshaw 2003 strategi includ educ intervent remind multi profession collabor combin intervent demon strate limit effect modifi physician behavior knowledg transfer smoke cessat intervent repres import area research result agreement recent meta analysi smoke cessat intervent hospit patient rigotti munafo murphi stead 2002 meta analysi intervent categor level intens includ follow discharg categori 1 minim intervent follow support categori 4 hospit contact follow 1 month classifica tion intervent fall categori 3 hospit contact follow 1 month meta analysi control trial categori 3 intens found increas smoke cessat rate rel risk 1.09 95 ci 0.91 1.31 random trial includ rigotti meta analysi pool abstin rate 12 month follow control group 13 rigotti al 2002 trial abstin rate control group 12 month follow 30 potenti explan patient cardio vascular diseas repres 60 studi popul higher cessat rate year hospit ocken al 1992 ortigosa al 2000 altern explan observ cessat rate control group indic form intervent alloc usual care group health care provid physician nonphysician work cardiorespiratori center integr advic smoke cessat part usual care intervent signific effect smoke cessat lancast stead 2004 mojica al 2004 note rigotti meta analysi categori 4 intervent signific increas quit rate rigotti al 2002 emphas point sustain follow support hospit discharg kei element success smoke cessat interven tion initi patient hospit random trial publish rigotti meta analysi reinforc statement quist paulsen gallefoss 2003 identifi signific com.ibm.drl.hbcp.predictor smok ing cessat 12 month follow nicotin depen denc length stai previou studi com.ibm.drl.hbcp.predictor smoke cessat hospit conduct patient admit cardiovascular event bolman de vri van breukelen 2002 dornela sampson grai water thompson 2000 hajek taylor mill 2002 ong cheong prabhakaran earnest 2005 rigotti mckool shiffman 1994 taylor al 1990 result conflict find smoke cessat predict nicotin addict constant empha size import nrt identifi efficaci dornela al 2000 taylor al 1990 intent quit bolman al 2002 hajek al 2002 rigotti al 1994 initi hospit ong al 2005 signific com.ibm.drl.hbcp.predictor variabl design individu intervent conclud smoke cessat interven tion moder intens deliv institut ineffect increas cessat rate 12 month follow hospit patient result trial divert deliv care inpati deliv smoke cessat intervent studi smoke cessat intervent higher intens high risk patient high level nicotin depend short stai hospit need nrt integr part intervent acknowledg author dr wilfrid pilon centr de recherch université laval robert giffard université laval ginett turbid rn msc chantal gosselin msc cliniqu d’aid aux fumeur pavillon de prévent de maladi cardiaqu hôpit laval institut universitair de cardiologi de pneumologi de l’université laval assist design implement intervent
british journal gener practic march 1999 191 origin paper tim lancast wendi dobbi katrina vo patricia yudkin mike murphi godfrei fowler summari background advic stop smoke gener practition gp repeatedli shown increas smoke cessat small measur amount studi suggest ad intens intervent advic increas effect unclear true gener practic aim determin advic doctor counsel follow train prac tice nurs effect advic ing peopl stop smoke method design random control trial hundr nineti gener practic patient ag older 18 year smoke cigarett dai gener practic oxfordshir berkshir buckinghamshir random inter vention verbal written advic gp extend counsel follow train practic nurs advic gp primari outcom sustain abstin smoke 12 month secondari outcom forward movement stage chang cycl result proport show sustain abstin 3.6 extend counsel group 4.4 advic group differ 0.8 95 confid interv 4.3 2.6 seventi 30 ran domiz extend counsel offer signific progress stage chang detect ed group conclus unselect gener practic patient smoke advic gp combin intens intervent follow practic nurs effect advic keyword practic nurs smoke advic random control trial introduct public health legisl measur havegreat potenti reduc preval smoke 1 continu assist exist smoker quit survei major smoker stop oxcheck studi patient undergo health check gener practic 76 current smoker regard habit harm quit 2 govern health polici 1990 gener prac tice respons advis treat pop ulat previou research3 5 shown potenti gener prac tice influenc attempt quit smoke question remain effect econom offer ing support smoke cessat primari care advic gp measur small effect cessat rate 3 5 easi deliv intens intervent shown higher success rate 5 difficult doctor implement sustain propos solut devolv smoke cessat prevent work practic nurs orient counsel techniqu import prevent recent research shown effect smoke advic nurs context gener health check 6 7 health messag deliv gener health check dilut support smoke cessat target approach need random trial american health mainten organ approach combin doctor nurs intervent effect doctor interven tion trial target patient consult physi cian larg manag care practic advic physi cian produc sustain quit rate 3.9 12 month rate approxim doubl 7.2 advic suppl ment form nurs run counsel 8 team approach prove sustain popular made low demand provid time model resourc british gener practic set determin support doctor advic nurs run smoke cessat intervent similarli effect british gener practic method conduct studi gener practic oxfordshir buckinghamshir berkshir practic previous state willing particip research practic nurs undertook train counsel smoker quit train consist full dai work counsel lor train motiv techniqu assist quit includ train nicotin replac product train research nurs provid continu support prac tice nurs visit practic monthli studi patient ag 18 year smoke cigarett dai elig enter studi recruit method includ opportunist recruit smoker attend surgeri unrel complaint letter random trial nurs assist strategi smoke cessat primari care lancast msc mrcgp gener practition dobbi bsc research assist vo rgn research nurs yudkin ma dphil statistician murphi msc ffphm deputi director fowler frcp frcgp professor gener practic imperi cancer research fund gener practic research group divis public health primari care institut health scienc oxford submit 23 januari 1998 final accept 30 octob 1998 british journal gener practic 1999 49 191 194 192 british journal gener practic march 1999 lancast dobbi vo al origin paper patient identifi smoker practic record subject receiv advic quit doctor person recruit opportunist letter read letter studi ask complet questionnair smoke habit enter studi complet questionnair random independ statist advis perform random comput gener random number alloc block 20 sequenti seal opaqu envelop open research nurs time recruit addit verbal written advic doctor individu al random intervent invit contact research nurs wish discuss studi receiv health educ author leaflet stop smoke made easier fact sheet nicotin replac therapi random extend counsel invit contact train practic nurs undertak intens counsel tailor initi visit nurs assess motiv quit readi ness chang receiv carbon monoxid breath test person messag health benefit quit intervent person counsel difficulti face stop instruct strategi tackl readi quit encourag set quit date schedul follow visit assess nicotin depend made advic nicotin replac therapi follow visit nurs provid advic port monitor nicotin replac minimum support provid initi 15 minut counsel session offer follow visit wish support follow visit offer 10 minut week initi visit biochem valid smoke cessat 12 month main endpoint shift attitud stop smoke judg stage chang model 9 sec ondari outcom measur stage chang model smok ing cessat consid stage process pre contem plation contempl prepar action mainten process cessat involv movement cycl occur prolong period time sur vei 80 smoker pre action stage 10 propos smoke cessat intervent success move smoker stage cycl abstin achiev order determin intervent effect movement cycl ask question base line follow question previou studi assess readi change8 sampl size calcul detect 5 signific 80 power 10 rate sustain abstin inten sive counsel group assum rate sustain absti nenc advic group 3 target sampl size 259 group obtain ethic approv studi research ethic committe health district studi place follow analysi survei particip postal questionnair 12 month random send remind respond ask report quitter provid saliva sampl cotinin estim salivari cotinin estim perform laboratori clinic trial servic unit oxford consid report quit valid salivari cotinin concentr 113.5 nmol 11 occup determin social class 12 main statist comparison proport sustain abstin group chi squar test test differ proport 95 confid interv calcul analysi basi intent treat patient agre par ticip includ analysi accept ed offer treatment assum subject pro vide follow inform continu smoker result hundr nineti smoker random studi period number pre sampl size hundr 81 complet follow questionnair month 374 75 12 month tabl 1 show baselin characterist random group similar demograph characterist smoke habit tabl 2 show abstin rate month 12 month sustain abstin rate smoke 12 month signific differ proport time point proport show sustain abstin 3.6 extend counsel group 4.4 advic group differ 0.8 95 confid interv 4.3 2.6 cotinin level suggest report quitter group continu smoke adjust quit rate 2.8 extend counsel group 4.0 intervent group thirti cent 74 alloc counsel made appoint fol low treatment cent 6 suc cess quitter 12 month follow tabl 3 show individu move advanc stage readi chang studi signific differ group move closer take action group collaps show forward chang fewer chang extend counsel group differ 5.7 13.2 1.7 discuss follow support smoke cessat gener practic clear previou research studi assess smoke statu report patient offer follow famili physician significantli higher quit rate 13 studi found signific bene fit follow 14 15 recent studi specif effect ad follow visit visit motiv smoker assess biochem valid cessat 16 signific differ group rate sustain abstin year author studi note report quit outcom studi benefit shown smoker time invest truth perceiv failur compli treatment studi similarli cast doubt routin offer intens interven tion includ follow report effect intens intervent greater advic control evalu smoke cessat intervent unselect gener practic popul show small effect effect worthwhil intervent sim ple cost basi continu effort gp mention give advic give smoke 5 british journal gener practic march 1999 193 lancast dobbi vo al origin paper tabl 1 baselin variabl treatment group.a extend counsel group intervent group 249 248 ag mean sd 43 14.2 44 14.2 sex male 111 44.6 128 51.6 femal 138 55.4 120 48.4 social class 7 2.8 11 4.4 ii 79 31.7 79 31.9 iii 44 17.7 42 16.9 iii 43 17.3 56 22.6 iv 38 15.3 26 10.5 11 4.4 7 2.8 unclassifi 27 10.8 27 10.9 marit statu marri 170 68.3 170 68.5 79 31.7 78 31.5 cigarett dai mean sd 17 8.8 17 8.4 number previou attempt quit mean sd 2.3 1 2.3 1 fagerstrom score mean sd 3.5 2.4 3.5 2.2 perceiv health problem relat smoke 88 35 85 34 confid abil chang 125 50.2 116 46.8 strong desir stop 170 68.3 168 67.7 readi chang pre contempl 84 33.7 94 37.9 contempl 116 46.6 116 46.8 prepar 48 19.3 36 14.5 apercentag valid respons number variabl add total miss valu tabl 2 smoke cessat rate treatment group extend counsel intervent 249 248 smoke month 23 9.2 20 8.1 smoke 12 month 17 6.8 28 11.3 smoke month 12 month 9 3.6 11 4.4 smoke month 12 month valid 8 3.3 10 4.0 percentag number random assum lost follow continu smoke tabl 3 chang readi quit treatment group 0 12 month extend counsel intervent move pre contempl contempl 9 3.6 17 6.9 move pre contempl prepar 5 2.0 2 0.8 move pre contempl action cessat 4 1.6 5 2.0 move contempl prepar 21 8.4 19 7.7 move contempl action cessat 9 3.8 15 6.0 move prepar action cessat 4 1.6 8 3.2 forward chang 52 20.9 66 26.6 194 british journal gener practic march 1999 lancast dobbi vo al origin paper intens intervent justifi benefit suffici great larger studi holli al found ad form nurs assist counsel physician advic produc differ quit rate 1 3.7 8 fail detect true effect intens intervent type 2 error direct point estim studi support worst confid interv suggest studi fail detect effect intervent 2.6 40 smoker counsel produc quitter effect pre repres expens option practic wish make team member studi differ holli import studi run larg american hmo patient receiv direct verbal advic doctor quit smoke random intervent pilot strategi gener practic practic maintain continu recruit busi surgeri administr structur prove unsustain maintain recruit combin opportunist approach recruit letter doctor smoker letter contain advic stop forc face face contact individu particip studi vari lev el motiv quit show suffici inter est stop fill questionnair random 65 smoker random extend counsel contempl prepar proce quit plan 30 offer offer quit rate low studi specif set test smoke cessat tai lore stage chang model train nurs includ discuss model infor mation match individu cur rent level motiv found evid intens counsel greater effect advic advanc smoker readi chang intens counsel worthwhil highli motiv individu request stop reach major smoker stop result favour devot primari care resourc intens smoke cessat intervent remain import health care profession deliv er firm consist messag quit smoke patient intervent advic nicotin replacement17 remain cornerston port smoke cessat primari care
telephon support adjunct transderm nicotin smoke cessat harri lando phd sharon rolnick phd mph david klevan md joachim roski ma linda chernei mph gari lauger introduct transderm nicotin deliveri sy tem produc end treatment result superior placebo gener doubl success rate placebo group 8 studi physician counsel individu counsel comprehens group counsel pro gram smoke cessat consi tentli demonstr greater success nicotin patch ad pro gram 2 previou research demon strate physician advic significantli increas quit rate 9 impact physician advic nicotin patch greater consist accord food drug administr recommen dation part comprehens stop smoke program smoker prefer quit attend counsel group program 0 minimum intens smoke cessat program physician support effici gener success ap proach manag care popul type program deliv singl face face session offer group set inform deliv effici low cost 3 singl session limit abil provid tailor intervent address individu patient issu pertain nicotin patch stop smoke inexpens follow option found enhanc treatment effect tele phone support 20 purpos current studi assess effect ness telephon support adjunct physician led orient smoke ce sation adjunct nicotin replac ment therapi nicotin patch hypothes proactiv telephon outreach significantli improv ab stinenc outcom orient session orient session toll free line method subject recruit memo describ studi physician group health minnesota larg midwestern health mainten organ hmo addi tion notic describ studi publish patient newslett individu hmo clinic subject elig elig requir includ ing 18 65 year ag histori smoke minimum 20 cigarett daili 2 year femal subject accept method birth control sexual activ addit subject requir motiv quit smoke reflect rate 7 0 10 scale desir quit 2 exclus criteria includ report posit histori heart diseas harri lando divis epidemi ologi school public health univers minnesota minneapoli joachim roski time studi sharon rolnick david klevan linda chemei group health foundat minneapoli minn gari lauger come pact radnor pa request reprint harri lando phd divis epidemiolog school public health univers minn sota 1300 st suit 300 minneapoli mn 55454 1015 paper accept novemb 15 1996 octob 1997 vol 87 10 telephon support symptomat peripher vascular diseas diabet report histori skin irrit allergi adhes preclud transderm system current recent treatment psychiatr ill chemic depen denci 6 month compl tion treatment current excess alcohol consum drink time week report regular psychotrop medic system steroid antihistamin preg nanci lactat intent pregnant studi current altern form nicotin replac therapi studi staff interview 912 patient studi elig 912 patient 403 elimin major reason exclus 68 17 take antidepress 56 14 smoke fewer 20 cigarett dai 52 13 fail attend orient session 40 10 65 year ag 25 6 reach schedul orient 22 5 report low motiv quit score 7 desir quit scale 19 5 member group health prior random subject smoke averag 27.8 cigarett dai smoke averag 23.4 year substanti percentag subject previou experi nicotin replac 34.8 nicotin gum 12.0 nicotin patch orient session elig particip invit group orient session subject randomli assign condit orient session attend orient session form basi sign up specif date time subject studi condi tion advanc random block design sequenti set orient session includ studi condit studi condi tion group orient session orient session reactiv telephon support subject strongli encourag call telephon hot line oper patch manufac turer orient session reactiv telephon support activ telephon outreach orient session approxim 90 minut dura tion session led group health physician d.k studi coordin l.c orient session subject overview studi explan data collect form instruct proper patch inform side effect relat smoke cessat patch inform provid pertain behavior psycholog issu quit smoke subject en courag question thirti orient session conduct studi goal recruit 500 subject goal reach orient session sched ul 5 sign orient session fail attend ject set quit date strongli encourag set date maximum 2 3 week orient session studi design subject receiv prescript prostep 22 mg nicotin patch wyeth ayerst laboratori radnor pa provid free studi partici pant subject requir fill prescript assign hmo phar maci initi prescript 2 week subject renew prescrip tion addit 4 week option request addit 2 week prescript 11 mg patch standard written materi de scribe patch provid recommen dation provid subject fill prescript 22 subject encourag patch full 6 week experi enc signific side effect engag smoke tobacco group orient subject receiv treat ment addit support packag insert nicotin patch contain inform lederl support servic includ descript toll free telephon line ser vice inform consent sign subject addit prescript nicotin patch subject assign line condit receiv registr card lederl support servic complet turn group orient session toll free support servic number discuss orient session subject strongli encourag call addit previous de scribe intervent compon counsel or telephon call subject assign line outreach condit counselor gain experi place support tele phone call subject smoke cessat studi 7'23 current studi receiv addit instruct materi specif pertain nicotin patch 2'22,24 initi call occur 1 week quit date 4 week 7 9 week fourth 12 week telephon ascertain subject fill prescript prostep reaction problem patch di cuss subject advis consult studi physician event system skin reaction advers event concomit medic record studi form telephon coun selor attempt reinforc success abstin call attempt made negoti quit date subject smoke telephon counselor aid ject identifi person relev cope strategi absti nenc continu mainten ject experienc continu difficulti remain abstin alert local smoke cessat resourc follow questionnair mail subject postag paid turn envelop 2 5 8 12 week quit date purpos follow quit date initi date establish subject true subject negoti quit date addit extens questionnair mail 6 12 month subject quit date subject report nicotin patch quit behavior smoke statu addit rate fill prescript monitor puter pharmaci record subject assign group support servic ask servic subject report abstin 6 month follow schedul carbon monoxid measur verifi report 25 27 particip fail return 2 5 8 week questionnair contact telephon ask effort made contact individu respond questionnair inform respond 12 week questionnair collect telephon total number call nonrespon dent prior 6 month follow american journal public health 1671octob 1997 vol 87 10 lando al limit order reduc potenti confound telephon support telephon assess statist analysi chi squar test dichotom variabl analys vari anc continu variabl determin statist signific mean differ baselin subject characterist treatment differ point preval continu cigarett smoke abstin level follow time point assess mix model logist regress method account correl 35 group randomli assign treatment condit 28 bonfer roni adjust made multipl pairwis comparison sampl size chosen treatment arm base 80 statist power detect true 15 differ 6 month cigarett smoke abstin level treatment group respons rate determin basi respons survei pharmaci record con sult determin patch account determin ing respons rate outcom statu result baselin subject characterist shown tabl 1 fewer women orient session condit condit correct number test perform differ longer signific differ condit term baselin characterist approach stati tical signific kei outcom current studi consid abstin 6 month follow extens effort made contact subject mail telephon point respons rate 6 month 99 respons rate earlier follow up 81 week 2 71 week 5 60 week 8 67 week 12 respons rate 12 month 82 differ respons rate condit nonrespond count smoker purpos data analysi lederl record fewer 1 elig subject call lederl support servic counsel strong encourag pharmaci dispens record averag studi subject fill 5 week 22 mg patch prescript 1 week 11 mg patch prescript differ found group number patch dispens report discontinu patch advers event averag 3.76 4 call complet refus accept call rare total subject combin 0.6 subject reach tele phone 2.5 subject reach 8.1 reach 2 fewer call 13 reach 3 call fewer call averag 10 15 minut durat abstin outcom present tabl 2 3 point outcom differ condit approach statist signific car bon monoxid assess administ 6 month follow tend corrobor subject report 111 subject report 6 month absti nenc 105 96 evidenc carbon mon oxid level cutoff disconfir mation 8 part million29 6 subject exceed criterion count smoker discuss activ telephon outreach pect significantli enhanc effec tive nicotin replac context minim intervent promis result tele phone outreach previous obtain laboratori 7 30 differ abstin outcom treatment condit limit telephon line inten 1672 american journal public health tabl 1 comparison treatment group characterist baselin manag care base smoke cessat program orient line orient orient telephon session line outreach mean mean mean femal 46.6 174 61.3 173 60.5 162 caucasian 97.1 172 98.2 169 96.9 161 colleg educ 46.6 174 45.7 173 43.8 162 emploi full time 79.9 174 78.0 173 76.5 162 cigarett typic dai 27.6 172 28.5 171 27.4 160 past month total year smoke 23.4 174 23.7 173 23.2 162 quit attempt previou 12 1.1 172 1.4 172 1.1 159 month lifetim quit attempt 6.1 168 5.1 172 5.2 157 longest time period 193.7 171 174.2 170 182.4 161 cigarett physician advic quit 81.6 174 76.7 172 82.7 162 particip formal cessat 26.0 173 22.0 173 20.4 162 treatment previou nicotin gum 38.5 174 31.8 173 34.0 162 previou nicotn patch 12.1 174 12.9 171 11.1 162 confid abil quit 8.7 153 8.3 154 8.5 145 24 hour confid abil quit 6.6 168 6.5 164 6.4 154 perman pound desir 15.5 170 17.0 168 14.9 159 weight fagerstrom test nicotin 5.2 174 5.1 173 5.0 162 depend ag 41.3 168 42.9 170 41.6 156 note statist signific mean differ baselin subject characterist determin chi squar test dichotom varabl analys varianc continu variabl unadjust 01 longer signific correct number test perform differ condit baselin characterist approach statist signific prior adjust octob 1997 vol 87 10 telephon support sive promot servic unexpect proport elig smoker reactiv line shown occas small order 1 2 3 studi proport line greater 4 16 short term longer term abstin rate encourag lack differ condi tion 1 2'4'5'32'33 adher nico tine patch gener good nonetheless extens train ing provid telephon counselor telephon call fail enhanc absti nenc outcom distribut free patch factor subject enrol studi anticip receiv patch cost interest treatment compon poor candid telephon port 34 subject recept telephon call tend rate help effort quit smoke failur subject support servic suggest offer type reactiv line limit requir particip current studi stringent particip previou telephon intervent studi poten tial pool 912 subject 403 44 elimin studi 68 17 take antid pressant unlik case prior telephon intervent ject requir attend face face orient session rate motiv quit 5 elimin exclud basi low motiv proactiv telephon outreach effect broader spectrum potenti quitter major subject condit receiv telephon call part follow data collect call patch patch reactiv telephon support group primarili volv request return question nair nonrespond receiv call reactiv effect 35 studi subject discrimin assess call intervent call hand call request retum questionnair collect data deliber limit prior 6 month follow minim contami tabl 2 short term abstin smoke treatment group treatment condit orient orient orient session line line telephon 174 173 outreach 162 24 hoursa 89 91 94 2 week 66 65 65 5 week 60 50 52 8 week 45 38 37 12 week 38 34 26 note figur 24 hour repres smoke previou 7 dai asubject report 24 hour abstin statu 2 week follow survei tabl 3 long term abstin smoke treatment group treatment condit orient orient orient session line line telephon 174 173 outreach 162 6 month point prevalencea 23 19 25 12 month point prevalencea 22 20 21 6 month continuousb 15 15 17 12 month continuousb 14 13 13 ano smoke previou 7 dai bno smoke quit date nation assess interven tion condit select evalua tion current studi limit includ intens face face orient session placebo patch telephon condit face face contact includ lack outcom differ condit test necessarili telephon outreach ineffec tive effect demonstr present context current studi consid definit term address question telephon support import adjunct transderm nico tine deliveri system work need determin type group format current studi superior individu physician medic practition advic addit studi shed light issu optim price nicotin replac format content behav ioral intervent produc optim complianc abstin la acknowledg research support grant lederl laboratori portion work present ninth world confer tobacco health pari franc octob 1994
1 2 2 0 drug alcohol depend 140 2014 208 212 content list sciencedirect drug alcohol depend journa homepag www.e lsev ier locat drugalcdep hort commun rize conting manag smoke cessat random rial avid ledgerwooda cynthia arfkena nanci petryb sheila alessib depart psychiatri behavior neurosci wayn state univers school medicin 3901 chrysler drive detroit mi 48201 usa depart medicin univers connecticut health center 263 farmington av farmington ct 06030 usa rticl histori eceiv 30 octob 2013 eceiv revis form 27 march 2014 ccept 27 march 2014 vailabl onlin 13 april 2014 eyword rize onting manag igarett background:adjunctivebehavior smokingcess treatmentshav thepotenti improveoutcom standard care present studi aim 1 compar standard care sc smoke week counsel andmonitor sc prize base contingencymanag cm involv ing chanc earn prize dai demonstr smoke abstin carbon monoxid 6ppm 2 compar rel efficaci prize reinforc schedul tradit cm schedul earli enhanc cm schedul provid greater reinforcementmagnitud initi week treatment equal reinforc method particip 81 nicotin depend cigarett smoker randomli assign condit obacco reatment efficaci result prize cm result signific reduct cigarett smoke rel sc reduc tion appar follow found meaning differ tradit enhanc cm condit conclusions:ourfind reveal prize cm lead signific reduct smoke treatment rel control intervent benefit extend long term 2014 publish elsevi ireland introduct cigarett smoke result 1 5 death xtraordinari econom cost center diseas control revent 2008 conting manag cm demon trate efficaci treat substanc disord dutra al 008 prendergast al 2006 includ smoke ledgerwood 008 cm costli reinforc exce ng 1000 higgin al 2004 lamb al 2004 petri al 2000 2012 develop prize reinforc program lower cost design demonstr efficaci cocain opioid alco ol poli substanc depend patient date small random pilot examin prize cm smoke ubstanc abus patient prize cm engend greater pro ortion neg test standard care alessi al 2008 hepres studyexamin theefficacyofprizecmfor smoke ina andom trial supplementari materi found access onlin version aper http dx.doi.org enter doi author tel 1 313 993 1380 fax 1 313 993 1372 mail address dledgerw med.wayne.edu d.m ledgerwood ttp dx.doi.org 10.1016 j.drugalcdep 2014.03.032 376 8716 2014 publish elsevi ireland purpos evalu schedul increas reinforc magnitud earli treatment reinforc mag nitud paramet increas treatment respons petri al 2004 increas long term abstin kenford al 1994 higgin al 2006 examin random clinic trial treatment seek smoker aim present studi assess efficaci prize base cm cigarett smoke compar tradit versu earli treatment enhanc reinforc schedul 2 method 2.1 particip particip nicotin depend smoker 81 respond advertis local newspap bulletin board health fair broadcast messag staff larg health center univers inclus criteria fager ström test nicotin depend heatherton al 1991 score 4 ag 18 english literaci exclus criteria uncontrol psychiatr disord acut suicid psychosi current substanc depend exclud nicotin caffein dx.doi.org 10.1016 j.drugalcdep 2014.03.032 http www.sciencedirect.com scienc journal 03768716 http www.elsevier.com locat drugalcdep http crossmark.crossref.org dialog doi 10.1016 j.drugalcdep 2014.03.032 domain pdf mailto:dledgerw med.wayne.edu dx.doi.org 10.1016 j.drugalcdep 2014.03.032 lcoho 2 2 2 2 1 2 2 2 4 2 2 d.m ledgerwood al drug ecoveri patholog gambl receiv smok ng treatment recruit occur decemb 2007 januari 011 2 procedur individu screen elig schedul ntake intak written inform consent elf report assess urin cotinin test lete intak particip attend clinic daili sep rate 5 hour mondai fridai 5 week unexcus bsenc consid posit read excus absenc e.g famili emerg consequ follow ssessment occur 2 6 month start treatment ith 20 compens follow 3 measur 3.1 demograph demograph data collect intak screen suicid psychosi substanc abus dapt structur clinic interview dsm iv tr al 2002 assess inclus exclus patholog gam ling assess norc dsm screen gerstein al 999 3.2 smoke histori smoke histori includ ag smoke smoke daili cigarett smoke daili 3.3 fagerström test nicotin depend fagerström test icotin depend questionnair assess nicotin depend fagerstrom 1978 3.4 expir carbonmonoxid expir carbonmonoxid evel assess intak daili baselin reatment follow up ec50 mp micro mon tor bedfont level 6ppm consid smoke neg reinforc purpos consist studi rang 8ppm corbi al 2000 lamb al 2004 3.5 urinari cotinin urinari cotinin sampl collect ntake mondai week 2 5 follow up test ccutest nicalerttm test strip system jant pharmac corpora ion encino ca treatment week 2 4 cotinin sampl erv ameasur weekend smoke abstin 100ng ml establish cm bonu draw 4 baselin particip receiv 1 sampl independ result ith 20 bonu submit 10 sampl motiv lianc submit 5 sampl requir random individu discontinu refer treatment lsewher baselin phase allow assess smoke pre reatment time prepar quit baselin visit articip met research therapist review smoke essat quit guid prepar quit u. public health ervic june 2000 base standard care fior al 2008 hemateri emphasizemotiv social support behavior kill reduc smoke random assign treatment condi ion stratif gender 6ppm aselin 1 occur treatment dai 1 quit at statistician prepar sequenti number random depend 140 2014 208 212 209 envelop conceal group assign assign random izat cm condit standard treatment occur 2 1 ratio ensur adequ power compar cm condit 2.5 treatment 2.5.1 standard care sc standard care sc week 2 5 involv monitoringcoandcotinin andbrief counsel fioreet al 2008 particip receiv 1 sampl test result 20 weekli bonu submit sampl maximum 120 dur ing session therapist provid feedback cotinin test result briefli 5min discuss recent smok ing abstin prais quit effort 2.5.2 tradit prize cm tcm addit sc tcm patient earn chanc win prize neg cotinin sam ple similar petri martin 2002 petri al 2000 compens complianc submit sampl treatment dai 1 particip drew prize reduc 3ppm intak level subsequ draw conting read 6ppm draw prize urn increas 1 5 consecut dai daili test met criterion level 6ppm refus mit sampl unexcus absenc reset draw thenext neg sampl tcm prize urn contain 250 slip paper typic prize percentag e.g petri martin 2002 50 125 result prize 44.8 small worth 1 e.g snack toi letri 4.8 larg worth 20 e.g gift certif electron 0.4 jumbo worth 100 e.g dvd player gift certif reinforc weekend abstin cotinin sampl 100ng ml onmondai result bonu draw inweek 3 5 180 draw 15 bonu draw cotinin neg test 2.5.3 earli treatment enhanc prize reinforc ecm ecm particip receivedsc coand cotininemonitor reinforc ment criteria draw reinforc criteria ident tcm chanc receiv rein forcement earli treatment schedul enhanc provid guarante prize 100 probabl versu 50 chanc tcm neg test treatment week 1 week 1 ecm urn includ 91.2 small 8 larg 0.8 jumbo prize remain week urn 65.8 slip result prize 30 small 4 larg 0.2 jumbo prize draw cotinin neg test made urn 100 win slip reinforc magnitud cm condit 2.6 analysi emploi intent treat approach includ particip enter treatment phase analys pare combin cm condit versu sc tcm versu ecm chi squar test analyz baselin characterist outcom averag longest durat smok ing abstin dai lda percent test 4ppm criterion reinforc 6ppm maxi mize opportun reinforc 4ppm analysi ensur conserv report find dai abstin defin consecut test 4ppm session encompass weekend particip consid abstin consecut dai test 2 lcoho sc 0.01 tabl 1 particip attend averag sd 87.8 16.0 base 10 d.m ledgerwood al drug mmediat weekend neg unex absenc broke string abstin excus bsenc preced neg sam le linear mix model analyz group differ level baselin treatment fix factor includ reatment condit time 50 test session condi ion time interact case includ random effect ariabl test assess lda attend lda data er normal squar root transform analysi ith raw data present tabl facilit interpret ent neg number test 4ppm divid number treatment session attend maximum 40 ent neg data prize dollar earn ransform normal mann whitnei test nalys run cutoff 6ppm reinforc riterion lda percent neg predict igher stringent 4ppm irect signific remain uthor chi squar analysiswasus groupdiffer follow up 7 dai point preval ppa report smoke ast 7 dai cotinin 100ng ml miss data analyz smoke posit 1 emograph smoke treatment outcom variabl treatment condit ongest durat abstin percent neg carbonmonoxid test treatm versu enhanc cm condit includ outcom variabl note longest du test mann whitnei test variabl standard 17 tradit cm 28 enha 3 ag sd 44.0 12.1 45.8 11.7 44.5 gender male 7 41.2 10 35.7 14 3 femal 10 58.8 18 64.3 22 6 race european american 5 29.4 7 31.8 15 4 african american 12 70.6 21 70.0 20 5 0 0 0 0 1 2.8 emploi 16 94.1 24 85.7 29 8 marit marri 5 29.4 10 35.7 13 3 marri cohab 6 35.3 6 21.4 11 30 widow 1 5.9 1 3.6 1 2.8 seper divorc 5 29.4 11 39.3 11 3 educ sd 13.4 1.9 14.1 1.8 14.6 incom median iq rang 22,000 22,900 17,500 23,750 23,0 ag smoke sd 16.1 3.5 17.7 5.1 16.3 number cigarett dai sd 19.3 8.8 14.7 9.8 16.8 fagerstrom score sd 6.4 1.2 6.0 1.2 6.4 1 treatment outcom longest durat abstin dai 1.6 3.2 6.9 8.6 3.7 5 percent neg test 4ppm session attend median iq rang 2.5 13.6 42.4 79.6 29.1 percent baselin session attend 93.5 9.3 85.7 15.5 86.7 percent treatment session attend 74.7 31.0 69.8 24.4 68.5 total prize dollar amount median iq rang 121.00 197.55 120 prize dollar amount week 1 median iq rang 21.00 46.00 23.5 depend 140 2014 208 212 3 result 3.1 demograph supplement fig 11 particip flow tabl 1 demograph baselin data cm particip significantli educ sc differ signific ps 0.05 cigarett dai rang 14.7 19.3 0.10 averag fagerström score reveal moder at nicotin depend 3.2 standard care versu cm baselin level similar cm sc fig 1 lin ear mix model analysi reveal signific time condit interact 50 2860.37 2.71 0.001 cm particip reduc level time rel sc cm treatedparticip demonstr significantli greater lda sc particip 0.05 tabl 1 medium effect size 0.50 percentag neg test greater cm line 70.3 28.5 treatment session differ condit tabl 1 combin conting manag condit mean standard deviat nt attend data standard versu combin cm condit tradit ration abstin squar root transform prior analysi test statist nced cm 6 combin cm condit 64 standard combin cm 2 tradit enhanc 2 12.7 45.1 12.2 79 0.32 0.75 62 0.40 0.69 8.9 24 37.5 2 1 81 0.08 0.78 2 1 64 0.07 0.80 1.1 40 62.5 1.7 22 34.4 2 2 81 0.45 0.80 2 2 64 2.98 0.23 5.6 41 64.1 1 1.6 0.6 53 82.8 2 1 81 1.36 0.24 2 1 64 0.29 0.59 6.1 23 35.9 2 3 81 0.90 0.83 2 3 64 0.88 0.83 6 17 256.6 2 3.1 0.6 22 34.4 2.0 14.3 1.9 79 2.00 0.05 62 1.18 0.24 00 29,972 18,000 28,000 636.00 0.24 487.50 0.97 3.6 16.9 4.3 78 0.77 0.44 61 1.28 0.21 8.0 15.9 8.8 77 1.40 0.16 60 0.92 0.36 2 6.2 1.2 77 0.55 0.59 60 1.26 0.21 7 5.1 7.2 79 2.21 0.05 62 1.63 0.11 52.3 36.1 55.3 774.00 0.01 433.00 0.33 18.5 86.3 17.1 79 1.68 0.10 65 0.22 0.83 30.7 69.1 27.9 79 0.72 0.48 62 0.18 0.86 56 257.09 120.56 216.51 507.5 0.81 0 54.00 23.00 48.00 595.5 0.37 d.m ledgerwood al drug alcohol depend 140 2014 208 212 211 cm oth 3 2 3 4 ig 1 averag daili carbonmonoxid level part permillion combin reatment 0.05 tradit enhanc cm condit differ eac ondit enhanc readabl graph month 2 6 follow rate 85 77 ithout signific differ treatment condit ps 10 cm sc differ ppa 2 month 6.3 0 2 1 81 1.12 0.29 6 month follow 6.3 5.9 2 1 81 0.00 0.96 3 tradit versu earli enhanc cm linear mixedmodel analysi compar tcm ecm reveal im main effect 50 2193.12 25.77 0.001 level ecreas time condit condi ion main effect time condit interact signific 0.05 fig 1 tcm ecm condit differ significantli lda ercentag neg test attend tabl 1 ppa month 10.7 2.8 2 1 64 1.69 0.19 6 month ollow 10.7 2.8 2 1 64 1.69 0.19 4 prize earn approxim 81 cm particip earn prize median 120.56 differ earn tcm ecm ur week 1 week nonsignific tabl 1 discuss find demonstr prize cm efficaci moke abstin intervent consist research onei voucher cm smoke ledgerwood 2008 prize cm illicit substanc petri al 2000 2012 alessi al 2008 pilot studi prize cm smoke found signifi ant differ outcom tcm ecm thought hat provid schedul increas chanc win prize arli treatment result abstin initi ubsequ abstin base find higher magnitud reinforc result outcom petri al 2004 owev data consist studi reveal tart bonus enhanc cm effect silverman ndition show signific reduct rel baselin rel standard er note tradit enhanc condit present combin cm al 1998 tcm lda percent neg nonsignificantli higher ecm level theweek 1 enhancedperiodwer compar condit tcm ecm schedul initialmagnitud table1demonstr realiti earli magnitud reinforc receiv differ group cm facilit greater smoke reduct treatment differ appar follow cm studi smoke primarili reveal longer term benefit cm ledgerwood 2008 notabl high relaps rate found efficaci smoke cessat intervent piasecki al 2002 present studi limit sampl size rela tive small importantli treatment requir intens person visit schedul difficult sustain popul e.g rural popul low socioeconom statu summari prize cm efficaci promot initi smok ing abstin nicotin depend smoker research method improv respons rate maintain abstin need author disclosur role fund sourc studi fund nih grant r21 da021839 helen lycaki joe young sr fund state michi gan funder role studi design collect analysi interpret data write report decis submit paper public contributor dr ledgerwood studi princip investig con tribut aspect studi design data collect analysi manuscript prepar dr arfken assist dr ledgerwood conduct data analysi manuscript write dr petri alessi contribut develop studi design assist 2 lcoho 2 101 1546 1560 12 d.m ledgerwood al drug ata analysi assist prepar manuscript author ontribut approv final manuscript onflict interest cknowledg ken bate lisa sulkowski melissa william joi oor caren steinmil debra kish kati linehan bojana kneze ic ashleywiedemann veeral patel staff psychiatr addict research center assist project ppendix supplementari data supplementari data articl found onlin version http dx.doi.org 10.1016 j.drugalcdep 014.03.032 efer lessi s.m petri n.m urso 2008 conting manag promot smok ing reduct residenti substanc abus patient appl behav anal 41 617 622 enter diseas control prevent 2008 smoke attribut mortal year potenti life lost product loss unit state 2000 2004 mmwr 57 1226 1228 orbi e.a roll j.m ledgerwood d.m schuster c.r 2000 conting manag ment intervent treat substanc abus adolesc feasibl studi exp clin psychopharmacol 8 371 376 utra stathopoul basden s.l leyro t.m power m.b otto m.w 2008 ameta analyt reviewof psycosoci intervent substanc disord psychiatri 165 179 187 agerstrom 1978 measur degre physic depend tobacco smok ing refer individu treatment addict behav 3 235 241 irst m.b gibbon spitzer r.l william j.b.w 2002 structur clinic interview dsm iv tr axi disord research version patient edit scid biometr research york state psychiatr institut york ny depend 140 2014 208 212 fior m.c jaen c.r baker t.b bailei w.c benowitz n.l curri s.j dorfman s.f froelich e. goldstein m.g healton c.g nez henderson heyman r.b al 2008 treat tobacco depend 2008 updat u. depart ment health human servic public health servic rockvil md gerstein murphi toce hoffmann palmer johnson al 1999 gambl impact behavior studi univers chicago chicago heatherton t.f kozlowski l.t frecker r.c fagerstrom k.o 1991 fager strom test nicotin depend revis fagerstrom toler questionnair br addict 86 1119 1127 higgin s.t heil s.h dumeer a.m thoma c. solomon l.j bernstein i.m 2006 smoke statu initi week quit com.ibm.drl.hbcp.predictor smoke cessat outcom pregnant women drug alcohol depend 85 138 141 higgin s.t heil s.h solomon l.j bernstein i.m lussieur j.p abel r.l lynch badger g.j 2004 pilot studi voucher base incent promot absti nenc cigarett smoke pregnanc postpartum nicotin tob re 6 1015 1020 kenford s.l fior m.c jorenbi d.e smith s. wetter baker t.b 1994 pre dict smoke cessat quit nicotin patch jama 271 589 594 lamb r.j morral a.r kirbi k.c iguchi m.y galbicka 2004 shape smoke cessat percentil schedul drug alcohol depend 76 247 259 ledgerwood d.m 2008 conting manag smoke cessat curr drug abus rev 1 340 349 petri n.m alessi s.m ledgerwood d.m 2012 random trial conting manag deliv commun therapist consult clin psychol 80 286 298 petri n.m martin 2002 low cost conting manag treat cocain opioid abus methadon patient consult clin psychol 70 398 405 petri n.m martin coonei j.l kranzler h.r 2000 give prize conting manag treatment alcohol depend consult clin psychol 68 250 257 petri n.m tedford austin nich carrol k.m rounsavil b.j 2004 prize reinforc conting manag treat cocain abus low addict 99 349 360 piasecki t.m fior m.c mccarthi d.e baker t.b 2002 lost dynam formul smoke relaps prone addict 97 1093 1108 prendergast podu finnei greenwel roll j.m 2006 contingencyman agement treatment substanc disord meta analysi addict silverman wong c.j umbricht schneiter montoya i.d schuster c.r preston k.l 1998 broad benefici effect cocain abstin reinforc methadon patient consult clin psychol 66 811 824 http dx.doi.org 10.1016 j.drugalcdep 2014.03.032 http dx.doi.org 10.1016 j.drugalcdep 2014.03.032 prize conting manag smoke cessat random trial 1 introduct 2 method 2.1 particip 2.2 procedur 2.3 measur 2.3.1 demograph 2.3.2 smoke histori 2.3.3 fagerstrom test nicotin depend 2.3.4 expir carbon monoxid 2.3.5 urinari cotinin 2.4 baselin 2.5 treatment 2.5.1 standard care sc 2.5.2 tradit prize cm tcm 2.5.3 earli treatment enhanc prize reinforc ecm 2.6 analysi 3 result 3.1 demograph 3.2 standard care versu cm 3.3 tradit versu earli enhanc cm 3.4 prize earn 4 discuss role fund sourc contributor conflict interest acknowledg appendix supplementari data refer
effect nicotin inhal smoke cessat otc set scott leischow phd jame ranger moor phd myra muramoto md mph eva matthew mph object evalu ef fectiv nicotrol nico tine inhal aid smoke cessat counter otc versu health care provid hcp condit method hundr twenti healthi smoker random treat ment condit year result follow visit abstin rate hcp group 2 3 time observ otc group absti nenc 1 year 77 otc condit versu 3.08 hcp condit 01 haler low conclus otc nicotin inhal appear ineffect quit rate improv hcp assist kei word smoke cessat otc nicotin inhal nicotin replac 2004;28 4 291 301 numer achiev intobacco control past de cade preval smoke unit state gradual declin 1990 approxim 25.7 men 21.5 women 1999 estim 70 smok er unit state quit approxim 46 scott leischow act associ director havior research program divis cancer control popul scienc nation cer institut bethesda md jame ranger moor assist professor public health arizona cer center univers arizona myra muramoto associ professor depart fam.ili com.mun medicin univers arizona eva matthew research specialist mel enid zuckerman arizona colleg public health univers arizona tucson az address correspond dr leischow act associ director behavior research program divis cancer control popul sci enc nation cancer institut execut plaza north room 4060 6130 execut boulevard msc 7337 bethesda md 20892 7337 mail scott.leischow nih.gov attempt quit year effort unsuccess meta analys strongli suggest nicotin replac therapi includ nico tine gum patch nasal sprai inhal approxim doubl likelihood abstin 1.5 2.7 recommend line treatment nicotin depend odd ratio base studi plete studi environ similar prescript otc nicotin patch nicotin gum approv otc medic meta analys otc efficaci complet nicotin patch analys found odd ratio favor nicotin patch pla cebo substan tial methodolog variabl investig 2 otc studi nicotin patch requir particip pai medic user otc medic purchas medic effort minim. behavior support otc health behav 2004;28 4 291 301 291 effect otc nicotin inhal studi requir particip attend 6 visit 6 week treat ment make unclear studi reflect real world otc environ data suggest placebo effect substanti smoke cessat stud i number visit posit affect quit rate studi dem onstrat efficaci otc medic consid caution fact studi found nico tine patch effect otc environ ment leischow al studi pare otc health care provid intervent includ placebo group includ schedul visit requir particip pai medic studi found 1 year quit rate 5 otc group compar quit rate recent meta anali si otc nrt studi 6 month quit rate averag 7 1 higher 6 quit rate found meta analysi quit rate fur thermor 2 analys state surveil lanc data fail demonstr effect otc nrt mix result studi assess otc nrt addit research need order consum determin treatment vwu benefit smoke cessat attempt nicotin inhal shown safe efficaci clinic trial sale estim inhal lag patch gum indic potenti bar rier access market penetr possibl nicotin inhal remain prescript product light establish efficaci safeti nicotin inhal clinic set includ behavior support respons evalua tion nrt otc set current studi conduct pri mari purpos evalu effec tive nicotin inhad aid smoke cessat counter simul comparison health care provid hcp condit addit impact individu particip characterist demograph health statu withdraw symptom crav ing mood qualiti life alcohol consumpt medic assess paper focu effi caci result medic subject characterist predict cessat method subject recruit screen random method similar earlier studi particip 520 recruit part larger recruit ment effort multipl studi local print broadcast media potenti elig studi figur 1 depict studi flow subject particip uniqu identifi initi stage recruit po sibl ascertain number individu al assess elig advertis ment announc avail smoke cessat research program provid studi telephon number interest individu formal tele phone screen conduct format studi site criteria elig provid phone interest person vite site screen evalu studi research clinic time ask complet smoke statu health histori de mograph questionnair determin elig purchas medic clude health care provid contact elig particip 18 year ag older report chronic smok er durat studi complet studi requir includ willing intent purchas studi medic sign inform con particip exclud experienc heart attack cva cerebrovascular accid 3 month current diagnosi stabl angina irregular heart rate histori allergi nicotin menthol inhal constitu medic condit deem accept studi health care pro vider women pregnant breastfeed report medic approv form birth control unwil exclud enrol nicotin replac studi exclud 2 member household elig particip particip ask read 292 leischow al figur 1 particip flow follow assess elig l̂̂ andom otc treatment condit 260 hcp treatment condit 260 2 week follow 177 6 week follow 15 12 week follow 126 26 week follow 126 52 week follow 132 2 week follow 160 6 week follow 131 1 12 week follow 125 26 week follow 17 52 week follow 126 note uniqu identifi initi stage recruit ascertain number individu assess elig visit week 12 52 conduct telephon abstin report week 52 site verif schedul packag insert nicotin haler advis consult pri mari care physician contraindicatori medic condit prior purchas medic partici pant advis medic cost ask write intent purchas medic addition particip provid part studi consent form descrip tion treatment condit assign inform consent obtain breath carbon monoxid level assess particip assign 1 2 rea tment condit ion counter health care provid puter gener random alloc se quenc creat studi statisti cian provid staff conduct screen appoint partici pant particip enter studi number inform group assign health behav 2004;28 4 291 301 293 effect otc nicotin inhal medic purchas treatment intervent otc condit particip otc condit allow purchas medic immedi ran domiz condit quir make medic purchas 4 week elig particip studi par ticip instruct nico tine inhal 3 month medica tion purchas occur ad libitum interv 26 week initi medic purchas studi instruct consent form guidelin purchas par ticip schedul 2 week follow visit allow 7 dai sched ul window particip purchas medic 4 week exclud studi determin reason failur purchas medic instruct nicotin inhal provid packag insert addit research program phone number provid answer que tion inhal local commu niti tobacco cessat resourc studi staff provid person behavior treatment materi advic counter group health care provid condit elig purchas hcp group began particip attend appoint studi health care provid legal responsi biliti approv health care provid determin medic elig prescript medic unlik otc medic subject sign randomli hcp condit assess elig medic case real world method adopt protocol virtual pharmaceut compani test medic otc appoint schedul 2 week initi screen visit conduct nurs practition experi enc provid smoke cessat treatment particip medic eligibil iti studi confirm appoint addit psychoso cial behavior counsel smoke cessat pamphlet provid instruct inhal prescript nicotin inhal health care provid train deliv approxim 10 minut smoke cessat counsel instruc tion proper inhal person aliz advic quit relat subject medic histori review nci patient educ booklet clear air quit smoke quit discuss time special attent sec tion booklet relev individu subject concern quit ting content durat hcp behavior counsel set target quit dai problem solv discuss person trigger smoke cord time visit addit alli durat discuss specif address inhal guidelin record determin medic eligi biliti behavior counsel partici pant provid prescript f'or 1 month suppli medic 4 box 168 inhal 2 month refil valid simu late otc site requir medic purchas ident otc condit purchas 4 week purchas particip schedul 2 week follow visit allovnng 7 dai schedul win dow particip wish continu medic 3 month requir speak health care pro vider request addit prescrip tion total 26 week treatment condit requir particip set quit date abstin smoke purchas medi cation medic label en courag abstin cost box nicotin inhal 7 trai 6 cartridg trai 20.00 10 mg nicotin inhal cartridg deliv approxim 5 mg nicotin inhala tion fouow treatment group follow appoint conduct week 2 6 12 26 52 week 2 6 26 held studi site week 12 52 complet telephon research assist attempt contact studi particip week 52 specif withdrawn con prior report smoke 294 leischow al statu concern inadequ follow earlier otc studi result failur detect abstin studi particip abstin report week 52 site verif visit sched ul attend visit compens 10.00 travel expens condit schedul follow up unschedul medic purchas visit inform collect smoke statu smoke pat tern subject smoke advers event concomi tant medic nicotin inhal mood alcohol consumpt report continu abstin breath carbon monoxid 9ppm tween week 2 6 primari deter minant smoke cessat success analyt method preliminari anali si test test proport rank sum chi squar test compar sociodemograph characterist level nicotin depend periment group confirm success random continu abstin defin smoke time 2 week follow visit point preval absti nenc defin smoke 7 dai visit test proport cross section parison continu point preva lenc abstin rate cross section quit rate calcul intent treat criterion elig partici pant includ analysi intent treat analysi includ participeint purchas medic conserv definit fda determin efficaci smoke cessa tion medic particip miss visit treat smoke particip claim abstin verif obtain cross section analys compa rabl previou literatur fulli statist power lon gitudin data longitudin analysi point preval abstin conduct recommen dation recent methodolog con ferenc sponsor societi search nicotin cind tobacco gen eral estim equat gee ap proach take advantag inform provid multipl mea surement account nonindepend repeat measur explicitli model correl matrix error term gee model incorpor logist link function accommod dichotom outcom result coeffici interpret occur ordinari logist regress analysi gee model accommod miss data loss statist power bia data miss random pattern mixtur model develop account portion bia due nonrandom miss pattern 2 set gee model develop set treat miss visit miss verif miss ing data set cross section analysi treat case smoke result demograph tabl 1 displai demograph charac terist assess initi screen ing treatment group entir sampl mean ag 47.7 51 femal averag cigarett dai 25.8 mean fagerstrom score 6 suggest averag subject depend nicotin signific differ 05 level 2 treatment group demograph variabl efficaci 24 hour o3 measur confid particip quit tobacco 24 hour confid level higher otc group baselin ciga rett dai fagerstrom score margin 10 higher hcp otc group content intens hcp behav ioral intervent mean durat behavior counsel hcp group 8.2 4,6 minut 116 hcp particip data 46.6 discuss inhal health care provid averag dura tion discuss inhal 5.2 3.5 minut inhal purchas analys inhal purchas data complet subgroup purchas medic health behav 2004;28 4 291 301 295 effect otc nicotin inhal tabl 1 demograph characterist random subject variabl screen carbon monoxid ag maie white educ year baselin cig year smoke pack year fagerstrom quit attempt motiv quit efficaci 24 hr expect 1 year note intent entir ampl 513 514 515 520 511 514 514 513 509 499 515 515 515 wilcoxon ank sum est test fisher exact test test transform data mean 27.07 47.71 0.493 0.898 14.23 25.80 30.01 23.75 6.01 8.34 4.6 4.02 4.07 sd 12.41 12.39 2.40 11.84 12.70 9.98 2.38 14.81 0.64 1.07 l.oi 258 259 260 260 257 259 259 259 257 249 260 260 260 treat otc mean 26.90 47.05 0.462 0.892 14.35 24.88 29.24 23.05 5.82 8.53 4.62 4.12 4.10 sd 12.65 12.21 2.35 11.46 12.33 9.43 2.37 15.06 0.61 1.01 0.99 255 255 255 260 254 255 255 254 252 250 255 255 255 hcp mean 27.25 49.39 0.526 0.904 14.11 26.74 30.80 24.46 6.20 8.15 4.57 3.91 4.04 sd 12.20 12.60 2.45 12.17 13.04 10.48 2.38 14.58 0.68 1.12 1.03 0.61 0.22 0.16 0.77 0.27 0.09 0.16 0.12 0.07 0.39 0.53 0.03 0.61 tabl 2 displai total number haler box purchas total num ber purchas visit differ 2 treatment group averag number box purchas 26 week 3.2 consider variabl maximum number box purchas singl visit 12 maximum number box purchas 26 week treat variabl purchas box cartridg purchas daili cartridg visit 2 daili cartridg visit 3 daili cartridg 6 month note fisher exact 26 week tabl 2 inhal purchas entir ampl 520 465 335 242 395 test mean sd 89.4 3.20 4.03 2.64 1.90 2.25 1.95 1.86 1.74 treatment phase wilcoxon ank sum est 260 239 175 111 206 otc mean 91.9 3.26 2.66 2.23 1.84 sd 4.28 2.01 2.10 1.68 260 226 160 131 189 hcp mean 86.9 3.15 2.61 2.27 1.89 sd 3.74 2.01 1.82 1.80 0.09 0.54 0.83 0.49 0.93 296 tabl 3 verifi point preval week 2 6 26 52 verifi continu abstin otc 6.92 18 3.85 10 1.54 4 0.77 2 hcp 13.46 35 10.77 28 4.62 12 3.08 8 note 05 01 001 intent treat miss stnoke report abstin miss verif continu verifi point otc 11.15 29 10.77 28 6.15 16 3.08 8 smoke leischow al abstin preval abstin hcp 21.54 56 20.77 54 11.54 30 8.46 22 ment phase 26 tabl 2 present averag daili inhal report schedul visit week 2 week 6 averag 26 week studi combin inform visit week 2 6 12 26 time inhal differ significantli group declin time group number box purchas consider variabl num ber inhal dai rang ofo 10 cross section analysi abstin rate tabl 3 show percent abstin treatment group schedul visit compar continu point preval abstin hcp group higher abstin rate otc group time point abstin criteria rate continu abstin significantli higher hcp group otc group week 2 6 26 continu absti nenc rate 13.46 6.92 05 10.77 3.85 01 4.62 1.54 05 hcp otc group differ ob serv week 52 statist signific dai point preval absti nenc significantli higher hcp group otc group time point rang 21.54 8.46 week 2 52 hcp group 11.15 3.08 otc group 001 week 2 01 week 52 gener hcp intervent result abstin rate approxim 2 3 time higher otc group longitudin analysi abstin rate tabl 4 show 4 gee model model 1 2 treat miss visit miss verif miss data model 3 4 treat occas smoke model 1 3 effect treatment group time interact term point preval ab stinenc model 2 4 pattern mixtur model pattern mixtur mod el miss data pattern enter covari control nonrandom associ outcom num ber miss visit model show consist higher abstin rate hcp particip neg time trend result consist cross section result signific interac tion effect found model note efficaci shown tabl 1 significantli higher baselin otc group hcp group efficaci relat success quit potenti confound analysi gender balanc baselin differenti attrit result otc group significantli greater pro portion femal hcp group time variabl health behav 2004;28 4 291 301 297 effect otc nicotin inhal tabl 4 7 dai point preval smoke abstin quasi likelihood estim gener estim equat variabl treatment roup otc 0 hcp 1 week wk treatment wk interact gender femalem maie seir efficaci 24 iiour miss visit observ waldchi squar model 1 beta se 1.066 0.268 0.001 0.014 0.014 0.016 0.419 0.218 0.281 0.107 1 adjust 95 cl 2.904 1.719 4.909 i.ooi 0.973 1.029 1.014 0 983 1.045 0658 0.429 1.009 1.324 1.073 1.634 750 i9.67 model 2 beta se 1.059 0.265 0.001 0.012 0.014 0.014 0.474 0.228 0.288 o.iil 0.453 0.096 750 66.02 adjust 95 ci 2.883 1.714,4.850 1.001 0.978 1.024 0i4 0.987 1.041 0.623 0.398 0.974 1.334 i.o71 655 0.636 0.527 0.76 model 3 beta se 0.818 0.233 0.028 0.007 0.004 0.008 0.242 0.213 0.218 0.108 204 58.37 adjust 95 cl 2.266 1.436 3.579 0.972 0.959 0.986 1.004 0.988 1.020 0.785 0.517 i.i92 1.244 1.007 1.536 model 4 beta se 1.012 0.253 0 0 3 1 0.007 0.003 0.009 0.408 0.224 0.251 0.113 0.855 0.071 adjust 95 ci 2.751 1.675,4.518 0.969 0.956 0.983 1.003 0.985 1.021 0.665 0.428 1.031 1.285 1.030 1.603 0.425 0.370 0.488 2049 194.95 note 0.05 0.01 0.001 otc counter set hcp health care practition set number parenthes semirobust standard error se model 1 2 treat miss visit miss verif miss data model 3 4 treat miss visit miss verif smoke paramet report slope coeffici odd ratio exp slope coeffici sociodemograph smoke characterist reason potenti variat group 20 assess potenti confound found includ final model includ potenti confound distribut variabl posit effect hcp intervent quit attenu at treatment effect 10 20 greater found model efficaci gender includ result shown particip miss clinic visit smoke visit observ miss random assump tion unten make pattern mixtur model model 2 4 prefer model 1 3 miss visit treat smoke model 4 high correl tween number miss visit smok ing statu result stronger coeffi cient number miss visit model 4 compar model 2 fact number miss visit signifi model show result axtifactu set model pattern mixtur model suggest stronger treatment group differ 4 model probabil iti abstin hcp particip consist higher otc par ticip indic relat ship stabl face treatment miss data model odd ratio 7 dai point preval abstin hcp rela tive otc particip rang 2.27 2.90 discuss present studi design sess nicotin 298 leischow al inhal smoke cessat otc set result compar absti nenc rate inhal conjunct health care provid support studi found follow visit abstin rate heaith care provid condit significantli higher outcom fairli consist strict continu abstin lax point preval criteria simi larli differ treatment condit remain intent treat particip medic purchas condit compar fact chose purchas inhal er includ analysi differ abstin rate 2 treatment increas result shown import outcom present studi low abstin level treatment condit otc condit strin gent analysi continu abstin intent treat group absti nenc rate otc group 1 end 1 year point preval abstin rate group higher 3 argument made quit rate low particip lost follow absti nent assum cross section analys miss subject smoker estim bias low determin extent bia precis subject lost follow studi fda guidelin smoke cessat clinic trial includ kind track sy tem assess possibl call subject week 52 elig call withdrawn consent contact total 258 individu individu 132 otc group 126 hcp group group equal repr sent report continu abstin rate point 1.5 otc group 4.6 hcp group low abstin rate found studi due rea son screen process stringent lengthi pharmacotherapi studi design review fda nico tine inhal safe medic studi includ smoker motiv quit smoke order balanc collect ing inform addit analys mini mize time spent data collect data collect de facto treatment otc condit particip readi ness quit assess focus attent studi treatment outcom understand ing futur studi need teas addit factor affect treat ment outcom unlik clini cal trial studi follow visit recent ph clinic guidelin tobacco cessat demonstr posit associ tween number visit treatment outcom provid follow visit rel lack contact result lower abstin rate conduct control studi evalu at switch smoke cessat medic prescript otc complic balanc data collect track goal lifelik nrt otc switch studi includ 6 weekli follow visit post quit dai visit effect treatment increas rate absti nenc condit con found effect medic improp nicotin inhal contribut low absti nenc rate found studi nicotin inhal difficult draw compar cigarett result work order suffici quan titi nicotin prevent withdraw experi nicotin inhal adher recommend do ing regimen uncommon fact inhal pattern observ present studi suggest adher suffici product design chang nicotin doubl edg sword increas abus liabil iti consum behavior nicotin inhal puf topographi health behav 2004;28 4 291 301 299 effect otc nicotin inhal alter efficaci inhal depend clear user puff inhal nicotin need suppress withdraw addit proactiv health educ need optim correct nicotin inhal limi tation present studi addit mention placebo group studi want compar treatment head head studi great est relev clinic practic placebo increas quit rate affect particip motiv expecta tion want particip pai cost medic order reflect real otc situat decid ethic charg particip placebo inhal low abstin rate found studi argu outcom artifici high placebo outcom studi respect respect similar earlier studi similar design assess effi caci otc nicotin patch studi found abstin rate differ otc hcp condit present studi patch otc likewis found abstin rate otc group low result studi consist studi compar otc nrt prescrip tion nrt studi found signifi cantli higher quit rate prescrip tion group otc group present studi sess otc inhal nrt medic quir signific behavior support program efficaci reason found increas efficaci hcp condit studi otc patch studi hcp treatment present studi consi tentli provid nurs practition consider prior experi provid smoke cessat treatment provid hcp intervent studi note intent hcp group test imperfect clinic interven tion optim hcp intervent provid case trial consider clinic standard izat requir suggest hcp nonresearch set standard provid recommend smoker find increas quit rate 46 adher hcp speak type intervent increas role hcp otc patch studi multipl hcp includ physician provid counsel 2 counsel visit increas variabl hcp counsel effort otc patch studi result inadequ intervent compar ab stinenc rate 2 treatment condit present studi generaliz real world environ result demon strate hcp intervent addit nicotin inhal increas quit rate otc haler conclus drawn result present studi health care provid make differ smoker simpli purchas nicotin inhal hope health care provid main critic part smoke cessa tion process environ easi access otc smoke cessat medic otc nicotin haler result adequ ab stinenc rate adjunct behav ioral support provid effect behavior support packag includ abstin rate otc studi higher actual behavior support materi smoke cessat experi except rule free servic toll free number addit research behavior support materi meth od potenti increas abstin rate otc medic purchas need medica tion adher inadequ nicotin inhal deliv nico tine puff puff basi smoker frustrat nico tine suppress withdraw symptom 300 leischow al strategi increas adher need result studi suggest nicotin inhal ap prove otc ineffec tive necessarili ampl evid nicotin inhal er appropri abstin rate compar form nrt effect adjunct port provid otc inhal smoker reason chanc quit medica tion fill medicin cabinet medic col lect dust continu smoke acknowledg grate pharmacia upjohn pfizer provid nicotin inhal studi ind project provid dhh grant da08885 sjl
origin investig bupropion cognit behavior therapi weight concern women smoker michel levin phd kenneth perkin phd melissa kalarchian phd yu cheng phd patricia houck ms jennif slane ma marsha marcu phd background previous document cogni tive behavior therapi smoke relat weight con cern concern improv cessat rate efficaci combin concern cessat medic unknown sought determin combin concern bupropion therapi enhanc abstin weight concern women smoker method random doubl blind placebo control trial weight concern women 349 86 white receiv smoke cessat counsel random 1 2 adjunct counsel compon concern standard standard cessat treat ment ad discuss smoke topic spe cific weight focu 1 2 medic condit bu propion hydrochlorid sustain releas placebo 6 month rate durat biochem veri fi prolong abstin primari outcom point preval abstin postcess weight gain nicotin withdraw depress symptom weight concern evalu result women concern group higher rate abstin 34.0 longer time laps standard 21 05 concern 11.5 005 group 6 month rate prolong abstin concern standard group dif fer significantli 12 month abstin rate du ration differ standard group 21 19 compar standard group 10 7 6 12 month differ abstin women postcess weight gain weight concern standard produc greater decreas nicotin withdraw depress symptom standard conclus weight concern women smoker ceiv combin concern sustain abstin effect relat differ postcess weight gain weight concern trial registr clinicaltrials.gov identifi nct00006170 arch intern med 2010;170 6 543 550 women smokersareconcernedabouttheweight gain monli accompani anattempt quit smok ing.weight concernedsmokersarelesslik intend quit smoke 1 drop treatment 2 poorer ce sation outcom treatment 3,4 gain weight cessation5 smoker weight concern base ra tional prevent weight gain improvecessationr initi treatmentap proach forweight concernedsmok volvedaddingweightcontrol intervent diet cessat counsel 6 weight control intervent improv rate sustain abstinence5,7,8 andmayevenbecounterproduct 9,10 reasonedthataddressingtheconcernssmok er postcess weight gain treatment tar thanpreventionof theweightgainitself 6 developed6 evaluated5 cognit behavior intervent design toaddresswomen’sconcernsaboutpostc sation weight gain previou investig 5 pare standard smoke cessat coun sele 3 distinct adjunct treat ment equat therapeut time attent cognit behavior therapi weight concern concern behav ioral weight control bw standard ce sation treatment ad discuss smoke topic specif weight focu standard medic provid result document concern bw significantli improv abstin 1 6 12 month follow assess ment rel standard continu ou biochem verifi abstin rate 1 year 21 13 9 concern bw standard author affili depart psychiatri western psychiatr institut clinic univers pittsburgh medic center pittsburgh pennsylvania dr levin perkin kalarchian marcu ms houck depart statist psychiatri univers pittsburgh pittsburgh pennsylvania dr cheng depart psycholog michigan state univers east lans ms slane reprint arch intern med vol 170 6 mar 22 2010 www.archinternmed.com 543 2010 american medic associ right reserv download http archinte.jamanetwork.com univers aberdeen user 11 25 2015 pharmacolog approach smoke ce sation frequent clinic practic effect combin cessat counsel 11 13 sought test ad pharmacotherapi concern intervent enhanc smoke cessat weight concern women reason bupropion hydrochlorid sustain releas wide efficaci smoke cessat agent 14,15 par ticularli effect combin concern weight concern women abil tenuat weight gain reliev neg mood specifi calli bupropion therapi shown decreas weight gain cessat end 7 week treatment period16,17 1 year 17 addit weight concern women smoker pre viou episod depress enter cessat treat ment elev depress symptom 18 bupropion therapi allevi depress symptom cessat 19 studi design test combin bupropion therapi weight concern counsel improv rate sustain abstin weight concern women smoker hypothes addit bupropion concern increas rate smoke absti nenc rel placebo hypothes take bupropion weight concern coun sele efficaci standard smok ing cessat treatment receiv stan dard cessat counsel bupropion therapi produc higher abstin rate compar pla cebo final sought evalu combin weight concern counsel bupropion therapi postcess weight gain mood nicotin drawal symptom weight gain concern method studi design random doubl blind placebo control trial conduct septemb 1999 octob 2005 2 experiment manipul counsel concern standard medic bupropion placebo creat 4 treatment condit weight conc rn buprop ion concern igh concern placebo concern standard cessat counsel bupropion standard standard cessat counsel placebo standard studi design particip flow summar figur 1 figur 2 studi approv institut review board univers pittsburgh pittsburgh pennsylvania particip particip 349 women smoker ag 18 65 year motiv quit smoke smoke mini mum 10 cigarett dai endors concern post cessat weight gain assess 2 question rate scale 1 100 extrem 1 concern gain weight quit 2 concern quit smoke caus perman gain 10 15 pound amount typic gain weight concern women quit 5 eli gibl women requir score 50 higher question 5 women recruit gener popul poster advertis mail particip particip previou studi weight concern women detail figur 2 potenti particip clude current major depress disord suicid drug alcohol depend past year psychot disord condit lower seizur thresh medic contraind bupropion control hypertens bupropion past year 1 week pregnanc intent preg nant year current smoke weight loss treatment report tabl 1 baselin differ particip characterist screen procedur interest women invit inform meet inform consent obtain schedul physic examin blood work psychiatr inter view particip borderlin hypertens 140 159 90 99 hg requir obtain physician ap proval particip structur clinic interview diagnost statist manual mental disord fourth edit diagnosi scid administ telephon train clinician elig women randomli assign block 8 17 standard concern hypothes focus predominantli 3 4 condit concern concern standard women concern group ran domiz bupropion placebo 1 1 ratio standard group random 3 2 ratio studi medic suppli glaxosmithklin counsel session provid free charg studi medic studi medic initi treatment se sion target quit date tqd 10 14 dai set screen random smoke cessat counsel concern standard booster session drug target quit date session 1 2 3 4 5 8 12 15 18 week 1 week 2 week 3 month 1 month 3 month 6 month 12 figur 1 studi design overview bupropion hydrochlorid sustain releas concern cognit behavior therapi weight concern placebo standard standard cessat counsel ad discuss smoke topic specif weight focu reprint arch intern med vol 170 6 mar 22 2010 www.archinternmed.com 544 2010 american medic associ right reserv download http archinte.jamanetwork.com univers aberdeen user 11 25 2015 bupropion hydrochlorid sustain releas 150 mg pla cebo administ daili 2 dai daili 300 mg bupropion hydrochlorid mainder 26 week treatment session women met studi nurs assess advers effect vital sign document birth control review medic adher provid refil bupropion toler event medic reason medic discontinu 33 9.5 includ antidepress initia tion 3 increas blood pressur 11 prescript medic contraind bupropion 3 tori stroke previous report 1 edema 2 allerg reaction 13 reason medi random drug 5 random drug 3 total assess 12 mo 168 total assess 6 mo 183 total assess 3 mo 202 total assess 1 mo 252 assess 12 mo 57 assess 12 mo 37 assess 6 mo 64 assess 6 mo 40 assess 3 mo 70 assess 3 mo 39 assess 1 mo 86 assess 1 mo 52 concern 106 concern 87 alloc concern 198 assess elig 5182 excluded4638 meet inclus criteria1542 interested3096 excluded187 psychiatr disorders11 weight concern exclusion2 medic unabl drug42 chang mind132 sign consent544 alloc standard 159 intent treat analys 349 193 random medic assess 12 mo 46 assess 12 mo 28 assess 6 mo 47 assess 6 mo 32 assess 3 mo 56 assess 3 mo 37 assess 1 mo 64 assess 1 mo 50 standard 89 standard 67 156 random medic 357 random counsel figur 2 particip disposit figur 1 legend abbrevi tabl 1 baselin characterist treatment group characterist total sampl 349 treatment group concern 106 concern 87 standard 89 standard 67 ag mean sd 42.0 10.1 42.1 9.2 42.6 10.0 41.0 11.2 42.3 10.4 77 educ colleg graduat 33 36 27 36 36 49 white 86 88 87 85 84 92 weight mean sd kg 73.3 15.1 72.2 15.0 73.1 14.0 74.6 16.8 73.4 14.5 74 bmi mean sd 27.3 5.5 27.3 5.7 27.2 4.9 27.2 5.6 27.8 5.9 91 cigarett dai mean sd 20.7 8.4 20.8 8.9 20.4 8.5 20.1 7.0 21.6 9.1 72 nicotin depend scale 0 10a 5.2 2.2 5.1 2.5 5.1 2.1 5.1 2.1 5.6 2.1 52 previou quit attempt mean sd 3.1 2.6 2.9 1.8 3.3 3.0 3.0 2.4 3.5 3.2 48 bdi mean sd 7.3 6.6 6.4 6.1 6.8 6.6 8.0 6.1 8.2 8.1 09 abbrevi bupropion hydrochlorid sustain releas bdi beck depress inventori bmi bodi mass index calcul weight kilogram divid height meter squar concern cognit behavior therapi weight concern placebo standard standard cessat treatment ad discuss smoke topic specif weight focu aa score 10 repres depend reprint arch intern med vol 170 6 mar 22 2010 www.archinternmed.com 545 2010 american medic associ right reserv download http archinte.jamanetwork.com univers aberdeen user 11 25 2015 cation discontinu differ bupropion placebo 08 except allerg reaction 5.64 0.65 bupropion placebo 02 adher studi medic evalu elec tronic event monitor medic event monitor system aardex zug switzerland contain pressur activ microprocessor electron record medi cation bottl open data electron event monitor regularli download compar percentag pre scribe dose 30 dai treatment pair wise differ group evalu partici pant 2.3 fail return electron event monitor assess women major 75 pre scribe dose measur open electron cap dai women random receiv bupro pion adher receiv placebo take 78.9 69.6 prescrib dose 02 dif ferenc medic adher concern standard 83 studi counsel counsel involv 12 90 minut group session deliv 3 month clinician master degre train follow treatment manual particip receiv cessat counsel focus prepar quit benefit cessa tion cope smoke urg relaps prevent concern standard intervent differ addit content relat weight concern concern intervent goal concern intervent reduc con cern postcess weight gain promot smoke ce sation base assumpt maladapt thought belief eat shape weight prevent women accept modest 4.5 kg weight gain smoke ce sation therapi focus restructur thought food eat weight reevalu belief impor tanc low weight ideal shape 20 session includ cation cessat relat weight gain benefit ce sation rel modest weight gain disadvantag diet quit cognit strategi identifi restructur maladapt thought smoke eat belief gain weight unattract lesson target strain eat encourag moder consumpt healthi meal snack 6,21 standard intervent standard intervent directli address weight concern equat therapeut contact time tween 2 counsel condit women encourag discuss aspect smoke cessat relat cial situat role signific fam ili friend foster cessat discuss discu sion cessat relat weight concern redirect social situat relat smoke attend averag women attend 7.9 12 treatment session 8.6 8.0 7.4 7.5 concern concern standard standard group tendanc rate differ significantli group f3,345 3.18 02 post hoc test women concern group attend significantli session concern group major women 51 attend adequ number treatment session 75 proport adequ attend similar treatment group 23 3.58 31 differ women tend 75 treatment session baselin para meter 06 assess demograph inform smoke histori nicotin de pendenc collect prior random assess smoke secondari outcom complet base line prior counsel session weight concern assess month 3 6 12 beck depress inven tori bdi 22 assess depress symptom total score 3 visit prior tqd averag creat precess baselin tobacco withdraw assess visual analog scale rang 0 100 se vere 12 symptom tobacco withdraw women weigh street cloth shoe prior session height measur baselin mount stadiomet bodi mass index calcul weight kilogram divid height meter squar pre cessat weight comput mean weight 3 treatment session prior tqd postcess weight chang calcul differ precess weight assess tqd abstin visit tqd women interview smok ing time line follow back method 23 expir air carbon monoxid collect vitalograph breathco monitor vitalograph lenexa kansa sali vari sampl collect immedi assess ment visit 1 3 6 12 month read 8 ppm cotinin level 15 µg convert nano mole liter multipli 5.675 confirm smoke 24 follow visit 17 women 4.9 report addit cessat medic 71 nico tine replac therapi nrt 23 bupropion 6 rate cessat medic vari group 23 0.29 73 relaps defin report smoke 7 con secut dai point tqd biochem indi cation smoke 25 smoke 7 dai consecu tive consid relaps biochem marker smoke women drop treat ment consid relaps dai visit abstin verifi case cotinin measur confirm abstin women code relaps point preval abstin defin report smoke 7 dai prior assess read 8 ppm 1 3 6 12 month assess tqd prolong abstin defin meet criteria point preval abstin point prior includ current assess point statist analys statist test 2 side type error rate 0.05 evalu analys baselin variabl compar 2 test analysi varianc analys primari outcom smoke cessat rate durat reprint arch intern med vol 170 6 mar 22 2010 www.archinternmed.com 546 2010 american medic associ right reserv download http archinte.jamanetwork.com univers aberdeen user 11 25 2015 abstin evalu intent treat basi gardless medic adher treatment receiv attend follow visit rate prolong abstin compar end cessat counsel 3 month drug treatment 6 month follow 12 month logist regress model 3 hypothes contrast late hypothes contrast compar concern concern determin ad bupropion therapi special weight concern counsel enhanc abstin rate compar concern standard determin addit concern intervent improv abstin women receiv bupropion compar standard standard test bupropion concern intervent women smoker concern postcess weight gain evalu durat abstin surviv curv num ber dai relaps plot compar log rank test 3 hypothes contrast examin 6 12 month analys repeat 17 women cessat aid result chang exclud women report anali se includ women bodi weight examin maintain prolong abstin resumpt smoke confound analys weight chang separ mix effect model control precess bodi weight run subject time consid ran dom effect 3 plan contrast examin de pressiv symptom nicotin withdraw weight gain con cern evalu women maintain prolong abstin mix effect model control precess valu analys perform base line 3 6 12 month reflect initi quit end counsel medic treatment studi plan group con trast examin model squar root tran format appli depress symptom nicotin withdraw symptom adjust posit skew power determin log rank statist pare 2 surviv curv 2 side level 05 40 refer differ comput studi design power 0.80 greater detect 13.5 differ abstin rate concern standard concern concern 125 women group detect 15 differ standard standard 75 women standard group succeed recruit 349 women result smoke cessat 31.8 21.8 16.3 women met crite ria prolong abstin 3 6 12 month result 7 dai point preval abstin similar tabl 2 tabl 3 hypothes bupropion therapi improv abstin rate receiv concern group significantli women concern group maintain abstin 3 40.6 18.4 001 6 34.0 11.5 001 12 month 23.6 8.1 006 illustr figur 3 12 month fo low women concern group significantli slower time relaps concern group median number dai relaps 266 46 con trast bupropion therapi confer signific ben efit period activ drug treatment receiv standard counsel cessat rate 3 6 month tend larger standard standard tabl 2 tabl 3 rate significantli 07 addit 12 month dif ferenc abstin rate standard standard 05 time relaps 6 12 month similar standard standard 07 drug treatment 6 month women concern group slower time laps standard group 05 women concern group higher statist rate pro long abstin women standard group 3 40.6 32.6 25 6 month 34.0 21.4 053 12 month 23.6 19.1 45 women receiv bupropion concern intervent significantli creas abstin rate rel standard counsel ing surviv curv significantli 12 month 14 figur 3 tabl 2 rate biochem verifi prolong point preval abstin assess target quit date treatment group month target quit date concern 106 concern 87 standard 89 standard 67 prolong abstin 3 41 18 33 19 6 34 11 21 10 12 24 8 19 7 point preval abstin 3 42 18 37 25 6 37 11 26 13 12 29 10 27 16 abbrevi tabl 1 footnot treatment group abbrevi reprint arch intern med vol 170 6 mar 22 2010 www.archinternmed.com 547 2010 american medic associ right reserv download http archinte.jamanetwork.com univers aberdeen user 11 25 2015 weight gain depress symptom nicotin withdraw weight concern tabl 4 women maintain ab stinenc group differ weight gain plan contrast 37 3 month abstin women concern group gain mean sd 4.98 0.79 kg compar 5.31 0.96 5.49 1.29 kg women standard concern group women maintain abstin depress symptom withdraw differ ent women receiv concern concern standard 3 month tabl 4 women standard group report greater decreas depress t473 3.48 001 nicotin withdraw t471 2.30 005 symptom 3 month standard group 6 12 month differ depress withdraw symptom women concern group pare concern women standard group compar standard group comment weight concern impedi success smok ing cessat women result trial suggest combin bupropion therapi cognit behavior treatment design address wom en concern postcess weight gain improv smoke cessat outcom specif combina tion produc highest rate prolong abstin significantli delai relaps 6 month medic women present studi receiv bupropion concern interven tion margin enhanc cessat rate 6 month assess differ concern standard statist sig nific 1 year size effect concern abstin small benefit combin tervent noteworthi previou intervent combin pharmacolog approach specif nicotin replac behavior weight control smoker quit smoke fail improv quit rate 9,10 contrast current find suggest add ing bupropion therapi smoke ce sation medic special counsel inter vention weight concern smoker enhanc quit rate period activ treatment 6 month studi combin pharmacolog intensifi counsel weight con cern produc cessat rate women smoker concern postcess weight gain subgroup difficulti quit 2 4 tabl 3 plan contrast prolong abstin cohen effect size estim month target quit date abstin cohen concern concern concern 106 concern 87 3 41 18 001 51 6 34 11 001 57 12 24 8 006 45 concern standard concern 106 standard 89 3 41 33 25 17 6 34 21 053 29 12 24 19 45 12 standard standard standard 89 standard 67 3 33 19 07 32 6 21 10 08 31 12 19 7 046 37 abbrevi tabl 1 footnot treatment group abbrevi 1.0 0.6 0.8 0.4 0.2 0.0 0 2 4 6 8 10 12 time relaps mo pr op tio ye la ps standard 67 concern 106 standard 89 concern 87 lr χ2 16.79 001 3 figur 3 time relaps treatment group note log rank lr 23 19.06 001 group comparison 6 month 1 concern standard lr 2 3.81 051 2 concern concern lr 2 15.74 001 3 standard standard lr 2 2.51 11 group comparison 12 month 1 lr 23 16.79 001 2 concern standard lr 2 2.20 14 3 concern concern lr 2 11.5 001 4 standard standard lr 2 3.4 07 figur 1 legend abbrevi reprint arch intern med vol 170 6 mar 22 2010 www.archinternmed.com 548 2010 american medic associ right reserv download http archinte.jamanetwork.com univers aberdeen user 11 25 2015 althoughconcern bdidnotaffectwom en levelofweightgainconcern findingsdemonstrat ing thebenefitsof thecombinationsuggest themecha nism combin treatment aid abstin warrant research concern interven tion act complet separ weight concern current measur chang weight concern sensit impact intervent research larger sampl examin interact mood weightgain andweightconcernsmayhelpexplainsuccess ful cessat public health import smok ingcess interventionthatcan improveratesofpro long abstin refractori group women smokers2 4 warrant consider addit result merit comment find ing combin standard sociat significantli higher abstin rate bet ter time relaps rel standard drug treatment suggest lack efficaci bupropion weight concern women smoker small sampl size contrast result interpret cautious nonsignific differ enc abstin rate 1 year concern standard intervent women take bu propion contrast find prior trial 5 concern intervent medic im prove rate smoke abstin attenu weight gain cessat sampl women similar demograph characterist women pre studi weight concern women smoker interest pharmacotherapi differ present nonmed trial wai assess lack weight gain attenu women receiv concern intervent relat differ enc result trial conclus weight concern women smok er bupropion therapi increas cessat rate ad special weight concern intervent ad standard counsel bine bupropion therapi weight concern coun sele intervent tend improv cessat rate significantli lengthen abstin durat period activ treatment rel standard cessa tion counsel futur research focu po sibl mechan explain efficaci special iz counsel bupropion therapi address issu relat practic wider dissemin spe cializ counsel intervent weight concern women smoker result serv guid fur ther develop pharmacolog behavior ap proach smoker comorbid concern accept public septemb 15 2009 correspond michel levin phd depart psychiatri western psychiatr institut clinic univers pittsburgh medic center 3811 o’hara st pittsburgh pa 15213 levinem upmc.edu author contribut author full access data studi respons integr data accuraci data anali tabl 4 weight depress symptom nicotin withdraw women met criteria prolong abstin baselin 3 6 12 month target quit datea variabl treatment group particip 3 6 12 mo month target quit date 3 101 6 72 12 54 weight chang kg concern 43 36 25 4.98 0.79 3.96 0.62 4.85 0.97 standard 16 10 7 5.31 0.96 3.10 0.85 4.47 1.18 concern 29 19 17 5.49 1.29 3.81 1.17 5.38 1.85 standard 13 7 5 3.77 1.42 2.71 1.40 5.05 2.16 depress symptomsb concern 43 36 25 0.07 0.07 0.14 0.12 0.31 0.23 standard 16 10 7 0.37 0.20 0.38 0.28 0.11 0.17 concern 29 19 17 0.01 0.03 0.24 0.30 0.83 0.70 standard 13 7 5 0.19 0.22 0.12 0.25 0.09 0.26 nicotin withdrawalc concern 43 36 25 1.01 0.43 1.52 0.61 4.63 1.80 standard 16 10 7 2.67 0.86 1.94 0.96 4.65 2.30 concern 29 19 17 0.63 0.58 0.69 0.78 2.99 2.60 standard 13 7 5 0.09 0.23 0.20 0.49 1.59 2.30 weight concernsd concern 43 36 25 7.46 6.64 21.10 7.35 23.79 8.93 standard 16 10 7 13.16 8.16 25.95 9.75 27.88 10.60 concern 29 19 17 9.25 11.06 13.60 13.44 12.57 16.52 standard 13 7 5 6.00 12.89 2.43 16.72 1.50 20.74 abbrevi tabl 1 footnot adata mean se note signific differ group weight chang weight concern bthe beck depress inventory22 assess depress symptom ca squar root transform data conduct prior analysi nicotin withdraw assess visual analog scale rang 0 100 sever 12 symptom tobacco withdraw dweight concern assess question 15 pound weight gain affect motiv quit smoke stai quit rang 0 to100 100 repres highest level concern reprint arch intern med vol 170 6 mar 22 2010 www.archinternmed.com 549 2010 american medic associ right reserv download http archinte.jamanetwork.com univers aberdeen user 11 25 2015 si studi concept design levin perkin mar cu acquisit data levin kalarchian slane marcu analysi interpret data levin kin kalarchian cheng houck marcu draft manuscript levin perkin kalarchian cheng houck marcu critic revis manuscript import intellectu content levin perkin kalar chian houck slane marcu statist analysi cheng houck obtain fund perkin mar cu administr technic materi support levin kalarchian houck slane marcu studi supervi sion levin kalarchian marcu financi disclosur dr marcu serv consul tant glaxosmithklin sanofi aventi dr perkin serv consult glaxosmithklin fund support research support grant r01 da 04174 nation institut drug abus dr marcu dr levin effort partial support grant k01da15396 nation institut drug abus dr levin glaxosmithklin provid bupro pion hydrochlorid sr 150 mg match placebo oral administr free charg role sponsor fund agenc role design conduct studi collect man agement analysi interpret data prepar review approv manuscript previouspresentation:portionsof thisarticlewerepres ed 13th annual meet societi research onnicotineandtobacco february22,2007 austin texa addit contribut susan sereika phd assist electron event monitor data analys doniel neal ba carolyn font rn meghan wisinski bs provid valuabl research assist women particip research
lou al bmc famili practic 2013 14 91 http www.biomedcentral.com 1471 2296 14 91 research articl open access support smoke cessat chronic obstruct pulmonari diseas behavior intervent random control trial peian lou1 yanan zhu2 peipei chen1 pan zhang1 jiaxi yu1 ning zhang1 na chen1 lei zhang1 hongmin wu2 jing zhao2 abstract background cigarett smoke major risk factor chronic obstruct pulmonari diseas copd fewer smoke cessat measur conduct commun smoker copd china aim studi assess prevent effect behavior intervent smoke cessat potenti impact factor smoker copd china method randomis control smoke cessat trial 3562 patient copd current smoker alloc intervent group receiv behavior intervent control group receiv usual care year primari efficaci endpoint complet continu abstin smoke begin month 24 end month 30 particip month 48 result continu smoke abstin rate month 24 30 significantli higher particip receiv behavior intervent receiv usual care 46.4 3.4 0.001 continu abstin rate month 24 36 45.8 4.0 month 24 48 44.3 5.1 higher particip receiv behavior intervent control group famili member famili physician nurs smoke identifi influenc smoke cessat conclus behavior intervent doubl smoke cessat rate patient copd compli gener practition famili member famili physician nurs smoke main risk factor smoke cessat trial registr chines clinic trial registr chictr trc 12001958 keyword chronic obstruct pulmonari diseas smoker behavior intervent smoke cessat risk factor background chronic obstruct pulmonari diseas copd progress system inflammatori diseas usu alli abnorm respons noxiou particl gase tobacco smoke suscept indi vidual cigarett smoke worldwid risk factor copd 1,2 account 80 90 copd patient 3 løkke colleagu found smoke significantli increas cumul incid copd 25 year follow studi 4 highest correspond loupeian2004 yahoo.com.cn 1the xuzhou center diseas control prevent 142 west erhuan road xuzhou citi jiangsu provinc peopl republ china 221006 full list author inform end articl 2013 lou al license biom central common attribut licens http creativec reproduct medium provid incid stage copd 35.5 oc cur continu smoker incid smoker 7.8 4 compar cigarett smoke statu copd patient zhou al found greater amount smoke deeper inha lation airwai start smoke earlier ag greater risk copd 5 kanner al investi gate mild stage copd patient continu smo king speed forc expiratori volum 1 fev1 declin suffer lower airflow ill stop smoke protect peopl mild copd addit loss lung function 6 open access articl distribut term creativ ommons.org licens 2.0 permit unrestrict distribut igin work properli cite http www.chictr.org usercent project listbycreater.aspx mailto:loupeian2004 yahoo.com.cn http creativecommons.org licens 2.0 lou al bmc famili practic 2013 14 91 page 2 10 http www.biomedcentral.com 1471 2296 14 91 quit smoke cost effect method prevent lung function deterior copd patient longitudin cohort studi show continu smoker steep declin lung function stop smoke smoker lung function 7 lung health studi confirm smoke cessat reduc smoke relat declin lung function 8,9 copd patient sever impair lung function stop smoke lung func tion recov subsequ declin tend normal 10,11 hand smoke cessat improv airwai hyperrespons copd patient 12 smoke cessat earli stage benefit copd prognosi 7,8,11,13 effect stop smoke stage analys 1,377 exclud analysi complet exhal carbon monoxid level test 11 incomplet data 15 14 healthcar lost follow unabl contact 20 discontinu intervent di 370 1,814 alloc 7 healthcar center receiv alloc intervent 1,793 refus particip 21 behavior intervent 7 healthcar center figur 1 consort figur trial profil 14 data suggest import copd patient quit smoke earli 5 china 40 million peopl suffer copd 1.28 million di year 15 80 90 patient copd smoker 16 efficaci smoke cessat method establish patient copd 17 19 stringent advic pharmacolog therapi appli copd patient quit smoke compar gener smoker 20 examin influenc factor commun base smoke cessat trial current smoker copd china present studi conduct random control trial assess efficaci year beha vioral intervent help patient copd quit analys 1,230 exclud analysi complet exhal carbon monoxid level test 9 incomplet data 8 center lost follow unabl contact 26 discontinu intervent di 457 1,748 alloc commun receiv alloc intervent 1,730 refus particip 18 randomis control 7 healthcar center lou al bmc famili practic 2013 14 91 page 3 10 http www.biomedcentral.com 1471 2296 14 91 smoke explor potenti factor potenti bar smoke cessat method studi design studi random control trial conduct form januari 2008 2012 involv month patient recruit year interven tion year monitor recruit practic place 28 commun base previou epidemio logic studi 21 fourteen healthcar center enrol studi gener healthcar center intervent group receiv support implement behavior tervent program control healthcar cen ter deliv usual care random place healthcar center level healthcar center classi fi class high low task deleg gener practition nurs healthcar center class randomli alloc group consort figur 1 side 0.05 base side type 1 error α 0.05 80 power de tect 25 rel reduct quit rate allow 20 loss follow group minimum 7 healthcar center 50 patient copd group studi approv ethic committe xuzhou center diseas control prevent region ethic vet board xuzhou china addit agreement receiv relev health center inform consent obtain particip subject patient recruit famili physician 14 healthcar unit rural area xuzhou citi china januari march 2008 patient meet criteria baselin copd diagnos standard set global initi chronic obstruct lung diseas gold 22 mean particip underw standard measur lung function post bronchodil forc expiratori volum 1 fev1 forc vital capac fvc 70 counti peopl hospit revers airwai obstruct measur standard amer ica thorac societi guidelin 15 400 ml improv fev1 400 μg salbutamol spacer 23 studi popul consist current smoker stage copd patient ag 35 year older smoke 1 cigarett dai previou year stop smoke 3 month year exclud particip unstabl medic disord psychiatr affect lung function current diagnosi major depress particip consid loss follow contact di move place withdraw consent refus proce invalid data complet studi due reason behavior intervent screen phase individu select date stop smoke target dai told attempt stop dai patient told aim studi 136 gener practition work 7 healthcar center intervent group 6 hour train behavior intervent quit smoke train includ ingredi tobacco potenti harm smoke smoke copd harm exposur tobacco smoke smoke impact economi weigh pro con smoke smoke cessat copd patient quit smoke benefit quit smoke deal smoke crave prevent relaps smoke develop smoke cessat program quit smoke motiv interview team gener practition includ assi tant nurs establish healthcar cen ter intervent group respons supervis advis patient copd regist healthcar center quit smoke task includ home visit patient copd week obtain current condit quit smoke patient record time quit smoke patient quit smoke gener practition follow patient week month month end studi mean respons examin hale carbon monoxid level copd patient month particip ask meet gether discuss relev question quit smoke share experi quit smoke profession group includ respiratori rehabilita tion nutrit sport psycholog specialist rou tine visit copd patient healthcar center month gener practition healthcar center report follow statu pa tient copd smoke cessat condit month profession group assess smoke ce sation condit develop focu follow period patient focu team gener practition focu improv patient quit smoke follow period profession group provid physiolog support includ benefit smoke cessat deal obes tabl 1 baselin characterist healthcar unit intervent group control group unit 7 7 popul 301,785 298,467 annual capita incom yuan 21,345 464 21,545 471 capita hous area m2 25.6 6.4 25.6 6.5 medic staff 2,162 2,147 medic staff constitut doctor 654 38.1 648 37.0 nurs 1,041 38.7 1,058 41.0 medic staff educ background undergradu 1,576 1,573 junior colleg 482 479 medic staff profession titl senior titl 559 855 intermedi titl 881 878 figur number percentag state lou al bmc famili practic 2013 14 91 page 4 10 http www.biomedcentral.com 1471 2296 14 91 studi last year follow period personnel support offer easili access particip particip test exhal car bon monoxid level baselin month follow period baselin patient interview gen eral practition profession group healthcar center particip ask quit smoke particip quit smoke booklet includ harm ingredi cigarett smoke diseas includ copd benefit quit smoke deal crave smoke wai quit smoke patient intervent group strongli en courag stop smoke receiv smok ing cessat advic baselin interview consist 5 8 minut discuss member profe sional group smoke habit smoke cessa tion advic focus risk develop copd lung cancer coronari arteri diseas harm ef fect famili member particip want stop smoke provid plan quit smok ing ask particip set date stop smoke target dai patient smoke twenti cigarett dai decreas ciga rett dai dai patient stop smoke encourag stop smoke month decreas cigarett dai week suggest particip postpon time long smoke drink water talk turn attent thing recommend ef fectiv wai postpon smoke time pharmaco logic treatment smoke addict provid current studi smoke statu exhal carbon monoxid measur baselin month follow period confirm smoke statu healthcar center primari efficaci measur continu abstin smoke 2 year start month 24 end month30 defin continu abstin particip report cigarett dai 6 month confirm exhal carbon mon oxid valu 10 part million secondari measur efficaci continu absti nenc month 24 36 24 48 continu abstin enc month 24 48 defin particip continu abstin month 24 36 diari cigarett count week 37 48 exhal carbon monoxid valu 10 ppm month 48 assess influenc factor particip ask complet questionnair includ ag sex current employ statu educa tion level marit statu physic activ alcohol number smoke famili member number cigarett smoke motiv stop smoke smoke pack year averag daili number cigarett smoke divid 20 multipli smoke year comorbid clude chronic bronchiti emphysema asthma lung diseas diabet treatment blood pressur stroke coronari heart diseas angina heart attack heart diseas condit record pa tient baselin report educ categor high school high school high school level alcohol drink defin consumpt 30 alcohol week year height weight measur bodi mass index bmi calcul bmi weight kilo gram divid height meter squar bmi categor underweight 18.5 kg m2 normal 18.5 24.0 kg m2 overweight obes 24.0 kg m2 24 mental health depress anxieti evalu at hospit anxieti depress scale had 25 dyspnea measur medic research council mrc dyspnea scale 26 fagerström test nicotin depend ftnd 27 usual care particip control group treat healthcar provid gener practition usual manner tabl 2 characterist smoke rate baselin variabl intervent group 1,814 control group 1,748 sex men 868 100 840 100 women 946 100 908 100 ag 40 292 100 279 100 50 370 100 358 100 60 507 100 490 100 70 478 100 463 100 80 167 100 158 100 educ level high 159 100 152 100 middl 327 100 323 100 low 1328 100 1273 100 household incom high 148 100 146 100 middl 1529 100 1466 100 low 137 100 136 100 alcohol user 659 100 628 100 1155 100 1120 100 comorbid 473 100 459 100 1341 100 1289 100 depress 640 100 622 100 1174 100 1126 100 anxieti 343 100 337 100 1471 100 1411 100 pack year 30 604 100 572 100 30 648 100 631 100 40 562 100 545 100 nicotin addict fagerström score 0 3 526 100 502 100 4 6 648 100 654 100 7 640 100 592 100 mrc scale 0 91 100 89 100 1 358 100 346 100 2 524 100 499 100 3 502 100 486 100 4 339 100 328 100 tabl 2 characterist smoke rate baselin continu smoke histori famili member 1128 100 1075 100 686 100 673 100 smoke histori respons doctor nurs 798 100 778 100 1016 100 970 100 mrc medic research council lou al bmc famili practic 2013 14 91 page 5 10 http www.biomedcentral.com 1471 2296 14 91 content number usual care servic standard particip follow up 2 month ask symptom aggrav medic statist analys analys intent treat popul consist patient month studi particip withdrew studi smoker spss window version 11.5 spss data analysi test consid signific 0.05 baselin demograph smoke char acterist mean score mrc mental health compar assess potenti differ tween intervent group control test analyz differ mean score group chi squar test evalu stat istic signific smoke cessat rate group studi effect ag sex educa tion level household incom alcohol user depress anxieti smoke pack year nicotin addict dyspnea smoke histori famili member smoke histori respons doctor nurs patient multi variat logist regress variabl ad basic model includ intervent group assign centr candid variabl 0.05 enter multipl logist regress model analysi analyz risk factor affect quit smoke odd ratio confid interv ci valu calcul result gener characterist particip baselin group drawn singl district similar annual averag incom access health servic main demographi baselin tabl 1 3562 smoker 26.8 complet follow visit i. 46 subject move region 39 declin particip follow visit miscellan reason 20 complet exhal car bon monoxid level test 23 incomplet data 827 di intervent 370 control 457 χ2 28.76 tabl 3 abstin rate intervent follow phase month continu abstin intervent group control group 1377 1230 6 79 5.7 3 0.2 0.001 12 198 14.4 11 0.9 0.001 18 342 24.8 24 2.0 0.001 24 508 36.9 36 2.9 0.001 30 639 46.4 42 3.4 0.001 36 630 45.8 49 4.0 0.001 42 622 45.2 57 4.6 0.001 48 610 44.3 63 5.1 0.001 cigarett month 6 onward lou al bmc famili practic 2013 14 91 page 6 10 http www.biomedcentral.com 1471 2296 14 91 0.001 total number lost behavior interven tion control group 437 518 signific differ lost rate observ behavior intervent control group χ2 13.94 0.001 statist signific diff renc smoke histori ag sex attend follow respond final 2607 subject analyz studi 1377 beha vioral intervent group 1230 control group figur 1 behavior intervent group mean ag median smoke year median nicotin depend scale median mrc scale 61.6 10.2 year 37.8 11.7 pack year 5.1 2.1 2.4 1.5 re pectiv control group mean ag 61.5 10.1 year median smoke year 37.6 11.5 pack year median nicotin depend scale 5.0 1.9 statist signific differ indic observ group descript characterist behavior intervent control group shown tabl 2 show statisti calli signific differ intervent control group ps 0.05 quit smoke rate rate continu abstin month 24 end month 30 higher intervent group control group 46.4 3.4 0.001 639 1377 46.4 particip receiv behavior intervent remain abstin compar 42 1230 3.4 receiv usual care rate continu abstin significantli higher behavior intervent usual care 24 month intervent phase 48 month follow visit tabl 3 48 month follow particip receiv behavior intervent remain abstin receiv usual care 44.3 5.1 0.001 behavior intervent significantli usual care month 36 48 follow phase 0.001 signific differ continu smoke absti nent rate consist observ subgroup ag gender educ level household incom alcohol user comorbid i. higher smoke cessat rate intervent group control group tabl 4 verifi quit smoke success smoke cessat 4 year follow confirm low exhal level 610 ject mean exhal sustain quitter sig nificantli lower mean 3.7 ppm sd 1.5 compar continu smoker mean 15.7 ppm sd 5.1 0.001 subject continu smoker report reduc cigarett smoke dai end 4 year follow mean 14.5 sd 7.2 compar baselin mean 20.5 sd 9.2 risk factor affect smoke cessat independ com.ibm.drl.hbcp.predictor success smoke cessat clude women older ag drinker comorbid lower had anxieti had lower had depress had smoke pack year lower fagerström score higher mrc score tabl 5 patient quit smoke famili physician nurs nonsmok famili member smoke tabl 5 word famili physician nurs famili member smoke strong predic tor failur quit smoke confound plai role multipl logist regress analysi show signific effect alcohol drinker comorbid had had smoke pack year fagerström score mrc score famili member smo king famili physician nurs smoke pre dictor smoke cessat adjust ag gender tabl 5 famili member smoke strongest com.ibm.drl.hbcp.predictor sustain smoke 12.1 discuss result show behavior intervent group high rate abstin smoke 24 month smoker copd compar control group advantag usual care continu 24 month discontinu behavior intervent show famili physician nurs famili member smoke strong com.ibm.drl.hbcp.predictor failur quit smoke popul attribut risk copd late cigarett smoke higher 45 28,29 smoke cessat effici slow copd progress lung health studi lh exam in effect tobacco intervent copd tabl 4 observ frequenc abstin month 31 end month 48 variabl smoke cessat group 1377 control group 1230 differ 95 ci sex men 265 659 40.2 28 601 4.7 35.5 23.6 49.8 0.001 women 345 718 48.0 35 628 5.6 42.4 27.8 58.6 0.001 ag 40 87 221 39.4 5 197 2.5 36.9 29.5 45.6 0.001 50 118 280 42.1 11 250 4.4 37.7 26.5 50.1 0.001 60 171 385 44.4 17 343 5.0 39.4 26.6 53.4 0.001 70 167 362 53.8 17 323 5.3 48.5 37.8 60.7 0.001 80 67 129 51.9 13 117 11.1 40.8 33.5 49.2 0.001 educ level high 74 143 51.7 8 129 6.2 45.5 37.7 54.3 0.001 middl 137 313 43.8 14 280 5.1 38.7 25.4 53.2 0.001 low 399 921 43.3 41 821 5.0 38.3 20.6 57.3 0.001 household incom high 48 112 42.8 7 114 6.1 36.7 30.3 43.9 0.001 middl 524 1173 44.7 53 1051 5.0 39.7 20.5 59.8 0.001 low 38 92 41.2 3 65 4.6 36.6 31.3 42.4 0.001 alcohol user 201 498 40.4 17 434 3.9 36.5 25.6 49.4 0.001 409 879 46.5 46 796 5.8 40.7 26.4 56.1 0.001 comorbid 0.001 68 136 50.0 15 121 12.4 37.6 25.3 55.4 0.001 542 1241 43.4 48 1109 3.9 39.5 20.7 58.6 0.001 depress 95 513 18.5 13 518 2.5 16.0 12.7 20.5 0.001 515 864 59.6 50 712 7.0 52.6 41.9 63.5 0.001 anxieti 0.001 81 258 31.4 9 230 4.0 27.4 20.1 35.7 0.001 529 1119 47.3 54 1000 5.4 42.1 33.3 51.1 0.001 pack year 30 266 564 47.2 32 504 6.3 40.9 32.4 50.4 0.001 30 200 454 44.1 18 406 4.4 39.7 31.8 48.2 0.001 40 144 359 40.1 13 320 4.1 36.0 29.7 43.3 0.001 nicotin addict fagerström score 0 3 243 432 56.3 25 386 6.5 49.8 35.6 64.6 0.001 4 6 233 486 47.9 23 434 5.3 42.6 29.1 56.7 0.001 7 134 459 29.2 15 320 4.7 24.5 13.4 36.6 0.001 mrc scale 0 21 70 30.0 2 71 2.8 27.2 22.6 32.3 0.001 1 107 272 39.3 7 243 2.9 36.4 27.5 46.3 0.001 2 175 398 44.0 17 356 4.8 39.2 27.7 51.7 0.001 3 178 380 46.8 20 339 5.9 40.9 28.1 54.4 0.001 4 129 257 50.2 15 221 6.8 43.4 31.1 56.7 0.001 lou al bmc famili practic 2013 14 91 page 7 10 http www.biomedcentral.com 1471 2296 14 91 tabl 4 observ frequenc abstin month 31 end month 48 continu smoke histori famili member 247 816 30.3 28 729 3.8 26.5 13.2 40.1 0.001 363 561 64.7 37 501 7.4 57.3 38.9 76.2 0.001 smoke histori respons doctor nurs 214 589 36.3 22 526 4.2 32.1 21.7 43.9 0.001 396 788 50.3 41 704 5.8 44.5 32.1 57.6 0.001 tabl 5 multipl logist regress analys factor failur smoke cessat variabl 95 ci valu gender femal 1.00 0.001 male 1.50 1.28 1.77 comorbid 1.00 0.000 1 19 1.08 1.38 alcohol drink 1.00 0.001 0.61 0.51 0.72 depress 1.00 0.003 1.26 1.09 1.40 anxieti 1.00 0.000 1.25 1.07 1.43 pack year 30 1.00 30 1.08 1.01 1.24 0.009 40 1.55 1.34 2.21 0.000 nicotin addict fagerström score 0 3 1.00 4 6 1.25 1.09 1.49 0.002 7 1.62 1.29 2.15 0.000 mrc scale 4 1.00 3 1.37 1.12 1.66 0.001 2 1.52 1.28 1.81 0.000 1 1.65 1.35 2.01 0.000 0 1.72 1.37 2.21 0.000 famili member smoke 1.00 0.000 12.1 18.7 35.2 famili doctor smoke 1.00 0.000 4.7 2.26 10.4 mrc medic research council lou al bmc famili practic 2013 14 91 page 8 10 http www.biomedcentral.com 1471 2296 14 91 progress current smoker 8 smoker mild moder copd 4 month terval check smoke statu complianc smoke cessat determin report verifi measur expir carbon monoxid sali vari cotinin level 4 year follow 22 patient copd continu abstin smoker group receiv special tobacco treatment con trast 5 patient usual care group continu abstin smoker smoke habit ori ginal lung health studi treatment group tend con verg 93 particip abstin lung health studi abstin 11 year 30 behavior intervent show con sistent significantli higher continu smoke abstin enc rate 44.3 patient copd compar control group 5.7 year found 22.6 smoker reduc amount cigarett smoke data highlight feasibl efficaci conduct commun base smoke cessat patient copd long term follow studi warrant evalu longitudin effect smoke cessat studi identifi import factor potenti impact smoke cessat includ women older drinker comorbid dyspnea patient depress anxieti higher smoke pack year nicotin addict difficult quit smoke result provid addit inform potenti method improv manag copd patient previou studi found femal smoker copd experi faster declin lung func tion male smoker 31 studi femal smoker larger gain lung function stop smoke compar male quitter 32 data strongli suggest smoke cessat par ticularli import women increas suscept copd progress continu smoke obtain benefit quit smoke pare male smoker result strong biolog evid tool conduct commun base intervent convinc women quit smoke consist observ studi women copd easi quit smoke lou al bmc famili practic 2013 14 91 page 9 10 http www.biomedcentral.com 1471 2296 14 91 time found import factor famili member smoke famili physician smoke sig nificantli smoke cessat china luker conduct systemat review assess effect famili focus smoke cessat intervent patient copd 33 conclus obtain effect famili focus intervent clude factor marit statu smoke statu hous hold member support smoke cessat neg impact smoke doctor nurs smoke cessat copd patient displai great challeng face commun base intervent doctor nurs provid posit attitud health ledg persuad copd patient quit smoke plai critic role improv efficaci smoke cessat intervent messag quit smoke benefit health diseas progress convinc provid doctor nurs smoker hand data suggest lot space improv smoke cessat firstli persuad doctor nurs quit smoke strength current studi includ commun base intervent design larg sampl size randomli se lect intervent control group low rate loss follow accur smoke cessat data obtain questionnair exhal mea urement made current result reliabl limit moder durat year evalu long term efficaci smoke cessat detail data comparison lung function clinic outcom copd patient smoke cessat limit potenti reduc efficaci quit smoke previou studi demonstr smoke cessat slower declin lung function reduc risk hospit total mortal studi 8 know smoker lung function declin motiv patient quit smoke 18,34,35 data strongli encourag adopt lung function detec tion commun base intervent improv efficaci smoke cessat conclus summari commun base studi reveal year behavior intervent significantli decreas smok ing rate smoke patient copd import factor identifi posi tive neg impact smoke cessat smoke behavior famili member respons doctor nurs smoke cessat long term follow smoke patient copd valid lung function improv effect commun base inter vention benefit prognosi copd patient compet interest author declar compet interest author contribut lz pl particip write titl abstract contribut write manuscript draft review full text yn conceptu studi particip design titl abstract screen full text screen data extract analysi draft manuscript pc pz perform literatur search particip titl abstract screen full text review contribut manuscript draft jy nz conceptu studi particip design titl abstract screen full text screen contribut manuscript draft nc lz contribut concept studi particip studi design contribut manuscript draft hw jz lead author origin review contribut concept studi particip studi design contribut manuscript draft author read approv final manuscript acknowledg research fund scienc technolog project xuzhou citi 2007 xm07c037 research independ fund organ funder studi influenc studi design data collect analysi interpret data write report decis submit articl public author detail 1the xuzhou center diseas control prevent 142 west erhuan road xuzhou citi jiangsu provinc peopl republ china 221006 2depart respiratori medicin hospit xuzhou medic colleg 99 west huaiai road xuzhou citi jiangsu provinc peopl republ china 221006 receiv 20 march 2013 accept 18 june 2013 publish 27 june 2013
efficaci motiv interview smoke cessat tuberculosi clinic tshwane south africa random control trial goedel louwagie1 kolawol okuyemi2 olalekan ayo yusuf1,3 school health system public health faculti health scienc univers pretoria south africa 1 depart famili medicin commun health univers minnesota minneapoli mn usa2 dean director offic school oral health scienc faculti health scienc univers limpopo medunsa campu south africa3 abstract background aim tuberculosi tb patient smoke risk advers tb outcom long term health effect smoke studi aim determin efficaci motiv interview lai health care worker lhcw assist tb patient quit smoke design multi centr group parallel individu random control trial set primari care tuberculosi clinic south african township particip newli diagnos adult tb patient identifi current smoker random motiv interview lhcw intervent group 205 smoke cessat advic tb nurs control group 204 measur primari outcom report sustain 6 month smoke abstin exhal carbon monoxid test offer half particip secondari outcom sustain abstin 3 month 7 dai point preval abstin 1 3 6 month quit attempt alloc conceal primari analysi reli intent treat multi level analysi account site heterogen effect find report 6 month sustain abstin 21.5 intervent group versu 9.3 control group rel risk rr 2.29 95 confid interv ci 1.34 3.92 biochem verifi 6 month sustain abstin higher intervent group rr 2.21 95 ci 1.08 4.51 166 partici pant offer carbon monoxid test report 3 month sustain abstin 25.4 intervent group 12.8 control group rr 1.98 95 ci 1.24 3.18 conclus motiv interview lai counsellor promot smoke cessat tuberculosi patient south africa approxim doubl sustain smoke abstin 6 month compar advic keyword hiv lai health care worker random control trial tobacco tobacco cessat tuberculosi correspond goedel louwagi faculti health scienc school health system public health privat bag 323 pretoria 0001 sa south africa mail goedele.louwagi up.ac.za submit 5 februari 2014 initi review complet 10 march 2014 final version accept 16 june 2014 introduct south africa highest number incid tuberculosi tb case world 1 infect human immunodefici viru hiv impor tant driver epidem coinfect rate approxim 60 1 treatment success rate remain low death treatment interrupt fre quent neg outcom 1 import int grate hiv tb servic recogn progress integr servic made 1 potenti import driver tb epidem contributor poor tb treatment outcom activ tobacco smoke establish risk factor tb infect progress activ tb diseas mortal iti tb 2 4 smoker sever clinic manifest poorer outcom dy tb smoker increas risk delai sputum convers 5 tb treatment failur 6 tb recurr 7 9 possibl drug resist anc 10 tobacco smoke impair lung defenc mecha nism structur alter cellular humour immun 11 14 behaviour characterist smoker research report bs_bs_banner doi 10.1111 add 12671 2014 societi studi addict addict 109 1942 1952 mailto:goedele.louwagi up.ac.za lower drug adher 15,16 partial explain poorer outcom tb patient smoke tobacco tobacco smoke harm hiv tb coinfect patient risk addit short long term mortal morbid due tobacco smoke hiv infect 17 21 patient hiv surviv longer era highli activ antiretrovir therapi haart increasingli import prevent long term advers health relat tobacco smoke smoke cessat intervent introduc easili tb smoke affect lung diagnos tb ideal learn opportun 22 studi report promi ing exploratori pilot result integr tobacco cessat servic tb care 22 26 larg cluster random control trial pakistan behaviour support session bupropion highli effect assist patient suspect tb quit 27 knowledg tobacco ce sation trial undertaken popul tb patient high hiv coinfect rate effect ness differ dualli infect tb patient sever ill neg outcom expec tanci life function posit neg motiv quit provis art care smoke cessat servic tb ser vice add layer complex feasibl integr servic understaf health system studi aim determin efficaci motiv interview lai health care worker lhcw assist tb patient tobacco cessat set high hiv tb coinfect rate method studi set particip studi place largest tb clinic soshanguv larg urban township citi tshwane metropolitan municip south africa purpos select studi larg number tb patient primari care facil offer tb diagnosi treatment counsel test hiv referr antiretrovir treat ment servic lhcw assist varieti admini trativ counsel task clinic purpos studi lhcw select train data collector tobacco cessa tion counsellor paid stipend 160 dollar month minimum 11 year school 1 year experi lhcw major previous complet formal counsel cours adult patient initi tb treatment clinic approach particip studi par ticip exclud 18 ill particip unabl understand lan guag questionnair administ smoke tb treatment 1 month initi plan sampl size 548 base assum 10 sustain quit rate control 20 intervent group 80 power side test includ 20 attrit percentag base estim studi protocol smoke cessat tb patient 28 assumpt tb patient particu larli motiv quit 22,23 due slower recruit smoker anticip period project fund permiss grant institut ethic committe review actual number smoker need sampl size minimum 400 estim base con serv estim 5 cessat control group 15 intervent group take account 20 attrit trial design procedur multi centr group parallel individu random control trial rct lhcw identifi current smoker patient await registr tb patient clinic baselin screen ing questionnair valid report current smoke statu perform stage current smoker alloc lhcw intervent control arm mean sequen tialli number seal opaqu envelop ensur alloc conceal random sequenc gener independ epidemiologist involv research project 1 1 alloc random block size 2 4 6 8 10 particip alloc intervent arm receiv motiv interview mi session 15 20 minut lhcw refer tb nurs work consult room tb treatment particip belong random intervent control group receiv short standard iz smoke cessat messag tb nurs tobacco extrem harm health stop smoke tb heal lower risk tb futur reduc risk heart diseas cancer protect children tb pro fession nurs advis stop tobacco interest health patient receiv smoke cessat tuberculosi servic 1943 2014 societi studi addict addict 109 1942 1952 smoke cessat booklet suppli nation council smoke south africa 29 blind respond lhcw intervent receiv lhcw site site tb nurs blind alloc arm follow questionnair administ lhcw particip routin 1 3 6 month tb treatment visit particip miss plan visit remind telephon follow inter view particip unabl back clinic person interview telephon tb nurs charg clinic underw 1 dai train project deliv tobacco cessat messag lhcw receiv depth train administ questionnair enrol random procedur 3 dai mi train weekli 2 weekli supervisori site visit research coordin site durat project baselin leg studi pilot clinic stagger fashion 6 week minor made questionnair intervent intervent base mi 30 mi defin direct client centr counsel style elicit behaviour chang help client explor resolv ambival 31 method moder effect clinic condit includ smoke cessat 32 34 short form commonli refer mi develop busi clini cal set smoke cessat simpl page approach consist quick assess patient iden tifi problem solut set target 30 approach studi messag risk tailor rela tionship smoke tb lhcw help patient highli motiv quit highli confid abil quit quit plan 35 lhcw receiv 3 dai depth train tobacco cessat mi tobacco cessat experienc mi counsellor trainer train involv video tape role plai feedback session ensur counsellor understood principl spirit mi appli primari skill open end question affirma tion reflect listen summari consist patient encount pre post train test administ immedi train start work shop insuffici 36,37 site follow practic session organ approxim 4 month videotap role plai inform reinforc knowledg skill outcom measur outcom measur russel standard criteria 38 variat allow laps fact particip biochem verifi outcom measur primari outcom report 6 month sustain abstin respond ask back period interview 6 month ago ignor 2 week inter view smoke cigarett smoke tobacco product part inter view similar question ask 3 month follow question question permiss laps defin hugh al 39 actual analysi stringent criterion smoke initi window period partici pant appear misunderstand complex que tion relat permiss laps particip miss result 1 3 month regard success 6 month provid smoke past 6 month 38 particip made conflict statement report smoke 3 month declar sustain abstin 6 month classifi continu smoker secondari outcom sustain 3 month absti nenc 7 dai point preval abstin ppa 1 3 6 month intervent quit attempt defin smoke 24 hour intent quit 1 month follow enquir receipt cessat advic smoke cessat booklet tb nurs enrol visit report smoke abstin biochem verifi pico smokerlyz carbon monoxid monitor bedfont scientif maidston uk standard recommend cut read 10 part million p.p.m signifi smoke 38 select prefer monitor ing devic eas exclud user smokeless tobacco 38,40,41 due financi constraint exhal monitor rotat half clinic chang half month half respond offer test follow visit patient monitor alloc clinic spe cific time point approach introduc bogu pipe line procedur increas likelihood truth answer 1944 goedel louwagi al 2014 societi studi addict addict 109 1942 1952 follow period 4 week post date actual follow date allow 38 pre date period permit 1 week 1 month follow 3 week 3 month follow 4 week 6 month follow baselin measur questionnair translat commonli local languag back translat english ensur accuraci translat implement translat english tb hiv relat informa tion obtain particip standard individu tb record question tobacco adapt global adult tobacco survei question nair 42 heavi smoke index hsi wake smoke cigarett cigarett smoke dai indic tobacco depend 43 collect inform demograph socio econom psychosoci indic influ enc smoke cessat rate recent depress symptom 44 perceiv stress 45 social support 46 illicit drug alcohol problem 47 enquir smoke relat characterist efficaci 48 confid motiv quit stage chang 49 ethic consider inform consent obtain particip smoke baselin screen questionnair par ticip trial particip identifi current smoker includ inform natur studi procedur involv potenti benefit harm withdraw time altern treatment confidenti compens lunch parcel dollar trial regist south african doh 27 0811 3539 pan african pactr 201311000695277 clinic trial regist approv ethic committe univers pretoria protocol 116 2011 funder influenc data collect analysi report data manag analysi data doubl enter microsoft excel ana lyse stata version 12 50 rel risk rr primari secondari estim multi level poisson regr sion analysi account site heterogen effect repeat analysi adjust base line variabl pre studi protocol hsi ag durat smoke alcohol problem absolut risk differ calcul determin bio chemic verifi smoke abstin type analysi perform limit subgroup studi particip offer test includ studi particip particip refus test count continu smoker primari analysi intent treat itt patient lost follow follow window period assum contin u smoke result analys protocol elig patient patient lost follow exclud analysi result particip follow trial execut subject recruit 14 septemb 2011 25 april 2013 end octob 2013 2411 patient screen elig 69 consent studi 1505 current smoker remaind exclud reason list fig 1 result 205 particip random intervent 204 control follow rate 82.4 80.2 76.5 1 3 6 month follow differ signifi cantli arm total 21 particip di follow 10 control group 4.9 11 mi group 5.4 0.83 baselin characterist thirti 42 44 122 102 63 smoker enrol respect tb facil baselin characterist arm trial similar minor differ group tabl 1 outcom heterogen effect site rela tive risk result calcul facil random effect level analysi primari outcom report 6 month sustain abstin high intervent group control group 21.5 versu 9.3 rr 2.29 95 confi denc interv ci 1.34 3.92 absolut differ enc 12 result similar adjust pre potenti com.ibm.drl.hbcp.predictor rr 2.31 95 ci 1.33 4.01 6 month 165 particip underw exhal test particip refus test count continu smoker offer test biochem verifi quit rate signifi smoke cessat tuberculosi servic 1945 2014 societi studi addict addict 109 1942 1952 cantli higher intervent arm control arm 28.9 versu 13.3 crude rr 2.21 95 ci 1.08 4.51 adjust rr 2.33 95 ci 1.11 4.90 subgroup analysi associ remain signific rr 2.15 95 ci 1.06 4.40 studi particip includ denomi nator tabl 2 secondari outcom month sustain abstin high intervent group control group unadjust 25.4 versu 12.8 rr 1.98 95 ci 1.24 3.18 adjust analys rr 2.04 95 ci 1.24 3.35 biochem verifi 3 month abstin rate significantli higher inter vention group adjust analysi crude analysi report 7 dai ppa higher intervent group 1 3 month follow quit attempt differ intervent arm tabl 3 similar slightli stronger associ found protocol analys primari secondari outcom result present respond 87 confirm tb nurs enquir smoke statu enrol third case nurs advis patient stop smoke gener tailor advic tb 68.1 10 patient 10.3 receiv tb tailor smoke cessat messag 11 advis reduc smoke rest receiv messag 10.6 smoker receiv smoke cessat booklet baselin 82.4 quarter 74.6 report read tabl 4 discuss current studi show mi counsel lhcw effect assist tb patient quit tobacco smoke rel absolut effect figur 1 consort flow diagram ainclud patient diagnos tuberculosi tb patient found treatment 1 month patient fact past smoker b22 24 34 window period count smoker intent treat itt analysi 1946 goedel louwagi al 2014 societi studi addict addict 109 1942 1952 higher result systemat review effect mi tb popul 33,34 high cessat rate studi possibl partial attribut low prior exposur type smoke cessat counsel studi popul 51 judgement client centr approach mi crucial success rate care context patient expos paternalist con descend counsel style 52 lastli partici pant ill tb hiv link smoke tb easili understood 22 effect intervent lower cluster rct patient suspect tb pakistan higher quit rate pakistan studi possibl explain intens smoke cessat intervent behaviour chang consult 30 40 minut shorter session buproprion report quit rate high control group similar pakistan tb studi 27 explan advic smoke cessat booklet provid tb nurs aid particip quit answer tabl 1 baselin characterist particip mi group 205 control group 204 men 188 205 91.7 180 204 88.2 ag mean sd 409 40.3 sd 10.3 42.3 sd 10.1 educ primari school 66 200 33.0 85 204 41.7 high school 100 200 50.0 94 204 46.1 complet high school higher 34 200 17.0 25 204 12.3 marit statu marri 52 202 25.7 62 204 30.4 divorc separ widow 16 202 7.9 21 204 10.3 marri 134 202 66.3 121 204 59.3 asset score median iqr 404 4 3 4 4 3 4 hungri 1 dai month 30 202 14.9 33 203 16.3 employ categori unemploi 55 199 27.6 60 201 29.9 work full part time 131 199 65.8 130 201 64.7 workinga 13 199 6.5 11 201 5.5 household earn zarb 1 500 74 201 36.8 64 202 31.7 zar 501 2500 100 201 49.8 101 202 50.0 zar 2500 27 201 13.4 37 202 18.3 depress symptom past 2 week 57 181 31.5 69 182 37.9 perceiv stress score rang 0 16 median iqr 401 8 5 10 8 5 9 mo social supportc rang 1 100 median iqr 392 75 59.2 88.2 75 56.6 89.5 alcohol problem 109 203 53.7 91 199 45.7 illicit drug 26 199 13.1 33 197 16.8 episod tuberculosi 170 198 85.9 177 200 88.5 pulmonari tuberculosi 183 200 91.5 189 203 93.1 hiv posit 164 187 87.7 156 188 83.0 ag start smoke median iqr 316 17 15 20 18 15 20 year regular smoke median iqr 372 20.0 14.2 26.8 20.7 14.4 28.9 daili cigarett consumption median iqr 8 5 14 8 5 12 mean sd 341 10.0 sd 7.1 9.8 sd 7.1 heavi smoke index 4 37 182 20.3 40 188 21.3 quit attempt past 12 month 104 198 52.5 103 200 51.5 motiv score median iqr rang 1 10 400 9 7 10 9 7 10 confid score median iqr rang 1 10 401 9 6 10 9 6 10 efficaci score median iqr rang 9 45 389 26 18 35 25 18 36 prepar stage chang 106 187 56.7 116 190 61.1 aretir unabl work homemak student bzar 8.7 1 dollar time end studi cmedic outcom survei weight score 0 100 dcage cut annoi guilt ey open score 2 edaili smoker mi motiv interview sd standard deviat iqr interquartil rang smoke cessat tuberculosi servic 1947 2014 societi studi addict addict 109 1942 1952 tabl 2 primari outcom 6 month sustain abstin intervent control absolut differ crude rra adjust rrb 95 ci 95 ci 95 ci report 6 month sustain abstinencec 44 205 21.5 19 204 9.3 0.12 0.05;0.19 2.29 1.34;3.92 2.31 1.33;4.01 biochem verifi 6 month sustain abstinenc particip offer test 166e 24 83 28.9 11 83 13.3 0.16 0.03;0.28 2.21 1.08;4.51 2.33 1.11;4.90 biochem verifi 6 month sustain abstinencec participantsf 24 205 11.7 11 204 5.4 0.06 0.01;0.12 2.15 1.06;4.40 2.14 1.01;4.51 aunivari multi level poisson regress facil random effect bmulti level poisson regress facil random effect adjust heavi smoke index hsi ag durat smoke alcohol problem pre studi protocol 395 entir sampl 161 biochem verifi result cparticip lost follow 6 month visit window period consid smoke dself report sustain abstin 6 month carbon monoxid 10 part million p.p.m e166 particip offer test refus level particip refus assum 10 p.p.m fassum particip come window period offer test level 10 p.p.m rr rel risk ci confid interv tabl 3 secondari outcom intervent control absolut differ crude rra adjust rrb 95 ci 95 ci 95 ci 6 month follow report 7 dai ppac 92 205 44.9 82 204 40.2 0.05 0.05 0.14 1.12 0.83 1.50 1.09 0.80 1.47 3 month follow report sustain 3 month abstinencec 52 205 25.4 26 204 12.8 0.13 0.05 0.20 1.98 1.24 3.18 2.04 1.24 3.35 biochem verifi sustain 3 month abstin particip offer test 156d 21 83 25.3 10 73 13.7 0.12 0.01 0.24 2.03 0.95 4.33 2.32 1.02 5.27 biochem verifi sustain 3 month abstin particip 409 21 205 10.2 10 204 4.9 0.05 0.01 0.10 2.08 0.98 4.42 2.39 1.05 5.43 report 7 dai ppac 81 205 39.5 56 204 27.5 0.12 0.03 0.21 1.44 1.02 2.03 1.44 1.01 2.05 1 month follow report 7 dai ppac 72 205 35.1 45 204 22.1 0.13 0.04 0.22 1.59 1.10 2.31 1.58 1.07 2.34 biochem verifi 7 dai ppa particip offer test 168f 39 79 48.4 25 89 28.1 0.21 0.07 0.36 1.76 1.06 2.90 1.74 1.01 3.01 biochem verifi 7 dai ppa particip 409 39 205 19.0 25 204 12.3 0.07 0.01 0.14 1.55 0.94 2.56 1.63 0.95 2.79 success quit attempt 139 205 67.8 125 204 61.3 0.07 0.03 0.16 1.11 0.87 1.41 1.09 0.85 1.40 aunivari multi level poisson regress facil random effect bmulti level poisson regress facil random effect adjust heavi smoke index hsi ag durat smoke alcohol problem pre studi protocol 395 entir sampl 151 161 3 1 month biochem verifi subgroup cparticip lost follow window period consid smoke d156 particip offer test refus test carbon monoxid level particip refus assum 10 part million p.p.m eself report sustain abstin 3 month 10 p.p.m assum particip come window period offer test level 10 f168 particip offer test refus test gself report 7 dai point preval abstin ppa 10 p.p.m assum particip come window period offer test level 10 rr rel risk ci confid interv 1948 goedel louwagi al 2014 societi studi addict addict 109 1942 1952 question tobacco health belief motiv quit led reflect harm effect smoke alter subsequ smoke behaviour lastli ill tb suffi cient induc peopl stop smoke 22,24,26 con sider effect control group found behaviour intervent south african tb patient 53 21 report death trial extrem difficult obtain exact death commun set death occur due smoke cessat trial particip ill tb hiv posit death relat hiv tb 54 unrel tobacco cessat death rate differ significantli arm major death occur 3 month tb registr studi limit high centag patient trace follow visit loss follow rate similar intervent control group fur thermor patient lost follow consid smoker itt analysi mi offer singl session lhcw unabl monitor intervent fidel video tape actual mi session real patient consid invas patient context standard clinic care lhcw intens train deliv mi adequ 55 outcom similar expect mi follow measur blind introduc respond interview bia report report quit rate partial explain high report 7 dai ppa obtain 6 month follow attempt minim report offer potenti test exhal monitor drawback monitor short half life smoker morn read give misleadingli low result 56 half particip offer test offer pharmacotherapi smoker smoke cessat medic expens public primari care clinic south africa insuffici evid effect ness light smoker 57,58 longest follow 6 month advis follow patient 12 month evid tb patient relaps smoke feel tb treat 22,24,26 6 month chosen time period coincid minimum durat tb treatment lastli result trial generaliz primari care clinic set extrapol similar public health clinic south africa conclus mi deliv lhcw effec tive assist tb patient smoke cessat trial condit south african set relev studi demonstr effect popul light smoker result smoke cessat tb patient high hiv coinfect rate low medium incom countri south africa impor tant find smoke cessat servic deliv lhcw demonstr studi 59 61 free valuabl nurs time clinic task import south african context tb patient receiv treatment tb hiv condit manag parallel fashion provid 62 tb nurs spend great deal time refer patient hiv servic ad intens smoke cessat tabl 4 deliveri cessat messag tuberculosi tb nurs receipt smoke cessat bookleta respond intervent control valuen tb nurs inquir smoke baselin 282 324 87.0 146 162 90.1 136 162 84.0 0.098b messag tb nurs messag 30 282 10.6 12 146 8.2 18 136 13.2 0.278b advis stop smoke 192 282 68.1 104 146 71.2 88 136 64.7 advis reduc smoke 31 282 11.0 13 146 8.9 18 136 13.2 tb relat cessat messag 29 282 10.3 17 146 11.6 12 136 8.8 us score tb nurs messag median iqr 247 5 4 5 5 4 5 5 4 5 0.060c smoke cessat booklet receiv 230 283 82.4 121 145 83.5 109 134 81.3 0.644b read part smoke cessat booklet 160 224 74.6 69 105 69.1 91 119 79.1 0.089b aall question pose 1 month follow visit analysi limit particip 1 month bχ2 test cwilcoxon rank sum test iqr interquartil rang smoke cessat tuberculosi servic 1949 2014 societi studi addict addict 109 1942 1952 counsel task lead poor implementa tion unsustain lhcw fit neatli enhanc role lhcw outlin south africa nation health insur plan 63 base find recommend care implement mi lhcw tb clinic tshwane success programm roll part south africa ad smoke cessat tb programm reduc long term smoke relat complic crucial tb hiv relat treatment outcom clinic trial registr pan african clinic trial pactr201311000695277 south african clinic trial doh 27 0811 3539 declar interest k.o receiv pfizer fund fda approv research project unrel project involv nicotin patch bupropion vareniclin o.a.a awarde unrestrict pfizer cation grant mayo clinic global bridg health allianc project receiv honorarium speaker 2012 congress south african dental asso ciation session treatment fund pfizer acknowledg project support fund kncv tuberculosi foundat grant 12.402.2 mvdw 10.0696 cal global bridg health care allianc tobacco depend treatment nation research foundat south africa grant 80843 funder role conceptu studi data analysi report result nation council smoke south africa provid smoke cessat booklet grate fieldwork supervisori staff ms kodi enthusiast hard work tb nurs facil tshwane district health manag team support
origin articl effect warn smoker perceiv risk worri motiv quit rene magnan ph.d amber köblitz m. desire zielk m. kevin mccaul ph.d publish onlin 3 march 2009 societi behavior medicin 2009 abstract background research motiv smoke cessat focus belief cognit peopl risk percept attent direct worri neg affect smoke purpos test manipul encourag smoker worri smoke behavior contrast risk percept worri com.ibm.drl.hbcp.predictor contempl quit smoke method smoker randomli assign con dition carri person digit assist 2 week signal smoker read smoke consequ statement daili hassl statement result 2 week experiment smoker report greater perceiv risk worri develop medic condit compar control smoker perceiv risk worri independ mediat relationship experiment manipul increas contempl quit smoke worri strongest mediat multipl mediat model conclus worri foremost motiv smoker attempt quit keyword smoke smoker motiv quit worri smoke perceiv risk introduct major 45 million smoker unit state quit year dai 1 crucial understand motiv smoker make quit attempt review 35 articl investig motiv quit mccaul al 2 found health concern overwhelmingli common com.ibm.drl.hbcp.predictor cessat motiv public involv retrospect cross section design smoker recal reason quit current smoker describ reason quit reason correl motiv quit illustr retrospect design orlean al 3 ask 4,000 younger older smoker quit previous rate import quit motiv smoker ag rank top quit motiv order effect futur health effect present health effect kviz al 4 conduct studi com.ibm.drl.hbcp.util cross section approach interview ag group current smoker plan quit health concern strongli predict plan quit 3 month smoker ag studi research ask smoker reason quit time succeed eiser al 5 survei smoker express interest quit retest 1 year smoker chose import reason quit list explan health cost dirti habit concern particip chose health import reason cost reason differenti success unsuccess quitter ann behav med 2009 37 46 57 doi 10.1007 s12160 009 9085 8 magnan köblitz zielk mccaul north dakota state univers fargo usa magnan depart psycholog 1 univers mexico msc03 2220 albuquerqu nm 87131 1161 usa mail rmagnan unm.edu experiment compar smoker quit trier mention health social reason nontrier smoker motiv smoke relat health concern gener health strong com.ibm.drl.hbcp.predictor motiv quit smoke gregor al 6 found perceiv health predict motiv smoke reduc neg affect unrel motiv quit smoke prokhorov 7 found higher level physic ill lower level readi chang health concern import com.ibm.drl.hbcp.predictor quit attempt reason smoker ration decis process focus perceiv risk smoke relat ill decid quit order avoid consequ smoker smoke relat health issu begin worri consequ smoke worri prompt decis quit risk worri health behavior theori health protect behavior risk element 8 ignor affect e.g worri health belief model hbm 9 posit order chang health behavior consequ current behavior e.g perceiv risk outweigh benefit transtheoret model 10 stage model behavior chang propos knowledg risk move smoker think quit take concret step quit consist theori perceiv risk protect health behavior mammographi screen 11 influenza vaccin 12 smoke behavior perceiv risk correl intent quit 5 motiv quit quit attempt 13 addition data suggest risk produc motiv 14 15 outcom increas risk percept smok ing facilit movement quit 8 16 research increas smoker motiv quit increas creat worri smoke worri construct close ti risk percept e.g 17 thought cognit color affect 18 talli eysenck 19 suggest worri apprais risk element e.g like hood loss slovic 20 21 discuss idea risk feel decis make slovic al propos system interact decis make process analyt i. cognit system experienti i. affect system feel part affect system contribut guid decis make 22 research propos worri serv construct purpos studi szabo lovibond 23 particip record worri time forti percent worrisom thought report reflect problem solv process import distinguish worri individ ual differ approach worri worrier report high level trait state anxieti 24 trait worri scale correl anxieti depress psychosomat symptom 25 present studi concern worrier myriad type neg affect patholog worrier worri specif smoke mccaul mullen 26 propos nonpatholog worri motiv protect behavior reason includ experi worri add cognit storehous reason health protect action 27 worri issu salient serv persist remind worri serv cue action motiv attempt manag avers worri ing similar find risk percept data illustr associ worri health protect behavior studi show worri predict uptak mammographi screen 28 smoker plan desir quit 29 lipku prokhorov 30 found smoke relat worri perceiv risk stronger desir quit smoke similarli dijkstra brosschot 31 discov worri smoke consequ predict quit attempt cigarett smoker idea worri influenc motiv quit support relat individu differ literatur anxieti sensit tendenc peopl fear experienc anxieti peopl anxieti sensit tend motiv quit smoke individu anxiou health 32 33 suggest anxieti sensit person worri health consequ smoke regard increas worri turn contribut motiv quit smoke theori data suggest risk worri import motiv smoker quit numer studi show risk worri relat correl averag 0.30 34 36 summari interest increas smoker motiv quit increas risk percept worri theoret import increas risk worri confront smoker inform consequ smoke inform smoke consequ readili avail smoker avoid inform ann behav med 2009 37 46 57 47 recent studi forc smoker confront inform smoke 26 experi attempt manipul worri influenc risk percept colleg student smoker read card familiar inform smoke consequ inform time dai week compar smoker read statement studi smoker smoke card condit report significantli worri smok ing consequ expect card influenc perceiv risk importantli smoker smoke card condit report greater motiv quit control smoker effect weak 0.06 purpos current studi directli compar cognit risk percept affect worri com.ibm.drl.hbcp.predictor contempl quit smoke experi differ mccaul al 26 import wai person digit assist pda present smoker factual statement neg social esthet health outcom smoke confront smoker combin smoke risk i. health social esthet risk purposefulli intend chang risk percept worri test rel influenc chang motiv quit consequ statement includ commonli smoke behavior e.g lung cancer lesser correl e.g mental declin compar procedur mccaul al includ risk statement 20 8 ask particip risk 2 week 1 week includ approxim statement record dai reduc possibl smoker avoid consequ inform ask particip memor statement assum recal instruct produc greater rumin aspect worri instruct previous design group design includ group randomli assign colleg student commu niti smoker group learn neg consequ smoke experiment group learn inform daili hassl control group smoker read statement 2 week statement particip answer question assess worri statement caus applic statement live addition particip complet pretest posttest 6 month follow questionnair assess week particip complet pda questionnair time daili studi approv institut review board north dakota state univers method particip approxim equal number colleg student 67 commun smoker 60 recruit student commun member exclud complet week 2 protocol final sampl includ 119 daili smoker 51 male 68 femal averag 26.33 year ag sd 9.84 singl 75.6 smoker 92.4 white 7.6 american indian alaskan nativ 4 unidentifi ethnic 5 student popu lation recruit biannual screen question nair administ psycholog class begin semest student report smoke cigarett dai invit particip student receiv extra credit 17 monei 80 35 combin 11 commun smoker recruit person advertis local newspap receiv monei compens 75 80 encourag complianc particip receiv full compens complet 80 84 pda questionnair percentag point 80 complianc 2.25 half extra credit point subtract total compens commun smoker student smoker fell cut student complianc 86.0 sd 9 ident commun complianc 86.1 sd 13 procedur particip laboratori individu group learn chang smoke behavior particip randomli assign experiment control condit 2 1 ratio.mor smoker assign experiment group provid adequ power group analys experiment smoker 81 told purpos studi learn commun smoke relat inform smoker control smoker 38 told purpos studi learn daili hassl smoker everydai live give consent smoker complet pretest particip ask carri pda read consequ smoke experiment daili hassl control time daili week 1 time daili week 2 experiment conduct 45 min train session explain procedur technic administr pda palm os emul conclus train smoker assign pda schedul return appoint week week 1 smoker return laboratori check 48 ann behav med 2009 37 46 57 pda particip complet week record return posttest approxim 6 month 6.60 month sd 1.03 particip contact phone follow questionnair recontact rate 79.8 95 63 experiment smoker 32 control smoker 119 smoker successfulli contact approxim proport student 83 52 commun smoker 77 43 plete follow χ2 1 1 test compar pretest score complet follow reveal signific differ smoker complet follow questionnair report think quit 5.96 sd 3.18 complet questionnair 7.33 sd 2.28 117 2.41 0.017 measur demograph variabl background data collect pretest includ ag gender educ marit statu ethnic current smoke behavior measur current smoke behavior pretest question ag start smoke year smoke lifetim number cigarett smoke dai nicotin depend administ fagerström test nicotin depen denc revis ftnd 37 pretest ftnd item e.g smoke ill bed dai sum creat score rang 1 10 higher score higher nicotin depend alpha 0.64 contempl quit smoke contempl ladder 38 assess particip level readi quit smoke questionnair time point ladder 11 point scale rang 0 thought quit 10 i’m take action quit scale decent discrimin valid 39 wide smoke research e.g 40 42 predict smoke cessat 43 trait worri penn state worri questionnair pswq administ pretest 16 item assess trait worri 44 item phrase posit e.g tend worri thing neg e.g situat make worri respons rang 1 typic 5 typic sum higher score higher trait worri alpha 0.91 measur trait worri includ level specif worri smoke smoke worri risk percept item assess worri risk percept smoke worri assess time point risk percept assess pretest posttest item point respons scale 1 7 extrem item assess worri worri develop medic condit e.g worri develop smoke relat medic condit worri harm e.g worri smoke bother nonsmok averag item assess worri medic condit pretest 0.74 item assess worri harm pretest 0.73 creat composit score item assess risk percentag risk develop medic condit e.g scale 0 absolut chanc 100 guarante happen chanc develop type cancer lifetim continu smoke risk e.g extent smoke harm averag item creat composit score percentag risk develop medic condit pretest 0.77 item creat composit score risk pretest 0.54 efficaci quit smoke item assess efficaci quit smoke pretest posttest 45 particip rate level confi denc abil quit decid scale 1 confid 10 confid research 46 47 similar 10 point scale borrelli mermelstein 46 found efficaci strong com.ibm.drl.hbcp.predictor smoker abstain effect size 0.65 behavior chang singl question posttest ask smoke behavior past week smoker report ask describ categor 1 quit 2 think quit 3 awar smoke behavior 4 smoke ann behav med 2009 37 46 57 49 recal statement posttest smoker recal consequ hassl statement read open end format smoker recal credit recal gener idea statement 6 month follow follow questionnair measur current smok ing statu person report longer smoke ask quit call complet person smoke ask averag number cigarett smoke dai number quit attempt length quit attempt complet studi contempl quit smoke worri effect smoke develop smoke relat medic condit describ effect studi list consequ hassl statement rememb pda procedur smoker read statement dai week 1 statement dai week 2 reduct statement week 1 week 2 implement reduc time commit facilit adher protocol smoker complet event conting signal conting interv conting record 48 reduc predict record time pda smoker carri zire 31 pda manufactur palm unit state measur 4.4 2.9 weigh 4.1 oz satellit form 5.2 softwar creat pda databas applic collect studi data event conting record smoker complet questionnair event cigarett morn morn questionnair cigarett afternoon afternoon questionnair cigarett even even questionnair particip remind event conting record pda alarm set 10 30 a.m 1 00 p.m 7 00 p.m dai alarm accompani remind remind morn afternoon even questionnair smoker complet morn questionnair 12 00 p.m afternoon questionnair 12 00 5 00 p.m even questionnair 5 00 11 00 p.m record consid noncompli record smoker read statement answer question signal conting record signal time dai week 1 random 1 random 4 questionnair time dai week 2 random 1 random 2 questionnair time random signal comput random 60 min prespecifi time point week 1 time 10 30 a.m 2 30 p.m 5 00 p.m 8 00 p.m week 2 time 4 00 8 00 p.m complianc defin complet record hour signal predetermin time pda beep displai messag time complet random question nair record smoker read statement answer question interv conting record predetermin time record dai studi smoker complet interv conting questionnair immedi bed end dai questionnair remind beep pda record complianc depend respond 8 00 p.m 4 00 a.m record smoker read statement answer question pda questionnair structur particip read statement smoke hassl 15 ask memor order statement random twenti smoke consequ statement cover health social esthet risk smoke lessen habitu statement studi 12 statement week 1 remain week 2 statement chosen base data collect 49 smoker type smoke thought worri experi enc daili daili hassl includ 20 statement drawn daili hassl scale 50 cover stress monei worri 12 statement week 1 remain week 2 read statement particip answer question statement worri 0 4 great deal statement appli 0 4 great deal statement question respons includ directli statement experiment smoker answer 98.3 sd 3.94 correctli control smoker 50 ann behav med 2009 37 46 57 answer 99.1 sd 1.59 correctli worri appli score creat individu statement averag smoker rate statement result 20 separ worri appli score complianc complianc particip 86.10 week studi analys compar student commun complianc condit complianc weekli complianc dai week mondai tuesdai complianc dai studi complianc signific ts 1.00 fs 1.44 analys varianc anova assess questionnair type signific 7 944 3.53 0.001 post hoc analys reveal gener particip compliant random 1 morn questionnair i. earlier dai time result recruit colleg student commun smoker increas generaliz result volunt group differ significantli 12 pretest variabl specif student younger 1 115 70.33 0.001 addict test ftnd 1 115 27.91 0.001 report smoke fewer cigarett typic dai 1 115 16.01 0.001 report smoke fewer year 1 115 67.53 0.001 confid quit smoke 1 115 7.45 0.01 ensur result experiment control comparison due differ volunt volunt group initi test factor analys made differ outcom main effect interact treatment condit report pretest questionnair anova assess pretest differ condit 1 tabl 1 present mean standard deviat past smoke behavior smoke belief feel pretest differ found experiment smoker score higher trait worri pswq score 1 115 6.09 0.02 0.49 control pswq score chang outcom subsequ analys present analys covari effect statement experiment smoker report worri 2.49 sd 0.86 smoke statement control smoker read daili hassl 1.76 sd 0.81 1 117 18.97 0.001 0.87 tabl 2 present mean worri score experiment statement experiment smoker report worri statement 93 lung cancer patient die 5 year statement nonsmok awar smoke smell experiment smoker report significantli worri health consequ 2.64 sd 0.89 esthet 2.27 sd 0.95 social consequ 2.23 sd 0.93 ps 0.001 0.40 0.45 experiment smoker felt smoke statement appli 2.29 sd 0.81 control smoker felt daili hassl appli 1.95 sd 0.96 1,117 5.04 0.03 0.46 experiment smoker felt statement social 2.34 sd 0.82 health 2.32 sd 0.85 experiment 81 control 38 ag 26.00 9.62 27.03 10.39 year smoke 10.72 9.47 10.67 10.24 number cigarett smoke typic 7 dai 13.78 7.75 13.53 7.41 addict ftnd 1 10 3.57 2.24 3.18 1.97 ag smoke began 15.17 2.72 16.08 3.51 efficaci quit 1 10 6.91 2.61 6.76 2.87 worri medic condit 1 7 4.09 1.46 4.12 1.71 worri harm 1 7 4.08 1.51 3.92 1.67 risk medic condit 72.77 20.43 65.28 19.11 risk 1 7 4.96 1.38 4.83 1.39 contempl quit 0 10 6.89 2.43 7.39 2.75 penn state worri questionnair 16 80 51.00 12.60 44.63 13.42 tabl 1 pretest score smoker experiment control group rang scale measur list descript 0.02 treatment condit differ ann behav med 2009 37 46 57 51 consequ appli esthet con sequenc 2.18 sd 0.89 ps 0.01 0.19 0.16 posttest questionnair analys covari ancova form posttest worri percept risk percept efficaci measur control pretest counter part smoker experiment condit report posttest worri develop medic condit adjust adj 5.06 sd 1.26 control smoker adj 4.28 sd 1.28 1 115 9.59 0.002 0.61 report greater perceiv risk medic consequ smoke adj 75.04 sd 15.79 control smoker adj 62.39 sd 1.28 1 111 15.71 0.001 0.80 signific effect obtain worri perceiv risk ps 0.14 consist lesser worri report read social consequ statement efficaci differ group signific mean favor experiment smoker adj 7.46 sd 1.89 adj 6.80 sd 1.95 1 115 3.03 0.09 0.35 posttest smoker list smoke relat ill experiment smoker list 4.81 sd 2.13 control smoker 3.34 sd 1.55 1 117 14.50 0.001 0.79 experiment smoker mention lung cancer 81 50 χ2 1 12.56 0.001 phi 8 0.32 cardiovascular ill e.g heart attack 84 41 χ2 1 13.17 0.001 8 0.33 ill discolor skin 53 16 χ2 1 7.31 0.007 8 0.25 data manipul success fulli creat worri perceiv risk oneself critic initi question experi risk worri manipul effect contempl quit ancova reveal smoker experiment condit closer quit posttest adj 8.35 sd 1.98 control smoker adj 7.25 sd 2.01 1 115 7.82 0.006 0.56 mediat analys mediat analys control pretest valu contempl quit mediat variabl conceptu question worri risk tabl 2 averag worri report statement experiment smoker statement worri 0 4 93 lung cancer patient die 5 yearsa 2.88 1.05 emphysema disabl incur diseas make breath struggl breath strawa 2.84 1.04 smoker die averag 13 14 year earlier smokersa 2.81 1.03 smoke relat brain damag senilea 2.76 1.07 emphysema ill caus smoke lead enlarg heart end heart failur deatha 2.73 1.04 smoker make 10 bypass patientsa 2.71 1.06 smoke heart attack lead death u.s.a 2.70 96 smoker older rate mental declin time faster nonsmokersa 2.61 1.05 smoke increas likelihood oral gum cancer facial disfigur paina 2.58 99 smoke blood vessel harden faster make blood clot time likelya 2.52 94 secondhand smoke 3,000 nonsmok die lung cancer u. yearc 2.50 1.10 smoke bad breath stain teeth reduc abil tast food irrit gum tissuesb 2.48 1.03 20 death unit state caus smokinga 2.46 98 decad smoke leav last creas wrinklesb 2.36 1.12 passiv smoke increas risk stroke 80 nonsmok partner smokersc 2.34 1.06 smoker face deep line mouth ey grayish appear ad medic dictionari 1985b 2.25 1.09 28 smoker suffer cold cough regularli compar 7 gener populationa 2.21 1.00 smoker 40 facial wrinkl nonsmok 60sb 2.16 1.10 blood vessel ey easili damag smoke caus bloodshot appear itchinessb 2.12 1.04 nonsmok awar smoke smell itc 1.85 1.17 health consequ statement esthet consequ statement social consequ statement 52 ann behav med 2009 37 46 57 predict contempl quit mediat analys worri perceiv risk harm efficaci conduct manipul weak effect construct mediat analys includ pretest covari bootstrap procedur outlin preacher hay 51 statist control covari model procedur bootstrap resampl techniqu creat bia correct 95 confid interv 95 ci indirect effect mediat variabl interv includ effect significantli greater consid good mediat model bootstrap recom mend due greater power rel sobel method 52 detect mediat effect 53 recommend larg due assumpt sobel test sampl size larg sampl size decreas sobel test conserv 54 figur 1a displai unstandard coeffici separ mediat result worri perceiv risk develop medic condit respec tive figur 1a show smoker experiment condit report worri smoker control note 01 001 model control pretest contempl pretest worri develop medic condit upper coeffici repres path control worri lower coeffici repres path control worri note 05 01 001 model control pretest contempl pretest risk upper coeffici repres path control risk lower coeffici repres path control risk note 01 001 model control pretest contempl pretest risk pretest worri develop medic condit upper coeffici repres path control worri risk lower coeffici repres path control worri risk 1.04 worri medic condit treatment contempl 58 71 perceiv risk medic condit 12.4 1.03 03 12.27 perceiv risk medic condit treatment contempl 72 1.08 49 74 worri medic condit treatment contempl 72 47 01 fig 1 relationship treatment contempl quit mediat worri develop medic condit unstan dardiz estim effect 0.01 0.001 model control pretest contempl pretest worri develop medic condit upper coeffici repres path control worri lower coeffici repres path control worri relationship treatment contem plation quit mediat perceiv risk develop medic condit unstandard estim effect 0.05 0.01 0.001 model control pretest contempl pretest risk upper coeffici repres path control risk lower coeffici repres path control risk relationship treatment contempl quit mediat worri perceiv risk develop medic condit unstandard estim effect 0.01 0.001 model control pretest contempl pretest risk pretest worri develop medic condit upper coeffici repres path control worri risk lower coeffici repres path control worri risk ann behav med 2009 37 46 57 53 condit 113 2.96 0.004 smoker worri smoke thought quit 113 3.55 0.001 final control worri direct effect treatment contem plation quit longer signific 113 1.88 0.06 bootstrap estim indirect effect worri significantli 95 ci 0.1189 0.7362 indic worri good mediat relationship tabl 3 present intercorrel construct mediat model figur 1b show smoker experiment condit report greater perceiv risk control smoker 109 3.79 0.001 smoker perceiv greater risk smoke thought quit 109 2.09 0.04 final control perceiv risk direct effect treatment contempl quit longer signific 109 1.66 0.10 bootstrap estim indirect effect perceiv risk significantli 95 ci 0.0403 0.7077 indic perceiv risk good mediat relationship addit mediat analysi simultan includ ed worri perceiv risk develop medic condit fig 1c multipl media tion procedur outlin preacher hay 51 procedur bootstrap resampl tech niqu includ bia correct ci specif indirect effect ci total indirect effect combin indirect effect worri risk mediat effect treatment contempl quit 95 ci 0.1001 0.9812 smoker experiment condit experienc worri perceiv risk turn led greater think quit specif indirect effect worri good mediat 95 ci 0.0835 0.7656 risk contribut indirect effect condit contempl relationship worri account 95 ci 0.1702 0.4727 addit mediat analys explor effect variabl moder manipul effect pretest efficaci trait worri gender volunt group ag nicotin depend number cigarett smoke pretest signific interact result analys report behavior chang posttest experiment smoker 64.2 report chang smoke behavior control smoker 29.7 χ2 1 12.13 0.001 8 0.32 specif 43 53.1 experiment smoker report quit 18.9 control smoker χ2 1 12.14 0.001 8 0.32 follow 63 experiment smoker 14.3 32 control smoker 6.3 report quit smoke χ2 1 1.34 0.20 ϕ 0.12 ad individu quit previou 6 month forti experiment smoker 67.4 19 control smoker 59.4 report quit attempt χ2 1 1.40 0.20 8 0.13 84 continu smoker experiment control differ enc maintain follow period specifi calli ancova control pretest measur reveal signific main effect contempl quit 1.40 worri develop medic condit 1 posttest contempl quit success quit follow 0.09 strongli quit attempt 0.42 addition signific differ occur number cigarett smoke dai number quit attempt ps 0.10 recal smoke statement posttest follow smoker recal statement receiv seventi percent experiment smoker 86.8 control smoker recal tabl 3 intercorrel construct mediat model 1 2 3 4 5 6 7 8 1 condit 2 pretest contempl 0.09 3 pretest worri medic condit 0.01 0.29 4 pretest risk medic condit 0.17 0.27 0.26 5 posttest contempl 0.17 0.52 0.34 0.21 6 posttest worri medic condit 0.21 0.06 0.64 0.19 0.37 7 posttest risk medic condit 0.39 0.06 0.29 0.59 0.26 0.26 0.37 0.05 0.01 0.001 54 ann behav med 2009 37 46 57 messag posttest 0.07 follow smoker recal statement rememb gener subject matter state ment smoker statement emphysema smoker face exper iment smoker recal type health consequ statement 88.2 esthet consequ statement 39.2 social consequ statement 17.6 10 control smoker recal specif statement topic studi mention statement gener worri 60 30 control smoker list concern monei appear 20 list job stress lone ness 10 list lack sleep discuss purpos studi contrast influenc risk belief worri cessat motiv contrast research area manipul cognit affect typic correl strategi 55 smoker read warn consequ smoke report greater worri perceiv risk develop medic condit due smoke compar control smoker report worri greater perceiv risk harm warn produc stronger motiv quit experiment smoker end studi compar control smoker experiment smoker quit experi approxim half experiment smoker report quit 2 week intervent 53 higher control smoker 19 nontreat charact studi definit explain high rate entertain possibl conceiv rate attribut simpli expans definit quit attempt smoker count categori quit rang momentari decis abstain multipl dai quit attempt altern conceiv manipul fact creat short live quit attempt effect increas worri mediat analys demonstr kei variabl increas motiv quit extent smoker worri health consequ smok ing result disappear follow interview approxim 6.5 month studi end import note motiv effect warn significantli affect quit attempt smoke cessat studi motiv quit predict quit attempt sampl follow interv 0.42 data suggest creat worri cigarett smoker motiv abandon behavior causal chain warn worri motiv quit attempt modestli strong link prevent current studi reveal behavior effect net effect experiment manipul product interven step causal sequenc 54 present studi chain run manipul worri 0.28 worri motiv quit 0.36 motiv behavior chang 0.42 multipl term yield small effect intervent behavior 0.04 public health perspect small effect import fair question effect warn messag fail specul reason straightforward possibl warn messag produc effect activ process notion suggest risk worri effect disappear rapidli dai week experi end warn messag produc effect stai power experi mental smoker recal memori smoke diseas control smoker altern explan effect warn messag erod longer time period smoker studi smoke averag 11 year habitu wai deal neg smoke relat inform e.g avoid studi probabl abruptli gradual resum prestudi habit interest surpris find present studi warn produc worri present 20 statement experiment group 12 health social esthet experiment smoker report momentari worri health statement statement data fit find review connect reason quit actual quit 2 35 studi review report health concern strongest motiv quit attempt data smoker remain naïv consequ behavior e.g 56 suggest continu focu devast health effect cigarett smoke valid public health approach suggest fit recent warn attach cigarett packag canada cigarett warn label 50 front back packag displai graphic imag written warn peter al 57 found ann behav med 2009 37 46 57 55 smoker expos canadian label stronger neg affect reaction label smoker expos u. label addition smoker expos canadian label express neg affect exposur smoke cue smoker expos u. label retrospect analysi hammond al 58 contact 191 canadian smoker ask motiv quit thirti percent sampl cite cigarett pack warn label influenc motiv quit focus health import influenc worri curiou regard theoret model health protect behavior pai attent affect construct worri note dilemma recent paper investig health behavior context weinstein colleagu 12 studi extent risk measur predict prospect respond obtain flu vaccin com.ibm.drl.hbcp.predictor behavior statement includ type affect word e.g anticip regret feel risk worri 59 short evid accumul show health behavior theori neglect import affect variabl strength studi result held number variabl intuit moder motiv effect trait worri effect result worri import specif smoke similarli background variabl smoke addict demograph variabl e.g gender ag fail moder result addition colleg student studi behav similarli volun teer older longer term addict smoker suggest find gener specif sampl studi summari studi show warn messag creat worri move smoker motiva tional continuum closer quit import worri feel incorpor theori purport understand health protect behavior risk messag creat worri precis featur messag import present research rais question risk messag deliv creat worri health profession obtain similar effect singl power person warn effect risk messag maintain long hospitaliza tion prompt worri smoke enhanc cessat method creat worri risk messag effect health behavior marijuana alcohol answer question import warn plai role encourag smoker quit improv public health author note lindsai anderson interview kit o’neil ross crosbi procedur rene magnan univers mexico desire zielk indiana univers purdu univers indianapoli work paper support grant k05 ca92633 r21 ca098962 nation cancer institut fourth author
efficaci moder intens exercis aid smoke cessat women random control trial bess marcu beth lewi joseph hogan teresa king anna albrecht beth bock alfr parisi raymond niaura david abram receiv 29 decemb 2004 accept 8 june 2005 evid suggest vigor intens exercis intervent effect smoke cessat women studi examin efficaci moder intens exercis program present studi examin efficaci moder intens exercis smoke cessat femal smoker healthi sedentari femal smoker n5217 randomli assign 8 week cognit behavior smoke cessat program moder intens exercis cbt cessat program equal contact cbt subsampl receiv nicotin replac therapi result cbt cbt group equal attain smoke cessat end treatment measur cotinin verifi 7 dai point preval abstin 20.2 cbt 18.5 cbt cbt group report smoke cessat measur 7 dai point preval 3 month follow 11.9 4.6 05 compar cbt group group differ found 12 month 7 dai point preval 7.3 cbt 8.3 cbt continu abstin 0.9 cbt 0.9 cbt addition particip cbt group higher adher exercis prescript significantli achiev smoke cessat end treatment particip report lower adher exercis find empir support moder intens exercis adjunct treatment cbt smoke cessat limit futur studi compar moder vigor intens physic activ test rel efficaci introduct health risk quarter 22 american women smoke cigarett u. depart health human servic usdhh 2001 women smoke increas risk coronari heart diseas type cancer emphysema bronchiti lung diseas usdhh 2001 lung cancer heart diseas ill directli link smoke lead death women usdhh 2001 belief smoke control weight neg mood strong factor initi smoke adolesc girl sustain smoke adulthood usdhh 2001 concern postcess weight gain bradi 1999 depress symptom psycholog stress prevent women initi treatment ginsburg al 1997 weeklei klesg reylea 1992 weight gain hallmark smoke cessat consid smoker norm part nicotin withdraw syndrom hugh higgin bickel 1994 averag weight gain cessat 10 13 pound ginsburg al 1997 mcbride french piri jefferi 1996 piri al 1992 approxim 25 issn 1462 2203 print issn 1469 994x onlin 2005 societi research nicotin tobacco doi 10.1080 14622200500266056 bess marcu ph.d beth lewi ph.d anna albrecht r.n m. beth bock ph.d raymond niaura ph.d david abram ph.d center behavior prevent medicin brown medic school miriam hospit provid ri joseph hogan sc.d center statist scienc brown univers provid ri teresa king ph.d bridgewat state colleg bridgewat ma alfr parisi m.d divis cardiolog brown medic school miriam hospit provid ri correspond bess marcu ph.d center behavior prevent medicin brown medic school miriam hospit 1 hoppin street coro build suit 500 provid ri 02903 usa tel 1 401 793 8176 fax 1 401 793 8056 mail bmarcu lifespan.org nicotin tobacco research volum 7 number 6 decemb 2005 871 880 nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org women quit gain excess 15 pound exceed 30 pound hudmon gritz clayton nisenbaum 1999 nide al 1994 williamson al 1991 addit weight gain depress symptom stress crave cigarett increas likelihood relaps smoke doherti kinnunen militello garvei 1995 niaura al 2001 swan ward jack 1996 shiffman gny richard pati 1996 smoke cessat intervent need effect address concern femal smoker regular exercis address weight concern depress mood stress crave smoke cessat studi examin efficaci vigor intens exercis intervent smoke cessat ussher taylor west mcewen 2000 studi found vigor intens exercis efficaci marcu albrecht niaura abram thompson 1991 marcu al 1995 1999 hill 1985 russel epstein johnston block blair 1988 taylor houston miller haskel debusk 1988 limit studi find efficaci includ small sampl size hill 1985 russel al 1988 taylor al 1988 failur demonstr increas fit level subject assign exercis group russel al 1988 formal smoke cessat treatment taylor al 1988 program hill 1985 lack pharmacotherapi hill 1985 russel al 1988 taylor al 1988 absenc comparison group control contact time hill 1985 recent studi examin efficaci moder intens exercis smoke cessat hill rigdon johnson 1993 martin al 1997 ussher west mcewen taylor stepto 2003 moder intens exercis signific advantag vigor intens reason individu adher moder vigor intens exercis blair connelli 1996 achiev walk frequent report type exercis manson al 1999 stofan dipietro davi kohl blair 1998 moder intens activ requir medic supervis 4 moder intens exercis vigor intens exercis lead injuri american colleg sport medicin 1995 moder intens exer cise shown reduc cigarett crave withdraw symptom abstin smoker ussher nunziata croplei west 2001 hill colleagu 1993 conduct exercis smoke cessat intervent men women ag 50 year older complet treatment particip group i. behavior treatment behavior treatment nicotin gum behavior treatment moder intens exercis moder intens exercis equal report smoke cessat 12 month end treat ment behavior train group achiev higher rate cessat exercis condit martin colleagu 1997 conduct similar studi recov alcohol patient behavior counsel moder intens exer cise effect behavior counsel nicotin gum standard treatment group differ signific 6 12 month studi target specif popul e.g older adult alcohol patient result gener izabl gener popul smoker recent ussher colleagu 2003 conduct studi male femal smoker randomli assign 7 week individu smok ing cessat program includ nicotin replac therapi exercis counsel health educ advic differ group smoke abstin cbt group report anxieti stress week smoke abstin irrit 2 week abstin restless 3 week abstin ussher al 2003 studi limit exercis intervent reli sole exercis consult clear particip receiv requir dose exercis advantag moder intens activ iti limit moder intens trial conduct ussher al 2003 exist trial examin efficaci moder intens exercis smoke cessat present studi name commit quit ii ctqii rando mize control trial design examin efficaci moder intens exercis smoke cessat intervent present studi base cognit behavior smoke cessat treatment vigor intens exercis program shown effect femal smoker rel contact control group marcu al 1999 intervent combin home base supervis exercis method research design particip ctqii randomli assign cognit behavior smoke cessat treatment design women supervis group home base moder intens exercis cbt cbt equal contact time staff cbt 872 random trial moder intens exercis aid smoke cessat nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org exercis program supervis moder intens class home base program suffici frequenc intens durat produc cardio vascular adapt king haskel taylor kraemer debusk 1991 chose home base method moder intens exercis easili integr lifestyl particip continu physic activ trial king taylor haskel 1993 outcom variabl 7 dai point preval abstin continu absti nenc assess end treatment 8 week 3 12 month follow up assess exercis capac baselin end treatment detail studi design marcu lewi al 2003 studi conduct group treatment exercis facil miriam hospit provid rhode island particip random recruit sedentari femal smoker ag 18 65 year regularli smoke 5 cigarett dai 1 year sedentari defin particip 90 min week exercis moder intens consist previou studi e.g king haskel young oka stefanick 1995 potenti particip recruit rhode island southern massachusett area newspap adver tisement flyer potenti particip call telephon number list newspap advertis ment complet telephon screen interview determin elig elig particip schedul exercis test appoint exclus criteria includ medic problem medic impair exercis perform toler current treatment psychiatr disord stanc abus hypertens respiratori lung problem prescript medic 3 month smoke cessat medic group assign base random code gener comput softwar program stratifi base particip patch usag decis institut review board miriam hospit provid rhode island approv studi particip complet written consent form prior particip research program assess particip underw symptom limit maxim treadmil exercis test baselin complet 8 week treatment balk protocol exercis test calcul exercis prescript determin studi elig determin baselin fit level balk 1970 determin particip receiv train effect exercis test repeat week 8 function capac express estim peak oxygen consumpt vo2 calibr scale assess height weight baselin weekli intervent end treatment follow assess session treatment smoke cessat program particip condit particip 8 week cognit behavior group base smoke cessat interven tion abbrevi version previou 12 week intervent studi examin efficaci vigor intens exercis smoke cessat marcu al 1999 marcu king albrecht parisi abram 1997 cognit behavior intervent last 1 hr includ tradit topic stimulu control topic relev women includ weight manag balanc famili work manual therapist written materi particip ensur standard deliveri intervent counselor master ph.d level individu train treatment protocol treatment session tape record sampl session listen ph.d level therapist provid feedback counselor treatment length 8 week chosen factor minimum number session need deliv cognit behavior treatment assist partici pant total withdraw nicotin briefer intervent generaliz effect reduc cost compar longer intervent minimum number week need show train effect aerob exercis accord public health servic ph tobacco cessat guidelin fior al 1996 option nicotin patch free charg studi arm begin cohort particip 13 cohort averag 17 particip cohort patch offer cohort 1 4 cohort conduct prior 1996 guidelin recommend patch patch protocol present studi base recommend ph guidelin fior al 1996 state 6 8 week patch treatment suffici manag withdraw symptom learn strategi stai nicotin tobacco research 873 nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org abstin nicotin patch option standard offer behavior strategi potenti altern patch appeal particip seek nicotin replac therapi requir patch limit generaliz find particip ask week patch dose particip instruct purchas patch counter week 7 particip instruct particip ask patch week 7 particip choos patch began quit dai dai 8 week 2 gradual reduc dose intervent longer patch week treatment particip receiv patch dai start 21 mg patch quit dai taper 14 mg patch dai 22 week 4 taper 7 mg patch dai 36 week 6 particip smoke fewer 10 cigarett dai weigh 100 pound began treatment 14 mg patch quit dai taper 7 mg patch dai 29 week 5 dai 50 week 7 particip discontinu patch cbt cognit behavior treatment smok ing cessat exercis particip exercis condit receiv exercis intervent addit smoke cessat treatment particip requir exercis gym minimum session week last approxim 1 hr occur night smoke cessat intervent exercis session occur immedi cbt session particip began exercis 1 week quit dai remaind week particip option exercis gym home instruct particip 4 dai exercis 30 min occas addit 45 min exercis session session last 1 hr includ 15 min stretch occur smoke cessat session chose schedul research individu adher home base exercis program group base program king al 1993 particip receiv telephon call miss weekli person exercis session addit prompt home base exercis implement exercis prescript base peak heart rate obtain baselin exercis test specif prescript particip exercis produc 45 59 heart rate reserv 50 69 maximum heart rate e.g walk 4 metabol equival met 5 dai week total 165 min week usdhh 1996 instruct particip engag exercis moder intens rang 11 12 borg scale 6 20 borg 1982 particip complet 5 min warm 45 min exercis 5 min cool stretch supervis exercis session exercis specialist document particip perceiv exert level heart rate particip instruct engag addit dai exercis supervis open gym record home base physic activ parti cipant complet log review exercis specialist week accuraci home log verifi data object monitor physic activ i. actigraph manufactur technolog mti fort walton beach florida goal 165 min week moder intens exercis amount approxim center diseas control prevent american colleg sport medicin recom mendat expend 1,000 kcal week fletcher 1997 pate al 1995 usdhh 1996 cbt cognit behavior treatment smoke cessat contact control particip cbt group attend 8 week well program film lectur discuss handout lifestyl health issu last 1 hr week addit smoke cessat program marcu al 1999 protocol successfulli previou studi marcu al 1995 1999 purpos group control contact time studi staff reduc risk differenti attrit group outcom measur main outcom measur studi 7 dai point preval abstin absenc patch particip instruct discontinu patch week 7 particip patch end treatment consid quit receiv nicotin patch quit statu assess weekli intervent end treatment i. week 8 3 12 month follow up expir carbon monoxid bedfont carbon monoxid analyz salivari cotinin level verifi quit statu criteria 7 dai point preval abstin cotinin level 57 nmol 10 ng ml etzel 1990 carbon monoxid level 8 ppm ossip klein al 1986 examin continu abstin quit dai dai 8 end treatment i. week 8 3 month follow 12 month follow 874 random trial moder intens exercis aid smoke cessat nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org data analys object design consider object studi compar smoke cessat rate cbt cbt group specif predict cbt group exhibit higher rate 7 dai point preval abstin continu abstin cbt group end treatment i. week 8 3 12 month follow up measur effect differ cessat rate studi design 80 power detect 18.3 net differ 7 dai point preval abstin studi arm 5 type error rate alpha side call random 86 partici pant group 172 total end treatment follow analys power com.ibm.drl.hbcp.util tail alpha 05 side test current analys effect size deriv data previou trial examin vigor intens physic activ i. commit quit ctqi check obviou violat balanc random compar kei baselin variabl test chi squar test primari outcom analyz intent treat principl lachin 2000 object compar effect random cbt cbt objec tive compar result current moder intens trial previou studi examin efficaci vigor intens physic activ i. ctqi data analys con duct sa assumpt dropout miss data convent smoke cessat trial lichtenstein glasgow 1992 categor particip smoker attend assess session drop trial secondari analysi compar dropout rate arm log rank test version rank sum test special censor event time data handl patch includ indic patch model make adjust effect cessat stage squar estim model paramet comput robust standard error e.g royal 1986 account nonconst varianc inher binari outcom begin trial patch standard care quit smoke fior al 1996 studi design studi exercis effect absenc patch offer women patch compli wide accept standard practic elimin possibl confound relat patch patch offer women prior random woman declin patch offer patch point studi patch counter record patch week statist adjust variabl explain patch made regress model includ covari binari indic intent patch result particip total 1,065 women screen telephon determin initi elig 695 deem inelig 289 health condit 180 regular exercis 72 psychiatr condi tion 154 remain exclus criteria medic impair exercis perform toler total 153 elig chose particip remain 217 particip studi 217 femal smoker mean age542.8 year random trial 13 cohort averag 17 particip cohort found signific differ particip treatment condit baselin demograph psychosoci measur sampl 82.5 white 6.9 black 6.0 hispan 3.2 cape verdian 0.5 asian 0.9 endors tabl 1 summar descript statist sampl 176 particip offer nicotin patch 88.6 chose found differ condit nicotin patch offer patch 87.4 cbt group 89.9 cbt group tabl 1 mean baselin characterist studi arm characterist exercis group control group ag year 42.52 10.39 43.02 10.33 educ year 13.58 2.40 13.36 1.97 weight pound 156.43 33.91 152.22 34.99 height inch 64.52 2.39 64.20 2.41 bodi mass index 26.48 5.59 25.96 5.55 waist hip ratio 0.80 0.08 0.78 08 percentag bodi fat 35.71 7.06 35.91 6.76 fagerström toler questionnair score 4.98 2.27 4.71 2.39 smoke rate cigarett dai 21.04 9.34 20.15 9.38 year smoke 26.49 10.39 26.22 9.77 carbon monoxid level ppm 19.20 10.61 20.21 10.60 estim vo2 peak ml kg min 30.71 6.12 30.68 5.67 note standard deviat parenthes nicotin tobacco research 875 nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org adher cbt group attend 72.1 weekli smoke cessat session 70.5 weekli onsit supervis exercis session cbt group attend 71.9 weekli smoke cessat session 70.0 weekli well session found differenti loss follow group cbt group 54.1 attend end treatment assess session 39.4 attend 3 month follow session 24.8 attend 12 month follow session cbt group 58.9 attend end treatment assess session 42.1 attend 3 month follow session 31.8 attend 12 month follow session particip cbt group 27.1 exercis averag 110 min week intervent third prescrib 165 min week treatment averag 15.20 particip cbt group met exceed prescript exercis 165 min week particip report third 67.84 total exercis minut treat ment complet home cbt group exercis averag 87.00 min week sd567.17 treatment exercis particip train heart rate averag 44.3 sd519 mean heart rate reserv 74.3 maximum heart rate particip attend end treatment assess averag absolut estim percent chang baselin posttest vo2 peak significantli increas baselin end treatment cbt group 5.51 unchang cbt group 2.60 1 117 53.78 p5.054 intent treat sampl estim percent chang baselin posttest vo2 peak significantli increas baselin end treatment cbt group 3.828 unchang cbt group 2.887 1 210 54.338 p5.038 weight particip cbt group continu abstin end treatment gain averag 3.86 pound sd55.66 continu abstin gain averag 2.98 pound sd54.15 particip cbt group continu abstin end treatment averag weight gain 4.56 pound sd55.05 continu abstin averag weight gain 2.86 pound sd55.14 differ signific treatment group smoke outcom group differ 19 20 108 women cbt group 20 22 109 women cbt group achiev 7 dai point preval abstin end treat ment differ 2 round 95 confid interv 29 13 continu abstin outcom cessat rate 11 15 differ 3 95 confid interv 26 12 differ 3 12 month follow up summar tabl 2 result cbt cbt group equal achiev 7 dai point preval abstin end treatment 3 month follow cbt group significantli achiev 7 dai point preval abstin cbt group group differ found 12 month group differ contin uou abstin end treatment follow up summar tabl 2 signific differ observ continu abstin timepoint tabl 2 compar present find result previou vigor intens smoke cessat trial ctqi effect exercis examin direct effect exercis adher smoke cessat particip cbt group conduct analysi particip cbt group compar particip adher exercis protocol adher particip code exercis 110 min third recommend 165 min exercis week meet requir data obtain physic activ log partici pant complet physic activ log categor meet requir ment number week meet requir 110 min exercis total particip range50 7 week final exercis variabl enter chi squar regress analysi predict smoke cessat specif found 1 week increas number week meet exceed 110 min exercis week odd achiev ing smoke cessat end treatment measur 7 dai point preval absti nenc increas 39.6 01 control ethnic employ statu baselin bodi mass index smoke rate baselin tabl 3 876 random trial moder intens exercis aid smoke cessat nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org discuss contrari hypothesi particip cbt i. cognit behavior smoke treat ment exercis cbt i. cognit beha vioral smoke treatment contact control group equal report smoke cessa tion end treatment particip adher exercis recom mendat conduct addit analys understand direct effect moder intens exercis smoke cessat specif found particip cbt group higher level exercis particip intervent phase relat higher likelihood achiev smoke cessat end treatment limit find observ particip randomli assign high versu low adher exercis particip compli physic activ quit reason unrel engag physic activ addit research need high adher moder intens exercis achiev examin efficaci moder intens activ high adher exercis achiev improv ing social support exercis offer commun base program conveni research facil e.g ymca mail mail exercis prompt moder versu vigor intens exercis present moder intens physic activ studi previou studi examin efficaci vigor intens exercis found femal smo ker receiv cognit behavior smoke cessa tion treatment vigor intens exercis significantli achiev 7 dai point preval abstin 3 month follow tabl 2 comparison moder intens trial ctqii previou vigor intens trial ctqi studi follow exercis group control group n5109 n5108 ctqii 7 dai point preval abstin end treatment 20.2 18.5 45 3 month follow 11.9 4.6 04 12 month follow 7.3 8.3 49 ctqii continu abstin end treatment 14.7 11.1 44 3 month follow 7.3 3.7 19 12 month follow 0.9 0.9 75 n5134 n5147 ctqi 7 dai point preval abstin end treatment 30.6 21.8 09 3 month follow 24.6 13.6 02 12 month follow 19.4 13.6 19 ctqi continu abstin end treatment 19.4 10.2 03 3 month follow 16.4 8.2 03 12 month follow 11.9 5.4 05 note ctqii commit quit ii current moder intens trial ctqi commit quit previou vigor intens trial signific differ group 05 tabl 3 effect exercis smoke cessat particip cbt group paramet degre freedom estim standard error wald chi squar intercept 1 23.6384 2.0897 3.0315 0817 number week met exercis criteria 1 0.3336 0.1262 6.9944 0082 ethnic 1 20.4226 0.6831 0.3827 5361 employ 1 1.1274 0.8750 1.6599 1976 bodi mass index 1 0.0441 0.0487 0.8184 3657 smoke rate 1 20.0047 0.0361 0.0170 8960 nicotin tobacco research 877 nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org end treatment 12 month unlik present moder intens exercis trial particip exercis group vigor intens trial achiev continu abstin timepoint pare contact control condit tabl 2 compar outcom current moder intens trial i. ctqii previou vigor intens trial i. ctqi import differ trial prematur conclud vigor intens physic activ efficaci moder intens physic activ elabor differ trial implica tion discuss fit fit i. estim maxim vo2 stress test particip baselin end treatment half moder trial compar vigor trial fit present studi similar studi deliv moder intens physi cal activ marcu napolitano lewi 2003 exercis intens present trial adequ produc increas continu smoke cessat rate limit assess fit particip attend posttest assess 46 sampl weight previou trial examin vigor ou intens exercis partici pant quit particip cbt group gain significantli weight partici pant contact control condit differ weight gain observ group present trial dose exercis insuffici produc signific differ weight gain cbt cbt condi tion present trial addition nicotin patch attenu weight gain cessat hill roe taren muramoto leischow 2002 jorenbi hatsukami smith fior 1996 contribut lack weight gain differ condit possibl support particip present trial gain fewer pound particip vigor intens trial present studi shorter durat vigor intens trial 8 week 12 week protocol differ base particip re pons consum satisfact survei admini tere vigor intens exercis trial pilot studi present moder intens exercis trial made protocol present trial list exercis intens differ contribut discrep result trial addit studi conduct prematur definit conclud vigor intens exercis efficaci moder intens exercis smoke cessat differ trial present trial includ 8 session intervent protocol previou trial includ 12 session intervent protocol particip previou trial achiev smoke cessat group receiv lengthier smoke cessat intervent particip present trial possibl cbt group exhibit similar smoke cessat rate trial 12 month follow 10.2 vigor intens trial 11.1 moder intens trial adher exercis prescript lower present trial previou trial particip adher exercis prescript find present trial approxim find previou trial particip cbt group adher exercis achiev smoke cessa tion particip exercis particip previou trial instruct particip supervis session gym time week particip present trial requir attend supervis gym base session week particip exercis remain dai gym gym particip moder intens group particip gym fourth begin cohort 5 particip present trial offer nicotin replac patch particip previou trial offer nicotin replac expect particip present trial particip previou trial achiev smoke cessat exercis particip cbt group studi similar smoke cessat rate final compar vigor intens trial baselin particip present trial weigh older higher percentag bodi fat report higher level trait anxieti report lower efficaci maintain weight smoke cessat marcu al 1999 differ cohort composit plai role find observ studi 878 random trial moder intens exercis aid smoke cessat nivers berdeen ovem ber 25 2015 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org limit limit present studi warrant discuss fit assess intervent phase unclear particip physic activ intervent phase continu activ end treatment unclear individu adher exercis intervent adopt exercis intervent phase began nicotin replac cohort 5 cohort opportun nicotin replac major sampl offer nicotin replac chose offer cohort affect result final studi limit generaliz partici pant respond newspap advertis particip exclud medic condit result select sampl futur direct limit present trial particip receiv adequ dose exercis lack adher moder intens exercis prematur conclud vigor intens exercis effect moder intens exercis smok ing cessat moder intens exercis potenti reach greater number femal smoker vigor intens activ addi tional research warrant examin efficaci moder intens activ specif adequ test efficaci moder intens activ random control trial achiev high adher moder intens exercis need present trial began studi publish demonstr efficaci theori base exercis intervent promot moder intens exercis e.g dunn al 1997 marcu al 1999 intervent includ cognit behavior strategi increas physic activ sedentari adult face face i. group base program face face e.g print base intervent strate gi shown efficaci dunn al 1997 marcu al 1999 smoker benefit intervent smoker encount uniqu barrier exercis stress quit smoke interfer adher exercis program smoker bene fit intens face face exercis program provid smoker intens intervent shown efficaci research improv adher exercis adequ test efficaci moder intens exercis smoke cessat contrari hypothesi cbt cbt intervent equal prevent weight gain smoke cessat find moder intens exercis assist smoke cessat help femal smoker feel concern weight gain attempt cessat word quit smoke weight gain attenu moder intens exercis poor adher exercis present trial addit studi need examin impact moder intens exercis weight gain attenu definit conclu sion made weight gain moder intens exercis acknowledg project support part grant nation cancer institut ca77249 nation heart lung blood institut hl64342 hl68422 author melissa napolitano john jakic contribut trial robin cram heinrich doll manoj eapen santina ficara joyc lee mari robert sue sullivan janic tripolon regina traficant shira dunsig numer contribut well speaker gave time studi staff center cardiac fit import research particip
journal consult clinic psycholog copyright 1997 american psycholog associ 1997 vol 65 1 190 194 0022 006x 97 3.00 prospect evalu smoke intervent 205 recov alcohol year result project scrap tobacco john martin karen calla christi patten san diego state univers univers california san diego mark polarek richard hofstett jame noto dian beach san diego state univers total 205 113 male 92 femal nonhospit recov alcohol 3 month continu abstin alcohol drug heavi tobacco depend fagerstrom toler questionnair score 7.7 mean number cigarett dai 26.8 mean number year smoke 24.4 random standard treatment st american lung associ quit program nicotin anonym meet 70 behavior counsel physic exercis bex 72 behavior counsel nicotin gum bnic 63 3 4 repeat measur design evalu effect intervent smoke outcom baselin posttreat 6 12 month follow up report smoke statu verifi biochem arid inform report verifi report significantli smoker bex quit posttreat 60 bnic 52 st 31 x2 2 205 17.85 01 6 month 29 27 21 12 month 27 27 26 follow 4 7 188 relaps alcohol drug alcohol relaps differ treatment group smoke statu length alcohol abstin smoke cessat outcom preval smoke alcohol abstin substanti estim rang 80 95 bobo 1989 5 10 popul alcohol helzer 1987 constitut consider number individu smoker high risk cardiovascular diseas excess drink cigarett smoke criqui wallac mishkel barrett connor hess 1981 recov er alcohol tend heavili addict nicotin kozlowski jelinek pope 1986 resist smoke intervent hugh 1993 observa john martin karen calfa christi patten depart psycholog san diego state univers school medicin univers california san diego mark polarek richard hofstett jame noto dian beach depart psycholog san diego state univers research support grant 2rt0053 califor nia tobacco relat diseas research program extend report articl request john martin express appreci mark myer critic review help editori feedback previou draft articl acknowledg signific contribut con duct studi data manag analysi carl william joan mask deborah melindrez simon laura kate barrett rachel wild jennin white correspond articl address john martin depart psycholog san diego state univers 6363 alvarado court suit 103 san diego california 92120 electron mail internet email:jmartin sdsu.edu tion treatment smoke larg unaddress high risk popul carmodi 1990 studi report suffer signific methodolog limit toneatto sobel sobel kozlowski 1995 recent investig suggest method effect enhanc smoke treatment outcom recov er alcohol bobo davi 1993 hugh 1993 retrospect survei studi relianc alcohol anonym aa 1976 principl treat ment focus gradual reduct nicotin intak rate nicotin replac therapi group support significantli increas likelihood success smoke cessat popul bobo 1989 bobo davi 1993 smoke cessa tion appear posit long term alcohol abstin bobo schill gilchrist schink 1986 hurt al 1994 addit studi examin success rate recov er alcohol stop smoke compar alcohol counterpart covei glassman stetner becker 1993 observ 6 month particip behavior smoke cessat program quit rate 25 abstain alcohol versu 27 nonalcohol smoker contrast hugh 1993 found year quit rate 7 abstain alcohol compar 19 individu report histori alcohol drug abus data inform respect likelihood smoke cessat alcohol smoker publish studi specif target popul smoke treatment articl report result larg interven 190 report tabl 1 particip demograph characterist condit st bex bnic total demograph 70 72 63 205 mean ag sd 41.5 9.7 40.5 8.9 43.6 11.0 41.8 9.9 femal 46 43 47 45 caucasian 95.7 90.4 91.9 92.7 mean sd year educ 14.7 2.5 14.3 2.4 14.7 2.6 14.6 2.5 marri partner 29 31 32 30 emploi 99 96 89 95 note st standard treatment bex behavior counsel exercis bnic behavior counsel nicotin gum emploi x2 2 63 6.60 04 comparison group nonsignific 191 ion trial date import populat ion high isk smoker rel efficaci safeti e.g alcohol relaps special adapt smoke treatment main tenanc program evalu method particip includ 205 smoker 113 men 92 women report signific histori alcohol abus depend 3 consecut month alcohol drug abstin 18 year ag consum averag 10 cigarett dai provid written permiss physician nicotin gum engag supervis home program moder aerob exercis exclusionari criteria includ psychotrop medic physic disabl hinder engag program moder at physic activ smoker recruit commun mean announc ment flier direct aa group total 363 particip respond recruit effort subsequ screen assess elig inclus studi initi phone screen volunt attend orient interview 363 spondent 220 met studi criteria 205 agre random treatment condit accept particip sign approv inform consent formal assess treatment initi de mograph smoke alcohol histori characterist inter vention group present tabl 1 tabl 2 high level smoke nicotin depend alcohol abstin aa program involv measur smoke report primari depend measur smoke statu assess pre posttreat 6 ind 12 month follow up addit report measur number ciga rett smoke brand nicotin level obtain major assess point perform alveolar carbon monoxid coa assess conclus treatment follow session standard method hugh frederiksen frazier 1978 particip requir provid phone number signific inform home work environ agre contact corrobor report data smoke drink drug inform contact phone major assess interv alcohol drug abstin level determin particip report corrobor inform report measur point particip assign behavior counsel exercis bex monitor weekli physic exercis activ home exercis log hand form mainten session follow up attend weekli treatment exercis session monitor smoker standard treatment st group instruct report nicotin anonym meet attend maint nanc phase return sign meet secretari postcard meet attend 4 week mainten final smoker assign behavior counsel nicotin gum bnic monitor nicotin gum daili basi 4 week mainten phase retrospect 6 12 month follow up procedur particip random treatment group 6 cohort approxim 36 particip st group modifi version standard american lung associ ala 1986 20 dai quit program combin nicotin anonym meet mainten counsel inter vention treatment implement train phd level master level smoke health educ weekli 60 75 rain group session mainten session supplement 4 week 12 step nicotin anonym meet 4 week treatment includ basic behavior compon monitor relax urg control instruct relaps prevent train quit contract larg scale smoke rate reduct week addit facilit group discuss particip instruct quit smoke week 4 session particip request attend nicotin anonym meet time week close parallel home mainten requir bnic bex bex group behavior counsel intervent group 2 3 consist weekli 60 75 min session gradual reduct schedul treatment deliveri adapt specifi calli recov alcohol smoker contrast mainten strategi behavior treatment packag repres refin program develop pilot work alcohol smoker martin calfa polarek myer hofstett 1995 gradual nicotin brand reduct method addit standard behavior compon monitor smoke stimulu control smoke episod treatment group conduct doctor master level group colead 1 year experi cofacilit treatment group techniqu supervis smoker group mentor em ploi adapt languag techniqu behavior interven 192 report tabl 2 baselin smoke alcohol histori condit sd st bex bnic total characterist 70 72 63 205 nicotin toler ftq score 7.9 1.8 7.7 2.0 7.6 1.7 7.7 1.8 year smoke 23.5 10.0 23.7 8.8 26.1 11.7 24.4 10.2 previou quit attempt 4,1 34.0 2.9 2.6 5.6 17.6 4.1 10.1 longest quit durat month 1.2 2.6 0.5 1.1 0.8 1.4 0.8 1.8 activ sponsor 73.9 70.4 70.0 71.5 year abstin alcohol drug 4.5 4.5 3.3 2.7 5.0 5.3 4.2 4.3 weekli aa meet 2.8 1.9 2.7 1.8 3.3 3.1 2.9 2.3 note comparison nonsignific st standard treatment bex behav ioral counsel exercis bnic behavior counsel nicotin gum ftq fagerstrom toler questionnair aa alcohol anonym 2 202 3.15 05 bnic 5.0 group year abstin alcohol bex 3.3 group tion group discuss 12 step recoveri process tradit philosophi facilit chosen group success graduat previou smoke treatment program alcohol smoker 6 month nonsmok activ member aa program begin week 8 bex particip moder aero bic exercis prescript includ site moder brisk walk outoor track laboratori exercis equip tread mill stair stepper stationari bicycl progress 15 45 min thrice weekli home exercis similar natur recommend american colleg sport medicin acsm 1991 bnic group behavior counsel similar bex group 2 combin postquit nicotin replac maint nanc prescript consult project scrap physician provid group 3 particip free suppli 2 mg nicotin gum nicorett merril dow lakesid pharmaceut cincinnati particip instruct chew piec nicotin gum dai prophylact strong urg particip continu nicotin gum 3 month postquit systemat fade 6 month postquit treatment deposit 50 collect initi particip deposit return conting session attend complet homework assign resu primari smoke outcom quit statu point preval rate 6 12 month follow up con tinuou abstin 1 week posttreat quit point parti cipant code nonsmok report smoke previou 24 hr 7 dai 1 week posttreat measur level 10 ppml data inform verifi particip smoke data purpos investig assum nonrespond verif unavail smoke al present report analyz discuss verifi smoke outcom data smoker report data contrast verifi smoke outcom data figur 1 figur 1 mean smoke quit rate group time verifi versu report outcom 1 wk post tx 1 week posttreat 6 month fu 6 month follow 12 mo fu 12 month follow st standard treatment bex behavior counsel exercis bnic behavior counsel nicotin gum symbol abstin rate st significantli bex 01 equal sign rate bex significantli bnic rate 1 recogn convent border separ nonsmok smoker coa 8 ppm slightli liber criterion 10 ppm part provid margin error determin smoke statu potenti elev carbon monoxid level nonsmok result chronic inspir automot smog warm weather high traffic condit major southern california metropoli san diego float lo angel report 193 verifi report significantli smoker bex quit posttreat 60 bnic 52 st 31 superior bex maintain bnic st condit 6 month 29 27 21 12 month 27 27 26 follow chi squar analysi perform time point verifi quit statu signifi differ verifi quit rate experiment group posttreat x2 2 205 17.85 01 higher quit rate bex 60 compar st 31 differ statist signific relaps alcohol drug abus assess signific inform collabor infor mant successfulli contact approxim 85 205 particip posttreat 1 2 177 relaps alcohol drug 6 month follow 2 4 178 relaps 1 year follow 4 7 188 relaps relaps alcohol drug smoke time relaps tempor relationship unknown signific group differ found respect alcohol relaps x2 2 205 05 smoke statu time point inform data relationship length sobrieti alcohol abstin alcohol relaps posttreat 07 35 6 month 05 51 12 month 12 09 follow discuss ion studi repres prospect clinic treatment comparison studi abstain alcohol find indi cate efficaci behavior base intervent result abstin rate gener consist studi provid treatment heavi smoker hurt al 1994 mothersil mcdowel rosser 1988 posttreat absti nenc rate significantli higher group receiv exercis mainten 60 st condit 31 posttreat treatment condit differ signific 6 12 month follow up ultim 1 year cessat rate 27 compar favor abli result intervent nicotin de pendent treatment resist nonalcohol smoker generaliz find limit select group alcohol smoker treat tabl 1 caution exercis gener result alcohol smoke popul importantli small percentag relaps alcohol drug found 2 4 attribut stress quit attempt quit smoke relaps alcohol drug abus appear independ length alcohol drug abstin fact length alcohol drug abstin like hood smoke cessat studi support find stress quit smoke prompt relaps alcohol drug bobo davi 1993 jeopard sobrieti smoke treatment serv enhanc small grow number studi result combi nation find safeti efficaci provid smoke treatment chemic depend treatment lend strong impetu smoke interventionist chemic depen denci treatment program strongli kind dual treatment studi noteworthi limit major drawback present evalu includ treatment control group alcohol formal treat smoke preval rate smoke popul necessarili declin year alcohol drug abstin myer brown 1994 toneatto sobel sobel kozlowski 1995 addit featur studi problemat includ inclus ala 1986 20 dai quit program st comparison special adapt intervent 12 step group pro cess nicotin anonym mainten meetingsmal blend treatment differenti st bnic group clinic research warrant im portant group comorbid smoker futur direct search includ systemat program tai lore treatment maintain behavior environmen tal support constraint studi critic need respect develop test comprehens effect mainten intervent limit consider fall cessat rate observ 6 month posttreat intervent heavili nicotin depend smoker signific histori alcohol depend address assess adapt individu alli tailor aggress smoke intervent specif abili ti psycholog behavior disabl indi vidual orlean hutchinson 1993 case point high preval major depress popul regier al 1990 schuckit 1986 comorbid alcohol ism major depress exert detriment effect likelihood smoke cessat covei al 1993 research hall mufioz reu 1994 patten press found treat depress smoker significantli im prove outcom importantli recov alcohol smoker test found signific lifetim histori major depress independ drink patten press suggest includ intervent address mood dysregul effort achiev maintain abstin tobacco special group high risk hap trimorbid smoker
origin paper develop cultur target smoke cessat intervent african american smoker alicia matthew æ lisa sánchez johnsen æ andrea king publish onlin 29 august 2009 springer scienc busi media llc 2009 abstract paper describ develop cultur target ct smoke cessat intervent low middl incom african american smoker base theoret base guidelin modif made standard treatment manual group base smoke cessat counsel incorpor cognit behav ioral motiv twelv step skill approxim 41 standard treatment materi modifi modul develop pilot studi conduct compar accept feasibl earli outcom african american smoker random iz ct intervent compar exist data african american smoker treat tar gete standard approach st outcom ct pilot studi promis result show high level fea sibil accept adher nicotin replac therapi higher quit rate retent follow compar st find suggest cultur target intens group base smoke cessat treatment plausibl effect improv smoke cessat outcom african american smoker warrant larger random trial keyword cultur target african american smoke intervent introduct tobacco smoke preval rate compar adult caucasian african american 21.9 21.5 1 similar ethnic racial group african american report strong desir quit smoke 2 fact caucasian quit smoke dai previou year 3 african american smoker success quit attempt compar caucasian smoker find persist control socioeconom fac tor 4 5 factor smoke cessat di pariti african american ethnic minor smoker complet understood lower abstin rate ethnic minor impli limit referr effect smoke cessat treatment 6 8 differenti outcom particip recommend treatment 9 higher rate smoke relaps period abstin compar gener popul 9 combin factor highlight develop effect smoke cessa tion intervent african american smoker popul increas risk morbid mortal tobacco 10 purpos studi describ develop earli outcom indica tor cultur target smoke cessat treatment program african american smoker term african american european american manuscript author acknowledg great heterogen ethnic classif african american refer identifi african american black ethnic origin trace black ethnic group africa matthew colleg nurs howard brown health center univers illinoi chicago 845 south damen avenu chicago il 60612 usa mail aliciak uic.edu sánchez johnsen king depart psychiatri behavior neurosci univers chicago 5841 south maryland avenu chicago il 60637 usa 123 commun health 2009 34 480 492 doi 10.1007 s10900 009 9181 5 factor higher african american smoke preval rate socio demograph factor influenc smoke behavior adult includ race ethnic ag gender educ se 11 cognit i. stage readi perceiv benefit barrier efficaci suscept diseas psychosoci factor i. stress neg affect impact health behavior 12 14 gener factor influenc smoke behavior addit factor hypothes contribut tobacco initi mainten african american factor thought influenc smoke behavior african american summar uniqu expo sure health risk high preval risk associ at uniqu exposur greater access cultur compet risk reduct approach 15 uniqu sociocultur exposur african american smoke behavior includ elev stress live area high poverti 16 presenc smoker home 17 permiss social norm relat smoke 18 includ smoke home 19 advic quit smoke health care provid 6 direct market african american muniti tobacco compani 20 contribut widen gap smoke cessat outcom african american experi higher prev alenc behavior relat tobacco smoke cessat outcom neg affect stress differenti alcohol pattern 21 22 knowledg neg health consequ smoke 23 lower perceiv threat develop advers health outcom smoke 24 limit access smoke cessat treat ment potenti drive forc current smoke trend african american 8 final discuss pauciti clinic research address cultur compet smoke cessat treat ment african american smoker smoke cessat intervent african american smoke cessat outcom african american vari consider depend treatment approach studi nicotin gum motiv interview reveal low quit rate 7 9 6 month 25 studi african american produc favor cessat outcom quit rate rang 14 18 studi nicotin patch intens behavior empower 26 studi buproprion motiv counsel result reveal fairli compar quit rate 6 month 21 bupropion 14 placebo 27 ethnic racial differ smoke topographi pattern smoke cessat cultur alli target smoke cessat intervent conduct african american 28 30 research preliminari support effect cul tural target smoke cessat program studi nicotin patch cultur target materi quit rate 6 month 27 31 unfortu nate previou effort evalu effect cultur target smoke cessat program african american limit com.ibm.drl.hbcp.util minim intervent strategi pamphlet print video group counsel review 32 random trial 32 reli sole bio chemic verifi report measur determin quit rate e.g 33 35 cultur target intervent recent updat tobacco depen denc clinic practic guidelin 10 stress addit research determin effect cultur target smoke cessat intervent racial ethnic minor cultur target defin singl intervent approach defin popul subgroup take account characterist share subgroup member 136 36 health promot intervent target belief knowledg stage readi combin construct 37 cultur target intervent document efficaci reduc health risk behavior varieti behavior popul group 38 42 mechan enhanc effect target intervent appear increas salienc inform target messag rememb view relev 37 health commun program materi suc ceed make inform relev intend audienc effect target inter vention suit maxim influenc behavior chang facilit address gener cultur specif barrier chang studi aim purpos studi cultur target standard commun base intens cognit behav ior smoke cessat treatment intervent proven effect african american 43 report theoret framework strategi guid commun health 2009 34 480 492 481 123 develop target intervent pre liminari find pilot test intervent urban sampl low middl incom african american smoker studi find import implic futur research aim increas effect cultur target smoke cessat approach method rational theoret framework research investig uniqu smoke cessat treatment african american smoker grow area research area health behavior chang dearth research guid theoret ground cross cultur approach 44 theoret framework underli develop cultur target smoke cessat program deriv pen 3 model health behavior 45 theoret ground strategi improv cultur appropri health promot program 36 pen 3 theoret model emphas cultur central reason health behavior primari con sider develop health promot pro gram 46 numer studi aid develop cultur center intervent e.g 46 48 pen 3 model influenc predecessor model includ health belief model 49 theori reason action 50 preced pro cede model 51 52 airhihenbuwa 45 phase pen 3 model phase person extend famili neighborhood compris target intervent identifi interven tion focus specif commun south side chicago high concentr low middl incom african american smoker 53 african ameri can lower socioeconom group highest level advers smoke outcom unit state 10 studi particip recruit part larger commun base initi reduc smoke behavior african american includ outreach commun base health center partnership local school student provid parent care provid inform smoke cessat treatment word mouth referr african american previous particip standard smoke cessat program phase pen 3 model percept enabl nurtur specif cultur factor affect tobacco african american identi fi integr standard treatment modul comprehens search extant literatur conduct identifi com.ibm.drl.hbcp.predictor smoke behavior bar rier smoke cessat e.g 16 54 55 strategi outlin kreuter colleagu 36 increas cultur relev smoke ce sation treatment african american includ peripher strategi e.g cultur packag includ imag exemplar african american evidenti strategi e.g enhanc perceiv rele vanc present evid impact smoke african american linguist strategi e.g languag vernacular idiom relev african american constitu involv strategi e.g includ ing facilit group member racial ethnic minor sociocultur strategi e.g discuss smoke relat risk context broader social cultur valu african american guid pen 3 model phase address posit existenti neg behavior impact smoke cessat african amer ican activ conduct phase project highli focus increas knowledg readi ness quit smoke remov cultur salient bar rier particip formal smoke cessat treatment program activ includ conduct orient session prior onset intervent studi specif address knowledg deficit effect smoke cessat treatment program myth danger nicotin replac ment therapi cultur norm quit cold turkei com.ibm.drl.hbcp.util sociocultur strategi highlight factor contribut high smoke preval nicotin depend african american commun discu sion focus level direct market african american commun form billboard sponsor ship sport social event advertis print media market african american 20 addit topic address includ exposur young african american tobacco product due avail abil cigarett neighborhood conveni store singl cigarett vendor law strategi tobacco compani increas appeal men tholat cigarett african american product increas health hazard statist highlight devast health econom cons quenc tobacco african american posit messag quit smoke health benefit individu famili member financi advantag quit smoke contribut health larger african american commun particip smoke cessat treatment research 482 commun health 2009 34 480 492 123 s04aw6 highlight s04aw6 highlight s04aw6 highlight cultur target ct treatment program develop com.ibm.drl.hbcp.core cultur target ct smoke cessat treatment manual deriv standard smoke cessat treatment program manual develop smoke cessat research ak univers chicago king rilei 2001 56 implement chicago conjunct respiratori health associ metropolitan chicago courag quit king 2008 57 standard treat ment st incorpor evid base method modifi clinic practic guidelin treat tobacco depend 58 tobacco depend treatment handbook guid practic 59 st grogram incorpor practic identifi clinic practic guidelin 58 group format includ content focus problem solv prepar quit intra treatment social support optim treatment dose 4 7 session length week 8 week nicotin replac therapi specif st program includ weekli group individu make session meet 6 week quit date target session session focu review past quit attempt identifi creat plan trigger note health financi gain quit custom motiv decision balanc sheet obtain social support present monitor wrap sheet place cigarett pack note number cigarett situat mood preced cigarett session quit date focus process particip experi dai modul crave withdraw emerg plan setback session compris group discuss modul high risk situat cognit techniqu manag high risk situat st program specif target cultur african american smoker previou trial african american smoker includ compon surfac structur target conduct set familiar african american ethnic homogen 60 surfac structur target match intervent messag materi observ characterist target popul increas cultur sensit intervent suffici address myriad sociocultur factor thought influenc smoke behavior racial ethnic minor group 60 43 full descript compon standard smoke cessat treatment program smoke cessat outcom sampl african american smoker natur progress program research move surfac structur target address deep structur variabl socio cultur variabl hypothes influ enc health behavior 60 cultur target version standard treatment program free smokin gener effect smoke cessat program deliv group format support 58 decis cultur adapt standard treatment pro gram oppos develop intervent base program evid base practic compar program sim ilar commun base smoke cessat program i. ac fresh start 61 promis result achiev earlier studi group standard inter vention african american smoker 57 adapt standard treatment program specif smoke cessat african american smoker consist call dissemin effect behavior intervent 62 tabl 1 outlin similar differ compon previous devel op st intervent king rilei 2001 56 ct intervent african american smoker main featur structur content length st ct treatment manual similar import dif ferenc manual exist tabl 1 primari differ ct versu st group focu theme relev african american smoker modifi materi cultur target theme imag messag ct treatment manual modif term content appear motiv approach made 41 14 34 modul addit modul ad includ evidenti sociocultur strategi statist health cons quenc smoke african american faith prayer cope strategi descript famou african american di tobacco relat diseas histor relationship tobacco industri african american gener countri e.g tobacco compani histor profit result cheap labor provid african ameri sharecropp profit result high level tobacco african american manual includ cultur specif trigger smoke smoke context norm barrier smoke cessa tion materi procedur ident st ct treatment manual figur 1 illustr modifi cultur target modul versu standard modul weight concern fig 1a commun health 2009 34 480 492 483 123 s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight exampl modul develop fig 1b counselor train st ct smoke cessat program design deliv master level clinician extens experi health care deliveri patient contact briefli counselor train ph.d level smoke cessat expert ak group train session cover content area 1 cog nitiv behavior approach program 2 smoke relat health inform 3 motiv inter view techniqu 4 strategi elicit barrier smoke cessat address barrier 5 role respons group facilit 6 partici pant confidenti 7 help particip deal smoke trigger crave laps 8 listen feedback skill 9 provid judgment support order increas cultur sensit interven tion counselor provid inform approach recogn address psychosoci cultur barrier gener principl support smoke cessat combin cultur alli target gener individu support facilit address wide rang psychosoci cultur deriv determin smoke behavior group coun selor receiv ongo supervis includ audio tape review session adher checklist emploi monitor treatment fidel period review perform consist accuraci 63 recruit african american smoker clinic addict research laboratori uni versiti chicago histori success recruit retent divers popul smoker smoke cessat trial i. colleg student women low incom lgbt african american smoker practic emploi research team recruit divers sampl includ hire recruit specialist lead outreach effort divers team outreach worker strategi conduct elig assess recruit field onlin gener type research approach typic clinic base recruit activ passiv commun reach method 64 66 clinic base recruit involv direct referr smoke patient medic provid clinic base recruit commun base health center serv target popul activ recruit approach consist outreach recruit street venu locat includ health fair festiv gym school church commun group organ locat member target popul social congreg passiv commun outreach includ post recruit inform target media tabl 1 similar differ cultur target ct target standard treatment st program target smoke cessat program ct target smoke cessat program st similar theoret basi stage chang health belief model stage chang health belief model deliveri channel group individu support group individu support counsel techniqu profession facilit profession facilit differ purpos increas smoke cessat outcom address gener cultur specif determin smoke e.g belief attitud norm increas smoke cessat outcom address gener popul deriv determin smoke counsel target counsel gener support gener support counsel inform deliveri didact print materi base statist health inform specif african american smoker didact print materi base statist inform gener popul smoker packag content imag color pictur convei relev african american peripher target gener content presum appeal broadli educ content increas perceiv relev present evid specif african american evidenti target gener content base aggreg data educ messag deliv domin languag languag relev african american linguist target deliv languag major context mean messag relev cultur valu belief behavior african american sociocultur target gener content base mainstream cultur involv larger commun involv target commun constitu involv target gener model intervent deliveri 484 commun health 2009 34 480 492 123 outlet post flyer person referr word mouth recruit materi design cultur salient i. imag pilot studi treatment manual develop individu expertis smoke cessat curriculum develop ment cultur target help refin materi conduct pilot test cultur target intens smoke cessat intervent african american compar outcom achiev standard treatment program part larger commu niti deliv smoke cessat studi compar accept feasibl patch adher quit rate particip random ct program versu combin data african american treat st program 43 ct st sampl recruit techniqu neighborhood inclus criteria group includ african american adult ag 18 65 smoke minimum 1 cigarett daili 12 month educ greater 9th grade stabl resid contact number abil session 5 smoke glamor famou african american grace stage presenc entertain music captur smile share common fact di prematur smoke relat moment reflect famou african american lost year live due tobacco member commun famili friend di tobacco relat honor memori learn experi goal mind rememb don’t join rank loui armstrong 1955 made america music ambassador 1964 record song dolli loui armstrong talent success musician work influenc jazz techniqu style smoker juli 6 1971 loui armstrong di lung infect heart complic trumpet buri wish nat king cole born montgomeri alabama grew chicago nat king cole singer pianist songwrit famou natur boi notabl unforgett african american radio tv show smoke 3 pack cigarett dai di lung cancer februari 15 1965 session 4 weight gain standard detegrat yllarutluc averag smoker gain 3 7 lb weight gain import issu african american smoker obes grow problem commun african american gain weight group doesn’t case averag smoker gain 3 7 lb fig 1 standard treatment left cultur target treatment modul session 4 weight gain experienc smoke cessat note peripher strategi relev african american ct version addit modul ct manual present session 5 famou african american di tobacco relat diseas evidenti strategi cultur target addit modul ct manual present session 6 histori tobacco african ancestor sociocultur strategi cultur target commun health 2009 34 480 492 485 123 understand spoken english exclus criteria includ current major medic psychiatr condit medi cation 3 month intak interview individu ask current interest quit smoke 10 point scale higher score mean interest quit person score 7 higher scale elig addit detail recruit screen procedur 43 studi approv univers chicago institut review board therapist random treatment group ct group lead caucasian femal st group lead caucasian femal caucasian male latino femal biraci femal procedur smoke cessat intervent deliv group format session last 75 90 min ct group conduct commun center st group conduct commun center commun site elementari school church hour weekli studi visit follow interview 3 6 month end treatment arriv week subject complet questionnair interview research assi tant provid expir air carbon monoxid sampl smokerlyz bedfont medford nj receiv weekli suppli nicotin patch procedur approxim 30 min immedi behavior therapi group counsel session quit date target week session 3 inter vention end treatment sixth studi visit particip receiv small monetari compens 40 gift card draw group 75 gift card nicotin replac therapi met elig nicotin replac therapi i. past advers reaction nrt compli mentari sampl nicotin patch nicoderm cq session 6 histori tobacco african american commun histori hundr year ago tobacco major cash crop south african american slave forc daili hard physic labor harvest crop tobacco compani made lot monei sale tobacco product found peopl quickli addict cigarett knew want produc tobacco crop increas slave cheap labor work bottom line tobacco compani built back african american todai african american commun target tobacco compani profit billboard magazin club store specif target advertis encourag start smoke hook hip imag smoker promis cool minti tast li harm menthol lower tar brand develop appeal african american chang show strength courag come program skill break chain addict tobacco affect famili commun larg share inform care move forward goal bottom line tobacco compani built back african american power chang healthi push forward smoke free congratul program work work continu skill commun church famili support fig 1 continu 486 commun health 2009 34 480 492 123 glaxosmithklin distribut session begin quit date monitor studi physician dose base baselin smoke level fol low c15 cigarett daili smoker receiv 21 mg daili 2 week 14 mg 1 week 7 mg 1 week 10 14 cigarett daili smoker receiv 14 mg daili 2 week 7 mg 1 week 1 9 cigarett daili smoker receiv 7 mg daili 2 week post treatment follow particip schedul follow interview month visit complet follow survei crave smoke behavior visit object measur smoke statu level engag booster group session approxim 30 min measur orient session particip complet questionnair assess demograph health histori smoke behavior level physic depend tobacco assess fagerström test nicotin depend ftnd 67 stage readi smoke cessat measur smoke contempl ladder 68 evalu respons orient session random group ct st group particip complet item questionnair assess impress intervent item rate 11 point likert type scale 0 strongli disagre 10 strongli agre level perceiv focu smoke issu tain african american commit assist african american smoke cessat potenti help program comfort felt program abil program address uniqu smoke issu uniqu smoke issu african american gener felt program good fit feasibl assess examin complet rate treatment program month post quit date month follow up accept assess particip post treatment rate program compon smoke cessat counselor includ perceiv help rate treatment element includ take weekli test identifi smoke trigger techniqu handl trig ger take care physic emot counter ing ration monitor wrap sheet deep breath address concern weight gain smoke cessat particip rate smoke cessat treatment counselor 5 point likert scale item work alli anc commun share feel eas quit therapist role therapist aid quit attempt total composit score therapist rate item calcul subject adher guidelin nicotin patch assess determin ratio total number patch report divid total number patch distribut particip dichotom main categori low 75 distribut patch high 75 patch distinct chosen approxim patch major dai treatment ensur steadi state nicotin level 69 treatment outcom determin 7 dai point preval smoke quit rate end treatment month follow report smoke behavior object verifi expir air carbon monoxid read 6 ppm higher level sampl provid particip conserv classifi relaps statist analys data analyz statistica excel softwar packag main outcom variabl attend patch adher biochem confirm dai point preval smoke quit rate data summa rize mean sem frequenc data group compar background smoke characterist test chi squar appropri at chi squar analys emploi explor differ retent adher smoke cessat quit rate st ct result sampl characterist ct group consist 8 african american smoker similar demograph smoke background char acterist smoker st studi total st intervent group 50 conduct averag member group ct st group differ demograph smoke variabl major sampl middl ag 45.4 year rang 26 67 femal 90 complet high school educ 13.1 rang 9 18 approxim 31 particip marri 69 emploi full part time third sampl low incom 42 report household incom 20,000 year commun health 2009 34 480 492 487 123 s04aw6 highlight 22 household incom 20,000 30,000 particip smoke averag 13 cigarett dai rang 3 60 major 86 prefer menthol cigarett averag particip initi smoke 17.7 year averag 2.4 prior quit attempt particip moder depend smoker index ftnd score 4.8 rang 1 9 baselin expir air level 15.4 ppm rang 1 45 result contempl ladder question nair reveal major particip prepar action stage 7.3 rang 5 10 evalu orient session ct group significantli higher rate st group percept specif program issu pertain african american smoker 1,14 19.30 0005 ct group margin signific higher rate st group ceiv abil program address uniqu individu smoke cessat gener african american smoker ps 07 ception program good fit 10 program retent medic adher program complet rate direction ct versu combin st group 100 74 st x2 1 2.68 10 retent 3 6 month up significantli ct versu st group 100 ct particip interv 64 58 st particip 3 month x2 1 4.18 04 6 month x2 1 5.67 02 ct group margin signific higher adher nico tine patch compar st 88 51 highli adher ent x2 1 3.63 06 ad hoc reason cite patch discontinu group includ mild side effect i. sleep problem skin irrit person feel patch longer need program rate ct group rate perceiv help smoke cessat treatment program compon higher st condit ct group signifi cantli higher rate st group perceiv effect strategi identifi smoke trigger 4.89 3.00 care physic emot 4.75 3.31 cognit exercis aim manag high risk smoke situat 4.75 3.72 fs 1,45 4.45 ps 05 ct group significantli higher therapist evalu rate st group 4.5 4.0 05 treatment outcom intent treat analys end treatment biochemi calli verifi quit rate direction ct group 63 versu st group 36 x2 1 2.38 12 month follow verifi quit rate remain direction higher ct 50 quit versu st group 26 quit month quit rate similar group 25 24 discuss african american higher expect preval risk factor e.g heavi drink obes di eas exacerb smoke e.g heart diseas 70 71 smoke relat health dispar continu challeng underserv popul score develop cultur interven tion reduc dispar present studi theoret development approach cultur target standard smoke cessat treatment program african american smoker fur ther describ result preliminari studi pare treatment outcom african american particip st versu ct smoke cessat treat ment program recent review literatur smoke cessat treatment program african american smoker high light eleven studi includ element cultur target 66 date target approach character surfac structur peripher level target inclus graphic imag relev african american cultur peripher level target serv increas appeal accept health promot materi success promot health behavior chang 60 lack theo retic ground approach consist standard cultur target intervent contribut inconsist find benefit cultur tar gete health promot materi cultur adapt st curriculum guid pen 3 model 45 strategi outlin kreuter colleagu 36 facilit identif psycho cultur variabl facilit hinder smoke cessat low incom african american smoker analys pre intervent orient session program evalu suggest ct condit perceiv address socio cultur compon smoke cessat compar st condit particip respons orient session suggest particip group st ct rate gener program compon 488 commun health 2009 34 480 492 123 similarli particip ct orient se sion higher score item measur perceiv specif program issu relev african american perceptu factor factor direct implic improv treatment outcom observ ct group compar st higher percentag particip ct program attend treatment session level treatment engag evidenc attend level associ at improv outcom number behavior chang program 10 ct group particip adher nrt recommend third ct particip take recommend dose ethnic racial minor iti accept nrt lower caucasian smoker 72 73 greater accep tanc nrt therapi sampl african american smoker signific nrt significantli increas likelihood success quit attempt 74 address cultur belief misinform neg health consequ nrt ori entat session contribut improv nrt adher final rate help treatment compon gener higher ct partici pant similar approach group addit qualit research need understand experi cognit behavior treatment compon context target target treatment approach result pilot studi demonstr abil train smoke cessat facilit accept popul recruit retain african american smoker intens group smoke cessat pro gram interestingli therapist evalu rate ct st group high effect appear independ ethnic race therapist data shown find underscor notion ethnic match prefer instanc therapist work effect ethnic group level cultur awar knowledg skill work specif target popu lation 75 futur research systemat determin accept outcom compar ethnic match unmatch therapist deliv cultur target smoke cessat intervent statist signific program compl tion long term retent rate direction ct versu st group long term retent african american smoke cessat clinic trial identifi critic concern evalu efficaci smoke cessat treatment 76 strategi suggest increas retent ethnic minor research studi 77 emploi ct st condit specul target treatment element ct foster sens belong commit research project feel contribut clinic research result understand african ameri live led initi program complet subsequ longer term retent 6 month follow preliminari natur pilot studi small sampl size quit rate outcom ct group suggest cultur target smoke cessat pro gram plausibl effect decreas smoke rate african american smoker warrant full efficaci studi end treatment biochem confirm quit rate 63 ct group quit smoke versu 36 st group quit rate direc tional ct group 3 month assess month quit rate similar st group intent treat biochem verifi quit rate end treatment follow compar observ caucasian smoker engag similar treatment i. nicotin patch intens counsel 78 quit 12 month consid benchmark indic smoke cessat treatment 79 addit research need improv long term abstin rate african amer ican smoker contextu factor observ african american commun hinder smoke ce sation e.g pressur quit serv midabl barrier long term cessat systemat address part intens relaps pre vention treatment numer strength studi includ theoret framework guid adapt exist smoke cessat program african american smoker process variabl element program view effect biochem con firm quit rate long term retent follow studi particip comparison data african american smoker receiv equival target smoke cessat intervent result consid light studi limit cultur target st program guid theoret framework extant literatur consult expert cultur behavior african american previou find research team obtain qualit data independ sampl focu group african american smoker improv abil captur addit variabl smoke behavior collect cultur alli specif measur e.g accultur minor stress experi discrimin provid commun health 2009 34 480 492 489 123 addit insight factor influenc group differ smoke behavior practic approach recruit african american smoker intervent research e.g 64 66 abil recruit african american men limit final due development exploratori natur project studi sampl size small impact power generaliz find futur studi conduct address limit replic studi find studi result provid support continu effort refin target smoke treatment pro gram aid smoke cessat african american smoker studi includ fail address element minor stress increas vulnera biliti continu smoke relaps african american minor stress includ experi discrimin highlight import research influenc health risk behavior 80 81 minor stress refer social stress result belong stigmat social categori gener life stressor 82 futur research need determin minor stress relat smoke initi mainten cessat area address current research african american smoker acknowledg studi fund grant illinoi depart public health illinoi tobacco free muniti program 23281104 studi support award nih nation institut drug abus dr andrea king k08 aa00276 award nih nation cancer institut 5k01ca098753 ccsg p30 ca14599 nih nation center minor health health dispar research l60md000577 dr sanchez johnsen author gratefulli acknowledg assist melissa lopez b.a.for technic assist format prepar articl elizabeth chilton shannon grube roslyn rilei data col lection databas manag glaxosmith kline consum health care pittsburg pa donat nicoderm cq pat che studi appreci extend staff chicago public school jane addam hull hous associ parkwai commun hous gift god church reverend john gai chisum chicago il facil conduct intervent group
www.elsevier.com locat pateduc patient educ counsel 64 2006 235 241 random control trial social support buddi intervent smoke cessat sylvia robert west peter hajek andi mcewen hayden mcrobbi health behaviour unit univers colleg london london uk wolfson institut prevent medicin bart london queen mari school medicin dentistri london uk clinic trial research unit univers auckland zealand receiv 20 juli 2005 receiv revis form 31 januari 2006 accept 18 februari 2006 abstract object assess effect includ social support intervent buddi system group treatment programm aid smoke cessat method hundr sixti smoker attend group smoker clinic group random group smoker pair person provid mutual support buddi condit 237 14 group receiv treatment buddi compon control 326 20 group particip weekli 4 week stop 26 week result smoker buddi condit smoker control condit stai abstin 1 4 26 week effect direct week post quit control potenti confound differ signific odd ratio 1.45 95 ci 0.92 2.29 0.06 conclus unabl show buddi system improv abstin rate group treatment programm due high level social support achiev group practic implic buddi system simpl low cost addit group treatment programm result studi suggest kind buddi system test add substanti success rate merit intens protract form buddi 2006 elsevi ireland right reserv keyword smoke social support control trial 1 introduct social support identifi import mainten health behaviour 1 studi examin ad specif type social support intervent buddi system improv effect ness group support programm help smoker stop individu social environ import smoke behaviour popul survei find peopl marri higher rate smoke author tel 44 1453 873438 fax 44 207 813 2848 mail address sivpiv aol.com 0738 3991 front matter 2006 elsevi ireland right reserv doi 10.1016 j.pec 2006.02.008 cessat peoplewho divorc separ widow 2 4 recent evid suggest marri predict cessat smoker approach servic 5,6 research sweden larg sampl popul found high level social particip smoke cessat mainten 7 appar smoker social environ increas chanc smoker reduc chanc stop 4,8 10 find attribut cue social factor social support chandola al 4 found gener measur social support predict smoke statu follow gener popul survei mailto:sivpiv aol.com http dx.doi.org 10.1016 j.pec 2006.02.008 al patient educ counsel 64 2006 235 241236 research found exist partner 11 13 friend 14 specif support attempt stop smoke predict success consist case 15,16 har benefit support success intervent prove difficult west 17 complet discuss intervent typic focuss support individu buddi special respons smoker stop field smoke cessat major studi focus attempt improv qualiti pre exist support relationship friend partner 18,19 studi typic involv small sampl result larg neg 17,20 studi look smoker stop pair smoker previous unknown stop 21 23 methodolog problem e.g small sampl size biochem valid 21,22 recent west al 23 similar intervent random control trial involv 172 smoker nurs led smoker clinic gener practic studi smoker stop pair 1 week quit date quitter subsequ appoint encourag phone dai week encourag deposit sum monei amount decid smoker return week conting smoker remain abstin compar control group smoker quit nurs support percentag smoker abstin 4 week higher buddi control condit 27 versu 12 0.01 west 17 review literatur includ studi length follow conclud benefit buddi support intervent clinic context park al 20 cochran review conclud partner support interven tion increas quit rate longer term 6 month comment intervent short term benefit review point scarciti posit find due methodolog problem e.g inadequ power divers studi make comparison difficult find led review conclud good qualiti larg scale research examin support intervent smoke cessat smoker uk treat group approach aim foster group commun mutual support 24 approach highli cost effect group 20 smoker treat success rate high found individu treatment 25 group approach routin involv buddi system similar evalu west al 23 anecdot report suggest quitter find buddi procedur benefici group gener high level group support case question aris intervent make independ contribut tradit group support mechan paper report result larg random control trial test hypothesi buddi system group treatment set increas abstin rate 2 method 2.1 design smoker attend group base treatment programm stop randomli assign receiv addit social support member group buddi condit addit educ inter vention control assign group individu avoid contamin condit particip subset take part random control trial glucos aid cessat meant particip receiv glucos sorbitol tablet start session visit 2 impact run group alloc smoker buddi glucos condit independ result larger glucos studi written separ conduct research type doubl blind trial research awar group alloc recruit group complet respond alloc group select occur particip made awar social support element research visit sentenc inform sheet particip ask pair smoker stop intervent occur visit 2 smoker attend initi session 1 week quit date attend quit date weekli 4 week particip group stop smoke dai 26 week quit date smoker alloc condit visit 1 visit ident condit intervent occur visit 2 quit date attend visit 2 includ analys data analys intent treat basi attend quit date consid smoker accord usual practic primari outcom measur abstin 26 week quit date secondari outcom measur abstin week 4 week quit date 2.2 sampl studi conduct site st georg hospit medic school sghm royal london al patient educ counsel 64 2006 235 241 237 hospit rlh stain health centr shc area high popul densiti smoke preval nation averag research experienc smoke cessat advisor attend train programm research screen enrol particip group ran treatment programm conduct follow up time point smoker recruit advertis local paper word mouth gp referr smoker 18 diabet smoke 10 cigarett dai unabl read write english respond affirm question ask current psychiatr condit exclud smoker exclud report prior quit date unabl attend treatment session expect leav area 12 month total 630 smoker recruit 34 group provid written inform consent session hundr sixti attend visit 2 quit date intervent implement differ made quit attempt term ag gender occup fagerstrom score cigarett smoke dai read fig 1 flow subject progress phase trial note studi invit provid inform consent start poin smoke cessat trial continu abstin outcom measur pa random subject includ analysi activ withdraw perceiv chanc stop determin particip attend visit 2 rate stop smoke import x2 7.23 df 2 0.05 individu attend visit 2 withdrew consent outcom data 563 particip total 237 smoker 14 group alloc buddi condit 326 smoker 20 group control condit fig 1 350 62 women 395 70 particip marri live partner 475 84 paid employ mean ag 43.6 year s.d 12.4 mean daili cigarett consumpt 23 s.d 8.6 mean expir carbon monoxid concentr quit date 28.8 ppm s.d 12.5 mean fagerstrom test nicotin depend ftnd score 5.6 s.d 2.3 averag number previou quit attempt 3.4 s.d 5.3 2.3 measur inform demograph characterist smoke pattern includ fagerstrom test nicotin depend ftnd 26 gather mean point data collect clinic session smoker flowchart figur lost follow set 0 rticip leav studi resum smoke fail attend onsent al patient educ counsel 64 2006 235 241238 postal questionnair prior session particip ask motiv determin perceiv chanc stop motiv assess question import give smoke altogeth attempt respons option 1 import 4 desper import determin assess item determin give smoke attempt respons option 1 determin 5 extrem determin perceiv likelihood stop assess item high rate chanc give smoke good attempt respons option 1 low 6 extrem high abstin measur accord russel standard 27 smoke visit respons option puff puff cigarett cigarett subject consid abstain gave respons follow point expir air carbon monoxid concentr 10 ppm 7 ppm ambient requir confirm smoke statu buddi particip ask week monei commit conting contract time phone buddi feel buddi addit benefit attempt stop smoke time end session quit date buddi intervent occur particip ask question extent feel reli turn attempt stop smoke time respons option 1 5 extrem 2.4 procedur begin studi group run 2 year recruit period 1999 2000 assign consecut number number random comput random number gener buddi solo condit chief investig rw initi telephon contact smoker invit attend group confirm postal questionnair complet prior visit smoke cessat group run weekli period 6 week particip expect attend visit session approxim 90 min durat remaind 60 min session procedur group studi intervent occur session quit date start session particip briefli individu alli read distribut sweet tablet time group complet questionnair collect treatment withdraw orient model smoke cessat model recommend practic system smoke cessat nation guidelin england 28 wide smoke cessat servic uk detail 24 session particip introduc group research explain treatment approach group discuss encourag partici pant offer gener advic come week continu smoke method avoid combat urg smoke discuss import complet abstin quit date stress prior experi withdraw symptom discuss session quit date particip stop smoke session onward session divid part queri research address period group discuss particip encourag discuss concern swap idea tip cessat social support buddi intervent occur final 20 minut session buddi system west al studi 23 system chosen standard procedur group clinic withdraw orient model shown efficaci previou research easi implement group set compar spous partner train recruit smoker volunt buddi buddi condit research explain rational system particip invit introduc involv smoke e.g hobbi interest ask choos buddi sit person swap name phone number buddi arrang time make call subsequ call altern dai week train advic smoker content call simpli buddi offer mutual support visit particip encourag place sum monei envelop retain research monei envelop return week conting smoker remain abstin group alloc control condit period time complet quiz smoke effect session particip discuss experi preced week concern week session buddi particip ask research monei week encourag continu offer phone support specif advic deal laps buddi issu deal laps gener address group session particip buddi drop particip encourag pair analys involv buddi pair base buddi select al patient educ counsel 64 2006 235 241 239 particip attend appoint attempt made contact telephon dai particip person contact attend appoint assum relaps smoke studi began medic stop smoke nicotin replac therapi nrt bupropion reimburs uk form part treatment protocol end studi made nation health servic prescript free free charg judg unreason withhold 28 group 450 particip nrt zyban 6 group 113 particip offer medic chanc group addit nrt zyban buddi group solo group result differ group concurr medic x2 32.1 df 1 0.01 control potenti confound analysi 2.5 data analysi studi power detect differ effect buddi system 4 week continu abstin assum 40 abstin control 50 buddi condit power detect size differ 80 logist regress analys kei outcom measur undertaken random effect model take account fact particip random group addition chanc baselin differ tabl 1 sampl baselin characterist characterist femal 1 occup unskil semi skill craft cleric secretari profession manag desper import stop time 1 greatli extrem determin stop time 2 rate chanc success extrem high 1 characterist mean score s.d buddi ag mean 43.4 12.1 fagerstrom score 5.5 2.4 cig dai 22.9 9.3 ag start smoke year 16.3 3.6 number previou quit attempt 3.1 3.2 longest time stop dai 196.6 530 quit date 28.0 12.9 x2 14.2 df 2 0.01 buddi solo particip found account regress 3 result tabl 1 baselin characterist studi group seri test chi squar analys perform compar number variabl chanc buddi sampl rate chanc stop highli visit i. prior exposur intervent differ signific chi squar analysi intervent site show number particip condit equal distribut site x2 10.21 df 2 0.01 random effect logist regress analys assess effect treatment abstin control medic venu confid quit primari outcom measur 78 partici pant 14 report continu abstin 26 week 15 48 solo condit 13 30 buddi condit differ signific tabl 2 secondari outcom measur 35 sampl 194 continu abstin 4 week follow higher proport buddi condit solo condit 39 92 versu 31 102 hundr seventi 49 particip abstin week treatment 56 133 buddi particip 44 142 solo particip potenti confound uddi solo 52 64.1 198 60.7 350 62.2 32 14 61 20 93 17 28 13 46 15 74 14 42 19 62 20 104 20 88 39 88 29 176 33 34 15 49 16 83 16 08 46 141 43 249 44 30 70.5 178 75 408 73 03 44 97 30 200 36 solo 43.7 12.6 43.6 12.4 5.6 2.1 5.6 2.3 23.1 8.1 23 8.6 16.1 4.3 16.2 4 3.5 6.5 3.4 5.3 253.4 685.5 229.3 624.4 29.3 12.2 28.8 12.5 al patient educ counsel 64 2006 235 241240 tabl 2 result random effect logist regress analys abstin buddi control condit outcom point unadjust odd ratio 95 ci adjust odd ratioa 95 ci 1 week 1.66 0.97 2.83 1.45 0.92 2.29 4 week 1.39 0.76 2.55 1.16 0.76 1.78 26 weeksb 0.84 0.48 1.48 0.79 0.48 1.29 adjust group medic usag venu baselin confid success primari outcom measur control signific effect abstin rate 1 4 week tabl 2 particip buddi group made averag 2.7 phone call week quit date drop 1.2 1.1 0.7 week hundr fifti 71 buddi particip deposit monei return conting member abstin amount rang 50 penc 50 mean 4.48 signific differ amount commit abstain week particip buddi group attend 1 week post quit session 60 found buddi benefici 103 buddi pair 21 20 continu abstin end treatment 41 case 40 pair abstin smoke particip abstin week differ 4 week abstin rate partner smoke smoke 77 versu 79 quit date buddi intervent occur differ group extent felt reli member buddi group report greater sens turn attempt stop smoke point 1,550 3.2 0.038 tail 4 discuss conclus 4.1 discuss signific benefit buddi system smoker stop 1 4 26 week quit date suggest buddi system repres signific addit group smoke cessat treatment result generalis includ smoker situat individu treatment programm level social support provid group limit scope addit effect provid buddi system observ lack effect abstin rate buddi intervent effect increas individu percept social support member buddi group report greater sens turn quit date effect sustain west 17 identifi studi buddi system type smoke cessat studi found effect 4 week final follow point 23 find replic previou studi involv group treatment studi pair initi visit 1 week prior quit date time smoker stop establish relationship partner fact intervent demonstr short term effect activ ingredi buddi intervent small group treatment programm worth examin intervent greater benefit context number possibl increas strength buddi intervent detail firmer guidanc frequenc content telephon call reinforc session sustain activ worth adopt rigor protocol establish relationship member buddi pair lost partner worthwhil pairingupsmokersat initialvisit onthequit dai 4.2 conclus present studi fail find buddi system improv short term long term abstin rate group treatment programm level social support provid group treatment remain limit scope detect addit benefit buddi system offer case individu treatment programm examin effect buddi system context warrant method increas intens durat buddi support 4.3 practic implic buddi system simpl low cost addit group treatment programm result studi suggest kind buddi system test add substanti success rate merit intens protract form buddi
random control clinic trial bupropion sr individu smoke cessat counsel daniel mccarthi thoma piasecki daniel lawrenc dougla jorenbi saul shiffman michael fior timothi baker receiv 4 2007 accept 23 juli 2007 efficaci bupropion sr individu counsel smoke cessat treatment assess random placebo control clinic trial adult daili smoker bupropion sr treatment counsel fulli cross factori design efficaci treatment combin estim rel placebo medic assess control condit intent treat analys bupropion sr increas abstin rate end treatment rel placebo medic condit biochem confirm 7 dai point preval abstin or51.97 95 ci 1.04 3.72 report prolong abstin or52.90 95 ci 1.66 5.06 bupropion sr treatment improv latenc laps relaps improv latenc laps relaps surviv analys medic effect modest 12 month point preval abstin or51.47 95 ci 0.74 2.92 prolong abstin or51.34 95 ci 0.66 2.72 counsel increas likelihood abstin time point odd ratio rang 0.80 1.16 abstin outcom full intent treat sampl counsel medic significantli interact time point ad counsel improv end treatment point preval abstin or51.17 95 ci 0.68 2.03 prolong abstin or51.26 95 ci 0.75 2.12 substanti offer conjunct activ medic introduct research identifi empir support treatment peopl stop smoke successfulli meta analys random clinic trial suggest treatment includ pharmacotherapi psychosoci intervent roughli doubl odd quit successfulli 6 month fior al 2000 hugh stead lancast 2004 lancast stead 2005 silagi lancast stead mant fowler 2004 stead perera lancast 2006 evid efficaci treatment accru year recent studi suggest empir support treatment declin efficaci irvin brandon 2000 irvin hendrick brandon 2003 trend declin efficaci explan e.g clinic trial method harden smoker reflect increas tobacco depend continu smoke fagerström al 1996 hugh brandon 2003 irvin brandon 2000 irvin al 2003 u. depart health human servic 2003 warner burn 2003 controversi suffici inform differenti compet expla nation declin treatment efficaci controversi bespeak ongo evalua tion postmarket pharmacotherapi wide dissemin psychosoci intervent issn 1462 2203 print issn 1469 994x onlin 2008 societi research nicotin tobacco doi 10.1080 14622200801968343 daniel mccarthi ph.d depart psycholog rutger univers piscatawai nj thoma piasecki ph.d depart psycholog scienc univers missouri columbia columbia mo daniel lawrenc ph.d depart ophthalmolog visual scienc univers wisconsin school medicin public health madison wi dougla jorenbi ph.d michael fior m.d m.p.h depart medicin center tobacco research intervent univers wisconsin school medicin public health madison wi saul shiffman ph.d depart psycholog univers pittsburgh pittsburgh pa timothi baker ph.d depart psycholog univers wisconsin madison center tobacco research intervent univers wisconsin school medicin public health madison wi correspond daniel mccarthi ph.d depart psycholog rutger univers 152 frelinghuysen road piscatawai nj 08854 usa tel 1 732 445 2418 fax 1 732 445 2263 mail demccart rci.rutgers.edu nicotin tobacco research volum 10 number 4 april 2008 717 729 nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org data current studi larg scale placebo control clinic trial compris adult smoker interest quit studi test independ treatment sustain releas bupropion zyban glaxosmithklin multisess indivi dual smoke cessat counsel base u. public health servic ph clinic practic guid line fior al 2000 activ treatment studi fulli cross factori design allow compar effect pharmacotherapi versu psychosoci treatment combin specif treatment test wide evid support efficaci e.g fior al 2000 richmond zwar 2003 studi hypothes base previou research review fior al 2000 hugh stead al 2004 lancast stead 2005 richmond zwar 2003 expect main effect abstin counsel medic treatment end treatment year target quit date meta analys bupropion sr treatment suggest bupropion sr increas odd successfulli quit 6 month factor fior al 2000 hugh stead al 2004 addit bupropion antagon nicotin receptor rauhut neugebau dwoskin bardo 2003 slemmer martin damaj 2000 predict bupropion retard progress smoke laps full blown relaps defin smoke 7 dai row meta analys gener support efficaci counsel treatment offer counsel 1.5 fold increas odd quit smoke successfulli rel comparison condit fior al 2000 lancast stead 2005 neg find report intens problem solv focus counsel intervent e.g bronson flynn solomon vacek secker walker 1989 burl marshal seinder 1991 fior al 2004 jorenbi al 1995 ph clinic practic guidelin meta analys suggest cessat odd ratio improv increas intens counsel i. durat session number session fior al 2000 reason 10 min minimum counsel session offer total session studi major trial bupropion sr efficaci offer form psychosoci treatment adjunct pharmacotherapi richmond zwar 2003 previou trial system atic manipul presenc counsel offer combin bupropion sr trial address question addit benefit counsel trial group multisess cognit behavior treatment cbt versu medi cation manag particip random bupropion sr nortriptylin placebo author trial found evid efficaci cbt stand treatment evid cbt treatment augment long term abstin rate activ medic condit hall al 2002 trial examin effect telephon counsel program versu tailor mail program phone call offer combin 150 mg 300 mg bupropion sr pharmacotherapi clinic care set swan al 2003 studi found signific effect increas intens behavior treatment interact counsel condit bupropion sr dose 3 month follow 9 month particip receiv moder intens telephon coun sele 1.21 95 ci 1.08 1.32 001 time abstin receiv tailor mail bupropion sr dose studi systemat evalu effect psychosoci treatment context bupropion sr pharma cotherapi yield discrep result trial report posit result swan al 2003 effect size adjuv counsel versu tailor mail modest compar psychosoci treatment involv person person contact present studi expect counsel bupropion sr interact effect counsel larger context placebo medic context activ bupropion sr treatment studi fail find effect addit psychosoci treatment form pharmacotherapi e.g jorenbi al 1995 lancast stead 2005 lando al 1997 research demonstr efficaci psychosoci treatment fior al 2000 lancast stead 2005 orlean al 1991 addit studi examin addit effect counsel interven tion offer bupropion sr hall al 2002 swan al 2003 yield compel evid counsel attribut benefit earlier research behavior counsel modest addit effect offer nicotin patch therapi fior smith jorenbi baker 1994 addit effect elus recent research e.g fior al 2004 hypothes state test data sampl 463 adult daili smoker enrol random placebo control doubl blind clinic trial bupropion sr 718 random control clinic trial bupropion sr nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org s04aw6 highlight s04aw6 highlight individu counsel particip engag exten sive prequit assess prior 9 week treatment phase 1 year target quit date accord recent recom mendat report smoke cessat outcom hugh al 2003 present multipl abstin endpoint includ prolong abstin biochem verifi 7 dai point preval abstin end treatment 6 month postquit end 12 month follow period present result surviv analys base time laps smoke quit dai time end prolong abstin time laps full relaps method design enrol smoker randomli assign receiv activ placebo bupropion sr session 10 min individu cessat counsel control condit involv medica tion manag assess counsel studi activ drug placebo 6two counsel counsel factor ial design figur 1 particip particip adult ag 18 year older recruit madison wisconsin area mass media call volunt report smoke 10 cigarett dai expir carbon monoxid level exceed 9 ppm particip report motiv quit smoke reflect score 3 4 point report scale fulfil studi requir potenti particip screen psychopatholog bipolar disord psychosi current depress contraind bupropion sr e.g uncontrol hyperten sion histori seizur disord histori eat disord current heavi drink risk pregnanc current breast feed particip exclud score center epidemiolog studi depress ce scale radloff 1977 16 interview licens clinician suggest symptom relat clinic depress exclus criter ion includ prevent neg effect smoke cessat attempt depress particip mood safeti target enrol 480 particip base priori power analys ensur power greater 75 detect 7 differ 12 month abstin rate total 463 particip pass screen enrol studi attend studi visit demograph characterist enrol sampl summar tabl 1 measur earli offic visit particip provid demo graphic inform tabl 1 batteri report measur assess nicotin depend smoke histori affect psychiatr symptom fagerström test nicotin depend ftnd heatherton kozlowski frecker fagerström 1991 measur discuss report report data smoke behavior collect palmtop comput interview electron diari palm vx palmtop comput palm santa clara california pro gram invivodata pittsburgh pennsylvania administ multipl ecolog momentari assess report stone shiffman 1994 wake dai morn report assess smoke bedtim prompt medic random prompt occur pseudo random time dai assess smoke report even report complet bedtim assess number cigarett smoke preced 24 hr remind particip medic particip ask initi report slip smoke quit date addit daili smoke total assess treatment follow phase time line follow back smoke calen dar interview method 1 year postquit procedur studi procedur approv institut review board individu respond mass media call volunt screen elig telephon elig individu invit group orient session studi detail written inform consent obtain addit screen e.g test perform orient session offic visit e.g physic exam particip consid enrol pass round screen data attrit point screen process cohort data retain initi cohort rate prospect particip loss exclus base cohort depict figur 1 random occur enrol staff screen enrol particip unawar nicotin tobacco research 719 nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org experiment condit assign random random number list block studi pill look ident placebo activ medic condit packag contain label particip identif number prior particip enrol ment research staff interact partici pant blind particip medic condit assign research staff particip blind counsel condit particip attend offic visit includ baselin assess session 3 week prior quit date particip attend offic visit 8 week quit date dai 0 3 7 14 21 28 42 56 post quit complet monthli follow phone call particip provid breath sampl test visit provid blood sampl assess cotinin metabolit nicotin level baselin end treatment claim abstin figur 1 particip flow diagram number particip enrol treat analyz depict entir enrol sampl number peopl screen enrol estim data cohort assum 22.86 enrol rate base cohort data 720 random control clinic trial bupropion sr nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org s04aw6 highlight s04aw6 highlight advers event assess visit treatment phase addit attend visit particip complet electron diari entri 2 week preced 4 week target quit date peopl claim abstin 6 12 month postquit ask attend offic visit test 5 dai telephon interview total remuner attend studi visit includ follow confirm visit exce 200 particip inform payment con tingent return electron diari end record period treatment particip began take pill 150 mg bupropion sr placebo morn 1 week quit dai increas 150 mg pill dai 4 dai prior quit particip instruct continu take 300 mg dai 8 week postquit counsel consist prequit se sion session quit dai postquit session 4 week quit dai accord recommend ph clinic practic guidelin fior al 2000 10 min counsel session focus prepara tion quit dai e.g dispos cigarett put paraphernalia strive complet abstin cope problem solv e.g identifi trigger relaps appli lesson learn past laps relaps current quit attempt provid psychoeduc distract cope relaps prevent e.g long term plan psychoeduc relaps risk intratreat social support e.g empathi encourag counsel aim promot mainten quit smoke motiv encourag particip identifi record multipl reason quit tabl 1 demograph characterist enrol sampl treatment condit variabl placebo counsel placebo counsel activ medic counsel activ medic counsel sex n5463 femal 61 54.0 63 52.1 57 49.1 52 46.0 race ethnic n5460 hispan 1 0.9 0 3 2.6 1 0.9 white 104 92.0 104 86.7 103 89.6 101 90.2 black 5 4.4 6 5.0 7 6.1 8 7.1 4 3.5 10 8.3 5 4.3 3 2.7 marit statu n5461 marri 45 40.2 42 34.7 55 47.4 56 50.0 divorc 29 25.9 16 13.2 22 19.0 18 16.1 marri 23 20.5 46 38.0 26 22.4 22 19.6 cohabit 9 8.0 12 9.9 9 7.8 14 12.5 separ 4 3.6 3 2.5 1 0.9 2 1.8 widow 2 1.8 2 1.7 3 2.6 0 educ n5461 high school 6 5.3 6 5.0 3 2.6 5 4.5 high school 30 26.5 18 15.0 30 25.9 26 23.2 colleg 50 44.2 65 54.2 53 45.7 56 50.0 colleg degre 27 23.9 31 25.8 30 25.9 25 22.3 employ statu n5455 emploi 93 82.3 95 78.5 91 78.4 97 85.8 unemploi 6 5.3 9 7.5 5 4.3 5 4.4 homemak 3 2.7 2 1.7 5 4.5 8 7.2 student 5 4.5 3 2.5 3 2.7 1 0.9 retir 2 1.8 6 5.0 6 5.4 0 disabl 3 2.7 5 4.2 2 1.8 0 household incom n5453 25,000 30 27.5 53 44.2 35 31.02 23 20.7 25,000 34,999 20 18.3 16 13.3 13 11.5 21 18.9 35,000 49,999 25 22.9 13 10.8 24 21.2 26 23.4 50,000 34 31.2 38 31.7 41 36.3 41 36.9 mean ag year n5463 39.42 11.34 37.82 12.82 41.03 12.64 36.76 11.39 mean ag cigarett year n5463 13.42 3.51 13.53 3.53 13.97 4.45 12.97 3.78 mean number cigarett smoke dai n5463 21.37 8.11 21.98 11.90 22.47 10.10 21.87 11.24 mean number previou quit attempt n5425 6.86 13.88 6.95 11.41 5.86 9.84 4.09 4.40 mean baselin level n5462 25.04 11.73 21.91 10.91 24.79 11.03 25.90 12.28 mean baselin ftnd score n5457 5.27 2.07 4.95 2.56 5.12 2.30 5.10 2.51 note mean valu includ standard deviat parenthes valu number subject percentag ftnd fagerström test nicotin depend nicotin tobacco research 721 nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight develop wai remind reason quit dai particip receiv counsel receiv psychoeduc med icat adher inform target quit dai gener support encourag ment studi staff receiv specif counsel intervent list particip counsel condit complet studi visit assess counsel condit slightli shorter session assign counsel counsel comparison condit roughli 80 fewer minut contact staff receiv target intervent offer counsel condit attrit prior quit date 13.0 enrol sampl drop studi figur 1 leav 403 particip expos treatment made quit attempt total 265 particip 57.2 enrolle attend 12 studi visit miss earli termin monthli follow contact rate rang 47 enrolle 9 month postquit 63 12 month postquit mean number studi visit attend 9.67 sd53.41 12 mean number follow interview complet 5.21 sd54.09 10 monthli phone call 3 12 month post quit attrit rate differ treatment condit quit date conclus treatment phase follow point chi squar valu 05 minor statu gender unrel attend point chi squar valu 05 colleg graduat significantli attend quit date visit complet studi visit complet follow interview lower level educ chi squar valu 05 total ftnd score invers relat probabl stai studi quit date or50.87 95 ci 0.77 0.98 follow interview complet neg relat ftnd score baselin ce score posit relat ag univari logist regress time point shown variabl gender ethnic minor statu includ covari model predict abstin report relat baselin characterist relaps risk ahluwalia harri catlei okuyemi mayo 2002 burn al 2000 hall al 2002 niaura al 2001 shiffman al 1996 smith al 2003 swan al 2003 wetter al 2005 model test baselin covari includ model assess robust treatment effect abstin smoke outcom code time laps relaps 7 consecut dai smoke level hugh al 2003 determin base dichotom variabl indic smoke versu abstin dai base electron diari report retrospect smoke calendar data 7 dai point preval abstin end treatment confirm biochem test serum cotinin test total 10 individu 9 confirm 7 dai point preval abstin end treatment cotinin level exceed convent cutoff abstin 15 ng ml srnt subcommitte biochem verif 2002 addit 40 individu 8.6 total sampl 36.0 111 particip confirm claim abstin declin provid blood sampl cotinin test requir separ visit laboratori analys conduct wai approach individu provid serum cotinin consid relaps approach peopl confirm abstin provid blood sampl consid abstin result consist approach abstin rate 6 12 month postquit base report complet abstin smoke 7 dai preced follow interview averag read 10 ppm 6 month follow 65 87 74.7 peopl claim abstin provid breath sampl 12 month follow 83 99 83.8 report abstain provid breath sampl claim abstin 3.1 test disconfirm 6 month postquit claim 4.8 test disconfirm 12 month postquit extrem case test 4 8 week earli late exclud averag delai report assess 4.30 sd53.32 dai 6 month follow 5.81 sd58.13 dai 12 month postquit comput prolong abstin recommend hugh al 2003 particip 2 week grace period consid fail prolong absti nenc report smoke 7 dai row point 2 week postquit end treatment 6 month postquit 1 year postquit particip stop provid studi data end follow period treat relaps prolong abstin claim base report measur collect follow period subject biochem verif differenti laps smoke fewer 7 dai row 722 random control clinic trial bupropion sr nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org relaps smoke 7 dai instanc peopl claim relaps provid breath sampl mark high level 10 ppm end 2 week grace period treat individu relaps achiev prolong abstin chang direct signific level relat treatment condit prolong absti nenc outcom report result treatment adher full intent treat sampl n5463 partici pant attend averag counsel session receiv medic attend nonsignificantli session m56.65 sd52.54 receiv placebo pill m56.19 sd52.69 1 461 53.63 06 addit 81 peopl counsel condit attend session 67 attend peopl receiv activ medic attend session placebo group 85.0 76.9 x2 1 234 52.47 17 attend counsel session placebo condit 75.2 58.7 x2 1 234 57.20 01 appear receiv activ medica tion receiv greater dose counsel placebo medic condit treatment outcom relat dropout i. peopl quit successfulli drop treatment differenti counsel attend reflect differ efficaci activ versu placebo medic report data medic usag sug gest high level adher analysi complet electron diari record particip report take 97.0 morn medic dose 94.8 even dose miss case miss report equip ment problem count noncompli rate declin slightli 95.0 morn dose 93.0 even dose adher differ treatment condit activ medic condit report significantli lower medic administr morn 95.9 98.2 x2 1 11,927 551.31 001 even 93.1 96.6 x2 1 10,218 564.87 001 particip placebo medic condit report medic adher rate exceed 90 group medic adher differ counsel condit x2 1 11,084 5.04 84 morn medic x2 1 10,317 5.07 40 even medic advers event total count advers event report treatment displai tabl 2 number percentag particip medic condit report advers event odd ratio activ medic condit rel placebo condit confid interv present advers event mild moder advers event occur e.g stroke aneurysm occur placebo condit particip activ medic condit report advers event frequent particip placebo medic condit report tabl 2 total count event report number percentag particip placebo activ medic condit report advers event collaps counsel condit symptom count placebo medic activ medic odd ratio 95 confid interv advers event 318 75 32.1 102 44.5 1.70 1.17 2.49 insomnia 45 10 4.3 35 15.3 4.04 1.95 8.37 upper respiratori infect 44 21 9.0 19 8.3 0.92 0.48 1.76 depress 41 25 10.7 15 6.6 0.59 0.30 1.14 headach 19 5 2.1 14 6.1 2.98 1.06 8.42 lower respiratori problem 16 7 3.0 8 3.5 1.17 0.42 3.29 feel jitteri 16 5 2.1 11 4.8 2.31 0.79 6.76 nausea 15 5 2.1 9 3.9 1.87 0.62 5.68 feel dizzi lighthead 12 3 1.3 9 3.9 3.15 0.84 11.79 dry mouth 10 1 0.4 9 3.9 9.53 1.20 75.86 digest problem 7 1 0.4 6 2.6 6.27 0.75 52.49 troubl concentr 6 2 0.9 4 1.7 2.06 0.37 11.37 increas blood pressur 6 2 0.9 4 1.7 2.06 0.37 11.37 fatigu 5 3 1.3 2 0.9 0.68 0.11 4.10 vertigo 3 0 3 1.3 vivid dream 3 1 0.4 2 0.9 2.05 0.19 22.80 70 24 10.3 35 15.3 1.58 0.91 2.75 note ath odd ratio confid interv comput vertigo nicotin tobacco research 723 nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org insomnia dry mouth headach significantli placebo recipi efficaci point preval prolong abstin rate displai treatment figur 2 tabl 3 present odd ratio confid interv activ treatment versu control condit 7 dai point preval prolong abstin fewer 7 dai smoke row 2 end treatment 6 12 month postquit activ bupropion sr treatment recipi 2.0 4.2 time achiev point preval prolong abstin end treatment receiv placebo pill counsel statu bupropion sr counsel interact influenc abstin end treatment point preval or51.01 95 ci 0.42 2.43 prolong or51.11 95 ci 0.51 2.42 229 particip receiv activ medica tion addit counsel modest increas odd quit confid interv effect larg point preval or51.17 95 ci 0.68 2.03 prolong or51.26 95 ci 0.75 2.12 6 month postquit odd ratio point preval abstin rate modest 1.6 treatment condit rel control condit time prolong abstin requir verif 1.6 2.2 time activ medic condit control condit odd ratio interact term suggest addit counsel effect con fidenc interv wide point preval or51.43 95 ci 0.50 4.09 prolong or51.17 95 ci 0.48 2.86 receiv activ medic addit counsel significantli predict point preval absti nenc or51.43 95 ci 0.70 2.90 prolong abstin or51.29 95 ci 0.72 2.31 6 month postquit 12 month follow odd ratio rang 1.3 1.6 activ medic condit versu control condit confid interv figur 2 abstin rate treatment condit proport peopl attain biochem confirm abstin end treatment 6 month follow 12 month follow present proport particip maintain prolong abstin 2 week postquit follow time point percentag abstin present column error bar repres 95 confid interv 724 random control clinic trial bupropion sr nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org larg bupropion sr counsel sig nificantli interact influenc point preval abstin or51.29 95 ci 0.49 3.45 pro long abstin or51.35 95 ci 0.49 3.67 odd ratio suggest addit benefit counsel confid interv larg addit counsel receiv activ medic n5229 increas odd achiev point preval absti nenc or51.03 95 ci 0.55 1.95 prolong abstin or51.16 95 ci 0.60 2.23 1 year postquit pattern result inclus baselin control variabl i. gender minor statu colleg educ ag baselin ftnd ce score regress model shown similarli result consi tent intent treat sampl n5463 subsampl attend quit date n5403 effect tend stronger select sampl quit dai attende tabl 3 surviv analysi kaplan meier surviv analys lost case full intent treat sampl treat censor present tabl 4 figur 3 result reveal signific differ surviv prior laps relaps defin end tabl 3 result logist regress analys predict abstinencea kei time point treatment condit full intent treat sampl sampl attend quit dai visit end treat ment point preval end treatment prolong 6 month point preval 6 month prolong 12 month point preval 12 month prolong 95 ci 95 ci 95 ci 95 ci 95 ci 95 ci intent treat sampl n5463 placebo counsel 1.00 placebo counsel 1.16 0.59 2.27 1.13 0.63 2.02 1.00 0.46 2.18 1.10 0.56 2.16 80 0.38 1.69 86 0.40 1.83 activ counsel 1.97 1.04 3.72 2.90 1.66 5.06 1.13 0.52 2.44 1.65 0.86 3.15 1.47 0.74 2.92 1.34 0.66 2.72 activ counsel 2.31 1.23 4.35 3.65 2.08 6.40 1.61 0.78 3.36 2.13 1.13 4.02 1.52 0.77 3.02 1.55 0.77 3.12 quit dai attende n5403 placebo counsel 1.00 placebo counsel 1.29 0.65 2.55 1.28 0.70 2.33 1.10 0.50 2.41 1.22 0.61 2.42 87 0.41 1.86 94 0.44 2.02 activ counsel 2.09 1.09 4.01 3.35 1.87 6.26 1.17 0.54 2.54 1.74 0.90 3.36 1.54 0.77 3.08 1.40 0.68 2.86 activ counsel 2.39 1.26 4.55 4.12 2.28 7.42 1.63 0.78 3.42 2.19 1.15 4.19 1.54 0.77 3.08 1.57 0.77 3.18 note ci confid interv odd ratio apoint preval abstin time point defin 7 dai point preval abstin biochem verif prolong abstin time point defin smoke 7 consecut dai 2 week time point tabl 4 result surviv analys latenc dai laps end prolong abstin relaps initi laps treatment miss case treat censor treatment laps latenc end prolong abstin latenc laps relaps latenc median surviv 95 ci log rank median surviv 95 ci log rank median surviv 95 ci log rank placebo counsel 1 16.23a 001 40 21.54 58.46 11.82a 008 29 23.01 34.99 9.30a 03 placebo counsel 1 0.49 1.51 55 29.44 80.56 42 22.86 61.15 activ counsel 4 1.62 6.38 65b 42 103 79.53 126.47 1.52b 22 79 49.71 108.29 1.02b 31 activ counsel 8 0 19.02 155 106.70 203.31 121 43.65 198.35 placebo 1 15.27c 001 48 35.53 60.47 10.44c 001 33 29.86 36.14 7.86c 005 activ medic 5 2.31 7.69 114 74.15 153.85 88 58.50 117.50 counsel 2 0.86 3.14 02d 89 73 45.85 100.15 1.17d 28 42 27.10 56.90 1.22d 27 counsel 2 0.29 3.71 100 63.26 136.74 63 38.54 87.46 note ci5confid interv alog rank chi squar comparison treatment condit df53 n5463 blog rank chi squar comparison activ counsel activ counsel condit df51 n5229 clog rank chi squar comparison placebo activ medic condit collaps counsel condit df51 n5463 dlog rank chi squar comparison counsel counsel condit collaps medic condit df51 n5463 nicotin tobacco research 725 nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org prolong abstin 2 52 week postquit laps relaps treatment condit receiv activ medic significantli longer surviv time prior laps relaps receiv placebo medic collaps counsel condit main effect counsel observ addit effect counsel context activ medic detect tabl 4 log rank chi squar valu comparison conserv intent treat surviv ana lyse assum smoker lost follow resum smoke dai provid data yield similar result laps relaps dai estim total 72 particip 15.6 enrol sampl 7 provid data target quit date assum quit dai median surviv time pattern differ function medic counsel previou analysi lower rang 0 5 dai laps 14 48 dai relaps condit equal 6 dai laps relaps condit restrict surviv analys particip attend quit date visit chang pattern result conduct surviv analys cox regress analys includ baselin covari shown chang pattern result signific level specif comparison vari function sampl covari includ surviv model gener pattern signific medic effect counsel effect persist model discuss present studi provid evid bupropion sr produc higher short term abstin rate adult daili smoker increas latenc laps prolong durat laps relaps interv evid sustain bupro pion sr benefit translat health benefit weaker result show evid meaning benefit individu counsel context placebo activ medic pattern result character moder initi medic effect lack benefit attribut counsel persist variat outcom code model sampl particip abstin rate odd ratio prolong abstin appear impress report prolong abstin smoke 7 dai row 2 week grace period base report data biochem confirm interpret caution lack confirm account discrep 6 month point preval prolong abstin combin treatment effect result present studi partial replic prior find efficaci bupropion sr observ 1 year prolong absti nenc rate similar prolong continu abstin rate peopl treat bupropion sr report e.g ferri burchett 1994 hall al 2002 jorenbi al 1999 tonnesen al 2003 biochem confirm 12 month point preval abstin rate similar report earlier bupropion sr trial e.g 23.1 hurt al 1997 swan al 2003 recent figur 3 kaplan meier surviv curv treatment axi repres latenc dai smoke event quit date full sampl enrolle vertic broken line mark end treatment dai 56 axi repres cumul proport particip laps relaps time sign depict censor case laps relaps 365 dai quit date lost follow panel depict surviv prior laps panel depict prolong surviv 2 week grace period start quit date event panel repres return smoke 7 dai row panel depict latenc laps relaps smoke 7 dai row 726 random control clinic trial bupropion sr nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org studi bupropion treatment clinic practic 21.0 paluck al 2006 magnitud treatment effect studi partial consist previou research observ odd ratio bupro pion sr treatment gener close confid interv bupropion sr effect report recent meta analys fior al 2000 hugh stead al 2004 wu wilson dimoula mill 2006 confid interv wide similarli low odd ratio long term follow up report previous literatur e.g hai al 2001 zellweg boelcskei carrozzi sepper hider 2005 treatment yield higher initi abstin rate observ unlik swan colleagu 2003 observ reliabl increas likelihood quit counsel ad bupropion sr treatment magnitud effect modest lower expect base previou research e.g odd ratio rang 1.4 1.7 individu counsel fior al 2000 hall colleagu 2002 similarli report lack addit benefit efficaci stand psychosoci treatment combin pharmacotherapi fail demonstr session individu counsel affect point preval prolong abstin latenc return smoke presenc placebo medic failur replic efficaci counsel ing emphas motiv social support problem solv demand examin failur unpreced e.g bronson al 1989 fior al 2004 counsel atten danc account lack counsel efficaci particip attend averag counsel session offer altern explan intens assess contact studi staff provid nonspecif potent ingredi counsel intervent particip studi slate receiv counsel abstin rate higher report unassist quitter roughli 5 center diseas control prevent 2002 find reflect nonspecif effect studi particip counsel effect case suggest content counsel medic man agement assess unimport explan deliv counsel ing ineffect counselor colleg ag bachelor level staff train super vise period audiotap review licens psychologist year experi smoke cessat counselor problem execut counsel account lack efficaci problem detect qualiti control measur final disappoint result reflect broader trend diminish efficaci smoke cessat treatment remain popul smoker harden i. nicotin depend character higher level risk factor account declin effect size individu counsel inter vention time irvin brandon 2000 harden account fact recent intens psychosoci treatment tend produc effect larg magnitud e.g hall humfleet reu munoz cullen 2004 power adequ 75 detect 10 increas abstin rate activ control condit sampl result strongest effect activ medic counsel versu control condi tion small convent standard number need treat combin medic counsel person control condit achiev 12 month prolong 12 month point preval abstin 16 effect size correspond cohen 0 2 kraemer kupfer 2006 small magnitud treatment effect observ lack power explain failur demonstr signific main effect bupropion sr counsel 1 year follow requir larg sampl 1,113 group achiev good power 80 detect signific differ observ abstin rate function ad counsel bupropion sr express term number need treat prefer odd ratio kraemer kupfer 2006 treat 43 addit smoker individu counsel person achiev 1 year prolong abstin context activ bupropion sr treatment limit interpret signific null result studi temper concern lack treatment control condit make imposs rule possibl placebo medic effect reduc abil detect treatment differ particu larli counsel counsel placebo medic condit con clude current data counsel offer confer substanti reliabl benefit particip receiv placebo activ medic nicotin tobacco research 727 nivers berdeen februari 17 2016 http ntr.oxfordjournals.org ow nload http ntr.oxfordjournals.org abil gener result broader popul smoker limit major smoker attempt quit smoke formal assist individu differ particip research divers wai hugh keeli naud 2004 sampl report unusu heavi smoke high score ftnd sensit measur depend com.ibm.drl.hbcp.predictor cessat success piper mccarthi baker 2006 environ mental restrict forc smoker chang smoke pattern research volunt differ smoker wai addit assess reactiv attrit render result replic gener izabl frequent prolong assess smoker influ enc report behavior initi abstin rate similar report studi high dose patch therapi group cogni tive behavior therapi involv similarli intens electron diari assess shiffman al 2006 7 dai point preval abstin rate 1 month treatment 29 55 placebo activ patch condit shiffman al 2006 studi similar 1 month point preval rate 30 placebo condit 49 activ bupropion condit observ present studi research report null result counsel regimen burden ecolog momentari assess bronson al 1989 burl al 1991 dornela sampson grai water thompson 2000 attrit problem present studi attrit substan tialli skew result reason attrit roughli equival treatment condit explan weak treatment effect result similar analys conduct full intent treat sampl subsampl smoker remain studi target quit dai consist weaken argument treatment effect dilut prequit attrit major peopl drop report return smoke prior loss follow peopl report complet postquit abstin prior drop studi intent treat analys accur conclus result random control clinic trial bupropion sr multisess individu smoke cessat support efficaci bupropion sr treatment ongo provid compel evid long term efficaci bupropion sr individu counsel data join grow bodi research suggest efficaci previous valid treatment wane smoker volunt clinic trial intens treatment e.g irvin brandon 2000 shift sand suggest continu evalu establish treatment promot understand eventu revers neg trend result suggest improv prolong acut treatment tobacco depend acknowledg work support transdisciplinari tobacco research center grant p50ca084724 nation cancer institut p50da19706 nation institut drug abus author staff center tobacco research intervent univers wisconsin school medicin public health dougla jorenbi receiv research support nabi biopharmaceut pfizer consult fee nabi biopharmaceut saul shiffman serv consult glaxosmithklin consum healthcar exclus basi regard ing counter smoke cessat product partner compani develop nicotin medic cofound invivodata electron diari servic clinic research 1998 univers wisconsin appoint dr fior name chair made unrestrict gift univers glaxowellcom glaxosmithklin provid complimentari activ placebo medic studi glaxosmithklin involv design data collect analysi report studi
lifestylesl ieni mcdowel mothersil rosser hartman random trial approach smoke cessat summari hundr sixti patient volunt smoke cessat trial randomli alloc control group intervent singl counsel visit physician session group health educ session group behavior modif progress assess smoke diari support saliva thiocyan test intervent 12 month group approach show signific improv compar control group immedi intervent differ longer statist signific 12 month group method prove cost effecf physician intervent group examin heavi light smoker pattern result emerg heavi smoker physician led intervent prove success group approach quit result disappoint program success help peopl reduc smoke fam physician 1985 31 845 851 sommair troi cent soixant patient se sont volontair prete un etud sur la cessat du tabagism furent distribu au hasard soit group control soit l'un de troi model d'intervent un seul visit de consult avec medecin huit session educ en group huit session de group visant modifi le comport le particip ont inscrit leur progr individuel dan journal de tabagism mesur le thiocyan salivair avant com.ibm.drl.hbcp.inforetrieval.apr l'intervent com.ibm.drl.hbcp.inforetrieval.apr douz moi comparativ au group control seul le approch de group ont revel un amelior signif immediat com.ibm.drl.hbcp.inforetrieval.apr l'intervent ce differ n'etaient valid sur le plan statistiqu ou douz moi tard le method de group se sont avere avantageus du point de vue cou't benefic l'intervent fait par le medecin cepend l'examen de differ sou group tel le gro fumeur ou le fumeur moder obtenu differ resultat pour le tre gro fumeur l'intervent du medecin s'est avere presqu aussi com.ibm.drl.hbcp.util le approch de group le resultat globaux d'arret definitif furent decev mai le programm s'aver davantag com.ibm.drl.hbcp.util pour aider le gen diminu de fumer kei word smoke cessat educ behavior modif dr mcdowel director health care research unit univers ottawa dr mothersil clinic psychologist depart mental health servic holi cross hospit calgari dr rosser certific fellow colleg professor chairman depart famili medicin univers ottawa ms hartman work depart psycholog children hospit eastern ontario reprint request dr ian mcdowel health care research unit univers ottawa 451 smyth road ottawa k1h 8m5 ariou studi exam in role famili physi cian encourag patient stop smoke argument support role summar rosser 1 2 boost research find russel 3 report routin advic smoke fam ili doctor influenc 5 smoker quit cumu lativ effect physician give advic exert import influenc smoke rate na tional level random trial plicat russel find ontario carri famili medicin centr ottawa civic hospit 1979 1980.4 percentag pa tient smoke year fam physician vol 31 april 1985 intervent similar found russel control group show consider higher quit rate russel studi signific differ experiment control popul quit attri bute influenc physi cian state pure person decis physician act cata lyst decis al readi poor perform russel control group appear con trari observ impor tant number peopl stop smoke assist formal ce satior program success chang 845 11,1111111110 control group confound result studi north karelia mrfit heart di eas prevent trial 5 6 stewart studi 4 found formal attempt replic russel studi bodi knowledg issu main slim reason studi contain low level intervent compar russel mean type program appli famili practic tensiv group educ program led practic nurs ac cordingli present trial de sign intens intervent feasibl effec tive encourag smoke cessat famili practic object trial 1 compar impact therapi reduc amount cigaret smoke 2 analyz type smoker respond type smoke cessat therapi formul hy pothes explain associ 3 rel cost type therapi pare cost effect identi fiabl group smoker present discuss concentr object pare smoke rate month cessat program method patient routin sche dule appoint famili physician met fol low criteria serv subject 1 overag 15 2 year smoke 3 smoke cigaret dai 4 express willing join studi patient 56 physician repr sent group practic particip studi total 366 recruit achiev poster leaflet wait room announc smoke cessa tion program interest telephon number call regist random social demograph data collect particip informa tion smoke histori current smok ing habit batteri question attitud smoke includ smoke typolog scale 7 question assess individ ual determin quit confid includ pre dictor success address sec ond studi object test motiv particip trial subject ask complet questionnair home return mail return ing complet materi ran domli assign tervent control group satisfact intervent method record inter vention measur smoke rate subject diari record number cigaret smoke daili week encourag accur rec ord particip told requir undergo saliva thiocyan test carri small sampl case attend follow session particip fail attend follow session return diari mail thiocyan anal yse appli bias group present result test smoke diari data analyz give mean median number cigaret smoke dai calcu late smoke rate percentag individu smoke rate entri trial quit smok ing includ calcul rate test occur intervent baselin immedi at post intervent 12 month durat intervent differ post intervent diari complet slightli interv base line rang week month control group complet diari month baselin strenuou attempt made tain contact particip follow period attrit detail result section particip provid data point 12 month smoke rate patient month follow place miss 12 month informa tion appli 20 case smoke month case miss outcom data month follow qw nutrit elderli dr louis davi ph.d head te gerontolog nutrit unit london queen elizabeth colleg explain motiv elderli improv food habit articl entitl effect approach reach senior copi nutrit quarterli articl write nutrit servic dairi bureau canada 20 holli street toronto ontario m4 3bl send copi dr davi articl dr address_____________ citi provice________________ postal code___________ 846 discard analys tall 30 case 8.2 intervent physician encourag compris 15 minut counsel session tailor patient smok ing pattern print materi pro duce u. nation cancer stitut help smoker quit kit explanatori guid physician written materi patient memo nurs nic otin gum interven tion call follow contact mail patient enclos print materi design encourag continu attempt quit introduc tori brief session held 12 physician administ approach group health educ close structur treatment de sign foster mutual support pro vide discuss pertin inform review problem experienc group member intervent oper kick ma terial develop mission british columbia lung associ materi comprehens manual group leader subject met group 10 15 weekli 90 minut session famili medicin centr addit booster se sion held week treatment session review progress problem group led regist public health nurs experienc run lifestyl modif group special ed ucat teacher experienc lead smoke cessat group group behavior modif approach repres highli structur group intervent deriv psycholog theori intervent includ behavior rehears subject practis respons turn cigaret verbal action cope urg smoke side effect quit program taught cognit restructur pro vide method challeng belief obstacl smoke ce sation relax procedur cogni tive cope method maintain cessat prevent relaps behavior modif compris therapi session held week week week week famili medicin centr health educ approach booster session held week end treatment behavior modifi cation group led therapist held master educa tion degre psycholog control group subject alloc control group told smoke statu review 12 month time simulta neousli follow treat ment group design assess impact smoke habit record smoke level result nineti patient alloc physician intervent 90 group health educ 93 group behavior modif 93 control group evalu compar group sociodemograph data examin random adequ sig nific differ group case 13 14 demograph variabl examin statist signific dif ferenc group term occup chi squar 30.2 18 d.f 0.04 averag ag studi sampl 36.3 rang 16 70 60 fe male 45 univers educ 59 emploi fulltim 54 marri averag number cigaret smoke baselin 23.8 dai eighti percent quit past made averag attempt 49 state extrem quit program particip year month follow physician group havior modif group 15 control contact result base remain 336 patient follow control group difficult involv studi tend care ful inform address averag smoke rate baselin 336 case 25 cigaret dai outcom smoke rate tabl 1 show mean median smoke rate group percent ag smoke interven tion group start compar smoke rate control group tabl 1 mean median number cigaret smoke number quit intak post intervent 12 month mean median cig cig smoke smoke baselin intervent dai dai smoke smoke rate physician encourag 87 baselin 25.2 24.7 0 100 post 15.3 15.4 17.2 66.0 mo 19.6 21.6 11.5 83.0 12 mo 20.2 24.6 14.9 86.5 group health educ 84 baselin 26.2 25.2 0 100 post 12.9 10.5 34.5 54.2 mo 17.4 18.0 20.2 72.3 12 mo 18.2 19.8 16.7 81.7 group behavior modif 87 baselin 25.0 24.7 0 100 post 12.5 7.75 39.1 46.7 mo 18.5 19.25 18.4 73.0 12 mo 18.5 19.9 17.2 77.1 control 78 baselin 23.4 22.5 0 100 post 20.1 20.5 10.3 91.9 mo 21.5 24.5 17.9 93.2 12 mo 21.7 23.5 14.1 95.0 fam physician vol 31 april 1985848 8 hour nitroglycerin prescrib inform nitroglycerin sustain releas tablet therapeut classif anti angin agent indic nitrong sr tablet prevent attack angina pectori chronic angina effort contraind nitrong sr tablet contraind patient sever anemia increas intraocular pre increas intracrani pressur hypoten sion nitrong sr contraind patient idiosyncrasi organ nitrat warn data safe nitrong sr earli phase.of myocardi infarct period clinic laboratori find unstabl insuffici establish safeti nitrong sr patient congest heart failur requir care clinic hemo dynam monitor nitrat depend occur patient chronic avoid withdraw effect administr nitrong sr gradual reduc 4 6 week industri worker continu expos nitrat chest pain acut myocardi infarct sudden death occur temporari withdraw nitrat exposur precaut headach symptom hypotens weak dizzi aris suddenli recumb posit due overdosag occur dose reduc nitrong sr discontinu nitroglycerin potent vasodil slight decreas mean blood pressur approxi mate 10 15 hg patient therapeut dosag caution exer cise drug patient prone affect hypotens nitrong sr tablet intend relief acut attack angina pectori sublin gual nitroglycerin prepar purpos toler drug cross toler nitrat nitrit occur advers effect headach common side effect esp cialli higher dosag nitrong sr headach treat concomit administr mild analges headach unrespons treatment dose nitrong sr reduc product discontinu frequent postur hypotens increas heart rate faint flush dizzi nausea vomit report symptom treatment overdosag symptom overdosag primarili relat vasodil includ cutan flush headach nausea dizzi hypotens methemoglobinemia specif antidot treatment primarili symptomat support dosag administr adult recommend initi dosag 1 tablet 3 time dai breakfast late afternoon meal retir dosag increas progress 2 tablet 3 time dai avail sustain releas tablet 2.6 mg bottl 100 1000
psychiatri 162 7 juli 2005 1311 articl http ajp.psychiatryonline.org improv rate quit smoke veteran posttraumat stress disord mile mcfall ph.d andrew saxon m.d charl thompson m.d dan yoshimoto m.a carol malt m.s.w kristi strait troster ph.d evan kanter m.d ph.d xiao hua andrew zhou ph.d cynthia dougherti a.r.n.p ph.d bonni steel r.n ph.d object smoke highli preval refractori peopl post traumat stress disord ptsd studi aim improv rate quit smoke veteran ptsd int grate treatment nicotin depend mental health care method smoker undergo treatment ptsd 66 randomli assign 1 tobacco treatment deliv mental health provid integr psychiatr care integr care ver su 2 cessat treatment deliv sepa rate ptsd care smoke cessa tion specialist usual standard care dai point preval abstin primari outcom measur 2 4 6 9 month random assign ment data analyz gen eral estim equat approach intent treat principl result subject assign integr care time ject undergo usual standard care abstain smoke follow assess interv odd ratio 5.23 subject integr care condit significantli subject usual standard care receiv tran dermal nicotin nicotin gum receiv greater number smok ing cessat counsel session stop smoke worsen ing symptom ptsd depress conclus smoke cessat inter vention safe incorpor routin mental health care ptsd effect treatment deliv er separ special smoke cessat clinic integr cessat treatment psychiatr care potenti improv smoke quit rate popul chronic mental ill smoker psychiatri 2005 162 1311 1319 posttraumat stress disord ptsd preval mental disord 1 2 vet eran administr va health care enrolle 3 4 gener popul ptsd high rate smoke 45 5 versu nation averag 23 6 fourfold increas risk nicotin depend 7 rate smoke veteran ptsd 53 66 8 10 approxim doubl va enrolle gener 30 11 greater proport smoker combat relat ptsd smoke heavili 25 cigarett dai compar veteran smoke ptsd 48 versu 28 8 ptsd asso ciat smoke quit rate 23 5 half lifetim smoker mental disord 12 fall bottom rank quit rate 13 mental disord 5 smoker ptsd exp rienc nicotin withdraw symptom respons encount trauma relat stimuli 13 report smoke order reliev anxieti tension 8 research suggest dynam relationship tween ptsd tobacco argu coordin approach treatment disord pharmacolog behavior treatment nicotin depend shown efficaci control clinic trial 12 14 treatment abil health care organ de liver effect individu primari care provid infrequ appli cost effect tobacco cessat intervent smoker 15 18 fact 60 70 smoker quit 6 11 nicotin depend treatment patient mental disord neglect psychiatr patient receiv cessat counsel 38 primari care visit 12 visit psychi atrist 16 referr patient specialti smoke cessa tion clinic commonli altern primari care base deliveri tobacco treatment effect clinic compromis poor patient complianc rate attend low 13 14 19 20 limit capac provid repeat intervent chronic relaps disord nic otin depend limit creat situat 17 smoker nation largest health care system va report receiv desir cessat treatment previou year 11 simultan treatment interwoven disord singl provid team shown promis clinic effect patient sever mental ill 1312 psychiatri 162 7 juli 2005 ptsd quit smoke http ajp.psychiatryonline.org ness comorbid substanc disord 21 22 studi test approach improv effect tobacco cessat servic deliveri tegrat treatment smoke routin mental health care patient ptsd specif ran domiz control clinic trial compar effect ness method deliv guidelin base smoke cessat treatment patient receiv va mental health care 1 smoke cessat inter vention integr ongo mental health care deliv mental health provid integr care ver su 2 smoke cessat intervent deliv sepa rate mental health care smoke cessat spe cialist usual standard care hypothes integr care result higher rate smoke cessat usual standard care secondari object studi determin smoke cessa tion worsen ptsd depress symptom anticip possibl import high occurr depress ptsd 23 prior research show smoke abstin exacerb depress individu histori disord 24 27 method subject subject 66 recruit va puget sound health care system ptsd clinic special outpati treatment chronic ptsd tabl 1 report demograph smoke characterist studi group psychomet ric data show moder sever level symptom ptsd checklist 28 beck depress inventori 29 ject integr care usual standard care condit differ significantli baselin characterist valu 0.05 subject includ smoke 10 cigarett dai express willing receiv smoke cessat treatment met dsm iv criteria ptsd exclus criteria 1 smokeless tobacco pipe cigar 2 presenc stabl axi disord 3 current substanc depend di order tobacco provid complet descrip tion studi written inform consent obtain subject randomli assign integr care 33 versu usual standard care 33 smoke cessat rate refus particip studi 3 seek smoker treatment condit studi subject receiv psychotrop medic ptsd particip studi prescrib ptsd clinic psychiatrist nurs practition subject receiv psychotherapi assign case manag coordin mental health care case manag includ psychologist social worker addict therapist technician integr care experiment condit subject randomli assign integr care receiv smoke cessat intervent administ assign ptsd clinic prescrib case manag integr care model clinic intervent primari care practition publish u. public health servic clinic practic guidelin titl treat tobacco depend 14 ptsd clinic staff receiv approxim 3 hour train need consult smoke cessat treatment clinic director m.m deliv intervent treatment manual request author operation intervent session subject receiv smoke cessat protocol medic bupropion transderm nicotin nicotin polacrilex gum nicotin sprai psychiatrist nurs practition man ag pharmacolog treatment ptsd prescrib integr care usual standard care condit agre adopt practic routin prescrib bupropion tran dermal nicotin nicotin gum sprai order standard iz medic protocol condit pre scriber allow discret select medic depend patient prefer medi cal contraind com.ibm.drl.hbcp.core behavior counsel compon integr care administ case manag consist 1 assess tobacco statu abstin histori individu rea son quit 2 educ health risk smoke benefit quit 3 advic quit smoke 4 applica tion motiv intervent ambival smoker 5 set ting date quit 6 behavior counsel subject pre tabl 1 baselin characterist subject receiv integr care versu usual standard carea variabl veteran receiv integr care veteran receiv usual standard care mean sd mean sd ag year 33 52.9 11.1 33 52.3 8.1 male sex 29 88 32 97 white race 26 79 31 94 marri 18 55 14 44 unemploi 27 82 27 84 receiv depart veteran affair disabl 29 88 33 79 number current axi disord 33 2.0 0.7 33 1.9 0.6 ptsd checklist score 33 63.7 13.1 33 63.1 13.0 beck depress inventori score 33 29.6 9.5 33 27.4 10.7 cigarett smoke dai 33 25.2 11.8 33 29.3 15.8 fagerstrom test nicotin depend score 33 5.9 2.1 32 6.4 2.0 expir carbon monoxid ppm 33 24.5 10.4 33 27.6 13.7 year spent smoke 33 33.4 13.4 29 29.3 9.5 live smoker 14 42 12 41 confid quittingb 33 2.3 1.1 29 2.7 1.0 statist signific differ studi condit baselin characterist 0.05 rate made 5 point likert scale rang 0 4 extrem s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight psychiatri 162 7 juli 2005 1313 mcfall saxon thompson al http ajp.psychiatryonline.org pare quit smoke cope smoke urg barrier abstin develop problem solv skill 7 read materi 8 intrasess support assist iden tifi extrasess social support 9 direct behavior method reduc anxieti consist relax train tape written materi stress manag protocol requir case manag administ individu behavior counsel session weekli basi follow contact session averag 20 minut interven tion roll regularli schedul visit address ptsd comorbid mental disord subject treatment plan ordinarili includ individu session case manag subject receiv group therapi ptsd case manag er schedul separ individu smoke cessat session deliv com.ibm.drl.hbcp.core behavior counsel session clini cian discret period assess smoke statu reinstat cessat treatment subject relaps usual standard care comparison condit subject randomli assign usual standard care refer va puget sound health care system smok ing cessat clinic nurs personnel staf clinic train mayo clinic nicotin depend treatment center extens experi cessat treatment clinic deliv u. public health servic guidelin adher cessat treatment 14 clinic provid algo rithm integr care provid prescrib smoke cessa tion medic subject attend group orient class individu session receiv med icat behavior counsel unrestrict access usual standard care treatment session provid subject number treatment contact receiv deter mine clinic recommend usual standard care provid prefer initi subject ject assign usual standard care condit receiv ab solut tobacco cessat intervent ptsd clinic provid measur deliveri studi treatment consum health informa tion perform set administr databas account ing servic deliv va track smoke cessat medic receiv subject da tabas provid inform proport subject fill prescript studi medic dose medic number smoke cessat behavior counsel session deliv subject extract va computer patient record system clinician requir document patient visit adher integr care case manag treatment manual assess independ review computer patient record system record contain provid docu mentat intervent deliv visit spe cialli prepar chart templat list total 31 specif protocol intervent prescrib manual interven tion constitut com.ibm.drl.hbcp.core behavior counsel compon integr care e.g set record quit date identifi strategi cope withdraw symptom se sion case manag check intervent deliv chart templat provid narr summari smoke statu treatment progress studi coordin d.y ind pendent review chart note provid treatment session order comput clinician record adher protocol intervent percentag total recom mend review show 80 behavior counsel intervent prescrib treatment manual report edli administ smoke outcom dai point preval abstin verifi expir carbon monoxid 10 ppm primari outcom measur compar integr care usual standard care 2 4 6 9 month random assign period random provid consist marker subject initi treatment process convent end treatment phase initi quit date start point abstin measur fol low studi aim compar tobacco cessat treatment practic clinic set spe cific guidelin adher treatment chronic relaps condit tobacco disord continu process requir multipl quit attempt reapplic interven tion aim recycl patient relaps 14 30 31 con sistent expert recommend 12 14 31 studi treat ment defin discret episod care mark fix endpoint number session singl quit date repeat 7 dai point preval abstin proxi prolong abstin consist prior research 32 36 repeat 7 dai point preval abstin base consecut follow assess interv 4 6 9 month random assign 2 month assess includ comput allow subject stabiliza tion period recov laps initi intervent 37 repeat 7 dai point preval abstin conserv measur prolong abstin mea sure correl highli 0.85 0.94 38 39 mental health qualiti assur outcom ptsd check list 28 beck depress inventori 29 complet subject baselin 6 9 month follow up ject rate symptom occur prior week ptsd checklist beck depress inventori assess mental health symptom time order determin smoke cessat worsen symptom patient satisfact outcom subject studi condit rate satisfact amount qualiti smoke cessat treatment receiv 4 point likert scale 1 dissatisfi 4 satisfi rate gather termin 9 month studi assess data analysi abstin data analyz intent treat analysi margin logist regress method gener estim equat statist approach analyz smok ing cessat outcom data conform recommend expert panel societi research nicotin tobacco 39 gener estim equat method advantag account correl peat measur data point sensi tive pattern chang time 40 covari anal ysi baselin measur sever nicotin depend fagerstrom test nicotin depend 41 depr sion beck depress inventori depress includ covari evid show advers af fect smoke cessat outcom 42 44 effect smoke cessat mental health symptom 6 9 month follow assess analyz comput ing chang baselin score ptsd checklist beck depress inventori assess interv separ mann whitnei test compar chang score continu smoker versu subject abstin assess interv categor variabl abstin statu analyz chi squar test distribut continu variabl analyz student test nonparametr s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight s04aw6 highlight 1314 psychiatri 162 7 juli 2005 ptsd quit smoke http ajp.psychiatryonline.org test mann whitnei spearman correl form nonnorm distribut variabl result deliveri studi treatment smoke cessat medic tabl 2 present proport subject receiv integr care usual standard care obtain prescript studi medic fill pharmaci subject randomli assign integr care significantli subject receiv usual standard care receiv prescript transderm nicotin nico tine gum differ studi condit signific smoke cessat medica tion subject integr care receiv type smoke cessat medic i. gum patch sprai bupropion subject usual standard care int grate care mean 2.5 sd 0.7 usual standard care mean 1.7 sd 1.0 3.21 0.01 tail nineti percent subject integr care fill pre scription type smoke cessat medic studi compar 64 subject usual standard care χ2 7.3 df 1 0.01 tail tabl 3 show subject condit receiv smoke cessat medic dose treatment consist u. public health servic practic guidelin 14 behavior counsel subject randomli assign integr care particip behavior counsel smoke cessat session 88 subject usual standard care treat ment contact subject integr care receiv aver ag 5.15 sd 1.2 manual driven protocol smoke cessat session compar averag 2.6 sd 2.1 session subject usual standard care 5.35 0.0001 tail addit provid initi fol low contact mean 3.9 sd 3.9 deliv tegrat care subject involv assess smoke statu reapplic intervent deem appro priat case manag number smoke ce sation session receiv subject significantli correl number assess occas abstin smoke rs 0.35 0.004 tail smoke cessat outcom subject complianc follow assess 83 assess interv 83 month 2 81 month 4 81 month 6 84 month 9 medic record retrospect subject interview data determin smoke statu 96 remain observ percent obser vation miss handl record ject presumpt smoker studi condit differ significantli number miss obser vation 0.05 figur 1 present smoke abstin data sessment interv result gener esti mate equat analysi assess interv odd smoke interv time greater subject integr care subject usual standard care odd ratio 5.23 95 confid interv 1.76 15.54 0.002 tail proport subject achiev abstin sessment interv greater subject int grate care integr care 52 versu usual standard care 25 χ2 4.82 df 1 0.02 tail ject integr care abstin follow assess period compar subject usual standard care mean 1.1 sd 1.4 integr care versu mean 0.4 sd 0.8 usual stan dard care 2.38 0.02 tail repeat 7 dai point preval abstin rate 12 int grate care 3 usual standard care stati tical nonsignific differ χ2 1.66 df 1 0.20 tail qualiti assur outcom group score ptsd checklist beck depress inventori gather 6 9 month chang significantli baselin 0.05 chang score significantli abstain versu continu smoker assess interv 0.05 satisfact treatment subject integr care significantli satisfi amount smoke cessat treat ment receiv compar subject usual standard care mean 3.9 sd 0.3 integr care versu mean 3.5 sd 0.7 usual standard care 3.21 0.001 tail rate qualiti treatment significantli higher integr care condit mean 3.7 sd 0.5 integr care versu mean 3.4 sd 0.6 usual standard care 2.08 0.04 tail tabl 2 proport subject receiv smoke cessat medicationsa medic veteran receiv integr care veteran receiv usual standard care analysi χ2 df 1 bupropion 20 60.6 16 48.5 0.55 0.46 transderm nicotin 31 93.9 22 66.7 6.13 0.02 nicotin gum 29 87.9 14 42.4 13.08 0.001 nicotin sprai 1 3.0 3 9.1 0.27 0.61 prescript written medic fill pharmaci psychiatri 162 7 juli 2005 1315 mcfall saxon thompson al http ajp.psychiatryonline.org discuss studi demonstr feasibl train men tal health provid integr guidelin base smoke cessat treatment mental health care veteran ptsd ptsd clinic prescrib readili incorpor deliveri tobacco cessat medic clinic practic case manag document high rate adher prescrib behavior counsel tervent absenc verif independ rate session content limit valid find integr model smoke cessa tion treatment test effect ptsd pa tient care provid va smoke cessat specialist measur point preval abstin differ studi condit repeat 7 dai point preval abstin measur 12 int grate care 3 usual standard care sig nific ow limit statist power studi complet random trial ptsd clinic staff deliv integr care 107 addit patient indic sustain intervent routin clinic practic patient carbon monoxid verifi 10 ppm repeat 7 dai point preval absti nenc quit rate measur 4 6 9 month treatment onset 15 subject integr care particip greater number smoke cessat counsel session subject usual standard care significantli receiv transderm nicotin nicotin gum receiv combin tobacco cessat pharmacotherapi shown improv smoke quit rate mono therapi 14 find suggest integr care effect vehicl usual standard care deliv cessat treatment suffici tensiti integr care success engag subject cessat treatment higher satisfact rate integr care usual standard care encourag medic compli anc addition continu therapeut relat ship afford integr care oppos epi sodic care provid usual standard care improv access ongo monitor pro vider initi relaps manag research shown dose respons relationship num ber smoke cessat contact smoke outcom 14 33 35 higher quit rate extend versu tobacco treatment 45 fact treatment trial suggest cessat relat number counsel session receiv specif therapeut method smoker posit tori depress 32 35 success smoke cessat treatment veteran ptsd similarli requir greater number contact extend time guidelin recommend smoke cessat treatment yield point preval quit rate 15 25 u. public health servic meta analys 6,000 studi volv follow assess 5 month 12 dividu mental disord typic exclud smoke cessat clinic trial review u. public health servic activ psychiatr comorbid complic cessat effort signif icantli reduc quit rate 5 46 49 fact point preval quit rate observ studi fell rang report meta analys treatment tri al encourag subject chronic mental ill experienc moder sever symptom ptsd depress research need improv repeat 7 dai point preval absti nenc quit rate 12 integr care condit applic integr care longer period order promot recycl strategi test increas intens initi integr care tabl 3 quantiti smoke cessat medic receiv subjectsa medic measur veteran receiv integr care veteran receiv usual standard care analysi mean sd mean sd df tail bupropion dose mg dai 20 281.3 46.4 16 285.2 33.9 0.29 33.78 0.77 dai suppli 20 141.8 114.5 16 97.1 93.2 1.29 33.98 0.21 number prescript fill 20 3.8 2.8 16 2.9 2.3 1.10 34.00 0.28 transderm nicotin dose mg dai 31 23.7 5.4 22 24.0 7.7 0.12 35.35 0.91 dai suppli 31 103.0 119.1 22 79.6 58.2 0.95 46.13 0.35 number prescript fill 31 4.6 4.8 22 3.2 2.4 1.43 46.16 0.16 nicotin gum dose mg dai 29 7.6 2.8 14 6.2 3.2 1.42 22.70 0.17 dai suppli 29 79.9 69.5 14 66.1 66.3 0.63 26.92 0.54 number prescript fill 29 2.8 2.4 14 2.6 2.7 0.26 23.18 0.80 nicotin sprayb number bottl receiv 1 1.0 3 4.7 3.5 dai suppli 1 14.0 3 80.0 45.8 number prescript fill 1 1.0 3 2.0 1.7 prescript written medic fill pharmaci signific test conduct small number observ studi condit 1316 psychiatri 162 7 juli 2005 ptsd quit smoke http ajp.psychiatryonline.org intervent effort prevent earli relaps smok ing applic integr care systemwid basi prolong smoke quit rate 12 potenti produc 10,000 quitter popul ptsd patient va esti mate deriv va databas 11 50 51 exist remark smoke cessat clinic trial involv individu current mental disord provid standard comparison present studi number studi conduct smoker histori past major depress 32 36 52 53 studi provid appro priat standard comparison present studi preponder evid trial substanti hypothesi histori posit smoker quit histori neg smoker 54 clinic trial involv smoker current mental di order meet minimum recommend standard abstin follow assess 6 month 37 55 focus schizophrenia alcohol depen denc singl point preval abstin rate ter minal 6 month follow assess studi smok er schizophrenia 11 56 12 57 7 17 58 19 59 singl point preval abstin rate termin 12 month assess studi alcohol depend patient 12 60 13 19 61 quit rate studi clinic sampl roughli equival slightli lower singl point preval quit rate integr care report studi 61 report prolong abstin peat 7 dai point preval abstin follow month 1 3 6 12 found quit rate 10 12 activ tobacco cessat treatment involv recov er alcohol result compar peat 7 dai point preval abstin quit rate 12 present studi rate smoke abstin integr care ject studi termin half observ 2 month assess mechan contribut smoke relaps ptsd patient deserv explor specif pre post cessat neg affect state 24 32 33 44 46 62 increas symptom depress immedi fol low quit attempt 63 increas relaps suscept suppress sustain quit rate studi heighten withdraw sensit predict relaps smoker histori depress studi 64 65 possibl explain continu smoke ptsd patient stop smoke treatment trial associ at worsen symptom ptsd depress measur 6 9 month treatment onset sult consist studi show mood disturb result stop smoke 32 46 66 studi show 25 27 67 individu histori depress compar result attenu mark differ studi group i. current ptsd versu histori major depress explan find deserv consider transient symptom exacerb late postcess nicotin withdraw oc cur shortli subject cessat attempt undetect outcom measur discret time point studi fact 86 subject present research receiv anti depress medic bupropion smok ing cessat ptsd prevent potenti deterior effect possibl support evid show sertralin reduc nicotin drawal symptom 53 nortriptylin allevi postcess neg affect 35 smoker tori major depress subject experienc worsen psychiatr symptom quit smoke simpli resum smoke order manag symptom data support lat ter explan symptom ptsd depress chang baselin 6 9 month sessment subject continu smoke compar quit nonsignific differ subject quit symptom measur reflect low statist power ow ing small number quitter involv compari son month 6 9 interpret studi find limit methodolog shortcom investig follow convent measur outcom demarc quit date end inter vention period smoke cessat treatment conceptu continu process involv reappli figur 1 point preval smoke abstin rate veteran posttraumat stress disord integr care versu usual standard carea signific effect group odd ratio 5.23 95 ci 1.76 15.54 0.001 tail 0 2 4 6 9 10 20 veteran receiv integr care 33 veteran receiv standard care 33 rc st fr time month 30 40 50 psychiatri 162 7 juli 2005 1317 mcfall saxon thompson al http ajp.psychiatryonline.org cation treatment multipl quit attempt 31 compar find research mea sure outcom initi quit date limit biomark longer term nonsmok statu ideal supplement pire carbon monoxid order verifi subject port continu abstin assess verifi standard biolog assai continu abstin data base subject report inform subject report smoke statu gener valid 68 proport subject receiv prescript fill pharmaci report specif measur medic adher includ impo sibl determin degre medic ad herenc affect outcom ptsd patient current substanc abus disord includ studi current substanc depend find gener smoker ptsd comorbid substanc depend disor der final larger studi group requir order conclud definit integr care effect usual standard care smoke cessat clinic set servic deliveri studi conduct spirit clinic effect trial order promot gener izat real world health care set 69 end treatment repres practic broad subject inclus criteria ensur studi group reflect popul va ptsd clinic patient threat intern valid inher trial 69 studi pro vide favor test feasibl outcom apa recommend 49 implement smoke cessat treatment practic base set patient cur rent mental disord addit studi integr model smoke cessat treatment mental ill patient warrant extraordinarili high preval heavi smoke individu 41 5 50 70 present part intern societi traumat stress studi orlean dec 6 9 2001 northwest network mental ill research educ clinic center center excel substanc abus treatment educ bio statist unit health servic research develop center excel depart veteran affair seattl wash univers washington school medicin depart psy chiatri behavior scienc school nurs seattl address correspond reprint request dr mcfall va puget sound health care system ptsd program 116 mhc 1660 lumbian seattl wa 98108 miles.mcfal med.va.gov mail support depart veteran affair northwest net work mental ill research educ clinic center center excel substanc abus treatment educ grant univers washington alcohol drug abus institut
proactiv intervent smoke cessat gener medic practic quasi random control trial examin efficaci comput tailor letter physician deliv advic christian meyer1 sabina ulbricht1 sebastian baumeister1 anja schumann2 jeannett rüge1 gallu bischof3 han jürgen rumpf3 ulrich john1 univers greifswald depart epidemiolog social medicin greifswald germani 1 bremen institut prevent research social medicin bremen germany2 univers lübeck depart psychiatri psychotherapi research group s:tep substanc abuse:treat epidemiolog prevent lübeck germany3 onlineopen articl free onlin www.blackwel synergy.com abstract aim test efficaci comput gener tailor letter ii practition deliv advic smoke cessat assess condit compar intervent directli design quasi random control trial set total 34 randomli select gener practic german region par ticip rate 87 particip total 1499 consecut patient ag 18 70 year daili cigarett smoke particip rate 80 intervent tailor letter intervent group receiv indi vidual person letter advic deliv routin consult practition onsit train session intervent base transtheoret model behaviour chang measur report point preval prolong abstin 6 12 18 24 month follow up find particip complet follow 6 month prolong abstin 18.3 tailor letter intervent group 14.8 advic intervent group 10.5 assess control group assum lost follow smoker rate 10.2 9.7 6.7 analys includ follow up confirm statist signific effect intervent compar assess complet case analysi tailor letter intervent significantli effect advic 24 hour odd ratio 1.4 0.047 7 dai point preval abstin 1.4 0.068 prolong abstin altern assumpt particip lost follow conclus studi demonstr long term efficaci low cost intervent smoke cessat gener practic intervent suitabl reach entir popul gener practic smoke patient comput gener letter promis option overcom barrier provid smoke cessat counsel routin keyword comput expert system opportunist counsel primari medic care smoke cessat transtheoret model correspond christian meyer institut epidemiolog social medicin univers greifswald walter rathenau str 48 17487 greifswald germani mail chmeyer uni greifswald.d submit 23 februari 2007 initi review complet 15 2007 final version accept 11 septemb 2007 articl permit accord creativ common deed attribut 2.5 permit commerci exploit introduct assist patient quit smoke regard cost effect measur clinic practic 1 recent review confirm simpl intervent advic deliv physician small signific effect cessat rate 2 public health perspect implement intervent research report doi 10.1111 1360 0443.2007.02031 2007 author journal compil 2007 societi studi addict addict 103 294 304 http www.bla mailto:chmey uni greifswald.d primari medic care promis major smoke popul reach 1 year intervent small effect capabl substanti reduc smoke attribut diseas popul level 3 systemat screen advis patient smoke cessat routin basi adopt clinic practic guidelin 4,5 recommend implement insuffici practic 6 11 lack time patient insuffici motiv chang report major barrier provis smoke interven tion practition 11 14 provis time save opportunist counsel approach allow inclus patient irrespect readi chang smoke behaviour expect crucial improv implement 15 comput base smoke intervent alterna tive interperson counsel 16 inter vention compris letter tailor characterist individu smoker 17 evid tailor materi effec tive intervent untailor materi 18 studi test tailor materi primari medic care set reveal mix result 19 22 efficaci trial provid allow direct comparison physician deliv counsel ling comput tailor materi gener practic set object present studi test short long term efficaci advic deliv repres sampl gener practition comput gener tailor letter randomli select popul adult smoke patient method part project proactiv intervent smoke cessat gener medic practic pro gp conduct random control trial compar effect advic deliv practition train opportunist counsel techniqu comput gener tailor letter assess sampl step sampl gener repres sampl patient germani primari medic care provid gener practition gp work privat practic paid fee servic health insur compani popul public privat health insur step 44 149 practic select ran domli practition regist primari medic care vorpommern rural area north east germani practic provid primari care 34 remain 39 87.2 part includ 39 gp step period 3 week consecu tive patient screen smoke statu research nurs cover complet offic hour total regist 11 560 practic attend tabl 1 number consult vari studi week season effect patient visit practic repeatedli studi period 1664 sequent exclud recruit leav 9896 patient exclud 7696 patient fulfil inclus criteria i. ag 18 70 year smoke daili past 4 week 383 patient exclud reason e.g ill cognit impair insuffici languag capabl screen refus miss patient fulfil inclus criteria 1862 1499 80.5 con sent part recruit place april 2002 septemb 2003 tabl 1 recruit retent particip studi week assess studi week tailor letter studi week advic consult 4290 3836 3434 patient consult 3993 93.1 3229 84.2 2674 77.9 fulfil inclus criteria patient 756 18.9 602 18.6 504 18.8 agre particip patient fulfil inclus criteria 609 80.6 488 81.1 402 79.8 particip follow patient agre particip month 3 389 79.7 month 6 480 78.8 333 68.2 324 80.6 month 12 453 74.4 319 65.4 311 77.4 month 18 419 68.8 302 61.9 283 70.4 month 24 396 65.0 279 57.2 266 66.2 flow diagram detail reason exclus particip request consult includ multipl practic visit patient patient recurr visit practic alloc group belong time practic visit proactiv smoke intervent gener practic 295 2007 author journal compil 2007 societi studi addict addict 103 294 304 assign com.ibm.drl.hbcp.util quasi random base time practic attend patient studi week alloc assess control condit ii patient week assign tai lore letter intervent iii patient week assign advic intervent chose fix sequenc studi condit avoid coun sell activ practition week practition receiv counsel train studi week 2 3 reduc potenti bia patient attend practic repeat edli studi week schedul 2 week patient attend practic fre quentli lower probabl inclus studi group tabl 1 intervent tailor letter letter tailor principl transtheoret model ttm behaviour chang 23 letter gener research institut comput expert system structur compa rabl system develop velic al 16 system studi base initi version provid cancer leagu switzerland 24 reprogram modifi respect feedback paragraph norm data letter tailor stage chang defin current smoke statu intent quit smoke score decision balanc efficaci process chang question nair letter base data gather baselin assess includ norm feedback i. feedback depend individu score pare popul norm stage 1 week practic visit 3 month 6 month letter addition includ ips feedback i. inform tailor individu chang previou assess construct letter accompani select seri manual cover specif inform relev stage chang ttm inform particip practic team practition advic 2 hour onsit train session provid practition research part compris introduct epidemiolog smoke smoke relat diseas nicotin depend view evid base intervent smoke cessa tion princip ttm part introduc advic intervent studi protocol studi week adopt el ment health behaviour chang counsel 25 intervent structur desktop resourc provid ing flow chart illustr adequ element counsel session gener commun strate gi prompt counsel basic inform smoke relat variabl e.g cigarett smoke dai degre nicotin depend carbon monoxid exhal air stage chang assess wait room practition summari sheet match desktop resourc intervent design 10 minut includ manual provid patient tailor letter condit intervent deliv practition visit regular consult baselin assess ment wait room assess intervent usual practic routin pro vide control group inform particip practic team practi tioner manual provid assess baselin assess 22 side questionnair administ wait room includ item cover ing socio econom statu smoke behaviour ttm psycholog construct smoke psy chosoci resourc screen alcohol disor der present analysi gener health assess euroqol visual analogu scale eq va 26 fagerstöm test nicotin depend ftnd determin degre nicotin depend 27 carbon monoxid concentr exhal air measur research nurs 28 conduct outcom assess 6 12 18 24 month initi practic visit addit assess perform 3 month tailor letter condit purpos intervent follow assess includ item cover ttm construct smoke behaviour com.ibm.drl.hbcp.util medic care smoke cessat aid qualiti life recent consensu consid follow ing report point preval abstin pro long abstin measur primari outcom measur 29 24 hour point preval abstin i. smoke puff past 24 hour prece ing follow ii 7 dai point preval abstin i. smoke puff past 7 dai preced follow iii 4 week prolong abstin i. smoke past 4 week preced follow iv 296 christian meyer al 2007 author journal compil 2007 societi studi addict addict 103 294 304 6 month prolong abstin i. smoke past 6 month preced follow outcom assess ment collect comput assist telephon interview part standard procedur establish survei unit institut measur ensur high qualiti data includ doubl entri paper pencil question nair regular train monitor supervis interview experienc research psychologist autom consist check interview interview blind treatment alloc involv handl tailor letter question nair particip reach telephon respons rate shown tabl 1 contact main reason respons refus particip rang 8.8 6 month 3.7 24 month particip lost follow statist analysi analys differ respect potenti con founder baselin smoke cessat follow intervent group assess group cluster practic account appli sampl survei method stata version 9.2 30 associ smoke abstin treatment group estim logist gener estim equat gee proc genmod procedur sa version 9.1 level cluster prac tice site individu examin implic miss data sampl attrit studi conclus seri addit analys undertaken regress imput method imput miss data covari measur baselin covari adjust model comput miss data replac imput valu regr sion imput conduct ic procedur stata 31 conduct seri anali se make assumpt drop complet case analysi i. smoke statu follow includ model ii miss follow observa tion code smoker iii carri forward replac miss iv weight estim equat wee model 32 34 wee involv step step analysi sampl select model construct baselin data predict particip wave basi model probabl studi par ticip estim mvpred procedur stata step data analys logist gee model full data observa tion individu weight invers probabl studi particip adjust sampl select bia result refer assumpt iii miss data report paper provid author request result baselin characterist baselin characterist sampl shown tabl 2 random procedur bias due exclud particip attend practic studi condi tion test studi group respect differ enc baselin characterist signific differ process evalu prepar intend number tai lore letter suffici data baselin 3 month 6 month assess avail hundr 62.7 particip receiv letter 100 20.5 82 16.8 manual tailor letter 12 month follow 89.1 tailor letter intervent group confirm receiv letter manual assess group 3.5 fals rememb receiv ing materi patient alloc advic group practition rate counsel activ form directli consult advic i. commun includ activ participa tion patient 353 87.8 partici pant addition smoke address i. patient particip activ communi cation consult 35 8.7 particip leav 14 3.5 particip document counsel activ practition practitio ner estim counsel last 7 minut standard deviat sd 2.9 averag manual hand practition 343 85.3 particip 12 month follow 41.5 advic group rememb receipt manual train practition held recruit assess tailor letter group patient counsel practic visit compar pre viou counsel activ baselin 12 month follow baselin 24.0 particip report smoke address practition 12 month 12 month follow proactiv smoke intervent gener practic 297 2007 author journal compil 2007 societi studi addict addict 103 294 304 24.1 assess group 25.6 tai lore letter group 46.6 advic group report practition address smoke past year outcom tabl 3 show point preval prolong abstin follow preval figur tabl 2 distribut potenti confound valu number percentag state assess tailor letter advic total subject 609 488 402 1499 socio demograph variabl gender 0.204 male 309 50.7 242 49.6 223 55.5 774 femal 300 49.3 246 50.4 179 44.5 725 mean sd ag 34.8 13.4 33.8 13.2 33.1 12.5 1499 0.228 educ level 0.403 10 year school 209 34.3 151 30.9 117 29.1 477 10 year school 294 48.3 256 52.5 217 54.0 767 10 year school 84 13.8 68 13.9 59 14.7 211 inform 22 3.6 13 2.7 9 2.2 44 unemploi 0.396 86 14.1 62 12.7 66 16.4 214 416 68.3 334 68.4 267 66.4 1017 inform 107 17.6 92 18.9 69 17.2 268 marri live stabl partnership 0.717 409 67.2 323 66.2 279 69.4 1011 186 30.5 152 31.1 118 29.4 456 inform 14 2.3 13 2.7 5 1.2 32 health relat variabl mean sd rate health index eq va 70.7 20.5 69.9 19.1 69.7 19.8 1260 0.800 inform 103 16.9 74 15.2 62 15.4 239 reason consult practition 0.764 acut problem 283 46.5 225 46.1 195 48.5 703 chronic problem 140 23.0 115 23.6 97 24.1 352 prevent check 142 23.3 120 24.6 83 20.6 345 inform 44 7.2 28 5.7 27 6.7 99 smoke relat variabl mean sd number cigarett smoke dai 16.2 7.6 16.4 7.7 16.9 7.9 1490 0.464 inform 4 0.7 4 0.8 1 0.2 9 mean sd ftnd 3.3 2.1 3.1 2.0 3.3 2.1 1452 0.463 inform 26 4.3 15 3.1 6 1.5 47 intent quit smoke 0.248 intent 412 67.7 312 63.9 247 61.4 971 6 month 160 26.3 133 27.3 128 31.8 421 4 week 27 4.4 29 5.9 26 6.5 82 inform 10 1.6 14 2.9 1 0.2 25 24 hour quit attempt past year attempt 426 70.0 340 69.7 274 68.2 1040 0.847 1 attempt 183 30.0 146 29.9 128 31.8 457 inform 0 0.0 2 0.4 0 0.0 2 mean sd carbon monoxid exhal air p.p.m 16.7 10.2 16.3 9.4 15.7 9.5 1350 0.506 inform 67 11.0 46 9.4 36 9.0 149 smoke partner 0.620 253 41.5 201 41.2 181 45.0 635 138 22.7 113 23.2 86 21.4 337 partner 140 23.0 124 25.4 90 22.4 354 inform 78 12.8 50 10.2 45 11.2 173 bivari comparison valid case adjust sampl design rao scott correct c2 statist categor variabl adjust wald test statist continu variabl ftnd fagerstöm test nicotin depend sd standard deviat eq va euroqol visual analogu scale p.p.m part million 298 christian meyer al 2007 author journal compil 2007 societi studi addict addict 103 294 304 ta bl 3 po pr ev al en ce pr ol ge ab st en ce fo di ffe fo llo ps ac ro ss st dy gr ou ps ut fo llo ss es sm en ly ta ilo le tt er ri ef ad vi ce ab st en os fo llo ed os cl ud ed ba se lin ab st en os fo llo ed os cl ud ed ba se lin ab st en os fo llo ed os cl ud ed ba se lin 2 4 ou 6 2 8 5 8 4 6 3 9 1 1 8 8 0 2 4 7 5 6 0 ab st en ce 1 2 4 3 9 5 7 1 5 4 1 7 0 1 1 1 4 7 1 5 3 1 1 7 1 8 5 9 1 4 2 9 7 7 7 2 5 6 1 5 8 5 3 1 8 9 1 3 2 2 4 6 5 1 6 4 1 0 7 8 2 2 9 7 1 6 8 6 2 2 3 3 1 5 4 7 ay 6 1 7 3 6 2 8 3 1 9 4 6 4 1 6 5 0 4 0 ab st en ce 1 2 3 8 8 4 6 2 4 4 1 4 0 9 0 3 7 1 2 1 9 2 1 8 5 1 1 2 3 8 4 6 7 2 2 4 1 3 7 5 0 1 7 8 1 2 4 2 4 5 7 1 4 4 9 4 7 5 2 7 2 1 5 4 5 7 2 1 4 1 4 2 4 ee 6 1 5 3 1 2 5 2 2 6 7 4 5 1 3 4 0 3 2 ab st en ce 1 2 3 6 8 0 5 9 4 0 1 2 7 8 2 3 9 1 2 7 9 7 1 8 4 8 1 1 6 7 9 6 3 2 1 1 1 2 9 4 5 1 5 9 1 1 2 2 4 5 7 1 4 4 9 4 7 2 2 6 0 1 4 8 5 6 2 1 1 1 3 9 6 1 2 7 1 6 1 1 1 9 6 1 3 9 1 5 4 9 3 7 ab st en ce 1 8 2 5 6 0 4 1 3 6 1 2 0 7 4 3 4 1 2 1 8 5 2 4 4 1 1 0 5 6 7 5 0 1 8 3 1 0 2 3 9 1 4 8 9 7 proactiv smoke intervent gener practic 299 2007 author journal compil 2007 societi studi addict addict 103 294 304 calcul exclud particip miss follow data assum particip miss follow data smoker absti nenc increas time studi group absolut differ abstin rate intervent assess group highest rate found tailor letter interven tion group advic intervent group assess control group explor long term stabil earli intervent effect calcul percentag particip report abstin preced 6 month 12 month subsequ follow up exclud ing particip miss follow up construct measur 1.5 assess control group 341 6.0 14 232 tailor letter intervent group 3.6 10 224 advic intervent group stop smoke 6 month main tain abstin month 24 assum particip miss follow smoker respect figur 0.8 609 2.9 14 488 2.5 10 402 assumpt missing differ control intervent group statist signific gee analys allow test intervent effect simultan assess time ing longitudin inform i. obser vation irrespect particip previou follow time test robust find ing respect potenti bia caus miss follow observ tabl 4 show result approach i. wee analysi adjust outcom probabl particip follow up gee analysi assum miss follow smoker comparison interven tion group assess group stati tical signific effect estim tailor letter intervent lower rigid assumpt miss data base tabl 4 gee analys treatment effect procedur account miss data outcom measur contrast group refer crude analys adjust analys 95 ci 95 ci particip lost follow assum smoker 7 dai point abstin tailor letter versu assess 0.001 1.7 1.3 2.4 0.002 1.7 1.2 2.4 advic versu assess 0.016 1.5 1.1 2.2 0.026 1.5 1.1 2.2 tailor letter versu advic 0.470 1.1 0.8 1.6 0.522 1.1 0.8 1.6 6 month prolong abstin tailor letter versu assess 0.004 1.9 1.2 2.8 0.013 1.7 1.1 2.7 advic versu assess 0.005 1.9 1.2 2.9 0.011 1.8 1.1 2.9 tailor letter versu advic 0.931 1.0 0.6 1.5 0.869 1.0 0.6 1.5 weight estim equat adjust probabl follow particip 7 dai point abstin tailor letter versu assess 0.001 2.1 1.5 3.0 0.001 2.0 1.4 2.9 advic versu assess 0.010 1.6 1.1 2.3 0.022 1.6 1.1 2.3 tailor letter versu advic 0.158 1.3 0.9 1.8 0.177 1.3 0.9 1.9 6 month prolong abstin tailor letter versu assess 0.001 2.1 1.3 3.2 0.005 1.9 1.2 3.1 advic versu assess 0.004 1.9 1.2 3.1 0.009 1.9 1.2 3.0 tailor letter versu advic 0.793 1.1 0.7 1.6 0.896 1.0 0.7 1.6 complet tabl includ analys outcom measur assumpt miss data request gener estim equat model predict smoke cessat take account cluster correl practic subject measur period model base unstructur correl structur repeat observ subject 12 18 24 month assess consid 7 dai point abstin 12 18 24 month assess 6 month prolong abstin includ com.ibm.drl.hbcp.predictor variabl studi group time includ com.ibm.drl.hbcp.predictor variabl studi group time ag gender educ level reason consult practition fagerstöm test nicotin depend 24 hour quit attempt past year intent quit ci confid interv odd ratio 300 christian meyer al 2007 author journal compil 2007 societi studi addict addict 103 294 304 estim crude analys wee approach odd 7 dai point preval 6 month prolong abstin 2.1 time higher tailor letter intervent group compar assess control group comparison advic intervent group assess control group reveal odd ratio 1.6 1.9 respec tive time variabl highli signific model reflect increas abstin time studi group analys adjust base line characterist particip show minor cf column tabl 3 test linear trend rel effect intervent follow time expand gee main effect model includ time intervent interact term analys reveal signific interact comparison intervent reveal odd ratio 1.4 24 hour point preval abstin gee analysi exclud particip lost follow indic larger effect tailor letter data report tabl 3 crude analysi 0.047 95 confid interv ci 1.0 1.9 adjust analysi 0.037 95 ci 1.0 2.0 differ approach sig nific 7 dai point preval abstin crude analysi 0.068 odd ratio 1.4 95 ci 1.0 1.9 adjust analysi 0.063 1.4 95 ci 1.0 2.0 regard prolong abstin numer differ lower vanish complet analys take account altern assumpt lost follow statisti calli signific discuss studi demonstr intervent i. comput tailor letter session practition deliv advic effect reduc ing proport current smoke compar intervent comput tailor letter equival advic tend effect respect point preval absti nenc thirdli repres sampl prac tition patient gener find entir popul patient gener practic regard efficaci tailor letter inter vention popul studi replic result studi compar recruit proce dure follow period 22,35,36 found previ ousli studi cessat rate control group rate expect chang base popul data reason particip studi focus smoke recurr assess psy cholog construct relat smoke behaviour chang form minim intervent 36 gener practic base smoke interven tion studi reveal abstin rate 1 year increas 40 assess compar assess control group 37 effect relev germani low tobacco control measur low counsel activ primari medic care 38,39 rel interven tion effect underestim result line previou find german studi 40,41 proport smoker intend quit substanti higher compar proport found american studi expect lower quit rate reduc intervent effect hand intervent capit patient practition rela tionship favour psycholog state discuss practic visit 42 result impli implement class intervent primari care benefici permiss smoke cultur high proport smoker intend quit contrast studi gener practic base studi comput tailor intervent unit kingdom reveal favour result recruit ing patient mail proport smoker receiv treatment consider lower 42 20 9 21 compar studi person recruit practic select process previou studi limit generaliz entir popu lation smoke patient differ studi design explain lower intervent effect pre viou studi reli biochem confirm absti nenc refrain approach studi demonstr collect saliva sampl feasibl valid restrict quitter rate analys saliva sampl claim quitter previou research 63 20 31 21 low intens intervent low demand characterist studi valid report smoke behaviour compar epidemiolog cal clinic studi stronger interperson involv denial smoke 43 ii uk studi restrict tai lore letter preclud feedback intra individu chang time provis behaviour strategi smoker readi quit move action 20 studi provid maximum letter number patient receiv full intervent dose substanti lower studi 21 studi test efficaci number intervent letter find clear dose respons proactiv smoke intervent gener practic 301 2007 author journal compil 2007 societi studi addict addict 103 294 304 relationship 44 meta analysi physician deliv advic reveal studi includ follow interven tion effect 2 strength advic intervent highli feasibl 14 individu train session held practic site allow implement interven tion randomli select practic period 1 week support provid research nurs vast major elig patient receiv counsel regular practic hour rel effect advic compar assess condit close result report recent meta analysi pool studi physician advic smoke cessat 2 due high quit rate studi absolut differ cessat 2.5 found meta analysi standard structur advic mean train materi i. inform sheet patient smoke relat characterist desktop resourc studi design evalu activ deliv practition activ learn method e.g role plai context bound train effect 45 hand higher intens train expect decreas particip rate practition take popul impact yardstick aspect consid compar inter vention includ studi efficaci tailor letter intervent superior outcom measur statist signific reach outcom measur robust assumpt miss data interpret find complic fact consider overlap studi condi tion intervent includ manual train improv qualiti quantiti advic patient data frequenc advic give year prior inter vention suggest effect quantiti assess tailor letter group receiv advic exceed routin care test minim intervent smoker small differ enc import futur studi includ larger sampl need establish differ intervent respect broad implementa tion cost effect consider futur research technolog tailor letter intervent fewer resourc advic involv high cost work time practition limit studi germani nicotin replac medic reimburs health insur compani intervent includ recommend nicotin replac therapi smoker intend quit small pro portion particip 5.7 report medi cation follow provid free nicotin replac medic increas effici intervent 46,47 ii practic includ studi receiv fair amount support i. presenc studi nurs practic organ screen ing baselin assess administr tailor letter intervent research staff sy temat implement intervent limit 1 week integr intervent routin care broad implement con sider structur organiz factor e.g adequ reimburs practition distribut intervent materi train practition staff implement mainten adequ comput hard softwar iii proport particip lost follow proport vari studi group miti gate fact quarter patient complet follow lost unabl contact 10 refus procedur account respons bia chang find iv com.ibm.drl.hbcp.util quasi random procedur base time prac tice attend fix sequenc studi group patient attend practic frequent repres studi group found signific baselin differ adjust analys baselin characterist reveal pattern result due season effect number patient regist lower inter vention condit work load practitio ner provid advic slightli lower averag conclus minim intervent potenti substanti reduc smoke entir popul smoke patient long term intervent effect observ studi demonstr clinician effort address smoke cessat reason invest time effect obviou intervent base comput expert system technolog valuabl exten sion establish treatment opportun light limit resourc increas demand respect prevent measur assign gener practition 48 comput gener tailor letter promis option overcom exist barrier routin provid smoke cessat intervent acknowledg proactiv intervent smoke cessat gener medic practic pro gp project part 302 christian meyer al 2007 author journal compil 2007 societi studi addict addict 103 294 304 german research network earlint earli substanc intervent fund german feder ministri research educ grant 01eb0120 01eb0420 social ministri state mecklenburg vorpommern grant ix311a 406.68.43.05 german research foundat deutsch forschungsgemeinschaft grant jo150 6 1 author christian goez program final version expert system soft ware survei manag softwar brigitt kubowicz almut thürck isetta assist studi organ practic extend krebsliga schweiz cancer leagu switzer land provid initi version expert system softwar appreci advic member at statist consult group uni versiti california lo angel usa final particip practition patient support
jobnam pm 25 3 96 page 1 sess 38 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 reach midlif older smoker tailor intervent routin medic care1 glen morgan ph.d 2 elizabeth noll b.a traci orlean ph.d barbara rimer dr.p.h kweku amfoh m.phil georg bonnei ph.d wyom vallei famili practic resid kingston pennsylvania 18704 fox chase cancer center philadelphia pennsylvania 19111 duke univers durham north carolina 27708 background older adult achiev sig nific health benefit smoke cessat program specif target popul studi test effect offic base smoke cessat program tailor midlif older smoker method paper describ random con troll trial compar usual care physician deliv quit smoke advic counsel midlif older smoker ag 50 74 outpati medic practic assign interven tion experiment condit train deliv quit smoke advic counsel delai tervent control practic usual care pro cedur thirti practic accru patient practic includ analys result conserv measur quit report quit rate 6 month follow 15.41 intervent group versu 8.16 subject delai intervent group 0.005 baselin subject 659 characterist late 6 month abstin includ number pre viou quit attempt quit 24 hr past year desir quit confid quit perceiv health benefit lower nicotin depend conclus smoke abstin significantli increas train physician kei offic clinic staff interven older smoker intervent tailor ag cohort suc cessfulli efficaci integr routin care 1996 academ press kei word older adult smoke cessat offic base intervent introduct todai older smoker ag era smoke consid glamor safe good mood weight control physician en dors medic psycholog benefit smok ing legaci gener long term heavi smoker individu 50 year older constitut fastest grow ag cohort unit state repr sent 1 4 american 1 12 million american smoker pass 50th birthdai 2 smok ing remain signific health hazard u. ag popul smoke doubl mortal rate peopl 65 older3 major risk factor 6 top 14 death 4 smoke complic number ill common older peopl clude heart diseas high blood pressur circulatori vascular condit duoden ulcer osteoporosi diabet 5 8 impair effect medic prescrib treat chronic condit 9 substanti benefit accru smoke cessat 20 30 40 year tobacco addict ce sation smoke extend year life year activ life prevent reduc impact acut chronic ill limit independ 10 review rimer al 10 benefit cessat condit heart diseas stroke e.g heramnson al 11 howard al 12 benefit cessat respiratori function occur longer period time symptomat patient show improv lung function stop smoke 13,14 1990 sur geon gener report15 conclud smoke cessa tion benefici ag reason older american declar import target nation tobacco control initi 16,17 clear smoker ag benefit quit older adult virtual smoke cessat program address special older smoker 10 except hill al 18 random 82 smoker ag 50 condit havior placebo control exercis 12 portion paper present societi behavior medicin annual meet boston 1994 1 research support nci grant ca34856 nih grant 1r01hl50489 2 correspond reprint request ad dress wyom vallei famili practic resid 540 pierc st kingston pa 18704 prevent medicin 25 346 354 1996 articl 0065 346 0091 7435 96 18.00 copyright 1996 academ press right reproduct form reserv jobnam pm 25 3 96 page 2 sess 38 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 month follow abstin rate behavior condit time exercis condit group differ fail achiev statist signific signific differ exercis group aggreg data condit favor studi hill al 18 suggest com.ibm.drl.hbcp.util behavior orient group approach older smoker smoker attend formal cessat program 19,20 smoke intervent physician provid opportun person smoke cessa tion messag reach signific number smoker 21 seventi percent smoker 50 older physician year 22 aver ag smoker visit physician 4.3 time year 23 visit offer opportun provid smoke cessat advic counsel smoker plan quit ag 50 younger plan quit 3 month 24 studi demonstr increas cessat rate consequ physician advic counsel 25 28 specif direct older smoker vetter ford29 evalu impact direct advic physician combin nurs assist smoke cessat 471 smoker ag 60 year subject ran domiz intervent condit invit letter visit gener practition nonurg matter physician inform patient import stop smoke nurs offer advic lifestyl modif special attent smoke standard behav ioral intervent introduc month ab stinenc statu verifi expir air carbon monox id statist higher intervent group 14 versu 9 demonstr impact medic advic intervent deliv context regular health care visit studi test effect smoke cessat intervent design address quit concern smoke pattern older smoker studi expand past research com.ibm.drl.hbcp.util approach specif tailor older smoker integr routin care hypoth esiz cessat guid address barrier concern motiv quit older smoker superior gener guid 30 exist print materi focus special older smoker includ promi nentli photo graphic tailor includ attent graphic style prefer older adult inclus content specif older smoker benefit quit ag earlier phase studi conduct commun demonstr superior tailor guid gener smoke cessat guid rimer al 30 descript developmen tal process clear horizon guid method studi popul medic practic primari care practic cruit particip 2 year random control trial compar usual care quit smoke ad vice counsel midlif older smoker ag 50 74 recruit occur februari 1991 februari 1992 suburban philadelphia eastern pennsylvania criteria particip willing particip offic base train ing program absenc formal smoke inter vention program provid project abil accru 25 ag elig patient 3 month 81 practic initi express interest project interview phone project guid line elig criteria 49 practic met criteria agre particip studi recruit mail physician particip hmo n4 23 advertis region state medic societi journal 4 1 contact prac tice identifi investig 4 25 entir practic physician kei nonphysician offic staff random interven tion n4 23 delai intervent n4 26 condi tion author strategi facilit provid adher research intervent pro tocol e.g patient enrol aid cue remind er offic staff practic intervent aid regular staff contact small gift patient accrual prove difficult expect due select natur enrol smoker smoker ag 50 74 provid overestim number older smoker practic practic rang 5 50 week 36 week averag patient accrual base origin estim effect size expect varianc practic minimum number patient requir practic calcul power contour plot 31 practic accru fewer patient exclud order suffici power detect hypothes differ quit rate left 18 intervent periment 21 delai intervent control practic specialti includ famili medicin 4 20 intern medicin 4 17 cardiolog 4 1 ob gyn 4 1 differ spe cialti condit patient elig particip elig ag 50 74 physician noncrisi visit smoker sta tu smoker defin cigarett previou 7 dai 32 subject assur quit smoke par tailor intervent older smoker 347 jobnam pm 25 3 96 page 3 sess 37 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 ticip project purpos aspect elig ensur trial includ elig smoker motiv smoker patient meet criteria complet que tionnair smoke habit provid inform consent prior health care provid requir procedur implement equival condit provid train train program design offic base present principl pharmaceu tical academ detail 33 physician kei fice clinic staff delai intervent condit provid 45 60 min site train master doctor level psycholo gist health educ train includ presen tation background rational project clude special older smoker train object goal practic data collect guidelin continu educ credit physician nurs provid practic requir identifi coordin interfac project staff delai intervent practic instruct provid usual care older smoker accrual follow period practic intervent condit receiv site train implement modifi na tional cancer institut nci smoke cessat inter vention nci program deriv exp rienc physician base smoke cessat inter vention trial involv 4,000 smoker 34 intervent protocol compris step smoke opportun advis smoker stop assist patient stop smoke arrang follow support 35 intervent physician train prais patient previou quit effort provid sonal feedback link smoke symptom di cuss health benefit quit older smoker give clear messag stop smoke patient copi smoke cessat guid tailor older smoker clear horizon ask give quit smoker precontempl stage declin receiv guid base counsel overcom quit barrier smoker contempl stage receiv guid base counsel set quit plan quit date prescript nicotin gum nicotin patch time free 1 week sampl nicotin gum circumst smoker follow letter draft clear horizon offic physician 1 week visit smoker receiv follow clear horizon quitlin counsel call project staff 2 4 week intervent visit reinforc effort explor barrier discuss quit plan materi treatment guid clear horizon guide36 smoke program design long term heavi smoker ag 50 older 30 model aarp magazin modern matur writ ten 8th grade read level introduc ef fectiv quit smoke strategi exampl smoker 50 60 70 guid de sign address individu stage smoke divid section decid quit prepar initi cessat mainten pro vide explicit inform health cons quenc continu smoke health benefit quit older long term smoker guid pretest extens older adult found interest understand commun trial clear horizon prove appeal ing effect gener guid signifi cantli help motiv smoke cessat 30 medic record flowchart author develop flowchart medic record form help patient stop smoke provid intervent guidelin serv prompt data record practic investig facilit team approach enabl intervent practic follow nci protocol step step fig 1 form referenc kei smoke tori question present guidelin review clear horizon guid suggest phrase coun sele patient smoke form de sign streamlin intervent research proto col easili integr routin pri mari care data collect physician complet questionnair close enrol percept ef fectiv give quit advic program effect feasibl patient intervent telephon program staff tween 2 4 week offic visit follow counsel check provid adher enc treatment protocol follow telephon terview conduct profession interview 6 month enrol statist analysi descript statist comput baselin follow measur identifi covari se lect process outcom measur bivari parison conduct x2 test categor variabl mantel haenszel x2 analysi ordin variabl test continu variabl morgan al 348 jobnam pm 25 3 96 page 4 sess 37 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 group random intervent trial standard logist regress model comput condit combin model physician practic group unit random respond practic correl outcom influenc group physician practic variabl individu respond patient vari abl correl logist regress model account depend respond practic com.ibm.drl.hbcp.util corr late model origin develop account de pendenc household famili member 37,38 depend measur log odd scale standard logist regress model clude paramet standard logist regr sion paramet describ dependen ci control group intervent group result analysi summar separ standard logist correl model tabl 3 result baselin patient profil baselin demograph smoke characterist particip n4 659 present tabl 1 sampl popul 56 femal aver ag ag 60.1 year smoke 20 cigarett dai m4 20.1 sd4 12.1 quarter fig 1 help patient stop smoke tailor intervent older smoker 349 jobnam pm 25 3 96 page 5 sess 37 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 particip report smoke cigarett 30 min awaken indic high nico tine depend delai intervent practic differ significantli mean number patient enrol gender patient enrol report quit attempt last 24 hr previou year shown tabl 1 patient condit differ ag averag number ciga rett smoke daili time elaps cigarett morn contempl statu smoker delai intervent practic slightli younger 59.5 year versu 60.9 year report slightli higher averag daili cigarett 20.9 cigarett versu 19.0 cigarett report smoke 30 min awaken 81 versu 72 contempl plan quit 6 month 82 versu 88 practic provid adher check provid adher enc recommend treatment protocol immedi at intervent patient contact follow counsel call ask specif physi cian activ fig 1 outlin activi ti recommend patient stage chang physician quit messag de liveri clear horizon guid mail follow letter remain activ option base patient stage chang ness nicotin gum tabl 2 show high level complianc achiev requir intervent step 88 patient report clear physician quit advic enrol ment 95 report receiv clear horizon guid 35 report receiv smoke follow letter preprint follow letter provid research team mail intervent patient 7 dai index visit patient interview 2 4 week enrol receiv letter conceiv mail occur de lai follow interview window hand offic base system remind prompt requir accomplish mail prove overli burdensom practic addit option counsel step note tabl 2 report 37 45 patient nicotin gum prescript sampl report 31 patient physician appar continu address smoke older patient initi interven tabl 1 baselin characterist studi group delai n4 279 n4 380 n4 659 demograph mean ag 60.9 59.5 60.1 sex femal ns 54.5 57.6 56.3 smoke relat behavior mean cigarett smoke 19.0 20.9 20.1 dai mean number year 43.0 41.6 42.1 smoke smoke 30 min 72.3 81.1 77.4 wake quit 24 hr ns 50.4 49.2 49.7 12 month think 88.0 82.3 84.7 quit year note test x2 test categor variabl mantel haenszel x2 ordin variabl test interv variabl ns signific 0.01 0.05 0.001 0.01 0.001 tabl 2 patient report interact physician 2 4 week follow intervent n4 259 doctor recommend stop smoke 88.4 doctor gave clear horizon guid 95.8 receiv letter quit plan doctor visit 35.1 talk quit method guid option 44.8 set quit date option 37.1 doctor prescrib nicotin gum option 30.9 doctor gave sampl nicotin gum option 31.7 doctor ask set appoint talk quit option 38.6 morgan al 350 jobnam pm 25 3 96 page 6 sess 37 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 tion 6 month follow 358 64 particip report talk doctor smoke initi visit signific differ delai practic respect receiv advic quit discuss smoke set quit date nicotin gum fig 2 primari care provid survei tele phone shortli close enrol period assess feasibl perceiv efficaci tervent result base complet inter view 14 18 intervent practic 79 physician inter vention practic report spend 3 10 min patient implement counsel interven tion 43 thought older smoke pa tient recept advic quit physician group influ enc counsel patient fact older patient acut health prob lem requir attent 50 percept complianc medic quit advic 50 provid percept protocol gener provid er rate protocol practic help highli rate featur intervent report 14 primari physician tervent practic survei counsel call clear horizon guid 78.5 half found hav ing suppli nicotin gum prove help 46 highli rate reinforc letter overwhelm major physician 93 express increas confid counsel older patient stop smoke particip intervent nineti percent patient react fa vorabl clear horizon counsel materi al 86 plan continu basic clear horizon approach older smoke patient report barrier identifi inter vention physician survei patient ceiv lack interest quit 43 smoke cessat 659 patient complet baselin que tionnair 573 87 contact telephon interview 6 month follow particip classifi abstin report smoke cigarett previou 7 dai 32 report quit rate respond 6 month sur vei 4 573 17.8 treatment group compar 9.3 control group 0.005 count nonrespond smoker 4 659 quit rate 15.4 interven tion 8.2 delai intervent 0.005 fig 2 quit rate doubl par ticip intervent group month abstin rate differ immedi at intervent particip base receiv prescript nicotin gum 19 versu 18 regress model summar tabl 3 con firm intervent effect report virtual correl practic assign fig 2 patient report physician interact quit rate 6 month follow studi group.n differ due miss data 0.001 0.01 0.001 tailor intervent older smoker 351 jobnam pm 25 3 96 page 7 sess 37 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 control signific neg correl intervent group found neg estim reflect substanti heterogen subject sign treatment group variat subject treatment effect remain signifi x2 test compar correl model standard logist model signific 0.001 correl model provid portray practic relat differ control practic correl practic relat variabl explor model e.g physician spe cialti practic locat practic size group size signific 4 0.054 combin logist regress combin neg intervent depend correl model sug gest practic effect deterior patient accru respect respond individu disposi tional variabl confid abil quit good 0.05 number quit techniqu 0.05 remain backward select procedur combin model number quit tech niqu posit impact quit rate signific intervent control group pool combin correl model confid quit good posi tive impact quit rate signific intervent group model absenc intervent confid abil quit good import individu characterist variabl discuss month abstin rate doubl train physician staff deliv smoke ce sation intervent tailor midlif older adult offic base intervent includ test design tailor manual flow chart facilit cue intervent follow project staff prac tice com.ibm.drl.hbcp.util team approach integr smoke cessat treatment routin care physician train effect judg high provid adher enc level report patient base favor physician rate major intervent group physician continu address smoke cessat patient 6 month initi visit suggest intervent tegrat routin care cessat abstin rate achiev studi compar favor physician initi minim contact intervent studi demonstr differ 12 month fol low 39,40 ocken colleagues27 found train ing medic resid smoke intervent achiev 17.4 abstin rate patient 6 month follow compar 9.1 usual care wilson al 41 found combin counsel nicotin polacrilex superior usual care 8.8 versu 4.4 3 month sustain abstin 12 month fol low result attain singl train protocol base pharmaceut academ detail method 33 past studi gener includ schedul follow visit patient current studi physician en courag follow patient 70.8 pa tient discuss smoke 54.9 discuss set quit date physician initi visit import baselin variabl distinguish quit provid awar older younger smok er think quit power com.ibm.drl.hbcp.predictor cessat older smoker addict quit suggest tabl 3 estim standard error regress analys 6 month quit statu standard logist regress model correl logist variabl intervent control combin regress model patient characterist ag 1.1596 1.3195 1.3825 1.3195 1.2655 0.8613 1.0739 0.8621 number quit 0.1850 0.1090 0.1417 0.1606 0.1784 0.0894 0.3392 0.1077 techniqu confid quit 0.2148 0.1396 0.4332 0.1628 0.3128 0.1057 0.2823 0.0934 good practic characterist constant 2.3200 0.3864 3.4659 0.4772 3.1730 0.3314 2.9787 0.2727 intervent 0.6263 0.2644 0.8628 0.1374 group size 0.2786 0.1854 0.1658 0.2005 0.2216 0.1373 0.1182 0.0913 depend control 0.0875 0.1182 intervent 1.006 0.2706 note x2 compar standard combin correl model 16.689 2 degre freedom 0.001 signific 5 level morgan al 352 jobnam pm 25 3 96 page 8 sess 37 output mon jul 1 10 54 31 1996 xypag worksmart tsp000 70452i 14 aggress pharmacolog therapi set ting date feel confid want quit significantli relat quit rela tionship suggest concret provid interven tion provid thing encourag patient set quit date concret commit step quit practic vari condit number patient accru rate accrual im mediat delai treatment group differ baselin variabl literatur pre analys show abstin smoke differ rais concern physician experiment group select patient appear candi date intervent base symptom perceiv motiv limit sampl size group prevent post hoc analys regress model ing procedur perform adjust poten tialli confound effect group differ intrigu find relationship number patient accru intervent arm treatment outcom suggest busi primari care practic qualiti impact smok ing intervent diminish greater number patient accru patient intervent minut deliv pa tient greater cumul demand practic resourc result impli practic offic system simplifi identif treatment smoker approach ideal interven patient recom mend nci guidelin 35 conserv estim smoke statu nonrespond count smoker logist conduct commun base inter vention preclud biochem verif smoke statu limit studi velic al 42 project fals report rate 5 10 minim contact studi organiz factor import influenc practic particip studi practic recruit target physician ancillari staff nurs practic coordin plai central role intervent data collect communi cation project staff commit share staff accrual falter extrem unusu staff member pa sive subvert intervent anecdot evid reflect occur staff member smoke felt overburden respons success practic appear top commit strong practic offic coordin initi explor variabl recent research provid terest evid smoke cessat counsel differ provid type 43 import area futur inquiri system atic identif evalu organiz fac tor physician staff attribut affect particip recruit intervent studi tailor intervent older smoker expand address patient factor includ extent smoke relat di eas presenc neg affect effect ho pital 21 intervent studi di semin varieti set channel thousand physician train advis assist arrang follow model develop nci fund research 35 model adapt readili includ messag spe cific older smoker nci cancer inform servic 1 800 4 cancer train inform specialist provid special counsel older smok er similarli aarp fox chase cancer cen ter develop special train program benefit quit older smoker proactiv call difficult implement set distribut clear horizon guid mean provid comput base system prompt provid gener patient tailor educ materi hold great promis studi evalu smoke interven tion tailor midlif older smoker integr routin primari medic care studi support show benefit physician counsel older smoker benefit younger counterpart offic base quit smoke counsel provid ply intervent requir minim involv multipl provid cogniz organiz factor com.ibm.drl.hbcp.util true team approach con sistent commit provid staff popul ag increasingli import weav tailor approach practic int gral part prevent medic care
addict behavior vol 11 pp 443 446 1986 print usa right reserv 0306 4603 86 3.00 oo copyright 1986 pergamon journal report smoke cessat famili practic effect advic nicotin chew gum prescript andrea page david walter ronald schlegel allan univers waterloo ontario canada abstract efficaci physician anti smoke intervent 289 patient famili practic set assess design includ treatment condit physician advic physician advic offer nicotin chew gum ncg prescript advic group permit assess effect repeat test ncg group higher rate abstin follow point differ approach statist signific 3 month lo comparison ncg group reveal significantli user abstin 1 3 month follow similar pattern occur proport attempt cessat smoke reduct dose respons rela tionship gum outcom identifi long term user 20 dai 86 abstin 3 month versu 18 short term user ncg role famili practic promot short term cessat nicotin chew gum ncg recent modal intervent physician smoker ncg present physician option introduc specif phar maceut aid advic effect evalu strategi famili practic set identifi prioriti research area 5th world congress smoke health ossip klein 1983 studi examin effect ncg yield initi encourag result clinic popula tion fagerstrom 1982 jarvi 1983 gener pauciti studi primari care set hugh miller 1984 russel merrimen edward 1983 compar offer ncg gener practic advic condit treatment control twelv month abstin rate 8.8 treatment 3.9 control group achiev statist signific gum provid directli patient cost encourag result replic typic primari care condit purpos studi assess effec tive physician advic quit smoke evalu effect ncg prescrib physician smoke patient method famili practition full time practic particip studi 4 week period receptionist ask patient ag 18 65 year research support part sustain fund research award canadian colleg famili physician canada dr walter dr bryant univers waterloo social scienc human research grant fund request reprint extend version ronald schlegel depart health studi univers waterloo waterloo ontario canada n2l 3gl 443 444 andrea page al enter offic complet health statu questionnair demograph smoke exercis diet inform collect subject attach letter de scribe purpos studi request consent follow interview 3 6 month block 3 practic dai dai randomli assign group physician advic physician advic ncg prescript advic group special arrang patient appoint dai treatment effect attribut dai expect chi squar analysi involv dai week abstin complet 3 6 month follow analys prove signific nonsignific justifi ing individu unit analysi analys report research pa tient enter physician offic assign condit dai singl blind design subject awar treatment group fact evalu experiment group advic group receiv physician intervent intend con trol effect repeat test physician attent advic group receiv messag physician determin patient situat individu practition counsel style physician complianc card complet patient record treatment advic ncg group includ inform intervent offer prescript script ncg 2 mg standard manufactur patient instruct sheet 1 3 6 month telephon interview interview remain blind patient experiment group final section interview requir ncg inform subject ncg addit item ask ncg question includ inform gum usag determin length gum usag number piec chew dai week side effect perceiv help gum result discuss total 806 patient complet health statu questionnair thirti cent 312 identifi daili smoker 289 sign consent particip includ follow analysi subject refus particip reveal baselin variabl signific differ group attri tion reduc total 227 6 month follow survei origin particip sampl 68 femal 196 mean ag 32.5 year averag report number cigarett smoke dai 18.8 sd 10.3 mean smoke onset ag 18.2 year main report depend variabl measur studi includ attempt cessat 24 hour current abstin reduct daili smoke rate baselin level nonabstin subject chi squar analysi attempt treatment condit month follow ncg group significantli ol greater number subject attempt stop smoke control advic group ncg group 46.2 subject attempt cessat compar 25.0 26.3 advic advic group expect greater number subject attempt quit smoke result greater number succe appear case ncg group abstin rate 1 month 10.7 approxim high rate group tabl 1 chi squar analysi show differ signific 3 month ncg group abstin rate smoke cessat 445 tabl 1 comparison abstin rate 1 3 6 month physician intervent treatment condit time advic advic ncg 1 montha 5.9 10.7 68 93 3 month 8.9 19.2 67 78 6 month 12.0 75 aabstin defin 14 dai cigarett babstin defin 90 dai cigarett inew year occur approxim 2 month intervent season factor affect group equal reflect upward trend abstin rate group 19.2 achiev statist signific lo advic advic rate 8.9 9.9 abstin rate group similar 6 month intervent question examin daili cigarett consumpt nonabstin subject analysi varianc anova demonstr ncg group reduc mean daili consumpt 2.1 2.5 2.9 cigarett 1 3 6 month rate significantli advic advic group rate result smoke behavior measur reveal trend greater ef fectiv ncg condit differ statist signifi post hoc divis ncg group user nonus allow amin subject compli ncg treatment 33.3 32 subject report gum subject group offer prescript nicotin gum user vari 1 80 dai nonus ncg group compar advic advic group subject recogn analys pertain select compliant group ncg user tempt cessat rate ncg user 89.3 month follow compar 27.7 nonus 25.0 control 26.3 advic group repres highli signific differ oool subject pli receiv intend intervent substan tial effect term attempt cessat ncg user higher abstin rate follow point differ ncg user group statist signific month 21.4 abstin 05 3 month 34.5 abstin ol follow trend signific persist 6 month 17.2 abstin pattern effect demonstr anova cigarett reduc tion unsuccess quitter ncg reduc daili consumpt 7.2 cigarett ool 6.4 cigarett ol 4.6 cigarett 1 3 6 month duncan multipl rang test mean 1 3 month ncg user statist group i. ncg nonus advic advic 446 andrea page al attempt made address longer term impact ncg rela tion longer term gum ncg group divid short long term gum user subject gum 20 dai 25 defin short term user versu gum greater 20 dai 7 classifi long term user chi squar analys 85.7 abstin rate 3 month long term ncg user significantli oool short term user 18.2 nonus 10.2 abstin rate long term gum user drop 42.9 6 month statist signific 07 group analys complet order determin relationship variabl measur baselin length ncg intent quit physi cian assist 32 07 ag smoke onset 40 03 spous exsmok nonsmok 34 05 frequenc exer cise spous 34 06 posit relat margin person continu ncg longer period time character start smoke social port environ e.g physician spous conduc smoke cessat par ticular health promot gener i. spousal level physic activ advic offer ncg show promis valuabl intervent strategi famili physician effect ncg statist signific short term futur research address complianc ncg supplement ncg offer behavior intervent pertain mainten
prevent medicin 32 182 190 2001 doi 10.1006 pmed 2000.0791 onlin http www.idealibrary.com effect minim contact smoke cessat program dutch gener practition random control trial1 marcel pieters ph.d 2 erwin seydel ph.d hein devri ph.d aart mudd ph.d gerjo kok ph.d univers twent depart commun studi netherland press maastricht univers depart health maastricht univers psycho publish onlin background recent dutch gener prac tition contribut tobacco control due factor lack feasibl intervent program adult smoker minim contact behavior intervent stage chang concept effect ness test random trial method twenti gener practition practic assist train appli pro gram 530 smoke patient enrol ran domli assign intervent usual treatment condit analysi treatment effect perform logist regress analysi back ward stepwis procedur confound effect base line differ elimin result 12 month follow report absti nenc rate includ nonrespond smoker differ significantli intervent subject control 13.4 7.3 point preval odd ratio 1.51 0.05 analysi consecut abstin defin abstin 6 12 month fol low show 8.2 intervent group compar 3.1 control sustain absti nenc 6 month odd ratio 3.04 0.001 conclus result effect smok ing cessat program dutch gener prac tice shown feasibl 1 studi support grant dutch cancer societi nederlands kankerbestrijd koningin wilhelmina fond 2 reprint request address univers twent depart commun studi p.o box 217 7500 ae ensched netherland mail m.e.pieters wmw utwente.nl 18 ucat promot netherland logi faculti netherland januari 5 2001 outcom gener consist recent interna tional literatur 2001 american health foundat academ kei word smoke smoke cessat prevent physician gener practition rct tobacco health educ introduct netherland preval adult smoke behavior declin rapidli 60 1958 37 late 1980 1991 smok ing preval stabil 35 1,2 conclus drawn remark chang addict habit place rela tive short period 25 year time effect innov wai promot nonsmok ing appar netherland smoke cessat promot number wai vari local organ group program wide varieti mass media public iti rang method lack individu ori ent interperson counsel method exist esp cialli suitabl larg scale reason gener practition quali fi fill gap gener practition gp potenti influenti intermedi smoke cessa tion credibl sourc inform 3,4 regular interperson contact virtu alli smoker estim netherland annual 70 smoker visit gp 5 numer studi shown theori base behavior intervent gener practition effect 4,6 13 success program includ varieti element motiv counsel 2 0091 7435 01 35.00 copyright 2001 american health foundat academ press right reproduct form reserv smoke cessat provid behavior chang techniqu set quit ting date follow contact written materi nicotin replac therapi nrt 7,14,15 match program smoker readi quit 16 1990 dutch gp contribut reduct tobacco consumpt smoke regist systemat fre quenci antismok counsel gener practic low limit straightforward advic quit smoke relat contact reason 17 21 literatur sev eral factor respons situat gp experienc increas work load lack financi reimburs prevent health educ activ carri gp perceiv lack skill successfulli influenc patient lifestyl behavior lack materi support patient doctor appar barrier gp adopt smoke cessat intervent similar countri review richmond anderson 22 earli 1990 minim contact behavior tervent develop dutch gener practic account barri er preliminari analysi delphi panel gp reveal prevail attitud routin dutch gp call short pro gram characterist easili applic i. complex intervent consum gp consult time flexibl i. adapt gp person style requir major offic organiza tion enabl task divis involv practic sistant studi report effect interven tion program smoke behavior random popula tion smoke patient visit gp compar usual treatment random trial prior feasibl studi show intervent program detail sec tion suffici met aforement criteria 23 result trial recent led dissemin intervent program nation scale 24 present estim 28 dutch gener practition appli program routin 25 gener practic 183 method sampl approxim 250 gener practic region approach directli written invit au thoriz region gp associ fol low present local meet gp 25 practic respond 18 enrol studi involv 22 gp 19 practic assist sampl practic appear match dutch popu lation gener practic relev variabl ag smoke behavior size patient popul degre urban 23,26 particip ceiv 2 skill train detail intro duction research goal procedur skill train particip receiv introduct smoke behavior nicotin addict stage chang theori behavior chang process train rele vant counsel techniqu skill role plai ing divid gp offic assist group form main part train final prepar need implement intervent pro gram everydai offic routin discuss offic assist addition train appli random inform consent pro cedur 2 week practic test period patient recruit period incorpor analys procedur con cern studi measur interven tion evalu 2 week research telephon interview offic assist gp interview partici pant practic separ answer verifi practic receiv instruc tion adjust adher practic month period monitor short telephon interview interview question theme address research procedur patient correctli form recruit random carri correctli pretest questionnair complet fore alloc patient start interven tion protocol program fidel extent treatment carri complet correctli patient intervent group assess sev eral detail question element treatment protocol analysi reveal gen eral gp compli intervent protocol signific deviat concern effort gp put counsel motiv patient minor gp consid wast time major briefli motiv group patient accord origin protocol gp encourag 184 pieter follow protocol al low freedom point long conclud consult unmotiv patient explicit advic quit smoke patient ag 18 70 year recruit wai poster wait room invit patient particip studi smoke behavior practic assist proactiv approach pa tient wait room subsequ particip fill pretest questionnair separ page ad questionnair serv written inform consent form inform consent form col lect research staff subject receiv gen eral inform import develop wai support smoke cessat number follow measur confidenti data inform experi mental natur studi control made awar exist cessat program inform consent procedur studi design approv independ advisori committe consist regul nation associ dutch gener prac tition lhv hand complet questionnair ject assign group offic assist prestructur alloc list random place practic impli exposur control group treatment sourc bia gp ask regist consult smok ing discuss smoker alloc intervent group enabl identif control patient expos treatment section case subsequ exclud analys disadvantag random proce dure involv ethic problem gp ingli withhold patient poten tialli effect treatment relev patient suffer health problem relat tobacco gp permit case intervent control patient patient exclud analys 537 patient recruit 269 inter vention group 268 control group due mention problem 7 control subject exclud leav 530 elig subject 269 inter vention 261 control treatment control group smoker receiv usual treatment im ply receiv counsel advic smoke contact reason initi patient case al counsel limit straightforward stop smok ing advic accompani referr local municip health organ receiv motiv counsel manual offer follow care 45 17.2 control report convers smoke 12 month follow period practic assist gp gener characterist treatment tervent take averag approxim 10 min patient includ follow session task divis gp offic assist assi tant cari intak administr procedur includ hand written materi gp perform behavior counsel counsel tailor smoker motiv stage larg accord stage chang concept 16 question quit attempt think wai quit plan quit attempt frequenc think quit subject classifi low pre contempl moder contempl highli motiv prepar intervent consist element shown effect numer studi 4,6,7,10,13 15,27 30 assess level nicotin depend low high motiv stage reinforc motiv quit discuss outcom expect emphas posi tive short term outcom reinforc perceiv abil quit di cuss expect abstin difficulti high risk relaps situat suggest strategi barrier set quit date smoker readi quit reinforc manag capabl hand manual thor oughli pretest 31 advis nrt depend smoker note netherland patient receiv reimburs nrt time studi carri gum product follow meet offer smoker set quit date measur smoke behavior demograph variabl tabl 1 behavior determin tabl 2 assess valid written question nair biochem valid report absti nenc perform nicotin dependencea scale 4 2 13 5 0.73 8.4 8.5 motiv quit scale 4 2 20 5 0.82 note subject characterist patient intervent contro signific baselin differ studi group indica nicotin depend estim item adapt fager enhanc accuraci post treatment port smoke behavior abstin bogu pipe line procedur introduc 1 month follow neg outcom expect ns note effect treatment smoke statu includ nonrespond 5 481 correct baselin differ odd ratio rep probabl base line variabl recod tha higher chanc quit result 1 14.8 13.8 5 6.7 5 0.01 group socioeconom variabl smoke behavior statist ed trömscal 35,36 respond motiv give accur report awar research verifi smoke cessat gener practic 185 tabl 1 subject characterist studi group base line subject characterist intervent control differ ag year 35.8 35.6 sex femal 58.4 61.6 educ low 15.5 16.7 moder 63.6 59.9 high 20.9 23.4 smoke year smoke 18.7 18.1 ag onset 16.4 16.4 cigarett dai 10 13.3 20.4 5 4.3 5 0.04 11 24 70.0 67.9 25 16.7 14.1 questionnair 32 telephon contact random select confeder 5 20 shortlyup questionnair patient ask give tele phone number rel close friend call 1 month follow reveal discrep smoke statu report question confeder contact research team follow period expect nair report confeder tabl 2 treatment effect abstin follow 1 month 12 month consecut 6 1 12 independ variabl 95 ci 95 ci 95 ci variabl base line daili cigarett consumpt ns ns ns nicotin depend 1.19 1.0 1.3 0.016 1.31 1.1 1.5 0.000 1.39 1.2 1.7 0.001 quit motiv 1.13 1.0 1.2 0.004 ns ns social support ns ns ns efficaci ns ns ns attitud ns ns ns posit outcom expect ns ns ns neg outcom expect 1.15 1.0 1.3 0.019 1.13 1.0 1.3 0.032 ns intervent 2.56 1.8 3.8 0.000 1.51 1.1 2.1 0.009 3.04 1.7 5.6 0.000 interact term intervent 3 nicotin depend ns ns ns quit motiv ns ns ns attitud ns ns ns posit outcom expect ns ns ns ns 1.21 1.1 1.4 0.009 nt smoker backward stepwis logist regress analysi ort 95 confid interv 95 ci high score predict theori 186 pieter abstin follow assess vari abl smoke statu smoke cigarett averag daili cigarett consump tion 0;1 5;6 10;11 15;16 20;21 25 25 spondent consist answer i. smoke cig arett smoke cigarett daili count nonsmok addit point preval measur follow up rigor measur consecut ab stinenc construct combin smoke statu follow up consecut abstin defin nonsmok 6 month 12 month follow point suc cess quit impli abstin 26 week start 6 month intervent criterion chanc miss delai effect sleeper effect 33 intervent reduc analys analysi treatment effect 1 12 month point preval consecut abstin perform logist regress analysi backward stepwis procedur 34 confound effect baselin differ elimin addition confirm effect intervent sustain abstin univari analysi varianc form compar averag number week smoke free final follow confound effect differenti exposur extern sourc antismok messag test x2 analysi result subject respons rate 1 month follow 74 5 393 follow 530 patient approach result respons rate 6 month follow 64 5 339 78 5 416 12 month respons rate studi group compar follow questionnair 1 month significantli control patient respond 81 compar 67 intervent group x2 5 8.5 df 5 1 0.01 rel increas respons rate 12 month result addit effort reach nonrespon dent 95 initi nonrespond con tact telephon interview assess patient smoke statu urg return questionnair attrit diminish consider approxim half patient compli major group smok ing statu assess telephon main characterist total popul shown tabl 1 socio demograph variabl al vari significantli intervent control group regard sex ag educ level popul consid repres averag dutch visitor gener practic 23 account contact reason reg istrat gp appear 19.1 contact patient alloc intervent group health problem present relat tobacco respect smoke behavior studi group vari significantli variabl baselin patient intervent group smoke cigarett dai motiv quit bia confound effect intervent test variabl smoke behavior follow univari analysi vari anc number cigarett smoke daili signifi cantli smoke statu 1 5 6.2 0.05 6 5 6.4 0.05 12 month 5 13.6 0.001 high daili tobacco consumpt baselin lower chanc quit long term confound variabl motiv quit smoke smoke statu 1 month 5 12.5 0.001 high motiv quit baselin correl higher chanc short term quit interact effect variabl found analys confound correct effect practic regist outcom 269 intervent show major intervent success 175 patient 65.5 agre set quit date nicotin chew gum time product nicotin replac therapi prescrib gp 25 patient intervent group 9.4 analys intervent group test con tribut nicotin replac intervent effect signific due low statist power small differ gum user nonus follow care provid 37 interven tion subject 13.8 12 month tervent 1 month follow abstin report 27.6 5 50 respond intervent group 4.9 5 10 control respond includ ing nonrespond smoker rate esti mate conserv 18.6 3.8 6 month report cessat rate respond intervent patient decreas 19.5 quit rate control respond increas 6.3 includ nonrespond amount 11.9 versu 3.8 12 month report quit rate intervent group order manual accompani smoke cessat group drop 17.6 5 36 contrast control respond quit rate increas 9 5 19 inclus nonrespond result quit rate 13.4 7.3 consecut abstin criterion 15.3 respond intervent group consid success quitter compar 5.3 control respond includ miss subject smoker success rate half high 8.2 5 22 versu 3.1 5 8 tabl 2 show quit rate intervent group significantli higher control group 1 month odd ratio 2.56 12 month follow odd ratio 1.51 rigor consecut abstin criterion odd ratio 3.04 control baselin differ addit treatment effect baselin variabl independ smoke cessat low level nicotin depen denc baselin appear contribut higher chanc quit sustain abstin likewis perceiv fewer con quit i. neg outcom expect predict abstin 1 12 month high motiva tion quit baselin higher chanc quit 1 month follow interact term found signific patient intervent group neg outcom expect baselin higher chanc achiev consecut abstin intent treat approach aforement logist regress analys replic incorporat ing control exclud ini tial analys exposur interven tion produc ident outcom subject appear miss valu baselin variabl includ regress model note half follow year contrast expect declin proport quitter intervent modal consider increas observ control group larg number control patient undertook quit attempt year earli quitter intervent group normal pattern relaps place case expect intervent group nonsmok 12 month maintain abstin longer period test assumpt mean number smoke free week current quit attempt compar 12 month quitter studi group 5 53 appear nonsmok inter vention group point sustain abstin 29 week nonsmok control group report 17 week nonsmok averag gener practic 187 result univari signific varianc 5 4.3 0.05 control quit rate 12 month high comparison literatur report 6,7,15 addit analys perform que tionnair subject ask contact doctor follow year reveal 18 control patient 8.6 report discuss smoke gp specif 4 11 control patient quit smoke 6 month report discuss smoke gp preced 6 month natur contact retriev import extern influenc occur time experi nationwid mass media stop smoke campaign 37 start shortli follow campaign includ weekli broadcast prime time televis show televi sion quit session exposur cam paign messag sourc inform roughli assess 6 month control patient expos stop smoke activ x2 5 11.9 df 5 1 0.001 stop smoke leaflet x2 5 8.3 df 5 1 0.01 differ exist 12 month x2 5 5.3 df 5 1 0.05 respond control televis patient report abstin 12 month differ found specif campaign element activ 12 month discuss result studi effect easili applic smoke cessat intervent dutch gener practition doctor cooper offic assist shown minut persuad larg proport smoke patient undertak quit tempt signific find underlin fact studi popul consist larg repres sampl smoker visit gp wide rang reason unrel smoke nrt small minor intervent subject gener outcom suggest generaliz approach primari care physician base cessat intervent standard intern literatur 13 signific short term impact appear conserv estim 15 net gain quit rate 1 month program effect long term proport patient abstin 12 month roughli doubl inter vention program applic pro gram tripl chanc patient reach 188 pieter sustain abstin estim measur con secut nonsmok 6 12 month follow abstin rate consist compar intern research odd ratio point preval quit 12 month 1.51 fall rang report recent cochran meta analysi odd ratio 1.69 confid interv 1.45 1.98 odd ratio reach consecut absti nenc studi 3.04 suggest strong long term effect 15 absolut gain consecu tive abstin rate 5.1 encourag compar averag 2.5 gain report cochran meta analysi caution need interpret result absenc biochem verifica tion nonsmok caus overestim point preval estim argu report smoke behavior fairli accu rate 38 valid cessat report increas follow point 39 small overreport bia quit import evid report decept rate vari systemat control intervent group 7,32,40 45 studi appli wai en hanc accuraci report e.g bogu pipelin procedur check consist multi ple measur measur point preval quit ting behavior studi differ past 7 dai measur consid standard 14 collater verif abstin report combin altern measur result overestim cessat rate studi assum bia affect cessat rate studi group equal compromis strength treatment effect report studi show high quit rate 12 month control patient 7.3 account probabl hawthorn effect report 6,7,15 increas 3.8 quitter 1 6 month 7.3 12 month observ explan obser vation explor studi inter action control group element inter vention consid special attent paid extern influenc differenti impact control group avoid interact treatment control subject gp instruct provid usual care smoke consult nonint vention patient regist case identifi control patient expos intervent element exclud analys data give al reason member control group expos intervent consequ choic random subject randomiz ing gp control treatment condit proce dure chosen reason provid mediat effect control studi effici patient unit analysi limit number practic requir analys influenc stop smoke me sage occur time follow control group frequent extens expos extern inform sourc observ particip studi made control subject suscept inform smoke cessat intervent subject point receiv inform act e.g quit inclin exposur control extern influenc inter vention contribut conserv estim treatment effect fourth select bia due irregular random procedur express pretreat differ studi group number cigarett smoke daili level motiv quit confound ing variabl opposit affect differ cessat rate control regr sion model expect limit valid result report margin studi data gather smoke patient approach refus particip studi inform refus rate result select subject quit limit generaliz result studi gener popul real life averag dutch gp meet resist gp involv experi mental set expect order enhanc program effect relaps prevent word gp program pai attent mainten nonsmok achiev quit attempt amount follow care provid quitter studi minim 14 return follow worthwhil fact state intens cessat counsel strong dose respons relat effect 13 intensifi intervent addit pand element bear mind practic limit gp offic telephon support coun sele offic assist time consum extens gp adopt smoke cessat nrt deserv promin role program note 9 patient inter vention group made nrt studi result research past decad nrt regular part type smoke cessat intervent 13,14 promot nrt current reluct dutch gp advis treatment cost depend smoker quit lessen
intern journal epidemiolog intern epidemiolog associ 1985 vol 14 3 print great britain evalu gener practition smoke intervent programm robyn richmond ian webster richmond school commun medicin faculti medicin univers south wale kensington sydnei nsw 2033 australia webster evalu gener practition smoke intervent programm internationa journal epidemiolog 1985 14 396 401 studi made smoke cessat programm man gener practic determin efficaci gener practition counsel follow treatment group 33 patient abstain month compar 3 control group report smoke statu verifi blood test patient success attend visit compar fulli attend 48 6 continu smoker significantli higher blood concentr cotinin thiocyan carboxyhaemoglobin cigarett smoke month entri 30 decreas state cigarett consumpt suggest smoker reduc number cigarett smoke compens increas inhal gener practition australia wide intervent programm similar success major impact smoke habit million smoker australia 16 65 year ag total cost visit fraction medic treatment cigarett relat diseas chang preval rate cigarett smoker australia 1974 approxim 40 male 31 femal smoke cigarett trend male smoke declin whilst femal smoke increas 2 gener practition uniqu opportun counsel patient smoke medic con sultat approxim million peopl australia ag 16 65 year repr sent 80 ag group visit gener practition annual 3 studi countri involv gener prac tition particip smoke intervent pro gramm result long term abstent rate 3 23 4 7 nicotin chew gum paper present result gener prac tition intervent programm smoke cessat subject method assign group studi conduct man gener practic sydnei patient randomli alloc treatment group 100 smoker control school commun medicin faculti medicin univers south wale kensington sydnei nsw 2033 australia group 100 smoker control group compris 200 smoker smoker smoke patent visit gp specif medic complaint smoker randomli alloc treatment control group altern dai 15 smoker refus particip studi random exclud analysi smoke group approxi mate equal number particip ag group 16 20 year group greater represent control group sixti cent smoker 74 smoker 30 year ag male treatment group 55 group 34 44 marri peopl group 49 group 69 orc 67 major particip lower middl class daniel grade occup 8 compris bu driver offic clerk shop assist hairdress discrimin function test perform examin differ sampl characterist smoker group major differ import implic interpret result variabl enter analysi ag sex social class marit statu educ cigarett consumpt durat smoke analysi reveal group 396 nivers olleg ondon januari 13 2017 http ije.oxfordjournals.org ow nload http ije.oxfordjournals.org evalu gener practition smoke intervent programm 397 significantli male marri peopl group variabl predict respons intervent programm dif ferenc sampl characterist entri regard significantli affect outcom result studi particip treatment group made visit control group made visit doctor month period patient exclud ag 16 65 year inadequ understand english languag intent leav sydnei month attend visit entri includ result continu smoker visit attend month visit categor dropout irrespect attend previou visit reason drop visit includ sudden job transfer domest problem ill loss interest continu programm blood lung function test measur lung function blood concentra tion tobacco product made initi visit particip complet month particip lung function test subject group repeat blood test blood analys plasma cotinin ga chromatographi 12.5 mx0.2 i.d 9 plasma thiocyan colorimetr assai ion exchang chromato graphi amerlyst a21 resin 10 carboxyhaemo globin autom spectrophotometr method oximet lung function test limit spirometri perform wedg spiro meter vitalograph measur ment fev fvc intervent techniqu treatment group patient attend doctor time studi period week month visit particip blood spirometri perform weight measur detail questionnair administ questionnair provid inform relat medic smoke histori level depend cigarett motiva tion quit anxieti control patient dai diari record pattern smoke week week patient ask reduc cigarett consumpt visit emphasi patient educ attempt chang attitud smoke smoke behaviour achiev provid particip result blood lung function test abnorm test result discuss term risk develop cigarett relat diseas displai 12 photograph illustr exampl lung heart diseas increas incid smoker shown patient gener practition step step guid present handbook assist administ intervent programm 12 gener practition gave patient manual smoker 13 written author present inform smoke habit person exercis strategi maintain abstin visit patient strongli advis quit smoke gradual reduc doctor discuss withdraw symptom weight manag stitut altern smoke counter argument ration smoke suggest social support network week month visit gener practition continu support encourag abstent patient discuss problem success overcom smoke urg month visit weight measur blood lung function test repeat result compar initi valu follow questionnair determin psychosoci health particip percept smoke cessat programm administ cost visit time studi medic benefit schedul common wealth depart health 13.20 standard consult 5 25 minut surgeri 24.50 long consult 25 45 minut visit gener practition standard long consult depend patient present complaint visit long consult patient educ fourth sixth visit standard consulta tion total cost 100.00 fraction cost incur medic treatment cigarett relat diseas cost assai cotinin carboxyhaemoglobin thiocyan 6.00 person studi wider applic programm gener practic salivari cotinin measur result forti treatment group abstin treatment visit 36 remain abstin week 30 month 33 month tabl 1 smoke statu month valid blood cotinin cot carboxyhaemoglobin cohb thiocyan scn level subject nivers olleg ondon januari 13 2017 http ije.oxfordjournals.org ow nload http ije.oxfordjournals.org 398 intern journal epidemiolog tabl 1 number subject treatment group smoke categori follow visit smoke statu treatment group abstain reduc smoker 1 49 origin consumpt continu smoke 50 100 origin consumpt attend dropout total 5 week 36 7 49 100 follow visit 3 month 30 5 7 58 100 6 month 33 6 36 25 100 report verifi famili fellow worker smoker report abstin blood concentr similar smoker question confirm continu smoke statu enabl reclassifi smoker con tinu smoker reduc half initi cigarett consumpt month remaind smoke 50 100 initi consumpt dropout tabl 1 appar larg increas number smoker month compar week month due attend earlier visit subsequ respons written telephon request attend treatment visit import outcom 31 64 48 subject attend treatment visit abstin month contrast 36 6 attend visit 3 control smoker stop smoke month compar 33 treat group twelv subject smoke group regular smoke occasion cigarett period dropout rate programm month 25 treatment group 23 control group smoker 9 control group smoker sixti cent particip consid part doctor role peopl quit smoke attitud express smoker group tabl 2 particip 70 satisfi chanc success outcom increas programm administ doctor abstain continu smoker group similar expect doctor involv health main reason major particip treatment group 81 wish stop smoke major abstain group consid discuss spirometri 88 blood test result 85 import motiv factor decis stop smoke continu smoker convinc 50 43 respec tive join programm main factor perceiv particip caus relaps quit smoke attempt habit 33 domest stress 31 work stress 17 factor remain major cite end month relaps smoker continu smoker group consum signifi cantli fewer cigarett 17 13 s.d dai month entri 26 16 s.d dai 0.0001 tabl 3 week programm cigarett consumpt continu smoker reduc 67 month reduct 30 relationship number cigarett smoke dai ratio scn cot cohb cigarett smoke entri tabl 2 number particip studi group consid doctor import slop smoke process doctor job total treatment 56 42 98 group 57 47 67 43 33 53 100 control group smoker 57 37 94 61 51 71 39 29 49 100 100 43 143 control group smoker smoker 70 45 62.5 77.5 30 ii 22.5 37.5 100 56 80 69.5 90.5 20 9.5 30.5 100 note particip answer question 95 confid limit nivers olleg ondon januari 13 2017 http ije.oxfordjournals.org ow nload http ije.oxfordjournals.org evalu gener practition smoke intervent programm tabl 3 mean scn cotinin cohb level cigarett smoke initi month follow attend treatment group subject 399 smoke statu treatment group 1st visit abstain month continu smoker month month visit continu smoker scn cigarett cotinin cigarett mean thiocyan mean cig dai mean cotinin mean cig dai mean cigarett intak 24 26 17 scn cig 4.55 3.7 5.4 5.67 4.6 6.7 11.04 8.06 14.02 cohb cigarett 95 confid cotinin cig 68.78 50.4 87.2 95.37 77.8 112.9 120.85 86.57 155.13 cohb cig 0.17 0.14 0.21 0.23 0.20 0.27 0.36 0.24 0.48 mean carboxyhaemoglobin mean limit ig dai month continu smoker treatment group shown tabl 3 mean report number cigarett smoke dai declin month scn cot cohb concentr similar entri concentr cigarett consum significantli increas blood con centrat cigarett smoke control group chang appreci studi period discuss result show gener practition strateg posit successfulli counsel patient smoke cessat intervent programm compar effect 33 abstin treatment group compar 3 control group report verifi blood test result compar favour gp base pro gramm 4 7 largest studi russel al uk 4'5 estim gener prac tition achiev simpl advic stop smoke russel programm patient counsel minut routin consult page prescript pamphlet quit sampl particip report outcom verifi nicotin concentr saliva modest abstin rate 5 4 low intens programm outcom encourag show smoker respond advic doctor maintain abstin week 12 month studi patient longer counsel session entri provid educ pamphlet evalu month 6 twenti cent complet follow appoint month entri stop smoke compar 12 group receiv similar counsel entri follow report valid interpret result qualifi misreport smoke statu abstain found rang 5 25 14 16 6 studi research committe british thorac societi found 10 smoker attend hospit chest clinic quit respons verbal advic 16 evid cigarett relat diseas kei motiv factor studi note health main reason quit studi hunt bespalec investig relaps 84 smok ing modif studi found 25 20 abstain end treatment remain abstin month relaps occur 90 dai treatment 17 import find studi abstin rate maintain week month suggest follow support main reason relaps studi domest work stress specif intern extern cue habit studi found report reduc cigarett consumpt poor index reduc exposur tobacco product result tendenc continu smoker regul tobacco exposur constant level whilst continu smoker treatment group nivers olleg ondon januari 13 2017 http ije.oxfordjournals.org ow nload http ije.oxfordjournals.org 400 intern journal epidemiolog report 30 decreas cigarett consumpt month blood concentr scn cot cohb chang blood concentr cigarett consum increas find impli continu smoker report intak month reduct cigarett consumpt tobacco product accompani increas inhal whilst explan oper evid studi smoker titrat intak cigarett product appar reduct cigarett intak 18 22 experi shown smoker switch high low nicotin cigarett increas number cigarett smoke smoke cigarett inhal deepli 19 22 implic report consumpt cigarett accur method assess success smoke cessat pro gramm 22'23 importantli advic quit complet gradual reduc cigarett consumpt educ patient danger smoke perform spirometri draw blood regular follow practic compat gener practition accept role inform blood lung function test result correla tion cardiovascular respiratori diseas regard import motiv factor patient decis quit smoke particip consid part doctor role peopl quit smoke chanc success outcom increas doctor encourag educ reinforc abstain smoke patient attend visit significantli success fulli attend shown gener prac tition success control hypertens diseas reduc death attribut stroke 25 achiev mainten drug therapi dietari educ respect salt calori intak reinforc regular follow visit gener practition counsel advers effect smoke health maintain abstin regular follow visit prevent cigarett relat diseas half smoker attend treatment visit studi abstin month indicat ing time effort expend smoker gp week reward incorpor intervent programm daili medic practic effect approach achiev commun wide smoke cessat gener practition australia wide techniqu smoke patient compris patient popul 33 absten tion rate major impact million smoker australia 16 65 year ag organ workshop teach gener prac tition programm smoke intervent acknowledg studi fund nation heart founda tion australia grate par ticip doctor 400 patient major studi 54 subject pilot trial depart biochemistri royal princ alfr hospit sydnei analysi blood sampl author acknowledg support advic dr david richmond secretari assist ms nola johnson
journal epidemiolog commun health 1978 32 275 281 randomis control trial effect middl ag men advic stop smoke geoffrei rose hamilton depart ofmed statist andepidemiolog london school ofhygien tropic medicin summari randomis control trial smoke cessat report 1445 male smoker ag 40 59 high risk cardiorespiratori diseas 714 men intervent group recal seri person interview doctor year 51 intervent group report smoke cigarett report duction compar normal care group men intervent group show declin preval sputum product dyspnoea ventilatori function improv rate declin significantli slow evid effect blood pressur level electrocardiograph find year sick absenc year mortal follow continu averag 7 9 year 98 13 7 intervent group di compar 94 12 9 normal care group 95 confid limit mortal rang 2 63 favour intervent 4 37 favour normal care power trial reduc smoke cessat normal care group conclud smoke cessat middl ag men improv symptom progress chronic bronchiti revers risk cigarett smoker life estim observ studi averag life span cigarett smoker shorter smoker thought necessarili reduct direct consequ smoke royal colleg physician 1977 easi establish extent harm effect smoke lung cardiovascular system arrest revers smoke abandon year result observ studi encourag doll hill 1964 hammond 1966 kahn 1966 show men stop smoke 10 year previous mortal rate higher contemporari smoke interpret observ studi straightforward men stop smoke repres sampl smoker tend higher social class smoke inhal favour cigarett lower yield tar nicotin favour health characterist comparison mortal group bias observ studi estim extent advers effect smoke revers characterist relat initi decis stop influenc chanc sustain success stop longer period properli compar healthili constitut group stop recent order provid unbias estim consequ smoke cessat middl ag men set randomis control trial 1968 encourag late professor reid secondari aim studi develop evalu effect mean persuad middl ag men stop smoke choic sampl size estim previou studi gener post offic gpo mortal sick ness retir rate men ag rang govern employ rate doubl trial plan restrict high risk group valu rel mor taliti risk smoker continu smoker obtain studi doll hill 1964 hammond 1966 estim expect annual number death retir coronari heart diseas 275 276 bronchiti lung cancer high risk gpo men continu smoke 50 stop smoke assump tion made time sick retir rate reduc pro rata provid estim rate expect group trial half intervent group advic acquir rate smoker earlier observ studi sampl size calcul suffici provid 80 chanc detect differ enc exist 95 confid year period follow number 2n approxim 1500 high risk smoker event actual power trial expect civil servant prove substanti lower smoke rate mortal rate gpo men bronchiti prove imposs suffici complet data sick retir major end point trial death loss power partli offset extend period follow subject geoffrei rose hamilton 2 score rank smoker estim risk major ill death cardiorespiratori diseas distribut score test govern depart ment examin earli studi cut point determin 10i214 score 10 men 32 smoker exceed expect yield requir number 1500 high risk smoker defin elig trial 3 record elig men review exclud receiv medic care heart blood pressur found sever hypertens diastol pressur 3 115 hg diabet major concomit diseas earli trial men intervent group suffer tem porari mental ill shortli stop smoke subsequ exclud trial men take psychotrop drug record previou psychiatr inpati treatment 4 delai year occur initi screen examin recal subject interview connect trial men exclud trial particip drawn men interv ha undergon cardiorespiratori screen examin smoke ation whitehal studi male civil servant london method preval find remain year mortal result studi smoker enter report reid al 1974 reid al 1976 trandomli rose al 1977a 1977b survei includ normal care 16 016 men ag 40 59 year selec tion made cigarett smoker special manag high cardiorespiratori risk 1 risk score calcul man men smoke cigarett dai score report scri base modif multivari tition explaini linear discrimin function coeffici calcul normal practic truett al 1967 predict coronari hand men heart diseas chd framingham men invol ag 30 62 complet cardiorespiratori risk year score calcul return 0 07 ag year 0 01 plasma cholesterol mg 100 ml 0 02 systol blood pressur hg 0 01 blood sugar mg 100 ml hour 50 glucos load 1 5 histori angina 0 5 histori myocardi infarct 2 0 histori intennitt claudic 3 0 major ecg find minnesota code 1 1 2 1o0 minor ecg find minnesota code 1 3 4.1 4 5 1 3 7 1 1v5 histori phlegm month winter 0 5 histori exert dyspnoea 2 0 fev1.0 2 2 1v0 fevi 2 2 3 0 di move stop 1445 high risk elig cigarett ith trial alloc intervent group 714 men group 731 men follow normal care group full een result gener prac ing leav action awar iv trial year ooint studi ask examin research randomis control trial examin popular men benefici check men intervent group receiv letter invit appoint order discuss result previou exam inat default visit last 15 minut doctor explain man reason recal discoveri diseas evid case smoke repres averag risk futur health ask detail risk fit promin risk life doctor spent minut explain scientif evid stop smoke bring benefit illustr chart overhead projector emphasi evid posit benefit stop hazard con tinu smoke briefli review practic stop hard want stop final minut interview stress import choic confront subject urg give care thought told fact situat decis receiv appoint return week time decis reach want stop pleas give advic contact men role expert offer inform interest figur author threat end interview gave man sign copi booklet prepar specif studi visit half men fact complet stop smoke cigarett men stop year 80 immedi interview remaind answer question rais discuss techniqu problem stop aim complet cessat cigarett smoke worth attempt evid time discourag wish smoke cigar pipe end visit man smoke record card complet daili post back week receiv person repli 15 minut interview place 10 week month point interven record card person letter examin men intervent group year year point carri dai staff normal care men mortal follow particip achiev oper nation health servic central regist intervent men entri trial reckon occur dai recal visit normal care men date recal group sick absenc data year follow record sick retir insuffici complet analysi result composit group expect select procedur men trial distinguish tabl 1 increas preval product cough indic earli myocardi ischaemia averag level main coronari risk factor reduc ventilatori function group balanc tabl 1 comparison group base result initi screen examin intervent normal care 714 731 mean ag year 52 8 53.0 grade administr profession execut 60 1 62 6 cleric 39 9 37.4 cigarett dai mean 19 1 18 9 morn phlegm winter 53.5 587 mean fev1.0 1 2 67 2 61 angina 8.6 10 2 ecg suspect ischaemia 8 6 10 4 mean bodi weight kg 74 6 74 6 mean systol bp hg 140 2 140 6 mean plasma cholesterol mg ioml 2153 210 4 mean blood glucos mg 100 ml 74 1 74 2 smoke habit men attend year year examin complet administ questionnair procedur group ident unabl attend return complet questionnair post part follow purpos made imperson standardis avoid pressur intervent subject deni underestimatecontinu smoke tabl 2 show result respons rate higher normal care group men year contact move london dead pessimist assumpt respond intervent men continu smoke basi estim 277 tabl 2 smoke statu year year year intervent normal care intervent normal care complet questionnair 577 81 626 86 456 64 511 70 smoker 2271363 56 75 1621 260 74 100pipe ciga 1361 191 98 261 cigarett reduc 50 83 23 42 17 reduct nil 50 131 528 150 394 mean cigarett dai attend 4 8 16d6 662 15 7 smoke data incomplet minimum success rate relat total number men advis 714 men 363 51 year 260 36 year question smoke cigarett altern assumpt attend rep resent sampl basi success rate respond questionnair 63 year 58 year correct lie extrem cigarett smoke pipe cigar smoke cigarett claim reduc number mean cigarett consumpt intervent group 191 dai initi survei ap parent fell 4 8 dai year trial 6'2 dai year normal care group 75 men 10 total cigarett year 100 men 14 year reflect partli normal pattern smoker partli strong systemat trend civil servant abandon cigarett smoke assum questionnair correctli complet result tabl 2 suggest cigarett smoke intervent group year reduc 54 level normal care group base proport particip report complet cessat base estim mean cigarett consumpt reduct level 29 normal care group estim year 74 39 direct attempt made valid men statement avoid show disapprov condemn continu smoker strong impress men report complet cessat speak truth undoubtedli smoke heavili exagg at size reduct year examin provid indirect support men statement preval phlegm relat state cigarett consumpt rate unchang continu heavi smoker reduc stop complet intermedi claim reduc quantiti differ enc similar observ normal care men report smoke chang subject kind pressur person characterist assess entri trial found increas probabl smoke cessat smoke 20 cigarett dai report inhal filter tip previou attempt stop marit statu marri profession execut employ grade smoke cessat year frequent highest lowest grade neurotic eysenck person inventori inter vention subject divid randomli counsel success rate year significantli time prepar report 1978 undertak postal survei group differ smoke habit repli receiv 60 survivor group intervent group 215 men 59 respond report smoke cigarett earlier success maintain level normal care group unprompt strong drift smoke 156 41 re pondent cigarett averag cigarett consumpt report intervent group respond 7 9 dai 66 normal care group 12 0 dai symptom examin find men stop smoke pleas rep resent achiev long con sider desir phase initi irrit claim felt fitter enjoi food commonli report benefit clearer nose 36 278 geoffrei rose hamilton tabl 3 find year year year intervent normal care intervent normal care complet questionnair 577 626 456 511 examin 552 614 400 478 morn phlegm 31 0 49 2 30 9 46 6 dyspnoea 9 9 12 9 10 9 13 6 fev1 chang 1 0 075 0 115 0 056 0 037 fvc chang 1 0 132 0 153 0 001 0 002 weight chang kg 2 05 0 28 0 29 0 18 systolicbpchang mmhg 055 1i59 3 62 0 39 diastol bp chang hg 1i02 0o50 060 0 30 plasma cholesterol mg 100 ml 37 3 28 0 angina ofeffort 7 8 9 1 9 2 10 8 chest pain discomfort 17 0 22 2 21 6 30 3 ecg myocardi infarct 0 9 1.1 0 5 0 2 valu chang mean subject base line year figur origin screen examin 15 24 month previous year year result tabl 3 summaris find group year trial report preval morn phlegm reduc half intervent group examin suggest larger benefit stop smoke exert dyspnoea reduc ventilatori function measur remain fact tendenc recov ventilatori function intervent group men stop smoke year period rate declin fev1.0 fvc 14 slower intervent group differ aros year statisti calli highli signific weight gain 2 kg intervent group year reflect larger gain men men show chang initi pre trial survei smoker averag lower blood pressur smoker smoke withdraw lead clear rise compar normal group chang laboratori procedur affect compar absolut level plasma cholesterol trial affect rel posit group appear smoke cessat produc slight fall preval rate angina specif chest pain discomfort lower intervent group differ signific electrocardiograph find unremark sick absenc govern depart concern provid sick absenc record year follow 88 men tabl 4 small excess intervent group dai lost attri bute bronchiti balanc defici cardiovascular contrast analysi report men part year examin suggest 30 reduct intervent group discrep repres select attend bias report emphasis import independ unbias check tabl 4 sick absenc mean number ofdai year trial intervent normal care record 627 88 643 88 bronchiti 1 43 0 94 cardiovascular diseas 1.19 1 97 12 1 12 5 report 9 1 13 1 mortal mortal follow period averag 7 9 year rang 10 year result shown tabl 5 intervent group 98 men 13.7 di normal care group 94 men l2 9 95 confid interv differ 2 63 favour inter vention group 4 37 favour noimal care group result mortal equal neg analys group durat follow ag diseas statu entri trial tabl 5 mortal death rate 100 man year year 1 7 year 7 year total intervent 714 8 1 13 70 1 73 20 2 28 98 1 74 normal care 731 5 0 69 68 1 63 21 2 46 94 1 63 estim specif rate unstabl merit report small number fulli report due randomis control trial 279 geoffrei rose hamilton discuss trial undertaken order avoid bias built observ studi compar men choos stop smoke choos continu anti smoke advic form part control multifactori trial prevent coronari heart diseas trial report studi plan aim isol specif effect anti smoke advic outcom cardiorespiratori diseas method randomis control trial excel avoid bia sadli lack statist power true prevent trial end point fewer adher advic poor fortun success rate previous record 50 intervent group report complet cessat cigarett smoke year studi similar method gener practic set porter mccullough 1972 obtain 37 success smoke withdraw clinic deal select volunt gener alli obtain year success rate 20 attribut success work health consciou recept group civil servant method encourag result relat previous report power trial dilut respons intervent group year trial reduc smoke normal care group optimist estim assum questionnair respons accur sampl respond follow inquiri repres cigarett load intervent group year trial reduc normal care level end follow period third true differ cigarett smoke group substanti inter vention group continu smoke cigar pipe spite limit conclus consequ anti smoke intervent 1 condit method medic intervent consider alter cigarett smoke habit middl ag men grate doctor interest 2 men earli chronic bronchiti stop smoke cigarett preval chronic sputum product declin report lessen dyspnoea airwai obstruct assess fev1.0 improv subsequ rate declin slow 3 weight gain problem minor 4 blood pressur level show clear chang preval angina possibl reduc electrocardiograph find unalt 5 sick absenc rate evid reduc 6 disappointingli find evid reduct total mortal interpret unexpectedli neg find essenti rememb trial limit statist power result consist real benefit longev fail detect inadequ number larg report observ studi advic benefit 95 confid level involv save 2 3 men live 7 9 year follow period 50 stop smoke benefit larger conclus cessat cigarett smoke middl ag men improv product cough slow progress poten tialli disabl airwai obstruct rever ibil risk smoker life overestim previou observ studi civil servic medic depart late sir daniel thompson subject gave conscienti support miss jane pateman srn miss linda colwel department head collabor friend late professor donald reid cost studi met gener grant tobacco research council reprint professor geoffrei rose london school hygien tropic medicin keppel street london wcie 7ht
journal epidemiolog commun health 1992 46 75 77 randomis control trial anti smoke advic final 20 year result geoffrei rose linda colwel abstract studi object aim measur experiment effect middl ag men stop smoke design studi randomis control trial set subject subject 1445 male smoker initi ag 40 59 year select whitehal studi survei 16 016 civil servant basi high risk cardiorespiratori diseas main result 20 year 620 death 231 coronari heart diseas 96 case lung cancer 159 cancer compar intervent normal care group total mortal 7 lower fatal coronari heart diseas 13 lower lung cancer death registr 11 lower excess rate cancer report previous persist decad trial conclus result consist observ studi impli smoke cessat middl ag men substanti improv chanc avoid lung cancer fatal heart attack estim trial 100 men stop smoke 10 consequ aliv 20 year randomis singl factor trial measur health outcom anti smoke advic remain report result 10 year 2 particip 20 year present final report depart epidemiolog popul scienc london school hygien tropic medicin keppel street london wc1e 7ht unit kingdom rose colwel correspond miss colwel accept public decemb 1991 method detail publish previous 1968 70 examin 16 016 male civil servant ag 40 59 year whitehal studi result select 1445 cigarett smoker highest cardiorespiratori risk score randomli alloc intervent 714 men normal care 731 men intervent group receiv individu advic relat smoke health declar stop smoke receiv support 12 month averag visit year trial 630o 8400 respond intervent group longer smoke cigarett men smoke pipe cigar 10 year trial report net reduct cigarett smoke 5300 cigarett daili end ofth 10 year net reduct fallen 30 due reduc consumpt normal care group reflect gener declin smoke civil servant due late amend notif figur 10 year result differ slightli previou report 2 10 year offollow mortal intervent group 1800 lower normal care group coronari heart diseas 2300 lower lung cancer death lung cancer higher 28 13 death excess show site specif deriv equal unexpectedli high rate intervent men low rate receiv normal care intervent men unrel smoke cessat interpret uncertain thought due chanc 2 follow ofal men continu good offic nation health servic central registri base death certif cancer registr attempt made establish current smoke habit survivor retir hard trace result tabl present life tabl probabl main outcom stage trial compar decad advantag intervent group fatal coronari heart diseas decad continu smaller 9 180 lung cancer death registr advantag maintain 12 0 8 lung cancer death registr concern decad remark excess intervent group persist fact incid decad 800 lower intervent group take result tabl durat trial intervent group experienc 1300 reduct 9500 ci 33 13 0 fatal coronari heart diseas 100 reduct 95 0 ci 41 380 lung cancer 1600 excess 950o ci 15 59 lung cancer 70 reduct 95 ci 20 900 total mortal tabl ii present find separ ag group 40 49 50 59 year entri 60 69 70 79 year survivor older men modest advantag intervent group 1000 coronari geoffrei rose linda colwel heart diseas total mortal consist earlier period follow younger men hand earlier period larg excess coronari heart diseas death intervent group give advantag 5 00 lung cancer advantag modest increas persist excess lung cancer prevent mortal benefit younger ag group result analys entri characterist tabl iii small number multipl subgroup hypothes find view caution fatal coronari heart diseas advantag intervent group unrel plasma cholesterol level 1304 men ischaem type electrocardiograph reduct coronari heart diseas 1300 compar excess 2 men presenc exert dyspnoea entri 158 men larg advantag intervent total mortal 30 00 fatal coronari heart diseas 460 discuss trial larger observ studi influenc select bia smoker random sampl smoker weight hand health consciou socioeconom advantag individu health prospect averag hand stop smoke ill health net effect opposit bias uncertain resolut call randomis trial factor reduc power trial includ wide confid interv reflect insuffici number dilut effect incomplet complianc intervent group progress reduct smoke control men 10 year small differ smoke rate group make allow effect result gener consist expect deriv observ studi impli smoke cessat middl ag men substanti improv chanc avoid lung cancer fatal heart attack 20 year 3 0 survivor intervent control group estim true effect smoke figur doubl order fact half stop smoke increas smoke cessat control men estim 100 men stop smoke 10 consequ aliv 20 year previou report2 conclud exhaust analysi data tabl life tabl probabl death death cancer registr normal care nc intervent group ag valu percentag number event bracket tabl ii rate ratio total number event interventionl normal care ag entri 40 49 year 50 59 year year coronari lung cancer includ cancer includ trial group heart diseas registr registr death 0 10 nc 8 9 62 3 6 25 4 0 27 17 8 130 7 3 49 3 3 22 6 7 45 17 2 123 nc 0 82 0 92 1 68 0 97 10 20 nc 11 0 64 5 1 26 8 3 45 26 6 194 100 56 4 5 23 7 6 42 24 2 173 nc 091 088 092 091 0 20 nc 19 9 126 8 8 51 12 3 72 44 4 324 17 3 105 7 8 45 14 3 87 41 5 296 nc 0 87 0 89 1 16 0 93 rate ratio event lung cancer cancer year ag coronari includ includ trial year heart diseas registr registr death 0 10 40 49 1 72 17 0 91 4 2 19 17 1 75 47 10 20 0 20 50 59 40 49 50 59 40 49 50 59 0 76 92 0 95 26 0 96 85 1 18 43 087 177 0 94 43 0 23 5 1 01 44 0 43 9 0 98 87 1 56 55 2 28 10 0 83 77 2 22 27 1 04 132 0 92 234 0 87 59 0 94 321 1 18 106 0 93 555 tabl iii 20 year mortal ratio intervent normal care coronari heart diseas find initi examin initi characterist ischaem ecg plasma cholesterol mmol litr dyspnoea fev1.0 group 137 1304 6 5 1154 36 5 288 158 1287 1 02 0 87 0 86 088 0 54 0 93 2 2 386 1 17 2 2 1058 0 79 mortal ratio coronari heart diseas 1 12 0 92 0 93 0 97 0 70 0.99 1 18 0 85 76 randomis control trial anti smoke advic differ lung cancer mortal incid trial due chanc effect intervent 10 year follow excess incid persist reason chang tent conclus addit subgroup find excess coronari heart diseas death younger men intervent group earli year trial number larg prior hypothesi examin multipl subgroup reduc strength ofth find similar earli excess note unit kingdom section larg european trial ofmultifactori prevent ofcoronari heart diseas 3 anti smoke advic major intervent smoke cessat gener popul prevent measur gradual process experiment studi trial civil servant intervent group stop smoke stage 800 smoke cigarett visit physiolog adapt chronic advers exposur abrupt withdraw induc period destabilis analog effect withdraw alcohol addict drug extend follow morbid trial rememb benefit smoke cessat confin mortal report note earli trial intervent group experienc reduc preval nasal obstruct commonest benefit product cough dyspnoea lost ventilatori function recov subsequ rate declin slower control men 1 rose hamilton pj randomis control trial effect middl ag men advic stop smoke epidemiol commun health 1978 32 275 81 2 rose hamilton pj colwel shiplei mj randomis control trial anti smoke advic 10 year result epidemiol commun health 1982 36 102 8 3 rose tunstal pedo hd heller rf uk heart diseas prevent project incid mortal result lancet 1983 1062 6 77
british medic journal 28 juli 1979 231 paper origin effect gener practition advic smoke russel wilson taylor baker british medicalj7ourn 1979 2 231 235 summari conclus week 2138 cigarett smoker attend surgeri 28 gener practition gp group practic london alloc group group 1 compris intervent control group 2 compris questionnair control group 3 advis gp stop smoke group 4 advis stop smoke leaflet warn adequ data follow obtain 1884 patient 88 month 1567 73 year motiv intent stop smoke evid immedi advic peopl stop smoke advic achiev motiv peopl stop smoke increas success rate effect strongest month evid month enhanc leaflet warn follow addit effect longer term lower relaps rate stop enhanc leaflet warn follow proport stop smoke month smoke year 0 3 1 6 3 3 5 1 group 0 001 result suggest gp adopt simpl routin expect 25 long term success yearli gp uk particip yield exce half million smoker year target match increas present 50 special withdraw clinic 10 000 introduct potenti highli effect approach smoke great britain remain virtual untri collect effort 20 000 gener practition gp 90 adult visit gp year 2the averag number attend exceed year 3 smoker attend smoker 4 gp 18 million 20 million smoker britain year mass media confront smoker similar scale face face commun persuas educ major anti smoke campaign effect role special withdraw clinic limit size problem attract smoker attend difficult case highli depend chanc success gp hand kind smoker includ succe necessarili intens treatment support potenti gp work collect immens genuin success rate 5 nation higher success rate obtain intens method specialis clinic chest clinic 6 7 screen clinic 8 hospit 0 straightforward firm advic stop smoke accompani treatment support effect protract treatment special withdraw clinic attempt gp persuad patient stop smoke vari result 14 clear averag long term success rate simpl firm advic stop smoke routin gp patient smoke cigarett decid assess print instruct leaflet patient increas complianc 5 6 subject method doctor twenti 29 doctor group practic london part remain doctor smoker declin doctor particip serv locum 28 addict research unit institut psychiatri london se5 8af russel mrcp mrcpsych senior lectur wilson bsc research worker taylor bsc statistician baker frcgp gener practition 232 gp cigarett smoker pipe cigar smoker 11 smoker smoke practic south woodford practic 1 ilford practic 2 kentish town practic 3 hern hill practic 4 peckham practic 5 select conveni nearbi provid spread citi outer suburb practic 2 3 site newer type local author health centr tradit practic set gp practic approach refus particip doctor patient repres gener practic london patient sampl compris cigarett smoker ag 16 attend surgeri doctor week 29 april 26 1974 attend sole collect prescript nurs exclud screen question cigarett smoker put elig patient includ trial patient uncertain includ stop smoke week subject exclud cigarett dai total 2138 elig cigarett smoker attend surgeri week 1884 88 provid adequ data follow month 1567 73 0 gave adequ data follow year loss month due administr procedur difficulti attribut patient sampl repres suggest respons rate 88 third addit loss year due address advic control procedur patient assign group group 1 serv control simpli name follow group 2 complet questionnair control questionnair effect advis stop smoke group 3 advis stop smoke group 4 advis stop smoke inform leaflet warn advic stop smoke simpl firm doctor style minut routin consult page inform leaflet give smoke issu depart health social secur distribut famili doctor 1968 ideal leaflet warn follow separ meant substanti enlarg studi assign group random alloc consecut patient group arriv busi surgeri feasibl elig patient assign dai attend attend dai alloc group group base total intak elig patient dai week sundai dai week sequenc week balanc group interview post practic select elig patient administ questionnair ensur correct procedur special procedur adopt doctor follow protocol correctli error case doctor thought uneth give withhold advic note questionnair questionnair anonym identifi numer code pilot test gener practic satisfactori smoke questionnair contain 31 question concern smoke attitud habit simpl design complet 15 20 minut wait doctor inform obtain limit british medic journal 28 juli 1979 includ social class patient group 2 4 attitud stabil check repeat question smoke questionnair complet patient group 2 4 immedi doctor question reflect attitud smoke motiv stop smoke doctor advic reproduc pilot studi satisfactori 08 09 month follow sheet post patient group month index attend head smoke stabil questionnair contain question current smoke attempt stop smoke make chang smoke month attend stamp address envelop photocopi letter doctor express interest peopl chang smoke habit reason question nair group 1 refer made questionnair advic doctor attend surgeri month remind dai case week respond follow sheet cover letter stamp return envelop repeat week record deliveri respond visit interview year follow sheet headeti smoke survei final follow post patient group 1975 year index attend contain question current smoke desir give smoke attempt stop chang smoke habit past week question month follow sheet postal follow procedur similar month biochem valid valid report outcom obtain 23 patient measur nicotin concentr saliva 7 fourteen claim stop smoke salivari nicotin valu consist give decept rate 700 select patient satisfactori decept rate 7 reliabl result signific differ practic measur outcom month year attitud motiv intent immedi receiv advic doctor result practic pool present tabl attitud motiv intent immedi consult doctor group 1 questionnair exclud disson smokerst result express mean score respons point point scale signific group 2 group 3 group 4 oiffeec 543 51 1 520 group percentag 68 7 71 6 68 5 ns disson 67 1 73 7 73 9 0 02 smoker chang 1 6 2 1 5 4 0 01 wantt stop 2 90 3 04 2 88 ns smokin 2 91 3314 3 08 0 02smoke chang 0 01 0 101 0 211 0 005 wanttog 3 05 3 04 2 96 nswant 3 12 3 02 3 04 ns smoke chang 006 0 02 0 08 ns worryabout 1.91 2 03 2 02 nsworri 1 85 2 03 2 07 0 002 smoke chang 005 0 01 005 005 confid 3 00 2 92 3 06 ns abil give 2 92 2 95 3 00 ns smoke chang 0 09 0 03 0 06 ns intent give 2 08 2 18 2 16 ns upsmok 2 03 2 35 2 41 0o0001up smoke chang 0 05 0 171j 0 24j1 0 0001 result base peopl answer question con sultat averag 93 940 9200 group 2 3 4 ta disson smoker stop easili signific group 0 05 0 01 ip 0 001 british medic journal 28 juli 1979 effect attitud motiv intent tabl show attitud smoke motiv give smoke confid abil give smoke week intent give smoke complet week immedi doctor expect signific differ group measur doctor signific doctor group 2 receiv advic simpl advic group 3 produc slight increas desir stop smoke increas intent give smoke complet week effect significantli enhanc leaflet doctor warn follow group 4 effect worri smoke minim signific decreas desir continu smoke increas confid abil stop advic accompani leaflet warn follow variabl sensit advic enhanc leaflet warn follow intent stop smoke week doctor 10 01 12'4 9 60 group 2 4 intend stop compar 9 4o0 19 0 17 8 significantli greater advic group group 2 0 001 test net proport month follow tabl ii iv show smoke behaviour month follow spontan smoke patient group 1 receiv advic questionnair 10 2o0 stop smoke month 3 0 claim stop success rate group 1 patient stop 286 thirti point cent attempt chang stop 19 0 reduc cigarett consumpt averag reduct claim 4 5 daili questionnair effect simpli complet smoke questionnair appar influenc smoke habit month outcom group 2 month similar group 1 tabl ii iv effect simpl advic compar control group 1 2 combin patient simpl advic leaflet warn follow group 3 show slight increas proport stop tabl ii manag stop smoke tabl iii differ signific tendenc patient group 3 show higher rate attempt tabl ui result month follow percentag smoker report attempt modifi smoke habit group 1 group 2 group 3 group 4 signific 411 519 471 483 differ attempt 10 2 9 2 13 2 17 2 179 stop 0 001 attempt 31 4 28 7 33 8 31 5 1'1 2 1 ns chang attempt 58 4 62 1 53 0 51 3 14 7 0 005 attempt chang 85 reduc consumpt 3 attempt chang pipe cigar 7 lower tar brand tabl ili result month follow percentag smoker report chang smoke behaviour group 1 group 2 group 3 group 4 signific 401 502 453 466 differencet stop 3 0 3 0 4 6 7 5 2 1211 smoke 0 001 reduc smoke 19 0 17 3 20 3 21 5 2 9 ns chang 78 1 79 6 75 0 71 0 x2 11 2 0 02 tabl 62 patient 3 3 fewer tabl ii data achiev miss patient made compris 15 gave cigarett chang pipe cigar 25 chang lower tar brand includ chang categori tz14 z2 test linear trend 233 tabl iv result month follow success rate attempt stop smoke signific group 1 group 2 group 3 group 4 differ 42 48 62 83 attempt stop succeed 12 28 6 15 31 3 21 33 9 35 42 2 xl 2 7 ns 2 2test linear trend smoke simpl advic significantli increas success rate attempt stop tabl iv effect advic leaflet warn follow compar control group 1 2 combin group 4 patient show significantli higher rate stop smoke x2 17 8 df 1 0 001 tabl ii patient show greater tendenc stop smoke x2 14'3 df 1 0'01 tabl iii due higher rate stop slightli higher success rate 422 0 group 4 compar 30oo0 group 1 2 combin signific x2 2 4 df 1 tabl iv slightli patient reduc consumpt group 4 group 1 2 tabl iii differ signific differ group 3 4 month follow signific year follow 1884 patient adequ data follow month 1567 gave adequ data follow year loss due address loss vari consider practic 1500 9q6 290 100 16q90o 1180o practic 1 5 z2 56'4 df 4 o001 signific differ practic measur outcom year loss similar group 173 16'81 16 80o 15 5 2 0.6 ns fact patient lost follow differ significantli initi cigarett consumpt respons month suggest loss substanti bia result year long term success effect advic long term success highli signific tabl compar 0 30o tabl result year follow percentag subject smoke smoke group 1 group 2 group 3 group 4 signific 340 430 389 408 differencet smoke 89 7 86 0 83 3 80 9 xl 12 2 smoke 10 3 14 0 16 7 19 1j 0 001 stop month 03 1 6 33 5 1 xl 245 0.001 stop month 8 8 11 2 12 9 13 0 z'l 3 5 ns stop 1 2 1 2 0 5 1.0 subject stop month relaps stop includ stop month tz1 z2 test linear trend control group 1 5.100 patient group 4 stop smoke month index attend smoke year effect stop month follow smoke year stop time month follow tabl 225 patient smoke year 100 44 0 stop month effect advic appar month significantli smoker advic group stop month month follow 5 6 group 1 2 compar 11 1 group 3 4 x2 495 0'05 effect persist ovei month 5 7 7'8 4'4 x2 1 ns effect relaps rate 83 patient stop smoke 234 month 68 8 10 19 31 group 1 4 year 7 3 6 10 patient group relaps smoke fisher exact test tail group 3 4 differ group 1 10o level suggest advic gp reduc tendenc relaps cigarett consumpt tabl vi averag cigarett consumpt group reflect combin result reduc stop smoke decreas significantli greater group 3 4 differ extrem small small signific decreas consumpt month year follow up group light smoker stop smoke initi con sumption stop month averag 11 0 cigarett daili compar 16 7 daili achiev chang 0001 tabl vi cigarett consumpt initi month year express mean number cigarett daili group 1 group 2 group 3 group 4 signific 340 430 389 408 differencet initi 16 2 16 6 15 7 ns month follow 16 6 15 2 15 4 13 9 0 005 year follow 15.1 142 13 7 13 1 002 initi cigarett consumpt group 1 initi questionnair averag initi consumpt group 16 2 cigarett daili tsignific differ group test analys varianc linear trend comparison individu doctor pronounc variat result achiev doctor success rate month follow term proport patient advic group 3 4 stop smoke rang nil 11 number patient doctor small differ reach signific analysi relat success rate individu doctor variabl smoke habit techniqu give advic report separ discuss effect advic result show gp advic stop smoke effect enhanc leaflet warn follow attitud motiv intent stop smoke evid immedi advic month follow 750 patient group 4 stop smoke compar 3 0o0 control suggest 45 0 patient respond stop smoke effect appar ensu month significantli patient advic group give smoke advic significantli reduc relaps rate month year follow up term long term success 5 1 11 smoker group 4 stop smoke month smoke year compar 030 control true long term success rate 50 effect advic specif motiv intent stop increas proport patient stop confid abil give smoke increas success rate similarli attempt reduc smoke success increas advic rate chang low tar cigarett pipe cigar british medic journal 28 juli 1979 extrem low leaflet contain tip stop smoke expect enhanc success rate reduc relaps rate manag stop case confid abil stop score immedi leaflet read expect increas confid affect confid rate differ mean daili cigarett consumpt consist smoke behaviour extrem small partli advic effect rate reduc smoke light smoker heavi smoker tend stop effect mean consumpt group main effect advic peopl stop smoke achiev short term motiv stop increas success rate addit effect long term lower relaps rate stop give leaflet warn follow enhanc short term effect ad effect longer term implic result group 4 advis stop smoke inform leaflet warn 21 patient claim stop smoke month year smoke extrem stringenc assum reason make exclud trace fail provid adequ data smoke time year follow base 21 success year 530 patient origin alloc group 4 long term success rate base cigarett smoker attempt stop 4 low compar 20 25 long term success rate report withdraw clinic gp cigarett smoker routin work withdraw clinic difficulti attract client comparison 21 year success group 4 result advis week intak smoker 28 gp subtract averag 4 spontan long term success week group 1 2 2 decept rate 12 70 net yield smoker 15 week 28 gp equival fortnight 25 year gp result suggest 20 000 gp britain adopt simpl measur total yield exce half million smoker year possibl similar result obtain ensu year target match set 10 000 specialis smoke withdraw clinics.l8 experi leaflet record booklet avail time consum aid nicotin chew gum expect prescrib drug result improv hope find encourag individu gp share prompt health author ensur aid inform readili freeli gp gener practition ordin partner allow conduct studi practic dr crabb dr elisabeth horder dr newland dr burton dr gregg dr lefevr allow pilot work practic iyer statist jean crutch secretari work interview provid social commun plan research london ni david smith help design questionnair colleagu eiser british medic journal 28 juli 1979 235 jarvi raw sutton gave advic analysi write financi support provid depart ment health social secur medic research council
british medic journal volum 287 10 decemb 1983 clinic topic effect nicotin chew gum adjunct gener practition advic smoke russel merriman stapleton taylor abstract studi design offer prescript nicotin chew gum enhanc efficaci gener practition advic stop smoke sampl 1938 cigarett smoker attend surgeri 34 gener practition group practic assign week attend balanc design group intervent control advic booklet advic booklet offer nicotin gum follow month year result show clear advantag offer nicotin gum 0001 correct refus fail chemic valid switch cigarett pipe cigar pro portion abstin month ab tinent year 3 9 41 8 8 group percentag base cigarett smoker attend surgeri includ stop gum group gum 47 effect offer prescript gum motiv smoker stop increas success rate reduc relaps rate stop select subgroup 8 box 105 piec gum achiev success rate 24 feasibl effect gener prac tition includ offer nicotin gum instruct part minim intervent routin cigarett smoker gener practition adopt routin similar success expect achiev 35 40 long term smoker year save live ofabout 10 ofthem ifrepl gener practition countri yield smoker million year introduct recognis intens treatment method stop peopl smoke success limit addict research unit institut psychiatri london se5 russel frcp frcpsych senior lectur merriman phd senior psychologist stapleton msc statistician england gross associ market research survei 21 buckingham palac road london sw1 taylor ba manag director correspond dr russel larg number smoker led consider cost efficaci minim intervent approach rational strategi yield long term smoker greater therapist counsellor advis spend time smoker focus intens effort method low prove success rate achiev minim effort readili applic larg number smoker term public health time consum intens method higher success rate respect impress power role gener practition exercis intervent smoke everydai work gener prac tition 17 million cigarett smoker britain 95 british popul attend doctor surgeri year 75 attend year 2 3 previou studi show advic smoke gener practition style leaflet warn follow achiev success rate 5 1 abstin year compar 0 3 intervent control 4 small effect highli signific statist reason state potenti creat smoker occur intens method recent report shown nicotin chew gum substanti increas success rate obtain smoker clinic 5 6 effect intens support adjunct gener practition advic present studi design offer prescript nicotin gum enhanc efficaci routin advic gener practition reassess advic offer nicotin gum subject method doctor thirti doctor group practic part locum assist practic south london eleph castl east dulwich gipsi hill larg town kent maidston tonbridg tunbridg well practic select list previou survei 7 claim throughput 400 patient week 15 practic approach particip part practic difficulti partner sick outright refus patient target sampl compris cigarett smoker ag 16 attend surgeri doctor 4 27 novemb 1980 answer screen question cigarett smoker includ studi patient 1782 british medic journal volum 287 10 decemb 1983 unsur includ stop smoke week subject answer exclud ifthei smoke dai total 2176 elig cigarett smoker attend surgeri recruit period 70 unwil unabl time fill initi questionnair exclud 2106 96.8 recruit studi 16 di 152 move unknown address year follow exclud leav 1938 89 follow tabl analysi base 1938 patient 327 provid adequ data month year follow count continu smoker averag ag 1938 patient 40 5 year 57 women proport social class ii iiin iiim iv 11 26 33 31 averag cigarett consumpt 17 5 dai variabl differ significantli group tabl detail number cigarett smoker recruit group month year group 1 group 2 group 3 advic advic advic total control booklet nicorett elig 659 761 756 2176 recruit 637 740 729 2106 di follow 4 9 3 16 move unknown address 49 56 47 152 1 year follow 584 675 679 1938 respond 4 month 1 year 486 568 557 1611 respond 98 107 122 327 balanc order assign subject group week attend significantli fewer subject group 1 9 3 df 2 0 01 occur larger number recruit week week practic assign undertak advic procedur week happen chanc smallest practic reason heavier recruit week subject reattend count remain group determin attend number recruit week 2 3 920 78 week 1 figur assign group patient assign group random alloc consecut patient group involv intervent doctor feasibl patient assign group week ofattend attend week practic assign group order group week balanc practic practic group week studi boost number patient studi run extra dai dai group similarli balanc order group base total intak elig adult cigarett smoker attend practic week dai patient reattend period studi remain alloc group determin attend intervent control procedur procedur group group 1 control receiv intervent doctor group 2 advis stop smoke cigarett advic simpl firm doctor style minut routin consult doctor hand patient give smoke booklet warn invit return want booklet produc jointli ash action smoke health health educ council distribut gener practition britain group 3 receiv procedur group 2 addit offer prescript nicotin chew gum nicorett 2 mg contraind offer accept doctor gave instruct gum8 manufactur booklet written instruct gum nation health servic prescript suppli studi free charg obtain present prescript practic receptionist 1783 interview post practic identifi elig patient ascertain social class administ questionnair ensur correct procedur slip paper subject fill doctor return interview schedul procedur abandon individu case ethic clinic reason group 3 subject doctor slip offer nicotin gum accept declin patient case offer reason doctor stuck colour disc patient record signifi group procedur reattend year follow questionnair follow initi smoke questionnair fill subject wait room doctor addit address contain 17 item concern smoke habit motiva tion intent stop confid give cigarett pilot test patient complet 10 minut month year follow questionnair ident consist singl sheet head smoke survei inquir current smoke habit attempt give cigarett detail nicotin gum post patient photocopi cover letter doctor practic notepap cover letter group express interest patient smoke cigarett freepost return envelop address doctor practic enclos month follow remind respond week week respond remind record deliveri respond visit home interview procedur year follow respond mail visit interview simpli count continu smoker biochem valid third claim cigarett month year check measur expir air carbon monoxid 9 level greater 7 ppm ambient air level attribut smoke measur made health visitor attach practic call patient home purpos result studi design offer prescript nicotin gum enhanc effect gener practition advic stop smoke test effect advic offer gum effect advic test comparison group 1 2 effect nicotin gum comparison group 2 3 data practic tabl ii result month follow percentag cigarett smoker report attempt success give cigarett group 1 group 2 group 3 signific 584 675 679 group differ give 36 6 46 1 61 1 78 5 0 001 gave cigarett januari 2 9 2 9 4 6 4 6 9 4 9 5 26 7 0 001 jan feb 4 3 4 4 4 3 4 6 6 2 6 9 x2 4 5 ns mar com.ibm.drl.hbcp.inforetrieval.apr 2 2 2 4 4 0 4 4 3 5 4 2 4 1 ns month unknown 0 9 1 2 1 0 0 3 ns total gave 10 3 14 1 20 2 24 9 0 001 percentag base sampl respond class continu smoker give percentag parenthes calcul base progress adjust exclus stop previou period month cessat unknown percentag show cessat rate period valu base appear control sampl group 1 tendenc smoker give year evid effect tax increas 10 march 1981 increas averag price cigarett 18 mail month follow questionnair 16 march 1784 pool report alter result analys glim statist packag 10 tabl ii show short term outcom month tabl iii show long term result year spontan cessat rate spontan cessat formal intervent shown result control group 1 long term cessat rate group 6 tabl iii compris report month follow smoke report year smoke tabl ii iii show spontan cessat frequent year time 18 increas price cigarett budget march effect spontan cessat tabl uii result year follow percentag cigarett smoker report give cigarett month follow smoke year group 1 group 2 group 3 signific 584 675 679 group differ smoke month year 6 0 6 4 11 9 x2 18 5 0 001 smoke month smoke year 7 4 8 2 4 4 5 2 4 3 5 4 x2 53 ns total smoke year 13 4 10 8 16 2 x2 8 5 0 02 data base questionnair month year follow respond count continu smoker percentag parenthes explain tabl ii effect advic advic procedur appli group 2 subject statist signific effect month follow compar group 1 group 2 patient give x2 115 0001 stop smoke month x2 4 2 0 05 effect long term abstin repres report abstin month follow year follow statist signific 6 0 644 group 1 2 x2 0 8 tabl iii effect nicotin chew gum effect offer avail nicotin chew gum reflect comparison group 2 3 result tabl ii iii show patient group 3 give smoke x2 30 9 0 001 month follow x2 8 9 0 005 smoke year follow x2 12 8 0 001 effect gum greatest januari week intervent longer evid term smoker give fourth month onward intervent motiv smoker stop offer avail gum increas success rate long term success rate smoke month year follow stop 13 8 19 5 group 2 3 x2 4 1 0 05 effect gum lower relaps rate stop smoke month follow proport relaps smoke month year follow 54 7 40 9 group 2 3 x2 43 005 greater efficaci group 3 intervent achiev fact result base subject 53 gum complex relat initi cigarett consumpt gum success rate present report heavier smoker tend gum heavi gum higher success rate select subgroup 8 group 3 box gum 105 piec long term success rate 34 6 24 correct fail valid noteworthi success occur heavier smoker averag british medic journal volum 287 10 decemb 1983 initi consumpt 23 3 cigarett dai compar 12 0 13 0 dai success group 2 1 12 1 dai remain success group 3 adjust long term success rate claim cigarett month year estim averag 7.4 smoke pipe cigar 22 fail biochem valid proport group fail valid 19 29 20 group 1 3 x2 3 0 ns factor adjust doctor decis clinic ethic reason follow case procedur patient group patient group 1 2 report receiv nicotin gum proport correct procedur 10 4 15 4 1620o group 1 3 x2 10 3 0 01 long term success rate smoke month year adjust exclud correct procedur correct estim averag fail valid smoke pipe cigar adjust made assum correct factor absolut estim success rate group 3900 4 1 8 8 x2 14 6 0 001 discuss effect nicotin gum result show clear increas success rate advic gener practition stop smoke accom pani offer treatment nicotin chew gum patient offer gum give smoke week abstin follow month year effect gum motiv patient give smoke increas success rate reduc relaps rate stop month emphasis result base cigarett smoker doctor wish stop respond year follow count continu smoker higher success rate group offer nicotin gum achiev fact result base subject 53 gum make claim base data report extent observ efficaci nicotin gum attribut pharmacolog factor studi design purpos includ placebo control concern instanc gum effect set natur effect drug gum doubt placebo effect firm evid clinic base placebo control trial 5 6 nicotin absorpt studi pharmaco logic evid reviewed8 gum placebo effect advic failur gener practition intervent gum group 2 achiev short term effect contrast find earlier studi 4 addit glanc rate spontan cessat appear higher previou studi number reason differ studi includ short term follow period month month point follow year effect requir analysi subject report emphasis direct comparison cessat rate british medic journal volum 287 10 decemb 1983 1785 studi mislead criterion success short term long term follow base period short term follow implic result previou studi effect gener practition advic smoke 4 calcul advic routin smoker yield averag 25 long term smoker year 28 gener practi tioner studi similar calcul offer nicotin chew gum adjunct advic stop smoke carri routin produc net yield spontan cessat rate intervent control averag 38 smoker doctor year 34 doctor present studi statist analys probabl refer practic kent london atyp exclus singlehand practic assum gener practition achiev similar result collect effort produc million smoker year royal colleg physician 2 5 4 10 cigarett smoker die smoke mean doctor choos practis prevent save live 10 patient year gener practition part studi thorough schedul procedur midst usual consult patient grate gener practition act coordin practic dr curson dr dr edward dr england dr mann dr ritchi dr donaldson allow pilot questionnair surgeri rosemari shankster coordin interview work jean howard secretari colleagu colin taylor martin jarvi robert west gave advic financi support provid medic research council ab leo research foundat sweden
brie phy ic ian ini ia ted quit smoke strateg i cl inica oncolog set ing tria coordin eastern cooperat ve oncolog group robert schnoll bin zhang montserrat rue jame krook wayn spear alfr marcu paul engstrom purpos tobacco cancer patient creas risk relaps diminish treatment efficaci worsen qualiti life patient smoke diagnosi continu smoke patient regular contact oncologist efficaci physician base smoke cessat treatment evalu method cancer patient 432 randomli sign usual care nation institut health nih physician base smoke intervent primari 7 dai point preval abstin 6 12 month studi entri result 6 month follow signifi differ quit rate usual care 11.9 intervent 14.4 group signifi differ usual care 13.6 inter vention 13.3 group 12 month follow patient quit smoke 6 month head neck lung cancer began smoke ag 16 report baselin cessat guid treatment 6 month show greater baselin desir quit patient quit smoke 12 month smoke 15 fewer cigarett dai head neck lung cancer group cessat program show greater baselin desir quit final greater adher physician nih model physician smoke treat ment patient intervent versu usual care group conclus train physician provid smok ing cessat treatment cancer patient enhanc physician adher clinic practic guidelin physi cian smoke cessat intervent fail yield signific gain long term quit rate cancer patient clin oncol 21 355 365 2003 american societi clinic oncolog rang advers health consequ tobacco usear document wide acknowledg gener awar import wai continu tobacco cancer patient compro mise patient health studi cancer patient show continu smoke diagnosi treatment reduc sur vival time 1 3 increas risk recurr primari tumor 4 6 reduc treatment efficaci 7 exacerb prolong treatment induc complic mucos dry mouth loss tast voic impair pulmonari function wound heal tissu bone necrosi 8 12 signific increas risk neg health effect upward quarter cancer patient smoke diagnosi continu diagno si 13 19 find lend strong support integr formal smoke cessat clinic servic comprehens cancer center 20 year steadi accumul research efficaci smoke cessat intervent provid medic context 20,21 treatment approach receiv sizabl amount research attent physician base intervent 22 approach physician train deliv cessat advic assist yield absti nenc rate 10 11 22 24 effect intervent approach attribut fact hospit visit physician repres window opportun patient motiv quit smoke recept smoke cessat treatment 20,21,25 patient highli respect physician opinion recommend enter medic en counter focu health readi engag action relev improv quit smoke 26 growth physician base smoke interven tion spur number addit factor includ find 90 smoker achiev abstin formal clinic pro gram so27 observ approach treat nicotin addict reach substanti number smoker 80 smoker visit physician year 28 recent emphasi assess effect smoke treatment term impact abstin rate yield intervent multipli particip rate 29,30 physician base smoke intervent repres potent address epidem tobacco unit state light accumul data support effect physician base smoke intervent public health agenc urg physician implement smoke intervent provid treatment guidelin train manual 31 model physician base smoke treatment refer 5 devis agenc healthcar research qualiti 32 screen tobacco advis provid fox chase cancer center philadelphia pa dana farber cancer institut boston ma duluth clinic duluth mn park nicollet health servic st loui park mn amc research center denver submit april 18 2002 accept septemb 19 2002 address reprint request robert schnoll phd psychosoci behavior medicin program fox chase cancer center 510 township line cheltenham pa 19012 email ra_schnol fccc.edu 2003 american societi clinic oncolog 0732 183x 03 2102 355 20.00 355journal clinic oncolog vol 21 2 januari 15 2003 pp 355 365 doi 10.1200 jco 2003.04.122 download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv person strong quit messag assess evalu smoker readi quit assist provid cessat counsel ing pharmacotherapi guid arrang ap prais cessat progress model yield 10 11 quit rate upward 80 smoker reach treatment approach physician base smoke treatment potenti yield sizabl reduct popul rate tobacco date potenti effect model reduc continu tobacco cancer patient explor review literature33 uncov studi smoke treatment cancer patient 34 38 studi conduct small sampl fail maintain suffici intern valid 33 provid cancer patient formal cessat assist 39 cancer patient smoke remain group smoker smoke intervent adequ evalu studi examin effect 5 physician base smoke cessat intervent promot long term abstin cancer patient expect patient smoke randomli chosen receiv physician base smoke intervent show higher quit rate 6 month 12 month follow time point versu patient smoke receiv usual care addit explor sociodemograph ag sex medic cancer site stage behavior desir quit expecta tion quit factor smoke histori level nicotin addict number year smoke predict long term abstin except 13,40 suffici assess factor predict long term tobacco cancer patient analys provid import inform design smoke cessa tion intervent popul 33 final explor degre physician base intervent enhanc physician adher 5 model improv rate physician assess smoke behavior provid explan effect physician base inter vention patient quit rate method particip studi origin conduct fox chase cancer center philadelphia pa cooper decemb 1990 1991 institut member eastern cooper oncolog group ecog southwestern oncolog group cancer leukemia group particip studi tabl 1 cooper ecog assum direct studi june 1992 close june 1999 particip 19 year ag older diagnos stage ii cancer type stage iii iv breast prostat testicular cancer lymphoma ecog perform statu score 0 1 elig patient inform consent schedul return treatment site report smoke cigarett past 30 dai identifi smoker hundr thirti patient randomli assign patient drop inelig duplic registr leav final sampl 432 procedur particip physician recruit site identifi potenti elig patient standard intak evalu form elig patient studi object explain present inform consent form consent patient complet baselin assess includ evalu smoke histori behavior factor strongli relat abil quit smoke desir quit sociodemograph medic data record medic chart report random assign usual care condit physician base intervent conduct permut block dynam balanc recruit site patient randomli assign usual care arm 218 receiv standard care recruit physician ethic stand point withhold quit advic prevent patient seek cessat treatment studi patient usual care arm provid physician quit advic sought assist quit end studi patient arm smoke instruct call 1 800 4 cancer assist referr cessat program patient randomli assign physician base intervent 217 receiv quit advic assist physician visit accord nation institut health guidelin physician base smoke intervent 31 patient site tumor receiv intervent intervent physician provid 5 minut quit advic emphas benefit quit improv gener health specif health benefit cancer patient lower chanc recurr convinc patient set quit date work patient identifi quit date discuss nicotin replac therapi nrt patient provid prescript patient exhibit high nicotin depend provid patient smoke cessat guid freedom smoke famili 41 1 800 4 cancer telephon number addit assist referr cessat program assess cessat progress subsequ medic visit ecog train data coordin assist physician standard intervent ponent site patient contact telephon complet 6 month 12 month assess contain inform baselin assess question 6 month assess assess physician adher smoke cessat treatment model physician discuss patient smoke habit tabl 1 accrual institut institut patient pre ecog oversight mayo carl clinic ccop 1 1.0 va medic center syracus 4 3.9 medic center delawar 5 4.8 metro minnesota ccop 14 13.5 columbia river ccop 62 59.6 marshfield clinic 18 17.3 total 104 23.9 ecog oversight albani medic colleg 6 1.8 john hopkin univers 14 4.2 mayo clinic 96 29.0 univers pennsylvania 6 1.8 univers wisconsin 9 2.7 vermont region cancer center 12 3.6 univers florida gainesvil 21 6.3 vanderbilt univers 7 2.1 metro minnesota ccop abbott nw 155 46.8 lankenau hospit 4 1.2 washington medic center 1 0.3 total 331 76.1 abbrevi ccop commun clinic oncolog program nw northwest 356 smoke cessat cancer patient download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv measur sociodemograph data sociodemograph data absent medic chart collect patient ag sex race level educ marit statu medic data data patient diagnosi health collect medic chart patient includ cancer site time diagnosi durat diagnosi baselin assess cancer stage ecog perform statu physic symptom troubl breath pain tight chest diseas condit diabet high blood pressur heart troubl attack emphysema chronic bronchiti asthma smoke histori particip ag smoke initi averag number cigarett smoke dai past 7 dai smoke wake assess level nicotin addict household smoke number lifetim 24 hour quit attempt quit past year advis quit health care worker individu counsel group counsel nrt quit smoke past 6 month reduc amount smoke quit quit smoke guid form tobacco cigarett cigar contempl quit smoke 6 month behavior data attitudin variabl assess potenti com.ibm.drl.hbcp.predictor quit previou studi link abil quit smoke 40 likert type question rang 0 4 desir quit smoke assess quit smoke likert type question rang 0 4 neg expect quit assess problem irrit angri tens quit smoke sum score form com.ibm.drl.hbcp.predictor variabl analys higher score composit variabl repres greater desir quit greater neg expect quit smoke statu variabl serv primari outcom measur assess 7 dai point preval abstin previou studi 14 patient consid abstin report smoke 1 week interview 7 dai point preval abstin measur smoke statu reliabl valid common measur smoke statu 24 hour point preval 30 dai prolong abstin 6 month prolong absti nenc 42 nondeceas nonrespond consid smoker follow assess physician adher 5 model 6 month follow patient report physician adher physician base smoke cessat clinic guidelin 5 format assess physician discuss smoke patient suggest patient quit smoke review patient benefit quit help patient set quit date follow letter patient quit plan provid patient quit smoke materi pro vide prescript nrt statist analys outset fisher exact test jonckheer terpstra test categor order categor variabl wilcoxon rank sum statist continu variabl assess baselin differ studi arm regard sociodemograph medic behavior smoke histori data address studi object stage compar proport patient quit smoke studi arm side fisher exact test deceas patient includ analys consid particip deceas complet follow assess smoker side fisher exact test assess differ long term quit rate studi arm result stratifi sex bayesian model assess baselin com.ibm.drl.hbcp.predictor long term abstin follow includ particip miss data covari bayesian approach includ subject model miss data covari fairli high level miss data tabl 2 tabl 3 tabl 6 unknown repres miss data tabl 4 tabl 5 miss data standard approach multipl logist regress complet case data paramet estim bias precis obtain inform deceas patient includ analys consid particip nondeceas nonr sponsiv smoker univari logist regress analysi select baselin variabl includ bayesian model baselin variabl potenti com.ibm.drl.hbcp.predictor sociodemo graphic variabl ag sex marit statu educ medic variabl cancer site time diagnosi stage smoke histori variabl 11 variabl list earlier behavior variabl desir quit smoke neg expect quit treatment arm usual care versu physician base intervent noninform prior sign regress coeffici 0,106 proper imput miss valu prior distribut covari assum bernoulli distribut uniform 0,1 bug program bayesian infer gibb sampl algorithm estim coeffici 95 credibl interv 43 paramet estim mean sd 10,000 gibb sampl 95 credibl interv comput lower upper 2.5th percentil 10,000 gibb sampl build final model includ variabl side valu 25 univari analysi time variabl elimin 95 credibl interv includ null odd ratio or lower 1.5 variabl or 1.5 95 credibl interv includ null clinic signifi canc check assumpt sampl nonrespons mecha nism jointli ignor compar distribut respons variabl presenc absenc miss data covari found indic nonignor miss data valu side state final explor degre intervent affect physician adher 5 model calcul proport studi arm patient physician assist quit smoke aim primarili exploratori natur restrict analys descript analysi result descript sociodemograph medic smoke histori data sampl shown tabl 2 3 behavior data shown tabl differ condit signific differ patient characterist studi arm 05 male usual care arm physician base intervent 39 29 lower proport patient usual care arm report experienc ing heart troubl heart attack past year patient physician base intervent 3.7 11.6 variabl relat long term quit rate includ covari subsequ analys effect physician base smoke intervent long term quit rate tabl 4 top show quit rate 6 month studi arm 14 patient 3.2 deceas follow includ analysi addit 55 patient 12.7 lost follow consid smoker signific differ studi arm attrit caus death refus complet assess 6 month 13.2 patient report 357schnoll al download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv tabl 2 patient characterist treatment arm sociodemograph medic data patient characterist usual care physician base intervent number patient 217 215 432 ag median 55 55 55 rang 24 77 20 81 20 81 sex male 85 39.2 63 29.3 148 34.3 femal 132 60.8 152 70.7 284 65.7 race white 155 71.4 158 73.5 313 72.5 hispan 1 0.5 0 0.0 1 0.2 black 5 2.3 5 2.3 10 2.3 nativ american 2 0.9 1 0.5 3 0.7 0 0.0 1 0.5 1 0.2 unknown 54 24.9 50 23.3 104 24.1 level educ grade school high school 30 13.8 27 12.5 57 13.1 high school graduat ged 82 37.8 77 35.8 159 36.8 colleg technic school 68 31.3 79 36.7 147 34.0 colleg grad 30 13.8 30 14.0 60 13.9 unknown 7 3.2 2 0.9 9 2.1 marit statu marri 15 6.9 13 6.0 28 6.5 widow 19 8.8 28 13.0 47 10.9 marri 138 63.6 140 65.1 278 64.4 divorc separ 43 19.8 33 15.3 76 17.6 unknown 2 0.9 1 0.5 3 0.7 primari site cancer bladder 3 1.4 1 0.5 4 0.9 head neck 9 4.1 7 3.3 16 3.7 lung 17 7.8 12 5.6 29 6.7 188 86.6 195 90.7 383 88.7 time diagnosi 6 month 118 54.4 118 54.9 236 54.6 6 month 99 45.6 97 45.1 196 45.4 stage ii 172 79.3 171 79.5 343 79.4 iii iv 45 20.7 44 20.5 89 20.6 physic symptom diseas condit troubl breath short breath 94 43.3 88 40.9 182 42.1 112 51.6 115 53.5 227 52.6 unknown 11 5.1 12 5.6 23 5.3 frequent cough heavi chest cold 94 43.3 79 36.7 173 40.1 110 50.7 119 55.4 229 53.0 unknown 13 6.0 17 7.9 30 6.9 tire short time 93 42.9 92 42.8 185 42.8 108 49.8 109 50.7 217 50.2 unknown 16 7.3 14 6.5 30 6.9 pain tight chest 42 19.4 49 22.8 91 21.1 158 72.8 152 70.7 310 71.7 unknown 17 7.8 14 6.5 31 7.2 diabet 7 3.2 12 5.6 19 4.4 188 86.7 188 87.4 376 87.0 unknown 22 10.1 15 7.0 37 8.6 high blood pressur 44 20.3 42 19.5 86 19.9 155 71.4 159 74.0 314 72.7 unknown 18 8.3 14 6.5 32 7.4 heart troubl heart attack 8 3.7 25 11.6 33 7.6 187 86.2 172 80.0 359 83.1 unknown 22 10.1 18 8.4 40 9.3 emphysema chronic bronchiti asthma 40 18.4 43 20.0 83 19.2 157 72.4 156 72.6 313 72.5 unknown 20 9.2 16 7.4 36 8.3 incomplet data unknown equival miss data 358 smoke cessat cancer patient download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv tabl 3 patient characterist treatment arm smoke histori data patient characterist usual care physician base intervent start smoke regularli cigarett dai median 17 17 17 rang 7 40 5 43 5 43 unknown 3 0 3 past 7 dai cigarett smoke typic dai median 20 20 20 rang 0 60 0 70 0 70 unknown 18 25 43 wake smoke cigarett 15 minut 112 51.6 110 51.2 222 51.4 16 30 minut 57 26.3 53 24.7 110 25.5 30 minut 44 20.3 49 22.8 93 21.5 unknown 4 1.8 3 1.4 7 1.6 peopl household smoke smoker 120 55.3 107 49.8 227 52.5 smoker 96 44.2 105 48.8 201 46.5 unknown 1 0.5 3 1.4 4 0.9 time quit smoke stai 24 hour 27 12.4 21 9.8 48 11.1 1 3 time 136 62.7 133 61.9 269 62.3 4 6 time 31 14.3 38 17.7 69 16.0 7 time 20 9.2 23 10.7 43 10.0 unknown 3 1.4 0 0.0 3 0.7 quit stai 24 hour past year 116 53.5 122 56.7 238 55.1 99 45.6 91 42.3 190 44.0 unknown 2 0.9 2 0.9 4 0.9 health worker recommend stop smoke past year 152 70.0 168 78.1 320 74.1 60 27.6 45 20.9 105 24.3 unknown 5 2.3 2 0.9 7 1.6 quit smoke counsel program 11 5.1 13 6.0 24 5.6 155 71.4 157 73.0 312 72.2 unknown 51 23.5 45 20.9 96 22.2 group program clinic 25 11.5 37 17.2 62 14.4 144 66.4 141 65.6 285 66.0 unknown 48 22.1 37 17.2 85 19.7 nicotin gum nicotin skin patch 68 31.3 91 42.3 159 36.8 108 49.8 101 47.0 209 48.4 unknown 41 18.9 23 10.7 64 14.8 past 6 month cut back number cigarett 148 68.2 166 77.2 314 72.7 36 16.6 34 15.8 70 16.2 unknown 33 15.2 15 7.0 48 11.1 quit 97 44.7 103 47.9 200 46.3 76 35.0 69 32.1 145 33.6 unknown 44 20.3 43 20.0 87 20.1 quit smoke guid treatment 23 10.6 34 15.8 57 13.2 132 60.8 124 57.7 256 59.3 unknown 62 28.6 57 26.5 119 27.5 past month form tobacco cigarett pipe 203 93.5 205 95.3 408 94.4 7 3.2 6 2.8 13 3.0 daili 5 2.3 3 1.4 8 1.9 unknown 2 0.9 1 0.5 3 0.7 think quit 6 month 182 83.9 181 84.2 363 84.0 27 12.4 29 13.5 56 13.0 unknown 8 3.7 5 2.3 13 3.0 359schnoll al download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv quit smoke signific differ studi arm 11.9 usual care patient report abstin versu 14.4 patient physician base intervent report abstin 27 quit rate 12 month shown bottom tabl 4 23 patient 5.3 deceas follow includ analysi addit 78 patient 18.1 lost follow consid smoker signific differ studi arm attrit caus death refus complet assess 6 month 13.4 patient report quit smoke signific differ studi arm 13.6 usual care patient report abstin versu 13.3 patient physician base intervent report abstin 52 final signific differ quit rate 6 month 12 month result stratifi sex 6 month quit rate male 12.5 usual care arm 15.0 physician base intervent arm 34 12 month quit rate male 13.6 usual care arm 14.8 physician base intervent arm 46 femal 6 month quit rate 11.0 usual care arm 13.1 physician base inter vention arm 45 12 month quit rate 13.6 usual care arm 9.8 physician base intervent arm 34 examin com.ibm.drl.hbcp.predictor long term smoke cessat variabl valu 25 univari analysi 6 month follow cancer site head neck lung ag start smoke 16 year number ciga rett smoke dai 15 advis quit health care worker individu cessat counsel group cessat counsel nrt quit past 6 month quit smoke guid exhibit high level desir quit median 18 report contempl quit 6 month variabl 25 univari analysi 12 month follow cancer site head neck lung versu cancer stage ii iii iv time diagnosi 6 month 6 month marit statu marri number cigarett smoke dai 15 nicotin addict time wake smoke group cessat counsel nrt reduc amount smoke past 6 month quit smoke guid treatment past 6 month exhibit strong desir quit median 18 variabl select bayesian model tabl 5 top show result bayesian multipl regress quit smoke 6 month 418 nond ceas patient variabl significantli 6 month cessat ag smoke initi 16 year tabl 5 bayesian multipl regress model quit smoke 6 month 12 month follow up variabl se 95 ci 6 month follow 418 constant 3.475 0.383 ag start smoke 16 year 16 year 0.910 0.337 2.48 1.30 4.88 quit smoke guid 0.817 0.391 2.26 1.04 4.75 desir quit smoke 18 18 1.065 0.339 2.90 1.54 5.71 cancer site head neck lung 1.219 0.398 3.38 1.55 7.33 12 month follow 409 constant 3.487 0.403 number cigarett smoke 15 15 0.939 0.328 2.56 1.35 4.86 group cessat program 1.246 0.363 3.48 1.66 6.98 desir quit smoke 18 18 0.566 0.317 1.76 0.94 3.30 cancer site head neck lung 0.644 0.440 1.90 0.77 4.42 time diagnosi 6 6 month 0.681 0.338 1.98 1.03 3.85 tabl 4 quit smoke percentag 6 month 12 month arm patient quit smoke statu usual care physician base intervent 1 side pn number patient 217 215 432 6 month follow deceas 7 3.2 7 3.3 14 3.2 lost refus interview 28 12.9 27 12.6 55 12.7 quit smoke 27 25 11.9 30 14.4 55 13.2 185 88.1 178 85.6 363 86.8 12 month follow deceas 11 5.1 12 5.6 23 5.3 lost refus interview 37 17.1 41 19.1 78 18.1 quit smoke 52 28 13.6 27 13.3 55 13.4 178 86.4 176 86.7 354 86.6 360 smoke cessat cancer patient download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv 2.48 95 confid interv ci 1.30 4.88 quit smoke guid treatment past 6 month 2.26 95 ci 1.04 4.75 exhibit strong desir quit smoke median 18 2.90 95 ci 1.54 5.71 cancer site head neck lung versu 3.38 95 ci 1.55 7.33 bayesian multipl regress model 12 month quit shown tabl 5 bottom variabl retain com.ibm.drl.hbcp.predictor quit 12 month number cigarett smoke dai 15 2.56 95 ci 1.35 4.86 group counsel cessat program 3.48 95 ci 1.66 6.98 exhibit strong desir quit smoke median 18 1.76 95 ci 0.94 3.30 cancer site head neck lung versu 1.90 95 ci 0.77 4.42 time diagnosi present cancer 6 month 6 month 1.98 95 ci 1.03 3.85 physician adher smoke cessat treatment guidelin tabl 6 show proport physician studi condit adher basi patient report aspect 5 model tabl greater proport physician physician base intervent discuss smok ing behavior patient provid quit advic patient discuss benefit quit advis assist patient establish quit date provid follow letter summar quit plan provid quit smoke materi provid prescript nrt assist compar proport physician usual care condit discuss analys yield import find contrari hypothesi find provis physician base smoke intervent creas long term quit rate cancer patient find consist studi gritz al 36 report signific differ rate quit patient provid physician base cessat treatment patient randomli assign control comparison group find contradict gener literatur effect physician base smoke intervent physician base intervent yield upward 10 11 increas quit rate versu usual care 22 explan null find find result methodolog confound ing caus inabl true control group studi arm receiv activ treatment find greater adher 5 model physician intervent condit tabl 6 substanti proport patient usual care condit receiv potent aspect cessat intervent 56 patient usual care condit receiv quit advic physician 35 usual care patient benefit quit discuss 19 usual care patient receiv nrt addit usual care condit standard great variabl oncologist approach deal tobacco patient number tabl 6 adher help intervent 6 month follow physician practic usual care physician base intervent doctor discuss smoke habit visit 78 37.1 133 63.9 100 47.6 44 21.2 unknown 32 15.2 31 14.9 doctor clinic recommend stop smoke 118 56.2 157 75.5 60 28.6 25 12.0 unknown 32 15.2 26 12.5 doctor talk benefit quit 74 35.2 137 65.9 63 30.0 33 15.9 unknown 73 34.8 38 18.2 doctor staff set quit date 11 5.2 77 37.0 130 61.9 99 47.6 unknown 69 32.9 32 15.4 doctor send follow letter quit plan 6 2.9 104 50.0 129 61.4 46 22.1 unknown 75 35.7 58 27.9 doctor give materi quit smoke 36 17.1 164 78.8 144 68.6 15 7.2 unknown 30 14.3 29 13.9 doctor give prescript nicotin gum nicotin patch 40 19.1 70 33.6 141 67.1 111 53.4 unknown 29 13.8 27 13.0 note unknown equival miss data 361schnoll al download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv physician usual care condit provid continu quit advic assist follow durat appear studi condit diverg term proport patient receiv cessat counsel assist tabl 6 futur studi area research design control confound influenc physician behavior evalu physician base intervent differ intens content focu test treatment control group explan null find low intens physician base intervent eval uat suffici increas long term quit rate cancer patient consid hard com.ibm.drl.hbcp.core smoker continu smoke diagnosi low rate long term quit condit 13.2 13.4 6 month 12 month follow up compar previou inter vention studi cancer patient lend support explan studi evalu benefit nurs manag 5 model base smoke intervent lung cancer patient brown al34 found 10 14 71 patient intervent condit abstin 6 month follow versu 11 55 patient usual care group compar quit advic litera ture provid usual care condit intervent condit studi brown al34 consist structur clinic session involv quit advic guidanc establish quit date teach behavior cognit strategi manag stress provis support encourag ment guid recommend nrt bupropion follow telephon booster contact regress model present studi found patient intens form smoke treatment group counsel nrt quit smoke long term support explan futur studi area assess higher intens intervent physician base intervent adjunct behavior pharmacolog treatment understand low impact physician base intervent suffici initi quit healthi smoker medic context adequ smoker diagnos cancer explan lack statist impact intervent relat inclus patient primari cancer link tobacco breast testicular cancer lymphoma intervent larg part reli high level quit motiv individu diagnos tobacco relat ill inclu sion patient lower level desir quit necessarili perceiv current health problem link tobacco contribut low cessat rate condit creat scenario begin studi make treatment effect support explan higher cessat rate demonstr prior smoke intervent studi head neck lung cancer pa tient 34,36,37 addit present analys found cancer site strong com.ibm.drl.hbcp.predictor long term quit rate patient head neck lung tumor etiolog strongli link tobacco exhibit significantli higher quit rate patient diagnos form cancer case physician base intervent test effect patient manifest tobacco relat ill final explan null find concern outcom measur select studi assess quit rate cessat advic focus long term abstin physician interven tion yield signific increas initi quit provis cessat advic effect promot long term mainten abstin assess quit rate quit advic distinct initi quit long term abstin import physician base treatment motiv initi cessat fail promot long term abstin low cost relaps prevent techniqu incorpor intens intervent outset adjunct physician quit advic import find studi concern result predict model long term quit model identifi medic smoke behavior factor assess baselin link patient abil quit smoke long term mention tumor site effect likelihood quit patient diagnos head neck lung cancer substanti abstin 6 month 12 month follow versu patient tumor site find attrib utabl awar patient etiolog head neck lung tumor strongli link tobacco recognit turn spark greater quit motiv studi head neck cancer patient found attribut diseas tobacco predict abil quit smoke diagnosi 44 altern smoke rate lower head neck cancer patient greater likelihood physic disabl treatment cancer type make imposs smoke boost quit motiv eventu cessat intens intervent target patient tumor tradition link tobacco addit intervent target patient longer time diagnosi patient abstin 12 month follow report previous 38,40 diagnosi risk smoke increas time initi debilit medic treatment symptom make imposs patient smoke altern suffici time elaps treatment complet patient minim serious diagnosi commit maintain abstin tobacco final smoke rate lower outset result strong messag physician requir patient abstain smoke treatment time elaps effect messag fade explan find highlight relaps prevent patient variabl assess baselin relat patient smoke histori predict long term quit regress model patient start smoke ag 16 362 smoke cessat cancer patient download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv smoke greater number year patient smoke 15 cigarett dai heavier smoker quit follow link smoke durat amount smoke hand abil quit smoke hand shown larg prospect studi noncanc popul 45,46 addit patient report quit smoke guid treatment past 6 month group cessat program quit smoke long term find support literatur demonstr benefit treatment 32,47 result replic previous found smoke histori abil quit patient start smoke younger ag patient heavi smoker requir intens cessat treatment method promot cessat intervent explor increas likelihood patient abstain tobacco long term final patient show strong desir quit smoke baselin abstin long term prospect studi show desir quit smoke refer quit motiv readi chang stage chang consist com.ibm.drl.hbcp.predictor smoke cessat 36,48 treatment studi show initi motiv quit smoke predict success smoke intervent 49 quit motiv predict outcom treatment studi cancer patient 36,38 data spark develop behavior chang theori transtheoret mod el 50 clinic approach motiv interview ing 51 import contribut research match clinic techniqu individu level quit motiv 52 instanc action orient techniqu nrt behavior counsel promot quit motiv quit method met resi tanc low quit motiv unmotiv smoker requir uniqu set techniqu design boost motiv prepar person engag action orient strategi 52 gener popul smoker intervent cancer patient smoke tailor person level readi quit maxim impact treatment import find concern effect interven tion physician adher 5 model potenti benefit physician base smoke intervent 20 25 u. smoker receiv smoke cessat counsel physician 53 explan low rate physician adher 5 model lack train smoke cessat counsel physician ferri al54 survei 120 u. undergradu medic program found 2.4 school requir student complet tobacco educ studi found physician intervent condit show greater adher 5 model provid physician basic train conduct smoke intervent improv physician practic caveat highlight sourc bia patient recal physician practic yield unr measur physician behavior measur 6 month physician intervent patient forgotten physician provid treatment artifici lower rate adher patient recal influenc made quit attempt fail patient reluct report physician attempt encourag cessat provid rational inabl maintain abstin find view context addit limit report versu biochem verif determin smoke statu unreli 55 number patient incorrectli classifi follow up import note larg studi shown fals report rate 3 5 56,57 decept occur studi rate small futur studi evalu smoke intervent cancer patient biochem verif smoke statu extern valid studi limit sampl lack ethnic divers patient ethnic found patient abil quit smoke diagnosi futur studi area sampl approxim ethnic distribut u. cancer patient mention true control group confound content exposur smoke cessat treatment patient usual care arm undermin studi intern valid fourth practic con straint requir patient randomli assign physician physician implement usual care physician base intervent method olog approach affect data expect yield type error declar physician base intervent effect physician knowledg treatment condit patient influenc treatment approach favor studi hypothesi null find treatment condit case type ii error plausibl acknowledg methodolog shortcom physician provid treatment explain null find final elig criteria allow recent quitter includ studi procedur artifici increas quit rate product random assign procedur proport individu condit expect equival limit acknowledg studi make import contribut literatur smoke treatment cancer patient previou study36 test physician base smoke cessat cancer patient recognit address tobacco cancer patient grow studi guid impl mentat clinic initi import studi suggest intens smoke intervent popul basic physician base treatment develop relaps prevent strategi provis physician advic basic assist guid referr nrt standard care effect primari care set substanti proport cancer patient tobacco relat neoplasm 363schnoll al download ascopubs.org cruciform librari cruciform build januari 13 2017 144.082.008.035 copyright 2017 american societi clinic oncolog right reserv stage recoveri intens cessat treatment includ antidepress formal behavior counsel tailor patient quit motiv 33 long term relaps prevent form quit line support group seamless integr intens smoke intervent relaps prevent ap proach oncolog context repres import prioriti comprehens cancer center potenti promis approach assist patient achiev qualiti life acknowledg ecog coordin studi e1y92 robert comi md support nation cancer institut nation institut health depart health human servic grant ca23318 ca66636 ca21115 ca27525 ca13650 content author respons necessarili repres view nation cancer institut
cancer control 2 239 246 random trial smoke cessat intervent gener practic itali nereo segnan antonio ponti renaldo battista carlo senor stefano rosso stanlei shapiro daniela aimar receiv 23 april 1991 accept 1 1991 purpos studi examin effect practic base approach assist patient primari care physician quit smoke sustain cessat forti nonsmok gener practition volunt studi period train random 923 smoke client unselect motiv quit intervent group minim intervent consist singl counsel session handout quit techniqu ii repeat counsel includ reinforc session month 1 3 6 9 iii repeat counsel nicotin gum iv repeat counsel spirometri biochem valid smoke statu assess 12 month recruit proport verifi quitter 12 month 4.8 percent subject random minim intervent group compar 5.5 percent 7.5 percent 6.5 percent random repeat counsel group treatment group outcom significantli time counsel 0.05 level lack power contamin low attend reinforc session account interpret result kei word biochem verif counsel gener practic itali nicotin gum random trial smoke cessat spirometri introduct strong associ cigarett smoke increas morbid mortal respiratori cardiovascular neoplast diseas docu ment make smoke import public health problem intervent propos cur tail tobacco emploi commun approach 2 target individu clini cal encount 5 privileg posit primari care physician prevent recogn studi countri 70 percent patient averag practic doctor year 90 percent year 7 random control trial suggest physician intervent posit impact cigarett smoke behavior patient 8 18 overview 39 trial 19 evalu kei element smoke cessat intervent de segnan ponti senor rosso ms aimar epidemiolog unit usl torino francesco da paola 31 10123 torino itali dr battista depart epidemiolog biostatist famili medicin medicin mcgill univers divis clinic epidemiolog depart medicin montreal gener hospit dr shapiro depart epidemiolog biostatist mcgill univers montreal quebec canada address correspond dr segnan studi financ health educ grant piedmont health author adm act 4195 41 86 dr battista research scholar nation health research develop program ottawa canada 1991 rapid commun oxford cancer control vol 2 1991 239 segnan al face face advic reinforc session identifi import compon success itali 46 percent male 18 percent femal ag 14 year older smoke preva lenc male stabl countri femal vari turin 27 percent women ag 14 current smoker 2 resid itali entitl servic primari care phy ician gp nation health servic gp practic capit basi respons defin group individu provid free access primari care act gatekeep speci alist hospit care purpos studi examin effect gp base approach assist patient quit smoke su tain cessat method forti nonsmok gp 400 individu list particip trial voluntari basi agre recruit male femal patient 20 60 year ag smoker free life threaten diseas intervent delin entail charg patient minim intervent consist session face face counsel dai patient recruit explanatori bro chure provid patient session ii repeat counsel rc subject recruit group receiv coun sell group invit follow appoint month 1 3 6 9 antismok messag reinforc appoint date rec ord physician brochur pro vide patient patient remind return visit telephon call dai appoint call made subject attend previou return visit iii rc nicotin gum visit ject instruct doctor cor rect drug includ advis daili dose gum provid quantiti suf ficient follow visit occas gum subject recommend period longer month iv rcplu spirometri subject receiv written prescript ask set appoint ment spirometr test special cen cancer control vol 2 1991 240 ter nation health servic report form show estim lung ag subject 21 physician expect di cuss result patient follow visit stress maintain lung func tion damag particip physician attend hour train session expert inter person commun introduc counsel techniqu devot organiza tional aspect studi session offer month begin studi attend 40 percent particip gp physician schedul recruit specif dai week time gp offer recruit elig subject offic predetermin random sequenc intervent packag close number envelop materi pertain intervent provid gp begin studi envelop indistinguish block treat ment alloc base sequenc random number research staff check physician plianc procedur assign compar ing envelop number date recruit physician request subject inform consent fore random intervent start immedi recruit recruit last februari octob 1988 shortli recruit subject contact telephon train interview independ studi staff question smoke habit characterist addit tele phone interview perform month 6 12 recruit collect inform ject smoke statu complianc inter vention baselin characterist primari outcom studi biochemi calli verifi smoke cessat 12 month recruit sustain month follow interview report smoke statu valid determin urinari cotinin level subject report quit smoke week sixth month twelfth month interview ask provid urin sampl sampl research center averag week report smok ing cessat home visit offer analys cotinin concentr perform radioimmunoassai valid sampl ga chromatographi cotinin valu smoke cessat clinic trial tabl 1 select charact ic 44 par ipa ing phy ic ian wi sampl tu gener rac ioner variabl studi gp sampl gp ag 40 28 63.6 114 50.7 40 16 36.4 111 49.3 sex male 34 77.3 189 84.0 femal 10 22.7 36 16.0 smoke habit current smoker 0 0.0 77 34.2 smoker 17 38.6 52 23.1 smoker 24 54.6 80 35.6 miss 3 6.8 16 7.1 number patient list 400 0 0.0 46 20.4 401 800 15 34.1 86 38.2 801 1500 20 45.5 56 31.3 1500 9 20.4 37 20.7 random sampl 225 gener practition gp drawn spring 1986 file turin gp 1,158 data smoke habit obtain person interview inform ag sex number client larger file administr purpos adjust comput cotinin creatinin ratio standard creatinin excret urin flow 22 base shape distribut coti creatinin ratio experi cotinin determin larger data set 23'24 cut distinguish current smoker quitter set 100 ng mg complet recruit follow interview total 923 subject random treatment group eighti subject refus recruit ment physician number subject recruit consider lower anticip 52 percent gp recruit 20 smoker 41 percent recruit 20 39 gp percent recruit 40 subject initi tele phone interview subsequ recruit car ri 91 percent 923 subject percent refus percent trace fol low interview month 6 12 complet 91 percent percent refus percent untrac 87 percent cent refus percent untrac subject physician subject characterist select characterist physician volunt studi report tabl 1 random sampl gp practis turin volunt includ slightli larger proport younger femal physician tabl show differ smoke habit number client tabl 2 characterist patient present treatment group databas cover person enlist nation health servic gener prac tice provid data ag sex recruit subject remain inform obtain telephon interview data show similar distribut treatment variabl includ potenti con founder smoke habit number previou attempt quit health statu elig criteria includ ag 20 60 44 recruit subject younger subject older 37 subject retain analysi content intervent sixth month questionnair ask subject physician prescrib recruit visit tabl 3 seventi percent subject random minim intervent group mi report receiv advic quit physician propos correct intervent subject report 67 percent case repeat counsel group rc 93 percent 84 cent nicotin gum rcn spirometri rc group mi group cancer control vol 2 1991 241 segnan al tabl 2 subject characterist random rea tment group ropor ion subject level variabl consid variabl treatment group minim repeat nicotin spirometri intervent counsel gum 62 275 294 292 ag 31 12.9 21.8 23.5 18.5 31 40 25.8 27.3 21.8 28.8 41 50 37.1 26.2 30.3 27.4 50 24.2 24.7 24.5 25.3 gender femal 32.3 39.6 36.7 40.1 male 67.7 60.4 63.3 59.9 educ 5th grade 30.2 25.5 25.7 29.6 6th 12th grade 45.3 48.2 48.9 42.7 13th grade 24.5 26.3 25.4 27.7 marit statu marri 88.7 77.3 79.8 83.5 cigarett smoke daili 10 14.8 18.3 19.9 15.2 11 20 63.0 52.4 47.6 57.8 20 22.2 29.3 32.6 27.0 previou attempt quit 0 35.2 34.8 36.1 35.2 1 25.9 29.2 27.5 25.1 2 38.9 36.0 36.4 39.7 symptom relat smoke 51.9 51.4 50.9 52.3 perceiv health excel 13.2 16.6 17.8 14.6 good 43.4 38.9 45.0 39.3 fair 37.7 36.8 28.6 37.5 poor 5.7 7.7 8.6 8.6 combin repeat counsel miss valu mi 1 educ marit statu perceiv health rc 1 number cigarett 1 educ marit statu 2 number cigarett 4 number cigarett 1 symptom perceiv health tabl 3 percentag physic ian complianc wi tudi protocol subject report ea tment roup prescript treatment group mi rc rcn rc 60 257 268 264 advic quit follow visit follow visit gum follow visit spirometri follow visit splrometri gum 75.0 24.5 1.9 8.3 10.0 67.3 4.5 2.7 15.0 7.8 92.5 1.1 0.0 0.4 0.4 83.7 0.0 0.0 0.7 4.2 100.0 100.0 100.0 100.0 miss valu group 1 minim intervent mi repeat counsel nicotin gum rcn 3 repeat counsel rc 6 repeat counsel spirometr test rc 242 cancer control vol 2 1991 25 percent subject told return counsel nicotin gum prescrib half case rc group hand 25 percent mention pre scription follow visit percent report prescript gum spirometri studi protocol physician suppos set specif date follow write time date studi leaflet subject subject invit doctor recollect phy ician compli fulli protocol 53 percent rc 58 percent rcn 66 percent rc case 29 percent rc 17 percent rcn percent rc case appoint made subject gener invit back follow visit subject complianc intervent sourc inform physician record follow visit treatment group subject report sixth month twelfth month interview treatment group mi group physician subject report rcn group character slightli greater number follow visit physician report subject treatment group follow visit follow visit potenti attend month recruit hand 54 percent subject mi group report discuss smoke doctor month fol low recruit compar 31 percent rcn 37 percent rc 38 percent rc group 38 percent subject mi group discuss smoke doctor period compar 45 percent rc 46 percent rc 52 percent rcn subject random group schedul rein forc session examin physician record show patient claim receiv prescrip tion nicotin gum 24 subject doctor record condit contradict gum cardiovascular problem peptic ulcer dental prosthesi inform 19 subject report prescript spirometri inform refus physician record concord subject report eighti percent subject nicotin gum smoke cessat clinic trial group receiv prescript gum group subject 55 percent report gum dai week 133 subject report nic otin gum week 21 percent gum week 34 percent month 45 percent intermedi period time averag number piec gum con sume dai subject 4.8 hundr twenti subject spi rometri group 50.2 percent test prescrib report spirometri refer 111 take test confirm test center result smoke cessat rate 12 month present tabl 4 rang 4.8 percent mi 7.5 percent rcn differ signific 0.05 level subject trace year fol low death ill exclus subject analysi chang result cessat rate month higher twelv month group report tabl 5 averag preval report quit sixth month twelfth month follow preval smoker bio chemic valid year fol low 128 subject 16 percent report smoke cessat 44 refus test relaps biochem verif 11 cotinin cut level tabl 4 year preval biochem verifi smoke cessat treatment group nl n2 ci minim intervent 62 3 4.8 1.0 13.5 repeat counsel 275 15 5.5 2.6 8.4 repeat counsel nicotin gum 294 22 7.5 4.3 10.7 repeat counsel spirometri 292 19 6.5 3.5 9.5 total 923 59 6.4 4.8 8.0 nl number subject random treatment group n2 number valid quitter ci 95 confid interv cancer control vol 2 1991 243 segnan al tabl 5 number proport valid quitter random treatment group month follow nl n2 ci minim intervent 62 3 4.8 1.0 13.5 repeat counsel 275 16 5.8 2.9 8.7 repeat counsel nicotin gum 294 23 7.8 4.6 11.0 repeat counsel spirometri 292 23 7.9 4.6 11.2 total 923 65 7.0 5.3 8.7 number subject random treatment group n2 number valid quitter ci 95 confid interv discuss outcom singl treatment group differ significantli mi group repeat counsel group higher rate smoke cessat observ compar mi ratio 1.2 1.4 1.6 power studi lower anticip combin repeat counsel nicotin gum spirometr test result import differ smoke cessat rate studi cessat rate rcn group highest 95 percent confid interv wide 11 percent comparison result random studi conduct gener practic countri sl emploi partial design difficult number reason account cessat rate italian gener popul lower femal industr countriesi 1986 interview random sampl 1,421 person turin smoke habit percent percent smoker report quit smoke ag equal year younger current ag trial specif design contrast cite stud i 12'13'1 17 assess effect physician advic popul select motiv quit smoke studi unverifi report quitter count continu smoker requir month abstin appli proport report quitter vali date biochem vari 47 percent 53 cent group attempt enhanc attend includ posit advic subject physician remind offer free 244 cancer control vol 2 1991 park refus true quitter studi greatest number ject test biochem verif trial cite attend decept rate fall rang studi complianc tabl 3 low rcn rc group subject rc group fourth mi group report phy ician compli prescript proto col repeat counsel group greater number visit doctor smoke discuss differ high expect 50 cent subject visit minim intervent group comparison group effect result studi diminish differ ce sation rate mi group tabl 3 show larger number subject ran domiz simpl repeat counsel recal advic return attend follow visit show pattern addit analysi perform take consider treatment subject report receiv random 106 subject report receiv mi group random percent valid quitter 12 month poten tial select recal subject select contami nation treatment group physician respons low quit rate group previou studi review report data complianc wilson 16 report subject random nicotin gum treatment recal receiv prescript physician 59 percent 63 percent case treat ment group studi physician adher protocol prescrib return visit 83.3 percent russel 4 report ten percent 16 percent case intervent group physician follow correct studi procedur complianc return visit lung function test low experi 40 percent subject attend return visit report studi 50 percent compli spirometr test found trial 12'16 attend return visit higher cessat rate complianc nicotin gum hand higher complianc level report author except fagerstr6m 90 percent complianc studi gum hand directli doctor possibl enhanc complianc comparison spirometr test note plianc report low time prescrib intervent requir visit physician offic attend smoke cessat class tm health visitor 9 spirometri group test lower cessat rate compil hand nicotin group exclud subject present ing contraind small group nicotin gum review trial evalu nicotin gum prescript 12 16 put contraind gum exclus criteria 12'13 gp contraind account time recruit physician judg 24 percent subject random nicotin gum group contraind drug prescrib gum analysi maintain subject nicotin gum group 33 percent report smoke cessat 12 month percent bio chemic verifi quitter exclus contraind nicotin gum elig criteria substanti dilut effect nicotin gum treatment author recent trial smoke cessat 26 design evalu effect degre physician involv point intens physician train individu inter vention increas number cessat attempt patient prevent relaps train program particip gp focus specif object individu commun patient smoke reason quit ii propos quit date agre iii discuss problem encount attempt fail di cuss individu strategi prevent relaps cessat accomplish anticip success intervent partial due short durat train effect physician train dilut fact control subject initi intervent term counsel group limit present studi consist ent view repeat counsel gener practition posit effect cessat rate client knowledg trial conduct itali share methodolog problem encount similar studi canadian british australian gener practic set smoke cessat clinic trial acknowledg author gratefulli acknow ledg support simg italian associ gener practic advic dr ven triglia nejrotti contribut physician involv trial contribut dr quadrino maggiorotti arossa dr scherer analytisch forschungslabor munich germani dr voria ospedal maggior san giovanni torino itali dr puntoni lab oratori clinic physiolog italian research council pisa itali perform urin analys biochem verif smoke statu serono spa provid nicotin gum studi anti smoke committe municip torino aci automobil club italiano help wai author grate dr ernst input earlier stage studi ms azana endicott ms dian telmoss technic assist
prevent medicin 27 412 421 1998 articl pm970286 com.ibm.drl.hbcp.predictor smoke cessat physician counseling1 carlo senor m.d m.sc 2 renaldo battista m.d sc.d stanlei shapiro ph.d nereo segnan m.d m.sc antonio ponti m.d m.p.h stefano rosso m.d m.sc daniela aimar m.sc cpo piemont unitá di epidemiologia asl 1 10123 turin itali depart epidemiolog biostatist mcgill univers divis clinic epidemiolog montreal gener hospit montreal quebec canada introduct background purpos studi iden quit smoke cyclicaltifi com.ibm.drl.hbcp.predictor quit gener prac process environment factor interact withtition gp anti smoke counsel smoker characterist stage cessa method studi determin character preced framework success quit tion cycl 1 recogn magnifi ting 1 year sustain abstin biochem con forc favor cessat physician implement firm 6 12 month follow 861 smok effect intervent integr effort er random intervent group base comprehens anti smoke strategi physi repeat counsel rc rc spirometr test cian elicit smoker valuabl rc nicotin gum smoke cessat trial carri inform reason maintain turin itali healthi habit barrier resourc result gp intervent work male chang negoti adopt healthier 2.30 95 ci 1.13 4.52 marri 3.63 95 ci behavior 2 1.37 9.59 smoker smoker maintain larg amount inform abstin 1 month past 6.78 spect determin quit smoke 95 ci 1.56 29.52 quit attempt narrow focu studi limit relevance10.91 95 ci 2.37 50.13 spontan result popul smoker contacted reduc coffe consumpt 3.30 physician offic case find con 95 ci 1.59 6.82 heavi smoker 20 cig dai cern smoker volunt formal quitting0.48 95 ci 0.24 0.93 live smok program progress stageer 1 smoker household 0.44 95 ci prepar action smoking0.22 0.90 give previou anti preliminari process act smoke advic gp repres strong barrier select mechan make impossibleto success healthi smoker 0.19 95 ci 0.07 determin relat volunt source0.52 report symptom short popul smoker aspir quitter 3,4 breath 0.63 95 ci 0.39 9.20 evid observ studi gener pop interact com.ibm.drl.hbcp.predictor treatment condi tion ulat transfer gener practic conclus assess factor influenc quit set attempt quit initi ting gp tailor messag address at prompt individu medic advic exist barrier patient com.ibm.drl.hbcp.util studi address issu identifi sourc chang q1998 american health foundat aca cation com.ibm.drl.hbcp.predictor quit context smoke demic press cessat trial gener practic primari care clin kei word smoke cessat counsel gener ic 5 8 determin short term 4 6 practition month success long term abstin 1 3 year identifi conflict find report respect role of1 studi fund usl torino c. health statu ag gender educ level support fellowship lega italiana la lotta contro predict role individu pretreat charac tumori 2 reprint request address fax 11 5662005 terist assess studi refer time 412 0091 7435 98 25.00 copyright 1998 american health foundat academ press right reproduct form reserv com.ibm.drl.hbcp.predictor smoke cessat 413 interv rang 4 month 3 year 1 paper address issu english speak country.year sustain abstin recommend standard end point assess efficaci anti smoke intervent consid methodsind consolid modif smoke habit 9,10 interpret report find difficult absenc uniform time studi popul refer evalu process chang misclassif smoke statu bia random trial evalu effect intervent gener practic result analys decept rate vari ing 7 28 form turin itali minim intervent session face face counsel repeat counselingcontext intervent trial 11 15 indic report smoke statu inaccur par rc subject receiv counsel group invit follow ticularli smoker feel pressur give case subject enrol cessat pro visit schedul 9 month rc nicotin gum nicotin gum 2 mg offer addit coun gram report abstin biochem vali date studi 6 small number sele intervent rc spirometri subject receiv addit counsel session written pre smoker 22 limit strength conclus studi determin success quit scription spirometri method adopt main result detail medic advic unselect smoker en roll larg smoke cessat trial itali 14 14 evid studi conduct generalth outcom interest biochem valid abstin sustain 1 year analysi practic explor specif effect addit ma neuver support counsel gp incon base preced model propos green 16 model incorpor concept defin clusiv spirometri studi 12 specif contribut assess thehealth belief construct 17,18 recogn role complex relationship intern effect nicotin gum demonstr clinic set contradictori find haveextern determin behavior take account addit factor relev orient report us ther com.ibm.drl.hbcp.api nonselect smoker gener practiceof physician deliv prevent intervent ac cord framework health behavior 19 21 consist find studi biochem valid report quittingcan function collect influenc kind factor classifi predispos en perform 11 13,15,22 result trial suggest import role nicotin reinforc factor predispos factor includ knowledg attitud belief valu gum respect 2 mg dose studi spirometr test independ determi demograph factor relat motiv individu act 16 pp 69 70 enabl factor nant quit support repeat counsel gp nonselect group smokers.mai defin resourc impl mentat health behavior includ individu effect rc intervent attrib ut anti smoke counsel reinforc byskil implement desir behavior 16 75 reinforc factor includ environ follow visit effect assum substanti equival smoker ran mental influenc determin health ac tion support 16 77 domiz group effect repeat counsel demonstr inth role factor assess stan dard refer time recommend trial 12,13,23,24 assumpt valid smoker alloc group althoughevalu effect gener practition gp deliv anti smoke intervent preced proport quitter significantli group compar rc intervent themodel provid conceptu framework sort ing determin behavior chang categori statist power comparison low studi size group 62 smokersconveni design structur educ plan result analysi flaw enrol 2 quitter 14 test interact effect analysi bia result relianc report issu similar studi smoker random group exclud analysi focus identifica biochem valid perform addit methodolog aspect tion com.ibm.drl.hbcp.predictor success quit peat counseling.noteworthi mention 414 senor al definit quitter account durat abstin assum indic serious intent give up.thos smoker report quit smoke 1 week follow interview sociodemograph variabl set variabl form 6 12 month recruit includ ag gender birthplac marit statu educa ask provid urin sampl cotinin determina tion occup level code ital tion result recent review 10 ian nation censu descript occup 31 studi initi quit attempt 25 collaps job categori white collar blue defin long term quitter subject collar tradesmen report report abstin biochem verifi organiz factor influenc probabl 6 12 month assess quit adjust occup level 32,33 explor issu job decis latitud sourc inform scale propos karasek 34 smoke adapt behavior main recruit questionnair gp ask tain handl environment stress 35 37 smoker enrol trial consent answer higher degre decis make freedom stressfula phone interview schedul 2 week work situat facilit habit change.initi counsel session recruit interview collect inform smoke histori adop enabl factorst health promot behavior environment port knowledg health effect smoke presenc past experi success behavior chang symptom attribut smoke sociodemo consid indic individu skill deal graphic characterist addit inform con problem relat modif establish cern health statu habit item previou experi behav health follow period deriv ioral chang includ indic trigger 12 month follow questionnair decis autonom decis medic advic character determin reinforc factor predispos factor account larg variat report attitud belief adopt health protect number friend job colleagu behavior habitu seat belt en analysi proport smoker total num gagement regular physic exercis consid ber friend colleagu mention previou medic indic individu attitud effort advic repres dichotom scale includ aim improv health expect habit ing categori smoker report advic modif attitud nonsmok mea reduc tobacco consumpt 32 men sure requir smoker report tion invit stop smoke complet nonsmok consent light cigarett 441 person experi diseas influenc analysisindividu belief health hazard smoke collect inform histori smoke relat adjust odd ratio comput unconditionalsymptom chronic cough short breath sob logist regress variabl select base sta chronic diseas health impair tistic signific 0.1 univariateassoci perceiv risk 18,26 28 belief analysi exist evid roleabl quit measur time recruit class factor consid interview expect difficulti quit gender educ level diagnosi chronic di eas test multivari model base onsmok relat variabl cigarett consumpt express cigarett dai time find recent italian nation health sur vei suggest influenc thesecruit visit time cigarett morn ing item deriv fagerstroem toler factor process quit 38 base avail evid 39 43 analysi effect modificationquestionnair 29 report perform discrimin smoker continu focus interrelationship ag gender amount smoke health statu physi smoker 30 measur depend variabl consid includ durat smok cian advic investig modifica tion effect determin quitting habit ag start smoke number previou quit attempt durat longest abstin smoker expos specif intervent seri separ model built test role ofperiod classifi past quit attempt take com.ibm.drl.hbcp.predictor smoke cessat 415 factor i. job relat variabl emploi tabl 1a subject plan pregnanc women univari analysi predispos factor account tailor anti smoke messag 95 specif subgroup smoker group con confidencesid restrict model includ subject demograph factor interv live emploi subject femal marit statu 782 smoker potenti determin interest singl widow divorc 1case enter signific marri live common law 3.62 1.50 8.76 com.ibm.drl.hbcp.predictor identifi stage analysi ag year 861 consequ exclud smoker random 20 29 1 30 39 1.25 0.55 2.85 group explor build predict 40 49 0.91 0.38 2.15 model smoker retain 50 1.12 0.48 2.62 analysi perform emploi logist gender 861 procedur sa packag 44 likelihood ratio femal 1 x2 test term final model male 1.53 0.82 2.84 birthplac 779 northern itali 1result region 1.34 0.74 2.42 educ level degre achiev gp approach 1,006 smoker recruit 923 781 91.7 gave consent enrol elementari school degre 1 trial 861 subject random intermedi degre 1.35 0.63 2.89 high school univers degre 1.45 0.62 3.34 rc group consid analysi 861 occup level 600 smoker 782 90.8 complet recruit inter blue collar 1view refus 6.4 trace 2.8 742 86.2 tradesmen 0.44 0.13 1.53 plete 12 month follow interview refus white collar 0.79 0.39 1.56 6.6 trace 7.2 689 smoker 88.1 job decis latitud 600 intermedi high 1those complet recruit interview low 0.34 0.11 1.08 plete questionnair proport valid smoker 1 year follow 5.8 50 rc group cessat period shorter 1 month 7.58 95 ci 1.79 32.05 interestingli assumingunivari analysi group refer likelihood suc predispos factor marit statu appear cess high smoker quit attemptth import com.ibm.drl.hbcp.predictor success socio 8.83 95 ci 1.99 39.20 demograph factor consid tabl 1a smoker appar posit attitud prevent ofwho marri live common law signifi diseas infer report engag incantli quit singl health protect behavior withdivorc widow 3.62 95 ci 1.50 8.76 likelihood give tobacco tabl 1c attitudesmok perform job requir lower skill level nonsmok show paradoxicalcharacter time low degre control effect smoker declar askedov work pace show lower tendenc quit present nonsmok permiss smoke 0.34 95 ci 0.11 1.08 probabl quit tend quit 0.58 95 ci 0.32 ting significantli occu 1.05 direct percept ill health consequ ofpat level smoke repres suffici cue givingpretreat smoke histori tobacco tabl 1c trend modifiedth probabl success quit tabl 1b heav smoker report recent diagnosi theier smoker 20 cigarett dai previou 2 year cardiovascular respiratori illnesslik quit compar smoker report lower data shown similarli degre confid level consumpt 0.56 95 ci 0.31 1.01 sonal capabl succe quit associ clear trend appar favor smoker at smoker likelihood give up.report longer durat previou episod absti nenc absolut number attempt enabl factor facilit effect past experi enc behavior chang appar relat onlydid plai role smoker report sustain episod abstent past coffe drink smoker report implement previou resolut reduc cof succe compar reduc tobacco consumpt maintain fee consumpt quit 2.43 416 senor al tabl 1ctabl 1b univari analysi predispos factor univari analysi predispos factor 95 95 confid confid attitud belief intervalsmok relat variabl interv cigarett smoke dai 782 predict difficulti quit 770 1 19 1 20 0.56 0.31 1.01 difficult 1 difficult 1.87 0.90 3.88 durat previou abstin 545 easi easi 1.55 0.69 3.47 symptom attribut smoking0 1 1 6 month 5.87 0.77 44.85 781 symptom 17 12 month 9.34 1.10 79.53 13 month 12.88 1.57 105.62 minor complaint cough 1.20 0.60 2.39 symptom specif ill 0.65 0.29 1.47 histori previou attempt quit 782 symptom short breath 741 reduc averag amount abstin 1 1 month 1 1.24 0.69 2.22 abstin 1 month 1 7.58 1.79 32.05 attempt symptom chronic cough 741 1no previou quit attempt 8.83 1.99 39.20 number previou attempt quit 0.75 0.40 1.41 diagnosi chronic diseas 782 1 cardiovascular 741 11 1.05 0.49 2.24 2 0.73 0.33 1.60 1.00 0.46 2.20 respiratori 741 3 4 1.39 0.56 3.49 5 1.14 0.37 3.54 1 1.34 0.65 2.76 level depend 781 cigarett bed 1 sport activ 782 rare 1first cigarett morn coffe 1.41 0.54 3.69 cigarett dai 2.56 0.83 7.91 season 1.47 0.77 2.81 regular 0.91 0.39 2.11 ag start smoke 780 15 1 seat belt 779 rare 115 18 1.20 0.62 2.32 19 0.50 0.19 1.31 long trip 0.47 0.14 1.58 0.74 0.37 1.46 attitud nonsmok 782 rare ask nonsmok 1 permiss smoke ask nonsmok 0.58 0.32 1.05 95 ci 1.27 4.65 tabl 1d trigger deci permiss smokes import smoker reduc coffe medic advic show increas probabl success 0.63 95 ci 0.08 4.79 multivari analysi reinforc factor subject live adjust factor includ pre smoker show significantli lower probabl dictiv model enrol smoker tabl quit compar subject live 2 gender emerg addit marit statu smoker 0.45 95 ci 0.24 0.83 tabl 1d sociodemograph variabl signific proport smoke friend show signifi com.ibm.drl.hbcp.predictor men quit women effect emploi smoker proba 2.30 95 ci 1.13 4.52 ag educ level biliti success significantli reduc 50 show influenc likelihood quit cowork regular smoker 0.24 smoke relat variabl heavi smoke 95 ci 0.11 0.54 quantiti smoker pack dai show strong neg associ issu report colleagu attitud ation quit 0.48 95 ci 0.24 0.93 smoker quit attempt influenc smoker report previou episod sustain absti probabl quit smoker nenc 6.78 95 ci 1.56 29.52 invit gp stop reduc tobacco quit 10.91 95 ci 2.37 50.13 consumpt show lower tendenc quit compar show high chanc success compar report previou anti smok report shorter abstin period reduct averag tobacco consumption. advic 0.59 95 ci 0.33 1.07 com.ibm.drl.hbcp.predictor smoke cessat 417 0.39 9.20 restrict analysi thoset 1d smoker mention signific friend univari analysi found indic effect friend smoke 95 habit probabl success confid role environ reinforc factor interv confirm result analysi enabl factor strict smoker live tabl reduc coffe consumpt 764 2 group likelihood success decreas 1 sharpli smoker live oneautonom decis 2.43 1.27 4.65 regular smoker 0.44 95 ci 0.22 0.90 medic advic 0.63 0.08 4.79 slim diet 782 effect determin identifi 1 model fit group substanti autonom decis 0.76 0.26 2.19 chang role gender 2.03 95 ci medic advic 0.43 0.13 1.42 0.95 4.34 slightli reduced.reduc alcohol consumpt emploi smoker data shown 782 1 gender longer show influenc individu autonom decis medic 1.27 0.63 2.54 likelihood quit occup relat determin advicea influenti factor sociodemographicincreas physic exercis 709 variabl lower autonomi organ work activityno 1 autonom decis 1.04 0.52 2.19 lower probabl quit medic advic 1.82 0.17 10.91 0.24 95 ci 0.06 0.98 compar blue reinforc factor collar worker white collar worker number smoker household compli gp counsel 0.40 95 ci 782 0.16 0.98 attitud nonsmok emergednon 1 1 0.45 0.24 0.83 signific com.ibm.drl.hbcp.predictor group smoker claim proport smoke friend ing nonsmok permiss 782 smoke quit 0.42 95 ci 0.18 friend 1 0.94 environment neg reinforc repr smoke friend 50 0.91 0.25 3.33 sent cowork smoke habit 50 moresmok friend 50 0.85 0.25 2.90 proport smoke cowork smoke cowork 0.26 95 ci 0.11 0.60 605 presenc smoker household smoke colleagu 50 1 regular smoker live household smoke colleagu 50 0.24 0.11 0.54 0.34 95 ci 0.14 0.81 highli influential.expect attitud cowork probabl quit smoker men 600 support 1 tion advis gp stop low discourag 1.23 0.16 9.62 independ eventu symptom sob 0.41 neutral 1.67 0.21 13.02 95 ci 0.18 0.93 previou gp advic 781 pregnanc data shown repres powerfulno 1 0.59 0.33 1.07 trigger chang femal smoker 4.85 95 ci 1.26 18.64 lower number cigarettesa quitter group report medic advic 2 categori smoke appear signific predictorhav lump success quit women conclus con cern determin quit women limit low number quitter enabl factor previou resolut follow slim diet 13 women enrol trial predict role factor modi creas probabl success men women spontan reduct coffe con fi intervent inclus analysi smoker random csumption appear strong com.ibm.drl.hbcp.predictor suc cess quit 3.30 95 ci 1.59 6.82 group produc chang result pre sented.th effect gp advic modifi relat presenc symptom sob previou advic quit repres strong neg reinforc factor discuss asymptomat smoker 0.19 95 ci 0.07 0.52 influenc probabl result analysi substanti confirm success quit resultquit smoker report symptom sob time recruit 0.63 95 ci collect influenc group factor 418 senor al tabl 2 multivari model subject recruit subject live 685 632 95 confid 95 confid interv interv marit statu singl widow divorc 1 1 marri live common law 3.63 1.37 9.59 2.99 1.01 8.87 gender femal 1 1 male 2.30 1.13 4.52 2.03 0.95 4.34 cigarett smoke dai 20 1 1 20 0.48 0.24 0.93 0.49 0.24 0.98 histori previou attempt quit reduc averag amount abstin 1 month 1 1 abstin 1 month 1 attempt 6.78 1.56 29.52 13.42 1.77 101.59 previou quit attempt 10.91 2.37 50.13 21.91 2.78 172.91 reduc coffe consumpt 1 1 autonom decis 3.30 1.59 6.82 3.29 1.54 7.03 medic advic 0.68 0.08 5.45 0.70 0.09 5.73 previou gp advic 1 1 symptom 0.19 0.07 0.52 0.18 0.06 0.50 previou gp advic short breath report 0.63 0.39 9.20 0.64 0.37 9.73 symptom short breath 1 1 advic 0.79 0.31 2.03 0.66 0.25 1.77 smoker household 1 1 0.44 0.22 0.90 rel influenc tend vari rate observ smoker report previou episod sustain abstin assubgroup smoker gp intervent work male marri smoker lighter smoker 20 reduc coffe con sumption confirm fact success quitter cancigarett dai smoker quit tempt maintain abstin advantag skill accumul past experi chang smoke habit gainingat 1 month past live nonsmok control addict behavior intervent gp provid nece reduc spontan coffe consumpt asymp tomat smoker report advis sari support patient overcom exist barrier success recogn role environmentalstop past give strong neg effect previou gp counsel pressur 45 confirm relat famili work environ observ othernot observ smoker experienc symptom sob suggest gp studi 46,47 friend plai import role ag group gp counsel hardlytend reiter restrict rang messag em phasiz primarili health hazard counterbal societ pressur favor maint nanc smoke women beenprecis awar factor influenc cessat gp maxim effect effi suggest tobacco advertis campaign link smoke desir role model favor lowerci anti smoke effort tailor messag patient com.ibm.drl.hbcp.util resourc awar smoke relat risk women 48,49 continu elus tohavior chang biomed explana tion repres compon patient orient coun smoke cessat report sur vei 30,38,50,51 sele advic effect convei practic indic incorpor individu consist hypothesi stress major determin smoker everperi behavior modif higher success com.ibm.drl.hbcp.predictor smoke cessat 419 consolid behavior chang 35 impact gp smoker enter gp offic plan evalu smoker motiv evenadvic low smoker job al low opportun develop altern strate target undifferenti smoker inten sive involv gp anti smoke counsel cangi cope stress associ quit smoke job strain report survei 52 impact consist find popul survei 60 62 40 smokersus index base stress construct ap pli studi job characterist recruit trial rememb advis quit past 23 apparentlytim quit measur time survei undertaken step action ing reduc daili consumpt medic advicefin report previou studi 5,6,8,38,50,53,54 heavier smoker found dif repres trigger subject attempt stop beficult give encourag preliminari result program offer gp opportun refer easi estim base gener popul survei 38,60,63,64 hard com.ibm.drl.hbcp.core smoker special clinic tensiv support 55 repres promis option educ gap quit rate continu widen 65,66 absenc effect educationalto enhanc effect gp intervent find predict role fac level probabl success support find similar studi smoker expos individ tor consist exist evid studi conduct countri nonetheless smoke ualiz physician counsel 5,6,8 indic implement gp intervent limit nega cultur influenc behavior exclud effect specif determin differ tive effect lower educ impact anti smoke efforts. cultur context lower quit rate observ white collar acknowledgmentswork contrari report studi 56,57 explain author grate dr abrahamowicz dr joseph fact itali subject higher socioeconom input preliminari phase analysi dr joseph hodg help comment earlierlevel tend gp sourc draft paper author gratefulli acknowledg supportof lifestyl counsel recognit doctor role simg societá italiana di medicina general advicehelp patient quit emerg dr ventriglia nejrotti implement studi factor distinguish quitter continu trial contribut dr mag ing smoker 6 similarli subject claim usu giorotti alli account nonsmok right appar assum smoke behavior matter refer negoti gp felt free enjoi 1 prochaska jo diclement cc stage process changea long damag accept smoke integr model chang consultpeopl counsel reinforc clin psychol 1983;51 390 5 case percept individu risk profil 2 willm dg ja wilson dc gilbert jr taylor dw lindsai complet inform al patient perspect physician deliv smoke 80 subject recruit cessat intervent prev med 1991;7 2 95 100 differ determin observ 3 mcfall rm smoke cessat research consult clin psychol 1978;40 4 703 12 trend shown 58 heavier 4 wagner eh scoenbach vj orlean ct al particip asmok accept health interview smoke cessat program popul base perspect amboth diseas subject live prev med 1990;6 5 258 66 tend overrepres subject lost fol 5 jackson ph stapleton aj russel mah merriman rj pre low nonrespond tend dictor outcom gener practition intervent quit 58 smoke prev med 1986;15 244 53 recent literatur suggest stage 6 richmond rl austin webster iw predict abstain respect individu disposit smoke ce smoke cessat programm administ gener prac tition int epidemiol 1988;17 3 530 4 sation identifi 1 invest physi cian energi counsel smoker 7 wilson dh wakefield steven id rohrsheim rc esterman aj graham nmh sick smoke evalu targetedreadi behavior chang bring ce minim smoke cessat intervent gener practic medsat rate 59 role factor consid aust 1990;152 518 21 analysi 8 hebert jr kristel ocken jk landon luippold gold cessat smoker motiv make quit berg rj al patient characterist effect tempt object studi evalu physician deliv anti smoke intervent prev med 1992;21 557 73 impact physician deliv counsel offer 420 senor al 9 midanik lt polen mr hunkel em tekawa soghikian 32 westman eden shirom job stress cigarett smoke cessat condit effect peer support soc scimethodolog issu evalu stop smoke program public health 1985;75 6 634 8 med 1985;20 6 637 44 10 ocken jk hymnowitz lagu shaten jb cigarett smok 33 sorensen pechacek tf pallonen occup worksit ing mrfit comparison smoke behavior chang norm attitud smoke cessat public si uc studi group forum prev med 1991;20 564 73 health 1986;76 5 544 9 11 jamrozik fowler vessei wald placebo control trial 34 karasek ra baker marxer ahlbom theorel tgt job nicotin chew gum gener practic bmj 1984;289 794 7 decis latitud job demand cardiovascular diseas pro spectiv studi swedish men public health12 richmond rl webster iw smoke cessat programm 1981;71 7 694 705 gener practic med aust 1985;142 190 4 35 ocken jk nutal benfari rc hurwitz ocken psy 13 wilson dm taylor dw gilbert rj aj lindsai willm chosoci model smoke cessat mainten cessa dj al random trial famili physician intervent tion prev med 1981;10 623 38 smoke cessat jama 1988;260 11 1570 85 36 sorensen pechacek tf attitud smoke cessation14 segnan ponti battista rn senor rosso shapiro sh men women behav med 1987;10 2 129 37 al random trial smoke cessat intervent gener practic itali cancer control 1991;2 239 46 37 swenson smoke habit smoke cessat north carolina nurs women health 1989;15 2 29 48.15 hugh jr gust sw keenan rm fenwick jw healei ml nicotin placebo gum gener medic practic jama 38 la vecchia negri pagano ferraroni socio demo 1989;261 9 1300 5 graphic determin stop smoke italian popula tion base survei soz praeventivm 1991;30 154 8.16 green lw kreuter mw deed sg partridg kb health educa tion plan diagnost approach palo alto ca mayfield 39 myer rosner abbei willet stampfer mj bain 1980 al smoke behavior particip nurs health studi public health 1987;77 5 628 30.17 becker mh health belief model person health behav ior health educ monogr 1974;214 409 19 40 kaprio koskenvuo prospect studi psycholog characterist health behavior morbid cigarett smok 18 erak sa becker mh strecher vj kirscht jp smoke behav er prior quit compar persist smoker ior cessat techniqu health decis model smoker clin epidemiol 1988;41 2 139 50 med 1985;78 817 25 41 piri pl murrai dm luepker rv gender differ ciga 19 lam sze pc sack hs chalmer tc meta analysi ran rett smoke quit cohort young adult jdomiz trial nicotin chew gum lancet 1987;2;27 9 public health 1991;81 3 324 7.20 silagi mant fowler lodg meta analysi efficaci 42 coamb rb li kozlowski lt ag interact heavinessof nicotin replac therapi smoke cessat lancet smoke predict success cessat smoke j1994;343 139 42 epidemiol 1992;135 3 240 6.21 tang jl law wald effect nicotin replac 43 freund km d’agostino rb belang aj kannel wb soke jtherapi help peopl stop smoke bmj 1994 308 21 6 iii com.ibm.drl.hbcp.predictor smoke cessat framingham studi am22 gilbert jr wilson dm ja taylor dw lindsai ea singer epidemiol 1992;135 9 957 64 willm dj smoke cessat primari care random 44 sa institut sa stat user guid version 6 4th ed carycontrol trial nicotin bear chew gum fam pract nc sa institut 1989.1989;28 1 49 55 45 venter mh jacob dr luepker rv maiman la gillum rp 23 wilson wood johnston sicurella random clinic spous concord smoke pattern minnesota hearttrial support follow cigarett smoker famili prac survei epidemiol 1984;120 4 608 16 tice med assoc 1982;126 127 9 46 hymnowitz sexton ocken jk grandit cigarette24 fagerstroem ko effect nicotin chew gum follow smoke mrfit baselin factor smokingappoint physician base smoke cessat prev med cessat relaps forum prev med 1991;20 590 601.1984;13 517 27 47 venter mh solberg li kottk te brekk pechacek tf 25 cohen lichtenstein prochaska jo rossi js gritz er carr grimm rh jr smoke pattern social contract smok cr al debunk myth quit evid er smoker smoker doctor help smokers10 prospect studi person attempt quit smoke studi prev med 1987;16 626 35 psychol 1989;44 11 1355 65 48 waldron pattern gender differ smoke 26 croog sh richard np health belief smoke pattern soc sci med 1991;32 9 989 05 heart patient wive longitudin studi public health 1977;67 10 921 30 49 kaufman nj smoke young women physician role stop equal opportun killer jama 1994;271 8 629 30.27 pederson ll complianc physician advic quit smoke review literatur prev med 1982;11 71 84 50 sorli pd kannel wb descript cigarett smoke cessa tion resumpt framingham studi prev med28 hansen wb malott ck perceiv person immun de 1990;19 335 45 velop belief suscept consequ smoke prev med 1986;15 363 72 51 pierc jp intern comparison trend cigarett smok ing preval public health 1989;79 2 152 7.29 fagerstroem ko schneider ng measur nicotin depend review fagerstroem toler questionnair behav 52 green kl johnson jv effect psychosoci work organiza med 1989;12 2 159 82 tion pattern cigarett smoke male chemic plant employe public health 1990;80 11 1368 71.30 kabat gc wynder el determin quit smoke public health 1987;77 10 1301 5 53 mcwother wp boyd gm mattson com.ibm.drl.hbcp.predictor quit smoke nhane follow experi clin epidemiol31 istituto central di statistica classificazion dell professioni dell attivitá economich roma istat 1987 1990;43 12 1399 405 com.ibm.drl.hbcp.predictor smoke cessat 421 54 lundberg rosen rosen stop smoke result 60 fior mc novotni te pierc jp giovino ga hatziandreu ej newcomb pa al method quit smoke unitedfrom panel survei live condit sweden soc sci med 1991;32 5 619 22 state cessat program jama 1990;263 20 2760 5 61 anda rf remington pl sienko dg davi rm physicians55 russel mah stapleton ja hajek jackson ph belcher advis smoker quit jama 1987;257 14 1916 9 district programm reduc smoke sustain interven tion gener practition affect preval epidemiol 62 frank winklebi ma altman dg rockhil fortmann sp muniti health 1988;42 111 5 com.ibm.drl.hbcp.predictor physician smoke cessat advic jama 1991;266 22 3139 44.56 sorensen pechacek tf occup sex differ smoke smoke cessat occup med 1986;28 5 360 4 63 wagenknecht le perkin ll cutter gr sidnei burk gl manolio ta al cigarett smoke behavior strongli related57 covei ls zang ea wynder el cigarett smoke occupa educ statu cardia studi prev med 1990 tional statu 1977 1990 public health 1992 19 158 69.82 9 1230 4 64 pierc jp fiorc mc novotni te hatziandreu ej davi rm 58 armstrong bk white saracci respons rate arm trend cigarett smoke unit state educationalstrong bk editor principl exposur measur epid differ increas jama 1989;261 1 56 60 miologi london oxford univ press 1992 65 pierc jp fiorc mc novotni te hatziandreu ej davi rm 59 kottk te solberg li brekk ml conn sa maxwel brekk trend cigarett smoke unit state project tomj doctor help smoker develop clinic base year 2000 jama 1989;261 1 61 5 smoke intervent system burn dm cohen sj kottk te grtz er editor tobacco clinician washington 66 rosen han wall chang smoke habit swe den health int epidemiolu. depart health human servic 1994 nih public 94 3693 monogr 5 1990;19 316 21
reduc matern smoke relaps long term evalu pediatr intervention1 herbert severson ph.d 2 judi andrew ph.d edward lichtenstein ph.d michael wall m.d laura aker b. oregon research institut 1715 franklin boulevard eugen oregon 97403 oregon health scienc univers portland oregon 97201 background pediatr care visit provid clinic opportun counsel mother smoke deleteri effect environ mental tobacco smoke et infant health method forti oregon pediatr offic en roll 2,901 women smoke quit pregnanc survei newborn offic visit randomli assign offic provid advic andmateri tomoth eachwel care visit 6 month postpartum pro mote quit relaps prevent result intervent reduc smoke 5.9 2.7 relaps 55 45 6 month follow logist regress analysi 12 month reveal signific treatment effect intervent posit effect secondari outcom variabl readi quit attitud knowl edg et multipl logist regress analysi indi cate husband partner smokingwa strongest com.ibm.drl.hbcp.predictor matern quit relaps conclus pediatr offic base intervent significantli affect smoke relaps preven tion mother newborn effect decreas time consist prompt provid give advic materi care visit provid low cost intervent reduc infant et exposur 1997 academ press kei word smoke cessat relaps prevent pediatrician postpartum environment tobacco smoke introduct matern cigarett smoke pregnanc postpartum deleteri health effect fetu newborn infant 1 3 risk smoke pregnant decad 4 larg bodi epidemiolog data accru document risk exposur environment tobacco smoke et infant young children 5,6 risk includ increas rate upper lower respiratori infect otiti media asthma 6 matern smoke pri mari sourc et exposur young infant 7,8 nation survei estim approxim 30 women smoker pregnant rate vari ag socioeconom statu ethnic mother 9,3 public risk fetu 20 40 women quit smok ing learn pregnant 10 12,3 addit 3 16 quit pregnanc 10 quit smoke pregnant appear asso ciat higher level educ attain socioeconom statu rel nonquitt 13 35 women sampl report quit smoke pregnanc factor relat quit younger ag higher level educ lower smoke level partner smoke consum alcohol 14 intervent health care provid context medic care encourag pregnant women quit smoke 15 recent meta analysi random trial prenat smoke ce sation conclud intervent result 50 increas smoke cessat 16 tensiv counsel multipl contact portiv materi follow result larger ce sation effect 16 women quit smoke preg nanci highli relaps postpartum es timat 70 80 women quit pregnanc relaps year birth child 12 studi examin postpartum relaps pat tern attempt reduc relaps mother newborn 3,17 public health offici suggest encourag assist parent smoke cessat relaps avoid role pediatrician 18 1 project fund nation heart lung blood institut grant ro1 hl43923 2 reprint request address fax 541 484 1108 prevent medicin 26 120 130 1997 articl pm960115 120 0091 7435 97 25.00 copyright 1997 academ press right reproduct form reserv regularli schedul pediatr care visit offer uniqu opportun relat parent smoke infant health mother seek advic pediatrician care protect babi recept advic quit resum smoke protect infant exposur environment tobacco smoke pedia trician provid advic present format effect environment tobacco smoke parent repeat care offic visit offer opportun inforc smoke messag parent statewid survei pediatrician main ver mont assess attitud practic pedia trician provis smoke cessat relaps prevent advic parent patient 19 major report advis parent quit smoke 75 40 smoke tori 11 record parent smoke sta tu child chart 19 major barrier provid ing smoke cessat advic includ lack time lack confid perceiv lack support commun consist survei physician 15 8.5 pediatrician ceiv train smoke cessat method 87 learn method modif matern smoke mom studi provid pediatrician staff train ing materi advis mother newborn smoke cessat relaps prevent studi enrol 2,901 mother newborn 1,583 receiv intervent regularli schedul babi visit 6 month postpartum 6 month postpartum intervent modest signific effect matern smoke rate stronger effect pre vent relaps smoker 20 intervent produc mother atti tude knowledg et effect toler allow smoke home intervent place 6 month postpartum interest examin longer term durabl effect report data 12 month follow women enrol studi evalu intervent rel measur offic adher protocol studi evalu patient variabl ag educ ethnic partner smoke weight gain pariti breast feed readi quit 21 com.ibm.drl.hbcp.predictor quit relaps 1 year postpartum method design pediatr practic block random iz minim 23 practic extend 26 prac tice intervent block variabl locat portland metropolitan area versu number practition 1 2 4 ù5 mother newborn tend practic subject mother unit statist analysi adjust practic level effect practition recruit member oregon academi pediatr portland area interst 5 corridor 4 158 invit mail telephon particip invit 128 pediatrician 49 practic agre particip pediatrician mean ag 43.0 year rang 29 64 differ condit ag pediatrician eighteen nurs practition physician assi tant includ particip practic enrol studi enrol occur visit pediatrician offic condit typic 2 week postpartum visit mother fill health questionnair answer que tion smoke month prior pregnant includ studi subs quent questionnair item allow breakdown mother smoker smoke quitter smoke total 13,495 sur vei complet mother newborn repr sent 76 mother newborn offic 3,204 mother report smoke prior pregnanc 2,901 form complet follow figur 1 show breakdown number smoker quitter studi condit extens descript studi design enrol ment procedur appear previou paper 20 minim extend intervent intervent minim tend condit began pediatrician hospit visit deliveri fig 1 mother gardless smoke statu receiv packet mate rial brochur letter mother sign pediatrician nurseri sign messag materi design alert mother reduc newborn exposur passiv smoke encourag mother quit smoke stai quit stop pregnanc hospit visit intervent constitut minim condit extend condit deliv addit inter vention babi visit gener alli occur 2 3 week 2 month 4 month 6 month birth elig mother categor reduc matern smoke relaps 121 smoker report current ciga rett quitter smoke hav ing smoke month prior pregnanc babi chart tag label denot mother smoke statu addit visual prompt af fix chart visit newborn checklist sheet prompt provid follow intervent protocol written project materi tailor mother current smoke statu insert chart receptionist nurs intervent protocol compris advic encourag visit accompani spe cialli develop written materi special devel op video shown visit detail intervent present wall al 20 physician staff train practic random senior member research team met pediatrician nurs practitio ner physician assist extend condi tion 45 60 min train session set written materi provid guid line give inform advic support contain summari effect passiv smoke infant health develop separ meet held offic staff delin practic aspect studi implement particu larli enrol mother studi minimi zation potenti disrupt offic flow search staff visit offic frequent start support staff problem solv visit offic condit 2 week interv collect studi form discuss practic obstacl implement follow assess outcom data obtain 6 12 month follow questionnair mail particip questionnair accompani 2 bill incent return form cover letter state respond enter monthli lotteri chanc win 100.00 subject return questionnair mail questionnair 2 week mail respond mail telephon que tionnair administ measur outcom measur mother consid sustain quitter report smoke puff past 7 dai 6 12 month assess current smoker extent smoke estim midpoint categor variabl cigarett smoke dai 1 4 5 10 11 20 20 measur mother knowledg health effect passiv smoke 7 item cronbach 4 0.65 attitud et 4 item 4 0.66 obtain complet written question nair com.ibm.drl.hbcp.predictor measur prospect com.ibm.drl.hbcp.predictor vari abl obtain baselin mean questionnair enrol com.ibm.drl.hbcp.predictor informa tion includ birth date ethnic racial background cation number alcohol drink past week current recent smoke statu number chil dren number smoker home smoke allow home variabl assess addict current smoker creat standard iz sum amount smoke time daili cigarett quitter ask confid stai quit current smoker ask smoke interest quit mean contempl ladder 21 11 item scale rang thought quit 0 take action quit fig 1 subject distribut condit smoke statu severson al 122 smoke 10 measur serv secondari outcom measur gaug impact interven tion readi quit number concurr com.ibm.drl.hbcp.predictor assess 6 12 month follow partner household member smoke report mother alcohol consumpt breast feed prac tice weight gain loss infant ill histori partner consid current smoker mother check smoke regularli smoke avoid cut amount smoke babi partner consid nonsmok er mother quit smoke continu smoke smoke mother report receipt intervent compo nent written materi verbal advic video com.ibm.drl.hbcp.predictor provid protocol adher provid adher protocol estim wai telephon survei mother condit assess report receipt intervent compon chart review extens intervent condit determin requisit label checklist place telephon survei telephon survei ran domli chosen 15 mother perform 1 2 week 2 4 month care vi question survei direct ob tain recal estim physician offic compli anc protocol mother ask receiv written materi oral advic project video clinic visit simi lar question includ 6 month follow questionnair data collect mother condit chart review protocol requir mother report smoke prior pregnanc identifi label affix babi chart indic wheth er mother current smoker quitter i. quit pregnanc checklist affix chart prior visit pro vider circl item checklist protocol event deliv occur ascertain procedur adher constraint practic confiden tialiti hire person intervent practic conduct chart review project staff train design chart review provid feedback chart chart anoni mousli respect patient individu provid practic identifi proce dure yield score practic presenc smoker quitter label chart percent ag checklist affix actual visit visit checklist percentag mark provid indic intervent event oc cur data obtain extend intervent practic result attrit analys analys present paper base respons 2,003 2,901 mother enrol studi 69.0 mother complet 6 12 month assess 898 moth er complet assess 12 babi di 4 longer live ba bi 44 refus complet 6 12 month assess ment 838 locat assess proport mother extend 69.1 minim 68.9 condit complet assess similar significantli higher pro portion quitter enrol 74.9 smok er enrol 65.9 complet 6 12 month survei x2 4 2901 4 25.06 0.001 mother complet assess older mean ag 26.12 versu 23.99 2821 4 9.30 0.001 graduat high school 78.0 versu 62.7 x2 4 2719 4 86.22 0.001 caucasian 87.4 versu 82.1 x2 4 2624 4 12.72 0.001 child 52.2 versu 26.26 x2 4 2901 4 164.2 0.001 husband smoke 51.7 versu 58.9 x2 4 2901 4 13.07 0.001 attrit dif ferenc amount smoke prior pregnanc amount smoke enrol mother drink past week comparison mother minim extend condit mother extend condit complet 6 12 month assess older mean ag 26.4 versu 25.8 1946 4 2.39 0.05 educ x2 4 1,884 4 15.37 0.01 husband partner smoke 49 versu 55.5 x2 4 2241 4 7.67 0.01 mother minim condit differ condit number previou children ethnic mother mother smoke statu pregnanc amount smoke prior pregnanc mother allow smoke home mother drink alcohol past week smoker enrol differ condit mother level tobacco addic tion amount smoke enrol contempl quit smoke quitter enrol differ confid remain nonsmok differ condit ag educ husband partner smoke statu reduc matern smoke relaps 123 sequent outcom analys analys examin predict outcom control variabl practic effect unit random studi practic unit analysi mother mix model analysi varianc mother nest practic practic nest condit minim versu tend examin effect interven tion analysi quit rate practic smoker enrol nest design practic mother quit smoke result varianc practic intrapractic depen denc measur intraclass correl initi smoke statu quit smoker enrol ment relaps quitter enrol low 0.002 0.0009 0.013 design effect analysi quit rate analys effect intervent de pendent variabl practic effect nonsignifi intraclass intrapractic correl rang 0.0002 0.025 purpos simplif practic effect present effect extend intervent smoke cessat percentag tabl 1 assum mother enrol studi complet 6 12 month assess smok er time assess result show mother quit smoke pregnanc receiv extend intervent signifi cantli maintain cessat 12 month period 4 200 609 32.8 mother receiv minim intervent 4 109 417 26.1 mother smoke enrol receiv extend interven tion significantli quit 6 month assess stai quit 12 month assess period 4 25 1073 2.3 mother receiv minim inter vention 4 10 802 1.2 logist regr sion control ag educ husband partner smoke statu enrol effect intervent sustain quit ei ther smoker odd ratio 1.78 95 ci 0.84 3.74 quitter odd ratio 1.25 95 ci 0.93 1.68 enrol ment effect secondari outcom variabl secondari outcom interest chang relat probabl futur quit attempt mother quit smoke relaps quit univari mix model analys covari practic nest condit control ag educ husband smoke initi measur outcom variabl examin differ condit secondari outcom analys main effect practic signific report outcom variabl correl ind pendent signific level adjust bonferroni correct maintain level 0.05 singl variabl 0.01 consid signific mother smoker enrol continu smoke 12 month pe riod mother particip extend inter vention smoke significantli fewer cigarett dai higher readi quit smoke measur contempl ladder report likelihood quit smoke neg attitud smoke demon strate knowledg danger pa sive smoke exposur compar mother minim condit tabl 2 mother quit smoke enrol subsequ laps mother particip extend tervent report significantli higher likelihood quit mother partici pate minim condit effect signifi 4 8.04 0.01 control mother educ ag partner smoke statu enrol com.ibm.drl.hbcp.predictor sustain quit potenti com.ibm.drl.hbcp.predictor includ characterist pediatr practic locat portland versu portland practic size prospect vari abl measur enrol concurr vari abl measur 6 12 month com.ibm.drl.hbcp.predictor prospect com.ibm.drl.hbcp.predictor includ characterist mother environ pariti newborn num ber smoker hous allow smoke home enrol characterist mother enrol addict cigarett num tabl 1 12 month quit rate function intervent minim extend x2n continu quit quitter enrol 109 417 26.1 200 609 32.8 5.28 smoker enrol 10 802 1.2 25 1,073 2.3 2.94 12 month quit quitter enrol 163 417 39.1 261 609 42.9 1.45 smoker enrol 38 802 4.7 59 1,073 5.5 0.54 note result base tail test mother particip assess consid smoker 0.05 severson al 124 ber cigarett smoke dai intent quit smok ing measur contempl ladder cut pregnanc amount smoke prior pregnanc abstin alcohol past week confid remain nonsmok advic materi receiv pediatrician receipt index number written materi receiv number time verbal advic receiv watch video receiv teddi bear packet hospit health infant 6 month number emerg room physician visit acut ill number visit respiratori ill number cough cold concurr com.ibm.drl.hbcp.predictor includ characterist mother environ 6 month smoke statu husband partner number smoker home forbid smoke home smoke statu husband partner 12 month characterist mother 6 month abstin alcohol past week nurs babi weight gain loss weight gain loss 12 month separ univari analys predict quit perform smoker quitter enrol intervent condit signific univari pre dictor condit select entri hierarchi forward multipl regress determin combin variabl pre dict sustain quit condit educ ag partner smoke statu enrol en tere regress equat practic variabl prospect com.ibm.drl.hbcp.predictor measur enrol final concurr com.ibm.drl.hbcp.predictor mea sure 6 12 month amount varianc explain pair variabl compris sig nific univari com.ibm.drl.hbcp.predictor interact condit evalu hierarchi clu ter pair variabl contribut varianc enter interact signific drop equat remain pair variabl evalu entri pair explain varianc enter smoker enrol control ag educa tion partner smoke statu enrol sig nific univari com.ibm.drl.hbcp.predictor sustain quit smoker enrol condit partner smoke statu 6 month minim odd ratio 9.79 95 ci 0.67 57.55 0.01 extend 8.67 95 ci 2.89 26.01 0.01 12 month minim odd ratio 7.34 95 ci 1.28 42.02 0.01 extend odd ratio 8.20 ci 2.70 24.95 0.01 addit univari com.ibm.drl.hbcp.predictor sustain quit smoker enrol extend condi tion forbid smoke home odd ratio 9.92 ci 2.91 33.74 0.01 weight loss odd ratio 1.24 ci 1.05 1.47 0.05 result hierarchi logist regress tabl 3 interact condit signific interact drop analysi tabl 3 su tain quit smoker enrol predict partner smoke statu time pe riod forbid smoke home result suggest smoke mother enrol ment quit stai quit tabl 3 result multivari logist regress predict continu quit smoker enrol variabl odd ratio confid interv condit 0.55 1.73 0.76 3.97 ag 0.01 0.99 0.95 1.09 1.01 educ 0.09 0.92 0.71 1.67 1.09 partner nonsmok 1.35 3.87 1.60 9.36 enrol partner nonsmok 1.40 4.06 1.28 12.90 6 month forbid smoke 1.72 5.61 2.24 14.04 home 6 month partner nonsmok 1.85 6.39 1,95 20.98 12 month weight loss 12 month 0.20 1.22 1.05 1.42 note signific univari com.ibm.drl.hbcp.predictor consid entri 0.05 0.01 0.001 tabl 2 effect intervent mother continu smoke 4 1,200 variabl adjust meansa fminim extend cigarett smoke dayb 12.88 11.65 8.78 readi quit smoke contempl ladder 5.95 6.49 16.49 likelihood quit smokingb 3.10 3.33 8.63 posit attitud smoke 8.88 8.25 9.43 knowledg danger passiv smoke exposur 4.64 5.09 17.12 control ag educ husband smoke statu enrol control variabl enrol 0.01 0.001 reduc matern smoke relaps 125 partner nonsmok enrol part ner quit smoke enrol 6 month remain nonsmok 6 month partner quit smoke 6 12 month remain nonsmok 12 month mother port forbid smoke home 6 month assess maintain cessat concern weight loss appear significantli relat cessat quit smoke stai quit lost significantli weight birth child con tinu smoke quitter enrol signific com.ibm.drl.hbcp.predictor maintain cessat quitter enrol ei ther condit confid remain smoker minim odd ratio 1.62 ci 1.15 2.27 0.01 extend odd ratio 1.66 95 ci 1.30 2.11 0.01 forbid smoke hous minim odd ratio 1.95 95 ci 1.05 3.62 0.05 extend odd ratio 1.85 95 ci 1.11 3.11 0.01 abstin alcohol past week 6 month assess ment minim odd ratio 1.81 95 ci 1.01 3.25 0.05 extend odd ratio 1.71 95 ci 1.14 2.57 0.01 quitter enrol minim con dition addit signific com.ibm.drl.hbcp.predictor absti nenc alcohol past week enrol odd ratio 2.09 95 ci 1.04 4.20 0.05 num ber medic visit respiratori ill odd ratio 1.89 ci 1.13 3.17 0.05 quitter enrol ment extend condit addit signific com.ibm.drl.hbcp.predictor partner nonsmok 6 month odd ratio 2.70 ci 1.51 4.82 0.01 12 month odd ratio 3.27 ci 1.87 5.73 0.01 number smoker home 6 month odd ratio 2.58 ci 1.51 4.42 0.01 weight loss odd ratio 1.18 ci 1.06 1.32 0.01 hierarchi logist regress signific com.ibm.drl.hbcp.predictor relaps tabl 4 husband smoke statu enrol chang husband smoke sta tu 12 month confid remain smoker enrol consumpt alcohol 6 month interact weight loss condi tion interpret interact suggest mother extend condit laps lost weight birth child maintain cessat al weight gain loss includ com.ibm.drl.hbcp.predictor expect difficulti return prepregn weight relaps weight loss predict relaps expect direct power com.ibm.drl.hbcp.predictor rela tion mother mainten relaps husband smoke statu statu analyz women smok er enrol quit remain quit 12 month assess 4 35 hu band start smoke enrol 6 month 28.6 husband quit main quit contrast women smoke 12 month period 4 1,745 5.9 husband start smoke en rollment 6 month 7.8 husband quit smoke enrol 6 month simi lar pattern evid relaps mother quit enrol relaps 6 12 month 4 717 11.7 husband start smoke enrol 6 month addit 9.1 husband start smoke 6 12 month assess contrast 5.5 mother maintain cessat 12 month assess 4 309 husband start smoke enrol ment 6 month assess 2.9 hu tabl 4 result multivari logist regress predict continu quit quitter enrol variabl odd ratio confid interv condit 0.134 1.14 0.80 1.63 ag 0.035 1.04 1.00 1.07 educ 0.017 1.02 0.85 1.22 partner nonsmok enrol 0.53 1.70 1.00 2.87 confid remain nonsmok 0.47 1.60 1.30 1.96 partner nonsmok 6 month 0.35 1.42 0.82 2.44 forbid smoke home 6 month 0.56 1.75 1.15 2.67 abstain alcohol past week 6 month 0.51 1.66 1.16 2.38 weight loss 6 month 0.09 1.09 1.00 1.20 weight loss condit 6 month 0.22 1.25 1.05 1.48 partner nonsmok 12 month 0.86 2.35 1.40 3.97 note signific univari com.ibm.drl.hbcp.predictor consid entri 0.05 0.01 severson al 126 band start smoke 6 12 month assess report receipt intervent result 2 4 month phone probe report previous 20 briefli data time period show mother extend con dition report receiv significantli substan tialli advic mother minim condit twofold differ report advic quit 68 versu 27 2 month 59 versu 33 4 month practic adher chart review data reveal consider variabl protocol implement practic pre enc mom label subject chart rang 24 94 median 69 look presenc checklist serv prompt pro vider intervent patient visit patient fre quentli attend care visit data show implement mom protocol decai time visit 1 4 median percentag checklist chart 61 50 32 24 relationship offic adher enc protocol studi outcom assess correl measur practic adher quit relaps analyz practic relationship number md checklist percentag enrol mother identifica tion sticker chart correl percentag quitter relaps percentag smoker quit factor significantli relat studi outcom 4 0.34 0.25 relaps 0.34 0.13 quit md checklist present chart 85 checklist show intervent activ check cost data cost data gather intent perform cost effect analysi inter vention conclud analysi justifi small margin nonsignifi intervent effect cessat 12 month signific effect reduc parent smoke 6 month cessat relaps pre vention outcom 20 provid benefit infant addition observ signific knowledg et reduc et exposur increas readi quit cost data assess replic intervent cost includ train time time involv staff assess advic counsel mate rial estim practic pediatrician offic staff time cost gin implement mom intervent 500 200 budget facilit staff cost determin record smoke statu mother enter prac tice approxim 20 75 mother inter vention cost profession time staff time written materi smoker quitter total 10 15 mother visit 10 smoke mother need assist quit tempt detail cost inform author discuss result pediatr offic base intervent moder support pediatrician nurs staff provid smoke cessat ad vice materi mother smoke quit pregnanc pediatrician privat practic signific impact ma ternal smoke evidenc result 6 month follow effect reduc time mom intervent margin effect 12 month follow univari analysi logist regress analysi signifi suggest differ due ini tial differ group control initi group differ signific effect program 6 month conserv analysi report wall al 20 previou public quit rate 6 12 month follow modest conserv intent treat model count mother lost follow complet 6 12 month follow smoker intervent signific 6 month fol low signific 12 month continu quit 6 12 month mother complet assess sustain quit strin gent endpoint criterion typic result lower quit rate point preval estim 22,23 appear program effect 6 month follow reduc nonsignific 12 month concern due increas quit rate 6 12 month mother minim prac tice quit rate mother smoke enrol extend offic mini mal offic 6 month 5.9 versu 2.7 differ enc declin 5.5 versu 4.7 12 month increas quit minim offic due increas anti smoke activ pediatrician minim offic continu mind intervent provid inform packet mother hospit visit offic visit weekli staff reduc matern smoke relaps 127 pick enrol form pe riod media profess increas tention issu et i. articl rela tionship sid et factor made issu salient minim intervent pediatrician prompt offic activ issu report minim offic anxiou project materi provid mother effect program quitter erod 6 12 month assess relaps prevent effect 6 month longer signific appear prompt continu relaps women quit smoke pregnanc women continu smoke pregnanc advic obstetrician relaps pediatr care visit 2 week postpartum difficult group target cessat smoker repres group minim advic materi provid pediatrician suffici intens mag nitud impact smoke behavior pre dictor mother quit smoke 6 12 month postpartum allow smoke home husband partner smoke interest strongest com.ibm.drl.hbcp.predictor quit mother report allow smoke home 6 month pro gram materi emphas detriment ef fect et babi health mother told avoid expos child et mother report comfort smoke quit smoke intermedi step make hous smoke free import step quit character stage chang futur program emphas prohibit smoke hous women readi quit smoke consist focu group feedback mother report et health effect inform felt comfort restrict household smoke quit women quit smoke pregnanc postpartum relaps rate high consist literatur recent studi report estim rang 40 90 women return smoke 6 month postpartum 1,12,17 rate surprisingli high smoke cessat pregnanc occur trimest deliveri mother absti nent 6 month longer 10 appear women context pregnanc time limit defin event tobacco abstin easili maintain stress transit parenthood contrib ut relaps 24 focu relaps prevent mother critic maintain abstin establish reduc infant exposur risk et com.ibm.drl.hbcp.predictor woman quit smoke pregnanc remain nonsmok confid remain nonsmok husband smoke statu consumpt alcohol beverag 6 month weight loss 6 month husband smoke statu major factor woman relaps difficult remain nonsmok live partner continu smoke laps factor influenc moth er report confid remain nonsmok alcohol consumpt cite author high risk situat relaps 25 confirm alcohol 6 month predict subsequ relaps concern weight gain loss continu smoke cessat issu receiv creas attent 26 28 studi appear women lost weight relaps consist ciga rett part effort lose weight gain pregnanc women concern return prepregn weight cigarett consist studi report concern weight gain sig nific com.ibm.drl.hbcp.predictor relaps 6 month postpartum 17 futur program postpartum women emphasi issu materi counsel provid husband smoke statu predict assess point enrol 6 month 12 month decreas signific time strong associ husband smoke statu subsequ quit critic natur relationship attempt reduc women smoke mom program contact father present care visit print materi aim encourag mother quit defici pediatr offic intervent inaccess father lack materi specif father creativ effort video newslett mail direct father 29 outreach part comprehens effort affect matern smoke mom project letter father evalu father read affect futur program make concert effort impact father evalu receipt ma terial smoke cessat nonsmok pri mari endpoint studi interest examin variabl relat relat behavior encourag observ mother expos intervent smoke signifi cantli fewer cigarett dai knowledg severson al 128 et neg attitud smoke report higher stage readi quit smoke 12 month mother mini mal condit extend intervent mother port neg attitud et exposur knowledg deleteri effect et quit attempt mother im pact program meet criterion quit prochaska al 30 de scribe tobacco cessat process move stage readi behavior port mother receiv intervent indi cate increas likelihood readi quit smok ing women make continu quit tempt benefici suggest averag smoker report multipl quit attempt succeed 31 concern medic offic base interven tion depend commit goodwil provid degre practition implement recommend procedur 22,23 mom studi pediatrician nurs prac tition nurs front offic staff plai role identifi mother smoke statu tag ba bi chart sticker prompt subs quentli give mother materi advic encour ag tobacco abstin intervent de sign flexibl adapt clinic practic procedur involv chang routin potenti obstacl program full implement busi pediatr clin ic frequent time pressur measur practic complianc pro tocol wai compel ling chart review review chart show declin protocol adher success visit offic carri recommend pro cedur visit 61 time sequent visit 2 4 6 month visit show de cline percentag mother babi chart tag prompt intervent steadi de cline percentag mother receiv inter vention suggest prompt provid pre viou studi shown repeat messag creas effect smoke cessat women 10 care visit provid regularli schedul opportun provid support tobacco abstin current studi sticker prompt chart provid offer advic materi care visit prob lem studi depend prompt provid develop system commit ment sticker prompt offic staff decai protocol adher observ studi explain part decreas cessat rate smoker increas relaps observ quitter time futur program achiev outcom staff prompt provid advic materi care visit prompt critic 85 time staff note intervent activ md checklist put chart mom label appear 69 chart md checklist consist futur studi focu wai ensur patient identif provid prompt sheet chart experi adopt program pediatrician kei staff critic full implement research report involv commit nurs offic personnel critic adher protocol 22,23 program enthusiast endors pediatrician nurs front offic staff particip adopt decis observ higher rate protocol adher pediatr care visit offer uniqu clinic op portun discuss effect tobacco smoke infant develop health pediatrician nurs offer cessat relaps prevent me sage context regular offic visit intervent lead reduc exposur infant et long term impact matern smoke disappoint evid reduc smoke increas knowledg et effect higher stage readi quit smoke part mother previou research involv home visit smoke mother demonstr tensiv intervent significantli reduc infant passiv smoke lower respiratori ill 32 current offic program de sign easili integr care visit provid low intens program broadli adopt low cost public health intervent fu ture research focu wai increas con sistenc program advic implement consist implement offic staff previ ou research advoc health care visit opportun time counsel adult quit smoke studi concern et exposur infant vehicl extend approach pediatr offic acknowledg author acknowledg profession effort sue jordan maya william provid intervent servic pediatr clinic sue jordan collect cost data barb eisenhardt data entri maureen barcklei data analyt servic
secondari smoke prevent univers set random comparison experienti theori base intervent standard didact intervent increas cessat motiv vani nath simmon thoma brandon univers south florida lee moffitt cancer center research institut object colleg repres untap opportun reach grow number student smoker risk progress regular smoke aim studi test efficaci theori base experienti intervent increas motiv quit smoke reduc smoke behavior design studi 3 arm random design examin efficaci experienti secondari prevent intervent control group includ tradit didact smoke intervent experienti intervent nutrit main outcom measur 2 primari depend variabl chang report intent quit smoke measur pre postintervent chang smoke behavior month intervent result hypothes experienti smoke intervent effect control group increas motiv quit effect found femal particip 1 month follow smoke intervent produc higher rate smoke cessat reduct nutrit control condit conclus find support potenti efficaci intens experienti intervent femal smoker keyword tobacco colleg smoker intervent smoke motiv quit increas adolesc smoke middl school high school student reach colleg popul wechsler rigotti gledhil hoyt lee 1998 fact young adult year ag 18 24 highest preval smoke thoni echeagarai wagner 2000 colleg student report current smoker rigotti lee wechsler 2000 substanti effort direct prevent tobacco adolesc attent paid begun smoke primari prevent effort view ultim goal tobacco control effort secondari prevent i. treatment earli stage tobacco depend deserv attent colleg ag youth repres youngest popul tobacco industri legal target make colleg student vulner market strategi facilit addict rigotti moran wechsler 2005 cig arett market colleg student eas stress caus transit teen year adulthood ling glantz 2002 colleg student smoke behavior en trench young adolesc start smoke colleg heavier smoker young adult center diseas control prevent 2001 smoke rate lower older adult smoker current colleg smoker 32 smoke cigarett dai 13 smoke pack dai rigotti al 2000 fluctuat smoke behavior colleg year suggest behavior malleabl older adult smoker wetter al 2004 addit colleg student cognit outcom expect effect smoke specif develop brandon baker 1991 copeland brandon quinn 1995 unlik declin illicit drug drink typic occur colleg gotham sher wood 1997 smoke persist adulthood breslau peterson 1996 underscor time intervent colleg repres transit period smoke creat uniqu window opportun smoke intervent public health campaign smoker continu under timat health consequ long term tobacco wein stein marcu moser 2005 student wrongli number homicid cocain relat death exce num ber tobacco relat death giacopassi vandiv 1999 deni symptom relat smoke time report respiratori difficulti short breath persist cough prokhorov al 2003 colleg minim consequ smoke smoke resid room tobacco purchas meal card vani nath simmon thoma brandon depart psychol ogi univers south florida tobacco research intervent program lee moffitt cancer center research institut tampa florida research support grant cancer research prevent foundat halei courvil jessica mccabe assist data collect paul jacobsen william sacco cheryl kirstein loui penner help suggest correspond articl address vani nath simmon thoma brandon tobacco research intervent program lee moffitt cancer center research insti tute 4115 fowler avenu tampa fl 33617 mail nathv moffitt.usf.edu brandont moffitt.usf.edu health psycholog copyright 2007 american psycholog associ 2007 vol 26 3 268 277 0278 6133 07 12.00 doi 10.1037 0278 6133.26.3.268 268 gardin 2002 half survei colleg report offer smoke cessat program report resourc wechsler kellei siebr kuo rigotti 2001 student motiv seek typic cessat program creativ proactiv secondari prevent ef fort need date research colleg student smok ing character descript natur colleg student sampl conveni uncontrol feasibl studi e.g obermay rilei asif jean mari 2004 lack systemat research aim develop intervent specif colleg student smok er present studi test experienti intervent base theori empir research social psycholog liter atur attitud behavior chang research suggest experienti activ learn produc endur attitud behavior tradit didact instruct miller wozniak rust miller slezak 1996 onion bartzoka 1998 viswesvaran schmidt 1992 inform deliv manner effect typic didact noninteract method passiv relai infor mation e.g pamphlet video experienti intervent colleg student alcohol expect chal leng paradigm dark goldman 1993 1998 intervent colleg student alcohol placebo beverag underag observ drink beverag prior opportun social interact ask guess student receiv alcohol versu placebo subsequ discov guess chanc procedur found reduc subsequ drink particip lack high qualiti placebo cigarett fact smoker expect reflect accur effect drug make paradigm unfeas tobacco intervent experienti activ learn characterist intervent serv model current studi prior research suggest present smoker risk inform effect strategi smoker cognit disson reduc techniqu festing 1957 discount person relev messag offer intervent e.g halpern 1994 jenk 1992 mcmaster lee 1991 disson theori relev smoker contin ualli expos health risk inform awar risk inconsist continu smoke result psycho logic discomfort motiv reduc basi disson theori smoker reduc disson chang behavior quit smoke misinterpret ignor inform increas disson ad cognit conson behavior smoker claim addict smoke behavior hand jenk 1992 contend posit effect smoke worth risk line disson theori smoker endors greater number ration smoke nonsmok smoker equal level factual knowledg mcmaster lee 1991 half smoker sampl endors statement smoker harm cigarett smoker total revers damag health decid ing give smoke similarli consist cognit disson interpret magnitud risk denial posi tive magnitud smoke dawlei fleisher dawlei 1985 halpern 1994 cognit disson theori appli health relat intervent stone aronson crain winslow fri 1994 principl disson theori encourag adopt safe sex practic colleg student specif induc hypocrisi particip write proattitudin speech advoc condom remind failur condom past particip videotap requir make public commit condom particip subsequ purchas signifi cantli condom control condit preliminari studi explor applic disson enhanc intervent colleg smoker simmon webb brandon 2004 randomli assign 144 smoker condit 2 2 factori design particip ask prepar counterattitudin essai factor 1 risk smoke factor 2 feasibl quit smoke particip control condit wrote essai histori tobacco particip read essai video camera told video intervent adolesc smoker primari experiment find signific teract factor intent quit smoke manipul increas intent effect addit primari correl find hypothes degre cognit disson intent quit smoke find studi suggest attitud intent quit smoke influenc experienti intervent current studi extend line research increas potenc social psycholog element includ follow measur smoke behavior primari aim present studi test efficaci theori base experienti intervent increas motiv quit smoke reduc smoke behavior method experiment design hypothesi condit includ experienti smoke inter vention exp smoke control condit control condit standard didact smoke intervent standard rep resent tradit educ smoke intervent al low test experienti theori base intervent effect typic didact intervent control condit experienti nutrit intervent exp nutrit compris experienti intervent diet nu trition provid health relat comparison condit control experienti compon mul tipl assess primari depend variabl chang report intent quit smoke measur pre postintervent chang smoke behavior month intervent hypothes exp smoke intervent produc greatest cessa tion motiv behavior compar control group secondari depend variabl examin potenti mediat includ risk percept smoke relat outcom expect cognit disson smoke relat knowledg demo 269smoke cessat colleg student graphic smoke histori variabl examin moder particip student identifi smoker screen que tionnair distribut classroom freshman orienta tion session univers south florida februari 2003 juli 2003 contact screen telephon inclus criteria 18 24 year ag speak read english smoke cigarett week smoke statu assess seri question screen questionnair mask focu studi prevent particip determin elig found 287 smoker met inclus criteria agre particip 215 136 femal 79 male arriv schedul appoint ment random intervent condit consti tute final sampl figur 1 sampl size yield power 80 detect group differ small medium effect size cohen 1988 measur smoke statu questionnair instrument ascertain current smoke statu smoke statu question nair includ fagerström test nicotin depend ftnd heatherton kozlowski frecker fagerström 1991 standard measur nicotin depend figur 1 particip flow diagram exp nutrit experienti nutrit intervent exp smoke exp riential smoke intervent standard standard didact smoke intervent 270 nath simmon brandon contempl ladder biener abram 1991 pri mari depend variabl contempl ladder continu ou measur motiv quit smoke compris 10 rung rang thought quit take action quit particip circl number ladder term think quit evid contempl ladder com.ibm.drl.hbcp.predictor smoke cessat establish biener abram 1991 herzog abram em mon linnan 2000 instrument administ baselin immedi intervent 1 month follow stage chang questionnair prochaska diclement 1983 secondari measur intent quit stage chang questionnair consist item measur quit motiv predict attempt quit smoke actual cessat diclement al 1991 administ intervent 1 month follow risk percept questionnair singl measur tool assess smoke risk percept weinstein 1998 current studi risk assess risk percept questionnair partici pant likelihood develop smoke relat diseas e.g lung cancer emphysema 7 point likert scale 1 extrem 7 extrem addit question ask particip perceiv chanc develop smoke relat diseas signific differ smoke risk percept found tervent group question prior studi simmon al 2004 smoke consequ questionnair scq brandon baker 1991 scq develop colleg student measur smoke relat outcom expect factor posit reinforc sensori satisfact neg reinforc ment neg affect reduct appetit weight control neg consequ coeffici alpha reliabl scale rang 91 96 scq measur outcom expect due intervent disson thermomet devin tauer barron elliot vanc 1999 elliot devin 1994 14 item instrument measur affect discomfort cognit disso nanc particip ask feel 7 point likert scale 1 appli 7 appli prior research found measur reliabl predict intent quit smoke simmon al 2004 3 item discomfort factor uncomfort uneasi bother repres distinct affec tive consequ disson induct test smoke knowledg measur partici pant retain smoke inform administ 10 item multipl choic test smoke knowledg develop studi base factual inform particip expos smoke intervent behavior measur behavior measur movement smoke cessat smoke cessat pam phlet exit experiment room number pamphlet group particip follow ing intervent record summari assess procedur baselin particip complet demograph question nair contempl ladder postintervent measur includ risk percept questionnair smoke statu que tionnair smoke consequ questionnair disson thermomet contempl ladder stage chang question nair test smoke knowledg compar nutrit focus questionnair administ con sistent cover stori particip exit studi number smoke cessat pamphlet pick record month particip call timelin follow back procedur sobel sobel 1992 recreat daili smoke behavior contempl ladder stage chang questionnair verbal intervent condit particip schedul appoint group 3 8 immedi prior start group experiment open conceal envelop prepar start studi reveal random assign intervent condit durat intervent type approxim 60 90 min particip paid 20 experienti smoke intervent exp smoke partici pant arriv obtain inform consent tell particip purpos studi develop approach health promot high school student particip random exp smoke condit told goal project creat seri health video high school senior varieti health relat topic research suggest attitud chang greatest individu chose engag disson enhanc hypocrit behavior e.g harmon jone 2000 zanna cooper 2000 particip question rememb particip complet voluntari particip emphas free choic wenzlaff lepag 2000 partici pant told choic discuss tobacco smok ing proper diet nutrit experiment led group choos tobacco topic state topic left cover nutrit smoke smoker smoke video nice chose smoke topic decis topic goal strategi foster appear choic particip feel make decis tobacco topic chosen particip engag discuss smoke relat topic e.g health risk smoke high cost cigarett gener discuss hand par ticip list 15 point ask incorpor discuss freedom add comment felt convinc high school student quit smoke particip publicli advoc belief inconsist behavior e.g current smoker state hazard smoke induc hypocrisi motiv behavior chang e.g eitel friend 1999 leak friend wadhwa 1999 deliveri speech video induc public commit prove effect tool 271smoke cessat colleg student pal highlight 26 inform health consequ pal highlight 24 inform social environment consequ pal highlight 74 incompat belief pal highlight 9 commit attitud chang e.g dickerson thibodeau aronson miller 1992 discuss videotap plai back particip view cognit disson theori festing 1957 posit peopl experi psycholog discomfort result feel hypocrit motiv reduc discomfort chang attitud behavior draycott dabb 1998 experienti nutrit intervent exp nutrit proce dure ident exp smoke condit group guid choos make nutrit relat video standard didact smoke intervent standard partici pant shown antismok video butt proven quit smoke plan american cancer societi ameri lung associ question answer session experiment follow debrief month intervent reach 1 partici pant follow call assess smoke statu particip paid 15 call debrief told earli stage research tape shown high school student result particip averag 20.2 year ag sd 1.7 smoke mean 55.4 cigarett week sd 45.9 3.4 year sd 2.3 mean ftnd score 2.0 sd 2.6 eighti percent sampl caucasian particip randomli assign exp smoke 72 exp nutrit 71 standard 72 condit seri analys varianc chi squar analys group equival demograph smoke histori variabl readi quit smoke tabl 1 depict unadjust contempl ladder score baselin postintervent 1 month follow investig differ intervent group respect readi quit conduct analys covari ancova baselin score covari adjust mean report subsequ analys predict control baselin score differ postintervent contempl ladder score found condit 2 211 15.61 001 specif immedi intervent particip exp smoke condit report higher intent quit smoke particip exp nutrit condit 6.99 5.85 1 140 30.25 001 2 178 standard condit 6.96 6.27 1 141 8.38 004 2 056 particip standard condit report greater readi quit smoke particip exp nutrit condit 6.49 6.08 1 140 6.57 011 2 045 1 month intervent remain signif icant differ group respect readi quit 2 210 15.18 001 specif particip exp smoke standard condit continu report higher intent quit smoke compar exp nutrit condit ps 001 2 187 2 098 particip exp smoke condit continu report greater readi quit compar standard condit 7.52 7.10 differ longer signific 1 month follow 233 exploratori analys conduct examin observ relationship condit readi quit moder demograph smoke variabl test moder ator includ ag educ grade point averag cigarett week fagerström score gender result demonstr gender met criteria moder specif signifi interact term condit gender suggest gen der act moder relationship condit motiv quit 2 209 5.90 003 figur 2 femal particip exp smoke con dition produc greater chang readi quit stan dard exp nutrit condit tabl 1 contempl ladder score time unadjust mean sampl condit preintervent postintervent 1 month follow sd sd sd full sampl exp smoke 5.47 3.02 6.76a 2.67 7.42a 2.44 standard 6.00 2.24 6.47b 2.20 7.19a 2.07 exp nutrit 6.06 2.86 6.10c 2.82 5.82b 2.50 women exp smoke 5.02 2.94 6.72a 2.54 7.50a 2.31 standard 6.10 1.98 6.56b 2.00 7.45a 1.97 exp nutrit 5.87 2.86 5.89c 2.80 5.64b 2.57 men exp smoke 6.32 3.04 6.80a 2.94 7.28a 2.73 standard 5.86 2.63 6.32a 2.50 6.78a 2.20 exp nutrit 6.38 2.88 6.46a 2.90 6.11b 2.39 note column mean subscript show signific differ control prein tervent score exp smoke experienti smoke intervent standard standard didact smoke intervent exp nutrit experienti nutrit intervent 272 nath simmon brandon pal highlight link 74 9 cognit disson moder effect gender seri ancova conduct gender examin differ condit readi quit control baselin score found signific differ postintervent con templat ladder score femal particip 2 132 16.45 001 male particip 2 75 1.09 341 pairwis comparison femal particip exp smoke condit report higher intent quit smoke intervent femal particip standard condit 7.10 6.17 1 88 8.60 004 2 089 exp nutrit condit 7.07 5.53 1 89 34.28 001 2 278 femal student standard condit report higher postintervent ladder score femal student exp nutrit condit 1 86 4.11 046 2 046 robust gender effect observ intervent analys conduct gender 1 month postintervent signific differ found femal particip contempl ladder score 2 131 15.43 001 ladder score differ male particip condit 2 75 1.97 146 1 month intervent femal particip exp smoke standard condit continu report higher inten tion quit compar exp nutrit condit ps 001 2 249 2 153 femal par ticip exp smoke condit report higher inten tion quit compar standard condit 7.70 7.24 differ longer signific 1 month postintervent 278 stage chang movement stage chang assess secondari measur ce sation motiv postintervent 1 month follow group differ found postintervent examin chang postintervent follow categor particip advanc progress stage assess point regress move back stage stabl stage movement expect stage movement significantli intervent group kruskal walli 2 2 209 17.67 001 greater proport particip exp smoke group 37.7 advanc motiv quit exp nutrit 10.0 001 standard group 22.9 008 signific differ observ tween standard exp nutrit condit 092 stage chang movement examin gender femal particip stage distribut significantli intervent group kruskal walli 2 2 132 22.45 001 signific differ observ male particip 2 2 77 461 794 pairwis parison femal particip exp smoke group 44.4 advanc motiv quit exp nutrit 6.7 standard group 21.4 ps 001 signific differ stage movement standard exp nutrit condit 106 behavior measur behavior measur impact number quit smoke pamphlet pick intervent record hypothes proport particip pamphlet significantli condit 2 2 215 8.47 014 specif greater proport individu exp smoke pick pamphlet smoke cessat 46 intervent standard 29 2 1 144 4.27 039 exp nutrit 24 2 1 143 7.53 006 group differ figur 2 mean postintervent contempl ladder score gender control preintervent ladder score exp smoke experienti smoke intervent exp nutrit experienti nutrit interven tion standard standard didact smoke intervent 273smoke cessat colleg student control condit signific natur measur unabl test gender effect smoke cessat reduct 1 month follow investig influenc intervent smoke behavior conduct chi squar analys examin differ enc intervent group proport particip reportedli quit smoke reduc smoke rate 1 month intervent success cessat de fine standard 7 dai point preval abstin criteria i. smoke 7 consecut dai prior follow hugh al 2003 analys reveal signific differ group proport quit smoke 2 2 214 6.55 038 greater proport particip exp smoke intervent group 9.9 standard group 12.5 quit smoke compar exp nutrit group 1.4 2 1 142 4.77 029 2 1 143 6.76 009 exp smoke standard condit differ quit rate 616 gender differ found cessat rate condit interest examin smoke behavior broadli includ reduct smoke rate 1 month follow signific differ observ group proport particip report quit smoke reduc number cigarett smoke 2 2 214 14.96 001 greater proport particip exp smoke condit report quit cut compar exp nutrit condit 67.6 35.2 2 1 142 14.91 001 particip standard condit report greater reduct smoke exp nutrit condit 52.8 35.2 034 differ proport exp smoke standard condit approach signifi canc 67.6 52.8 07 result examin gender femal male particip signific differ enc observ group proport particip reportedli reduc number cigarett smoke 2 2 135 13.66 001 pairwis comparison femal particip exp smoke standard condit report greater reduct smoke exp nutrit condit 69.6 31.3 001 54.5 31.3 026 greater percentag femal particip exp smoke condit report reduct smoke compar standard condit 69.6 54.5 differ signif icant 142 process measur mediat analys addit assess smoke motiv behavior examin differ potenti mediat vari abl tabl 2 signific differ observ group smoke knowledg neg cons quenc smoke expect disson affect result smoke knowledg neg consequ expect expect direct compar particip exp nutrit standard condit particip exp smoke condit demonstr greater smoke knowl edg report stronger neg consequ expect intervent ps 001 addit smoke intervent produc greater level disson relat affect compar exp nutrit condit ps 01 differ found risk percept test gender interact potenti mediat variabl interact found guidelin outlin baron kenni 1986 smoke relat knowledg risk percept disson smoke relat outcom expect examin potenti mediat test mediat satisfi criteria diation mediat analys conduct separ femal particip fail meet requir mediat discuss date dearth smoke cessat intervent design assist alarmingli high number colleg student smoker patterson lerman kaufman neuner audrain mcgovern 2004 current studi test experienti interven tion colleg smoker find encourag regard femal smoker outcom measur posttreat readi chang follow tabl 2 mean standard deviat process measur experiment condit measur exp smoke standard exp nutrit 2 212 sd sd sd smoke knowledg 93.06 8.98a 81.67 11.13b 51.97 14.30c 235.96 neg consequ expect 6.46 1.36a 5.98 1.25b 5.58 1.33c 7.97 disson 2.43 1.43a 2.35 1.12a 1.79 0.79b 6.67 risk percept 42.94 9.36a 40.51 9.88a 39.72 10.45a 2.06 note smoke knowledg 10 item scale mean reflect percentag item answer correctli neg consequ expect subscal smoke consequ questionnair rang score 0 9 disson discomfort scale disson thermomet rang score 1 7 risk percept score rang 7 56 mean subscript statist signific 05 signific differ comparison exp smoke experienti smoke intervent standard standard didact smoke intervent exp nutrit experienti nutrit inter vention 01 274 nath simmon brandon readi stage chang pamphlet select cessat follow smoke reduct follow femal particip exp smoke condit outperform exp nutrit condit measur posttreat readi stage chang pamphlet select exp smoke condit perform standard intervent standard condit outper form exp nutrit condit measur pamphlet select find provid initi support efficaci femal smoker experienti disson base inter vention enhanc colleg student motiv quit smoke unexpect support standard didact video intervent differenti gender effect intervent effect found femal smoker consist prior research demonstr success appli cation social psycholog health intervent eitel friend 1999 wilson al 2002 anticip exp smoke intervent ineffect male smok er experienti intervent found gender effect alcohol experienti expect challeng para digm dark goldman 1993 1998 develop vali date male sampl recent studi fail replic effect femal sampl dunn lau cruz 2000 musher eizenman kulick 2003 explan femal partic ipant respond favor exp smoke intervent particip condit encourag incorpor neg feel experi smoke task reli person inform emphas disclosur studi found women disclos e.g arliss 1991 pearson 1985 femal smoker comfort task social aspect group discuss relev women interperson social orient e.g marku oyserman 1989 studi gender differ smoke support idea gender specif intervent need perkin colleagu perkin 2001 perkin jacob sander caggiula 2002 found male smoker reinforc greater extent nicotin effect femal smoker femal smoker motiv contextu social smoke cue i. social interact male smoker women affect social influenc gilpin pierc goodman burn shopland 1992 experi greater social pressur quit smoke fior al 1990 found group format smoke cessat prefer women men mermelstein borrelli 1995 note studi report examin main effect gender gender treatment interact sex differ neg affect withdraw cope style sug gest treatment gender requir optim outcom piper fox welsch fior baker 2001 greater effort warrant examin har gender differ improv tobacco intervent smoke behavior exp smoke intervent produc increas motiva tion quit smoke femal student compar standard didact intervent particip exp smoke condit pick smoke cessat pamphlet found differ smoke intervent smoke cessa tion 1 month follow smoke condit produc greater cessat exp nutrit condit explan lack differenti cessat effect intervent contrast typic cessat program particip seek assist quit mean baselin score contempl ladder repres quit readi interven tion focus cessat expect smaller effect cessat intervent involv singl session success health interven tion colleg student multisess paradigm dark goldman 1993 wier krumml 2004 length number smoke intervent session found posit cessat outcom u. depart health human servic 2000 stronger effect emerg multisess format intens intervent includ specif cessat focus advic strengthen social psycholog part intervent lead greater behavior chang e.g strengthen hypocrisi colleg smoker speak directli high school student limit intervent potenc produc cessat examin intermedi variabl motiv move eventu cessat variabl veal effect quit motiv select smoke cessat pamphlet reduct smoke motiv measur predict subsequ cessat abram herzog emmon lin nan 2002 longitudin design need test intermedi variabl produc long term effect smoke cognit disson smoke group exhibit higher level disson relat affect compar exp nutrit group exp smoke intervent appar produc greater disson standard didact intervent surpris rela tive low level disson report factor ac count studi report measur psycholog discomfort sensit focus captur group differ futur research benefit addit physiolog measur arous e.g galvan skin respons elliot devin 1994 score disson measur reflect disson level reduc particip increas intent quit smoke immedi intervent final cessat motiv produc mechan disson reduct interact natur exp smoke intervent produc greater efficaci led particip process smoke risk inform deeper simpli social experiment demand report intent quit smok ing percept theori bem 1972 weiner 1974 offer altern disson theori explain chang result behavior videotap testimoni studi futur studi broaden search mediat explor altern wai measur kei theoret mediat 275smoke cessat colleg student limit futur research addit limit mention studi reli report measur smoke behavior pri mari focu studi intermedi motiv measur follow smoke stronger object indic biochem assai e.g urin coti recogn gender effect albeit understand retrospect hypothes priori attenu confid robust find final experienti intervent studi adopt systemat colleg student practic challeng overcom e.g recruit smoker elimin decept videotap possibl exist translat research typic colleg student sampl colleg screen current smoker requir partici pate smoke cessat program similar program mandat colleg drink nontobacco drug elimin decept current studi tell colleg student assist need creat smoke cessat video request edit video enhanc experienti experi research identifi suffici el ment intervent greatli inform develop futur intervent instanc make public commit kei factor simpli watch oneself video i. critic video shown high school student summari studi demonstr efficaci experienti smoke intervent increas intent quit modifi smoke behavior colleg student gender moder relationship condit readi ness quit smoke smoke intervent efficaci femal particip find broader literatur gender differ support research develop gender specif smoke inter vention colleg student find offer encourag colleg smoker recept malleabl secondari prevent effort experienti intervent
base fundament belief digniti equal human join seek combat real poverti diseas world bank world bank atla washington dc world bank 1989 2 kirkman rve morri webb user experi mate sersu neuroform brioish journal offamili plan 1990;15 107 1 1 3 duncan harper ashwel muit buchan jone rermin pregnanc lesson prevent british journal familv plan 1990;15 112 7 4 dowl socio educ model instal commun base nfp servic deliveri system rural philippin intern feder famili life promot abstract paper present iv'th congress intern feder famili life promot ottawa canada june 29 30 juli 1 1986 ottawa serena 1986 31 2 accept 21 1990 effect smoke cessat programm gener practic randomis clinic trial karen slama selina redman janic perkin alexand reid robertw sanson fisher abstract object evalu structur behaviour chang smoke cessat intervent design gener practic design randomis control clinic trial set gener practic newcastl australia patient 311 patient identifi smoker screen question entrol studi 101 assign structur behaviour chang programm 104 simpl advic pro gramm adapt previou research 106 control group signific differ found group demograph smoke relat variabl studi intervent patient simpl advic group receiv statement advic gener practition pamphlet structur intervent group strategi includ attitud behaviour chang programm techniqu aid complianc amount ofsmok group assess report valid measur salivari cotinin concentr main outcom measur signific increas cessat rate conclus signific differ control structur behaviour chang group found month follow report abstin simpl advic programm produc signific differ enc control group gener practition evalu structur programm highlight difficulti relat durat interven tion structur programm present form effect programm gener practic introduct gener practic potenti import set commun approach smoke cessat gener practition contact larg proport popul credibl sourc plausibl messag convei person contact 2 initi randomis clinic trial intervent found gener practition advic produc higher cessat rate advic 3 recent trial produc similar result 4 physician appar fail routin counsel smoke patients67 time skill effort need gener practition signific cessat rate achiev line multipl session programm produc result intervent 36 patient report cessat year multi session programm suitabl routin high expenditur time requir gener practition smoke cessat programm wide adopt cost time effort reduc perform randomis clinic trial pare control group minim intervent group group receiv intens smoke cessat programm orient individu hope structur behaviour intervent effect accept routin gener practition subject method twenti gener practition south wale express interest smoke cessat research invit part studi 17 74 agre patient approach await consult includ report smoker ag 18 64 year read speak english previou research report smoke correspond close saliva cotinin concentra tion 9 elig consent patient ask complet questionnair consult question nair ask demograph data inform smoke behaviour addit questionnair includ question patient health belief fear cost smoke cessat particip doctor patient randomli assign treatment simpl advic tailor behaviour chang programm gener prac tition ask patient permiss audiotap consult control group receiv inform advic smoke simpl advic group receiv statement advic smoke cessat brochur similar previou research 9 structur behaviour chang intervent con sist compon shown tabl iii nicotin gum prescrib particip patient told contact univers measur cessat report smoke behaviour measur telephon home base interview conduct 12 month interview unawar patient group biochem valid report abstin perform pair ion liquid chromatographi analysi salivari cotinin concentr abstin consid valid detect cotinin present 50 nmol accept audiorecord consult faculti medicin univers newcastl newcastl south wale australia 2308 karen slama phd consult behaviour scienc relat medicin selina redman phd senior lectur behaviour scienc relat medicin janic perkin ba research assist behaviour scienc relat medicin alexand reid fracgp associ professor gener practic robert sanson fisher phd professor ofbehaviour scienc relat medicin request reprint correspond professor sanson fisher braledj7 1990;300 1707 9 bmj volum 300 30 june 1990 1707 time stopwatch obtain inform durat intervent normal consult record allow gener practition adher smoke cessat protocol assess gener practition ask predict impact intervent patient assess behaviour programm particip patient ask expect advis smoke dislik receiv advic satisfact specif inform provid gener practition train hour long train session includ descript protocol trial detail descript videotap demonstr behaviour pro gramm open discuss dossier ofbackground inform provid refer trial gener practition record practic session behaviour programm individu meet held discuss difficulti omiss result 1056 patient approach inclus studi screen question identifi 359 smoker total number attend surgeri 34 preval exclud doctor medic condit exclud incomplet pretest data thirti patient includ analysi locat follow patient refus audiotap final sampl size tabl number percentag ofpati abstain 95 confid interv ofpercentag month month 12 month base report chemic valid control group simpl advic group behaviour group signific group abstain group abstain group abstain differ report abstin month 106 10 9 104 15 14 101 19 19 yjx 4 64 3to 14 8to21 11 to26 003 6month 106 12 11 104 12 11 101 18 18 yl1 87 5 1 7 5 1 7 10 25 0 17 12month 106 12 11 104 11 10 101 17 17 yj 142 5 17 3 14 10 24 0 23 v'alid abstin month 104 2 2 97 2 2 92 7 8 controlvsimplep 0 1 5 1 5 2 1 3 control behaviour 0 07t 6 month 104 6 6 103 7 7 99 12 12 2 70 1 10 2 12 6 19 10 12month 106 8 8 104 5 5 101 12 12 z2l 127 3 13 1 to9 6to 18 026 xij test linear trend tone month valid result test fisher exact test small expect frequenc tabl ii anumb percentag patient consecut abstin base report chemic valid 95 cotnfid interv ofpercentag fisher exact test control group simpl advic behaviour group control zv control 106 group 104 101 simpl behaviour report patient abstin 1 3 3 7 7 0 1 0 028 land 6 month 3 0 6 2 12 patient abstin 1 1 2 2 6 6 0 1 0 052 1,6 12 month 3 5 11 v'alid patient abstin 1 1 1 1 6 6 0 1 0 052 and6month to3 to3 ii patientsabstinentat 1 1 1 1 5 5 0 1 0 095 1 6 12 month 3 3 to9 tail probabl tabl iii percentag gener practition compon structur behaviour chang intervent protocol protocol compon compon attitud chang 91 diseas smoke 97 risk smoke 95 risk apprais 89 benefit cessat 80 efficaci 56 reassur fear 80 confid boost 46 persist stress 42 behaviour aid 82 contract 90 avoid cue smoke 88 cold turkei 86 attent benefit cessat 78 encourag social support 70 commun aid 48 written reinforc pamphlet 99 warmth commit 45 name area discuss 35 summaris inform 13 consist 311 smoker 106 control 104 simpl advic group 101 behaviour chang programm signific differ found group demograph smoke relat variabl motiv signific differ health belief found group pretest questionnair month follow item perceiv gener risk smoke chang significantli behaviour group repeat measur analysi varianc 7 99 001 behaviour group 61 sign contract stop smoke abstin follow point month follow 57 behaviour group report stop smoke signific differ report cessat rate found group month subsequ follow up tabl biochem valid abstin tail fisher exact test show signific differ month control behaviour group control simpl advic group linear trend x2 analysi show signific differ group 12 month consecut abstin cessat rate consecu tive abstin smoker calcul patient biochem valid smoker follow point patient valid abstin month provid sampl nicotin gum attend measur time regard abstin subsequ valid 12 month follow up patient smoke statu valid count smoker tabl ii show proport smoker maintain abstin month 12 month differ control simpl advic group control behaviour group assess tail fisher exact test differ control simpl advic group report valid measur reach signific 0 1 time period report valid measur differ control behaviour group ap proach signific gener practition adher protocol tabl iii doctor made compon behaviour programm health belief behaviour aid compon inter vention half includ efficaci enhanc ment hand brochur bmj volum 300 30 june 19901708 present contain munic aid durat gener practition averag 8 8 minut sd 3 3 minut present structur behaviour intervent total time spent smoker 8 7 minut longer averag consult time control group 9 0 minut 5 6 simpl advic interven tion 1 4 minut 0 7 total time averag 0o12 minut longer averag control consul tation gener practition satisfact complet studi gener practition felt success 45 behaviour programm group 29 simpl advic group rate 43 behaviour intervent 13 simpl intervent long trial half doctor smoke cessat programm smoker routin patient satisfact halfof total sampl patient thought doctor give advic smoke 80 disapprov doctor suggest stop smoke behaviour group significantli greater satisfact inform divers smoke relat diseas analysi varianc 4 63 005 greater approv receiv suggest stop smoke x2 6 93 0 01 signific differ group found discuss result studi simpl advic structur behaviour chang intervent result statist signific increas number patient stop smoke long term rel control group valid cessat rate 5 patient structur group remain abstin 12 month effort need gener practition learn behaviour intervent programm cost minut patient justifi recommend programm simpl advic evid struc ture behaviour chang programm effect motiv patient stop smoke short term month consult 57 smoker behaviour group report stop smoke compar 35 simpl advic 26 control group nicotin true physiolog depend gener practition provid follow session patient ifcess maintain long term half gener practition prepar behaviour chang intervent routin find encourag suggest half respond found pro gramm accept disappoint find 43 pro gramm long implement routin smoke cessat programm result signific reduct smoke rate invari multisess programm take longer period find suggest gener prac tition realis potenti help patient stop smoke effect inter vention develop gener prac tition revis prioriti care time prevent intervent revis necessit restructur time gener practic accommod antismok intervent take longer prevent procedur smear cervic cancer backlog patient gener chang dealt continu load moder 1 australian bureau statist australian htalth survei 1977 78 doctor consult canberra australian bureau statist 1980 catalogu 4319.0 2 cockburn killer campbel sanson fisher rw measur gener practition attitud medic care fam pract 1987;4 192 9 3 russel mah wilson taylor baker cd effect gener practition advic smoke brmedj 1979 ii 23 1 5 4 stewart pj rosser ww impact routin advic smoke cessat famili physician med assocj 1982;126 1051 4 5 russel mah stapleton ja jackson ph tlajek belcher district programm reduc smoke effect clinic support intervent gener practition br medj 1987;295 1240 4 6 chu fz dai rg smoke recognit famili physician ji fam pract 1981;12 657 60 7 fleme dm lawrenc msta evalu record inform prevent measur 38 practices.i coll gen pract 1984;31 615 20 8 richmond rl austin webster iw year evalu programm gener practition patient stop smoke br med 1986;292 803 6 9 dickinson ja wigger eeder sr sanson fisher rw gener prac tition detect patient smoke statu aledj aust 1989;150 420 6 10 jarvi mj tunstal 1 edo feyerabend vessei salooje comparison test distinguish smoker nonsmok amj public health 1987;77 1435 8 11 benowitz nc pharmacolog aspect cigarett smoke nicotin addict englj med 1988;20 1318 30 accept 16 march 1990 medicin media bbc 1 life investig earlier pictur sarah green late blue peter stand birmingham public hous jar exhal cigarett smoke hand made earlier insid pub discuss part carbon monoxid million radio 1 disc jockei simon mayo man call mr smoke bbc 1 popular scienc programm life popular take thur dai 8pm slot tomorrow world holidai aim present current scientif medic environment issu wall wall serious passiv smoke bald bottl nose dolphin refriger cfc offer inform opinion sprinkl humour pop presenta tion beat music punchi subtitl programm hard campaign edg sarah simon lead team investi gativ report attract femal man seek stori chase guilti expos absurd govern ment compani polici strang appal scene show dump ofwast north sea british coal felt optimist call naiv nikki spencer youth energi spirit inter rogat man nation river author made feel back pub simon term dr martin jarvi imperi cancer research fund passiv smoke sarah street canvass view good burgher birmingham telephon poll conclud viewer express prefer smoke public place ban execut produc david patterson plan report back stori polici occur armchair activist seri fiona godle editori registrar bmj7 bmj volum 300 30 june 1990 1709
famili practic impact routin advic smoke cessat famili physician paula stewart md ccfp walter rosser md ccfp cigarett smoke continu major health problem physician ask advis patient hazard smoke control trial undertaken measur impact famili physician advic cigarett smoker routin offic visit signific differ found measur determin outcom desir stop smoke attempt stop success stop control intervent group result discuss relat health belief model suggest made increas impact famili physician smoke cessat practic la cigarett continu d'otr problam de sant majeur en cons6quenc demand6 de made cin d'inform leur patient de danger du tabagism un atud de contr6l entrepris afin de mesur l'influenc de conseil prodigua aux fumeur par le mbdecin de famil au cour d'une visit de routin aucun diffbrenc n'a retrouva entr le group cibl group tamoin dan le troi mesur utilisa pour datermin le rasultat soit le dasir de cesser de fumer un tent d'arrat l'arrat raussi ce rbsultat sont discuta en rapport avec le modal de souci pour la santa de suggest sont offert en vue d'augment l'influenc pourraient avoir le madecin de famil dan leur pratiqu sur l'abandon de fumer world health organ state ciga rett smoke major prevent ill health prematur death literatur abound direct physician give advic smoke patient assum influenc power benefici 2 5 studi measur influenc vari methodolog result russel col leagues6 conduct control trial compar con trol group subject ask univers ottawa resid depart epidemiolog commun medicin tchairman depart famili medicin reprint request dr paula stewart depart epidemiolog commun medicin univers ottawa 1461 heron ottawa ont k1v 6a6 smoke control group complet questionnair smoke habit advic intervent group found 5.1 subject advic pamphlet 3.3 advic stop smoke 1 month smoke 1 year compar 0.3 1.6 control subject 0.001 basi find russel colleagu suggest primari care physician time give advic cigarett smoke patient routin offic visit studi britain felt import conduct similar trial canada adopt practic regular basi purpos random control trial measur effect advic smoke routin physi cian urban canadian famili practic method patient enter studi sept 5 nov 8 1979 ottawa civic hospit famili medicin centr famili practic teach unit univers ottawa staf 5 part time physician 22 resid patient assign staff physician resid admit practic gener continu care physician physician particip studi cigarett smoker patient 11 year ag includ smok er exsmok nonsmok attend centr entri period complet question nair present past smoke habit wait physician patient smoke cigar pipe exsmok nonsmok exclud studi ciga rett smoker defin smoke cigarett dai randomli assign control intervent group nurs drew envelop assign instruct patient direct patient physician offic patient intervent group discuss answer questionnair physician begin offic visit receiv advic cigarett smoke larg round red label smoker put chart physician instruct give advic manner thought effect patient patient assign control group questionnair discuss cma journal 1 1982 vol 126 1051 physician patient receiv advic smoke physician felt uneth withhold advic intervent group vari wai receiv advic occas receiv advic subsequ visit year pamphlet entitl excus excus group identifi smoker label chart readili visibl group receiv advic combin group group analysi result fifti chart randomli select assess degre complianc physician smoker sticker 47 chart studi protocol requir physician attach sticker patient chart discuss smoke presenc sticker suggest patient receiv advic hand physician attach sticker patient left advic smoke physician told chart check nurs help ensur studi protocol maintain smoker mail similar questionnair februari octob 1980 determin smoke statu follow period train interview made attempt contact nonr spondent telephon data questionnair read directli comput file check consist made data analys statist packag social scienc 2 result particip 2002 questionnair hand entri period studi 0.1 patient refus answer questionnair 78 3.9 questionnair reject illeg uninterpret patient present famili medicin centr 36 cigarett smoker ag sex distribut dura tion cigarett smoke proport stop smoke previou year want stop smoke time entri studi similar control intervent group smoker 77 smoke 5 year 28 stop smoke previou year approxim third 63 smoker want stop smoke result intervent measur evalu impact advic smoke routin physician desir stop smoke attempt stop success stop respons particip smoke end follow period determin effect tabl statu respond end 5 12 month follow period patient questionnair questionnair questionnair advic advic pamphlet statu 187 345 159 5 month total respond 145 77.5 258 74.7 123 77.4 attempt stop smoke 37 25.5 52 20.2 30 24.4 successfulli stop smoke 21 14.5 26 10.1 20 16.3 12 month total respond 128 68.4 229 66.4 94 59.1 attempt stop smoke 76 59.4 127 55.5 54 57.4 successfulli stop smoke 15 11.7 24 10.5 12 12.8 stop smoke 5 month resum smoke 12 month 4 3.1 7 3.1 4 4.3 tabl il desir quit smoke particip smoke end follow period patient questionnair questionnair questionnair advic advic pamphlet outcom 81 144 62 chang desir stop smoke year stop stop chang desir stop smoke chang 5 12 month chang 5 12 month change5 12 month 10 25.0 3 20.0 chang 20 50.0 17 21.0 43 53.1 21 25.9 4 19.0 1 4.8 16 76.2 1052 cma journal 1 1982 vol 126 29 20.1 75 52.1 40 27.8 10 25.0 10 25.0 20 50.0 18 29.0 29 46.8 15 24.2 1 6.7 3 20.0 11 73.3 advic reflect chang patient desir stop smoke patient consid stop smoke smoke 1 dai follow period patient includ resum smoke patient consid success stop stop smoke follow period smoke answer follow questionnair 76 particip complet 5 month follow questionnair 65 12 month follow questionnair intens effort trace nonrespond tabl nonrespond move citi time reason found statist signific differ 0.05 outcom group tabl ii intervent group advic advic pamphlet proport patient attempt stop smoke successfulli stop significantli control group proport smoke end 5 12 month follow period includ stop end start similar 10 15 group 3 4 particip stop smoke end follow period consider 10 15 stop time particip 75 chang desir stop stop smoke follow year tabl ii determin physician advic impact group chang desir number small consist trend fact smoker chang mind follow year 12 month follow questionnair particip ask thought cigarett smoke harm health tabl iii show high level awar group discuss result studi suggest give routin advic cigarett smoke effect famili physician promot smoke russel colleagu study6 show 3 5 group receiv advic physician stop smoke 7 month conclus studi caus differ control group russel colleagu control group low long term rate quit 0.3 1.6 found routin advic physician effect motiv patient stop smoke increas rate success similar propor tion patient control group seri stop smoke patient long term success specul reason differ chang factor affect smoke cessat proport adult smoke decreas past year modifi health belief model summar jenkin 3 propos framework understand factor requir individu modifi behav iour stop smoke knowledg integr exist belief knowl edg person threaten thought motiv attempt chang lifestyl individu skill produc chang deriv intern extern resourc light health belief model surpris found physician advic smoke impact smoker fill questionnair particip awar cigarett smoke harm physician tell knew particip case symptom diseas relat smoke fore physician advic benefit import motiv factor imagin peopl advic physician stop smoke neg factor attack habit chang smoker studi lack resourc perman chang behaviour approxim 50 particip stop smok ing 1 dai 3 stop 7 month advic physician stop smoke add individu resourc combat long stand habit firmli incorpor lifestyl conclus studi suggest famili physician reli sole word advic routin offic visit promot nonsmok smoker assist decid quit kit referr local smoke cessat pro gram continu follow research primari care set determin type format educ materi effect promot smoke cessat understand physician advic effect natur support system individu chang behaviour signific cma journal 1 1982 vol 126 1053 tabl il awar end 12 month follow period effect cigarett smoke health patient goven questonnair questionnair questonnair advic advic pamphlet respons 128 229 94 harm 119 93.0 198 86.5 82 87.2 harm 7 5.5 25 10.9 9 9.6 respons 2 1.6 6 2.6 3 3.2 impact pattern smoke achiev physician offic cleric medic nurs staff ottawa civic hospit famili medicin centr project studi support faculti health scienc depart famili medicin univers ottawa
smoke statu gener practition affect efficaci smoke cessat counsel sabina ulbricht sebastian baumeist christian meyer carsten oliv schmidt anja schumann han jürgen rumpf ulrich john aunivers greifswald institut epidemiolog social medicin greifswald germani bhelmholtz centr münchen german research center environment health institut epidemiolog germani cunivers greifswald institut commun medicin greifswald germani dunivers leipzig coordin centr clinic trial leipzig germani eunivers lübeck depart psychiatri psychotherapi research group s:tep substanc abus treatment epidemiolog prevent lübeck germani patient educ counsel 74 2009 23 28 articl histori receiv 21 januari 2008 receiv revis form 22 juli 2008 accept 22 juli 2008 keyword smoke gener practition counsel intervent smoke statu object examin associ smoke statu gener practition gp abstin rate patient receiv gp deliv advic smoke cessat method quasi experiment multilevel studi follow assess 6 12 18 24 month baselin conduct random sampl 39 gener practic defin area particip rate 87.2 patient ag 18 70 consecut screen smoke statu 11,560 3 week assign control group week 1 comput expert system intervent week 2 person counsel interventionwith gp week 3 current analysi patient particip studi week 2 exclud total 1260 patient fulfil inclus criteria 80.2 part 609 patient studi week 1 402 patient studi week 3 gp particip train session smoke counsel held studi week 2 3 report 4 week 6 month prolong abstin measur 6 12 18 24 month follow up assess result smoke statu gp significantli relat 4 week prolong abstin 6 month prolong abstin patient main effect model model reveal intervent group modifi effect smoke statu gp likelihood quit smoke signific interact effect found smoke statu gp intervent group abstin measur conclus smoke statu gp posit effect counsel patient practic implic consider lifestyl behaviour variabl smoke statu gp essenti research efficaci smoke intervent 2008 elsevi ireland right reserv content list sciencedirect patient educ counsel journa homepag www.e lsev ier locat pateduc studi review local ethic committe univers greifswald ethic safeguard met perceiv conflict financi interest relat research report manuscript author particip suffici work public respons content studi pro gp proactiv smoke intervent gener medic practic part research collabor earli substanc intervent earlint fund german feder ministri educ research grant no 01eb0120 01eb0420 social ministri state mecklenburg west pomerania grant ix311a406.68.43.05 author institut epidemiolog social medicin univers greifswald walther rathenau str 48 17487 greifswald germani tel 49 3834 867732 fax 49 3834 867701 mail address ulbricht uni greifswald.d ulbricht 0738 3991 front matter 2008 elsevi ireland right reserv doi 10.1016 j.pec 2008.07.047 1 introduct proactiv intervent counsel advic deliv gener practition gp increas odd quit smoke 1,2 evid physician train effect increas smoke cessat activ organiz factor import ensur success deliveri intervent 1 smoke cessat intervent tool gp desktop resourc effect prompt gp advis patient 3 avail cost effect intervent recommend major practic guidelin 4,5 transfer systemat screen smoke cessat advis routin care inadequ 6 8 neg belief attitud smoke counsel gp partli respons defici gp report mailto:ulbricht uni greifswald.d http www.sciencedirect.com scienc journal 07383991 http dx.doi.org 10.1016 j.pec 2008.07.047 ulbricht al patient educ counsel 74 2009 23 2824 lack time absenc patient interest low confid abil conduct smoke cessat counsel 9 gp germani lack reimburs consid barrier engag smoke cessat promot 10 result studi reimburs gp smoke cessat counsellingmeasur increas rate smoke statu ascertain deliveri smoke cessat advic 11 smoke statu gp discuss major factor influenc provis smoke cessat counsel 12 countri low smoke preval physician translat knowledg danger tobacco healthcar practic problemat countri higher proport smoke gp studi found level gener tobacco control activ includ comprehens legisl regul relat smoke tobacco market smoke preval physician european countri 10 smoke rate 10 report physician countri high level tobacco control norwai sweden finland netherland 13 17 contrast smoke rate physician sampl 18 germani 29 spain 32 franc 39 greec 18 21 physician smoke record patient tobacco motiv promot smoke cessat 10,22 24 particip smoke cessat trial 25 studi found associ smoke statu gp readi provid counsel 26 contrast studi found readi particip studi aim implement smoke cessat intervent lower smoke physician compar smoke physician 25 studi found associ smoke statu gp efficaci aminim smoke intervent 25 patient receiv smoke cessat counsel systemat select gp studi procedur place assur systemat assess smoke statu consecut patient particip practic total level counsel activ low 40 particip gp appli intervent 25 knowledg studi investig associ gp smoke statu patient smoke outcom period 24month studi add knowledg assess smoke statu patient offer systemat counsel relationship smoke statu gp smoke statu patient effect counsel examin studi 2 method studi part research program proactiv smoke intervent gener medic practic pro gp creat quasi experiment studi design compar effect comput expert system person counsel provid train gp care usual control condit assign studi arm base time patient attend 1 patient appoint studi week alloc care usual control condit 2 patient secondweek receiv comput program intervent 3 patient week assign person counsel intervent fix time frame essenti order avoid risk counsel activ gp affect counsel train session held studi week 2 3 current studi interest know smoke statu gp influenc success person counsel intervent analys includ patient studi week 1 3 2.1 gp sampl random sampl 39 gener practic drawn list gp regist primari care defin region northeastern germani particip rate 87.2 34 practic hand practic total 37 gener practition particip studi averag ag practition 47.5 year s.d 8.2 48.8 femal practic 59 locat urban area i. citi 50,000 inhabit practition 24.6 9 current smoker 2.2 patient sampl particip practic studi nurs assess smoke statu sex ag consecut patient period 3 week current smoker ag 18 70 year visit practic time studi period consid elig current smoke defin daili smoke cigarett 4 week inclus criteria suffici languag intellectu capabl fill questionnair written inform consent part studi patient select particip consent ask fill questionnair assess smoke habit socio econom characterist wait room total 11,560 consecut patient screen smoke statu total 1260 patient studi week 1 3 fulfil inclus criteria number 1011 80.2 agre particip patient consent part studi 609 patient studi week 1 alloc control group total 402 patient week receiv person smoke counsel gp person counsel deliv gp regular consult visit 2.3 studi procedur patient visit practic studi week alloc control group intervent provid group begin counsel intervent period week gp fill questionnair ag smoke statu subsequ gp receiv singl 2 train session smoke cessat counsel practic room gp train sessionswer provid member research team train compris modul 1 epidemiolog find smoke relat diseas diagnosi pathogenesi nicotin depend 2 basic tailor intervent base transtheoret model behaviour chang 3 principl behaviour chang counsel 27,28 gp receiv desktop resourc dr ensur standardis counsel procedur prior consult studi nurs provid document sheet gp referwhil counsel thiswa record smoke relat inform patient cigarett smoke dai urg smoke carbon monoxid exhal air stage chang document sheet serv remind gp counsel counsel intervent design 10 min structur dr dr includ set sentenc open close counsel session dr cover varieti convers modul stage chang ulbricht al patient educ counsel 74 2009 23 28 25 page dr depict overview stage chang counsel topic gp quickli easili choos relev modul address smoke counsel session complet provis manual tailor patient stage chang intervent deliv regular treatment baselin assess 2.4 patient assess 2.4.1 baselin current smoke statu number cigarett smoke dai assess urg smoke measur fagerström test nicotin depend 29 scale combin item score rang 0 low depend 10 high depend readi quit smoke assess stage algorithmof transtheoreticalmodel 30 individu consid precontempl stage intend quit smoke 6 month patient readi quit timefram alloc contempl stage patient assign prepar stage intend quit 4 week attempt quit 12 month subject prepar stage contempl stage prepar stage combin analysi patient educ level measur respond highest level formal educ complet educ level divid group elementari compulsori educ 10 year secondari educ 10 year higher educ 12 year 2.4.2 outcom outcom assess conduct 6 12 18 24month baselin follow assess includ item cover smoke behaviour report outcom measur defin 4 week prolong abstin i. smoke 4 week preced follow 6 month prolong abstin i. smoke 6 month preced follow 31 tabl 1 demograph smoke behaviour characterist patient control group 609 ag mean s.d 34.8 13.4 sex femal 300 49.3 male 309 50.7 educ year school 10 209 34.3 10 294 48.3 10 84 13.8 inform 22 3.6 stage chang precontempl 412 67.7 contempl 160 26.3 prepar 27 4.4 inform 10 1.6 ftnd scorea mean s.d 3.2 2.1 inform 26 4.3 ftnd fagerström test nicotin depend bivari comparison adjust sampl design rao scott correct x2 statist 2.5 data analys initi bivari analys compar smoke relat socio econom baselin characterist patient control intervent group account potenti cluster practic appli sampl survei method stata version 9.2 stata command svytab analys time point differ abstin preval patient control intervent group depend smoke statu gp abstin preval figur 95 confid interv 95 ci report relationship patient variabl gp factor outcom measur investig multilevel logist regress model model hierarch data structur depend variabl measur lowest level explanatori variabl measur level data set level structur time point level 1 nest patient level 2 nest gener practic level 3 multilevel model includ step model includ main effect time intervent group variabl indic gp smoker patient level control gender ag urg smoke stage chang variabl time includ follow point 6 12 18 24 month baselin code 1 2 3 4 centr endpoint studi i. 24 month model ad product term repres cross level interact gp smoke statu intervent group odd ratio 95 ci report effect measur tabl 2 multilevel model estim gllamm procedur stata 9.2 32 gllamm dealt miss data assumpt miss data point relat depend variabl covari label miss random mar 33 3 result tabl 1 describ smoke relat socio econom baselin characterist patient control intervent group subsequ patient pseudo random intervent group 402 33.1 12.5 0.106 0.193 179 44.5 223 55.5 0.231 117 29.1 217 54.0 59 14.7 9 2.2 0.059 247 61.4 128 31.9 26 6.5 1 0.2 3.3 2.1 0.874 6 1.5 categor variabl adjust wald test statist continu variabl tabl 2 result multilevel regress analysi 4 week 4 6 month 6 prolong nicotin abstin 24 month follow model 1 4 model 2 4 model 1 6 model 2 6 95 ci 95 ci 95 ci 95 ci fix effect time month 1.149 1.118 1.181 1.149 1.119 1.181 1.199 1.143 1.259 1.200 1.144 1.260 interventionc 1.856 1.123 3.065 0.553 0.218 1.403 2.288 1.269 4.126 0.706 0.241 2.063 ag 0.997 0.978 1.015 0.998 0.979 1.017 1.000 0.979 1.024 1.003 0.981 1.026 sex 0.847 0.512 1.402 0.822 0.496 1.361 0.791 0.436 1.435 0.771 0.425 1.400 ftnd 0.662 0.579 0.757 0.672 0.588 0.768 0.713 0.609 0.834 0.723 0.618 0.846 stage chang 2.349 1.420 3.884 2.50 1.509 4.148 2.369 1.314 4.271 2.523 1.395 4.567 gp smoke status 0.910 0.536 1.547 0.459 0.233 0.902 0.839 0.451 1.561 0.409 0.181 0.926 gp smoker interventionc 5.704 1.876 17.342 5.589 1.530 20.413 varianc standard error random effect level 2 patient 17.174 3.636 16.416 2.884 31.201 9.662 41.896 11.994 level 3 gp 1.362e 14 0.000 2.540e 10 0.000 1.204 0.169 8.357e 16 0.000 fagerström test nicotin depend 4 1 smoke 4 week 0 smoke 4 week 6 1 smoke 6 month 0 smoke 6 month 6 1 intervent group 0 control group 6 1 contempl prepar 0 precontempl 6 1 smoke gp 0 smoke gp 0.05 0.01 0.001 ulbricht al patient educ counsel 74 2009 23 2826 baselin differ examin differ reach statist signific tabl 2 present estim outcom measur 4 week prolong abstin obtain stepwis multilevel regress analysi thedepend variablewa dichotom 0 patient smoke 4 week 1 patient smoke 4 week result model 1 reveal patient receiv person counsel intervent achiev abstin abstin increas time studi group patient relat variabl higher stage chang lower level nicotin depend associatedwith higher probabl quit smoke smoke statu gp significantli relat 4 week outcomemeasur themain effectsmodel result outcom i. 6 month prolong abstin similar 4 week outcom tabl 2 main effect model smoke fig 1 week prolong preval abstin 95 confid interv control intervent group follow up differenti smoke statu gp intervent posit 6 month abstin increas time model 1 higher stage chang lower level nicotin depend higher probabl quit smoke 6 month figur depict preval 4 week 6 month prolong abstin measur control group higher preval abstin patient visit smoke gp compar patient treat smoke gp contrast patient receiv counsel intervent data show higher rate abstin counsellor smoker fig 1 2 includ interact smoke statu gp intervent multilevel regress model find smoke statu gp posit effect abstin measur counsel patient suggest effect smoke statu gp modifi intervent condit fig 2 month prolong preval abstin 95 confid interv control intervent group follow up differenti smoke statu gp ulbricht al patient educ counsel 74 2009 23 28 27 4 discuss conclus 4.1 discuss studi investig relationship smoke statu gp outcom measur analysi interact gp smoke statu realiz patient counsel intervent achiev abstin compar control condit import main effect model patient receiv person counsel intervent quit smoke find differ outcom measur smoke statu gp patient receiv smoke counsel intervent smoke gp benefit comparison patient counsel smoke gp contrast find smoke gp effect control group smoke gp effect intervent group attain abstin illustr fig 1 2 reflect addit benefit smoke counsel train smoke gp intervent period comparison smoke gp possibl counsel train session prompt smoke gp confront smoke behaviour subsequ decreas confid provid counsel find studi add knowledg efficaci smoke cessat advic providedbi smokinggps.howev studi evalu smoke counsel directli link opportun provid smoke counsel systemat measur long term outcom data patient high preval smoke gp random sampl approxim 25 import provid smoke intervent engag major gp behaviour difficulti engag smoke gp studi aim implement smoke cessat intervent illustratedwith anecdot begin studi recruit procedur smoke gp reserv smoke counsel practic afraid label hypocrit provid smoke counsel dai smoke pub peopl even typic rural area gp act rolemodel themed practic achiev high particip rate gp import understand local context studi protocol gp provid counsel smoke patient period 1 week respect report frequenc counsel activ find differ smoke smoke gp 26 data french studi gp provid effect smoke counsel smoke statu 25 interpret result import note limit studi sampl gp repres specif region germani result gener region countri gp provid smoke counsel short period 1 week ensur high complianc counsel consecut patient smoker withheld tape record patient particip inform number consult counsel session provid gp time studi initi 24 month follow fourth inform smoke gp motiv quit quit attempt final statist power studi limit respect effect physician level factor lifestyl beha vioural variabl smoke gp level patient level essenti research efficaci intervent 4.2 conclus studi demonstr high particip rate randomli select gp patient smoke cessat intervent studi gener patient receiv person counsel gp quit compar control group benefit counsel intervent higher patient counsel smoke gp suggest effect smoke statu gp modifi person intervent condit 4.3 practic implic effect strategi support smoke practition counsel activ addit futur studi examin counsel train measur elev readi chang smoke behaviour gp acknowledg wewould dr j.r thyrian proofread help commentari write articl studi part german research network earlint earli substanc intervent fund german ministri educ research grant no 01eb0120 01eb0420 social ministri mecklenburg west pomerania grant ix311a406.68.43.05
random control trial comput base tailor intervent increas smoke cessat counsel primari care physician marina unrod phd 1 meredith smith mpa phd 1 bonni spring phd 2 judith depu edd mph 3 william redd phd 1 gari winkel phd 4 1depart oncolog scienc mount sinai school medicin york ny usa 2depart prevent medicin northwestern univers evanston il usa 3center behavior prevent medicin miriam hospit brown medic school provid ri usa 4depart psycholog citi univers york york ny usa object primari care visit repres import venu interven larg popul smoker physician adher smoke cessat clinic guidelin 5a remain low evalu effect comput tailor intervent design increas smoke cessat counsel primari care physician method physician patient ran domiz intervent control condit addit smoke cessat train interven tion physician patient receiv page report character patient smoke habit histori offer tailor recommend physi cian perform 5a assess patient exit interview quit rate smoke behavior assess 6 month postintervent patient phone interview intervent effect test sampl 70 physician 518 patient result analyz gener mix linear model control cluster measur main result intervent physician exceed control assess 5.06 95 ci 3.22 7.95 advis 2.79 95 ci 1.70 4.59 assist set goal 4.31 95 ci 2.59 7.16 assist provid written materi 5.14 95 ci 2.60 10.14 assist provid referr 6.48 95 ci 3.11 13.49 assist discuss medic 4.72;95 ci 2.90 7.68 arrang 8.14 95 ci 3.98 16.68 valu 0.0001 intervent patient 1.77 ci 0.94 3.34 0.078 timesmor control abstin 12 versu 8 differ approach reach statist signific surpass control number dai quit 18.4 versu 12.2 05 number quit attempt conclus comput tailor report improv physician implement 5a modest effect patient smoke behavior 6 month postintervent kei word smoke cessat comput tailor intervent primari care doi 10.1007 s11606 006 0069 0 2007 societi gener intern medicin 2007;22 478 484 espit steadi declin unit state smokingpreval past decad roughli 45 million adult continu smoke tobacco remain lead prevent morbid mortal 1 advanc high intens clinic base intervent yield moder high abstin rate treatment reach smoker reach larger spectrum smoker effect low intens intervent need public health servic clinic practic guidelin tobacco dependence2 acknowledg uniqu role health care provid plai promot smoke cessat effort larg number smoker commun guidelin recommend visit physician perform 5a smoke statu advis smoker quit assess readi quit assist quit arrang follow 70 smoker physician annual 3 make medic visit critic teachabl moment deliveri smoke cessat messag intervent deliv pri mari care physician shown increas cessat 4,5 potenti impact data smoker offer smoke cessat assist routin medic visit 6 8 medic chart review studi reveal 21 physician provid smoke cessat counsel ing 1.3 regularli recommend nicotin replac ment therapi 9 patient report yield low rate physician deliveri smoke cessat servic statewid survei document 51 smoker ask smoke 45.5 advis quit 14.9 offer assist quit 3 schedul smoke relat follow 10 incorpor smoke cessat counsel medic practic remain challeng portion result present annual meet societi behavior medicin paper present boston massachu sett 2005 poster present baltimor maryland 2004 research conduct mount sinai school medicin york ny support agenc healthcar research qualiti r01hs10547 0182 award meredith smith mpa phd marina unrod phd lee moffitt cancer center research institut receiv march 1 2006 revis august 4 2006 accept novemb 10 2006 publish onlin februari 6 2007 478 technolog offer promis approach potenti extend reach intervent offer experienc clinician expert system comput program implement decision algorithm similar experienc clinician practic system base stage readi framework evalu individu smoke histori person feedback report counsel messag tai lore smoker readi chang result studi provid smoker person aliz stage base report enhanc cessat rate 11 17 current studi test intervent int grate tailor expert system report face face physician deliv counsel primari care set base patient assess respons tailor report gener distribut physician patient smoke current intervent innov wai unlik previou comput tailor intervent direct patient current intervent target patient physician real time medic visit maxim time strap primari care environ tailor report abli shorter previous test version interven tion object 1 bolster rate physician deliv smoke cessat servic 2 increas patient quit rate provid smoker physician report time health care visit expect cue physician deliv smoke cessat counsel activ patient elicit counsel addit cu function report intend compens limit physician time knowledg counsel techniqu bolster treatment capac hypothes intervent surpass usual care physician implement 5a quit rate length quit attempt number quit attempt stage chang progress method studi design recruit random control trial conduct examin effect tailor smoke cessat intervent direct physician patient routin offic visit partnership lead york citi nyc manag care organ identifi potenti elig physician largest metropolitan borough bronx brooklyn manhattan queen borough divid geograph area physician sampl area ensur geograph repr sentat studi approv institut review board particip underw inform consent process physician recruit initi facsimil invit telephon call physician recruit physician consent particip contact studi director screen elig elig criteria includ intern famili medicin specialti plan continu practic current locat 1 year 75 patient visit week primarili english speak patient fewer 25 geriatr patient physician paid 150 physician interven tion condit receiv addit 50 recognit greater time commit expect random number gener assign physician inter vention usual care control physician learn group assign sign inform consent physician recruit occur septemb 2002 2004 total 579 physician contact facsimil 70 successfulli recruit complet studi flowchart fig 1 project staff screen patient physician wait room identifi smoker offer opportun partic ipat studi staff continu recruit physician offic 10 dai 10 smoker enrol whichev initi assess complet immedi patient appoint includ inform gener report assess occur immedi medic visit contain question physician 5a perfor manc patient usual care condit complet assess receiv report patient contact 6 month initi enrol telephon follow interview assess outcom report abstin biochem valid saliva cotinin test smoker paid 20 complet initi assess 10 follow interview elig smoker requir 18 year smoke past 7 dai smoke 100 cigarett lifetim particip requir english speak plan retain physician 12 month total 5,826 smoker nonsmok screen 580 met elig criteria agre particip sixti withdrawn due comput malfunct schedul time constraint total 518 smoker complet ed initi assess 465 complet 6 month assess fig 1 initi patient assess measur tailor expert system report contempl ladder assess readi quit18,19 base stage identifi prochaska diclement 20 patient classifi precontempl quit contempl quit 6 month prepar plan quit 30 dai action recent quit smoke fagerstrom test nicotin dependence21,22 measur depend level pro con scale identifi perceiv posit neg featur smoke 23 efficaci scale identifi main temp tation smoke measur patient confid smoke specif situat 24 addit inform tailor report includ smoke quantiti durat past quit attempt durat exist medic condit exacerb smoke smoke cessat expert system intervent health educ provid individu physician train smoke cessat counsel base 5a clinic 479unrod al smoke cessat intervent primari care physiciansjgim practic guidelin train conduct 40 minut visit physician offic academ detail approach 25 educ explain report encourag physician review patient enrol studi physician control condit train instruct continu usual smoke cessat practic report contain smoke relat inform recommend base inform provid patient assess fig 2 sampl minim time burden maxim user friendli patient assess last 5 10 minut report page patient enter inform directli laptop comput minim assist research staff copi report automat print assess ment complet research staff gave copi patient hand physician report offic staff patient chart physician review appoint outcom measur perform 5a physician 5a perform measur exit assess complet patient assess contain question doctor smoke readi figur 1 patient physician recruit flowchart 480 unrod al smoke cessat intervent primari care physician jgim quit assess advis quit smoke advis set goal quit assist 1 give written materi quit assist 2 refer quit smoke program assist 3 talk quit smoke medic assist 4 make follow appoint discuss smoke arrang question previous assess found yield reliabl respons prior studi 3,037 adult smoker 26 measur smoke behavior primari outcom measur 7 dai point preval abstin defin smoke past 7 dai secondari smoke outcom includ longest quit attempt dai total number 24 hour quit attempt stage chang progress saliva cotinin sampl obtain 35 subsampl report quitter abstin bioverifi 88 14 16 sampl collect cotinin 25 ng ml consist studi report quit rate 27 evid differenti report accuraci intervent control group base bioverif stage chang pro gressionwa assess examin differ base line 6 month stage statist analysi base comput tailor intervent studi 11,14 sume 12.5 7.5 quit rate treatment control group power 0.80 alpha 0.05 requir detect low moder size group differ 564 descript statist character sampl baselin differ group determin pearson chi squar test categor variabl ind pendent sampl test continu variabl differ found variabl incorpor covari subsequ outcom analys import element design nest patient physician practic physician perform 5a analyz hierarch gener linear model analysi vari anc control baselin variabl identifi covari patient 7 dai point preval abstin analyz gener linear model logit link function figur 2 sampl expert system report 481unrod al smoke cessat intervent primari care physiciansjgim physician cluster variabl mix linear model physician cluster variabl examin longest quit attempt number quit attempt stage chang progress result sampl characterist physician particip 83 caucasian 13 asian 1 african american averag ag physician 51.1 sd 8.1 74 male averag year postmedi cal school 24.3 sd 8.6 physician specialti 68 intern medicin 32 famili medicin percent physician current smoker 67 smoker 29 smoker differ physician random intervent control group measur demograph medic practic factor patient demograph smoke characterist present tabl 1 major patient caucasian femal intervent control group differ demograph variabl patient smoke averag 14 cigarett daili report mild moder nicotin depend intervent control group differ chronic daili smoke intervent group smoker 25 year smoke histori number year smoke control smoke outcom analys physician 5a perform gee gener linear model intervent physician exceed control assess advis assist arrang 0.0001 fig 3 patient report intervent control physician assess patient readi quit smoke 5.06 95 ci 3.22 7.95 intervent control physician advis patient quit smoke 2.79 95 ci 1.70 4.59 time intervent control physician provid quit smoke assist includ set goal 4.31 95 ci 2.59 7.16 provid written materi 5.14 95 ci 2.60 10.14 discuss smoke cessat medic 4.72 95 ci 2.90 7.68 refer quit smoke program 6.48 95 ci 3.11 13.49 final intervent physician arrang follow discuss smoke 5 time rate control physician 8.14 95 ci 3.98 16.68 month smoke cessat outcom smoke outcom present tabl 2 dai point preval abstin higher intervent group 12 control group 8 differ ap proach reach signific 1.77 95 ci 0.94 3.34 078 intervent patient surpass control number dai quit number 24 hour quit attempt stage chang progress analyz creat chang score variabl calcul differ baselin 6 month stage score intervent condit signific com.ibm.drl.hbcp.predictor chang indic larger pro figur 3 patient report 5a perform physician 518 rate base patient exit interview occur immedi postvisit group differ statist signific 482 unrod al smoke cessat intervent primari care physician jgim portion intervent control patient displai forward movement stage 3.84 df 465 0.05 discuss studi test effect comput tailor intervent increas provis smoke cessat counsel physician quit rate patient smoke primari find physician receiv intervent perform 5a specif intervent increas rate physician advis patient quit doubl rate assess readi quit assist quit arrang follow assist arrang activ shown problemat term physician adher 6,8 significantli creas intervent larg intervent effect physician 5a perfor manc 6 month smoke cessat rate modestli higher patient receiv intervent effect approach reach statist signific intervent result longer quit attempt strongest determin cessat success 28 greater stage chang forward movement associ at enhanc quit attempt 19 12 quit rate observ intervent patient consist quit rate achiev intervent primari care set ting 29 32 control group cessat rate 8 higher predict secular trend 33 result small group differ treatment effect factor contribut high control group quit rate smoker control condit expos activ treatment ingredi part assess patient ask smoke statu assess readi quit 5a assess sensit smoker control group quit smoke reason small cessat effect anticip sampl size consequ reduct statist power detect group differ averag patient caseload physician lower expect basi focu group conduct studi mencement addit proport patient identifi smoker 15 significantli expect 20 30 found primari care studies29,34 estim 25 smoke preval nyc studi design attain intend enrol target low smoke base rate current studi reflect 11 smoke preval declin observ nyc attribut comprehens citywid tobacco control measur implement concurr 35 import limit studi minor physician contact particip enrol larg proport refus particip reach demograph inform nonparticipa tor physician current studi highli select group intervent modest effect smoke behavior innov integr comput technolog routin medic visit highli effect enhanc 5a adher impact physician behavior current intervent compar favor primari care intervent 29,31,34,36,37 instanc produc comprehens improv 5a perform interven tion featur vital sign stamp34 smoke assess questionnair 29 produc greater gain advis assist compar significantli intens compon intervent includ physician tutori vital sign stamp physician perform feedback nicotin replac ment therapi telephon counsel 31 smoke outcom current intervent compar intervent consist train physician cessat counsel 36 cessat rate surpass interven tion consist 2 hour tutori prompt 37 70 u. smoker visit physician annual modest cessat rate translat signific public health benefit public health approach telephon quitlin physician advic referr import maxim resourc 38,39 import aspect intervent minim time burden staff resourc need implement intervent physician spent averag 3.8 minut di cuss smoke minim burden increas likelihood integr busi clinic practic themain requir integr avail patient access comput printer encourag smoker complet assess physician visit incorpor comput er tailor program routin medic practic challeng current intervent address previ ousli identifi barriers40 streamlin administr time directli target patient current smoker tabl 2 smoke cessat outcom 6 month postintervent outcom measur intervent 237 control 228 7 dai point preval abstin 12 8 0.078 longest quit attempt dai sd 18.4 36.7 12.4 29.6 0.05 number 24 hour quit attempt sd 2.1 3.4 2.1 3.5 0.91 tabl 1 baselin characterist studi particip intervent 270 control 248 ag sd 43.5 14.7 42.8 14.2 gender 58 64 race caucasian 61 63 african american 20 20 19 17 hispan 15 19 educ ba 32 37 cig dai sd 13.3 8.7 14.4 9.9 fagerstrom sd 3.5 2.7 3.8 2.6 smoke daili 25 year 64.4 71.0 0.05 25 year 35.6 29.0 0.05 longest quit attempt 1 month 58.5 50.2 1 month 41.5 49.8 stage chang precontempl 5.6 8.5 contempl 53.7 50.0 prepar 40.7 41.5 statist signific differ group 483unrod al smoke cessat intervent primari care physiciansjgim research staff recruit patient current studi al practic help reduc demand offic staff diminish number smoker reach possibl readminist intervent return smoker enhanc intervent impact manuscript describ cost effect intervent review current studi show comput tailor intervent significantli increas primari care physi cian implement 5a result modest effect smoke outcom intervent hold promis reach main object smoke cessat clinic practic guidelin interven smoker visit physician increas rate guidelin implement potenti enorm public health impact research need increas potenc intervent regard quit rate determin integr outpati health care set acknowledg author acknowledg shannon erisman quinn leyden contribut data collect potenti financi conflict interest disclos author marina unrod phd tobacco research intervent program lee moffitt cancer center research institut 4115 fowler av tampa fl 33617 usa mail unrodm moffitt.usf.edu
smoke prevent peopl ag 60 random control trial norman vetter dian ford summari studi aim test hypothesi peopl ag 60 older respond assist stop smoke singl gener practition visit back practic nurs 14 smoker discontinu habit 6 month intervent period intervent group show improv standard measur breathless introduct prevent smoke retir peopl subject fulli research inform suggest worthwhil pursuit work shown longev improv older peopl stop smoke coronari heart diseas death rate 65 74 year peopl recent similar smoker death lung cancer bronchiti benefit stop ping smoke take 5 year term morbid suggest smoker move quickli state smoker bone densiti pulmonari function muscl strength 1 studi set test hypothesi elderli peopl persuad reduc smoke benefit paper present preliminari result studi method patient ag 60 year larg group practic includ studi group practic chosen includ princip gener practition base health centr practic premis small town surround countrysid high proport popul regist practic 2705 peopl ag 60 regist group practic record famili practition committe postal question nair mid june 1986 questionnair includ seri question measur angina breath less bronchit symptom intermitt clau dicat standard london school hygien tropic medicin questionnair 2 3 part incorpor mrc questionnair respiratori symptom 4 5 measur physic disabl base townsend 6 consist item consid essenti daili live question smoke habit base gener household survei 7 respond identifi current cigarett smoker random control intervent group intervent undertaken part time practic nurs 6 month period practic nurs experi health promot past practic previou employ emphasi put blood pressur reduct dietari advic member intervent group invit letter gener practition urgent matter gener ag ag 1990 19 164 168 smoke prevent peopl ag 60 6s practition inform import stop smoke avail practic nurs subject opportun discuss problem stop smoke practic nurs nurs undertook gener health promot approach offer advic lifestyl factor gener concentr assist give smoke identifi smoker que tionnair intervent control group postal questionnair 6 month intervent complet i. 1 year initi questionnair peopl claim questionnair stop smoke intervent control group visit research offic carbon monoxid breath monitor check smoke statu compar respons questionnair breathless angina intermitt claudic code subject move improv grade same:non symptom present occas same:sever symptom highest grade time intermedi grade chang occur wors case score wors grade time compar differenti end scale score wors top bottom point result sixti cent questionnair return mail initi respond remind 6 week 2705 peopl ag 60 regist practic famili practition committe 220 di 71 move area remain 2414 173 trace 39 refus particip 1 commun total 2201 respond 1626 74 claim smoker 104 pipe smoker 471 21 cigarett smoker hundr thirti cigarett smoker alloc control group 237 intervent group tabl compar group term sex ag signific differ approxi mate 10 subject fail respond questionnair tabl 11 show proport peopl tabl comparison intervent control group ag group year men 60 64 65 69 70 74 75 100 total women 60 64 65 69 70 74 75 100 total intervent 42 36 21 23 122 46 33 18 18 115 control 55 31 17 20 123 47 30 14 20 111 smoke 6 month complet intervent phase reduct proport smoke group intervent group reduct 14 greater control group 9 cent intervent group 2 control claim stop posit read carbon monoxid monitor count smoke group differ group number valid smoker statist signific 2 4.5 0.05 ag group higher proport intervent group stop smoke compar control group proport stop fell increas ag 18 ag 60 64 7 ag 75 continu smoke 50 intervent group 38 control reduc intak thirti cent intervent group 38 control chang number cigar ett smoke differ reach statist signific 5 level evid group subject increas smoke time intervent 166 vetter ford tabl ii smoke statu 6 month intervent group ag group smoke stop valid valid left area di miss data 60 64 58 1 16 0 3 10 81 1 12 0 1 7 38 4 10 6 5 6 ag group year 65 69 44 1 5 0 3 8 70 74 29 3 5 0 1 1 23 1 1 2 0 4 20 2 3 3 6 7 75 27 1 2 2 6 2 145 10 34 9 15 24 61 4 14 4 6 10 175 4 20 4 10 21 75 2 9 2 4 9 intervent control tabl iii show angina questionnair signific differ interven tion control group tabl iv show breathless statist signific differ 8 improv breathless intervent group compar control 2.1 0.05 tabl show intermitt claudic statu signific differ group order ascertain interven tion possibl caus improv minor tabl iii angina 6 month alloc group intervent control angina wors di left area miss data total 10 165 5 6 15 9 27 237 4 71 2 3 6 4 11 100 19 159 11 9 10 4 22 234 68 5 4 4 2 9 100 tabl iv breathless 6 month alloc group intervent control breathless grade 4 wors di left area miss data total 35 107 14 10 22 15 9 25 237 15 45 6 4 9 6 4 11 100 24 105 25 12 34 10 4 20 234 10 45 11 5 15 4 2 100 symptom comparison made symptom trembl nausea irrit intervent control group tabl vi show control subject show worsen symptom subject intervent group differ statist signific differ group proport symptom improv evid intervent harm smoke prevent peopl ag 60 167 tabl intermitt claudic alloc group intervent intermitt claudic max grade wors di left area miss data total 24 123 11 8 17 15 9 30 237 0 10 54 5 3 7 6 4 13 100 control 28 127 12 12 18 10 4 23 234 12 54 5 5 8 4 2 10 100 tabl vi symptom worsen 6 month alloc group symptom worsen worsen di move miss data total intervent 118 73 15 9 22 237 50 31 6 4 9 100 control 104 97 10 4 19 234 0 0 44 41 4 2 8 100 studi shown part time nurs back singl intervent gener practition reduct smoke 6 month intervent period ceas intervent group show improv breathless compar intervent intervent psy chotherapeut effect breathless concomit effect symptom measur angina particu larli suscept suggest breathless measur standard iz questionnair robust import com.ibm.drl.hbcp.predictor mortal independ measur respiratori function 9 sympto matic measur relationship short term instanc forc expiratori volum differ angina intermitt claudic record group evid disproportion chang minor symptom relat intervent intervent group show worsen minor symptom control smoke habit studi group record initi postal questionnair show 24 men 19 women smoke cigarett lower nation figur 30 men 23 women 60 found smoker 7 public help elderli peopl stop smoke tend bland extrem comment smoke remain pleasur elderli peopl 10 number textbook health promot 11 advisori group 12 omit subject american convinc import approach 13 comment benefit confin potenti improv long eviti surgeon gener report health promot diseas prevent healthi older peopl program includ advic exercis nutrit medica tion injuri prevent smoke cessat prevent servic 14 reduct smoke studi compar favour studi younger subject studi 1550 subject ag 18 65 year symptom show valid figur 12 stop smoke 6 month 15 present studi aim complet commun cross section symptom intervent support akin present studi subject ag 16 gave 8 valid success rate 1 year 16 nicotin chew gum studi led similar proport smoker 6 month present trial 17 168 vetter ford previou studi report symptom elderli ag group relat antismok intervent conclud enabl older peopl part health promot exercis facil easili practition effect short term consequ probabl reduct breathless elderli peopl involv long term reduc gener practition workload acknowledg due mr sheila penk grand chariti support studi dr jone partner caldicot health centr mr janic strom
